FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Rex, FE
   Borges, CAD
   Kafer, PS
AF Rex, Franciel Eduardo
   de Souza Borges, Cleber Augusto
   Kafer, Pamela Suelen
TI Spatial analysis of the COVID-19 distribution pattern in Sao Paulo
   State, Brazil
SO CIENCIA & SAUDE COLETIVA
LA English
DT Article
DE Coronavirus; Respiratory disease; Pandemic; Kernel density
ID ACUTE RESPIRATORY SYNDROME; KERNEL DENSITY-ESTIMATION;
   INFECTIOUS-DISEASE; SYNDROME SARS
AB At the end of 2019, the outbreak of COVID-19 was reported in Wuhan, China. The outbreak spread quickly to several countries, becoming a public health emergency of international interest. Without a vaccine or antiviral drugs, control measures are necessary to understand the evolution of cases. Here, we report through spatial analysis the spatial pattern of the COVID-19 outbreak. The study site was the State of Sao Paulo, Brazil, where the first case of the disease was confirmed. We applied the Kernel Density to generate surfaces that indicate where there is higher density of cases and, consequently, greater risk of confirming new cases. The spatial pattern of COVID-19 pandemic could be observed in Sao Paulo State, in which its metropolitan region standed out with the greatest cases, being classified as a hotspot. In addition, the main highways and airports that connect the capital to the cities with the highest population density were classified as medium density areas by the Kernel Density method. It indicates a gradual expansion from the capital to the interior. Therefore, spatial analyses are fundamental to understand the spread of the virus and its association with other spatial data can be essential to guide control measures.
C1 [Rex, Franciel Eduardo] Univ Fed Parana, Av Prefeito Lothario Meissner, BR-80210170 Curitiba, Parana, Brazil.
   [de Souza Borges, Cleber Augusto] Hosp & Maternidade Santa Rita, Alta Floresta, MT, Brazil.
   [Kafer, Pamela Suelen] Univ Fed Rio Grande do Sul, Ctr Estadual Pesquisas Sensoriamento Remoto & Met, Porto Alegre, RS, Brazil.
RP Rex, FE (corresponding author), Univ Fed Parana, Av Prefeito Lothario Meissner, BR-80210170 Curitiba, Parana, Brazil.
EM francielrexx@gmail.com
OI Rex, Franciel Eduardo/0000-0003-0876-8500
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -
   BrazilCAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq)
FX The authors are thankful to the Instituto Brasileiro de Geografia e
   Estatistica (IBGE) for providing the data used in this research. This
   study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brazil and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq). The authors declare no
   conflict of interest.
CR Ali SH, 2006, URBAN STUD, V43, P491, DOI 10.1080/00420980500452458
   Brasil. Ministerio da Saude (MS), BRAS AMPL MON COR
   Cai XJ, 2013, INT J GEOGR INF SCI, V27, P222, DOI 10.1080/13658816.2012.663918
   Chen ZL, 2020, CHIN MED J
   DALEY R, 2015, COMPUTER SCI INFORM, V3, P149
   Lange MMA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-881
   DNIT-Departamento Nacional de Infraestrutura de Transportes, 2003, MAP MULT SHAP
   ESRI, ARCG DESKT HELP
   Fleming CH, 2017, METHODS ECOL EVOL, V8, P571, DOI 10.1111/2041-210X.12673
   He J, 2020, COMP ANAL COVID 19 T, DOI [10.1101/2020.04.09.20053223v1, DOI 10.1101/2020.04.09.20053223V1]
   IBGE, 2019, CID EST
   Joventino IP, 2012, J COMPLEMENT INTEGR, V9, P1, DOI [10.1515/1553-3840.1534, DOI 10.1515/1553-3840.1534]
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   KRISHNAMOORTHI N, 2016, IMP J INTERDISCIP RE, V2, P144
   Lai PC, 2004, ENVIRON HEALTH PERSP, V112, P1550, DOI 10.1289/ehp.7117
   Liu Q, 2020, REMOTE SENS-BASEL, V12, DOI 10.3390/rs12101576
   Mendez N, 2017, ARCH PUBLIC HEALTH, V75, DOI 10.1186/s13690-017-0233-5
   Muniz-Rodriguez K, 2020, TRANSMISSION POTENTI
   Murugesan B, 2020, J GEOGR STUD, V4, P1, DOI [10.21523/gcj5.20040101, DOI 10.21523/GCJ5.20040101]
   Nakaya T, 2010, T GIS, V14, P223, DOI 10.1111/j.1467-9671.2010.01194.x
   Ogen Y, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138605
   Ornell F., 2020, BRAZ J PSYCHIAT
   Ray EL, 2017, STAT MED, V36, P4908, DOI 10.1002/sim.7488
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101613
   Sabel C, 1998, ESRI US C
   Sahafizadeh E, 2020, ESTIMATING REPROD NU
   Silverman Bernard W., 1986, DENSITY ESTIMATION S, V26
   Vaz Fernanda Pires Cecchetti, 2017, Rev. Bras. Saude Mater. Infant., V17, P475, DOI 10.1590/1806-93042017000300004
   Wang JF, 2006, B WORLD HEALTH ORGAN, V84, P965, DOI 10.2471/BLT.06.030247
   Wang W, 2014, PHYS REV E, V90, DOI 10.1103/PhysRevE.90.042803
   World Health Organisation, 2020, CRIT PREP READ RESP
   Yang C., 2020, ARXIV200504224V1
   Zhang GM, 2018, ECOL INDIC, V93, P387, DOI 10.1016/j.ecolind.2018.04.002
   Zhou C, 2020, GEOGRAPHY SUSTAINABI, V1, P77, DOI DOI 10.1016/J.GEOSUS.2020.03.005
NR 34
TC 0
Z9 0
U1 3
U2 3
PU ABRASCO-ASSOC BRASILEIRA POS-GRADUACAO & SAUDE COLETIVA
PI RIO DE JANEIRO
PA AVENIDA BRASIL, 4036, SALA 700 MANGUINHOS-1, RIO DE JANEIRO, 21040-36,
   BRAZIL
SN 1413-8123
EI 1678-4561
J9 CIENC SAUDE COLETIVA
JI Cienc. Saude Coletiva
PD SEP
PY 2020
VL 25
IS 9
BP 3377
EP 3384
DI 10.1590/1413-81232020259.17082020
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NK8TK
UT WOS:000567003000005
PM 32876254
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Paumgartten, FJR
   de Oliveira, ACAX
AF Roma Paumgartten, Francisco Jose
   Amado Xavier de Oliveira, Ana Cecilia
TI Off label, compassionate and irrational use of medicines in Covid-19
   pandemic, health consequences and ethical issues
SO CIENCIA & SAUDE COLETIVA
LA English
DT Article
DE SARS-CoV-2; Drug adverse events; Pharmacotherapy; Hydroxychloroquine;
   Antibiotics
ID SARS; CHLOROQUINE; DRUG
AB When Covid-19 emerged in December last year, there was no vaccine nor was there specific effective treatment for this fast-spreading and life-threatening viral respiratory infection. Clinical trials were planned and are in progress to investigate whether drugs used for influenza, HIV and other viruses, and also anthelmintics (ivermectin, nitazoxanide, niclosamide), and antimalarials (chloroquine, hydroxychloroquine) showing antiviral activity in in vitro assays, are effective and safe for Covid-19. So far there is no convincing evidence that these antiviral and antiparasitic drugs are of any benefit for Covid-19. Notwithsanding the absence of evidence of clinical efficacy, these drugs are widely used outside of clinical trials (off label) for prophylaxis and treatment of this viral infection. The rationale behind the prescription of macrolide antibiotics (azithromycin) for Covid-19 is obscure as well. The widespread prescription and use of drugs of unproven efficacy and safety for Covid-19 is at odds with the rational use of medicines, a cornerstone principle of pharmacotherapy advanced by WHO in 1985. This irrational use of drugs is cause for concern because some of them are associated with serious heart disorders and deaths.
C1 [Roma Paumgartten, Francisco Jose; Amado Xavier de Oliveira, Ana Cecilia] Fiocruz MS, Escola Nacl Saude Publ, Av Brasil 4036-913, BR-21040361 Rio De Janeiro, RJ, Brazil.
RP Paumgartten, FJR (corresponding author), Fiocruz MS, Escola Nacl Saude Publ, Av Brasil 4036-913, BR-21040361 Rio De Janeiro, RJ, Brazil.
EM paum@ensp.fiocruz.br
OI Paumgartten, Francisco Jose Roma/0000-0002-6207-0149
CR Al Idrus A., GILEADS REMDESIVIR S
   Amici C, 2006, ANTIVIR THER, V11, P1021
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   D'Alessandro S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8010085
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1610
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gbinigie K, 2020, WHAT IS EVIDENCE USI
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   MAY F, 2008, J PHARM PRACT RES, V38, P89
   Mercuro NJ, 2020, JAMA CARDIOL, DOI DOI 10.1001/JAMACARDIO.2020.1834
   Nguyen LS, 2020, CIRCULATION, V142, P303, DOI 10.1161/CIRCULATIONAHA.120.048238
   Park Su Eun, 2020, Clin Exp Pediatr, V63, P119, DOI 10.3345/cep.2020.00493
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Paumgartten FJR, 2020, VIGIL SANIT DEBATE, V8, P39, DOI 10.22239/2317-269x.01596
   Paumgartten FJR, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311X00088520, 10.1590/0102-311x00088520]
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Rossignol JF, 2014, ANTIVIR RES, V110, P94, DOI 10.1016/j.antiviral.2014.07.014
   Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Tai DYH, 2007, ANN ACAD MED SINGAP, V36, P438
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   The National Institute for Health and Care Excellence (NICE), 2020, COV 19 RAP GUID MAN
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Tsang Kenneth, 2004, Curr Opin Investig Drugs, V5, P179
   US Food and Drug Administration Coronavirus (COVID-19), 2020, UPD FDA ISS EM US AU
   US Food and Drug Administration (FDA), 2020, HYDR CHLOR COV 19 DR
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, REP WHO CHIN JOINT M
   World Health Organization, 2002, PROM RAT US MED COR
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
NR 34
TC 0
Z9 0
U1 4
U2 4
PU ABRASCO-ASSOC BRASILEIRA POS-GRADUACAO & SAUDE COLETIVA
PI RIO DE JANEIRO
PA AVENIDA BRASIL, 4036, SALA 700 MANGUINHOS-1, RIO DE JANEIRO, 21040-36,
   BRAZIL
SN 1413-8123
EI 1678-4561
J9 CIENC SAUDE COLETIVA
JI Cienc. Saude Coletiva
PD SEP
PY 2020
VL 25
IS 9
BP 3413
EP 3419
DI 10.1590/1413-81232020259.16792020
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NK8TK
UT WOS:000567003000009
PM 32876249
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU da Silva, AF
   Estrela, FM
   Soares, CFSE
   de Magalhaes, JRF
   Lima, NS
   Morais, AC
   Gomes, NP
   Lima, VLD
AF da Silva, Andrey Ferreira
   Estrela, Fernanda Matheus
   Soares e Soares, Caroline Fernandes
   Fernandes de Magalhaes, Julia Renata
   Lima, Nayara Silva
   Morais, Ariane Cedraz
   Gomes, Nadirlene Pereira
   de Azevedo Lima, Vera Lucia
TI Marital violence precipitating/intensifying elements during the Covid-19
   pandemic
SO CIENCIA & SAUDE COLETIVA
LA English
DT Article
DE COVID-19; Pandemic; Intimate partner violence
AB The study aims to identify marital violence precipitating/intensifying elements during the COVID-19 pandemic. This is a narrative review of the literature, and the search was carried out in May 2020. We employed the PubCovid-19 platform, which is indexed in the United States National Library of Medicine (PubMed) and the Excerpta Medica (EMBASE) database. English descriptors "Domestic violence", "COVID-19", and "Intimate Partner Violence" were used in the search, and nine papers were selected for full-text reading. Three empirical categories were elaborated from the exploration of the selected material: Economic instability, Alcohol and other drugs use/ abuse, and Weaker women's support network. Support networks for women in situations of marital violence should be expanded in this pandemic context, with emphasis on the use of digital technologies as possible tools for screening pandemic-related violence cases.
C1 [da Silva, Andrey Ferreira; Fernandes de Magalhaes, Julia Renata; Gomes, Nadirlene Pereira] Univ Fed Bahia, Esc Enfermagem, Av Dr Augusto Viana S-N, BR-40110060 Salvador, BA, Brazil.
   [Estrela, Fernanda Matheus; Soares e Soares, Caroline Fernandes; Morais, Ariane Cedraz] Univ Estadual Feira de Santana, Dept Saude, Feira De Santana, BA, Brazil.
   [Lima, Nayara Silva] Secretaria Municipal Saude, Salvador, BA, Brazil.
   [de Azevedo Lima, Vera Lucia] Univ Fed Para, Belem, Para, Brazil.
RP da Silva, AF (corresponding author), Univ Fed Bahia, Esc Enfermagem, Av Dr Augusto Viana S-N, BR-40110060 Salvador, BA, Brazil.
EM silva.andrey1991@hotmail.com
RI SILVA, ANDREY FERREIRA/AAX-8179-2020; Estrela, Fernanda
   Matheus/ABH-7549-2020
OI SILVA, ANDREY FERREIRA/0000-0002-1038-7443; Estrela, Fernanda
   Matheus/0000-0001-7501-6187; Pereira Gomes,
   Nadirlene/0000-0002-6043-3997
CR Bradbury-Jones C, 2020, J CLIN NURS
   Bradley NL, 2020, CAN MED ASSOC J
   Brasil. Ministerio da Saude (MS), 2020, COR BRAS
   Brasil. Ministerio da Saude (MS), 2020, B EPIDEMIOLOGICO
   Commonwealth Bank Group, 2020, EARL LOOK COR AFF HO
   Estadao Sao Paulo, 2007, DOIS AN AP KATR NEW
   Euronews, 2020, DOM VIOL CAS JUMP 30
   Higgins N, 2020, BBC NEWS
   Kathryn LH, 2020, PEDIATRICS
   La Provincia, 2020, COR CAS VIOL DONN RA
   Mahase E, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1872
   Mazza M, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113046
   Nogueira L., 2020, COVID 19 BRASIL SE T
   Peterman A, 2020, PANDEMICS VIOLENCE W
   Roesch E, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1712
   Croda JHR, 2020, EPIDEMIOL SERV SAUDE, V29, DOI [10.5123/S1679-49742020000100021, 10.5123/s1679-49742020000100021]
   Rafael RDR, 2020, REV LAT-AM ENFERM, V28, DOI 10.1590/1518-8345.4475.3344
   Saadat S, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138870
   Scandinavian Way, 2020, GROENL IMP RESTR EXT
   Toledo JA, 2017, B ACAD PAUL PSICOL, V37, P139
   United Nations Population Fund HQ (UNFPA), 2020, COVID 19 RES TECN PR
   Universidade Federal de Minas Gerais (UFMG), 2020, EST UFMG VIOL DOM PO
   Usher K, 2020, INT J MENT HEALTH NU, V29, P549, DOI 10.1111/inm.12735
   van Gelder N, 2020, EClinicalMedicine, V21, P100348, DOI 10.1016/j.eclinm.2020.100348
   Vieira PR, 2020, REV BRAS EPIDEMIOL, P23
   Wanqing Z., 2020, 6 TONE
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
NR 27
TC 0
Z9 0
U1 3
U2 3
PU ABRASCO-ASSOC BRASILEIRA POS-GRADUACAO & SAUDE COLETIVA
PI RIO DE JANEIRO
PA AVENIDA BRASIL, 4036, SALA 700 MANGUINHOS-1, RIO DE JANEIRO, 21040-36,
   BRAZIL
SN 1413-8123
EI 1678-4561
J9 CIENC SAUDE COLETIVA
JI Cienc. Saude Coletiva
PD SEP
PY 2020
VL 25
IS 9
BP 3475
EP 3480
DI 10.1590/1413-81232020259.16132020
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NK8TK
UT WOS:000567003000016
PM 32876252
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Herman, P
   Vincent, C
   Winkler, CP
   Loundon, N
   Couloigner, V
   Tankere, F
   Tringali, S
   Gallet, P
   Papon, JF
   Montava, M
   Lavieille, JP
   Charpiot, A
   Schmerber, S
AF Herman, P.
   Vincent, C.
   Winkler, C. Parietti
   Loundon, N.
   Couloigner, V.
   Tankere, F.
   Tringali, S.
   Gallet, P.
   Papon, J. -F.
   Montava, M.
   Lavieille, J. -P.
   Charpiot, A.
   Schmerber, S.
TI Consensus statement. Corticosteroid therapy in ENT in the context of the
   COVID-19 pandemic
SO EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Anosmia; Prednisone; Bell's palsy; Sudden hearing
   loss
AB This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60 dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Herman, P.] Lariboisiere Univ Hosp, AP HP, Dept Otorhinolaryngol Head & Neck Surg, Paris, France.
   [Vincent, C.] Lille Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Lille, France.
   [Winkler, C. Parietti; Gallet, P.] Nancy Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Nancy, France.
   [Loundon, N.; Couloigner, V.] Necker Hosp Sick Children, Dept Otorhinolaryngol Head & Neck Surg, AP HP, Paris, France.
   [Tankere, F.] La Pitie Salpetriere Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, AP HP, Paris, France.
   [Tringali, S.] Lyon South Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Lyon, France.
   [Papon, J. -F.] Bicetre Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, AP HP, Le Kremlin Bicetre, France.
   [Montava, M.; Lavieille, J. -P.] La Concept Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, AP HM, Marseille, France.
   [Charpiot, A.] Hautepierre Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Strasbourg, France.
   [Schmerber, S.] CHU38 Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Grenoble, France.
RP Herman, P (corresponding author), Lariboisiere Univ Hosp, AP HP, Dept Otorhinolaryngol Head & Neck Surg, Paris, France.; Herman, P (corresponding author), Dept Otorhinolaryngol Head & Neck Surg, 2 Rue Ambroise Pare, F-75010 Paris, France.
EM philippe.herman099@gmail.com
RI SCHMERBER, Sebastien/D-1789-2016
OI SCHMERBER, Sebastien/0000-0001-5778-7201
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Butowt R, 2020, ACS CHEM NEUROSCI, V11, P1200, DOI 10.1021/acschemneuro.0c00172
   Eliezer M, 2020, JAMA OTOLARYNGOL, V146, P674, DOI 10.1001/jamaoto.2020.0832
   Gagyor I, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001869.pub9
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Lescanne E, 2020, EUR ANN OTORHINOLARY, V137, P303, DOI 10.1016/j.anorl.2020.05.007
   Light Joshua P, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P378, DOI 10.1097/01.moo.0000134438.91734.38
   Madhok VB, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001942.pub5
   Nevoux J, 2018, EUR ANN OTORHINOLARY, V135, pS29, DOI 10.1016/j.anorl.2017.12.006
   Patel Mitesh, 2017, J Otol, V12, P117, DOI 10.1016/j.joto.2017.06.002
   Qiang QF, 2017, ACTA OTO-LARYNGOL, V137, P598, DOI 10.1080/00016489.2016.1260157
   Radulesco T, 2020, EUR ANN OTORHINOLARY, DOI [10.1016/j.anorl.2020.04.013, DOI 10.1016/J.ANORL.2020.04.013[S1879-7296(20)30103]
   Sennaroglu L, 2001, OTOLARYNG HEAD NECK, V125, P537, DOI 10.1016/S0194-5998(01)31520-6
   Thai Van H, 2020, EUR ANN OTORHINOLARY
   Xydakis MS, 2020, LANCET INFECT DIS, DOI [10.1016/S1473-3099(20)30293, DOI 10.1016/S1473-3099(20)30293[S1473-3099(20)30293-0]
NR 15
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER MASSON, CORP OFF
PI PARIS
PA 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE
SN 1879-7296
EI 1879-730X
J9 EUR ANN OTORHINOLARY
JI Eur. Ann. Otorhinolaryngol.-Head Neck Dis.
PD SEP
PY 2020
VL 137
IS 4
BP 315
EP 317
DI 10.1016/j.anorl.2020.04.014
PG 3
WC Otorhinolaryngology
SC Otorhinolaryngology
GA NK6KL
UT WOS:000566839900014
PM 32482571
OA Green Published
DA 2021-01-01
ER

PT J
AU Burgoyne, N
   Cohn, AS
AF Burgoyne, Nancy
   Cohn, Aaron Samuel
TI Lessons from the Transition to Relational Teletherapy During COVID-19
SO FAMILY PROCESS
LA English
DT Article
DE Online Therapy; Telemedicine; Telepsychology; Family Therapy; Couple
   Therapy; Conjoint Therapy; Private Practice; Treatment; Health Care
   Delivery; Organizational Change
ID COGNITIVE-BEHAVIORAL THERAPY; INTERNET; TELEHEALTH; COMMUNICATION;
   MINDFULNESS; TECHNOLOGY; DEPRESSION; MARRIAGE; ANXIETY; COUPLES
AB When the World Health Organization declared the coronavirus outbreak a pandemic, clinicians were challenged to maintain continuity of care. Teletherapy became the primary means of service delivery for many who had never or only sparingly used it. The Family Institute at Northwestern University, in response to encouraging findings with respect to the effectiveness of teletherapy and recognizing advantages with respect to access to care, launched our teletherapy services in 2018. As a relationship-based organization, we were keen to exploit the opportunity that teletherapy provides to integrate additional members of the client system into the treatment. Over these two plus years, we have learned a great deal. Our learning was greatly accelerated by our transition to a 100% teletherapy practice in the wake of the pandemic. Teletherapy is a different context. Intentionally managing the context's constraints and exploiting its strengths is key to providing high-quality couple and family therapy. This step is often overlooked or resisted when teletherapy is an occasional add-on to a face-to-face practice.
C1 [Burgoyne, Nancy; Cohn, Aaron Samuel] Northwestern Univ, Family Inst, Evanston, IL 60208 USA.
RP Burgoyne, N (corresponding author), Northwestern Univ, Family Inst, Evanston, IL 60208 USA.
EM nburgoyne@family-institute.org; acohn@family-institute.org
OI Cohn, Aaron/0000-0003-3166-7628
CR Alavi N, 2016, J PSYCHIATR PRACT, V22, P2, DOI 10.1097/PRA.0000000000000119
   American Psychological Association, 2013, GUID PRACT TEL
   American Psychological Association, 2020, OFF TECHN CHECKL TEL
   Baer RA, 2007, PSYCHOL INQ, V18, P238, DOI 10.1080/10478400701598306
   Bargh JA, 2004, ANNU REV PSYCHOL, V55, P573, DOI 10.1146/annurev.psych.55.090902.141922
   Bateson G, 1979, MIND NATURE NECESSAR
   BC-TMH Board Certified-TeleMental Health Provider, 2020, CTR CRED ED
   Bischoff RJ, 2004, CONTEMP FAM THER, V26, P179, DOI 10.1023/B:COFT.0000031242.83259.fa
   Bischoff RJ, 2004, AM J FAM THER, V32, P173, DOI 10.1080/01926180490437376
   Blumer MLC, 2015, CONTEMP FAM THER, V37, P113, DOI 10.1007/s10591-015-9330-1
   Bordin E. S., 1994, WORKING ALLIANCE THE, P13, DOI DOI 10.1037/H0085885
   Bosman J., 2020, NY TIMES
   Breunlin DC, 2014, FAM PROCESS, V53, P462, DOI 10.1111/famp.12083
   Burgoyne N., 2018, ENCY COUPLE FAMILY T, DOI [10.1007/978-3-319-15877-8_912-1, DOI 10.1007/978-3-319-15877-8_912-1]
   Caldwell B. E., 2017, BEST PRACTICES ONLIN
   Campbell AM, 2020, FORENSIC SCI INT REP, V2, DOI [10.1016/j.fsir.2020.100089, DOI 10.1016/J.FSIR.2020.100089]
   Campos D, 2018, NEUROPSYCH DIS TREAT, V14, P879, DOI 10.2147/NDT.S153041
   Carlbring P, 2018, COGN BEHAV THERAPY, V47, P1, DOI 10.1080/16506073.2017.1401115
   CE Certificate Program in TeleMental Health & Digital Ethics, 2019, CE CERT PROGR TELEME
   Chambers AL, 2012, COUPLE FAM PSYCHOL, V1, P31, DOI 10.1037/a0027505
   Chimiklis AL, 2018, J CHILD FAM STUD, V27, P3155, DOI 10.1007/s10826-018-1148-7
   Comer JS, 2017, J CONSULT CLIN PSYCH, V85, P178, DOI 10.1037/ccp0000155
   Davis S. D., 2018, ENCY COUPLE FAMILY T, P1, DOI [10.1007/978-3-319-15877-8_508-1, DOI 10.1007/978-3-319-15877-8_508-1]
   Doss BD, 2016, J CONSULT CLIN PSYCH, V84, P285, DOI 10.1037/ccp0000063
   Doss BD, 2013, FAM PROCESS, V52, P139, DOI 10.1111/famp.12020
   Farero AM, 2015, CONTEMP FAM THER, V37, P281, DOI 10.1007/s10591-015-9343-9
   Fosslien L., 2020, HARVARD BUSINESS REV
   Gilkey SL, 2009, FAM SOC, V90, P37, DOI 10.1606/1044-3894.3843
   Goldman R. N., 2018, ENCY COUPLE FAMILY T, P1, DOI [10.1007/978-3-319-15877-8_194-2, DOI 10.1007/978-3-319-15877-8_194-2]
   Hertlein KM, 2014, CONTEMP FAM THER, V36, P58, DOI 10.1007/s10591-013-9284-0
   Hicks B., 2017, INT J PLAY THERAPY, V26, P138, DOI [10.1037/pla0000033, DOI 10.1037/PLA0000033]
   Hilty DM, 2013, TELEMED E-HEALTH, V19, P444, DOI 10.1089/tmj.2013.0075
   Holmqvist M, 2014, SLEEP MED, V15, P187, DOI 10.1016/j.sleep.2013.10.013
   Jencius M., 2001, FAMILY J COUNSELING, V9, P295, DOI DOI 10.1177/1066480701093009
   Long R. P., 2019, MINIMUM STANDARDS SY
   MARGOLIN G, 1982, AM PSYCHOL, V37, P788, DOI 10.1037/0003-066X.37.7.788
   Mott JM, 2014, PSYCHIAT SERV, V65, P106, DOI 10.1176/appi.ps.201300056
   Negretti MA, 2001, CONTEMP FAM THER, V23, P275, DOI 10.1023/A:1011178915547
   Nilsson A, 2018, J GAMBL STUD, V34, P539, DOI 10.1007/s10899-017-9704-4
   Paris M, 2018, AM J PUBLIC HEALTH, V108, P1535, DOI 10.2105/AJPH.2018.304571
   Pasarelu CR, 2016, COGN BEHAV THERAPY, V46, P1, DOI 10.1080/16506073.2016.1231219
   Pinsof W. M., 2018, INTEGRATIVE SYSTEMIC
   Polizzi C, 2020, CLIN NEUROPSYCHIATR, V17, P59, DOI 10.36131/CN20200204
   Rampage C, 2014, FAM PROCESS, V53, P489, DOI 10.1111/famp.12074
   Roddy MK, 2020, PREV SCI, V21, P861, DOI 10.1007/s11121-020-01100-y
   Sapru Iman, 2016, Int J Adolesc Med Health, V30, DOI 10.1515/ijamh-2016-0069
   Sherratt TN, 2017, ELS, P1, DOI [10.1002/9780470015902.a0027503, DOI 10.1002/9780470015902.A0027503]
   Sibley MH, 2017, J PSYCHOPATHOL BEHAV, V39, P467, DOI 10.1007/s10862-017-9598-6
   Slone NC, 2012, PSYCHOL SERV, V9, P272, DOI 10.1037/a0027607
   Sprenkle D. H., 2009, COMMON FACTORS COUPL
   Turgoose D, 2018, J TELEMED TELECARE, V24, P575, DOI 10.1177/1357633X17730443
   US Department of Health and Human Services, 2016, REP C E HLTH TEL
   White FA, 2015, REV GEN PSYCHOL, V19, P129, DOI 10.1037/gpr0000036
   Widdershoven M., 2017, INFANT OBSERVATION, V20, P72, DOI [10.1080/13698036.2017.1378528, DOI 10.1080/13698036.2017.1378528]
   Wittenborn AK, 2019, J MARITAL FAM THER, V45, P20, DOI 10.1111/jmft.12338
NR 55
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-7370
EI 1545-5300
J9 FAM PROCESS
JI Fam. Process
PD SEP
PY 2020
VL 59
IS 3
BP 974
EP 988
DI 10.1111/famp.12589
PG 15
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA NL5AR
UT WOS:000567429000012
PM 32692867
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Janowitz, T
   Gablenz, E
   Pattinson, D
   Wang, TC
   Conigliaro, J
   Tracey, K
   Tuveson, D
AF Janowitz, Tobias
   Gablenz, Eva
   Pattinson, David
   Wang, Timothy C.
   Conigliaro, Joseph
   Tracey, Kevin
   Tuveson, David
TI Famotidine use and quantitative symptom tracking for COVID-19 in
   non-hospitalised patients: a case series
SO GUT
LA English
DT Article
ID PHARMACOKINETICS
AB Objective Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient reported outcome measures in non-hospitalised patients with COVID-19 who self-administered high-dose famotidine orally.
   Design Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, famotidine use, drug-related side effects, temperature measurements, oxygen saturations and symptom scores were obtained using questionnaires and telephone interviews. Based on a National Institute of Health (NIH)-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches and anosmia) and general unwellness on a four-point ordinal scale modelled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalised symptom scores were statistically compared.
   Results Ten consecutive patients with COVID-19 who self-administered high-dose oral famotidine were identified. The most frequently used famotidine regimen was 80 mg three times daily (n=6) for a median of 11 days (range: 5-21 days). Famotidine was well tolerated. All patients reported marked improvements of disease related symptoms after starting famotidine. The combined symptom score improved significantly within 24 hours of starting famotidine and peripheral oxygen saturation (n=2) and device recorded activity (n=1) increased.
   Conclusions The results of this case series suggest that high-dose oral famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.
C1 [Janowitz, Tobias; Gablenz, Eva; Tuveson, David] Cold Spring Harbor Lab, Canc Ctr, Cold Spring Harbor, NY 11724 USA.
   [Janowitz, Tobias] Northwell Hlth Canc Inst, New Hyde Pk, NY USA.
   [Gablenz, Eva] Heidelberg Univ, Med Fac, Heidelberg, Germany.
   [Pattinson, David] Univ Cambridge, Dept Zool, Cambridge, England.
   [Wang, Timothy C.] Columbia Univ, Med Ctr, New York, NY USA.
   [Conigliaro, Joseph] Dept Med, Div Gen Internal Med, Manhasset, NY USA.
   [Conigliaro, Joseph; Tracey, Kevin] Northwell Hlth, Feinstein Inst Med Res, Manhasset, NY 11030 USA.
RP Janowitz, T; Tuveson, D (corresponding author), Cold Spring Harbor Lab, One Bungtown Rd, Cold Spring Harbor, NY 11724 USA.; Tracey, K (corresponding author), Northwell Hlth, Feinstein Inst Med Res, Manhasset, NY 11030 USA.
EM janowitz@cshl.edu; KJTracey@northwell.edu; dtuveson@cshl.edu
OI Tuveson, David/0000-0002-8017-2712
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [5P30CA045508-30, R35GM118182-01]
FX TJ and DT are supported by NIH grant 5P30CA045508-30. KT is supported by
   NIH grant R35GM118182-01.
CR ECHIZEN H, 1991, CLIN PHARMACOKINET, V21, P178, DOI 10.2165/00003088-199121030-00003
   Food and Drug Agency, 1986, FOOD DRUG AGENCY INF
   Freedberg DE, 2020, FAMOTIDINE USE IS AS
   Harris P, 2020, ALL US RES PROGRAM C
   Howden CW, 1996, CLIN THER, V18, P36
   Kwong E, 2017, J CLIN EPIDEMIOL, V81, P22, DOI 10.1016/j.jclinepi.2016.09.002
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rome BN, 2020, NEW ENGL J MED, V382, P2282, DOI 10.1056/NEJMp2009457
   STAIGER C, 1984, BRIT J CLIN PHARMACO, V18, P105, DOI 10.1111/j.1365-2125.1984.tb05031.x
   TAKABATAKE T, 1985, EUR J CLIN PHARMACOL, V28, P327, DOI 10.1007/BF00543332
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
NR 13
TC 8
Z9 8
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD SEP
PY 2020
VL 69
IS 9
BP 1592
EP 1597
DI 10.1136/gutjnl-2020-321852
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NL6ZW
UT WOS:000567562200009
PM 32499303
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Snyder, CM
   Hoyt, K
   Gouglas, D
   Johnston, T
   Robinson, J
AF Snyder, Christopher M.
   Hoyt, Kendall
   Gouglas, Dimitrios
   Johnston, Thomas
   Robinson, James
TI Designing Pull Funding For A COVID-19 Vaccine
SO HEALTH AFFAIRS
LA English
DT Article
ID RESEARCH-AND-DEVELOPMENT; INDUSTRY
AB A widely accessible vaccine is essential to mitigate the health and economic ravages of coronavirus disease 2019 (COVID-19). Without appropriate incentives and coordination, however, firms might not respond at sufficient speed or scale, and competition among countries for limited supply could drive up prices and undercut efficient allocation. Programs relying on "push" incentives (direct cost reimbursement) can be complicated by the funder's inability to observe firms' private cost information. To address these challenges, we propose a "pull" program that incentivizes late-stage development (Phase III trials and manufacturing) for COVID-19 vaccines by awarding advance purchase agreements to bidding firms. Using novel cost and demand data, we calculated the optimal size and number of awards. In baseline simulations, the optimal program induced the participation of virtually all ten viable vaccine candidates, spending an average of $110 billion to generate net benefits of $2.8 trillion-nearly double the net benefits generated by the free market.
C1 [Snyder, Christopher M.] Dartmouth Coll, Dept Econ, Econ, Hanover, NH 03755 USA.
   [Hoyt, Kendall] Dartmouth, Geisel Sch Med, Med, Hanover, NH USA.
   [Gouglas, Dimitrios] Coalit Epidem Preparedness Innovat CEPI, Oslo, Norway.
   [Johnston, Thomas] CEPI, Business Dev, Washington, DC USA.
   [Robinson, James] CEPI, Sci Advisory Comm, Washington, DC USA.
RP Snyder, CM (corresponding author), Dartmouth Coll, Dept Econ, Econ, Hanover, NH 03755 USA.
EM chris.snyder@dartmouth.edu
FU Nuclear Threat Initiative
FX A preliminary version of this article was presented at the Dickey Center
   International Relations and Foreign Policy Seminar, May 22, 2020, and
   the Masters in Healthcare Delivery Sciences Seminar, June 18, 2020, both
   at Dartmouth College, in Hanover, New Hampshire. Christopher Snyder and
   Kendall Hoyt are grateful for funding from the Nuclear Threat Initiative
   for initial research on this topic. Snyder receives textbook royalties
   from Cengage Learning. The authors thank Sophie Smith and Blake Dignes
   for excellent research assistance; Amrita Misha for editorial
   assistance; and Susan Athey, Michael Kremer, Alex Tabarrok, and the
   other members of the Accelerate Health Technologies research group for
   helpful conversations. The authors are grateful to the Health Affairs
   editors (including Don Metz) and anonymous reviewers for extensive,
   insightful comments, which substantially improved the manuscript. An
   unedited version of this article was published online July 23, 2020, as
   a Fast Track Ahead Of Print article. That version is available in the
   online appendix.
CR ANUPINDI R, 1993, MANAGE SCI, V39, P944, DOI 10.1287/mnsc.39.8.944
   Athey S, 2020, NY TIMES
   Athey S, 2020, PROJECT SYNDICATE
   Boler EA, 2015, AM ECON REV, V105, P3704, DOI 10.1257/aer.20121530
   Chalkidou K, 2020, LEAVE NO ONE USING B
   Chaturvedi A, 2011, M&SOM-MANUF SERV OP, V13, P227, DOI 10.1287/msom.1100.0319
   Chau V, 2013, ADV MARKET COMMITMEN
   Chen FR, 2007, MANAGE SCI, V53, P1562, DOI 10.1287/mnsc.1070.0716
   DiMasi JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/j.jhealeco.2016.01.012
   DiMasi JA, 2007, MANAG DECIS ECON, V28, P469, DOI 10.1002/mde.1360
   Ellison G, 2011, AM ECON J-MICROECON, V3, P1, DOI 10.1257/mic.3.1.1
   Gavi, 2020, COVAX ACT ACC VACC P
   Gouglas D, 2018, LANCET GLOB HEALTH, V6, pE1386, DOI 10.1016/S2214-109X(18)30346-2
   International Monetary Fund, 2020, WORLD EC OUTLOOK
   Kremer Al, 2004, STRONG MED CREATING
   Kremer M, 2001, INNOVATION POLICY EC, V1
   Kremer M, 2020, AEA PAP P, V110, P269, DOI 10.1257/pandp.20201017
   Kremer M, 2015, Q J ECON, V130, P1167, DOI 10.1093/qje/qjv012
   Lee CY, 2002, J EVOL ECON, V12, P307, DOI 10.1007/s00191-002-0117-9
   Mahshie A., 2020, WASHINGTON EXAM 0515
   Sertkaya A, 2016, CLIN TRIALS, V13, P117, DOI 10.1177/1740774515625964
   Silverman R, 2020, RACE COVID 19 VACCIN
   Snyder CM, 2011, HEALTH AFFAIR, V30, P1508, DOI 10.1377/hlthaff.2011.0403
   Walker PGT, 2020, GLOBAL IMPACT COVID
   Wong CII, 2020, ESTIMATING PROBABILI, DOI [10.1101/2020.04.09.20059600v1, DOI 10.1101/2020.04.09.20059600V1]
   World Bank, 2020, GDP PER CAP CURR US
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7
NR 28
TC 0
Z9 0
U1 2
U2 2
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD SEP
PY 2020
VL 39
IS 9
BP 1633
EP 1642
DI 10.1377/hlthaff.2020.00646
PG 10
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA NK9YE
UT WOS:000567083100022
PM 32701395
OA Bronze
DA 2021-01-01
ER

PT J
AU Nasrallah, AA
   Farran, SH
   Nasrallah, ZA
   Chahrour, MA
   Salhab, HA
   Fares, MY
   Khachfe, HH
   Akl, EA
AF Nasrallah, Ali A.
   Farran, Sarah H.
   Nasrallah, Zainab A.
   Chahrour, Mohamad A.
   Salhab, Hamza A.
   Fares, Mohamad Y.
   Khachfe, Hussein H.
   Akl, Elie A.
TI A large number of COVID-19 interventional clinical trials were
   registered soon after the pandemic onset: a descriptive analysis
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Article
DE Novel coronavirus disease; COVID-19; Clinical trials; Trial
   registration; Trial characteristics
ID PNEUMONIA
AB Background and Objective: There is a pressing need for evidence-based interventions to address the devastating clinical and public health effects of the coronavirus disease 2019 (COVID-19) pandemic. The number of registered trials related to COVID-19 is increasing by the day. The objective of this study was to describe the characteristics of the currently registered interventional clinical trials related to COVID-19.
   Methods: We searched the World Health Organization's International Clinical Trials Registry Platform on May 15th, 2020. We included any entry that is related to COVID-19. We abstracted and then descriptively analyzed the following characteristics of the registered trials: study design, status, phase, primary endpoints, experimental interventions, and geographic location among other qualifiers.
   Results: We identified 1,308 eligible registered trials. Most trials were registered with ClinicalTrials.gov (n = 703; 53.7%) and the Chinese Clinical Trial Registry (n = 291; 22.2%). The number of participants to be enrolled across these trials was 734,657, with a median of 110 participants per trial. The most commonly studied intervention category was pharmacologic (n = 763; 58.3%), with antiparasitic medications being the most common subcategory. Although over half of the trials were already recruiting, we identified published peer-reviewed results for only 8 of those trials.
   Conclusion: There is a relatively large number of registered trials but with very few results published so far. Although our findings suggest an appropriate initial response by the research community, the real challenge will be to get these trials completed, published, and translated into practice and policy. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Nasrallah, Ali A.; Farran, Sarah H.; Nasrallah, Zainab A.; Chahrour, Mohamad A.; Salhab, Hamza A.; Fares, Mohamad Y.; Khachfe, Hussein H.] Amer Univ Beirut, Fac Med, Beirut, Lebanon.
   [Salhab, Hamza A.; Fares, Mohamad Y.; Khachfe, Hussein H.] Lebanese Univ, Neurosci Res Ctr, Beirut, Lebanon.
   [Fares, Mohamad Y.] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland.
   [Akl, Elie A.] Amer Univ Beirut, Dept Internal Med, Beirut, Lebanon.
   [Akl, Elie A.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
RP Akl, EA (corresponding author), Amer Univ Beirut, Med Ctr, Dept Internal Med, POB 11-0236, Beirut 11072020, Lebanon.
EM ea32@aub.edu.lb
RI Salhab, Hamza/AAX-1622-2020; Khachfe, Hussein H./AAC-3520-2020; Akl,
   Elie/K-5269-2019
OI Salhab, Hamza/0000-0003-3575-7938; Khachfe, Hussein
   H./0000-0001-7537-9033; 
CR Administration U. S. FDA, 2020, COR COVID 19 UPD DAI
   Akl EA, 2017, J CLIN EPIDEMIOL, V91, P47, DOI 10.1016/j.jclinepi.2017.08.009
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 2020, MEDRXIV
   Beigel J. H., 2020, N ENGL J MED
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Cao Tang W, 2020, HYDROXYCHLOROQUINE P
   Chahrour M, 2020, CUREUS, V12, DOI 10.7759/cureus.7357
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen ZW, 2020, EFFICACY HYDROXYCHLO
   Ciani O, 2017, VALUE HEALTH, V20, P487, DOI 10.1016/j.jval.2016.10.011
   Clement C, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2983-y
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Eisen MB, 2020, ELIFE, V9, P1
   Elliott JH, 2017, J CLIN EPIDEMIOL, V91, P23, DOI 10.1016/j.jclinepi.2017.08.010
   Esposito S, 2016, EXPERT REV RESP MED, V10, P79, DOI 10.1586/17476348.2016.1126182
   Evans Scott R, 2010, J Exp Stroke Transl Med, V3, P8
   Frie K, 2020, BJGP OPEN, V1, P1
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, INT J ANTIMICROB AGE
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Gorbalenya A. E., 2020, SEVERE ACUTE RESP SY
   Grasselli G, 2020, JAMA
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Huang M, 2020, PRELIMINARY EVIDENCE
   Infection M, 2020, COR COUNTR HYDR REC
   Kabisch M, 2011, DTSCH ARZTEBL INT, V108, P663, DOI 10.3238/arztebl.2011.0663
   Lab G.C.D., OUR WORLD DAT
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Mahevas M, 2020, NO EVIDENCE CLIN EFF
   McLeod C, 2019, CONT CLIN TRIAL COMM, V16, DOI 10.1016/j.conctc.2019.100486
   Millán-Oñate José, 2020, Infect., V24, P187, DOI 10.22354/in.v24i3.848
   Oyston P, 2012, J MED MICROBIOL, V61, P889, DOI 10.1099/jmm.0.039180-0
   Pasquali SK, 2012, PEDIATRICS, V130, pE1269, DOI 10.1542/peds.2011-3565
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   RISMANBAF A, 2020, ARCH ACAD EMERG MED, V8
   Spina S, 2020, LANCET, V395, pE49, DOI 10.1016/S0140-6736(20)30493-1
   WHO, 2020, WHO INT CLIN TRIALS
   World Health Organization, 2020, COR DIS COVID 2019 S
   World Health Organization, 2020, NAM COR DIS COVID 19
   Wu J, 2020, EMORY HELPS LEAD RES
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 48
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0895-4356
EI 1878-5921
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD SEP
PY 2020
VL 125
BP 170
EP 178
DI 10.1016/j.jclinepi.2020.06.005
PG 9
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA NK7XP
UT WOS:000566946100024
PM 32526460
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Turnham, HL
   Dunn, M
   Hill, E
   Thornburn, GT
   Wilkinson, D
AF Turnham, Helen Lynne
   Dunn, Michael
   Hill, Elaine
   Thornburn, Guy T.
   Wilkinson, Dominic
TI Consent in the time of COVID-19
SO JOURNAL OF MEDICAL ETHICS
LA English
DT Article
DE informed consent; allocation of health care resources; autonomy;
   decision-making; Distributive justice
AB The COVID-19 pandemic crisis has necessitated widespread adaptation of revised treatment regimens for both urgent and routine medical problems in patients with and without COVID-19. Some of these alternative treatments maybe second-best. Treatments that are known to be superior might not be appropriate to deliver during a pandemic when consideration must be given to distributive justice and protection of patients and their medical teams as well the importance given to individual benefit and autonomy. What is required of the doctor discussing these alternative, potentially inferior treatments and seeking consent to proceed? Should doctors share information about unavailable but standard treatment alternatives when seeking consent? There are arguments in defence of non-disclosure; information about unavailable treatments may not aid a patient to weigh up options that are available to them. There might be justified concern about distress for patients who are informed that they are receiving second-best therapies. However, we argue that doctors should tailor information according to the needs of the individual patient. For most patients that will include a nuanced discussion about treatments that would be considered in other times but currently unavailable. That will sometimes be a difficult conversation, and require clinicians to be frank about limited resources and necessary rationing. However, transparency and honesty will usually be the best policy.
C1 [Turnham, Helen Lynne] Oxford Univ Hosp NHS Fdn Trust, Paediat Crit Care, Oxford, England.
   [Dunn, Michael] Univ Oxford, Ethox Ctr, Oxford, England.
   [Hill, Elaine] Oxford Univ Hosp NHS Fdn Trust, Cardiothorac Crit Care & Anaesthesia, Oxford, England.
   [Thornburn, Guy T.] Oxford Univ Hosp NHS Fdn Trust, Consultant Cleft & Plast Surg Spires Cleft Ctr, Oxford, England.
   [Wilkinson, Dominic] Univ Oxford, Oxford Uehiro Ctr Pract Eth, Oxford, England.
RP Turnham, HL (corresponding author), Oxford Univ Hosp NHS Fdn Trust, Oxford OX3 9DU, England.
EM helen.turnham@ouh.nhs.uk
OI Dunn, Michael/0000-0002-5603-6200; Wilkinson,
   Dominic/0000-0003-3958-8633; Turnham, Helen/0000-0003-1011-2885
FU Wellcome trustWellcome Trust [WT106587/Z/14/Z.]
FX DW was supported for this work by a grant from the Wellcome trust
   WT106587/Z/14/Z.
CR [Anonymous], 2020, INTERIM TREATMENT CH
   General Medical Council, DEC MAK CONS
   Hill Dickinson, 2018, INF CONS EXT REAS AL
   Royal College of Surgeons of England, UPD INT GEN SURG GUI
   The Institute for Fiscal Studies, 2020, WID IMP COR PAND NHS
NR 5
TC 2
Z9 2
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-6800
EI 1473-4257
J9 J MED ETHICS
JI J. Med. Ethics
PD SEP
PY 2020
VL 46
IS 9
BP 565
EP 568
DI 10.1136/medethics-2020-106402
PG 4
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA NK8NJ
UT WOS:000566987200002
PM 32522812
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Holm, S
AF Holm, Soren
TI Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines
   and treatments: bioethics in Utopia
SO JOURNAL OF MEDICAL ETHICS
LA English
DT Article
DE research ethics; research on special populations
AB A number of papers have appeared recently arguing for the conclusion that it is ethically acceptable to infect healthy volunteers with severe acute respiratory syndrome coronavirus 2 as part of research projects aimed at developing COVID-19 vaccines or treatments. This position has also been endorsed in a statement by a working group for the WHO. The papers generally argue that controlled human infection (CHI) is ethically acceptable if (1) the risks to participants are low and therefore acceptable, (2) the scientific quality of the research is high, (3) the research has high social value, (4) participants give full informed consent, and (5) there is fair selection of participants. All five conditions are necessary premises in the overall argument that such research is ethically acceptable. The arguments concerning risk and informed consent have already been critically discussed in the literature. This paper therefore looks specifically at the arguments relating to condition 3 'high social value' and condition 5 'fair selection of participants' and shows that whereas they may be valid, they are not sound. It is highly unlikely that the conditions that are necessary for ethical CHI trials to take place will be fulfilled. Most, if not all, CHI trials will thus be well intentioned but unethical.
C1 [Holm, Soren] Univ Manchester, Sch Social Sci, Dept Law, CSEP, Manchester M13 9PL, Lancs, England.
   [Holm, Soren] Univ Oslo, Ctr Med Eth, HELSAM, Oslo, Norway.
RP Holm, S (corresponding author), Univ Manchester, Sch Social Sci, Dept Law, CSEP, Manchester M13 9PL, Lancs, England.
EM soren.holm@manchester.ac.uk
OI Holm, Soren/0000-0002-7200-5607; Holmen, Sebastian/0000-0003-2774-941X;
   Ploug, Thomas/0000-0002-3693-0547
CR [Anonymous], FRANCE 24
   Bambery B, 2016, PUBLIC HEALTH ETH-UK, V9, P92, DOI 10.1093/phe/phv026
   Chappell RY, 2020, PANDEMIC ETHICS CASE
   Council for International Organizations of Medical Sciences, 2016, ETH GUID HLTH REL RE
   Dawson L, 2020, J INFECT DIS, DOI [10.1093/infdis/jiaa314., DOI 10.1093/INFDIS/JIAA314]
   Day Sooner, COVID 19 HUM CHALL T
   Devlin H, 2020, GUARDIAN
   Edelblute HB, 2015, J EMPIR RES HUM RES, V10, P65, DOI 10.1177/1556264614568280
   Elliott C, 2020, ETHICAL PATH COVID V
   Emanuel EJ, 2005, AM J BIOETHICS, V5, P9, DOI 10.1080/15265160500244959
   Eyal N, 2020, J INFECT DIS, V222, P169, DOI 10.1093/infdis/jiaa217
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Fisher JA, 2020, ADVERSE EVENTS RACE
   Grady C, 2017, CLIN TRIALS, V14, P526, DOI 10.1177/1740774517722130
   Jamrozik E, 2020, LANCET INFECT DIS, V20, pE198, DOI 10.1016/S1473-3099(20)30438-2
   MacKay D, 2020, AM J BIOETHICS, V20, P5, DOI 10.1080/15265161.2019.1701731
   Miller FG, 2007, HASTINGS CENT REP, V37, P24, DOI 10.1353/hcr.2007.0044
   Monahan T, 2015, ECON SOC, V44, P545, DOI 10.1080/03085147.2015.1113703
   Office for National Statistics, COR COVID 19 REL DEA
   Ozawa S, 2019, HEALTH POLICY PLANN, V34, P1, DOI 10.1093/heapol/czz119
   Philip C, 2020, TIMES
   Plotkin SA, 2020, VACCINE, V38, P3987, DOI 10.1016/j.vaccine.2020.04.039
   Radcliffe-Richards J, 1998, LANCET, V351, P1950, DOI 10.1016/S0140-6736(97)08211-1
   Savulescu J, 2020, J MED ETHICS BLOG
   Shah SK, 2020, SCIENCE, V368, P832, DOI 10.1126/science.abc1076
   Weijer C, 1996, CAMB Q HEALTHC ETHIC, V5, P334, DOI 10.1017/S0963180100007155
   WHO, 2020, KEY CRIT ETH ACC COV
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   World Medical Association, 2013, WMA DECL HELS ETH PR
   Zvonareva O, 2019, CLIN TRIALS, V16, P563, DOI 10.1177/1740774519877851
NR 30
TC 0
Z9 0
U1 5
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-6800
EI 1473-4257
J9 J MED ETHICS
JI J. Med. Ethics
PD SEP
PY 2020
VL 46
IS 9
BP 569
EP 573
DI 10.1136/medethics-2020-106476
PG 5
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA NK8NJ
UT WOS:000566987200003
PM 32616623
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Aquino, YSJ
   Cabrera, N
AF Aquino, Yves S. J.
   Cabrera, Nicolo
TI Hydroxychloroquine and COVID-19: critiquing the impact of disease public
   profile on policy and clinical decision-making
SO JOURNAL OF MEDICAL ETHICS
LA English
DT Article
DE history of health ethics; bioethics; distributive justice; informed
   consent; public health ethics; clinical ethics
ID INFORMED-CONSENT; OFF-LABEL; TRIALS
AB The controversy surrounding the use of hydroxychloroquine (HCQ), an antimalarial drug, for COVID-19 has raised numerous ethical and policy problems. Since the suggestion that HCQ has potential for COVID-19, there have been varying responses from clinicians and healthcare institutions, ranging from adoption of protocols using HCQ for routine care to the conduct of randomised controlled trials to an effective system-wide prohibition on its use for COVID-19. In this article, we argue that the concept of 'disease public profile' has become a prominent, if not the sole, determinant in decision-making across various healthcare responses to the pandemic. In the case of COVID-19, the disease's public profile is based on clinical and non-clinical factors that include contagiousness, clinical presentation and media coverage. In particular, we briefly examine the dangers of a heightened public profile in magnifying the inequality of diseases and undermining three key ethical concepts, namely (1) evidence-based practice, (2) sustainable allocation and (3) meaningful consent.
C1 [Aquino, Yves S. J.] Macquarie Univ, Dept Philosophy, Sydney, NSW, Australia.
   [Cabrera, Nicolo] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Div Infect Dis, Houston, TX 77030 USA.
RP Aquino, YSJ (corresponding author), Macquarie Univ, Philosophy, Sydney, NSW 2109, Australia.
EM ysjames@gmail.com
OI Aquino, Yves Saint James/0000-0003-0981-0029
FU  [COVID-19]
FX The authors would like to thank the Journal of Medical Ethics Blog for
   posting an early and more concise version of this paper entitled
   'Ethical rationing: Hydroxychloroquine, COVID-19 and the inequality of
   diseases'.
CR American Medical Association, ETH SOUND INN MED PR
   American Thoracic Society, 2020, ATS PUBL NEW GUID CO
   Angus DC, 2020, JAMA-J AM MED ASSOC, V323, P1895, DOI 10.1001/jama.2020.4984
   Australian Medical Association, 2014, LOTS CONS GOING OFF
   AV H, 2020, ANN INTERN MED
   Beauchamp TL, 2010, ETHICS CONSENT THEOR, V56
   Bekiempis V., 2020, GUARDIAN
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Bhimraj A, 2020, INFECTION
   Bromwich D, 2017, J MED ETHICS, V43, P108, DOI 10.1136/medethics-2015-103122
   Brown RF, 2004, SOC SCI MED, V58, P2445, DOI 10.1016/j.socscimed.2003.09.007
   Caplan AL, 2006, J SUBST ABUSE TREAT, V31, P117, DOI 10.1016/j.jsat.2006.06.009
   Carter M, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5399
   Centers for Disease Control and Prevention, 2020, INFL FLU PREL SEAS 2
   Chen T, 2020, BUZZFEED NEWS
   CLARK P, 1993, ANN INTERN MED, V119, P1067, DOI 10.7326/0003-4819-119-11-199312010-00002
   Costedoat-Chalumeau N, 2013, ANN RHEUM DIS, V72, P1786, DOI 10.1136/annrheumdis-2012-202322
   Cui Y, 2020, J INFECT DIS
   Czarnecki M, 2020, POL ARCH MED WEWN
   Daniels N, 2006, HASTINGS CENT REP, V36, P22, DOI 10.1353/hcr.2006.0058
   Field RI, 2008, KENNEDY INST ETHIC J, V18, P111
   Fisher JA, 2013, KENNEDY INST ETHIC J, V23, P355, DOI 10.1353/ken.2013.0018
   FOX RI, 1993, SEMIN ARTHRITIS RHEU, V23, P82, DOI 10.1016/S0049-0172(10)80012-5
   Gabler E, 2020, SOME DOCTORS STOCKPI
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gazarian M, 2006, MED J AUSTRALIA, V185, P544, DOI 10.5694/j.1326-5377.2006.tb00689.x
   Goh KJ, 2020, ANN ACAD MED SINGAP, V49, P108
   Griffin R., 2020, BLOOMBERG
   Hewlett S, 1996, J MED ETHICS, V22, P232, DOI 10.1136/jme.22.4.232
   Jun C, 2020, J ZHEJIANG U, V49
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   King Samantha, 2006, PINK RIBBONS INC BRE
   Largent EA, 2009, ARCH INTERN MED, V169, P1745, DOI 10.1001/archinternmed.2009.314
   Lenzer J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1335
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Mackenzie C ., 2014, ROUTLEDGE COMPANION, P301
   Mian A, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01556-3
   Nugent AC, 2017, BIOETHICS, V31, P443, DOI 10.1111/bioe.12349
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Piller C, SCIENCE, DOI [10.1126/science.abd1697, DOI 10.1126/SCIENCE.ABD1697]
   Roberts L, 2020, POLIO MEASLES OTHER
   Rowland C, 2020, RUN ANTIMALARIA DRUG
   Sciama Y, 2020, SCIENCE, DOI [10.1126/science.abc1786, DOI 10.1126/SCIENCE.ABC1786]
   Singer P, 1998, HOSP Q, V1
   Solnica A, 2020, J MED ETHICS, V46, P441, DOI [10.1136/medethics-2020-106294, 10.1136/medethics-2020-106242]
   Song PP, 2014, INTRACTABLE RARE DIS, V3, P94, DOI 10.5582/irdr.2014.01015
   Steinberg I, 2020, CORONAVIRUS RES DONE
   Thomas KK, 2020, HLTH DISPARITIES ARE
   Tsakonas E, 1998, LUPUS, V7, P80
   Vigdor N, 2020, NY TIMES
   Wang Y, 2020, J MED VIROL
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yazdany J, 2020, ANN INTERN MED, V172, P754, DOI 10.7326/M20-1334
NR 53
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-6800
EI 1473-4257
J9 J MED ETHICS
JI J. Med. Ethics
PD SEP
PY 2020
VL 46
IS 9
BP 574
EP 578
DI 10.1136/medethics-2020-106306
PG 5
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA NK8NJ
UT WOS:000566987200004
PM 32647045
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tortonese, S
   Scriabine, I
   Anjou, L
   Loens, C
   Michon, A
   Benabdelhak, M
   Ouali, S
   Morin, G
   Laifi, M
   Dobosziewicz, H
   Guillet, M
   Dekeyser, M
   Nguyen, LBL
   Grunenwald, A
   Dang, J
   Desbuissons, G
   Becquemont, L
   Snanoudj, R
   Legendre, C
   Hebibi, H
   Lefevre, E
   Beaudreuil, S
   Zaidan, M
AF Tortonese, Sarah
   Scriabine, Ivan
   Anjou, Louis
   Loens, Christopher
   Michon, Arthur
   Benabdelhak, Mohammed
   Ouali, Sarah
   Morin, Gabriel
   Laifi, Marwa
   Dobosziewicz, Helene
   Guillet, Matthieu
   Dekeyser, Manon
   Nguyen, Liem Binh Luong
   Grunenwald, Anne
   Dang, Julien
   Desbuissons, Geoffroy
   Becquemont, Laurent
   Snanoudj, Renaud
   Legendre, Christophe
   Hebibi, Hadia
   Lefevre, Edouard
   Beaudreuil, Severine
   Zaidan, Mohamad
CA AP-HP Univ Inserm Covid-19 Res
TI COVID-19 in Patients on Maintenance Dialysis in the Paris Region
SO KIDNEY INTERNATIONAL REPORTS
LA English
DT Article
DE coronavirus; COVID-19; hemodialysis; kidney; peritoneal dialysis
ID CLINICAL CHARACTERISTICS; HEMODIALYSIS-PATIENTS
AB Introduction: Coronavirus disease 2019 (COVID-19) represents a serious threat to patients on maintenance dial-ysis. The clinical setting, mortality rate, and prognostic factors in these patients have not been well established.
   Methods: We included all dialyzed patients with COVID-19 referred to our dialysis center between March 11 and April 11, 2020. Data were obtained through the review of the medical records and were censored at the time of data cutoff, on May 11, 2020.
   Results: Forty-four patients on maintenance dialysis with COVID-19 were referred to our dialysis unit during the COVID-19 epidemic. Median age was 61 years (interquartile range [IQR]: 51.5-72.5); 65.9% were men. Comorbidities included hypertension (97.7%), diabetes mellitus (50%), and chronic cardiac (38.6%) and respiratory (27.3%) diseases. Initial symptoms were fever (79.5%), shortness of breath (29.5%), cough (43.2%), and diarrhea (13.6%). Three profiles of severity were distinguished based on the World Health Organization (WHO) progression scale. Forty-one (93.2%) were hospitalized and only 3 were maintained on outpatient hemodialysis. Thirty-three (75%) patients required oxygen therapy, including 15 (45.5%) who were referred to the intensive care unit. Overall, 27.3% of patients died, and 58.5% were discharged from hospital, including only 2 (13.3%) of those admitted to the intensive care unit. By multivariate analysis, cough, thrombopenia <120 g/l, lactate dehydrogenase (LDH) level greater than 2 times the upper limit of normal, and blood C-reactive protein (CRP) >175 mg/l were significantly associated with death.
   Conclusion: A major outbreak of COVID-19 occurred in the Paris region, and spread among dialyzed pa-tients. Our study underscores the severity of COVID-19 in these patients and identified prognostic markers. (C) 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Tortonese, Sarah; Scriabine, Ivan; Anjou, Louis; Loens, Christopher; Michon, Arthur; Benabdelhak, Mohammed; Ouali, Sarah; Morin, Gabriel; Laifi, Marwa; Dobosziewicz, Helene; Guillet, Matthieu; Dekeyser, Manon; Grunenwald, Anne; Dang, Julien; Desbuissons, Geoffroy; Snanoudj, Renaud; Legendre, Christophe; Lefevre, Edouard; Beaudreuil, Severine; Zaidan, Mohamad] Hop Bicetre, AP HP, Serv Nephrol Dialyse & Transplantat, Le Kremlin Bicetre, France.
   [Dobosziewicz, Helene; Guillet, Matthieu; Dekeyser, Manon; Becquemont, Laurent; Snanoudj, Renaud; Zaidan, Mohamad] Univ Paris Sud, Univ Paris Saclay, UVSQ, Villejuif, France.
   [Nguyen, Liem Binh Luong] Inst Pasteur, Unite Epidemiol Malad Emergentes, Paris, France.
   [Nguyen, Liem Binh Luong] Univ Paris, Hop Cochin, Ctr Invest Clin CIC Cochin Pasteur, Paris, France.
   [Becquemont, Laurent] INSERM, Ctr Rech Epidemiol & Sante Populat CESP, Villejuif, France.
   [Hebibi, Hadia] Nephrocare, Serv Nephrol Dialyse, Villejuif, France.
   [Hebibi, Hadia] Hop Thiais, Serv Nephrol Dialyse, Thiais, France.
   [Zaidan, Mohamad] Hop Necker Enfants Malad, Inst Malad Genet, INSERM, U1163, Paris, France.
RP Zaidan, M (corresponding author), Univ Paris Saclay, Hop Univ Bicetre, AP HP, Serv Nephrol Dialyse & Transplantat, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, France.
EM mohamad.zaidan@aphp.fr
OI Dang, Julien/0000-0002-5690-7424
CR Alberici F, 2020, KIDNEY INT, V98, P20, DOI 10.1016/j.kint.2020.04.030
   [Anonymous], COVID 19 NEWS INF
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Fisher M, KIDNEY, V360, DOI [10.34067/KID.000367202, DOI 10.34067/KID.000367202]
   Goicoechea M, 2020, KIDNEY INT, V98, P27, DOI 10.1016/j.kint.2020.04.031
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kliger AS, 2020, CLIN J AM SOC NEPHRO, V15, P707, DOI 10.2215/CJN.03340320
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Ma Y, 2019, 2019 NOVEL CORONAVIR, DOI [10.1101/2020.02.24.20027201, DOI 10.1101/2020.02.24.20027201]
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Scarpioni R, 2020, G ITAL NEFROL, V37, P2020
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang R, 2020, AM J KIDNEY DIS, V76, P141, DOI 10.1053/j.ajkd.2020.03.009
   Wilson N, 2020, EMERG INFECT DIS, V26, P1339, DOI 10.3201/eid2606.200320
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
NR 21
TC 4
Z9 5
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2468-0249
J9 KIDNEY INT REP
JI Kidney Int. Rep.
PD SEP
PY 2020
VL 5
IS 9
BP 1535
EP 1544
DI 10.1016/j.ekir.2020.07.016
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA NN2ZY
UT WOS:000568662700021
PM 32838082
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Song, Y
   Fields, E
AF Song, Yang
   Fields, Elise
TI Pharmacological Advances of Chloroquine and Hydroxychloroquine: From
   Antimalarials to Investigative Therapies in COVID-19
SO NATURAL PRODUCT COMMUNICATIONS
LA English
DT Article
DE chloroquine; hydroxychloroquine; covid-19; broad-spectrum antiviral;
   antitumor; clinical pharmacology
ID IN-VITRO; COMBINATION; GEMCITABINE; RESISTANCE; MALARIA; TRIAL; LINE
AB During the coronavirus disease 2019 (COVID-19) pandemic, numerous existing chemicals have been screened for antiviral potential against the emerging coronavirus severe acute respiratory syndrome coronavirus 2. Chloroquine and hydroxychloroquine, after exhibiting potent in vitro efficacy, have gained tremendous attention. Both therapeutics are derivatives of natural alkaloid quinine and were first synthesized to treat malaria. Thereafter, the pharmaceutical applications of the agents have expanded to many new areas. In this article, the medicinal history and pharmacological activities of chloroquine and hydroxychloroquine are summarized. Antimalarial, anti-inflammatory, antitumor, antiviral properties, and therapeutic potential in the emerging viral infection COVID-19 are discussed. Pharmacokinetics, adverse effects, and toxicities are reviewed.
C1 [Song, Yang; Fields, Elise] St Joseph Med Ctr, CHI Franciscan Hlth, Dept Pharm Serv, Tacoma, WA 98405 USA.
RP Song, Y (corresponding author), St Joseph Med Ctr, CHI Franciscan Hlth, Dept Pharm Serv, Tacoma, WA 98405 USA.
EM songx298@gmail.com
CR Achan J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-144
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   ALVING AS, 1948, J CLIN INVEST, V27, P60, DOI 10.1172/JCI101974
   [Anonymous], 2001, AR CHLOR PRESCR INF
   [Anonymous], 2012, PLAQ HYDR PRESCR INF
   [Anonymous], CDC MAL TRAV MAL INF
   BEDOYA V, 1970, CANCER RES, V30, P1262
   Boone BA, 2015, ANN SURG ONCOL, V22, P4402, DOI 10.1245/s10434-015-4566-4
   Briceno Eduardo, 2003, Neurosurg Focus, V14, pe3
   Browning DJ, 2014, HYDROXYCHLOROQUINE C, P35, DOI DOI 10.1007/978-1-4939-0597-3_2
   BRUCECHWATT LJ, 1988, BRIT MED J, V296, P1486, DOI 10.1136/bmj.296.6635.1486
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Choi JH, 2012, APMIS, V120, P597, DOI 10.1111/j.1600-0463.2012.02876.x
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   COVID-19 Treatment Guidelines Panel, 2020, COVID 19 TREATM GUID
   D'Alessandro S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8010085
   da Silva JC, 2013, CLINICS, V68, P766, DOI 10.6061/clinics/2013(06)07
   de Olano J, 2019, AM J EMERG MED, V37, DOI 10.1016/j.ajem.2019.158387
   Eyal S, 2018, TOXINS, V10, DOI 10.3390/toxins10120491
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Fu ZP, 2018, MOL ONCOL, V12, P529, DOI 10.1002/1878-0261.12179
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Golden EB, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.12.FOCUS14748
   INGLOT AD, 1969, J GEN VIROL, V4, P203, DOI 10.1099/0022-1317-4-2-203
   Jordan P, 1999, J TOXICOL-CLIN TOXIC, V37, P861, DOI 10.1081/CLT-100102466
   Kanvinde S, 2018, ACTA BIOMATER, V82, P158, DOI 10.1016/j.actbio.2018.10.027
   Kim KA, 2003, ARCH PHARM RES, V26, P631, DOI 10.1007/BF02976712
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu LQ, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109339
   Magagnoli J, 2020, MED, DOI [10.1016/j.medj.2020.06.001, DOI 10.1016/J.MEDJ.2020.06.001]
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Meyer CG, 2004, TROP MED INT HEALTH, V9, P1239, DOI 10.1111/j.1365-3156.2004.01357.x
   Molejon Maria Ines, 2018, Oncotarget, V9, P30837, DOI 10.18632/oncotarget.25745
   Muller-Calleja N, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-210012
   O'Hara MH, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3545
   Plantone D, 2018, CLIN DRUG INVEST, V38, P653, DOI 10.1007/s40261-018-0656-y
   Plewes K, 2019, INFECT DIS CLIN N AM, V33, P39, DOI 10.1016/j.idc.2018.10.002
   Rebecca VW, 2019, CANCER DISCOV, V9, P220, DOI 10.1158/2159-8290.CD-18-0706
   RIOU B, 1988, NEW ENGL J MED, V318, P1, DOI 10.1056/NEJM198801073180101
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Samaras P, 2017, CANCER CHEMOTH PHARM, V80, P1005, DOI 10.1007/s00280-017-3446-y
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   SEELER AO, 1946, J INFECT DIS, V79, P156, DOI 10.1093/infdis/79.2.156
   SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J
   Song Y, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106080
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Sun K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.35
   TETT SE, 1993, CLIN PHARMACOKINET, V25, P392, DOI 10.2165/00003088-199325050-00005
   Tonnesmann E, 2013, IMMUNOPHARM IMMUNOT, V35, P434, DOI 10.3109/08923973.2013.780078
   Valderramos SG, 2006, TRENDS PHARMACOL SCI, V27, P594, DOI 10.1016/j.tips.2006.09.005
   Varisli L, 2020, IMMUNOLOGY, V159, P257, DOI 10.1111/imm.13160
   Verbaanderd C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.781
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warhurst DC, 2003, J ANTIMICROB CHEMOTH, V52, P188, DOI 10.1093/jac/dkg319
   White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107
   Xu CH, 2016, J PHARM SCI-US, V105, P884, DOI 10.1002/jps.24663
   Xu RH, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013553
   Yang DH, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060796
   Yao X, 2020, CLIN INFECT DIS
   Yusuf IH, 2017, EYE, V31, P828, DOI 10.1038/eye.2016.298
   Zheng YZ, 2009, CANCER INVEST, V27, P286, DOI 10.1080/07357900802427927
NR 65
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1934-578X
EI 1555-9475
J9 NAT PROD COMMUN
JI Nat. Prod. Commun.
PD SEP
PY 2020
VL 15
IS 9
DI 10.1177/1934578X20953648
PG 7
WC Chemistry, Medicinal; Food Science & Technology
SC Pharmacology & Pharmacy; Food Science & Technology
GA NM1UE
UT WOS:000567888500001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Yang, AP
   Liu, H
   Liu, F
   Fan, LX
   Liao, WQ
   Guo, JL
   He, K
AF Yang, Anping
   Liu, Hui
   Liu, Fang
   Fan, Lixia
   Liao, Wanqin
   Guo, Jialiang
   He, Kan
TI Study of the Mechanism of the Reyanning Mixture Involved in Treating
   Novel Coronavirus Pneumonia Based on Network Pharmacology
SO NATURAL PRODUCT COMMUNICATIONS
LA English
DT Article
DE SARS-CoV-2; reyanning mixture; network pharmacology; pathway; TCM
ID DRUG; P53; ACTIVATION
AB At present, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread all over the world, and the best way to effectively carry out drug diagnosis and treatment presents difficulties for all medical staff. In China, some traditional Chinese medicines (TCMs) have been successfully applied to the treatment of SARS-CoV-2 and have achieved good clinical results, including the Reyanning mixture. In this study, we systematically analyzed the mechanism of the Reyanning mixture and its effects against SARS-CoV-2 based on the method of network pharmacology. Here, we used the TCM Systems Pharmacology database and employed a similarity algorithm to screen and identify the bioactive ingredients and potential targets of the Reyanning mixture. The GeneCards database was used to predict and screen the disease targets and build the active ingredient target network diagram. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to construct the target signal pathway associations. The STRING tool was used to reconstruct the protein-protein interaction network. As a result, 27 candidate targets, such as tumor necrosis factor, interferon gamma, tumor protein P53, C-reactive protein, and peroxisome proliferator-activated receptor gamma, were identified among the 33 bioactive ingredients of the 4 TCMs in the Reyanning mixture with effects on treating SARS-CoV-2. These targets were significantly enriched in 20 KEGG pathways and associated with 48 diverse GO terms. All of these targets may play a role in inhibiting inflammatory reactions, regulating immune function, and reducing lung injury to achieve the purpose of treating SARS-CoV-2.
C1 [Yang, Anping; Liu, Hui; Liu, Fang; Fan, Lixia; Liao, Wanqin; Guo, Jialiang] Sch Stomatol & Med Univ, Dept Basic Med & Biomed Engn, Foshan, Guangdong, Peoples R China.
   [He, Kan] Anhui Univ, Ctr Stem Cell & Translat Med, Sch Life Sci, Dept Biostat, 111 Jiulong Rd, Hefei 230601, Peoples R China.
RP He, K (corresponding author), Anhui Univ, Ctr Stem Cell & Translat Med, Sch Life Sci, Dept Biostat, 111 Jiulong Rd, Hefei 230601, Peoples R China.; Yang, AP (corresponding author), Foshan Univ, Sch Stomatol & Med, Dept Basic Med & Biomed Engn, 18 Jiangwan First Rd, Foshan, Guangdong, Peoples R China.
EM 914559936@qq.com; hekan_803@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81872832]; Natural Science Foundation
   Project of Anhui Province [1 908 085MC87]; Scientific Research
   Foundation; Academic & Technology Leaders Introduction Project; 211
   Project of Anhui UniversityAnhui University [10117700023]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article. We
   acknowledge financial supports by the National Natural Science
   Foundation of China (#81872832), Natural Science Foundation Project of
   Anhui Province (#1 908 085MC87) and the Scientific Research Foundation
   and Academic & Technology Leaders Introduction Project, and 211 Project
   of Anhui University (#10117700023).
CR Abu N, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2102-3
   Bao Lei, 2020, Zhongguo Zhong Yao Za Zhi, V45, P1465, DOI 10.19540/j.cnki.cjcmm.20200303.401
   Bufalo MC, 2015, J PHARM PHARMACOL, V67, P740, DOI 10.1111/jphp.12364
   Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Goetze S, 1999, HYPERTENSION, V33, P183, DOI 10.1161/01.HYP.33.1.183
   Guo L, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2019.11.005
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007-1110
   Huang CH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18092018
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   KABELITZ D, 1989, IMMUNOL LETT, V20, P241, DOI 10.1016/0165-2478(89)90087-4
   Lee HE, 2017, TOX RESEARCH, V33, P283, DOI 10.5487/TR.2017.33.4.283
   Lentsch AB, 1999, J IMMUNOL, V162, P1071
   Ling CQ, 2020, J INTEGR MED-JIM, V18, P87, DOI 10.1016/j.joim.2020.02.004
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Liu ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep21146
   Malaguarnera L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11050946
   Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9
   Perlman L, 2011, J COMPUT BIOL, V18, P133, DOI 10.1089/cmb.2010.0213
   Plohmann B, 1997, PHARMAZIE, V52, P953
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Ruddigkeit L, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-27
   Schreiber S, 1999, LANCET, V353, P459, DOI 10.1016/S0140-6736(98)03339-X
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sharma R, 2016, J IMMUNOTOXICOL, V13, P20, DOI 10.3109/1547691X.2014.995243
   Snider SA, 2018, J BIOL CHEM, V293, P11600, DOI 10.1074/jbc.RA118.003180
   Society of Pediatrics Chinese Medical Association, 2020, Zhonghua Er Ke Za Zhi, V58, P169, DOI [10.3760/cma.j.issn.0578-1310.2020.0004, 10.3760/cma.j.issn.0578-1310.2020.03.001]
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang PF, 2019, ACS INFECT DIS, V5, P974, DOI 10.1021/acsinfecdis.9b00039
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhao W Z, 1986, Zhong Yao Tong Bao, V11, P54
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 38
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1934-578X
EI 1555-9475
J9 NAT PROD COMMUN
JI Nat. Prod. Commun.
PD SEP
PY 2020
VL 15
IS 9
DI 10.1177/1934578X20954593
PG 12
WC Chemistry, Medicinal; Food Science & Technology
SC Pharmacology & Pharmacy; Food Science & Technology
GA NM1VC
UT WOS:000567890900001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Vaugeois, JM
AF Vaugeois, Jean-Marie
TI Psychotropics drugs with cationic amphiphilic properties may afford some
   protection against SARS- CoV-2: A mechanistic hypothesis
SO PSYCHIATRY RESEARCH
LA English
DT Letter
C1 [Vaugeois, Jean-Marie] Univ Caen, ABTE, Normandie Univ, Univ Rouen, F-76000 Rouen, France.
   [Vaugeois, Jean-Marie] UFR Sante, Dept Pharm, 22 Blvd Gambetta, F-76183 Rouen 1, France.
RP Vaugeois, JM (corresponding author), Dept Pharm, Lab ABTE, Equipe Toxemac EA 4651, UFR Sante, 22 Blvd Gambetta, F-76183 Rouen 1, France.
EM jean-marie.vaugeois@univ-rouen.fr
OI Vaugeois, Jean-Marie/0000-0001-8296-672X
CR Aimo A, 2020, EUR J PREV CARDIOL, DOI 10.1177/2047487320919233
   Lin HP, 2018, BRIT J PHARMACOL, V175, P3640, DOI 10.1111/bph.14429
   Plaze M, 2020, ENCEPHALE, V46, pS35, DOI 10.1016/j.encep.2020.04.010
   Salata C, 2017, EXPERT REV ANTI-INFE, V15, P483, DOI 10.1080/14787210.2017.1305888
   Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517
   Sun HM, 2013, BIOORG MED CHEM LETT, V23, P4587, DOI 10.1016/j.bmcl.2013.06.034
NR 6
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD SEP
PY 2020
VL 291
AR 113220
DI 10.1016/j.psychres.2020.113220
PG 2
WC Psychiatry
SC Psychiatry
GA NK6UY
UT WOS:000566871300046
PM 32540682
OA Green Published
DA 2021-01-01
ER

PT J
AU Herzberg, DL
   Sukumaran, HP
   Viscusi, E
AF Herzberg, Daniel L.
   Sukumaran, Harry P.
   Viscusi, Eugene
TI NSAIDs for analgesia in the era of COVID-19
SO REGIONAL ANESTHESIA AND PAIN MEDICINE
LA English
DT Article
ID ANTIINFLAMMATORY DRUGS NSAIDS
AB Globally, non-steroidal anti-inflammatory drugs (NSAIDs) are highly used to treat pain. With the rise of the COVID-19 pandemic, the safety of NSAIDs use has been called into question. These concerns are worthy of review. At present, there is no compelling data showing that NSAIDs worsen the severity of COVID-19 symptoms or increase one's likelihood of contracting the illness. For patients in pain and without symptoms that could potentially be attributed to COVID-19 (cough, fevers/ chills, lethargy, myalgias, anosmia and so on), NSAIDs should continue to remain a viable option to provide analgesia to patients in need.
C1 [Herzberg, Daniel L.; Sukumaran, Harry P.] Wayne State Univ, Dept Anesthesiol & Pain Med, Detroit Med Ctr, Detroit, MI 48201 USA.
   [Herzberg, Daniel L.] MedStar Georgetown Univ Hosp, Dept Emergency Med, Washington, DC USA.
   [Viscusi, Eugene] Thomas Jefferson Univ, Dept Anesthesiol, Sidney Kimmel Med Coll, Philadelphia, PA USA.
RP Herzberg, DL (corresponding author), Wayne State Univ, Dept Anesthesiol & Pain Med, Detroit Med Ctr, Detroit, MI 48201 USA.
EM dherzber@dmc.org
CR Barkin RL, 2010, DRUG AGING, V27, P775, DOI 10.2165/11539430-000000000-00000
   Chang Ming-Cheng, 2011, Acta Anaesthesiol Taiwan, V49, P105, DOI 10.1016/j.aat.2011.08.003
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1168
   Epperly H, 2016, JPN J INFECT DIS, V69, P248, DOI 10.7883/yoken.JJID.2014.577
   European Medicines Agency, 2020, EMA GIV ADV US NON S
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Food and Drug Administration, 2020, FDA ADV PAT US NON S
   Hung IFN, 2017, CHEST, V151, P1069, DOI 10.1016/j.chest.2016.11.012
   Krietsch Boerner L., 2020, CHEM ENG NEWS
   Little P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1185
   PACIFICI R, 1994, J PHARMACOL EXP THER, V269, P1112
   Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886
   Roy S, 1996, NEUROCHEM RES, V21, P1375, DOI 10.1007/BF02532379
   ScienceAlert, 2020, UPD WHO NOW DOESNT R
   Sodhi M., 2020, CHEST, V3692, P30572
   Varrassi G, 2020, ADV THER, V37, P1705, DOI 10.1007/s12325-020-01321-1
   Wan Y, 2020, J VIROL, V94
   World Health Organization, 2020, US NON STER ANT INFL
NR 18
TC 2
Z9 2
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1098-7339
EI 1532-8651
J9 REGION ANESTH PAIN M
JI Region. Anesth. Pain Med.
PD SEP
PY 2020
VL 45
IS 9
BP 677
EP 678
DI 10.1136/rapm-2020-101584
PG 2
WC Anesthesiology
SC Anesthesiology
GA NK9DO
UT WOS:000567029500001
PM 32499385
OA Green Published, Green Accepted, Bronze
DA 2021-01-01
ER

PT J
AU Yates, PA
   Newman, SA
   Oshry, LJ
   Glassman, RH
   Leone, AM
   Reichel, E
AF Yates, Paul A.
   Newman, Steven A.
   Oshry, Lauren J.
   Glassman, Robert H.
   Leone, Ashton M.
   Reichel, Elias
TI Doxycycline treatment of high-risk COVID-19-positive patients with
   comorbid pulmonary disease
SO THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
LA English
DT Article
DE COVID-19; doxycycline; pulmonary disease; SARS-CoV-2; therapeutic
AB Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients with pulmonary compromise, such as lung cancer, autoimmune disease, and pneumonia. For early stages of mild to moderate disease, care is entirely supportive. Antiviral drugs such as remdesivir may be of some benefit but are reserved for severe cases given limited availability and potential toxicity. Repurposing of safer, established medications that may have antiviral activity is a possible approach for treatment of earlier-stage disease. Tetracycline and its derivatives (e.g. doxycycline and minocycline) are nontraditional antibiotics with a well-established safety profile, potential efficacy against viral pathogens such as dengue fever and chikungunya, and may regulate pathways important in initial infection, replication, and systemic response to SARS-CoV-2. We present a series of four high-risk, symptomatic, COVID-19(+)patients, with known pulmonary disease, treated with doxycycline with subsequent rapid clinical improvement. No safety issues were noted with use of doxycycline. Doxycycline is an attractive candidate as a repurposed drug in the treatment of COVID-19 infection, with an established safety profile, strong preclinical rationale, and compelling initial clinical experience described here. The reviews of this paper are available via the supplemental material section.
C1 [Reichel, Elias] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Yates, Paul A.; Newman, Steven A.; Leone, Ashton M.] Univ Virginia, Sch Med, Dept Ophthalmol, Charlottesville, VA 22908 USA.
   [Oshry, Lauren J.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
   [Glassman, Robert H.] Weill Cornell Med, Dept Med, New York, NY USA.
RP Reichel, E (corresponding author), Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
EM reichelconsulting@gmail.com
CR Brasier AR, 2010, CARDIOVASC RES, V86, P211, DOI 10.1093/cvr/cvq076
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Chen W, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00362-2
   Choi B, 2017, CIRCULATION, V135, P1935, DOI 10.1161/CIRCULATIONAHA.116.024270
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13437
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Emingil G, 2008, J PERIODONTOL, V79, P469, DOI [10.1902/jop.2008.070165, 10.1902/jop.2008.070165 ]
   Fredeking Terry M, 2015, Recent Pat Antiinfect Drug Discov, V10, P51
   Garassino M., 2020, AM ASS CANC RES ANN
   Griffin MO, 2010, AM J PHYSIOL-CELL PH, V299, pC539, DOI 10.1152/ajpcell.00047.2010
   Kong MYF, 2015, VIRUSES-BASEL, V7, P4230, DOI 10.3390/v7082817
   Kumar N, 2008, J VIROL, V82, P9880, DOI 10.1128/JVI.00909-08
   Malek AE, 2019, IDCases, V18, DOI 10.1016/j.idcr.2019.e00630
   Phillips JM, 2017, J VIROL, V91, DOI 10.1128/JVI.01564-16
   Rothan HA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126360
   Santa-Cecilia FV, 2016, NEUROTOX RES, V29, P447, DOI 10.1007/s12640-015-9592-2
   Sargiacomo C, 2020, AGING-US, V12, P6511, DOI 10.18632/aging.103001
   Sweiss NJ, 2020, CHEST, V158, P892, DOI 10.1016/j.chest.2020.04.033
   TEVELTHUIS AJW, 2010, PLOS PATHOG, V0006
   Wang XL, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-020-0424-9
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
NR 21
TC 1
Z9 1
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1753-4658
EI 1753-4666
J9 THER ADV RESPIR DIS
JI Ther. Adv. Respir. Dis.
PD SEP
PY 2020
VL 14
AR 1753466620951053
DI 10.1177/1753466620951053
PG 5
WC Respiratory System
SC Respiratory System
GA NM2OW
UT WOS:000567942300001
PM 32873175
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alamri, MA
   Altharawi, A
   Alabbas, AB
   Alossaimi, MA
   Alqahtani, SM
AF Alamri, Mubarak A.
   Altharawi, Ali
   Alabbas, Alhumaidi B.
   Alossaimi, Manal A.
   Alqahtani, Safar M.
TI Structure-based virtual screening and molecular dynamics of
   phytochemicals derived from Saudi medicinal plants to identify potential
   COVID-19 therapeutics
SO ARABIAN JOURNAL OF CHEMISTRY
LA English
DT Article
DE Antiviral; COVID-19; MD simulation; SARS-CoV-2; Virtual screening;
   Protease
ID CORONAVIRUSES; EXTRACTS
AB Coronavirus disease 2019 (COVID-19) has affected almost every country in the world by causing a global pandemic with a high mortality rate. Lack of an effective vaccine and/or antiviral drugs against SARS-CoV-2, the causative agent, has severely hampered the response to this novel coronavirus. Natural products have long been used in traditional medicines to treat various diseases, and purified phytochemicals from medicinal plants provide a valuable scaffold for the discovery of new drug leads. In the present study, we performed a computational screening of an in-house database composed of similar to 1000 phytochemicals derived from traditional Saudi medicinal plants with recognised antiviral activity. Structure-based virtual screening was carried out against three druggable SARS-CoV-2 targets, viral RNA-dependent RNA polymerase (RdRp), 3-chymotrypsin-like cysteine protease (3CL(pro)) and papain like protease (PLpro) to identify putative inhibitors that could facilitate the development of potential anti-COVID-19 drug candidates. Computational analyses identified three compounds inhibiting each target, with binding affinity scores ranging from -9.9 to -6.5 kcal/mol. Among these, luteolin 7-rutinoside, chrysophanol 8-(6-galloylglucoside) and kaempferol 7-(6 ''-galloylglucoside) bound efficiently to RdRp, while chrysophanol 8-(6-galloylglucoside), 3,4,5-tri-O-galloylquinic acid and mulberrofuran G interacted strongly with 3CL(pro), and withanolide A, isocodonocarpine and calonysterone bound tightly to PLpro. These potential drug candidates will be subjected to further in vitro and in vivo studies and may assist the development of effective anti-COVID-19 drugs. (c) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Alamri, Mubarak A.; Altharawi, Ali; Alabbas, Alhumaidi B.; Alossaimi, Manal A.; Alqahtani, Safar M.] Prince Sattam Bin Abdulaziz Univ, Dept Pharmaceut Chem, Coll Pharm, POB 173, Al Kharj 11942, Saudi Arabia.
RP Alamri, MA (corresponding author), Prince Sattam Bin Abdulaziz Univ, Dept Pharmaceut Chem, Coll Pharm, POB 173, Al Kharj 11942, Saudi Arabia.
EM m.alamri@psau.edu.sa
RI Altharawi, Ali/E-6194-2019; Alabbas, Alhumaidi/ABF-7189-2020
OI Altharawi, Ali/0000-0002-6491-6611; Alabbas,
   Alhumaidi/0000-0001-9353-6653
FU Prince Sattam Bin Abdulaziz University
FX Authors would like to thank Prince Sattam Bin Abdulaziz University for
   their support and providing the necessary computational tools to conduct
   this study.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Aati H, 2019, J ETHNOBIOL ETHNOMED, V15, DOI 10.1186/s13002-018-0263-2
   Alamri MA, 2020, ARAB J CHEM, V13, P5107, DOI 10.1016/j.arabjc.2020.02.010
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Arbab AH, 2017, EXP THER MED, V14, P626, DOI 10.3892/etm.2017.4530
   Babel O, 2011, J CHEMINF
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bitencourt-Ferreira G, 2019, METHODS MOL BIOL, V2053, P93, DOI 10.1007/978-1-4939-9752-7_7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   El-Toumy SA, 2018, FOOD SCI HUM WELL, V7, P91, DOI 10.1016/j.fshw.2018.01.001
   FDA, 2020, COR COVID 19 UPD FDA
   Gao Y, 2020, SCIENCE
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Huey R, 2008, USING AUTODOCK 4 AUT, P54
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Lung JH, 2020, J MED VIROL, V92, P693, DOI 10.1002/jmv.25761
   Mani JS, 2020, VIRUS RES, V284, DOI 10.1016/j.virusres.2020.197989
   Mesecar A, 2020, A TAXONOMICALLY DRIV
   Mishra AP, 2018, CELL MOL BIOL, V64, P27, DOI 10.14715/cmb/2018.64.8.5
   Neamah S.I., 2009, BIOACTIVE COMPOUNDS
   Needle D, 2015, ACTA CRYSTALLOGR D, V71, P1102, DOI 10.1107/S1399004715003521
   Osipiuk J., 2020, THE CRYSTAL STRUCTUR
   Park JY, 2012, BIOORGAN MED CHEM, V20, P5928, DOI 10.1016/j.bmc.2012.07.038
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Ramajayam R, 2011, RECENT DEVELOPMENT O
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Song MK, 2020, CHEMBIOCHEM, V21, P2950, DOI 10.1002/cbic.202000244
   Studio D., 2008, DISC STUD
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   ul Qamar M.T., 2020, J PHARM ANAL
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yin W., 2020, SCIENCE
   Yuan L, 2015, J BIOL CHEM, V290, P3172, DOI 10.1074/jbc.M114.619890
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 43
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1878-5352
EI 1878-5379
J9 ARAB J CHEM
JI Arab. J. Chem.
PD SEP
PY 2020
VL 13
IS 9
BP 7224
EP 7234
DI 10.1016/j.arabjc.2020.08.004
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA NK3VN
UT WOS:000566662100008
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Zhao, J
   Yang, XD
   Wang, CH
   Song, S
   Cao, K
   Wei, TH
   Ji, QX
   Zheng, WQ
   Li, JL
   Zhou, X
   Liu, J
AF Zhao, Jie
   Yang, Xiaodong
   Wang, Chenghua
   Song, Shuai
   Cao, Kun
   Wei, Taohua
   Ji, Qiaoxue
   Zheng, Wanqun
   Li, Jiali
   Zhou, Xue
   Liu, Jie
TI Original Yidu-toxicity blocking lung decoction ameliorates inflammation
   in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking
   lung syndrome by eliminating IL-6 and TNF-a
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE SARS-COV-2; Chinese medicine; Clinical treatment
ID CYTOKINE RELEASE SYNDROME; SEMEN ARMENIACAE AMARUM
AB The present study investigates the differences in inflammatory agents alterations, immune function, and leukocyte differential count evaluation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome after the recommended Chinese medicine prescription of Yidu-toxicity blocking lung decoction. A total of 40 patients with yidu-toxicity blocking lung syndrome, diagnosed as severe pneumonia of SARS-COV-2 following the latest Chinese national recommendations for the diagnosis and treatment of pneumonia caused by SARS-COV-2 (the 5th edition), were recruited. They were randomly divided into the pure western medicine therapy group (PWM) and integrated into Chinese and Western medicine therapy group (ICW). The general strategies were given to both groups according to the national recommendations, and the ICW group was given Yidu-toxicity blocking lung decoction extraorally. A radioimmunoassay method was adopted to detect the content of IL-6, IL-8,IL-2R,TNF-alpha, procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) in sera. Flow cytometry was used to determine the peripheral blood lymphocyte subsets (the levels of CD3+, CD4+, CD8+, and the ratios of CD4+/CD8+). The white blood cell counts (WBC#), neutrophils count(N#), and lymphocyte counts (L#) were measured using a fully automatic blood rheological instrument. The t-test or Rank Sum Test and Spearman analysis were conducted to evaluate the differences. The results showed that IL-6 (P = 0.013) and TNF-alpha (P = 0.035) levels in the PWM group were significantly higher than those in the ICW group after treatment. Infection related indicators such as WBC#, N#, L#, hs-CRP showed no differences. The analysis showed that there was no statistical difference in the values of CD4 and CD8 between the two groups. By the end of Day 29, all patients were discharged and the final cure rate for both group were 100 %.
   Taken together, we conclude that Yidu-toxicity blocking lung decoction could relieve inflammation of SARSCOV-2 patients with yidu-toxicity blocking lung syndrome by eliminating inflammatory agents. CM can serve as a complementary medication to western medicine, which should be highlighted in clinical settings.
C1 [Zhao, Jie; Wang, Chenghua; Ji, Qiaoxue; Zheng, Wanqun; Li, Jiali; Zhou, Xue] Anhui Med Univ, Dept Chinese Med, Affiliated Hosp 1, Hefei 230022, Peoples R China.
   [Yang, Xiaodong] Anhui Med Univ, Dept Gen Surg, Affiliated Hosp 1, Hefei 230022, Peoples R China.
   [Song, Shuai] Anhui Med Univ, Dept Pharm, Affiliated Hosp 1, Hefei 230022, Peoples R China.
   [Cao, Kun] Anhui Med Univ, Dept Orthopaed, Affiliated Hosp 1, Hefei 230022, Peoples R China.
   [Wei, Taohua] Anhui Univ Chinese Med, Dept Neurol, Affiliated Hosp 1, Hefei 230022, Peoples R China.
   [Liu, Jie] Goethe Univ Frankfurt am Main, Inst Med Virol, D-60596 Frankfurt, Germany.
RP Zhao, J (corresponding author), Anhui Med Univ, Dept Chinese Med, Affiliated Hosp 1, Hefei 230022, Peoples R China.
EM zhaojie0506888@126.com
FU National Natural Science FundNational Natural Science Foundation of
   China (NSFC) [81903994]
FX This study was sponsored by the National Natural Science Fund
   (81903994).
CR Betakova T, 2017, CURR PHARM DESIGN, V23, P2616, DOI 10.2174/1381612823666170316123736
   Carinci F, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m799
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen S, 2020, LANCET
   Fathi MAA, 2019, BIOORG CHEM, V84, P150, DOI 10.1016/j.bioorg.2018.11.032
   Frey N, 2017, BEST PRACT RES CL HA, V30, P336, DOI 10.1016/j.beha.2017.09.002
   Gao Z, 2011, J TRADIT CHIN MED, V31, P303, DOI 10.1016/S0254-6272(12)60008-9
   Giladi ND, 2015, ONCOTARGET, V6, P22680, DOI 10.18632/oncotarget.4205
   Godel P, 2018, INTENS CARE MED, V44, P371, DOI 10.1007/s00134-017-4943-5
   Hansen MB, 2020, IMMUN INFLAMM DIS, V8, P170, DOI 10.1002/iid3.292
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jang HJ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3684845
   Ji S, 2017, EUR J MED RES, V22, DOI 10.1186/s40001-017-0293-6
   Kaur S, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2020.115327
   Kiesel B.F., 2016, CANCER CHEMOTH PHARM, V78
   Kui L, 2020, CHIN MED J
   Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729
   Lee J.W., 2016, CHIN J INTEGR MED
   Li H, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1093/ecam/neq022
   Liu DL, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0653-x
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Murthy H, 2019, IMMUNOTARGETS THER, V8, P43, DOI 10.2147/ITT.S202015
   Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4
   Obstfeld AE, 2017, BLOOD, V130, P2569, DOI 10.1182/blood-2017-08-802413
   Rooney C, 2018, NAT MED, V24, P705, DOI 10.1038/s41591-018-0068-9
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Sohrabi C., 2020, INT J SURG
   Song S, 2016, J ETHNOPHARMACOL, V179, P356, DOI 10.1016/j.jep.2015.12.019
   Song S, 2015, J PHARMACEUT BIOMED, V109, P67, DOI 10.1016/j.jpba.2015.02.004
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tsang MSM, 2018, MOLECULES, V23, DOI 10.3390/molecules23112776
   Wu Z, 2020, JAMA
   Xi SY, 2013, J TRADIT CHIN MED, V33, P272, DOI 10.1016/S0254-6272(13)60139-9
   Xiang S., J HUAZHONG U SCI TEC, V33
   Xiang YT, 2020, LANCET, V395, P684, DOI 10.1016/S0140-6736(20)30375-5
   Xu W, 2020, INT J BIOL MACROMOL, V147, P616, DOI 10.1016/j.ijbiomac.2020.01.081
   Xu WF, 2013, J ETHNOPHARMACOL, V148, P88, DOI 10.1016/j.jep.2013.03.073
   Xu Z, 2020, LANCET RESP MED
   Yang WJ, 2020, SURG INFECT, V21, P677, DOI 10.1089/sur.2019.317
   Yu XK, 2018, J ETHNOPHARMACOL, V224, P177, DOI 10.1016/j.jep.2018.05.034
NR 40
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD SEP
PY 2020
VL 129
AR 110436
DI 10.1016/j.biopha.2020.110436
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NJ9SR
UT WOS:000566384000009
PM 32768938
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Antunes, B
   Bowers, B
   Winterburn, I
   Kelly, MP
   Brodrick, R
   Pollock, K
   Majumder, M
   Spathis, A
   Lawrie, I
   George, R
   Ryan, R
   Barclay, S
AF Antunes, Barbara
   Bowers, Ben
   Winterburn, Isaac
   Kelly, Michael P.
   Brodrick, Robert
   Pollock, Kristian
   Majumder, Megha
   Spathis, Anna
   Lawrie, Iain
   George, Rob
   Ryan, Richella
   Barclay, Stephen
TI Anticipatory prescribing in community end-of-life care in the UK and
   Ireland during the COVID-19 pandemic: online survey
SO BMJ SUPPORTIVE & PALLIATIVE CARE
LA English
DT Article
DE end of life care; drug administration; home care; terminal care;
   supportive care; nursing home care
ID PALLIATIVE CARE; MEDICATION KIT; HOME; CAREGIVERS
AB Background Anticipatory prescribing (AP) of injectable medications in advance of clinical need is established practice in community end-of-life care. Changes to prescribing guidelines and practice have been reported during the COVID-19 pandemic. Aims and objectives To investigate UK and Ireland clinicians' experiences concerning changes in AP during the COVID-19 pandemic and their recommendations for change. Methods Online survey of participants at previous AP national workshops, members of the Association for Palliative Medicine of Great Britain and Ireland and other professional organisations, with snowball sampling. Results Two hundred and sixty-one replies were received between 9 and 19 April 2020 from clinicians in community, hospice and hospital settings across all areas of the UK and Ireland. Changes to AP local guidance and practice were reported: route of administration (47%), drugs prescribed (38%), total quantities prescribed (35%), doses and ranges (29%). Concerns over shortages of nurses and doctors to administer subcutaneous injections led 37% to consider drug administration by family or social caregivers, often by buccal, sublingual and transdermal routes. Clinical contact and patient assessment were more often remote via telephone or video (63%). Recommendations for regulatory changes to permit drug repurposing and easier community access were made. Conclusions The challenges of the COVID-19 pandemic for UK community palliative care has stimulated rapid innovation in AP. The extent to which these are implemented and their clinical efficacy need further examination.
C1 [Antunes, Barbara; Bowers, Ben; Winterburn, Isaac; Kelly, Michael P.; Majumder, Megha; Spathis, Anna; Ryan, Richella; Barclay, Stephen] Univ Cambridge, Dept Publ Hlth & Primary Care, Primary Care Unit, Cambridge CB2 0SR, Cambs, England.
   [Brodrick, Robert; Ryan, Richella] Arthur Rank Hosp Char, Community Specialist Palliat Care Team, Cambridge, England.
   [Brodrick, Robert] Papworth Hosp NHS Fdn Trust, Palliat Med, Cambridge, England.
   [Pollock, Kristian] Univ Nottingham, Sch Nursing, Nottingham, England.
   [Lawrie, Iain] North Manchester Gen Hosp, Palliat Med, Manchester, Lancs, England.
   [Lawrie, Iain] Univ Manchester, Manchester Med Sch, Manchester, Lancs, England.
   [George, Rob] St Christophers Hosp, Med, London, England.
   [George, Rob] Kings Coll London, Cicely Saunders Inst, Sch Med Educ, London, England.
RP Antunes, B (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Primary Care Unit, Cambridge CB2 0SR, Cambs, England.
EM bc521@medschl.cam.ac.uk
RI Bowers, Ben/C-4128-2016; Antunes, Barbara/G-2888-2013; Bowers,
   Ben/AAR-7022-2020
OI Bowers, Ben/0000-0001-6772-2620; Antunes, Barbara/0000-0003-1655-7391;
   Bowers, Ben/0000-0001-6772-2620; Winterburn, Isaac/0000-0003-4844-7496;
   Spathis, Anna/0000-0002-9837-7281
FU National Institute for Health Research (NIHR) Applied Research
   Collaboration East of England (ARC EoE) programme - National Institute
   for Health Research (NIHR) School for Primary Care Research
FX BA, IW and SB are funded by the National Institute for Health Research
   (NIHR) Applied Research Collaboration East of England (ARC EoE)
   programme. The views expressed are those of the author(s) and not
   necessarily those of the NHS, the NIHR or the Department of Health and
   Social Care. BB is funded by the National Institute for Health Research
   (NIHR) School for Primary Care Research.
CR [Anonymous], 2012, HUMAN MED REGULATION
   Bishop MF, 2009, J PALLIAT MED, V12, P37, DOI 10.1089/jpm.2008.0193
   Bowers B, 2020, BR J GEN PRACT
   Bowers B, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1615
   Bowers B, 2019, PALLIATIVE MED, V33, P160, DOI 10.1177/0269216318815796
   Bowers B, 2017, J ADV NURS, V73, P2385, DOI 10.1111/jan.13319
   Department of Health & Social Care, NOV COR COVID 19 STA
   Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34
   Faull C, 2013, BMJ SUPPORT PALLIAT, V3, P91, DOI 10.1136/bmjspcare-2012-000193
   GIG Cymru NHS Wales, CARER ADM NEED SUBC
   Harrop E, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0165-9
   Health Improvement Scotland, ALT REG MED NORM GIV
   Healthcare Improvement Scotland, SCOTT PALL CAR GUID
   Healy S, 2018, PALLIATIVE MED, V32, P1208, DOI 10.1177/0269216318773878
   Healy S, 2013, PALLIATIVE MED, V27, P562, DOI 10.1177/0269216312464262
   Hill A, FAMILIES EXPECTED PR
   Israel F, 2008, INT J PALLIAT NURS, V14, P390, DOI 10.12968/ijpn.2008.14.8.30774
   Jansen K, 2018, J PAIN SYMPTOM MANAG, V55, P508, DOI 10.1016/j.jpainsymman.2017.06.010
   Kirchherr J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201710
   Lee L, 2016, INT J PALLIAT NURS, V22, P369, DOI 10.12968/ijpn.2016.22.8.369
   Leigh AE, 2013, J PALLIAT MED, V16, P356, DOI 10.1089/jpm.2012.0304
   Ministry of Health, 2017, AR WHAK PRINC GUID L
   National Institute for Health and Care Excellence, CAR DYING AD LAST DA
   National Institute for Health and Care Excellence, COVID 19 RAP GUID MA
   National Institute for Health and Care Excellence, 2017, CAR DYING AD LAST DA
   National Institute for Health and Care Excellence, MAN MED CAR HOM
   Payne S, 2015, BMJ SUPPORT PALLIAT, V5, P181, DOI 10.1136/bmjspcare-2014-000658
   Perkins E, 2016, HLTH SERVICES DELIVE, V4, P1, DOI [10.3310/hsdr04200, DOI 10.3310/HSDR04200]
   Poolman M, 2020, CARER ADM NEEDED SUB
   Rosenberg JP, 2015, AM J HOSP PALLIAT ME, V32, P484, DOI 10.1177/1049909114531326
   Ryan R, 2020, BMJ SUPP PALLIAT CAR, V10, pA4
   Staats K, 2018, J HOSP PALLIAT NURS, V20, pE1, DOI 10.1097/NJH.0000000000000518
   Twycross R, 2018, PALLIATIVE CARE FORM
   Victoria State Government, 2017, ANT MED
   Wilson E, 2016, PRIMARY HLTH CARE, V26, P22, DOI DOI 10.7748/PHC.2016.E1151
   Wilson E, 2018, J PAIN SYMPTOM MANAG, V56, P962, DOI 10.1016/j.jpainsymman.2018.08.019
   Wilson E, 2015, PALLIATIVE MED, V29, P60, DOI 10.1177/0269216314543042
   Yap R, 2014, J PALLIAT MED, V17, P575, DOI 10.1089/jpm.2013.0364
NR 38
TC 1
Z9 1
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2045-435X
EI 2045-4368
J9 BMJ SUPPORT PALLIAT
JI BMJ Support. Palliat. Care
PD SEP
PY 2020
VL 10
IS 3
BP 343
EP 349
DI 10.1136/bmjspcare-2020-002394
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA NK8QP
UT WOS:000566995600032
PM 32546559
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Einav, S
   Ippolito, M
   Cortegiani, A
AF Einav, Sharon
   Ippolito, Mariachiara
   Cortegiani, Andrea
TI Inclusion of pregnant women in clinical trials of COVID-19 therapies:
   what have we learned?
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Letter
DE clinical trial; COVID-19; drug development; pregnancy; randomised
   controlled trial
EM andrea.cortegiani@unipa.it
OI Ippolito, Mariachiara/0000-0001-9851-6301
CR [Anonymous], 2020, ICNARC REPORT COVID
   Breslin Noelle, 2020, Am J Obstet Gynecol MFM, V2, P100118, DOI 10.1016/j.ajogmf.2020.100118
   Ferrazzi E, 2020, MODE DELIVERY CLIN F, DOI [10.2139/ssrn.3562464, DOI 10.2139/SSRN.3562464]
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Liu Yangli, 2020, J Infect, DOI 10.1016/j.jinf.2020.02.028
   Zaigham M, 2020, ACTA OBSTET GYN SCAN, V99, P823, DOI 10.1111/aogs.13867
NR 6
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD SEP
PY 2020
VL 125
IS 3
BP E326
EP E328
DI 10.1016/j.bja.2020.05.020
PG 4
WC Anesthesiology
SC Anesthesiology
GA NK6CX
UT WOS:000566820200062
PM 32532425
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Palmer, K
   Dick, J
   French, W
   Floro, L
   Ford, M
AF Palmer, Kieran
   Dick, Jonathan
   French, Winifred
   Floro, Lajos
   Ford, Martin
TI Methemoglobinemia in Patient with G6PD Deficiency and SARS-CoV-2
   Infection
SO EMERGING INFECTIOUS DISEASES
LA English
DT Letter
ID GLUCOSE-6-PHOSPHATE-DEHYDROGENASE
AB We report a case of intravascular hemolysis and methemoglobinemia, precipitated by severe acute respiratory syndrome coronavirus 2 infection, in a patient with undiagnosed glucose-6-phosphate dehydrogenase deficiency. Clinicians should be aware of this complication of coronavirus disease as a cause of error in pulse oximetry and a potential risk for drug-induced hemolysis.
C1 [Palmer, Kieran; Dick, Jonathan; French, Winifred; Floro, Lajos; Ford, Martin] Kings Coll Hosp Natl Hlth Serv Fdn Trust, London, England.
   [Palmer, Kieran] Kings Coll Hosp Natl Hlth Serv Fdn Trust, Renal Dept, Denmark Hill, London SE5 9RS, England.
   [Dick, Jonathan; French, Winifred; Floro, Lajos; Ford, Martin] Kings Coll Hosp Natl Hlth Serv Fdn Trust, London, England.
RP Palmer, K (corresponding author), Kings Coll Hosp Natl Hlth Serv Fdn Trust, Renal Dept, Denmark Hill, London SE5 9RS, England.
EM kieran.palmer3@nhs.net
CR Araujo Tiago, 2018, Trop Med Infect Dis, V4, DOI 10.3390/tropicalmed4010006
   Au WY, 2011, ANN HEMATOL, V90, P1237, DOI 10.1007/s00277-011-1167-6
   Aydemir D, 2020, PATHOG GLOB HEALTH, V114, P109, DOI 10.1080/20477724.2020.1751388
   Cappellini MD, 2008, LANCET, V371, P64, DOI 10.1016/S0140-6736(08)60073-2
   Delgado-Roche L, 2020, ARCH MED RES
   Efferth T, 2006, CELL DEATH DIFFER, V13, P527, DOI 10.1038/sj.cdd.4401807
   Hassan Kowthar S, 2014, Oman Med J, V29, P135, DOI 10.5001/omj.2014.33
   Kassi EN, 2020, J CELL MOL MED, V24, P4913, DOI 10.1111/jcmm.15312
   Nur E, 2020, AM J HEMATOL, V95, P725, DOI 10.1002/ajh.25821
   Wu YH, 2008, J INFECT DIS, V197, P812, DOI 10.1086/528377
NR 10
TC 2
Z9 2
U1 0
U2 0
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD SEP
PY 2020
VL 26
IS 9
BP 2279
EP 2281
DI 10.3201/eid2609.202353
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA NK5VB
UT WOS:000566799800058
PM 32579876
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hogg, A
   Huey, R
   Scott, MG
   Ferguson, A
AF Hogg, Anita
   Huey, Rachel
   Scott, Michael G.
   Ferguson, Andrew
TI Informing critical care drug requirements in response to the COVID-19
   pandemic
SO EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE
LA English
DT Article
DE drug procurement; pharmacy management (organisation; financial); public
   health; intensive & critical care; infectious diseases; quality in
   health care
AB Objectives The main aim was to develop a process to estimate critical care drug requirements to robustly inform regional procurement planning and preparedness in response to the COVID-19 pandemic. The objectives were to identify critical care drugs required, obtain patient usage data and consider current regional practice to establish the requirement. Method Health and Social Care (HSC) Trusts across Northern Ireland (NI) identified critical care drugs required and an estimation of average daily usage data. The Microsoft Excel database was constructed to compile Trust data and establish regional requirement. The database was refined further according to real-world data from NI HSC Trusts, Intensive Care National Audit and Research Centre report on COVID-19 in critical care, daily regional COVID-19 figures and other available National data. Components of a tool originally developed for H1N1 and updated for COVID-19 were adapted to reflect the NI context and used in the regional database. The database was clinically reviewed to ensure that it accurately reflected current regional practice given the evolving nature of the pandemic. Results The critical care drugs required in the pandemic, usage data and current regional practice were identified to establish requirement. A regional database was constructed and used to produce a model for calculating approximate critical drug requirements. The model was used to map critical drug requirements to available stock in Trusts and wholesalers/suppliers, enabling the identification of treatment capacity for these medicines regionally, both currently and for projected surges. Data have also been used in the preparation of weekly regional situation reports provided to both the HSC Board and the Department of Health. Conclusion The process developed is a robust approach to assist in informing regional critical care drug requirements in response to the COVID-19 pandemic. Further application has been demonstrated in regional procurement planning and preparedness.
C1 [Hogg, Anita; Huey, Rachel; Scott, Michael G.] Northern Hlth & Social Care Trust, Med Optimisat Innovat Ctr, Antrim BT41 2RL, North Ireland.
   [Ferguson, Andrew] Belfast Hlth & Social Care Trust, Intens Care Med Dept, Belfast, Antrim, North Ireland.
RP Hogg, A (corresponding author), Northern Hlth & Social Care Trust, Med Optimisat Innovat Ctr, Antrim BT41 2RL, North Ireland.
EM anita.hogg@northerntrust.hscni.net
OI Hogg, Anita/0000-0002-4369-305X; Scott, Michael/0000-0003-4048-0937
CR BNF Joint Formulary Committee, BRIT NATL FORMULARY
   Coronavirus.data.gov.uk, 2020, COR COVID 19 CAS UK
   Department of Health, 2000, CISC VIS NETW IND GL
   Department of Health, 2020, DAIL COVID 19 FIG 28
   ICNARC, 2020, ICNARC REP COVID 19
NR 5
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2047-9956
EI 2047-9964
J9 EUR J HOSP PHARM-S P
JI Eur. J. Hosp. Pharm.-Sci. Pract.
PD SEP
PY 2020
VL 27
IS 5
BP 263
EP 266
DI 10.1136/ejhpharm-2020-002368
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NK8OV
UT WOS:000566991000004
PM 32661105
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Palanques-Pastor, T
   Lopez-Briz, E
   Andres, JLP
AF Palanques-Pastor, Tomas
   Lopez-Briz, Eduardo
   Poveda Andres, Jose Luis
TI Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a
   therapeutic option against COVID-19
SO EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE
LA English
DT Article
DE clinical pharmacy; immunology; intensive & critical care; infectious
   diseases; hospital pharmacy education
AB The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6.
C1 [Palanques-Pastor, Tomas; Lopez-Briz, Eduardo; Poveda Andres, Jose Luis] Hosp Univ & Politecn La Fe, Pharm Dept, Valencia 46026, Spain.
RP Palanques-Pastor, T (corresponding author), Hosp Univ & Politecn La Fe, Pharm Dept, Valencia 46026, Spain.
EM palanques_tom@gva.es
CR Centro de Coordinacion de Alertas y Emergencias Sanitarias, 2020, INF CIENT TECN ENF C
   European Medicines Agency, 2019, SUMM PROD CHAR SILT
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Kim S, 2012, RHEUMATOL INT, V32, P2601, DOI 10.1007/s00296-012-2423-3
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   San-Miguel J, 2014, BLOOD, V123, P4136, DOI 10.1182/blood-2013-12-546374
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Sun D, 2020, WORLD J PEDIATR, V16, P251, DOI 10.1007/s12519-020-00354-4
   van Rhee F, 2020, LANCET HAEMATOL, V7, pE209, DOI 10.1016/S2352-3026(19)30257-1
   van Rhee F, 2014, LANCET ONCOL, V15, P966, DOI 10.1016/S1470-2045(14)70319-5
   Wan SX, 2020, BRIT J HAEMATOL, V189, P428, DOI 10.1111/bjh.16659
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Xu X, 2020, EFFECTIVE TREATMENT
NR 14
TC 2
Z9 2
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2047-9956
EI 2047-9964
J9 EUR J HOSP PHARM-S P
JI Eur. J. Hosp. Pharm.-Sci. Pract.
PD SEP
PY 2020
VL 27
IS 5
BP 297
EP 298
DI 10.1136/ejhpharm-2020-002322
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NK8OV
UT WOS:000566991000011
PM 32499314
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Jain, S
   Workman, V
   Ganeshan, R
   Obasare, ER
   Burr, A
   DeBiasi, RM
   Freeman, JV
   Akar, J
   Lampert, R
   Rosenfeld, LE
AF Jain, Shashank
   Workman, Virginia
   Ganeshan, Raj
   Obasare, Edinrin R.
   Burr, Alicia
   DeBiasi, Ralph M.
   Freeman, James V.
   Akar, Joseph
   Lampert, Rachel
   Rosenfeld, Lynda E.
TI Enhanced electrocardiographic monitoring of patients with Coronavirus
   Disease 2019
SO HEART RHYTHM
LA English
DT Article
DE COVID-19; QT prolongation; ECG; Hydroxychloroquine; Torsades de pointes
AB BACKGROUND Many of the drugs being used in the treatment of the ongoing pandemic coronavirus disease 2019 (COVID-19) are associated with QT prolongation. Expert guidance supports electrocardiographic (ECG) monitoring to optimize patient safety.
   OBJECTIVE The purpose of this study was to establish an enhanced process for ECG monitoring of patients being treated for COVID-19.
   METHODS We created a Situation Background Assessment Recommendation tool identifying the indication for ECGs in patients with COVID-19 and tagged these ECGs to ensure prompt over reading and identification of those with QT prolongation (corrected QT interval 120 ms; corrected QT interval 500 ms for QRS duration > 120 ms). This triggered a phone call from the electrophysiology service to the primary team to provide management guidance and a formal consultation if requested.
   RESULTS During a 2-week period, we reviewed 2006 ECGs, corresponding to 524 unique patients, of whom 103 (19.7%) met the Situation Background Assessment Recommendation tool-defined criteria for QT prolongation. Compared with those without QT prolongation, these patients were more often in the intensive care unit (60 [58.3%] vs 149 [35.4%]) and more likely to be intubated (32 [31.1%] vs 76 [18.1%]). Fifty patients with QT prolongation (48.5%) had electrolyte abnormalities, 98 (95.1%) were on COVID-19-related QT-prolonging medications, and 62 (60.2%) were on 1-4 additional non-COVID-19-related QT-prolonging drugs. Electrophysiology recommendations were given to limit modifiable risk factors. No patient developed torsades de pointes.
   CONCLUSION This process functioned efficiently, identified a high percentage of patients with QT prolongation, and led to relevant interventions. Arrhythmias were rare. No patient developed torsades de pointes.
C1 [Jain, Shashank; Workman, Virginia; Ganeshan, Raj; Obasare, Edinrin R.; Burr, Alicia; DeBiasi, Ralph M.; Freeman, James V.; Akar, Joseph; Lampert, Rachel; Rosenfeld, Lynda E.] Yale Univ, Sch Med, Sect Cardiovasc Med, Dana 3,789 Howard Ave, New Haven, CT 06510 USA.
RP Rosenfeld, LE (corresponding author), Yale Univ, Sch Med, Sect Cardiovasc Med, Dana 3,789 Howard Ave, New Haven, CT 06510 USA.
EM lynda.rosenfeld@yale.edu
RI Jain, Shashank/B-7815-2017
OI Jain, Shashank/0000-0002-4935-3566
CR Aromolaran AS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208321
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Capel RA, 2015, HEART RHYTHM, V12, P2186, DOI 10.1016/j.hrthm.2015.05.027
   Chang D, 2020, J AM COLL CARDIOL, V75, P2992, DOI 10.1016/j.jacc.2020.04.032
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Choi Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1574806
   Fintelman-Rodrigues N., 2020, BIORXIV, DOI [10.1101/2020.04.04.020925, DOI 10.1101/2020.04.04.020925]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Roden DM, 2020, J AM COLL CARDIOL, V75, P2623, DOI 10.1016/j.jacc.2020.04.016
   Simpson TF, VENTRICULAR ARRHYTHM
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu CI, 2020, HEART RHYTHM, V17, P1456, DOI 10.1016/j.hrthm.2020.03.024
   Yang T, 1996, CIRCULATION, V93, P407, DOI 10.1161/01.CIR.93.3.407
   Zhang MD, 2017, CARDIOVASC TOXICOL, V17, P434, DOI 10.1007/s12012-017-9401-7
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 17
TC 8
Z9 8
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1547-5271
EI 1556-3871
J9 HEART RHYTHM
JI Heart Rhythm
PD SEP
PY 2020
VL 17
IS 9
BP 1417
EP 1422
DI 10.1016/j.hrthm.2020.04.047
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NJ8ZM
UT WOS:000566333900001
PM 32387247
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Chorin, E
   Wadhwani, L
   Magnani, S
   Dai, M
   Shulman, E
   Nadeau-Routhier, C
   Knotts, R
   Bar-Cohen, R
   Kogan, E
   Barbhaiya, C
   Aizer, A
   Holmes, D
   Bernstein, S
   Spinelli, M
   Park, DS
   Stefano, C
   Chinitz, LA
   Jankelson, L
AF Chorin, Ehud
   Wadhwani, Lalit
   Magnani, Silvia
   Dai, Matthew
   Shulman, Eric
   Nadeau-Routhier, Charles
   Knotts, Robert
   Bar-Cohen, Roi
   Kogan, Edward
   Barbhaiya, Chirag
   Aizer, Anthony
   Holmes, Douglas
   Bernstein, Scott
   Spinelli, Michael
   Park, David S.
   Stefano, Carugo
   Chinitz, Larry A.
   Jankelson, Lior
TI QT interval prolongation and torsade de pointes in patients with
   COVID-19 treated with hydroxychloroquine/azithromycin
SO HEART RHYTHM
LA English
DT Article
DE COVID-19; QT interval; Torsade de pointes; Hydroxy-chloroquine;
   Azithromycin
ID ABORTED CARDIAC-ARREST; RISK-FACTORS; AZITHROMYCIN; DEATH
AB BACKGROUND There is no known effective therapy for patients with coronavirus disease 2019 (COVID-19). Initial reports suggest-ing the potential benefit of hydroxychloroquine/azithromycin (HY/ AZ) have resulted in massive adoption of this combination world-wide. However, while the true efficacy of this regimen is unknown, initial reports have raised concerns about the potential risk of QT in-terval prolongation and induction of torsade de pointes (TdP).
   OBJECTIVE The purpose of this study was to assess the change in corrected QT (QTc) interval and arrhythmic events in patients with COVID-19 treated with HY/AZ.
   METHODS This is a retrospective study of 251 patients from 2 cen-ters who were diagnosed with COVID-19 and treated with HY/AZ. We reviewed electrocardiographic tracings from baseline and until 3 days after the completion of therapy to determine the progression of QTc interval and the incidence of arrhythmia and mortality.
   RESULTS The QTc interval prolonged in parallel with increasing drug exposure and incompletely shortened after its completion. Extreme new QTc interval prolongation to .500 ms, a known marker of high risk of TdP, had developed in 23% of patients. One patient developed polymorphic ventricular tachycardia suspected as TdP, requiring emergent cardioversion. Seven patients required prema-ture termination of therapy. The baseline QTc interval of patients exhibiting extreme QTc interval prolongation was normal.
   CONCLUSION The combination of HY/AZ significantly prolongs the QTc interval in patients with COVID-19. This prolongation may be responsible for life-threatening arrhythmia in the form of TdP. This risk mandates careful consideration of HY/AZ therapy in light of its unproven efficacy. Strict QTc interval monitoring should be performed if the regimen is given.
C1 [Chorin, Ehud; Wadhwani, Lalit; Dai, Matthew; Shulman, Eric; Nadeau-Routhier, Charles; Knotts, Robert; Bar-Cohen, Roi; Kogan, Edward; Barbhaiya, Chirag; Aizer, Anthony; Holmes, Douglas; Bernstein, Scott; Spinelli, Michael; Park, David S.; Chinitz, Larry A.; Jankelson, Lior] NYU, Grossman Sch Med, Leon H Charney Div Cardiol, Cardiac Electrophysiol,NYU Langone Hlth, 560 1st Ave, New York, NY 10016 USA.
   [Magnani, Silvia; Stefano, Carugo] Univ Milan, Div Cardiol, Dept Hlth Sci, San Paolo Hosp, Milan, Italy.
RP Jankelson, L (corresponding author), NYU, Grossman Sch Med, Leon H Charney Div Cardiol, Cardiac Electrophysiol,NYU Langone Hlth, 560 1st Ave, New York, NY 10016 USA.
EM Lior.jankelson@nyumc.org
OI Magnani, Silvia/0000-0002-3233-5564; Aizer, Anthony/0000-0001-6550-0178;
   Barbhaiya, Chirag/0000-0003-3479-936X
CR Borba MGS, 2020, CHLOROQUINE DIPHOSPH, DOI [10.1101/2020.04.07.20056424, DOI 10.1101/2020.04.07.20056424]
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chico RM, 2011, EXPERT OPIN DRUG MET, V7, P1153, DOI 10.1517/17425255.2011.598506
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Drew BJ, 2010, CIRCULATION, V121, P1047, DOI 10.1161/CIRCULATIONAHA.109.192704
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giudicessi JR, 2020, HEART RHYTHM, V17, P1487, DOI 10.1016/j.hrthm.2020.04.045
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Goldenberg I, 2008, CIRCULATION, V117, P2184, DOI 10.1161/CIRCULATIONAHA.107.701243
   Hancox JC, 2013, THER ADV INFECT DIS, V1, P155, DOI 10.1177/2049936113501816
   Helfenbein ED, 2006, J ELECTROCARDIOL, V39, pS123, DOI 10.1016/j.jelectrocard.2006.05.018
   Hobbs JB, 2006, JAMA-J AM MED ASSOC, V296, P1249, DOI 10.1001/jama.296.10.1249
   Huang BH, 2007, PACE, V30, P1579, DOI 10.1111/j.1540-8159.2007.00912.x
   Jain S, 2020, HEART RHYTHM, V17, P1417, DOI 10.1016/j.hrthm.2020.04.047
   Justo D, 2006, EUR J INTERN MED, V17, P254, DOI 10.1016/j.ejim.2005.12.003
   KAY GN, 1983, J AM COLL CARDIOL, V2, P806
   Kezerashvili A, 2007, J INTERV CARD ELECTR, V18, P243, DOI 10.1007/s10840-007-9124-y
   Lakkireddy DR, 2020, HEART RHYTHM, V17, pE233, DOI 10.1016/j.hrthm.2020.03.028
   Lane J.C., 2020, SAFETY HYDROXYCHLORO, DOI [10.1101/2020.04.08.20054551, DOI 10.1101/2020.04.08.20054551]
   Marill KA, 2001, ACAD EMERG MED, V8, P117, DOI 10.1111/j.1553-2712.2001.tb01275.x
   Morgan ND, 2013, JCR-J CLIN RHEUMATOL, V19, P286, DOI 10.1097/RHU.0b013e31829d5e50
   Pedersen HS, 2007, AM J CARDIOL, V100, P876, DOI 10.1016/j.amjcard.2007.04.020
   Postema PG, 2014, CURR CARDIOL REV, V10, P287, DOI 10.2174/1573403X10666140514103612
   Sauer AJ, 2007, J AM COLL CARDIOL, V49, P329, DOI 10.1016/j.jacc.2006.08.057
   Szekely Y, 2020, HEART RHYTHM, V17, P1452, DOI 10.1016/j.hrthm.2020.04.046
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu CI, 2020, HEART RHYTHM, V17, P1456, DOI 10.1016/j.hrthm.2020.03.024
   Yang ZJ, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.115.003560
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zeltser D, 2003, MEDICINE, V82, P282, DOI 10.1097/00005792-200307000-00007
NR 31
TC 44
Z9 44
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1547-5271
EI 1556-3871
J9 HEART RHYTHM
JI Heart Rhythm
PD SEP
PY 2020
VL 17
IS 9
BP 1425
EP 1433
DI 10.1016/j.hrthm.2020.05.014
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NJ8ZM
UT WOS:000566333900003
PM 32407884
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Szekely, Y
   Lichter, Y
   Abu Shrkihe, B
   Bruck, H
   Oster, HS
   Viskin, S
AF Szekely, Yishay
   Lichter, Yael
   Shrkihe, Bander Abu
   Bruck, Hila
   Oster, Howard S.
   Viskin, Sami
TI Chloroquine-induced torsades de pointes in a patient with coronavirus
   disease 2019
SO HEART RHYTHM
LA English
DT Article
DE Chloroquine; COVID-19; Drug-induced long QT syndrome; QT interval;
   Torsades de pointes
C1 [Szekely, Yishay; Viskin, Sami] Tel Aviv Univ, Dept Cardiol, Sourasky Tel Aviv Med Ctr, Tel Aviv, Israel.
   [Szekely, Yishay; Lichter, Yael; Shrkihe, Bander Abu; Bruck, Hila; Oster, Howard S.; Viskin, Sami] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
   [Lichter, Yael] Tel Aviv Univ, Dept Intens Care, Sourasky Tel Aviv Med Ctr, Tel Aviv, Israel.
   [Shrkihe, Bander Abu; Bruck, Hila; Oster, Howard S.] Tel Aviv Univ, Dept Internal Med, Sourasky Tel Aviv Med Ctr, Tel Aviv, Israel.
RP Szekely, Y (corresponding author), Tel Aviv Sourasky Med Ctr, Dept Cardiol, Weizmann 6, IL-64239 Tel Aviv, Israel.
EM yishays@tlvmc.gov.il
OI Szekely, Yishay/0000-0003-1398-3563; Lichter, Yael/0000-0002-1805-4600
CR [Anonymous], CARDIOLOGY MAGAZINE
   Baker P, NY TIMES
   Barber M, 2019, CARDIOVASC RES, V115, P878, DOI 10.1093/cvr/cvz020
   Borba MGS, 2020, CHLOROQUINE DIPHOSPH, DOI [10.1101/2020.04.07.20056424, DOI 10.1101/2020.04.07.20056424]
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Haeusler IL, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1188-2
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Smit C, 2020, CLIN PHARMACOKINET, V59, P659, DOI 10.1007/s40262-020-00891-1
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   World Health Organization, 2017, MAL POL ADV COMM M 2, P36
   Wu CI, 2020, HEART RHYTHM, V17, P1456, DOI 10.1016/j.hrthm.2020.03.024
NR 14
TC 12
Z9 12
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1547-5271
EI 1556-3871
J9 HEART RHYTHM
JI Heart Rhythm
PD SEP
PY 2020
VL 17
IS 9
BP 1452
EP 1455
DI 10.1016/j.hrthm.2020.04.046
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NJ8ZM
UT WOS:000566333900007
PM 32380291
OA Green Published
DA 2021-01-01
ER

PT J
AU Dona, D
   Di Chiara, C
   Sharland, M
AF Dona, D.
   Di Chiara, C.
   Sharland, M.
TI Multi-drug-resistant infections in the COVID-19 era: a framework for
   considering the potential impact
SO JOURNAL OF HOSPITAL INFECTION
LA English
DT Letter
C1 [Dona, D.; Sharland, M.] St Georges Univ London, Inst Infect & Immun, Paediat Infect Dis Res Grp, London, England.
   [Sharland, M.] Univ Padua, Dept Woman & Child Hlth, Padua, Italy.
RP Dona, D (corresponding author), St George Hosp, Paediat Infect Dis Res Grp, Inst Infect & Immun, 5th Floor,Lanesborough Wing,Blackshaw Rd, London SW17 0QT, England.
EM daniele.dona@unipd.it
CR Jolivet S, 2020, J HOSP INFECT, V105, P10, DOI 10.1016/j.jhin.2020.02.012
   Kaier K, 2012, CLIN MICROBIOL INFEC, V18, P941, DOI 10.1111/j.1469-0691.2012.03956.x
   Liu YS, 2019, SPE J, V24, P2020, DOI 10.2118/188917-PA
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Siegel JD, 2007, AM J INFECT CONTROL, V35, pS165, DOI 10.1016/j.ajic.2007.10.006
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 6
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0195-6701
EI 1532-2939
J9 J HOSP INFECT
JI J. Hosp. Infect.
PD SEP
PY 2020
VL 106
IS 1
BP 198
EP 199
DI 10.1016/j.jhin.2020.05.020
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA NJ9YY
UT WOS:000566400600024
PM 32425287
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sardu, C
   Maggi, P
   Messina, V
   Iuliano, P
   Sardu, A
   Iovinella, V
   Paolisso, G
   Marfella, R
AF Sardu, Celestino
   Maggi, Paolo
   Messina, Vincenzo
   Iuliano, Pasquale
   Sardu, Antonio
   Iovinella, Vincenzo
   Paolisso, Giuseppe
   Marfella, Raffaele
TI Could Anti-Hypertensive Drug Therapy Affect the Clinical Prognosis of
   Hypertensive Patients With COVID-19 Infection? Data From Centers of
   Southern Italy
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE Angiotensin-converting enzyme 2; anti-hypertensive drugs; COVID-19;
   hypertension
AB BACKGROUND Coronavirus disease 2019 (COVID-19) is the cause of a pandemic disease, with severe acute respiratory syndrome by binding target epithelial lung cells through angiotensin-converting enzyme 2 in humans. Thus, patients with hypertension with COVID-19 could have worse prognosis. Indeed, angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers may interfere with angiotensin-converting enzyme 2 expression/activity. Thus, patients with hypertension undergoing angiotensin-converting enzyme inhibitor and/or angiotensin receptor blockers drug therapy may be at a higher risk of contracting a serious COVID-19 infection and should be monitored. Moreover, in the present study we investigated the effects of angiotensin-converting enzyme inhibitor versus angiotensin receptor blockers versus calcium channel blockers on clinical outcomes as mechanical ventilation, intensive care unit admissions, heart injury, and death in 62 patients with hypertension hospitalized for COVID-19 infection. METHODS AND RESULTS The multicenter study was prospectively conducted at Department of Infectious Diseases of Sant'Anna Hospital of Caserta, and of University of Campania "Luigi Vanvitelli" of Naples, at Department of Advanced Surgical and Medical Sciences of University of Campania "Luigi Vanvitelli," Naples, and at General Medical Assistance Unit "FIMG," Naples, Italy. Lowest values of left ventricle ejection fraction predicted deaths (1.142, 1.008-1.294,P<0.05), while highest values of interleukin-6 predicted the admission to intensive care unit (1.617, 1.094-2.389), mechanical ventilation (1.149, 1.082-1.219), heart injuries (1.367, 1.054-1.772), and deaths (4.742, 1.788-8.524). CONCLUSIONS Anti-hypertensive drugs didn't affect the prognosis in patients with COVID-19. Consequently, tailored anti-inflammatory and immune therapies in addition to chronic antihypertensive therapy, could prevent a worse prognosis, as well as improve the clinical outcomes in patients with hypertension with COVID-19 infection.
C1 [Sardu, Celestino; Paolisso, Giuseppe; Marfella, Raffaele] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, Piazza Miraglia 2, I-80126 Naples, Italy.
   [Maggi, Paolo; Iuliano, Pasquale] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Phys & Prevent Med, Naples, Italy.
   [Messina, Vincenzo] St Anna Hosp, Dept Infect Dis, Caserta, Italy.
   [Sardu, Antonio; Iovinella, Vincenzo] Federaz Italiana Med Gen, FIMG, Naples, Italy.
RP Sardu, C (corresponding author), Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, Piazza Miraglia 2, I-80126 Naples, Italy.
EM drsarducele@gmail.com
OI marfella, raffaele/0000-0003-3960-9270; Messina,
   Vincenzo/0000-0003-1323-5127; Sardu, Celestino/0000-0001-5099-3790
CR [Anonymous], 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016948
   Brojakowska A, 2020, J AM COLL CARDIOL, V75, P3085, DOI 10.1016/j.jacc.2020.04.028
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Marfella R, 2020, DIABETES METAB
   Paz Ocaranza Maria, 2020, Nat Rev Cardiol, V17, P116, DOI 10.1038/s41569-019-0244-8
   Sardu C, 2020, DIABETES CARE, V43, P1408, DOI 10.2337/dc20-0723
   Sardu C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051417
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339
NR 9
TC 12
Z9 12
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD SEP 1
PY 2020
VL 9
IS 17
AR e016948
DI 10.1161/JAHA.120.016948
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NK8AG
UT WOS:000566953100012
PM 32633594
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Beck, MJ
   Hensher, DA
AF Beck, Matthew J.
   Hensher, David A.
TI Insights into the impact of COVID-19 on household travel and activities
   in Australia - The early days under restrictions
SO TRANSPORT POLICY
LA English
DT Article
DE Coronavirus; COVID-19; Travel activity; Working; Working from home; Air
   travel; Shopping; Attitudes; Survey; Australia
AB When 2020 began, we had no idea what was to unfold globally as we learnt about the Novel-Coronavirus in Wuhan, in the Hubei province of China. As this virus spread rapidly, it became a matter of time before many countries began to implement measures to try and contain the spread of the disease. COVID-19 as it is referred to, resulted in two main approaches to fighting the viral pandemic, either through a progressive set of measures to slow down the number of identified cases designed to 'flatten the curve' over time (anticipated to be at least six months), or to attack it by the severest of measures including a total lock-down and/or herding exposure to fast track 'immunisation' while we await a vaccine. The paper reports the findings from the first phase of an ongoing survey designed to identify the changing patterns in travel activity of Australian residents as a result of the stage 2 restrictions imposed by the Australian government. The main restrictions, in addition to social distancing of at least 1.5 m, are closure of entry to Australia (except residents returning), and closure of non-essential venues such as night clubs, restaurants, mass attendee sporting events, churches, weddings, and all social gatherings in any circumstance. With some employers encouraging working from home and others requiring it, in addition to job losses, and many children attending school online from home, the implications on travel activity is extreme. We identify the initial impacts associated with the first month of stricter social distancing measures introduced in Australia.
C1 [Beck, Matthew J.; Hensher, David A.] Univ Sydney, Inst Transport & Logist Studies ITLS, Business Sch, Sydney, NSW 2006, Australia.
RP Beck, MJ (corresponding author), Univ Sydney, Inst Transport & Logist Studies ITLS, Business Sch, Sydney, NSW 2006, Australia.
EM Matthew.Beck@sydney.edu.au; David.Hensher@sydney.edu.au
CR [Anonymous], 2020, CITYMAPPER MOBILITY
   [Anonymous], 2020, GOOGLE COMMUNITY MOB
   Bureau of Infrastructure, 2015, TRANSP REG EC BITRE
   Butt C., 2020, CORONAVIRUS TURNED P
   Chang SL, 2020, MODELLING TRANSMISSI
   Domencich T.A., 1975, URBAN TRAVEL DEMAND
   Graetz C, 2020, BMC ORAL HEALTH, V20, DOI 10.1186/s12903-020-01129-z
   Greene W.H., 2010, MODELING ORDERED CHO
   Harrington W, 2001, TRANSPORT RES A-POL, V35, P87, DOI 10.1016/S0965-8564(99)00048-8
   Hensher DA, 2014, TRANSPORT RES A-POL, V61, P227, DOI 10.1016/j.tra.2014.02.017
   Stanley CE, 2020, INVERTEBR NEUROSCI, V20, DOI 10.1007/s10158-020-00243-5
   Treasury, 2020, TREAS EC RESP COR
   WSP, 2020, TOLL ROAD PRIC POST
NR 13
TC 8
Z9 8
U1 8
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-070X
EI 1879-310X
J9 TRANSPORT POLICY
JI Transp. Policy
PD SEP
PY 2020
VL 96
BP 76
EP 93
DI 10.1016/j.tranpol.2020.07.001
PG 18
WC Economics; Transportation
SC Business & Economics; Transportation
GA NK1IK
UT WOS:000566492800007
PM 32834680
OA Green Published
DA 2021-01-01
ER

PT J
AU Martinez, MA
AF Angel Martinez, Miguel
TI Clinical Trials of Repurposed Antivirals for SARS-CoV-2
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE COVID-19; SARS-CoV-2; antivirals
ID LOPINAVIR/RITONAVIR; REMDESIVIR; COVID-19; MODEL
AB The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir-ritonavir, ribavirin, interferons, and hydroxychloroquine. Unfortunately, the first open-label, randomized, controlled trials are showing poor efficacy of these repurposed drugs. These results highlight the necessity of identifying and characterizing specific and potent SARS-CoV-2 antivirals.
C1 [Angel Martinez, Miguel] Univ Autonoma Barcelona UAB, Hosp Univ Germans Trias i Pujol, IrsiCaixa, Badalona, Spain.
RP Martinez, MA (corresponding author), Univ Autonoma Barcelona UAB, Hosp Univ Germans Trias i Pujol, IrsiCaixa, Badalona, Spain.
EM mmartinez@irsicaixa.es
RI Martinez, Miguel Angel/K-6435-2014
OI Martinez, Miguel Angel/0000-0002-6681-4950
FU Spanish Ministry of Science and InnovationSpanish Government
   [PID2019-103955RB-100]
FX This work was supported by the Spanish Ministry of Science and
   Innovation (PID2019-103955RB-100).
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   John Hopkins University Center for Systems Science and Engineering, 2020, COVID 19 DASHB
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li XG, 2020, SCI PROGRESS-UK, V103, DOI 10.1177/0036850419877359
   Li YC, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100984
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Magagnoli J, 2020, OUTCOMES HYDROXYCHLO
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Manjili RH, 2020, J IMMUNOL, V205, P12, DOI 10.4049/jimmunol.2000413
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Riva A, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104826
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   US Food and Drug Administration, 2020, EM US AUTH HYDR SULF
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 38
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD SEP
PY 2020
VL 64
IS 9
AR e01101-20
DI 10.1128/AAC.01101-20
PG 6
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA NK0WJ
UT WOS:000566461500007
PM 32631826
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hung, HC
   Ke, YY
   Huang, SY
   Huang, PN
   Kung, YA
   Chang, TY
   Yen, KJ
   Peng, TT
   Chang, SE
   Huang, CT
   Tsai, YR
   Wu, SH
   Lee, SJ
   Lin, JH
   Liu, BS
   Sung, WC
   Shih, SR
   Chen, CT
   Hsu, JTA
AF Hung, Hui-Chen
   Ke, Yi-Yu
   Huang, Sheng Yu
   Huang, Peng-Nien
   Kung, Yu-An
   Chang, Teng-Yuan
   Yen, Kuei-Jung
   Peng, Tzu-Ting
   Chang, Shao-En
   Huang, Chin-Ting
   Tsai, Ya-Ru
   Wu, Szu-Huei
   Lee, Shiow-Ju
   Lin, Jiunn-Horng
   Liu, Bing-Sin
   Sung, Wang-Chou
   Shih, Shin-Ru
   Chen, Chiung-Tong
   Hsu, John Tsu-An
TI Discovery of M Protease Inhibitors Encoded by SARS-CoV-2
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Mpro; antiviral research; GC376; M protease
ID 3CL PROTEASE; CORONAVIRUS; REPLICATION; OUTBREAK
AB The coronavirus (CoV) disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome CoV-2 (SARS-CoV-2) is a health threat worldwide. Viral main protease (M-pro, also called 3C-like protease [3CL(pro)]) is a therapeutic target for drug discovery. Herein, we report that GC376, a broad-spectrum inhibitor targeting M-pro in the picornavirus-like supercluster, is a potent inhibitor for the M-pro encoded by SARS-CoV-2, with a half-maximum inhibitory concentration (IC50) of 26.4 +/- 1.1 nM. In this study, we also show that GC376 inhibits SARS-CoV-2 replication with a half-maximum effective concentration (EC50) of 0.91 +/- 0.03 mu M. Only a small portion of SARS-CoV-2 M-pro was covalently modified in the excess of GC376 as evaluated by mass spectrometry analysis, indicating that improved inhibitors are needed. Subsequently, molecular docking analysis revealed that the recognition and binding groups of GC376 within the active site of SARS-CoV-2 M-pro provide important new information for the optimization of GC376. Given that sufficient safety and efficacy data are available for GC376 as an investigational veterinary drug, expedited development of GC376, or its optimized analogues, for treatment of SARS-CoV-2 infection in human is recommended.
C1 [Hung, Hui-Chen; Ke, Yi-Yu; Kung, Yu-An; Chang, Teng-Yuan; Peng, Tzu-Ting; Chang, Shao-En; Huang, Chin-Ting; Tsai, Ya-Ru; Wu, Szu-Huei; Lee, Shiow-Ju; Chen, Chiung-Tong; Hsu, John Tsu-An] Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Miaoli, Taiwan.
   [Hsu, John Tsu-An] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu, Taiwan.
   [Yen, Kuei-Jung; Lin, Jiunn-Horng] Agr Technol Res Inst ATRI, Dept Anim Technol Labs, Miaoli, Taiwan.
   [Huang, Sheng Yu; Huang, Peng-Nien; Shih, Shin-Ru] Chang Gung Univ, Res Ctr Emerging Viral Infect, Taoyuan, Taiwan.
   [Huang, Peng-Nien] Linkou Chang Gung Mem Hosp, Dept Pediat, Div Infect Dis, Taoyuan, Taiwan.
   [Shih, Shin-Ru] Linkou Chang Gung Mem Hosp, Dept Lab Med, Taoyuan, Taiwan.
   [Liu, Bing-Sin; Sung, Wang-Chou] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Miaoli, Taiwan.
RP Chen, CT; Hsu, JTA (corresponding author), Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Miaoli, Taiwan.; Shih, SR (corresponding author), Chang Gung Univ, Res Ctr Emerging Viral Infect, Taoyuan, Taiwan.; Shih, SR (corresponding author), Linkou Chang Gung Mem Hosp, Dept Lab Med, Taoyuan, Taiwan.
EM srshih@mail.cgu.edu.tw; ctchen@nhri.edu.tw; tsuanhsu@nhri.edu.tw
FU Ministry of Health and Welfare, Taiwan; Featured Areas Research Center
   Program within Ministry of Education (MOE) in Taiwan; Ministry of
   Science and Technology (MOST) in TaiwanMinistry of Science and
   Technology, Taiwan
FX This work was financially supported by a special government fund to
   tackle the COVID-19 pandemic from the Ministry of Health and Welfare,
   Taiwan, and a 5-year grant for the Research Center for Emerging Viral
   Infections (Chang Gung University) from The Featured Areas Research
   Center Program within the framework of the Higher Education Sprout
   Project by the Ministry of Education (MOE) and the Ministry of Science
   and Technology (MOST) in Taiwan.
CR Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Cournia Z, 2017, J CHEM INF MODEL, V57, P2911, DOI 10.1021/acs.jcim.7b00564
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gawehn E, 2016, MOL INFORM, V35, P3, DOI 10.1002/minf.201501008
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hatada R, 2020, J CHEM INF MODEL, V60, P3593, DOI 10.1021/acs.jcim.0c00283
   Hsieh HP, 2017, ABSTR PAP AM CHEM SO, V253
   Hsu JTA, 2004, FEBS LETT, V574, P116, DOI 10.1016/j.febslet.2004.08.015
   Hu B, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0422-1
   Hung HC, 2011, J INFECT DIS, V203, P1784, DOI 10.1093/infdis/jir174
   Hung HC, 2009, ANTIVIR RES, V81, P123, DOI 10.1016/j.antiviral.2008.10.006
   Hussey RJ, 2011, BIOCHEMISTRY-US, V50, P240, DOI 10.1021/bi1008497
   John SES, 2015, BIOORG MED CHEM LETT, V25, P5072, DOI 10.1016/j.bmcl.2015.10.023
   Kankanamalage ACG, 2018, EUR J MED CHEM, V150, P334, DOI 10.1016/j.ejmech.2018.03.004
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12
   Kuo CJ, 2004, BIOCHEM BIOPH RES CO, V318, P862, DOI 10.1016/j.bbrc.2004.04.098
   Lei J, 2017, FEBS LETT, V591, P3190, DOI 10.1002/1873-3468.12827
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Mandadapu SR, 2012, BIOORG MED CHEM LETT, V22, P4820, DOI 10.1016/j.bmcl.2012.05.055
   Shiao HY, 2013, J MED CHEM, V56, P5247, DOI 10.1021/jm4006059
   Sisay M, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104779
   Tiew KC, 2011, BIOORG MED CHEM LETT, V21, P5315, DOI 10.1016/j.bmcl.2011.07.016
   Venkatachalam CM, 2003, J MOL GRAPH MODEL, V21, P289, DOI 10.1016/S1093-3263(02)00164-X
   WHO, 2020, REP WHO CHIN JOINT M
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu CJ, 2004, ANTIMICROB AGENTS CH, V48, P2693, DOI 10.1128/AAC.48.7.2693-2696.2004
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 31
TC 0
Z9 0
U1 5
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD SEP
PY 2020
VL 64
IS 9
AR e00872-20
DI 10.1128/AAC.00872-20
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA NK0WJ
UT WOS:000566461500005
PM 32669265
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Marzolini, C
   Stader, F
   Stoeckle, M
   Franzeck, F
   Egli, A
   Bassetti, S
   Hollinger, A
   Osthoff, M
   Weisser, M
   Gebhard, CE
   Baettig, V
   Geenen, J
   Khanna, N
   Tschudin-Sutter, S
   Mueller, D
   Hirsch, HH
   Battegay, M
   Sendi, P
AF Marzolini, Catia
   Stader, Felix
   Stoeckle, Marcel
   Franzeck, Fabian
   Egli, Adrian
   Bassetti, Stefano
   Hollinger, Alexa
   Osthoff, Michael
   Weisser, Maja
   Gebhard, Caroline E.
   Baettig, Veronika
   Geenen, Julia
   Khanna, Nina
   Tschudin-Sutter, Sarah
   Mueller, Daniel
   Hirsch, Hans H.
   Battegay, Manuel
   Sendi, Parham
TI Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and
   Hydroxychloroquine Plasma Concentrations
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE COVID-19; lopinavir-ritonavir; levels; hydroxychloroquine; inflammation
ID DRUG-METABOLIZING-ENZYMES; C-REACTIVE PROTEIN; LOPINAVIR/RITONAVIR;
   INTERLEUKIN-6; IMPACT
AB Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine release, which can downregulate the expression of metabolizing enzymes. This cascade affects drug concentrations in the plasma. We investigated the association between lopinavir (LPV) and hydroxychloroquine (HCQ) plasma concentrations and the levels of the acute-phase inflammation marker C-reactive protein (CRP). LPV plasma concentrations in 92 patients hospitalized at our institution were prospectively collected. Lopinavir-ritonavir was administered every 12 hours, 800/200 mg on day 1 and 400/100 mg on day 2 until day 5 or 7. HCQ was given at 800 mg, followed by 400 mg after 6, 24, and 48 h. Hematological, liver, kidney, and inflammation laboratory values were analyzed on the day of drug level determination. The median age of study participants was 59 (range, 24 to 85) years, and 71% were male. The median durations from symptom onset to hospitalization and treatment initiation were 7 days (interquartile range [IQR], 4 to 10) and 8 days (IQR, 5 to 10), respectively. The median LPV trough concentration on day 3 of treatment was 26.5 mu g/ml (IQR, 18.9 to 31.5). LPV plasma concentrations positively correlated with CRP values (r = 0.37, P < 0.001) and were significantly lower when tocilizumab was preadministered. No correlation was found between HCQ concentrations and CRP values. High LPV plasma concentrations were observed in COVID-19 patients. The ratio of calculated unbound drug fraction to published SARS-CoV-2 50% effective concentrations (EC50) indicated insufficient LPV concentrations in the lung. CRP values significantly correlated with LPV but not HCQ plasma concentrations, implying inhibition of cytochrome P450 3A4 (CYP3A4) metabolism by inflammation.
C1 [Marzolini, Catia; Stader, Felix; Stoeckle, Marcel; Franzeck, Fabian; Weisser, Maja; Baettig, Veronika; Khanna, Nina; Tschudin-Sutter, Sarah; Hirsch, Hans H.; Battegay, Manuel; Sendi, Parham] Univ Hosp Basel, Div Infect & Hosp Hyg, Basel, Switzerland.
   [Marzolini, Catia; Stader, Felix; Stoeckle, Marcel; Franzeck, Fabian; Bassetti, Stefano; Osthoff, Michael; Weisser, Maja; Baettig, Veronika; Geenen, Julia; Khanna, Nina; Tschudin-Sutter, Sarah; Hirsch, Hans H.; Battegay, Manuel; Sendi, Parham] Univ Basel, Basel, Switzerland.
   [Franzeck, Fabian] Univ Hosp Basel, Res & Anal Serv, Basel, Switzerland.
   [Egli, Adrian] Univ Hosp Basel, Div Clin Bacteriol & Mycol, Basel, Switzerland.
   [Egli, Adrian] Univ Basel, Dept Biomed, Appl Microbiol Res, Basel, Switzerland.
   [Bassetti, Stefano; Osthoff, Michael; Geenen, Julia] Univ Hosp Basel, Div Internal Med, Basel, Switzerland.
   [Bassetti, Stefano; Osthoff, Michael; Geenen, Julia] Univ Hosp Basel, Dept Clin Res, Basel, Switzerland.
   [Hollinger, Alexa; Gebhard, Caroline E.] Univ Hosp Basel, Intens Care Unit, Basel, Switzerland.
   [Mueller, Daniel] Univ Hosp Zurich, Inst Clin Chem, Zurich, Switzerland.
   [Hirsch, Hans H.] Univ Basel, Transplantat & Clin Virol, Dept Biomed, Basel, Switzerland.
   [Sendi, Parham] Univ Bern, Inst Infect Dis, Bern, Switzerland.
RP Sendi, P (corresponding author), Univ Hosp Basel, Div Infect & Hosp Hyg, Basel, Switzerland.; Sendi, P (corresponding author), Univ Basel, Basel, Switzerland.; Sendi, P (corresponding author), Univ Bern, Inst Infect Dis, Bern, Switzerland.
EM catia.marzolini@usb.ch; parham.sendl@usb.ch
RI Marzolini, Catia/C-8253-2019; Sendi, Parham/R-3286-2018
OI Sendi, Parham/0000-0002-7347-6312; Hirsch, Hans H./0000-0003-0883-0423;
   Khanna, Nina/0000-0002-2642-419X; Tschudin-Sutter,
   Sarah/0000-0003-4875-5368; Mueller, Daniel/0000-0002-4674-4019
FU Adolf and Mary Mil Foundation; Swiss National foundationSwiss National
   Science Foundation (SNSF) [31CA30 196140]
FX C.M. was supported by the Adolf and Mary Mil Foundation. F.S. was
   supported by a grant from the Swiss National foundation (grant number
   324730_188504). C.E.G. was supported by a grant from the Swiss National
   foundation (grant number 31CA30 196140).
CR Atzori C, 2003, AIDS, V17, P1710, DOI 10.1097/00002030-200307250-00022
   Baldelli S, 2020, J ANTIMICROB CHEMOTH, V75, P2704, DOI 10.1093/jac/dkaa190
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Croxtall JD, 2010, DRUGS, V70, P1885, DOI 10.2165/11204950-000000000-00000
   Dickmann LJ, 2011, DRUG METAB DISPOS, V39, P1415, DOI 10.1124/dmd.111.038679
   Dumond JB, 2015, JAIDS-J ACQ IMM DEF, V70, P510, DOI 10.1097/QAI.0000000000000777
   Eichbaum C, 2013, EUR J CLIN PHARMACOL, V69, P1795, DOI [10, 10.1007/s00228-013-1530-8]
   Eron JJ, 2004, J INFECT DIS, V189, P265, DOI 10.1086/380799
   Fajgenbaum DC, 2020, INFECT DIS THER, V9, P435, DOI 10.1007/s40121-020-00303-8
   Fan J, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa623, DOI 10.1093/CID/CIAA623.]
   Ford N, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25489
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gregoire M, 2020, J ANTIMICROB CHEMOTH, V75, P2702, DOI 10.1093/jac/dkaa195
   Hefner G, 2016, PSYCHOPHARMACOLOGY, V233, P1695, DOI 10.1007/s00213-015-3976-0
   Kojima T, 2013, MOD RHEUMATOL, V23, P977, DOI [10.3109/s10165-012-0782-y, 10.1007/s10165-012-0782-y]
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Lee W, 2005, J BIOL CHEM, V280, P9610, DOI 10.1074/jbc.M411092200
   Markanday A, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv098
   Martin-Blondel G, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa558
   Morgan ET, 2009, CLIN PHARMACOL THER, V85, P434, DOI 10.1038/clpt.2008.302
   Morgan ET, 2008, DRUG METAB DISPOS, V36, P205, DOI 10.1124/dmd.107.018747
   Morita S, 2016, THER DRUG MONIT, V38, P259, DOI 10.1097/FTD.0000000000000261
   Mueck W, 2013, BRIT J CLIN PHARMACO, V76, P455, DOI 10.1111/bcp.12075
   Nijland HMJ, 2008, AIDS, V22, P931, DOI 10.1097/QAD.0b013e3282faa71e
   Ofotokun I, 2007, J CLIN PHARMACOL, V47, P970, DOI 10.1177/0091270007302564
   Papanicolaou DA, 2000, J CLIN ENDOCR METAB, V85, P1331, DOI 10.1210/jc.85.3.1331
   Renton Kenneth W, 2005, Expert Opin Drug Metab Toxicol, V1, P629, DOI 10.1517/17425255.1.4.629
   Schoergenhofer C, 2020, ANN INTERN MED, V173, P670, DOI 10.7326/M20-1550
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Stader F, 2020, J ANTMICROB CHEMOTHE, DOI [10.1093/jac/dkaa253, DOI 10.1093/JAC/DKAA253.]
   Stader F, 2020, CLIN PHARMACOKINET, V59, P383, DOI 10.1007/s40262-019-00822-9
   Testa S, 2020, J THROMB HAEMOST, V18, P1320, DOI 10.1111/jth.14871
   Tripathy S, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106028
   Vreugdenhil B, 2018, BRIT J CLIN PHARMACO, V84, P1980, DOI 10.1111/bcp.13627
   World Health Organization, 2020, SOL CLIN TRIAL COVID
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu CH, 2016, J PHARM SCI-US, V105, P884, DOI 10.1002/jps.24663
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang SY, 2020, CLIN DRUG INVEST, V40, P511, DOI 10.1007/s40261-020-00917-3
NR 41
TC 7
Z9 7
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD SEP
PY 2020
VL 64
IS 9
AR e01177-20
DI 10.1128/AAC.01177-20
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA NK0WJ
UT WOS:000566461500023
PM 32641296
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sharifipour, E
   Shams, S
   Esmkhani, M
   Khodadadi, J
   Fotouhi-Ardakani, R
   Koohpaei, A
   Doosti, Z
   Golzari, SEJ
AF Sharifipour, Ehsan
   Shams, Saeed
   Esmkhani, Mohammad
   Khodadadi, Javad
   Fotouhi-Ardakani, Reza
   Koohpaei, Alireza
   Doosti, Zahra
   Golzari, Samad E. J.
TI Evaluation of bacterial co-infections of the respiratory tract in
   COVID-19 patients admitted to ICU
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE 2019-nCoV; COVID-19; Co-infection; Bacteria; A. baumannii; S. aureus
AB Background: COVID-19 is known as a new viral infection. Viral-bacterial co-infections are one of the biggest medical concerns, resulting in increased mortality rates. To date, few studies have investigated bacterial superinfections in COVID-19 patients. Hence, we designed the current study on COVID-19 patients admitted to ICUs.
   Methods: Nineteen patients admitted to our ICUs were enrolled in this study. To detect COVID-19, reverse transcription real-time polymerase chain reaction was performed. Endotracheal aspirate samples were also collected and cultured on different media to support the growth of the bacteria. After incubation, formed colonies on the media were identified using Gram staining and other biochemical tests. Antimicrobial susceptibility testing was carried out based on the CLSI recommendations.
   Results: Of nineteen COVID-19 patients, 11 (58%) patients were male and 8 (42%) were female, with a mean age of similar to 67 years old. The average ICU length of stay was similar to 15 days and at the end of the study, 18 cases (95%) expired and only was 1 case (5%) discharged. In total, all patients were found positive for bacterial infections, including seventeen Acinetobacter baumannii (90%) and two Staphylococcus aureus (10%) strains. There was no difference in the bacteria species detected in any of the sampling points. Seventeen of 17 strains of Acinetobacter baumannii were resistant to the evaluated antibiotics. No metallo-beta-lactamases-producing Acinetobacter baumannii strain was found. One of the Staphylococcus aureus isolates was detected as methicillin-resistant Staphylococcus aureus and isolated from the patient who died, while another Staphylococcus aureus strain was susceptible to tested drugs and identified as methicillin-sensitive Staphylococcus aureus.
   Conclusions: Our findings emphasize the concern of superinfection in COVID-19 patients due to Acinetobacter baumannii and Staphylococcus aureus. Consequently, it is important to pay attention to bacterial co-infections in critical patients positive for COVID-19.
C1 [Sharifipour, Ehsan] Qom Univ Med Sci, Neurosci Res Ctr, Qom, Iran.
   [Shams, Saeed; Fotouhi-Ardakani, Reza; Doosti, Zahra] Qom Univ Med Sci, Cellular & Mol Res Ctr, Fac Med, Pardis Campus, Qom, Iran.
   [Esmkhani, Mohammad] Ali Ebne Abitaleb Hosp, Qom, Iran.
   [Khodadadi, Javad] Qom Univ Med Sci, Dept Infect Dis, Fac Med, Qom, Iran.
   [Fotouhi-Ardakani, Reza] Qom Univ Med Sci, Dept Med Biotechnol, Fac Med, Qom, Iran.
   [Koohpaei, Alireza] Qom Univ Med Sci, Fac Hlth, Occupat Hlth & Safety Dept, Qom, Iran.
   [Golzari, Samad E. J.] Klinikum Dortmund, Dept Anaesthesiol & Intens Care Med, Dortmund, Germany.
RP Shams, S (corresponding author), Qom Univ Med Sci, Cellular & Mol Res Ctr, Fac Med, Pardis Campus, Qom, Iran.
EM sshamsmed@gmail.com
FU Research Council of Qom University of Medical Sciences
FX The study was supported by Research Council of Qom University of Medical
   Sciences.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD SEP 1
PY 2020
VL 20
IS 1
AR 646
DI 10.1186/s12879-020-05374-z
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA NM2RN
UT WOS:000567949200005
PM 32873235
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Licari, A
   Castagnoli, R
   Votto, M
   Brambilla, I
   Ciprandi, G
   Marseglia, GL
AF Licari, Amelia
   Castagnoli, Riccardo
   Votto, Martina
   Brambilla, Ilaria
   Ciprandi, Giorgio
   Marseglia, Gian Luigi
CA Italian Study Grp Biologics allerg
TI Biologic Use in Allergic and Asthmatic Children and Adolescents During
   the COVID-19 Pandemic
SO PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY
LA English
DT Article
DE asthma; COVID-19; biologics; children; adolescents
AB Background:Biologics are the cornerstone of therapy in children and adolescents with severe or uncontrolled allergic diseases, such as asthma, atopic dermatitis, and chronic urticaria. Since the World Health Organization (WHO) declared severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection a pandemic in March 2020, some scientific societies have released statements on the use of biologics in allergic children and adolescents. Materials and Methods:Given the very limited data in Italy on use of biological therapies in allergic children and adolescents during the coronavirus disease 2019 (COVID-19) pandemic, a multicenter observational nationwide survey was conducted to collect this information. The 11-question survey was designed to determine (1) the number of allergic children and adolescents treated with omalizumab, mepolizumab, or dupilumab for asthma, atopic dermatitis, and chronic urticaria; (2) the number of these patients who developed COVID-19; and (3) severity of COVID-19 symptoms. Twenty pediatric centers participated, and data were collected from February to April 2020. Results:Three hundred eight children and adolescents (mean age 12.8 years, 161 males) were treated with biologics. Only 3 subjects (1%) who had been treated with omalizumab experienced paucisymptomatic COVID-19, but those symptoms promptly resolved. Of the 9 patients treated with mepolizumab, none had COVID-19 or asthma exacerbations. Of the 6 asthmatic subjects and 7 patients with chronic urticaria treated with dupilumab, none had COVID-19. Also, there was no worsening of the underlying disease. Conclusion:These very preliminary outcomes suggest that continuing biologics seem to be safe. Therefore, biologics could be continued in patients with severe allergic diseases, but withheld once contracted COVID-19.
C1 [Licari, Amelia; Castagnoli, Riccardo; Votto, Martina; Brambilla, Ilaria; Marseglia, Gian Luigi] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Pediat, Pediat Clin, Pavia, Italy.
   [Ciprandi, Giorgio] Casa Cura Villa Montallegro, Allergy Clin, Genoa, Italy.
RP Ciprandi, G (corresponding author), Casa Cura Villa MontallegroGenoa, Allergy Clin, Via P Boselli 5, I-16146 Genoa, Italy.
EM gio.cip@libero.it
RI Castagnoli, Riccardo/AAF-8555-2019; Votto, Martina/ABB-8116-2020;
   Ciprandi, Giorgio/G-7462-2012; Licari, Amelia/J-5898-2016
OI Castagnoli, Riccardo/0000-0003-0029-9383; Votto,
   Martina/0000-0002-4271-8649; Ciprandi, Giorgio/0000-0001-7016-8421;
   Licari, Amelia/0000-0002-1773-6482
CR Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364
   Brambilla I, 2020, OBESITY, V28, P1369, DOI 10.1002/oby.22878
   Brambilla I, 2020, PEDIATR INFECT DIS J, V39, pE160, DOI 10.1097/INF.0000000000002730
   Bush A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041237
   Cardinale F, 2020, ITAL J PEDIATR, V46, DOI 10.1186/s13052-020-00843-2
   Centers for Disease Control and Prevention, 2020, PEOPL MOD SEV ASTHM
   Ciprandi G, 2020, ANN ALLERGY ASTHMA I
   Comberiati P, 2019, J ALLER CL IMM-PRACT, V7, P2689, DOI 10.1016/j.jaip.2019.05.053
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Duan LP, 2020, ENERGY TECHNOL-GER, V8, DOI 10.1002/ente.201901401
   Global Initiative for Asthma-GINA, 2020, COVID 19 GINA ANSW F
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009
   Jartti T, 2017, J ALLERGY CLIN IMMUN, V140, P895, DOI 10.1016/j.jaci.2017.08.003
   Just J, 2019, PEDIAT ALLERG IMM-UK, V30, P159, DOI 10.1111/pai.13007
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Licari A, 2020, ALLERGY, V75, P2402, DOI 10.1111/all.14369
   Lindsley AW, 2020, J ALLERGY CLIN IMMUN, V146, P1, DOI 10.1016/j.jaci.2020.04.021
   Pfaller Birgit, 2020, Allergy, DOI 10.1111/all.14282
   Van Kerkhove MD, 2019, EMERG INFECT DIS, V25, P1802, DOI 10.3201/eid2510.190130
NR 20
TC 0
Z9 0
U1 2
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2151-321X
EI 2151-3228
J9 PEDIAT ALLER IMM PUL
JI Pediatr. Allergy Immunol. Pulmonol.
PD SEP 1
PY 2020
VL 33
IS 3
BP 155
EP 158
DI 10.1089/ped.2020.1214
EA SEP 2020
PG 4
WC Allergy; Immunology; Pediatrics; Respiratory System
SC Allergy; Immunology; Pediatrics; Respiratory System
GA NR2OA
UT WOS:000566825600001
OA Bronze
DA 2021-01-01
ER

PT J
AU Russo, V
   Di Maio, M
   Attena, E
   Silverio, A
   Scudiero, F
   Celentani, D
   Lodigiani, C
   Di Micco, P
AF Russo, Vincenzo
   Di Maio, Marco
   Attena, Emilio
   Silverio, Angelo
   Scudiero, Fernando
   Celentani, Dario
   Lodigiani, Corrado
   Di Micco, Pierpaolo
TI Clinical impact of pre-admission antithrombotic therapy in hospitalized
   patients with COVID-19: A multicenter observational study
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; Atrial fibrillation; Anticoagulation;
   Anticoagulant therapy; Antiplatelet therapy; Mortality; Acute distress
   respiratory syndrome
AB Little is still known about the clinical features associated with the occurrence of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus disease 2019 (COVID-19). The aim of the present study was to describe the prevalence of pre-admission antithrombotic therapies in patients with COVID-19 and to investigate the potential association between antithrombotic therapy and ARDS, as disease clinical presentation, or in-hospital mortality.
   We enrolled 192 consecutive patients with laboratory-confirmed COVID-19 admitted to emergency department of five Italian hospitals. The study population was divided in two groups according to the evidence of ARDS at chest computed tomography at admission. Propensity score weighting adjusted regression analysis was performed to assess the risk ARDS at admission, and death during hospitalization, in patients treated or not with antiplatelet and anticoagulant agents.
   ARDS was reported in 73 cases (38 %), who showed more likely hypertension compared to those without ARDS (57.8 % vs 49.6 %; P = 0.005). Thirty-five patients (18.5 %) died during the hospitalization. Not survived COVID-19 patients showed a statistically significant increased age (77 +/- 8.31 vs 65.57 +/- 8.31; P = 0.001), hypertension (77.1 % vs 53.5 %; P = 0.018) and coronary artery disease prevalence (28.6 % vs 10.2 %; P = 0.009). Both unadjusted and adjusted regression analyses showed no difference in the risk of ARDS at admission, or death during hospitalization, between patients treated or not with antiplatelets or anticoagulants.
   Pre-admission antithrombotic therapy, both antiplatelet and anticoagulant, does not seem to show a protective effect in severe forms of COVID-19 with ARDS at presentation and rapidly evolving toward death.
C1 [Russo, Vincenzo] Univ Campania Luigi Vanvitelli, Dept Translat Med Sci, Monaldi & Cotugno Hosp, Chair Cardiol, Naples, Italy.
   [Di Maio, Marco] Eboli Hosp, Div Cardiol, Salerno, Italy.
   [Attena, Emilio] San Giuliano Hosp, Div Cardiol, Naples, Italy.
   [Silverio, Angelo] San Giovanni Dio & Ruggi dAragona Univ Hosp, Cardiovasc & Thorac Dept, Div Cardiol, Salerno, Italy.
   [Scudiero, Fernando] Hlth Author Bergamo East, Cardiol Unit, Milan, Italy.
   [Celentani, Dario] Rivoli Hosp, Cardiol Unit, Turin, Italy.
   [Lodigiani, Corrado] Humanitas Res Hosp, Thrombosis & Hemorrhag Ctr, Rozzano, Italy.
   [Lodigiani, Corrado] Humanitas Univ, Rozzano, Italy.
   [Di Micco, Pierpaolo] Fatebenefratelli Hosp Naples, Med Unit, Naples, Italy.
RP Russo, V (corresponding author), Univ Campania Luigi Vanvitelli, Monaldi Hosp, Dept Translat Med Sci, Pzzale Ettore Ruggeri, I-80131 Naples, Italy.
EM v.p.russo@libero.it
RI Russo, Vincenzo/ABH-1766-2020
OI Silverio, Angelo/0000-0001-9749-8092; DI MAIO, MARCO/0000-0001-8665-9890
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Di Micco P, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051371
   Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   RICARDO AIC, 2020, LANCET RESP MED, V27, DOI DOI 10.1016/J.TEAC.2020.E00097
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
NR 10
TC 9
Z9 9
U1 1
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD SEP
PY 2020
VL 159
AR 104965
DI 10.1016/j.phrs.2020.104965
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NK0KP
UT WOS:000566430900008
PM 32474087
OA Green Published
DA 2021-01-01
ER

PT J
AU Sanchis-Gomar, F
   Perez-Quilis, C
   Favaloro, EJ
   Lippi, G
AF Sanchis-Gomar, Fabian
   Perez-Quilis, Carme
   Favaloro, Emmanuel J.
   Lippi, Giuseppe
TI Statins and other drugs: Facing COVID-19 as a vascular disease
SO PHARMACOLOGICAL RESEARCH
LA English
DT Letter
C1 [Sanchis-Gomar, Fabian; Perez-Quilis, Carme] Univ Valencia, Fac Med, Dept Physiol, Ave Blasco Ibanez 15, Valencia 46010, Spain.
   [Sanchis-Gomar, Fabian; Perez-Quilis, Carme] INCLIVA Biomed Res Inst, Valencia, Spain.
   [Favaloro, Emmanuel J.] Westmead Hosp, Inst Clin Pathol & Med Res ICPMR, NSW Hlth Pathol, Sydney Ctr Thrombosis,Haematol, Westmead, NSW, Australia.
   [Favaloro, Emmanuel J.] Westmead Hosp, Inst Clin Pathol & Med Res ICPMR, NSW Hlth Pathol, Sydney Ctr Haemostasis,Haematol, Westmead, NSW, Australia.
   [Lippi, Giuseppe] Univ Verona, Dept Neurosci Biomed & Movement, Sect Clin Biochem, Verona, Italy.
RP Sanchis-Gomar, F (corresponding author), Univ Valencia, Fac Med, Dept Physiol, Ave Blasco Ibanez 15, Valencia 46010, Spain.
EM fabian.sanchis@uv.es
RI ; Lippi, Giuseppe/X-7198-2018
OI Favaloro, Emmanuel J/0000-0002-2103-1661; Lippi,
   Giuseppe/0000-0001-9523-9054; Sanchis-Gomar, Fabian/0000-0003-0424-4208
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Bifulco M, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104803
   De Spiegeleer A, 2020, J AM MED DIR ASSOC, V21, P909, DOI 10.1016/j.jamda.2020.06.018
   El Sabbagh A, 2018, J INVASIVE CARDIOL, V30, P406
   Lippi G, 2020, PROG CARDIOVASC DIS, V63, P390, DOI 10.1016/j.pcad.2020.03.001
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
NR 6
TC 1
Z9 1
U1 4
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD SEP
PY 2020
VL 159
AR 105033
DI 10.1016/j.phrs.2020.105033
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NK0KP
UT WOS:000566430900007
PM 32562814
DA 2021-01-01
ER

PT J
AU Yuan, SF
   Chan, JFW
   Chik, KKH
   Chan, CCY
   Tsang, JOL
   Liang, RH
   Cao, JL
   Tang, KM
   Chen, LL
   Wen, K
   Cai, JP
   Ye, ZW
   Lu, G
   Chu, H
   Jin, DY
   Yuen, KY
AF Yuan, Shuofeng
   Chan, Jasper F. W.
   Chik, Kenn K. H.
   Chan, Chris C. Y.
   Tsang, Jessica O. L.
   Liang, Ronghui
   Cao, Jianli
   Tang, Kaiming
   Chen, Lin-Lei
   Wen, Kun
   Cai, Jian-Piao
   Ye, Zi-Wei
   Lu, Gang
   Chu, Hin
   Jin, Dong-Yan
   Yuen, Kwok-Yung
TI Discovery of the FDA-approved drugs bexarotene, cetilistat,
   diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments
   with a robust two-tier screening system
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Antiviral; Coronavirus; COVID-19; Library; SARS-CoV-2; Treatment;
   Cetilistat; Diiodohydroxyquinoline; Abiraterone; Bexarotene
ID RESPIRATORY SYNDROME CORONAVIRUS; LIPASE INHIBITOR; VIRUS
AB Coronavirus Disease 2019 (COVID-19) caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a crude case fatality rate of about 0.5-10 % depending on locality. A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50 % maximal effective concentrations (EC50) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals, we established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abiraterone acetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro antiSARS-CoV-2 activity (EC50 1.13-2.01 mu M). Bexarotene demonstrated the highest Cmax:EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine, and ivermectin. These results demonstrated the efficacy of the two-tier screening system and identified potential COVID-19 treatments which can achieve effective levels if given by inhalation or systemically depending on their pharmacokinetics.
C1 [Yuan, Shuofeng; Chan, Jasper F. W.; Chik, Kenn K. H.; Chan, Chris C. Y.; Tsang, Jessica O. L.; Liang, Ronghui; Cao, Jianli; Tang, Kaiming; Chen, Lin-Lei; Cai, Jian-Piao; Ye, Zi-Wei; Chu, Hin; Yuen, Kwok-Yung] Univ Hong Kong, Li Ka Shing Fac Med, Carol Yu Ctr Infect,Pokfulam, Dept Microbiol,State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.
   [Yuan, Shuofeng; Chan, Jasper F. W.; Chik, Kenn K. H.; Chan, Chris C. Y.; Tsang, Jessica O. L.; Liang, Ronghui; Cao, Jianli; Tang, Kaiming; Chen, Lin-Lei; Cai, Jian-Piao; Ye, Zi-Wei; Chu, Hin; Yuen, Kwok-Yung] Univ Hong Kong, Ctr Virol Vaccinol & Therapeut, Hlth InnoHK, Hong Kong, Peoples R China.
   [Chan, Jasper F. W.; Yuen, Kwok-Yung] Univ Hong Kong, Dept Clin Microbiol & Infect Control, Shenzhen Hosp, Shenzhen, Guangdong, Peoples R China.
   [Chan, Jasper F. W.; Lu, Gang; Yuen, Kwok-Yung] Hainan Med Univ, Hainan Med Univ Univ Hong Kong Joint Lab Trop Inf, Haikou, Hainan, Peoples R China.
   [Chan, Jasper F. W.; Lu, Gang; Yuen, Kwok-Yung] Univ Hong Kong, Pokfulam, Hong Kong, Peoples R China.
   [Wen, Kun] Southern Med Univ, Zhujiang Hosp, Div Lab Med, Guangzhou, Guangdong, Peoples R China.
   [Lu, Gang] Hainan Med Univ, Dept Pathogen Biol, Haikou, Hainan, Peoples R China.
   [Lu, Gang] Hainan Med Univ, Key Lab Translat Trop Med, Minist Educ, Haikou, Hainan, Peoples R China.
   [Jin, Dong-Yan] Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, Pokfulam, Hong Kong, Peoples R China.
RP Chan, JFW; Yuen, KY (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Carol Yu Ctr Infect,Pokfulam, Dept Microbiol,State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.
EM jfwchan@hku.hk; kyyuen@hku.hk
FU Health@InnoHK (Centre for Virology, Vaccinology and Therapeutics),
   Innovation and Technology Commission, The Government of the Hong Kong
   Special Administrative Region of the People's Republic of China;
   National Program on Key Research Project of China [2020YFA0707500,
   2020YFA0707504]; Research Grants Council, Hong Kong Special
   Administrative RegionHong Kong Research Grants Council [T11/707/15];
   High Level-Hospital Program, Health Commission of Guangdong Province,
   China; Shaw Foundation of Hong Kong; Respiratory Viral Research
   Foundation Limited; Chow Sin Lan Charity Fund Limited; Chan Yin Chuen
   Memorial Charitable Foundation; Hong Kong Hainan Commercial Association
   South China Microbiology Research Fund; Jessie & George Ho Charitable
   Foundation; Perfect Shape Medical Limited
FX This study was partly supported by funding from Health@InnoHK (Centre
   for Virology, Vaccinology and Therapeutics), Innovation and Technology
   Commission, The Government of the Hong Kong Special Administrative
   Region of the People's Republic of China; the National Program on Key
   Research Project of China (grant no. 2020YFA0707500 and 2020YFA0707504);
   the Theme-Based Research Scheme (T11/707/15) of the Research Grants
   Council, Hong Kong Special Administrative Region; and the High
   Level-Hospital Program, Health Commission of Guangdong Province, China;
   and donations of Richard Yu and Carol Yu, the Shaw Foundation of Hong
   Kong, Michael Seak-Kan Tong, May Tam Mak Mei Yin, Respiratory Viral
   Research Foundation Limited, Hui Ming, Hui Hoy and Chow Sin Lan Charity
   Fund Limited, Chan Yin Chuen Memorial Charitable Foundation, Marina
   Man-Wai Lee, the Hong Kong Hainan Commercial Association South China
   Microbiology Research Fund, the Jessie & George Ho Charitable
   Foundation, Perfect Shape Medical Limited, and Kai Chong Tong. The
   funding sources had no role in the study design, data collection,
   analysis, interpretation, or writing of the report.
CR Arasaratnam M, 2019, CANCER CHEMOTH PHARM, V84, P139, DOI 10.1007/s00280-019-03862-x
   BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018
   Bryson A, 2009, BRIT J CLIN PHARMACO, V67, P309, DOI 10.1111/j.1365-2125.2008.03311.x
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan JFW, 2013, TRENDS MICROBIOL, V21, P544, DOI 10.1016/j.tim.2013.05.005
   Chan JFW, 2013, J INFECT DIS, V207, P1743, DOI 10.1093/infdis/jit123
   Che XY, 2005, J INFECT DIS, V191, P2033, DOI 10.1086/430355
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   Chu H, 2020, CLIN INFECT DIS
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Dragnev KH, 2007, CLIN CANCER RES, V13, P1794, DOI 10.1158/1078-0432.CCR-06-1836
   Duc I, 2003, J STEROID BIOCHEM, V84, P537, DOI 10.1016/S0960-0760(03)00078-5
   Esteva FJ, 2003, J CLIN ONCOL, V21, P999, DOI 10.1200/JCO.2003.05.068
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gniadecki R, 2007, BRIT J DERMATOL, V157, P433, DOI 10.1111/j.1365-2133.2007.07975.x
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2004, EMERG INFECT DIS, V10, P1550, DOI 10.3201/eid1009.040058
   Liston DR, 2017, CLIN CANCER RES, V23, P3489, DOI 10.1158/1078-0432.CCR-16-3083
   Padwal R, 2008, CURR OPIN INVEST DR, V9, P414
   RICKARDS A. G., 1949, JOUR TROP MED AND HYG, V52, P33
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   WHO-World Health Organization, 2020, 77 WHO
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x
   Yuan SF, 2016, J ANTIMICROB CHEMOTH, V71, P2489, DOI 10.1093/jac/dkw194
   Yuan SF, 2016, ANTIVIR RES, V125, P34, DOI 10.1016/j.antiviral.2015.11.005
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 39
TC 5
Z9 6
U1 5
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD SEP
PY 2020
VL 159
AR 104960
DI 10.1016/j.phrs.2020.104960
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NK0LJ
UT WOS:000566432900005
PM 32473310
OA Green Published
DA 2021-01-01
ER

PT J
AU Chua, HR
   MacLaren, G
   Choong, LHL
   Chionh, CY
   Khoo, BZE
   Yeo, SC
   Sewa, DW
   Ng, SY
   Choo, JCJ
   Teo, BW
   Tan, HK
   Siow, WT
   Agrawal, RV
   Tan, CS
   Vathsala, A
   Tagore, R
   Seow, TYY
   Khatri, P
   Hong, WZ
   Kaushik, M
AF Chua, Horng-Ruey
   MacLaren, Graeme
   Choong, Lina Hui-Lin
   Chionh, Chang-Yin
   Khoo, Benjamin Zhi En
   Yeo, See-Cheng
   Sewa, Duu-Wen
   Ng, Shin-Yi
   Choo, Jason Chon-Jun
   Teo, Boon-Wee
   Tan, Han-Khim
   Siow, Wen-Ting
   Agrawal, Rohit Vijay
   Tan, Chieh-Suai
   Vathsala, Anantharaman
   Tagore, Rajat
   Seow, Terina Ying-Ying
   Khatri, Priyanka
   Hong, Wei-Zhen
   Kaushik, Manish
TI Ensuring Sustainability of Continuous Kidney Replacement Therapy in the
   Face of Extraordinary Demand: Lessons From the COVID-19 Pandemic
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
ID ACCELERATED VENOVENOUS HEMOFILTRATION; REGIONAL CITRATE ANTICOAGULATION;
   PERITONEAL-DIALYSIS; ACID-BASE; HEMODIALYSIS; CATHETERS; INJURY; SAFETY;
   RISK; INTENSITY
AB With the exponential surge in patients with coronavirus disease 2019 (COVID-19) worldwide, the resources needed to provide continuous kidney replacement therapy (CKRT) for patients with acute kidney injury or kidney failure may be threatened. This article summarizes subsisting strategies that can be implemented immediately. Pre-emptive weekly multicenter projections of CKRT demand based on evolving COVID-19 epidemiology and routine workload should be made. Corresponding consumables should be quantified and acquired, with diversification of sources from multiple vendors. Supply procurement should be stepped up accordingly so that a several-week stock is amassed, with administrative oversight to prevent disproportionate hoarding by institutions. Consumption of CKRT resources can be made more efficient by optimizing circuit anticoagulation to preserve filters, extending use of each vascular access, lowering blood flows to reduce citrate consumption, moderating the CKRT intensity to conserve fluids, or running accelerated KRT at higher clearance to treat more patients per machine. If logistically feasible, earlier transition to intermittent hemodialysis with online-generated dialysate, or urgent peritoneal dialysis in selected patients, may help reduce CKRT dependency. These measures, coupled to multicenter collaboration and a corresponding increase in trained medical and nursing staffing levels, may avoid downstream rationing of care and save lives during the peak of the pandemic.
C1 [Chua, Horng-Ruey; Teo, Boon-Wee; Vathsala, Anantharaman; Khatri, Priyanka; Hong, Wei-Zhen] Natl Univ Singapore Hosp, Dept Med, Div Nephrol, Singapore, Singapore.
   [Chua, Horng-Ruey; MacLaren, Graeme; Teo, Boon-Wee; Siow, Wen-Ting; Agrawal, Rohit Vijay; Vathsala, Anantharaman] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [MacLaren, Graeme] Natl Univ Singapore Hosp, Dept Cardiac Thorac & Vasc Surg, Cardiothorac Intens Care Unit, Singapore, Singapore.
   [Choong, Lina Hui-Lin; Choo, Jason Chon-Jun; Tan, Han-Khim; Tan, Chieh-Suai; Kaushik, Manish] Singapore Gen Hosp, Dept Renal Med, Singapore, Singapore.
   [Choong, Lina Hui-Lin; Sewa, Duu-Wen; Ng, Shin-Yi; Choo, Jason Chon-Jun; Tan, Han-Khim; Tan, Chieh-Suai; Kaushik, Manish] Duke NUS Med Sch, Singapore, Singapore.
   [Chionh, Chang-Yin] Changi Gen Hosp, Dept Renal Med, Singapore, Singapore.
   [Khoo, Benjamin Zhi En; Yeo, See-Cheng] Tan Tock Seng Hosp, Dept Renal Med, Singapore, Singapore.
   [Yeo, See-Cheng] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Sewa, Duu-Wen] Singapore Gen Hosp, Dept Resp & Crit Care Med, Singapore, Singapore.
   [Ng, Shin-Yi] Singapore Gen Hosp, Dept Surg Intens Care, Singapore, Singapore.
   [Siow, Wen-Ting] Natl Univ Singapore Hosp, Dept Med, Div Resp & Crit Care Med, Singapore, Singapore.
   [Agrawal, Rohit Vijay] Natl Univ Singapore Hosp, Dept Anaesthesia, Singapore, Singapore.
   [Tagore, Rajat] Ng Teng Fong Gen Hosp, Dept Med, Div Renal Med, Singapore, Singapore.
   [Seow, Terina Ying-Ying] Sengkang Gen Hosp, Dept Med, Div Renal Med, Singapore, Singapore.
   [Khatri, Priyanka; Hong, Wei-Zhen] Alexandra Hosp, Fast & Chron Programmes, Singapore, Singapore.
RP Chua, HR (corresponding author), Natl Univ Hlth Syst, Level 10 Med Off,Tower Block,1E Kent Ridge Rd S, Singapore 119228, Singapore.
EM horng_ruey_chua@nuhs.edu.sg
RI Teo, Boon Wee/E-4976-2014
OI Teo, Boon Wee/0000-0002-4911-8507
FU Baxter
FX Dr Chua reports prior research funding from Baxter in an
   investigator-initiated trial on CKRT. Dr Kaushik reports speaker fees
   from Baxter and Fresenius Medical Care. The remaining authors declare
   that they have no relevant financial interests.
CR Al Rifai A, 2018, HEMODIAL INT, V22, P50, DOI 10.1111/hdi.12550
   Allegretti AS, 2020, AM J NEPHROL, V51, P318, DOI 10.1159/000506412
   [Anonymous], 2012, KIDNEY INT S, V2, P107, DOI DOI 10.4172/2155-9910.1000107
   Baldwin I, 2009, SEMIN DIALYSIS, V22, P189, DOI 10.1111/j.1525-139X.2008.00547.x
   Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413
   Bellomo R, 2013, INTENS CARE MED, V39, P429, DOI 10.1007/s00134-012-2800-0
   Brain M, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0445-5
   Brown EA, 2016, CLIN J AM SOC NEPHRO, V11, P1522, DOI 10.2215/CJN.07040716
   Burgner A, 2020, CLIN J AM SOC NEPHRO, V15, P720, DOI 10.2215/CJN.03750320
   Chionh CY, 2013, CLIN J AM SOC NEPHRO, V8, P1649, DOI 10.2215/CJN.01540213
   Chionh CY, 2010, NEPHROL DIAL TRANSPL, V25, P3155, DOI 10.1093/ndt/gfq178
   Chionh CY, 2009, CONTRIB NEPHROL, V163, P278, DOI 10.1159/000223811
   Chua HR, 2020, J INTENSIVE CARE MED, V35, P527, DOI 10.1177/0885066618764617
   Chua HR, 2014, AM J KIDNEY DIS, V64, P909, DOI 10.1053/j.ajkd.2014.04.022
   Chua HR, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2012.08.016
   Clase CM, 2001, J THROMB THROMBOLYS, V11, P127, DOI 10.1023/A:1011272632286
   Connor MJ, 2017, ADV CHRONIC KIDNEY D, V24, P213, DOI 10.1053/j.ackd.2017.05.003
   Culley CM, 2006, AM J HEALTH-SYST PH, V63, P756, DOI 10.2146/ajhp050402
   Cullis B, 2014, PERITON DIALYSIS INT, V34, P494, DOI 10.3747/pdi.2013.00222
   Dimkovic Nada, 2009, Adv Perit Dial, V25, P165
   Fealy N, 2017, CRIT CARE MED, V45, pE1018, DOI 10.1097/CCM.0000000000002568
   Gabriel DP, 2008, KIDNEY INT, V73, pS87, DOI 10.1038/sj.ki.5002608
   Gashti CN, 2008, AM J KIDNEY DIS, V51, P804, DOI 10.1053/j.ajkd.2008.01.012
   Goettler CE, 2002, CRIT CARE, V6, P452, DOI 10.1186/cc1814
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Henderson S, 2009, NEPHROL DIAL TRANSPL, V24, P3499, DOI 10.1093/ndt/gfp312
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Hong WZ, 2019, J NEPHROL, V32, P605, DOI 10.1007/s40620-019-00616-z
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Joannidis M, 2020, INTENS CARE MED, V46, P654, DOI 10.1007/s00134-019-05869-7
   Jonckheer J, 2019, NUTR CLIN PRACT, V34, P37, DOI 10.1002/ncp.10231
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Lim CC, 2015, CARDIORENAL MED, V5, P157, DOI 10.1159/000381068
   Malard B, 2018, INTENS CARE MED EXP, V6, DOI 10.1186/s40635-018-0177-2
   Mendu ML, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0760-x
   Ministry of Health Singapore, 2019, RES STAT
   Ministry of Health Singapore, COVID 19 SIT REP
   Mitchell A, 2003, CLIN NEPHROL, V59, P106
   Morgera S, 2009, CRIT CARE MED, V37, P2018, DOI 10.1097/CCM.0b013e3181a00a92
   OudemansvanStraaten H, 2015, ACUTE NEPHROLOGY CRI, P203
   Parienti JJ, 2008, JAMA-J AM MED ASSOC, V299, P2413, DOI 10.1001/jama.299.20.2413
   Poh CB, 2020, NEPHROLOGY, V25, P305, DOI 10.1111/nep.13656
   Ponce Daniela, 2011, Adv Perit Dial, V27, P118
   Shum HP, 2014, ASAIO J, V60, P413, DOI 10.1097/MAT.0000000000000085
   Tan HK, 2019, BLOOD PURIFICAT, V47, P59, DOI 10.1159/000499633
   Tan HK, 2000, INTENS CARE MED, V26, P1652, DOI 10.1007/s001340000691
   Tolwani AJ, 2006, CLIN J AM SOC NEPHRO, V1, P79, DOI 10.2215/CJN.00040505
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yagi N, 1998, AM J KIDNEY DIS, V32, P1023, DOI 10.1016/S0272-6386(98)70078-2
   Yasuda H, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0539-4
   Zhai ZG, 2020, THROMB HAEMOSTASIS, V120, P937, DOI 10.1055/s-0040-1710019
NR 53
TC 5
Z9 5
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD SEP
PY 2020
VL 76
IS 3
BP 392
EP 400
DI 10.1053/j.ajkd.2020.05.008
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA NJ2DA
UT WOS:000565854500013
PM 32505811
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sourial, MY
   Sourial, MH
   Dalsan, R
   Graham, J
   Ross, M
   Chen, W
   Golestaneh, L
AF Sourial, Maryanne Y.
   Sourial, Mina H.
   Dalsan, Rochelle
   Graham, Jay
   Ross, Michael
   Chen, Wei
   Golestaneh, Ladan
TI Urgent Peritoneal Dialysis in Patients With COVID-19 and Acute Kidney
   Injury: A Single-Center Experience in a Time of Crisis in the United
   States
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
ID CRITICALLY-ILL PATIENTS; ACUTE-RENAL-FAILURE
AB At Montefiore Medical Center in The Bronx, NY, the first case of coronavirus disease 2019 (COVID-19) was admitted on March 11, 2020. At the height of the pandemic, there were 855 patients with COVID-19 admitted on April 13, 2020. Due to high demand for dialysis and shortages of staff and supplies, we started an urgent peritoneal dialysis (PD) program. From April 1 to April 22, a total of 30 patients were started on PD. Of those 30 patients, 14 died during their hospitalization, 8 were discharged, and 8 were still hospitalized as of May 14, 2020. Although the PD program was successful in its ability to provide much-needed kidney replacement therapy when hemodialysis was not available, challenges to delivering adequate PD dosage included difficulties providing nurse training and availability of supplies. Providing adequate clearance and ultrafiltration for patients in intensive care units was especially difficult due to the high prevalence of a hypercatabolic state, volume overload, and prone positioning. PD was more easily performed in non-critically ill patients outside the intensive care unit. Despite these challenges, we demonstrate that urgent PD is a feasible alternative to hemodialysis in situations with critical resource shortages.
C1 [Sourial, Maryanne Y.; Sourial, Mina H.; Dalsan, Rochelle; Ross, Michael; Chen, Wei; Golestaneh, Ladan] Albert Einstein Coll Med, Dept Med, Montefiore Med Ctr, Bronx, NY USA.
   [Graham, Jay] Albert Einstein Coll Med, Montefiore Einstein Ctr Transplantat, Dept Surg, Montefiore Med Ctr, Bronx, NY USA.
   [Chen, Wei] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA.
RP Sourial, MY (corresponding author), Montefiore Med Ctr, Div Nephrol, 3411 Wayne Ave,Ste 5H, Bronx, NY 10467 USA.
OI Golestaneh, Ladan/0000-0003-1848-582X
FU American Society of Nephrology Carl W. Gottschalk Research Grant;
   National Institute of Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [K23 DK114476]
FX Dr Chen is supported by the American Society of Nephrology Carl W.
   Gottschalk Research Grant and National Institute of Diabetes and
   Digestive and Kidney Diseases (K23 DK114476).
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Chionh CY, 2013, CLIN J AM SOC NEPHRO, V8, P1649, DOI 10.2215/CJN.01540213
   Chionh CY, 2010, NEPHROL DIAL TRANSPL, V25, P3155, DOI 10.1093/ndt/gfq178
   Cullis B, 2014, PERITON DIALYSIS INT, V34, P494, DOI 10.3747/pdi.2013.00222
   El Shamy Osama, 2020, Kidney Med, V2, P377, DOI 10.1016/j.xkme.2020.04.001
   Gabriel DP, 2008, KIDNEY INT, V73, pS87, DOI 10.1038/sj.ki.5002608
   Gabriel DP, 2007, PERITON DIALYSIS INT, V27, P277
   Gabriel DP, 2006, RENAL FAILURE, V28, P451, DOI 10.1080/0886022060081245
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Li PKT, 2016, PERITON DIALYSIS INT, V36, P481, DOI 10.3747/pdi.2016.00078
   Liu L, 2017, COCHRANE DB SYST REV, V12
   Ponce D, 2012, CLIN J AM SOC NEPHRO, V7, P887, DOI 10.2215/CJN.11131111
   Ronco C, 2001, NEPHROL DIAL TRANSPL, V16, P230, DOI 10.1093/ndt/16.2.230
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Srivatana V, 2020, KIDNEY360, V1, P410
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 18
TC 3
Z9 3
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD SEP
PY 2020
VL 76
IS 3
BP 401
EP 406
DI 10.1053/j.ajkd.2020.06.001
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA NJ2DA
UT WOS:000565854500014
PM 32534129
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Chen, J
   Wang, YK
   Gao, Y
   Hu, LS
   Yang, JW
   Wang, JR
   Sun, WJ
   Liang, ZQ
   Cao, YM
   Cao, YB
AF Chen, Jian
   Wang, Yong-kui
   Gao, Yuan
   Hu, Ling-San
   Yang, Jiang-wei
   Wang, Jian-ru
   Sun, Wen-jie
   Liang, Zhi-qiang
   Cao, Ye-min
   Cao, Yong-bing
TI Protection against COVID-19 injury by qingfei paidu decoction via
   anti-viral, anti-inflammatory activity and metabolic programming
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Qingfei paidu decoction; COVID-19; Functional units of network
   pharmacology; Anti-viral; Anti-inflammatory; Metabolic programming
ID VIRUS
AB Qingfei Paidu decoction (QFPD), a multi-component herbal formula, has been widely used to treat COVID-19 in China. However, its active compounds and mechanisms of action are still unknown. Firstly, we divided QFPD into five functional units (FUs) according to the compatibility theory of traditional Chinese medicine. The corresponding common targets of the five FUs were all significantly enriched in Go Ontology (oxidoreductase activity, lipid metabolic process, homeostatic process, etc.), KEGG pathways (steroid biosynthesis, PPAR signaling pathway, adipocytokine signaling pathway, etc.), TTD diseases (chronic inflammatory diseases, asthma, chronic obstructive pulmonary Disease, etc.), miRNA (MIR183), kinase (CDK7) and TF (LXR). QFPD contained 257 specific targets in addition to HCoV, pneumonia and ACE2 co-expression proteins. Then, network topology analysis of the five components-target-pathway-disease networks yielded 67 active ingredients. In addition, ADMET estimations showed that 20 compounds passed the stringent lead-like criteria and in silico drug-likeness test with high gastrointestinal absorption and the median lethal dose (LD50> 1600 mg/kg). Moreover, 4 specific ingredients (M3, S1, X2 and O2) and 5 common ingredients (MS1, MX16, SX1, WO1 and XO1) of QFPD presented good molecular docking score for 2019-nCov structure and non-structure proteins. Finally, drug perturbation of COVID-19 network robustness showed that all five FUs may protect COVID-19 independently, and target 8 specifically expressed drug-attacked nodes which were related to the bacterial and viral responses, immune system, signaling transduction, etc. In conclusion, our new FUNP analysis showed that QFPD had a protection effect on COVID-19 by regulating a complex molecular network with safety and efficacy. Part of the mechanism was associated with the regulation of anti-viral, anti-inflammatory activity and metabolic programming.
C1 [Chen, Jian; Liang, Zhi-qiang; Cao, Ye-min; Cao, Yong-bing] Shanghai Univ Tradit Chinese Med, Shanghai TCM Integrated Hosp, Shanghai 200082, Peoples R China.
   [Chen, Jian; Cao, Ye-min; Cao, Yong-bing] Shanghai Acad Tradit Chinese Med, Inst Vasc Anomalies, Shanghai 200082, Peoples R China.
   [Wang, Yong-kui] Zhengzhou Univ, Dept Orthopaed, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China.
   [Gao, Yuan] Tradit Chinese Recovery & Treatment Ctr, Zhejiang Rehabil Med Ctr, Hangzhou 310053, Peoples R China.
   [Hu, Ling-San] Bao An Hosp Tradit Chinese Med, Shenzhen 518133, Peoples R China.
   [Yang, Jiang-wei] Tongde Hosp Zhejiang Prov, Mental Hlth Ctr, Hangzhou 310012, Peoples R China.
   [Wang, Jian-ru] Henan Univ Tradit Chinese M, Affiliated Hosp 1, Zhengzhou 450000, Peoples R China.
   [Sun, Wen-jie] Shanghai Univ Tradit Chinese Med, Putuo Hosp, Dept Gen Surg, Shanghai 200062, Peoples R China.
RP Liang, ZQ; Cao, YM; Cao, YB (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai TCM Integrated Hosp, Shanghai 200082, Peoples R China.
EM liangzhiqiang006@163.com; 595488832@qq.com; 1156387264@qq.com
FU Shanghai Natural Science FoundationNatural Science Foundation of
   Shanghai [17ZR1427600]; National Science and Technology Major Projects
   for "Major New Drugs Innovation and Development"
   [2018ZX09201008-002-091, 2018ZX09201008-002-092]; Threeyear Action Plan
   of "strong and excellent Chinese Medicine" in Hongkou District
   [HGY-MGB-2018-01-01]; Shanghai Science and Technology Support Project in
   Biomedicine Field [18401932900]; Budgetary Projects of Shanghai
   University of Traditional Chinese Medicine [2019LK046]; Special Clinical
   Research Project of Health Profession of Shanghai Municipal Commission
   of Health [20194Y0081]
FX This work was supported by the Shanghai Natural Science Foundation
   (17ZR1427600), National Science and Technology Major Projects for "Major
   New Drugs Innovation and Development" (2018ZX09201008-002-091 and
   2018ZX09201008-002-092), Threeyear Action Plan of "strong and excellent
   Chinese Medicine" in Hongkou District (HGY-MGB-2018-01-01), Shanghai
   Science and Technology Support Project in Biomedicine Field
   (18401932900), Budgetary Projects of Shanghai University of Traditional
   Chinese Medicine (2019LK046), Special Clinical Research Project of
   Health Profession of Shanghai Municipal Commission of Health
   (20194Y0081).
CR [Anonymous], 2020, COVID 19 GLOBAL PAND
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918
   Chand K, 2020, ARAB J CHEM, V13, P8248, DOI [10.1142/S0192415X20500378, 10.1016/j.arabjc.2020.01.009]
   Chen J, 2020, BIOTECHNOL APPL BIOC, DOI 10.1002/bab.1934
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng PW, 2006, INT IMMUNOPHARMACOL, V6, P1003, DOI 10.1016/j.intimp.2006.01.011
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Go JT, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-627
   Guo FF, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00049
   Holcakova J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089228
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007-1110
   Hsieh CF, 2012, J ETHNOPHARMACOL, V143, P57, DOI 10.1016/j.jep.2012.05.061
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang SR, 2020, INT J MED ROBOT COMP, V16, DOI 10.1002/rcs.2081
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Kitano H, 2007, NAT REV DRUG DISCOV, V6, P202, DOI 10.1038/nrd2195
   Kong R., 2020, ARXIV200300163
   Li YT, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-398
   Lin CC, 2020, J ETHNOPHARMACOL, V253, DOI 10.1016/j.jep.2020.112656
   Liu F., 2020, 20029181 MEDRXIV, V2020, P28
   Liu N, 2020, TMR MOD HERBAL MED, V3, P1
   Liu ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep21146
   Obayashi T, 2019, NUCLEIC ACIDS RES, V47, pD55, DOI 10.1093/nar/gky1155
   Ortiz CLD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52764-8
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Schang LM, 2002, J VIROL, V76, P7874, DOI 10.1128/JVI.76.15.7874-7882.2002
   Sedger LM, 2013, MOL IMMUNOL, V56, P781, DOI 10.1016/j.molimm.2013.07.009
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sun WJ, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109656
   Tambyah PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076811
   Tan L, 2020, ADV SCI, V7, DOI 10.1002/advs.201902070
   Teague SJ, 1999, ANGEW CHEM INT EDIT, V38, P3743, DOI 10.1002/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.3.CO;2-L
   Walters JRF, 2002, CURR OPIN GASTROEN, V18, P161, DOI 10.1097/00001574-200203000-00002
   Wang J., 2020, 20020545 MEDRXIV
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Yang Y, 2015, J ETHNOPHARMACOL, V169, P49, DOI 10.1016/j.jep.2015.04.011
   Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
   Zhao B., 2020, BIORXIV, V2020
   Zheng NN, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/529458
   Zhou Y., 2020, 20020263 MEDRXIV, V2020, P3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 45
TC 9
Z9 9
U1 13
U2 15
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD SEP
PY 2020
VL 129
AR 110281
DI 10.1016/j.biopha.2020.110281
PG 16
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NJ9PA
UT WOS:000566374500008
PM 32554251
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xin, SY
   Cheng, XQ
   Zhu, B
   Liao, XL
   Yang, F
   Song, LN
   Shi, Y
   Guan, XF
   Su, RY
   Wang, J
   Xing, LM
   Xu, XP
   Jin, L
   Liu, YP
   Zhou, W
   Zhang, DW
   Liang, L
   Yu, Y
   Yu, R
AF Xin, Siyi
   Cheng, Xueqi
   Zhu, Bo
   Liao, Xiaolong
   Yang, Feng
   Song, Lina
   Shi, Yan
   Guan, Xuefeng
   Su, Renyi
   Wang, Jian
   Xing, Limin
   Xu, Xiping
   Jin, Lin
   Liu, Yanping
   Zhou, Wei
   Zhang, Dongwei
   Liang, Liang
   Yu, You
   Yu, Rui
TI Clinical retrospective study on the efficacy of Qingfei Paidu decoction
   combined with Western medicine for COVID-19 treatment
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE COVID-19; Qingfei Paidu decoction; Traditional Chinese medicine;
   Clinical trials
ID CHINESE MEDICINE; CORONAVIRUS; SARS
AB Background: Coronavirus disease 2019 (COVID-19)(2) has emerged as a global pandemic. However, as effective treatments for this disease are still unclear, safe and efficient therapies are urgently needed. Qingfei Paidu decoction (QPD)(3) is strongly recommended in the Chinese Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 6th Edition). However, clinical research data on the effects of QPD on COVID-19 are scarce. Our study aimed to explore the effects of combined treatment with QPD and Western medicine on COVID-19.
   Methods: In this study, 63 patients with confirmed COVID-19 were analyzed. During the first 14 days of hospitalization, patients with deteriorating symptoms were administered QPD along with Western medicine therapy (the antiviral medicine selected from interferon, lopinavir, or arbidol). The clinical characteristics and blood laboratory indices (blood routine, inflammatory factors, and multi-organ biochemical indices) were examined, and the total lung severity scores were evaluated in each patient by reviewing chest computed tomography before treatment and at the end of treatment.
   Results: Before QPD treatment, the combined treatment group showed higher blood C-reactive protein levels and more severe pulmonary inflammation and clinical symptoms than the Western medicine treatment group. Both groups met the discharge criteria after a similar length of hospitalization. At the end of treatment, circulating white blood cells, total lymphocyte count, and glutamic-oxaloacetic transaminase levels improved dramatically in both groups (P < 0.05). In contrast, C-reactive protein, creatine kinase, creatine kinase-myocardial band, lactate dehydrogenase, and blood urea nitrogen levels were improved only in the combined treatment group (P < 0.05), and C-reactive protein and creatine kinase were the most pronounced (P < 0.01). Compared with baseline, at the end of treatment, the proportion of patients with normal values of C-reactive protein, total lymphocyte count, and lactate dehydrogenase were increased in the combined treatment group (P < 0.05), whereas no significant difference was observed in the Western medicine treatment group (P > 0.05).
   Conclusion: The combination of QPD with Western medicine demonstrated significant anti-inflammatory effects compared with those of only Western medicine in patients with mild and moderate COVID-19; however, neither mortality nor length of hospitalization was affected. Moreover, the combined treatment tended to mitigate the extent of multi-organ impairment. Long-term randomized controlled trials with follow-up evaluations are required to confirm the results presented here.
C1 [Xin, Siyi; Cheng, Xueqi; Zhu, Bo; Liao, Xiaolong; Yang, Feng; Song, Lina; Su, Renyi; Wang, Jian; Xing, Limin; Xu, Xiping; Jin, Lin; Liu, Yanping; Zhou, Wei] Hubei Univ Med, Affiliated Hosp, Xiangyang 1 Peoples Hosp, Xiangyang 441000, Hubei, Peoples R China.
   [Shi, Yan; Guan, Xuefeng; Yu, Rui] Liaoning Univ Tradit Chinese Med, Shenyang 110847, Liaoning, Peoples R China.
   [Zhang, Dongwei; Liang, Liang] Liaoning Univ Tradit Chinese Med, Affiliated Hosp 1, Shenyang 110031, Liaoning, Peoples R China.
   [Yu, You] Liaoning Univ Tradit Chinese Med, Affiliated Hosp 2, Shenyang 110034, Liaoning, Peoples R China.
RP Yu, R (corresponding author), Liaoning Univ Tradit Chinese Med, Dept Sci & Technol, 79 Chongshan E Rd, Shenyang 110847, Liaoning, Peoples R China.
EM xinsiyi_122744763@163.com; cheng_xueqi@163.com; 274770142@qq.com;
   122744763@qq.com; haitang76@163.com; nana_loving2012@163.com;
   446139675@qq.com; lnzygxf@163.com; 1574980469@qq.com; Wj3421218@163.com;
   xinglimin97@126.com; 4251061945@qq.com; 466843190@qq.com;
   smilelyp2014@163.com; yiyang291314@163.com; lovezdw1980@126.com;
   soso314@163.com; 526385550@qq.com; yurui196909@163.com
OI CHENG, Xueqi/0000-0001-9909-0015
FU Liaoning Province "Xingliao Talent Program" Innovation Leading Talent
   Project [XLYC1802004]; National Nature Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81903005];
   Natural Science Foundation of Hubei ProvinceNatural Science Foundation
   of Hubei Province [2017CFB674]
FX This work was supported by: Liaoning Province "Xingliao Talent Program"
   Innovation Leading Talent Project (XLYC1802004); National Nature Science
   Foundation of China (81903005); and Natural Science Foundation of Hubei
   Province (2017CFB674).
CR Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2020.02.033, 10.1016/j.jiph.2019.02.033]
   [Anonymous], 2020, NOVEL CORONAVIRUS PN
   [Anonymous], 2015, GEN PRINCIPLES CLIN
   Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Chen Z, 2004, PHYTOTHER RES, V18, P592, DOI 10.1002/ptr.1485
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1039, DOI 10.1001/jama.2020.1490
   Deng YF, 2012, PHARM BIOL, V50, P401, DOI 10.3109/13880209.2011.608076
   Gray PE, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104776
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsu CH, 2006, J ALTERN COMPLEM MED, V12, P505, DOI 10.1089/acm.2006.12.505
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu Bao-yan, 2005, Zhongguo Zhong Yao Za Zhi, V30, P1874
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Lu HM, 2006, J ETHNOPHARMACOL, V104, P245, DOI 10.1016/j.jep.2005.09.012
   Poon PMK, 2006, AM J CHINESE MED, V34, P13, DOI 10.1142/S0192415X0600359X
   Wu J, 2020, INVEST RADIOL, V55, P257, DOI 10.1097/RLI.0000000000000670
   Xin YM, 2020, ADV MATER TECHNOL-US, V5, DOI 10.1002/admt.202000018
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhang JH, 2020, J INFECTION, V80, P690, DOI 10.1016/j.jinf.2020.02.001
   [赵静 Zhao Jing], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P829
NR 24
TC 4
Z9 4
U1 7
U2 7
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD SEP
PY 2020
VL 129
AR 110500
DI 10.1016/j.biopha.2020.110500
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NJ9TU
UT WOS:000566386900013
PM 32768975
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Borger, V
   Weiss, DJ
   Anderson, JD
   Borras, FE
   Bussolati, B
   Carter, DRF
   Dominici, M
   Falcon-Perez, JM
   Gimona, M
   Hill, AF
   Hoffman, AM
   de Kleijn, D
   Levine, BL
   Lim, R
   Lotvall, J
   Mitsialis, SA
   Monguio-Tortajada, M
   Muraca, M
   Nieuwland, R
   Nowocin, A
   O'Driscoll, L
   Ortiz, LA
   Phinney, DG
   Reischl, I
   Rohde, E
   Sanzenbacher, R
   Thery, C
   Toh, WS
   Witwer, KW
   Lim, SK
   Giebel, B
AF Boerger, Verena
   Weiss, Daniel J.
   Anderson, Johnathon D.
   Borras, Francesc E.
   Bussolati, Benedetta
   Carter, David R. F.
   Dominici, Massimo
   Falcon-Perez, Juan M.
   Gimona, Mario
   Hill, Andrew F.
   Hoffman, Andrew M.
   Kleijn, Dominique de
   Levine, Bruce L.
   Lim, Rebecca
   Lotvall, Jan
   Mitsialis, S. Alex
   Monguio-Tortajada, Marta
   Muraca, Maurizio
   Nieuwland, Rienk
   Nowocin, Anna
   O'Driscoll, Lorraine
   Ortiz, Luis A.
   Phinney, Donald G.
   Reischl, Ilona
   Rohde, Eva
   Sanzenbacher, Ralf
   Thery, Clotilde
   Toh, Wei Seong
   Witwer, Kenneth W.
   Lim, Sai Kiang
   Giebel, Bernd
TI International Society for Extracellular Vesicles and International
   Society for Cell and Gene Therapy statement on extracellular vesicles
   from mesenchymal stromal cells and other cells: considerations for
   potential therapeutic agents to suppress coronavirus disease-19
SO CYTOTHERAPY
LA English
DT Article
ID STEM-CELLS; LUNG INJURY; EXOSOMES; HETEROGENEITY; MICROVESICLES; MODELS
AB STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight. (C) 2020 International Society for Cell and Gene Therapy. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
C1 [Boerger, Verena; Giebel, Bernd] Univ Duisburg Essen, Univ Hosp Essen, Inst Transfus Med, Virchowstr 179, D-45147 Essen, Germany.
   [Weiss, Daniel J.] Univ Vermont, Dept Med, Burlington, VT USA.
   [Anderson, Johnathon D.] Univ Calif Davis, Dept Otolaryngol, Stem Cell Program, Davis, CA 95616 USA.
   [Borras, Francesc E.] Hlth Sci Res Inst Germans Trias & Pujol IGTP, REMAR IVECAT Grp, Can Ruti Campus, Badalona, Spain.
   [Borras, Francesc E.] Germans Trias & Pujol Univ Hosp, Nephrol Serv, Badalona, Spain.
   [Bussolati, Benedetta] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Turin, Italy.
   [Carter, David R. F.] Oxford Brookes Univ, Dept Biol & Med Sci, Oxford, England.
   [Dominici, Massimo] Univ Hosp Modena, Dept Med & Surg Sci Children & Adults, Modena, Italy.
   [Falcon-Perez, Juan M.] Basque Res & Technol Alliance BRTA, Ctr Cooperat Res Biosci CIC bioGUNE, Exosomes Lab, Derio, Spain.
   [Falcon-Perez, Juan M.] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Falcon-Perez, Juan M.] Basque Fdn Sci, Ikerbasque, Bilbao, Spain.
   [Gimona, Mario; Rohde, Eva] Paracelsus Med Univ PMU, GMP Unit, Spinal Cord Injury & Tissue Regenerat Ctr Salzbur, Salzburg, Austria.
   [Gimona, Mario] Paracelsus Med Univ PMU, EV TT Transfer Ctr, Spinal Cord Injury & Tissue Regenerat Ctr Salzbur, Salzburg, Austria.
   [Hill, Andrew F.] La Trobe Univ, La Trobe Inst Mol Sci, Bundoora, Vic, Australia.
   [Hoffman, Andrew M.] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA.
   [Kleijn, Dominique de] Univ Med Ctr Utrecht, Dept Vasc Surg, Utrecht, Netherlands.
   [Kleijn, Dominique de] Netherlands Heart Inst, Utrecht, Netherlands.
   [Levine, Bruce L.] Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA.
   [Lim, Rebecca] Monash Univ, Hudson Inst Med Res, Dept Obstet & Gynaecol, Melbourne, Vic, Australia.
   [Lim, Rebecca] Ritchie Ctr, Melbourne, Vic, Australia.
   [Lotvall, Jan] Univ Gothenburg, Sahlgrenska Acad, Krefting Res Ctr, Inst Med, Gothenburg, Sweden.
   [Mitsialis, S. Alex] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
   [Mitsialis, S. Alex] Boston Childrens Hosp, Boston, MA USA.
   [Monguio-Tortajada, Marta] Hlth Sci Res Inst Germans Trias & Pujol IGTP, ICREC Res Program, Can Ruti Campus, Badalona, Spain.
   [Monguio-Tortajada, Marta] Germans Trias & Pujol Univ Hosp, Cardiol Serv, Badalona, Spain.
   [Muraca, Maurizio] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy.
   [Nieuwland, Rienk] Univ Amsterdam, Lab Expt Clin Chem, Dept Clin Chem, Amsterdam, Netherlands.
   [Nieuwland, Rienk] Univ Amsterdam, Vesicle Observat Ctr, Amsterdam UMC, Amsterdam, Netherlands.
   [Nowocin, Anna] Med & Healthcare Prod Regulatory Agcy, Natl Inst Biol Stand & Control NIBSC, Biotherapeut, Potters Bar, Herts, England.
   [O'Driscoll, Lorraine] Triniy Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, Ireland.
   [O'Driscoll, Lorraine] Triniy Coll Dublin, Trinity Biomed Sci Inst, Dublin, Ireland.
   [Ortiz, Luis A.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA.
   [Phinney, Donald G.] Scripps Res Inst, Dept Mol Therapeut, Jupiter, FL USA.
   [Reischl, Ilona] Fed Off Safety Hlth Care BASG, Vienna, Austria.
   [Reischl, Ilona] Austrian Agcy Hlth & Food Safety AGES, Inst Surveillance, Vienna, Austria.
   [Rohde, Eva] Salzburger Landeskliniken GesmbH SALK, Univ Hosp, Dept Transfus Med, Salzburg, Austria.
   [Sanzenbacher, Ralf] Paul Ehrlich Inst, Fed Inst Vaccines & Biomed, Sect Tissue Engn & Cell Therapeut, Langen, Germany.
   [Thery, Clotilde] PSL Res Univ, Inst Curie, INSERM, U932/, Paris, France.
   [Toh, Wei Seong] Natl Univ Singapore, Fac Dent, Singapore, Singapore.
   [Witwer, Kenneth W.] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD USA.
   [Witwer, Kenneth W.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Lim, Sai Kiang] Agcy Sci Technol & Res, Inst Mol & Cellular Biol, Singapore, Singapore.
RP Giebel, B (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Inst Transfus Med, Virchowstr 179, D-45147 Essen, Germany.; Lim, SK (corresponding author), Agcy Sci Technol & Res, Inst Mol & Cellular Biol, Singapore, Singapore.; Witwer, KW (corresponding author), Johns Hopkins Univ, Sch Med, 733 N Broadway,MRB 827, Baltimore, MD 21205 USA.
EM kwitwer@jhmi.edu; Lim_Sai_Kiang@imcb.a-star.edu.sg;
   bernd.giebel@uk-essen.de
RI Witwer, Kenneth W./G-1626-2013; ortiz, luis a/H-9851-2013; Dominici,
   Massimo/K-8014-2016; thery, clotilde/F-6373-2013; BORRAS, FRANCESC
   E./P-2287-2017
OI Witwer, Kenneth W./0000-0003-1664-4233; ortiz, luis
   a/0000-0003-4510-7066; thery, clotilde/0000-0001-8294-6884; Anderson,
   Johnathon/0000-0001-5404-2298; BORRAS, FRANCESC E./0000-0003-4038-1912
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [KL2 TR001859, UL1 TR001860] Funding
   Source: Medline; NHLBI NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [T32 HL086350] Funding Source: Medline
CR Arslan F, 2013, STEM CELL RES, V10, P301, DOI 10.1016/j.scr.2013.01.002
   Borger V, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071450
   Chance TC, 2019, J TRAUMA ACUTE CARE, V87, pS74, DOI 10.1097/TA.0000000000002225
   Chen G, 2020, J CLIN INVEST, V130
   Chen TS, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-47
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Doeppner TR, 2015, STEM CELL TRANSL MED, V4, P1131, DOI 10.5966/sctm.2015-0078
   Giebel B, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.03.49
   Gimona M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061190
   Hao Q, 2019, J IMMUNOL, V203, P1961, DOI 10.4049/jimmunol.1801534
   Huang RQ, 2019, AGING-US, V11, P7996, DOI 10.18632/aging.102314
   Khatri M, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0774-8
   Khoury M, 2020, CYTOTHERAPY
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   Kordelas L, 2014, LEUKEMIA, V28, P970, DOI 10.1038/leu.2014.41
   Laffey JG, 2017, AM J RESP CRIT CARE, V196, P266, DOI 10.1164/rccm.201701-0107CP
   Lener T, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.30087
   Liu JP, 2019, INT J MED SCI, V16, P1238, DOI 10.7150/ijms.35369
   Magro C, 2020, TRANSL RES
   Mahida RY, 2020, AM J RESP CELL MOL B
   Mansouri N, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128060
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monsel A, 2015, AM J RESP CRIT CARE, V192, P324, DOI 10.1164/rccm.201410-1765OC
   Morrison TJ, 2017, AM J RESP CRIT CARE, V196, P1275, DOI 10.1164/rccm.201701-0170OC
   Nassar Wael, 2016, Biomater Res, V20, P21, DOI 10.1186/s40824-016-0068-0
   Pachler K, 2017, CYTOTHERAPY, V19, P458, DOI 10.1016/j.jcyt.2017.01.001
   Park KS, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1352-4
   Phinney DG, 1999, J CELL BIOCHEM, V75, P424, DOI 10.1002/(SICI)1097-4644(19991201)75:3<424::AID-JCB8>3.0.CO;2-8
   Phinney DG, 2012, J CELL BIOCHEM, V113, P2806, DOI 10.1002/jcb.24166
   Qin C, 2020, CLIN INFECT DIS
   Radtke S, 2016, CELL CYCLE, V15, P540, DOI 10.1080/15384101.2015.1128591
   Reiner AT, 2017, STEM CELL TRANSL MED, V6, P1730, DOI 10.1002/sctm.17-0055
   Rohde E, 2019, CYTOTHERAPY, V21, P581, DOI 10.1016/j.jcyt.2018.12.006
   Silachev DN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030258
   Varkouhi AK, 2019, ANESTHESIOLOGY, V130, P778, DOI 10.1097/ALN.0000000000002655
   Vogel W, 2003, HAEMATOLOGICA, V88, P126
   Wang C, 2020, STROKE
   Willis GR, 2018, AM J RESP CRIT CARE, V197, P104, DOI 10.1164/rccm.201705-0925OC
   Witwer KW, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1609206
   Worthington EN, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072318
   Yang Y., 2020, EXUBERANT ELEVATION
   Zhang B, 2018, CYTOTHERAPY, V20, P687, DOI 10.1016/j.jcyt.2018.02.372
   Zhang B, 2014, STEM CELLS DEV, V23, P1233, DOI 10.1089/scd.2013.0479
   Zhu YG, 2014, STEM CELLS, V32, P116, DOI 10.1002/stem.1504
NR 45
TC 7
Z9 7
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465-3249
EI 1477-2566
J9 CYTOTHERAPY
JI Cytotherapy
PD SEP
PY 2020
VL 22
IS 9
BP 482
EP 485
DI 10.1016/j.jcyt.2020.05.002
PG 4
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Hematology; Medicine, Research & Experimental
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
   & Experimental Medicine
GA NK1KB
UT WOS:000566497100003
PM 32425691
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Postel-Vinay, S
   Massard, C
   Soria, JC
AF Postel-Vinay, Sophie
   Massard, Christophe
   Soria, Jean-Charles
TI Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we
   consider a specific patient management?
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Phase 1; COVID-19; SARS-Cov-2; Drug development
AB The outbreak of the Coronavirus disease (COVID-19) pandemic has deeply challenged healthcare systems and care of patients with cancer. Phase 1 studies are among the most complicated clinical trials and require thorough patient selection, as well as intensive patient monitoring. In this perspective, we discuss the key factors that should be considered for the conduct of phase 1 trials and management of COVID-19-positive patients with cancer enrolled in such trials. We notably present the risks and challenges raised by COVID-19-infected phase 1 patients, in terms of safety, toxicity causality assessment, drug efficacy evaluation and clinical research priorities. We finally propose some guidelines for the conduct of phase 1 trials and management of COVID-19-infected patients in a pandemic time. (c) 2020 Elsevier Ltd. All rights reserved.
C1 [Postel-Vinay, Sophie; Massard, Christophe; Soria, Jean-Charles] Gustave Roussy, DITEP, Drug Dev Dept, Villejuif, France.
   [Postel-Vinay, Sophie; Massard, Christophe; Soria, Jean-Charles] Univ Paris Sud, Univ Paris Saclay, Fac Med, Le Kremlin Bicetre, France.
   [Postel-Vinay, Sophie] Gustave Roussy, Inserm Unit U981, ATIP Avenir Grp, Villejuif, France.
RP Postel-Vinay, S (corresponding author), Gustave Roussy, DITEP, Drug Dev Dept, Villejuif, France.
EM sophie.postel-vinay@gustaveroussy.fr
RI Soria, Jean-Charles/F-3619-2014
OI Postel-Vinay, Sophie/0000-0001-5562-1857
CR Barlesi F, 2020, AACR ANN C 2020, P2020
   Chakiba C, 2018, NEW ENGL J MED, V378, P2242, DOI 10.1056/NEJMc1803837
   de Miguel M, 2020, CANCER
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gibbons HR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46516-x
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Horby P., 2020, EFFECT DEXAMETHASONE
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Michot J -M, 2020, ANN ONCOL
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Sanchez-Ventura J, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1511-7
   Sud A, 2020, COLLETARAL DAMAGE IM
   Zhang L., 2020, ANN ONCOL
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD SEP
PY 2020
VL 137
BP 235
EP 239
DI 10.1016/j.ejca.2020.07.009
PG 5
WC Oncology
SC Oncology
GA NK4UK
UT WOS:000566726800025
PM 32805640
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Haroon, A
   Alnassani, M
   Aljurf, M
   Ahmed, SO
   Shaheen, M
   Hanbli, A
   Chaudhari, N
   El Fakih, R
AF Haroon, Alfadil
   Alnassani, Momen
   Aljurf, Mahmoud
   Ahmed, Syed Osman
   Shaheen, Marwan
   Hanbli, Amr
   Chaudhari, Naeem
   El Fakih, Riad
TI COVID-19 post Hematopoietic Cell Transplant, a Report of 11 Cases from a
   Single Center
SO MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
LA English
DT Article
DE Coronavirus; COVID-19; SARS-CoV-2; Hematopoietic cell transplant; Bone
   marrow transplant; Stem cell transplant; Multiple myeloma; Acute
   lymphoblastic leukemia; Lymphoma
AB In late 2019 the coronavirus disease-2019 (COVID-19) pandemic caused by SARS Coronavirus 2 (SARS- CoV-2) started in Wuhan, China. Life has changed radically since then. Data emerging from the first hit countries show a tendency for a complicated course and higher mortality in some subgroups of infected patients. Cancer patients are immunosuppressed from their disease and the therapy they receive. Hematopoietic cell transplant (HCT) recipients are a subgroup of patients that are severely immunocompromised and may be at an even higher risk of a complicated course during this infection. Reports describing the course of these patients with COVID-19 disease are limited. We herein report the onset, progression, and outcome of 11 sequential cases of HCT recipients infected by SARS-CoV-2 treated in our center. The patients' age ranged from 17 to 60 years, the duration from transplant to infection ranged from day +5 to 192 months, six patients were post-allo-HCT, four post-auto-HCT, and one had both allo and autoHCT. The presenting symptoms were not different from other viral illnesses. The majority (seven patients) had mild COVID-19 stage, while 3 had a moderate stage on presentation. None of the patients required oxygen supplementation nor mechanical ventilation.
C1 [Haroon, Alfadil; Alnassani, Momen; Aljurf, Mahmoud; Ahmed, Syed Osman; Shaheen, Marwan; Hanbli, Amr; Chaudhari, Naeem; El Fakih, Riad] King Faisal Specialist Hosp & Res Ctr, Ctr Oncol, Riyadh, Saudi Arabia.
RP Haroon, A; El Fakih, R (corresponding author), KFSHRC, Ctr Oncol, Sect Adult Hematol HSCT, POB 3354, Riyadh 11471, Saudi Arabia.
EM halfadil@kfshrc.edu.sa; riadfakih@hotmail.com
CR Anurathapan U, 2020, BONE MARROW TRANSPL, V55, P2359, DOI 10.1038/s41409-020-0969-3
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Gavillet M, 2020, LEUKEMIA RES, V92, DOI 10.1016/j.leukres.2020.106353
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01227-2020
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Miyashita H, 2020, ANN ONCOL, DOI [10.1016/j.annonc.2020.04.006, DOI 10.1016/J.ANN0NC.2020.04.006]
   Niederwieser D, 2019, ONE HALF MILLION HEM, DOI [10.1182/blood-2019-125232, DOI 10.1182/BLOOD-2019-125232]
   Saraceni F, 2020, TRANSPL INFECT DIS, DOI 10.1111/tid.13401
   Vicent MG, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28514
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   World Health O, 2020, INF CONS PRIOR CAND, P2020
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
NR 15
TC 1
Z9 1
U1 0
U2 0
PU MATTIOLI 1885
PI FIDENZA
PA VIA DELLA LODESANA 649-SX, FIDENZA, 43046 PR, ITALY
EI 2035-3006
J9 MEDITERR J HEMATOL I
JI Med. J. Hematol. Infect. Dis.
PD SEP 1
PY 2020
VL 12
AR e2020070
DI 10.4084/MJHID.2020.070
PG 8
WC Hematology; Infectious Diseases
SC Hematology; Infectious Diseases
GA NJ7PN
UT WOS:000566235200001
PM 32952981
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Frauenfelder, C
   Brierley, J
   Whittaker, E
   Perucca, G
   Bamford, A
AF Frauenfelder, Claire
   Brierley, Joe
   Whittaker, Elizabeth
   Perucca, Giulia
   Bamford, Alasdair
TI Infant With SARS-CoV-2 Infection Causing Severe Lung Disease Treated
   With Remdesivir
SO PEDIATRICS
LA English
DT Article
ID CHILDREN
AB We describe the case of an infant who developed severe pulmonary SARS-CoV-2 infection in the fifth week of life and was treated with remdesivir. We describe an ex-premature infant presenting with severe acute respiratory syndrome coronavirus 2 infection in the fifth week of life. In current reports, researchers indicate that acute symptomatic severe acute respiratory syndrome coronavirus 2 infection is relatively rare and much less severe than in adults. This case highlights that infection can be associated with life-threatening pulmonary disease in young infants and that infection can follow a similar disease course to that described in adults. We provide first data on the use of the novel antiviral remdesivir in a young child and an innovative approach to expedited approval from a multidisciplinary clinical team and bioethics committee for compassionate access to the drug.
C1 [Frauenfelder, Claire; Brierley, Joe; Perucca, Giulia; Bamford, Alasdair] Great Ormond St Children Natl Hlth Serv Fdn Trust, London, England.
   [Frauenfelder, Claire] Univ Adelaide, Div Surg, Adelaide Med Sch, Adelaide, SA, Australia.
   [Whittaker, Elizabeth] Imperial Coll Healthcare Natl Hlth Serv Trust, Dept Paediat Infect Dis, London, England.
   [Bamford, Alasdair] UCL, Great Ormond St Inst Child Hlth, London, England.
RP Bamford, A (corresponding author), Great Ormond St Hosp Children NHS Fdn Trust, Dept Paediat Infect Dis, Great Ormond St, London WC1N 3JH, England.
EM a.bamford@ucl.ac.uk
OI Whittaker, Elizabeth/0000-0002-7944-8793
CR Aghdam MK, 2020, INFECT DIS-NOR, V52, P427, DOI 10.1080/23744235.2020.1747634
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Brierley J, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc1915778
   Brierley J, 2009, ARCH DIS CHILD, V94, P651, DOI 10.1136/adc.2008.155317
   Chawla S, 2017, J PEDIATR-US, V189, P113, DOI 10.1016/j.jpeds.2017.04.050
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   De Luca D, 2017, LANCET RESP MED, V5, P657, DOI 10.1016/S2213-2600(17)30214-X
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dornemann J, 2017, J INFECT DIS, V215, P171, DOI 10.1093/infdis/jiw493
   European Medicines Agency, EMA PROV REC COMP US
   Ferguson KN, 2017, JAMA PEDIATR, V171, P165, DOI 10.1001/jamapediatrics.2016.3015
   Frauenfelder C, 2020, INT J PEDIATR OTORHI, V134, DOI 10.1016/j.ijporl.2020.110030
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Han YN, 2020, J MED VIROL, V92, P1596, DOI 10.1002/jmv.25835
   Jouvet P, 2015, PEDIATR CRIT CARE ME, V16, P428, DOI 10.1097/PCC.0000000000000350
   Kam KQ, 2020, CLIN INFECT DIS, V71, P847, DOI 10.1093/cid/ciaa201
   Kelvin AA, 2020, LANCET INFECT DIS, V20, P633, DOI 10.1016/S1473-3099(20)30236-X
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Kochi AN, 2020, J CARDIOVASC ELECTR, V31, P1003, DOI 10.1111/jce.14479
   Kuriyama A, 2017, CHEST, V151, P1002, DOI 10.1016/j.chest.2017.02.017
   Larcher V, 2018, BIOETHICS, V32, P36, DOI 10.1111/bioe.12381
   Le HT, 2020, LANCET CHILD ADOLESC, V4, P405, DOI 10.1016/S2352-4642(20)30091-2
   Li W, 2020, PEDIATR RADIOL, V50, P796, DOI 10.1007/s00247-020-04656-7
   Lovato A, 2020, ENT-EAR NOSE THROAT, V99, P569, DOI 10.1177/0145561320920762
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Markovitz BP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001000.pub2
   Maughan EF, CELL INTRINSIC DIFFE, DOI [10.1101/2020.04.20.027144, DOI 10.1101/2020.04.20.027144]
   McCreary EK, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz538
   Park JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e124
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   Sinha IP, 2020, LANCET RESP MED, V8, P446, DOI 10.1016/S2213-2600(20)30152-1
   Smith LS, 2013, PEDIATR CRIT CARE ME, V14, P631, DOI 10.1097/PCC.0b013e318291753f
   Spiteri G, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.9.2000178
   Tagarro Alfredo, 2020, JAMA Pediatr, DOI 10.1001/jamapediatrics.2020.1346
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wei M, 2020, JAMA-J AM MED ASSOC, V323, P1313, DOI 10.1001/jama.2020.2131
   Zhang ZJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00697-2020
NR 41
TC 2
Z9 2
U1 0
U2 0
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD SEP
PY 2020
VL 146
IS 3
AR e20201701
DI 10.1542/peds.2020-1701
PG 6
WC Pediatrics
SC Pediatrics
GA NF0ME
UT WOS:000562996900070
PM 32554811
OA Bronze
DA 2021-01-01
ER

PT J
AU Chapple, LAS
   Fetterplace, K
   Asrani, V
   Burrell, A
   Cheng, AC
   Collins, P
   Doola, R
   Ferrie, S
   Marshall, AP
   Ridley, EJ
AF Chapple, Lee-anne S.
   Fetterplace, Kate
   Asrani, Varsha
   Burrell, Aidan
   Cheng, Allen C.
   Collins, Peter
   Doola, Ra'eesa
   Ferrie, Suzie
   Marshall, Andrea P.
   Ridley, Emma J.
TI Nutrition management for critically and acutely unwell hospitalised
   patients with coronavirus disease 2019 (COVID-19) in Australia and New
   Zealand
SO AUSTRALIAN CRITICAL CARE
LA English
DT Article
DE COVID-19; Pandemic; Nutrition; Critical illness; Artificial feeding
ID ENTERAL NUTRITION; ICU
AB Coronavirus disease 2019 (COVID-19) results from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical features and subsequent medical treatment, combined with the impact of a global pandemic, require specific nutritional therapy in hospitalised adults. This document aims to provide Australian and New Zealand clinicians with guidance on managing critically and acutely unwell adult patients hospitalised with COVID-19. These recommendations were developed using expert consensus, incorporating the documented clinical signs and metabolic processes associated with COVID-19, the literature from other respiratory illnesses, in particular acute respiratory distress syndrome, and published guidelines for medical management of COVID-19 and general nutrition and intensive care. Patients hospitalised with COVID-19 are likely to have preexisting comorbidities, and the ensuing in-flammatory response may result in increased metabolic demands, protein catabolism, and poor gly-caemic control. Common medical interventions, including deep sedation, early mechanical ventilation, fluid restriction, and management in the prone position, may exacerbate gastrointestinal dysfunction and affect nutritional intake. Nutrition care should be tailored to pandemic capacity, with early gastric feeding commenced using an algorithm to provide nutrition for the first 5-7 days in lower-nutritional -risk patients and individualised care for high-nutritional-risk patients where capacity allows. Indirect calorimetry should be avoided owing to potential aerosole exposure and therefore infection risk to healthcare providers. Use of a volume-controlled, higher-protein enteral formula and gastric residual volume monitoring should be initiated. Careful monitoring, particularly after intensive care unit stay, is required to ensure appropriate nutrition delivery to prevent muscle deconditioning and aid recovery. The infectious nature of SARS-CoV-2 and the expected high volume of patient admissions will require con-tingency planning to optimise staffing resources including upskilling, ensure adequate nutrition supplies, facilitate remote consultations, and optimise food service management. These guidelines provide rec-ommendations on how to manage the aforementioned aspects when providing nutrition support to patients during the SARS-CoV-2 pandemic. Crown Copyright (c) 2020 Published by Elsevier Ltd on behalf of Australian College of Critical Care Nurses Ltd. All rights reserved.
C1 [Chapple, Lee-anne S.] Royal Adelaide Hosp, Intens Care Res, Adelaide, SA, Australia.
   [Chapple, Lee-anne S.] Univ Adelaide, Discipline Acute Care Med, Adelaide, SA, Australia.
   [Fetterplace, Kate] Royal Melbourne Hosp, Allied Hlth Clin Nutr, Melbourne, Vic, Australia.
   [Fetterplace, Kate] Univ Melbourne, Dept Med, Parkville, Vic, Australia.
   [Asrani, Varsha] Auckland City Hosp, Nutr & Dietet, Auckland, New Zealand.
   [Asrani, Varsha] Univ Auckland, Surg & Translat Res STaR Ctr, Auckland, New Zealand.
   [Asrani, Varsha] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand.
   [Burrell, Aidan] Alfred Hosp, Intens Care Unit, Melbourne, Vic, Australia.
   [Burrell, Aidan; Ridley, Emma J.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Publ Hlth & Preventat Med, Melbourne, Vic, Australia.
   [Cheng, Allen C.] Alfred Hlth, Dept Infect & Epidemiol, Melbourne, Vic, Australia.
   [Collins, Peter] Griffith Univ, Sch Allied Hlth Sci, Nutr & Dietet, Gold Coast, Australia.
   [Collins, Peter] Menzies Hlth Inst, Patient Centred Hlth Serv, Southport, Qld, Australia.
   [Doola, Ra'eesa] Princess Alexandra Hosp, Dietet Dept, Brisbane, Qld, Australia.
   [Doola, Ra'eesa] Univ Queensland, Mater Res Inst, Brisbane, Qld, Australia.
   [Ferrie, Suzie] Royal Prince Alfred Hosp, Nutr & Dietet Dept, Sydney, NSW, Australia.
   [Ferrie, Suzie] Univ Sydney, Sydney, NSW, Australia.
   [Marshall, Andrea P.] Griffith Univ, Sch Nursing & Midwifery, Gold Coast, Australia.
   [Marshall, Andrea P.] Griffith Univ, Menzies Hlth Inst, Gold Coast, Australia.
   [Marshall, Andrea P.] Gold Coast Hlth, Southport, Qld, Australia.
   [Ridley, Emma J.] Alfred Hosp, Nutr Dept, Melbourne, Vic, Australia.
RP Ridley, EJ (corresponding author), Level 3,553 St Kilda Rd, Melbourne, Vic 3004, Australia.
EM lee-anne.chapple@adelaide.edu.au; kate.fetterplace@mh.org.au;
   VarshaA@adhb.govt.nz; aidan.burrell@monash.edu; allen.cheng@monash.edu;
   peter.collins@griffith.edu.au; raeesa.doola@health.qld.gov.au;
   suzie.ferrie@health.nsw.gov.au; a.marshall@griffith.edu.au;
   emma.ridley@monash.edu
OI Collins, Peter/0000-0002-5273-8213; Chapple, Lee-anne
   S/0000-0002-9818-2484
CR Australian and New Zealand Intensive Care Society, 2020, ANZICS COVID 19 GUID
   Chapman M, 2018, NEW ENGL J MED, V379, P1823, DOI 10.1056/NEJMoa1811687
   Chapple Lee-Anne, 2020, Aust Crit Care, V33, P300, DOI 10.1016/j.aucc.2020.02.008
   Chapple LAS, 2016, CLIN NUTR, V35, P1315, DOI 10.1016/j.clnu.2016.02.009
   Del Bene VE, 1990, CLIN METHODS HIST PH
   McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI 10.1177/0148607115621863
   Merriweather J, 2014, J CLIN NURS, V23, P654, DOI 10.1111/jocn.12241
   Reignier J, 2004, CRIT CARE MED, V32, P94, DOI 10.1097/01.CCM.0000104208.23542.A8
   Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137
   Ridley EJ, 2020, CURR OPIN CLIN NUTR, V23, P111, DOI 10.1097/MCO.0000000000000637
   Ridley EJ, 2019, JPEN-PARENTER ENTER, V43, P88, DOI 10.1002/jpen.1196
   Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037
   Wittholz K, 2020, J HUM NUTR DIET, V33, P414, DOI 10.1111/jhn.12719
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xiao F, 2020, SCI TECHNOL BUILT EN, V26, P1, DOI 10.1080/23744731.2019.1707955
   Yan CH, 2020, INT FORUM ALLERGY RH, V10, P806, DOI 10.1002/alr.22579
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 17
TC 4
Z9 5
U1 8
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1036-7314
EI 1878-1721
J9 AUST CRIT CARE
JI Aust. Crit. Care
PD SEP
PY 2020
VL 33
IS 5
BP 399
EP 406
DI 10.1016/j.aucc.2020.06.002
PG 8
WC Critical Care Medicine; Nursing
SC General & Internal Medicine; Nursing
GA NI9KC
UT WOS:000565663500002
PM 32682671
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Braun, P
   Haffner, S
   Davila, LA
   Braun, J
   Woodcock, BG
AF Braun, Peter
   Haffner, Steffen
   Davila, Lukas Aguirre
   Braun, Julian
   Woodcock, Barry G.
TI Predictions for the COVID-19 pandemic in Germany using the modified
   Bateman SIZ model
SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE COVID-19 disease; prediction scenarios; modified Bateman SIZ model;
   model robustness and sensitivity; Germany
AB Aims of the study: To obtain predictions for the course of the COVID-19 pandemic in Germany using the modified Bateman SIZ model and input variables based on the status quo in July 2020. To predict the effect of a change in t(alpha), on the course of the pandemic. To evaluate the robustness and sensitivity of the model in response to a change in the input parameters. Materials and methods: Start parameters for the modified Bateman SIZ model were obtained from observational data published by the Robert-Koch-Institute in Berlin for the period June 1 to July 13, 2020. The robustness and sensitivity of the model were determined by changing the input parameter for the doubling-time (t(alpha)) by +/- 5% and +/- 10%. Results:, The predictions show that small changes. +/- 5%, in the doubling-time, t(alpha) for the rate of increase in the number of new infections, can have a major effect, both positive and negative, on the course of the pandemic. The model predicted that the number of persons infected with the virus would reach 1 million within 8 years. A 5% longer t(alpha) would reduce the number of infected persons by similar to 75%. In contrast, a 5% shorter doubling-time would increase the number of infections over 8 years to similar to 9 million when the number of infectious persons would exceed 100,000 at the end of 2022. The pandemic is predicted to have disappeared by the end of 2024. Discussion: Predictions for the course of the COVID-19 pandemic in Germany based on the status quo up to July 13, 2020 have been obtained using the modified Bateman SIZ model. There are several important assumptions necessary to apply the model and thus the results must be interpreted with caution. The model. previously used to predict the course of the COVID-19 pandemic in the city of Heidelberg (pop. 166,000) gives comparable predictive data for the whole of Germany (pop. 83 million) and thus appears to be both sensitive and robust. Conclusion: Since a shorter doubling-time for the number of infectious persons by only 5% would result in a major clinical emergency, interventional measures such as vaccination are urgently needed. Taking into consideration that a SARS-CoV-2 vaccine is not yet available and the efficacy of the Corona-Warn-App has yet to be shown, a relaxation in the lockdown conditions in Germany in 2020 appears premature.
   What is known about this subject
   - The modified Bateman SIZ model has been used to predict the course of the COVID-19 pandemic in the city of Heidelberg pop. 166,00 using observational data.
   - The model has not been applied to the whole population of Germany.
   What this study adds
   - Predictions for the number of infected persons and the daily increase in the number of infectious persons during the course of the COVID-19 pandemic in Germany have been obtained for the whole population using the modified Bateman SIZ model.
   - Small changes (5%) in doubling-time, which reflects the known variability in ta seen in the observational data, markedly influenced the predicted course of the pandemic and the effects of a 10% even more so, confirming the sensitivity and robustness of the modified Bateman SIZ model.
C1 [Braun, Peter; Woodcock, Barry G.] Arbeitsgemeinschaft Immunoglobuline Anticanc Anti, Rodermark, Germany.
   [Haffner, Steffen] Paul Ehrlich Inst, Langen, Germany.
   [Davila, Lukas Aguirre] Nuvisan GmbH, Neu Ulm, Germany.
   [Braun, Julian] European Flight Acad, Bremen, Germany.
RP Braun, P (corresponding author), AGIGAAT, POB 200232, D-63308 Rodermark, Germany.
EM braun-roedermarkt@t-online.de
RI Goodin, Amie/Z-3189-2019
OI Goodin, Amie/0000-0002-0020-8720
CR Bateman H, 1910, P CAMB PHILOS SOC, V15, P423
   Braun P, 2020, INT J CLIN PHARM TH, V58, P417, DOI 10.5414/CP203846
   Lassmann A., CORONAVIRUS VORHERSA
   Merle U, 2020, INT J CLIN PHARM TH, V58, P366, DOI 10.5414/CP203824
NR 4
TC 2
Z9 2
U1 3
U2 3
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0946-1965
J9 INT J CLIN PHARM TH
JI Int. J. Clin. Pharmacol. Ther.
PD SEP
PY 2020
VL 58
IS 9
BP 467
EP 474
DI 10.5414/CP203688
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NE9LJ
UT WOS:000562924600002
PM 32800093
DA 2021-01-01
ER

PT J
AU Brody, AA
   Sadarangani, T
   Jones, TM
   Convery, K
   Groom, L
   Bristol, AA
   David, D
AF Brody, Abraham A.
   Sadarangani, Tina
   Jones, Tessa M.
   Convery, Kimberly
   Groom, Lisa
   Bristol, Alycia A.
   David, Daniel
TI Family- and Person-Centered Interdisciplinary Telehealth: Policy and
   Practice Implications Following Onset of the COVID-19 Pandemic
SO JOURNAL OF GERONTOLOGICAL NURSING
LA English
DT Article
ID CARE; STATE; SERVICES; THERAPY
AB With the onset of the COVID-19 pandemic, telehealth was thrust to the forefront, becoming one of the most predominant forms of care almost overnight. Despite years of research, practice, and policymaking, tenets for providing telehealth in an interdisciplinary, family- and person-centered fashion, and across a wide breadth of settings remain underdeveloped. In addition, although telehealth has the potential to increase equity in care, it can also further exacerbate disparities. The current article discusses the opening created by the pandemic and provides recommendations for how to make permanent changes in telehealth policy and practice to allow for interdisciplinary, person- and family-centered care while also taking care to address issues of equity and ethics and privacy issues related to telehealth and remote monitoring.
C1 [Brody, Abraham A.] NYU, Rory Meyers Coll Nursing, Nursing & Med, 433 First Ave, New York, NY 10010 USA.
   [Convery, Kimberly; Bristol, Alycia A.] NYU, Rory Meyers Coll Nursing, Hartford Inst Geriatr Nursing, New York, NY 10010 USA.
   [Sadarangani, Tina; Groom, Lisa; David, Daniel] NYU, Rory Meyers Coll Nursing, New York, NY 10010 USA.
   [Jones, Tessa M.] NYU, Silver Sch Social Work, New York, NY 10010 USA.
RP Brody, AA (corresponding author), NYU, Rory Meyers Coll Nursing, Nursing & Med, 433 First Ave, New York, NY 10010 USA.; Brody, AA (corresponding author), NYU, Rory Meyers Coll Nursing, Hartford Inst Geriatr Nursing, New York, NY 10010 USA.
EM ab.brody@nyu.edu
OI Bristol, Alycia/0000-0001-5027-9984; Brody, Abraham/0000-0002-3405-7043
FU National Institute on AgingUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [R01AG055610, R33AG061904]; National Institute of Nursing
   ResearchUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Nursing
   Research (NINR) [P20018075]
FX The authors have disclosed no potential conflicts of interest, financial
   or otherwise. This work was partially funded by awards R01AG055610,
   R33AG061904 from the National Institute on Aging and P20018075 from the
   National Institute of Nursing Research. The sponsors played no role in
   the drafting of this manuscript.
CR Alexander L., 2020, PREPARING NEXT PANDE
   Bakitas M, 2020, J PAIN SYMPTOM MANAG, V59, P466
   Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198
   Barkauskas Violet H, 2011, Nurs Adm Q, V35, P34, DOI 10.1097/NAQ.0b013e3182032165
   Barnsteiner J. H., 2014, PERSON FAMILY CTR CA
   Bartz C., 2017, J INT SOC TELEMEDICI, V5, P1
   Cabacungan AN, 2019, TRANSPL P, V51, P665, DOI 10.1016/j.transproceed.2018.12.032
   Chi NC, 2015, J TELEMED TELECARE, V21, P37, DOI 10.1177/1357633X14562734
   Dorsey ER, 2016, NEW ENGL J MED, V375, P1400, DOI 10.1056/NEJMc1610233
   Edmunds Margo, 2017, EGEMS (Wash DC), V5, P1303, DOI 10.13063/2327-9214.1303
   Esperat MCR, 2012, J AM ACAD NURSE PRAC, V24, P24, DOI 10.1111/j.1745-7599.2011.00677.x
   Grey M, 2015, NURS OUTLOOK, V63, P162, DOI 10.1016/j.outlook.2014.10.003
   Health Resources and Services Administration, 2020, TEL PROGR
   Khairat S, 2019, J AM MED INFORM ASSN, V26, P796, DOI 10.1093/jamia/ocz108
   Klugman CM, 2018, AM J BIOETHICS, V18, P38, DOI 10.1080/15265161.2018.1498933
   Lee AC, 2018, J ORTHOP SPORT PHYS, V48, P736, DOI 10.2519/jospt.2018.0613
   Lor M, 2016, NURS OUTLOOK, V64, P352, DOI 10.1016/j.outlook.2016.02.006
   Park J, 2018, HEALTH AFFAIR, V37, P2060, DOI 10.1377/hlthaff.2018.05101
   Perdew C, 2017, AM J HEALTH-SYST PH, V74, P1093, DOI 10.2146/ajhp160625
   Possin KL, 2019, JAMA INTERN MED, V179, P1658, DOI 10.1001/jamainternmed.2019.4101
   Ravindranath M., 2020, SENATORS PUSH PERMAN
   Reckrey JM, 2020, GERONTOLOGIST, V60, P745, DOI 10.1093/geront/gnz067
   Reed ME, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.5873
   Renda M, 2018, INT J TELEREHABILITA, V10, P3, DOI 10.5195/ijt.2018.6244
   Shigekawa E, 2018, HEALTH AFFAIR, V37, P1975, DOI 10.1377/hlthaff.2018.05132
   Speyer R, 2018, J REHABIL MED, V50, P225, DOI 10.2340/16501977-2297
   Wolff JL, 2015, J GEN INTERN MED, V30, P1497, DOI 10.1007/s11606-015-3359-6
   Young HM, 2020, J GERONTOL NURS, V46, P19, DOI 10.3928/00989134-20200515-01
NR 28
TC 0
Z9 0
U1 6
U2 6
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0098-9134
EI 1938-243X
J9 J GERONTOL NURS
JI J. Gerontol. Nurs.
PD SEP
PY 2020
VL 46
IS 9
BP 9
EP 13
DI 10.3928/00989134-20200811-03
PG 5
WC Geriatrics & Gerontology; Gerontology; Nursing
SC Geriatrics & Gerontology; Nursing
GA NJ1JO
UT WOS:000565798500003
PM 32845343
DA 2021-01-01
ER

PT J
AU Mattos-Silva, P
   Felix, NS
   Silva, PL
   Robba, C
   Battaglini, D
   Pelosi, P
   Rocco, PRM
   Cruz, FF
AF Mattos-Silva, Paula
   Felix, Nathane Santanna
   Silva, Pedro Leme
   Robba, Chiara
   Battaglini, Denise
   Pelosi, Paolo
   Macedo Rocco, Patricia Rieken
   Cruz, Fernanda Ferreira
TI Pros and cons of corticosteroid therapy for COVID-19 patients
SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
LA English
DT Article
DE COVID-19; SARS-COV-2; Inflammation; Steroids; Dexamethasone
AB In December 2019, an outbreak of severe pneumonia was reported in Wuhan, China. Later described as COVID-19 (coronavirus disease 2019), this infection caused by a virus from the Coronaviridae family (SARS-CoV-2) has spread globally. Effective therapies for this new disease are urgently needed. In this short communication, we will evaluate the use of corticosteroids as an adjunctive pharmacological therapy in the management of COVID-19 and describe its pros and cons in light of the latest available evidence.
C1 [Mattos-Silva, Paula; Felix, Nathane Santanna; Silva, Pedro Leme; Macedo Rocco, Patricia Rieken; Cruz, Fernanda Ferreira] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, Rio De Janeiro, Brazil.
   [Robba, Chiara; Battaglini, Denise; Pelosi, Paolo] Osped Policlin San Martino, IRCCS Oncol & Neurosci, Dept Anesthesia & Intens Care, Genoa, Italy.
   [Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost DISC, Genoa, Italy.
RP Cruz, FF (corresponding author), Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, Ctr Ciencias Saude, Ave Carlos Chagas Filho 373,Bloco C1-045, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM pmattoss@biof.ufrj.br; nathanufelix@gmail.com; pedroleme@biof.ufrj.br;
   kiarobba@gmail.com; battaglini.denise@gmail.com; ppelosi@hotmail.com;
   prmrocco@biof.ufrj.br; ffcruz@biof.ufrj.br
RI Battaglini, Denise/X-6446-2019
OI Battaglini, Denise/0000-0002-6895-6442; Rieken Macedo Rocco,
   Patricia/0000-0003-1412-7136; Silva, Pedro/0000-0001-5838-4949
FU Carlos Chagas Filho Rio de Janeiro State Research Foundation, Rio de
   Janeiro, Brazil; Brazilian Council for Scientific and Technological
   Development (CNPq), Brasilia, BrazilNational Council for Scientific and
   Technological Development (CNPq); Coordination for the Improvement of
   Higher Education Personnel (CAPES), Brasilia, BrazilCAPES; Department of
   Science and Technology (DECIT) - Brazilian Ministry of HealthDepartment
   of Science & Technology (India)Department of Science & Technology
   (DOST), Philippines; National Institute of Science and Technology for
   Regenerative Medicine
FX This work was supported by grants from the Carlos Chagas Filho Rio de
   Janeiro State Research Foundation, Rio de Janeiro, Brazil; the Brazilian
   Council for Scientific and Technological Development (CNPq), Brasilia,
   Brazil; Coordination for the Improvement of Higher Education Personnel
   (CAPES), Brasilia, Brazil; Department of Science and Technology (DECIT)
   - Brazilian Ministry of Health; and the National Institute of Science
   and Technology for Regenerative Medicine.
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bhimraj A, 2020, INFECT DIS SOC AM GU
   Horby P., 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22., DOI 10.1101/2020.06.22]
   Lam Christopher W K, 2004, Clin Biochem Rev, V25, P121
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835
   Wang Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0158-2
   WHO, 2020, COR DIS COVID 19 SIT
NR 10
TC 3
Z9 3
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1569-9048
EI 1878-1519
J9 RESP PHYSIOL NEUROBI
JI Respir. Physiol. Neuro.
PD SEP
PY 2020
VL 280
AR 103492
DI 10.1016/j.resp.2020.103492
PG 3
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA NI9BM
UT WOS:000565640800012
PM 32659271
OA Green Published
DA 2021-01-01
ER

PT J
AU Pagano, A
   Porta, G
   Bosso, G
   Allegorico, E
   Serra, C
   Dello Vicario, F
   Minerva, V
   Russo, T
   Altruda, C
   Arbo, P
   Mercurio, V
   Numis, FG
AF Pagano, A.
   Porta, G.
   Bosso, G.
   Allegorico, E.
   Serra, C.
   Dello Vicario, F.
   Minerva, V
   Russo, T.
   Altruda, C.
   Arbo, P.
   Mercurio, V
   Numis, F. G.
TI Non-invasive CPAP in mild and moderate ARDS secondary to SARS-CoV-2
SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
LA English
DT Article
DE COVID 19; Coronavirus; SARS COV 2
AB Background: During the COVID-19 outbreak, a very high number of infected patients developed pneumonia and many of them complicated with acute respiratory distress syndrome. The optimal management of respiratory failure and the role of lung ultrasound imaging in the evaluation of efficacy of treatment are unknown.
   Methods: In March 2020 we treated 18 patients with mild and moderate ARDS secondary to SARS-CoV-2 with non-invasive continuous positive airway pressure therapy (NI-CPAP). All patients underwent lung ultrasound imaging to verify the entity of lung recruitment after NI-CPAP initiation.
   Results: After one hour of treatment we observed a significant improvement in PaO2/FiO2 ratio in 10 patients. Notably, only 50 % of them reached an effective improvement in lung aeration detectable with lung ultrasound. In the other 50 % or patients the improvement in PaO2/FiO2 might be related to blood redistribution and reverse of hypoxic vasoconstriction.
   Conclusion: NI-CPAP is a valid therapeutic option in mild and moderate ARDS secondary SARS-CoV-2. Lung recruitment detected by means of lung ultrasound is a relevant but not the exclusive mechanism that underlies the therapeutic efficacy of NI-CPAP in this clinical setting.
C1 [Pagano, A.; Porta, G.; Bosso, G.; Allegorico, E.; Serra, C.; Dello Vicario, F.; Minerva, V; Russo, T.; Altruda, C.; Arbo, P.; Numis, F. G.] Santa Maria Grazie Hosp Naples, Emergency Dept, ASL Napoli Nord 2, Naples, Italy.
   [Mercurio, V] Univ Naples Federico II, Naples, Italy.
RP Pagano, A (corresponding author), Via Scalea 17 B, I-80055 Portici, NA, Italy.
EM antoniopag82@gmail.com.it
OI Pagano, Antonio/0000-0003-2322-8457; Bosso, Giorgio/0000-0002-2759-8343
CR Brambilla A, 2014, INTENS CARE MED, V40, P1187, DOI 10.1007/s00134-014-3351-3
   Chiumello D, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1820-0
   Cosentini R, 2010, CHEST, V138, P114, DOI 10.1378/chest.09-2290
   Duca A., 2020, LANCET
   Gattinoni L, 2001, AM J RESP CRIT CARE, V164, P1701, DOI 10.1164/ajrccm.164.9.2103121
   Gattinoni L., 2006, NEW ENGL J MED, V319, P698
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Kangelaris KN, 2016, CRIT CARE MED, V44, P120, DOI 10.1097/CCM.0000000000001359
   Mongodi S., 2014, CRIT CARE, DOI [10.1186/cc13475., DOI 10.1186/CC13475]
   Navalesi P., 2013, PRINCIPLES PRACTICE, P253
   Pagano A, 2018, RESP PHYSIOL NEUROBI, V255, P7, DOI 10.1016/j.resp.2018.04.007
   Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Rouby JJ, 2018, AM J RESP CRIT CARE, V198, P398, DOI 10.1164/rccm.201802-0227LE
NR 15
TC 2
Z9 4
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1569-9048
EI 1878-1519
J9 RESP PHYSIOL NEUROBI
JI Respir. Physiol. Neuro.
PD SEP
PY 2020
VL 280
AR 103489
DI 10.1016/j.resp.2020.103489
PG 4
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA NI9BM
UT WOS:000565640800013
PM 32629100
OA Green Published
DA 2021-01-01
ER

PT J
AU Li, C
   Wang, L
   Ren, LZ
AF Li, Chang
   Wang, Lin
   Ren, Linzhu
TI Antiviral mechanisms of candidate chemical medicines and traditional
   Chinese medicines for SARS-CoV-2 infection
SO VIRUS RESEARCH
LA English
DT Article
DE Severe acute respiratory syndrome coronavirus; 2 (2019 novel
   coronavirus, SARS-CoV-2); Coronavirus disease 2019 (COVID-19); Medicine;
   Antiviral
ID SHUFENGJIEDU CAPSULE; DISEASE 2019; CORONAVIRUS; COVID-19; CHLOROQUINE;
   PNEUMONIA; VIRUS; ANTIBIOTICS; RITONAVIR; EVOLUTION
AB The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) has rapidly become a global pandemic. Up to now, numerous medicines have been applied or approved for the prevention and control of the virus infection. However, the efficiency of each medicine or combination is completely different or still unknown. In this review, we discuss the types, characteristics, antiviral mechanisms, and shortcomings of recommended candidate medicines for SARS-CoV-2 infection, as well as perspectives of the drugs for the disease treatment, which may provide a theoretical basis for drug screening and application.
C1 [Ren, Linzhu] Jilin Univ, Coll Anim Sci, Jilin Prov Key Lab Anim Embryo Engn, Key Lab Zoonoses Res,Minist Educ, 5333 Xian Rd, Changchun 130062, Peoples R China.
   [Li, Chang] Chinese Acad Med Sci, Mil Vet Inst, Acad Mil Med Sci, Res Unit Key Technol Prevent & Control Virus Zoon, Changchun 130122, Peoples R China.
   [Wang, Lin] Jilin Univ, Coll Vet Med, Minist Educ, Key Lab Zoonoses Res, Changchun 130062, Peoples R China.
RP Ren, LZ (corresponding author), Jilin Univ, Coll Anim Sci, Jilin Prov Key Lab Anim Embryo Engn, Key Lab Zoonoses Res,Minist Educ, 5333 Xian Rd, Changchun 130062, Peoples R China.
EM renlz@jlu.edu.cn
FU Changchun Science and Technology Bureau emergency project [2020RW002];
   National Key Research and Development Program of China [2017YFD0500103];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31772747]; Jilin Province Science and
   Technology Development Projects [20200402043NC]; Science and Technology
   Research Program during the 13th Five-Year Plan Period of Jilin
   Educational Committee [JJKH20190172KJ]
FX This work was financially supported by the Changchun Science and
   Technology Bureau emergency project [No.2020RW002]; the National Key
   Research and Development Program of China [No. 2017YFD0500103]; the
   National Natural Science Foundation of China [No. 31772747]; the Jilin
   Province Science and Technology Development Projects [No.
   20200402043NC]; and the Science and Technology Research Program during
   the 13th Five-Year Plan Period of Jilin Educational Committee [No.
   JJKH20190172KJ]. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adamsick ML, 2020, J AM SOC NEPHROL, V31, P1384, DOI 10.1681/ASN.2020050589
   Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   Amirian ES, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100128
   Ang L, 2020, INTEGR MED RES, V9, DOI 10.1016/j.imr.2020.100407
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Belhadi D., 2020, BRIEF REV ANTIVIRAL
   Bessiere F, 2020, JAMA CARDIOL, DOI DOI 10.1001/JAMACARDIO.2020.1787
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Cantwell SL, 2010, TOP COMPANION ANIM M, V25, P53, DOI 10.1053/j.tcam.2009.10.006
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Ceccarelli G, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106029
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chang R., 2020, REPOSITIONING CHLORO, DOI [10.20944/preprints202003.0279.v1, DOI 10.20944/PREPRINTS202003.0279.V1]
   Chang YC, 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2., 10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   Chen C., 2020, FAVIPIRAVIR VERSUS A
   Chen WY, 2020, J MED VIROL, V92, P2702, DOI 10.1002/jmv.26142
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Colson P, 2016, INT J ANTIMICROB AG, V48, P349, DOI 10.1016/j.ijantimicag.2016.07.004
   Cui Q., 2020, AGTR2 ONE POSSIBLE N, DOI DOI 10.20944/PREPRINTS202002.0194.V1
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Davies M, 2020, DRUG SAFETY, V43, P645, DOI 10.1007/s40264-020-00952-1
   Delaleu J., 2020, J ALLERGY CLIN IMMUN, VS2213-2198, P30580
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Ding YW, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1585-7
   Dong L, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/637969
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Du B, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P173, DOI 10.3760/cma.j.issn.1001-0939.2020.03.005
   Du Y.X., 2020, CLIN PHARM THER, V1844
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gao Y, 2020, SIGNAL PROCESS, V167, DOI 10.1016/j.sigpro.2019.107284
   Gao Yu-lei, 2013, Zhonghua Shao Shang Za Zhi, V29, P162
   Gautret P., 2020, HYDROXYCHLOROQUINE A
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Government C., 2020, CHIN MED INF PLATF
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo Q., 2001, HOST INFECTIVITY PRE, V2020
   Haviernik J, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040184
   He YH, 2006, WORLD J GASTROENTERO, V12, P7346, DOI 10.3748/wjg.v12.i45.7346
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu K. E., 2020, PHYTOMEDICINE, P153242, DOI [10.1016/j.phymed.2020.153242, DOI 10.1016/J.PHYMED.2020.153242]
   Huang YF, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104939
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Ji S, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109652
   Jiang S., 2020, VIROL SIN, P1
   Jiang SD, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104989
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Kearney J., 2020, CHLOROQUINE POTENTIA, DOI DOI 10.20944/PREPRINTS202003.0275.V1
   Khan M, 2010, J MED VIROL, V82, P817, DOI 10.1002/jmv.21663
   Kim JH, 2014, NAT PROD COMMUN, V9, P65
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Kratky M, 2011, MINI-REV MED CHEM, V11, P956, DOI 10.2174/138955711797068382
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Li C, 2020, TRANSBOUND EMERG DIS, V67, P1485, DOI 10.1111/tbed.13620
   Li C, 2020, INFECT GENET EVOL, V82, DOI 10.1016/j.meegid.2020.104285
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Li Y., 2020, EXPLORATORY RANDOMIZ
   Li YM, 2017, BIOMED PHARMACOTHER, V94, P758, DOI 10.1016/j.biopha.2017.07.118
   Lin L, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2019.102311
   Lin S., 2001, MOL MODELING EVALUAT, V2020
   Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013
   Liu H, 2020, CHIN PERSP JOURNAL C, P1
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu S, 2020, BIOINFORMATICS, V36, P1066, DOI 10.1093/bioinformatics/btz725
   Liu Shaohua, 2020, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V32, P397, DOI 10.3760/cma.j.cn121430-20200313-00338
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Liu ZL, 2020, J TRADIT CHIN MED, V40, P467, DOI 10.19852/j.cnki.jtcm.2020.03.016
   Lokugamage K.G., 2003, SARS COV 2 IS SENSIT
   Luan Rong-Sheng, 2020, Sichuan Da Xue Xue Bao Yi Xue Ban, V51, P131, DOI 10.12182/20200360505
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Mei JY, 2019, BIOSCI TRENDS, V13, P530, DOI 10.5582/bst.2019.01332
   Mercuro NJ, 2020, JAMA CARDIOL, DOI DOI 10.1001/JAMACARDIO.2020.1834
   Monte Serrano J., 2020, MED CLIN-BARCELONA, VS0025-7753, P30280
   multicenter collaboration group of Department of S. Technology of Guangdong P. Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus, ZHONGHUA JIE HE HE H, V43, p[2020, E019]
   Omar A., 2020, MOL DOCKING REVEALS, DOI [10.26434/chemrxiv.12061302.v1., DOI 10.26434/CHEMRXIV.12061302.V1]
   Pindiprolu SKSS, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109765
   Prc N.H.C., 2020, GUID PREV DIAGN TREA
   Proskurnina EV, 2020, MOLECULES, V25, DOI 10.3390/molecules25071577
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Ren Yue, 2020, Zhongguo Zhong Yao Za Zhi, V45, P1225, DOI 10.19540/j.cnki.cjcmm.20200224.405
   Rios P., 2020, EFFECTIVENESS SAFETY
   Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8
   Sevrioukova IF, 2014, CURR TOP MED CHEM, V14, P1348, DOI 10.2174/1568026614666140506120647
   Sheahan T.P., 2020, ORALLY BIOAVAILABLE
   Shen Jue, 2013, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V25, P743
   Sinha Neeraj, 2020, Postgrad Med J, V96, P550, DOI 10.1136/postgradmedj-2020-137785
   Sohini C., 2020, REPURPOSING DRUGS MA
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   Tabata S., 2020, NONSEVERE VS SEVERE
   Tan YW, 2018, ANTIVIR RES, V149, P143, DOI 10.1016/j.antiviral.2017.11.017
   Tao ZG, 2017, J PROTEOME RES, V16, P4009, DOI 10.1021/acs.jproteome.7b00409
   Theoharides T.C., 2020, J BIOL REGUL HOMEOST, V34
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Tong T, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00326-w
   TORJESEN I, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2263
   Vankadari N, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105998
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang GP, 2020, J PHYSIOL BIOCHEM, V76, P539, DOI 10.1007/s13105-020-00758-w
   Wang K., 2020, SARS COV 2 INVADES H
   Wang X., 2020, RES SQUARE, DOI [10.21203/rs.3.rs-21103/v1, DOI 10.21203/RS.3.RS-21103/V1]
   Wang Y, 2020, CHIN J CHIN MAT MED, V45, P2249
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Williamson B.N., 2020, CLIN BENEFIT REMDESI
   Xu J, 2020, COMPLEMENT THER CLIN, V39, DOI 10.1016/j.ctcp.2020.101165
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Xu P, 2020, MICROBES INFECT, V22, P200, DOI 10.1016/j.micinf.2020.05.012
   Yan L, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20041228
   Yang MT, 2016, ANTIVIR RES, V133, P223, DOI 10.1016/j.antiviral.2016.08.010
   Yao H., 2020, PATIENT DERIVED MUTA
   Yao X, 2020, CLIN INFECT DIS, DOI [10. 1093/cid/ciaa237.ciaa237, DOI 10.1093/CID/CIAA237.CIAA237]
   Ye C., 2020, THEORETICAL STUDY AN, DOI [10.26434/chemrxiv.12016236.v1.chemrxiv., DOI 10.26434/CHEMRXIV.12016236.V1.CHEMRXIV]
   Yuan XH, 2016, MOLECULES, V21, DOI 10.3390/molecules21050559
   Zhao Wenming, 2020, Yichuan, V42, P212, DOI 10.16288/j.yczz.20-030
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 128
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD SEP
PY 2020
VL 286
AR 198073
DI 10.1016/j.virusres.2020.198073
PG 10
WC Virology
SC Virology
GA NI7JM
UT WOS:000565525400014
PM 32592817
OA Green Published
DA 2021-01-01
ER

PT J
AU Feng, YZ
   Huang, JH
   Qu, CH
   Huang, MJ
   Chen, ZC
   Tang, DY
   Xu, ZG
   Wang, BC
   Chen, ZZ
AF Feng, Yingzhu
   Huang, Jiuhong
   Qu, Chuanhua
   Huang, Mengjun
   Chen, Zhencong
   Tang, Dianyong
   Xu, Zhigang
   Wang, Bochu
   Chen, Zhongzhu
TI Future perspective: high-throughput construction of new ultrasensitive
   cytokine and virion liquid chips for high-throughput screening (HTS) of
   anti-inflammatory drugs or clinical diagnosis and treatment of
   inflammatory diseases
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE Bacterial; viral infection; Signaling cross-talk; Anti-inflammatory;
   High-throughput construction; Cytokine; virion liquid
ID SIMPLEX-VIRUS TYPE-1; SECRETION; BIOSENSORS; IL-1-BETA; PATHWAY; COMPLEX
AB Pathogen-host cell interactions play an important role in many human infectious and inflammatory diseases. Several pathogens, includingEscherichia coli(E. coli),Mycobacterium tuberculosis(M. tb), and even the recent 2019 novel coronavirus (2019-nCoV), can cause serious breathing and brain disorders, tissue injury and inflammation, leading to high rates of mortality and resulting in great loss to human physical and mental health as well as the global economy. These infectious diseases exploit the microbial and host factors to induce serious inflammatory and immunological symptoms. Thus the development of anti-inflammatory drugs targeting bacterial/viral infection is an urgent need. In previous studies, YojI-IFNAR2, YojI-IL10RA, YojI-NRP1,YojI-SIGLEC7, and YojI-MC4R membrane-protein interactions were found to mediateE. coliinvasion of the blood-brain barrier (BBB), which activated the downstream anti-inflammatory proteins NACHT, LRR and PYD domains-containing protein 2(NLRP2), using a proteomic chip conjugated with cell immunofluorescence labeling. However, the studies of pathogen (bacteria/virus)-host cell interactions mediated by membrane protein interactions did not extend their principles to broad biomedical applications such as 2019-nCoV infectious disease therapy. The first part of this feature article presents in-depth analysis of the cross-talk of cellular anti-inflammatory transduction signaling among interferon membrane protein receptor II (IFNAR2), interleukin-10 receptor subunit alpha (IL-10RA), NLRP2 and [Ca2+]-dependent phospholipase A2(PLA2G5), based on experimental results and important published studies, which lays a theoretical foundation for the high-throughput construction of the cytokine and virion solution chip. The paper then moves on to the construction of the novel GPCR recombinant herpes virion chip and virion nano-oscillators for profiling membrane protein functions, which drove the idea of constructing the new recombinant virion and cytokine liquid chips for HTS of leading drugs. Due to the different structural properties of GPCR, IFNAR2, ACE2 and Spike of 2019-nCoV, their ligands will either bind the extracellular domain of IFNAR2/ACE2/Spike or the specific loops of the GPCR on the envelope of the recombinant herpes virions to induce dynamic charge distribution changes that lead to the variable electron transition for detection. Taken together, the combined overview of two of the most innovative and exciting developments in the immunoinflammatory field provides new insight into high-throughput construction of ultrasensitive cytokine and virion liquid chips for HTS of anti-inflammatory drugs or clinical diagnosis and treatment of inflammatory diseases including infectious diseases, acute or chronic inflammation (acute gouty arthritis or rheumatoid arthritis), cardiovascular disease, atheromatosis, diabetes, obesity, tissue injury and tumors. It has significant value in the prevention and treatment of these serious and painful diseases.
C1 [Feng, Yingzhu; Huang, Jiuhong; Qu, Chuanhua; Huang, Mengjun; Chen, Zhencong; Tang, Dianyong; Xu, Zhigang; Wang, Bochu; Chen, Zhongzhu] Chongqing Univ Art & Sci, Coll Pharm, Chongqing 402160, Peoples R China.
   [Feng, Yingzhu; Huang, Jiuhong; Qu, Chuanhua; Huang, Mengjun; Chen, Zhencong; Tang, Dianyong; Xu, Zhigang; Wang, Bochu; Chen, Zhongzhu] Chongqing Univ Art & Sci, Int Acad Targeted Therapeut & Innovat IATTI, Chongqing 402160, Peoples R China.
   [Feng, Yingzhu; Wang, Bochu] Chongqing Univ, Coll Bioengn, Key Lab Biotheol Sci & Technol, Minist Educ, Chongqing 400045, Peoples R China.
RP Feng, YZ; Wang, BC; Chen, ZZ (corresponding author), Chongqing Univ Art & Sci, Coll Pharm, Chongqing 402160, Peoples R China.; Feng, YZ; Wang, BC; Chen, ZZ (corresponding author), Chongqing Univ Art & Sci, Int Acad Targeted Therapeut & Innovat IATTI, Chongqing 402160, Peoples R China.; Feng, YZ; Wang, BC (corresponding author), Chongqing Univ, Coll Bioengn, Key Lab Biotheol Sci & Technol, Minist Educ, Chongqing 400045, Peoples R China.
EM hnxtfyz123@163.com; wangbc2000@126.com; 389404093@qq.com
FU Novel Coronavirus Pneumonia Emergency Science and Technology Special
   Natural Science Fund, Yongchuan district, Chongqing City (YCSTC)
   [2020nb0219]; Talent Introduction Project of College of Pharmacy &
   International Academy of Targeted Therapeutics and Innovation (IATTI),
   Chongqing University of Arts and Sciences [R2019SXY12]; Key Laboratory
   of Biorheological Science and Technology (Chongqing University),
   Ministry of Education [CQKLBST-2020-004]
FX This work was funded by the Novel Coronavirus Pneumonia Emergency
   Science and Technology Special Natural Science Fund, Yongchuan district,
   Chongqing City (YCSTC, 2020nb0219), Talent Introduction Project of
   College of Pharmacy & International Academy of Targeted Therapeutics and
   Innovation (IATTI), Chongqing University of Arts and Sciences
   (R2019SXY12), and Key Laboratory of Biorheological Science and
   Technology (Chongqing University), Ministry of Education
   (CQKLBST-2020-004).
CR Ana F, 2007, J IMMUNOL, V179, P8519, DOI [10.4049/jimmunol.179.12.8519, DOI 10.4049/JIMMUNOL.179.12.8519]
   Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101
   Barbara B, 2006, BIOCHIM BIOPHYS ACTA, V1761, P1280, DOI [10.1016/j.bbalip.2006.07.008, DOI 10.1016/J.BBALIP.2006.07.008]
   CAI WZ, 1988, J MOL BIOL, V201, P575, DOI 10.1016/0022-2836(88)90639-0
   Desai P, 2008, J VIROL, V82, P11354, DOI 10.1128/JVI.00956-08
   Desai PJ, 2012, J VIROL, V86, P594, DOI 10.1128/JVI.05988-11
   Duncan CJA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4227
   Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398
   Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939
   Ezaki J, 2011, AUTOPHAGY, V7, P727, DOI 10.4161/auto.7.7.15371
   Fan XD, 2008, ANAL CHIM ACTA, V620, P8, DOI 10.1016/j.aca.2008.05.022
   Feng YZ, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18092823
   Feng YZ, 2018, ANAL CHEM, V90, P10958, DOI 10.1021/acs.analchem.8b02513
   Feng YZ, 2016, MINI-REV MED CHEM, V16, P846, DOI 10.2174/1389557515666150511152922
   Fernandez GM, 2019, MOL CELL, V75, P30442
   Fraser DA, 2009, J IMMUNOL, V183, P6175, DOI 10.4049/jimmunol.0902232
   Gee HY, 2011, CELL, V146, P746, DOI 10.1016/j.cell.2011.07.021
   Hu SH, 2013, ANAL CHEM, V85, P8046, DOI 10.1021/ac401795y
   Kim KS, 2008, NAT REV MICROBIOL, V6, P625, DOI 10.1038/nrmicro1952
   Laela MB, 2019, J CLIN IMMUNOL, V39, P277, DOI [10.1007/s10875-019-00638-z, DOI 10.1007/S10875-019-00638-Z]
   Li MR, 2006, ELECTROCHIM ACTA, V51, P5478, DOI 10.1016/j.electacta.2006.02.023
   Li S, 2020, CLIN REV ALLERG IMMU, V58, P71, DOI 10.1007/s12016-019-08747-8
   Ma GZ, 2018, J AM CHEM SOC, V140, P11495, DOI 10.1021/jacs.8b07461
   Manso J, 2007, J ELECTROANAL CHEM, V603, P1, DOI 10.1016/j.jelechem.2007.02.004
   Mao X, 2007, TALANTA, V73, P420, DOI 10.1016/j.talanta.2007.04.004
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   NOVICK D, 1995, J LEUKOCYTE BIOL, V57, P712
   PETER D, 2010, NATURE, V464, P1357, DOI DOI 10.1038/NATURE08938
   Piccioli P, 2013, SEMIN IMMUNOL, V25, P425, DOI 10.1016/j.smim.2013.10.007
   Rosengren B, 2006, BBA-MOL CELL BIOL L, V1761, P1301, DOI 10.1016/j.bbalip.2006.06.008
   Schett G, 2016, NAT REV RHEUMATOL, DOI [10.1038/nrrheum.166., DOI 10.1038/NRRHEUM.166]
   Seena V, 2009, SOLID STATE SCI, V11, P1606, DOI 10.1016/j.solidstatesciences.2009.06.009
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0
   Syu GD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09938-9
   Tsutsumi N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6340
   Usacheva A, 2002, J IMMUNOL, V169, P1302, DOI 10.4049/jimmunol.169.3.1302
   Wells AD, 2000, J IMMUNOL, V165, P2432, DOI 10.4049/jimmunol.165.5.2432
   Wu Y, 2019, CLIN INTERV AGING, V14, P1277, DOI 10.2147/CIA.S200637
   Yamaguchi M, 2018, MUCOSAL IMMUNOL, V11, P615, DOI 10.1038/mi.2017.99
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang CG, 2019, NATURE, V567, P394, DOI 10.1038/s41586-019-1000-2
   Zhou T, 2020, NATURE, V583, P609, DOI 10.1038/s41586-020-2422-6
NR 42
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
EI 1618-2650
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD NOV
PY 2020
VL 412
IS 28
SI SI
BP 7685
EP 7699
DI 10.1007/s00216-020-02894-0
EA SEP 2020
PG 15
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA OC8OJ
UT WOS:000565128500003
PM 32870351
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Auld, SC
   Caridi-Scheible, M
   Blum, JM
   Robichaux, C
   Kraft, C
   Jacob, JT
   Jabaley, CS
   Carpenter, D
   Kaplow, R
   Hernandez-Romieu, AC
   Adelman, MW
   Martin, GS
   Coopersmith, CM
   Murphy, DJ
AF Auld, Sara C.
   Caridi-Scheible, Mark
   Blum, James M.
   Robichaux, Chad
   Kraft, Colleen
   Jacob, Jesse T.
   Jabaley, Craig S.
   Carpenter, David
   Kaplow, Roberta
   Hernandez-Romieu, Alfonso C.
   Adelman, Max W.
   Martin, Greg S.
   Coopersmith, Craig M.
   Murphy, David J.
CA Emory COVID-19 Quality Clinical Re
TI ICU and Ventilator Mortality Among Critically III Adults With
   Coronavirus Disease 2019
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE coronavirus; critical care; intubation; mortality; respiration;
   artificial; respiratory distress syndrome; adult
AB Objectives: To determine mortality rates among adults with critical illness from coronavirus disease 2019.
   Design: Observational cohort study of patients admitted from March 6, 2020, to April 17, 2020.
   Setting: Six coronavirus disease 2019 designated ICUs at three hospitals within an academic health center network in Atlanta, Georgia, United States.
   Patients: Adults greater than or equal to 18 years old with confirmed severe acute respiratory syndrome-CoV-2 disease who were admitted to an ICU during the study period.
   Interventions: None.
   Measurements and Main Results: Among 217 critically ill patients, mortality for those who required mechanical ventilation was 35.7% (59/165), with 4.8% of patients (8/165) still on the ventilator at the time of this report. Overall mortality to date in this critically ill cohort is 30.9% (67/217) and 60.4% (131/217) patients have survived to hospital discharge. Mortality was significantly associated with older age, lower body mass index, chronic renal disease, higher Sequential Organ Failure Assessment score, lower Pao(2)/Fio(2) ratio, higher D-dimer, higher C-reactive protein, and receipt of mechanical ventilation, vasopressors, renal replacement therapy, or vasodilator therapy.
   Conclusions: Despite multiple reports of mortality rates exceeding 50% among critically ill adults with coronavirus disease 2019, particularly among those requiring mechanical ventilation, our early experience indicates that many patients survive their critical illness.
C1 [Auld, Sara C.; Caridi-Scheible, Mark; Blum, James M.; Jabaley, Craig S.; Carpenter, David; Martin, Greg S.; Coopersmith, Craig M.; Murphy, David J.] Emory Crit Care Ctr ECCC, Atlanta, GA 30329 USA.
   [Auld, Sara C.; Martin, Greg S.; Murphy, David J.] Emory Univ, Sch Med, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30303 USA.
   [Auld, Sara C.; Jacob, Jesse T.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
   [Caridi-Scheible, Mark; Blum, James M.; Jabaley, Craig S.] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA.
   [Blum, James M.; Robichaux, Chad] Emory Univ, Sch Med, Dept Biomed Informat, Atlanta, GA USA.
   [Blum, James M.; Robichaux, Chad; Martin, Greg S.] Georgia Clin & Translat Sci Alliance CTSA, Atlanta, GA USA.
   [Kraft, Colleen; Jacob, Jesse T.; Hernandez-Romieu, Alfonso C.; Adelman, Max W.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA.
   [Kraft, Colleen] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
   [Kaplow, Roberta] Emory Univ Hosp, Emory Healthcare, 1364 Clifton Rd NE, Atlanta, GA 30322 USA.
   [Coopersmith, Craig M.] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA.
   [Murphy, David J.] Emory Healthcare, Off Qual & Risk, Atlanta, GA 30303 USA.
RP Murphy, DJ (corresponding author), Emory Crit Care Ctr ECCC, Atlanta, GA 30329 USA.; Murphy, DJ (corresponding author), Emory Univ, Sch Med, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30303 USA.; Murphy, DJ (corresponding author), Emory Healthcare, Off Qual & Risk, Atlanta, GA 30303 USA.
EM david.j.murphy@emory.edu
FU National Institutes of Health (NIH)/National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [K23 AI134182]; NIH/Clinical
   and Translational Science Awards [UL1TR002378]; National Institutes of
   Health (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; Clew Medical; UptoDate; Grifols
FX This work was supported by the following grants: National Institutes of
   Health (NIH)/National Institute of Allergy and Infectious Diseases K23
   AI134182 (to Dr. Auld), NIH/Clinical and Translational Science Awards
   UL1TR002378.; Drs. Auld and Blum received support for article research
   from the National Institutes of Health (NIH). Dr. Blum's institution
   received funding from the NIH received funding from Clew Medical. Dr.
   Jacob received funding from UptoDate. Dr. Martin received funding from
   Grifols. The remaining authors have disclosed that they do not have any
   potential conflicts of interest.
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Begley S, 2020, STATNEWSCOM
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Bhatraju PK, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2682
   Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536
   Dondorp AMHM, 2020, AM J TROP MED HYG, DOI 10.4269/ajtmh20-0283
   Estenssoro E, 2010, AM J RESP CRIT CARE, V182, P41, DOI [10.1164/201001-0037OC, 10.1164/rccm.201001-0037OC]
   Hamilton J, 2020, NATL PUBLIC RADIO
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Intensive Care National Audit and Research Centre, 2020, ICNARC REP COVID 19
   Ravani S, 2020, SAN FRANCISCO CHRONI
   Richardson S., 2020, JAMA
   Wu C, 2015, JAMA INTERN MED, V30, P994
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zambon M, 2008, CHEST, V133, P1120, DOI 10.1378/chest.07-2134
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 16
TC 38
Z9 38
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD SEP
PY 2020
VL 48
IS 9
BP E799
EP E804
DI 10.1097/CCM.0000000000004457
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA NI3RD
UT WOS:000565272500009
PM 32452888
OA Green Published
DA 2021-01-01
ER

PT J
AU Sanchez-Gonzalez, A
   Lavalle, LLF
   Esteban-Fernandez, A
   Ruiz, M
   Hevia, V
   Comeche, B
   Conde, MS
   Alvarez, S
   Alvaro, JL
   Poblador, AF
   Palacios, MH
   Gutierrez, AD
   Medina, AA
   Mayayo, ES
   Duque, G
   Dos Santos, VG
   Moreno-Guillen, S
   Revilla, JB
AF Sanchez-Gonzalez, Alvaro
   Lavalle, Luis Lopez-Fando
   Esteban-Fernandez, Alberto
   Ruiz, Mercedes
   Hevia, Vital
   Comeche, Belen
   Sanchez Conde, Matilde
   alvarez, Sara
   Lorca alvaro, Javier
   Fraile Poblador, Agustin
   Hevia Palacios, Manuel
   Dominguez Gutierrez, Ana
   Artiles Medina, Alberto
   Sanz Mayayo, Enrique
   Duque, Gemma
   Gomez Dos Santos, Victoria
   Moreno-Guillen, Santiago
   Burgos Revilla, Javier
TI What Should Be Known by a Urologist About the Medical Management of
   COVID-19's Patients?
SO CURRENT UROLOGY REPORTS
LA English
DT Article
DE COVID-19; Medical management; Review; SARS-CoV-2; Treatment; Urologist
AB Purpose of Review The alarming number of confirmed COVID-19 cases put a strain on the healthcare systems, which had to reallocate human and technical resources to respond to the emergency. Many urologists became integrated into multidisciplinary teams, dealing with this respiratory illness and its unknown management. It aims to summarize the epidemiological, clinical, diagnostical, and therapeutical characteristics of COVID-19, from a practical perspective, to ease COVID-19 management to non-physician staff. Recent Findings We performed a narrative review of the literature regarding COVID-19, updated to May 8th, 2020, at PubMed and COVID resource platforms of the main scientific editorials. COVID-19, characterized by fever, myalgias, dyspnea, and dry cough, varies widely from asymptomatic infection to death. Arrhythmias and thrombotic events are prevalent. Lymphopenia and inflammatory reactant elevation on laboratory, as well as bilateral and peripheral ground-glass opacities or consolidations on X-Ray, are usually found in its assessment. Little is known about SARS-CoV-2 immunology. To date, no therapy has demonstrated efficacy in COVID-19. Of-level or compassionate-use therapies are prescribed in the context of clinical trials. We should become familiar with specific adverse events and pharmacological interactions. The COVID-19 pandemic has paralyzed the urological activity, and its long-term consequences are unpredictable. Despite not being used to deal with respiratory diseases, the urologists become easily qualified to manage COVID-19 by following protocols and being integrated into multidisciplinary teams, helping to overcome the pandemic.
C1 [Sanchez-Gonzalez, Alvaro; Lavalle, Luis Lopez-Fando; Ruiz, Mercedes; Hevia, Vital; alvarez, Sara; Lorca alvaro, Javier; Fraile Poblador, Agustin; Hevia Palacios, Manuel; Dominguez Gutierrez, Ana; Artiles Medina, Alberto; Sanz Mayayo, Enrique; Duque, Gemma; Gomez Dos Santos, Victoria; Burgos Revilla, Javier] Univ Alcala De Henares, Dept Urol, Ramon & Cajal Univ Hosp, IRYCIS, Madrid, Spain.
   [Esteban-Fernandez, Alberto] Univ Rey Juan Carlos, Severo Ochoa Univ Hosp, Serv Cardiol, Leganes, Madrid, Spain.
   [Comeche, Belen; Sanchez Conde, Matilde; Moreno-Guillen, Santiago] Univ Alcala De Henares, Dept Infect Dis, Ramon & Cajal Univ Hosp, IRYCIS, Madrid, Spain.
RP Lavalle, LLF (corresponding author), Univ Alcala De Henares, Dept Urol, Ramon & Cajal Univ Hosp, IRYCIS, Madrid, Spain.
EM llfando@gmail.com
RI Artiles-Medina, Alberto/ABE-6266-2020; Fando, Luis Lopez/ABB-2936-2020;
   Hevia, Vital/R-9553-2018
OI Hevia, Vital/0000-0001-9498-1150; ESTEBAN, ALBERTO/0000-0002-3839-7336;
   Sanchez, Alvaro/0000-0002-8051-2115
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Grag S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI [10.15585/mmwr.mm6915e3, DOI 10.15585/MMWR.MM6915E3]
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gutierrez-Ocampo E, 2020, TRAVEL MED INFECT DI, DOI 10.1016/j.tmaid.2020.101623
   Hevia V, 2020, ACTAS UROL ESP, V44, P450, DOI 10.1016/j.acuro.2020.04.006
   James M, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.6019, DOI 10.1001/JAMA.2020.6019.THIS]
   Kooraki S, 2020, J AM COLL RADIOL, V17, P447, DOI 10.1016/j.jacr.2020.02.008
   Lei S, 2020, E CLIN MED
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Llau JV, 2020, PROPUESTA RECOMENDAC
   Lopez J, 2020, CONTROL EPIDEMIOLOGI
   Mcintosh AK, 2020, CORONAVIRUS DIS 2019
   Naspro R, 2020, NAT REV UROL, V17, P251, DOI 10.1038/s41585-020-0312-1
   Park M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040967
   Ribal MJ, 2020, EUR UROL, V78, P21, DOI 10.1016/j.eururo.2020.04.056
   Tang YW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00512-20
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2020, CLIN MAN SEV AC RESP, P1
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization (WHO), 2020, 87 WHO
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 29
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1527-2737
EI 1534-6285
J9 CURR UROL REP
JI Curr. Urol. Rep.
PD SEP 1
PY 2020
VL 21
IS 10
AR 44
DI 10.1007/s11934-020-00995-y
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA NI2XY
UT WOS:000565221300001
PM 32870407
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lamb, YN
AF Lamb, Yvette N.
TI Remdesivir: First Approval
SO DRUGS
LA English
DT Article
ID GS-5734
AB The antiviral agent remdesivir (Veklury(R); Gilead Sciences), nucleotide analogue prodrug, has broad-spectrum activity against viruses from several families. Having demonstrated potent antiviral activity against coronaviruses in preclinical studies, remdesivir emerged as a candidate drug for the treatment of the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, during the current global pandemic. Phase III evaluation of remdesivir in the treatment of COVID-19 commenced in early 2020 and has thus far yielded promising results. In late May 2020, Taiwan conditionally approved the use of remdesivir in patients with severe COVID-19. This was followed by a rapid succession of conditional approvals in various countries/regions including the EU and Canada. Preceding these conditional approvals, an emergency use authorization for remdesivir had been granted in the USA (on 1 May 2020) and a special approval for emergency use was granted in Japan (on 7 May 2020). This article summarizes the milestones in the development of remdesivir leading to its first conditional approval for the treatment of COVID-19.
C1 [Lamb, Yvette N.] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand.
RP Lamb, YN (corresponding author), Springer Nat, Private Bag 65901, Auckland 0754, New Zealand.
EM dru@adis.com
CR [Anonymous], 2020, FACT SHEET HLTH CAR
   [Anonymous], 2020, ARAB HOSP MAGAZINE
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Burwick R, AIDS 2020 COVID 19 C
   Chiotos K, 2020, AIDS 2020 COVID 19 C
   Gilead Sciences, 2020, VOL LIC AGR REMD
   Gilead Sciences, 2020, VEKL INTR INJ 100MG
   Gilead Sciences Canada Inc, 2020, PROD MON REMD INJ RE
   Gilead Sciences Ireland UC, 2020, VEKL REMD EU SUMM PR
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Humeniuk R, 2020, CTS-CLIN TRANSL SCI, V13, P896, DOI 10.1111/cts.12840
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Mansuri Z, 2020, PRIM CARE COMPANION, V22
   Maserati R, AIDS 2020 COVID 19 C
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Olender SA, AIDS 2020 COVID 19 C
   Pruijssers Andrea J, 2020, bioRxiv, DOI 10.1101/2020.04.27.064279
   Saha A, 2020, ARCH MED RES, V51, P585, DOI 10.1016/j.arcmed.2020.05.001
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Somani VG, 2020, APPROVAL FAVIPIRAVIR
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Williamson BN, 2020, NATURE, DOI 10.1038/s41586-020-2423-5
   World Health Organization, 2020, TIM WHOS RESP COVID
   Yang K, 2020, CTS-CLIN TRANSL SCI, V13, P842, DOI 10.1111/cts.12815
NR 30
TC 3
Z9 3
U1 3
U2 3
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PD SEP
PY 2020
VL 80
IS 13
BP 1355
EP 1363
DI 10.1007/s40265-020-01378-w
EA SEP 2020
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA NK8HT
UT WOS:000565134300001
PM 32870481
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Race, M
   Ferraro, A
   Galdiero, E
   Guida, M
   Nunez-Delgado, A
   Pirozzi, F
   Siciliano, A
   Fabbricino, M
AF Race, M.
   Ferraro, A.
   Galdiero, E.
   Guida, M.
   Nunez-Delgado, A.
   Pirozzi, F.
   Siciliano, A.
   Fabbricino, M.
TI Current emerging SARS-CoV-2 pandemic: Potential direct/indirect negative
   impacts of virus persistence and related therapeutic drugs on the
   aquatic compartments
SO ENVIRONMENTAL RESEARCH
LA English
DT Article
DE Coronavirus; COVID-19; SARS-CoV-2; Wastewater; Drugs persistence
ID RESPIRATORY SYNDROME CORONAVIRUS; WASTE-WATER TREATMENT; SARS
   CORONAVIRUS; SPIKE PROTEIN; NUCLEIC-ACID; SURVIVAL; COVID-19; COV;
   IDENTIFICATION; TRANSMISSION
AB The purpose of the present work is to provide a complete overview of possible direct/indirect implications on the quality of aquatic compartments due to the recent SARS-CoV-2 outbreak. With this aim, the environmental impacts are mainly related to i) the virus persistence in sewage and wastewaters, and ii) possible fate in aquatic compartments of drugs tested and administered to SARS-CoV-2 infected patients. Because SARS-CoV-2 spread is very recent, and there is a lack of specific studies on this strain, the virus persistence in wastewaters, the parameters influencing the persistence, as well as the detection methodologies are referenced to the general coronaviruses group. However, the present detailed report of up-to-date knowledge on this topic can provide a useful source for further studies focusing on more deepened investigations of SARS-CoV-2 behaviour in the environment. Such a perspective is significant not only for the control of virus diffusion but also represents a crucial point for the identification of produced alteration to the environmental quality.
C1 [Race, M.] Univ Cassino & Southern Lazio, Dept Civil & Mech Engn, Via Biasio 43, I-03043 Cassino, Italy.
   [Ferraro, A.; Pirozzi, F.; Fabbricino, M.] Univ Naples Federico II, Dept Civil Architectural & Environm Engn, Via Claudio 21, I-80125 Naples, Italy.
   [Galdiero, E.; Guida, M.; Siciliano, A.] Univ Naples Federico II, Dept Biol, Via Cinthia, I-80126 Naples, Italy.
   [Nunez-Delgado, A.] Univ Santiago de Compostela, Engn Polytech Sch, Dept Soil Sci & Agr Chem, Campus Univ Lugo, Santiago De Compostela, Spain.
RP Race, M (corresponding author), Univ Cassino & Southern Lazio, Dept Civil & Mech Engn, Via Biasio 43, I-03043 Cassino, Italy.
EM marco.race@unicas.it
FU Italian Ministry of Education, University and Research (MIUR)Ministry of
   Education, Universities and Research (MIUR) [CUP E65D18000820006]
FX Dr. Ferraro would like to thank the Italian Ministry of Education,
   University and Research (MIUR), which provided financial support for a
   12 months post-doctoral grant in the framework of the research project
   entitled "Dipartimenti di Eccellenza" per Ingegneria Civile, Edile e
   Ambientale - CUP E65D18000820006.
CR Acree WE, 2012, TOXICITY AND DRUG TESTING, P261
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Babic D, 2017, ENVIRON ENG-VILNIUS, DOI 10.3846/enviro.2017.131
   Barcelo D, 2020, J ENVIRON CHEM ENG, V8, DOI 10.1016/j.jece.2020.104006
   Barcena M, 2009, P NATL ACAD SCI USA, V106, P582, DOI 10.1073/pnas.0805270106
   Bosch A, 2006, FOOD MICROBIOL FOOD, P151
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Cantalupo PG, 2011, MBIO, V2, DOI 10.1128/mBio.00180-11
   Cao Z, 2020, ESTIMATING EFFECTIVE
   Carducci A, 2020, WATER RES, V179, DOI 10.1016/j.watres.2020.115907
   Carter M, 2015, GUIDE RES TECHNIQUES, P219, DOI [10.1016/B978-0-12-800511-8.00010-1, DOI 10.1016/B978-0-12-800511-8.00010-1, 10.1016/b978-0-12-800511-8.00010-1]
   Casanova L, 2009, WATER RES, V43, P1893, DOI 10.1016/j.watres.2009.02.002
   Casanova LM, 2015, ENVIRON SCI TECH LET, V2, P76, DOI 10.1021/acs.estlett.5b00029
   Casanova LM, 2010, APPL ENVIRON MICROB, V76, P2712, DOI 10.1128/AEM.02291-09
   Cascella M, 2020, STATPEARLS
   Chen V, 2013, INVEST OPHTH VIS SCI, V54
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   COOPER P. D., 1961, ADVANCES IN VIRUS RES, V8, P319
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Daouk S, 2015, J ENVIRON MANAGE, V160, P324, DOI 10.1016/j.jenvman.2015.06.037
   Daughton C, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138149
   Daughton CG, 2020, SCI TOTAL ENVIRON, V736, DOI 10.1016/j.scitotenv.2020.139631
   Daughton CG, 2014, SCI TOTAL ENVIRON, V466, P315, DOI 10.1016/j.scitotenv.2013.06.111
   EMEA, 2006, CPMPSWP444700 EMEA
   FASS safety data sheet, 2019, ENV RISK ASS SUMM
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Funke J, 2016, WATER RES, V98, P75, DOI 10.1016/j.watres.2016.03.045
   Gormley M, 2020, LANCET GLOB HEALTH, V8, pE643, DOI 10.1016/S2214-109X(20)30112-1
   Gormley M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171556
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gundy PM, 2009, FOOD ENVIRON VIROL, V1, P10, DOI 10.1007/s12560-008-9001-6
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Haladyj Ewa, 2018, Reumatologia (Warsaw), V56, P164, DOI 10.5114/reum.2018.76904
   He YX, 2006, VACCINE, V24, P5498, DOI 10.1016/j.vaccine.2006.04.054
   Hill A, 2014, CLIN INFECT DIS, V58, P928, DOI 10.1093/cid/ciu012
   Hoffmann F., 2018, ENV RISK ASS SUMM TO
   Hoffmann F., 2006, A47338 RCC RCC LTD
   Hoffmann F., 2006, A47327 RCC RCC LTD
   Hoffmann F., 2006, RCC STUDY A47340
   Hoffmann F., 2006, A47351 RCC RCC LTD
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Howard PH, 2011, ENVIRON SCI TECHNOL, V45, P6938, DOI 10.1021/es201196x
   Ikehata K., 2009, Water Environment Research, V81, P2126, DOI 10.2175/106143009X12445568400773
   Izaguirre G, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090837
   Jain S, 2013, WATER AIR SOIL POLL, V224, DOI 10.1007/s11270-012-1410-3
   Jia HP, 2006, ADV EXP MED BIOL, V581, P479
   Kallen KJ, 2002, BBA-MOL CELL RES, V1592, P323, DOI 10.1016/S0167-4889(02)00325-7
   La Rosa G, 2020, WATER RES, V179, DOI 10.1016/j.watres.2020.115899
   La Rosa G, 2012, ANN I SUPER SANITA, V48, P397, DOI 10.4415/ANN_12_04_07
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Lodder W, 2020, LANCET GASTROENTEROL, V5, P533, DOI 10.1016/S2468-1253(20)30087-X
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Magro L, 2017, LAB CHIP, V17, P2347, DOI 10.1039/c7lc00013h
   Mao K, 2020, ENVIRON SCI TECHNOL, V54, P3733, DOI 10.1021/acs.est.0c01174
   Medema G., 2020, PRESENCE SARS CORONA, DOI [10.1101/2020.03.29, DOI 10.1101/2020.03.29]
   Naddeo V, 2020, ENVIRON SCI-WAT RES, V6, P1213, DOI 10.1039/d0ew90015j
   Nal B, 2005, J GEN VIROL, V86, P1423, DOI 10.1099/vir.0.80671-0
   Nunez-Delgado A, 2020, SCI TOTAL ENVIRON, V727, DOI 10.1016/j.scitotenv.2020.138647
   Olaitan O.J., 2017, AFRICAN J SCI NAT, V3, P50
   Orive G, 2020, SCI TOTAL ENVIRON, V732, DOI 10.1016/j.scitotenv.2020.139298
   Pan XF, 2020, LANCET INFECT DIS, V20, P410, DOI 10.1016/S1473-3099(20)30114-6
   Ramesh M, 2018, TOXICOL REP, V5, P18, DOI 10.1016/j.toxrep.2017.11.006
   Rendal C, 2011, ENVIRON TOXICOL CHEM, V30, P354, DOI 10.1002/etc.391
   Reusken C.B., 2020, SARSCOV2, V25
   Richardson SD, 2012, ANAL CHEM, V84, P747, DOI 10.1021/ac202903d
   Russo D, 2017, WATER RES, V122, P591, DOI 10.1016/j.watres.2017.06.020
   Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Straub J. O., 2010, GREEN SUSTAINABLE PH, P127
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tsai CT, 1999, J APPL MICROBIOL, V86, P827, DOI 10.1046/j.1365-2672.1999.00732.x
   Venkiteshwaran A, 2009, MABS-AUSTIN, V1, P432, DOI 10.4161/mabs.1.5.9497
   Venugopal Anila, 2020, Curr Opin Environ Sci Health, V17, P8, DOI 10.1016/j.coesh.2020.05.003
   Wang XW, 2005, WORLD J GASTROENTERO, V11, P4390
   Wang XW, 2005, J VIROL METHODS, V128, P156, DOI 10.1016/j.jviromet.2005.03.022
   Wang XW, 2005, J VIROL METHODS, V126, P171, DOI 10.1016/j.jviromet.2005.02.005
   WHO, 2019, MERS GLOB SUMM ASS R
   WHO, 2003, CONS DOC EPID SERV A
   Wigginton KR, 2015, ENVIRON SCI-WAT RES, V1, P735, DOI [10.1039/c5ew00125k, 10.1039/C5EW00125K]
   Wigginton KR, 2020, ENVIRON SCI TECHNOL, V54, P3736, DOI 10.1021/acs.est.0c01476
   Wolff MH, 2005, BIRK ADV INFECT DIS, P201
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   World Health Organization, 2020, COR DIS 2019 COVID 1
   World Health Organization (WHO), 2020, WHO ANN COVID 19 OUT
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wurtzer S., 2020, EVALUTION LOCKDOWN I
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Ye YY, 2016, ENVIRON SCI TECHNOL, V50, P5077, DOI 10.1021/acs.est.6b00876
   Yeo C, 2020, LANCET GASTROENTEROL, V5, P335, DOI 10.1016/S2468-1253(20)30048-0
   Zambrano-Monserrate MA, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138813
   Zanin GM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093024
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zurita JL, 2005, AQUAT TOXICOL, V75, P97, DOI 10.1016/j.aquatox.2005.07.009
NR 99
TC 2
Z9 2
U1 13
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD SEP
PY 2020
VL 188
AR 109808
DI 10.1016/j.envres.2020.109808
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA NH4OS
UT WOS:000564651700007
PM 32544725
OA Green Published
DA 2021-01-01
ER

PT J
AU De Biasi, S
   Lo Tartaro, D
   Meschiari, M
   Gibellini, L
   Bellinazzi, C
   Borella, R
   Fidanza, L
   Mattioli, M
   Paolini, A
   Gozzi, L
   Jaacoub, D
   Faltoni, M
   Volpi, S
   Milic, J
   Sita, M
   Sarti, M
   Pucillo, C
   Girardis, M
   Guaraldi, G
   Mussini, C
   Cossarizza, A
AF De Biasi, Sara
   Lo Tartaro, Domenico
   Meschiari, Marianna
   Gibellini, Lara
   Bellinazzi, Caterina
   Borella, Rebecca
   Fidanza, Lucia
   Mattioli, Marco
   Paolini, Annamaria
   Gozzi, Licia
   Jaacoub, Dina
   Faltoni, Matteo
   Volpi, Sara
   Milic, Jovana
   Sita, Marco
   Sarti, Mario
   Pucillo, Carlo
   Girardis, Massimo
   Guaraldi, Giovanni
   Mussini, Cristina
   Cossarizza, Andrea
TI Expansion of plasmablasts and loss of memory B cells in peripheral blood
   from COVID-19 patients with pneumonia
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE B cells; Coronavirus; COVID-19; plasmablasts; SARS-CoV-2;
   carboxyfluorescein succinimidyl ester CFSE; principal components (PCs);
   principal component analysis (PCA); Uniform Manifold Approximation and
   Projection (UMAP)
ID SARS CORONAVIRUS; DOWN-REGULATION; ALPHA; DIFFERENTIATION;
   PROLIFERATION; RECEPTOR; PROTEIN; IL-6
AB Studies on the interactions between SARS-CoV-2 and humoral immunity are fundamental to elaborate effective therapies including vaccines. We used polychromatic flow cytometry, coupled with unsupervised data analysis and principal component analysis (PCA), to interrogate B cells in untreated patients with COVID-19 pneumonia. COVID-19 patients displayed normal plasma levels of the main immunoglobulin classes, of antibodies against common antigens or against antigens present in common vaccines. However, we found a decreased number of total and naive B cells, along with decreased percentages and numbers of memory switched and unswitched B cells. On the contrary, IgM(+)and IgM(-)plasmablasts were significantly increased. In vitro cell activation revealed that B lymphocytes showed a normal proliferation index and number of dividing cells per cycle. PCA indicated that B-cell number, naive and memory B cells but not plasmablasts clustered with patients who were discharged, while plasma IgM level, C-reactive protein, D-dimer, and SOFA score with those who died. In patients with pneumonia, the derangement of the B-cell compartment could be one of the causes of the immunological failure to control SARS-Cov2, have a relevant influence on several pathways, organs and systems, and must be considered to develop vaccine strategies.
C1 [De Biasi, Sara; Lo Tartaro, Domenico; Gibellini, Lara; Bellinazzi, Caterina; Borella, Rebecca; Fidanza, Lucia; Mattioli, Marco; Paolini, Annamaria; Gozzi, Licia; Cossarizza, Andrea] Univ Modena & Reggio Emilia, Sch Med, Dept Med & Surg Sci Children & Adults, Modena, Italy.
   [Meschiari, Marianna; Jaacoub, Dina; Faltoni, Matteo; Volpi, Sara; Milic, Jovana; Guaraldi, Giovanni; Mussini, Cristina] AOU Policlin, Infect Dis Clin, Modena, Italy.
   [Meschiari, Marianna; Jaacoub, Dina; Faltoni, Matteo; Volpi, Sara; Milic, Jovana; Sita, Marco; Girardis, Massimo; Guaraldi, Giovanni; Mussini, Cristina] Univ Modena & Reggio Emilia, Modena, Italy.
   [Sita, Marco; Girardis, Massimo] AOU Policlin, Dept Anesthesia & Intens Care, Modena, Italy.
   [Sarti, Mario] AOU Policlin, Clin Microbiol Unit, Modena, Italy.
   [Pucillo, Carlo] Univ Udine, Dept Med, Lab Immunol, Udine, Italy.
   [Cossarizza, Andrea] Natl Inst Cardiovasc Res, Bologna, Italy.
RP Cossarizza, A (corresponding author), Dept Med & Surg Sci Children & Adults, Via Campi 287, I-41125 Modena, Italy.
EM andrea.cossarizza@unimore.it
FU Ministero della Salute, Bando Ricerca COVID-19 [2020-2021] Funding
   Source: Medline
CR Blanco E, 2018, J ALLERGY CLIN IMMUN, V141, P2208, DOI 10.1016/j.jaci.2018.02.017
   Chavele KM, 2015, J IMMUNOL, V194, P2482, DOI 10.4049/jimmunol.1401190
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   Cossarizza A., 2020, CYTOMETRY A, V97
   Cossarizza A, 2020, CYTOM PART A, V97, P340, DOI 10.1002/cyto.a.24002
   Cossarizza A, 2019, EUR J IMMUNOL, V49, P1457, DOI 10.1002/eji.201970107
   De Biasi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17292-4
   Dijkman R, 2012, J GEN VIROL, V93, P1924, DOI 10.1099/vir.0.043919-0
   Frasca D, 2014, EXP GERONTOL, V54, P116, DOI 10.1016/j.exger.2014.01.004
   Frasca D, 2012, J IMMUNOL, V188, P279, DOI 10.4049/jimmunol.1003964
   Friederichs K, 2001, EUR J BIOCHEM, V268, P6401, DOI 10.1046/j.0014-2956.2001.02586.x
   Frieman M, 2008, VIRUS RES, V133, P101, DOI 10.1016/j.virusres.2007.03.015
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Guaraldi G., 2020, LANCET RHEUMATOL
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Iwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123
   Jego G, 2001, BLOOD, V97, P1817, DOI 10.1182/blood.V97.6.1817
   Lin Y, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0079-7
   Merluzzi S, 2010, BLOOD, V115, P2810, DOI 10.1182/blood-2009-10-250126
   Nasi M, 2019, J INFECT DIS, V219, P1743, DOI 10.1093/infdis/jiy730
   Nie YC, 2004, J INFECT DIS, V190, P1119, DOI 10.1086/423286
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Quah BJ, 2010, JOVE-J VIS EXP, V44, P2259, DOI DOI 10.3791/2259
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   RIECKMANN P, 1991, J IMMUNOL, V146, P3462
   Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015
   Weber LM, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0415-5
NR 29
TC 4
Z9 3
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD SEP
PY 2020
VL 50
IS 9
BP 1283
EP 1294
DI 10.1002/eji.202048838
PG 12
WC Immunology
SC Immunology
GA NI5PT
UT WOS:000565404100004
PM 32910469
OA Bronze
DA 2021-01-01
ER

PT J
AU Zou, GJ
   Liu, Y
   Gao, HJ
AF Zou, Guijin
   Liu, Yue
   Gao, Huajian
TI EML webinar overview: Simulation-assisted discovery of membrane
   targeting nanomedicine
SO EXTREME MECHANICS LETTERS
LA English
DT Article
DE Membrane targeting; Antibiotics; Bacterial persister; Membrane
   selectivity; Cholesterol-based selectivity; Size-based selectivity;
   Modelling and simulation; Drug discovery; Antiviral agents; Coronavirus
ID STAPHYLOCOCCUS-AUREUS INFECTIONS; MOLECULAR-DYNAMICS; PERSISTERS
AB The COVID-19 pandemic has brought infectious diseases again to the forefront of global public health concerns. In this EML webinar (Gao, 2020), we discuss some recent work on simulation-assisted discovery of membrane targeting nanomedicine to counter increasing antimicrobial resistance and potential application of similar ideas to the current pandemic. A recent report led by the world health organization (WHO) warned that 10 million people worldwide could die of bacterial infections each year by 2050. To avert the crisis, membrane targeting antibiotics are drawing increasing attention due to their intrinsic advantage of low resistance development. In collaboration with a number of experimental groups, we show examples of simulation-assisted discovery of molecular agents capable of selectively penetrating and aggregating in bacterial lipid membranes, causing membrane permeability/rupture. Through systematic all-atom molecular dynamics simulations and free energy analysis, we demonstrate that the membrane activity of the molecular agents correlates with their ability to enter, perturb and permeabilize the lipid bilayers. Further study on different cell membranes demonstrates that the selectivity results from the presence of cholesterol in mammalian but not in bacterial membranes, as the cholesterol can condense the hydrophobic region of membrane, preventing the penetration of the molecular agents. Following the molecular penetration, we establish a continuum theory and derive the energetic driving force for the domain aggregation and pore growth on lipid membrane. We show that the energy barrier to membrane pore formation can be significantly lowered through molecular aggregation on a large domain with intrinsic curvature and a sharp interface. The theory is consistent with experimental observations and validated with coarsegrained molecular dynamics simulations of molecular domain aggregation leading to pore formation in a lipid membrane. The mechanistic modelling and simulation provide some fundamental principles on how molecular antimicrobials interact with bacterial membranes and damage them through domain aggregation and pore formation. For treating viral infections and cancer therapy, we discuss potential size- and lipid-type-based selectivity principles for developing membrane active nanomedicine. These studies suggest a general simulation-assisted platform to accelerate discovery and innovation in nanomedicine against infectious diseases.
   EML Webinar speakers are updated at https://imechanica.org/node/24132 (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Zou, Guijin; Gao, Huajian] ASTAR, Inst High Performance Comp, Singapore 138632, Singapore.
   [Liu, Yue; Gao, Huajian] Brown Univ, Sch Engn, Providence, RI 02912 USA.
   [Gao, Huajian] Nanyang Technol Univ, Coll Engn, Sch Mech & Aerosp Engn, 70 Nanyang Dr, Singapore 639798, Singapore.
RP Gao, HJ (corresponding author), ASTAR, Inst High Performance Comp, Singapore 138632, Singapore.; Gao, HJ (corresponding author), Brown Univ, Sch Engn, Providence, RI 02912 USA.; Gao, HJ (corresponding author), Nanyang Technol Univ, Coll Engn, Sch Mech & Aerosp Engn, 70 Nanyang Dr, Singapore 639798, Singapore.
EM huajian.gao@ntu.edu.sg
RI Zou, Guijin/N-5554-2018
OI Zou, Guijin/0000-0003-0047-7012; Liu, Yue/0000-0002-3153-6962
FU U.S. National Science FoundationNational Science Foundation (NSF)
   [CMMI-1562904]; Nanyang Technological UniversityNanyang Technological
   University; Institute of High Performance Computing, A*STAR,
   SingaporeAgency for Science Technology & Research (ASTAR)
FX This work was supported by the U.S. National Science Foundation (Grant
   CMMI-1562904) and a start-up grant from the Nanyang Technological
   University and Institute of High Performance Computing, A*STAR,
   Singapore.
CR Allison KR, 2011, NATURE, V473, P216, DOI 10.1038/nature10069
   Bhattacharyya C, 2020, GLOBAL SPREAD SARS C, DOI [10.1101/2020.05.04.075911, DOI 10.1101/2020.05.04.075911]
   Chopra I, 2002, J APPL MICROBIOL, V92, p4S, DOI 10.1046/j.1365-2672.92.5s1.13.x
   Coates ARM, 2008, TRENDS PHARMACOL SCI, V29, P143, DOI 10.1016/j.tips.2007.12.001
   Conlon BP, 2013, NATURE, V503, P365, DOI 10.1038/nature12790
   Deleu M, 2014, BBA-BIOMEMBRANES, V1838, P3171, DOI 10.1016/j.bbamem.2014.08.023
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Grubaugh ND, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0690-4
   Harayama T, 2018, NAT REV MOL CELL BIO, V19, P281, DOI 10.1038/nrm.2017.138
   Holmes E.C., 2009, EVOLUTION EMERGENCE
   Hong C, 2014, LANGMUIR, V30, P11993, DOI 10.1021/la502363b
   Hub JS, 2010, J CHEM THEORY COMPUT, V6, P3713, DOI 10.1021/ct100494z
   Hurdle JG, 2011, NAT REV MICROBIOL, V9, P62, DOI 10.1038/nrmicro2474
   Isralewitz B, 2001, CURR OPIN STRUC BIOL, V11, P224, DOI 10.1016/S0959-440X(00)00194-9
   Jackman JA, 2018, NAT MATER, V17, P971, DOI 10.1038/s41563-018-0194-2
   Kim W, 2020, MBIO, V11, DOI 10.1128/mBio.01140-20
   Kim W, 2019, P NATL ACAD SCI USA, V116, P16529, DOI 10.1073/pnas.1904700116
   Kim W, 2018, NATURE, V556, P103, DOI 10.1038/nature26157
   KUMAR S, 1992, J COMPUT CHEM, V13, P1011, DOI 10.1002/jcc.540130812
   Lee AS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.33
   Lee MT, 2013, P NATL ACAD SCI USA, V110, P14243, DOI 10.1073/pnas.1307010110
   Lehar SM, 2015, NATURE, V527, P323, DOI 10.1038/nature16057
   Levin BR, 2006, NAT REV MICROBIOL, V4, P556, DOI 10.1038/nrmicro1445
   Lewis K, 2010, ANNU REV MICROBIOL, V64, P357, DOI 10.1146/annurev.micro.112408.134306
   Liu C, 2011, CLIN INFECT DIS, V52, pE18, DOI 10.1093/cid/ciq146
   Ojha AK, 2008, MOL MICROBIOL, V69, P164, DOI 10.1111/j.1365-2958.2008.06274.x
   Rajamuthiah R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089189
   Romanov B. K., 2020, SAFE RISK PHARMACOTH, V8, P3, DOI [DOI 10.30895/2312-7821-2020-8-1-3-8, 10.30895/2312-7821-2020-8-1-3-8]
   The O.F., 2019, NO TIME WAIT SECURIN
   Tong SYC, 2015, CLIN MICROBIOL REV, V28, P603, DOI 10.1128/CMR.00134-14
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
NR 31
TC 0
Z9 0
U1 12
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-4316
J9 EXTREME MECH LETT
JI EXTREME MECH. LETT.
PD SEP
PY 2020
VL 39
AR 100817
DI 10.1016/j.eml.2020.100817
PG 5
WC Engineering, Mechanical; Materials Science, Multidisciplinary; Mechanics
SC Engineering; Materials Science; Mechanics
GA NH2WK
UT WOS:000564535600013
PM 32537481
OA Green Published
DA 2021-01-01
ER

PT J
AU Gupta, T
   Gupta, SK
AF Gupta, Tania
   Gupta, Shishir K.
TI Potential adjuvants for the development of a SARS-CoV-2 vaccine based on
   experimental results from similar coronaviruses
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE COVID-19; SARS; SARS-CoV-2; Adjuvant; Vaccine; Coronavirus; MERS
ID RECEPTOR-BINDING DOMAIN; T-CELL RESPONSES; ANTIBODY-DEPENDENT
   ENHANCEMENT; HELMINTH ONCHOCERCA-VOLVULUS; SYSTEMIC HUMORAL IMMUNITY;
   INFLUENZA-VIRUS VACCINE; COV SPIKE GLYCOPROTEIN; PHASE-I TRIAL;
   SARS-COV; DELTA INULIN
AB The extensive efforts around the globe are being made to develop a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or assistance from other immunostimulatory molecules. Further, the vaccine should be able to induce protective levels of antibodies rapidly with the least amount of antigen used. This decreases the cost of a vaccine and makes it affordable. As the pandemic has hit most countries across the globe, there will be an overwhelming demand for the vaccine in a quick time. Incorporating a suitable adjuvant in a SARS-CoV-2 vaccine may address these requirements. This review paper will discuss the experimental results of the adjuvanted vaccine studies with similar coronaviruses (CoVs) which might be useful to select an appropriate adjuvant for a vaccine against rapidly emerging SARS-CoV-2. We also discuss the current progress in the development of adjuvanted vaccines against the disease.
C1 [Gupta, Tania] Dr GC Negi Coll Vet & Anim Sci, Palampur 176062, Himachal Prades, India.
   [Gupta, Shishir K.] CSIR, Cent Drug Res Inst, Lucknow 226031, Uttar Pradesh, India.
RP Gupta, T (corresponding author), Dr GC Negi Coll Vet & Anim Sci, Palampur 176062, Himachal Prades, India.
EM dr.tania603@gmail.com
CR Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   Aguilar JC, 2007, VACCINE, V25, P3752, DOI 10.1016/j.vaccine.2007.01.111
   Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Anwar MA, 2019, MED RES REV, V39, P1053, DOI 10.1002/med.21553
   Atsmon J, 2012, J CLIN IMMUNOL, V32, P595, DOI 10.1007/s10875-011-9632-5
   Aucouturier Jerome, 2002, Expert Rev Vaccines, V1, P111, DOI 10.1586/14760584.1.1.111
   Azizi Ali, 2005, Genet Vaccines Ther, V3, P7, DOI 10.1186/1479-0556-3-7
   Bisht H, 2005, VIROLOGY, V334, P160, DOI 10.1016/j.virol.2005.01.042
   Bodewes R, 2010, J VIROL, V84, P7943, DOI 10.1128/JVI.00549-10
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002
   Cao WP, 2017, VACCINE, V35, P3318, DOI 10.1016/j.vaccine.2017.05.004
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Chabot S, 2005, VACCINE, V23, P1374, DOI 10.1016/j.vaccine.2004.09.010
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen WH, 2014, HUM VACC IMMUNOTHER, V10, P648, DOI 10.4161/hv.27464
   Chlibek R, 2016, VACCINE, V34, P863, DOI 10.1016/j.vaccine.2015.09.073
   Coccia M, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0027-3
   Coleman CM, 2017, VACCINE, V35, P1586, DOI 10.1016/j.vaccine.2017.02.012
   Coleman CM, 2014, VACCINE, V32, P3169, DOI 10.1016/j.vaccine.2014.04.016
   Coler RN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016333
   Cooper PD, 2011, GLYCOBIOLOGY, V21, P595, DOI 10.1093/glycob/cwq201
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cox RJ, 2011, VACCINE, V29, P8049, DOI 10.1016/j.vaccine.2011.08.042
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Deng Y, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0056-7
   Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632
   Diefenbach CSM, 2008, CLIN CANCER RES, V14, P2740, DOI 10.1158/1078-0432.CCR-07-4619
   Du L., 2013, J VIROL
   Du LY, 2016, EXPERT REV VACCINES, V15, P1123, DOI 10.1586/14760584.2016.1167603
   Duthie MS, 2011, IMMUNOL REV, V239, P178, DOI 10.1111/j.1600-065X.2010.00978.x
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Folegatti PM, 2020, LANCET INFECT DIS
   Fries LF, 2001, INFECT IMMUN, V69, P4545, DOI 10.1128/IAI.69.7.4545-4553.2001
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gai Wei-wei, 2011, Virologica Sinica, V26, P81, DOI 10.1007/s12250-011-3183-z
   Gai WW, 2008, VIRAL IMMUNOL, V21, P27, DOI 10.1089/vim.2007.0079
   Galli G, 2009, P NATL ACAD SCI USA, V106, P7962, DOI 10.1073/pnas.0903181106
   Ghimire TR, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0972-0
   Gordon D, 2014, VACCINE, V32, P6469, DOI 10.1016/j.vaccine.2014.09.034
   Gordon DL, 2016, VACCINE, V34, P3780, DOI 10.1016/j.vaccine.2016.05.071
   Graham B.S., 2010, PLOS ONE, V5
   Gupta SK, 2014, EXPERT REV VACCINES, V13, P909, DOI 10.1586/14760584.2014.920236
   Gupta SK, 2014, CLIN VACCINE IMMUNOL, V21, P261, DOI 10.1128/CVI.00669-13
   Hamid MMA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020547
   He YX, 2009, J IMMUNOL, V182, P4005, DOI 10.4049/jimmunol.0800531
   HogenEsch H, 2002, VACCINE, V20, pS34, DOI 10.1016/S0264-410X(02)00169-X
   Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14
   Honda-Okubo Y, 2012, VACCINE, V30, P5373, DOI 10.1016/j.vaccine.2012.06.021
   Hotez P.J., 2020, DEV LOW COST ACCESIB
   Hu MC, 2007, VACCINE, V25, P6334, DOI 10.1016/j.vaccine.2007.06.017
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang Y, 2009, J CLIN VIROL, V44, P287, DOI 10.1016/j.jcv.2009.01.009
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Iwata-Yoshikawa N, 2014, J VIROL, V88, P8597, DOI 10.1128/JVI.00983-14
   Jiang J, 2016, VACCINE, V34, P887, DOI 10.1016/j.vaccine.2016.01.003
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Jones T, 2004, VACCINE, V22, P3691, DOI 10.1016/j.vaccine.2004.03.035
   Jung SY, 2018, VACCINE, V36, P3468, DOI 10.1016/j.vaccine.2018.04.082
   Kim YS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01093
   Ko EJ, 2018, HUM VACC IMMUNOTHER, V14, P3041, DOI 10.1080/21645515.2018.1495301
   Ko EJ, 2016, J VIROL, V90, P6976, DOI 10.1128/JVI.00339-16
   Koch T., 2020, LANCET INFECT DIS
   Kommareddy S, 2017, IMMUNOPOTENTIATORS IN MODERN VACCINES, 2ND EDITION, P249, DOI 10.1016/B978-0-12-804019-5.00013-X
   Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087
   Kumar S, 2004, INFECT IMMUN, V72, P949, DOI 10.1128/IAI.72.2.949-957.2004
   Kusi KA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-182
   Lakhan N, 2016, J IMMUNOL METHODS, V439, P37, DOI 10.1016/j.jim.2016.09.008
   Lambkin-Williams R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163089
   Lan JM, 2017, VACCINE, V35, P10, DOI 10.1016/j.vaccine.2016.11.064
   Lan JM, 2015, EBIOMEDICINE, V2, P1438, DOI 10.1016/j.ebiom.2015.08.031
   Leroux-Roels I, 2013, VACCINE, V31, P2196, DOI 10.1016/j.vaccine.2012.05.035
   Li J, 2013, VIRAL IMMUNOL, V26, P126, DOI 10.1089/vim.2012.0076
   Lien SP, 2007, BIOCHEM BIOPH RES CO, V358, P716, DOI 10.1016/j.bbrc.2007.04.164
   Lin JT, 2007, ANTIVIR THER, V12, P1107
   Liu SJ, 2006, VACCINE, V24, P3100, DOI 10.1016/j.vaccine.2006.01.058
   Liu YV, 2011, VACCINE, V29, P6606, DOI 10.1016/j.vaccine.2011.06.111
   Lobigs M, 2010, J GEN VIROL, V91, P1407, DOI 10.1099/vir.0.019190-0
   Lokugamage KG, 2008, VACCINE, V26, P797, DOI 10.1016/j.vaccine.2007.11.092
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Lu R, 2020, LANCET, V395, P565
   Luo F, 2018, VIROL SIN, V33, P201, DOI 10.1007/s12250-018-0009-2
   Lurie N, 2020, N ENGL J MED
   MacDonald AJ, 2005, VACCINE, V23, P3446, DOI 10.1016/j.vaccine.2005.01.098
   MacDonald AJ, 2004, PARASITE IMMUNOL, V26, P53, DOI 10.1111/j.0141-9838.2004.00685.x
   MALLETT CP, 1995, INFECT IMMUN, V63, P2382, DOI 10.1128/IAI.63.6.2382-2386.1995
   Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Modjarrad K, 2019, LANCET INFECT DIS, V19, P1013, DOI 10.1016/S1473-3099(19)30266-X
   O'Hagan DT, 2007, EXPERT REV VACCINES, V6, P699, DOI 10.1586/14760584.6.5.699
   O'Hagan DT, 2011, EXPERT REV VACCINES, V10, P447, DOI [10.1586/ERV.11.23, 10.1586/erv.11.23]
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Pedersen GK, 2014, HUM VACC IMMUNOTHER, V10, P2408, DOI 10.4161/hv.29583
   Petrovsky N, 2015, VACCINE, V33, P5920, DOI 10.1016/j.vaccine.2015.09.030
   Petrovsky N, 2015, DRUG SAFETY, V38, P1059, DOI 10.1007/s40264-015-0350-4
   Plante M, 2001, VACCINE, V20, P218, DOI 10.1016/S0264-410X(01)00268-7
   Pockros PJ, 2007, J HEPATOL, V47, P174, DOI 10.1016/j.jhep.2007.02.025
   Qin E, 2006, VACCINE, V24, P1028, DOI 10.1016/j.vaccine.2005.06.038
   Qu D, 2005, VACCINE, V23, P924, DOI 10.1016/j.vaccine.2004.07.031
   Quinlan B. D., 2020, BIORXIV, DOI [10.1101/2020.04.10.036418, DOI 10.1101/2020.04.10.036418]
   Ren W, 2020, RECOMBINANT SARS COV, DOI [10.1101/2020.04.21.052209, DOI 10.1101/2020.04.21.052209]
   Roberts A, 2008, VIRUS RES, V133, P20, DOI 10.1016/j.virusres.2007.03.025
   Roberts A, 2010, VIRAL IMMUNOL, V23, P509, DOI 10.1089/vim.2010.0028
   Sabbatini P, 2012, CLIN CANCER RES, V18, P6497, DOI 10.1158/1078-0432.CCR-12-2189
   Santini-Oliveira M, 2016, VACCINE, V34, P586, DOI 10.1016/j.vaccine.2015.10.027
   Saxena M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00725
   Schultze V, 2008, VACCINE, V26, P3209, DOI 10.1016/j.vaccine.2008.03.093
   Shalaby KH, 2012, J IMMUNOL, V189, P2793, DOI 10.4049/jimmunol.1201194
   Shirota H, 2017, IMMUNOPOTENTIATORS IN MODERN VACCINES, 2ND EDITION, P163, DOI 10.1016/B978-0-12-804019-5.00009-8
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stadler K, 2005, EMERG INFECT DIS, V11, P1312, DOI 10.3201/eid1108.041003
   Tai W, 2017, J VIROL, V91, P1
   Tai WB, 2016, VIROLOGY, V499, P375, DOI 10.1016/j.virol.2016.10.005
   Takada A, 2003, REV MED VIROL, V13, P387, DOI 10.1002/rmv.405
   Takasuka N, 2004, INT IMMUNOL, V16, P1423, DOI 10.1093/intimm/dxh143
   Tang J, 2015, HUM VACC IMMUNOTHER, V11, P1244, DOI 10.1080/21645515.2015.1021527
   Tang L, 2004, DNA CELL BIOL, V23, P391, DOI 10.1089/104454904323145272
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8
   Tirado SMC, 2003, VIRAL IMMUNOL, V16, P69, DOI 10.1089/088282403763635465
   Tomljenovic L, 2011, CURR MED CHEM, V18, P2630, DOI 10.2174/092986711795933740
   Tseng CT, 2012, IMMUNIZATION SARS CO
   Ulanova M, 2001, INFECT IMMUN, V69, P1151, DOI 10.1128/IAI.69.2.1151-1159.2001
   Van Braeckel E, 2011, CLIN INFECT DIS, V52, P522, DOI 10.1093/cid/ciq160
   van Doorn E, 2016, HUM VACC IMMUNOTHER, V12, P159, DOI 10.1080/21645515.2015.1071455
   van Doremalen N., 2020, BIORXIV
   Walls A.C., 2020, CELL
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang C, 2017, ONCOTARGET, V8, P12686, DOI 10.18632/oncotarget.8475
   Wang C, 2017, ANTIVIR RES, V140, P55, DOI 10.1016/j.antiviral.2016.12.019
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang JK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030209
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wang YX, 2017, HUM VACC IMMUNOTHER, V13, P153, DOI 10.1080/21645515.2016.1225637
   WHO, 2020, WHO DIR GEN REM MED
   Wu AP, 2013, CELL HOST MICROBE, V14, P446, DOI 10.1016/j.chom.2013.09.001
   Wu D, 2020, J MICROBIOLOGY IMMUN
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao WJ, 2008, VACCINE, V26, P5022, DOI 10.1016/j.vaccine.2008.07.028
   Xu ZJ, 2020, GEROSCIENCE, DOI 10.1007/s11357-020-00209-w
   Yang T, 2020, J MT SCI-ENGL, V17, P2108, DOI 10.1007/s11629-019-5772-5
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Yu J, 2020, SCIENCE
   Zakhartchouk AN, 2007, VACCINE, V25, P136, DOI 10.1016/j.vaccine.2006.06.084
   Zhao GY, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-9
   Zhao JC, 2012, J VIROL, V86, P11416, DOI 10.1128/JVI.01410-12
   Zhao K, 2011, VACCINE, V29, P6670, DOI 10.1016/j.vaccine.2011.06.100
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou ZM, 2006, VACCINE, V24, P3624, DOI 10.1016/j.vaccine.2006.01.059
   Zhu F.-C., 2020, LANCET
NR 156
TC 5
Z9 5
U1 10
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD SEP
PY 2020
VL 86
AR 106717
DI 10.1016/j.intimp.2020.106717
PG 13
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA NH6TI
UT WOS:000564800300002
PM 32585611
OA Green Published
DA 2021-01-01
ER

PT J
AU Yu, CJ
   Kang, L
   Chen, JD
   Zang, N
AF Yu, Chengjun
   Kang, Lian
   Chen, Jiadong
   Zang, Na
TI Evaluation of safety, efficacy, tolerability, and treatment-related
   outcomes of type I interferons for human coronaviruses (HCoVs) infection
   in clinical practice: An updated critical systematic review and
   meta-analysis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Human coronavirus; MERS-CoV; SARS-CoV; SARS-CoV-2; Type I interferons
ID EAST RESPIRATORY SYNDROME; SARS; RIBAVIRIN; COV; REPLICATION; PNEUMONIA;
   GUANGZHOU; OUTBREAK; FEATURES; VITRO
AB Background: There is no vaccine or specific antiviral treatment for HCoVs infection. The use of type I interferons for coronavirus is still under great debate in clinical practice.
   Materials and methods: A literature search of all relevant studies published on PubMed, Cochrane library, Web of Science database, Science Direct, Wanfang Data, and China National Knowledge Infrastructure (CNKI) until February 2020 was performed.
   Results: Of the 1081 identified articles, only 15 studies were included in the final analysis. Comorbidities and delay in diagnosis were significantly associated with case mortality. Type I interferons seem to improve respiratory distress, relieve lung abnormalities, present better saturation, reduce needs for supplemental oxygen support. Type I interferons seem to be well tolerated, and don't increase life threating adverse effects. Data on IFNs in HCoVs are limited, heterogenous and mainly observational.
   Conclusions: Current data do not allow making regarding robust commendations for the use of IFNs in HCoVs in general or in specific subtype. But we still recommend type I interferons serving as first-line antivirals in HCoVs infections within local protocols, and interferons may be adopted to the treatments of the SARS-CoV-2 as well. Well-designed large-scale prospective randomized control trials are greatly needed to provide more robust evidence on this topic.
C1 [Yu, Chengjun; Kang, Lian; Chen, Jiadong; Zang, Na] Chongqing Med Univ, Childrens Hosp, Chongqing, Peoples R China.
   [Zang, Na] Chongqing Key Lab Children Urogenital Dev & Tissu, Chongqing, Peoples R China.
   [Kang, Lian; Chen, Jiadong; Zang, Na] Natl Clin Res Ctr Child Hlth & Disorders, Chongqing, Peoples R China.
   [Yu, Chengjun; Kang, Lian; Chen, Jiadong; Zang, Na] Minist Educ, Key Lab Child Dev & Disorders, Chongqing, Peoples R China.
   [Yu, Chengjun; Zang, Na] China Int Sci & Technol Cooperat Base Child Dev &, Chongqing, Peoples R China.
   [Yu, Chengjun; Kang, Lian; Chen, Jiadong; Zang, Na] Chongqing Key Lab Pediat Chongqing, Chongqing, Peoples R China.
   [Zang, Na] Chongqing Med Univ, Childrens Hosp, Dept Resp Med, 136 Zhongshan 2nd Rd, Chongqing, Peoples R China.
RP Zang, N (corresponding author), Chongqing Med Univ, Childrens Hosp, Dept Resp Med, 136 Zhongshan 2nd Rd, Chongqing, Peoples R China.
EM zangna1214@126.com
FU Foundation of Children's Hospital of Chongqing Medical University;
   Venture & Innovation Support Program for Chongqing Overseas Retureness
   [cx2018150]
FX The study was supported by the Foundation of Children's Hospital of
   Chongqing Medical University and the Venture & Innovation Support
   Program for Chongqing Overseas Retureness (cx2018150).
CR Al Ghamdi M, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1492-4
   Al-Hameed F, 2016, J INTENSIVE CARE MED, V31, P344, DOI 10.1177/0885066615579858
   Al-Qaseer M., 2015, J INFECT DIS THERAPY, V03
   Al-Tawfiq J.A., 2014, INT J INFECT DIS IJI, V20
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Cheng VCC, 2004, J INFECTION, V49, P262, DOI 10.1016/j.jinf.2004.07.010
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4
   Gurney J, 2017, HUM REPROD, V32, P1118, DOI 10.1093/humrep/dex047
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hung I.F., LANCET LONDON ENGLAN
   Khalid I, 2016, RESP CARE, V61, P340, DOI 10.4187/respcare.04325
   Khalid M, 2014, ANN SAUDI MED, V34, P396, DOI 10.5144/0256-4947.2014.396
   Khalid M, 2015, ANTIVIR THER, V20, P87, DOI 10.3851/IMP2792
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Memish ZA, 2014, CLIN MICROBIOL INFEC, V20, P469, DOI 10.1111/1469-0691.12562
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Morgenstern B, 2005, BIOCHEM BIOPH RES CO, V326, P905, DOI 10.1016/j.bbrc.2004.11.128
   Morra ME, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1977
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Shalhoub S, 2015, J ANTIMICROB CHEMOTH, V70, P2129, DOI 10.1093/jac/dkv085
   Strayer David R., 2014, Infectious Disorders - Drug Targets, V14, P37
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Thabet F, 2015, SAUDI MED J, V36, P484, DOI 10.15537/smj.2015.4.10243
   TURNER RB, 1986, J INFECT DIS, V154, P443, DOI 10.1093/infdis/154.3.443
   Wang B, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.101300
   Wu W, 2003, CHINESE MED J-PEKING, V116, P811
   Zaki AM, 2012, PROCEEDINGS OF THE ASME PRESSURE VESSELS AND PIPING CONFERENCE, VOL 2, P369
   Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0
   Zhou Q, 2020, INTERFERON A2B TREAT
   Zhu N, 2020, NEW ENGLAND J MED
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 37
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD SEP
PY 2020
VL 86
AR 106740
DI 10.1016/j.intimp.2020.106740
PG 11
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA NH7AC
UT WOS:000564817900012
PM 32645630
OA Green Published
DA 2021-01-01
ER

PT J
AU Zhang, XH
   Zhang, Y
   Qiao, WZ
   Zhang, J
   Qi, ZG
AF Zhang, Xiuhong
   Zhang, Yan
   Qiao, Weizhen
   Zhang, Ji
   Qi, Zhigang
TI Baricitinib, a drug with potential effect to prevent SARS-COV-2 from
   entering target cells and control cytokine storm induced by COVID-19
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE COVID-19; Cytokine storm; Baricitinib; JAK-STAT; Pharmaceutical care
ID PLACEBO; PATHWAY
AB In December 2019, a novel coronavirus pneumonia (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly broke out in China and rapidly spread all over the world. Recently, a cell surface protein, known as angiotensin-converting enzyme II (ACE2), has been identified to be involved in receptor-mediated endocytosis for SARS-CoV-2 entry to the cells. Many studies have reported the clinical characteristics of COVID-19: sudden deterioration of disease around 1-2 weeks after onset; much lower level of lymphocytes, especially natural killer (NK) cells in peripheral blood; extremely high pro-inflammatory cytokines and C reactive protein (CRP). About 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. Baricitinib intracellularly inhibits the proinflammatory signal of several cytokines by suppressing Janus kinase (JAK) JAK1/JAK2. It has been demonstrated clinical benefits for the patients with rheumatoid arthritis (RA), active systemic lupus erythematosus and atopic dermatitis with good efficacy and safety records. Baricitinib is expected to interrupt the passage and intracellular assembly of SARS-CoV-2 into the target cells mediated by ACE2 receptor, and treat cytokine storm caused by COVID-19. Several clinical trials are currently investigating the drug, and one of which has been completed with encouraging results. In this paper, we will elaborate the role of cytokine storm mediated by JAK-STAT pathway in severe COVID-19, the possible mechanisms of baricitinib on reducing the viral entry into the target cells and cytokine storm, the key points of pharmaceutical care based on the latest research reports, clinical trials progress and drug instruction from the US FDA, so as to provide reference for the treatment of severe COVID-19.
C1 [Zhang, Xiuhong; Qi, Zhigang] Nanjing Med Univ, Dept Pharm, Wuxi Peoples Hosp, Wuxi 214023, Jiangsu, Peoples R China.
   [Zhang, Yan] Nanjing Med Univ, Wuxi Maternal & Child Hlth Hosp, Res Dept, Wuxi 214002, Jiangsu, Peoples R China.
   [Qiao, Weizhen] Nanjing Med Univ, Wuxi Peoples Hosp, Ctr Clin Res, Wuxi 214023, Jiangsu, Peoples R China.
   [Zhang, Ji] Nanjing Med Univ, Wuxi Peoples Hosp, Lung Transplant Ctr, Wuxi 214023, Jiangsu, Peoples R China.
RP Qi, ZG (corresponding author), 299 Qingyang Rd, Wuxi 214023, Jiangsu, Peoples R China.
EM qizhigang058518@163.com
FU Wuxi medical and health guidance plan for scientific and technological
   development [NZ2019004]; Jiangsu Pharmaceutical Association-Aosaikang
   Hospital Pharmacy Fund [A201729]; Jiangsu Pharmaceutical
   AssociationTianqing Hospital Pharmacy Fund [Q2019087]
FX The preparation of this review was supported by Wuxi medical and health
   guidance plan for scientific and technological development (NZ2019004),
   Jiangsu Pharmaceutical Association-Aosaikang Hospital Pharmacy Fund
   (A201729) and Jiangsu Pharmaceutical AssociationTianqing Hospital
   Pharmacy Fund (Q2019087).
CR Benveniste EN, 2014, J INTERF CYTOK RES, V34, P577, DOI 10.1089/jir.2014.0012
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Fei ZhiYong, 2019, Chinese Journal of Nosocomiology, V29, P380
   Gadina M, 2018, J LEUKOCYTE BIOL, V104, P499, DOI 10.1002/JLB.5RI0218-084R
   Genovese M.C., 2019, ANN RHEUM DIS S, V78
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Keystone EC, 2015, ANN RHEUM DIS, V74, P333, DOI 10.1136/annrheumdis-2014-206478
   Kunwar S, 2018, CLIN RHEUMATOL, V37, P2611, DOI 10.1007/s10067-018-4199-7
   Liu J, 2020, LONGITUDINAL CHARACT, DOI [10.1101/ 2020.02.16.20023671, DOI 10.1101/2020.02.16.20023671, 10.1101/2020.02.16.20023671]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma YePing, 2019, Chinese Journal of Nosocomiology, V29, P1007
   Marrero MB, 2005, VASC PHARMACOL, V43, P307, DOI 10.1016/j.vph.2005.09.002
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Praveen D, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105967
   Richardson PJ, 2020, LANCET INFECT DIS, V20, P1013, DOI 10.1016/S1473-3099(20)30270-X
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Simpson EL, 2020, BRIT J DERMATOL, V183, P242, DOI 10.1111/bjd.18898
   Smolen JS, 2019, J RHEUMATOL, V46, P7, DOI 10.3899/jrheum.171361
   Sorrell FJ, 2016, STRUCTURE, V24, P401, DOI 10.1016/j.str.2015.12.015
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Taylor PC, 2019, ARTHRITIS RHEUMATOL, V71, P1042, DOI 10.1002/art.40841
   Taylor PC, 2017, NEW ENGL J MED, V376, P652, DOI 10.1056/NEJMoa1608345
   The U.S. Food and Drug Administration, INF OL BAR TABL OR U
   Wallace DJ, 2018, LANCET, V392, P222, DOI 10.1016/S0140-6736(18)31363-1
   Wan S., 2020, CHARACTERISTICS LYMP, DOI [10.20021832, DOI 10.1101/2020.02.10.20021832, 10.1101/2020.02. 10.20021832, 10.1101/2020.02.10.20021832]
   Xu K.J., 2020, ZHEJIANG DA XUE XUE
   Yamaoka K, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-253
   Zegeye MM, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0268-4
   Zhang J.W., 2020, ZHONGGUO YAO XUE ZA
   Zhang SY, 2020, CLIN DRUG INVEST, V40, P511, DOI 10.1007/s40261-020-00917-3
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
NR 36
TC 7
Z9 7
U1 12
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD SEP
PY 2020
VL 86
AR 106749
DI 10.1016/j.intimp.2020.106749
PG 5
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA NH6TI
UT WOS:000564800300004
PM 32645632
OA Green Published
DA 2021-01-01
ER

PT J
AU Demers-Mathieu, V
   Dung, M
   Mathijssen, GB
   Sela, DA
   Seppo, A
   Jarvinen, KM
   Medo, E
AF Demers-Mathieu, Veronique
   Dung, M.
   Mathijssen, Gabrielle B.
   Sela, David A.
   Seppo, Antti
   Jarvinen, Kirsi M.
   Medo, Elena
TI Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid
   protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk
SO JOURNAL OF PERINATOLOGY
LA English
DT Article; Early Access
ID POLYREACTIVE ANTIBODIES; MONOMERIC IGA; DIPHTHERIA; TETANUS; SARS;
   IMMUNIZATION; PROTECTION; PREGNANCY; VACCINE
AB Objective This study evaluated the presence and the levels of antibodies reactive to SARS-CoV-2 S1 and S2 subunits (S1 + S2), and nucleocapsid protein. Study design The levels of SARS-CoV-2 S1 + S2- and nucleocapsid-reactive SIgM/IgM, IgG and SIgA/IgA were measured in human milk samples from 41 women during the COVID-19 pandemic (2020-HM) and from 16 women 2 years prior to the outbreak (2018-HM). Results SARS-CoV-2 S1 + S2-reactive SIgA/IgA, SIgM/IgM and IgG were detected in 97.6%, 68.3% and 58.5% in human milk whereas nucleocapsid-reactive antibodies were detected in 56.4%, 87.2% and 46.2%, respectively. S1 + S2-reactive IgG was higher in milk from women that had symptoms of viral respiratory infection(s) during the last year than in milk from women without symptom. S1 + S2- and nucleocapsid-reactive IgG were higher in the 2020-HM group compared to the 2018-HM group. Conclusions The presence of SARS-CoV-2-reactive antibodies in human milk could provide passive immunity to breastfed infants and protect them against COVID-19 diseases.
C1 [Demers-Mathieu, Veronique; Dung, M.; Mathijssen, Gabrielle B.; Medo, Elena] Medolac Labs, Dept Neonatal Immunol & Microbiol, Boulder City, NV 89005 USA.
   [Demers-Mathieu, Veronique; Sela, David A.] Univ Massachusetts Amherst, Dept Food Sci, Amherst, MA 01003 USA.
   [Seppo, Antti; Jarvinen, Kirsi M.] Univ Rochester, Med Ctr, Dept Pediat, Pediat Allergy Immunol, Rochester, NY 14642 USA.
RP Demers-Mathieu, V (corresponding author), Medolac Labs, Dept Neonatal Immunol & Microbiol, Boulder City, NV 89005 USA.; Demers-Mathieu, V (corresponding author), Univ Massachusetts Amherst, Dept Food Sci, Amherst, MA 01003 USA.
EM vdemers-m@medolac.com
RI Demers-Mathieu, Veronique/I-1923-2016; Sela, David/H-2301-2015
OI Demers-Mathieu, Veronique/0000-0002-7937-6355; Sela,
   David/0000-0002-3354-7470
FU Medolac Laboratories A Public Benefit Corporation
FX The authors (VDM, DMD, GBM and ED) disclosed receipt of the financial
   support from Medolac Laboratories A Public Benefit Corporation for the
   conduct of the study.
CR Aaby P, 2014, NAT IMMUNOL, V15, P895, DOI 10.1038/ni.2961
   Abu Raya B, 2014, VACCINE, V32, P5632, DOI 10.1016/j.vaccine.2014.08.006
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1424
   Centers for Disease Control and Prevention (CDC), 2019, VACC PREGN
   Chan KH, 2013, J INFECTION, V67, P130, DOI 10.1016/j.jinf.2013.03.015
   Cifarelli V, 2019, CELL MOL GASTROENTER, V7, P503, DOI 10.1016/j.jcmgh.2018.12.002
   Corthesy Blaise, 2003, Current Pharmaceutical Biotechnology, V4, P51, DOI 10.2174/1389201033378020
   Demers-Mathieu V, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071567
   Demers-Mathieu V, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040920
   Demers-Mathieu V, 2018, NEONATOLOGY, V114, P242, DOI 10.1159/000489387
   Demers-Mathieu V, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050631
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Frank Nicole M, 2019, BMC Pediatr, V19, P339, DOI 10.1186/s12887-019-1693-2
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gunti S, 2015, J INFECT DIS, V212, pS42, DOI 10.1093/infdis/jiu512
   Halperin BA, 2011, CLIN INFECT DIS, V53, P885, DOI 10.1093/cid/cir538
   Healy CM, 2013, CLIN INFECT DIS, V56, P539, DOI 10.1093/cid/cis923
   Janda A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00022
   Jarvinen Kirsi M, 2018, F1000Res, V7, P1822, DOI 10.12688/f1000research.16717.2
   Jiang C, 2020, MICROBES INFECT, V22, P236, DOI 10.1016/j.micinf.2020.05.005
   Johns Hopkins University & Medicine, 2020, COVID 19 DASHB CTR S
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maertens K, 2014, VACCINE, V32, P1786, DOI 10.1016/j.vaccine.2014.01.083
   Mouquet H, 2012, CELL MOL LIFE SCI, V69, P1435, DOI 10.1007/s00018-011-0872-6
   Patrick David M, 2006, Can J Infect Dis Med Microbiol, V17, P330
   Robertson CA, 2004, EMERG INFECT DIS, V10, P345, DOI 10.3201/eid1002.030736
   Schlaudecker EP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070867
   Stubbe H, 2000, J IMMUNOL, V164, P1952, DOI 10.4049/jimmunol.164.4.1952
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   TAYLOR HP, 1985, J EXP MED, V161, P198, DOI 10.1084/jem.161.1.198
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wrammert J, 2011, J EXP MED, V208, P181, DOI 10.1084/jem.20101352
   Yu Y, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-20792/v1, DOI 10.21203/RS.3.RS-20792/V1]
NR 37
TC 1
Z9 1
U1 4
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0743-8346
EI 1476-5543
J9 J PERINATOL
JI J. Perinatol.
DI 10.1038/s41372-020-00805-w
EA SEP 2020
PG 10
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA NI8RP
UT WOS:000565614700003
PM 32873904
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ahmad, SI
AF Ahmad, Shamim I.
TI 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose
   as possible therapeutic options for the Coronavirus, COVID-19 infection
SO MEDICAL HYPOTHESES
LA English
DT Article
ID PHOSPHORYLASE-DEFICIENCY; NUCLEOSIDES; CATABOLISM
AB The recent global pandemic created by the Coronavirus SARS-CoV-2, started in Wuhan, China in December 2019, has generated panic, both in term of human death (4-5% of infected patients identified through testing) and the global economy. Human sufferings seem to be continuing, and it is not clear how long this will continue and how much more destruction it is going to cause until complete control is achieved.
   One of the most disturbing issues is Covid-19 treatment; although a large number of medications, previously used successfully with other viruses (including Chinese herbal medicines and anti-malaria drugs), are under consideration, there remain questions as to whether they can play a satisfactory role for this disease.
   Global attempts are ongoing to find the drugs for the treatment of this virus but none of the antiviral drugs used for treatment of other human viral infection is working and hence attempts to find new drugs are continuing. Here the author is proposing that 5-Fluorouracil (5-FU) which when used on its own is failing as an antiviral agent due to the removal of this compound by proof reading ability exceptionally found in Coronaviruses. The author here is proposing to test 5-FU in combination with a number of deoxynucleosides on animal models infected with this Covid-19. Should encouraging results ensue, therapies could then be tried on patients.
C1 [Ahmad, Shamim I.] Univ Leicester, Dept Genet & Genome Biol, Leicester LE1 7RH, Leics, England.
RP Ahmad, SI (corresponding author), Univ Leicester, Dept Genet & Genome Biol, Leicester LE1 7RH, Leics, England.
EM Shamim.ahmad@ntu.ac.uk
CR Agostini ML, 2019, J VIROL, V93, DOI 10.1128/JVI.01348-19
   AHMAD SI, 1969, MOL GEN GENET, V104, P351, DOI 10.1007/BF00334234
   AHMAD SI, 1971, MOL GEN GENET, V111, P77, DOI 10.1007/BF00286556
   Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   [Anonymous], 2020, PUR NUCL PHOSPH DEF
   Bassi MR, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.00380-18, 10.1128/aac.00380-18]
   Cao Y, 2018, CANCER CHEMOTH PHARM, V82, P1081, DOI 10.1007/s00280-018-3676-7
   CARSON DA, 1977, P NATL ACAD SCI USA, V74, P5677, DOI 10.1073/pnas.74.12.5677
   Demetriadou C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1487-3
   Dong L, 2020, DRUG DISCOV, V14, P48
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Hirano M, 2004, NUCLEOS NUCLEOT NUCL, V23, P1217, DOI 10.1081/NCN-200027485
   Inoko K, 2018, CANCER GENE THER, V25, P184, DOI 10.1038/s41417-018-0020-7
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Maurer S, 2019, INT J ONCOL, V55, P347, DOI 10.3892/ijo.2019.4835
   PRITCHARD RH, 1971, MOL GEN GENET, V111, P84, DOI 10.1007/BF00286557
   Sexton NR, 2016, J VIROL, V90, P7415, DOI 10.1128/JVI.00080-16
   Smith EC, 2015, J VIROL, V89, P6418, DOI 10.1128/JVI.00110-15
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   Staal GE, 2020, ERYTHROCYTE METABOLI, DOI [10.1172/JCL109639, DOI 10.1172/JCL109639]
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   van den Bovenkamp K, 2018, ORAL ONCOL, V77, P131, DOI 10.1016/j.oraloncology.2017.12.017
   Wang D, 2018, J CELL MOL MED, V22, P6202, DOI 10.1111/jcmm.13907
   Yadak R, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00031
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhang Q, 2020, J MED VIROL, V92, P540, DOI [10.1002/jmv.25733, 10.1080/07391102.2020.1771421]
NR 28
TC 0
Z9 0
U1 6
U2 6
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD SEP
PY 2020
VL 142
AR 109754
DI 10.1016/j.mehy.2020.109754
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NI2OU
UT WOS:000565195600027
PM 32438240
OA Green Published
DA 2021-01-01
ER

PT J
AU Belen-Apak, FB
   Sarialioglu, F
AF Belen-Apak, F. B.
   Sarialioglu, F.
TI The old but new: Can unfractioned heparin and low molecular weight
   heparins inhibit proteolytic activation and cellular internalization of
   SARS-CoV2 by inhibition of host cell proteases?
SO MEDICAL HYPOTHESES
LA English
DT Article
DE SARS-CoV2; COVID-19; Host proteases; Factor Xa; Heparin; Low molecular
   weight heparin
ID RESPIRATORY SYNDROME CORONAVIRUS; SPIKE PROTEIN; SARS-COV
AB Currently, our world is facing the 2019 Novel Coronavirus (COVID-19) outbreak and tremendous efforts are made for developing drugs to treat and vaccines to prevent the disease. At present, there is no specific antiviral drug or vaccine for COVID-19. The pathogenic infectivity of the virus requires the S1 subunit of the spike (S) protein to bind the host cell receptor, angiontensin converting enzyme (ACE2). While the binding to host cell receptor is the first step of infection, the entrance of the virus into the cell needs the cleavage of S1-S2 subunits to expose S2 for fusion to cell membrane via host proteases including cathepsins, cell surface transmembrane protease/serine (TMPRSS) proteases, furin, trypsin and factor Xa. Previous in vitro studies have shown that factor Xa inhibition can decrease viral infectivity. We suppose that host cell proteases including furin (as expressed highly in lungs), factor Xa and cathepsin are possible targets to decrease viral burden, therefore unfractioned heparin and low molecular weight heparin-LMWH (specifically dalteparin and tinzaparin for their anti inflammatory action) can be potential inhibitors of multiple endoproteases involved in virus infectivity. Our hypothesis needs to be tested in in vitro and clinical studies, however as we are in an urgent situation as the burden of SARS-CoV2 is increasing all around the world, we recommend the usage of unfractioned heparin or LMWH in intensive care unit (ICU) and non-ICU hospitalized patients with the risk-benefit judgement of the clinician. Whether our hypothesis is clinically applicable and successful in decreasing viral infection will be evaluated for further studies.
C1 [Belen-Apak, F. B.; Sarialioglu, F.] Baskent Univ, Fac Med, Dept Pediat Hematol & Oncol, Ankara, Turkey.
RP Belen-Apak, FB (corresponding author), Baskent Univ, Fac Med, Dept Pediat Hematol & Oncol, Ankara, Turkey.
EM draidabb@gmail.com
CR Bassi DE, 2017, MOL CARCINOGEN, V56, P1182, DOI 10.1002/mc.22550
   Chen LL, 2005, J VIROL, V79, P7095, DOI 10.1128/JVI.79.11.7095-7103.2005
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Dimakakos EP, 2018, CLIN APPL THROMB-HEM, V24, P697, DOI 10.1177/1076029617729215
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Du LY, 2007, BIOCHEM BIOPH RES CO, V359, P174, DOI 10.1016/j.bbrc.2007.05.092
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Han YS, 2005, BIOCHEMISTRY-US, V44, P10349, DOI 10.1021/bi0504761
   Higgins WJ, 2010, J BIOL CHEM, V285, P3722, DOI 10.1074/jbc.M109.037358
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lee MJ, 2013, PHARMACOLOGY, V92, P238, DOI 10.1159/000355837
   Li JY, 2019, INT J BIOL MACROMOL, V134, P63, DOI 10.1016/j.ijbiomac.2019.05.031
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Mannello F, 2008, CLIN BIOCHEM, V41, P1466, DOI 10.1016/j.clinbiochem.2008.09.104
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Oduah EI, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9030038
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 17
TC 9
Z9 9
U1 4
U2 6
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD SEP
PY 2020
VL 142
AR 109743
DI 10.1016/j.mehy.2020.109743
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NI2OU
UT WOS:000565195600036
PM 32335456
OA Green Published
DA 2021-01-01
ER

PT J
AU Derwand, R
   Scholz, M
AF Derwand, R.
   Scholz, M.
TI Does zinc supplementation enhance the clinical efficacy of
   chloroquine/hydroxychloroquine to win today's battle against COVID-19?
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Therapy; Chloroquine; Hydroxychloroquine; Zinc
ID CHLOROQUINE; INFECTIONS
AB Currently, drug repurposing is an alternative to novel drug development for the treatment of COVID-19 patients. The antimalarial drug chloroquine (CQ) and its metabolite hydroxychloroquine (HCQ) are currently being tested in several clinical studies as potential candidates to limit SARS-CoV-2-mediated morbidity and mortality. CQ and HCQ (CQ/HCQ) inhibit pH-dependent steps of SARS-CoV-2 replication by increasing pH in intracellular vesicles and interfere with virus particle delivery into host cells. Besides direct antiviral effects, CQ/HCQ specifically target extracellular zinc to intracellular lysosomes where it interferes with RNA-dependent RNA polymerase activity and coronavirus replication. As zinc deficiency frequently occurs in elderly patients and in those with cardiovascular disease, chronic pulmonary disease, or diabetes, we hypothesize that CQ/HCQ plus zinc supplementation may be more effective in reducing COVID-19 morbidity and mortality than CQ or HCQ in monotherapy. Therefore, CQ/HCQ in combination with zinc should be considered as additional study arm for COVID-19 clinical trials.
C1 [Derwand, R.] Alexion Pharma Germany GmbH, Landsberger Str 300, D-80687 Munich, Germany.
   [Scholz, M.] LEUKOCARE AG, Klopferspitz 19, Munich, Germany.
RP Scholz, M (corresponding author), LEUKOCARE AG, Klopferspitz 19, Munich, Germany.
EM martin.scholz@leukocare.com
CR Anderson RA, 2001, J AM COLL NUTR, V20, P212, DOI 10.1080/07315724.2001.10719034
   Braun LA, 2013, INT J CLIN PRACT, V67, P717, DOI 10.1111/ijcp.12040
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Ervin RB, 2002, J NUTR, V132, P3422
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Kaushik N, 2017, J VIROL, V91, DOI 10.1128/JVI.00754-17
   Kearney J., 2020, PREPRINTS, DOI [10.20944/preprints202003.0275.v1, DOI 10.20944/PREPRINTS202003.0275.V1]
   Kupferschmidt K., 2020, SCIENCE
   Li CC, 2019, DRUG DISCOV TODAY, V24, P726, DOI 10.1016/j.drudis.2019.01.018
   Prasad AS, 2007, AM J CLIN NUTR, V85, P837
   Read SA, 2019, ADV NUTR, V10, P696, DOI 10.1093/advances/nmz013
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Smith T, COVID 19 DRUG THERAP
   Velthuis AJWT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001176
   Xue J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109180
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 19
TC 22
Z9 22
U1 2
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD SEP
PY 2020
VL 142
AR 109815
DI 10.1016/j.mehy.2020.109815
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NI2OU
UT WOS:000565195600014
PM 32408070
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hamizi, K
   Aouidane, S
   Belaaloui, G
AF Hamizi, Kamel
   Aouidane, Souhila
   Belaaloui, Ghania
TI Etoposide-based therapy for severe forms of COVID-19
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; Haemophagocytic lymphohistiocytosis; HLH; Etoposide
ID HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HLH
AB The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19.
C1 [Hamizi, Kamel; Belaaloui, Ghania] Batna 2 Univ, Fac Med, Lab Acquired & Constitut Genet Dis MAGECA, Batna, Algeria.
   [Hamizi, Kamel] Anticanc Ctr Batna, Radiotherapy Serv, Batna, Algeria.
   [Aouidane, Souhila] Amar Telidji Univ, Fac Med, Laghouat, Algeria.
RP Belaaloui, G (corresponding author), Batna 2 Univ, Fac Med, Lab Acquired & Constitut Genet Dis MAGECA, Batna, Algeria.
EM g.belaaloui@univ-batna2.dz
RI Belaaloui, Ghania/AAF-2922-2019
OI Belaaloui, Ghania/0000-0003-0431-7286
CR Aleem A, 2005, CLIN LAB HAEMATOL, V27, P395, DOI 10.1111/j.1365-2257.2005.00728.x
   Bergsten E, 2017, BLOOD, V130, P2728, DOI 10.1182/blood-2017-06-788349
   Beutel G, 2011, CRIT CARE, V15, DOI 10.1186/cc10073
   Cron RQ, 2019, CYTOKINE STORM SYNDROME, P1, DOI 10.1007/978-3-030-22094-5
   Ehl S, 2018, J ALLER CL IMM-PRACT, V6, P1508, DOI 10.1016/j.jaip.2018.05.031
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Han SW, 2020, CANCER MED-US, V9, P6667, DOI 10.1002/cam4.3289
   Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039
   Henter JI, 2010, LANCET, V376, P2116, DOI 10.1016/S0140-6736(10)61345-1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imashuku S, 2001, J CLIN ONCOL, V19, P2665, DOI 10.1200/JCO.2001.19.10.2665
   Imashuku S, 2003, MED PEDIATR ONCOL, V41, P103, DOI 10.1002/mpo.10314
   Imashuku S, 1999, BLOOD, V93, P1869
   Janka G, 2009, KLIN PADIATR, V221, P278, DOI 10.1055/s-0029-1237386
   Johnson TS, 2014, J IMMUNOL, V192, P84, DOI 10.4049/jimmunol.1302282
   Liu Y, 2020, INFECT DIS-NOR, V52, P858, DOI 10.1080/23744235.2020.1794027
   Ruan Q, 2020, INTENSIVE CARE MED
   Tian S, 2020, J THORAC ONCOL
   Trottestam H, 2011, BLOOD, V118, P4577, DOI 10.1182/blood-2011-06-356261
   WHO, 67 WHO
   World Health Organization, CLIN MAN SEV AC RESP
   Yildiz H, 2020, QJM
NR 22
TC 2
Z9 3
U1 8
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD SEP
PY 2020
VL 142
AR 109826
DI 10.1016/j.mehy.2020.109826
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NI2OU
UT WOS:000565195600041
PM 32416415
OA Green Published
DA 2021-01-01
ER

PT J
AU Klimke, A
   Hefner, G
   Will, B
   Voss, U
AF Klimke, A.
   Hefner, G.
   Will, B.
   Voss, U.
TI Hydroxychloroquine as an aerosol might markedly reduce and even prevent
   severe clinical symptoms after SARS-CoV-2 infection
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; Hydroxychloroquine aerosol; Pharmacotherapy; Prevention;
   SARS-CoV-2
ID RESPIRATORY SYNDROME CORONAVIRUS
AB Covid-19 is a new coronavirus disease first described in December 2019. This respiratory illness is severe and potentially fatal. Severe cases make up to 15%, lethality ranges between 1.5 and more than 10%. What is urgently needed is an efficient pharmacological treatment for the treatment of severe cases. During the infection of alveolar epithelial cells of the lung, the ACE2 receptor has a central function. The antimalarial drugs chloroquine phosphate (CQ) and hydroxychloroquine (HCQ) impair in vitro the terminal glycosylation of ACE2 without significant change of cell-surface ACE2 and, therefore, might be potent inhibitors of SARS-CoV-2 infections. Starting inhibition at 0.1 mu M, CQ completely prevented in vitro infections at 10 mu M, suggesting a prophylactic effect and preventing the virus spread 5 h after infection. In a first clinical trial, CQ was effective in inhibiting exacerbation of pneumonia, improving lung imaging findings, promotion of virus-negative conversion, and shortening the disease. In addition, HCQ, which is three times more potent than CQ in SARS-CoV-2 infected cells (EC50 0.72 mu M), was significantly associated with viral load reduction/disappearance in COVID-19 patients compared to controls. Theoretically, CQ and HCQ could thus be effectively used in the treatment of SARS-CoV pneumonia. From a pharmacological standpoint, however, the major problems of oral treatment with these drugs are possible severe side effects and toxicity. Concretely, this relates to (a) the inconsistent individual bioavailability of these drugs at the alveolar target cells, depending on intestinal resorption, hepatic first-pass metabolism and accumulation in liver, spleen and lung, and (b) the need for a relatively high concentration of 1-5 mu M at the alveolar surface.
   Therefore, we propose in a first dose estimation the use of HCQ as an aerosol in a dosage of 2-4 mg per inhalation in order to reach sufficient therapeutic levels at the alveolar epithelial cells. By using a low-dose non-systemic aerosol, adverse drug reactions will markedly be reduced compared with oral application. This increase in tolerability enables a broader use for prevention and after contact with an infected person, which would be an advantage especially for the high-risk, often multi-morbid and elderly patients.
   Empirical data on self-medication with a one-week aerosol application by two of the authors is presented. Inhalation was well tolerated without relevant side effects.
C1 [Klimke, A.; Voss, U.] Vitos Klinikum Hochtaunus, Friedrichsdorf, Germany.
   [Klimke, A.] Heinrich Heine Univ Duesseldorf, Dusseldorf, Germany.
   [Hefner, G.] Vitos Rheingau Eltville, Klin Forens Psychiat, Eltville, Germany.
   [Will, B.] Rhein Friedrich Wilhelms Univ Bonn, Univ Hosp UKB, Bonn, Germany.
   [Voss, U.] Goethe Univ Frankfurt Main, Abt Allgemeine Psychol 2, Frankfurt, Germany.
RP Klimke, A (corresponding author), Vitos Klinikum Hochtaunus, Klin Psychiat & Psychotherapie, Emil Sioli Weg 1-3, D-61381 Friedrichsdorf, Germany.
EM ansgar.klimke@vitos-hochtaunus.de
CR Baud D., 2020, LANCET INFECT DIS
   Blignaut M, 2019, CARDIOVASC DRUG THER, V33, P1, DOI 10.1007/s10557-018-06847-9
   Cao B, 2020, NEW ENGL J MED, V382
   Cass LMR, 1999, CLIN PHARMACOKINET, V36, P1, DOI 10.2165/00003088-199936001-00001
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   Chen Y, ADJUNCTIVE CORTICOST
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   FRISKHOLMBERG M, 1979, CLIN PHARMACOL THER, V25, P345
   Gao J., 2020, BIOSCIENCE TRENDS
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gentile I, 2020, REV RECENT CLIN TRIA, V15, P84, DOI 10.2174/1574887115999200228100745
   Goel P, 2019, STATPEARLS
   GOOD MI, 1982, J CLIN PSYCHOPHARM, V2, P40, DOI 10.1097/00004714-198202000-00005
   Hamer O. W., 2020, ROFOFORTSCHRITTE GEB
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Kearney J, 2020, CHLOROQUINE POTENTIA
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   MCLACHLAN AJ, 1994, BRIT J RHEUMATOL, V33, P235
   Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001
   Qiu R., 2020, OUTCOME REPORTING PR
   SALOME CM, 1981, THORAX, V36, P580, DOI 10.1136/thx.36.8.580
   Schwartzman S, 2019, RHEUM DIS CLIN N AM, V45, P359, DOI 10.1016/j.rdc.2019.04.008
   Su Z., 2020, BIORXIV
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yao X, 2020, CLIN INFECT DIS
   Zhang Z., THERAPEUTIC EFFECT H
   Zhou F., 2020, LANCET
NR 33
TC 8
Z9 8
U1 10
U2 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD SEP
PY 2020
VL 142
AR 109783
DI 10.1016/j.mehy.2020.109783
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NI2OU
UT WOS:000565195600043
PM 32402766
OA Green Published
DA 2021-01-01
ER

PT J
AU Raha, S
   Mallick, R
   Basak, S
   Duttaroy, AK
AF Raha, Syamal
   Mallick, Rahul
   Basak, Sanjay
   Duttaroy, Asim K.
TI Is copper beneficial for COVID-19 patients?
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Copper; Coronavirus; COVID-19; SARS-CoV-2; Contact killing;
   Cu-deficiency; ROS; Th1/Th2 cells; CuONPs; Blood cells; Immunity; Cupric
   chloride; Viral infection
ID LIPID PROFILE; DEFICIENCY; INACTIVATION; VIRUS; IRON; DIET
AB Copper (Cu) is an essential micronutrient for both pathogens and the hosts during viral infection. Cu is involved in the functions of critical immune cells such as T helper cells, B cells, neutrophils natural killer (NK) cells, and macrophages. These blood cells are involved in the killing of infectious microbes, in cell-mediated immunity and the production of specific antibodies against the pathogens. Cu-deficient humans show an exceptional susceptibility to infections due to the decreased number and function of these blood cells. Besides, Cu can kill several infectious viruses such as bronchitis virus, poliovirus, human immunodeficiency virus type 1(HIV-1), other enveloped or nonenveloped, single- or double-stranded DNA and RNA viruses. Moreover, Cu has the potent capacity of contact killing of several viruses, including SARS-CoV-2. Since the current outbreak of the COVID-19 continues to develop, and there is no vaccine or drugs are currently available, the critical option is now to make the immune system competent to fight against the SARS-CoV-2. Based on available data, we hypothesize that enrichment of plasma copper levels will boost both the innate and adaptive immunity in people. Moreover, owing to its potent antiviral activities, Cu may also act as a preventive and therapeutic regime against COVID-19.
C1 [Raha, Syamal] Inventis Solut Inc, Edmonton, AB, Canada.
   [Mallick, Rahul] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, Joensuu, Finland.
   [Basak, Sanjay] ICMR Natl Inst Nutr, Mol Biol Div, Hyderabad, Telangana, India.
   [Duttaroy, Asim K.] Univ Oslo, Fac Med, Inst Basic Med Sci, Dept Nutr, Oslo, Norway.
RP Duttaroy, AK (corresponding author), Univ Oslo, Fac Med, Inst Basic Med Sci, Dept Nutr, Oslo, Norway.
EM a.k.duttaroy@medisin.uio.no
RI Basak, Sanjay/N-1635-2014; Mallick, Rahul/AAL-6843-2020
OI Basak, Sanjay/0000-0002-8161-5597; Mallick, Rahul/0000-0002-4065-3474
CR Alarcon-Corredor OM, 2004, ARCH LATINOAM NUTR, V54, P413
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   BALA S, 1992, P NATL ACAD SCI USA, V89, P6794, DOI 10.1073/pnas.89.15.6794
   Besold AN, 2016, J BIOL INORG CHEM, V21, P137, DOI 10.1007/s00775-016-1335-1
   Bonham M, 2002, BRIT J NUTR, V87, P393, DOI 10.1079/BJN2002558
   Burkhead J. L., 2013, LIPID METABOLISM, P39, DOI DOI 10.5772/51819
   Chambers A, 2010, J TOXICOL ENV HEAL B, V13, P546, DOI 10.1080/10937404.2010.538657
   DANKS DM, 1988, ANNU REV NUTR, V8, P235, DOI 10.1146/annurev.nu.08.070188.001315
   Failla ML, 1998, NUTR REV, V56, pS59
   Gaetke LM, 2014, ARCH TOXICOL, V88, P1929, DOI 10.1007/s00204-014-1355-y
   Grass G, 2011, APPL ENVIRON MICROB, V77, P1541, DOI 10.1128/AEM.02766-10
   Han YS, 2005, BIOCHEMISTRY-US, V44, P10349, DOI 10.1021/bi0504761
   Hodgkinson V, 2012, J BIOL CHEM, V287, P13549, DOI 10.1074/jbc.R111.316406
   Hopkins RG, 1997, J NUTR, V127, P257
   Hu X, 2020, LANCET
   Iakovidis Isidoros, 2011, Mol Biol Int, V2011, P594529, DOI 10.4061/2011/594529
   Ishida T, 2018, WORLD SCI, V99, P148
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   KELLEY DS, 1995, AM J CLIN NUTR, V62, P412
   Keshavarz P, 2017, AM J MED SCI, V353, P552, DOI 10.1016/j.amjms.2017.03.022
   KOLLER LD, 1987, AM J CLIN NUTR, V45, P997
   Li CX, 2015, P NATL ACAD SCI USA, V112, pE5336, DOI 10.1073/pnas.1513447112
   Linder MC, 1996, AM J CLIN NUTR, V63, P797
   Miyamoto D, 1998, ANTIVIR RES, V39, P89, DOI 10.1016/S0166-3542(98)00034-5
   Munoz C, 2007, BRIT J NUTR, V98, pS24, DOI 10.1017/S0007114507833046
   Noyce JO, 2007, APPL ENVIRON MICROB, V73, P2748, DOI 10.1128/AEM.01139-06
   Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298
   Percival SS, 1998, AM J CLIN NUTR, V67, p1064S, DOI 10.1093/ajcn/67.5.1064S
   REISER S, 1985, AM J CLIN NUTR, V42, P242
   SAGRIPANTI JL, 1993, APPL ENVIRON MICROB, V59, P4374, DOI 10.1128/AEM.59.12.4374-4376.1993
   Sucipto Teguh Hari, 2018, Afr J Infect Dis, V12, P116, DOI [10.21010/ajid.v12i1s.17, 10.2101/Ajid.12v1S.17]
   TYRRELL DA, 1966, LANCET, V1, P76
   van Doremalen N, 2020, N ENGL J MED
   Warnes SL, 2011, APPL ENVIRON MICROB, V77, P6049, DOI 10.1128/AEM.00597-11
   Warnes SL, 2015, MBIO, V6, DOI 10.1128/mBio.01697-15
   Wazir SM, 2017, J COMMUNITY HOSP INT, V7, P265, DOI 10.1080/20009666.2017.1351289
   Weiss G, 2018, CLIN MICROBIOL INFEC, V24, P16, DOI 10.1016/j.cmi.2017.01.018
   WILLIAMS DM, 1983, SEMIN HEMATOL, V20, P118
   Xu DH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128205
NR 39
TC 10
Z9 10
U1 2
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD SEP
PY 2020
VL 142
AR 109814
DI 10.1016/j.mehy.2020.109814
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NI2OU
UT WOS:000565195600039
PM 32388476
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Mohtadi, N
   Ghaysouri, A
   Shirazi, S
   Ansari, S
   Shafiee, E
   Bastani, E
   Kokhazadeh, T
   Tavan, H
AF Mohtadi, Negar
   Ghaysouri, Abas
   Shirazi, Samira
   Ansari, Sara
   Shafiee, Elham
   Bastani, Elham
   Kokhazadeh, Taleb
   Tavan, Hamed
TI Recovery of severely ill COVID-19 patients by intravenous immunoglobulin
   (IVIG) treatment: A case series
SO VIROLOGY
LA English
DT Article
DE IVIG; COVID-19; Improvement
AB Introduction: During the recent months, COVID-19 has turned to a global crisis claiming high mortality and morbidity among populations. Despite the high prevalence of the disease, it has currently no definitive treatment. We here reported the effects of intravenous immunoglobulin (IVIG) administration in severely ill COVID-19 patients diagnosed based on PCR and radiology tests.
   Case presentation: Five severely ill COVID-19 patients in whom standard treatments failed were administrated with IVIG which prevented the deterioration of clinical symptoms. All the patients were treated with high-dose IVIG (0.3-0.5 g/kg) for 5 consecutive days so that no patient would receive lower than 25 g of the drug. All the patients showed a desirable therapeutic response and were discharged from the hospital with a stable clinical condition after being recovered.
   Conclusion: Treatment with IVIG at the therapeutic dose of 0.3-0.5 g/kg can improve the clinical condition and O2 saturation and prevent the progression of pulmonary lesions in COVID-19 patients with severe symptoms in whom standard treatments have failed.
C1 [Mohtadi, Negar] Ilam Univ Med Sci, Shahid Mostafa Khomaeini Hosp, Sch Med, Ilam, Iran.
   [Ghaysouri, Abas; Bastani, Elham] Ilam Univ Med Sci, Sch Med, Dept Internal Med, Ilam, Iran.
   [Shirazi, Samira] Ilam Univ Med Sci, Shahid Mostafa Khomaeini Hosp, Sch Med, Dept Cardiol, Ilam, Iran.
   [Ansari, Sara] Ilam Univ Med Sci, Shahid Mostafa Khomaeini Hosp, Sch Med, Dept Radiol, Ilam, Iran.
   [Shafiee, Elham; Kokhazadeh, Taleb; Tavan, Hamed] Ilam Univ Med Sci, Shahid Mostafa Khomeini Hosp, Clin Res Dev Unit, POB 6939177143, Ilam, Iran.
RP Tavan, H (corresponding author), Ilam Univ Med Sci, Shahid Mostafa Khomeini Hosp, Clin Res Dev Unit, POB 6939177143, Ilam, Iran.
EM hamedtavan@gmail.com
OI /0000-0003-4213-9230
FU Deputy of Research and Technology of Ilam University of Medical Sciences
   [IR.MEDILAM.REC.1399.008]
FX This research was approved and supported by the Deputy of Research and
   Technology of Ilam University of Medical Sciences under the ethical code
   of IR.MEDILAM.REC.1399.008.
CR BUSSEL JB, 1995, IMMUNOL INVEST, V24, P451, DOI 10.3109/08820139509062794
   Cao W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa102
   Dalakas MC, 2003, NEUROLOGY, V60, P1736, DOI 10.1212/01.WNL.0000074394.15882.83
   Ghaysouri A., 2020, TRAVEL MED INFECT DI, DOI [10.1016/j.tmaid.2020.101657, DOI 10.1016/J.TMAID.2020.101657]
   Kile S., 2020, AM J ALZHEIMERS DIS, V35
   Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374
   Shalman A, 2020, J CLIN NEUROSCI, V74, P247, DOI 10.1016/j.jocn.2020.01.067
   Xie Y, 2020, J INFECTION, V81, P340, DOI 10.1016/j.jinf.2020.03.044
NR 8
TC 6
Z9 7
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD SEP
PY 2020
VL 548
BP 1
EP 5
DI 10.1016/j.virol.2020.05.006
PG 5
WC Virology
SC Virology
GA NH2OR
UT WOS:000564515300001
PM 32530808
OA Green Published
DA 2021-01-01
ER

PT J
AU Vinglis, E
   Beirness, D
   Boase, P
   Byrne, P
   Johnson, J
   Jonah, B
   Mann, RE
   Rapoport, MJ
   Seely, J
   Wickens, CM
   Wiesenthal, DL
AF Vinglis, Evelyn
   Beirness, Doug
   Boase, Paul
   Byrne, Patrick
   Johnson, Jennifer
   Jonah, Brian
   Mann, Robert E.
   Rapoport, Mark J.
   Seely, Jan
   Wickens, Christine M.
   Wiesenthal, David L.
TI Coronavirus disease 2019: What could be the effects on Road safety?
SO ACCIDENT ANALYSIS AND PREVENTION
LA English
DT Article
DE COVID-19; Road safety; Collisions; Research
ID ECONOMIC RECESSION; TRAFFIC FATALITIES; GREAT RECESSION; IMPACT; RISK;
   DRIVERS; CRASHES; EUROPE; HEALTH; SPEED
AB In March 2020, the World Health Organization declared COVID-19 a world-wide pandemic. Countries introduced public health measures to contain and reduce its spread. These measures included closures of educational institutions, non-essential businesses, events and activities, as well as working from and staying at home requirements. These measures have led to an economic downturn of unprecedented proportions. Generally, as economic activity declines, travel decreases and drivers are exposed to a lower risk of collisions. However, research on previous economic downturns suggests economic downturns differentially affect driver behaviours and situations. COVID-19 pandemic effects on road safety are currently unknown. However, preliminary information on factors such as the increased stress and anxiety brought about by the COVID-19 pandemic, more "free" (idle) time, increased consumption of alcohol and drugs, and greater opportunities for speeding and stunt driving, might well have the opposite effect on road safety. Using an interactionist model we identify research questions for researchers to consider on potential person and situation factors associated with COVID-19 that could affect road safety during and after the pandemic. Collaborative efforts by researchers, and public and private sectors will be needed to gather data and develop road safety strategies in relation to the new reality of COVID-19.
C1 [Vinglis, Evelyn] Western Univ, Schulich Sch Med & Dent, London, ON, Canada.
   [Beirness, Doug] Canadian Ctr Subst Use & Addict, Ottawa, ON, Canada.
   [Boase, Paul] Transport, Rd Safety & Motor Vehicle Regulat, Ottawa, ON, Canada.
   [Byrne, Patrick] Ontario Minist Transportat & Commun, Res & Evaluat Off, Ottawa, ON, Canada.
   [Johnson, Jennifer] Bayside Med Ctr, Penetanguishene, ON, Canada.
   [Jonah, Brian] Rd Safety Canada Consulting, Ottawa, ON, Canada.
   [Mann, Robert E.] Univ Toronto, Ctr Addict & Mental Hlth, Inst Mental Hlth Policy Res, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Rapoport, Mark J.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Psychiat, Fac Med, Toronto, ON, Canada.
   [Seely, Jan] Western Univ, Schulich Sch Med & Dent, Dept Family Med, Populat & Community Hlth Unit, London, ON, Canada.
   [Wickens, Christine M.] Ctr Addict & Mental Hlth, Inst Mental Hlth Policy Res, Toronto, ON, Canada.
   [Wickens, Christine M.] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada.
   [Wickens, Christine M.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Wickens, Christine M.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
   [Wickens, Christine M.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada.
   [Wiesenthal, David L.] York Univ, Dept Psychol, Toronto, ON, Canada.
RP Vinglis, E (corresponding author), Western Univ, Schulich Sch Med & Dent, London, ON, Canada.
EM evingili@uwo.ca
OI Byrne, Patrick/0000-0002-5276-5393
CR Ahangari H, 2014, TRANSPORT RES REC, P48, DOI 10.3141/2465-07
   Ahmed MZ, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102092
   Antoniou C, 2016, ACCIDENT ANAL PREV, V92, P89, DOI 10.1016/j.aap.2016.03.025
   Austin D, 2008, EFFECTS GASOLINE PRI
   Australian Road Safety Foundation, 2020, COVID 19 COMPL DRIV
   BBC, 2020, BBC
   Bellon T., 2020, CHRONICLE HERAL 0415
   Benzie R, 2020, TORONTO STAR
   Bergal J., 2020, PEW STATELINE   0420
   Bloomberg News, 2020, BLOOMBERG NEWS
   British Columbia Automobile Association, 2020, SLOW MOR KIDS AR PLA
   Brown D., 2020, LONDON FREE PRE 0412
   Bucsky P., 2020, TRANSP RES INTERDISC, V8, P100141, DOI [10.1016/j.trip.2020.100141, DOI 10.1016/J.TRIP.2020.100141]
   Canada Health Infoway, 2020, EXP HLTH CAR COVID 1
   Canadian Centre on Substance Use and Addiction, 2020, 20201621 CCSA
   Canadian Medical Association, 2020, WHAT CAN THINK VIRT
   Canadian Trucking Alliance, 2020, CTA SNAPSH NAT DRIV
   Carter D., 2020, EFFECTS COVID 19 SHU
   Chi GQ, 2013, J TRANSP GEOGR, V28, P1, DOI 10.1016/j.jtrangeo.2012.08.015
   Chi GQ, 2010, J SAFETY RES, V41, P493, DOI 10.1016/j.jsr.2010.10.003
   City News, 2020, CITY NEWS
   City of Toronto, 2020, CITY TORONTO URGES D
   Dazio S., 2020, LOCK YOUR CARS VEHIC
   De Vos J., 2020, TRANSPORTATION RES I
   Dickinson K., 2020, BLACKBURN NEWS  0513
   Dula CS, 2010, ACCIDENT ANAL PREV, V42, P2050, DOI 10.1016/j.aap.2010.06.016
   Evans P., 2020, CBC BUSINESS    0619
   Fitzpatrick M., 2020, CBC NEWS
   Gonzalez-Sanguino C, 2020, BRAIN BEHAV IMMUN, V87, P172, DOI 10.1016/j.bbi.2020.05.040
   Grabowski DC, 2004, J POLICY ANAL MANAG, V23, P575, DOI 10.1002/pam.20028
   He MM, 2016, SOC SCI MED, V155, P1, DOI 10.1016/j.socscimed.2016.02.016
   Hogan S., 2020, CBC NEWS
   Hristova B., 2020, CBC NEWS
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   International Labour Organization, 2020, ILOS POL FRAM RESP C
   Kaji M., 2020, ABC NEWS
   Kroyer HRG, 2014, ACCIDENT ANAL PREV, V62, P143, DOI 10.1016/j.aap.2013.09.007
   Kunst A., 2020, HAVE YOU DELIBERATEL
   LAMM R, 1985, ACCIDENT ANAL PREV, V17, P429, DOI 10.1016/0001-4575(85)90038-7
   Liu NQ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112921
   Lloyd L, 2015, ACCIDENT ANAL PREV, V80, P274, DOI 10.1016/j.aap.2015.03.026
   Lockwood M., 2020, TRAFFIC TRENDS SAFET
   MacLeod M., 2020, CTV NEWS
   Maheshri V, 2016, J RISK UNCERTAINTY, V52, P255, DOI 10.1007/s11166-016-9239-6
   Mccartt AT, 2009, TRAFFIC INJ PREV, V10, P209, DOI 10.1080/15389580802677807
   McNamara A, 2013, ACCIDENT ANAL PREV, V55, P178, DOI 10.1016/j.aap.2013.02.034
   Ministry of Transportation of Ontario, 2020, ONT EXT VAL PER DRIV
   MOORE VM, 1995, EPIDEMIOLOGY, V6, P258, DOI 10.1097/00001648-199505000-00012
   National Safety Council, 2020, MOT VEH FAT RAT JUMP
   Occupational Health & Safety, 2020, MOT VEH FAT RAT 14 M
   Organization for Economic Cooperation and Development/International Transport Forum (OECD/ITF), 2015, WHY DOES ROAD SAF IM
   Paparella N., 2020, CTV NEWS LONDON 0422
   Ragland DR, 2005, J GERONTOL A-BIOL, V60, P399, DOI 10.1093/gerona/60.3.399
   Rangwala SH, 2010, MOBILE DNA-UK, V1, DOI 10.1186/1759-8753-1-10
   Reynolds C., 2020, CANADIAN PRESS  0330
   Rho H.J., 2020, BASIC DEMOGRAPHIC PR
   Ronna BB, 2016, J OCCUP ENVIRON MED, V58, P828, DOI 10.1097/JOM.0000000000000806
   Sharpe K., 2020, CTV NEWS
   Shilling F., 2020, SPECIAL REPORT UPDAT
   Simons-Morton B, 2016, SAFETY, V2, DOI 10.3390/safety2040020
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Statistics Canada, 2020, CAN EC DASHB COVID 1
   Thompson M., 2020, CTV NEWS LONDON 0510
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Vingilis E., 1986, HLTH ED RES, V1, P273, DOI DOI 10.1093/HER/1.4.273
   Vingilis E, 2013, TRANSPORT RES F-TRAF, V21, P30, DOI 10.1016/j.trf.2013.08.003
   WAGENAAR AC, 1984, ACCIDENT ANAL PREV, V16, P191, DOI 10.1016/0001-4575(84)90013-7
   Walton V., 2020, HALIFAX TODAY   0516
   Weaver J., 2020, CBC             0604
   Wegman F, 2017, ACCIDENT ANAL PREV, V102, P51, DOI 10.1016/j.aap.2017.01.022
   WHO, 2020, COR DIS COVID 19 PAN
   Wickens CM, 2014, INT J MENT HEALTH AD, V12, P524, DOI 10.1007/s11469-014-9487-0
   Wickens CM, 2013, J AFFECT DISORDERS, V145, P253, DOI 10.1016/j.jad.2012.04.046
   Wiesenthal D.L., 2012, APPL EVOLUTIONARY PS, V1, P399
   Williams M., 2020, CBC NEWS
   Yannis G, 2014, SAFETY SCI, V63, P42, DOI 10.1016/j.ssci.2013.10.017
   Yuen J., 2020, TORONTO SUN
   Zadorsky J., 2020, CTV NEWS LONDON 0428
NR 78
TC 2
Z9 2
U1 13
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0001-4575
EI 1879-2057
J9 ACCIDENT ANAL PREV
JI Accid. Anal. Prev.
PD SEP
PY 2020
VL 144
AR 105687
DI 10.1016/j.aap.2020.105687
PG 6
WC Ergonomics; Public, Environmental & Occupational Health; Social
   Sciences, Interdisciplinary; Transportation
SC Engineering; Public, Environmental & Occupational Health; Social
   Sciences - Other Topics; Transportation
GA NG7VB
UT WOS:000564188000012
PM 32683133
OA Green Published
DA 2021-01-01
ER

PT J
AU van Grunsven, J
AF van Grunsven, Janna
TI Perceptual breakdown during a global pandemic: introducing
   phenomenological insights for digital mental health purposes
SO ETHICS AND INFORMATION TECHNOLOGY
LA English
DT Article; Early Access
DE Digital mental health; Loss of perceptual world-familiarity; COVID-19
   pandemic; Phenomenology; Well-being; Affordances; Ego-depletion; Online
   therapy; Social interaction technologies
AB Online therapy sessions and other forms of digital mental health services (DMH) have seen a sharp spike in new users since the start of the COVID-19 pandemic. Having little access to their social networks and support systems, people have had to turn to digital tools and spaces to cope with their experiences of anxiety and loss. With no clear end to the pandemic in sight, many of us are likely to remain reliant upon DMH for the foreseeable future. As such, it is important to articulate some of the specific ways in which the pandemic is affecting our self and world-relation, such that we can identify how DMH services are best able to accommodate some of the newly emerging needs of their users. In this paper I will identify a specific type of loss brought about by the COVID-19 pandemic and present it as an important concept for DMH. I refer to this loss asloss of perceptual world-familiarity.Loss of perceptual world-familiarity entails a breakdown in the ongoing effortless responsiveness to our perceptual environment that characterizes much of our everyday lives. To cash this out I will turn to insights from the phenomenological tradition. Initially, my project is descriptive. I aim to bring out how loss of perceptual world-familiarity is a distinctive form of loss that is deeply pervasive yet easily overlooked-hence the relevance of explicating it for DMH purposes. But I will also venture into the space of the normative, offering some reasons for seeing perceptual world-familiarity as a component of well-being. I conclude the paper with a discussion of how loss of perceptual world-familiarity affects the therapeutic setting now that most if not all therapeutic interactions have transitioned to online spaces and I explore the potential to augment these spaces with social interaction technologies. Throughout, my discussion aims to do justice to the reality that perceptual world-familiarity is not an evenly distributed phenomenon, that factors like disability, gender and race affect its robustness, and that this ought to be reckoned with when seeking to incorporate the phenomenon into or mitigate it through DMH services.
C1 [van Grunsven, Janna] Delft Univ Technol, Delft, Netherlands.
RP van Grunsven, J (corresponding author), Delft Univ Technol, Delft, Netherlands.
EM J.B.vanGrunsven@tudelft.nl
RI van+Grunsven, Janna/AAY-7127-2020
CR BAIER A, 1986, ETHICS, V96, P231, DOI 10.1086/292745
   Bakker D, 2016, JMIR MENT HEALTH, V3, DOI 10.2196/mental.4984
   Bierbooms J, NEW NORMAL MENTAL HE
   Charles T, 2005, CAMBRIDGE COMPANION
   Chris Thornhill, 2020, STANFORD ENCY PHILOS
   Dreyfus HL, 2007, INQUIRY, V50, P352, DOI 10.1080/00201740701489245
   Feijt M, 2020, CYBERPSYCH BEH SOC N, V23, P860, DOI 10.1089/cyber.2020.0370
   Feijt MA, 2018, ANN REV CYBERTHERAPY, V16, P25
   Gibson J.J., 1979, ECOLOGICAL APPROACH
   Heidegger M., 1962, BEING TIME
   Janssen JH, 2010, IEEE T AFFECT COMPUT, V1, P72, DOI 10.1109/T-AFFC.2010.13
   Khular D, 2020, CHALLENGES POSTCOVID
   Merleau-Ponty Maurice, 2012, PHENOMENOLOGY PERCEP
   Muraven M, 2012, OXFORD HDB HUMAN MOT
   Rietveld E, 2014, ECOL PSYCHOL, V26, P325, DOI 10.1080/10407413.2014.958035
   Ryan RM, 1997, J PERS, V65, P529, DOI 10.1111/j.1467-6494.1997.tb00326.x
   Sacks O.W., 1995, ANTHR MARS 7 PARADOX
   Stein Edith, 1989, PROBLEM EMPATHY
   Westerlund MU, 2020, OMEGA-J DEATH DYING, V81, P272, DOI 10.1177/0030222818765807
   Wilson NM, 2020, ANAESTHESIA, V75, P1086, DOI 10.1111/anae.15093
   YOUNG IM, 1980, HUM STUD, V3, P137, DOI 10.1007/BF02331805
NR 21
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-1957
EI 1572-8439
J9 ETHICS INF TECHNOL
JI Ethics Inf. Technol.
DI 10.1007/s10676-020-09554-y
EA SEP 2020
PG 8
WC Ethics; Information Science & Library Science; Philosophy
SC Social Sciences - Other Topics; Information Science & Library Science;
   Philosophy
GA NI1CD
UT WOS:000565095000001
PM 32905100
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hoque, MN
   Chaudhury, A
   Akanda, MAM
   Hossain, MA
   Islam, MT
AF Hoque, M. Nazmul
   Chaudhury, Abed
   Akanda, Md Abdul Mannan
   Hossain, M. Anwar
   Islam, Md Tofazzal
TI Genomic diversity and evolution, diagnosis, prevention, and therapeutics
   of the pandemic COVID-19 disease
SO PEERJ
LA English
DT Article
DE SARS-CoV-2; Genetic diversity; Genome evolution; Diagnostics;
   Therapeutics; Vaccines
ID ACUTE RESPIRATORY SYNDROME; MERS-COV; NEUTRALIZING ANTIBODIES;
   CORONAVIRUS PNEUMONIA; SARS; SPIKE; SARS-COV-2; BINDING; PROTEIN;
   TRANSMISSION
AB The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by a novel evolutionarily divergent RNA virus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus first emerged in Wuhan, China in December 2019, and subsequently spreaded around the world. Genomic analyses revealed that this zoonotic virus may be evolved naturally but not a purposefully manipulated laboratory construct. However, currently available data are not sufficient to precisely conclude the origin of this fearsome virus. Comprehensive annotations of the whole-genomes revealed hundreds of nucleotides, and amino acids mutations, substitutions and/or deletions at different positions of the ever changing SARS-CoV-2 genome. The spike (S) glycoprotein of SARS-CoV-2 possesses a functional polybasic (furin) cleavage site at the S1-S2 boundary through the insertion of 12 nucleotides. It leads to the predicted acquisition of 3-O-linked glycan around the cleavage site. Although real-time RT-PCR methods targeting specific gene(s) have widely been used to diagnose the COVID-19 patients, however, recently developed more convenient, cheap, rapid, and specific diagnostic tools targeting antigens or CRISPR-Cas-mediated method or a newly developed plug and play method should be available for the resource-poor developing countries. A large number of candidate drugs, vaccines and therapies have shown great promise in early trials, however, these candidates of preventive or therapeutic agents have to pass a long path of trials before being released for the practical application against COVID-19. This review updates current knowledge on origin, genomic evolution, development of the diagnostic tools, and the preventive or therapeutic remedies of the COVID-19. We also discussed the future scopes for research, effective management, and surveillance of the newly emerged COVID-19 disease.
C1 [Hoque, M. Nazmul] Bangabandhu Sheikh Mujibur Rahman Agr Univ BSMRAU, Dept Gynecol Obstet & Reprod Hlth, Gazipur, Bangladesh.
   [Hoque, M. Nazmul; Hossain, M. Anwar] Univ Dhaka, Dept Microbiol, Dhaka, Bangladesh.
   [Chaudhury, Abed] Charles Sturt Univ, Orange, NSW, Australia.
   [Akanda, Md Abdul Mannan] Bangabandhu Sheikh Mujibur Rahman Agr Univ BSMRAU, Dept Plant Pathol, Gazipur, Bangladesh.
   [Hossain, M. Anwar] Jashore Univ Sci & Technol, Jashore, Bangladesh.
   [Islam, Md Tofazzal] Bangabandhu Sheikh Mujibur Rahman Agr Univ BSMRAU, Inst Biotechnol & Genet Engn IBGE, Gazipur, Bangladesh.
RP Islam, MT (corresponding author), Bangabandhu Sheikh Mujibur Rahman Agr Univ BSMRAU, Inst Biotechnol & Genet Engn IBGE, Gazipur, Bangladesh.
EM tofazzalislam@bsmrau.edu.bd
RI Islam, Tofazzal/F-2563-2010
OI Islam, Tofazzal/0000-0002-7613-0261
CR Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286
   Adachi S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00811
   Agostini ML, 2019, J VIROL, V93, DOI 10.1128/JVI.01348-19
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Almofti YA, 2018, AM J MICROBIOLOGICAL, V6, P94, DOI DOI 10.12691/AJMR-6-3-5
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   [Anonymous], 2020, DETECTION 2019 NOVEL
   [Anonymous], 2020, SPECIFIC PRIMERS PRO
   [Anonymous], 2017, XINHUA
   [Anonymous], 2020, CDC 2019 NOVEL CORON
   Armijos-Jaramillo V, 2020, EVOL APPL, V13, P2168, DOI 10.1111/eva.12980
   Badawi MM, 2016, AM J MICROBIOLOGICAL, V4, p101~121, DOI DOI 10.12691/AJMR-4-4-2
   Baer CF, 2008, PLOS BIOL, V6, P233, DOI 10.1371/journal.pbio.0060052
   Bal A, 2020, CLIN MICROBIOL INFEC, V26, P960, DOI 10.1016/j.cmi.2020.03.020
   Bastola A, 2020, LANCET INFECT DIS, V20, P279, DOI 10.1016/S1473-3099(20)30067-0
   Boni MF, 2020, EVOLUTIONARY ORIGINS, DOI [10.1101/2020.03.30.015008, DOI 10.1101/2020.03.30.015008]
   Brassey J., 2020, DO WEATHER CONDITION
   Broughton JP, 2020, NAT BIOTECHNOL, V38, P870, DOI 10.1038/s41587-020-0513-4
   Callaway E, 2020, NATURE, V579, P482, DOI 10.1038/d41586-020-00758-2
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carrasco-Hernandez R, 2017, ILAR J, V58, P343, DOI 10.1093/ilar/ilx026
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng VCC, 2004, J INFECTION, V49, P262, DOI 10.1016/j.jinf.2004.07.010
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   Chiara M, 2020, BIORXIV, DOI [10.1101/2020.06.26.172924., DOI 10.1101/2020.06.26.172924]
   Clover B., 2020, CLOVER INITIATES DEV
   Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Di L, 2020, P NATL ACAD SCI USA, V117, P2886, DOI 10.1073/pnas.1919800117
   Drew DA, 2020, SCIENCE, V368, P1362, DOI 10.1126/science.abc0473
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Freundt EC, 2010, J VIROL, V84, P1097, DOI 10.1128/JVI.01662-09
   Gao GF, 2018, CELL, V172, P1157, DOI 10.1016/j.cell.2018.02.025
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Geo-Vax, 2020, GEOV BRAV WUH CHIN C
   Guo GQ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00410
   Harvey C., 2020, E E NEWS        0309
   Hemida MG, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100127
   Hindson J, 2020, NAT REV GASTRO HEPAT, V17, P259, DOI 10.1038/s41575-020-0295-7
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Hoque MNA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49468-4
   Huang J. M., 2020, BIORXIV, DOI [10.1101/2020.03.16.993816, DOI 10.1101/2020.03.16.993816]
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Inovio IP, 2020, IN SEL CEP DEV VACC
   Islam MR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70812-6
   Islam MT, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0309-7
   Jackwood MW, 2012, INFECT GENET EVOL, V12, P1305, DOI 10.1016/j.meegid.2012.05.003
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Johnson, 2020, WHAT YOU NEED KNOW L
   Kalita P., 2020, DESIGN PEPTIDE BASED, DOI [10.20944/preprints202003.0433.v1., DOI 10.20944/PREPRINTS202003.0433.V1, 10. 20944/PREPRINTS202003.0433.V1]
   Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108
   Kellner MJ, 2019, NAT PROTOC, V14, P2986, DOI 10.1038/s41596-019-0210-2
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan S, 2020, J CLIN MICROBIOL, V58, DOI [10.1128/JCM.01297-20, 10.1128/JCM.00187-20]
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   Kupferschmidt K, 2020, SCIENCE, DOI [10.1126/science.abd3683, DOI 10.1126/SCIENCE.ABD3683]
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lane R, 2020, LANCET, V395, P1247, DOI 10.1016/S0140-6736(20)30796-0
   Lau SY, 2020, EMERG MICROBES INFEC, V9, P837, DOI 10.1080/22221751.2020.1756700
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li GR, 2018, ADV SCI, V5, DOI 10.1002/advs.201800275
   Li H, 2020, LEUKEMIA, V34, P1503, DOI 10.1038/s41375-020-0848-3
   Li Y, 2019, TRENDS BIOTECHNOL, V37, P730, DOI 10.1016/j.tibtech.2018.12.005
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Lin XQ, 2020, KOREAN J RADIOL, V21, P365, DOI 10.3348/kjr.2020.0078
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luke T, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1061
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Nishiura H, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020488
   Nuccetelli M, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0275-2
   Ou J, 2020, BIORXIV, DOI [10.1101/2020.03.15.991844, DOI 10.1101/2020.03.15.991844]
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Rahman MS, 2020, PEERJ, V8, DOI 10.7717/peerj.9572
   Regla-Nava JA, 2015, J VIROL, V89, P3870, DOI 10.1128/JVI.03566-14
   Reid AH, 1999, P NATL ACAD SCI USA, V96, P1651, DOI 10.1073/pnas.96.4.1651
   Reynard O, 2015, VIRUSES-BASEL, V7, P6233, DOI 10.3390/v7122934
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sanofi, 2020, DEP HLTH HUM SERV AD
   Sardar R, 2020, COMP ANAL SAR COV2 G, DOI [10.1101/2020.03.21.001586, DOI 10.1101/2020.03.21.001586]
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shen ZJ, 2020, CLIN INFECT DIS, V71, P713, DOI 10.1093/cid/ciaa203
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shi SQ, 2006, MOL IMMUNOL, V43, P1791, DOI 10.1016/j.molimm.2005.11.005
   Shirato Kazuya, 2020, Jpn J Infect Dis, V73, P304, DOI 10.7883/yoken.JJID.2020.061
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Sui JH, 2005, J VIROL, V79, P5900, DOI 10.1128/JVI.79.10.5900-5906.2005
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
   Toots M, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax5866
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Valencia DN, 2020, CUREUS, V12, DOI 10.7759/cureus.7386
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang NS, 2019, CELL REP, V28, P3395, DOI 10.1016/j.celrep.2019.08.052
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   Wang XS, 2020, ACS NANO, V14, P2497, DOI 10.1021/acsnano.0c00022
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wei Q, 2020, CHIN J DISINFECT, V37, P59, DOI DOI 10.11726/J.ISSN.1001-7658.2020.01.019
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao K, 2020, NATURE, P1, DOI DOI 10.24252/NATURE.V7I1A1
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Yin C, 2020, ARXIV200310965
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang F., 2020, PROTOCOL DETECTION C
   Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153
   Zhang L, 2020, GENOME WIDE VARIATIO, DOI [10.1101/2020.04.27.20081349, DOI 10.1101/2020.04.27.20081349]
   Zhou HX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10897-4
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhou ZM, 2006, VACCINE, V24, P3624, DOI 10.1016/j.vaccine.2006.01.059
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 151
TC 1
Z9 1
U1 4
U2 4
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD SEP 1
PY 2020
VL 8
AR e9689
DI 10.7717/peerj.9689
PG 35
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NH1ZY
UT WOS:000564476600002
PM 33005486
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, HT
   Zhu, GZ
   Yan, L
   Lu, Y
   Fang, QY
   Shao, FM
AF Zhang, Hongtao
   Zhu, Guizhen
   Yan, Lei
   Lu, Yang
   Fang, Qiying
   Shao, Fengmin
TI The absorbing filter Oxiris in severe coronavirus disease 2019 patients:
   A case series
SO ARTIFICIAL ORGANS
LA English
DT Article
DE coronavirus disease 2019; cytokine storm; hemodynamics; Oxiris
AB Hypercytokines cause acute respiratory distress syndrome (ARDS) in coronavirus disease 2019 (COVID-19) patients, which is the main reason for intensive care unit treatment and the leading cause of death in COVID-19 patients. Cytokine storm is a critical factor in the development of ARDS. This study evaluated the efficacy and safety of Oxiris filter in the treatment of COVID-19 patients. Five patients with COVID-19 who received continuous renal replacement therapy (CRRT) in Henan provincial people's hospital between January 23, 2019 and March 28, 2020, were enrolled in this study. Heart rate (HR), mean arterial pressure (MAP), oxygenation index (PaO2/FiO(2)), renal function, C-reactive protein (CRP), cytokines, procalcitonin (PCT), acute physiology and chronic health evaluation II (APACHE II), sequential organ failure score (SOFA), and prognosis were compared after CRRT. Five COVID-19 patients, three males and two females, aged 70.2 +/- 19.6 years, were enrolled. After treatment, HR (101.4 +/- 14.08 vs. 83.8 +/- 6.22 bpm/min), CRP (183 +/- 25.21 vs. 93.78 +/- 70.81 mg/L), IL-6 (3234.49 (713.51, 16038.36) vs. 181.29 (82.24, 521.39) pg/mL), IL-8 (154.86 (63.97, 1476.1) vs. 67.19 (27.84, 85.57) pg/mL), and IL-10 (17.43 (9.14, 41.22) vs. 4.97 (2.39, 8.70) pg/mL), APACHE II (29 +/- 4.92 vs. 18.4 +/- 2.07), and SOFA (17.2 +/- 1.92 vs. 11.2 +/- 3.4) significantly decreased (P < .05), while MAP (75.8 +/- 4.92 vs. 85.8 +/- 6.18 mm Hg), and PaO2/FiO(2)(101.2 +/- 7.49 vs. 132.6 +/- 26.15 mm Hg) significantly increased (P < .05). Among the five patients, negative conversion of nucleic acid test was found in three cases, while two cases died. No adverse events occurred during the treatment. Our study observed a reduced level of overexpressed cytokines, stabilization of hemodynamic status, and staged improvement of organ function during the treatment with Oxiris filter.
C1 [Zhang, Hongtao; Zhu, Guizhen; Yan, Lei; Lu, Yang; Fang, Qiying; Shao, Fengmin] Zhengzhou Univ, Dept Nephrol, Peoples Hosp, 7 Weiwu Rd, Zhengzhou 450003, Peoples R China.
RP Shao, FM (corresponding author), Zhengzhou Univ, Dept Nephrol, Peoples Hosp, 7 Weiwu Rd, Zhengzhou 450003, Peoples R China.
EM shaofengmin2013@126.com
FU Youth Foundation of Zhengzhou University [20200017]
FX The Youth Foundation of Zhengzhou University, Grant/Award Number:
   20200017
CR Al-Dorzi HM, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0203-z
   Broman ME, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220444
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Fleischmann C, 2016, AM J RESP CRIT CARE, V193, P259, DOI 10.1164/rccm.201504-0781OC
   General Office of the National Health Commission, 2020, NOT ISS COVID 19 DIA
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lehmann C, 2008, CAN J ANAESTH, V55, P155, DOI 10.1007/BF03016089
   Malard B, 2018, INTENS CARE MED EXP, V6, DOI 10.1186/s40635-018-0177-2
   Ronco C, 2003, ARTIF ORGANS, V27, P792, DOI 10.1046/j.1525-1594.2003.07289.x
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schwindenhammer V, 2019, BLOOD PURIFICAT, V47, P29, DOI 10.1159/000499510
   Tan HK, 2019, BLOOD PURIFICAT, V47, P59, DOI 10.1159/000499633
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Turani F, 2019, BLOOD PURIFICAT, V47, P54, DOI 10.1159/000499589
   Villa G, 2019, BLOOD PURIFICAT, V47, P16, DOI 10.1159/000499356
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Zhang Chun, 2019, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V31, P1531, DOI 10.3760/cma.j.issn.2095-4352.2019.12.019
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-564X
EI 1525-1594
J9 ARTIF ORGANS
JI Artif. Organs
PD DEC
PY 2020
VL 44
IS 12
BP 1296
EP 1302
DI 10.1111/aor.13786
EA SEP 2020
PG 7
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA PG3JJ
UT WOS:000564343700001
PM 32779737
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gurung, AB
   Ali, MA
   Lee, J
   Abul Farah, M
   Al-Anazi, KM
AF Gurung, Arun Bahadur
   Ali, Mohammad Ajmal
   Lee, Joongku
   Abul Farah, Mohammad
   Al-Anazi, Khalid Mashay
TI Structure-based virtual screening of phytochemicals and repurposing of
   FDA approved antiviral drugs unravels lead molecules as potential
   inhibitors of coronavirus 3C-like protease enzyme
SO JOURNAL OF KING SAUD UNIVERSITY SCIENCE
LA English
DT Article
DE Coronaviruses; 3C-like protease; SARS-CoV; MERS-CoV; Molecular docking;
   Virtual screening; FDA approved drugs; Antiviral drugs; Phytochemicals
ID PATHOGENESIS; PROGRAM; GENOME; GENE
AB Coronaviruses are enveloped positive-strand RNA viruses belonging to family Coronaviridae and order Nidovirales which cause infections in birds and mammals. Among the human coronaviruses, highly pathogenic ones are Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV) which have been implicated in severe respiratory syndrome in humans. There are no approved antiviral drugs or vaccines for the treatment of human CoV infection to date. The recent outbreak of new coronavirus pandemic, coronavirus disease 2019 (COVID-19) has caused a high mortality rate and infections around the world which necessitates the need for the discovery of novel anti-coronaviral drugs. Among the coronaviruses proteins, 3C-like protease (3CL(pro)) is an important drug target against coronaviral infection as the auto-cleavage process catalysed by the enzyme is crucial for viral maturation and replication. The present work is aimed at the identification of suitable lead molecules for the inhibition of 3CL(pro) enzyme via a computational screening of the Food and Drug Administration (FDA) approved antiviral drugs and phytochemicals. Based on binding energies and molecular interaction studies, we shortlisted five lead molecules (both FDA approved drugs and phytochemicals) for each enzyme targets (SARS-CoV-2 3CL(pro), SARS-CoV 3CL(pro) and MERS-CoV 3CL(pro)). The lead molecules showed higher binding affinity compared to the standard inhibitors and exhibited favourable hydrophobic interactions and a good number of hydrogen bonds with their respective targets. A few promising leads with dual inhibition potential were identified among FDA approved antiviral drugs which include DB13879 (Glecaprevir), DB09102 (Daclatasvir), molecule DB09297 (Paritaprevir) and DB01072 (Atazanavir). Among the phytochemicals, 11,646,359 (Vincapusine), 120,716 (Alloyohimbine) and 10,308,017 (Gummadiol) showed triple inhibition potential against all the three targets and 102,004,710 (18-Hydroxy-3-epi-alpha-yohimbine) exhibited dual inhibition potential. Hence, the proposed lead molecules from our findings can be further investigated through in vitro and in vivo studies to develop into potential drug candidates against human coronaviral infections. (C) 2020 The Author(s). Published by Elsevier B.V.
C1 [Gurung, Arun Bahadur] North Eastern Hill Univ, Dept Basic Sci & Social Sci, Shillong 793022, Meghalaya, India.
   [Ali, Mohammad Ajmal] King Saud Univ, Coll Sci, Dept Bot & Microbiol, Riyadh 11451, Saudi Arabia.
   [Lee, Joongku] Chungnam Natl Univ, Dept Environm & Forest Resources, 99 Daehak Ro, Daejeon 34134, South Korea.
   [Abul Farah, Mohammad; Al-Anazi, Khalid Mashay] King Saud Univ, Coll Sci, Dept Zool, Genet Lab, Riyadh 11451, Saudi Arabia.
RP Gurung, AB (corresponding author), North Eastern Hill Univ, Dept Basic Sci & Social Sci, Shillong 793022, Meghalaya, India.; Lee, J (corresponding author), Chungnam Natl Univ, Dept Environm & Forest Resources, 99 Daehak Ro, Daejeon 34134, South Korea.
EM arunbgurung@gmail.com; joongku@cnu.ac.kr
FU King Saud University, Riyadh, Saudi ArabiaKing Saud University
   [RSP-2019/154]; Chungnam National University, Daejeon, Republic of Korea
FX The authors would like to extend their sincere appreciation to the
   Researchers Supporting Project number (RSP-2019/154), King Saud
   University, Riyadh, Saudi Arabia. J. Lee thanks to Chungnam National
   University, Daejeon, Republic of Korea for the funding support. The
   authors thank the Deanship of Scientific Research and RSSU at King Saud
   University for their technical support.
CR Abd El-Aziz TM, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104327
   Anadon A., 2016, NUTRACEUTICALS EFFIC, P855, DOI [10.1016/B978-0-12-802147-7.00060-7, DOI 10.1016/B978-0-12-802147-7.00060-7]
   ANJANEYULU ASR, 1975, TETRAHEDRON LETT, P1803
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Eckhardt B.J., 2017, INFECT DIS, P1293, DOI [10.1016/B978-0-7020-6285-8.00152-0., 10.1016/B978-0-7020-6285-8.00152-0, DOI 10.1016/B978-0-7020-6285-8.00152-0]
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Gorbalenya AE, 2001, ADV EXP MED BIOL, V494, P1
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:6<490::AID-JCC1>3.3.CO;2-V
   Hezode C, 2018, LIVER INT, V38, P21, DOI 10.1111/liv.13638
   Kannan D, 2018, INT J MED RES HEALTH, V7, P1
   Khare C.P., 2007, INDIAN MED PLANTS IL, P1, DOI 10.1007/978-0-387-70638-2_1743
   Lacroix A, 2017, INFECT GENET EVOL, V48, P10, DOI 10.1016/j.meegid.2016.11.029
   Lai M., 2001, FIELDS VIROLOGY, P1163
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Lundstrom K, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050109
   Simas PVM, 2015, EMERG INFECT DIS, V21, P729, DOI 10.3201/eid2104.141783
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Needle D, 2015, ACTA CRYSTALLOGR D, V71, P1102, DOI 10.1107/S1399004715003521
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Padron-Regalado E, 2020, INFECT DIS THER, V9, P255, DOI 10.1007/s40121-020-00300-x
   Pathala D, 2015, J PHARMACOGN PHYTOCH, V4, P127
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yeon JE, 2018, CLIN MOL HEPATOL, V24, P169, DOI 10.3350/cmh.2018.1004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
   Ziebuhr J, 2001, J BIOL CHEM, V276, P33220, DOI 10.1074/jbc.M104097200
NR 39
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1018-3647
EI 2213-686X
J9 J KING SAUD UNIV SCI
JI J. King Saud Univ. Sci.
PD SEP
PY 2020
VL 32
IS 6
BP 2845
EP 2853
DI 10.1016/j.jksus.2020.07.007
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NI4FG
UT WOS:000565309200004
PM 32837113
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Costanzo, L
   Palumbo, FP
   Ardita, G
   Antignani, PL
   Arosio, E
   Failla, G
AF Costanzo, Luca
   Palumbo, Francesco Paolo
   Ardita, Giorgio
   Antignani, Pier Luigi
   Arosio, Enrico
   Failla, Giacomo
CA Italian Soc Vasc Invest
   Italian Soc Vasc Med
TI Coagulopathy, thromboembolic complications, and the use of heparin in
   COVID-19 pneumonia
SO JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS
LA English
DT Article
DE COVID-19; Pneumonia; Thrombosis; Coagulopathy; D-dimer;
   Low-molecular-weight heparin
ID ACUTE RESPIRATORY SYNDROME; INNATE IMMUNITY; INFECTIONS; MECHANISMS;
   THROMBOSIS; PATHOLOGY; CELLS
AB The SARS-CoV-2 (COVID-19) is causing a pandemic and potentially fatal disease of global public health concern. Viral infections are known to be associated with coagulation impairment; thus, thrombosis, hemorrhage, or both may occur. Understanding the pathophysiologic mechanisms underlying the development of coagulation disorders during viral infection is essential for the development of therapeutic strategies. Coagulopathy in COVID-19 infection is emerging as a precipitant factor for severe respiratory complications and death. An increase in coagulation markers, such as fibrinogen and D-dimer, has been found in severe COVID-19 cases. Heparin, clinically used as an anticoagulant, also has anti-inflammatory properties, including binding of inflammatory cytokines, inhibition of neutrophil chemotaxis, and protection of endothelial cells, and a potential antiviral effect. We hypothesized that low-molecular-weight heparin may attenuate cytokine storm in COVID-19 patients; therefore, low-molecular-weight heparin could be a valid adjunctive therapeutic drug for the treatment of COVID-19 pneumopathy. In this paper, we review potential mechanisms involved in coagulation impairment after viral infection and the possible role of heparin in the treatment of COVID-19 patients.
C1 [Costanzo, Luca; Palumbo, Francesco Paolo; Ardita, Giorgio; Failla, Giacomo] Univ Catania, AOU Policlin Vittorio Emanuele, Dept Cardiovasc Dis, Angiol Unit,San Marco Hosp, Catania, Italy.
   [Antignani, Pier Luigi] Nuova Villa Claudia, Vasc Ctr, Rome, Italy.
   [Arosio, Enrico] Univ Verona, Dept Med, Verona, Italy.
RP Costanzo, L (corresponding author), Univ Catania, AOU Policlin Vittorio Emanuele, Dept Cardiovasc Dis, San Marco Hosp, Viale Carlo Azeglio Ciampi, I-95121 Catania, Italy.
EM lucacost84@gmail.com
CR Alquwaizani M, 2013, CURR EMERG HOSP ME R, V1, P83, DOI 10.1007/s40138-013-0014-6
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Branchford BR, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00142
   Brinkhous KM, 1939, AM J PHYSIOL, V125, P683
   Chong PY, 2004, ARCH PATHOL LAB MED, V128, P195
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Day M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1375
   Esmon CT, 2011, J THROMB HAEMOST, V9, P182, DOI 10.1111/j.1538-7836.2011.04323.x
   Fox SE, 2020, LANCET RESP MED
   Fuchs TA, 2012, ARTERIOSCL THROM VAS, V32, P1777, DOI 10.1161/ATVBAHA.111.242859
   Fulton Ross B, 2009, Aging health, V5, P775, DOI 10.2217/ahe.09.69
   Ghezzi S, 2017, ANTIVIR RES, V140, P13, DOI 10.1016/j.antiviral.2016.12.023
   Goeijenbier M, 2012, J MED VIROL, V84, P1680, DOI 10.1002/jmv.23354
   Gralinski LE, 2015, J PATHOL, V235, P185, DOI 10.1002/path.4454
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hirsh J, 2001, CHEST, V119, p64S, DOI 10.1378/chest.119.1_suppl.64S
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hwang DM, 2005, MODERN PATHOL, V18, P1, DOI 10.1038/modpathol.3800247
   Iba Toshiaki, 2015, Intensive Care Med Exp, V3, P36, DOI 10.1186/s40635-015-0072-z
   Ji HL, 2020, PHYSIOL REV, V100, P1065, DOI 10.1152/physrev.00013.2020
   Johnston A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207410
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725
   Langer HF, 2009, J CELL MOL MED, V13, P1211, DOI 10.1111/j.1582-4934.2009.00811.x
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Levi M, 2007, CRIT CARE MED, V35, P2191, DOI 10.1097/01.CCM.0000281468.94108.4B
   Li J, 2019, J INFLAMM-LOND, V16, DOI 10.1186/s12950-019-0213-3
   Liao JK, 2013, J CLIN INVEST, V123, P540, DOI 10.1172/JCI66843
   LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Ma JQ, 2015, INT J CLIN EXP MED, V8, P5547
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Mousavi S, 2015, ADV PHARMACOL SCI, V2015, DOI 10.1155/2015/507151
   Mycroft-West C, 2019 CORONAVIRUS SAR, DOI [10.1101/2020.02.29.971093v1.full, DOI 10.1101/2020.02.29.971093V1.FULL]
   Obi AT, 2019, J VASC SURG-VENOUS L, V7, P317, DOI 10.1016/j.jvsv.2018.08.010
   Oduah EI, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9030038
   OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829
   ROBSON SC, 1994, BRIT J HAEMATOL, V86, P322, DOI 10.1111/j.1365-2141.1994.tb04733.x
   Shodell M, 2002, SCAND J IMMUNOL, V56, P518, DOI 10.1046/j.1365-3083.2002.01148.x
   Shorr AF, 2002, CHEST, V121, P1262, DOI 10.1378/chest.121.4.1262
   Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799
   Smeeth L, 2006, LANCET, V367, P1075, DOI 10.1016/S0140-6736(06)68474-2
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Vicenzi E, 2004, EMERG INFECT DIS, V10, P413, DOI 10.3201/eid1003.030683
   Wiwanitkit V, 2008, BLOOD COAGUL FIBRIN, V19, P5, DOI 10.1097/MBC.0b013e3282f185a6
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   Wu YP, 2006, THROMB HAEMOSTASIS, V96, P100, DOI 10.1160/TH05-12-0827
   Xie Y, 2020, RADIOL CARDIOTHORAC, V2, pe200067, DOI [10.1148/ryct.2020200067, DOI 10.1148/RYCT.2020200067]
   Xu J, 2010, HAMOSTASEOLOGIE, V30, P5
   Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Yun SH, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9060143
   Zhang YR, 2019, PROG MOL BIOL TRANSL, V163, P41, DOI 10.1016/bs.pmbts.2019.02.004
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu CR, 2019, J TRAUMA ACUTE CARE, V87, P614, DOI 10.1097/TA.0000000000002387
NR 56
TC 4
Z9 4
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-333X
J9 J VASC SURG-VENOUS L
JI J. Vasc. Surg.-Venous Lymphat. Dis.
PD SEP
PY 2020
VL 8
IS 5
BP 711
EP 716
DI 10.1016/j.jvsv.2020.05.018
PG 6
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA NF8IM
UT WOS:000563536500004
PM 32561465
OA Green Published
DA 2021-01-01
ER

PT J
AU Luo, Z
   Su, KY
   Zhang, XW
AF Luo, Zhen
   Su, Keying
   Zhang, Xuewu
TI Potential of Plant Proteins DigestedIn Silicoby Gastrointestinal Enzymes
   as Nutritional Supplement for COVID-19 Patients
SO PLANT FOODS FOR HUMAN NUTRITION
LA English
DT Article
DE COVID-19; Spike; Protein supplementation; Oligopeptides; In
   silicoevaluation
ID RECEPTOR
AB Currently, no specific drug and vaccine are available for the new coronavirus SARS-CoV-2, and nutritional supplementation should be helpful. This study tried to provide reference for protein supplementation. Specifically,in silicomethod was employed to simulate protein degradation by gastrointestinal enzymes and to produce a large number of active peptides, then, the binding ability of these peptides to SARS-CoV-2 spike protein receptor-binding domain (RBD) was evaluated. The results showed that wheat-derived alpha/beta-gliadin, oat-derived avenin, and ribulose bisphosphate carboxylase small chain of different origin could be good protein source in generating potent binders to SARS-CoV-2 spike RBD. In addition, some high-affinity oligopeptides (such as PISCR, VQVVN, PQQQF, etc.) were identified as potential binders of SARS-CoV-2 spike RBD. In summary, a number of plant proteins could be helpful for COVID-19 patients when supplemented with these proteins, the identified oligopeptides could be used as lead compound to design potential entry inhibitors against SARS-CoV-2.
C1 [Luo, Zhen; Su, Keying; Zhang, Xuewu] South China Univ Technol, Coll Food Sci & Engn, 381 Wushan Rd, Guangzhou 510640, Peoples R China.
   [Su, Keying] Guangzhou Coll Technol & Business, Guangzhou, Peoples R China.
RP Zhang, XW (corresponding author), South China Univ Technol, Coll Food Sci & Engn, 381 Wushan Rd, Guangzhou 510640, Peoples R China.
EM snow_dance@sina.com
CR Chia TJ, 2010, FISH SHELLFISH IMMUN, V28, P434, DOI 10.1016/j.fsi.2009.11.020
   Cian RE, 2018, PLANT FOOD HUM NUTR, V73, P241, DOI 10.1007/s11130-018-0682-1
   Cooke Fiona J., 2003, International Journal of Infectious Diseases, V7, P80, DOI 10.1016/S1201-9712(03)90001-4
   Dimitrov DS, 2003, CELL, V115, P652, DOI 10.1016/S0092-8674(03)00976-0
   Hong SM, 2016, J AGR FOOD CHEM, V64, P2072, DOI 10.1021/acs.jafc.6b00279
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Minkiewicz P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235978
   Sainz B, 2006, VIRUS RES, V120, P146, DOI 10.1016/j.virusres.2006.03.001
   Struck AW, 2012, ANTIVIR RES, V94, P288, DOI 10.1016/j.antiviral.2011.12.012
   Vermeirssen V, 2004, BRIT J NUTR, V92, P357, DOI 10.1079/BJN20041189
   Zhang M, 2019, PLANT FOOD HUM NUTR, V74, P225, DOI 10.1007/s11130-019-00724-y
   Zhao HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22008
   Zhou P, 2018, NUCLEIC ACIDS RES, V46, pW443, DOI 10.1093/nar/gky357
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 15
TC 0
Z9 0
U1 7
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0921-9668
EI 1573-9104
J9 PLANT FOOD HUM NUTR
JI Plant Food Hum. Nutr.
PD DEC
PY 2020
VL 75
IS 4
BP 583
EP 591
DI 10.1007/s11130-020-00850-y
EA SEP 2020
PG 9
WC Plant Sciences; Chemistry, Applied; Food Science & Technology; Nutrition
   & Dietetics
SC Plant Sciences; Chemistry; Food Science & Technology; Nutrition &
   Dietetics
GA OT9DA
UT WOS:000565119800001
PM 32870435
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, TNJ
   Chau, B
   Lui, M
   Lam, GT
   Lin, N
   Humbert, S
AF Wang, Tina J.
   Chau, Brian
   Lui, Mickey
   Giang-Tuyet Lam
   Lin, Nancy
   Humbert, Sarah
TI Physical Medicine and Rehabilitation and Pulmonary Rehabilitation for
   COVID-19
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Pulmonary Rehabilitation; Inpatient Rehabilitation; Multidisciplinary;
   Interdisciplinary Rehabilitation; COVID-19
ID ACUTE RESPIRATORY SYNDROME; EXERCISE CAPACITY; IMPACT; VENTILATION;
   COHORT; COPD; SARS
AB This analysis extrapolates information from previous studies and experiences to bring physical medicine and rehabilitation perspective and intervention to the multidisciplinary treatment of COVID-19. The purpose of pulmonary rehabilitation in COVID-19 patients is to improve symptoms of dyspnea, relieve anxiety, reduce complications, minimize disability, preserve function, and improve quality of life. Pulmonary rehabilitation during the acute management of COVID-19 should be considered when possible and safe and may include nutrition, airway, posture, clearance technique, oxygen supplementation, breathing exercises, stretching, manual therapy, and physical activity. Given the possibility of long-term disability, outpatient posthospitalization pulmonary rehabilitation may be considered in all patients hospitalized with COVID-19.
C1 [Wang, Tina J.; Chau, Brian; Lui, Mickey; Giang-Tuyet Lam; Lin, Nancy; Humbert, Sarah] Loma Linda Univ, Sch Med, Loma Linda Vet Adm Hosp, Dept Phys Med & Rehabil, Loma Linda, CA USA.
RP Wang, TNJ (corresponding author), Dept PM&R, 26001 Redlands Blvd, Redlands, CA 92373 USA.
CR AAPM&R Board of Governors, 2020, AAPM R POS STAT NEC
   Alison JA, 2017, RESPIROLOGY, V22, P800, DOI 10.1111/resp.13025
   Bailey DL, 2019, SEMIN NUCL MED, V49, P58, DOI 10.1053/j.semnuclmed.2018.10.008
   BHUYAN U, 1989, THORAX, V44, P480, DOI 10.1136/thx.44.6.480
   Bissett B, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2783-0
   Boutou AK, 2011, RESPIROLOGY, V16, P451, DOI 10.1111/j.1440-1843.2010.01909.x
   Burtin C, 2012, EUR RESPIR J, V40, P338, DOI 10.1183/09031936.00111811
   CASCIARI RJ, 1981, CHEST, V79, P393, DOI 10.1378/chest.79.4.393
   Chinese Association of Rehabilitation Medicine, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE029, DOI 10.3760/cma.j.cn112147-20200228-00206
   Chlif M, 2015, RESP CARE, V60, P549, DOI 10.4187/respcare.03206
   CRAWFORD ABH, 1989, J APPL PHYSIOL, V66, P2511
   Cullen Deborah L, 2002, Respir Care, V47, P986
   Dentice RL, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-017-0568-2
   Dowman L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006322.pub3
   Elad D, 2008, RESP PHYSIOL NEUROBI, V163, P121, DOI 10.1016/j.resp.2008.05.002
   Fink James B, 2002, Respir Care, V47, P769
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Gosselink R, 2004, Chron Respir Dis, V1, P163, DOI 10.1191/1479972304cd020rs
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   HARMONY W N, 1956, Phys Ther Rev, V36, P106
   Hui DS, 2005, THORAX, V60, P401, DOI 10.1136/thx.2004.030205
   Intensive Care National Audit and Research Centre, 2020, ICNARC REP COVID 19
   Janssens Jean-Paul, 2018, Rev Med Suisse, V14, P2054
   Jenkins S, 2011, INTERN MED J, V41, P416, DOI 10.1111/j.1445-5994.2010.02169.x
   Jones SE, 2018, J THORAC DIS, V10, pS1390, DOI 10.21037/jtd.2018.03.18
   Kang SW, 2000, AM J PHYS MED REHAB, V79, P222, DOI 10.1097/00002060-200005000-00002
   Katz S, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0723-4
   Lim PA, 2004, ARCH PHYS MED REHAB, V85, P1365, DOI 10.1016/j.apmr.2004.01.022
   Lin L, 2020, Zhonghua Yi Xue Za Zhi, V100, pE001, DOI 10.3760/cma.j.issn.0376-2491.2020.0001
   Liu W, 2018, EXP THER MED, V16, P1953, DOI 10.3892/etm.2018.6396
   Maltais F, 2011, AM J RESP CRIT CARE, V184, P381, DOI 10.1164/rccm.201012-2031IM
   Manning F, 1999, PHYS THER, V79, P456, DOI 10.1093/ptj/79.5.456
   Mayer AF, 2018, PHYSIOTHERAPY, V104, P9, DOI 10.1016/j.physio.2017.08.007
   McCormack R, 2017, CLIN MED INSIGHTS-AR, V10, DOI 10.1177/1179544117725026
   McIlwaine M, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0086-2016
   McKoy NA, 2012, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858
   Ngai JC, 2010, RESPIROLOGY, V15, P543, DOI 10.1111/j.1440-1843.2010.01720.x
   Ngai SPC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009953.pub2
   Paiva DN, 2015, REV PORT PNEUMOL, V21, P76, DOI 10.1016/j.rppnen.2014.05.005
   PELOSI P, 1994, AM J RESP CRIT CARE, V149, P8, DOI 10.1164/ajrccm.149.1.8111603
   Puhan MA, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005305.pub4
   Rattes C, 2018, RESP PHYSIOL NEUROBI, V254, P16, DOI 10.1016/j.resp.2018.03.015
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST
   Tang X, 2020, CHEST, V158, P195, DOI 10.1016/j.chest.2020.03.032
   Venkataraman T, 2017, ANTIVIR RES, V143, P142, DOI 10.1016/j.antiviral.2017.03.022
   Vogiatzis I, 2012, COMPR PHYSIOL, V2, P1779, DOI 10.1002/cphy.c110015
   Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x
   Wilson LM, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011231.pub2
   Xie LX, 2005, CHEST, V127, P2119, DOI 10.1378/chest.127.6.2119
   Yang F, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P180, DOI 10.3760/cma.j.issn.1001-0939.2020.03.007
NR 52
TC 1
Z9 1
U1 10
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0894-9115
EI 1537-7385
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD SEP
PY 2020
VL 99
IS 9
BP 769
EP 774
DI 10.1097/PHM.0000000000001505
PG 6
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA NF8PB
UT WOS:000563553900006
PM 32541352
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Antony, A
   Connelly, K
   De Silva, T
   Eades, L
   Tillett, W
   Ayoub, S
   Morand, E
AF Antony, Anna
   Connelly, Kathryn
   De Silva, Thilinie
   Eades, Laura
   Tillett, William
   Ayoub, Sally
   Morand, Eric
TI Perspectives of Patients With Rheumatic Diseases in the Early Phase
   ofCOVID-19
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; INFECTION RISK; UNCERTAINTY
AB Objective To determine health perceptions of patients with rheumatic diseases in the early phase of the coronavirus disease 2019 (COVID-19) pandemic. Methods Rheumatology patients at a single center received via text message the Australian Rheumatology AssociationCOVID-19 information sheet and an invitation to participate in a deidentified survey. Patient concerns regarding risks conferred by their rheumatologic disease or medications, impact of receiving the information sheet on the likelihood of staying on medication, and acceptance of telehealth were ascertained. Results A total of 2,630 patients received the text message, and the survey response rate was 21% (n = 550). The mean +/- SDage of the participants was 52 +/- 15.2 years, and 75.3% were female. Participants' highest ranked concern was that their medications would increase the severity of theirCOVID-19 symptoms (76.1%). The highest levels of concern were seen in patients taking combination conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and/or a biologic/targeted syntheticDMARD. There was no association between prednisolone dose and concern. While 63% of patients planned to continue their antirheumatic medications, a further 30% were more likely to continue taking their medications because of receiving the information. Telehealth was acceptable to 98.4% of patients, but 28.1% felt this was only appropriate while infection control measures were in place. Conclusion Concerns regarding the risk ofCOVID-19 among patients taking antirheumatic drugs are common. Proactive dissemination of information is needed to address misconceptions related to medication risk, improve medication adherence, and minimize the risk of flares. Telehealth is acceptable to most patients during theCOVID-19 pandemic.
C1 [Antony, Anna; Connelly, Kathryn; Ayoub, Sally; Morand, Eric] Monash Univ, Clayton, Vic, Australia.
   [Antony, Anna; Connelly, Kathryn; De Silva, Thilinie; Eades, Laura; Ayoub, Sally; Morand, Eric] Monash Hlth, Clayton, Vic, Australia.
   [Tillett, William] Royal United Hosp NHS Trust, Royal Natl Hosp Rheumat Dis, Bath, Avon, England.
   [Tillett, William] Univ Bath, Bath, Avon, England.
RP Antony, A (corresponding author), Monash Med Ctr, Dept Rheumatol, 246 Clayton Rd, Clayton, Vic 3168, Australia.
EM anna.antony@monash.edu
RI ; Morand, Eric/I-4718-2013
OI Antony, Anna/0000-0002-2459-1736; Morand, Eric/0000-0002-9507-3338
CR Au K, 2011, ANN RHEUM DIS, V70, P785, DOI 10.1136/ard.2010.128637
   Cleanthous S, 2013, PSYCHOL HEALTH, V28, P171, DOI 10.1080/08870446.2012.701628
   Cleanthous S, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0432-8
   Cleanthous S, 2014, RHEUMATOLOGY, V53, P126
   Danza A, 2013, LUPUS, V22, P1286, DOI 10.1177/0961203313493032
   Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524
   DUFFY KNW, 1991, J RHEUMATOL, V18, P1180
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Leggett P, 2001, BRIT J GEN PRACT, V51, P746
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   OBrien J., 2020, CORONAVIRUS COVID 19
   Poulsen KA, 2015, INT J RHEUM DIS, V18, P304, DOI 10.1111/1756-185X.12491
   Smitten AL, 2008, J RHEUMATOL, V35, P387
   Venerito V, 2020, RHEUMATOL INT, V40, P827, DOI 10.1007/s00296-020-04566-9
   Youssef J, 2016, RHEUM DIS CLIN N AM, V42, P157, DOI 10.1016/j.rdc.2015.08.004
NR 15
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
EI 2151-4658
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD SEP
PY 2020
VL 72
IS 9
BP 1189
EP 1195
DI 10.1002/acr.24347
PG 7
WC Rheumatology
SC Rheumatology
GA NG4NA
UT WOS:000563959400001
PM 32526068
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Altmayer, V
   Saheb, S
   Rohaut, B
   Marois, C
   Cao, A
   Gallo, A
   Le Guennec, L
   Weiss, N
   Demeret, S
AF Altmayer, Victor
   Saheb, Samir
   Rohaut, Benjamin
   Marois, Clemence
   Cao, Albert
   Gallo, Antonio
   Le Guennec, Loic
   Weiss, Nicolas
   Demeret, Sophie
TI Therapeutic plasma exchange in a critically ill Covid-19 patient
SO JOURNAL OF CLINICAL APHERESIS
LA English
DT Article; Early Access
DE critically ill Covid-19; cytokine release syndrome; cytokine storm;
   plasma exchange; SARS-CoV-2
AB Here we describe the effect of therapeutic plasma exchange with 5% albumin as sole replacement solution for the management of Covid-19. A 74-year-old man was admitted for severe Covid-19 acute respiratory distress syndrome. Based on the growing body of evidence that cytokine release syndrome, and especially interleukin-6, plays a key role in critically ill Covid-19 patients, we decided to implement therapeutic plasma exchange as a rescue therapy. The patient's clinical status rapidly improved, and biological records showed convincing results of decrease in interleukin-6 and inflammatory parameters under treatment. This case presents a proof-of-concept for the use of therapeutic plasma exchange with 5% albumin as sole replacement solution in a critically ill Covid-19 patient with cytokine release syndrome. This could constitute a major benefit in terms of security compared to long-lasting immunosuppressive monoclonal antibodies, or to therapeutic plasma exchange with plasma as replacement fluid. Hence, we think that a further evaluation of risk-benefit balance of this therapy in severe cases of Covid-19 should rapidly be undertaken.
C1 [Altmayer, Victor; Rohaut, Benjamin; Marois, Clemence; Cao, Albert; Le Guennec, Loic; Weiss, Nicolas; Demeret, Sophie] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Dept Neurol,Unite Med Intens Reanimat Neurol, Paris, France.
   [Saheb, Samir; Gallo, Antonio] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Serv Hematol,Unite Hemobiotherapie, Paris, France.
   [Rohaut, Benjamin] ICM, Inst Cerveau & Moelle Epiniere, Paris, France.
   [Rohaut, Benjamin] INSERM, U1127, Paris, France.
   [Rohaut, Benjamin] CNRS, UMR, Paris, France.
   [Rohaut, Benjamin; Le Guennec, Loic] Sorbonne Univ, Paris, France.
   [Weiss, Nicolas] Sorbonne Univ, Brain Liver Pitie Salpetriere BLIPS Study Grp, Ctr Rech St Antoine Malad Metabol Biliaires & Fib, INSERM,UMR S 938,Inst Cardiometab & Nutr ICAN, Paris, France.
RP Demeret, S (corresponding author), Sorbonne Univ, La Pitie Salpetriere Hosp, AP HP, Neurol ICU,Dept Neurol, 47-83 Blvd Hop, F-75013 Paris, France.
EM sophie.demeret@aphp.fr
RI Rohaut, Benjamin/O-9250-2017; Gallo, Antonio/M-1188-2013
OI Rohaut, Benjamin/0000-0001-6752-8756; Gallo, Antonio/0000-0002-8887-994X
CR Brown BL, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102790
   Colafrancesco S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01439
   Keith P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2836-4
   Knaup H, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2220-9
   Ma J, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108408
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Reeves JH, 2002, BLOOD PURIFICAT, V20, P282, DOI 10.1159/000047021
   Reverberi Roberto, 2007, Blood Transfus, V5, P164, DOI 10.2450/2007.0032-07
   Rimmer E, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0699-2
   Shi H, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105974
   Wang CS, 2020, INTENS CARE MED, V46, P1475, DOI 10.1007/s00134-020-06065-8
   Zhang L, 2020, BRIT J HAEMATOL, V190, pE181, DOI 10.1111/bjh.16890
NR 12
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2459
EI 1098-1101
J9 J CLIN APHERESIS
JI J. Clin. Apheresis
DI 10.1002/jca.21830
EA SEP 2020
PG 4
WC Hematology
SC Hematology
GA NH1WA
UT WOS:000564466100001
PM 32875601
OA Bronze
DA 2021-01-01
ER

PT J
AU Blasi, A
   von Meijenfeldt, FA
   Adelmeijer, J
   Calvo, A
   Ibanez, C
   Perdomo, J
   Reverter, JC
   Lisman, T
AF Blasi, Annabel
   von Meijenfeldt, Fien A.
   Adelmeijer, Jelle
   Calvo, Andrea
   Ibanez, Cristina
   Perdomo, Juan
   Reverter, Juan C.
   Lisman, Ton
TI In vitro hypercoagulability and ongoing in vivo activation of
   coagulation and fibrinolysis in COVID-19 patients on anticoagulation
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE anticoagulation; coagulation; COVID-19; fibrinolysis
ID THROMBIN
AB Background COVID-19 is associated with a substantial risk of venous thrombotic events, even in the presence of adequate thromboprophylactic therapy. Objectives We aimed to better characterize the hypercoagulable state of COVID-19 patients in patients receiving anticoagulant therapy. Methods We took plasma samples of 23 patients with COVID-19 who were on prophylactic or intensified anticoagulant therapy. Twenty healthy volunteers were included to establish reference ranges. Results COVID-19 patients had a mildly prolonged prothrombin time, high von Willebrand factor levels and low ADAMTS13 activity. Most rotational thromboelastometry parameters were normal, with a hypercoagulable maximum clot firmness in part of the patients. Despite detectable anti-activated factor X activity in the majority of patients, ex vivo thrombin generation was normal, and in vivo thrombin generation elevated as evidenced by elevated levels of thrombin-antithrombin complexes and D-dimers. Plasma levels of activated factor VII were lower in patients, and levels of the platelet activation marker soluble CD40 ligand were similar in patients and controls. Plasmin-antiplasmin complex levels were also increased in patients despite an in vitro hypofibrinolytic profile. Conclusions COVID-19 patients are characterized by normal in vitro thrombin generation and enhanced clot formation and decreased fibrinolytic potential despite the presence of heparin in the sample. Anticoagulated COVID-19 patients have persistent in vivo activation of coagulation and fibrinolysis, but no evidence of excessive platelet activation. Ongoing activation of coagulation despite normal to intensified anticoagulant therapy indicates studies on alternative antithrombotic strategies are urgently required.
C1 [Blasi, Annabel; Calvo, Andrea; Ibanez, Cristina; Perdomo, Juan] Univ Barcelona, Anesthesiol Dept, Hosp Clin, Inst Invest Biomed Agusti Pi & Sunyer IDIBAPS, Barcelona, Spain.
   [von Meijenfeldt, Fien A.; Adelmeijer, Jelle; Lisman, Ton] Univ Groningen, Surg Res Lab, Dept Surg, Univ Med Ctr Groningen, Groningen, Netherlands.
   [Reverter, Juan C.] Hosp Clin Barcelona, Dept Hemostasis, Agusti Pi & Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain.
RP Lisman, T (corresponding author), Univ Med Ctr Groningen, Dept Surg, BA33,Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM j.a.lisman@umcg.nl
OI Lisman, Ton/0000-0002-3503-7140; Ibanez-Esteve,
   Cristina/0000-0002-9774-4836
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Blasi A, 2020, HEPATOLOGY, V71, P1381, DOI 10.1002/hep.30915
   Bos S, 2019, THROMB HAEMOSTASIS, V119, P246, DOI 10.1055/s-0038-1676954
   Buja LM, 2020, CARDIOVASC PATHOL, V48, DOI 10.1016/j.carpath.2020.107233
   Ciceri Fabio, 2020, Crit Care Resusc, V22, P95
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Hunt BJ, 2020, BRIT J HAEMATOL, V190, pE133, DOI 10.1111/bjh.16907
   Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959
   Kleiss SF, 2016, THROMB RES, V140, P36, DOI 10.1016/j.thromres.2016.02.011
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lisman T, 2012, J THROMB HAEMOST, V10, P1312, DOI 10.1111/j.1538-7836.2012.04770.x
   Lisman T, 2003, BLOOD COAGUL FIBRIN, V14, P557, DOI 10.1097/00001721-200309000-00007
   Lisman T, 2019, LIVER TRANSPLANT, V25, P359, DOI 10.1002/lt.25412
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Meltzer ME, 2008, PLOS MED, V5, P751, DOI 10.1371/journal.pmed.0050097
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Schut AM, 2015, J THROMB HAEMOST, V13, P1320, DOI 10.1111/jth.12980
   Thachil J, 2020, SEMIN THROMB HEMOST, V46, P777, DOI 10.1055/s-0040-1712155
   von Meijenfeldt FA, 2018, LIVER TRANSPLANT, V24, P1716, DOI 10.1002/lt.25329
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wright FL, 2020, J AM COLL SURGEONS, V231, P193, DOI 10.1016/j.jamcollsurg.2020.05.007
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 27
TC 6
Z9 6
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD OCT
PY 2020
VL 18
IS 10
BP 2646
EP 2653
DI 10.1111/jth.15043
EA SEP 2020
PG 8
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA NU9GL
UT WOS:000564295500001
PM 32762118
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hoerger, M
   Alonzi, S
   Perry, LM
   Voss, HM
   Easwar, S
   Gerhart, JI
AF Hoerger, Michael
   Alonzi, Sarah
   Perry, Laura M.
   Voss, Hallie M.
   Easwar, Sanjana
   Gerhart, James I.
TI Impact of the COVID-19 Pandemic on Mental Health: Real-Time Surveillance
   Using Google Trends
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE pandemic; anxiety; mindfulness; Internet-based therapy; search engine
AB In the wake of COVID-19, the capacity to track emerging trends in mental health symptoms and needs will guide public health responses at multiple ecological levels. Using Google Trends to track population-level mental health-related Google searches in the United States, this investigation identified pandemic-associated spikes in searches related to anxiety symptoms and remote treatments for anxiety. such as deep breathing and body scan meditation. As other discernable population-level changes in mental health have yet to emerge, continued surveillance is warranted.
C1 [Hoerger, Michael] Tulane Univ, Dept Psychol, Tulane Canc Ctr, New Orleans, LA 70118 USA.
   [Hoerger, Michael] Tulane Univ, Dept Psychiat, Tulane Canc Ctr, New Orleans, LA 70118 USA.
   [Hoerger, Michael] Tulane Univ, Dept Med, Tulane Canc Ctr, New Orleans, LA 70118 USA.
   [Hoerger, Michael] Tulane Univ, AB Freeman Sch Business, New Orleans, LA 70118 USA.
   [Alonzi, Sarah] Loyola Univ, Dept Psychol, New Orleans, LA 70118 USA.
   [Perry, Laura M.; Voss, Hallie M.; Easwar, Sanjana] Tulane Univ, Dept Psychol, 6400 Freret St,Stern Hall 3070, New Orleans, LA 70118 USA.
   [Gerhart, James I.] Cent Michigan Univ, Dept Psychol, Mt Pleasant, MI 48859 USA.
RP Hoerger, M (corresponding author), Tulane Univ, Dept Psychol, 6400 Freret St,Stern Hall 3070, New Orleans, LA 70118 USA.
EM mhoerger@tulane.edu
OI Alonzi, Sarah/0000-0001-8775-7281
CR Choi HY, 2012, ECON REC, V88, P2, DOI 10.1111/j.1475-4932.2012.00809.x
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Nuti SV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109583
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Stephens-Davidowitz S., 2017, EVERYBODY LIES BIG D
NR 5
TC 0
Z9 0
U1 10
U2 10
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD SEP
PY 2020
VL 12
IS 6
BP 567
EP 568
DI 10.1037/tra0000872
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA NF1AP
UT WOS:000563034700001
PM 32790441
DA 2021-01-01
ER

PT J
AU Webb, J
   Shah, LD
   Lynch, HF
AF Webb, Jamie
   Shah, Lesha D.
   Lynch, Holly Fernandez
TI Ethically Allocating COVID-19 Drugs Via Pre-approval Access and
   Emergency Use Authorization
SO AMERICAN JOURNAL OF BIOETHICS
LA English
DT Article
DE Biomedical research; health policy; human subjects research;
   pharmaceutical industry; research ethics; rationing; resource allocation
AB Allocating access to unapproved COVID-19 drugs available via Pre-Approval Access pathways or Emergency Use Authorization raises unique challenges at the intersection of clinical care and research. In conditions of scarcity, prioritization approaches should minimize harm, maximize benefit, and promote fairness. To promote continued data collection, patients seeking access to unproven COVID-19 drugs should receive lower priority for allocation when they decline to participate in clinical trials, either of the requested drug or other investigational products, offering a comparable balance of risks and benefits; special attention should be paid to concerns of voluntariness and distrust. In addition, institutional treatment protocols that can contribute more robust real world data should be preferred to single patient requests for access, with priority for inclusion based on traditional clinical allocation criteria relying on available evidence. Fairness demands distribution of these protocols across a diverse range of sites, particularly those serving marginalized populations, among other protections.
C1 [Webb, Jamie] NYU, Grossman Sch Med, New York, NY 10003 USA.
   [Shah, Lesha D.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Lynch, Holly Fernandez] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Lynch, HF (corresponding author), Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.
EM lynchhf@pennmedicine.upenn.edu
OI Shah, Lesha/0000-0003-0656-5240
FU Greenwall Foundation
FX Holly Fernandez Lynch receives research funding from the Greenwall
   Foundation.
CR Abdallah H., 2020, PHILADELPHIA INQUIRE
   Adams B., 2020, GILEAD SHARES SLIP 2
   [Anonymous], 2020, NY TIMES
   Azad A., 2020, CNN
   Baumann J., 2020, BLOOMBERG LAW
   Beauchamp T.L., 2009, PRINCIPLES BIOMEDICA
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Biospace, 2020, PLUR REP PREL DAT IT
   Boodman E, 2020, STAT
   Byrd JB, 2020, CIRCULATION, V141, P2045, DOI 10.1161/CIRCULATIONAHA.120.047347
   Caplan AL, 2018, J MED ETHICS, V44, P761, DOI 10.1136/medethics-2016-103917
   Centers for Disease Control and Prevention, 2020, COVID 19 RAC ETHN MI
   Centers for Disease Control and Prevention, 2020, CHAR HLTH CAR PERS C
   Chen D. T., 2020, PRIORITIZE HLTH CARE
   Cohen G., 2015, IDENTIFIED VERSUS ST
   Collins FS, 2020, JAMA-J AM MED ASSOC, V323, P2455, DOI 10.1001/jama.2020.8920
   Crutchfield P., 2020, COMMUNITIES HLTH DIS
   DeJong C, 2020, JAMA-J AM MED ASSOC, V323, P2367, DOI 10.1001/jama.2020.8914
   Dunn A, 2020, BUSINESS INSIDER
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   European Biotechnology, 2020, COVID 19 SOLN APPR C
   Facher L, 2020, STAT
   Fajgenbaum DC, 2020, INFECT DIS THER, V9, P435, DOI 10.1007/s40121-020-00303-8
   Folkers K. M., 2020, WAKE FOREST J LAW PU
   Frakt A, 2020, NY TIMES
   Gilead Sciences, 2020, GIL SCI STAT ACC REM
   Griffith DM, 2020, J GEN INTERN MED, V35, P2969, DOI 10.1007/s11606-020-05868-1
   Herper M., 2020, STAT
   Ison MG, 2020, JAMA-J AM MED ASSOC, V323, P2365, DOI 10.1001/jama.2020.8863
   Jecker NS, 2020, AM J BIOETHICS, V20, P128, DOI 10.1080/15265161.2020.1764140
   Johns Hopkins Institute for Clinical & Translational Research, 2020, COVID 19 J HOPK CLIN
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Kapczynski A, 2018, MINN LAW REV, V102, P2357
   Kolata G, 2020, NY TIMES
   Krebs CK, 2020, ADVISORY MEMORANDUM
   Largent Emily A, 2017, IRB, V39, P1
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Lim S, 2020, MAYO CLIN PROC, V95, P1946, DOI 10.1016/j.mayocp.2020.06.016
   Lowe D., 2020, SCI TRANSLATIONAL ME
   Lynch HF, 2020, J LAW MED ETHICS, V48, P365, DOI 10.1177/1073110520935352
   McGuire AL, 2020, AM J BIOETHICS, V20, P15, DOI 10.1080/15265161.2020.1764138
   Millum J, 2019, AM J BIOETHICS, V19, P21, DOI 10.1080/15265161.2019.1630497
   Minnesota Department of Health, 2020, ETH FRAM MAY 2020 AL
   Oppell R. A., 2020, NY TIMES
   Pan American Health Organization (PAHO), 2020, EM US UNPR INT OUTS
   Penn Medicine, 2020, REMD EM US AUTH GUID
   Pennsylvania Department of Health, 2020, ETH ALL FRAM EM TREA
   Piller C., 2020, SCI MAGAZINE
   Polak TB, 2020, BRIT J CLIN PHARMACO, V86, P1819, DOI 10.1111/bcp.14284
   Rome BN, 2020, NEW ENGL J MED, V382, P2282, DOI 10.1056/NEJMp2009457
   Rosenbaum S, 2018, COMMUNITY HLTH CTR G
   Sarpatwari A, 2020, JAMA-J AM MED ASSOC, V324, P331, DOI 10.1001/jama.2020.11932
   Savulescu J, 2020, BRIT J ANAESTH, V125, P253, DOI 10.1016/j.bja.2020.05.028
   Scharff DP, 2010, J HEALTH CARE POOR U, V21, P879, DOI 10.1353/hpu.0.0323
   SILVERMAN E., 2020, STAT
   Sokol D., 2020, BMJ OPINION
   Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689
   U.S. COVID Plasma, 2020, COVID 19 EXP ACC PRO
   U.S. Food & Drug Administration, 2020, LETT REV EUA CHLOR P
   U.S. Food & Drug Administration (FDA), 2020, CHLOR PHOSPH HYDR SU
   U.S. Food & Drug Administration (FDA), 2020, EXP ACC COMP US SUBM
   U.S. Food & Drug Administration (FDA), 2020, REMD EM US AUTH LETT
   U.S. Food & Drug Administration (FDA), 2016, GUID IND EXP ACC INV
   U.S. Food & Drug Administration (FDA), 2017, GUID IND OTH STAK EM
   U.S. Food & Drug Administration (FDA) B, 2020, EM US AUTH ARCH INF
   University of Pittsburgh School of Medicine (Pitt), 2020, ALL SCARC CRIT CAR R
   US Food and Drug Administration, 2020, EM US AUTH
   Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598
   Wertheimer A., 2014, COERCION
   White DB, 2020, JAMA-J AM MED ASSOC, V324, P329, DOI 10.1001/jama.2020.11464
   WHO, 2016, GUID MAN ETH ISS INF
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Zhai MZ, 2020, JAMA INTERN MED, V180, P1145, DOI 10.1001/jamainternmed.2020.2402
NR 73
TC 11
Z9 11
U1 2
U2 2
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1526-5161
EI 1536-0075
J9 AM J BIOETHICS
JI Am. J. Bioeth.
PD SEP 1
PY 2020
VL 20
IS 9
BP 4
EP 17
DI 10.1080/15265161.2020.1795529
PG 14
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA NE3LU
UT WOS:000562501500003
OA Bronze
DA 2021-01-01
ER

PT J
AU Webb, J
   Shah, L
   Lynch, HF
AF Webb, Jaime
   Shah, Lesha
   Lynch, Holly Fernandez
TI No Easy Answers in Allocating Unapproved COVID-19 Drugs Outside Clinical
   Trials
SO AMERICAN JOURNAL OF BIOETHICS
LA English
DT Letter
C1 [Webb, Jaime] NYU, Sch Med, New York, NY USA.
   [Shah, Lesha] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Lynch, Holly Fernandez] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Lynch, HF (corresponding author), Univ Penn, Perelman Sch Med, Med Eth & Hlth Policy, Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM lynchhf@pennmedicine.upenn.edu
OI Shah, Lesha/0000-0003-0656-5240
FU Greenwall Foundation
FX Holly Fernandez Lynch receives research funding from the Greenwall
   Foundation.
CR Edwards SJL, 2020, AM J BIOETHICS, V20, P39, DOI 10.1080/15265161.2020.1795516
   Gelinas L, 2020, AM J BIOETHICS, V20, P23, DOI 10.1080/15265161.2020.1795547
   Hamilton KW, 2020, AM J BIOETHICS, V20, P20, DOI 10.1080/15265161.2020.1795548
   Jefferson AA, 2020, AM J BIOETHICS, V20, P33, DOI 10.1080/15265161.2020.1795541
   Malhi GS, 2020, AM J BIOETHICS, V20, P36, DOI 10.1080/15265161.2020.1795537
   Master ZB, 2020, AM J BIOETHICS, V20, P26, DOI 10.1080/15265161.2020.1795540
   Mastroleo I, 2020, AM J BIOETHICS, V20, P41, DOI 10.1080/15265161.2020.1795539
   Spector-Bagdady K, 2020, AM J BIOETHICS, V20, P77, DOI 10.1080/15265161.2020.1779409
   Tomlinson T, 2020, AM J BIOETHICS, V20, P29, DOI 10.1080/15265161.2020.1795534
   Weber E, 2020, AM J BIOETHICS, V20, P31, DOI 10.1080/15265161.2020.1795538
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1526-5161
EI 1536-0075
J9 AM J BIOETHICS
JI Am. J. Bioeth.
PD SEP 1
PY 2020
VL 20
IS 9
BP W1
EP W4
DI 10.1080/15265161.2020.1805525
PG 4
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA NE3LU
UT WOS:000562501500001
PM 32840448
DA 2021-01-01
ER

PT J
AU Son, M
   Seo, J
   Yang, S
AF Son, Minkook
   Seo, Jeongkuk
   Yang, Sung
TI Association Between Renin-Angiotensin-Aldosterone System Inhibitors and
   COVID-19 Infection in South Korea
SO HYPERTENSION
LA English
DT Article
DE antihypertensive agents; COVID-19; hypertension; Republic of Korea;
   renin-angiotensin system
ID CONVERTING ENZYME-2
AB The severe acute respiratory syndrome coronavirus 2 is known to infect host cells by interacting with ACE2 (angiotensin-converting enzyme 2) expressed in the respiratory epithelium. There have been concerns on whether alterations of ACE2 expression by renin-angiotensin-aldosterone system (RAAS) inhibitors would contribute to the infectivity and severity of coronavirus disease 2019 (COVID-19). We performed a case-control study to investigate the association between RAAS inhibitors and risk and severity of COVID-19 infection in South Korea using the population-based data provided by the Korean National Health Insurance System. Of 16 281 subjects with hypertension, there were 950 (5.8%) confirmed COVID-19 cases. After case-control matching, multivariable-adjusted conditional logistic regression analysis was performed. The adjusted odds ratio and 95% CIs for COVID-19 infection and long-term hospitalization comparing exposure to RAAS inhibitors and nonexposure to RAAS inhibitors was 1.161 (0.958-1.407) and 0.863 (0.533-1.397), respectively. When comparing exposure to RAAS inhibitors and nonexposure to RAAS inhibitors for intensive care unit admission, high-flow oxygen therapy, and death, the adjusted odds ratios (95% CIs) were 1.515 (0.402-5.701), 0.663 (0.272-1.619), and 1.363 (0.513-3.662), respectively. In all analyses,Pvalues were not significant (P>0.05). The present study demonstrates the absence of an identifiable association between the exposure to RAAS inhibitors and risk and severity of COVID-19 infection, supporting the current medical guidelines and recommendations that patients should not discontinue RAAS inhibitors out of a concern that they are at increased risk for infection or severe illness of COVID-19.
C1 [Son, Minkook; Yang, Sung] Gwangju Inst Sci & Technol, Dept Biomed Sci & Engn, Gwangju, South Korea.
   [Yang, Sung] Gwangju Inst Sci & Technol, Sch Mech Engn, Gwangju, South Korea.
   [Seo, Jeongkuk] Armed Forces Goyang Hosp, Dept Internal Med, Goyang Si, South Korea.
RP Yang, S (corresponding author), Gwangju Inst Sci & Technol, Sch Mech Engn, Dept Biomed Sci & Engn, 123 Cheomdan Gwagiro, Gwangju 61005, South Korea.
EM syang@gist.ac.kr
CR Ahmed F, 2020, LANCET PUBLIC HEALTH, V5, pE240, DOI 10.1016/S2468-2667(20)30085-2
   Berlin David A, 2020, N Engl J Med, V383, P2451, DOI 10.1056/NEJMcp2009575
   Bever Lindsey, 2014, WASHINGTON POST
   Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   de Groot V, 2003, J CLIN EPIDEMIOL, V56, P221, DOI 10.1016/S0895-4356(02)00585-1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hong KH, 2020, ANN LAB MED, V40, P351, DOI 10.3343/alm.2020.40.5.351
   Hwang S, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0534-7
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   KCDC, 2020, UPD COVID 19 KOR MAY
   Kim AM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17041244
   Kim JA, 2018, DIABETES CARE, V41, P2610, DOI 10.2337/dc18-0802
   Kim MK, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050755
   Kim YJ, 2019, J KOREAN MED SCI, V34, DOI 10.3346/jkms.2019.34.e1
   Korean Society Hypertension (KSH), 2018, Clin Hypertens, V24, P13, DOI 10.1186/s40885-018-0098-0
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Lee G, 2018, J AM HEART ASSOC, V7, DOI [10.1161/jaha.117.007723, 10.1161/JAHA.117.007723]
   Lee SR, 2019, STROKE, V50, P2245, DOI 10.1161/STROKEAHA.119.025536
   Li JY, 2020, DIABETES OBES METAB, V22, P1935, DOI 10.1111/dom.14057
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Patanavanich R, 2020, NICOTINE TOB RES, V22, P1653, DOI 10.1093/ntr/ntaa082
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Shim E, 2020, INT J INFECT DIS, V93, P339, DOI 10.1016/j.ijid.2020.03.031
   Shojaee Sajad, 2020, Gastroenterol Hepatol Bed Bench, V13, P177
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   World Health Organization, 2020, 106 WHO
   Xing GA, 2010, GENET EPIDEMIOL, V34, P769, DOI 10.1002/gepi.20526
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 34
TC 4
Z9 4
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0194-911X
EI 1524-4563
J9 HYPERTENSION
JI Hypertension
PD SEP
PY 2020
VL 76
IS 3
BP 742
EP 749
DI 10.1161/HYPERTENSIONAHA.120.15464
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA NE5NO
UT WOS:000562647300020
PM 32654557
DA 2021-01-01
ER

PT J
AU Kostev, K
   Kumar, S
   Konrad, M
   Bohlken, J
AF Kostev, Karel
   Kumar, Sachin
   Konrad, Marcel
   Bohlken, Jens
TI Prescription rates of cardiovascular and diabetes therapies prior to and
   during the COVID-19 lockdown in Germany
SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE COVID-19; coronavirus; adherence; hypertension; diabetes; Germany;
   cross-sectional study
AB Aims: The aim of this study was to examine the development in the number of patients receiving cardiovascular or antidiabetic medications from pharmacies in the first quarter of 2020. Methods: This cross-sectional study was based on the data from more than 10 million patients in the IMS longitudinal prescription (LRx) database. The outcome of this study was the development in the number of patients receiving cardiovascular or diabetic medications from pharmacies in January, February, and March 2020, compared to January, February, and March 2019. Results: From March 2019 to March 2020, there was a 39% increase in angiotensin II antagonist prescriptions, a 33% increase in lipid-lowering drug prescriptions, a 32% increase in calcium channel blocker (CCB) prescriptions, a 30% increase in beta blocker prescriptions, a 27% increase in angiotensin-converting enzyme (ACE) inhibitor, vitamin k antagonist (VKA), and oral antidiabetic prescriptions, a 24% increase in diuretic prescriptions, and an 18% increase in insulin prescriptions. The largest increase was found in the age group of 18 - 40 years (e.g., 57% for VKA, 52% for CCB and angiotensin II antagonists), and the smallest increase occurred in the age group over 80 years (for example, 10% for VKA, 9% for oral antidiabetics, and 3% for insulins). Conclusion: The number of patients receiving their drugs from pharmacies was significantly higher in March 2020 than in March 2019, which is an indication of good therapy adherence. Additional studies are needed to examine adherence during the COVID-19 pandemic and possible age differences in adherence.
C1 [Kostev, Karel] IQVIA, Epidemiol, Unterschweinstiege 2-14, D-60549 Frankfurt, Germany.
   [Kumar, Sachin] IQVIA, Bangalore, Karnataka, India.
   [Konrad, Marcel] FOM Univ Appl Sci Econ & Management, Frankfurt, Germany.
   [Bohlken, Jens] Univ Leipzig, Inst Social Med Occupat Med & Publ Hlth ISAP, Med Fac, Leipzig, Germany.
RP Kostev, K (corresponding author), IQVIA, Epidemiol, Unterschweinstiege 2-14, D-60549 Frankfurt, Germany.
EM karel.kostev@iqvia.com
OI Konrad, Marcel/0000-0001-6798-5092
CR [Anonymous], 2014, DIABETES RES CLIN PR, V104, P1, DOI 10.1016/j.diabres.2012.10.001
   [Anonymous], RAIS BLOOD PRESS
   [Anonymous], 2015, J HUM HYPERTENS, V29, P247
   Arafat SMY, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113061
   Bickel H, 2018, DTSCH ARZTEBL INT, V115, P733, DOI 10.3238/arztebl.2018.0733
   Bluher Matthias, 2015, Clin Diabetes, V33, P55, DOI 10.2337/diaclin.33.2.55
   Bonora BM, 2020, DIABETES THER, V11, P1369, DOI 10.1007/s13300-020-00829-7
   Chudiak A, 2018, CLIN INTERV AGING, V13, P1409, DOI 10.2147/CIA.S162701
   Goffrier B, 2017, ADM PRAVALENZEN INZI
   Gossen N, 2016, RHEUMATOL INT, V36, P1113, DOI 10.1007/s00296-016-3448-9
   Hagge D, 2020, HNO, V68, P433, DOI 10.1007/s00106-020-00864-7
   Heidemann C, 2013, BUNDESGESUNDHEITSBLA, V56, P668, DOI 10.1007/s00103-012-1662-5
   Holstiege J, 2020, DIAGNOSEPRAVALENZ HY
   Kang LJ, 2020, BRAIN BEHAV IMMUN, V87, P11, DOI 10.1016/j.bbi.2020.03.028
   Kap E, 2019, INT J CLIN PHARM TH, V57, P329, DOI 10.5414/CP203410
   Kaye L, 2020, J ALLER CL IMM-PRACT, V8, P2384, DOI 10.1016/j.jaip.2020.04.053
   Korzilius H., 2020, DTSCH ARZTEBL, V117
   Kretchy I.A., 2020, RES SOCIAL ADM PHARM
   Mendes Rosa, 2019, J Clin Med Res, V11, P583, DOI 10.14740/jocmr3894
   Richter H, 2015, GER MED SCI, V13, pDoc14, DOI 10.3205/000218
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Trethewey SP, 2020, BR J GEN PRACT, V70
   Uchmanowicz B, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00168
   Vrijens B, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00100
   Williams B, 2018, J HYPERTENS, V36, P1953, DOI 10.1097/HJH.0000000000001940
   Yuen KF, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103513
NR 26
TC 0
Z9 0
U1 2
U2 2
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0946-1965
J9 INT J CLIN PHARM TH
JI Int. J. Clin. Pharmacol. Ther.
PD SEP
PY 2020
VL 58
IS 9
BP 475
EP 481
DI 10.5414/CP203849
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NE9LJ
UT WOS:000562924600003
PM 32729826
DA 2021-01-01
ER

PT J
AU Capone, CA
   Subramony, A
   Sweberg, T
   Schneider, J
   Shah, S
   Rubin, L
   Schleien, C
   Epstein, S
   Johnson, JC
   Kessel, A
   Misra, N
   Mitchell, E
   Palumbo, N
   Rajan, S
   Rocker, J
   Williamson, K
   Davidson, KW
AF Capone, Christine A.
   Subramony, Anupama
   Sweberg, Todd
   Schneider, James
   Shah, Sareen
   Rubin, Lorry
   Schleien, Charles
   Epstein, Shilpi
   Johnson, Jennifer C.
   Kessel, Aaron
   Misra, Nila
   Mitchell, Elizabeth
   Palumbo, Nancy
   Rajan, Sujatha
   Rocker, Josh
   Williamson, Kristy
   Davidson, Karina W.
CA Northwell Hlth COVID-19 Res Consor
TI Characteristics, Cardiac Involvement, and Outcomes of Multisystem
   Inflammatory Syndrome of Childhood Associated with severe acute
   respiratory syndrome coronavirus 2 Infection
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID KAWASAKI-DISEASE; SHOCK
AB We report on the presentation and course of 33 children with multisystem inflammatory syndrome in children and confirmed severe acute respiratory syndrome coronavirus 2 infection. Hemodynamic instability and cardiac dysfunction were prominent findings, with most patients exhibiting rapid resolution following anti-inflammatory therapy.
C1 [Capone, Christine A.; Subramony, Anupama; Sweberg, Todd; Schneider, James; Shah, Sareen; Rubin, Lorry; Schleien, Charles; Epstein, Shilpi; Kessel, Aaron; Misra, Nila; Mitchell, Elizabeth; Palumbo, Nancy; Rajan, Sujatha; Rocker, Josh; Williamson, Kristy; Davidson, Karina W.] Northwell Hlth, Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Pediat, Hempstead, NY USA.
   [Capone, Christine A.; Subramony, Anupama; Sweberg, Todd; Schneider, James; Shah, Sareen; Rubin, Lorry; Schleien, Charles; Epstein, Shilpi; Kessel, Aaron; Misra, Nila; Mitchell, Elizabeth; Palumbo, Nancy; Rajan, Sujatha; Rocker, Josh; Williamson, Kristy] Northwell Hlth, Cohen Childrens Med Ctr, New Hyde Pk, NY USA.
   [Johnson, Jennifer C.; Davidson, Karina W.] Northwell Hlth, Feinstein Inst Med Res, Inst Hlth Innovat & Outcomes Res, Manhasset, NY USA.
RP Schleien, C (corresponding author), Donald & Barbara Zucker Sch Med Hofstra Northwell, Pediat, 269-01 76th Ave, New Hyde Pk, NY 11040 USA.
EM cschleien@northwell.edu
OI Shah, Sareen/0000-0002-0510-9326; Schleien, Charles
   L/0000-0001-5748-5588
FU NIA NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [R24 AG064191] Funding Source: Medline; NLM NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Library of Medicine (NLM) [R01 LM012836] Funding
   Source: Medline
CR Baer AZ, 2006, ARCH PEDIAT ADOL MED, V160, P686, DOI 10.1001/archpedi.160.7.686
   Dionne A, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-3341
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Esper F, 2005, J INFECT DIS, V191, P499, DOI 10.1086/428291
   Kanegaye JT, 2009, PEDIATRICS, V123, pE783, DOI 10.1542/peds.2008-1871
   McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Rowley AH, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00374
   Schuster JE, 2017, J PEDIAT INF DIS SOC, V6, P386, DOI 10.1093/jpids/piw081
   Shekerdemian LS, 2020, JAMA PEDIATR, V174, P868, DOI 10.1001/jamapediatrics.2020.1948
   Shulman ST, 2020, J PEDIAT INF DIS SOC, V9, P285, DOI 10.1093/jpids/piaa062
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Zhang T, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P496, DOI 10.3760/cma.j.cn112147-20200311-00312
NR 15
TC 20
Z9 20
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD SEP
PY 2020
VL 224
BP 141
EP 145
DI 10.1018/j.jpeds.2020.08.044
PG 5
WC Pediatrics
SC Pediatrics
GA NE2FD
UT WOS:000562411900030
PM 32553873
DA 2021-01-01
ER

PT J
AU Weinberg, MS
   Patrick, RE
   Schwab, NA
   Owoyemi, P
   May, R
   McManus, AJ
   Gerber, J
   Harper, DG
   Arnold, SE
   Forester, B
AF Weinberg, Marc Scott
   Patrick, Regan E.
   Schwab, Nadine A.
   Owoyemi, Praise
   May, Rose
   McManus, Alison J.
   Gerber, Jessica
   Harper, David G.
   Arnold, Steven E.
   Forester, Brent
TI Clinical Trials and Tribulations in the COVID-19 Era
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Alzheimer disease; clinical trials; geriatrics; telemedicine
AB Advances in treating and preventing Alzheimer disease and other neurocognitive disorders of aging arise from rigorous preclinical and clinical research, with randomized controlled treatment trials as the last and definitive test. The COVID-19 pandemic has greatly disrupted ongoing interventional studies and researchers are scrambling to find ways to safely continue this critical work amidst rapidly shifting guidelines from sponsors, institutions, and state and federal guidelines. Here the authors describe novel approaches and work-flow adaptations to study visits, drug delivery and interim and endpoint safety and outcomes assessments to avoid sacrificing years of preparation and substantial financial investments, to work in the best interest of participants and their caregivers, and to continue on the path toward discovering disease-modifying treatments for the millions of individuals impacted by major neurocognitive disorders.
C1 Massachusetts Gen Hosp, Alzheimers Clin & Translat Res Unit, Boston, MA 02114 USA.
   McLean Hosp, Geriatr Psychiat Res Program, 115 Mill St, Belmont, MA 02178 USA.
   Harvard Med Sch, Boston, MA 02115 USA.
   [Weinberg, Marc Scott] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
   McLean Hosp, Adult Psychiat Residency Program, 115 Mill St, Belmont, MA 02178 USA.
   McLean Hosp, Dept Neuropsychol, 115 Mill St, Belmont, MA 02178 USA.
RP Weinberg, MS (corresponding author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
EM marc.weinberg@mgh.harvard.edu
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [R21 TR003040] Funding Source: Medline;
   NIMH NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R25 MH094612, R25 MH058818] Funding Source: Medline
CR American Psychological Association, OFF TECHN CHECKL TEL
   [Anonymous], 2020, ALZHEIMERS DEMENT, V16, P391, DOI 10.1002/alz.12068
   Belleville S, 2017, NEUROPSYCHOL REV, V27, P328, DOI 10.1007/s11065-017-9361-5
   Brearly TW, 2017, NEUROPSYCHOL REV, V27, P174, DOI 10.1007/s11065-017-9349-1
   Carotenuto A, 2018, JMIR MENT HEALTH, V5, DOI [10.2196/menta1.8097, 10.2196/mental.8097]
   Castanho Teresa Costa, 2017, J Alzheimers Dis Rep, V1, P15, DOI 10.3233/ADR-170007
   Conlon M, 2020, AM J GERIAT PSYCHIAT, V28, P368, DOI 10.1016/j.jagp.2019.07.006
   FDA, 2020, FDA GUID COND CLIN T
   Higgins-Dunn N., 2020, CNBC
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Inter Organizational Practice Committee, TEL NEUR COVID 19 PA
   Miller JB, 2017, ARCH CLIN NEUROPSYCH, V32, P541, DOI 10.1093/arclin/acx050
   Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704
   Qureshi Irfan A, 2018, Alzheimers Dement (N Y), V4, P746, DOI 10.1016/j.trci.2018.10.007
   Swanson C, 2019, P 2019 CLIN TRIALS A
   Swanson C.J., 2018, ALZHEIMERS DEMENT, V14, pP1668, DOI [10.1016/j.jalz.2018.07.009, DOI 10.1016/J.JALZ.2018.07.009]
   Wadsworth HE, 2018, ARCH CLIN NEUROPSYCH, V33, P1040, DOI 10.1093/arclin/acx140
   Wang DC, 2020, SURG INFECT, DOI 10.1089/sur.2020.133
   Watson JL, 2014, HEALTH AFFAIR, V33, P574, DOI 10.1377/hlthaff.2013.1314
   Yoshida K, 2019, J TELEMED TELECARE
NR 20
TC 5
Z9 5
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD SEP
PY 2020
VL 28
IS 9
BP 913
EP 920
DI 10.1016/j.jagp.2020.05.016
PG 8
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA NE1WB
UT WOS:000562387600002
PM 32507686
OA Green Published
DA 2021-01-01
ER

PT J
AU van Dijk, SDM
   Bouman, R
   Folmer, EH
   den Held, RC
   Warringa, JE
   Marijnissen, RM
   Voshaar, RCO
AF van Dijk, Silvia Dian Maria
   Bouman, Renske
   Folmer, Ewa H.
   den Held, Roos C.
   Warringa, Janet E.
   Marijnissen, Radboud M.
   Voshaar, Richard C. Oude
TI (Vi)-rushed Into Online Group Schema Therapy Based Day-Treatment for
   Older Adults by the COVID-19 Outbreak in the Netherlands
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Online multidisciplinary group therapy; schema therapy; aged; cognitive
   behavior therapy; Covid-19
ID DEPRESSION
AB Background: Societal measures in context of the COVID-19 outbreak forced us to transform our schema therapy based day-treatment for older adults with chronic affective disorders and personality problems into an online program. The objective of this paper is to present first impressions of this transformation. Methods: Using over-the-phone instructions initially, all patients were able to participate with the online therapy program. To reduce screen-time for patients, the nonverbal therapies were shortened. Four patients, aged 64-70 years, started our online program. Results: Therapists were positive about the online capabilities and resilience of patients to adapt to the new situation. Prejudices on limited effectiveness of online psychotherapy were counteracted. Sending homework by email and mail seems to facilitate therapy adherence. Nonverbal therapy could be important to stimulate the online group process. Conclusion: We were positively surprised by the online capabilities of our geriatric mental healthcare patients and encourage further formal effectiveness studies.
C1 [van Dijk, Silvia Dian Maria; Bouman, Renske; Folmer, Ewa H.; den Held, Roos C.; Warringa, Janet E.; Marijnissen, Radboud M.; Voshaar, Richard C. Oude] Univ Groningen, Univ Ctr Psychiat, Univ Med Ctr Groningen, Groningen, Netherlands.
RP van Dijk, SDM (corresponding author), Univ Med Ctr Groningen, Univ Ctr Psychiat, POB 30-001, NL-9700 RB Groningen, Netherlands.
EM s.d.m.van.dijk@umcg.nl
CR Berryhill MB, 2019, TELEMED E-HEALTH, V25, P435, DOI 10.1089/tmj.2018.0058
   Crabb RM, 2012, BRIT J CLIN PSYCHOL, V51, P459, DOI 10.1111/j.2044-8260.2012.02038.x
   Lobbestael J, 2010, BEHAV COGN PSYCHOTH, V38, P437, DOI 10.1017/S1352465810000226
   Mewton L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071825
   Santini ZI, 2020, LANCET PUBLIC HEALTH, V5, pE62, DOI 10.1016/S2468-2667(19)30230-0
   Topooco N, 2017, INTERNET INTERV, V8, P1, DOI 10.1016/j.invent.2017.01.001
   van Dijk SDM, 2019, BMC PSYCHIATRY, V19, DOI 10.1186/s12888-018-2004-4
   van Vreeswijk MF, 2014, CLIN PSYCHOL PSYCHOT, V21, P29, DOI 10.1002/cpp.1813
   Videler AC, 2014, INT PSYCHOGERIATR, V26, P1709, DOI 10.1017/S1041610214001264
   Young J.E., 1994, COGNITIVE THERAPY PE, V2nd. Ed.
NR 10
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD SEP
PY 2020
VL 28
IS 9
BP 983
EP 988
DI 10.1016/j.jagp.2020.05.028
PG 6
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA NE1WB
UT WOS:000562387600012
PM 32622730
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Schilling, S
   Mohanarajah, S
   Mengstu, A
   Khan, A
   Brown, WA
AF Schilling, Shirin
   Mohanarajah, Sinthuja
   Mengstu, Abraham
   Khan, Arif
   Brown, Walter A.
TI How a Psychopharmacology Clinical Trial Site in the Seattle Area Managed
   Clinical Trials and Patient Care During the COVID-19 Pandemic
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE COVID-19; Clinical Trials; Pulse oximeter; Coronavirus; Dementia
AB Objectives: As the COVID-19 pandemic developed in March 2020 in greater Seattle, our clinical trial site faced several ethical and clinical dilemmas. We remained open to research patients including high-risk elderly patients and adapted to changing health recommendations. Methods: Beginning March 14, 2020 we developed an in-person evaluation for potential risk of COVID-19. Included are the first 3 weeks of screening by our physicians for potential exposure to COVID-19, common symptoms, temperature, blood oxygen saturation, and heart rate. Individuals with higher risk (n = 23) were identified and managed. Results: The 825 evaluations included 37 staff 167 patients, and 152 visitors. No one needed isolation or transfer to acute care facility, staff attendance was 95%, all 33 geriatric patients continued in phase II trials, and others decreased by 5%. Conclusion: We share how we incorporated COVID-19 Center for Disease Control health recommendations to a clinical trial center and addition of pulse oximetry.
C1 [Schilling, Shirin; Mohanarajah, Sinthuja; Mengstu, Abraham; Khan, Arif] Northwest Clin Res Ctr, Bellevue, WA 98007 USA.
   [Schilling, Shirin; Khan, Arif] Pacific Northwest Univ, Dept Clin Med, Hlth Sci Coll Osteopath Med, Yakima, WA USA.
   [Khan, Arif] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
   [Brown, Walter A.] Brown Univ, Dept Psychiat, Providence, RI 02912 USA.
RP Schilling, S (corresponding author), Northwest Clin Res Ctr, Bellevue, WA 98007 USA.
EM sschilling@nwcrc.net
CR [Anonymous], 2020, WASHINGTON STATE COR
   Center for Disease Control and Prevention, 2020, INT US GUID RISK ASS
   Food and Drug Administration, 2020, GUID IND INV I REV B
   Inslee J., 2020, STAY HOME STAY HLTH
   Majumdar SR, 2011, CLIN INFECT DIS, V52, P325, DOI 10.1093/cid/ciq076
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 7
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD SEP
PY 2020
VL 28
IS 9
BP 999
EP 1003
DI 10.1016/j.jagp.2020.06.012
PG 5
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA NE1WB
UT WOS:000562387600015
PM 32680760
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Lascano, AM
   Epiney, JB
   Coen, M
   Serratrice, J
   Bernard-Valnet, R
   Lalive, PH
   Kuntzer, T
   Hubers, A
AF Lascano, A. M.
   Epiney, J-B
   Coen, M.
   Serratrice, J.
   Bernard-Valnet, R.
   Lalive, P. H.
   Kuntzer, T.
   Huebers, A.
TI SARS-CoV-2 and Guillain-Barre syndrome: AIDP variant with a favourable
   outcome
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE COVID-19; electrodiagnostic testing; immune-mediated disorder;
   immunoglobulin therapy; infection; polyradiculoneuropathy
ID INFECTION
AB Background and purposeThe spectrum of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2), includes different neurologic manifestations of the central and peripheral nervous system.
   MethodsFrom March through April 2020, in two university hospitals located in western Switzerland, we examined three patients with Guillain-Barre syndrome (GBS) following SARS-CoV-2.
   ResultsThese cases were characterized by a primary demyelinating electrophysiological pattern (Acute inflammatory demyelinating polyneuropathy or AIDP) and a less severe disease course compared to recently published case series. Clinical improvement was observed in all patients at week five. One patient was discharged from hospital after full recovery with persistence of minor neurological signs (areflexia). Two of the three patients remained hospitalized: one was able to walk and the other could stand up with assistance.
   ConclusionsWe report three cases of typical GBS (AIDP) occurring after SARS-CoV-2 infection and presenting with a favourable clinical course. Given the interval between COVID-19-related symptoms and neurological manifestations (mean of 15 days) we postulate a secondary immune-mediated mechanism rather than direct viral damage.
C1 [Lascano, A. M.; Lalive, P. H.; Huebers, A.] Geneva Univ Hosp, Fac Med, Dept Clin Neurosci, Div Neurol, Geneva, Switzerland.
   [Lascano, A. M.; Lalive, P. H.; Huebers, A.] Univ Geneva, Geneva, Switzerland.
   [Epiney, J-B; Bernard-Valnet, R.; Kuntzer, T.] Lausanne Univ Hosp, Dept Clin Neurosci, Serv Neurol, Ctr Hosp Univ Vaudois, Lausanne, Switzerland.
   [Epiney, J-B; Bernard-Valnet, R.; Kuntzer, T.] Univ Lausanne, Lausanne, Switzerland.
   [Coen, M.; Serratrice, J.] Univ Geneva, Serv Internal Med, Dept Med, Geneva Univ Hosp, Geneva, Switzerland.
   [Coen, M.; Serratrice, J.] Univ Geneva, Unit Dev & Res Med Educ UDREM, Fac Med, Geneva, Switzerland.
RP Lascano, AM (corresponding author), Geneva Univ Hosp, Div Neurol, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland.
EM Agustina.Lascano@hcuge.ch
RI ; Kuntzer, Thierry/O-8589-2016; Bernard-Valnet, Raphael/L-5971-2016
OI Coen, Matteo/0000-0002-6156-1691; Kuntzer, Thierry/0000-0002-7788-1673;
   Bernard-Valnet, Raphael/0000-0001-7447-344X
FU University Hospitals of Geneva and Lausanne
FX The authors would like to thank the patients as well as the Service of
   Internal Medicine from the University Hospitals of Geneva and Lausanne.
CR Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
NR 7
TC 13
Z9 13
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD SEP
PY 2020
VL 27
IS 9
BP 1751
EP 1753
DI 10.1111/ene.14368
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA ND8GE
UT WOS:000562140300023
PM 32478936
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kayem, G
   Lecarpentier, E
   Deruelle, P
   Bretelle, F
   Azria, E
   Blanc, J
   Bohec, C
   Bornes, M
   Ceccaldi, PF
   Chalet, Y
   Chauleur, C
   Cordier, AG
   Desbriere, R
   Doret, M
   Dreyfus, M
   Driessen, M
   Fermaut, M
   Gallot, D
   Garabedian, C
   Huissoud, C
   Luton, D
   Morel, O
   Perrotin, F
   Picone, O
   Rozenberg, P
   Sentilhes, L
   Sroussi, J
   Vayssiere, C
   Verspyck, E
   Vivanti, AJ
   Winer, N
   Alessandrini, V
   Schmitz, T
AF Kayem, Gilles
   Lecarpentier, Edouard
   Deruelle, Philippe
   Bretelle, Florence
   Azria, Elie
   Blanc, Julie
   Bohec, Caroline
   Bornes, Marie
   Ceccaldi, Pierre-Francois
   Chalet, Yasmine
   Chauleur, Celine
   Cordier, Anne-Gael
   Desbriere, Raoul
   Doret, Muriel
   Dreyfus, Michel
   Driessen, Marine
   Fermaut, Marion
   Gallot, Denis
   Garabedian, Charles
   Huissoud, Cyril
   Luton, Dominique
   Morel, Olivier
   Perrotin, Franck
   Picone, Olivier
   Rozenberg, Patrick
   Sentilhes, Loic
   Sroussi, Jeremy
   Vayssiere, Christophe
   Verspyck, Eric
   Vivanti, Alexandre J.
   Winer, Norbert
   Alessandrini, Vivien
   Schmitz, Thomas
TI A snapshot of the Covid-19 pandemic among pregnant women in France
SO JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION
LA English
DT Article
DE COVID 19; Respiratory complications; Risk factors; Lockdown
AB Objective: To describe the course over time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in French women from the beginning of the pandemic until mid-April, the risk profile of women with respiratory complications, and short-term pregnancy outcomes.
   Methods: We collected a case series of pregnant women with COVID-19 in a research network of 33 French maternity units between March 1 and April 14, 2020. All cases of SARS-CoV-2 infection confirmed by a positive result on real-time reverse transcriptase polymerase chain reaction tests of a nasal sample and/or diagnosed by a computed tomography chest scan were included and analyzed. The primary outcome measures were COVID-19 requiring oxygen (oxygen therapy or noninvasive ventilation) and critical COVID-19 (requiring invasive mechanical ventilation or extracorporeal membrane oxygenation, ECMO). Demographic data, baseline comorbidities, and pregnancy outcomes were also collected.
   Results: Active cases of COVID-19 increased exponentially during March 1-31, 2020; the numbers fell during April 1-14, after lockdown was imposed on March 17. The shape of the curve of active critical COVID-19 mirrored that of all active cases. By April 14, among the 617 pregnant women with COVID-19, 93 women (15.1 %; 95 %Cl 12.3-18.1) had required oxygen therapy and 35 others (5.7 %; 95 %CI 4.0-7.8) had had a critical form of COVID-19. The severity of the disease was associated with age older than 35 years and obesity, as well as preexisting diabetes, previous preeclampsia, and gestational hypertension or preeclampsia. One woman with critical COVID-19 died (0.2 %; 95 %CI 0-0.9). Among the women who gave birth, rates of preterm birth in women with non-severe, oxygen-requiring, and critical COVID-19 were 13/123 (10.6 %),14/29 (48.3 %), and 23/29 (79.3 %) before 37 weeks and 3/123 (2.4 %), 4/29 (13.8 %), and 14/29 (48.3 %) before 32 weeks, respectively. One neonate (0.5 %; 95 %CI 0.01-2.9) in the critical group died from prematurity.
   Conclusion: COVID-19 can be responsible for significant rates of severe acute, potentially deadly, respiratory distress syndromes. The most vulnerable pregnant women, those with comorbidities, may benefit particularly from prevention measures such as a lockdown. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Kayem, Gilles; Bornes, Marie; Ceccaldi, Pierre-Francois; Chalet, Yasmine; Cordier, Anne-Gael; Driessen, Marine; Fermaut, Marion; Luton, Dominique; Picone, Olivier; Sroussi, Jeremy; Vivanti, Alexandre J.; Alessandrini, Vivien; Schmitz, Thomas] AP HP, F-75004 Paris, France.
   [Azria, Elie] Grp Hosp St Joseph, F-75014 Paris, France.
   [Bretelle, Florence; Blanc, Julie] Assistance Publ Hop Marseille, F-13000 Marseille, France.
   [Bohec, Caroline] Ctr Hosp Pau, F-64000 Pau, France.
   [Chauleur, Celine] Ctr Hosp Univ St Etienne, F-42000 St Etienne, France.
   [Deruelle, Philippe] Ctr Hosp Univ Strasbourg, F-67000 Strasbourg, France.
   [Desbriere, Raoul] Hop St Joseph, F-13000 Marseille, France.
   [Doret, Muriel; Huissoud, Cyril] Hosp Civiles Lyon, F-69000 Lyon, France.
   [Dreyfus, Michel] Ctr Hosp Univ Caen, F-14000 Caen, France.
   [Gallot, Denis] Ctr Hosp Univ Clermont Ferrand, F-63000 Clermont Ferrand, France.
   [Garabedian, Charles] Univ Lille, Ctr Hosp Reg, F-59000 Lille, France.
   [Lecarpentier, Edouard] Ctr Hosp Intercommunal Creteil, F-94000 Creteil, France.
   [Morel, Olivier] Maternite Reg Nancy, F-54000 Nancy, France.
   [Perrotin, Franck] Ctr Hosp Reg Univ Tours, F-37000 Tours, France.
   [Rozenberg, Patrick] Ctr Hosp Intercommunal Poissy, F-78300 Poissy, France.
   [Sentilhes, Loic] Ctr Hosp Univ Bordeaux, F-33000 Bordeaux, France.
   [Vayssiere, Christophe] Ctr Hosp Univ Toulouse, F-31000 Toulouse, France.
   [Verspyck, Eric] Ctr Hosp Univ Rouen, F-76000 Rouen, France.
   [Winer, Norbert] Ctr Hosp Univ Nantes, F-44000 Nantes, France.
RP Kayem, G (corresponding author), Hop Trousseau, Serv Gynecol Obstet, AP HP, 26 Rue Dr Arnold Netter, F-75012 Paris, France.
EM gkayem@gmail.com
RI Vivanti, Alexandre/AAN-1693-2020; PICONE, Olivier/ABF-7916-2020
OI Vivanti, Alexandre/0000-0002-4921-0047; PICONE,
   Olivier/0000-0001-8421-9971
CR Breslin N, 2020, AM J OBSTET GYNECOL, V9
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen L, 2020, J MOL MED, V98, P1235, DOI 10.1007/s00109-020-01936-5
   Chen RY, 2020, J OBSTET GYNAECOL, DOI 10.1080/01443615.2020.1718621
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Knight M, 2020, AM J OBSTET GYNECOL
   Li YW, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104833
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Royston P., 2014, PTREND STATA MODULE
   Salje H, 2020, SCIENCE
   Sanders JM, 2020, JAMA
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   Valdes G, 2006, PLACENTA, V27, P200, DOI 10.1016/j.placenta.2005.02.015
   Yu N, 2020, LANCET INFECT DIS
NR 16
TC 23
Z9 24
U1 4
U2 4
PU ELSEVIER MASSON, CORP OFF
PI PARIS
PA 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE
SN 2468-7847
EI 1773-0430
J9 J GYNECOL OBSTET HUM
JI J. Gynecol. Obstet. Hum. Reprod.
PD SEP
PY 2020
VL 49
IS 7
AR 101826
DI 10.1016/j.jogoh.2020.101826
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA NE0JF
UT WOS:000562283600025
PM 32505805
OA Green Published
DA 2021-01-01
ER

PT J
AU Raimondo, D
   Borghese, G
   Mastronardi, M
   Mabrouk, M
   Salucci, P
   Lambertini, A
   Casadio, P
   Tonini, C
   Meriggiola, MC
   Arena, A
   Tarozzi, G
   Seracchioli, R
AF Raimondo, Diego
   Borghese, Giulia
   Mastronardi, Manuela
   Mabrouk, Mohamed
   Salucci, Paolo
   Lambertini, Agnese
   Casadio, Paolo
   Tonini, Claudia
   Meriggiola, Maria Cristina
   Arena, Alessandro
   Tarozzi, Giulia
   Seracchioli, Renato
TI Laparoscopic surgery for benign adnexal conditions under spinal
   anaesthesia: Towards a multidisciplinary minimally invasive approach
SO JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION
LA English
DT Article
DE General anaesthesia; Laparoscopy; Postoperative pain; Postoperative
   recovery; Spinal anaesthesia
ID REGIONAL ANESTHESIA; GENERAL-ANESTHESIA; CHOLECYSTECTOMY; MULTICENTER
AB Background: Laparoscopic gynaecological surgery is commonly performed under general anaesthesia with endotracheal intubation. In general surgery, locoregional anaesthesia was applied to laparoscopic procedures, increasing minimally invasive surgery advantages.
   Aims: To assess and compare postoperative pain after laparoscopic adnexal procedures for benign conditions under spinal anaesthesia (SA) versus general anaesthesia (GA). Furthermore, anaesthesiologic, surgical and clinical data were evaluated in both groups.
   Materials and Methods: This is a prospective cohort study performed in a tertiary level referral centre for minimally invasive gynaecological surgery (Gynaecology and Human Reproduction Physiopathology, University of Bologna). Women scheduled for adnexal laparoscopic surgery for benign conditions between February and May 2019 were assigned to receive either SA or GA with endotracheal intubation. A sample size of 13 women per group was needed to detect a 2-point difference in pain scores.
   Main findings: 13 women were enrolled in the SA arm, 15 in the GA arm. In the SA cohort, the most common intraoperative adverse event was shoulder pain, reported by 3/12 women. At 1, 8,12, 24 and 48 h after surgery pain was significantly lower in the SA arm (p <.05). Patients submitted to SA experienced no need for opioid drugs administration, unlike those receiving GA. Patients' mobilization and return of bowel function were noted significantly earlier in the SA group (p < .05).
   Conclusions: SA is a feasible, safe and effective anaesthesiologic technique for laparoscopic gynaecological procedures for benign conditions, allowing a better control of postoperative pain. Women undergoing SA achieve earlier mobilization and bowel canalization. During the Covid-19 pandemics, SA could be useful in reducing the need for invasive procedures on respiratory tract. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Raimondo, Diego; Borghese, Giulia; Mastronardi, Manuela; Mabrouk, Mohamed; Salucci, Paolo; Casadio, Paolo; Meriggiola, Maria Cristina; Arena, Alessandro; Seracchioli, Renato] Univ Bologna, S Orsola Hosp, Dipartimento Sci Med & Chirurg DIMEC, Gynaecol & Human Reprod Physiopathol, Via Massarenti 13, I-40138 Bologna, Italy.
   [Mabrouk, Mohamed] Univ Alexandria, Fac Med, Dept Obstet & Gynaecol, Champoll St, Al Mesallah Sharq, Alexandria Gove, Egypt.
   [Mabrouk, Mohamed] Univ Cambridge Clin Sch, Rosie Hosp, Fac Med, Dept Obstet & Gynaecol, Box 223,Robinson Way, Cambridge CB2 0SW, England.
   [Lambertini, Agnese; Tonini, Claudia] Univ Bologna, Dipartimento Sci Med & Chirurg DIMEC, Anaesthesiol & Resuscitat Unit, S Orsola Hosp, Via Massarenti 13, I-40138 Bologna, Italy.
   [Tarozzi, Giulia] Univ Bologna, S Orsola Hosp, Anaesthesiol & Pain Med Unit, Dipartimento Emergenza Urgenza, Via Albertoni 15, I-40138 Bologna, Italy.
RP Borghese, G (corresponding author), Univ Bologna, S Orsola Hosp, Dipartimento Sci Med & Chirurg DIMEC, Gynaecol & Human Reprod Physiopathol, Via Massarenti 13, I-40138 Bologna, Italy.
EM Die.raimondo@gmail.com; Giuliamaria.borghese@gmail.com;
   Manuela.mastronardi@gmail.com; Mohamed.mabrouk@aosp.bo.it;
   saluccip@gmail.com; Agnese.lambertini@aosp.bo.it;
   Paolo.casadio@aosp.bo.it; Claudia.tonini@aosp.bo.it;
   Cristina.meriggiola@unibo.it; Alessandroarena1588@aosp.bo.it;
   Giulia.tarozzi@aosp.bo.it; renato.seracchioli@unibo.it
OI Mastronardi, Manuela/0000-0003-3525-3692; Casadio,
   Paolo/0000-0001-7706-5580; Borghese, Giulia/0000-0002-9136-8323
CR Asgari Z, 2018, PAIN RES MANAG, V2018, DOI 10.1155/2018/9715142
   Asgari Z, 2017, PAIN RES MANAG, V2017, DOI 10.1155/2017/1721460
   Bertini L, 2006, MINERVA ANESTESIOL, V72, P689
   Bessa SS, 2012, J LAPAROENDOSC ADV S, V22, P550, DOI 10.1089/lap.2012.0110
   Bulletti C, 1996, HUM REPROD, V11, P287, DOI 10.1093/HUMREP/11.2.287
   Carli F, 2011, REGION ANESTH PAIN M, V36, P63, DOI 10.1097/AAP.0b013e31820307f7
   Das W, 2015, SAUDI J ANAESTH, V9, P184, DOI 10.4103/1658-354X.152881
   Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0
   Gramatica L, 2002, SURG ENDOSC, V16, P472, DOI 10.1007/s00464-001-8148-0
   Haydon GH, 1996, GASTROINTEST ENDOSC, V44, P124, DOI 10.1016/S0016-5107(96)70128-1
   Holdgate Anna, 2003, Emerg Med (Fremantle), V15, P441, DOI 10.1046/j.1442-2026.2003.00499.x
   Kim KH, 2017, MINIM INVASIV THER, V26, P39, DOI 10.1080/13645706.2016.1223695
   Kowalski CJ, 2013, PERSPECT BIOL MED, V56, P18, DOI 10.1353/pbm.2013.0004
   Muzii L, 2016, HUM REPROD, V31, P339, DOI 10.1093/humrep/dev313
   Pellegrino A, 2013, J MINIM INVAS GYN, V20, P230, DOI 10.1016/j.jmig.2012.11.009
   Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493
   Ross SB, 2013, SURG ENDOSC, V27, P1810, DOI 10.1007/s00464-012-2667-8
   Savelli L, 2011, ULTRASOUND OBST GYN, V38, P466, DOI 10.1002/uog.9072
   Seracchioli R, 2005, ANTICANCER RES, V25, P2423
   Seracchioli R, 2004, J AM ASSOC GYN LAP, V11, P332, DOI 10.1016/S1074-3804(05)60045-X
   Seracchioli R, 2003, J AM ASSOC GYN LAP, V10, P316, DOI 10.1016/S1074-3804(05)60254-X
   Seracchioli R, 2001, HUM REPROD, V16, P1261, DOI 10.1093/humrep/16.6.1261
   Singh R K, 2015, Med J Armed Forces India, V71, P126, DOI 10.1016/j.mjafi.2014.12.010
   Sinha R, 2009, J LAPAROENDOSC ADV S, V19, P323, DOI 10.1089/lap.2008.0393
   Tzovaras G, 2006, SURG ENDOSC, V20, P580, DOI 10.1007/s00464-005-0405-1
   Uccella S, 2016, GYNECOL ONCOL, V141, P211, DOI 10.1016/j.ygyno.2016.02.029
   van Zundert AAJ, 2007, BRIT J ANAESTH, V98, P682, DOI 10.1093/bja/aem058
   Vretzakis G, 2014, J ANESTH, V28, P429, DOI 10.1007/s00540-013-1736-z
   WANG XX, 2016, BIOMED RES INT, V2016
   Zullo F, 2000, FERTIL STERIL, V74, P376, DOI 10.1016/S0015-0282(00)00611-7
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER MASSON, CORP OFF
PI PARIS
PA 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE
SN 2468-7847
EI 1773-0430
J9 J GYNECOL OBSTET HUM
JI J. Gynecol. Obstet. Hum. Reprod.
PD SEP
PY 2020
VL 49
IS 7
AR 101813
DI 10.1016/j.jogoh.2020.101813
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA NE0JF
UT WOS:000562283600020
OA Green Published
DA 2021-01-01
ER

PT J
AU Barquera, R
   Collen, E
   Di, D
   Buhler, S
   Teixeira, J
   Llamas, B
   Nunes, JM
   Sanchez-Mazas, A
AF Barquera, Rodrigo
   Collen, Evelyn
   Di, Da
   Buhler, Stephane
   Teixeira, Joao
   Llamas, Bastien
   Nunes, Jose M.
   Sanchez-Mazas, Alicia
TI Binding affinities of 438 HLA proteins to complete proteomes of seven
   pandemic viruses and distributions of strongest and weakest HLA peptide
   binders in populations worldwide
SO HLA
LA English
DT Article
DE coronavirus; COVID-19; HIV; HLA population genetics; Indigenous
   Americans; influenza; natural selection; peptide-binding predictions;
   SARS-CoV-2
ID CLASS-I; BALANCING SELECTION; SOFT SWEEPS; DIVERSITY; MHC; ALLELES;
   EXPRESSION; EVOLUTION; FREQUENCIES; CHIMPANZEES
AB We report detailed peptide-binding affinities between 438 HLA Class I and Class II proteins and complete proteomes of seven pandemic human viruses, including coronaviruses, influenza viruses and HIV-1. We contrast these affinities with HLA allele frequencies across hundreds of human populations worldwide. Statistical modelling shows that peptide-binding affinities classified into four distinct categories depend on the HLA locus but that the type of virus is only a weak predictor, except in the case of HIV-1. Among the strong HLA binders (IC50 = 50), we uncovered 16 alleles (the top ones being A*02:02, B*15:03 and DRB1*01:02) binding more than 1% of peptides derived from all viruses, 9 (top ones including HLA-A*68:01, B*15:25, C*03:02 and DRB1*07:01) binding all viruses except HIV-1, and 15 (top ones A*02:01 and C*14:02) only binding coronaviruses. The frequencies of strongest and weakest HLA peptide binders differ significantly among populations from different geographic regions. In particular, Indigenous peoples of America show both higher frequencies of strongest and lower frequencies of weakest HLA binders. As many HLA proteins are found to be strong binders of peptides derived from distinct viral families, and are hence promiscuous (or generalist), we discuss this result in relation to possible signatures of natural selection on HLA promiscuous alleles due to past pathogenic infections. Our findings are highly relevant for both evolutionary genetics and the development of vaccine therapies. However they should not lead to forget that individual resistance and vulnerability to diseases go beyond the sole HLA allelic affinity and depend on multiple, complex and often unknown biological, environmental and other variables.
C1 [Barquera, Rodrigo] Max Planck Inst Sci Human Hist, Dept Archaeogenet, Jena, Germany.
   [Collen, Evelyn; Teixeira, Joao] Univ Adelaide, Australian Ctr Ancient DNA ACAD, Dept Genet & Evolut, Adelaide, SA, Australia.
   [Di, Da; Buhler, Stephane; Nunes, Jose M.; Sanchez-Mazas, Alicia] Univ Geneva, Dept Genet & Evolut, Anthropol Unit, Geneva, Switzerland.
   [Buhler, Stephane] Geneva Univ Hosp, Dept Diagnost, Transplantat Immunol Unit, Geneva, Switzerland.
   [Buhler, Stephane] Geneva Univ Hosp, Dept Diagnost, Natl Reference Lab Histocompatibil, Geneva, Switzerland.
   [Teixeira, Joao; Llamas, Bastien] Univ Adelaide, Ctr Excellence Australian Biodivers & Heritage, Sch Biol Sci, Adelaide, SA, Australia.
   [Llamas, Bastien] Univ Adelaide, Environm Inst, Adelaide, SA, Australia.
   [Nunes, Jose M.; Sanchez-Mazas, Alicia] Univ Geneva, Inst Genet & Genom Geneva IGE3, Geneva, Switzerland.
RP Nunes, JM; Sanchez-Mazas, A (corresponding author), Univ Geneva, Dept Genet & Evolut, Anthropol Unit, Geneva, Switzerland.
EM jose.deabreununes@unige.ch; alicia.sanchez-mazas@unige.ch
RI Teixeira, Joao C./AAE-4189-2020
OI Teixeira, Joao C./0000-0001-6417-4702; Barquera,
   Rodrigo/0000-0003-0518-4518; Buhler, Stephane/0000-0001-6675-5287
FU Australian Government Research Training Program Stipend (RTPS)Australian
   Government; Australian Research Council Discovery Indigenous
   ProjectAustralian Research Council [IN180100017]; Australian Research
   Council Future FellowshipAustralian Research Council [FT170100448];
   European Cooperation in Science and TechnologyEuropean Cooperation in
   Science and Technology (COST) [BM0803]; MaxPlanck-GesellschaftMax Planck
   Society; Schweizerischer Nationalfonds zur Forderung der
   Wissenschaftlichen ForschungAustrian Science Fund (FWF) [310030_188820,
   31003A_144180]
FX Australian Government Research Training Program Stipend (RTPS);
   Australian Research Council Discovery Indigenous Project, Grant/Award
   Number: IN180100017; Australian Research Council Future Fellowship,
   Grant/Award Number: FT170100448; European Cooperation in Science and
   Technology, Grant/Award Number: BM0803; MaxPlanck-Gesellschaft;
   Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen
   Forschung, Grant/Award Numbers: 310030_188820, 31003A_144180
CR Abdulla F, 2019, MICROB PATHOGENESIS, V137, DOI 10.1016/j.micpath.2019.103791
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Alicia SM, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20248
   Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   [Anonymous], 2019, SUMM INFL RISK ASS T
   Apps R, 2013, SCIENCE, V340, P87, DOI 10.1126/science.1232685
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Buhler S, 2016, IMMUNOGENETICS, V68, P401, DOI 10.1007/s00251-016-0918-x
   Buhler S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014643
   Carey BS, 2019, INT J IMMUNOGENET, V46, P307, DOI 10.1111/iji.12443
   De Groot NG, 2008, MOL ECOL, V17, P2074, DOI 10.1111/j.1365-294X.2008.03716.x
   de Groot NG, 2017, IMMUNOGENETICS, V69, P499, DOI 10.1007/s00251-017-1006-6
   El-Awar N, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/3406230
   Francisco RD, 2015, IMMUNOGENETICS, V67, P651, DOI 10.1007/s00251-015-0875-9
   Gfeller D, 2018, J IMMUNOL, V201, P3705, DOI 10.4049/jimmunol.1800914
   Gfeller D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01716
   Goeury T, 2018, HLA, V91, P148, DOI 10.1111/tan.13197
   Goeury T, 2018, HLA, V91, P36, DOI 10.1111/tan.13180
   Goulder PJR, 1996, AIDS RES HUM RETROV, V12, P1691, DOI 10.1089/aid.1996.12.1691
   Goulder PJR, 2000, J VIROL, V74, P5291, DOI 10.1128/JVI.74.11.5291-5299.2000
   Hermisson J, 2005, GENETICS, V169, P2335, DOI 10.1534/genetics.104.036947
   Hilton HG, 2017, IMMUNOGENETICS, V69, P567, DOI 10.1007/s00251-017-1001-y
   Hollenbach JA, 2001, HUM IMMUNOL, V62, P378, DOI 10.1016/S0198-8859(01)00212-9
   Holmes EC, 2004, PHILOS T R SOC B, V359, P1059, DOI 10.1098/rstb.2004.1478
   Hyun-Jung Lee Chloe, 2020, F1000Res, V9, P145, DOI 10.12688/f1000research.22507.1
   Jain S, 2019, MED MICROBIOL IMMUN, V208, P227, DOI 10.1007/s00430-019-00584-y
   Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Kaufman J, 2018, TRENDS IMMUNOL, V39, P367, DOI 10.1016/j.it.2018.01.001
   Kaur G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15924
   Key FM, 2014, CURR OPIN GENET DEV, V29, P45, DOI 10.1016/j.gde.2014.08.001
   Khan S, 2020, J CLIN MICROBIOL, V58, DOI [10.1128/JCM.01297-20, 10.1128/JCM.00187-20]
   Klein J, 2000, NEW ENGL J MED, V343, P702, DOI 10.1056/NEJM200009073431006
   KLEIN J, 1993, ANNU REV IMMUNOL, V11, P269, DOI 10.1146/annurev.immunol.11.1.269
   Leffler EM, 2013, SCIENCE, V339, P1578, DOI 10.1126/science.1234070
   Lenz TL, 2016, MOL BIOL EVOL, V33, P2555, DOI 10.1093/molbev/msw127
   Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9
   Lindo J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13175
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Manczinger M, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000131
   Mehra NK, 2010, HLA COMPLEX BIOL MED
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   Muraro E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00197
   Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20
   Novembre J, 2012, PHILOS T R SOC B, V367, P878, DOI 10.1098/rstb.2011.0305
   Nunes JM, 2014, TISSUE ANTIGENS, V83, P307, DOI 10.1111/tan.12356
   Otting N, 2019, IMMUNOGENETICS, V71, P13, DOI 10.1007/s00251-018-1080-4
   Parham P, 2005, NAT REV IMMUNOL, V5, P201, DOI 10.1038/nri1570
   Parham P., IMMUNE SYSTEM
   Patterson KB, 2002, AM J MED SCI, V323, P216, DOI 10.1097/00000441-200204000-00009
   Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101
   Pierini F, 2018, MOL BIOL EVOL, V35, P2145, DOI 10.1093/molbev/msy116
   Pinheiro J.C., 2000, MIXED EFFECTS MODELS, DOI [10.1007/b98882, DOI 10.1007/B98882]
   Pritchard JK, 2010, CURR BIOL, V20, pR208, DOI 10.1016/j.cub.2009.11.055
   R Core Team, 2018, R LANG ENV STAT COMP
   Racle J, 2019, NAT BIOTECHNOL, V37, P1283, DOI 10.1038/s41587-019-0289-6
   Riccio ME, 2011, HUM BIOL, V83, P405, DOI 10.3378/027.083.0306
   Robinson J, 2020, NUCLEIC ACIDS RES, V48, pD948, DOI 10.1093/nar/gkz950
   Sanchez-Mazas A, 2012, INT J IMMUNOGENET, V39, P459, DOI 10.1111/j.1744-313X.2012.01113.x
   Sanchez-Mazas Alicia, 2020, Swiss Med Wkly, V150, pw20214, DOI 10.4414/smw.2020.20214
   Sanchez-Mazas A, 2017, MOL ECOL, V26, P6238, DOI 10.1111/mec.14366
   Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594
   Shiina T, 2009, J HUM GENET, V54, P15, DOI 10.1038/jhg.2008.5
   Solberg OD, 2008, HUM IMMUNOL, V69, P443, DOI 10.1016/j.humimm.2008.05.001
   Spurgin LG, 2010, P ROY SOC B-BIOL SCI, V277, P979, DOI 10.1098/rspb.2009.2084
   Sun H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134334
   Takeshita LYC, 2014, TRANSFUS MED HEMOTH, V41, P352, DOI 10.1159/000368056
   Teixeira JC, 2015, MOL BIOL EVOL, V32, P1186, DOI 10.1093/molbev/msv007
   Venables W. N., 1999, MODERN APPL STAT S P
   Vina MAF, 2012, PHILOS T R SOC B, V367, P820, DOI 10.1098/rstb.2011.0320
   Wang Mingjun, 2014, Methods Mol Biol, V1184, P309, DOI 10.1007/978-1-4939-1115-8_17
   Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568
   Zhao WL, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006457
NR 73
TC 4
Z9 4
U1 3
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2059-2302
EI 2059-2310
J9 HLA
JI HLA
PD SEP
PY 2020
VL 96
IS 3
BP 277
EP 298
DI 10.1111/tan.13956
PG 22
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA ND2NB
UT WOS:000561740800003
PM 32475052
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Deng, XF
   Buckley, AC
   Pillatzki, A
   Lager, KM
   Faaberg, KS
   Baker, SC
AF Deng, Xufang
   Buckley, Alexandra C.
   Pillatzki, Angela
   Lager, Kelly M.
   Faaberg, Kay S.
   Baker, Susan C.
TI Inactivating Three Interferon Antagonists Attenuates Pathogenesis of an
   Enteric Coronavirus
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE pathogenesis; porcine epidemic diarrhea virus; SARS-CoV-2; coronavirus;
   endoribonuclease; interferon antagonist; nsp1; nsp15; nsp16; vaccine
ID MOUSE HEPATITIS-VIRUS; NONSTRUCTURAL PROTEIN-1; SARS-CORONAVIRUS;
   ENDORIBONUCLEASE; RNA; PNEUMONIA; PROVIDES; EVASION; GENOME; UNIQUE
AB Coronaviruses (CoVs) have repeatedly emerged from wildlife hosts and infected humans and livestock animals to cause epidemics with significant morbidity and mortality. CoVs infect various organs, including respiratory and enteric systems, as exemplified by newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The constellation of viral factors that contribute to developing enteric disease remains elusive. Here, we investigated CoV interferon antagonists for their contribution to enteric pathogenesis. Using an infectious clone of an enteric CoV, porcine epidemic diarrhea virus (icPEDV), we generated viruses with inactive versions of interferon antagonist nonstructural protein 1 (nsp1), nsp15, and nsp16 individually or combined into one virus designated icPEDV-mut4. Interferon-responsive PK1 cells were infected with these viruses and produced higher levels of interferon responses than were seen with wild-type icPEDV infection. icPEDV-mut4 elicited robust interferon responses and was severely impaired for replication in PK1 cells. To evaluate viral pathogenesis, piglets were infected with either icPEDV or icPEDVmut4. While the icPEDV-infected piglets exhibited clinical disease, the icPEDV-mut4-infected piglets showed no clinical symptoms and exhibited normal intestinal pathology at day 2 postinfection. icPEDV-mut4 replicated in the intestinal tract, as revealed by detection of viral RNA in fecal swabs, with sequence analysis documenting genetic stability of the input strain. Importantly, icPEDV-mut4 infection elicited IgG and neutralizing antibody responses to PEDV. These results identify nsp1, nsp15, and nsp16 as virulence factors that contribute to the development of PEDV-induced diarrhea in swine. Inactivation of these CoV interferon antagonists is a rational approach for generating candidate vaccines to prevent disease and spread of enteric CoVs, including SARS-CoV-2.
   IMPORTANCE Emerging coronaviruses, including SARS-CoV-2 and porcine CoVs, can infect enterocytes, cause diarrhea, and be shed in the feces. New approaches are needed to understand enteric pathogenesis and to develop vaccines and therapeutics to prevent the spread of these viruses. Here, we exploited a reverse genetic system for an enteric CoV, porcine epidemic diarrhea virus (PEDV), and outline an approach of genetically inactivating highly conserved viral factors known to limit the host innate immune response to infection. Our report reveals that generating PEDV with inactive versions of three viral interferon antagonists, nonstructural proteins 1, 15, and 16, results in a highly attenuated virus that does not cause diarrhea in animals and elicits a neutralizing antibody response in virus-infected animals. This strategy may be useful for generating live attenuated vaccine candidates that prevent disease and fecal spread of enteric CoVs, including SARS-CoV-2.
C1 [Deng, Xufang; Baker, Susan C.] Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL 60153 USA.
   [Buckley, Alexandra C.; Lager, Kelly M.; Faaberg, Kay S.] USDA ARS, Virus & Prion Res Unit, Natl Anim Dis Ctr, POB 70, Ames, IA 50010 USA.
   [Pillatzki, Angela] South Dakota State Univ, Anim Dis Res & Diagnost Lab, Brookings, SD 57007 USA.
RP Baker, SC (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL 60153 USA.; Buckley, AC (corresponding author), USDA ARS, Virus & Prion Res Unit, Natl Anim Dis Ctr, POB 70, Ames, IA 50010 USA.
EM alexandra.buckley@usda.gov; sbaker1@luc.edu
OI Baker, Susan/0000-0001-6485-8143
FU USDA-Loyola University ChicagoUniversity of Chicago [59-5030-8-003B];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI085089]; USDA ARS CRIS ProjectUnited
   States Department of Agriculture (USDA) [5030-32000-118-00D]
FX This work was funded by USDA-Loyola University Chicago cooperative
   agreement 59-5030-8-003B, NIH AI085089 (to S.C.B.), and USDA ARS CRIS
   Project 5030-32000-118-00D.
CR Bhardwaj K, 2004, J VIROL, V78, P12218, DOI 10.1128/JVI.78.22.12218-12224.2004
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Cheung KS, 2020, GASTROENTEROLOGY, DOI [10.1053/j.gastro.2020.03.065, DOI 10.1053/J.GASTRO.2020.03.065.]
   Connor RF, 2007, TRENDS MICROBIOL, V15, P51, DOI 10.1016/j.tim.2006.12.005
   Deng XF, 2019, J VIROL, V93, DOI [10.1128/JVI.02000-18, 10.1128/jvi.02000-18]
   Deng XF, 2017, P NATL ACAD SCI USA, V114, pE4251, DOI 10.1073/pnas.1618310114
   Du YS, 2018, SCIENCE, V359, P290, DOI 10.1126/science.aan8806
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Graham RL, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0175-7
   Hackbart M, 2020, P NATL ACAD SCI USA, V117, P8094, DOI 10.1073/pnas.1921485117
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hou YX, 2019, J VIROL, V93, DOI 10.1128/JVI.00406-19
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ivanov KA, 2004, P NATL ACAD SCI USA, V101, P12694, DOI 10.1073/pnas.0403127101
   Jung K, 2015, VET MICROBIOL, V178, P31, DOI 10.1016/j.vetmic.2015.04.022
   Kindler E, 2014, CURR OPIN MICROBIOL, V20, P69, DOI 10.1016/j.mib.2014.05.005
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Marazzi I, 2015, CURR OPIN MICROBIOL, V26, P123, DOI 10.1016/j.mib.2015.06.009
   Menachery VD, 2018, J VIROL, V92, DOI 10.1128/JVI.00710-18
   Menachery VD, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00346-17
   Menachery VD, 2017, MBIO, V8, DOI 10.1128/mBio.00665-17
   Mesev EV, 2019, NAT MICROBIOL, V4, P914, DOI 10.1038/s41564-019-0421-x
   Miller LC, 2016, J VET DIAGN INVEST, V28, P20, DOI 10.1177/1040638715621949
   Narayanan K, 2015, VIRUS RES, V202, P89, DOI 10.1016/j.virusres.2014.11.019
   Okda F, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0500-z
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Ricagno S, 2006, P NATL ACAD SCI USA, V103, P11892, DOI 10.1073/pnas.0601708103
   Smith GL, 2018, ADV VIRUS RES, V100, P355, DOI 10.1016/bs.aivir.2018.01.003
   Smith GL, 2013, J GEN VIROL, V94, P2367, DOI 10.1099/vir.0.055921-0
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Te Yeh M, 2020, CELL HOST MICROBE, V27, P736, DOI [10.1016/j.chom.2020.04.003, DOI 10.1016/J.CHOM.2020.04.003.]
   Thomas JT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139266
   Volk A, 2020, J VIROL, V94, DOI 10.1128/JVI.00178-20
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Xu W, 2018, J VIROL, V92, DOI 10.1128/JVI.00825-18
   Xu XL, 2006, J VIROL, V80, P7909, DOI 10.1128/JVI.00525-06
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zhang QZ, 2017, VIROLOGY, V510, P111, DOI 10.1016/j.virol.2017.07.009
   Zhou J, 2020, NAT MED, V26, P1077, DOI 10.1038/s41591-020-0912-6
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
   Zust R, 2011, NAT IMMUNOL, V12, P137, DOI 10.1038/ni.1979
NR 49
TC 0
Z9 0
U1 4
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2020
VL 94
IS 17
AR e00565-20
DI 10.1128/JVI.00565-20
PG 15
WC Virology
SC Virology
GA ND3DP
UT WOS:000561784500002
PM 32554697
DA 2021-01-01
ER

PT J
AU Prada, V
   Bellone, E
   Schenone, A
   Grandis, M
AF Prada, Valeria
   Bellone, Emilia
   Schenone, Angelo
   Grandis, Marina
TI The suspected SARS-Cov-2 infection in a Charcot-Marie-Tooth patient
   undergoing postsurgical rehabilitation: the value of telerehabilitation
   for evaluation and continuing treatment
SO INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH
LA English
DT Article
DE Charcot-Marie-Tooth disease; COVID-19; neuropathy; SARS-Cov-2;
   telerehabilitation
ID STROKE REHABILITATION; OVERWORK WEAKNESS; HEALTH; TRIAL; HOME
AB We report, to the best of our knowledge, the first case of a probable COVID-19 infection in a 28-year-old man with Charcot-Marie-Tooth disease. The diagnosis was established through a remote interaction with the patient after early discharge from outpatient therapy due to upcoming traveling restrictions. The COVID-19 disease appeared mild, without major respiratory problems, and no obvious neuromuscular deterioration was reported or observed. Telerehabilitation provided an opportunity to continue with hand rehabilitation after tendon transfer surgery, perform an ad-hoc online evaluation, and advise the patient how to prevent the spread of infection and cope with restrictions limiting outpatient visits. This experience seems valuable for further development of telerehabilitation in anticipation of future pandemics or adversarial events since it allows reaching out to patients unable to travel and overcomes the need for regular outpatient visits.
C1 [Prada, Valeria; Bellone, Emilia; Schenone, Angelo; Grandis, Marina] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet & Maternal, Genoa, Italy.
   [Bellone, Emilia; Schenone, Angelo; Grandis, Marina] Policlin IRCSS San Martino, Genoa, Italy.
RP Prada, V (corresponding author), Univ Genoa, Lgo P Daneo 3, I-16132 Genoa, Italy.
EM valeria.prada@gmail.com
RI Grandis, Marina/J-3627-2014
OI Grandis, Marina/0000-0001-6637-4425
CR Anderson C, 2000, STROKE, V31, P1024, DOI 10.1161/01.STR.31.5.1024
   Dey SK, 2020, J MED VIROL, V92, P632, DOI 10.1002/jmv.25743
   Hsieh YW, 2018, ARCH PHYS MED REHAB, V99, P2399, DOI 10.1016/j.apmr.2018.03.017
   Kvedar J, 2014, HEALTH AFFAIR, V33, P194, DOI 10.1377/hlthaff.2013.0992
   Barreto LCLS, 2016, NEUROEPIDEMIOLOGY, V46, P157, DOI 10.1159/000443706
   Linder SM, 2013, INT J STROKE, V8, P46, DOI 10.1111/j.1747-4949.2012.00971.x
   Parmanto B, 2009, INT J TELEREHABILITA, V1, P73
   Prada V, 2018, J PERIPHER NERV SYST, V23, P124, DOI 10.1111/jns.12270
   Reluga TC, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000793
   Remuzzi A, 2020, LANCET
   Sagliocco L, 2003, AM J PHYS MED REHAB, V82, P754, DOI 10.1097/01.PHM.0000087453.94529.0D
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Spiesshoefer J, 2019, J PERIPHER NERV SYST, V24, P283, DOI 10.1111/jns.12341
   van Pomeren M, 2009, J REHABIL MED, V41, P32, DOI 10.2340/16501977-0274
   Vinci P, 2003, ARCH PHYS MED REHAB, V84, P825, DOI 10.1016/S0003-9993(02)04949-3
   World Health Organization, 2020, COR DIS 2019 COVID 1, V2019, DOI [10.1001/jama.2020.2633, DOI 10.1001/JAMA.2020.2633, 10.1001/jama.2020.2633.]
NR 16
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0342-5282
EI 1473-5660
J9 INT J REHABIL RES
JI Int. J. Rehabil. Res.
PD SEP
PY 2020
VL 43
IS 3
BP 285
EP 286
DI 10.1097/MRR.0000000000000418
PG 2
WC Rehabilitation
SC Rehabilitation
GA NC6RC
UT WOS:000561343600017
PM 32317558
OA Green Published
DA 2021-01-01
ER

PT J
AU Schluenz, LA
   Ramos-Otero, GP
   Nawarskas, JJ
AF Schluenz, Lauren A.
   Ramos-Otero, Gerardo P.
   Nawarskas, James J.
TI Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease
   2019 Friend or Foe?
SO CARDIOLOGY IN REVIEW
LA English
DT Article
DE hydroxychloroquine; chloroquine; coronavirus; COVID-19; SARS-CoV-2
ID RESPIRATORY SYNDROME CORONAVIRUS
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to the health of many humans across the world as they confront coronavirus disease 2019 (COVID-19). Previous promising in vitro data that emerged after the SARS-CoV outbreak in 2003, along with the emergent need for pharmacologic management strategies in the fight against COVID-19, prompted interest in the use of chloroquine and hydroxychloroquine across the globe. Unfortunately, the in vitro activity of these drugs did not necessarily correlate with most in vivo studies, which showed no consistent efficacy. Safety is also a major concern, with these agents having a known risk of QT prolongation and proarrhythmic effects. In addition, clinical practice guidelines provide no clear consensus on the role of chloroquine or hydroxychloroquine for the management of COVID-19. The United States Food and Drug Administration has declared that the potential benefits of these agents no longer outweigh the possible risks, and unless new emerging information suggests a more favorable risk:benefit ratio, neither chloroquine nor hydroxychloroquine should be recommended for COVID-19 treatment or prevention at this time.
C1 [Schluenz, Lauren A.; Ramos-Otero, Gerardo P.] Univ New Mexico, Dept Pharm, Albuquerque, NM 87131 USA.
   [Nawarskas, James J.] Univ New Mexico, Dept Pharm Practice & Adm Sci, Albuquerque, NM 87131 USA.
RP Schluenz, LA (corresponding author), Univ New Mexico Hosp, Dept Pharm, 2211 Lomas Blvd NE, Albuquerque, NM 87106 USA.
EM lschluenz@salud.unm.edu
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   [Anonymous], DIAGN TREATM PROT CO
   Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Cohen E., 2020, US STOCKPILE STUCK 6
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   COVID-19 Treatment Guidelines Panel, COVID 19 TREATM GUID
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   ESDAILE J, 1991, NEW ENGL J MED, V324, P150
   FOX RI, 1993, SEMIN ARTHRITIS RHEU, V23, P82, DOI 10.1016/S0049-0172(10)80012-5
   Funck-Brentano C, 2020, LANCET
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Haeusler IL, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1188-2
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Lexicomp, 2020, LEX DRUGS
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mahevas M, 2020, INFECT DIS
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta B, 2020, JAMA HLTH FORUM, V1, pe200438
   Mercuro NJ, 2020, JAMA CARDIOL, DOI DOI 10.1001/JAMACARDIO.2020.1834
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   NIH, 2020, NIH HALTS CLIN TRIAL
   Pukrittayakamee S, 2014, ANTIMICROB AGENTS CH, V58, P3354, DOI 10.1128/AAC.02794-13
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Somer M, 2000, BRIT J CLIN PHARMACO, V49, P549, DOI 10.1046/j.1365-2125.2000.00197.x
   Szekely Y, 2020, HEART RHYTHM
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   TETT SE, 1993, CLIN PHARMACOKINET, V25, P392, DOI 10.2165/00003088-199325050-00005
   Timm JC, TRUMP SAYS HES TAKIN
   Trump DJ, 2020, HYDROXYCHLOROQUINE A
   US Food & Drug Administration, 2020, FDA CAUT US HYDR CHL
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Voss A, 2020, OFFICIAL STATEMENT I
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
NR 45
TC 2
Z9 2
U1 13
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1061-5377
EI 1538-4683
J9 CARDIOL REV
JI Cardiol. Rev.
PD SEP-OCT
PY 2020
VL 28
IS 5
BP 266
EP 271
DI 10.1097/CRD.0000000000000329
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NC6SG
UT WOS:000561346600009
PM 32769401
DA 2021-01-01
ER

PT J
AU Chen, Z
   Tong, L
   Zhou, Y
   Hua, C
   Wang, W
   Fu, J
   Shu, Q
   Hong, L
   Xu, H
   Xu, Z
   Chen, Y
   Mao, Y
   Ye, S
   Wu, X
   Wang, L
   Luo, Y
   Zou, X
   Tao, X
   Zhang, Y
AF Chen, Z.
   Tong, L.
   Zhou, Y.
   Hua, C.
   Wang, W.
   Fu, J.
   Shu, Q.
   Hong, L.
   Xu, H.
   Xu, Z.
   Chen, Y.
   Mao, Y.
   Ye, S.
   Wu, X.
   Wang, L.
   Luo, Y.
   Zou, X.
   Tao, X.
   Zhang, Y.
TI Childhood COVID-19: a multicentre retrospective study
SO CLINICAL MICROBIOLOGY AND INFECTION
LA English
DT Article
DE Child; Coronavirus disease-19; Diagnosis; Outcome; Treatment
ID CHINA
AB Objectives: To investigate the clinical and epidemiological characteristics of paediatric patients with coronavirus disease-19 (COVID-19).
   Methods: Paediatric patients diagnosed with COVID-19 between January 15 and March 15, 2020, from seven hospitals in Zhejiang Province, China, were collected retrospectively and analysed.
   Results: Thirty-two children with COVID-19, ranging in age from 3 months to 18 years, were enrolled. Family aggregation occurred in 87.5% of infant and preschool-aged children (7/8), and also school-aged children (14/16), but in only 12.5% (1/8) of adolescents (p < 0.05, p < 0.001). Most of these patients had mild symptoms: mainly fever (20/32) followed by cough (10/32) and fatigue (4/32). The average durations of viral RNA in respiratory samples and gastrointestinal samples were 15.8 d and 28.9 d, respectively. Detox duration in faeces decreased with age: 39.8 d, 27.5 d and 20.4 d in infants and preschool children, school children, and adolescents respectively (p(0-6,) (-18) <0.01, p(0-6, -14) <0.05). Pneumonia was found in 14 children, but there was no statistical significance in the incidence of pneumonia between different age groups. Thirty patients were treated with antiviral drugs, and all patients were stable and gradually improved after admission.
   Conclusions: Most children with COVID-19 had a mild process and a good prognosis. More attention should be paid to investigation of household contact history in the diagnosis of COVID-19 in young children. Viral RNA lasts longer in the gastrointestinal system than in the respiratory tract, especially in younger children. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
C1 [Chen, Z.; Tong, L.; Zhou, Y.; Hua, C.; Wang, W.; Fu, J.; Shu, Q.; Chen, Y.; Ye, S.; Tao, X.] Zhejiang Univ, Childrens Hosp, Sch Med, Hangzhou 310052, Peoples R China.
   [Chen, Z.; Tong, L.; Zhou, Y.; Hua, C.; Wang, W.; Fu, J.; Shu, Q.; Chen, Y.; Ye, S.; Tao, X.] Natl Childrens Reg Med Ctr, Natl Clin Res Ctr Child Hlth, Hangzhou 310052, Peoples R China.
   [Hong, L.; Luo, Y.] Zhejiang Ruian Peoples Hosp, Dept Paediat, Wenzhou 325200, Peoples R China.
   [Xu, H.; Zhang, Y.] Ningbo Women & Childrens Hosp, Dept Paediat, Ningbo 315012, Peoples R China.
   [Xu, Z.; Zou, X.] Huzhou Cent Hosp, Dept Paediat, Huzhou 313000, Zhejiang, Peoples R China.
   [Mao, Y.] First Peoples Hosp Yuhang Dist, Dept Paediat, Hangzhou 311100, Peoples R China.
   [Wu, X.] Cixi Peoples Hosp, Dept Paediat, Med & Hlth Grp, Cixi 315300, Peoples R China.
   [Wang, L.] Wenzhou Med Univ, Affiliated Taizhou Hosp, Dept Paediat, Wenzhou 317000, Zhejiang, Peoples R China.
RP Fu, J; Shu, Q (corresponding author), Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Sch Med, Hangzhou 310052, Peoples R China.
EM fjf68@zju.edu.cn; shuqiang@zju.edu.cn
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li M, 2020, CHIN J INFECT DIS, DOI [10.3760/cma.j.issn.1000-6680.2020.0007, DOI 10.3760/CMA.J.ISSN.1000-6680.2020.0007]
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Memish ZA, 2014, PEDIATR INFECT DIS J, V33, P904, DOI 10.1097/INF.0000000000000325
   She JT, 2020, J MED VIROL, V92, P747, DOI 10.1002/jmv.25807
   Tian Y, 2020, ALIMENT PHARM THER, V51, P843, DOI 10.1111/apt.15731
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang XL, 2017, LANCET INFECT DIS, V17, P822, DOI [10.1016/s1473-3099(17)30323-7, 10.1016/S1473-3099(17)30323-7]
   Wei M, 2020, JAMA-J AM MED ASSOC, V323, P1313, DOI 10.1001/jama.2020.2131
   Wu JG, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101673
NR 14
TC 3
Z9 3
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1198-743X
EI 1469-0691
J9 CLIN MICROBIOL INFEC
JI Clin. Microbiol. Infect.
PD SEP
PY 2020
VL 26
IS 9
DI 10.1016/j.cmi.2020.06.015
PG 4
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA NB3DH
UT WOS:000560393000034
PM 32599159
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dakay, K
   Kaur, G
   Gulko, E
   Santarelli, J
   Bowers, C
   Mayer, SA
   Gandhi, CD
   Al-Mufti, F
AF Dakay, Katarina
   Kaur, Gurmeen
   Gulko, Edwin
   Santarelli, Justin
   Bowers, Christian
   Mayer, Stephan A.
   Gandhi, Chirag D.
   Al-Mufti, Fawaz
TI Reversible cerebral vasoconstriction syndrome and dissection in the
   setting of COVID-19 infection
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Reversible cerebral vasoconstriction syndrome; Coronavirus; COVID-19;
   Convexity subarachnoid hemorrhage; Vertebral artery dissection
AB The current COVID-19 pandemic has recently brought to attention the myriad of neuro- logic sequelae associated with Coronavirus infection including the predilection for stroke, particularly in young patients. Reversible cerebral vasoconstriction syndrome (RCVS) is a well-described clinical syndrome leading to vasoconstriction in the intracra- nial vessels, and has been associated with convexity subarachnoid hemorrhage and oc- casionally cervical artery dissection. It is usually reported in the context of a trigger such as medications, recreational drugs, or the postpartum state; however, it has not been described in COVID-19 infection. We report a case of both cervical vertebral ar- tery dissection as well as convexity subarachnoid hemorrhage due to RCVS, in a pa- tient with COVID-19 infection and no other triggers. (c) 2020 Elsevier Inc. All rights reserved.
C1 [Dakay, Katarina; Kaur, Gurmeen; Santarelli, Justin; Gandhi, Chirag D.; Al-Mufti, Fawaz] New York Med Coll, Dept Neurosurg, 100 Woods Rd, Valhalla, NY 10595 USA.
   [Gulko, Edwin] New York Med Coll, Dept Radiol, Div Neuroradiol, Valhalla, NY USA.
   [Bowers, Christian] Univ New Mexico, Dept Neurosurg, Albuquerque, NM USA.
   [Mayer, Stephan A.] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA.
RP Al-Mufti, F (corresponding author), New York Med Coll, Dept Neurosurg, 100 Woods Rd, Valhalla, NY 10595 USA.
EM fawaz.al-mufti@wmchealth.org
RI Al-Mufti, Fawaz/AAZ-3360-2020
OI Al-Mufti, Fawaz/0000-0003-4461-7005; Kaur, Gurmeen/0000-0002-4732-8834
CR Divani AA, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104941
   Ducros A, 2012, LANCET NEUROL, V11, P906, DOI 10.1016/S1474-4422(12)70135-7
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Mawet J, 2013, NEUROLOGY, V81, P821, DOI 10.1212/WNL.0b013e3182a2cbe2
   Rocha EA, 2019, NEUROLOGY, V92, pe639, DOI 10.1212/WNL.0000000000006917
   Sharifi-Razavi A, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100669
   Topcuoglu MA, 2016, STROKE, V47, P1742, DOI 10.1161/STROKEAHA.116.013136
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD SEP
PY 2020
VL 29
IS 9
AR 105011
DI 10.1016/j.jstrokecerebrovasdis.2020.105011
PG 3
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA NB8EN
UT WOS:000560747000013
PM 32807426
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Benitez-Cardoza, CG
   Vique-Sanchez, JL
AF Benitez-Cardoza, Claudia Guadalupe
   Vique-Sanchez, Jose Luis
TI Potential inhibitors of the interaction between ACE2 and SARS-CoV-2
   (RBD), to develop a drug
SO LIFE SCIENCES
LA English
DT Article
DE ACE2; COVID-19; Drug by docking; Inhibitors of RBD; SARS-CoV-2
ID ANGIOTENSIN-CONVERTING ENZYME-2; SARS; DISCOVERY; IDENTIFICATION; SPIKE;
   MODEL
AB Aims: The COVID-19 disease caused by the SARS-CoV-2 has become a pandemic and there are no effective treatments that reduce the contagion. It is urgent to propose new treatment options, which are more effective in the interaction between viruses and cells. In this study was to develop a search for new pharmacological compounds against the angiotensin-converting enzyme 2 (ACE2), to inhibit the interaction with SARS-CoV-2.
   Materials and methods: Docking, virtual screening using almost 500,000 compounds directed to interact in the region between the residues (Gln24, Asp30, His34, Tyr41, Gln42, Met82, Lys353, and Arg357) in ACE2. The average of Delta G(binding), the standard deviation value and the theoretical toxicity from compounds were analyzed.
   Key findings: 20 best compounds directed to interact in ACE2 with a high probability to be safe in humans, validated by web servers of prediction of ADME and toxicity (ProTox-II and PreADMET), to difficult the interaction between ACE2 and region binding domain (RBD) of SARS-CoV-2.
   Significance: In this study, 20 compounds were determined by docking focused on the region of interaction between ACE2 and RBD of SARS-CoV-2 was carried out. The compounds are publicly available to validate the effect in in vitro tests.
C1 [Benitez-Cardoza, Claudia Guadalupe] Inst Politecn Nacl, ENMyH, Lab Invest Bioquim, Mexico City, DF, Mexico.
   [Vique-Sanchez, Jose Luis] Univ Autonoma Baja California, Fac Med, Mexicali, BC, Mexico.
RP Vique-Sanchez, JL (corresponding author), Univ Autonoma Baja California, Fac Med, Mexicali, BC, Mexico.
EM jvique@uabc.edu.mx
OI Vique-Sanchez, Jose Luis/0000-0001-8169-3715
FU SIP-IPN Mexico [20196821, 20200919]; PRODEP-SEP; SNI-CONACyTConsejo
   Nacional de Ciencia y Tecnologia (CONACyT); UABC; COFAA-IPN2
FX The authors are very grateful for the financial support from SIP-IPN
   Mexico (20196821, 20200919), COFAA-IPN2, PRODEP-SEP, SNI-CONACyT and
   UABC.
CR Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Calligari P, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040445
   Corporation, CHEMBRIDGE
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:6<490::AID-JCC1>3.3.CO;2-V
   Han DP, 2006, VIROLOGY, V350, P15, DOI 10.1016/j.virol.2006.01.029
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang JS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041131
   Huentelman MJ, 2004, HYPERTENSION, V44, P903, DOI 10.1161/01.HYP.0000146120.29648.36
   Labute P, 2008, J COMPUT CHEM, V29, P1693, DOI 10.1002/jcc.20933
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Oliveira MA, 1999, PEPTIDES, V20, P1195
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Soga S, 2007, J CHEM INF MODEL, V47, P400, DOI 10.1021/ci6002202
   Soler MJ, 2008, MED CLIN-BARCELONA, V131, P230
   Strawn WB, 1999, HYPERTENSION, V33, P207, DOI 10.1161/01.HYP.33.1.207
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Thangapandian S, 2011, INT J MOL SCI, V12, P9440, DOI 10.3390/ijms12129440
   Vankadari N, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105998
   Wadood A, 2017, PHARM BIOL, V55, P19, DOI 10.1080/13880209.2016.1225778
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wang L, 2017, EUR J MED CHEM, V137, P450, DOI 10.1016/j.ejmech.2017.05.045
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu YS, 2006, CURR MED CHEM, V13, P2003, DOI 10.2174/092986706777584988
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 40
TC 1
Z9 1
U1 19
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD SEP 1
PY 2020
VL 256
AR 117970
DI 10.1016/j.lfs.2020.117970
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NB8MC
UT WOS:000560767800014
PM 32553928
OA Green Published
DA 2021-01-01
ER

PT J
AU Hage-Melim, LID
   Federico, LB
   de Oliveira, NKS
   Francisco, VCC
   Correia, LC
   de Lima, HB
   Gomes, SQ
   Barcelos, MP
   Francischini, IAG
   da Silva, CHTD
AF Hage-Melim, Lorane Izabel da Silva
   Federico, Leonardo Bruno
   de Oliveira, Nayana Keyla Seabra
   Francisco, Viviane Cristina Cardoso
   Correia, Lenir Cabral
   de Lima, Henrique Barros
   Gomes, Suzane Quintana
   Barcelos, Mariana Pegrucci
   Francischini, Isaque Antonio Galindo
   Silva, Carlos Henrique Tomich de Paula da
TI Virtual screening, ADME/Tox predictions and the drug repurposing concept
   for future use of old drugs against the COVID-19
SO LIFE SCIENCES
LA English
DT Article
DE SARS-CoV-2; Computational drug repurposing; Coronavirus
ID TOXICITY; PROTEASE; FAVIPIRAVIR; INHIBITOR; SYSTEMS; AGENTS; DEREK
AB The new Coronavirus (SARS-CoV-2) is the cause of a serious infection in the respiratory tract called COVID-19. Structures of the main protease of SARS-CoV-2 (M-pro), responsible for the replication of the virus, have been solved and quickly made available, thus allowing the design of compounds that could interact with this protease and thus to prevent the progression of the disease by avoiding the viral peptide to be cleaved, so that smaller viral proteins can be released into the host's plasma. These structural data are extremely important for in silico design and development of compounds as well, being possible to quick and effectively identify potential inhibitors addressed to such enzyme's structure. Therefore, in order to identify potential inhibitors for M-pro, we used virtual screening approaches based with the structure of the enzyme and two compounds libraries, targeted to SARS-CoV-2, containing compounds with predicted activity against M-pro. In this way, we selected, through docking studies, the 100 top-ranked compounds, which followed to subsequent studies of pharmacokinetic and toxicity predictions. After all the simulations and predictions here performed, we obtained 10 top-ranked compounds that were again in silico analyzed inside the M-pro catalytic site, together some drugs that are being currently investigated for treatment of COVID-19. After proposing and analyzing the interaction modes of these compounds, we submitted one molecule then selected as template to a 2D similarity study in a database containing drugs approved by FDA and we have found and indicated Apixaban as a potential drug for future treatment of COVID-19.
C1 [Hage-Melim, Lorane Izabel da Silva; de Oliveira, Nayana Keyla Seabra; Francisco, Viviane Cristina Cardoso; Correia, Lenir Cabral; de Lima, Henrique Barros] Univ Fed Amapa, Lab Pharmaceut & Med Chem PharMedChem, Macapa, Amapa, Brazil.
   [Federico, Leonardo Bruno; Gomes, Suzane Quintana; Barcelos, Mariana Pegrucci; Francischini, Isaque Antonio Galindo; Silva, Carlos Henrique Tomich de Paula da] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Computat Lab Pharmaceut Chem, Ribeirao Preto, SP, Brazil.
   [Gomes, Suzane Quintana; Barcelos, Mariana Pegrucci; Silva, Carlos Henrique Tomich de Paula da] Univ Sao Paulo, Sch Philosophy Sci & Letters Ribeirao Preto, Dept Chem, Ribeirao Preto, SP, Brazil.
RP Hage-Melim, LID (corresponding author), Univ Fed Amapa, Lab Pharmaceut & Med Chem PharMedChem, Macapa, Amapa, Brazil.
EM lorane@unifap.br
RI Barcelos, Mariana Pegrucci/ABB-9924-2020; Federico, Leonardo
   Bruno/S-5368-2019
OI Barcelos, Mariana Pegrucci/0000-0003-4642-3116; Federico, Leonardo
   Bruno/0000-0002-2943-8802; De Lima, Henrique/0000-0002-8973-4902; Gomes,
   Suzane/0000-0003-3423-6313
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (Capes)CAPES; Drug Technologies
FX We acknowledge support from Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (Capes) and Drug Technologies.
CR Almazan F, 2014, VIRUS RES, V189, P262, DOI 10.1016/j.virusres.2014.05.026
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arya R, 2020, POTENTIAL INHIBITORS, DOI [10.26434/chemrxiv.11860011.v2, DOI 10.26434/CHEMRXIV.11860011.V2, 10.26434/chemrxiv.11860011.v2.]
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bleicher KH, 2003, NAT REV DRUG DISCOV, V2, P369, DOI 10.1038/nrd1086
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chandak N, 2014, J ENZYM INHIB MED CH, V29, P476, DOI 10.3109/14756366.2013.805755
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Crosby James C, 2020, J Am Coll Emerg Physicians Open, DOI 10.1002/emp2.12081
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   de Sisternes L, 2015, INVEST OPHTH VIS SCI, V56, P3415, DOI 10.1167/iovs.14-16345
   Eckert H, 2007, DRUG DISCOV TODAY, V12, P225, DOI 10.1016/j.drudis.2007.01.011
   Fagherazzi EV, 2012, PSYCHOPHARMACOLOGY, V219, P1133, DOI 10.1007/s00213-011-2449-3
   Fazeel Z, 2016, MAMC J MED SCI, V2, P63, DOI [10.4103/2394-7438.182723, DOI 10.4103/2394-7438.182723]
   Ferreira JV, 2017, CHEMMEDCHEM, V12, P1408, DOI 10.1002/cmdc.201700129
   Fischer A., INHIBITORS NOVEL COR
   Furuta Y, 2002, ANTIMICROB AGENTS CH, V46, P977, DOI 10.1128/AAC.46.4.977-981.2002
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Galucio JM, 2019, COMPUT BIOL CHEM, V83, DOI 10.1016/j.compbiolchem.2019.107102
   Gao H, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2019.126793
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Godden JW, 2000, J CHEM INF COMP SCI, V40, P163, DOI 10.1021/ci990316u
   Greene N, 1999, SAR QSAR ENVIRON RES, V10, P299, DOI 10.1080/10629369908039182
   Hayden FG, 2003, ANTIMICROB AGENTS CH, V47, P3907, DOI 10.1128/AAC.47.12.3907-3916.2003
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hohnloser SH, 2019, CIRCULATION, V139, P2292, DOI 10.1161/CIRCULATIONAHA.118.037955
   Hornak V, 2007, DRUG DISCOV TODAY, V12, P132, DOI 10.1016/j.drudis.2006.12.011
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Muster WG, 2008, DRUG DISCOV TODAY, V13, P303, DOI 10.1016/j.drudis.2007.12.007
   Nagata T, 2015, DISASTER MED PUBLIC, V9, P79, DOI 10.1017/dmp.2014.151
   Ntie-Kang F, 2016, DRUG DES DEV THER, V10, P2137, DOI 10.2147/DDDT.S108118
   Padilha EC, 2016, J BRAZIL CHEM SOC, V27, P1636, DOI 10.5935/0103-5053.20160043
   Ridings JE, 1996, TOXICOLOGY, V106, P267, DOI 10.1016/0300-483X(95)03190-Q
   Sang P, 2020, INSIGHT DERIVED MOL, DOI [10.26434/chemrxiv.11932995.v1, DOI 10.26434/CHEMRXIV.11932995.V1]
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Schrodinger, 2015, QIKPROP 4 4 US MAN
   Shoichet BK, 2004, NATURE, V432, P862, DOI 10.1038/nature03197
   Singh S. P., 2013, J BIOINFORMATICS INT, V2, P1, DOI DOI 10.1166/JBIC.2013.1030
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   WEEKS M H, 1960, Am Ind Hyg Assoc J, V21, P374, DOI 10.1080/00028896009344089
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yam J. C. S., 2006, Hong Kong Medical Journal, V12, P294
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 53
TC 3
Z9 3
U1 12
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD SEP 1
PY 2020
VL 256
AR 117963
DI 10.1016/j.lfs.2020.117963
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NB8LV
UT WOS:000560767000008
PM 32535080
OA Green Published
DA 2021-01-01
ER

PT J
AU Khodir, AE
   Samra, YA
   Said, E
AF Khodir, Ahmed E.
   Samra, Yara A.
   Said, Eman
TI A novel role of nifuroxazide in attenuation of sepsis-associated acute
   lung and myocardial injuries; role of TLR4/NLPR3/IL-1 beta signaling
   interruption
SO LIFE SCIENCES
LA English
DT Article
DE Nifuroxazide; LPS; TILR4; NALPR3; IL-1 beta
ID ANIMAL-MODELS; INFLAMMATION; TRANSDUCER; ENDOTOXIN; ACTIVATOR; SURVIVAL;
   CALCIUM; PATHWAY; HEART
AB Acute lung injury (ALI) and the subsequent multi-system organ failure is a serious health problem with devastating impacts on the health care systems. Indeed, the world has been facing an un-preceded situation in the past couple of months following COVID-19 infestation and the associated high-mortality rates mainly attributed to sepsis and the associated multiple organ failures of particular concern; acute respiratory distress syndrome post lung injury. The current study provides evidence on the ameliorative impact of nifuroxazide, and FDA approved antidiarrheal drug in attenuation of lipopolysaccharide (LPS)-induced ALI and myocarditis when administrated either in prophylactic or curative regimens. Nifuroxazide administration was associated with a significant improvement in lung and heart histopathological characteristics and architecture with retraction of LPS-induced inflammatory-infiltration. This was associated with retraction in serum biomarkers of cellular injury of which; LDH, CK-MB, and ALP. Nifuroxazide administration was associated with a significant improvement in both lung and heart oxidative status. Such positive outcomes were underlined by a significant inhibitory effect of nifuroxazide on lung and heart contents of toll-like receptor (4) (TLR4)/the inflammasome NALPR3/interleukin-1 beta (IL-1 beta). In conclusion: Nifuroxazide attenuates LPS-induced ALI and myocardial injury via interruption of TLR4/NALPR3/IL-1 beta signaling. Thus it can offer a potential approach for attenuation of sepsis in critically ill patients.
C1 [Khodir, Ahmed E.] Delta Univ Sci & Technol, Dept Pharmacol & Biochem, Int Coastal Rd, Mansoura, Dakahliya, Egypt.
   [Samra, Yara A.] Mansoura Univ, Dept Biochem, Fac Pharm, Mansoura 35516, Egypt.
   [Said, Eman] Mansoura Univ, Fac Pharm, Dept Pharmacol & Toxicol, Mansoura 35516, Egypt.
RP Said, E (corresponding author), Mansoura Univ, Fac Pharm, Dept Pharmacol & Toxicol, Mansoura 35516, Egypt.
EM emansaid@mans.edu.eg
OI Said, Eman/0000-0001-5529-6994
CR Antonucci E, 2014, J CRIT CARE, V29, P500, DOI 10.1016/j.jcrc.2014.03.028
   Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854
   Chaudhry H, 2013, IN VIVO, V27, P669
   Doi K, 2009, J CLIN INVEST, V119, P2868, DOI 10.1172/JCI39421
   Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1197, DOI 10.1164/rccm.200204-302OC
   Elsherbiny NM, 2018, TOXICOL MECH METHOD, V28, P467, DOI 10.1080/15376516.2018.1459995
   Figueiredo M.J., 2015, FRONTIERS, V1, P85
   Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709
   Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028
   Gul F, 2017, TURK J ANAESTHESIOL, V45, P129, DOI 10.5152/TJAR.2017.93753
   He X., 2016, SCI REP, V6, P1, DOI DOI 10.1038/SREP24261
   Horng T, 2014, TRENDS IMMUNOL, V35, P253, DOI 10.1016/j.it.2014.02.007
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Jia HJ, 2017, MOL MED REP, V16, P9480, DOI 10.3892/mmr.2017.7825
   Khodir AE, 2016, HUM EXP TOXICOL, V35, P388, DOI 10.1177/0960327115591372
   Khodir AE, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117610
   Khodir AE, 2014, CAN J PHYSIOL PHARM, V92, P839, DOI 10.1139/cjpp-2014-0191
   Kuzmich NN, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040034
   Luo Y, 2019, INVEST NEW DRUG, V37, P1006, DOI 10.1007/s10637-019-00724-4
   Luo YP, 2014, INT IMMUNOPHARMACOL, V20, P24, DOI 10.1016/j.intimp.2014.02.017
   MARTICH GD, 1991, J EXP MED, V173, P1021, DOI 10.1084/jem.173.4.1021
   Martin L, 2017, ANAESTHESIST, V66, P479, DOI 10.1007/s00101-017-0329-x
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Nelson EA, 2008, BLOOD, V112, P5095, DOI 10.1182/blood-2007-12-129718
   Ozturk Akcora Busra, 2020, FASEB Bioadv, V2, P77, DOI 10.1096/fba.2019-00070
   Papaioannou V.E., 2015, SEPTIC CARDIOMYOPATH
   Polat G, 2017, EURASIAN J MED, V49, P53, DOI 10.5152/eurasianjmed.2017.17062
   Azevedo LCP, 2008, SHOCK, V30, P60, DOI 10.1097/SHK.0b013e318181a425
   Pop-Began V, 2014, J Med Life, V7 Spec No. 2, P38
   Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004
   Said E, 2018, CHEM-BIOL INTERACT, V281, P111, DOI 10.1016/j.cbi.2017.12.030
   Sarvi S, 2018, CELL CHEM BIOL, V25, P1456, DOI 10.1016/j.chembiol.2018.09.005
   Schorr CA, 2014, TRENDS MOL MED, V20, P192, DOI 10.1016/j.molmed.2014.02.001
   Subramaniam A, 2013, BBA-REV CANCER, V1835, P46, DOI 10.1016/j.bbcan.2012.10.002
   Thompson M, 2000, PEDIATR RES, V47, P669, DOI 10.1203/00006450-200005000-00019
   Van Eeden S, 2012, AM J RESP CRIT CARE, V186, P11, DOI 10.1164/rccm.201203-0455PP
   Won C, 2015, HEPATOLOGY, V62, P1160, DOI 10.1002/hep.27968
   Yang F, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.63
   Yang Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1413-8
   Ye TH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.452
   Zhang Z, 2016, ANN TRANSL MED, V4
   Zhu YX, 2016, SCI REP-UK, V6, DOI 10.1038/srep20253
NR 42
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD SEP 1
PY 2020
VL 256
AR 117907
DI 10.1016/j.lfs.2020.117907
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NB8KN
UT WOS:000560763500013
PM 32504751
DA 2021-01-01
ER

PT J
AU Govindarajan, R
   Berry, JD
   Paganoni, S
   Pulley, MT
   Simmons, Z
AF Govindarajan, Raghav
   Berry, James D.
   Paganoni, Sabrina
   Pulley, Michael T.
   Simmons, Zachary
TI Optimizing telemedicine to facilitate amyotrophic lateral sclerosis
   clinical trials
SO MUSCLE & NERVE
LA English
DT Article
DE ALS; clinical trials; COVID-19; eConsent; telemedicine; telepresenter;
   telescreening
ID PSEUDOBULBAR AFFECT; ALSFRS-R; SCALE; RELIABILITY; TELEHEALTH;
   ENROLLMENT; INVENTORY; VALIDITY
AB Amyotrophic lateral sclerosis (ALS) has the largest drug pipeline among neuromuscular diseases, with over 160 companies actively involved in ALS research. There is a growing need to recruit trial participants, but ALS patients often have limited mobility and most ALS trials are conducted in a small number of major centers. These factors effectively limit patient participation, particularly for those in rural areas. The current coronavirus disease 2019 (COVID-19) pandemic has necessitated the more widespread use of telemedicine technology for clinical care, and has prompted consideration of its increased use for clinical trials. In this opinion piece, we describe the current state of telemedicine for recruitment, consenting, and screening of participants for clinical trials. We also summarize the available data on remote administration of outcome measures. Current challenges include validation of outcome measures for remote assessment, as well as technological, regulatory, and licensure barriers.
C1 [Govindarajan, Raghav] Univ Missouri, Dept Neurol, Columbia, MO 65212 USA.
   [Berry, James D.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
   [Berry, James D.] Massachusetts Gen Hosp, Neurol Clin Trials Unit, Boston, MA 02114 USA.
   [Paganoni, Sabrina] Massachusetts Gen Hosp, Healey Ctr ALS, Mass Gen Hosp, Boston, MA 02114 USA.
   [Paganoni, Sabrina] Harvard Med Sch, Spaulding Rehabil Hosp, Dept PM&R, Boston, MA 02115 USA.
   [Pulley, Michael T.] Univ Florida, Dept Neurol, Jacksonville, FL USA.
   [Simmons, Zachary] Penn State Hlth MS Hershey Med Ctr, Dept Neurol, Hershey, PA USA.
RP Govindarajan, R (corresponding author), Univ Missouri, Dept Neurol, Columbia, MO 65212 USA.
EM govindarajanr@health.missouri.edu
OI Simmons, Zachary/0000-0001-8574-5332
CR Abe K, 2017, LANCET NEUROL, V16, P505, DOI 10.1016/S1474-4422(17)30115-1
   Bakker LA, 2020, J NEUROL NEUROSUR PS, V91, P75, DOI 10.1136/jnnp-2019-321138
   Bedlack RS, 2008, AMYOTROPH LATERAL SC, V9, P257, DOI 10.1080/17482960802195913
   Bedlack RS, 2010, AMYOTROPH LATERAL SC, V11, P502, DOI 10.3109/17482968.2010.484494
   BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901
   Berry JD, 2019, ANN CLIN TRANSL NEUR, V6, P873, DOI 10.1002/acn3.770
   Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8
   Brooks BR, 2004, NEUROLOGY, V63, P1364
   Bunnell BE, 2020, TELEMED E-HEALTH, V26, P51, DOI 10.1089/tmj.2018.0221
   Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5
   Dunn A., 2019, BIOPHARMADIVE   0925
   EveryCRSReport.com, 2001, EVERYCRSREPORT  1024
   Felgoise SH, 2018, MUSCLE NERVE, V58, P646, DOI 10.1002/mus.26203
   Geronimo A, 2019, AMYOTROPH LAT SCL FR, V20, P348, DOI 10.1080/21678421.2019.1587633
   Geronimo A, 2017, AMYOTROPH LAT SCL FR, V18, P555, DOI 10.1080/21678421.2017.1338298
   Gibbons CJ, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-101
   Hirsch IB, 2017, CLIN THER, V39, P1064, DOI 10.1016/j.clinthera.2017.03.018
   Holland JC, 1998, PSYCHO-ONCOL, V7, P460, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<460::AID-PON328>3.0.CO;2-R
   Horton DK, 2018, AMYOTROPH LAT SCL FR, V19, P126, DOI 10.1080/21678421.2017.1406953
   Jackson NM, 2020, CORONAVIRUS OFFERS O
   Jenkinson C, 1999, AMYOTROPH LATERAL SC, V1, P33
   Kaufmann P, 2007, AMYOTROPH LATERAL SC, V8, P42, DOI 10.1080/17482960600888156
   Kruse CS, 2018, J TELEMED TELECARE, V24, P4, DOI 10.1177/1357633X16674087
   Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3
   McCormack MC, 2020, 2020 MEMBERS ATS PRO
   Melao A, CENTAUR PHASE 2 TRIA
   Montes J, 2006, NEUROLOGY, V67, P1294, DOI 10.1212/01.wnl.0000238505.22066.fc
   Nims P., 2013, ROLE TELEPRESENTER
   PERKINSON MA, 1994, J GERONTOL, V49, pS264, DOI 10.1093/geronj/49.5.S264
   Plowman EK, 2016, NEUROGASTROENT MOTIL, V28, P85, DOI 10.1111/nmo.12700
   Pulley MT, 2019, MUSCLE NERVE, V59, P34, DOI 10.1002/mus.26170
   Rutkove SB, 2019, AMYOTROPH LAT SCL FR, V20, P61, DOI 10.1080/21678421.2018.1541095
   Saltzman J., 2019, SPEED DRUG DEV MASS
   Sharpe TJ., 2019, ADOPTING ECONSENT BE, P18
   Smith RA, 2004, MULT SCLER J, V10, P679, DOI 10.1191/1352458504ms1106oa
   Stephens HE, 2016, AMYOTROPH LAT SCL FR, V17, P55, DOI 10.3109/21678421.2015.1069851
   Van De Rijn M, 2018, AMYOTROPH LAT SCL FR, V19, P143, DOI 10.1080/21678421.2017.1392577
   van Eijk RPA, 2019, J NEUROL, V266, P2387, DOI 10.1007/s00415-019-09427-5
   Weinstein RS, 2018, MED CLIN N AM, V102, P533, DOI 10.1016/j.mcna.2018.01.002
   Whisman MA, 2000, J CLIN PSYCHOL, V56, P545, DOI 10.1002/(SICI)1097-4679(200004)56:4<545::AID-JCLP7>3.0.CO;2-U
NR 40
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD SEP
PY 2020
VL 62
IS 3
BP 321
EP 326
DI 10.1002/mus.26921
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NA0WK
UT WOS:000559540100011
PM 32415876
OA Bronze
DA 2021-01-01
ER

PT J
AU Rao, P
   Shukla, A
   Parmar, P
   Rawal, RM
   Patel, B
   Saraf, M
   Goswami, D
AF Rao, Priyashi
   Shukla, Arpit
   Parmar, Paritosh
   Rawal, Rakesh M.
   Patel, Baldev
   Saraf, Meenu
   Goswami, Dweipayan
TI Reckoning a fungal metabolite, Pyranonigrin A as a potential Main
   protease (M-pro) inhibitor of novel SARS-CoV-2 virus identified using
   docking and molecular dynamics simulation
SO BIOPHYSICAL CHEMISTRY
LA English
DT Article
DE Main protease (M-pro); SARS-CoV-2 novel corona virus; Fungal
   metabolites; Docking; Molecular dynamics simulation
ID ACHILLES-HEEL; CORONAVIRUS; SARS; GROMACS; COMPLEX; DESIGN
AB The novel SARS-CoV-2 is the etiological agent causing the Coronavirus disease 2019 (COVID-19), which continues to become an inevitable pandemic outbreak. Over a short span of time, the structures of therapeutic target proteins for SARS-CoV-2 were identified based on the homology modelled structure of similar SARS-CoV transmission of 2003. Since the onset of the disease, the research community has been looking for a potential drug lead. Out of all the known resolved structures related to SARS-CoV, Main protease (M-pro) is considered an attractive anti-viral drug target on the grounds of its role in viral replication and probable non-interactive competency to bind to any viral host protein. To the best of our knowledge, till date only one compound has been identified and tested in-vivo as a potent inhibitor of M-pro protein, addressed as N3 (PubChem Compound CID: 6323191) and is known to bind irreversibly to M-pro suppressing its activity. Using computational approach, we intend to identify a probable natural fungal metabolite to interact and inhibit M-pro. After screening various small molecules for molecular docking and dynamics simulation, we propose Pyranonigrin A, a secondary fungal metabolite to possess potent inhibitory potential against the Main protease (M-pro) expressed in SARS-CoV-2 virus.
C1 [Rao, Priyashi; Rawal, Rakesh M.] Gujarat Univ, Univ Sch Sci, Dept Biochem & Forens Sci, Ahmadabad 380009, Gujarat, India.
   [Shukla, Arpit; Parmar, Paritosh; Patel, Baldev; Saraf, Meenu; Goswami, Dweipayan] Gujarat Univ, Univ Sch Sci, Dept Microbiol & Biotechnol, Ahmadabad 380009, Gujarat, India.
RP Goswami, D (corresponding author), Gujarat Univ, Univ Sch Sci, Dept Microbiol & Biotechnol, Ahmadabad 380009, Gujarat, India.
EM dweipayan.goswami@gujaratuniversity.ac.in
RI ; Shukla, Arpit/N-2597-2016
OI Parmar, Paritosh/0000-0001-6463-8124; Rawal, Rakesh/0000-0002-7985-1187;
   Rao, Priyashi/0000-0002-7203-8249; Shukla, Arpit/0000-0003-3099-0036;
   Goswami, Dweipayan/0000-0003-0165-0294; Saraf, Meenu/0000-0003-4964-9452
CR Arya R., 2020, POTENTIAL INHIBITORS
   Bekker H., 1993, GROMACS PARALLEL COM
   Berendsen HJC, 1981, INTERMOLECULAR FORCE, V1981, P331, DOI [10.1007/978-94-015-7658-1_21, DOI 10.1007/978-94-015-7658-1_21]
   Cui W, 2019, BIOCHEM BIOPH RES CO, V511, P794, DOI 10.1016/j.bbrc.2019.02.105
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   GASTEIGER J, 1979, J CHEM INF COMP SCI, V19, P43, DOI 10.1021/ci60017a011
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Jin Z., 2020, STRUCTURE MPRO COVID
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kong R., 2020, ARXIV200300163
   Krivov GG, 2009, PROTEINS, V77, P778, DOI 10.1002/prot.22488
   Linnakoski R, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02325
   Macchiagodena M., 2020, ARXIV09937
   Niu C, 2008, BIOORGAN MED CHEM, V16, P293, DOI 10.1016/j.bmc.2007.09.034
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3
   Riko R, 2014, J ANTIBIOT, V67, P179, DOI 10.1038/ja.2013.91
   St John SE, 2015, BIOORGAN MED CHEM, V23, P6036, DOI 10.1016/j.bmc.2015.06.039
   Tang MC, 2018, AICHE J, V64, P4182, DOI 10.1002/aic.16324
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Turner P., 2005, LAND MARGIN RES, P19
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wang FH, 2017, J MED CHEM, V60, P3212, DOI 10.1021/acs.jmedchem.7b00103
   Wang FH, 2016, J VIROL, V90, P1910, DOI 10.1128/JVI.02685-15
   WANG JM, 2001, ABSTR PAP AM CHEM 1, V222
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Yang HT, 2006, CURR PHARM DESIGN, V12, P4573, DOI 10.2174/138161206779010369
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zoete V., 2011, J COMPUT CHEM, V32
NR 34
TC 2
Z9 2
U1 11
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0301-4622
EI 1873-4200
J9 BIOPHYS CHEM
JI Biophys. Chem.
PD SEP
PY 2020
VL 264
AR 106425
DI 10.1016/j.bpc.2020.106425
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA MX8HL
UT WOS:000557960700009
PM 32663708
DA 2021-01-01
ER

PT J
AU Woodside, AG
AF Woodside, Arch G.
TI Interventions as experiments: Connecting the dots in forecasting and
   overcoming pandemics, global warming, corruption, civil rights
   violations, misogyny, income inequality, and guns
SO JOURNAL OF BUSINESS RESEARCH
LA English
DT Article
DE COVID-19; Intervention; Experiment; Marketing; Ultimate broadening
ID STATISTICAL SIGNIFICANCE; SIGNIFICANCE TESTS; PROGRESS; DONE
AB This essay applies the "ultimate broadening of the concept of marketing" for designing and implementing interventions in public laws and policy, national and local regulations, and everyday lives of individuals. The ultimate broadening of the concept of marketing: Marketing is any activity, message, emotion, or behavior by someone, firm, organization, government, community, or brand executed consciously or nonconsciously that may stimulate an observable or non-observable activity, emotion, attitude, belief, or thought by someone else, group, organization, firm or community. The broadening definition applies to the current interventions by national and state/provincial governments as well as healthcare facilities, medical science facilities, firms, and individuals to mitigate and eliminate the impact of the COVID-19 pandemic. Framing interventions as experiments is helpful in improving the quality of their designs, implementing them successfully, and validly interpreting their effectiveness. In January and February 2020, a few nations were exemplars for accurately forecasting the coming disaster of COVID-19 as a cause of illness and death and in designing/implementing effective mitigating strategies: Denmark, Finland, Republic of Korea, New Zealand, Norway, and Vietnam. While the COVID-19 prevention intervention tests now being run for several promising vaccines are true experiments, the researchers analyzing the data from these interventions may need prompting to examine the efficacy of each vaccine tested by modeling demographic subgroups for the members in the treatment and placebo groups in the randomized control trials.
C1 [Woodside, Arch G.] Boston Coll, 4801 Wigley Rd NE, Marietta, GA 30066 USA.
RP Woodside, AG (corresponding author), Boston Coll, Carroll Sch Mkt, Fulton Hall 450, Chestnut Hill, MA 02467 USA.
EM arch.woodside@bc.edu
CR [Anonymous], 2014, ECONOMIST
   [Anonymous], 1981, PRESIDENTIAL INAUGUR
   [Anonymous], 2011, ECONOMIST
   Armstrong J.S., 2010, PERSUASIVE ADVERTISI
   Armstrong JS, 2007, INT J FORECASTING, V23, P335, DOI 10.1016/j.ijforecast.2007.01.010
   Armstrong JS, 2007, INT J FORECASTING, V23, P321, DOI 10.1016/j.ijforecast.2007.03.004
   Armstrong JS, 2018, J GLOB SCHOLARS MARK, V28, P103, DOI 10.1080/21639159.2018.1441735
   Armstrong JS, 2015, J BUS RES, V68, P1717, DOI 10.1016/j.jbusres.2015.03.031
   Beaubien J., 2020, NPR NATL PUBLIC 0326
   Belvedere V, 2017, INT J FORECASTING, V33, P652, DOI 10.1016/j.ijforecast.2017.02.004
   Campbell D. T., 1963, EXPT QUASIEXPERIMENT
   CAMPBELL DT, 1969, AM PSYCHOL, V24, P409, DOI 10.1037/h0027982
   Fildes R, 2007, INTERFACES, V37, P570, DOI 10.1287/inte.1070.0309
   Franses PH, 2014, EXPERT ADJUSTMENTS OF MODEL FORECASTS: THEORY, PRACTICE AND STRATEGIES FOR IMPROVEMENT, P1, DOI 10.1017/CBO9781139963329
   Fukushima G.S., 2020, JAPAN TIMES
   Gigerenzer G., 1999, SIMPLE HEURISTICS MA
   Gossling S, 2020, J SUSTAIN TOUR, V29, P1, DOI 10.1080/09669582.2020.1758708
   Grove WM, 2000, PSYCHOL ASSESSMENT, V12, P19, DOI 10.1037/1040-3590.12.1.19
   Hauer E, 2004, ACCIDENT ANAL PREV, V36, P495, DOI 10.1016/S0001-4575(03)00036-8
   Hubbard R., 2015, CORRUPT RES CASE REC
   KOTLER P, 1969, J MARKETING, V33, P10, DOI 10.2307/1248740
   Laczniak G.R., 1979, J ACAD MARKET SCI, V7, P214, DOI DOI 10.1007/BF02721876
   Levy Sidney, 2003, CONSUMP MARK CULT, V6, P99, DOI DOI 10.1080/1025386032000099903
   Lin VS, 2014, ANN TOURISM RES, V48, P156, DOI 10.1016/j.annals.2014.06.005
   Low H., 2017, BBC
   Mariano W, 2020, ATLANTA J CONSTITUTI
   Markel H., 2017, JAMA-J AM MED ASSOC, V298, P644
   McClelland DC, 1998, PSYCHOL SCI, V9, P331, DOI 10.1111/1467-9280.00065
   McCloskey D., 2002, SECRET SINS EC
   McKercher B, 2004, ANN TOURISM RES, V31, P716, DOI 10.1016/j.annals.2003.11.002
   McKinley J., 2020, NY TIMES
   Meehl P., 1954, CLIN VS STAT PREDICT
   MEEHL PE, 1978, J CONSULT CLIN PSYCH, V46, P806, DOI 10.1037/0022-006X.46.4.806
   Novatorov E., 2016, J EC BIBLIO, V3, P450
   Sanders B., 2016, LOOK DENMARK
   Scheidel W., 2017, GREAT LEVELER VIOLEN
   Schulz K. F., 1999, JAMA-J AM MED ASSOC, V273, P408
   Tucker W. T., 1967, FDN THEORY CONSUMER
   UNWTO, 2020, COVID 19 UNWTO CALLS
   UNWTO (United Nations World Tourism Organisation), 2020, INT TOUR ARR COULD F
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wasserstein RL, 2016, AM STAT, V70, P131
   Wasserstein RL, 2016, AM STAT, V70, P129, DOI 10.1080/00031305.2016.1154108
   Wehrwein P., 2020, MANAGED HLTH EX 0429
   Woodside A. G., 2018, IMPROVING MARRIAGE M, P63
   Woodside AG, 2020, INT J CONTEMP HOSP M, V32, P889, DOI 10.1108/IJCHM-02-2019-0152
   Woodside AG, 2020, J BUS IND MARK, V35, P40, DOI 10.1108/JBIM-10-2018-0290
   Woodside AG, 2019, PSYCHOL MARKET, V36, P1046, DOI 10.1002/mar.21255
   Woodside AG, 2017, J GLOB SCHOLARS MARK, V27, P1, DOI 10.1080/21639159.2016.1265323
   Ziliak S.T., 2008, CULT STAT SIGNIFICAN
NR 50
TC 4
Z9 4
U1 25
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0148-2963
EI 1873-7978
J9 J BUS RES
JI J. Bus. Res.
PD SEP
PY 2020
VL 117
BP 212
EP 218
DI 10.1016/j.jbusres.2020.05.027
PG 7
WC Business
SC Business & Economics
GA MW2RD
UT WOS:000556889900019
PM 32536734
OA Green Published
DA 2021-01-01
ER

PT J
AU Grech, V
   Borg, M
AF Grech, Victor
   Borg, Michael
TI Influenza vaccination in the COVID-19 era
SO EARLY HUMAN DEVELOPMENT
LA English
DT Article
ID MORTALITY
AB Influenza spreads globally annually with significant paediatric and adult attack rates and considerable morbidity, mortality and the exacerbation of extant chronic disease. In the northern and southern hemispheres, outbreaks occur mainly in the respective winter seasons. Influenza vaccination is available but only partially effective. In the absence of a vaccine, in winter, novel coronavirus COVID-19 will also circulate in parallel with seasonal influenza. Thus far it appears that with the current strains of these two viruses, the clinical outcome of co-infection is not significantly worse than infection with COVID-19 alone. However, several strains of influenza circulate, including strains still to come. Similarly, COVID-19 has several strains, with probably more to come. This paper discusses these issues and estimates ideal minimum influenza vaccination coverage based on an estimated influenza Basic Reproduction Number (RO) of 0.9-2.1 so as to obtain herd immunity or approach it. There is a strong argument for attempting near universal population coverage with the annual influenza vaccine leading up to next winter.
C1 Univ Malta, Paediat Dept, Msida, Malta.
   Univ Malta, Pathol Dept, Msida, Malta.
RP Grech, V (corresponding author), Mater Dei Hosp, Paediat Dept, Msida, Malta.
EM victor.e.grech@gov.mt; michael.a.borg@gov.mt
CR Asciak R, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-68
   Borkenhagen LK, 2019, INT J INFECT DIS, V88, P113, DOI 10.1016/j.ijid.2019.08.002
   Camilleri SA, 2018, MULTIDISCIP RESP MED, V13, DOI 10.1186/s40248-018-0135-6
   Centers for Disease Control and Prevention, CDC SEASONAL FLU VAC
   Chean R., 2014, Healthcare Infection, V19, P42, DOI 10.1071/HI13041
   Coburn BJ, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-30
   Cuschieri S, 2020, J PUBLIC HEALTH-HEID, DOI 10.1007/s10389-020-01308-w
   Demicheli V, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001269.pub5
   Ding Q, 2020, J MED VIROL, V92, P1549, DOI 10.1002/jmv.25781
   Eccles R, 2005, LANCET INFECT DIS, V5, P718, DOI 10.1016/S1473-3099(05)70270-X
   Edmond MB, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofy214
   Freiberger M., 2019, UNDERSTANDING NUMBER
   Grech V, 2020, EARLY HUM DEV, V144, DOI 10.1016/j.earlhumdev.2020.105054
   Grech Victor, 2020, THE SYNAPSE
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ioannidis J.P., 2020, POPULATION LEVEL COV, DOI [10.1101/2020.04.05.20054361, DOI 10.1101/2020.04.05.20054361]
   Jefferson T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004879.pub4
   Kobasa D, 2007, NATURE, V445, P319, DOI 10.1038/nature05495
   Lu H, 2020, RISK ANAL, V40, P2040, DOI 10.1111/risa.13459
   Mitamura Keiko, 2006, Virus (Nagoya), V56, P109
   Murin S, 2005, CLEV CLIN J MED, V72, P916, DOI 10.3949/ccjm.72.10.916
   Murray CJL, 2006, LANCET, V368, P2211, DOI 10.1016/S0140-6736(06)69895-4
   Newall AT, 2012, PHARMACOECONOMICS, V30, P647, DOI 10.2165/11599130-000000000-00000
   Ogen Y, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138605
   Postma Maarten J, 2006, Expert Rev Pharmacoecon Outcomes Res, V6, P215, DOI 10.1586/14737167.6.2.215
   Putri WCWS, 2018, VACCINE, V36, P3960, DOI 10.1016/j.vaccine.2018.05.057
   Rechel B., 2018, THE ORGANIZATION AND
   Roussel Y, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105947
   Sansone K., 2020, MALTATODAY
   Somes MP, 2018, VACCINE, V36, P3199, DOI 10.1016/j.vaccine.2018.04.063
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   World Health Organisation, WORLDHEALTHRANKINGS
   World Health Organization WHO, 2018, INFL SEAS
   Yamauchi Yohei, 2020, Adv Virus Res, V106, P1, DOI 10.1016/bs.aivir.2020.01.001
NR 34
TC 1
Z9 1
U1 23
U2 23
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-3782
EI 1872-6232
J9 EARLY HUM DEV
JI Early Hum. Dev.
PD SEP
PY 2020
VL 148
AR 105116
DI 10.1016/j.earlhumdev.2020.105116
PG 4
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA MW0GZ
UT WOS:000556727000008
PM 32604011
OA Green Published
DA 2021-01-01
ER

PT J
AU Ahmed-Belkacem, R
   Sutto-Ortiz, P
   Guiraud, M
   Canard, B
   Vasseur, JJ
   Decroly, E
   Debart, F
AF Ahmed-Belkacem, Rostom
   Sutto-Ortiz, Priscila
   Guiraud, Mathis
   Canard, Bruno
   Vasseur, Jean-Jacques
   Decroly, Etienne
   Debart, Francoise
TI Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of
   SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Nucleoside; Bisubstrate; SAM analogs; Coronavirus; RNA
   methyltransferase; Inhibitor
ID CORONAVIRUS; DESIGN; CONSTRUCTION
AB The spreading of new viruses is known to provoke global human health threat. The current COVID-19 pandemic caused by the recently emerged coronavirus SARS-CoV-2 is one significant and unfortunate example of what the world will have to face in the future with emerging viruses in absence of appropriate treatment. The discovery of potent and specific antiviral inhibitors and/or vaccines to fight these massive outbreaks is an urgent research priority. Enzymes involved in the capping pathway of viruses and more specifically RNA N7- or 2'O-methyltransferases (MTases) are now admitted as potential targets for antiviral chemotherapy. We designed bisubstrate inhibitors by mimicking the transition state of the 2'-O-methylation of the cap RNA in order to block viral 2'-O MTases. This work resulted in the synthesis of 16 adenine dinucleosides with both adenosines connected by various nitrogen-containing linkers. Unexpectedly, all the bisubstrate compounds were barely active against 2'-O MTases of several flaviviruses or SARS-CoV but surprisingly, seven of them showed efficient and specific inhibition against SARS-CoV N7-MTase (nsp14) in the micromolar to submicromolar range. The most active nsp14 inhibitor identified is as potent as but particularly more specific than the broad-spectrum MTase inhibitor, sinefungin. Molecular docking suggests that the inhibitor binds to a pocket formed by the S-adenosyl methionine (SAM) and cap RNA binding sites, conserved among SARS-CoV nsp14. These dinucleoside SAM analogs will serve as starting points for the development of next inhibitors for SARS-CoV-2 nsp14 N7-MTase. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Ahmed-Belkacem, Rostom; Guiraud, Mathis; Vasseur, Jean-Jacques; Debart, Francoise] Univ Montpellier, ENSCM, CNRS, IBMM, Montpellier, France.
   [Sutto-Ortiz, Priscila; Canard, Bruno; Decroly, Etienne] Aix Marseille Univ, CNRS, AFMB, UMR 7257, 163 Ave Luminy, Marseille, France.
RP Debart, F (corresponding author), Univ Montpellier, ENSCM, CNRS, IBMM, Montpellier, France.; Decroly, E (corresponding author), Aix Marseille Univ, CNRS, AFMB, UMR 7257, 163 Ave Luminy, Marseille, France.
EM etienne.decroly@afmb.univ-mrs.fr; francoise.debart@umontpellier.fr
RI Debart, Francoise/D-4320-2019
OI Debart, Francoise/0000-0003-3422-3926; DECROLY,
   Etienne/0000-0002-6046-024X; Vasseur, Jean-Jacques/0000-0002-4379-6139
FU University of Montpellier
FX Rostom Ahmed-Belkacem acknowledges University of Montpellier for the
   financial support of his PhD work.
CR Abdel-Magid AF, 2006, ORG PROCESS RES DEV, V10, P971, DOI 10.1021/op0601013
   Ahmed-Belkacem R, 2019, EUR J ORG CHEM, V2019, P6486, DOI 10.1002/ejoc.201901120
   Aouadi W, 2017, ANTIVIR RES, V144, P330, DOI 10.1016/j.antiviral.2017.06.021
   Atdjian C, 2018, EUR J ORG CHEM, V2018, P4411, DOI 10.1002/ejoc.201800798
   Auffinger P, 2004, P NATL ACAD SCI USA, V101, P16789, DOI 10.1073/pnas.0407607101
   Becares M, 2016, J VIROL, V90, P5399, DOI 10.1128/JVI.03259-15
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Cherney RJ, 2003, J MED CHEM, V46, P1811, DOI 10.1021/jm020475w
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Decroly E, 2017, CURR OPIN VIROL, V24, P87, DOI 10.1016/j.coviro.2017.04.003
   Devisscher L, 2018, J MED CHEM, V61, P10126, DOI 10.1021/acs.jmedchem.8b01299
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Gana R, 2013, BMC STRUCT BIOL, V13, DOI 10.1186/1472-6807-13-6
   Halby L, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0072
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iwaki S, 2012, BIOORG MED CHEM LETT, V22, P2798, DOI 10.1016/j.bmcl.2012.02.071
   Kan T, 2004, CHEM COMMUN, P353, DOI 10.1039/b311203a
   KOLB M, 1982, J MED CHEM, V25, P550, DOI 10.1021/jm00347a014
   Ku YY, 2019, J ORG CHEM, V84, P4814, DOI 10.1021/acs.joc.8b02750
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Mitchell AJ, 2017, J AM CHEM SOC, V139, P13830, DOI 10.1021/jacs.7b07374
   Moss TA, 2013, CHEM-EUR J, V19, P3071, DOI 10.1002/chem.201203825
   Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321
   Oerum S, 2019, RNA BIOL, V16, P798, DOI 10.1080/15476286.2019.1589360
   Paesen GC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9749
   Pan XH, 2015, TETRAHEDRON, V71, P5124, DOI 10.1016/j.tet.2015.05.113
   Peyrane F, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1119
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Salahuddin A, 2013, BIOORGAN MED CHEM, V21, P3080, DOI 10.1016/j.bmc.2013.03.052
   Shultz James M, 2016, Disaster Health, V3, P11, DOI [10.1080/21665044.2016.1228326, 10.1080/21665044.2015.1129889]
   Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360
   Sun Y, 2014, ANTIVIR RES, V104, P156, DOI 10.1016/j.antiviral.2014.02.002
   Vermote A, 2016, BIOORGAN MED CHEM, V24, P4563, DOI 10.1016/j.bmc.2016.07.058
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yao Y, 2011, J AM CHEM SOC, V133, P16746, DOI 10.1021/ja206312b
   Yu YS, 2019, MEDCHEMCOMM, V10, P89, DOI 10.1039/c8md00474a
   Zhang J, 2016, ACS CHEM BIOL, V11, P583, DOI 10.1021/acschembio.5b00812
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 40
TC 2
Z9 2
U1 31
U2 32
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD SEP 1
PY 2020
VL 201
AR 112557
DI 10.1016/j.ejmech.2020.112557
PG 16
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA MV8CU
UT WOS:000556579600031
PM 32563813
OA Green Published
DA 2021-01-01
ER

PT J
AU Niessen, WMA
AF Niessen, W. M. A.
TI Tandem mass spectrometry of small-molecule antiviral drugs: 3. antiviral
   agents against herpes, influenza and other viral infections
SO INTERNATIONAL JOURNAL OF MASS SPECTROMETRY
LA English
DT Article
DE Antiviral drugs; Tandem mass spectrometry; Fragmentation; Herpes
   viruses; Influenza viruses; Nucleoside analogues; Neuraminidase
   inhibitors; Protein inhibitors; Broad-spectrum antiviral agents
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; SOLID-PHASE EXTRACTION; HUMAN PLASMA;
   CHICKEN MUSCLE; HYDROGEN/DEUTERIUM EXCHANGE; SIMULTANEOUS
   QUANTIFICATION; NEURAMINIDASE INHIBITOR; INDUCED DISSOCIATION;
   ANTIINFLUENZA DRUG; HUMAN URINE
AB For the treatment of various viral infections, antiviral drugs may be used. Liquid chromatography-mass spectrometry (LC-MS) with tandem mass spectrometry (MS-MS) operated in selected-reaction moni-toring (SRM) mode is the method of choice in quantitative bioanalysis of drugs, e.g., to establish bioavailability, to study pharmacokinetics, and later on possibly for therapeutic drug monitoring. In this study, the fragmentation in MS-MS of small-molecule antiviral drugs against herpes and influenza viruses is reviewed. In this way, insight is gained on the identity of the product ions used in SRM. Fragmentation schemes of antiviral agents are also relevant in the identification of drug metabolites or (forced) degradation products. As information of the fragmentation of antiviral drugs in MS-MS and the identity of the product ions is very much scattered in the scientific literature, it was decided to collect this information and to review it. In this third study, attention is paid to small-molecule antiviral agents used against herpes and influenza virus infections. In addition, some attention is paid to broad-spectrum antiviral agents, that are investigated with respect to their efficacy in challenging virus infections of this century, e.g., involving Ebola, Zika and corona viruses, like SARS-CoV-2, which is causing a world-wide pandemic at this very moment. The review provides fragmentation schemes of ca. 35 antiviral agents. The identity of the product ions used in SRM, i.e., elemental composition and exact-m/z, is tabulated, and more detailed fragmentation schemes are provided. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Niessen, W. M. A.] Hyphen MassSpec, Margrietstr 34, NL-2215 HJ Voorhout, Netherlands.
RP Niessen, WMA (corresponding author), Hyphen MassSpec, Margrietstr 34, NL-2215 HJ Voorhout, Netherlands.
EM mail@hyphenms.nl
CR Agilent Technologies, 2016, AG FOR TOX LC MS PER
   Allen GD, 1999, J CHROMATOGR B, V732, P383, DOI 10.1016/S0378-4347(99)00306-0
   Andersen PI, 2020, INT J INFECT DIS, V93, P268, DOI 10.1016/j.ijid.2020.02.018
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Arndt T, 2005, CLIN CHIM ACTA, V359, P125, DOI 10.1016/j.cccn.2005.03.040
   Avataneo V, 2020, J ANTIMICROB CHEMOTH, V75, P1772, DOI 10.1093/jac/dkaa152
   Barlow A, 2020, PHARMACOTHERAPY, V40, P416, DOI 10.1002/phar.2398
   Baughman TM, 2007, J CHROMATOGR B, V852, P505, DOI 10.1016/j.jchromb.2007.02.006
   Biswas S, 2014, ANTIMICROB AGENTS CH, V58, P3843, DOI 10.1128/AAC.02641-14
   Boktor S.W., 2020, INFLUENZA
   Breddernann A, 2008, J CHROMATOGR B, V861, P1, DOI 10.1016/j.jchromb.2007.11.029
   Brown SD, 2002, RAPID COMMUN MASS SP, V16, P1871, DOI 10.1002/rcm.792
   de Mello CPP, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.00967-18, 10.1128/aac.00967-18]
   Deng P, 2013, ANTIMICROB AGENTS CH, V57, P1743, DOI 10.1128/AAC.02282-12
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Field F.H., 1972, MASS SPECTROMETRY, P133
   Guan ZQ, 2001, J MASS SPECTROM, V36, P264, DOI 10.1002/jms.124
   Ishizuka H, 2010, J CLIN PHARMACOL, V50, P1319, DOI 10.1177/0091270009356297
   Junwal M, 2012, J PHARMACEUT BIOMED, V62, P48, DOI 10.1016/j.jpba.2012.01.001
   Kamel AM, 2004, EUR J MASS SPECTROM, V10, P239, DOI 10.1255/ejms.538
   Kamel AM, 2007, J AM SOC MASS SPECTR, V18, P1477, DOI 10.1016/j.jasms.2007.05.001
   Kanneti R, 2011, BIOMED CHROMATOGR, V25, P458, DOI 10.1002/bmc.1468
   KARNI M, 1980, ORG MASS SPECTROM, V15, P53, DOI 10.1002/oms.1210150202
   Krecmerova M, 2017, MINI-REV MED CHEM, V17, P818, DOI 10.2174/1389557517666170216151601
   Kwon S, 2011, ANAL SCI TECHNOL, V24, P78, DOI 10.5806/AST.2011.24.2.078
   Lee HW, 2007, J CHROMATOGR B, V852, P382, DOI 10.1016/j.jchromb.2007.01.044
   Lei MD, 2018, BIOMED CHROMATOGR, V32, DOI 10.1002/bmc.4103
   Levsel K, 2007, J MASS SPECTROM, V42, P1024, DOI 10.1002/jms.1234
   Li Y, 2017, EUR J DRUG METAB PH, V42, P757, DOI 10.1007/s13318-016-0390-x
   Li Y, 2009, J CHROMATOGR B, V877, P933, DOI 10.1016/j.jchromb.2009.02.044
   Lin CC, 2006, ANTIMICROB AGENTS CH, V50, P2368, DOI 10.1128/AAC.00118-06
   Lin CC, 2002, J CHROMATOGR B, V779, P241, DOI 10.1016/S1570-0232(02)00379-3
   Lindberg RH, 2015, TALANTA, V141, P164, DOI 10.1016/j.talanta.2015.03.066
   Lindegardh N, 2007, J CHROMATOGR B, V859, P74, DOI 10.1016/j.jchromb.2007.09.018
   Lindegardh N, 2008, J CHROMATOGR A, V1215, P145, DOI 10.1016/j.chroma.2008.11.009
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu ZC, 2015, J SEP SCI, V38, P1784, DOI 10.1002/jssc.201401461
   Ma JD, 2006, J CLIN PHARMACOL, V46, P103, DOI 10.1177/0091270005283286
   Maes A, 2009, BIOMED CHROMATOGR, V23, P132, DOI 10.1002/bmc.1093
   MCLAFFERTY FW, 1980, ORG MASS SPECTROM, V15, P114, DOI 10.1002/oms.1210150303
   Momper JD, 2010, J PHARMACEUT BIOMED, V53, P1015, DOI 10.1016/j.jpba.2010.06.034
   Mooney D, 2020, J CHROMATOGR A, V1618, DOI 10.1016/j.chroma.2020.460857
   Mu PQ, 2016, J CHROMATOGR B, V1023, P17, DOI 10.1016/j.jchromb.2016.04.036
   Niessen WMA, 2020, INT J MASS SPECTROM, V455, DOI 10.1016/j.ijms.2020.116371
   Niessen WMA, 2020, INT J MASS SPECTROM, V455, DOI 10.1016/j.ijms.2020.116370
   Niessen W.M.A, 2017, INTERPRETATION MS MS
   Oxford John S., 2005, Antiviral Chemistry & Chemotherapy, V16, P13
   Paules C, 2017, LANCET, V390, P697, DOI 10.1016/S0140-6736(17)30129-0
   Peng XD, 2011, CHROMATOGRAPHIA, V73, P1089, DOI 10.1007/s10337-011-2001-y
   Poole CL, 2018, CLIN THER, V40, P1282, DOI 10.1016/j.clinthera.2018.07.006
   Pyrc K., 2007, Infectious Disorders - Drug Targets, V7, P59, DOI 10.2174/187152607780090757
   Quenelle DC, 2018, ANTIVIR RES, V149, P1, DOI 10.1016/j.antiviral.2017.11.002
   Rabaan AA, 2017, J MED MICROBIOL, V66, P1261, DOI 10.1099/jmm.0.000565
   Rajanikanth K.N., 2019, WJPPA, V8, P1234, DOI [10.20959/wjpps20192-12868, DOI 10.20959/WJPPS20192-12868]
   Rower JE, 2020, J PHARMACEUT BIOMED, V184, DOI 10.1016/j.jpba.2020.113181
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shi XJ, 2015, J CHROMATOGR B, V1002, P353, DOI 10.1016/j.jchromb.2015.08.038
   Singh O, 2011, CLIN BIOCHEM, V44, P907, DOI 10.1016/j.clinbiochem.2011.04.003
   Suo DC, 2018, J CHROMATOGR B, V1095, P183, DOI 10.1016/j.jchromb.2018.07.025
   Tong TR, 2009, EXPERT OPIN THER PAT, V19, P357, DOI 10.1517/13543770802609384
   Tong TR, 2009, EXPERT OPIN THER PAT, V19, P415, DOI 10.1517/13543770802600698
   Wang YY, 2008, J MASS SPECTROM, V43, P1099, DOI 10.1002/jms.1394
   Wu YL, 2014, J CHROMATOGR B, V965, P197, DOI 10.1016/j.jchromb.2014.06.038
   Xiong X, 2011, J AOAC INT, V94, P1100
   Xu HR, 2007, J CHROMATOGR B, V848, P329, DOI 10.1016/j.jchromb.2006.10.053
   Xu YJ, 2019, J CHROMATOGR B, V1126, DOI 10.1016/j.jchromb.2019.06.024
   Yadav M, 2009, J CHROMATOGR B, V877, P680, DOI 10.1016/j.jchromb.2009.01.042
   Zhang DX, 2009, J PHARMACEUT BIOMED, V49, P1027, DOI 10.1016/j.jpba.2009.02.003
   Zhang QY, 2016, J SEP SCI, V39, P3998, DOI 10.1002/jssc.201600490
   Zhang XH, 2010, J CHROMATOGR B, V878, P492, DOI 10.1016/j.jchromb.2009.12.016
   Zhang XH, 2008, J CHROMATOGR B, V875, P349, DOI 10.1016/j.jchromb.2008.09.011
   Zhang YX, 2020, J PHARM ANAL, V10, P346, DOI 10.1016/j.jpha.2020.03.002
   Zonja B, 2014, J HAZARD MATER, V265, P296, DOI 10.1016/j.jhazmat.2013.10.008
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 74
TC 0
Z9 0
U1 14
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1387-3806
EI 1873-2798
J9 INT J MASS SPECTROM
JI Int. J. Mass Spectrom.
PD SEP
PY 2020
VL 455
AR 116377
DI 10.1016/j.ijms.2020.116377
PG 12
WC Physics, Atomic, Molecular & Chemical; Spectroscopy
SC Physics; Spectroscopy
GA MU3IV
UT WOS:000555567000010
PM 32834766
OA Green Published
DA 2021-01-01
ER

PT J
AU Anmella, G
   Arbelo, N
   Fico, G
   Murru, A
   Llach, CD
   Madero, S
   Gomes-da-Costa, S
   Imaz, ML
   Lopez-Pelayo, H
   Vieta, E
   Pintor, L
AF Anmella, G.
   Arbelo, N.
   Fico, G.
   Murru, A.
   Llach, C. D.
   Madero, S.
   Gomes-da-Costa, S.
   Imaz, M. L.
   Lopez-Pelayo, H.
   Vieta, E.
   Pintor, L.
TI COVID-19 inpatients with psychiatric disorders: Real-world clinical
   recommendations from an expert team in consultation-liaison psychiatry
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Psychiatry; Consultation liaison psychiatry; Psychopharmacology;
   Psychodrug; Interactions; COVID-19
ID HEALTH-CARE; ANTIPSYCHOTICS; PROLONGATION
AB Background: The management of coronavirus disease 2019 (COVID-19) in patients with comorbid psychiatric disorders poses several challenges, especially regarding drug interactions.
   Methods: We report three representative case-scenarios on patients with psychiatric disorders and COVID-19 to provide a practical approach based on the existing literature and the clinical experience of an expert team in consultation-liaison psychiatry.
   Case-centered recommendations: Psychopharmacological ongoing treatments should be prioritized and most doses should be reduced 25-50% of original dose if the patient receives lopinavir/ritonavir, with some excep-tions including quetiapine, asenapine, olanzapine, sertraline, lamotrigine, bupropion, and methadone. If the psychopharmacological usual doses are in the low-to-median range levels, a dose change during COVID-19 drugs co-administration is not recommended, but only ECG and clinical monitoring of adverse effects and drug levels if required. Furthermore, when introducing a psychopharmacological drug, dose titration should be progressive, with ECG monitoring if cardiotoxic interactions are present.
   (A) In agitated delirium, olanzapine is recommended as first-line antipsychotic and quetiapine should be avoided.
   (B) In severe mental illness (SMI), essential treatments should be maintained.
   (C) In non-SMI with depressive/anxiety symptoms, psychological support should be provided and symptoms identified and treated.
   Limitations: Most recommendations on pharmacological interactions provide only a limited qualitative approach and quantitative recommendations are lacking.
   Conclusions: Patients with psychiatric disorders and COVID-19 should be managed on a personalized basis considering several clinical criteria and, should not be excluded from receiving COVID-19 treatments. Risks of pharmacological interaction are not absolute and should be contextualized, and most psychopharmacological treatments should include an ECG with special attention to QTc interval.
C1 [Anmella, G.; Arbelo, N.; Llach, C. D.; Madero, S.; Gomes-da-Costa, S.; Imaz, M. L.; Pintor, L.] Univ Barcelona, IDIBAPS, Consultat Liaison Psychiat Unit, Inst Neurosci,Hosp Clin, 170 Villarroel St,12-0, Barcelona 08036, Catalonia, Spain.
   [Anmella, G.; Fico, G.; Murru, A.; Gomes-da-Costa, S.; Lopez-Pelayo, H.; Vieta, E.] Univ Barcelona, IDIBAPS, Bipolar & Depress Disorders Unit, Inst Neurosci,Hosp Clin,CIBERSAM, 170 Villarroel St,12-0, Barcelona 08036, Catalonia, Spain.
   [Lopez-Pelayo, H.] Univ Barcelona, RETICS Red Trastornos Adict, Clin Inst Neurosci, GRAC Addict Unit,Dept Psychiat,Hosp Clin,IDIBAPS, Villarroel 170, Barcelona 08036, Spain.
RP Pintor, L (corresponding author), Univ Barcelona, IDIBAPS, Consultat Liaison Psychiat Unit, Inst Neurosci,Hosp Clin, 170 Villarroel St,12-0, Barcelona 08036, Catalonia, Spain.
EM LPINTOR@clinic.cat
OI Fico, Giovanna/0000-0003-1785-7126
FU Instituto de Salud Carlos IIISubdireccion General de Evaluacion y
   Fomento de la investigacion, Plan Nacional 2019-2022 [PI19/00672];
   Spanish Ministry of Science, Innovation and Universities, Instituto de
   Salud Carlos III through a 'Juan Rodes' contract [JR19/00025]; European
   Social FundEuropean Social Fund (ESF)
FX Dr. Murru has received a grant (PI19/00672) from the Instituto de Salud
   Carlos IIISubdireccion General de Evaluacion y Fomento de la
   investigacion, Plan Nacional 2019-2022. Dr. Lopez-Pelayo has received
   funding from the Spanish Ministry of Science, Innovation and
   Universities, Instituto de Salud Carlos III through a 'Juan Rodes'
   contract (JR19/00025), with the support of the European Social Fund, and
   IDIBPAS is a CERCA Programme/Generalitat de Catalunya.
CR Anmella G, 2020, J AFFECT DISORDERS, V273, P422, DOI 10.1016/j.jad.2020.05.061
   [Anonymous], 2019, LANCET PSYCHIAT, V6, P793, DOI 10.1016/S2215-0366(17)30242-0
   Garriga M, 2020, ACTA PSYCHIAT SCAND, V141, P479, DOI 10.1111/acps.13173
   Hasnain M, 2014, CNS DRUGS, V28, P887, DOI 10.1007/s40263-014-0196-9
   Henderson C, 2014, LANCET PSYCHIAT, V1, P467, DOI 10.1016/S2215-0366(14)00023-6
   Kaufman KR, 2020, BJPSYCH OPEN, V6, DOI 10.1192/bjo.2020.25
   Kotfis K, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02882-x
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Liverpul drug interactions group, 2020, INT EXP COVID 19 THE
   McCreary E.K., 2020, OPEN FORUM INFECT DI, DOI DOI 10.1093/OFID/OFAA105/5811022
   Sartorious Norman, 2013, Shanghai Arch Psychiatry, V25, P68, DOI 10.3969/j.issn.1002-0829.2013.02.002
   Seminog OO, 2013, THORAX, V68, P171, DOI 10.1136/thoraxjnl-2012-202480
   Shah AA, 2014, J PSYCHIATR PRACT, V20, P196, DOI 10.1097/01.pra.0000450319.21859.6d
   Vieta E, 2020, REV PSIQUIATR SALUD, V13, P105, DOI 10.1016/j.rpsm.2020.04.004
   Yao H, 2020, LANCET PSYCHIAT, V7, pE21, DOI 10.1016/S2215-0366(20)30090-0
   2020, DRUG INTERACTIONSCHE
NR 18
TC 4
Z9 4
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0165-0327
EI 1573-2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD SEP 1
PY 2020
VL 274
BP 1062
EP 1067
DI 10.1016/j.jad.2020.05.149
PG 6
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA MV8KW
UT WOS:000556600700027
PM 32663933
DA 2021-01-01
ER

PT J
AU Gougis, P
   Fenioux, C
   Funck-Brentano, C
   Veyri, M
   Gligorov, J
   Solas, C
   Spano, JP
AF Gougis, Paul
   Fenioux, Charlotte
   Funck-Brentano, Christian
   Veyri, Marianne
   Gligorov, Joseph
   Solas, Caroline
   Spano, Jean-Philippe
TI Anticancer drugs and COVID-19 antiviral treatments in patients with
   cancer: What can we safely use?
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Letter
C1 [Gougis, Paul; Fenioux, Charlotte; Funck-Brentano, Christian] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, INSERM,CIC 1901 Paris Est,CLIP2 Galilee,Dept Phar, F-75013 Paris, France.
   [Gougis, Paul; Veyri, Marianne; Spano, Jean-Philippe] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, Dept Oncol, F-75013 Paris, France.
   [Gougis, Paul; Fenioux, Charlotte; Veyri, Marianne; Gligorov, Joseph; Spano, Jean-Philippe] Sorbonne Univ, AP HP, Inst Univ Cancerol, Paris, France.
   [Veyri, Marianne; Spano, Jean-Philippe] Inst Pierre Louis Epidemiol & Sante Publ, INSERM, Equipe Theravir, Paris, France.
   [Gligorov, Joseph] Sorbonne Univ, Tenon Hosp, AP HP, INSERM U 938,CLIP2 Galilee,Med Oncol Dept, Paris, France.
   [Solas, Caroline] Aix Marseille Univ, Hop La Timone, AP HM, INSERM 1207,IRD 190,UVE,Lab Pharmacocinet & Toxic, F-13005 Marseille, France.
RP Gougis, P (corresponding author), Hop La Pitie Salpetriere, Ctr Invest Clin Paris Est CIC 1901, Dept Pharmacol, 47-83 Blvd Hop, F-75013 Paris, France.
EM paul.gougis@aphp.fr
RI Funck-Brentano, Christian/C-2126-2009
OI Funck-Brentano, Christian/0000-0003-0406-5189
CR [Anonymous], 2012, CLIN RES INF DRUG IN
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Spano JP, 2016, ANN ONCOL, V27, P397, DOI 10.1093/annonc/mdv606
NR 3
TC 1
Z9 1
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD SEP
PY 2020
VL 136
BP 1
EP 3
DI 10.1016/j.ejca.2020.05.027
PG 3
WC Oncology
SC Oncology
GA MX0IC
UT WOS:000557411500002
PM 32610172
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Houot, R
   Levy, R
   Cartron, G
   Armand, P
AF Houot, Roch
   Levy, Ronald
   Cartron, Guillaume
   Armand, Philippe
TI Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE COVID-19; SARS-CoV-2; Vaccine; Anti-CD20 antibody; Rituximab
ID INFLUENZA VACCINATION; LYMPHOMA PATIENTS; RITUXIMAB; RESPONSES
AB A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic malignancies or autoimmune disorders) are particularly at risk of severe COVID-19 and, as such, are the most in need of a vaccine. Here, we review the reasons why anti-CD20 therapy may abrogate or diminish the efficacy of a vaccine against SARS-CoV-2 and we draw physicians' attention towards this potential risk so that it can be considered when evaluating the risk/benefit ratio of anti-CD20 therapy during the current pandemic. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Houot, Roch] Univ Rennes, INSERM U1236, CHU Rennes, Dept Hematol, Rennes, France.
   [Houot, Roch; Armand, Philippe] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Levy, Ronald] Stanford Univ, Sch Med, Dept Med Oncol, Stanford, CA USA.
   [Cartron, Guillaume] Univ Montpellier, Inst Genet Mol Montpellier, CHU Montpellier Univ Hospitality, Dept Hematol,CNRS UMR 5535, Montpellier, France.
RP Houot, R (corresponding author), CHU Rennes, Dept Hematol, F-35000 Rennes, France.
EM roch.houot@chu-rennes.fr
OI Houot, Roch/0000-0003-1729-8213
CR Bedognetti D, 2011, J IMMUNOL, V186, P6044, DOI 10.4049/jimmunol.1004095
   Bingham CO, 2010, ARTHRITIS RHEUM-US, V62, P64, DOI 10.1002/art.25034
   Chandrashekar A, 2020, SCIENCE, DOI [10.1126/SCIENCE.ABC4776, DOI 10.1126/SCIENCE.ABC4776(80-)]
   Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312
   Du LY, 2016, EXPERT REV VACCINES, V15, P1123, DOI 10.1586/14760584.2016.1167603
   Eisenberg RA, 2013, J CLIN IMMUNOL, V33, P388, DOI 10.1007/s10875-012-9813-x
   Kim W, 2013, EUR J NEUROL, V20, P975, DOI 10.1111/ene.12132
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Nazi I, 2013, BLOOD, V122, P1946, DOI 10.1182/blood-2013-04-494096
   Omarini C, 2020, EUR J CANCER, V133, P29, DOI 10.1016/j.ejca.2020.04.034
   Padron-Regalado E, 2020, INFECT DIS THER, V9, P255, DOI 10.1007/s40121-020-00300-x
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Takata T, 2009, J CLIN EXP HEMATOP, V49, P9, DOI 10.3960/jslrt.49.9
   van der Kolk LE, 2002, BLOOD, V100, P2257, DOI 10.1182/blood.V100.6.2257.h81802002257_2257_2259
   Williamson E., 2020, OPENSAFELY FACTORS A, DOI [10.1101/2020.05.06.20092999, DOI 10.1101/2020.05.06.20092999]
   Yri OE, 2011, BLOOD, V118, P6769, DOI 10.1182/blood-2011-08-372649
   Yu J, 2020, SCIENCE, DOI [10.1126/SCIENCE.ABC6284, DOI 10.1126/SCIENCE.ABC6284(80-)]
NR 19
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD SEP
PY 2020
VL 136
BP 4
EP 6
DI 10.1016/j.ejca.2020.06.017
PG 3
WC Oncology
SC Oncology
GA MX0IC
UT WOS:000557411500003
PM 32619884
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lee, S
   Lim, AR
   Kim, MJ
   Choi, YJ
   Kim, JW
   Park, KH
   Shin, SW
   Kim, YH
AF Lee, Soohyeon
   Lim, Ah-reum
   Kim, Min Ja
   Choi, Yoon Ji
   Kim, Ju Won
   Park, Kyong Hwa
   Shin, Sang Won
   Kim, Yeul Hong
TI Innovative countermeasures can maintain cancer care continuity during
   the coronavirus disease-2019 pandemic in Korea
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE COVID-19; Continuity of patient care; Metastatic cancer
ID DIAGNOSIS; COVID-19
AB Background: Even though Korea was known to have the highest number of coronavirus disease-2019 (COVID-19) infection in the early phase of the pandemic, Korea was able to successfully flatten the curve in a short period of time without extreme measures. We compared the status of cancer management before and after COVID-19 and analysed how cancer care continuity was maintained in Korea.
   Patients and methods: We investigated the medical records on the number of cancer diagnosis, cancer surgery, radiation therapy and scheduled chemotherapy conducted in Korea University Anam Hospital from January 1 to April 30, 2019 and from the same period in 2020. We also collected the data of metastatic cancer patients who were hospitalised due to respiratory disease.
   Results: Of all diagnoses, 1694 cancer diagnoses were made in the study period of 2019, and 1445 diagnoses in 2020 (decreased by 14.7%); the cancer surgery performed 830 and 800 cases; the set-up for radiation therapy decreased from 185 to 140 cases; the number of systemic chemotherapies for metastatic cancer patients treated in department of medical oncology increased from 2555 to 2878 cases. Among hospitalised patients, emergency centre visit, intensive care unit admission, discharge after recovery and death reveal no drastic changes.
   Conclusions: Routine cancer care for patients with metastatic cancer has been maintained without significant difference before and after the COVID-19 pandemic. The Korean government's innovative countermeasures in the early phase of outbreak made it possible for cancer care practitioners to provide cancer patients with regular care under the standard infection control protocol. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Lee, Soohyeon; Lim, Ah-reum; Choi, Yoon Ji; Kim, Ju Won; Park, Kyong Hwa; Shin, Sang Won; Kim, Yeul Hong] Korea Univ, Anam Hosp, Coll Med, Div Med Oncol,Dept Internal Med, Seoul, South Korea.
   [Kim, Min Ja] Korea Univ, Anam Hosp, Coll Med, Div Infect Dis,Dept Internal Med, Seoul, South Korea.
RP Kim, YH (corresponding author), Korea Univ, Div Oncol, Dept Internal Med, Anam Hosp,Coll Med, 73 Goryeodae Ro, Seoul 02841, South Korea.
EM yhk0215@korea.ac.kr
RI Lee, Soohyeon/AAX-9843-2020
OI Lee, Soohyeon/0000-0001-9665-062X; KIM, MIN JA/0000-0002-2125-7521
CR Cho Sung-Il, 2020, J Prev Med Public Health, V53, P65, DOI 10.3961/jpmph.20.084
   Choi JY, 2020, POSTGRAD MED J, V96, P399, DOI 10.1136/postgradmedj-2020-137738
   Choi S, 2020, CLIN EXP EMERG MED, V7, P73, DOI 10.15441/ceem.20.032
   COVID-19 National Emergency Response Center Epidemiology & Case Management Team Korea Centers for Disease Control & Prevention, 2020, Osong Public Health Res Perspect, V11, P60, DOI 10.24171/j.phrp.2020.11.1.09
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Dinmohamed AG, 2020, LANCET ONCOL, V21, P750, DOI 10.1016/S1470-2045(20)30265-5
   Hong KH, 2020, ANN LAB MED, V40, P351, DOI 10.3343/alm.2020.40.5.351
   Jones D, 2020, LANCET ONCOL, V21, P748, DOI 10.1016/S1470-2045(20)30242-4
   Kim Inho, 2020, Osong Public Health Res Perspect, V11, P67, DOI 10.24171/j.phrp.2020.11.2.02
   Kutikov A, 2020, ANN INTERN MED, V172, P756, DOI 10.7326/M20-1133
   Lee J, 2020, BRIT J SURG, P2020, DOI 10.1002/bjs.11697
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Oh J, 2020, HEALTH SYST REFORM, V6, DOI 10.1080/23288604.2020.1753464
   Oncology ASoC, 2020, ASCO SPEC REP GUID C
   Peck KR, 2020, CLIN MICROBIOL INFEC, V26, P805, DOI 10.1016/j.cmi.2020.04.025
   Sen-Crowe B, 2020, AM J EMERG MED, V38, P1537, DOI 10.1016/j.ajem.2020.04.072
   Sung H, 2020, CLIN CHEM, V66, P979, DOI 10.1093/clinchem/hvaa097
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 19
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD SEP
PY 2020
VL 136
BP 69
EP 75
DI 10.1016/j.ejca.2020.06.021
PG 7
WC Oncology
SC Oncology
GA MX0IC
UT WOS:000557411500010
PM 32652443
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Angelis, V
   Tippu, Z
   Joshi, K
   Reis, S
   Gronthoud, F
   Fribbens, C
   Okines, A
   Stanway, S
   Cottier, E
   McGrath, S
   Watkins, D
   Noble, J
   Bhosle, J
   Gerlinger, M
   Hamid, I
   Soliman, H
   Nenclares, P
   Jones, R
   Harrington, K
   Gennatas, S
AF Angelis, Vasileios
   Tippu, Zayd
   Joshi, Kroopa
   Reis, Sara
   Gronthoud, Firza
   Fribbens, Charlotte
   Okines, Alicia
   Stanway, Susannah
   Cottier, Emma
   McGrath, Sophie
   Watkins, David
   Noble, Jillian
   Bhosle, Jaishree
   Gerlinger, Marco
   Hamid, Intan
   Soliman, Heba
   Nenclares, Pablo
   Jones, Robin
   Harrington, Kevin
   Gennatas, Spyridon
TI Defining the true impact of coronavirus disease 2019 in the at-risk
   population of patients with cancer
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE COVID-19; Cancer; Systemic anticancer therapy; Chemotherapy;
   Radiotherapy
ID COVID-19
AB Background: In light of the coronavirus disease 2019 (COVID-19) pandemic, cancer centres in the United Kingdom and Europe re-organised their services at an unprecedented pace, and many patients with cancer have had their treatments severely disrupted. Patients with cancer were considered at high risk on sparse evidence, and despite a small number of emerging observational studies, the true incidence and impact of COVID-19 in the `at- risk' population of patients with cancer is yet to be defined.
   Methods: Epidemiological and clinical data were collected prospectively for patients attending the Royal Marsden Hospital and three network hospitals between March 1st and April 30th 2020 that were confirmed to have Severe acute respiratory syndrome coronavirus 2 (SARSCoV2) infection. Significance of clinical and pathological characteristics was assessed using the Fisher's exact test and Wilcoxon rank sum test, whilst univariate and multivariate logistic regression models were used to further assess risk. The number of patients attending in March/April 2020 for face-to-face attendances was also extracted.
   Findings: During the 2-month study period, 867 of 13,489 (6.4%) patients met the criteria leading to swab testing. Of the total at-risk population, only 113 of 13,489 (0.84%) were swab positive, 101 of 13,489 (0.75%) required hospital admission and 29 of 13,489 (0.21%) died of COVID-19. Of the patients that attended the hospital to receive cytotoxic chemotherapy alone or in combination with other therapy, 59 of 2001 (2.9%) were admitted to the hospital for COVID-19-related issues and 20 of 2001 (1%) died. Of the patients that collected targeted treatments, 16 of 1126 (1.4%) were admitted and 1 of 1126 (0.1%) died. Of the 11 patients that had received radiotherapy, 6 of 1042 (0.6%) required inpatient admission and 2 of 1042 (0.2%) died.
   Interpretations: Administration of systemic anticancer therapy appears to be associated with a modest risk of severe COVID-19 infection. Based on this snapshot taken as the first wave of COVID-19 hit our practice, we conclude that continuation of active cancer treatment, even in the palliative setting, is appropriate. (C) 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Angelis, Vasileios; Tippu, Zayd; Reis, Sara; Gronthoud, Firza; Okines, Alicia; Gerlinger, Marco; Hamid, Intan; Soliman, Heba; Nenclares, Pablo; Jones, Robin; Harrington, Kevin; Gennatas, Spyridon] Royal Marsden Hosp NHS Trust, Fulham Rd, London SW3 6JJ, England.
   [Joshi, Kroopa; Fribbens, Charlotte; Stanway, Susannah; McGrath, Sophie; Watkins, David; Noble, Jillian; Bhosle, Jaishree; Gerlinger, Marco] Royal Marsden Hosp NHS Trust, Downs Rd, Sutton SM2 5PT, Surrey, England.
   [Okines, Alicia; Jones, Robin; Harrington, Kevin] Inst Canc Res, 237 Fulham Rd, London SW3 6JB, England.
   [Stanway, Susannah; Cottier, Emma; Noble, Jillian] Croydon Univ Hosp, 530 London Rd, Thornton Heath CR7 7YE, England.
RP Gennatas, S (corresponding author), Royal Marsden Hosp NHS Trust, Fulham Rd, London SW3 6JJ, England.
EM Spyridon.gennatas@rmh.nhs.uk
RI Gennatas, Spyridon/ABE-4559-2020; Jones, Robin L/AAO-3738-2020
OI Gennatas, Spyridon/0000-0002-5635-7696; Jones, Robin
   L/0000-0003-4173-3844; Gerlinger, Marco/0000-0003-2719-299X
FU Royal Marsden Hospital NHS Trust
FX This study received funding from the Royal Marsden Hospital NHS Trust.
CR [Anonymous], 2020, CANC SERVICES LONDON
   Cancer Patient Management During the COVID-19, 2020, CANC PAT MAN COVID 1
   Dai M, 2020, CANCER DISCOV
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   JoharatnamHogan N, 2020, OUTCOMES 2019 NOVEL, DOI [10.1101/2020.04.16.20061127., DOI 10.1101/2020.04.16.20061127]
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liang X, 2020, CLIN ONCOL-UK, V32, P407, DOI 10.1016/j.clon.2020.03.016
   NHS England, 2020, CLIN GUID MAN NONC P
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Spicer J, 2020, NAT REV CLIN ONCOL, DOI 10.1038/s41571-020-0370-6
   The UK National Institute of Health and Care Excellence, 2020, COVID 19 RAP GUID DE
   UK Coronavirus Canc, 2020, LANCET ONCOL, V21, P622, DOI 10.1016/S1470-2045(20)30230-8
   Williams M, 2020, ESTIMATING RISKS COV, DOI [10.1101/2020.03.18.20038067, DOI 10.1101/2020.03.18.20038067]
NR 15
TC 3
Z9 3
U1 7
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD SEP
PY 2020
VL 136
BP 99
EP 106
DI 10.1016/j.ejca.2020.06.027
PG 8
WC Oncology
SC Oncology
GA MX0IC
UT WOS:000557411500014
PM 32659475
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Ullrich, S
   Nitsche, C
AF Ullrich, Sven
   Nitsche, Christoph
TI The SARS-CoV-2 main protease as drug target
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE COVID-19; Coronavirus; Protease inhibitors; Peptidomimetics; Antivirals
ID COV 3CL PROTEASE; SARS-CORONAVIRUS; SUBSTRATE-SPECIFICITY;
   MOLECULAR-BIOLOGY; M-PRO; INHIBITORS; MECHANISM; DISCOVERY; ORIGIN;
   BIOSYNTHESIS
AB The unprecedented pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is threatening global health. The virus emerged in late 2019 and can cause a severe disease associated with significant mortality. Several vaccine development and drug discovery campaigns are underway. The SARS-CoV-2 main protease is considered a promising drug target, as it is dissimilar to human proteases. Sequence and structure of the main protease are closely related to those from other betacoronaviruses, facilitating drug discovery attempts based on previous lead compounds. Covalently binding peptidomimetics and small molecules are investigated. Various compounds show antiviral activity in infected human cells.
C1 [Ullrich, Sven; Nitsche, Christoph] Australian Natl Univ, Res Sch Chem, Canberra, ACT 2601, Australia.
RP Nitsche, C (corresponding author), Australian Natl Univ, Res Sch Chem, Canberra, ACT 2601, Australia.
EM christoph.nitsche@anu.edu.au
OI Ullrich, Sven/0000-0003-4184-7024
FU Australian Research CouncilAustralian Research Council [DE190100015];
   PROMOS scholarship from the German Academic Exchange Service
FX C.N. thanks the Australian Research Council for a Discovery Early Career
   Research Award (DE190100015). S.U. acknowledges a PROMOS scholarship
   from the German Academic Exchange Service.
CR Agbowuro AA, 2018, MED RES REV, V38, P1295, DOI 10.1002/med.21475
   Al-Gharabli SI, 2006, CHEMBIOCHEM, V7, P1048, DOI 10.1002/cbic.200500533
   Al-Tawfiq JA, 2019, TRAVEL MED INFECT DI, V27, P27, DOI 10.1016/j.tmaid.2018.12.003
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bengtson J, 2002, AM HEART J, V143, P95, DOI 10.1067/mhj.2002.119896
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Bzowka M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093099
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chou CY, 2004, BIOCHEMISTRY-US, V43, P14958, DOI 10.1021/bi0490237
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   da Costa VG, 2020, ARCH VIROL, V165, P1517, DOI 10.1007/s00705-020-04628-0
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Douangamath A., 2020, BIORXIV, DOI [10.1101/2020.05.27.118117., DOI 10.1101/2020.05.27.118117, 10.1101/2020.05.27.118117 .]
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Du QS, 2004, PEPTIDES, V25, P1857, DOI 10.1016/j.peptides.2004.06.018
   Fan KQ, 2005, BIOCHEM BIOPH RES CO, V329, P934, DOI 10.1016/j.bbrc.2005.02.061
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grum-Tokars V, 2008, VIRUS RES, V133, P63, DOI 10.1016/j.virusres.2007.02.015
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hilgenfeld R, 2013, ANTIVIR RES, V100, P286, DOI 10.1016/j.antiviral.2013.08.015
   Ho BL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144865
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   Jackson PA, 2017, J MED CHEM, V60, P839, DOI 10.1021/acs.jmedchem.6b00788
   Jacobs J, 2013, J MED CHEM, V56, P534, DOI 10.1021/jm301580n
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   John SE, 2017, Patent No. [US20170313685, 20170313685]
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   Khosrawipour V, 2020, J MED VIROL, V92, P863, DOI 10.1002/jmv.25883
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lau H, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa037
   Lau SKP, 2020, EMERG INFECT DIS, V26, P1542, DOI 10.3201/eid2607.200092
   Li CY, 2020, EMERG INFECT DIS, V26, P1626, DOI 10.3201/eid2607.200718
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Liang PH, 2006, CURR TOP MED CHEM, V6, P361, DOI 10.2174/156802606776287090
   Liang RY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120721
   Lim LM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173466
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Muramatsu T, 2013, FEBS J, V280, P2002, DOI 10.1111/febs.12222
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Rut W., 2020, BIORXIV, DOI [10.1101/2020.03.07.981928, DOI 10.1101/2020.03.07.981928]
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X
   Schmidt MF, 2008, ANGEW CHEM INT EDIT, V47, P3275, DOI 10.1002/anie.200704594
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Steinmetzer T, 2020, J MED CHEM, V63, P1445, DOI 10.1021/acs.jmedchem.9b01060
   Steuber H, 2010, CURR TOP MED CHEM, V10, P323, DOI 10.2174/156802610790725470
   Stoermer M., 2020, HOMOLOGY MODELS CORO, DOI [10.26434/chemrxiv.11637294.v3., DOI 10.26434/CHEMRXIV.11637294.V3]
   Su H., 2020, BIORXIV, DOI [10.1101/2020.04.13.038687, DOI 10.1101/2020.04.13.038687]
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wei P, 2006, BIOCHEM BIOPH RES CO, V339, P865, DOI 10.1016/j.bbrc.2005.11.102
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Wilder-Smith A, 2005, EMERG INFECT DIS, V11, P1142, DOI 10.3201/eid1107.041165
   Wong G, 2020, ZOOL RES, V41, P213, DOI 10.24272/j.issn.2095-8137.2020.031
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia B, 2011, PROTEIN CELL, V2, P282, DOI 10.1007/s13238-011-1034-1
   Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071
   Xu YF, 2020, TRENDS MICROBIOL, V28, P239, DOI 10.1016/j.tim.2020.02.001
   Yang HT, 2006, CURR PHARM DESIGN, V12, P4573, DOI 10.2174/138161206779010369
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
   Zhang CT, 2020, J MED VIROL, V92, P1441, DOI 10.1002/jmv.25788
   Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu LL, 2011, ANTIVIR RES, V92, P204, DOI 10.1016/j.antiviral.2011.08.001
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 107
TC 7
Z9 7
U1 40
U2 40
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 1
PY 2020
VL 30
IS 17
AR 127377
DI 10.1016/j.bmcl.2020.127377
PG 8
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA MT3TL
UT WOS:000554890700006
PM 32738988
OA Green Published
DA 2021-01-01
ER

PT J
AU DuBose, T
AF DuBose, Todd
TI When COVID-19 Meets Pandemic Hope: Existential Care of, and in, the
   Impossible
SO JOURNAL OF HUMANISTIC PSYCHOLOGY
LA English
DT Article
DE existential therapy; pandemic; hope
AB This article is an adaptation of a talk given to the International Institute for Existential-Humanistic Psychology in Beijing, China, March 14, 2020. I describe the existential concerns embedded in the biological discourse related to COVID-19, and offer the proposal that hope is as pandemic as COVID-19, if not more so, and invite us to think of the category, "pandemic," in existential terms. Shortly after this talk was given, I found out that I tested positive with COVID-19, thus adding a lived existentiality to what was written.
C1 [DuBose, Todd] Chicago Sch Profess Psychol, 325 North Wells, Chicago, IL 60654 USA.
RP DuBose, T (corresponding author), Chicago Sch Profess Psychol, 325 North Wells, Chicago, IL 60654 USA.
EM tdubose@thechicagoschool.edu
CR Coen E., 2007, NO COUNTRY OLD MEN
   Rumi J., 2004, THE ESSENTIAL RUMI
NR 2
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-1678
EI 1552-650X
J9 J HUMANIST PSYCHOL
JI J. Humanist. Psychol.
PD SEP
PY 2020
VL 60
IS 5
SI SI
BP 564
EP 570
DI 10.1177/0022167820944645
PG 7
WC Psychology, Multidisciplinary
SC Psychology
GA MS6KN
UT WOS:000554382400002
OA Bronze
DA 2021-01-01
ER

PT J
AU Chen, XS
   Geiger, JD
AF Chen, Xuesong
   Geiger, Jonathan D.
TI Janus sword actions of chloroquine and hydroxychloroquine against
   COVID-19
SO CELLULAR SIGNALLING
LA English
DT Article
DE Chloroquine; Hydroxychloroquine; COVID-19; Endolysosome; Golgi;
   de-acidification
ID RESPIRATORY SYNDROME CORONAVIRUS; TUMOR-NECROSIS-FACTOR; V-ATPASE;
   ORGANELLE ACIDIFICATION; PLASMODIUM-FALCIPARUM; ANTIMALARIAL-DRUGS;
   SPIKE GLYCOPROTEIN; SARS CORONAVIRUS; AMINES INHIBIT; CANCER CELLS
AB Chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) have been thrust into our everyday vernacular because some believe, based on very limited basic and clinical data, that they might be helpful in preventing and/or lessening the severity of the pandemic coronavirus disease 2019 (COVID-19). However, lacking is a temperance in enthusiasm for their possible use as well as sufficient perspective on their effects and side-effects. CQ and HCQ have well-known properties of being diprotic weak bases that preferentially accumulate in acidic organelles (endolysosomes and Golgi apparatus) and neutralize luminal pH of acidic organelles. These primary actions of CQ and HCQ are responsible for their anti-malarial effects; malaria parasites rely on acidic digestive vacuoles for survival. Similarly, de-acidification of endolysosomes and Golgi by CQ and HCQ may block severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) integration into host cells because SARS-CoV-2 may require an acidic environment for its entry and for its ability to bud and infect bystander cells. Further, deacidification of endolysosomes and Golgi may underly the immunosuppressive effects of these two drugs. However, modern cell biology studies have shown clearly that de-acidification results in profound changes in the structure, function and cellular positioning of endolysosomes and Golgi, in signaling between these organelles and other subcellular organelles, and in fundamental cellular functions. Thus, studying the possible therapeutic effects of CQ and HCQ against COVID-19 must occur concurrent with studies of the extent to which these drugs affect organellar and cell biology. When comprehensively examined, a better understanding of the Janus sword actions of these and other drugs might yield better decisions and better outcomes.
C1 [Chen, Xuesong; Geiger, Jonathan D.] Univ North Dakota, Sch Med & Hlth Sci, Dept Biomed Sci, Grand Forks, ND 58203 USA.
RP Chen, XS (corresponding author), Univ North Dakota, Sch Med & Hlth Sci, Dept Biomed Sci, Grand Forks, ND 58203 USA.
EM xuesong.chen@und.edu
OI Chen, Xuesong/0000-0003-0714-1378
FU National Institute of Mental HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [R01MH100972, R01MH105329,
   R01MH119000]
FX Research reported in this publication was supported by the National
   Institute of Mental Health [R01MH100972, 2014], National Institute of
   Mental Health [R01MH105329, 2015], and National Institute of Mental
   Health [R01MH119000, 2019].
CR Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508
   Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   Axelsson MAB, 2001, GLYCOBIOLOGY, V11, P633, DOI 10.1093/glycob/11.8.633
   Barbosa S.D.S.R., 2020, EMPIRICAL TREATMENT
   Belizaire R, 2009, P NATL ACAD SCI USA, V106, P17463, DOI 10.1073/pnas.0908583106
   BERNSTEIN H, 1963, INVEST OPHTH VISUAL, V2, P384
   Bosch BJ, 2008, J VIROL, V82, P8887, DOI 10.1128/JVI.00415-08
   Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622
   Boya P, 2012, ANTIOXID REDOX SIGN, V17, P766, DOI 10.1089/ars.2011.4405
   Bright NA, 2005, CURR BIOL, V15, P360, DOI 10.1016/j.cub.2005.01.049
   BROWN WJ, 1984, J CELL BIOL, V99, P320, DOI 10.1083/jcb.99.1.320
   CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252
   Carlucci P, 2020, HYDROXYCHLOROQUINE A
   Carta S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00123
   Casey JR, 2010, NAT REV MOL CELL BIO, V11, P50, DOI 10.1038/nrm2820
   CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen ZW, 2020, EFFICACY HYDROXYCHLO
   Chew T, 2009, MOL IMMUNOL, V46, P393, DOI 10.1016/j.molimm.2008.10.010
   CHICUREL M, 1988, INFECT IMMUN, V56, P479, DOI 10.1128/IAI.56.2.479-483.1988
   Choi Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1574806
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Christensen KA, 2002, J CELL SCI, V115, P599
   Circu M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184922
   Colacurcio DJ, 2016, AGEING RES REV, V32, P75, DOI 10.1016/j.arr.2016.05.004
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Cysique LA, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0298-0
   D'Alessandro S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8010085
   Datta G, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00329
   Davido B., 2020, HYDROXYCHLOROQUINE P
   de Duve C, 2005, NAT CELL BIOL, V7, P847, DOI 10.1038/ncb0905-847
   DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9
   Demaurex N, 2002, NEWS PHYSIOL SCI, V17, P1
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Devhare PB, 2016, SCI REP-UK, V6, DOI 10.1038/srep26827
   Di Trani L, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-39
   Ding HJ, 2016, RHEUMATOLOGY, V55, P957, DOI 10.1093/rheumatology/kev357
   EMENY JM, 1979, J GEN VIROL, V43, P247, DOI 10.1099/0022-1317-43-1-247
   Esmail S, 2018, J BIOL CHEM, V293, P2787, DOI 10.1074/jbc.M117.818872
   Estes M L, 1987, Am J Med, V82, P447, DOI 10.1016/0002-9343(87)90444-X
   Ewald SE, 2008, NATURE, V456, P658, DOI 10.1038/nature07405
   Farrell DF, 2012, CLIN OPHTHALMOL, V6, P377, DOI 10.2147/OPTH.S27731
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gelman BB, 2005, JAIDS-J ACQ IMM DEF, V39, P422, DOI 10.1097/01.qai.0000164250.41475.f2
   Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Guerin V.L., 2020, REGENSBERG ANDREIS M
   Harley CA, 2001, J VIROL, V75, P1236, DOI 10.1128/JVI.75.3.1236-1251.2001
   Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008
   HIEBSCH RR, 1991, J BIOL CHEM, V266, P20323
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Huang MX, 2020, J MOL CELL BIOL, V12, P322, DOI 10.1093/jmcb/mjaa014
   Hui Liang, 2019, J Neuroimmune Pharmacol, DOI 10.1007/s11481-019-09862-1
   Hui L, 2019, J ALZHEIMERS DIS, V67, P393, DOI 10.3233/JAD-180941
   Hui L, 2012, ASN NEURO, V4, P243, DOI 10.1042/AN20120017
   Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286
   Huss M, 2009, J EXP BIOL, V212, P341, DOI 10.1242/jeb.024067
   Huynh KK, 2007, MICROBIOL MOL BIOL R, V71, P452, DOI 10.1128/MMBR.00003-07
   Jentsch TJ, 2007, J PHYSIOL-LONDON, V578, P633, DOI 10.1113/jphysiol.2006.124719
   Jeong JY, 2002, IMMUNOLOGY, V105, P83, DOI 10.1046/j.0019-2805.2001.01339.x
   Jeong JY, 1997, J IMMUNOL, V158, P4901
   Johnson DE, 2016, J CELL BIOL, V212, P677, DOI 10.1083/jcb.201507112
   Juurlink DN, 2020, CMAJ
   Kaplan YC, 2016, BRIT J CLIN PHARMACO, V81, P835, DOI 10.1111/bcp.12872
   Kellokumpu S, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00093
   Khan N, 2020, FASEB J, V34, P4147, DOI 10.1096/fj.201902534R
   Khan N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48777-y
   Khayat W, 2019, HUM MOL GENET, V28, P598, DOI 10.1093/hmg/ddy371
   Kim MS, 2020, TREATMENT RESPONSE H
   Kokkonen N, 2004, J BIOL CHEM, V279, P39982, DOI 10.1074/jbc.M406698200
   Kondapalli KC, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00172
   Kong FYS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174372
   Kono M, 2008, ANTIVIR RES, V77, P150, DOI 10.1016/j.antiviral.2007.10.011
   Kornak U, 2008, NAT GENET, V40, P32, DOI 10.1038/ng.2007.45
   Korolchuk VI, 2011, NAT CELL BIOL, V13, P453, DOI 10.1038/ncb2204
   Kuhn Y, 2007, CELL MICROBIOL, V9, P1004, DOI 10.1111/j.1462-5822.2006.00847.x
   Kuznik A, 2011, J IMMUNOL, V186, P4794, DOI 10.4049/jimmunol.1000702
   Lawrence RE, 2019, NAT CELL BIOL, V21, P133, DOI 10.1038/s41556-018-0244-7
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Linstedt AD, 1997, MOL BIOL CELL, V8, P1073
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lockwood TD, 2013, METALLOMICS, V5, P110, DOI 10.1039/c2mt20156a
   Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363
   LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0
   Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Magagnoli J, 2020, OUTCOMES HYDROXYCHLO
   Marceau F, 2012, TOXICOL APPL PHARM, V259, P1, DOI 10.1016/j.taap.2011.12.004
   Martin RE, 2009, SCIENCE, V325, P1680, DOI 10.1126/science.1175667
   Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   MCCHESNEY EW, 1967, TOXICOL APPL PHARM, V10, P501, DOI 10.1016/0041-008X(67)90089-0
   McGuire C, 2017, FRONT BIOSCI-LANDMRK, V22, P609, DOI 10.2741/4506
   Miao YX, 2015, CELL, V161, P1306, DOI 10.1016/j.cell.2015.05.009
   Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317
   Morissette G, 2004, J PHARMACOL EXP THER, V310, P395, DOI 10.1124/jpet.104.066084
   MOSCA JD, 1986, MOL CELL BIOL, V6, P2279, DOI 10.1128/MCB.6.6.2279
   Munz C, 2016, TRENDS IMMUNOL, V37, P755, DOI 10.1016/j.it.2016.08.017
   Murray RZ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00538
   Ng ML, 2003, J GEN VIROL, V84, P3291, DOI 10.1099/vir.0.19505-0
   OCHIAI H, 1995, ANTIVIR RES, V27, P425, DOI 10.1016/0166-3542(95)00040-S
   ODA K, 1985, EUR J BIOCHEM, V152, P605, DOI 10.1111/j.1432-1033.1985.tb09238.x
   OHKUMA S, 1981, J CELL BIOL, V90, P656, DOI 10.1083/jcb.90.3.656
   Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169
   Ooi EE, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-39
   ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273
   Ortega FG, 2019, NANOMED-NANOTECHNOL, V20, DOI 10.1016/j.nano.2019.102014
   Paroutis P, 2004, PHYSIOLOGY, V19, P207, DOI 10.1152/physiol.00005.2004
   Podsiadlo P, 2004, J BIOL CHEM, V279, P36219, DOI 10.1074/jbc.M400338200
   Prasad H, 2018, J BIOL CHEM, V293, P6721, DOI 10.1074/jbc.RA118.002025
   Price RN, 2014, LANCET INFECT DIS, V14, P982, DOI 10.1016/S1473-3099(14)70855-2
   Pu J, 2016, J CELL SCI, V129, P4329, DOI 10.1242/jcs.196287
   Puri S, 2002, TRAFFIC, V3, P641, DOI 10.1034/j.1600-0854.2002.30906.x
   Rahman N, 2016, J GEN PHYSIOL, V148, P325, DOI 10.1085/jgp.201611606
   RAINES MF, 1989, INVEST OPHTH VIS SCI, V30, P1726
   RANDOLPH VB, 1990, VIROLOGY, V174, P450, DOI 10.1016/0042-6822(90)90099-D
   RATLIFF NB, 1987, NEW ENGL J MED, V316, P191, DOI 10.1056/NEJM198701223160405
   REIJNGOUD DJ, 1976, BIOCHIM BIOPHYS ACTA, V448, P303, DOI 10.1016/0005-2736(76)90244-3
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Rivinoja A, 2006, J CELL PHYSIOL, V208, P167, DOI 10.1002/jcp.20653
   ROOS A, 1981, PHYSIOL REV, V61, P296
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Samanta D, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007855
   Savarino A, 2004, JAIDS-J ACQ IMM DEF, V35, P223, DOI 10.1097/00126334-200403010-00002
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   SCHLESINGER PH, 1988, ANTIMICROB AGENTS CH, V32, P793, DOI 10.1128/AAC.32.6.793
   SCHMIDT WK, 1995, MOL BIOL CELL, V6, P1271
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Schroeder RL, 2014, TOXICOL REP, V1, P963, DOI 10.1016/j.toxrep.2014.10.019
   Shabrawishi M.H., 2020, NEGATIVE NASOPHARYNG
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Singh S, 2020, OUTCOMES HYDROXYCHLO
   Sironi J, 2019, MOL PHARMACOL, V95, P127, DOI 10.1124/mol.118.113118
   Skinner-Adams TS, 2010, TRENDS BIOCHEM SCI, V35, P53, DOI 10.1016/j.tibs.2009.08.004
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Spector SA, 2008, AUTOPHAGY, V4, P704, DOI 10.4161/auto.6105
   Sperber K, 2009, PEDIATR RHEUMATOL, V7, DOI 10.1186/1546-0096-7-9
   Spiering MJ, 2019, J BIOL CHEM, V294, P18519, DOI 10.1074/jbc.CL119.011710
   Staring J, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216259
   Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005
   Tang W., 2020, HYDROXYCHLOROQUINE P
   TEVELTHUIS AJW, 2010, PLOS PATHOG, V0006
   THORENS B, 1986, NATURE, V321, P618, DOI 10.1038/321618a0
   Vezmar M, 1998, BIOCHEM PHARMACOL, V56, P733, DOI 10.1016/S0006-2952(98)00217-2
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang FJ, 2018, TRAFFIC, V19, P918, DOI 10.1111/tra.12613
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warhurst DC, 2003, J ANTIMICROB CHEMOTH, V52, P188, DOI 10.1093/jac/dkg319
   Weisz OA, 2003, TRAFFIC, V4, P57, DOI 10.1034/j.1600-0854.2003.40201.x
   Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858
   White JM, 2016, TRAFFIC, V17, P593, DOI 10.1111/tra.12389
   White NJ, 2014, LANCET, V383, P1439, DOI 10.1016/S0140-6736(14)60656-5
   Winzeler EA, 2008, NATURE, V455, P751, DOI 10.1038/nature07361
   Xu HX, 2015, ANNU REV PHYSIOL, V77, P57, DOI 10.1146/annurev-physiol-021014-071649
   XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169
   Xue J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109180
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Yao X, 2020, CRYST GROWTH DES, V20, P237, DOI 10.1021/acs.cgd.9b01095
   Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10-5278
   Zhang M, 2015, ELIFE, V4, DOI 10.7554/eLife.11205
   Zhitomirsky B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1227-0
   Zhitomirsky B, 2017, ONCOTARGET, V8, P45117, DOI 10.18632/oncotarget.15155
   Zhou DJ, 2008, AIDS, V22, P695, DOI 10.1097/QAD.0b013e3282f4a836
NR 173
TC 2
Z9 2
U1 13
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD SEP
PY 2020
VL 73
AR 109706
DI 10.1016/j.cellsig.2020.109706
PG 8
WC Cell Biology
SC Cell Biology
GA MQ1SV
UT WOS:000552679100028
PM 32629149
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Brunsdon, P
   Saluja, B
   Sahajwalla, C
AF Brunsdon, Priya
   Saluja, Bhawana
   Sahajwalla, Chandrahas
TI Clinical Pharmacology Considerations for Developing Small-Molecule
   Treatments for COVID-19
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE clinical pharmacology; COVID-19; pharmacology; review; SARS-CoV-2
ID CRITICALLY-ILL; SEPSIS; PHARMACOKINETICS; THERAPY
AB Numerous drugs are being investigated for the treatment of COVID-19, including antivirals and therapies targeting complications related to COVID-19. The clinical presentation of COVID-19 varies from mild fever, cough, and dyspnea in the early stages of disease to severe complications such as acute respiratory distress syndrome, systemic hyperinflammation, and sepsis. A thorough understanding of the disease pathogenesis and the disease complications is essential to developing effective therapies to treat this potentially life-threatening disease. This review offers key clinical pharmacology considerations involved in the development of small molecules for the treatment of COVID-19. They are based on the major observed disease complications that impact drug absorption, distribution, metabolism, and elimination. We also address considerations regarding potential drug interactions, alternative routes and methods of administration, and dosing in patients on hemodialysis.
C1 [Brunsdon, Priya; Saluja, Bhawana; Sahajwalla, Chandrahas] US FDA, Div Inflammat & Immune Pharmacol, Off Clin Pharmacol, Off Translat Sci,Ctr Drug Evaluat & Res, 10903 New Hampshire Ave,Bldg 51,Room 3142, Silver Spring, MD 20993 USA.
RP Sahajwalla, C (corresponding author), US FDA, Div Inflammat & Immune Pharmacol, Off Clin Pharmacol, Off Translat Sci,Ctr Drug Evaluat & Res, 10903 New Hampshire Ave,Bldg 51,Room 3142, Silver Spring, MD 20993 USA.
EM chandrahas.sahajwalla@fda.hhs.gov
CR [Anonymous], 2019, IMP REN IMP PAT DRUG
   Ari A, 2020, RESP MED, V167, DOI 10.1016/j.rmed.2020.105987
   Baker EH, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14416
   BECKWITH MC, 2004, HOSP PHARM, V39, P225
   Bohler J, 1999, KIDNEY INT, V56, pS24
   Charlton M, 2019, BJA EDUC, V19, P7, DOI 10.1016/j.bjae.2018.09.006
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   De Paepe P, 2002, CLIN PHARMACOKINET, V41, P1135, DOI 10.2165/00003088-200241140-00002
   Durvasula R, 2020, AM J KIDNEY DIS, V76, P4, DOI 10.1053/j.ajkd.2020.04.001
   Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Huang ZQ, 2013, CURR DRUG METAB, V14, P226
   Ibrahim M, 2015, MED DEVICES-EVID RES, V8, P131, DOI 10.2147/MDER.S48888
   Klimke A, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109783
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Morgan ET, 2009, CLIN PHARMACOL THER, V85, P434, DOI 10.1038/clpt.2008.302
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Parrish CR, PRACT GASTROENTEROL, V127, P16
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Silkstone VL, 2002, BRIT J CLIN PHARMACO, V54, P115, DOI 10.1046/j.1365-2125.2002.01632.x
   Sime FB, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-35
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Smith BS, 2012, CHEST, V141, P1327, DOI 10.1378/chest.11-1396
   Tashkin DP, 2016, INT J CHRONIC OBSTR, V11, DOI 10.2147/COPD.S114034
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   TRIGINER C, 1990, INTENS CARE MED, V16, P303, DOI 10.1007/BF01706354
   Varghese JM, 2011, CRIT CARE CLIN, V27, P19, DOI 10.1016/j.ccc.2010.09.006
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Williams NT, 2008, AM J HEALTH-SYST PH, V65, P2347, DOI 10.2146/ajhp080155
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 2020, WHO DIR GEN OP REM M
   Zhang Y, 2009, CLIN PHARMACOL THER, V85, P305, DOI 10.1038/clpt.2008.208
   Zhu LL, 2013, J CLIN PHARM THER, V38, P272, DOI 10.1111/jcpt.12041edit
NR 38
TC 0
Z9 0
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0091-2700
EI 1552-4604
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD SEP
PY 2020
VL 60
IS 9
BP 1147
EP 1154
DI 10.1002/jcph.1697
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MS6QO
UT WOS:000554398100002
PM 32579707
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Buioni, D
   Nardi, P
   Ruvolo, G
AF Buioni, Dario
   Nardi, Paolo
   Ruvolo, Giovanni
TI Thrombocytopenia and coagulation disorders due to COVID 19 infection
   with concomitant cardiovascular diseases requiring anti-platelet and
   anticoagulant therapy, which strategy?
SO CLINICA CHIMICA ACTA
LA English
DT Letter
C1 [Buioni, Dario; Nardi, Paolo; Ruvolo, Giovanni] Univ Policlin Tor Vergata, Cardiac Surg Unit, Viale Oxford 81, I-00133 Rome, Italy.
RP Buioni, D (corresponding author), Univ Policlin Tor Vergata, Cardiac Surg Unit, Viale Oxford 81, I-00133 Rome, Italy.
EM docyuk@libero.it
OI BUIONI, DARIO/0000-0002-1684-4561
CR Ashoub A, 2013, ANN CARD ANAESTH, V16, P215, DOI 10.4103/0971-9784.114258
   Koltai K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081803
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103
   Wada H, 2014, J INTENSIVE CARE, V2, DOI 10.1186/2052-0492-2-15
   Yang M, 2005, HEMATOLOGY, V10, P101, DOI 10.1080/10245330400026170
NR 7
TC 0
Z9 0
U1 8
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD SEP
PY 2020
VL 508
BP 109
EP 109
DI 10.1016/j.cca.2020.05.031
PG 1
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA ML1IJ
UT WOS:000549228300016
PM 32417209
OA Green Published
DA 2021-01-01
ER

PT J
AU Pati, S
   Houston, T
AF Pati, Sandipan
   Houston, Thomas
TI Assessing the risk of seizures with chloroquine or hydroxychloroquine
   therapy for COVID-19 in persons with epilepsy
SO EPILEPSY RESEARCH
LA English
DT Article
DE Chloroquine; Hydroxychloroquine; COVID-19; Epilepsy
ID INVOLVEMENT
AB Background: The goal of this systematic review is to assess the published literature for seizure risk with chloroquine or hydroxychloroquine therapy in persons with and without epilepsy. With the COVID-19 pandemic, there is a desperate need for treatment against the SARS CoV-2 virus. Chloroquine or hydroxychloroquine is one proposed medication that has received substantial public attention. However, the package insert states that these medications may provoke seizures in patients with epilepsy, and this has resulted in increased questions and anxiety in the epilepsy community.
   Methods: PubMed (1970 to March 27, 2020) and the Embase (1970 to March 27, 2020) were searched with the terms chloroquine or hydroxychloroquine and seizure or epilepsy, convulsions, or status epilepticus. Selected studies were reviewed, and the adverse drug reaction was classified.
   Results: Only eleven out of 31 studies were deemed eligible for systematic analysis. For chloroquine, eligible studies were- one prospective study(n = 109), two case series(n = 6), and six case reports. The dose of chloroquine ranged between 100-500 mg/day, except in one patient with a seizure, who was after taking 1000 mg. For hydroxychloroquine, there was one prospective observational study(n = 631) and one case report. The clinical trials failed to find any significant relation between seizures and chloroquine or hydroxychloroquine.
   Conclusion: Although the package insert describes an increased risk of seizure, the systematic review highlights that such a statement is not supported by class I evidence. Clinicians, therefore, need to understand that data regarding this specific topic is limited to case series and case reports. There is no substantial evidence to suggest that these medications can increase seizure risk.
C1 [Pati, Sandipan; Houston, Thomas] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
   [Pati, Sandipan; Houston, Thomas] Univ Alabama Birmingham, Epilepsy & Cognit Neurophysiol Lab, Birmingham, AL 35294 USA.
RP Pati, S (corresponding author), Univ Alabama Birmingham, Dept Neurol, Epilepsy & Cognit Neurophysiol Lab, CIRC 312 1719,6th Ave South, Birmingham, AL 35294 USA.
EM spati@uabmc.edu
CR AMABEOKU G, 1992, GEN PHARMACOL, V23, P225, DOI 10.1016/0306-3623(92)90015-C
   Armstrong MJ, 2018, NEUROL-CLIN PRACT, V8, P58, DOI 10.1212/CPJ.0000000000000417
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Crawley J, 2000, TROP MED INT HEALTH, V5, P860, DOI 10.1046/j.1365-3156.2000.00658.x
   Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hassanipour M, 2016, BRAIN RES BULL, V121, P124, DOI 10.1016/j.brainresbull.2015.11.020
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   World Health Organization, 2020, COR DIS 2019 COVID 1, V2019, DOI [10.1001/jama.2020.2633, DOI 10.1001/JAMA.2020.2633, 10.1001/jama.2020.2633.]
NR 10
TC 0
Z9 0
U1 12
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0920-1211
EI 1872-6844
J9 EPILEPSY RES
JI Epilepsy Res.
PD SEP
PY 2020
VL 165
AR 106399
DI 10.1016/j.eplepsyres.2020.106399
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA ML0KT
UT WOS:000549166700012
PM 32559589
OA Green Published
DA 2021-01-01
ER

PT J
AU Yin, CC
AF Yin, Changchuan
TI Genotyping coronavirus SARS-CoV-2: methods and implications
SO GENOMICS
LA English
DT Article
DE SARS-CoV-2; 2019-nCoV; Genotyping; Single-nucleotide polymorphism;
   COVID-19
ID SARS-CORONAVIRUS; NUCLEOCAPSID PROTEIN; MEMBRANE-PROTEIN; GENOME
   SEQUENCE; GLYCOPROTEIN; MUTATIONS; EVOLUTION; RESPONSES
AB The emerging global infectious COVID-19 disease by novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) presents critical threats to global public health and the economy since it was identified in late December 2019 in China. The virus has gone through various pathways of evolution. To understand the evolution and transmission of SARS-CoV-2, genotyping of virus isolates is of great importance. This study presents an accurate method for effectively genotyping SARS-CoV-2 viruses using complete genomes. The method employs the multiple sequence alignments of the genome isolates with the SARS-CoV-2 reference genome. The single-nucleotide polymorphism (SNP) genotypes are then measured by Jaccard distances to track the relationship of virus isolates. The genotyping analysis of SARS-CoV-2 isolates from the globe reveals that specific multiple mutations are the predominated mutation type during the current epidemic. The proposed method serves an effective tool for monitoring and tracking the epidemic of pathogenic viruses in their global and local genetic variations. The genotyping analysis shows that the genes encoding the S proteins and RNA polymerase, RNA primase, and nucleoprotein, undergo frequent mutations. These mutations are critical for vaccine development in disease control.
C1 [Yin, Changchuan] Univ Illinois, Dept Math Stat & Comp Sci, Chicago, IL 60607 USA.
RP Yin, CC (corresponding author), Univ Illinois, Dept Math Stat & Comp Sci, Chicago, IL 60607 USA.
EM cyin1@uic.edu
OI Yin, Changchuan/0000-0002-4147-4195
CR Alizon S, 2009, J EVOLUTION BIOL, V22, P245, DOI 10.1111/j.1420-9101.2008.01658.x
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Angelini MM, 2013, MBIO, V4, DOI 10.1128/mBio.00524-13
   Chen JL, 2020, MICROBES INFECT, V22, P69, DOI 10.1016/j.micinf.2020.01.004
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163
   Comas I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007815
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   DeDiego ML, 2008, VIROLOGY, V376, P379, DOI 10.1016/j.virol.2008.03.005
   Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151
   Follis KE, 2006, VIROLOGY, V350, P358, DOI 10.1016/j.virol.2006.02.003
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He RT, 2004, VIRUS RES, V105, P121, DOI 10.1016/j.virusres.2004.05.002
   Holmes EC, 2004, PHILOS T R SOC B, V359, P1059, DOI 10.1098/rstb.2004.1478
   Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   LEVANDOWSKY M, 1971, NATURE, V234, P34, DOI 10.1038/234034a0
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Li H, 2013, ARXIV13033997
   Li T, 2005, GENE THER, V12, P751, DOI 10.1038/sj.gt.3302479
   Liu J, 2010, J INFECT DIS, V202, P1171, DOI 10.1086/656315
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Nguyen D.D., 2020, BIORXIV
   Pfeiffer JK, 2003, P NATL ACAD SCI USA, V100, P7289, DOI 10.1073/pnas.1232294100
   Prentice E, 2004, J VIROL, V78, P9977, DOI 10.1128/JVI.78.18.9977-9986.2004
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Serrano P, 2009, J VIROL, V83, P12998, DOI 10.1128/JVI.01253-09
   Shu Y., 2020, EUROSURVEILLANCE, V22
   Sievers F, 2014, METHODS MOL BIOL, V1079, P105, DOI 10.1007/978-1-62703-646-7_6
   Sutton G, 2004, STRUCTURE, V12, P341, DOI 10.1016/j.str.2004.01.016
   Velthuis AJWT, 2012, NUCLEIC ACIDS RES, V40, P1737, DOI 10.1093/nar/gkr893
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   World Health Organization (WHO), 2020, SIT REP
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Yin CC, 2019, COMMUN INF SYST, V19, P57
   Yu CL, 2018, J AFFECT DISORDERS, V232, P305, DOI 10.1016/j.jad.2018.02.046
   Yu CL, 2017, J AFFECT DISORDERS, V220, P38, DOI 10.1016/j.jad.2017.05.044
   Yu CL, 2017, SCI REP-UK, V7, DOI 10.1038/srep44389
   Zhang LS, 2020, CLIN INFECT DIS, V71, P882, DOI 10.1093/cid/ciaa112
   Zhao P, 2005, VIROLOGY, V331, P128, DOI 10.1016/j.virol.2004.10.016
NR 44
TC 29
Z9 30
U1 16
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0888-7543
EI 1089-8646
J9 GENOMICS
JI Genomics
PD SEP
PY 2020
VL 112
IS 5
BP 3588
EP 3596
DI 10.1016/j.ygeno.2020.04.016
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA MJ4CX
UT WOS:000548038400010
PM 32353474
OA Green Published
DA 2021-01-01
ER

PT J
AU Haghani, M
   Bliemer, MCJ
   Goerlandt, F
   Li, J
AF Haghani, Milad
   Bliemer, Michiel C. J.
   Goerlandt, Floris
   Li, Jie
TI The scientific literature on Coronaviruses, COVID-19 and its associated
   safety-related research dimensions: A scientometric analysis and scoping
   review
SO SAFETY SCIENCE
LA English
DT Article
DE Safety; Novel coronavirus; 2019-nCov; COVID-19
ID SUPPLY CHAIN; HEALTH; INFECTION; DESIGN; RISK
AB The COVID-19 global pandemic has generated an abundance of research quickly following the outbreak. Within only a few months, more than a thousand studies on this topic have already appeared in the scientific literature. In this short review, we analyse the bibliometric aspects of these studies on a macro level, as well as those addressing Coronaviruses in general. Furthermore, through a scoping analysis of the literature on COVID-19, we identify the main safety-related dimensions that these studies have thus far addressed. Our findings show that across various research domains, and apart from the medical and clinical aspects such as the safety of vaccines and treatments, issues related to patient transport safety, occupational safety of healthcare professionals, biosafety of laboratories and facilities, social safety, food safety, and particularly mental/psychological health and domestic safety have thus far attracted most attention of the scientific community in relation to the COVID-19 pandemic. Our analysis also uncovers various potentially significant safety problems caused by this global health emergency which currently have attracted only limited scientific focus but may warrant more attention. These include matters such as cyber safety, economic safety, and supply-chain safety. These findings highlight why, from an academic research perspective, a holistic interdisciplinary approach and a collective scientific effort is required to help understand and mitigate the various safety impacts of this crisis whose implications reach far beyond the bio-medical risks. Such holistic safety-scientific understanding of the COVID-19 crisis can furthermore be instrumental to be better prepared for a future pandemic.
C1 [Haghani, Milad; Bliemer, Michiel C. J.] Univ Sydney, Business Sch, Inst Transport & Logist Studies, Camperdown, NSW, Australia.
   [Goerlandt, Floris] Dalhousie Univ, Dept Ind Engn, Halifax, NS B3H 4R2, Canada.
   [Li, Jie] Shanghai Maritime Univ, Sch Ocean Sci & Engn, Dept Safety Sci & Engn, Shanghai, Peoples R China.
RP Haghani, M (corresponding author), Univ Sydney, Business Sch, Inst Transport & Logist Studies, Camperdown, NSW, Australia.
EM milad.haghani@sydney.edu.au
CR Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101641
   Almeida J., 1968, NATURE, V220, P2
   Alves P.M.R., 2020, SCIMEDICINE J, V2, P44, DOI DOI 10.28991/SCIMEDJ-2020-0201-7
   Ambigapathy S, 2020, Malays Fam Physician, V15, P2
   Antoniadou N, 2015, AGGRESS VIOLENT BEH, V25, P363, DOI 10.1016/j.avb.2015.09.013
   Aslam S, 2020, J HEART LUNG TRANSPL
   Bachireddy C., 2020, JAMA J AM MED ASS
   Baghalian A, 2013, EUR J OPER RES, V227, P199, DOI 10.1016/j.ejor.2012.12.017
   Barari S., 2020, EVALUATING COVID 19
   Bayham J, 2020, LANCET PUBLIC HLTH, P30082
   Belingheri M, 2020, J HOSP INFECT, VS0195-6701, P30132, DOI 10.1016/j.jhin.2020.03.033
   Bi XW, 2019, SAFETY SCI, V118, P435, DOI 10.1016/j.ssci.2019.05.032
   Bozorgmehr K., 2020, LANCET PUBLIC HLTH
   BradburyJones C., J CLIN NURSING
   Cellina M., 2020, DIAGNOSTIC INTERVENT
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen MG, 2020, INT J EMERG MARK, DOI 10.1108/IJOEM-12-2019-1048
   Chen R., 2020, CANADIAN J ANESTHESI
   Chen TY, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101635
   Chen W.H., 2020, CURR TROPICAL MED RE
   Chen YS, 2020, J AM ACAD DERMATOL, V82, P1034, DOI 10.1016/j.jaad.2020.02.030
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Cortegiani A, 2020, J CRIT CARE
   Dalton L., 2020, LANCET CHILD ADOLESC
   Davis C., 2020, J ADOLESC HLTH
   Daw MA, 2020, TRAVEL MED INFECT DI
   de Bruin Y.B., 2020, SAFETY SCI
   Decaro N, 2020, RES VET SCI, V131, P21, DOI 10.1016/j.rvsc.2020.04.009
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dodd R.Y., 2020, TRANSFUS MED REV
   Molero GD, 2017, SAFETY SCI, V100, P168, DOI 10.1016/j.ssci.2016.10.007
   Eldin C., 2020, TRAVEL MED INFECT DI
   Fadel M, 2020, LANCET PUBLIC HEALTH, V5, pE193, DOI 10.1016/S2468-2667(20)30051-7
   Feliciani C, 2018, TRANSPORT RES C-EMER, V91, P124, DOI 10.1016/j.trc.2018.03.027
   Feng Z.-H., 2020, PUBLIC HLTH
   De Giorgio A, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101655
   Givi B, 2020, JAMA OTOLARYNGOL HEA
   Grant MJ, 2009, HEALTH INFO LIBR J, V26, P91, DOI 10.1111/j.1471-1842.2009.00848.x
   Gray PE, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104776
   Greenberg N, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1211
   Greenhalgh T, 2020, BMJ, V368
   Hafiz H, 2020, REGULATING PANDEMIC
   Haghani M, 2018, TRANSPORT RES B-METH, V107, P253, DOI 10.1016/j.trb.2017.06.017
   Hamzavi I.H., 2020, J AM ACAD DERMATOL
   Hatchett RJ, 2007, P NATL ACAD SCI USA, V104, P7582, DOI 10.1073/pnas.0610941104
   Joob B., 2020, BRAIN BEHAV IMMUNITY
   Jun J, 2020, WORLDV EVID-BASED NU, V17, P182, DOI 10.1111/wvn.12439
   Kabir M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101661
   Kang X, 2020, ZHEJIANG DA XUE XUE, V49
   Kluge HHP, 2020, LANCET, V395, P1237, DOI 10.1016/S0140-6736(20)30791-1
   Kooraki S, 2020, J AM COLL RADIOL, V17, P447, DOI 10.1016/j.jacr.2020.02.008
   Kuwahara K, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101638
   Law S., 2020, INT J INFECT DIS
   Lee V.J., 2020, LANCET INFECT DIS
   Li SJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062032
   Liew MF, 2020, CRIT CARE, V24, DOI [10.1186/s13054-020-2814-x, 10.1186/s13054-020-2828-4]
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu JJ, 2020, LANCET CHILD ADOLESC, P30096, DOI 10.106/S2352-4642(20)30096-1
   Lovato A, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2020.102474
   Luo Y, 2020, LANCET INFECT DIS
   Mingers J, 2015, EUR J OPER RES, V246, P1, DOI 10.1016/j.ejor.2015.04.002
   Montemurro N., 2020, BRAIN BEHAV IMMUN
   Murphy A., 2020, LANCET PUBLIC HLTH
   Ng J.J., 2020, J VASC SURG
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Ornell F., 2020, BRAZIL J PSYCH
   Pan F, 2010, COMPUT OPER RES, V37, P668, DOI 10.1016/j.cor.2009.06.017
   Paul R., 2019, READ PARAGRAPH ART C
   Peng F, 2020, N AM J ECON FINANC, V51, DOI 10.1016/j.najef.2018.08.018
   Rasmussen SA, 2020, AM J OBSTET GYNECOL
   Rasmussen T.E., 2020, J VASC SURG
   Rosenthal D.M., 2020, LANCET PUBLIC HLTH
   Schlagenhauf P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101658
   Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194
   Shan D, 2019, NEW SOLUT, V29, P371, DOI 10.1177/1048291119870762
   Shariatifar N., 2019, J FOOD SAFETY HYGIEN, V5, P58
   Sheng WH, 2020, J MICROBIOL IMMUNOL, V53, P363, DOI 10.1016/j.jmii.2020.03.033
   Shi Q, 2020, N AM J ECON FINANC, V51, DOI 10.1016/j.najef.2018.10.013
   Shigemura J, 2020, PSYCHIAT CLIN NEUROS, V74, P281, DOI 10.1111/pcn.12988
   Sodhi M, 2020, CHEST
   Sultan S, 2020, GASTROENTEROLOGY
   Tang C., 2006, INT J LOGIST-RES APP, V9, P33, DOI DOI 10.1080/13675560500405584
   Topalidou A., 2020, COVID 19 MATERNAL ME
   Useche SA, 2018, SAF HEALTH WORK-KR, V9, P454, DOI 10.1016/j.shaw.2018.01.003
   Van Bavel J. J., 2020, USING SOCIAL BEHAV S
   van Eck NJ, 2010, SCIENTOMETRICS, V82, P581, DOI 10.1007/s11192-010-0173-0
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   VANECK NJ, 2013, VOSVIEWER MANUAL, V1, P1
   VanLancker W., 2020, LANCET PUBLIC HLTH
   Viner RM, 2020, LANCET CHILD ADOLESC
   Waltman L, 2010, J INFORMETR, V4, P629, DOI 10.1016/j.joi.2010.07.002
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang GH, 2020, LANCET, V395, P945, DOI 10.1016/S0140-6736(20)30547-X
   Wang JZ, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101660
   WEF, 2020, GLOB RISKS REP 2020, P102
   Xu C, 2020, INT J CLOTH SCI TECH, V32, P499, DOI 10.1108/IJCST-02-2019-0017
   Yang YC, 2011, SAFETY SCI, V49, P382, DOI 10.1016/j.ssci.2010.09.019
   Yifan T., 2020, J PAIN SYMPTOM MANAG
   Yuan J., 2020, ECOSYST HEALTH SUST
   Zambrano LI, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101639
   Zhang W, 2020, LANCET INFECT DIS
   Zheng C., 2020, INT J INFECT DIS
   Zheng F, 2020, EUR J NEUROL, V27, pE57, DOI 10.1111/ene.14356
   Zheng RZ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101626
NR 105
TC 17
Z9 17
U1 76
U2 81
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-7535
EI 1879-1042
J9 SAFETY SCI
JI Saf. Sci.
PD SEP
PY 2020
VL 129
AR 104806
DI 10.1016/j.ssci.2020.104806
PG 18
WC Engineering, Industrial; Operations Research & Management Science
SC Engineering; Operations Research & Management Science
GA LZ3RQ
UT WOS:000541146200051
PM 32382213
OA Green Published
DA 2021-01-01
ER

PT J
AU Karalis, V
   Ismailos, G
   Karatza, E
AF Karalis, Vangelis
   Ismailos, George
   Karatza, Eleni
TI Chloroquine dosage regimens in patients with COVID-19: Safety risks and
   optimization using simulations
SO SAFETY SCIENCE
LA English
DT Article
DE COVID-19; Chloroquine; Dosage regimens; Dose related toxicity; Modeling
   and simulation
ID HYDROXYCHLOROQUINE; AZITHROMYCIN; EXPOSURE
AB Currently no specific medicinal treatment exists against the new SARS-CoV2 and chloroquine is widely used, since it can decrease the length of hospital stay and improve the evolution of the associated COVID-19 pneumonia. However, several safety concerns have been raised from chloroquine use due to the lack of essential information regarding its dosing. The aim of this study is to provide a critical appraisal of the safety information regarding chloroquine treatment and to apply simulation techniques to unveil relationships between the observed serious adverse events and overdosing, as well as to propose optimized dosage regimens. The dose related adverse events of chloroquine are unveiled and maximum tolerated doses and concentration levels are quoted. Among others, treatment with chloroquine can lead to severe adverse effects like prolongation of the QT interval and cardiomyopathy. In case of chloroquine overdosing, conditions similar to those produced by SARS-CoV2, such as pulmonary oedema with respiratory insufficiency and circulatory collapse, can be observed. Co-administration of chloroquine with other drugs for the treatment of COVID-19 patients, like azithromycin, can further increase the risk of QT prolongation and cardiomyopathy. For elder patients there is a high risk for toxicity and dose reduction should be made. This study unveils the risks of some widely used dosing regimens and binds the observed serious adverse events with dosing. Based on simulations, safer alternative dosage regimens are proposed and recommendations regarding chloroquine dosing are made.
C1 [Karalis, Vangelis; Karatza, Eleni] Natl & Kapodistrian Univ Athens, Sch Hlth Sci, Lab Biopharmaceut Pharmacokinet, Athens, Greece.
   [Ismailos, George] Expt Res Ctr ELPEN, ELPEN Pharmaceut, Pikermi, Attika, Greece.
RP Karalis, V (corresponding author), Natl & Kapodistrian Univ Athens, Sch Hlth Sci, Lab Biopharmaceut Pharmacokinet, Athens, Greece.
EM vkaralis@pharm.uoa.gr
CR Albertson T.E., 2012, CHLOROQUINE OTHER AM
   [Anonymous], 2016, SUMMARY PRODUCT CHAR
   Avdic E., 2020, CHLOROQUINE RECORD
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Bright R, 2020, REQUEST EMERGENCY US
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Furst DE, 1996, LUPUS, V5, pS11, DOI 10.1177/096120339600500104
   Hardman J.G., 2001, GOODMAN GILMANS PHAR, P1079
   Hoglund R, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1181-1
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Karunajeewa HA, 2010, ANTIMICROB AGENTS CH, V54, P1186, DOI 10.1128/AAC.01269-09
   Klinger G, 2001, LANCET, V358, P813, DOI 10.1016/S0140-6736(01)06004-4
   Mayo Clinic, CHLOR OR ROUT REC
   McEvoy G.K., 2006, AHFS DRUG INFORM, P859
   Mosholder AD, 2013, NEW ENGL J MED, V368, P1665, DOI 10.1056/NEJMp1302726
   Ndiaye N, 1999, ANN FR ANESTH, V18, P683, DOI 10.1016/S0750-7658(99)80157-9
   Olson K.R., 2004, POISONING DRUG OVERD, P166
   Perinel Sophie, 2020, Clin Infect Dis, V71, P2227, DOI 10.1093/cid/ciaa394
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Salman S, 2017, INT J ANTIMICROB AG, V50, P542, DOI 10.1016/j.ijantimicag.2017.05.011
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Singhi S, 1979, Indian J Pediatr, V46, P58, DOI 10.1007/BF02811499
   Smith ER, 2005, J EMERG MED, V28, P437, DOI 10.1016/j.jemermed.2004.12.011
   STIFF G, 1991, POSTGRAD MED J, V67, P678, DOI 10.1136/pgmj.67.789.678
   Svanstrom H, 2013, NEW ENGL J MED, V368, P1704, DOI 10.1056/NEJMoa1300799
   Ursing J, 2009, ANTIMICROB AGENTS CH, V53, P180, DOI 10.1128/AAC.01111-08
   Verbeeck RK, 2005, J PHARM SCI-US, V94, P1389, DOI 10.1002/jps.20343
   Wong YK, 2020, LANCET RHEUMATOL, V2, pE255, DOI 10.1016/S2665-9913(20)30093-X
   World Health Organization (WHO), INCHEM CHLOR PIM 123
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhao QY, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-36
NR 35
TC 4
Z9 4
U1 12
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-7535
EI 1879-1042
J9 SAFETY SCI
JI Saf. Sci.
PD SEP
PY 2020
VL 129
AR 104842
DI 10.1016/j.ssci.2020.104842
PG 9
WC Engineering, Industrial; Operations Research & Management Science
SC Engineering; Operations Research & Management Science
GA LZ3RQ
UT WOS:000541146200010
PM 32501367
OA Green Published
DA 2021-01-01
ER

PT J
AU Pikoulis, E
   Puchner, K
   Riza, E
   Kakalou, E
   Pavlopoulos, E
   Tsiamis, C
   Tokakis, V
   Boustras, G
   Terzidis, A
   Karamagioli, V
AF Pikoulis, Emmanouil
   Puchner, Karl
   Riza, Eleni
   Kakalou, Eleni
   Pavlopoulos, Elias
   Tsiamis, Constantinos
   Tokakis, Vassileios
   Boustras, Georgios
   Terzidis, Agis
   Karamagioli, Vasiliki
TI In the midst of the perfect storm: Swift public health actions needed in
   order to increase societal safety during the COVID-19 pandemic
SO SAFETY SCIENCE
LA English
DT Article
DE COVID 19; Societal safety; Public health; Socially vulnerable groups;
   Sero-prevalence
AB The phenomenal speed of COVID-19 has subjected the public health professionals worldwide to struggle to subdue the spread of the disease and its impact of the affected societies. The limited biomedical and epidemiological understanding of COVID-19 along with the lack of vaccines and therapeutics have led to the reception of draconian measures from the societal safety domain, limiting human interaction through social distancing. Grounded on the adopted approaches, interventions in sero-prevalence studies, mobilisation of the primary health care (PHC) sector, as well as target socially vulnerable groups should be taken into consideration by heath authorities.
C1 [Pikoulis, Emmanouil; Puchner, Karl; Riza, Eleni; Kakalou, Eleni; Pavlopoulos, Elias; Tsiamis, Constantinos; Tokakis, Vassileios; Terzidis, Agis; Karamagioli, Vasiliki] Natl & Kapodistrian Univ Athens, Sch Med, MSc Global Hlth Disaster Med, Dilou 1, Athens 11527, Greece.
   [Boustras, Georgios] European Univ Cyprus, CERIDES Excellence Innovat & Technol, 6 Diogenes St, CY-2404 Nicosia, Cyprus.
RP Karamagioli, V (corresponding author), Natl & Kapodistrian Univ Athens, Sch Med, MSc Global Hlth Disaster Med, Dilou 1, Athens 11527, Greece.
EM karamagioli@gmail.com
RI Riza, Elena/ABD-7629-2020
CR Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Barmparis GD, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109842
   Bozorgmehr K, 2020, LANCET PUBLIC HEALTH, V5, pE247, DOI 10.1016/S2468-2667(20)30078-5
   Cruz AT, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0834
   DOOS M, 1994, SAFETY SCI, V18, P15, DOI 10.1016/0925-7535(94)90038-8
   European Centre for Disease Prevention and Control, 2020, RAP RISK ASS NOV COR
   Garcia-Arroyo JA, 2020, SAFETY SCI, V121, P507, DOI 10.1016/j.ssci.2019.09.027
   Guldenmund F, 2013, SAFETY SCI, V52, P92, DOI 10.1016/j.ssci.2012.05.004
   Herper M., 2020, MIGHT EXPT DRUGS TRE
   Hoyland SA, 2018, SAFETY SCI, V110, P7, DOI 10.1016/j.ssci.2017.10.019
   ILO, 2020, SOC EC IMP COVID 19
   ILO, 2020, COVID 19 PROT WORK W
   Kuznia R., 2020, SEVERE SHORTAGES SWA
   Li Z, 2020, J MED VIROL
   WHO, 2020, REP WHO CHIN JOINT M
NR 15
TC 1
Z9 1
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-7535
EI 1879-1042
J9 SAFETY SCI
JI Saf. Sci.
PD SEP
PY 2020
VL 129
AR 104810
DI 10.1016/j.ssci.2020.104810
PG 2
WC Engineering, Industrial; Operations Research & Management Science
SC Engineering; Operations Research & Management Science
GA LZ3RQ
UT WOS:000541146200030
PM 32398901
OA Green Published
DA 2021-01-01
ER

PT J
AU Freedman, R
   Hunter, SK
   Law, AJ
   D'Alessandro, A
   Noonan, K
   Wyrwa, A
   Hoffman, MC
AF Freedman, Robert
   Hunter, Sharon K.
   Law, Amanda J.
   D'Alessandro, Angelo
   Noonan, Kathleen
   Wyrwa, Anna
   Hoffman, M. Camille
TI Maternal choline and respiratory coronavirus effects on fetal brain
   development
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Coronavirus; Pregnancy; Child development; Choline; Phosphatidylcholine;
   Attention
ID NICOTINIC ACETYLCHOLINE-RECEPTOR; C-REACTIVE PROTEIN;
   PHOSPHATIDYLCHOLINE SUPPLEMENTATION; IMMUNE ACTIVATION; DOUBLE-BLIND;
   TEMPERAMENT; PREGNANCY; SCHIZOPHRENIA; DISORDER; CHRNA7
AB Prenatal COVID-19 infection is anticipated by the U.S. Centers for Disease Control to affect fetal development similarly to other common respiratory coronaviruses through effects of the maternal inflammatory response on the fetus and placenta. Plasma choline levels were measured at 16 weeks gestation in 43 mothers who had contracted common respiratory viruses during the first 6-16 weeks of pregnancy and 53 mothers who had not. When their infants reached 3 months of age, mothers completed the Infant Behavior Questionnaire-Revised (IBQ-R), which assesses their infants' level of activity (Surgency), their fearfulness and sadness (Negativity), and their ability to maintain attention and bond to their parents and caretakers (Regulation). Infants of mothers who had contracted a moderately severe respiratory virus infection and had higher gestational choline serum levels (>= 7.5 mM consistent with U.S. Food and Drug Administration dietary recommendations) had significantly increased development of their ability to maintain attention and to bond with their parents (Regulation), compared to infants whose mothers had contracted an infection but had lower choline levels (< 7.5 mM). For infants of mothers with choline levels >= 7.5 mu M, there was no effect of viral infection on infant IBQ-R Regulation, compared to infants of mothers who were not infected. Higher choline levels obtained through diet or supplements may protect fetal development and support infant early behavioral development even if the mother contracts a viral infection in early gestation when the brain is first being formed.
C1 [Freedman, Robert; Hunter, Sharon K.; Law, Amanda J.; Noonan, Kathleen; Wyrwa, Anna; Hoffman, M. Camille] Univ Colorado, Sch Med, Dept Psychiat, F-546, Aurora, CO 80045 USA.
   [Law, Amanda J.] Dept Cell & Dev Biol, Aurora, CO USA.
   [D'Alessandro, Angelo] Dept Biochem & Mol Genet, Aurora, CO USA.
   [Hoffman, M. Camille] Univ Colorado, Sch Med, Dept Obstet & Gynecol, Div Maternal & Fetal Med, Aurora, CO 80045 USA.
RP Freedman, R (corresponding author), Univ Colorado, Sch Med, Dept Psychiat, F-546, Aurora, CO 80045 USA.
EM Robert.Freedman@cuanschutz.edu
RI Law, Amanda J/G-6372-2012
OI Law, Amanda J/0000-0002-2574-1564
FU National Institute of Child Health and Human DevelopmentUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Eunice Kennedy Shriver National Institute of Child Health &
   Human Development (NICHD) [K12HD001271-11]; National Center for
   Advancing Translational SciencesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1 TR001082];
   Anschutz Foundation; Institute for Children's Mental Disorders
FX Supported by the National Institute of Child Health and Human
   Development (K12HD001271-11 [to M.H.] and National Center for Advancing
   Translational Sciences (UL1 TR001082 [to all investigators]), and by the
   Institute for Children's Mental Disorders and the Anschutz Foundation
   (to R.F.). The funders had no role in (1) study design; (2) the
   collection, analysis, and interpretation of data; (3) the writing of the
   report; and (4) the decision to submit the paper for publication.
CR AHADI SA, 1993, EUR J PERSONALITY, V7, P359, DOI 10.1002/per.2410070506
   Birnbaum R, 2014, AM J PSYCHIAT, V171, P758, DOI 10.1176/appi.ajp.2014.13111452
   Brown AS, 2018, AM J PSYCHIAT, V175, P1073, DOI 10.1176/appi.ajp.2018.17121311
   Canetta S, 2014, AM J PSYCHIAT, V171, P960, DOI 10.1176/appi.ajp.2014.13121579
   Caudill MA, 2018, FASEB J, V32, P2172, DOI 10.1096/fj.201700692RR
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Cheatham CL, 2012, AM J CLIN NUTR, V96, P1465, DOI 10.3945/ajcn.112.037184
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Dreier JW, 2016, J CHILD PSYCHOL PSYC, V57, P540, DOI 10.1111/jcpp.12480
   Enlow MB, 2016, INFANT BEHAV DEV, V43, P24, DOI 10.1016/j.infbeh.2016.04.001
   Frazier CJ, 1998, J NEUROSCI, V18, P1187
   Freedman R, 2019, J PEDIATR-US, V208, P198, DOI 10.1016/j.jpeds.2018.12.010
   Freedman R, 2014, ANNU REV MED, V65, P245, DOI 10.1146/annurev-med-092112-142937
   Gartstein MA, 2003, INFANT BEHAV DEV, V26, P64, DOI 10.1016/S0163-6383(02)00169-8
   Gartstein MA, 2016, LEARN INDIVID DIFFER, V45, P299, DOI 10.1016/j.lindif.2015.12.022
   Hornig M, 2018, MOL PSYCHIATR, V23, P759, DOI 10.1038/mp.2017.119
   Jacobson SW, 2018, ALCOHOL CLIN EXP RES, V42, P1327, DOI 10.1111/acer.13769
   Kimberlin DW, 2020, JAMA-J AM MED ASSOC, V323, P1788, DOI 10.1001/jama.2020.4868
   Kunii Y, 2015, AM J PSYCHIAT, V172, P1122, DOI 10.1176/appi.ajp.2015.14080978
   Lips KS, 2005, PLACENTA, V26, P735, DOI 10.1016/j.placenta.2004.10.009
   MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P189, DOI 10.1001/archpsyc.1988.01800260109013
   Melbye H, 2004, BRIT J GEN PRACT, V54, P653
   Moore CJ, 2020, CAN J DIET PRACT RES, V81, P58, DOI 10.3148/cjdpr-2019-025
   Putnam SP, 2008, INFANT CHILD DEV, V17, P387, DOI 10.1002/ICD.582
   Ross RG, 2016, AM J PSYCHIAT, V173, P509, DOI 10.1176/appi.ajp.2015.15091188
   Rossi A, 2000, SCHIZOPHR RES, V44, P121, DOI 10.1016/S0920-9964(99)00223-6
   Slobodskaya HR, 2016, PERS INDIV DIFFER, V99, P127, DOI 10.1016/j.paid.2016.04.094
   Smith SEP, 2007, J NEUROSCI, V27, P10695, DOI 10.1523/JNEUROSCI.2178-07.2007
   Vasistha NA, 2020, MOL PSYCHIATR, V25, P2313, DOI 10.1038/s41380-019-0539-5
   Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339
   Wu BTF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043448
   Wu WL, 2015, BRAIN BEHAV IMMUN, V46, P192, DOI 10.1016/j.bbi.2015.02.005
   Zhang M, 2018, REPROD SCI, V25, P74, DOI 10.1177/1933719117702247
NR 33
TC 0
Z9 0
U1 28
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD SEP
PY 2020
VL 128
BP 1
EP 4
DI 10.1016/j.jpsychires.2020.05.019
PG 4
WC Psychiatry
SC Psychiatry
GA MA4ZV
UT WOS:000541924200001
PM 32474140
OA Green Published
DA 2021-01-01
ER

PT J
AU Khodadadi, E
   Maroufi, P
   Khodadadi, E
   Esposito, I
   Ganbarov, K
   Espsoito, S
   Yousefi, M
   Zeinalzadeh, E
   Kafil, HS
AF Khodadadi, Ehsaneh
   Maroufi, Parham
   Khodadadi, Ehsan
   Esposito, Isabella
   Ganbarov, Khudaverdi
   Espsoito, Silvano
   Yousefi, Mehdi
   Zeinalzadeh, Elham
   Kafil, Hossein Samadi
TI Study of combining virtual screening and antiviral treatments of the
   Sars-CoV-2 (Covid-19)
SO MICROBIAL PATHOGENESIS
LA English
DT Article
DE Coronavirus; SARS-CoV-2; COVID-19; Epitopes; Immune-informatics
ID ACUTE RESPIRATORY SYNDROME; N-TERMINAL DOMAIN; REGULATORY SEQUENCE TRS;
   CORONAVIRUS MERS-COV; AIDED DRUG DESIGN; NUCLEOCAPSID PROTEIN; SARS
   CORONAVIRUS; CRYSTAL-STRUCTURE; RNA-BINDING; VIRUS-REPLICATION
AB The recent epidemic outbreak of a novel human coronavirus called SARS-CoV-2 and causing the respiratory tract disease COVID-19 has reached worldwide resonance and a global effort is being undertaken to characterize the molecular features and evolutionary origins of this virus. Therefore, rapid and accurate identification of pathogenic viruses plays a vital role in selecting appropriate treatments, saving people's lives and preventing epidemics. Additionally, general treatments, coronavirus-specific treatments, and antiviral treatments useful in fighting COVID-19 are addressed. This review sets out to shed light on the SARS-CoV-2 and host receptor recognition, a crucial factor for successful virus infection and taking immune-informatics approaches to identify Band T-cell epitopes for surface glycoprotein of SARS-CoV-2. A variety of improved or new approaches also have been developed. It is anticipated that this will assist researchers and clinicians in developing better techniques for timely and effective detection of coronavirus infection. Moreover, the genomic sequence of the virus responsible for COVID-19, as well as the experimentally determined three-dimensional structure of the Main protease (Mpro) is available. The reported structure of the target Mpro was described in this review to identify potential drugs for COVID-19 using virtual high throughput screening.
C1 [Khodadadi, Ehsaneh; Kafil, Hossein Samadi] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz 5166614711, Iran.
   [Maroufi, Parham] Tabriz Univ Med Sci, Sch Med, Dept Orthopedy, Tabriz, Iran.
   [Khodadadi, Ehsan] Islamic Azad Univ, Dept Biol, Tabriz Branch, Tabriz, Iran.
   [Esposito, Isabella; Espsoito, Silvano] Univ Salerno, Dept Med, Fisciano, SA, Italy.
   [Ganbarov, Khudaverdi] Baku State Univ, Dept Microbiol, Baku, Azerbaijan.
   [Yousefi, Mehdi] Tabriz Univ Med Sci, Stem Cell Res Ctr, Tabriz, Iran.
   [Zeinalzadeh, Elham] Tabriz Univ Med Sci, Hematol & Oncol Res Ctr, Tabriz, Iran.
RP Kafil, HS (corresponding author), Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz 5166614711, Iran.
EM ehsaneh.khodadadi@gmail.com; Dr.parhammaroufi@yahoo.com;
   E.khodadadi@yahoo.com; Isabellaesposito@libero.it; Khuda1949@mail.ru;
   silvanoesposito@libero.it; yousefime@tbzmed.ac.ir;
   Elham_leyenda@yahoo.com; Kafilhs@tbzmed.ac.ir
RI Samadi Kafil, Hossein/B-5855-2012
OI Samadi Kafil, Hossein/0000-0001-6026-8795
FU Tabriz University of Medical Sciences [65174]
FX This study was supported by Tabriz University of Medical Sciences with
   grant number 65174.
CR Agarwala R, 2016, NUCLEIC ACIDS RES, V44, pD7, DOI [10.1093/nar/gkv1290, 10.1093/nar/gkx1095, 10.1093/nar/gks1189]
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Ahlquist P, 2003, J VIROL, V77, P8181, DOI 10.1128/JVI.77.15.8181-8186.2003
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Akerstrom S, 2005, J VIROL, V79, P1966, DOI 10.1128/JVI.79.3.1966-1969.2005
   Alves DS, 2004, BIOCHEM PHARMACOL, V68, P549, DOI 10.1016/j.bcp.2004.04.012
   ATHERTON JG, 1978, ARCH VIROL, V56, P195, DOI 10.1007/BF01317848
   Baumann CA, 1997, MECH AGEING DEV, V94, P85, DOI 10.1016/S0047-6374(96)01860-X
   BECK MA, 1994, J NUTR, V124, P345
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Burley SK, 1999, NAT GENET, V23, P151, DOI 10.1038/13783
   Cauwenberghs S, 2006, FEBS LETT, V580, P5313, DOI 10.1016/j.febslet.2006.08.082
   Cavasotto CN, 2008, J MED CHEM, V51, P581, DOI 10.1021/jm070759m
   Cavasotto CN, 2009, DRUG DISCOV TODAY, V14, P676, DOI 10.1016/j.drudis.2009.04.006
   Chai X, 2020, BIORXIV
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chang CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061196
   Chazal N, 2003, MICROBIOL MOL BIOL R, V67, P226, DOI 10.1128/MMBR.67.2.226-237.2003
   Chen IJ, 2013, BBA-PROTEINS PROTEOM, V1834, P1054, DOI 10.1016/j.bbapap.2013.03.003
   Chen JL, 2020, MICROBES INFECT, V22, P69, DOI 10.1016/j.micinf.2020.01.004
   Chen LL, 2005, J VIROL, V79, P7095, DOI 10.1128/JVI.79.11.7095-7103.2005
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cho CC, 2016, J BIOL CHEM, V291, P4894, DOI 10.1074/jbc.M115.700542
   Chou K.-C, 2010, NAT SCI, V109, P1091, DOI DOI 10.4236/NS.2010.210136
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Davis FP, 2007, PROTEIN SCI, V16, P2585, DOI 10.1110/ps.073228407
   Dimitrov DS, 2003, CELL, V115, P652, DOI 10.1016/S0092-8674(03)00976-0
   Diwan A. D., 2017, CANADIAN J BIOTECHNO, V1, P65, DOI [10. 24870/cjb. 2017, DOI 10.24870/CJB.2017]
   Du LY, 2008, VACCINE, V26, P1644, DOI 10.1016/j.vaccine.2008.01.025
   DUCHATEAU J, 1985, SURV IMMUNOL RES, V4, P94
   Durmus S, 2017, FEBS OPEN BIO, V7, P96, DOI 10.1002/2211-5463.12167
   Ekins S., 2016, F1000RESEARCH, V5
   Fan H, 2005, STRUCTURE, V13, P1859, DOI 10.1016/j.str.2005.08.021
   Fathizadeh H., 2020, INF MED, V28
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gao Zhan-cheng, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P332
   Gasull A, 2020, ELECTRON J DIFFER EQ
   Grossoehme NE, 2009, J MOL BIOL, V394, P544, DOI 10.1016/j.jmb.2009.09.040
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Guzzi PH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040982
   Hoffmann M., 2019, BIORXIV
   Hsieh PK, 2005, J VIROL, V79, P13848, DOI 10.1128/JVI.79.22.13848-13855.2005
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang HJ, 2010, J TAIWAN INST CHEM E, V41, P623, DOI 10.1016/j.jtice.2010.03.017
   Hughes JP, 2011, BRIT J PHARMACOL, V162, P1239, DOI 10.1111/j.1476-5381.2010.01127.x
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Hurle MR, 2013, CLIN PHARMACOL THER, V93, P335, DOI 10.1038/clpt.2013.1
   Jayaram H, 2006, J VIROL, V80, P6612, DOI 10.1128/JVI.00157-06
   Jo S, 2019, CHEM BIOL DRUG DES, V94, P2023, DOI 10.1111/cbdd.13604
   JOFFE MI, 1983, J CLIN INVEST, V72, P971, DOI 10.1172/JCI111069
   Kang S., 2020, ACTA PHARM SINICA B
   Kapetanovic IM, 2008, CHEM-BIOL INTERACT, V171, P165, DOI 10.1016/j.cbi.2006.12.006
   Keane SC, 2012, J BIOL CHEM, V287, P7063, DOI 10.1074/jbc.M111.287763
   Keil SD, 2016, TRANSFUSION, V56, P2948, DOI 10.1111/trf.13860
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Killerby ME, 2020, EMERG INFECT DIS, V26, P191, DOI 10.3201/eid2602.190697
   Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kumar S.J., 2020, DRUG VACCINE DESIGN
   Kumar Suresh, 2015, BMC Res Notes, V8, P9, DOI 10.1186/s13104-015-0976-4
   Kumar V, 2013, EXPERT OPIN THER PAT, V23, P1337, DOI 10.1517/13543776.2013.823159
   Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li J, 2016, BRIEF BIOINFORM, V17, P2, DOI 10.1093/bib/bbv020
   Li L., 2020, BIORXIV
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lin SM, 2020, J MED CHEM, V63, P3131, DOI 10.1021/acs.jmedchem.9b01913
   Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Liu SJ, 2006, VACCINE, V24, P3100, DOI 10.1016/j.vaccine.2006.01.058
   Liu X., 2020, RCSB PROTEIN DATA BA
   Lo YS, 2013, FEBS LETT, V587, P120, DOI 10.1016/j.febslet.2012.11.016
   Loewenstein Y, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-2-207
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo C, 2004, BIOCHEM BIOPH RES CO, V321, P557, DOI 10.1016/j.bbrc.2004.07.003
   Macalino SJY, 2015, ARCH PHARM RES, V38, P1686, DOI 10.1007/s12272-015-0640-5
   Marchler-Bauer A, 2011, NUCLEIC ACIDS RES, V39, pD225, DOI 10.1093/nar/gkq1189
   Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291
   Marzi A, 2004, J VIROL, V78, P12090, DOI 10.1128/JVI.78.21.12090-12095.2004
   MASTERS PS, 1990, ADV EXP MED BIOL, V276, P235
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Mohanasundaram Nachimuthu, 2018, Current Pharmacogenomics & Personalized Medicine, V16, P210, DOI 10.2174/1875692116666181108145230
   Momattin H, 2018, J INFECT PUBLIC HEAL, V11, P310, DOI 10.1016/j.jiph.2017.08.008
   Morgenstern B, 2005, BIOCHEM BIOPH RES CO, V326, P905, DOI 10.1016/j.bbrc.2004.11.128
   Morita M, 2013, CELL, V153, P112, DOI 10.1016/j.cell.2013.02.027
   Nelson GW, 2000, J GEN VIROL, V81, P181, DOI 10.1099/0022-1317-81-1-181
   Nonnecke BJ, 2014, J DAIRY SCI, V97, P5566, DOI 10.3168/jds.2014-8293
   Novac N, 2013, TRENDS PHARMACOL SCI, V34, P267, DOI 10.1016/j.tips.2013.03.004
   Ozma M.A., 2020, INF MED, V28
   Park JY, 2012, BIOL PHARM BULL, V35, P2036, DOI 10.1248/bpb.b12-00623
   Patel H, 2019, VIROLOGY, V537, P97, DOI 10.1016/j.virol.2019.08.013
   Peck KM, 2017, J VIROL, V91, DOI 10.1128/JVI.00534-17
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Ramajayam R., 2011, RECENT DEV 3C 3CL PR
   Rayman MP, 2012, LANCET, V379, P1256, DOI 10.1016/S0140-6736(11)61452-9
   Robbins RA, 1997, INT J BIOCHEM CELL B, V29, P857, DOI 10.1016/S1357-2725(96)00167-7
   Russell RB, 2004, CURR OPIN STRUC BIOL, V14, P313, DOI 10.1016/j.sbi.2004.04.006
   Saikatendu KS, 2007, J VIROL, V81, P3913, DOI 10.1128/JVI.02236-06
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Sawicki SG, 2009, VIRAL GENOME REPLICATION, P25, DOI 10.1007/b135974_2
   Semba RD, 1999, P NUTR SOC, V58, P719, DOI 10.1017/S0029665199000944
   Shang B, 2005, BIOCHEM BIOPH RES CO, V336, P110, DOI 10.1016/j.bbrc.2005.08.032
   Shang J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008392
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Takahashi S, 2015, BIOMED RES-TOKYO, V36, P219, DOI 10.2220/biomedres.36.219
   Talluri S., 2020, VIRTUAL HIGH THROUGH
   Tan YW, 2006, NUCLEIC ACIDS RES, V34, P4816, DOI 10.1093/nar/gkl650
   Tang TK, 2005, PROTEOMICS, V5, P925, DOI 10.1002/pmic.200401204
   Tsang K, 2003, RESPIROLOGY, V8, pS25, DOI 10.1046/j.1440-1843.2003.00525.x
   ul Qamar MT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1672-7
   Van Drie JH, 2007, J COMPUT AID MOL DES, V21, P591, DOI 10.1007/s10822-007-9142-y
   Velthuis AJWT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001176
   Veselovsky A. V., 2003, Current Drug Targets - Infectious Disorders, V3, P33, DOI 10.2174/1568005033342145
   Vickers NJ, 2017, CURR BIOL, V27, pR713, DOI 10.1016/j.cub.2017.05.064
   Vidalain PO, 2010, MICROBES INFECT, V12, P1134, DOI 10.1016/j.micinf.2010.09.001
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wang L, 2016, CELL HOST MICROBE, V19, P561, DOI 10.1016/j.chom.2016.04.006
   Wang NS, 2019, CELL REP, V28, P3395, DOI 10.1016/j.celrep.2019.08.052
   Wang RC, 2020, J INFECTION, V80, P354, DOI 10.1016/j.jinf.2020.01.017
   Wang SQ, 2007, BIOCHEM BIOPH RES CO, V354, P634, DOI 10.1016/j.bbrc.2006.12.235
   Wang S, 2008, VIRUS RES, V136, P8, DOI 10.1016/j.virusres.2008.03.004
   Warren SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070687
   Wessling-Resnick M, 2018, ANNU REV NUTR, V38, P431, DOI 10.1146/annurev-nutr-082117-051749
   Wichapong K, 2010, J MOL RECOGNIT, V23, P283, DOI 10.1002/jmr.977
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yeung KS, 2006, MED RES REV, V26, P414, DOI 10.1002/med.20055
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang AD, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1500-8
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhang QC, 2012, NATURE, V490, P556, DOI 10.1038/nature11503
   Zhang XW, 2004, BIOORGAN MED CHEM, V12, P2517, DOI 10.1016/j.bmc.2004.03.035
   Zhang Z, 2019, BIOINFORMATICS, V35, P723, DOI 10.1093/bioinformatics/bty694
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhao Y., 2020, BIORXIV
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 145
TC 3
Z9 3
U1 82
U2 90
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0882-4010
J9 MICROB PATHOGENESIS
JI Microb. Pathog.
PD SEP
PY 2020
VL 146
AR 104241
DI 10.1016/j.micpath.2020.104241
PG 9
WC Immunology; Microbiology
SC Immunology; Microbiology
GA LZ3OH
UT WOS:000541137400006
PM 32387389
OA Green Published
DA 2021-01-01
ER

PT J
AU Dexter, F
   Elhakim, M
   Loftus, RW
   Seering, MS
   Epstein, RH
AF Dexter, Franklin
   Elhakim, Mohamed
   Loftus, Randy W.
   Seering, Melinda S.
   Epstein, Richard H.
TI Strategies for daily operating room management of ambulatory surgery
   centers following resolution of the acute phase of the COVID-19 pandemic
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Article
ID POSTANESTHESIA CARE-UNIT; FAST-TRACK ELIGIBILITY; INTRAOPERATIVE
   BACTERIAL-CONTAMINATION; STAPHYLOCOCCUS-AUREUS TRANSMISSION;
   INTERVENTIONAL PAIN PROCEDURES; MANAGERIAL DECISION-MAKING; OUTPATIENT
   KNEE SURGERY; LAMINAR AIR-FLOW; REGIONAL ANESTHESIA; GENERAL-ANESTHESIA
AB We performed a narrative review to explore the economics of daily operating room management decisions for ambulatory surgery centers following resolution of the acute phase of the Coronavirus Disease 2019 (COVID-19) pandemic. It is anticipated that there will be a substantive fraction of patients who will be contagious, but asymptomatic at the time of surgery.
   Use multimodal perioperative infection control practices (e.g., including patient decontamination) and monitor performance (e.g., S. aureus transmission from patient to the environment). The consequence of COVID-19 is that such processes are more important than ever to follow because infection affects not only patients but the surgery center staff and surgeons.
   Dedicate most operating rooms to procedures that are not airway aerosol producing and can be performed without general anesthesia. Increase throughput by performing nerve blocks before patients enter the operating rooms. Bypass the phase I post-anesthesia care unit whenever possible by appropriate choices of anesthetic approach and drugs. Plan long-duration workdays (e.g., 12-h).
   For cases where the surgical procedure does not cause aerosol production, but general anesthesia will be used, have initial (phase I) post-anesthesia recovery in the operating room where the surgery was done. Use anesthetic practices that achieve fast initial recovery of the brief ambulatory cases.
   When the surgical procedure causes aerosol production (e.g., bronchoscopy), conduct phase I recovery in the operating room and use multimodal environmental decontamination after each case. Use statistical methods to plan for the resulting long turnover times. Whenever possible, have the anesthesia and nursing teams stagger cases in more than one room so that they are doing one surgical case while the other room is being cleaned.
   In conclusion, this review shows that while COVID-19 is prevalent, it will markedly affect daily ambulatory workflow for patients undergoing general anesthesia, with potentially substantial economic impact for some surgical specialties.
C1 [Dexter, Franklin; Loftus, Randy W.; Seering, Melinda S.] Univ Iowa, Iowa City, IA 52242 USA.
   [Elhakim, Mohamed] Royal Hobart Hosp, Dept Anesthesia & Crit Care Med, Hobart, Tas, Australia.
   [Epstein, Richard H.] Univ Miami, Coral Gables, FL 33124 USA.
RP Dexter, F (corresponding author), Univ Iowa, Dept Anesthesia, Div Management Consulting, 200 Hawkins Dr,6 JCP, Iowa City, IA 52242 USA.
EM Franklin-Dexter@UIowa.edu
RI Taha, Samy/N-4620-2019; Dexter, Franklin/V-1495-2019
OI Taha, Samy/0000-0003-0284-7806; Dexter, Franklin/0000-0001-5897-2484;
   Seering, Melinda/0000-0002-7783-9897
FU Anesthesia Patient Safety Foundation; Department of Anesthesia,
   University of Iowa
FX This study was funded in part by the Anesthesia Patient Safety
   Foundation and by the Department of Anesthesia, University of Iowa.
CR Agoliati A, 2010, ANESTH ANALG, V110, P1433, DOI 10.1213/ANE.0b013e3181d58052
   Ahn PH, 2020, PCORM, V19
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Albano D, 2020, J NUCL MED, V61, P632, DOI 10.2967/jnumed.120.246256
   Alsved M, 2018, J HOSP INFECT, V98, P181, DOI 10.1016/j.jhin.2017.10.013
   American Association of Nurse Anesthetists, WE DONT KNOW PAT COV
   Andersen BM, 2006, INFECT CONT HOSP EP, V27, P729, DOI 10.1086/503643
   Anesthesia Patient Safety Foundation, PREV PER COVID 19 TR
   Apfelbaum JL, 2002, ANESTHESIOLOGY, V97, P66, DOI 10.1097/00000542-200207000-00010
   Armstrong KPJ, 2004, CAN J ANAESTH, V51, P41, DOI 10.1007/BF03018545
   Ather B, AIRBORNE PRECAUTIONS
   Bayman EO, 2011, ANESTH ANALG, V113, P165, DOI 10.1213/ANE.0b013e31821c3e8e
   BERNSTEIN D, 1990, J DENT RES, V69, P874, DOI 10.1177/00220345900690030901
   Birnbach DJ, 2015, ANESTH ANALG, V120, P848, DOI 10.1213/ANE.0000000000000230
   Brown MJ, 2014, INT J HEALTH CARE Q, V27, P697, DOI 10.1108/IJHCQA-11-2013-0129
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P465, DOI 10.15585/mmwr.mm6915e4
   Chen WJ, 2004, J MED MICROBIOL, V53, P435, DOI 10.1099/jmm.0.45561-0
   Chin Alex W H, 2020, Lancet Microbe, V1, pe10, DOI 10.1016/S2666-5247(20)30003-3
   Clark C, 2014, AM J INFECT CONTROL, V42, P1223, DOI 10.1016/j.ajic.2014.07.016
   Coloma M, 2001, ANESTH ANALG, V93, P112
   Cullen Karen A, 2009, Natl Health Stat Report, P1
   Culver DA, 2003, AM J RESP CRIT CARE, V167, P1050, DOI 10.1164/rccm.200208-797CC
   Dexter EU, 2009, ANESTH ANALG, V108, P1257, DOI 10.1213/ane.0b013e31819a6dd4
   Dexter F, 2006, ANESTH ANALG, V102, P1491, DOI 10.1213/01.ane.0000202397.90361.1b
   Dexter F, 2005, ANESTHESIOLOGY, V103, P1259, DOI 10.1097/00000542-200512010-00023
   Dexter F, 2005, ANESTHESIOLOGY, V102, P1242, DOI 10.1097/00000542-200506000-00026
   Dexter F, 2004, ANESTHESIOLOGY, V101, P1444
   Dexter F, 1999, ANESTH ANALG, V88, P1053, DOI 10.1097/00000539-199905000-00016
   Dexter F, 2003, J CLIN ANESTH, V15, P206, DOI 10.1016/S0952-8180(03)00018-7
   Dexter F, 2002, ANESTH ANALG, V94, P933, DOI 10.1097/00000539-200204000-00030
   Dexter F, 2019, PCORM, V16, DOI DOI 10.1016/J.PCORM.2019.100076
   Dexter F, 2010, J STAT ED, V18, P3
   DEXTER F, 2018, PCORM, V13, P12
   Dexter F, 2007, ANESTH ANALG, V105, P1701, DOI 10.1213/01.ane.0000287686.23187.3f
   Dexter F, 2007, ANESTH ANALG, V105, P419, DOI 10.1213/01.ane.0000268539.85847.c9
   Dexter F, 2007, ANESTH ANALG, V105, P430, DOI 10.1213/01.ane.0000268540.85521.84
   Dexter F, 2020, ANESTH ANALG, V131, P37, DOI 10.1213/ANE.0000000000004829
   Dexter F, 2020, AM J INFECT CONTROL, V48, P682, DOI 10.1016/j.ajic.2019.09.025
   Dexter F, 2018, J CLIN ANESTH, V44, P107, DOI 10.1016/j.jclinane.2017.11.002
   Dexter F, 2017, J CLIN ANESTH, V42, P88, DOI 10.1016/j.jclinane.2017.08.016
   Dexter F, 2017, J CLIN ANESTH, V42, P57, DOI 10.1016/j.jclinane.2017.08.003
   Dexter F, 2016, ANESTH ANALG, V123, P1297, DOI 10.1213/ANE.0000000000001447
   Dexter F, 2016, A A CASE REP, V6, P329, DOI 10.1213/XAA.0000000000000298
   Dexter F, 2016, ANESTH ANALG, V122, P831, DOI 10.1213/ANE.0000000000001136
   Dexter F, 2014, ANESTH ANALG, V119, P1243, DOI 10.1213/ANE.0000000000000434
   Dexter F, 2013, ANESTH ANALG, V117, P205, DOI 10.1213/ANE.0b013e318291d388
   Dexter F, 2010, ANESTH ANALG, V110, P570, DOI 10.1213/ANE.0b013e3181b5dcb7
   Dexter F, 2009, ANESTH ANALG, V109, P900, DOI 10.1213/ane.0b013e3181b08855
   Drolet P, 2004, CAN J ANAESTH, V51, P1, DOI 10.1007/BF03018538
   Eggers M, 2019, INFECT DIS THER, V8, P581, DOI 10.1007/s40121-019-00260-x
   Eggers M, 2015, INFECT DIS THER, V4, P491, DOI 10.1007/s40121-015-0091-9
   Eijkemans MJC, 2010, ANESTHESIOLOGY, V112, P41, DOI 10.1097/ALN.0b013e3181c294c2
   Elhag D, 2018, J CLIN ANESTH, V49, P88, DOI 10.1016/j.jclinane.2018.06.021
   Epstein RH, 2020, PAIN PHYSICIAN, V23, pE7
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fredman B, 2002, ANESTH ANALG, V94, P560, DOI 10.1097/00000539-200203000-00015
   Friedman DM, 2006, ANN SURG, V243, P10, DOI 10.1097/01.sla.0000193600.97748.b1
   Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014
   GARDINER C, 2020, ANAESTHESIA, DOI DOI 10.1111/ARNAE.15089
   Gul S, 2018, SERV SCI, V10, P277, DOI 10.1287/serv.2018.0214
   Hadder B, 2018, AM J INFECT CONTROL, V46, P526, DOI 10.1016/j.ajic.2017.10.018
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Head SJ, 2011, CAN J ANESTH, V58, P725, DOI 10.1007/s12630-011-9518-2
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Inui S, 2020, RADIOL CARDIOTHORAC, V2, DOI [10.1148/ryct.2020200110, DOI 10.1148/RYCT.2020200110]
   Koff MD, 2009, ANESTHESIOLOGY, V110, P978, DOI 10.1097/ALN.0b013e3181a06ec3
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li YF, 2020, J MED VIROL, V92, P903, DOI 10.1002/jmv.25786
   Li YK, 2020, CURR MED SCI, V40, P295, DOI 10.1007/s11596-020-2176-2
   Loftus RW, 2008, ANESTHESIOLOGY, V109, P399, DOI 10.1097/ALN.0b013e318182c855
   Loftus RW, 2020, ANESTH ANALG, V131, pE27, DOI 10.1213/ANE.0000000000004854
   Loftus RW, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.1934
   Loftus RW, 2018, AM J INFECT CONTROL, V46, P1134, DOI 10.1016/j.ajic.2018.04.211
   Loftus RW, 2015, ANESTH ANALG, V120, P853, DOI 10.1213/ANE.0000000000000505
   Loftus RW, 2015, ANESTH ANALG, V120, P819, DOI 10.1213/ANE.0000000000000626
   Loftus RW, 2015, ANESTH ANALG, V120, P807, DOI 10.1213/ANE.0b013e3182a8c16a
   Loftus RW, 2015, ANESTH ANALG, V120, P827, DOI 10.1213/ANE.0000000000000123
   Loftus RW, 2012, ANESTH ANALG, V115, P1315, DOI 10.1213/ANE.0b013e31826d2aa4
   Loftus RW, 2012, ANESTH ANALG, V115, P1109, DOI 10.1213/ANE.0b013e31826a1016
   Loftus RW, 2012, ANESTH ANALG, V114, P1236, DOI 10.1213/ANE.0b013e31824970a2
   Loftus RW, 2019, BRIT J ANAESTH, V124, pe475
   Long CQ, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108961
   Luangkesorn KL, 2016, J STAT COMPUT SIM, V86, P262, DOI 10.1080/00949655.2015.1004065
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Marcon E, 2007, ANESTH ANALG, V105, P119, DOI 10.1213/01.ane.0000266495.79050.b0
   Marjamaa RA, 2009, HEALTH CARE MANAG SC, V12, P142, DOI 10.1007/s10729-008-9073-8
   Mascha EJ, 2020, ANESTH ANALG, V131, P24, DOI 10.1213/ANE.0000000000004849
   McIntosh C, 2006, ANESTH ANALG, V103, P1499, DOI 10.1213/01.ane.0000244535.54710.28
   Meng H, 2020, J INFECTION, V81, pE33, DOI 10.1016/j.jinf.2020.04.004
   Moghadas SM, 2020, P NATL ACAD SCI USA, V117, P9122, DOI 10.1073/pnas.2004064117
   Moore G, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-174
   Munoz-Price LS, 2019, INFECT CONT HOSP EP, V40, P1, DOI 10.1017/ice.2018.303
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Pavia M, 2018, AM J INFECT CONTROL, V46, P720, DOI 10.1016/j.ajic.2018.01.014
   Pearson ACS, 2019, ANESTH ANALG, V129, P493, DOI 10.1213/ANE.0000000000004253
   Pearson ACS, 2019, PAIN PHYSICIAN, V22, pE157
   Pedersen A, 2017, AORN J, V105, P159, DOI 10.1016/j.aorn.2016.11.019
   Phillips M, 2014, INFECT CONT HOSP EP, V35, P826, DOI 10.1086/676872
   Repici A, 2020, GASTROINTEST ENDOSC, V92, P192, DOI 10.1016/j.gie.2020.03.019
   Robinson A, 2019, AM J INFECT CONTROL, V47, P1240, DOI 10.1016/j.ajic.2019.03.028
   Rowlands J, 2014, AM J INFECT CONTROL, V42, P698, DOI 10.1016/j.ajic.2014.02.021
   Rubin GD, 2020, CHEST, V158, P106, DOI 10.1016/j.chest.2020.04.003
   Russell RA, 2013, J PERIANESTH NURS, V28, P3, DOI 10.1016/j.jopan.2012.06.007
   Sadrizadeh S, 2014, J INFECT PUBLIC HEAL, V7, P508, DOI 10.1016/j.jiph.2014.07.011
   Schmidt E, 2020, AM J INFECT CONTROL, V48, P675, DOI 10.1016/j.ajic.2019.09.016
   Sento Y, 2017, J ANESTH, V31, P601, DOI 10.1007/s00540-017-2341-3
   Smith MP, 2008, ANESTHESIOLOGY, V109, P25, DOI 10.1097/ALN.0b013e31817881c7
   Song D, 1999, J CLIN ANESTH, V11, P364, DOI 10.1016/S0952-8180(99)00061-6
   Song D, 1998, ANESTH ANALG, V86, P267, DOI 10.1097/00000539-199802000-00009
   Song DJ, 1998, ANESTH ANALG, V87, P1245, DOI 10.1097/00000539-199812000-00006
   Stepaniak PS, 2009, ANESTH ANALG, V108, P1249, DOI 10.1213/ane.0b013e318195e109
   Strum D P, 1997, J Med Syst, V21, P309, DOI 10.1023/A:1022824725691
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   Thenuwara KN, 2018, CAN J ANESTH, V65, P1296, DOI 10.1007/s12630-018-1220-1
   Tighe PJ, 2012, REGION ANESTH PAIN M, V37, P254, DOI 10.1097/AAP.0b013e31824889b6
   Twersky RS, 2008, ANESTH ANALG, V106, P1421, DOI 10.1213/ane.0b013e31816a6600
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Vasilopoulos T, 2019, J CLIN ANESTH, V55, P43, DOI 10.1016/j.jclinane.2018.12.045
   Wachtel Ruth E, 2010, J Grad Med Educ, V2, P624, DOI 10.4300/JGME-D-10-00064.1
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang JH, 2013, ANESTH ANALG, V116, P1333, DOI 10.1213/ANE.0b013e3182841226
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wei WE, 2020, MMWR-MORBID MORTAL W, DOI [10.15585/mmwr.mm6914e1external icon, DOI 10.15585/MMWR.MM6914E1EXTERNALICON]
   Weiser MC, 2018, J AM ACAD ORTHOP SUR, V26, pE105, DOI 10.5435/JAAOS-D-16-00891
   Weissman GE, 2020, ANN INTERN MED, V173, P21, DOI 10.7326/M20-1260
   WHYTE W, 1974, J HYG-CAMBRIDGE, V73, P61, DOI 10.1017/S0022172400023858
   Williams BA, 2004, ANESTHESIOLOGY, V100, P697, DOI 10.1097/00000542-200403000-00034
   Williams BA, 2002, ANESTHESIOLOGY, V97, P981, DOI 10.1097/00000542-200210000-00034
   Williams BA, 2000, ANESTHESIOLOGY, V93, P529, DOI 10.1097/00000542-200008000-00033
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu XQ, 2020, INT J GYNECOL OBSTET, V150, P58, DOI 10.1002/ijgo.13165
   Yang CY, 2020, MATH BIOSCI ENG, V17, P2708, DOI 10.3934/mbe.2020148
NR 133
TC 8
Z9 8
U1 15
U2 100
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0952-8180
EI 1873-4529
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD SEP
PY 2020
VL 64
AR 109854
DI 10.1016/j.jclinane.2020.109854
PG 7
WC Anesthesiology
SC Anesthesiology
GA LO3FL
UT WOS:000533514400030
PM 32371331
OA Green Published
DA 2021-01-01
ER

PT J
AU Landi, G
   Pakenham, KI
   Boccolini, G
   Grandi, S
   Tossani, E
AF Landi, Giulia
   Pakenham, Kenneth I.
   Boccolini, Giada
   Grandi, Silvana
   Tossani, Eliana
TI Health Anxiety and Mental Health Outcome During COVID-19 Lockdown in
   Italy: The Mediating and Moderating Roles of Psychological Flexibility
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE health anxiety; COVID-19; pandemic; depression; anxiety; psychological
   flexibility; quarantine
ID COMMITMENT THERAPY; EXPERIENTIAL AVOIDANCE; HYPOCHONDRIACAL FEARS;
   ACCEPTANCE; VALIDATION; INVENTORY; INFLEXIBILITY; METAANALYSIS;
   RESILIENCE; PREDICTORS
AB The COVID-19 emergency has severely affected the Italian population. During a pandemic, those with high health anxiety are at risk of adverse mental health outcomes, including peritraumatic distress and mood disturbance. No prior research has explored the role of psychological flexibility in protecting people at high risk of poorer mental health impacts due to health anxiety during a pandemic. Psychological flexibility is the cornerstone of psychological health and resiliency. According to acceptance and commitment therapy (ACT), it involves behaving consistently with one's chosen values even in the presence of emotional and mental discomfort. This study examined the mediating and moderating roles of psychological flexibility in the link between trait health anxiety and three mental health outcomes: COVID-19 peritraumatic distress, anxiety, and depression. We hypothesized that higher psychological flexibility would decrease the negative impacts of trait health anxiety on mental health outcomes. During the mandatory national lockdown (M= 35.70 days,SD= 8.41), 944 Italian adults (75.5% female,M= 38.86 years,SD= 13.20) completed an online survey consisting of standardized measures of psychological flexibility, trait health anxiety, COVID-19 distress, anxiety, and depression. Results indicated that psychological flexibility did not moderate the link between trait health anxiety and mental health outcomes. Rather, greater psychological flexibility mediated decreases in the adverse effects of trait health anxiety on COVID-19 distress, anxiety, and depression. In particular, two psychological flexibility processes, observing unhelpful thoughts rather than taking them literally (defusion) and values-based action (committed action), mediated decreases in the negative effects of trait health anxiety on all mental health outcomes. In contrast, the psychological flexibility process acceptance, which involves openness to inner discomfort, mediated increases in negative mental health outcomes. Overall, the combination of these processes mitigated the detrimental impacts of trait health anxiety on mental health during the emergency mandatory COVID-19 nationwide lockdown. Consistent with the ACT conceptualization of psychological flexibility, findings suggest embracing (rather than avoiding) inner discomfort and observing associated unhelpful thoughts, while also engaging in values-based action, increases resilience during adversity. Evidenced-based large-scale online public health interventions that target psychological flexibility in those experiencing health anxiety in the context of a pandemic are urgently needed. Many empirically-based ACT interventions are suited for this purpose.
C1 [Landi, Giulia; Grandi, Silvana; Tossani, Eliana] Univ Bologna, Dept Psychol, Bologna, Italy.
   [Landi, Giulia; Boccolini, Giada; Grandi, Silvana; Tossani, Eliana] Univ Bologna, Dept Psychol, Lab Psychosomat & Clinimetr, Cesena, Italy.
   [Pakenham, Kenneth I.] Univ Queensland, Sch Psychol, Brisbane, Qld, Australia.
RP Landi, G (corresponding author), Univ Bologna, Dept Psychol, Bologna, Italy.; Landi, G (corresponding author), Univ Bologna, Dept Psychol, Lab Psychosomat & Clinimetr, Cesena, Italy.
EM giulia.landi7@unibo.it
RI Tossani, Eliana/ABH-9643-2020; Landi, Giulia/J-5718-2016
OI Tossani, Eliana/0000-0002-6197-4496; Landi, Giulia/0000-0002-2576-3528
CR A-Tjak JGL, 2015, PSYCHOTHER PSYCHOSOM, V84, P30, DOI 10.1159/000365764
   Abramowitz JS, 2007, COGNITIVE THER RES, V31, P871, DOI 10.1007/s10608-006-9058-1
   Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8
   Alberts NM, 2013, J ANXIETY DISORD, V27, P68, DOI 10.1016/j.janxdis.2012.10.009
   Apolinario-Hagen J, 2020, ADV EXP MED BIOL, V1191, P291, DOI 10.1007/978-981-32-9705-0_17
   Asmundson GJG, 2020, J ANXIETY DISORD, V71, DOI 10.1016/j.janxdis.2020.102211
   Asmundson GJG, 2020, J ANXIETY DISORD, V70, DOI 10.1016/j.janxdis.2020.102196
   Asmundson GJG, 2010, CURR PSYCHIAT REP, V12, P306, DOI 10.1007/s11920-010-0123-9
   Bai ZG, 2020, J AFFECT DISORDERS, V260, P728, DOI 10.1016/j.jad.2019.09.040
   Bishop SJ, 2009, NAT NEUROSCI, V12, P92, DOI 10.1038/nn.2242
   Blakey SM, 2017, J CLIN PSYCHOL MED S, V24, P270, DOI 10.1007/s10880-017-9514-y
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Chawla N, 2007, J CLIN PSYCHOL, V63, P871, DOI 10.1002/jclp.20400
   Coto-Lesmes R, 2020, J AFFECT DISORDERS, V263, P107, DOI 10.1016/j.jad.2019.11.154
   Darlington R. B., 2017, DETECTING MANAGING I, P479
   Eakman AM, 2016, AM J OCCUP THER, V70, DOI 10.5014/ajot.2016.016519
   Eilenberg T, 2016, PSYCHOL MED, V46, P103, DOI 10.1017/S0033291715001579
   Eilenberg T, 2017, BEHAV RES THER, V92, P24, DOI 10.1016/j.brat.2017.01.009
   Eysenck MW, 2007, EMOTION, V7, P336, DOI 10.1037/1528-3542.7.2.336
   Fava GA, 2000, J CLIN PSYCHIAT, V61, P317, DOI 10.4088/JCP.v61n0414
   Fischer TD, 2016, J CONTEXT BEHAV SCI, V5, P169, DOI 10.1016/j.jcbs.2016.06.002
   Gao JL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231924
   Garfin DR, 2020, HEALTH PSYCHOL, V39, P355, DOI 10.1037/hea0000875
   Giovannetti AM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231380
   Gloster AT, 2017, J CONTEXT BEHAV SCI, V6, P166, DOI 10.1016/j.jcbs.2017.02.003
   Gold SD, 2007, BEHAV RES THER, V45, P549, DOI 10.1016/j.brat.2006.05.006
   Government of Italy, 2020, DECR PRES COUNC MIN
   Hawkes AL, 2014, ANN BEHAV MED, V48, P359, DOI 10.1007/s12160-014-9610-2
   Hawryluck L, 2004, EMERG INFECT DIS, V10, P1206, DOI 10.3201/eid1007.030703
   Hayes A.F., 2018, INTRO MEDIATION MODE
   Hayes S. C., 2012, ACCEPTANCE COMMITMEN
   Hayes SC, 2006, BEHAV RES THER, V44, P1, DOI 10.1016/j.brat.2005.06.006
   Hayes SC, 2019, LIBERATED MIND PIVOT
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   HYLAND P, 2020, ACTA PSYCHIAT S 0809, DOI DOI 10.31234/osf.io/8yqxr
   Italian Ministry of Health, 2020, COVID 19 CAS IT MAY
   Kashdan TB, 2010, CLIN PSYCHOL REV, V30, P865, DOI 10.1016/j.cpr.2010.03.001
   Kroenke K., 2010, INSTRUCTION MANUAL I
   Kumpula MJ, 2011, J ABNORM PSYCHOL, V120, P617, DOI 10.1037/a0023927
   Lazzerini M, 2020, LANCET GLOB HEALTH, V8, pE641, DOI 10.1016/S2214-109X(20)30110-8
   Li ZY, 2020, BRAIN BEHAV IMMUN, V88, P916, DOI 10.1016/j.bbi.2020.03.007
   Lin YY, 2020, J CONTEXT BEHAV SCI, V15, P73, DOI 10.1016/j.jcbs.2019.11.008
   Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093
   Makriyianis HM, 2019, J CONTEXT BEHAV SCI, V14, P82, DOI 10.1016/j.jcbs.2019.09.007
   Manea L, 2012, CAN MED ASSOC J, V184, pE191, DOI 10.1503/cmaj.110829
   Marshall EJ, 2016, J COGN PSYCHOTHER, V30, P60, DOI 10.1891/0889-8391.30.1.60
   Masuda A, 2011, PERS INDIV DIFFER, V50, P243, DOI 10.1016/j.paid.2010.09.037
   Mazzotti E, 2003, G ITAL PSICOPATOL, V9, P235
   Muthen L.K., 1998, MPLUS USERS GUIDE
   Novaes VP, 2018, SPAN J PSYCHOL, V21, DOI 10.1017/sjp.2018.14
   Pakenham K. I., 2011, OXFORD HDB STRESS HL, P242
   Pakenham KI, 2020, J CONTEXT BEHAV SCI, V17, P109, DOI 10.1016/j.jcbs.2020.07.003
   Pakenham KI, 2018, REHABIL PSYCHOL, V63, P29, DOI 10.1037/rep0000167
   Park J, 2017, NEUROSCIENCE, V345, P193, DOI 10.1016/j.neuroscience.2016.06.013
   Plummer F, 2016, GEN HOSP PSYCHIAT, V39, P24, DOI 10.1016/j.genhosppsych.2015.11.005
   Polizzi C, 2020, CLIN NEUROPSYCHIATR, V17, P59, DOI 10.36131/CN20200204
   Powers MB, 2009, PSYCHOTHER PSYCHOSOM, V78, P73, DOI 10.1159/000190790
   Presti G, 2020, CLIN NEUROPSYCHIATR, V17, P65, DOI 10.36131/CN20200206
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Ramaci T, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.01302
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rogge RD, 2019, J CONTEXT BEHAV SCI, V14, P90, DOI 10.1016/j.jcbs.2019.10.001
   Rolffs JL, 2018, ASSESSMENT, V25, P458, DOI 10.1177/1073191116645905
   Rossi R, 2020, COVID 19 PANDEMIC LO, DOI [10.1101/2020.04.09.20057802., DOI 10.1101/2020.04.09.20057802, 10.1101/2020.04.09.20057802]
   Ruiz FJ, 2010, INT J PSYCH PSYCHOL, V10, P125, DOI DOI 10.1080/028457199439937
   Ryan AK, 2020, AUST PSYCHOL, V55, P196, DOI 10.1111/ap.12429
   Salkovskis PM, 2002, PSYCHOL MED, V32, P843, DOI 10.1017/S0033291702005822
   Sirri L, 2008, PSYCHOTHER PSYCHOSOM, V77, P337, DOI 10.1159/000151387
   Sirri L, 2015, J PSYCHOSOM RES, V79, P259, DOI 10.1016/j.jpsychores.2015.07.002
   Skjernov M, 2020, J NERV MENT DIS, V208, P108, DOI 10.1097/NMD.0000000000001108
   Spijkerman MPJ, 2016, CLIN PSYCHOL REV, V45, P102, DOI 10.1016/j.cpr.2016.03.009
   Spinhoven P, 2016, COGNITIVE THER RES, V40, P150, DOI 10.1007/s10608-015-9747-8
   Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Stabbe OK, 2019, J CONTEXT BEHAV SCI, V12, P106, DOI 10.1016/j.jcbs.2019.03.003
   Swain J, 2013, CLIN PSYCHOL REV, V33, P965, DOI 10.1016/j.cpr.2013.07.002
   Taylor S., 2019, COGNITIVE BEHAV MODE, P49
   Tol WA, 2020, LANCET GLOB HEALTH, V8, pE254, DOI 10.1016/S2214-109X(19)30504-2
   Viskovich S, 2020, J CLIN PSYCHOL, V76, P929, DOI 10.1002/jclp.22848
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wheaton MG, 2012, COGNITIVE THER RES, V36, P210, DOI 10.1007/s10608-011-9353-3
   Wilson CG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204694
   Xiao H, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923921
   Xiao H, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923549
NR 85
TC 0
Z9 0
U1 7
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD AUG 31
PY 2020
VL 11
AR 2195
DI 10.3389/fpsyg.2020.02195
PG 14
WC Psychology, Multidisciplinary
SC Psychology
GA NQ0NG
UT WOS:000570565000001
PM 32982888
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jeong, HJ
   Min, S
   Chae, H
   Kim, S
   Lee, G
   Namgoong, SK
   Jeong, K
AF Jeong, Hye Jin
   Min, Sein
   Chae, Heelim
   Kim, Sarah
   Lee, Gunwoo
   Namgoong, Sung Keon
   Jeong, Keunhong
TI Signal amplification by reversible exchange for COVID-19 antiviral drug
   candidates
SO SCIENTIFIC REPORTS
LA English
DT Article
ID N-15 HYPERPOLARIZATION; SABRE; CHLOROQUINE; CORONAVIRUS
AB Several drug candidates have been proposed and tested as the latest clinical treatment for coronavirus pneumonia (COVID-19). Chloroquine, hydroxychloroquine, ritonavir/lopinavir, and favipiravir are under trials for the treatment of this disease. The hyperpolarization technique has the ability to further provide a better understanding of the roles of these drugs at the molecular scale and in different applications in the field of nuclear magnetic resonance/magnetic resonance imaging. This technique may provide new opportunities in diagnosis and research of COVID-19. Signal amplification by reversible exchange-based hyperpolarization studies on large-sized drug candidates were carried out. We observed hyperpolarized proton signals from whole structures, due to the unprecedented long-distance polarization transfer by para-hydrogen. We also found that the optimal magnetic field for the maximum polarization transfer yield was dependent on the molecular structure. We can expect further research on the hyperpolarization of other important large molecules, isotope labeling, as well as polarization transfer on nuclei with a long spin relaxation time. A clinical perspective of these features on drug molecules can broaden the application of hyperpolarization techniques for therapeutic studies.
C1 [Jeong, Hye Jin; Lee, Gunwoo; Jeong, Keunhong] Korea Mil Acad, Dept Chem, Seoul 01805, South Korea.
   [Min, Sein; Chae, Heelim; Kim, Sarah; Namgoong, Sung Keon] Seoul Womens Univ, Dept Chem, Seoul 01797, South Korea.
RP Jeong, K (corresponding author), Korea Mil Acad, Dept Chem, Seoul 01805, South Korea.
EM doas1mind@kma.ac.kr
FU National Research Foundation of Korea (NRF) - Korean government (MSIT)
   [2020R1C1C1007888]
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant funded by the Korean government (MSIT) (No. 2020R1C1C1007888).
CR Adams RW, 2009, SCIENCE, V323, P1708, DOI 10.1126/science.1168877
   Ariyasingha NM, 2019, J PHYS CHEM LETT, V10, P4229, DOI 10.1021/acs.jpclett.9b01505
   Atkinson KD, 2009, J AM CHEM SOC, V131, P13362, DOI 10.1021/ja903601p
   Barskiy DA, 2016, J AM CHEM SOC, V138, P8080, DOI 10.1021/jacs.6b04784
   Barskiy DA, 2014, J AM CHEM SOC, V136, P3322, DOI 10.1021/ja501052p
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chae H, 2020, ANAL CHEM, V55, P55
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Colell JFP, 2020, CHEM COMMUN, V56, P9336, DOI 10.1039/d0cc01330g
   Daniele V, 2015, CHEMPHYSCHEM, V16, P3413, DOI 10.1002/cphc.201500535
   Eshuis N, 2016, J MAGN RESON, V265, P59, DOI 10.1016/j.jmr.2016.01.012
   Glachet T, 2019, J AM CHEM SOC, V141, P13689, DOI 10.1021/jacs.9b07035
   Goldhill DH, 2018, P NATL ACAD SCI USA, V115, P11613, DOI 10.1073/pnas.1811345115
   Guastalegname M, 2020, CLIN INFECT DIS, V71, P888, DOI 10.1093/cid/ciaa321
   Hayden FG, 2019, CURR OPIN INFECT DIS, V32, P176, DOI 10.1097/QCO.0000000000000532
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iali W, 2019, ANGEW CHEM INT EDIT, V58, P10271, DOI 10.1002/anie.201905483
   Iali W, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aao6250
   Jeong HJ, 2020, ANALYST, V145, P6478, DOI 10.1039/d0an00967a
   Jeong K, 2019, MAGN RESON CHEM, V57, P44, DOI 10.1002/mrc.4791
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Lee SA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45660-8
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Linnik IV, 2019, EUR J PHARM SCI, V135, P32, DOI 10.1016/j.ejps.2019.05.004
   MACKENZIE AH, 1983, AM J MED, V75, P40, DOI 10.1016/0002-9343(83)91269-X
   Olaru AM, 2016, CHEM COMMUN, V52, P14482, DOI 10.1039/c6cc07109k
   Ratajczyk T, 2015, CHEM-EUR J, V21, P12616, DOI 10.1002/chem.201501552
   Rayner PJ, 2020, ANGEW CHEM, V132, P2732, DOI 10.1002/ange.201915098
   Richards JE, 2018, CHEM COMMUN, V54, P10375, DOI 10.1039/c8cc04826f
   Robertson TBR, 2019, CHEMISTRYOPEN, V8, P1375, DOI 10.1002/open.201900273
   Savarino A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0178-0
   Shchepin RV, 2017, J PHYS CHEM C, V121, P28425, DOI 10.1021/acs.jpcc.7b11485
   Spinelli Francesca Romana, 2020, Ann Rheum Dis, DOI 10.1136/annrheumdis-2020-217636
   Svyatova A, 2019, CHEM-EUR J, V25, P8465, DOI 10.1002/chem.201900430
   Tanner CPN, 2019, J CHEM PHYS, V151, DOI 10.1063/1.5108644
   Theis T, 2015, J AM CHEM SOC, V137, P1404, DOI 10.1021/ja512242d
   Tickner BJ, 2020, CATAL SCI TECHNOL, V10, P1343, DOI 10.1039/c9cy02498k
   TORJESEN I, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2263
   Truong ML, 2015, J PHYS CHEM C, V119, P8786, DOI 10.1021/acs.jpcc.5b01799
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
NR 45
TC 0
Z9 0
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 31
PY 2020
VL 10
IS 1
AR 14290
DI 10.1038/s41598-020-71282-6
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NP2UE
UT WOS:000570035500037
PM 32868801
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Luo, LL
   Xu, M
   Du, MY
   Kou, HM
   Liao, DY
   Cheng, ZP
   Mei, H
   Hu, Y
AF Luo, Lili
   Xu, Min
   Du, Mengyi
   Kou, Haiming
   Liao, Danying
   Cheng, Zhipeng
   Mei, Heng
   Hu, Yu
TI Early coagulation tests predict risk stratification and prognosis of
   COVID-19
SO AGING-US
LA English
DT Article
DE COVID-19; blood coagulation disorders; risk; prognosis; meta-analysis
ID DISSEMINATED INTRAVASCULAR COAGULATION; ACUTE RESPIRATORY SYNDROME;
   CRITICALLY-ILL PATIENTS; SEVERE SEPSIS; THROMBOCYTOPENIA; MANAGEMENT;
   CRITERIA
AB The ongoing outbreak of Coronavirus Disease 2019 (COVID-19) is hitting the world hard, but the relationship between coagulation disorders and COVID-19 is still not clear. This study aimed to explore whether early coagulation tests can predict risk stratification and prognosis. PubMed, Web of Science, Cochrane Library, and Scopus were searched electronically for relevant research studies published up to March 24, 2020, producing 24 articles for the final inclusion. The pooled standard mean difference (SMD) of coagulation parameters at admission were calculated to determine severe and composite endpoint conditions (ICU or death) in COVID-19 patients. Meta-analyses revealed that platelet count was not statistically related to disease severity and composite endpoint; elevated D-dimer correlated positively with disease severity (SMD 0.787 (0.277-1.298), P= 0.003, I-2 = 96.7%) but had no significant statistical relationship with composite endpoints. Similarly, patients with prolonged prothrombin time (PT) had an increased risk of ICU and increased risk of death (SMD 1.338 (0.551-2.125), P = 0.001, I-2 = 92.7%). Besides, increased fibrin degradation products (FDP) and decreased antithrombin might also mean the disease is worsening. Therefore, early coagulation tests followed by dynamic monitoring is useful for recognizing coagulation disorders accompanied by COVID-19 and guiding timely therapy to improve prognosis.
C1 [Luo, Lili; Xu, Min; Du, Mengyi; Kou, Haiming; Liao, Danying; Cheng, Zhipeng; Mei, Heng; Hu, Yu] Huazhong Univ Sci & Technol, Inst Hematol, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.
   [Luo, Lili; Xu, Min; Du, Mengyi; Kou, Haiming; Liao, Danying; Cheng, Zhipeng; Mei, Heng; Hu, Yu] Hubei Clin & Res Ctr Thrombosis & Hemostasis, Wuhan 430022, Peoples R China.
RP Mei, H; Hu, Y (corresponding author), Huazhong Univ Sci & Technol, Inst Hematol, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.; Mei, H; Hu, Y (corresponding author), Hubei Clin & Res Ctr Thrombosis & Hemostasis, Wuhan 430022, Peoples R China.
EM hmei@hust.edu.cn; huyu_whuh@hust.edu.cn
FU Key Special Project of Ministry of Science and Technology, China
   [2020YFC0845700]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [2020kfyXGY J029]; Emergency Fund of Huazhong University of Science and
   Technology for 2020 New Coronavirus Pneumonia
FX This study was supported by grant from the Key Special Project of
   Ministry of Science and Technology, China (No.2020YFC0845700), the
   Fundamental Research Funds for the Central Universities (NO. 2020kfyXGY
   J029), and the Emergency Fund of Huazhong University of Science and
   Technology for 2020 New Coronavirus Pneumonia.
CR Amgalan A, 2020, J THROMB HAEMOST, V18, P1514, DOI 10.1111/jth.14832
   [Anonymous], 2020, Chin Med J (Engl), DOI 10.1097/CM9.0000000000000819
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Asakura H, 2014, J INTENSIVE CARE, V2, DOI 10.1186/2052-0492-2-20
   Assinger A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00649
   BALLEM PJ, 1992, NEW ENGL J MED, V327, P1779, DOI 10.1056/NEJM199212173272503
   Bermejo-Martin JF, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110400
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen JL, 2020, MICROBES INFECT, V22, P69, DOI 10.1016/j.micinf.2020.01.004
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2020, J ALLERGY CLIN IMMUN, V146, P89, DOI 10.1016/j.jaci.2020.05.003
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Dhainaut JF, 2004, J THROMB HAEMOST, V2, P1924, DOI 10.1111/j.1538-7836.2004.00955.x
   Fan BE, 2020, AM J HEMATOL, V95, pE131, DOI 10.1002/ajh.25774
   Flaujac C, 2010, CELL MOL LIFE SCI, V67, P545, DOI 10.1007/s00018-009-0209-x
   Gando S, 2006, CRIT CARE MED, V34, P625, DOI 10.1097/01.CCM.0000202209.42491.38
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Grimmer B, 2017, J APPL PHYSIOL, V123, P1635, DOI 10.1152/japplphysiol.00120.2017
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Harrison CN, 2010, BRIT J HAEMATOL, V149, P352, DOI 10.1111/j.1365-2141.2010.08122.x
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iba T, 2019, J THROMB HAEMOST, V17, P1989, DOI 10.1111/jth.14578
   Johnson ED, 2019, AM J HEMATOL, V94, P833, DOI 10.1002/ajh.25482
   Kienast J, 2006, J THROMB HAEMOST, V4, P90, DOI 10.1111/j.1538-7836.2005.01697.x
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Levi M, 2011, BLOOD REV, V25, P33, DOI 10.1016/j.blre.2010.09.002
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu M, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE016, DOI [10.3760/cma.j.issn.1001-0939.2020.03.014, 10.3760/cma.j.issn.1001-0939.2020.0016]
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Llamas-Velasco M, 2020, BRIT J DERMATOL, V183, P591, DOI 10.1111/bjd.19222
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Peng Y D, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P450, DOI 10.3760/cma.j.cn112148-20200220-00105
   Qian GQ, 2020, QJM-INT J MED, V113, P474, DOI 10.1093/qjmed/hcaa089
   Qu R, 2020, J MED VIROL, V92, P1533, DOI 10.1002/jmv.25767
   Ralph AG, 2012, TOP COMPANION ANIM M, V27, P65, DOI 10.1053/j.tcam.2012.06.004
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   SATO N, 1995, AM J HEMATOL, V48, P168, DOI 10.1002/ajh.2830480306
   Schafer AI, 2015, JAMA-J AM MED ASSOC, V314, P1171, DOI 10.1001/jama.2015.8515
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Williamson DR, 2013, CHEST, V144, P1207, DOI 10.1378/chest.13-0121
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu YP, 2006, THROMB HAEMOSTASIS, V96, P100, DOI 10.1160/TH05-12-0827
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang SG, 2017, LANCET INFECT DIS, V17, P716, DOI 10.1016/S1473-3099(17)30227-X
   Yang XB, 2020, J THROMB HAEMOST, V18, P1469, DOI 10.1111/jth.14848
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang L, 2020, CIRCULATION, V142, P114, DOI 10.1161/CIRCULATIONAHA.120.046702
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 68
TC 0
Z9 0
U1 1
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD AUG 31
PY 2020
VL 12
IS 16
BP 15918
EP 15937
DI 10.18632/aging.103581
PG 20
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA NM2BC
UT WOS:000567906500006
PM 32860672
OA Green Published
DA 2021-01-01
ER

PT J
AU Liu, YF
   Liu, LN
   Wang, Y
   Du, XY
   Ma, H
   Yao, J
AF Liu, Yanfang
   Liu, Lina
   Wang, Ye
   Du, Xinyang
   Ma, Hong
   Yao, Jing
TI Clinical course and characteristics of patients with coronavirus disease
   2019 in Wuhan, China: a single-centered, retrospective, observational
   study
SO AGING-US
LA English
DT Article
DE COVID-19; SARS-CoV-2; chronic diseases; risk factors; infection
ID SARS-COV-2
AB Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the coronavirus disease 2019(COVID-19) pandemic. Despite the extensive studies aiming to understand the pathology of COVID-19, the clinicopathological characteristics and risk factors associated with COVID-19 remain mostly unclear. In this study, we assessed the clinical course and features of COVID-19 patients.
   Findings: There were 59 patients (54.1%) that had no fever. One-hundred (91.7%) patients required oxygen therapy, which improved percutaneous oxygen saturation (SpO2). Seventy-two (66.1%) patients aged over 60; these patients were more likely to develop respiratory symptoms. Only 13 (11.9%) patients were positive for anti-SARS-CoV-2 antibodies, SARS-CoV-2 nucleic acid, and computed tomography (CT) findings. We found significant differences in age, respiratory symptoms, and heart rates between patients with and without underlying conditions.
   Conclusions: Our findings suggest that oxygen plays an important role in the treatment of COVID-19 patients and that age and underlying diseases are significant risk factors for COVID-19. Most COVID-19 patients have no fever, and CT provides higher detection rates than antibody-and nucleic acid-based detection methods.
   Methods: We analyzed data from 109 confirmed COVID-19 cases. We compared the clinicopathological characteristic of patients stratified according to age and underlying diseases, as well as assessed the detection rates of different diagnostic methods.
C1 [Liu, Yanfang; Liu, Lina; Wang, Ye; Du, Xinyang; Ma, Hong; Yao, Jing] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan 430022, Peoples R China.
RP Ma, H; Yao, J (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan 430022, Peoples R China.
EM 2003XH1043@hust.edu.cn; 2007XH0839@hust.edu.cn
FU Joint Fund of Wuhan Union Hospital
FX This work was supported by the Joint Fund of Wuhan Union Hospital
   (No.02.03.2019-95).
CR CDC, 2020, GROUPS HIGH RISK SEV
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644
   Ghinai I, 2020, LANCET, V395, P1137, DOI 10.1016/S0140-6736(20)30607-3
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lo IL, 2020, INT J BIOL SCI, V16, P1698, DOI 10.7150/ijbs.45357
   Pan Y, 2020, CLIN CHEM, V66, P794, DOI 10.1093/clinchem/hvaa091
   Park Su Eun, 2020, Clin Exp Pediatr, V63, P119, DOI 10.3345/cep.2020.00493
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   World Health Organization, 2020, CLIN MAN SEV ACT RES
   Xu X, 2020, EUR J NUCL MED MOL I, V47, P1275, DOI 10.1007/s00259-020-04735-9
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Ye GM, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.001
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 0
Z9 0
U1 5
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD AUG 31
PY 2020
VL 12
IS 16
BP 15946
EP 15953
DI 10.18632/aging.103745
PG 8
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA NM2BC
UT WOS:000567906500008
PM 32833671
OA Green Published
DA 2021-01-01
ER

PT J
AU Chatterjee, S
   Sengupta, T
   Majumder, S
   Majumder, R
AF Chatterjee, Sabyasachi
   Sengupta, Tanusree
   Majumder, Samarpan
   Majumder, Rinku
TI COVID-19: a probable role of the anticoagulant Protein S in managing
   COVID-19-associated coagulopathy
SO AGING-US
LA English
DT Article
DE Protein S; hypoxia; cytokine storm; IL6; coagulopathy; ACE2
ID INTERLEUKIN-6; INFLAMMATION; CYTOKINES
AB The COVID-19 pandemic has caused monumental mortality, and there are still no adequate therapies. Most severely ill COVID-19 patients manifest a hyperactivated immune response, instigated by interleukin 6 (IL6) that triggers a so called "cytokine storm" and coagulopathy. Hypoxia is also associated with COVID-19. So far overlooked is the fact that both IL6 and hypoxia depress the abundance of a key anticoagulant, Protein S. We speculate that the IL6-driven cytokine explosion plus hypoxemia causes a severe drop in Protein S level that exacerbates the thrombotic risk in COVID-19 patients. Here we highlight a mechanism by which the IL6-hypoxia curse causes a deadly hypercoagulable state in COVID-19 patients, and we suggest a path to therapy.
C1 [Chatterjee, Sabyasachi; Majumder, Rinku] LSU Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.
   [Sengupta, Tanusree] Sri Sivasubramaniya Nadar Coll Engn, Dept Chem, Chennai, Tamil Nadu, India.
   [Majumder, Samarpan] LSU Hlth Sci Ctr, Dept Genet, New Orleans, LA 70112 USA.
RP Majumder, R (corresponding author), LSU Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.; Majumder, S (corresponding author), LSU Hlth Sci Ctr, Dept Genet, New Orleans, LA 70112 USA.
EM smaju1@lsuhsc.edu; rmajum@lsuhsc.edu
FU ASH Bridge Award;  [2R01HL118557-06]
FX 2R01HL118557-06 to RM, ASH Bridge Award to RM.
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Chattopadhyay R, 2012, ARTERIOSCL THROM VAS, V32, P2387, DOI 10.1161/ATVBAHA.112.250928
   Chau Vinh Q, 2020, JACC Case Rep, V2, P1315, DOI 10.1016/j.jaccas.2020.04.001
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   Chiappelli F, 2020, BIOINFORMATION, V16, P219, DOI [10.6026/97320630016222, 10.6026/97320630016219]
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   de Wolf CJF, 2006, ARTERIOSCL THROM VAS, V26, P2168, DOI 10.1161/01.ATV.0000236202.39165.eb
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Fricke DR, 2019, AGING-US, V11, P847, DOI 10.18632/aging.101798
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Hirsh J, 2001, ARTERIOSCL THROM VAS, V21, P1094, DOI 10.1161/hq0701.093686
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iba T, 2018, J THROMB HAEMOST, V16, P231, DOI 10.1111/jth.13911
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Levi M, 2010, CRIT CARE MED, V38, pS26, DOI 10.1097/CCM.0b013e3181c98d21
   Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Marongiu F, 2020, J THROMB HAEMOST, V18, P1511, DOI 10.1111/jth.14818
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   MEDURI GU, 1995, CHEST, V108, P1303, DOI 10.1378/chest.108.5.1303
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Panigrahy D, 2020, CANCER METAST REV, V39, P337, DOI 10.1007/s10555-020-09889-4
   Pilli VS, 2018, BLOOD, V132, P452, DOI 10.1182/blood-2018-04-841585
   Plautz WE, 2018, THROMB RES, V170, P133, DOI 10.1016/j.thromres.2018.08.018
   Plautz WE, 2018, ARTERIOSCL THROM VAS, V38, P816, DOI 10.1161/ATVBAHA.117.310588
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Tang N, 2020, J THROMB HAEMOST, V18, P1513, DOI 10.1111/jth.14843
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Ulhaq ZS, 2020, MED MALADIES INFECT, V50, P382, DOI 10.1016/j.medmal.2020.04.002
   Ullah Waqas, 2020, JACC Case Rep, V2, P1379, DOI 10.1016/j.jaccas.2020.04.008
   Vila N, 2000, J INTERF CYTOK RES, V20, P325, DOI 10.1089/107999000312478
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
NR 47
TC 0
Z9 0
U1 1
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD AUG 31
PY 2020
VL 12
IS 16
BP 15954
EP 15961
PG 8
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA NM2BC
UT WOS:000567906500009
PM 32826388
OA Green Published
DA 2021-01-01
ER

PT J
AU Rai, SN
   Qian, C
   Pan, JM
   Seth, A
   Srivastava, DK
   Bhatnagar, A
AF Rai, Shesh N.
   Qian, Chen
   Pan, Jianmin
   Seth, Anand
   Srivastava, Deo Kumar
   Bhatnagar, Aruni
TI Statistical design of Phase II/III clinical trials for testing
   therapeutic interventions in COVID-19 patients
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Article
DE Composite outcomes; COVID-19; Efficacy; Hospitalization; Interim
   analysis; Intubation; Power; Mortality; Sample size; Toxicity monitoring
ID RANDOMIZATION
AB Background Because of unknown features of the COVID-19 and the complexity of the population affected, standard clinical trial designs on treatments may not be optimal in such patients. We propose two independent clinical trials designs based on careful grouping of patient and outcome measures. Methods Using the World Health Organization ordinal scale on patient status, we classify treatable patients (Stages 3-7) into two risk groups. Patients in Stages 3, 4 and 5 are categorized as the intermediate-risk group, while patients in Stages 6 and 7 are categorized as the high-risk group. To ensure that an intervention, if deemed efficacious, is promptly made available to vulnerable patients, we propose a group sequential design incorporating four factors stratification, two interim analyses, and a toxicity monitoring rule for the intermediate-risk group. The primary response variable (binary variable) is based on the proportion of patients discharged from hospital by the 15(th)day. The goal is to detect a significant improvement in this response rate. For the high-risk group, we propose a group sequential design incorporating three factors stratification, and two interim analyses, with no toxicity monitoring. The primary response variable for this design is 30 day mortality, with the goal of detecting a meaningful reduction in mortality rate. Results Required sample size and toxicity boundaries are calculated for each scenario. Sample size requirements for designs with interim analyses are marginally greater than ones without. In addition, for both the intermediate-risk group and the high-risk group, the required sample size with two interim analyses is almost identical to analyses with just one interim analysis. Conclusions We recommend using a binary outcome with composite endpoints for patients in Stage 3, 4 or 5 with a power of 90% to detect an improvement of 20% in the response rate, and a 30 day mortality rate outcome for those in Stage 6 or 7 with a power of 90% to detect 15% (effect size) reduction in mortality rate. For the intermediate-risk group, two interim analyses for efficacy evaluation along with toxicity monitoring are encouraged. For the high-risk group, two interim analyses without toxicity monitoring is advised.
C1 [Rai, Shesh N.; Qian, Chen; Pan, Jianmin] Univ Louisville, James Graham Brown Canc Ctr, Biostat & Bioinformat Facil, Louisville, KY 40202 USA.
   [Rai, Shesh N.; Qian, Chen] Univ Louisville, Dept Biostat & Bioinformat, Louisville, KY 40202 USA.
   [Seth, Anand] SK Patent Associates LLC, Dublin, OH 43016 USA.
   [Srivastava, Deo Kumar] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA.
   [Bhatnagar, Aruni] Univ Louisville, Christina Lee Brown Envirome Inst, Dept Med, Louisville, KY 40202 USA.
RP Rai, SN (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Biostat & Bioinformat Facil, Louisville, KY 40202 USA.; Bhatnagar, A (corresponding author), Univ Louisville, Christina Lee Brown Envirome Inst, Dept Med, Louisville, KY 40202 USA.
EM shesh.rai@louisville.edu; aruni.bhatnagar@louisville.edu
OI Rai, Shesh/0000-0002-8377-353X
FU James Graham Brown Foundation; Owsley Brown II Family Foundation;
   University of Louisville Fellowship; Wendell Cherry Chair in Clinical
   Trial Research Fund, multiple National Institutes of Health (NIH)
   grantsUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [5P20GM113226, 1P42ES023716,
   5P30GM127607-02, 1P20GM125504-01, 2U54HL120163, 1P20GM135004,
   1R35ES0238373-01, 1R01ES029846, 1R01ES027778-01A1]; Kentucky Council on
   Postsecondary Education grant [PON2 415 1900002934]
FX A. Bhatnagar was supported in part by a grant from the James Graham
   Brown Foundation and the Owsley Brown II Family Foundation. C. Qian was
   supported by the University of Louisville Fellowship. S. N. Rai was
   partly supported with Wendell Cherry Chair in Clinical Trial Research
   Fund, multiple National Institutes of Health (NIH) grants (5P20GM113226,
   PI: McClain; 1P42ES023716, PI: Srivastava; 5P30GM127607-02, PI: Jones;
   1P20GM125504-01, PI: Lamont; 2U54HL120163, PI: Bhatnagar/Robertson;
   1P20GM135004, PI: Yan; 1R35ES0238373-01, PI: Cave; 1R01ES029846, PI:
   Bhatnagar; 1R01ES027778-01A1, PI: States;), and Kentucky Council on
   Postsecondary Education grant (PON2 415 1900002934, PI: Chesney).
CR Alexander PE, 2020, J CLIN EPIDEMIOL, V123, P120, DOI 10.1016/j.jclinepi.2020.04.016
   [Anonymous], 2016, STAT SOFTW DES SIM M
   [Anonymous], 2018, R LANG ENV STAT COMP
   [Anonymous], 2017, COMM TERM CRIT ADV E
   [Anonymous], R D COR DIS COVID 20
   [Anonymous], 2020, LANCET, DOI [10.1016/S1473-3099(20)30483-7, DOI 10.1016/S1473-3099(20)30483-7]
   Ball G, 2011, CONTEMP CLIN TRIALS, V32, pS11, DOI 10.1016/j.cct.2011.05.008
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Brothers RM, 2019, AM J PHYSIOL-HEART C, V317, pH777, DOI 10.1152/ajpheart.00126.2019
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carnethon MR, 2017, CIRCULATION, V136, pE393, DOI 10.1161/CIR.0000000000000534
   Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004
   Davoodi L, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13600
   DeMets DL, 2003, CIRCULATION, V107, pE70
   Eichler HG, 2020, CLIN PHARMACOL THER, V108, P730, DOI 10.1002/cpt.1891
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gorst SL, 2015, TRIALS, V16, DOI 10.1186/1745-6215-16-S3-A1
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   INGRAM DD, 1989, STAT MED, V8, P525, DOI 10.1002/sim.4780080502
   Ivanova A, 2005, BIOMETRICS, V61, P540, DOI 10.1111/j.1541-0420.2005.00311.x
   Ivanova A., 2015, Clinical Investigation, V5, P373
   Jennison C., 1999, GROUP SEQUENTIAL MET
   Jin Xinyao, 2020, Engineering (Beijing), V6, P1147, DOI 10.1016/j.eng.2020.03.002
   Kaiser LD, 2012, STAT MED, V31, P3858, DOI 10.1002/sim.5448
   Lewnard JA, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1923
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Lim E, 2008, ANN INTERN MED, V149, P612, DOI 10.7326/0003-4819-149-9-200811040-00004
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Meng YF, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008520
   Merton K, 2018, CURR MED RES OPIN, V34, P313, DOI 10.1080/03007995.2017.1391759
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Ray HE, 2011, CONTEMP CLIN TRIALS, V32, P428, DOI 10.1016/j.cct.2011.01.006
   Rees EM, 2020, COVID 19 LENGTH HOSP, DOI [10.1101/2020.04.30.20084780, DOI 10.1101/2020.04.30.20084780]
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Song GC, 2015, J BIOPHARM STAT, V25, P1206, DOI 10.1080/10543406.2015.1086779
   Srivastava DK, 2007, BIOMETRICAL J, V49, P351, DOI 10.1002/bimj.200610265
   Stolker JM, 2014, CIRCULATION, V130, P1254, DOI 10.1161/CIRCULATIONAHA.113.006588
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wang YM, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz053
   Yao Bin, 2013, Pharmaceutics, V5, P94, DOI 10.3390/pharmaceutics5010094
   Yu JH, 2016, STAT METHODS MED RES, V25, P64, DOI 10.1177/0962280212440535
   ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0
   Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004
NR 49
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD AUG 31
PY 2020
VL 20
IS 1
AR 220
DI 10.1186/s12874-020-01101-z
PG 16
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA NM1OM
UT WOS:000567873500001
PM 32867708
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Brizola, E
   Adami, G
   Baroncelli, GI
   Bedeschi, MF
   Berardi, P
   Boero, S
   Brandi, ML
   Casareto, L
   Castagnola, E
   Fraschini, P
   Gatti, D
   Giannini, S
   Gonfiantini, MV
   Landoni, V
   Magrelli, A
   Mantovani, G
   Michelis, MB
   Nasto, LA
   Panzeri, L
   Pianigiani, E
   Scopinaro, A
   Trespidi, L
   Vianello, A
   Zampino, G
   Sangiorgi, L
AF Brizola, E.
   Adami, G.
   Baroncelli, G. I.
   Bedeschi, M. F.
   Berardi, P.
   Boero, S.
   Brandi, M. L.
   Casareto, L.
   Castagnola, E.
   Fraschini, P.
   Gatti, D.
   Giannini, S.
   Gonfiantini, M. V.
   Landoni, V.
   Magrelli, A.
   Mantovani, G.
   Michelis, M. B.
   Nasto, L. A.
   Panzeri, L.
   Pianigiani, E.
   Scopinaro, A.
   Trespidi, L.
   Vianello, A.
   Zampino, G.
   Sangiorgi, L.
TI Providing high-quality care remotely to patients with rare bone diseases
   during COVID-19 pandemic
SO ORPHANET JOURNAL OF RARE DISEASES
LA English
DT Article
DE 2019-nCoV; Bone diseases; Care; Coronavirus; COVID-19; ERN; Rare
   diseases; Remote
ID OSTEOGENESIS IMPERFECTA; VITAMIN-D; PREGNANCY; CHILDREN; NERIDRONATE;
   PREVENTION; MANAGEMENT; ANESTHESIA; ADULTS; WOMEN
AB During the COVID-19 outbreak, the European Reference Network on Rare Bone Diseases (ERN BOND) coordination team and Italian rare bone diseases healthcare professionals created the "COVID-19 Helpline for Rare Bone Diseases" in an attempt to provide high-quality information and expertise on rare bone diseases remotely to patients and healthcare professionals. The present position statement describes the key characteristics of the Helpline initiative, along with the main aspects and topics that recurrently emerged as central for rare bone diseases patients and professionals. The main topics highlighted are general recommendations, pulmonary complications, drug treatment, trauma, pregnancy, children and elderly people, and patient associations role. The successful experience of the "COVID-19 Helpline for Rare Bone Diseases" launched in Italy could serve as a primer of gold-standard remote care for rare bone diseases for the other European countries and globally. Furthermore, similar COVID-19 helplines could be considered and applied for other rare diseases in order to implement remote patients' care.
C1 [Brizola, E.] IRCCS Ist Ortoped Rizzoli, Dept Rare Skeletal Disorders, Bologna, Italy.
   [Adami, G.; Gatti, D.] Univ Verona, Rheumatol Unit, Verona, Italy.
   [Baroncelli, G. I.] Univ Hosp, Dept Obstet Gynecol & Pediat, Div Pediat, Pisa, Italy.
   [Bedeschi, M. F.] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Med Genet Unit, Milan, Italy.
   [Berardi, P.; Panzeri, L.] Italian Osteogenesis Imperfecta Assoc AsItOI, Olgiate Molgora, LC, Italy.
   [Boero, S.; Michelis, M. B.; Nasto, L. A.] Childrens Hosp, IRCCS Giannina Gaslini Inst, Dept Paediat Orthopaed, Genoa, Italy.
   [Brandi, M. L.] Univ Florence, Dept Expt Biochem & Clin Sci, Florence, Italy.
   [Brandi, M. L.] Fdn FIRMO, Florence, Italy.
   [Castagnola, E.] IRCCS, Giannina Gaslini Inst, Infect Dis Dept, Genoa, Italy.
   [Fraschini, P.] IRCCS E Medea, Sci Inst, Bosisio Parini, LC, Italy.
   [Giannini, S.] Univ Padua, Clin Med 1, Dept Med, Padua, Italy.
   [Giannini, S.] Reg Ctr Osteoporosis, Padua, Italy.
   [Gonfiantini, M. V.] IRCCS, Bambino Gesu Childrens Hosp, Rare Dis & Med Genet Unit, Rome, Italy.
   [Landoni, V.] Valduce Hosp, Villa Beretta Rehabil Ctr, Lecce, Italy.
   [Magrelli, A.] Ist Super Sanita, Natl Ctr Drug Res & Evaluat, Rome, Italy.
   [Mantovani, G.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Endocrinol Unit, Milan, Italy.
   [Mantovani, G.] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Scopinaro, A.] Italian Federat Rare Dis Patients Assoc UNIAMO FI, Rome, Italy.
   [Trespidi, L.] Fdn IRCCS Ca Granda, Osped Maggiore Policlin, Obstet & Gynecol Unit, Milan, Italy.
   [Vianello, A.] Univ Padua, Resp Pathophysiol Div, Padua, Italy.
   [Zampino, G.] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Salute Donna Bambino & Sanita Pu, Rare Dis & Birth Defects Unit, Rome, Italy.
   [Sangiorgi, L.] IRCCS Ist Ortoped Rizzoli, Dept Rare Skeletal Disorders, Bologna, Italy.
   [Sangiorgi, L.] IRCCS Ist Ortoped Rizzoli, CLIBI Lab, Bologna, Italy.
RP Sangiorgi, L (corresponding author), IRCCS Ist Ortoped Rizzoli, Dept Rare Skeletal Disorders, Bologna, Italy.; Sangiorgi, L (corresponding author), IRCCS Ist Ortoped Rizzoli, CLIBI Lab, Bologna, Italy.
EM luca.sangiorgi@ior.It
RI Fraschini, Paolo/AAL-4260-2020; Magrelli, Armando/K-4330-2019; MICHELIS,
   MARIA BEATRICE/ABF-6555-2020; Brizola, Evelise/F-4699-2019; Casareto,
   Lorena/E-9806-2019
OI Fraschini, Paolo/0000-0002-5912-6447; Magrelli,
   Armando/0000-0002-5036-3710; Brizola, Evelise/0000-0001-8067-5101;
   Casareto, Lorena/0000-0002-9956-4038; Adami,
   Giovanni/0000-0002-8915-0755; Vianello, Andrea/0000-0002-8790-6029
FU European Union's Horizon 2020 research and innovation program [847078]
FX This publication has received funding from the European Union's Horizon
   2020 research and innovation program under grant agreement No 847078.
   The materials presented and views expressed here are the responsibility
   of the authors(s) only. The EC Commissions takes no responsibility for
   any use made of the information set out.
CR Ablon J, 2003, AM J MED GENET A, V122A, P201, DOI 10.1002/ajmg.a.20257
   Adami S, 2011, REUMATISMO, V63, P129, DOI 10.4081/reumatismo.2011.129
   Ahmad A, 2008, EUR CHILD ADOLES PSY, V17, P127, DOI 10.1007/s00787-007-0646-8
   Alapati D, 2017, RESP MED, V131, P18, DOI 10.1016/j.rmed.2017.07.063
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arcaro G, 2012, J CLIN ANESTH, V24, P55, DOI 10.1016/j.jclinane.2011.04.011
   Bajwah S, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00815-2020
   Berger KI, 2013, J INHERIT METAB DIS, V36, P201, DOI 10.1007/s10545-012-9555-1
   Bisson JI, 2007, BRIT J PSYCHIAT, V190, P97, DOI 10.1192/bjp.bp.106.021402
   Carpenter TO, 2018, NEW ENGL J MED, V378, P1987, DOI 10.1056/NEJMoa1714641
   Carpenter TO, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.101
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Costa S, 2020, CLIN MICROBIOL INFEC, V26, P1430, DOI 10.1016/j.cmi.2020.05.027
   Dahan-Oliel N, 2016, AM J MED GENET A, V170, P62, DOI 10.1002/ajmg.a.37377
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1165
   DePhillipo NN, 2020, J BONE JOINT SURG AM, V102, P933, DOI 10.2106/JBJS.20.00489
   Dogba MJ, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-153
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   dos Santos MC, 2018, DISABIL REHABIL, V40, P2281, DOI 10.1080/09638288.2017.1334236
   Evangelista T, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0398-y
   Fernandes Ana S C, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-212639
   Hill CL, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-54
   Holick MF, 2007, J BONE MINER RES, V22, pV28, DOI 10.1359/JBMR.07S211
   Hoover-Fong J, 2006, AM J OBSTET GYNECOL, V195, pS185, DOI 10.1016/j.ajog.2006.10.661
   Idolazzi L, 2017, BONE, V103, P144, DOI 10.1016/j.bone.2017.07.004
   Imel EA, 2019, LANCET, V393, P2416, DOI 10.1016/S0140-6736(19)30654-3
   Ipek MS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003298
   Kam KQ, 2020, CLIN INFECT DIS, V71, P847, DOI 10.1093/cid/ciaa201
   Karabiyik L, 2002, ACTA ANAESTH SCAND, V46, P618, DOI 10.1034/j.1399-6576.2002.460525.x
   Kluge HH, WHO STATEMENT OLDER
   Kourtis AP, 2014, NEW ENGL J MED, V370, P2211, DOI 10.1056/NEJMra1213566
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Liang H, 2020, ACTA OBSTET GYN SCAN, V99, P439, DOI 10.1111/aogs.13836
   LoMauro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035965
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583
   Miroliaee AE, 2018, J CRIT CARE, V44, P300, DOI 10.1016/j.jcrc.2017.08.040
   Montpetit K, 2011, J PEDIATR REHAB MED, V4, P13, DOI 10.3233/PRM-2011-0149
   Mueller B, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0905-4
   Namendys-Silva Silvio A, 2010, Crit Care, V14, P407, DOI 10.1186/cc8883
   Nishimura M, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0084-5
   Poon LC, 2020, ULTRASOUND OBST GYN, V55, P700, DOI 10.1002/uog.22013
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Savarirayan R, 2018, AM J OBSTET GYNECOL, V219, P545, DOI 10.1016/j.ajog.2018.07.017
   Sharma A, 2001, OBSTET GYNECOL SURV, V56, P563, DOI 10.1097/00006254-200109000-00022
   Sinha IP, 2020, LANCET RESP MED, V8, P446, DOI 10.1016/S2213-2600(20)30152-1
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Stephen LXG, 2016, SAMJ S AFR MED J, V106, pS90, DOI 10.7196/SAMJ.2016.v106i6.11005
   Suskauer SJ, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.2.e153
   Viapiana O, 2017, CALCIFIED TISSUE INT, V100, P341, DOI 10.1007/s00223-017-0236-9
   Wagner CL, 2008, PEDIATRICS, V122, P1142, DOI 10.1542/peds.2008-1862
   Wakap SN, 2020, EUR J HUM GENET, V28, P165, DOI 10.1038/s41431-019-0508-0
   Whyte MP, 2019, LANCET DIABETES ENDO, V7, P189, DOI 10.1016/S2213-8587(18)30338-3
   Wong SF, 2004, AM J OBSTET GYNECOL, V191, P292, DOI 10.1016/j.ajog.2003.11.019
   World Health Organization, COR DIS COVID 2019 S
   World Health Organization, COR DIS COVID 19 ADV
   World Health Organization, COR DIS COVID 19 TEC
   World Health Organization framework convention on tobacco control, WHO FRAMEWORK CONVEN
   Xia W, 2020, PEDIATR PULM, V55, P1169, DOI 10.1002/ppul.24718
   Yang H, 2020, ULTRASOUND OBST GYN, V55, P435, DOI 10.1002/uog.22006
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 63
TC 1
Z9 1
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1750-1172
J9 ORPHANET J RARE DIS
JI Orphanet J. Rare Dis.
PD AUG 31
PY 2020
VL 15
IS 1
AR 228
DI 10.1186/s13023-020-01513-6
PG 10
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA NM2HX
UT WOS:000567924200003
PM 32867855
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vijayaraghavan, BKT
   Jha, V
   Rajbhandari, D
   Myatra, SN
   John, O
   Ghosh, A
   Bassi, A
   Arfin, S
   Kunigari, M
   Joshi, R
   Donaldson, L
   Hammond, N
   Venkatesh, B
AF Tirupakuzhi Vijayaraghavan, Bharath Kumar
   Jha, Vivekanand
   Rajbhandari, Dorrilyn
   Myatra, Sheila Nainan
   John, Oommen
   Ghosh, Arpita
   Bassi, Abhinav
   Arfin, Sumaiya
   Kunigari, Mallikarjuna
   Joshi, Rohina
   Donaldson, Lachlan
   Hammond, Naomi
   Venkatesh, Balasubramanian
CA HOPE Investigators
TI Hydroxychloroquine plus personal protective equipment versus standard
   personal protective equipment alone for the prevention of COVID-19
   infections among frontline healthcare workers: the HydrOxychloroquine
   Prophylaxis Evaluation(HOPE) trial: A structured summary of a study
   protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Randomised controlled trial; protocol; hydroxychloroquine;
   health personnel
AB Objectives To evaluate the effect of the combination of hydroxychloroquine (HCQ) and standard personal protective equipment (PPE) compared to the use of standard personal protective equipment alone on the proportion of laboratory confirmed COVID-19 infections among frontline healthcare workers(HCWs) in India
   Trial design HOPE is an investigator initiated multi-centre open-label parallel group randomized controlled trial.
   Participants All HCWs currently working in an environment with direct exposure to patients with confirmed COVID-19 infection are eligible to participate in the trial. The trial aims to be conducted across 20-30 centres (public and private hospitals) in India. HCWs who decline consent, who have a confirmed COVID-19 infection, those who are already on chloroquine/HCQ for any indication, or if pregnant or breast-feeding, or have known QT prolongation or are on medications that when taken with HCQ can prolong the QTc will be excluded.
   Intervention and comparator: The interventions to be compared in this trial are standard practice (use of recommended PPE) and HCQ plus standard practice. In the standard practice arm, HCWs will use recommended PPE as per institutional guidelines and based on their roles. They will be discouraged from taking HCQ to prevent contamination and contacted every week for the duration of the study to ascertain if they have taken any HCQ. Any such use will be reported as a protocol violation.
   In the intervention arm, HCWs will be administered 800mg of HCQ as a loading dose on the day of randomization (as two 400mg doses 12hrs apart) and subsequently continued on 400mg once a week for 12 weeks. This will be in addition to the use of recommended PPE as per institutional guidelines and based on their roles. HCWs will collect the drug once every week from designated research and pharmacy staff at site. A weekly phone reminder will be provided to participants in this arm to ensure compliance. An ECG will be performed between 4-6 weeks in this arm and if the QTc is prolonged (greater than 450milliseconds), the drug will be stopped. Follow-up will however continue.
   Participants in both arms will receive a weekly phone call for evaluation of the primary outcome, to monitor protocol compliance and development of any adverse events (in the HCQ group). Main outcomes Participants will be followed on a weekly basis. The primary outcome is the proportion of HCWs developing laboratory confirmed COVID-19 infection within 6 months of randomization. We will also evaluate a number of secondary outcomes, including hospitalization related to suspected/confirmed COVID-19 infection, intensive care unit or high-dependency unit admission due to suspected/confirmed COVID-19 infection, all-cause mortality, need for organ support ( non-invasive or invasive ventilation, vasopressors and renal replacement therapy), ICU and hospital length of stay, readmission, days off work and treatment-related adverse events. Randomisation Randomisation will be conducted through a password-protected, secure website using a central, computer-based randomisation program. Randomisation will be stratified by participating institutions and by the role of HCW - nursing, medical and other. Participants will be randomised 1:1 to either standard practice only or HCQ plus standard practice. Allocation concealment is maintained by central web-based randomisation Blinding (masking) This is an unblinded study: study assigned treatment will be known to the research team and participant. Bias will be mitigated through an objective end point (laboratory confirmed COVID-19 infection).
   Numbers to be randomised (sample size): A total of 6,950 HCWs will be enrolled (3475 to the intervention) and (3475 to the standard practice group) to detect a 25% relative reduction, or 2.5% absolute reduction, in the infection rate from an estimated baseline infection rate of 10%, with 80% statistical power using a two-sided test at 5% level of significance. Available data from China and Italy indicate that the rate of infection among frontline healthcare workers varies between 4% to 12%. We therefore assumed a baseline infection rate of 10% among HCWs. This sample size allows for a potential loss to follow-up rate of 10% and a potential non-compliance rate of 10% in both the treatment and control arms. Trial Status HOPE protocol version 3.0 dated June 3(rd)2020. Recruitment started on 29(th)June 2020 and currently 56 participants have been enrolled. Planned completion of enrolment is January 31(st)2021. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest of expedited dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file2).
C1 [Tirupakuzhi Vijayaraghavan, Bharath Kumar] Apollo Hosp, Dept Crit Care Med, Chennai, Tamil Nadu, India.
   [Tirupakuzhi Vijayaraghavan, Bharath Kumar; Jha, Vivekanand; John, Oommen; Ghosh, Arpita; Bassi, Abhinav; Arfin, Sumaiya; Kunigari, Mallikarjuna; Joshi, Rohina] George Inst Global Hlth, New Delhi, India.
   [Jha, Vivekanand] Imperial Coll, Sch Publ Hlth, London, England.
   [Jha, Vivekanand] Manipal Acad Higher Educ, Manipal, India.
   [Rajbhandari, Dorrilyn] George Inst Global Hlth, Acad Project Operat, Crit Care Program, Sydney, NSW, Australia.
   [Myatra, Sheila Nainan] Tata Mem Hosp, Homi Bhabha Natl Inst, Dept Anaesthesiol Crit Care & Pain, Mumbai, Maharashtra, India.
   [John, Oommen; Ghosh, Arpita] MAHE, Prasanna Sch Publ Hlth, Manipal, India.
   [Joshi, Rohina] Univ New South Wales, Fac Med, Sydney, NSW, Australia.
   [Joshi, Rohina; Donaldson, Lachlan; Hammond, Naomi; Venkatesh, Balasubramanian] George Inst Global Hlth, Sydney, NSW, Australia.
   [Donaldson, Lachlan; Hammond, Naomi] Royal North Shore Hosp, St Leonards, NSW, Australia.
   [Venkatesh, Balasubramanian] Wesley Hosp, Brisbane, Qld, Australia.
   [Venkatesh, Balasubramanian] Univ Queensland, Brisbane, Qld, Australia.
RP Vijayaraghavan, BKT (corresponding author), Apollo Hosp, Dept Crit Care Med, Chennai, Tamil Nadu, India.; Vijayaraghavan, BKT (corresponding author), George Inst Global Hlth, New Delhi, India.
EM bharath@icuconsultants.com
OI Myatra, Sheila/0000-0001-6761-163X; Tirupakuzhi Vijayaraghavan, Bharath
   Kumar/0000-0002-1801-0667
FU Wesley Medical Research, Australia
FX Wesley Medical Research, Australia; Role of funding agency: The funder
   has no role in the design, conduct, analysis, interpretation of data or
   the decision to write up the manuscript.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 31
PY 2020
VL 21
IS 1
AR 754
DI 10.1186/s13063-020-04679-3
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NM1VN
UT WOS:000567892000001
PM 32867852
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Root-Bernstein, R
AF Root-Bernstein, Robert
TI Age and Location in Severity of COVID-19 Pathology: Do Lactoferrin and
   Pneumococcal Vaccination Explain Low Infant Mortality and Regional
   Differences?
SO BIOESSAYS
LA English
DT Article
DE Bacillus Calmette-Guerin; epidemiology; pneumococcus; polio; SARS-CoV-2;
   susceptibility; vaccination coverage
ID COMMUNITY-ACQUIRED PNEUMONIA; COST-EFFECTIVENESS; CONJUGATE VACCINE;
   SEROTYPE DISTRIBUTION; POLYSACCHARIDE VACCINATION; ANTIGENIC
   COMPLEMENTARITY; ANTIMICROBIAL RESISTANCE; CHANGING EPIDEMIOLOGY;
   INFLUENZA VACCINE; ADULT-POPULATIONS
AB Two conundrums puzzle COVID-19 investigators: 1) morbidity and mortality is rare among infants and young children and 2) rates of morbidity and mortality exhibit large variances across nations, locales, and even within cities. It is found that the higher the rate of pneumococcal vaccination in a nation (or city) the lower the COVID-19 morbidity and mortality. Vaccination rates with Bacillus Calmette-Guerin, poliovirus, and other vaccines do not correlate with COVID-19 risks, nor do COVID-19 case or death rates correlate with number of people in the population with diabetes, obesity, or adults over 65. Infant protection may be due to maternal antibodies and antiviral proteins in milk such as lactoferrin that are known to protect against coronavirus infections. Subsequent protection might then be conferred (and correlate with) rates ofHaemophilus influenzaetype B (Hib) (universal in infants) and pneumococcal vaccination, the latter varying widely by geography among infants, at-risk adults, and the elderly.
C1 [Root-Bernstein, Robert] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.
RP Root-Bernstein, R (corresponding author), Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.
EM rootbern@msu.edu
OI Root-Bernstein, Robert/0000-0002-3298-9306
CR Alicino C, 2017, VACCINE, V35, P5776, DOI 10.1016/j.vaccine.2017.09.005
   [Anonymous], 2006, MMWR-MORBID MORTAL W, V55, P1065
   Jimenez MA, 2014, ARCH BRONCONEUMOL, V50, P93, DOI 10.1016/j.arbres.2013.09.016
   Baldo V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166637
   Benin AL, 2003, J INFECT DIS, V188, P81, DOI 10.1086/375782
   Berger JR, 2020, J NEUROVIROL, V26, P143, DOI 10.1007/s13365-020-00840-5
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Blank PR, 2018, HUM VACC IMMUNOTHER, V14, P2706, DOI 10.1080/21645515.2018.1489948
   Brundage JF, 2006, LANCET INFECT DIS, V6, P303, DOI 10.1016/S1473-3099(06)70466-2
   Bula CJ, 1996, SCHWEIZ MED WSCHR, V126, P2082
   Castro Juan D, 2017, Rev. perú. med. exp. salud publica, V34, P633, DOI 10.17843/rpmesp.2017.344.2884
   Centers for Disease Control and Prevention, 2008 2018 AD VACC CO
   Centers for Disease Control and Prevention, CHILDH PNEUM CONJ VA
   Centers for Disease Control and Prevention, FLUVAXVIEW
   Chan D, 2010, PUBLIC HLTH EPIDEMIO, V19, P53
   Chang R., 2020, AUTHOREA, DOI [10.22541/au.158630054.41052564, DOI 10.22541/AU.158630054.41052564]
   Charley M., 2017, IMPACT PCV13 C UNPUB
   China CCDC, EP CHAR OUTBR 2019 N
   Choi Y. H., 2020, MEDRXIV PREPRINT, DOI [10.1101/2020.06.01.20119057, DOI 10.1101/2020.06.01.20119057]
   Chumakov K., US TODAY
   Ciruela P, 2018, VACCINE, V36, P7744, DOI 10.1016/j.vaccine.2018.05.026
   Clancy Cornelius J, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa524
   Cohen SA, 2010, VACCINE, V28, P4462, DOI 10.1016/j.vaccine.2010.04.035
   Contou D, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2769-y
   Corcoran M, 2019, Ir Med J, V112, P894
   Covian C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00970
   Cristiani L, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00749-2020
   Cucchiari David, 2020, Med Clin (Barc), V155, P502, DOI 10.1016/j.medcli.2020.05.022
   da Cunha SS, 2005, REV SAUDE PUBL, V39, P129, DOI 10.1590/s0034-89102005000100017
   DeAntonio R, 2019, HUM VACC IMMUNOTHER, V15, P49, DOI 10.1080/21645515.2018.1514225
   Debray A, 2019, EUR J CLIN MICROBIOL, V38, P1821, DOI 10.1007/s10096-019-03614-y
   Desmet S, 2018, LANCET INFECT DIS, V18, P830, DOI 10.1016/S1473-3099(18)30346-3
   Dyda A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1820-8
   Ezoji K, 2019, E MEDITERR HEALTH J, V25, P686, DOI 10.26719/emhj.19.039
   FAINSTEIN V, 1980, J INFECT DIS, V141, P172, DOI 10.1093/infdis/141.2.172
   Fan BE, 2020, AM J HEMATOL, V95, P723, DOI 10.1002/ajh.25785
   Farmanara N, 2018, CAN J PUBLIC HEALTH, V109, P369, DOI 10.17269/s41997-018-0018-9
   Fedson DS, 2011, EXPERT REV VACCINES, V10, P1143, DOI [10.1586/erv.11.99, 10.1586/ERV.11.99]
   Fiore Anthony E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Fry AM, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.4.e60
   GEORGE RC, 1983, BRIT J EXP PATHOL, V64, P655
   Gervaix A, 2014, CLIN THER, V36, P802, DOI 10.1016/j.clinthera.2014.03.001
   Giammanco GM, 2018, HUM VACC IMMUNOTHER, V14, P2248, DOI 10.1080/21645515.2018.1475812
   GONCZI S, 1987, B EXP BIOL MED+, V103, P686, DOI 10.1007/BF00841840
   Grilli G, 1997, EUR J EPIDEMIOL, V13, P287, DOI 10.1023/A:1007398606807
   Han NN, 2019, AMB EXPRESS, V9, DOI 10.1186/s13568-019-0900-8
   Harkonen T, 2000, J MED VIROL, V62, P383, DOI 10.1002/1096-9071(200011)62:3<383::AID-JMV11>3.0.CO;2-#
   Harris C., EURONEWS
   Hill HA, 2017, MMWR-MORBID MORTAL W, V66, P1171, DOI 10.15585/mmwr.mm6643a3
   Hirve S, 2016, INFLUENZA OTHER RESP, V10, P254, DOI 10.1111/irv.12374
   Hughes MM, 2018, AM J PUBLIC HEALTH, V108, P517, DOI 10.2105/AJPH.2017.304257
   Hull B, 2019, COMMUN DIS INTELL, V43, DOI 10.33321/cdi.2019.43.47
   Ieven M, 2018, CLIN MICROBIOL INFEC, V24, P1158, DOI 10.1016/j.cmi.2018.02.004
   Isaacman DJ, 2008, CLIN THER, V30, P341, DOI 10.1016/j.clinthera.2008.02.003
   Iyer AS, 2015, EXPERT REV VACCINES, V14, P85, DOI 10.1586/14760584.2015.963058
   Jones LG, 2010, J AM GERIATR SOC, V58, P2323, DOI 10.1111/j.1532-5415.2010.03181.x
   Kajikawa N, 2019, INFECT DIS HEALTH, V24, P212, DOI 10.1016/j.idh.2019.07.002
   Kaplan A, 2019, CAN FAM PHYSICIAN, V65, P625
   KIM SH, 2016, BIOMED RES INT, V2016
   Kislaya I, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209428
   Kumar M., 2014, VALUE HEALTH, V17
   Kumar N, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00111-17
   Kuo K, 2018, VALUE HEALTH, V21, pS67, DOI 10.1016/j.jval.2018.07.504
   Lang JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023710
   Lavoignet CE, 2019, EUR J CLIN MICROBIOL, V38, P1523, DOI 10.1007/s10096-019-03583-2
   Lewis P A, 1931, J Exp Med, V54, P361, DOI 10.1084/jem.54.3.361
   Lexau CA, 2005, JAMA-J AM MED ASSOC, V294, P2043, DOI 10.1001/jama.294.16.2043
   Linchevski I, 2009, VACCINE, V27, P2437, DOI 10.1016/j.vaccine.2009.01.135
   Liu GS, 2019, BIOMED ENVIRON SCI, V32, P438, DOI 10.3967/bes2019.058
   Ljungstrom LR, 2017, EUR J CLIN MICROBIOL, V36, P1767, DOI 10.1007/s10096-017-2990-z
   Lopalco P. L., 2006, EURO SURVEILL, V11
   Louisiana Department of Health, HEALTH DATA MANAG
   Lu PJ, 2015, AM J PREV MED, V49, pS412, DOI 10.1016/j.amepre.2015.03.005
   Luna-Muschi A, 2019, EPIDEMIOL INFECT, V147, DOI [10.1017/S0950268819000037, 10.1017/s0950268819000037]
   Mahamat A, 2013, HUM VACC IMMUNOTHER, V9, P128, DOI 10.4161/hv.22550
   Maraki S, 2018, INFECT CHEMOTHER, V50, P328, DOI 10.3947/ic.2018.50.4.328
   McLaughlin JM, 2019, HUM VACC IMMUNOTHER, V15, P841, DOI 10.1080/21645515.2018.1564434
   McNamee LA, 2006, INFECT IMMUN, V74, P6707, DOI 10.1128/IAI.00789-06
   MDHHS Michigan Department of Health and Human Services, MICH DEP HLTH HUM SE
   Mereckiene J., 2017, TECHNICAL REPORT
   Miller A., 2020, MEDRXIV PREPRINT, DOI [10.1101/2020.03.24.20042937, DOI 10.1101/2020.03.24.20042937]
   Misko IS, 1999, P NATL ACAD SCI USA, V96, P2279, DOI 10.1073/pnas.96.5.2279
   Miyasaka M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012661
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   Naito T, 2020, J INFECT CHEMOTHER, V26, P407, DOI 10.1016/j.jiac.2019.12.011
   National Institute for Communicable Diseases (South Africa), PNEUM CONJ VACC US L
   Nix EB, 2012, CLIN VACCINE IMMUNOL, V19, P766, DOI 10.1128/CVI.05675-11
   NYC Health, DAIL DAT SUMM
   Cruz-Hervert LP, 2013, SALUD PUBLICA MEXICO, V55, pS300
   Papadatou I, 2019, ANN HEMATOL, V98, P775, DOI 10.1007/s00277-019-03615-z
   Papadatou I, 2016, CLIN VACCINE IMMUNOL, V23, P388, DOI 10.1128/CVI.00721-15
   Park DC, 2019, ANN LAB MED, V39, P537, DOI 10.3343/alm.2019.39.6.537
   Pletz MW, 2016, VACCINE, V34, P2342, DOI 10.1016/j.vaccine.2016.03.052
   Porcheddu R, 2020, J INFECT DEV COUNTR, V14, P125, DOI 10.3855/jidc.12600
   Poscia A, 2017, EUR J PUBLIC HEALTH, V27, P1016, DOI 10.1093/eurpub/ckx150
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2
   Richter L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210081
   Root-Bernstein R., 2020, CROSS REACTIVITY SAR, DOI [10.20944/preprints202007.0141.v1, DOI 10.20944/PREPRINTS202007.0141.V1]
   Root-Bernstein R, 2009, AUTOIMMUNITY, V42, P1, DOI 10.1080/08916930802208540
   Root-Bernstein R, 2007, AUTOIMMUN REV, V6, P272, DOI 10.1016/j.autrev.2006.09.003
   Root-Bernstein R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134645
   Schuck-Paim C, 2019, LANCET GLOB HEALTH, V7, pE249, DOI 10.1016/S2214-109X(18)30455-8
   Schwarz TF, 2013, VACCINE, V31, P291, DOI 10.1016/j.vaccine.2012.10.077
   Serrano G, 2020, INT J RES HLTH SCI, V8, DOI DOI 10.5530/IJRHS.8.1.3
   Shibata N, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4186-x
   Shope R E, 1931, J Exp Med, V54, P373, DOI 10.1084/jem.54.3.373
   SHOPE RICHARD E., 1931, JOUR EXP MED, V54, P349, DOI 10.1084/jem.54.3.349
   Sings HL, 2017, VACCINE, V35, P5406, DOI 10.1016/j.vaccine.2017.05.075
   Song JY, 2013, YONSEI MED J, V54, P469, DOI 10.3349/ymj.2013.54.2.469
   Statens Serum Institute, SEL RISK GROUPS AR O
   Stefani C., 2013, J VIROL ANTIVIR RES, V2, P1
   Storhaug CL, 2017, LANCET GASTROENTEROL, V2, P738, DOI 10.1016/S2468-1253(17)30154-1
   Sun H., 2012, MILK PROTEIN
   Takeda H, 2019, J GLOB INFECT DIS, V11, P30, DOI 10.4103/jgid.jgid_167_17
   Theidel U, 2013, DTSCH ARZTEBL INT, V110, P743, DOI 10.3238/arztebl.2013.0743
   Tiley KS, 2018, VACCINE, V36, P6726, DOI 10.1016/j.vaccine.2018.09.032
   Toleman MS, 2016, SUPPORT CARE CANCER, V24, P2317, DOI 10.1007/s00520-015-3037-6
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Tozzi AE, 2014, VACCINE, V32, P793, DOI 10.1016/j.vaccine.2013.12.044
   Trama AM, 2014, CELL HOST MICROBE, V16, P215, DOI 10.1016/j.chom.2014.07.003
   Vestjens SMT, 2019, VACCINE, V37, P6558, DOI 10.1016/j.vaccine.2019.08.025
   Viner RM, 2020, LANCET, V395, P1741, DOI 10.1016/S0140-6736(20)31129-6
   Voysey M, 2017, VACCINE, V35, P5850, DOI 10.1016/j.vaccine.2017.09.002
   Wakabayashi H, 2014, J INFECT CHEMOTHER, V20, P666, DOI 10.1016/j.jiac.2014.08.003
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   Ward D., 2020, CASE FATALITY RATES, DOI [10.13140/RG.2.2.29057.89448, DOI 10.13140/RG.2.2.29057.89448]
   Wateska AR, 2020, AM J PREV MED, V58, P487, DOI 10.1016/j.amepre.2019.10.022
   WESTALL FC, 1986, LANCET, V2, P251
   Westerink MAJ, 2012, AGING DIS, V3, P51
   Wiese AD, 2019, EXPERT REV VACCINES, V18, P327, DOI 10.1080/14760584.2019.1582337
   Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1
   Williams WB, 2015, SCIENCE, V349, DOI 10.1126/science.aab1253
   Worldometers, CORONAVIRUS
   Xia W, 2020, PEDIATR PULM, V55, P1169, DOI 10.1002/ppul.24718
   Yang L, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3735-7
   Yang TU, 2015, INFECT CHEMOTHER, V47, P41, DOI 10.3947/ic.2015.47.1.41
   Yang TU, 2016, VACCINE, V34, P1623, DOI 10.1016/j.vaccine.2016.01.043
   Zahariadis George, 2006, Can Respir J, V13, P17
   Zhang DM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3326-z
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
NR 141
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0265-9247
EI 1521-1878
J9 BIOESSAYS
JI Bioessays
PD NOV
PY 2020
VL 42
IS 11
AR 2000076
DI 10.1002/bies.202000076
EA AUG 2020
PG 11
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA OK3HY
UT WOS:000567393700001
PM 32869330
OA Bronze
DA 2021-01-01
ER

PT J
AU Oso, BJ
   Adeoye, AO
   Olaoye, IF
AF Oso, Babatunde Joseph
   Adeoye, Akinwunmi Oluwaseun
   Olaoye, Ige Francis
TI Pharmacoinformatics and hypothetical studies on allicin, curcumin, and
   gingerol as potential candidates against COVID-19-associated proteases
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SAR-CoV-2; antiviral drugs; phytocompounds; autodock tool; SwissADME
ID MOLECULAR-DYNAMICS; SCORING FUNCTION; MODE; INHIBITORS; SOFTWARE;
   DOCKING
AB Medicinal plants have been known to provide the essential raw material for the majority of antiviral drugs. This study demonstrated the putative inhibitory potential of curcumin, allicin, and gingerol towards cathepsin K, COVID-19 main protease, and SARS-CoV 3 C-like protease. The pharmacokinetic properties were predicted through the SwissADME server while the corresponding binding affinity of the selected phytocompounds towards the proteins was computed using PyRx-Python Prescription 0.8 and the binding free energy were computed based on conventional molecular dynamics using LARMD server. The ADMET properties revealed all the drugs possess drug-like properties. Curcumin has the highest binding affinities with all the selected proteases while allicin has the lowest binding affinities towards the proteases. Moreover, it was observed that curcumin exhibited the highest binding free energy of -17.90 +/- 0.23, -18.21 +/- 0.25, and -9.67 +/- 0.08 kcal/mol for Cathepsin K, COVID-19 main protease, and SARS-CoV 3 C-like protease, respectively. Based on the activities of the phytocompounds against coronavirus target proteases involved in the viral entry as evident from the results, the study, therefore, suggests that these phytocompounds could be valuable for the development of drugs useful for the prevention of coronavirus entry and replication. Communicated by Ramaswamy H. Sarma
C1 [Oso, Babatunde Joseph; Olaoye, Ige Francis] McPherson Univ, Dept Biochem, Seriki Sotayo, Ogun State, Nigeria.
   [Adeoye, Akinwunmi Oluwaseun] Fed Univ Oye Ekiti, Dept Biochem, Oye Ekiti, Ekiti State, Nigeria.
RP Adeoye, AO (corresponding author), Fed Univ Oye Ekiti, Dept Biochem, Oye Ekiti, Ekiti State, Nigeria.
EM akinwunmi.adeoye@fuoye.edu.ng
RI Oso, Babatunde/B-4081-2018
OI Oso, Babatunde/0000-0001-8667-7108; Adeoye,
   Akinwunmi/0000-0002-2669-0607
CR Adcock SA, 2006, CHEM REV, V106, P1589, DOI 10.1021/cr040426m
   Adeoye AO, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02248
   ADEOYE AO, 2020, J BIOMOL STRUCT 0514, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1765876
   Arabzadeh Ali Mohammad, 2013, Pak J Biol Sci, V16, P180
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   Barrette-Ng IH, 2002, J BIOL CHEM, V277, P39960, DOI 10.1074/jbc.M206978200
   Birtley JR, 2005, J BIOL CHEM, V280, P11520, DOI 10.1074/jbc.M413254200
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chen Z, 2004, PHYTOTHER RES, V18, P592, DOI 10.1002/ptr.1485
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Drwal M. N., 2014, NUCLEIC ACIDS RES, V10
   Elena SF, 2005, J VIROL, V79, P11555, DOI 10.1128/JVI.79.18.11555-11558.2005
   Elokely KM, 2013, J CHEM INF MODEL, V53, P1934, DOI 10.1021/ci400040d
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Fonteh P, 2015, BIOMETALS, V28, P653, DOI 10.1007/s10534-015-9851-y
   GHOSH R, 2020, J BIOMOL STRUCT 0806, DOI DOI https://doi.org/10.1080/07391102.2020.1802347
   Greenwell M, 2015, INT J PHARM SCI RES, V6, P4103, DOI 10.13040/IJPSR.0975-8232.6(10).4103-12
   GUPTA MK, 2020, J BIOMOL STRUCT 0413, DOI DOI https://doi.org/10.1080/07391102.2020.1751300
   HAN Y, 2019, FRONT PHARMACOL, V10, DOI DOI https://doi.org/10.3389/fphar.2019.00434
   Hao GF, 2009, J PHYS CHEM B, V113, P4865, DOI 10.1021/jp807442n
   Harris JC, 2001, APPL MICROBIOL BIOT, V57, P282, DOI 10.1007/s002530100722
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   ICHIYE T, 1991, PROTEINS, V11, P205, DOI 10.1002/prot.340110305
   Jiang X, 2015, BIOCHEM BIOPH RES CO, V458, P908, DOI 10.1016/j.bbrc.2015.02.058
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646
   Kehinde I, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02565
   KHAN SA, 2020, J BIOMOL STRUCT 0411, DOI DOI https://doi.org/10.1080/07391102.2020.1751298
   KUMAR A, 2020, J BIOMOL STRUCT 0602, DOI DOI https://doi.org/10.1080/07391102.2020.1772112
   KUNITZ M, 1947, J GEN PHYSIOL, V30, P291, DOI 10.1085/jgp.30.4.291
   Lu J, 2018, J ENZYM INHIB MED CH, V33, P890, DOI 10.1080/14756366.2018.1465417
   Maheshwari RK, 2006, LIFE SCI, V78, P2081, DOI 10.1016/j.lfs.2005.12.007
   Mathew D, 2018, J FUNCT FOODS, V40, P692, DOI 10.1016/j.jff.2017.12.017
   Moghadamtousi SZ, 2015, MAR DRUGS, V13, P4520, DOI 10.3390/md13074520
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   OSO BJ, 2020, SN APPL SCI, V2, DOI DOI https://doi.org/10.1007/s42452-020-2275-5
   Pan YM, 2008, J AM CHEM SOC, V130, P5140, DOI 10.1021/ja077972s
   Raha K, 2005, J MED CHEM, V48, P4558, DOI 10.1021/jm048973n
   Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   ROSMALENA R, 2019, PATHOGENS, V8, DOI DOI https://doi.org/10.3390/pathogens8020085
   Sanchez-Linares I, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S14-S13
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Seal A, 2011, BIOINFORMATION, V5, P430, DOI 10.6026/97320630005430
   Senthilvel P, 2013, BIOINFORMATION, V9, P889, DOI 10.6026/97320630009889
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Song FX, 2020, RADIOLOGY, V295, P210, DOI 10.1148/radiol.2020200274
   SORKUN MC, 2019, SCI DATA, V6, DOI DOI https://doi.org/10.1038/s41597-019-0151-1
   Srikanth S, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00470
   Townsend EA, 2013, AM J RESP CELL MOL, V48, P157, DOI 10.1165/rcmb.2012-0231OC
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tseng YT, 2010, J BIOL CHEM, V285, P12862, DOI 10.1074/jbc.M109.030270
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   Younas M, 2018, RSC ADV, V8, P29714, DOI 10.1039/c8ra04879g
   2019, SCROTOSCOPIC SURGERY, P1
NR 56
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1813630
EA AUG 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NK2WI
UT WOS:000566596600001
PM 32876538
OA Bronze
DA 2021-01-01
ER

PT J
AU Dubbke-Laule, A
   Gnauck, M
   Straub, R
   Berthold, F
   Jenssen, C
AF Dubbke-Laule, Alexandra
   Gnauck, Manuela
   Straub, Ralf
   Berthold, Frank
   Jenssen, Christian
TI Quadruple negative SARS-CoV-2-PCR: still COVID-19 pneumonia!
SO DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
LA German
DT Article; Early Access
DE COVID-19; SARS-CoV-2; computed tomography; PCR; seroconversion
AB Zusammenfassung
   Anamnese und klinischer Befund Ein 78-jahriger Mann erkrankte Anfang April 2020 19 Tage nach einer Kreuzfahrt mit Schwache, Husten und Fieber und wurde 4 Tage spater mit zunehmender Luftnot vorstellig.
   Untersuchung und Diagnose Bei Aufnahme bestanden subfebrile Temperaturen, Belastungsdyspnoe und rechtsbasale Rasselgerausche. Das CRP war ma ss ig erhoht und die Sauerstoffsattigung gering reduziert. Im Thorax-CT fanden sich bilaterale Milchglasinfiltrate. Unmittelbar nach der Kreuzfahrt war ein nasopharyngealer Abstrich auf SARS-CoV-2 negativ.
   Therapie und Verlauf In Kenntnis der Tatsache, dass die symptomfreie Ehefrau des Patienten unmittelbar nach Ruckkehr von der Kreuzfahrt positiv auf SARS-CoV-2 getestet worden war, gingen wir von einer COVID-19-Erkrankung aus und hospitalisierten den Patienten. Zwei nasopharyngeale Abstriche und die Bronchiallavage ergaben negative Befunde fur SARS-CoV-2, die Diagnose COVID-19 wurde letztlich serologisch verifiziert.
   Folgerung Bei hochgradigem klinisch-anamnestischem Verdacht in Verbindung mit typischen Befunden der Thorax-Bildgebung sollte die Verdachtsdiagnose COVID-19 auch im Falle mehrfach negativer SARS-CoV-2-PCR aufrechterhalten bleiben. Die Serokonversion tritt einige Tage bis 2 Wochen nach Symptombeginn auf und kann im Verlauf zur endgultigen Diagnosesicherung genutzt werden.
   Abstract
   Medical history and clinical findings A 78-year-old man fell ill with weakness, coughing and fever 19 days after a cruise in early April 2020 and was admitted 4 days later with increasing shortness of breath.
   Examination and diagnosis On admission, the patient had subfebrile temperatures, exercise dyspnea, and right-basal rales. CRP was moderately elevated and oxygen saturation was slightly reduced. Thoracic CT showed bilateral ground-glass infiltrates. Immediately after the cruise a nasopharyngeal swab was negative for SARS-CoV-2.
   Therapy and course Due to the fact that the patient's asymptomatic wife had been tested positive for SARS-CoV-2 immediately after returning from the cruise, we suspected COVID-19 disease and admitted the patient to our isolation ward. Two nasopharyngeal swabs and bronchial lavage yielded negative results for SARS-CoV-2. Finally, suspected COVID-19 diagnosis was verified serologically.
   Conclusion In case of a high degree of clinical suspicion in combination with typical findings of thoracic imaging, the suspected diagnosis COVID-19 disease should be maintained even in case of multiple negative SARS-CoV-2-PCR. Seroconversion occurs a few days to 2 weeks after the onset of symptoms and can be used to confirm the diagnosis.
C1 [Dubbke-Laule, Alexandra; Gnauck, Manuela; Jenssen, Christian] Krankenhaus Markisch Oderland, Innere Med Klin, Protzeler Chaussee 5, D-15344 Strausberg, Germany.
   [Straub, Ralf] Praxis Radiol, Strausberg, Germany.
   [Berthold, Frank] IMD Labor Oderland, Frankfurt, Germany.
RP Jenssen, C (corresponding author), Krankenhaus Markisch Oderland, Innere Med Klin, Protzeler Chaussee 5, D-15344 Strausberg, Germany.
EM c.jenssen@khmol.de
CR Ai T., 2020, RADIOLOGY
   ander Heiden M, 2020, EPID B, V17, P10, DOI [10.25646/6692.2, DOI 10.25646/6692.2]
   Hao WD, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101627
   Hornuss D, 2020, DTSCH MED WSCHR
   Kim H, 2020, RADIOLOGY
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lechien JR, 2020, J INTERN MED, V288, P335, DOI 10.1111/joim.13089
   Li W, 2020, CLIN INFECT DIS
   Lippi G, 2020, CLIN CHEM LAB MED
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Long CQ, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108961
   Mallapaty Smriti, 2020, Nature, V580, P18, DOI 10.1038/d41586-020-00885-w
   Mizumoto K, 2020, INFECT DIS MODEL, V5, P264, DOI 10.1016/j.idm.2020.02.003
   Padoan A, 2020, CLIN CHIM ACTA, V507, P164, DOI 10.1016/j.cca.2020.04.026
   Stadnytskyi V, 2020, P NATL ACAD SCI USA, V117, P11875, DOI 10.1073/pnas.2006874117
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu JY, 2020, INFECT DIS THER, V9, P17, DOI 10.1007/s40121-020-00286-6
   Wu Z, 2020, JAMA
   Zhang XY, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018-020-01698-3
NR 19
TC 0
Z9 0
U1 4
U2 4
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0012-0472
EI 1439-4413
J9 DEUT MED WOCHENSCHR
JI Dtsch. Med. Wochenschr.
DI 10.1055/a-1202-3936
EA AUG 2020
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NI7NC
UT WOS:000565534800001
PM 32869227
DA 2021-01-01
ER

PT J
AU Hemmer, CJ
   Geerdes-Fenge, HF
   Reisinger, EC
AF Hemmer, Christoph J.
   Geerdes-Fenge, Hilte F.
   Reisinger, Emil C.
TI COVID-19: epidemiology and clinical facts
SO RADIOLOGE
LA German
DT Article
DE SARS-CoV-2; Polymerase chain reaction; Cytokine response; Acute
   respiratory distress syndrome; Vaccination
ID CORONAVIRUS
AB Until July 31, 2020, about 17.6 million SARS-CoV-2 infections and 680,000 deaths from COVID-19 were reported. SARS-CoV-2 is most likely transmitted by droplets and probably by aerosols. Patients become infectious 2-3 days before the onset of symptoms, and persons with asymptomatic infections are also infectious. COVID-19 affects the upper respiratory tract, lungs (pneumonia, acute respiratory distress syndrome [ARDS]), heart, liver, gastrointestinal tract, and other organs. SARS-CoV-2 uses ACE2 a receptor to enter host cells. Vasculitis, endothelial damage, thromboembolic events and organ failure are accompanied by a massive cytokine response. Elderly people and those with pre-existing diseases are particularly vulnerable. An efficient antiviral therapy is not yet available. Severely ill patients may benefit from dexamethasone and early treatment of complications. Candidate vaccines are currently being tested in clinical studies.
C1 [Hemmer, Christoph J.; Geerdes-Fenge, Hilte F.; Reisinger, Emil C.] Univ Med Rostock, Abt Tropenmed & Infekt Krankheiten, Ernst Heydemannstr 6, D-18055 Rostock, Germany.
RP Reisinger, EC (corresponding author), Univ Med Rostock, Abt Tropenmed & Infekt Krankheiten, Ernst Heydemannstr 6, D-18055 Rostock, Germany.
EM emil.reisinger@uni-rostock.de
CR ARD, 2020, TAGESSCHAU      0410
   Arevalo-Rodriguez I., 2020, FALSE NEGATIVE RESUL, DOI [10.1101/2020.04.16.20066787, DOI 10.1101/2020.04.16.20066787]
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bohmer MM, 2020, LANCET INFECT DIS, V20, P920, DOI 10.1016/S1473-3099(20)30314-5
   Bootsma MCJ, 2007, P NATL ACAD SCI USA, V104, P7588, DOI 10.1073/pnas.0611071104
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Eikenberry SE, 2020, INFECT DIS MODEL, V5, P293, DOI 10.1016/j.idm.2020.04.001
   Gaia C, 2020, RADIOL MED, V125, P931, DOI 10.1007/s11547-020-01256-1
   Gao XS, 2020, J INFECT DEV COUNTR, V14, P547, DOI 10.3855/jidc.12992
   Geerdes-Fenge HF, 2020, DTSCH ARZTEBL INT, V117, P297, DOI 10.3238/arztebl.2020.0297
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hamner L, 2020, MMWR-MORBID MORTAL W, V69, P606, DOI 10.15585/mmwr.mm6919e6
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Ho KF, 2020, SCI TOTAL ENVIRON, V735, DOI 10.1016/j.scitotenv.2020.139510
   Hoang A, 2020, LANCET, V24, P100433
   Ing AJ, 2020, THORAX, V75, P693, DOI 10.1136/thoraxjnl-2020-215091
   Islandischer Rundfunk (RUV), 2020, NIUND SMIT ISL HAF V
   Kampf G, 2020, J HOSP INFECT, V105, P587, DOI 10.1016/j.jhin.2020.01.022.
   Klironomos S, 2020, RADIOLOGY, V297, pE324, DOI 10.1148/radiol.2020202791
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Kreis Heinsberg, 2020, COR KREIS HEINSB
   Kremer S, 2020, NEUROLOGY, V95, pE1868, DOI 10.1212/WNL.0000000000010112
   Landesamt fur Gesundheit und Soziales Mecklenburg-Vorpommern, 2020, DAT COR PAND
   Li DS, 2020, KOREAN J RADIOL, V21, P505, DOI 10.3348/kjr.2020.0146
   Liu Anding, 2020, Clin Microbiol Infect, V26, P1703, DOI 10.1016/j.cmi.2020.07.009
   Longchamp A, 2020, RES PRACT THROMB HAE, V4, P842, DOI 10.1002/rth2.12376
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Reisinger EC, 2020, ARZTEBL MV, V2020, P124
   Reisinger EC, 2020, DEUT MED WOCHENSCHR, V145, pE96, DOI 10.1055/a-1197-4293
   Robert-Koch-Institut, 2020, SIT ZUM 01 08 2020
   Robert-Koch-Institut, 2020, COVID 19 FALLZ
   Robert-Koch-Institut, 2020, STECKBR COR KRANKH 1
   Rochwerg B, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2924
   Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980
   Smither SJ, 2020, EMERG MICROBES INFEC, V9, P1415, DOI 10.1080/22221751.2020.1777906
   Stein RA, 2011, INT J INFECT DIS, V15, pE510, DOI 10.1016/j.ijid.2010.06.020
   Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094
   Universitat Innsbruck, 2020, ISCHGL STUDIE 42 4 P
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   VFA-Verband der forschenden Pharmaunternehmen, 2020, IMPFST ZUM SCHUTZ CO
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Watson J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1808
   WHO Regionalburo fur Europa, 2020, COR DIS COVID 19 PAN
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Worldometers, 2020, WORLD ISR
   Worldometers, 2020, WORLD IR
   Worldometers, 2020, WORLD N CAR
   Worldometers, 2020, WORLD CAL
   Worldometers, 2020, WORLD SPAIN
   Worldometers, 2020, WORLD TEX
   Worldometers, 2020, WORLD GEORG
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Wuhan City Health Committee (WCHC), 2019, WUH MUN HLTH HLTH CO
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00243-2
   Ye W, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01105
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 62
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0033-832X
EI 1432-2102
J9 RADIOLOGE
JI Radiologe
PD OCT
PY 2020
VL 60
IS 10
SI SI
BP 893
EP 898
DI 10.1007/s00117-020-00741-y
EA AUG 2020
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA NU7LP
UT WOS:000564511600001
PM 32865603
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abhithaj, J
   Francis, D
   Sharanya, CS
   Arun, KG
   Sadasivan, C
   Variyar, EJ
AF Abhithaj, J.
   Francis, Dileep
   Sharanya, C. S.
   Arun, K. G.
   Sadasivan, C.
   Variyar, E. Jayadevi
TI Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor
   against SARS-CoV-2 and insights into their interactions with M-pro
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Covid-19; SARS-CoV-2; main protease; E-pharmacophore; molecular docking;
   simeprevir; protease inhibitors
ID HEPATITIS-C; CORONAVIRUS; DOCKING; SARS; PROTEIN; SERIES; VIRUS; GLIDE;
   MODEL
AB The world has come to a sudden halt due to the incessant spread of a viral pneumonia dubbed COVID-19 caused by the beta-coronavirus, SARS-CoV-2. The main protease of SARS-CoV-2 plays a key role in the replication and propagation of the virus in the host cells. Inhibiting the protease blocks the replication of the virus; therefore it is considered as an attractive therapeutic target. Here we describe the screening of the DrugBank database, a public repository for small molecule therapeutics, to identify approved or experimental phase drugs that can be repurposed against the main protease of SARS-CoV-2. The initial screening was performed on more than 13,000 drug entries in the target database using an energy optimised pharmacophore hypothesis AARRR. A sub-set of the molecules selected based on the fitness score was further screened using molecular docking by sequentially filtering the molecules through the high throughput virtual screening, extra precision and standard precision docking modalities. The best hits were subjected to binding free energy estimation using the MM-GBSA method. Approved drugs viz, Cobicistat, Larotrectinib and Simeprevir were identified as potential candidates for repurposing. Drugs in the discovery phase identified as inhibitors include the known cysteine protease inhibitors, Calpain inhibitor IV and an experimental cathepsin F inhibitor. In order to analyse the stability of the binding interactions, the known cysteine protease inhibitors viz, Simeprevir, calpain inhibitor IV and the cathepsin F inhibitor in complex M(pro)were subjected to molecular dynamics simulations at 100 ns. Based on the results Simeprevir was found to be a strong inhibitor of SARS-CoV-2 M-pro. Communicated by Ramaswamy H. Sarma
C1 [Abhithaj, J.; Sharanya, C. S.; Arun, K. G.; Sadasivan, C.; Variyar, E. Jayadevi] Kannur Univ, Dept Biotechnol & Microbiol, Thalassery Campus, Kannur 670661, Kerala, India.
   [Francis, Dileep] Kristu Jayanti Coll Autonomous, Dept Life Sci, Bengaluru, India.
RP Variyar, EJ (corresponding author), Kannur Univ, Dept Biotechnol & Microbiol, Thalassery Campus, Kannur 670661, Kerala, India.
EM ejayadevi@gmail.com
FU Indian Council for Medical Research (ICMR), New Delhi, IndiaIndian
   Council of Medical Research (ICMR); CSIR-SRFCouncil of Scientific &
   Industrial Research (CSIR) - India
FX Abhithaj J and Arun KG acknowledge the Indian Council for Medical
   Research (ICMR), New Delhi, India for the financial support. Sharanya CS
   acknowledge CSIR-SRF for the financial support. The authors would like
   to thank the Bioinformatics Infrastructure facility (BIF) at the
   Department of Biotechnology & Microbiology, Kannur University, supported
   by Department of Biotechnology (DBT), Government of India for
   computational facilities.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   ANDERSEN KG, 2020, NAT MED 0317, DOI DOI HTTPS://DOI.ORG/10.1038/S41591-020-0820-9
   ARUN KG, 2020, J BIOMOL STRUCT 0620, DOI DOI https://doi.org/10.1080/07391102.2020.1779819
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Baden LR, 2020, NEW ENGL J MED, V382, P1851, DOI 10.1056/NEJMe2005477
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Carragher NO, 2006, CURR PHARM DESIGN, V12, P615, DOI 10.2174/138161206775474314
   Chatel-Chaix L, 2010, VIRUSES-BASEL, V2, P1752, DOI 10.3390/v2081752
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Deeks ED, 2014, DRUGS, V74, P195, DOI 10.1007/s40265-013-0160-x
   Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822-006-9087-6
   FAKHAR Z, 2020, J BIOMOL STRUCT 0731, DOI DOI https://doi.org/10.1080/07391102.2020.1801510
   Flanagan S, 2014, EXPERT REV CLIN PHAR, V7, P691, DOI 10.1586/17512433.2014.956091
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   GHOSH R, 2020, J BIOMOL STRUCT 0806, DOI DOI https://doi.org/10.1080/07391102.2020.1802347
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hosseini FS, 2020, SIMEPREVIR POTENTIAL, DOI 10.20944/preprints202002.0438.v1
   IBRAHIM MAA, 2020, J BIOMOL STRUCT 0707, DOI DOI https://doi.org/10.1080/07391102.2020.1790037
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d
   KAPUSTA K, 2020, J BIOMOL STRUCT 0813, DOI DOI https://doi.org/10.1080/07391102.2020.1806930
   Li Z, 2019, ANTIVIR RES, V172, DOI 10.1016/j.antiviral.2019.104607
   Lyne PD, 2006, J MED CHEM, V49, P4805, DOI 10.1021/jm060522a
   Majumdar A, 2016, ALIMENT PHARM THER, V43, P1276, DOI 10.1111/apt.13633
   Mitja O, 2020, LANCET GLOB HEALTH, V8, pE639, DOI 10.1016/S2214-109X(20)30114-5
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Scott LJ, 2019, DRUGS, V79, P201, DOI 10.1007/s40265-018-1044-x
   SHARMA P, 2020, J BIOMOL STRUCT 0731, DOI DOI https://doi.org/10.1080/07391102.2020.1798286
   Sun HM, 2008, CURR MED CHEM, V15, P1018, DOI 10.2174/092986708784049630
   Tawari NR, 2010, J COMPUT CHEM, V31, P739, DOI 10.1002/jcc.21371
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang XQ, 2016, ACTA PHARM SIN B, V6, P26, DOI 10.1016/j.apsb.2015.09.008
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 41
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1813200
EA AUG 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NI0FL
UT WOS:000565034600001
PM 32873185
OA Bronze
DA 2021-01-01
ER

PT J
AU Pham, MQ
   Vu, KB
   Pham, TNH
   Huong, LT
   Tran, LH
   Tung, NT
   Vu, VV
   Nguyen, TH
   Ngo, ST
AF Pham, Minh Quan
   Vu, Khanh B.
   Han Pham, T. Ngoc
   Thuy Huong, Le Thi
   Tran, Linh Hoang
   Tung, Nguyen Thanh
   Vu, Van V.
   Nguyen, Trung Hai
   Ngo, Son Tung
TI Rapid prediction of possible inhibitors for SARS-CoV-2 main protease
   using docking and FPL simulations
SO RSC ADVANCES
LA English
DT Article
ID IN-SILICO; DRUG; OPTIMIZATION; CORONAVIRUS; ACCURACY; OUTBREAK
AB Originating for the first time in Wuhan, China, the outbreak of SARS-CoV-2 has caused a serious global health issue. An effective treatment for SARS-CoV-2 is still unavailable. Therefore, in this study, we have tried to predict a list of potential inhibitors for SARS-CoV-2 main protease (Mpro) using a combination of molecular docking and fast pulling of ligand (FPL) simulations. The approaches were initially validated over a set of eleven available inhibitors. Both Autodock Vina and FPL calculations produced consistent results with the experiments with correlation coefficients ofR(Dock)= 0.72 +/- 0.14 andR(W)= -0.76 +/- 0.10, respectively. The combined approaches were then utilized to predict possible inhibitors that were selected from a ZINC15 sub-database for SARS-CoV-2 Mpro. Twenty compounds were suggested to be able to bind well to SARS-CoV-2 Mpro. Among them, five top-leads areperiandrin V,penimocycline,cis-p-Coumaroylcorosolic acid,glycyrrhizin, anduralsaponin B. The obtained results could probably lead to enhance the COVID-19 therapy.
C1 [Pham, Minh Quan; Thuy Huong, Le Thi; Tung, Nguyen Thanh] Vietnam Acad Sci & Technol, Grad Univ Sci & Technol, Hanoi, Vietnam.
   [Pham, Minh Quan; Thuy Huong, Le Thi] Vietnam Acad Sci & Technol, Inst Nat Prod Chem, Hanoi, Vietnam.
   [Vu, Khanh B.] Int Univ, Sch Biotechnol, Ho Chi Minh City, Vietnam.
   [Vu, Khanh B.; Tran, Linh Hoang] Vietnam Natl Univ, Ho Chi Minh City, Vietnam.
   [Han Pham, T. Ngoc] Ton Duc Thang Univ, Fac Pharm, Ho Chi Minh City, Vietnam.
   [Tran, Linh Hoang] Ho Chi Minh Univ Technol HCMUT, Fac Civil Energeering, Ho Chi Minh, Vietnam.
   [Tung, Nguyen Thanh] Vietnam Acad Sci & Technol, Inst Mat Sci, Hanoi, Vietnam.
   [Vu, Van V.] Nguyen Tat Thanh Univ, NTT Hitech Inst, Ho Chi Minh City, Vietnam.
   [Nguyen, Trung Hai; Ngo, Son Tung] Ton Duc Thang Univ, Lab Theoret & Computat Biophys, Ho Chi Minh City, Vietnam.
   [Nguyen, Trung Hai; Ngo, Son Tung] Ton Duc Thang Univ, Fac Appl Sci, Ho Chi Minh City, Vietnam.
RP Ngo, ST (corresponding author), Ton Duc Thang Univ, Lab Theoret & Computat Biophys, Ho Chi Minh City, Vietnam.; Ngo, ST (corresponding author), Ton Duc Thang Univ, Fac Appl Sci, Ho Chi Minh City, Vietnam.
EM ngosontung@tdtu.edu.vn
RI Ngo, Son Tung/F-8964-2013; Nguyen, Trung Hai/W-4797-2019; Vu,
   Van/B-2098-2010
OI Ngo, Son Tung/0000-0003-1034-1768; Vu, Van/0000-0003-0009-6703
FU Vietnam National Foundation for Science & Technology Development
   (NAFOSTED)National Foundation for Science & Technology Development
   (NAFOSTED) [104.99-2019.57]
FX This work was supported by Vietnam National Foundation for Science &
   Technology Development (NAFOSTED) grant #104.99-2019.57.
CR A A.-S. Abd Al-Aziz, 2020, COMPUTATIONAL DESIGN
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Aliev AE, 2014, PROTEINS, V82, P195, DOI 10.1002/prot.24350
   Case D., 2018, AMBER 18, V18
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552
   Fauquet CM, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-64
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   Gao KF, 2020, J PHYS CHEM LETT, V11, P5373, DOI 10.1021/acs.jpclett.0c01579
   Hatada R, 2020, J CHEM INF MODEL, V60, P3593, DOI 10.1021/acs.jcim.0c00283
   Homeyer N, 2014, J CHEM THEORY COMPUT, V10, P3331, DOI 10.1021/ct5000296
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   MARSHALL GR, 1987, ANNU REV PHARMACOL, V27, P193
   Muhammet K., 2020, PHARMACOPHORE ANAL S
   Ngo Son Tung, 2020, J Chem Inf Model, DOI 10.1021/acs.jcim.0c00491
   Ngo ST, 2016, J CHEM INF MODEL, V56, P1344, DOI 10.1021/acs.jcim.6b00029
   Tama NM, 2018, CHEM PHYS LETT, V701, P65, DOI 10.1016/j.cplett.2018.04.024
   Nguyen NT, 2020, J CHEM INF MODEL, V60, P204, DOI 10.1021/acs.jcim.9b00778
   Mai NT, 2020, J MOL GRAPH MODEL, V100, DOI 10.1016/j.jmgm.2020.107648
   Tran PT, 2019, RSC ADV, V9, P29619, DOI 10.1039/c9ra05763c
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Ngo ST, 2017, CHEM PHYS LETT, V676, P12, DOI 10.1016/j.cplett.2017.03.034
   Ngo ST, 2016, J COMPUT CHEM, V37, P2734, DOI 10.1002/jcc.24502
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Subramanian G, 2016, J CHEM INF MODEL, V56, P1936, DOI 10.1021/acs.jcim.6b00290
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tung N. Son, 2020, ASSESSING POTENTIAL
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   WHO, 2019, 52 WHO
   Yu Wai C., 2020, F1000RESEARCH, V9, P129
   Yu WB, 2017, METHODS MOL BIOL, V1520, P85, DOI 10.1007/978-1-4939-6634-9_5
   Zhang HY, 2018, J CHEM INF MODEL, V58, P1669, DOI 10.1021/acs.jcim.8b00493
   Zhang HY, 2018, J CHEM INF MODEL, V58, P1037, DOI 10.1021/acs.jcim.8b00026
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 45
TC 1
Z9 1
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD AUG 31
PY 2020
VL 10
IS 53
BP 31991
EP 31996
DI 10.1039/d0ra06212j
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA NI2SV
UT WOS:000565206400034
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Abd El-Mordy, FM
   El-Hamouly, MM
   Ibrahim, MT
   Abd El-Rheem, GA
   Aly, OM
   Abd El-kader, AM
   Youssif, KA
   Abdelmohsen, UR
AF Abd El-Mordy, Fatma M.
   El-Hamouly, Mohamed M.
   Ibrahim, Magda T.
   El-Rheem, Gehad Abd
   Aly, Omar M.
   Abd El-kader, Adel M.
   Youssif, Khayrya A.
   Abdelmohsen, Usama Ramadan
TI Inhibition of SARS-CoV-2 main protease by phenolic compounds
   fromManilkara hexandra(Roxb.) Dubard assisted by metabolite profiling
   andin silicovirtual screening
SO RSC ADVANCES
LA English
DT Article
ID COV 3CL PROTEASE; CORONAVIRUS; FLAVONOIDS; STRATEGIES; REVEALS
AB SARS-CoV-2 is a novel coronavirus that was first identified during the outbreak in Wuhan, China in 2019. It is an acute respiratory illness that can transfer among human beings. Natural products can provide a rich resource for novel antiviral drugs. They can interfere with viral proteins such as viral proteases, polymerases, and entry proteins. Several naturally occurring flavonoids were reported to have antiviral activity against different types of RNA and DNA viruses. A methanolic extract ofManilkara hexandra(Roxb.) Dubard leaves is rich in phenolic compounds, mainly flavonoids. Metabolic profiling of the secondary metabolites ofManilkara hexandra(Roxb.) Dubard leaves methanolic extract (MLME), and bark ethyl acetate (MBEE) extract using LC-HRESIMS resulted in the isolation of18compounds belonging to a variety of constituents, among which phenolic compounds, flavones, flavonol glycosides and triterpenes were predominant. Besides, four compounds (I-IV) were isolated and identified as myricetinI, myricitrinII, mearnsitrinIII, and mearnsetin-3-O-beta-d-rutinosideIV(compoundIVis isolated for the first time from genusManilkara) and dereplicated in a metabolomic study as compounds3,5,6, and12, respectively. The molecular docking study showed that rutin, myricitrin, mearnsitrin, and quercetin 3-O-beta-d-glucoside have strong interaction with SARS-CoV-2 protease with high binding energy of -8.2072, -7.1973, -7.5855, and -7.6750, respectively. Interestingly, the results proved that rutin which is a citrus flavonoid glycoside exhibits the strongest inhibition effect to the SARS-CoV-2 protease enzyme. Consequently, it can contribute to developing an effective antiviral drug lead against the SARS-CoV-2 pandemic.
C1 [Abd El-Mordy, Fatma M.] Al Azhar Univ, Fac Pharm Girls, Dept Pharmacognosy, Cairo 11754, Egypt.
   [El-Hamouly, Mohamed M.] Al Azhar Univ, Fac Pharm Boys, Dept Pharmacognosy, Cairo 11371, Egypt.
   [Ibrahim, Magda T.] Sinai Univ, Fac Pharm, Dept Pharmacognosy, Kantara Branch, Kantara, Egypt.
   [El-Rheem, Gehad Abd] Natl Res Ctr, Dept Pharmacol, Giza 12622, Egypt.
   [Aly, Omar M.] Menia Univ, Fac Pharm, Dept Med Chem, Al Minya 61519, Egypt.
   [Abd El-kader, Adel M.; Abdelmohsen, Usama Ramadan] Deraya Univ, Fac Pharm, Dept Pharmacognosy, Al Minya 61111, Egypt.
   [Abd El-kader, Adel M.] Al Azhar Univ, Fac Pharm, Dept Pharmacognosy, Assiut 71524, Egypt.
   [Youssif, Khayrya A.] Modern Univ Technol & Informat, Fac Pharm, Dept Pharmacognosy, Cairo, Egypt.
   [Abdelmohsen, Usama Ramadan] Menia Univ, Fac Pharm, Dept Pharmacognosy, Al Minya 61519, Egypt.
RP Abdelmohsen, UR (corresponding author), Deraya Univ, Fac Pharm, Dept Pharmacognosy, Al Minya 61111, Egypt.; Abdelmohsen, UR (corresponding author), Menia Univ, Fac Pharm, Dept Pharmacognosy, Al Minya 61519, Egypt.
EM Usama.ramadan@mu.edu.eg
OI Abdelmohsen, Usama Ramadan/0000-0002-1014-6922
CR Abdelmohsen UR, 2014, MAR DRUGS, V12, P1220, DOI 10.3390/md12031220
   Allwood JW, 2010, PHYTOCHEM ANALYSIS, V21, P33, DOI 10.1002/pca.1187
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Asante I., 2009, PHARMACOGN J, V1, P201
   Banerjee S, 2015, J FOOD SCI TECH MYS, V52, P3158, DOI 10.1007/s13197-014-1487-3
   Chang CC, 2002, J FOOD DRUG ANAL, V10, P178
   Clarke CJ, 2008, TOXICOL PATHOL, V36, P140, DOI 10.1177/0192623307310947
   El-Desouky SK, 2009, Z NATURFORSCH B, V64, P447, DOI 10.1515/znb-2009-0416
   Fayek NM, 2012, PHARMACOGN RES, V4, P85, DOI 10.4103/0974-8490.94723
   Fernandes P., 2013, BIOMED RES INT, P1
   Gao YH, 2010, NAT PROD COMMUN, V5, P223
   Gursoy O, 2017, J CHEMINFORMATICS, V9, DOI 10.1186/s13321-017-0216-0
   Haggag EG, 2019, INT J NANOMED, V14, P6217, DOI 10.2147/IJN.S214171
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Kadam V., 2012, J PHARMACOGN PHYTOCH, V1, P64
   KAUL TN, 1985, J MED VIROL, V15, P71, DOI 10.1002/jmv.1890150110
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lohning E., 2017, CURR TOP MED CHEM, V17, P1
   Ma J, 2003, J NAT PROD, V66, P983, DOI 10.1021/np020576x
   Mahmoud II, 2001, PHYTOCHEMISTRY, V58, P1239, DOI 10.1016/S0031-9422(01)00365-X
   Mariyam Roqaiya, 2015, International Journal of Herbal Medicine, V2, P20
   Owis AI, 2020, RSC ADV, V10, P19570, DOI 10.1039/d0ra03582c
   Panche AN, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2016.41
   Patel K., 2019, BIOACTIVE FOOD DIETA, V2, P457, DOI DOI 10.1016/B978-0-12-813820-5.00026-X
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ram S., 2014, J PHARM BIOSCI, V2, P13
   Rambla JL, 2015, METHODS MOL BIOL, V1284, P221, DOI 10.1007/978-1-4939-2444-8_11
   Rehman M. T., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.12362333.v2, DOI 10.26434/CHEMRXIV.12362333.V2]
   Sayed AM, 2020, RSC ADV, V10, P19790, DOI 10.1039/d0ra04199h
   Sayed AM, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8070970
   Seidel V, 2000, PHYTOCHEMISTRY, V55, P439, DOI 10.1016/S0031-9422(00)00346-0
   SHEN CC, 1993, PHYTOCHEMISTRY, V34, P843, DOI 10.1016/0031-9422(93)85370-7
   Simelane MBC, 2013, MOLECULES, V18, P12313, DOI 10.3390/molecules181012313
   Singleton VL, 1999, METHOD ENZYMOL, V299, P152
   Thomas J., 2019, J EXPT CLIN SCI, V18, P1037
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Youssif K., 2019, PLOS ONE, P1
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 43
TC 2
Z9 2
U1 0
U2 0
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD AUG 31
PY 2020
VL 10
IS 53
BP 32148
EP 32155
DI 10.1039/d0ra05679k
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA NI2SV
UT WOS:000565206400052
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Wu, YR
   Hong, K
   Ruan, LG
   Yang, XB
   Zhang, JC
   Xu, JQ
   Pan, SW
   Ren, LH
   Chen, L
   Huang, CL
   Shang, Y
AF Wu, Yongran
   Hong, Ke
   Ruan, Lianguo
   Yang, Xiaobo
   Zhang, Jiancheng
   Xu, Jiqian
   Pan, Shangwen
   Ren, Lehao
   Chen, Lu
   Huang, Chaolin
   Shang, You
TI Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from
   Convalescent Plasma Therapy: A Retrospective Study
SO VIROLOGICA SINICA
LA English
DT Article; Early Access
DE Coronavirus disease 2019 (COVID-19); SARS-CoV-2; Prolonged positivity;
   Convalescent plasma therapy
ID RESPIRATORY SYNDROME CORONAVIRUS; EBOLA-VIRUS DISEASE; VIRAL LOAD;
   INFECTION; COVID-19; BLOOD
AB Convalescent plasma therapy has been implemented in a few cases of severe coronavirus disease 2019. No report about convalescent plasma therapy in treating patients with prolonged positivity of SARS-CoV-2 RNA has been published. In this study, we conducted a retrospective observational study in 27 patients with prolonged positivity of SARS-CoV-2 RNA, the clinical benefit of convalescent plasma therapy were analyzed. qRT-PCR test of SARS-CoV-2 RNA turned negative (<= 7 days) in a part of patients (early negative group, n = 15) after therapy, others (late negative group, n = 12) turned negative in more than 7 days. Pulmonary imaging improvement was confirmed in 7 patients in early negative group and 8 in late negative group after CP therapy. Viral load decreased in early negative group compared with late negative group at day 3, 5, 7 after implementing convalescent plasma therapy. Patients in early negative group had a shorter median length of hospital stay. In conclusion, convalescent plasma therapy might help eliminate virus and shorten length of hospital stay in patients with prolonged positivity of SARS-CoV-2 RNA.
C1 [Wu, Yongran; Yang, Xiaobo; Zhang, Jiancheng; Xu, Jiqian; Pan, Shangwen; Ren, Lehao; Shang, You] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Crit Care Med, Wuhan 430022, Peoples R China.
   [Hong, Ke; Ruan, Lianguo; Chen, Lu; Huang, Chaolin] Jinyintan Hosp, Res Ctr Translat Med, Wuhan 430022, Peoples R China.
RP Shang, Y (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Crit Care Med, Wuhan 430022, Peoples R China.; Huang, CL (corresponding author), Jinyintan Hosp, Res Ctr Translat Med, Wuhan 430022, Peoples R China.
EM chaolin2020@163.com; you_shanghust@163.com
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2020kfyXGYJ092]
FX This study was supported by the Fundamental Research Funds for the
   Central Universities (2020kfyXGYJ092).
CR Adair Luther B 2nd, 2020, Radiol Case Rep, V15, P819, DOI 10.1016/j.radcr.2020.04.031
   Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Al-Gethamy M, 2015, CLIN INFECT DIS, V60, P973, DOI 10.1093/cid/ciu1135
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   China National Health Commission, 2020, NEW COR PNEUM PREV C
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Hu XW, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138812
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Ivers LC, 2020, AM J TROP MED HYG, V102, P1149, DOI 10.4269/ajtmh.20-0260
   Kirby T, 2020, LANCET RESP MED, V8, P551, DOI 10.1016/S2213-2600(20)30218-6
   Kraaij-Dirkzwager M, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.21.20817
   Kraft CS, 2015, CLIN INFECT DIS, V61, P496, DOI 10.1093/cid/civ334
   Li N, 2020, J MED VIROL, V92, P2286, DOI 10.1002/jmv.25952
   Little P, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1728
   Liu WD, 2020, J INFECTION, V81, P329, DOI 10.1016/j.jinf.2020.03.063
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Saglietto A, 2020, LANCET, V395, P1110, DOI 10.1016/S0140-6736(20)30690-5
   Sahr F, 2017, J INFECTION, V74, P302, DOI 10.1016/j.jinf.2016.11.009
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shi D, 2020, J INFECT DIS, V222, P910, DOI [10.1093/infdis/jiaa388, DOI 10.1093/INFDIS/JIAA388]
   Spanakis N, 2014, INT J ANTIMICROB AG, V44, P528, DOI 10.1016/j.ijantimicag.2014.07.026
   Walsh KA, 2020, J INFECTION, V81, P357, DOI 10.1016/j.jinf.2020.06.067
   Wan R, 2020, INT J INFECT DIS, V95, P174, DOI 10.1016/j.ijid.2020.03.041
   Wang B, 2020, J MED VIROL, V92, P1684, DOI 10.1002/jmv.25946
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Yan D, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00799-2020
   Yang JR, 2020, J MED VIROL, V92, P1681, DOI 10.1002/jmv.25940
   Yang XB, 2020, J THROMB HAEMOST, V18, P1469, DOI 10.1111/jth.14848
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang YC, 2020, EMERG MICROBES INFEC, V9, P833, DOI 10.1080/22221751.2020.1756699
   ZHOU B, 2020, J THROMB THROMB 0418, DOI DOI 10.1093/cid/ciaa451
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 37
TC 1
Z9 1
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1674-0769
EI 1995-820X
J9 VIROL SIN
JI Virol. Sin.
DI 10.1007/s12250-020-00281-8
EA AUG 2020
PG 8
WC Virology
SC Virology
GA NH2FK
UT WOS:000564491200001
PM 32865701
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hagerty, SL
   Wielgosz, J
   Kraemer, J
   Nguyen, HV
   Loew, D
   Kaysen, D
AF Hagerty, Sarah L.
   Wielgosz, Joseph
   Kraemer, Jaclyn
   Nguyen, Hong, V
   Loew, Dorene
   Kaysen, Debra
TI Best Practices for Approaching Cognitive Processing Therapy and
   Prolonged Exposure During the COVID-19 Pandemic
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL;
   MENTAL-HEALTH; SMARTPHONE APP; PTSD COACH; EMERGENCY; VETERANS; CARE;
   PSYCHOTHERAPY; PROVIDERS
AB The COVID-19 pandemic presents major challenges for mental health care providers. In particular, providers who treat posttraumatic stress disorder (PTSD) are now tasked with determining whether to initiate trauma-focused therapy during the pandemic and, if so, whether and how to adapt treatment. The purpose of this communication is to identify and organize key considerations for whether and how to deliver commonly used evidence-supported therapy protocols for trauma treatment-specifically, cognitive processing therapy (CPT) and prolonged exposure (PE) therapy-during the ongoing COVID-19 pandemic for adults who currently meet the criteria for PTSD. Based on relevant public health and clinical literature, we present a structured guide that can be used by treatment teams and individual providers to evaluate whether initiating CPT or PE is indicated given a particular patient-provider pair and system context amidst pandemic conditions. In addition, we suggest appropriate action steps, including problem-solving strategies, evidence-informed modifications to CPT and PE, and alternative intervention approaches.
C1 [Hagerty, Sarah L.; Wielgosz, Joseph; Kraemer, Jaclyn; Nguyen, Hong, V; Loew, Dorene] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
   [Hagerty, Sarah L.; Wielgosz, Joseph; Kaysen, Debra] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA USA.
   [Hagerty, Sarah L.; Wielgosz, Joseph] Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific Mental Illness Res Educ & Clin Ctr, Palo Alto, CA USA.
   [Kaysen, Debra] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Palo Alto, CA USA.
RP Hagerty, SL (corresponding author), VA Palo Alto Hlth Care Syst, Palo Alto Div, 116B,3801 Miranda Ave, Palo Alto, CA 94304 USA.
EM shagerty@stanford.edu
CR Altare C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109022
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   American Psychological Association, 2017, CLIN PRACT GUID TRAT
   Bass JK, 2013, NEW ENGL J MED, V368, P2182, DOI 10.1056/NEJMoa1211853
   Berenz EC, 2012, PROF PSYCHOL-RES PR, V43, P154, DOI 10.1037/a0026138
   Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20
   Comfort LK, 2006, PUBLIC WORKS MANAG P, V10, P328, DOI 10.1177/1087724X06289052
   Department of Veterans Affairs (VA) and the Department of Defense (DoD), 2010, VA DOD CLIN PRACT GU
   Doran JM, 2017, J CLIN PSYCHOL, V73, P1259, DOI 10.1002/jclp.22445
   Duffy M, 2007, BRIT MED J, V334, P1147, DOI 10.1136/bmj.39021.846852.BE
   Erbes CR, 2014, MIL MED, V179, P1218, DOI 10.7205/MILMED-D-14-00014
   Foa EB, 2018, JAMA-J AM MED ASSOC, V319, P354, DOI 10.1001/jama.2017.21242
   Foa EB, 2011, DEPRESS ANXIETY, V28, P1043, DOI 10.1002/da.20907
   Galovski TE, 2012, J CONSULT CLIN PSYCH, V80, P968, DOI 10.1037/a0030600
   Garcia HA, 2014, PSYCHOL SERV, V11, P50, DOI 10.1037/a0035643
   Gillespie K, 2002, BEHAV RES THER, V40, P345, DOI 10.1016/S0005-7967(02)00004-9
   Graber MA, 2003, EMERG MED J, V20, P426, DOI 10.1136/emj.20.5.426
   Grieger TA, 2007, MIL MED, V172, P451, DOI 10.7205/MILMED.172.5.451
   Hamblen JL, 2019, PSYCHOTHERAPY, V56, P359, DOI 10.1037/pst0000231
   Held P, 2020, COGN BEHAV PRACT, V27, P126
   Hendriks L, 2018, EUR J PSYCHOTRAUMATO, V9, DOI 10.1080/20008198.2018.1425574
   Henslee AM, 2010, PROF PSYCHOL-RES PR, V41, P34, DOI 10.1037/a0018235
   Hughes P, 2015, INTERVENTION, V13, P60, DOI 10.1097/WTF.0000000000000082
   Hugo M, 2015, EMERG MED LOS ANG, V5, P1, DOI DOI 10.4172/2165-7548.1000285
   Jakupcak M, 2011, COGN BEHAV PRACT, V18, P85, DOI 10.1016/j.cbpra.2009.08.007
   Kalkman JP, 2017, INT J PROJ MANAG, V35, P889, DOI 10.1016/j.ijproman.2016.09.013
   Kapucu N, 2009, J HOMEL SECUR EMERG, V6
   Kaysen D, 2020, EUR J PSYCHOTRAUMATO, V11, DOI 10.1080/20008198.2020.1735162
   Kleim B, 2011, TRAUMATOLOGY, V17, P17, DOI DOI 10.1177/1534765611429079
   Knaevelsrud C, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-13
   Kuhn E, 2017, J CONSULT CLIN PSYCH, V85, P267, DOI 10.1037/ccp0000163
   Kuhn E, 2014, MIL MED, V179, P12, DOI 10.7205/MILMED-D-13-00271
   Miner A, 2016, PSYCHOL TRAUMA-US, V8, P384, DOI 10.1037/tra0000092
   Mollica RF, 2004, LANCET, V364, P2058, DOI 10.1016/S0140-6736(04)17519-3
   Moring JC, 2020, J TRAUMA STRESS, V33, P371, DOI 10.1002/jts.22544
   North CS, 2013, JAMA-J AM MED ASSOC, V310, P507, DOI 10.1001/jama.2013.107799
   Paladino L, 2017, J GLOB INFECT DIS, V9, P45, DOI 10.4103/jgid.jgid_24_17
   Reger MA, 2020, JAMA PSYCHIAT, V77, P1093, DOI 10.1001/jamapsychiatry.2020.1060
   Rietjens S. J. H., 2008, MANAGING CIVIL MILIT
   Rossi L, 2006, PUBLIC HEALTH NUTR, V9, P551, DOI 10.1079/PHN2005928
   Ruzek Josef I, 2016, Mhealth, V2, P37, DOI 10.21037/mhealth.2016.08.06
   Sciarrino NA, 2020, PSYCHOL TRAUMA-US, V12, pS69, DOI 10.1037/tra0000718
   Simpson NC, 2009, J OPER RES SOC, V60, pS126, DOI 10.1057/jors.2009.3
   Tuerk PW, 2013, PSYCHOL SERV, V10, P401, DOI 10.1037/a0030549
   Turgoose D, 2018, J TELEMED TELECARE, V24, P575, DOI 10.1177/1357633X17730443
   van Minnen A, 2012, EUR J PSYCHOTRAUMATO, V3, DOI 10.3402/ejpt.v3i0.18805
   Vetter Pauline, 2016, Lancet Infect Dis, V16, pe82, DOI 10.1016/S1473-3099(16)00077-3
   WACHEN JS, 2019, CURRENT TREATMENT OP, V6, P107, DOI DOI 10.1007/S40501-019-00169-9
   Watson PJ, 2011, AM PSYCHOL, V66, P482, DOI 10.1037/a0024806
   Weiss WM, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0622-7
NR 50
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD OCT
PY 2020
VL 33
IS 5
BP 623
EP 633
DI 10.1002/jts.22583
EA AUG 2020
PG 11
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA OA2DV
UT WOS:000564012700001
PM 32865850
OA Bronze
DA 2021-01-01
ER

PT J
AU Lei, L
   Qian, HB
   Yang, XF
   Zhang, XZ
   Zhang, D
   Dai, TX
   Guo, R
   Shi, L
   Cheng, YB
   Zhang, BJ
   Zhou, XB
   Hu, JS
   Guo, YL
AF Lei, Lei
   Qian, Hongbo
   Yang, Xiaofang
   Zhang, Xingzhe
   Zhang, Dan
   Dai, Tongxin
   Guo, Rui
   Shi, Lin
   Cheng, Yanbin
   Zhang, Baojun
   Zhou, Xiaobo
   Hu, Jinsong
   Guo, Yaling
TI The phenotypic changes of gamma delta T cells in COVID-19 patients
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE activation; COVID-19; innate immunity; SARS-CoV-2; gamma delta T cells
ID CORONAVIRUS; OUTBREAK; INNATE
AB A novel pneumonia-associated respiratory syndrome named coronavirus disease-2019 (COVID-19), which was caused by SARS-CoV-2?broke out in Wuhan, China, in the end of 2019. Unfortunately, there is no specific antiviral agent or vaccine available to treat SARS-CoV-2 infections. The information regarding the immunological characteristics in COVID-19 patients remains limited. Here, we collected the blood samples from 18 healthy donors (HD) and 38 COVID-19 patients to analyze changes on gamma delta T cell population. In comparison with HD, the gamma delta T cell percentage decreased, while the activation marker CD25 expression increased in response to SARS-CoV-2 infection. Interestingly, the CD4 expression was upregulated in gamma delta T cells reflecting the occurrence of a specific effector cell population, which may serve as a biomarker for the assessment of SARS-CoV-2 infection.
C1 [Lei, Lei; Yang, Xiaofang; Zhang, Xingzhe; Zhang, Dan; Shi, Lin; Cheng, Yanbin; Zhang, Baojun; Zhou, Xiaobo] Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Pathogen Microbiol & Immunol, Hlth Sci Ctr, Xian 710061, Shaanxi, Peoples R China.
   [Qian, Hongbo; Dai, Tongxin; Guo, Rui; Guo, Yaling] 8th Hosp Xian, Dept Clin Lab, Xian 710061, Shaanxi, Peoples R China.
   [Zhou, Xiaobo] Xi An Jiao Tong Univ, Key Lab Environm & Genes Related Dis, Hlth Sci Ctr, Xian, Peoples R China.
   [Zhou, Xiaobo] Xi An Jiao Tong Univ, Inst Infect & Immun, Translat Med Inst, Hlth Sci Ctr, Xian, Peoples R China.
   [Hu, Jinsong] Xi An Jiao Tong Univ, Dept Cell Biol & Genet, Hlth Sci Ctr, Xian 710061, Shaanxi, Peoples R China.
RP Zhou, XB (corresponding author), Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Pathogen Microbiol & Immunol, Hlth Sci Ctr, Xian 710061, Shaanxi, Peoples R China.; Guo, YL (corresponding author), 8th Hosp Xian, Dept Clin Lab, Xian 710061, Shaanxi, Peoples R China.; Hu, JS (corresponding author), Xi An Jiao Tong Univ, Dept Cell Biol & Genet, Hlth Sci Ctr, Xian 710061, Shaanxi, Peoples R China.
EM zhouxb@mail.xjtu.edu.cn; jinsong.hu@xjtu.edu.cn; 15102915638@126.com
RI Hu, Jinsong/AAX-1953-2020
OI Hu, Jinsong/0000-0003-0565-4567
FU COVID-19 special project from Xi'an Jiaotong University Foundation
   [xzy032020002]; Natural Science Foundation of Shaanxi Province,
   ChinaNatural Science Foundation of Shaanxi Province [2020JM-065]
FX COVID-19 special project from Xi'an Jiaotong University Foundation,
   Grant/Award Number: xzy032020002. Natural Science Foundation of Shaanxi
   Province, China 2020JM-065.
CR Born WK, 2006, CURR OPIN IMMUNOL, V18, P31, DOI 10.1016/j.coi.2005.11.007
   Garcia KC, 2009, NAT IMMUNOL, V10, P143, DOI 10.1038/ni.f.219
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Holtmeier Wolfgang, 2005, V86, P151, DOI 10.1159/000086659
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Knight A, 2010, BLOOD, V116, P2164, DOI 10.1182/blood-2010-01-255166
   Li H, 2013, CELL MOL IMMUNOL, V10, P159, DOI 10.1038/cmi.2012.70
   Li Z, 2015, CELL MOL IMMUNOL, V12, P604, DOI 10.1038/cmi.2014.77
   Li Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106064
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma Y, 2013, CHIN J VIRAL DIS, V3, P179
   Shiromizu CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02389
   Qi Q, 2009, BLOOD, V114, P564, DOI 10.1182/blood-2008-12-196345
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wen K, 2012, COMP IMMUNOL MICROB, V35, P289, DOI 10.1016/j.cimid.2012.01.010
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Xue CX, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01054
   Zhang BJ, 2018, J IMMUNOL, V201, P1452, DOI 10.4049/jimmunol.1800106
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziegler H, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00645
NR 23
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT
PY 2020
VL 24
IS 19
BP 11603
EP 11606
DI 10.1111/jcmm.15620
EA AUG 2020
PG 4
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA OH1OW
UT WOS:000564570200001
PM 32864865
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Peng, S
   Cao, FQ
   Xia, YF
   Gao, XD
   Dai, LP
   Yan, JH
   Ma, GH
AF Peng, Sha
   Cao, Fengqiang
   Xia, Yufei
   Gao, Xiao-Dong
   Dai, Lianpan
   Yan, Jinghua
   Ma, Guanghui
TI Particulate Alum via Pickering Emulsion for an Enhanced COVID-19 Vaccine
   Adjuvant
SO ADVANCED MATERIALS
LA English
DT Article
DE alum; cellular immune responses; COVID-19 vaccine adjuvant; Pickering
   emulsion; SARS-CoV-2
ID T-CELLS; CLEARANCE; MICROGELS; DESIGN; VIRUS; MERS
AB For rapid response against the prevailing COVID-19 (coronavirus disease 19), it is a global imperative to exploit the immunogenicity of existing formulations for safe and efficient vaccines. As the most accessible adjuvant, aluminum hydroxide (alum) is still the sole employed adjuvant in most countries. However, alum tends to attach on the membrane rather than entering the dendritic cells (DCs), leading to the absence of intracellular transfer and process of the antigens, and thus limits T-cell-mediated immunity. To address this, alum is packed on the squalene/water interphase is packed, forming an alum-stabilized Pickering emulsion (PAPE). "Inheriting" from alum and squalene, PAPE demonstrates a good biosafety profile. Intriguingly, with the dense array of alum on the oil/water interphase, PAPE not only adsorbs large quantities of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antigens, but also harbors a higher affinity for DC uptake, which provokes the uptake and cross-presentation of the delivered antigens. Compared with alum-treated groups, more than six times higher antigen-specific antibody titer and three-fold more IFN-gamma-secreting T cells are induced, indicating the potent humoral and cellular immune activations. Collectively, the data suggest that PAPE may provide potential insights toward a safe and efficient adjuvant platform for the enhanced COVID-19 vaccinations.
C1 [Peng, Sha; Cao, Fengqiang; Xia, Yufei; Ma, Guanghui] Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China.
   [Peng, Sha; Gao, Xiao-Dong] Jiangnan Univ, Sch Biotechnol, Minist Educ, Key Lab Carbohydrate Chem & Biotechnol, Wuxi 214122, Jiangsu, Peoples R China.
   [Cao, Fengqiang] Tokyo Univ Agr & Technol, Grad Sch Bioapplicat & Syst Engn, 2-24-16 Nakacho, Koganei, Tokyo 1848588, Japan.
   [Xia, Yufei; Ma, Guanghui] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Xia, Yufei; Ma, Guanghui] Chinese Acad Sci, Innovat Acad Green Manufacture, Beijing 100190, Peoples R China.
   [Dai, Lianpan] Chinese Acad Sci, Beijing Inst Life Sci, Beijing 100101, Peoples R China.
   [Yan, Jinghua] Chinese Acad Sci, Inst Microbiol, Beijing 100101, Peoples R China.
RP Xia, YF; Ma, GH (corresponding author), Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China.; Xia, YF; Ma, GH (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Xia, YF; Ma, GH (corresponding author), Chinese Acad Sci, Innovat Acad Green Manufacture, Beijing 100190, Peoples R China.
EM yfxia@ipe.ac.cn; ghma@ipe.ac.cn
OI Xia, Yufei/0000-0003-1215-6128
FU Foundation for Innovative Research Groups of the National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [21821005]; Pilot Project of Chinese Academy of Sciences
   [XDB29040303]; Original Innovation Project of Basic Frontier Scientific
   Research Program of Chinese Academy of Sciences [2020000071]; Youth
   Project of National Natural Science Foundation of China [21908229];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21776287]; Youth Innovation Promotion
   Association of the Chinese Academy of Sciences [2020000053]; Key
   External Cooperation Program of Chinese Academy of Sciences
   [122111KYSB20180021]
FX S.P. and F.C. contributed equally to this work. The authors express
   their appreciation on the unyielding support in RBD antigens from Prof.
   Fu Gao, Institute of Microbiology, Chinese Academy of Sciences. The
   authors thank Ms. Cui Song from State Key Laboratory of Biochemical
   Engineering, Chinese Academy of Science for her help of analysis via
   optimal tweezers. This work was supported by Project supported by the
   Foundation for Innovative Research Groups of the National Natural
   Science Foundation of China (Grant No. 21821005), the Pilot Project of
   Chinese Academy of Sciences (Grant No. XDB29040303), "From 0 to 1"
   Original Innovation Project of Basic Frontier Scientific Research
   Program of Chinese Academy of Sciences (No. 2020000071), Youth Project
   of National Natural Science Foundation of China (Grant No. 21908229),
   National Natural Science Foundation of China (Grant No. 21776287), Youth
   Innovation Promotion Association of the Chinese Academy of Sciences (No.
   2020000053), and Key External Cooperation Program of Chinese Academy of
   Sciences (122111KYSB20180021). All animal protocols were approved by the
   Institutional Animal Care and Use Committees at the Institute of Process
   Engineering, Chinese Academy of Sciences (approval ID: IPEAECA2017169).
   This study was performed in strict accordance with the Regulations for
   the Care and Use of Laboratory Animals and Guideline for Ethical Review
   of Animal (China, GB/T35892-2018). The authors modified all the
   techniques and procedures to provide for maximum comfort and minimal
   stress to the animals.
CR Allioux-Guerin M, 2009, BIOPHYS J, V96, P238, DOI 10.1529/biophysj.108.134627
   Benjaminsen RV, 2013, MOL THER, V21, P149, DOI 10.1038/mt.2012.185
   Brugger B, 2009, ANGEW CHEM INT EDIT, V48, P3978, DOI 10.1002/anie.200900239
   Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118
   Cheng C, 2018, ADV MATER, V30, DOI 10.1002/adma.201802669
   Cohen J, 2020, SCIENCE, V367, P234, DOI 10.1126/science.367.6475.234
   Copp JA, 2014, P NATL ACAD SCI USA, V111, P13481, DOI 10.1073/pnas.1412420111
   Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035
   Ebensen T, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00031
   Flach TL, 2011, NAT MED, V17, P479, DOI 10.1038/nm.2306
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0323-4
   Jiang H, 2018, ADV SCI, V5, DOI 10.1002/advs.201700426
   Jiang Y, 2020, ADV MATER, V32, DOI 10.1002/adma.202001808
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Jung SY, 2018, VACCINE, V36, P3468, DOI 10.1016/j.vaccine.2018.04.082
   Kadkhoda K, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00344-20
   Kalyuzhny Alexander E, 2005, Methods Mol Biol, V302, P15
   Kiser PF, 1998, NATURE, V394, P459
   Kiss E, 2012, MACROMOL BIOSCI, V12, P1181, DOI 10.1002/mabi.201200078
   Kwee BJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav6313
   Kwok MH, 2013, LANGMUIR, V29, P9581, DOI 10.1021/la402062t
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Leslie M, 2020, SCIENCE, V368, P809, DOI 10.1126/science.368.6493.809
   Leslie M, 2013, SCIENCE, V341, P26, DOI 10.1126/science.341.6141.26
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Moyer TJ, 2020, NAT MED, V26, P430, DOI 10.1038/s41591-020-0753-3
   O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061
   Pawlotsky JM, 2020, NAT REV GASTRO HEPAT, V17, P523, DOI 10.1038/s41575-020-0328-2
   Regnier M, 2012, VACCINE, V30, P6783, DOI 10.1016/j.vaccine.2012.09.020
   Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111
   Sun B, 2017, ADV OPT MATER, V5, DOI 10.1002/adom.201600937
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   THOMAS JL, 1994, BIOPHYS J, V67, P1101, DOI 10.1016/S0006-3495(94)80575-2
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wojnilowicz M, 2019, ACS NANO, V13, P187, DOI 10.1021/acsnano.8b05151
   Xia YF, 2018, NAT MATER, V17, P187, DOI [10.1038/NMAT5057, 10.1038/nmat5057]
   Xie YL, 2013, LAB CHIP, V13, P1772, DOI 10.1039/c3lc00043e
   Yoshida S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16347-w
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhao JX, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5393
NR 43
TC 1
Z9 1
U1 19
U2 19
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD OCT
PY 2020
VL 32
IS 40
AR 2004210
DI 10.1002/adma.202004210
EA AUG 2020
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA OB5MI
UT WOS:000564582700001
PM 32864794
OA Bronze
DA 2021-01-01
ER

PT J
AU Young, BE
   Fong, SW
   Chan, YH
   Mak, TM
   Ang, LW
   Anderson, DE
   Lee, CYP
   Amrun, SN
   Lee, B
   Goh, YS
   Su, YCF
   Wei, WE
   Kalimuddin, S
   Chai, LYA
   Pada, S
   Tan, SY
   Sun, L
   Parthasarathy, P
   Chen, YYC
   Barkham, T
   Lin, RTP
   Maurer-Stroh, S
   Leo, YS
   Wang, LF
   Renia, L
   Lee, VJ
   Smith, GJD
   Lye, DC
   Ng, LFP
AF Young, Barnaby E.
   Fong, Siew-Wai
   Chan, Yi-Hao
   Mak, Tze-Minn
   Ang, Li Wei
   Anderson, Danielle E.
   Lee, Cheryl Yi-Pin
   Amrun, Siti Naqiah
   Lee, Bernett
   Goh, Yun Shan
   Su, Yvonne C. F.
   Wei, Wycliffe E.
   Kalimuddin, Shirin
   Chai, Louis Yi Ann
   Pada, Surinder
   Tan, Seow Yen
   Sun, Louisa
   Parthasarathy, Purnima
   Chen, Yuan Yi Constance
   Barkham, Timothy
   Lin, Raymond Tzer Pin
   Maurer-Stroh, Sebastian
   Leo, Yee-Sin
   Wang, Lin-Fa
   Renia, Laurent
   Lee, Vernon J.
   Smith, Gavin J. D.
   Lye, David Chien
   Ng, Lisa F. P.
TI Effects of a major deletion in the SARS-CoV-2 genome on the severity of
   infection and the inflammatory response: an observational cohort study
SO LANCET
LA English
DT Article
ID GAMMA
AB Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with a 382-nucleotide deletion (Delta 382) in the open reading frame 8 (ORF8) region of the genome have been detected in Singapore and other countries. We investigated the effect of this deletion on the clinical features of infection.
   Methods We retrospectively identified patients who had been screened for the.382 variant and recruited to the PROTECT study-a prospective observational cohort study conducted at seven public hospitals in Singapore. We collected clinical, laboratory, and radiological data from patients' electronic medical records and serial blood and respiratory samples taken during hospitalisation and after discharge. Individuals infected with the Delta 382 variant were compared with those infected with wild-type SARS-CoV-2. Exact logistic regression was used to examine the association between the infection groups and the development of hypoxia requiring supplemental oxygen (an indicator of severe COVID-19, the primary endpoint). Follow-up for the study's primary endpoint is completed.
   Findings Between Jan 22 and March 21, 2020, 278 patients with PCR-confirmed SARS-CoV-2 infection were screened for the Delta 382 deletion and 131 were enrolled onto the study, of whom 92 (70%) were infected with the wild-type virus, ten (8%) had a mix of wild-type and.382-variant viruses, and 29 (22%) had only the Delta 382 variant. Development of hypoxia requiring supplemental oxygen was less frequent in the Delta 382 variant group (0 [0%] of 29 patients) than in the wild-type only group (26 [28%] of 92; absolute difference 28% [95% CI 14-28]). After adjusting for age and presence of comorbidities, infection with the Delta 382 variant only was associated with lower odds of developing hypoxia requiring supplemental oxygen (adjusted odds ratio 0.07 [95% CI 0.00-0.48]) compared with infection with wild-type virus only.
   Interpretation The Delta 382 variant of SARS-CoV-2 seems to be associated with a milder infection. The observed clinical effects of deletions in ORF8 could have implications for the development of treatments and vaccines. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Mak, Tze-Minn; Lin, Raymond Tzer Pin] Natl Publ Hlth Lab, Singapore, Singapore.
   [Young, Barnaby E.; Maurer-Stroh, Sebastian; Leo, Yee-Sin; Lye, David Chien] Natl Ctr Infect Dis, Singapore, Singapore.
   [Young, Barnaby E.; Leo, Yee-Sin; Lye, David Chien] Tan Tock Seng Hosp, Dept Infect Dis, Singapore, Singapore.
   [Chen, Yuan Yi Constance; Barkham, Timothy] Tan Tock Seng Hosp, Dept Lab Med, Singapore, Singapore.
   [Young, Barnaby E.; Leo, Yee-Sin; Lye, David Chien] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Fong, Siew-Wai; Chan, Yi-Hao; Lee, Cheryl Yi-Pin; Amrun, Siti Naqiah; Goh, Yun Shan; Renia, Laurent; Ng, Lisa F. P.] Agcy Sci Technol & Res, Infect Dis Horizontal Technol Ctr, Singapore, Singapore.
   [Fong, Siew-Wai; Chan, Yi-Hao; Lee, Cheryl Yi-Pin; Amrun, Siti Naqiah; Lee, Bernett; Goh, Yun Shan; Renia, Laurent; Ng, Lisa F. P.] Agcy Sci Technol & Res, Singapore Immunol Network, Singapore 138648, Singapore.
   [Maurer-Stroh, Sebastian] Agcy Sci Technol & Res, Bioinformat Inst, Singapore, Singapore.
   [Fong, Siew-Wai; Maurer-Stroh, Sebastian] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore.
   [Anderson, Danielle E.; Su, Yvonne C. F.; Kalimuddin, Shirin; Wang, Lin-Fa; Smith, Gavin J. D.] Natl Univ Singapore, Duke NUS Med Sch, Singapore 169857, Singapore.
   [Chai, Louis Yi Ann; Barkham, Timothy; Leo, Yee-Sin; Lye, David Chien] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Leo, Yee-Sin; Lee, Vernon J.] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
   [Ang, Li Wei; Wei, Wycliffe E.] Natl Ctr Infect Dis, Natl Publ Hlth & Epidemiol Unit, Singapore, Singapore.
   [Kalimuddin, Shirin] Singapore Gen Hosp, Dept Infect Dis, Singapore, Singapore.
   [Chai, Louis Yi Ann] Natl Univ Hlth Syst, Dept Med, Singapore, Singapore.
   [Pada, Surinder] Ng Teng Fong Gen Hosp, Dept Med, Infect Dis Serv, Singapore, Singapore.
   [Tan, Seow Yen] Changi Gen Hosp, Dept Infect Dis, Singapore, Singapore.
   [Sun, Louisa] Alexandra Hosp, Singapore, Singapore.
   [Parthasarathy, Purnima] Khoo Teck Puat Hosp, Dept Gen Med, Singapore, Singapore.
   [Maurer-Stroh, Sebastian] Global Initiat Sharing All Influenza Data, Munich, Germany.
   [Lee, Vernon J.] Minist Hlth, Singapore, Singapore.
RP Ng, LFP (corresponding author), Agcy Sci Technol & Res, Singapore Immunol Network, Singapore 138648, Singapore.; Smith, GJD (corresponding author), Natl Univ Singapore, Duke NUS Med Sch, Singapore 169857, Singapore.
EM gavin.smith@duke-nus.edu.sg; lisa_ng@immunol.a-star.edu.sg
OI Maurer-Stroh, Sebastian/0000-0003-0813-9640; Lye,
   David/0000-0003-0324-0205
FU Singapore National Medical Research Council's COVID-19 Research Fund
   [COVID19RF-001, COVID19RF-004, COVID19RF-007]; Biomedical Research
   Council COVID-19 fund [H20/04/g1/006]; National Medical Research Council
   SingaporeNational Medical Research Council, Singapore; A*ccelerate GAP
   from the Agency of Science, Technology, and Research
   [ACCL/19-GAP064-R20H-H]; National Institute of Allergy and Infectious
   Diseases (National Institutes of Health, US Department of Health and
   Human Services)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID)NIH National Institute of
   Neurological Disorders & Stroke (NINDS) [HHSN272201400006C]
FX National Medical Research Council Singapore.; This study was funded by
   grants from the Singapore National Medical Research Council's COVID-19
   Research Fund (grant numbers COVID19RF-001, COVID19RF-004, and
   COVID19RF-007), the Biomedical Research Council COVID-19 fund
   (H20/04/g1/006), and the A*ccelerate GAP-funded project
   (ACCL/19-GAP064-R20H-H) from the Agency of Science, Technology, and
   Research. YCFS and GJDS are supported by contract HHSN272201400006C from
   the National Institute of Allergy and Infectious Diseases (National
   Institutes of Health, US Department of Health and Human Services). We
   thank all clinical and nursing staff who provided care for the patients;
   staff at the Communicable Diseases Division of the Ministry of Health
   Singapore who contributed to the outbreak response and contact tracing;
   staff at the National Public Health and Epidemiology Unit of the
   National Centre for Infectious Diseases who assisted with data analysis;
   staff in the Singapore Infectious Disease Clinical Research Network and
   Infectious Disease Research and Training Office of the National Centre
   for Infectious Diseases for coordinating patient recruitment.
CR Alvarez-Diaz DA, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104390
   CHINESE SME, 2004, SCIENCE, V303, P1666, DOI DOI 10.1126/SCIENCE.1092002
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Gong YQ, 2020, EPIDEMIOL INFECT, V148, DOI [10.1017/S0950268820000771, 10.1080/22221751.2020.1782271]
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hachim A, 2020, SPIKE IDENTIFICATION, DOI [10.1101/2020.04.30.20085670, DOI 10.1101/2020.04.30.20085670]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   International Severe Acute Respiratory and Emerging Infection Consortium, COVID 19 CRF
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Lokman SM, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104389
   Ministry of Health Singapore, 2020, 9 MOR CAS DISCH 47 N
   Muth D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33487-8
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Reed JM, 2008, J INTERF CYTOK RES, V28, P611, DOI 10.1089/jir.2007.0145
   Su YCF, 2020, MBIO, V11, DOI 10.1128/mBio.01610-20
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, P2020, DOI 10.1038/s41392-020-0159-1
   Tewari K, 2007, J IMMUNOL, V179, P2115, DOI 10.4049/jimmunol.179.4.2115
   Tsuzuki T, 2012, HUM REPROD, V27, P523, DOI 10.1093/humrep/der405
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Van Dorp L, 2020, NO EVIDENCE INCREASE, DOI [10.1101/2020.05.21.108506, DOI 10.1101/2020.05.21.108506]
   Yong SEF, 2020, LANCET INFECT DIS, V20, P809, DOI 10.1016/S1473-3099(20)30273-5
   Zhang Y., 2020, ORF8 PROTEIN SARS CO, DOI [10.1101/2020.05.24.111823, DOI 10.1101/2020.05.24.111823]
NR 25
TC 12
Z9 12
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD AUG 29
PY 2020
VL 396
IS 10251
BP 603
EP 611
DI 10.1016/S0140-6736(20)31757-8
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC4NF
UT WOS:000579134100020
PM 32822564
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Perez-Martinez, A
   Guerra-Garcia, P
   Melgosa, M
   Frauca, E
   Fernandez-Camblor, C
   Remesal, A
   Calvo, C
AF Perez-Martinez, Antonio
   Guerra-Garcia, Pilar
   Melgosa, Marta
   Frauca, Esteban
   Fernandez-Camblor, Carlota
   Remesal, Agustin
   Calvo, Cristina
TI Clinical outcome of SARS-CoV-2 infection in immunosuppressed children in
   Spain
SO EUROPEAN JOURNAL OF PEDIATRICS
LA English
DT Article; Early Access
DE COVID-19; Transplant; Cancer; Immunosuppression
AB Limited information is available regarding SARS-CoV-2 infections in children with underlying diseases. A retrospective study of children less than 15 years old with primary or secondary immunosuppression infected with SARS-CoV-2 during March 2020 was performed. In this series, 8 immunocompromised patients with COVID-19 disease are reported, accounting for 15% of the positive cases detected in children in a reference hospital. The severity of the symptoms was mild-moderate in the majority with a predominance of febrile syndrome, with mild radiological involvement and in some cases with mild respiratory distress that required oxygen therapy. The rational and prudent management of these patients is discussed, evaluating possible treatments and options for hospitalization or outpatient follow-up. Conclusion: In our experience, monitoring of children with immunosuppression and COVID-19 disease can be performed as outpatients if close monitoring is possible. Hospitalization should be assessed when high fever, radiological involvement, and/or respiratory distress are present.
C1 [Perez-Martinez, Antonio; Guerra-Garcia, Pilar] Hosp Univ La Paz, Pediat Hematooncol Dept, Madrid, Spain.
   [Melgosa, Marta; Fernandez-Camblor, Carlota] Hosp Univ La Paz, Pediat Nephrol Dept, Madrid, Spain.
   [Frauca, Esteban] Hosp Univ La Paz, Pediat Hepatol Dept, Madrid, Spain.
   [Remesal, Agustin] Hosp Univ La Paz, Pediat Rheumatol Dept, Madrid, Spain.
   [Calvo, Cristina] Hosp Univ La Paz, Pediat & Infect Dis Dept, Paseo Castellano 261, Madrid 28046, Spain.
   [Calvo, Cristina] Fdn IdiPaz, Translat Res Network Pediat Infect Dis RITIP, Madrid, Spain.
RP Calvo, C (corresponding author), Hosp Univ La Paz, Pediat & Infect Dis Dept, Paseo Castellano 261, Madrid 28046, Spain.; Calvo, C (corresponding author), Fdn IdiPaz, Translat Res Network Pediat Infect Dis RITIP, Madrid, Spain.
EM antonioperezmartinez@yahoo.es; pilar.guerra@salud.madrid.org;
   marta.melgosa@salud.madrid.org; esteban.frauca@salud.madrid.org;
   carlotam.fernandez@salud.madrid.org; agusremesal@hotmail.com;
   ccalvorey@gmail.com
RI Calvo, Cristina/T-5028-2018
OI Calvo, Cristina/0000-0002-6503-3423; Guerra-Garcia,
   Pilar/0000-0002-7740-0614
CR Balduzzi A, 2020, BONE MARROW TRANSPL, V55, P1900, DOI 10.1038/s41409-020-0895-4
   Bouffet E, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28327
   Chen Z, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, P341, DOI 10.3760/cma.j.issn.0253-2727.2020.0004
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Min-Wei MD, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.2131.20, DOI 10.1001/JAMA.2020.2131.20]
   Siddiqi HK, J HEART LUNG TRASPLA
   Turner Dan, 2020, J Pediatr Gastroenterol Nutr, DOI 10.1097/MPG.0000000000002729
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 11
TC 1
Z9 1
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340-6199
EI 1432-1076
J9 EUR J PEDIATR
JI Eur. J. Pediatr.
DI 10.1007/s00431-020-03793-3
EA AUG 2020
PG 5
WC Pediatrics
SC Pediatrics
GA NF9XL
UT WOS:000563643400001
PM 32860101
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Sahebi, B
AF Sahebi, Bahareh
TI Clinical Supervision of Couple and Family Therapy during
   COVID-19Palabras clave(sic)(sic)(sic)
SO FAMILY PROCESS
LA English
DT Article
DE Clinical Supervision; Telesupervision; Distance Learning; Telebehavioral
   Health Training; Online Therapy; Telemedicine; Telepsychology; Family
   Therapy Training; Couple Therapy Training; Healthcare Delivery;
   Education
ID COMPETENCE
AB This paper addresses the need for a swift transition from in-person clinical supervision to telesupervision during the time of the COVID-19 global pandemic. Five specific areas will be discussed in the effort to enhance the quality of clinical supervision provided to couple and family therapists in training at this time including the following: (1) COVID-19 and the structural changes and technological adaptation of supervision; (2) culturally and contextually sensitive guidelines for clinical supervision during COVID-19; (3) the supervisee's competence and the clinical supervisory process; (4) the new set of boundaries and the supervisory role; (5) and the supervisory alliance and supervisees' vulnerabilities in the face of COVID-19.
C1 [Sahebi, Bahareh] Northwestern Univ, Ctr Appl Psychol & Family Studies, Marriage & Family Therapy Program, Sci, Evanston, IL 60201 USA.
   [Sahebi, Bahareh] Northwestern Univ, Sch Educ & Social Policy, Evanston, IL 60201 USA.
   [Sahebi, Bahareh] Family Inst, Evanston, IL USA.
RP Sahebi, B (corresponding author), Northwestern Univ, Family Inst, 618 Lib Pl, Evanston, IL 60201 USA.
EM Dr.Sahebi@northwestern.edu
CR Bacigalupe G, 2014, J FAM THER, V36, P339, DOI 10.1111/1467-6427.12042
   Bischoff RJ, 2002, J MARITAL FAM THER, V28, P371, DOI 10.1111/j.1752-0606.2002.tb01193.x
   Cabieses B, 2013, TELEMED E-HEALTH, V19, P879, DOI 10.1089/tmj.2012.0232
   Campbell J. M., 2000, BECOMING EFFECTIVE S
   Celano MP, 2010, PSYCHOTHERAPY, V47, P35, DOI 10.1037/a0018845
   Falicov CJ, 1995, FAM PROCESS, V34, P373, DOI 10.1111/j.1545-5300.1995.00373.x
   Greenberg L. S., 2002, EMOTION FOCUSED THER
   Greenberg LS, 2006, EMOTION FOCUSED THER
   Haley J., 1991, CONDUCTING 1 INTERVI, P8
   Hill EW, 2009, AUST NZ J FAM THER, V30, P1, DOI 10.1375/anft.30.1.1
   Hilty DM, 2004, CAN J PSYCHIAT, V49, P12, DOI 10.1177/070674370404900103
   Inman AG, 2006, J MARITAL FAM THER, V32, P73, DOI 10.1111/j.1752-0606.2006.tb01589.x
   Ladany N, 1999, J COUNS DEV, V77, P447, DOI 10.1002/j.1556-6676.1999.tb02472.x
   Liddle H. A., 1988, HDB FAMILY THERAPY T, P153
   Mason B, 2005, J FAM THER, V27, P298, DOI 10.1111/j.1467-6427.2005.00322.x
   Mead E., 1990, EFFECTIVE SUPERVISIO
   Minuchin S., 1981, FAMILY THERAPY TECHN
   Murphy MJ, 2005, J MARITAL FAM THER, V31, P283, DOI 10.1111/j.1752-0606.2005.tb01569.x
   Patterson J., 2009, ESSENTIAL SKILLS FAM
   Rajaei A, 2020, FAM J, V28, P48, DOI 10.1177/1066480719893958
   Rosenberg T, 2006, J MARITAL FAM THER, V32, P87, DOI 10.1111/j.1752-0606.2006.tb01590.x
   Satir V., 1991, SATIR MODEL FAMILY T
   Shapiro E., 2001, EYE MOVEMENT DESENSI
   Storm CL, 2001, J MARITAL FAM THER, V27, P227, DOI 10.1111/j.1752-0606.2001.tb01159.x
   Thomsen S. R., 1997, JOURNALISM MASS COMM, V52, P24
   Tillman B.A., 2000, MOMENTUM, V31, P24
   Todd T. C., 2002, COMPLETE SYSTEMIC SU, P1
   Todd T. C., 2014, COMPLETE SYSTEMIC SU, P314
   Whitaker C. A., 1988, DANCING FAMILY SYMBO
   Whiting JB, 2007, AM J FAM THER, V35, P139, DOI 10.1080/01926180600698434
NR 30
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-7370
EI 1545-5300
J9 FAM PROCESS
JI Fam. Process
PD SEP
PY 2020
VL 59
IS 3
BP 989
EP 996
DI 10.1111/famp.12591
EA AUG 2020
PG 8
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA NL5AR
UT WOS:000563617900001
PM 32743795
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Okamori, S
   Lee, H
   Kondo, Y
   Akiyama, Y
   Kabata, H
   Kaneko, Y
   Ishii, M
   Hasegawa, N
   Fukunaga, K
AF Okamori, Satoshi
   Lee, Ho
   Kondo, Yasushi
   Akiyama, Yuto
   Kabata, Hiroki
   Kaneko, Yuko
   Ishii, Makoto
   Hasegawa, Naoki
   Fukunaga, Koichi
TI Coronavirus disease 2019-associated rapidly progressive organizing
   pneumonia with fibrotic feature Two case reports
SO MEDICINE
LA English
DT Article
DE coronavirus disease 2019; organizing pneumonia; corticosteroids
AB Introduction: Pneumonia is one of the most important characteristics of coronavirus disease 2019 (COVID-19) and imaging findings of COVID-19 pneumonia are diverse and change over disease course. However, the detailed clinical course of organizing pneumonia (OP) caused by COVID-19 has not been clarified. Patient concerns: A 60-year-old man and a 61-year-old woman diagnosed with mild COVID-19 were admitted to our hospital. Their respiratory symptoms were deteriorating even after initiating treatment with antiviral drugs. Diagnosis: Chest X-rays and computed tomography scan showed a rapid progression of linear consolidation with reversed halo sign, distributed in subpleural and peri-bronchial regions. They also presented with pulmonary fibrosis findings, including traction bronchiectasis and marked lung volume reduction. They were diagnosed with rapidly progressing OP. Interventions: They were treated with systemic corticosteroids. Outcomes: The patients' imaging findings and respiratory conditions improved rapidly without any adverse effects. Conclusion: Physicians should carefully monitor patients with COVID-19, as they can develop rapidly progressive and fibrotic OP, which respond to corticosteroids.
C1 [Okamori, Satoshi; Lee, Ho; Akiyama, Yuto; Kabata, Hiroki; Ishii, Makoto; Fukunaga, Koichi] Keio Univ, Div Pulm Med, Sch Med, Shinju Ku, Tokyo, Japan.
   [Kondo, Yasushi; Kaneko, Yuko] Keio Univ, Div Rheumatol, Sch Med, Shinju Ku,Dept Med, Tokyo, Japan.
   [Hasegawa, Naoki] Keio Univ, Ctr Infect Dis & Infect Control, Sch Med, Shinju Ku, Tokyo, Japan.
RP Kabata, H (corresponding author), Keio Univ, Dept Med, Div Pulm Med, Sch Med,Shinju Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM kabata.h@keio.jp
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Baque-Juston M, 2014, DIAGN INTERV IMAG, V95, P771, DOI 10.1016/j.diii.2014.01.004
   Beardsley B, 2013, J CLIN PATHOL, V66, P875, DOI 10.1136/jclinpath-2012-201342
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Copin MC, 2020, INTENS CARE MED, V1, P3
   COVID-19 Treatment Guidelines, 2020, COVID 19 TREATM GUID
   Hani C, 2020, DIAGN INTERV IMAG, V101, P263, DOI 10.1016/j.diii.2020.03.014
   Hoa S, 2018, SCAND J RHEUMATOL, V47, P210, DOI 10.1080/03009742.2017.1334814
   Lansbury L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub3
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Roberton BJ, 2011, EUR RADIOL, V21, P2244, DOI 10.1007/s00330-011-2191-6
   Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST
   Wilson KC, 2020, COVID 19 INTERIM GUI
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu Y, 2020, RADIOL CARDIOTHORAC, V2, pe200031, DOI DOI 10.1148/RYCT.2020200031
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang Q, 2020, EUR J RADIOL, V127, DOI 10.1016/j.ejrad.2020.109008
   Yang SS, 2020, CAN J ANAESTH, V1, P3
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Ye ZK, 2020, CAN MED ASSOC J, V192, pE756, DOI 10.1503/cmaj.200645
NR 22
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG 28
PY 2020
VL 99
IS 35
DI 10.1097/MD.0000000000021804
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC4MP
UT WOS:000579132500043
PM 32871900
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Papatzikis, E
   Zeba, F
   Sarkamo, T
   Ramirez, R
   Grau-Sanchez, J
   Tervaniemi, M
   Loewy, J
AF Papatzikis, Efthymios
   Zeba, Fathima
   Sarkamo, Teppo
   Ramirez, Rafael
   Grau-Sanchez, Jennifer
   Tervaniemi, Mari
   Loewy, Joanne
TI Mitigating the Impact of the Novel Coronavirus Pandemic on Neuroscience
   and Music Research Protocols in Clinical Populations
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE COVID-19; music and neuroscience; music therapy; music and neuroscience
   research protocols; research crisis response
ID THERAPY
AB The COVID-19 disease and the systemic responses to it has impacted lives, routines and procedures at an unprecedented level. While medical care and emergency response present immediate needs, the implications of this pandemic will likely be far-reaching. Most practices that the clinical research within neuroscience and music field rely on, take place in hospitals or closely connected clinical settings which have been hit hard by the contamination. So too have its preventive and treatment measures. This means that clinical research protocols may have been altered, postponed or put in complete jeopardy. In this context, we would like to present and discuss the problems arising under the current crisis. We do so by critically approaching an online discussion facilitated by an expert panel in the field of music and neuroscience. This effort is hoped to provide an efficient basis to orient ourselves as we begin to map the needs and elements in this field of research as we further propose ideas and solutions on how to overcome, or at least ease the problems and questions we encounter or will encounter, with foresight. Among others, we hope to answer questions on technical or social problems that can be expected, possible solutions and preparatory steps to take in order to improve or ease research implementation, ethical implications and funding considerations. Finally, we further hope to facilitate the process of creating new protocols in order to minimize the impact of this crisis on essential research which may have the potential to relieve health systems.
C1 [Papatzikis, Efthymios; Zeba, Fathima] Canadian Univ Dubai, Dept Psychol, Dubai, U Arab Emirates.
   [Papatzikis, Efthymios] Latifa Women & Children Hosp, Dubai, U Arab Emirates.
   [Sarkamo, Teppo; Tervaniemi, Mari] Univ Helsinki, Fac Med, Dept Psychol & Logoped, Cognit Brain Res Unit, Helsinki, Finland.
   [Ramirez, Rafael] Univ Pompeu Fabra, Mus & Machine Learning Lab, Barcelona, Spain.
   [Grau-Sanchez, Jennifer] Bellvitge Biomed Res Inst, Cognit & Brain Plast Unit, Lhospitalet De Llobregat, Spain.
   [Grau-Sanchez, Jennifer] Autonomous Univ Barcelona, Escola Univ Infermeria & Terapia Ocupac Terrassa, Terrassa, Spain.
   [Tervaniemi, Mari] Univ Helsinki, Fac Educ Sci, Cicero Learning Network, Helsinki, Finland.
   [Loewy, Joanne] Icahn Sch Med, Mt Sinai Beth Israel, Louis Armstrong Ctr Music & Med, New York, NY USA.
RP Papatzikis, E (corresponding author), Canadian Univ Dubai, Dept Psychol, Dubai, U Arab Emirates.; Papatzikis, E (corresponding author), Latifa Women & Children Hosp, Dubai, U Arab Emirates.
EM efp331@mail.harvard.edu
OI Tervaniemi, Mari/0000-0002-9651-2929; Grau-Sanchez,
   Jennifer/0000-0002-8123-1745
FU Academy of FinlandAcademy of Finland [299044]; European Research Council
   (ERC)European Research Council (ERC) [803466]
FX TS was funded by the Academy of Finland (grant number 299044) and
   European Research Council (ERC, grant number 803466).
CR Begel V., 2018, MUSIC SCI, V1, P1, DOI [10.1177/2059204318794369, DOI 10.1177/2059204318794369]
   Benveniste S., 2008, P MULT COMP SCI INF, P133
   Benveniste S., 2010, THESIS
   Boulay M, 2011, TECHNOL HEALTH CARE, V19, P233, DOI 10.3233/THC-2011-0628
   Canga B, 2015, RESP MED, V109, P1532, DOI 10.1016/j.rmed.2015.10.001
   Cheever T, 2018, NEURON, V97, P1214, DOI 10.1016/j.neuron.2018.02.004
   Craig P, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1655
   Duffy M, 2019, NAT BIOTECHNOL, V37, P711, DOI 10.1038/s41587-019-0179-y
   Evans TM, 2018, NAT BIOTECHNOL, V36, P282, DOI 10.1038/nbt.4089
   Grau-Sanchez J, 2020, NEUROSCI BIOBEHAV R, V112, P585, DOI 10.1016/j.neubiorev.2020.02.027
   Hunt AM, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00342
   Kaplan B, 2008, CAMB Q HEALTHC ETHIC, V17, P401, DOI 10.1017/S0963180108080535
   Levecque K, 2017, RES POLICY, V46, P868, DOI 10.1016/j.respol.2017.02.008
   Loewy J., 2002, CARING CAREGIVER USE
   Loewy J, 2020, J ASTHMA, DOI 10.1080/02770903.2020.1712725
   Loewy J, 2013, PEDIATRICS, V131, P902, DOI 10.1542/peds.2012-1367
   Papatzikis E., 2017, INT J CROSS DISCIPLI, V8, P3179, DOI [10.20533/ijcdse.2042.6364.2017.0426, DOI 10.20533/IJCDSE.2042.6364.2017.0426]
   Porges S. W., 2018, MUSIC MED, V10, P117
   Putkinen V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47467-z
   Ramirez R., 2020, MUSIC THERAPY MOTION
   Ramirez R, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00354
   Sarkamo T, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00103
   Stanberry B, 2006, J TELEMED TELECARE, V12, P166, DOI 10.1258/135763306777488825
   TERVANIEMI M, 2018, FRONT ED, V3, P74, DOI DOI 10.3389/FEDUC.2018.00074
NR 24
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD AUG 28
PY 2020
VL 11
AR 2160
DI 10.3389/fpsyg.2020.02160
PG 6
WC Psychology, Multidisciplinary
SC Psychology
GA NQ0GU
UT WOS:000570548200001
PM 32982881
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Schramm, MA
   Venhoff, N
   Wagner, D
   Thiel, J
   Huzly, D
   Craig-Mueller, N
   Panning, M
   Hengel, H
   Kern, WV
   Voll, RE
AF Schramm, Markus A.
   Venhoff, Nils
   Wagner, Dirk
   Thiel, Jens
   Huzly, Daniela
   Craig-Mueller, Nils
   Panning, Marcus
   Hengel, Hartmut
   Kern, Winfried V.
   Voll, Reinhard E.
TI COVID-19 in a Severely Immunosuppressed Patient With Life-Threatening
   Eosinophilic Granulomatosis With Polyangiitis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; vasculitis; eosinophilic granulomatosis with
   polyangiitis; EGPA; immunosuppression; rituximab; cyclophosphamide
AB Immunosuppressive therapies increase the susceptibility of patients to infections. The current pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compels clinicians to develop recommendations for successful clinical management and surveillance of immunocompromised patients at high risk for severe disease progression. With only few case studies published on SARS-CoV-2 infection in patients with rheumatic diseases, we report a 25-year-old male who developed moderate coronavirus disease 2019 (COVID-19) with fever, mild dyspnea, and no major complications despite having received high-dose prednisolone, cyclophosphamide, and rituximab for the treatment of highly active, life-threatening eosinophilic granulomatosis with polyangiitis (EGPA).
C1 [Schramm, Markus A.; Venhoff, Nils; Thiel, Jens; Craig-Mueller, Nils; Voll, Reinhard E.] Univ Freiburg, Dept Rheumatol & Clin Immunol, Med Ctr, Fac Med, Freiburg, Germany.
   [Wagner, Dirk; Kern, Winfried V.] Univ Freiburg, Div Infect Dis, Dept Internal Med 2, Med Ctr,Fac Med, Freiburg, Germany.
   [Huzly, Daniela; Panning, Marcus; Hengel, Hartmut] Univ Freiburg, Fac Med, Med Ctr, Inst Virol, Freiburg, Germany.
RP Schramm, MA (corresponding author), Univ Freiburg, Dept Rheumatol & Clin Immunol, Med Ctr, Fac Med, Freiburg, Germany.
EM markus.schramm@uniklinik-freiburg.de
FU German Research Foundation (DFG)German Research Foundation (DFG) [TRR
   130, 12]
FX This work was supported by the German Research Foundation (DFG): TRR
   130, project 12 to RV.
CR He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Mikuls TR, 2020, ARTHRITIS RHEUMATOL, V72, pE1, DOI 10.1002/art.41437
   Wang B, 2020, J MED VIROL, V92, P1684, DOI 10.1002/jmv.25946
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
NR 6
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD AUG 28
PY 2020
VL 11
AR 2086
DI 10.3389/fimmu.2020.02086
PG 4
WC Immunology
SC Immunology
GA NQ0CQ
UT WOS:000570537100001
PM 32983161
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Guven, DC
   Sahin, TK
   Aktepe, OH
   Yildirim, HC
   Aksoy, S
   Kilickap, S
AF Guven, Deniz Can
   Sahin, Taha Koray
   Aktepe, Oktay Halit
   Yildirim, Hasan Cagri
   Aksoy, Sercan
   Kilickap, Saadettin
TI Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE coronavirus disease 2019 (COVID-19); pandemic; oncologic care; patient
   education; questionnaire; coronavirus disease 2019 (COVID-19) fear;
   coronavirus disease 2019 (COVID-19) knowledge
AB Coronavirus disease 2019 (COVID-19) is expected to significantly affect cancer patients due to adverse outcomes with COVID-19 and disruptions in cancer care. Another important point is the stress and anxiety burden of COVID-19, which could affect quality of life. Patient education is vital due to the vulnerability of the topic to disinformation. To determine the areas needing improvements in patient education, and coping with stress, the burden of the problem should be pictured. From this point, we aimed to assess the perspectives and fears of cancer patients about COVID-19 with resources of COVID-19 knowledge with a questionnaire. A total of 250 adult cancer patients applied to the outpatient chemotherapy unit of Hacettepe University Cancer Center between May 27, 2020, and June 9, 2020, invited to answer a questionnaire of 13 multiple-choice questions with a return rate of 78% (195/250). Most patients acquired their knowledge about COVID-19 from television (91.9%). Social media were the second most common source of knowledge (43.8%) with a predilection in younger patients, nonsmokers, targeted therapy- or immunotherapy-treated patients, and breast cancer patients (>65 vs. <65 years of age,p= 0.057; nonsmoker vs. ever-smoker,p= 0.036; targeted therapy and immunotherapy vs. chemotherapy,p= 0.004; breast cancer vs. other cancers,p= 0.019). The percentage of patients seeing the information about COVID-19 as adequate (38.9%) or inadequate (35.1%) was similar. More than 90% of the patients had a moderate to severe degree of COVID-19 fear. In addition, 27.6% of patients had false knowledge of glove using as a protective measure for COVID-19. More than half of the patients had another wrong knowledge as the need for the supplements for COVID-19 protection. A significant percentage of patients (84.7%) expected some level of disruption in oncological care with the expectation of a moderate-to-severe disruption was more common in the advanced-stage patients (p= 0.026). In our experience, most cancer patients had a significant degree of fear about both infecting COVID-19 and the disruption of cancer care by COVID-19. A significant amount of our patients had wrong information about the protection necessities, which denotes the need for better patient education about COVID-19.
C1 [Guven, Deniz Can; Sahin, Taha Koray; Aktepe, Oktay Halit; Yildirim, Hasan Cagri; Aksoy, Sercan; Kilickap, Saadettin] Hacettepe Univ, Canc Inst, Dept Med Oncol, Ankara, Turkey.
RP Guven, DC (corresponding author), Hacettepe Univ, Canc Inst, Dept Med Oncol, Ankara, Turkey.
EM denizcguven@hotmail.com
RI Guven, Deniz Can/ABC-5217-2020; Sahin, Taha Koray/ABH-1748-2020
OI Guven, Deniz Can/0000-0002-6924-9467; 
CR Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8
   Argenziano MG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1996
   Bulut C, 2020, TURK J MED SCI, V50, P563, DOI 10.3906/sag-2004-172
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Casanova M, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28318
   de Azambuja E, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000793
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Gebbia V, 2020, JCO GLOB ONCOL, V6, P722, DOI 10.1200/GO.20.00118
   Gottlieb M, 2020, ACAD EMERG MED, V27, P640, DOI 10.1111/acem.14036
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee SA, 2020, DEATH STUD, DOI [10.1080/07481187.2020.1853885, 10.1080/07481187.2020.1748481]
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   London AJ, 2020, SCIENCE, V368, P476, DOI 10.1126/science.abc1731
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P2368, DOI 10.1056/NEJMms2009984
   Vanni G, 2020, IN VIVO, V34, P1651, DOI 10.21873/invivo.11957
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, NAM COR DIS COV 19 V
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 22
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 28
PY 2020
VL 10
AR 1553
DI 10.3389/fonc.2020.01553
PG 6
WC Oncology
SC Oncology
GA NP9UL
UT WOS:000570515400001
PM 33014800
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Beck, TC
   Beck, KR
   Holloway, CB
   Hemings, RA
   Dix, TA
   Norris, RA
AF Beck, Tyler C.
   Beck, Kyle R.
   Holloway, Calvin B.
   Hemings, Richard A., Jr.
   Dix, Thomas A.
   Norris, Russell A.
TI The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of
   Hydroxychloroquine
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID-19; hydroxychloroquine; CCR4; SARS-CoV-2; immunomodulation
ID INCREASED CCR4 EXPRESSION; RHEUMATOID-ARTHRITIS; TNF-ALPHA; T-CELLS;
   PROTEIN; CHLOROQUINE; INFLAMMATION; BACTERIAL; THERAPY; DOCKING
AB The emergence of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) in China, reported to the World Health Organization on December 31, 2019, has led to a large global pandemic and is a major public health issue. As a result, there are more than 200 clinical trials of COVID-19 treatments or vaccines that are either ongoing or recruiting patients. One potential therapy that has garnered international attention is hydroxychloroquine; a potent immunomodulatory agent FDA-approved for the treatment of numerous inflammatory and autoimmune conditions, including malaria, lupus, and rheumatoid arthritis. Hydroxychloroquine has demonstrated promisein vitroand is currently under investigation in clinical trials for the treatment of COVID-19. Despite an abundance of empirical data, the mechanism(s) involved in the immunomodulatory activity of hydroxychloroquine have not been characterized. Using the unbiased chemical similarity ensemble approach (SEA), we identified C-C chemokine receptor type 4 (CCR4) as an immunomodulatory target of hydroxychloroquine. The crystal structure of CCR4 was selected for molecular docking studies using the SwissDock modeling software.In silico, hydroxychloroquine interacts with Thr-189 within the CCR4 active site, presumably blocking endogenous ligand binding. However, the CCR4 antagonists compound 18a and K777 outperformed hydroxychloroquinein silico, demonstrating energetically favorable binding characteristics. Hydroxychloroquine may subject COVID-19 patients to QT-prolongation, increasing the risk of sudden cardiac death. The FDA-approved CCR4 antagonist mogalizumab is not known to increase the risk of QT prolongation and may serve as a viable alternative to hydroxychloroquine. Results from this report introduce additional FDA-approved drugs that warrant investigation for therapeutic use in the treatment of COVID-19.
C1 [Beck, Tyler C.; Dix, Thomas A.] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Dix Lab, Charleston, SC 29425 USA.
   [Beck, Tyler C.; Norris, Russell A.] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Norris Lab, Charleston, SC 29425 USA.
   [Beck, Tyler C.; Hemings, Richard A., Jr.] Med Univ South Carolina, Coll Med, Charleston, SC 29425 USA.
   [Beck, Kyle R.] Ohio State Univ, Coll Pharm, 500 W 12Th Ave, Columbus, OH 43210 USA.
   [Holloway, Calvin B.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
RP Beck, TC (corresponding author), Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Dix Lab, Charleston, SC 29425 USA.; Beck, TC; Norris, RA (corresponding author), Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Norris Lab, Charleston, SC 29425 USA.; Beck, TC (corresponding author), Med Univ South Carolina, Coll Med, Charleston, SC 29425 USA.
EM beckt@musc.edu; norrisra@musc.edu
OI Holloway, Courtney Jean/0000-0003-3661-1957
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [HL007260]
FX This work was supported by an NIH training grant HL007260 to TB. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ankrum J., 2020, SCI TRANL MED, V12, DOI [10.1126/scitranslmed.abb5673, DOI 10.1126/SCITRANSLMED.ABB5673]
   Auerbach P., 2020, DRUGMATRIX IN VITRO
   Barros JF, 2019, J INVEST DERMATOL, V139, P1161, DOI 10.1016/j.jid.2018.10.039
   Bayry J, 2008, P NATL ACAD SCI USA, V105, P10221, DOI 10.1073/pnas.0803453105
   Bird L, 2018, NAT REV IMMUNOL, V18, P417, DOI 10.1038/s41577-018-0030-6
   Bitencourt-Ferreira G, 2019, METHODS MOL BIOL, V2053, P189, DOI 10.1007/978-1-4939-9752-7_12
   Boulos A, 2004, ANTIMICROB AGENTS CH, V48, P747, DOI 10.1128/AAC.48.3.747-752.2004
   CCR4, CCR4
   Centers for Disease Control and Prevention, 2020, CAS COR DIS COVID 19
   Chen A., 2020, EFFICACY HYDROXYCHLO
   De Biasi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17292-4
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dinarello Charles A, 2015, Temperature (Austin), V2, P8, DOI 10.1080/23328940.2015.1017086
   Drugs.com, 2020, ETANERCEPT
   Drugs.com, 2020, DACLIZUMAB
   Drugs.com, 2020, INFLIXIMAB
   Drugs.com, 2020, BARCITINIB
   Drugs.com, 2020, CANAKINUMAB
   Drugs.com, 2020, RUXOLITINIB
   Drugs.com, 2020, ANAKINRA
   Drugs.com, 2020, SILTUXIMAB
   Drugs.com, 2020, TOCILIZUMAB
   Drugs.com, 2020, CERTOLIZUMAB
   Drugs.com, 2020, HYDROXYCHLOROQUINE
   Drugs.com, 2020, BASILIXIMAB
   Drugs.com, 2020, RILONACEPT
   Drugs.com, 2020, GOLIMUMAB
   Drugs.com, 2020, ADALINUMAB
   Eskilsson A, 2014, J NEUROSCI, V34, P15957, DOI 10.1523/JNEUROSCI.3520-14.2014
   Food and Drug Administration, 2018, FDA APPR TREATM 2 RA
   Food and Drug Administration, 2020, FDA CAUT US HYDR CHL
   Francois B, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98960
   Gaballa S, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.4887.4887
   Gabay C, 2010, NAT REV RHEUMATOL, V6, P232, DOI 10.1038/nrrheum.2010.4
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gomes RN, 2013, SHOCK, V39, P63, DOI 10.1097/SHK.0b013e31827802b5
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grip O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005263
   Grosdidier A, 2007, PROTEINS, V67, P1010, DOI 10.1002/prot.21367
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Hase K, 2001, J LEUKOCYTE BIOL, V70, P749
   Herzig DS, 2014, CRIT CARE, V18, DOI 10.1186/cc13902
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jacobsen W, 2000, DRUG METAB DISPOS, V28, P1343
   Jung M, 2011, J ANTIBIOT, V64, P683, DOI 10.1038/ja.2011.64
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Klein A, 2017, ONCOTARGET, V8, P31079, DOI 10.18632/oncotarget.16076
   Kohler C., 2017, MOUSE CUTANEOUS MELA
   Lang P. T., 2018, PREPARING MOL DOCKIN
   Latifi SQ, 2002, INFECT IMMUN, V70, P4441, DOI 10.1128/IAI.70.8.4441-4446.2002
   Liang N, 2018, EXP THER MED, V15, P2436, DOI 10.3892/etm.2018.5708
   Live Science, 2020, LIVE SCI
   Luheshi GN, 1997, AM J PHYSIOL-REG I, V272, pR862
   Ma J., 2020, S CHINA MORNING POST
   Ma'ayan A, 2007, MT SINAI J MED, V74, P27, DOI 10.1002/msj.20002
   Mazzanti A, 2020, CIRCULATION, V142, P513, DOI 10.1161/CIRCULATIONAHA.120.048476
   Meng T., 2020, INSERT SEQUENCE SARS
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Power C. A., 2000, CCR4 Antagonists in Sepsis. WO2000067791A1, V16, Patent No. 2000067791
   Protein Atlas, CCR4
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Raoult D, 1999, ARCH INTERN MED, V159, P167, DOI 10.1001/archinte.159.2.167
   RAOULT D, 1990, ANTIMICROB AGENTS CH, V34, P1512, DOI 10.1128/AAC.34.8.1512
   RECOVERY, RAND EV COVID 19 THE
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Roskoski R, 2016, PHARMACOL RES, V111, P784, DOI 10.1016/j.phrs.2016.07.038
   Ross SH, 2018, ANNU REV IMMUNOL, V36, P411, DOI 10.1146/annurev-immunol-042617-053352
   Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230
   Sato T, 2013, PHARMACOLOGY, V91, P305, DOI 10.1159/000350390
   Schefold JC, 2011, CRIT CARE, V15, DOI 10.1186/cc10092
   Scher I., 2020, BUSINESS INSIDER
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shukla L, 2016, EUR J MED CHEM, V115, P14, DOI 10.1016/j.ejmech.2016.02.058
   Simmons G, 2011, VIROLOGY, V413, P265, DOI 10.1016/j.virol.2011.02.020
   SNYDMAN DR, 1990, ANN INTERN MED, V112, P102, DOI 10.7326/0003-4819-112-2-102
   Stefferl A, 1996, BRIT J PHARMACOL, V118, P1919, DOI 10.1111/j.1476-5381.1996.tb15625.x
   Stewart J., 2020, COVID 19 PREVENTION
   Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942
   Takahashi H, 2002, J LEUKOCYTE BIOL, V72, P1190
   Traeger T, 2008, INFECT IMMUN, V76, P5285, DOI 10.1128/IAI.00310-08
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walker J., 2020, NEWSWEEK
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang ZH, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/s13321-016-0130-x
   Wenzel J, 2005, J INVEST DERMATOL, V124, P1241, DOI 10.1111/j.0022-202X.2005.23755.x
   World Health Organization, 2020, GLOB RES COR RES
   Yang PT, 2004, CLIN EXP IMMUNOL, V138, P342, DOI 10.1111/j.1365-2249.2004.02617.x
   Yu XJ, 2017, BIODRUGS, V31, P151, DOI 10.1007/s40259-017-0223-8
NR 89
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 28
PY 2020
VL 11
AR 1253
DI 10.3389/fphar.2020.01253
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NP8QB
UT WOS:000570435100001
PM 32973504
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kuindersma, M
   Spronk, PE
AF Kuindersma, M.
   Spronk, P. E.
TI Ketanserin as potential additive drug to improve V/Q mismatch in
   COVID-19?
SO CRITICAL CARE
LA English
DT Letter
DE COVID-19; Coronavirus; Lung; Vasoconstriction; V/Q mismatch
C1 [Kuindersma, M.; Spronk, P. E.] Gelre Hosp, Dept Intens Care Med, Albert Schweitzerlaan 31, Apeldoorn, Netherlands.
   [Spronk, P. E.] Expertise Ctr Intens Care Rehabil Apeldoorn ExpIR, Apeldoorn, Netherlands.
RP Kuindersma, M (corresponding author), Gelre Hosp, Dept Intens Care Med, Albert Schweitzerlaan 31, Apeldoorn, Netherlands.
EM M.kuindersma@gelre.nl
CR Han TH, 2003, P NATL ACAD SCI USA, V100, P12504, DOI 10.1073/pnas.2133409100
   MEULEMAN TR, 1983, CRIT CARE MED, V11, P606, DOI 10.1097/00003246-198308000-00005
   Santamarina MG, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03125-9
   Vellinga NAR, 2015, J CRIT CARE, V30, P1156, DOI 10.1016/j.jcrc.2015.07.004
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
NR 5
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD AUG 28
PY 2020
VL 24
IS 1
AR 526
DI 10.1186/s13054-020-03257-y
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA NL4UV
UT WOS:000567413800001
PM 32859243
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yuan, M
   Liu, HJ
   Wu, NC
   Lee, CCD
   Zhu, XY
   Zhao, FZ
   Huang, DL
   Yu, WL
   Hua, YZ
   Tien, H
   Rogers, TF
   Landais, E
   Sok, D
   Jardine, JG
   Burton, DR
   Wilson, IA
AF Yuan, Meng
   Liu, Hejun
   Wu, Nicholas C.
   Lee, Chang-Chun D.
   Zhu, Xueyong
   Zhao, Fangzhu
   Huang, Deli
   Yu, Wenli
   Hua, Yuanzi
   Tien, Henry
   Rogers, Thomas F.
   Landais, Elise
   Sok, Devin
   Jardine, Joseph G.
   Burton, Dennis R.
   Wilson, Ian A.
TI Structural basis of a shared antibody response to SARS-CoV-2
SO SCIENCE
LA English
DT Article
ID POTENT NEUTRALIZING ANTIBODIES; VACCINE DESIGN
AB Molecular understanding of neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could accelerate vaccine design and drug discovery. We analyzed 294 anti-SARS-CoV-2 antibodies and found that immunoglobulin G heavy-chain variable region 3-53 (IGHV3-53) is the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein. Co-crystal structures of two IGHV3-53-neutralizing antibodies with RBD, with or without Fab CR3022, at 233- to 3.20 -angstrom resolution revealed that the germline-encoded residues dominate recognition of the angiotensin I converting enzyme 2 (ACE2)-binding site. This binding mode limits the IGHV3-53 antibodies to short complementarity-determining region H3 loops but accommodates light-chain diversity. These IGHV3-53 antibodies show minimal affinity maturation and high potency, which is promising for vaccine design. Knowledge of these structural motifs and binding mode should facilitate the design of antigens that elicit this type of neutralizing response.
C1 [Yuan, Meng; Liu, Hejun; Wu, Nicholas C.; Lee, Chang-Chun D.; Zhu, Xueyong; Yu, Wenli; Hua, Yuanzi; Tien, Henry; Wilson, Ian A.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
   [Zhao, Fangzhu; Huang, Deli; Rogers, Thomas F.; Landais, Elise; Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.
   [Zhao, Fangzhu; Landais, Elise; Sok, Devin; Jardine, Joseph G.; Burton, Dennis R.; Wilson, Ian A.] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.
   [Zhao, Fangzhu; Sok, Devin; Burton, Dennis R.; Wilson, Ian A.] Scripps Res Inst, Consortium HIV AIDS Vaccine Dev CHAVD, La Jolla, CA 92037 USA.
   [Rogers, Thomas F.] Univ Calif San Diego, Dept Med, Div Infect Dis, La Jolla, CA 92037 USA.
   [Landais, Elise; Sok, Devin; Jardine, Joseph G.] IAVI, New York, NY 10004 USA.
   [Burton, Dennis R.] MIT, Massachusetts Gen Hosp, Ragon Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Burton, Dennis R.] Harvard Univ, Cambridge, MA 02139 USA.
   [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
RP Wilson, IA (corresponding author), Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.; Wilson, IA (corresponding author), Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.; Wilson, IA (corresponding author), Scripps Res Inst, Consortium HIV AIDS Vaccine Dev CHAVD, La Jolla, CA 92037 USA.; Wilson, IA (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
EM wilson@scripps.edu
RI Liu, Hejun/L-9969-2014; Wu, Nicholas/H-3822-2015
OI Liu, Hejun/0000-0002-2412-7853; Huang, Deli/0000-0002-6989-639X; Zhao,
   Fangzhu/0000-0002-3172-1340; Yuan, Meng/0000-0001-9754-4503; Lee,
   Chang-Chun/0000-0002-5470-2484; Wu, Nicholas/0000-0002-9078-6697
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [K99 AI139445]; Bill and Melinda Gates
   FoundationBill & Melinda Gates Foundation [OPP1170236]; NIH NIAID CHAVD
   [UM1 AI44462]; IAVI Neutralizing Antibody Center; U.S. Department of
   Energy, Office of Science, Office of Basic Energy SciencesUnited States
   Department of Energy (DOE) [DE-AC02-76SF00515]; DOE Office of Biological
   and Environmental ResearchUnited States Department of Energy (DOE);
   National Institutes of Health, National Institute of General Medical
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [P41GM103393]
FX This work was supported by the NIH (grant no. K99 AI139445 to N.C.W.),
   the Bill and Melinda Gates Foundation (grant no. OPP1170236 to I.A.W.
   and D.R.B.), NIH NIAID CHAVD (grant no. UM1 AI44462 to I.A.W., D.S., and
   D.R.B.), and the IAVI Neutralizing Antibody Center. Use of the SSRL,
   SLAC National Accelerator Laboratory, is supported by the U.S.
   Department of Energy, Office of Science, Office of Basic Energy
   Sciences, under contract no. DE-AC02-76SF00515. The SSRL Structural
   Molecular Biology Program is supported by the DOE Office of Biological
   and Environmental Research and by the National Institutes of Health,
   National Institute of General Medical Sciences (including P41GM103393).
CR Abbott RK, 2020, IMMUNOL REV, V296, P120, DOI 10.1111/imr.12861
   Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Andreano E., 2020, 078154 BIORXIV, DOI [10.1101/2020.05.05.078154, DOI 10.1101/2020.05.05.078154]
   Andreano E., 2020, IDENTIFICATION NEUTR, DOI [10.1101/2020.05.05.078154, DOI 10.1101/2020.05.05.078154]
   Andrews SF, 2018, CURR OPIN IMMUNOL, V53, P96, DOI 10.1016/j.coi.2018.04.009
   Barnes Christopher O, 2020, bioRxiv, DOI 10.1101/2020.05.28.121533
   Boyd SD, 2010, J IMMUNOL, V184, P6986, DOI 10.4049/jimmunol.1000445
   Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Burton DR, 2020, CELL HOST MICROBE, V27, P695, DOI 10.1016/j.chom.2020.04.022
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chen X, 2015, J BIOL CHEM, V290, P21365, DOI 10.1074/jbc.M115.669895
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Chi XM, 2020, PEERJ, V8, DOI 10.7717/peerj.8886
   Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Huo J., 2020, NEUTRALIZATION SARS, DOI [10.1101/2020.05.05.079202, DOI 10.1101/2020.05.05.079202]
   Jardine JG, 2015, SCIENCE, V349, P156, DOI 10.1126/science.aac5894
   Ju B, 2020, POTENT HUMAN NEUTRAL, DOI [10.1101/2020.03.21.990770, DOI 10.1101/2020.03.21.990770, 10.1101/2020.03.21.990770.]
   Ju B., 2020, 990770 BIORXIV, DOI [10.1101/2020.03.21.990770, DOI 10.1101/2020.03.21.990770]
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lanzavecchia A, 2016, CURR OPIN IMMUNOL, V41, P62, DOI 10.1016/j.coi.2016.06.001
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li W., 2020, 093088 BIORXIV, DOI [10.1101/2020.05.13.093088, DOI 10.1101/2020.05.13.093088]
   Li WB, 2020, APPL PHYS EXPRESS, V13, DOI 10.35848/1882-0786/ab998e
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Parameswaran P, 2013, CELL HOST MICROBE, V13, P691, DOI 10.1016/j.chom.2013.05.008
   Pieper K, 2017, NATURE, V548, P597, DOI 10.1038/nature23670
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Setliff I, 2018, CELL HOST MICROBE, V23, P845, DOI 10.1016/j.chom.2018.05.001
   Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu NC, 2018, NAT STRUCT MOL BIOL, V25, P115, DOI 10.1038/s41594-018-0025-9
   Wu NC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15371
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382
   Yu L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00250
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zemlin M, 2003, J MOL BIOL, V334, P733, DOI 10.1016/j.jmb.2003.10.007
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zost SJ, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0998-x
   Zost Seth J, 2020, bioRxiv, DOI 10.1101/2020.05.12.091462
NR 51
TC 17
Z9 17
U1 12
U2 12
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 28
PY 2020
VL 369
IS 6507
BP 1119
EP +
DI 10.1126/science.abd2321
PG 38
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NL6KN
UT WOS:000567522200049
PM 32661058
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Abduljauwad, SN
   Habib, T
   Ahmed, HUR
AF Abduljauwad, Sahel N.
   Habib, Taimur
   Ahmed, Habib-ur-Rehman
TI Nano-clays as Potential Pseudo-antibodies for COVID-19
SO NANOSCALE RESEARCH LETTERS
LA English
DT Article
ID ANTICANCER DRUG; ORAL DELIVERY; MINERALS; RECEPTOR; NANOPARTICLES;
   PALYGORSKITE; BEHAVIOR; MODEL
AB Despite several efforts, the development of an effective vaccine for COVID-19 may take a much longer time. Traditional/natural medicine, already experienced by humans, could be an earlier solution. Considering the research team's experience in using nano-clays as high-affinity material for cancer metastasis, melanoma treatment, and bone regeneration, we propose to use these nano-clays for the prevention/treatment of COVID-19. Owing to high affinity, nano-clays would capture the viruses before the latter get engaged with human hACE2. In this study, molecular-level simulations and modeling of the interaction of coronavirus spike and hACE2 proteins were performed with and without nano-clays. The results showed a very high level of affinity/cohesiveness among SARS-CoV-2 spike and nano-clays as compared to the one between the former and hACE2. We premise that these nano-clays since already being used as drug carriers could also be injected as "clays-alone" medicine. Recommendations have also been provided for future in vitro and in vivo studies.
C1 [Abduljauwad, Sahel N.] King Fand Univ Petr & Minerals KFUPM, Civil & Environm Engn Dept, Dhahran, Saudi Arabia.
   [Habib, Taimur] Royal Coll Surg Ireland RCSI, Bahrain Campus, Busaiteen, Bahrain.
   [Ahmed, Habib-ur-Rehman] Engn & Res Int ERI, Riyadh, Saudi Arabia.
RP Ahmed, HUR (corresponding author), Engn & Res Int ERI, Riyadh, Saudi Arabia.
EM habibrehman@kfupm.edu.sa
CR Abduljauwad S. N., 2017, US patent, Patent No. [506747US, 506747]
   Abduljauwad Sahel N., RES PROGR
   Abduljauwad SN, 1998, GEOTECHNIQUE, V48, P103, DOI 10.1680/geot.1998.48.1.103
   Ahmed HR, 2017, J NAT GAS SCI ENG, V48, P85, DOI 10.1016/j.jngse.2017.02.007
   Ahmed HR, 2017, ARAB J GEOSCI, V10, DOI 10.1007/s12517-017-3234-3
   Ahmed HR, 2017, GEOTECHNIQUE, V67, P187, DOI 10.1680/jgeot.15.P.140
   Ahmed H. R., 2017, US Patent, Patent No. 10024016
   Ahmed H. R., 2017, US Patent, Patent No. [US9670409, 9670409, US9670409 Pat2015-087-01]
   Ahmed H. S. M., 2015, THESIS
   Ali Mohammad, 2018, WOODHEAD PUBLISHING, DOI [10.1016/C2016-0-05075-1, DOI 10.1016/C2016-0-05075-1]
   Azam S, 2000, J GEOTECH GEOENVIRON, V126, P538, DOI 10.1061/(ASCE)1090-0241(2000)126:6(538)
   Bothiraja C, 2014, MATER TECHNOL, V29, pB120, DOI 10.1179/1753555714Y.0000000174
   Callaway Ewen, 2020, NATURE, V580
   Chianelli R. R., 2013, U.S. Patent, Patent No. [8,563,595, 8563595]
   Choi G, 2016, INT J NANOMED, V11, P337, DOI 10.2147/IJN.S95611
   Clark KJ, 1998, VET MICROBIOL, V63, P137, DOI 10.1016/S0378-1135(98)00241-7
   Cohen Jon, 2020, RACE IS ANTIBODIES S
   Dias SD, 2013, EUR J CANCER, V49, P1654, DOI 10.1016/j.ejca.2013.01.015
   Dong YC, 2005, BIOMATERIALS, V26, P6068, DOI 10.1016/j.biomaterials.2005.03.021
   Guo MY, 2012, CHINESE J CHEM, V30, P2115, DOI 10.1002/cjoc.201200657
   Han S, 2014, APPL CLAY SCI, V101, P567, DOI 10.1016/j.clay.2014.09.020
   Hosseini F., CLAY MINER, V53, P53, DOI [10.1180/clm.2018.42018, DOI 10.1180/CLM.2018.42018]
   Javed B, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00188
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Kevadiya BD, 2012, EUR J PHARM SCI, V47, P265, DOI 10.1016/j.ejps.2012.04.009
   KONTA J, 1995, APPL CLAY SCI, V10, P275, DOI 10.1016/0169-1317(95)00029-4
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2008, J VIROL, V82, P6984, DOI 10.1128/JVI.00442-08
   Li SD, 2020, ACS NANO, V14, P7398, DOI 10.1021/acsnano.0c02912
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lin FH, 2002, BIOMATERIALS, V23, P1981, DOI 10.1016/S0142-9612(01)00325-8
   Martinez C. D, 2013, VIRT MULT C QUAESTI, P16
   Materials Studio, 2017, BIOVIA MAT STUDIO 20
   Murray HH, 2000, APPL CLAY SCI, V17, P207, DOI 10.1016/S0169-1317(00)00016-8
   Pincus HJ, 1993, GEOTECH TEST J, V16, P469, DOI DOI 10.1520/GTJ10287J
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Sahel N, NANOCLAYS POTENTIAL
   Sahel N, 2019, NATURE SCI REPORTS, DOI [10.1038/s41598-019-42498-y, DOI 10.1038/S41598-019-42498-Y]
   Sun B, 2008, BIOMATERIALS, V29, P475, DOI 10.1016/j.biomaterials.2007.09.038
   Volzone C, 2007, APPL CLAY SCI, V36, P191, DOI 10.1016/j.clay.2006.06.013
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wu KL, 2012, J BIOL CHEM, V287, P8904, DOI 10.1074/jbc.M111.325803
   Wu WJ, 2001, CLAY CLAY MINER, V49, P446, DOI 10.1346/CCMN.2001.0490511
   Yang GB, 2019, ADV MATER, V31, DOI 10.1002/adma.201805730
   Zhang Y, 2017, NANO RES, V10, P2633, DOI 10.1007/s12274-017-1466-x
   Zhang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep33335
NR 47
TC 1
Z9 1
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1931-7573
EI 1556-276X
J9 NANOSCALE RES LETT
JI Nanoscale Res. Lett.
PD AUG 28
PY 2020
VL 15
IS 1
AR 173
DI 10.1186/s11671-020-03403-z
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA NK7XJ
UT WOS:000566945500002
PM 32857226
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yu, Y
   Tu, J
   Lei, BX
   Shu, HQ
   Zou, XJ
   Li, RT
   Huang, CL
   Qu, YL
   Shang, Y
AF Yu, Yuan
   Tu, Jie
   Lei, Bingxin
   Shu, Huaqing
   Zou, Xiaojing
   Li, Ruiting
   Huang, Chaolin
   Qu, Yali
   Shang, You
TI Incidence and Risk Factors of Deep Vein Thrombosis in Hospitalized
   COVID-19 Patients
SO CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
LA English
DT Article
DE COVID-19; deep vein thrombosis (DVT); incidence rate; risk factors;
   ultrasound
ID EXCLUDING PULMONARY-EMBOLISM; SIMPLE CLINICAL-MODEL; VENOUS
   THROMBOEMBOLISM; D-DIMER; ULTRASONOGRAPHY; PREVENTION; MANAGEMENT;
   DIAGNOSIS
AB Deep vein thrombosis (DVT) is prevalent in patients with coronavirus disease 2019 (COVID-19). However, the risk factors and incidence rate of DVT remains elusive. Here, we aimed to assess the incidence rate and risk factors of DVT. All patients diagnosed with COVID-19 and performed venous ultrasound by ultrasound deparment between December 2019 and April 2020 in Wuhan Jin Yin-tan hospital were enrolled. Demographic information and clinical features were retrospectively collected. Notably, a comparison between the DVT and the non-DVT groups was explored. The incidence rate of venous thrombosis was 35.2% (50 patients out of 142). Moreover, the location of thrombus at the proximal extremity veins was 5.6% (n = 8), while at distal extremity veins was 35.2% (n = 50) of the patients. We also noted that patients with DVT exhibited a high level of D-dimer (OR 10.9 (95% CI, 3.3-36.0),P< 0.001), were admitted to the intensive care unit (OR 6.5 (95% CI, 2.1-20.3),P= 0.001), a lower usage of the anticoagulant drugs (OR 3.0 (95% CI, 1.1-7.8),P< 0.001). Finally, this study revealed that a high number of patients with COVID-19 developed DVT. This was observed particularly in critically ill patients with high D-dimer levels who required no anticoagulant medication.
C1 [Yu, Yuan; Shu, Huaqing; Zou, Xiaojing; Li, Ruiting; Shang, You] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Crit Care Med, Wuhan 430022, Peoples R China.
   [Tu, Jie; Lei, Bingxin; Qu, Yali] Jin Yin Tan Hosp, Ultrasound Dept, Wuhan 430023, Peoples R China.
   [Huang, Chaolin] Jin Yin Tan Hosp, Wuhan, Peoples R China.
RP Shang, Y (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Crit Care Med, Wuhan 430022, Peoples R China.; Qu, YL (corresponding author), Jin Yin Tan Hosp, Ultrasound Dept, Wuhan 430023, Peoples R China.
EM 49714972@qq.com; you_shanghust@163.com
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bernardi E, 2008, JAMA-J AM MED ASSOC, V300, P1653, DOI 10.1001/jama.300.14.1653
   Birdwell BG, 1998, ANN INTERN MED, V128, P1, DOI 10.7326/0003-4819-128-1-199801010-00001
   Bunce PE, 2011, CLIN INFECT DIS, V52, pE14, DOI 10.1093/cid/ciq125
   Cohen AT, 2006, BMJ-BRIT MED J, V332, P325, DOI 10.1136/bmj.38733.466748.7C
   Deitelzweig SB, 2011, J THROMB THROMBOLYS, V31, P133, DOI 10.1007/s11239-010-0503-3
   Geersing GJ, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1340
   Heit JA, 2015, NAT REV CARDIOL, V12, P464, DOI 10.1038/nrcardio.2015.83
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Kearon C, 1998, ANN INTERN MED, V129, P1044, DOI 10.7326/0003-4819-129-12-199812150-00009
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lucassen W, 2011, ANN INTERN MED, V155, P448, DOI 10.7326/0003-4819-155-7-201110040-00007
   Raskob GE, 2014, ARTERIOSCL THROM VAS, V34, P2363, DOI 10.1161/ATVBAHA.114.304488
   Sheng ZM, 2011, P NATL ACAD SCI USA, V108, P16416, DOI 10.1073/pnas.1111179108
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316
   Walters KA, 2016, J PATHOL, V238, P85, DOI 10.1002/path.4638
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153
   Wells PS, 2001, ANN INTERN MED, V135, P98, DOI 10.7326/0003-4819-135-2-200107170-00010
   Wells PS, 2000, THROMB HAEMOSTASIS, V83, P416
   World Health Organization, 2020, 192 WHO
   Wu Z, 2020, JAMA
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 27
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1076-0296
EI 1938-2723
J9 CLIN APPL THROMB-HEM
JI Clin. Appl. Thromb.-Hemost.
PD AUG 28
PY 2020
VL 26
AR 1076029620953217
DI 10.1177/1076029620953217
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA NK1WM
UT WOS:000566529400001
PM 32854513
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Smith, K
   Ostinelli, E
   Macdonald, O
   Cipriani, A
AF Smith, Katharine
   Ostinelli, Edoardo
   Macdonald, Orla
   Cipriani, Andrea
TI COVID-19 and Telepsychiatry: Development of Evidence-Based Guidance for
   Clinicians
SO JMIR MENTAL HEALTH
LA English
DT Article
DE digital mental health; telepsychiatry; evidence-based guidance;
   systematic review; mental health; COVID-19
ID INTERVENTIONS; HEALTH
AB Background: The coronavirus disease (COVID-19) presents unique challenges in health care, including mental health care provision. Telepsychiatry can provide an alternative to face-to-face assessment and can also be used creatively with other technologies to enhance care, but clinicians and patients may feel underconfident about embracing this new way of working.
   Objective: The aim of this paper is to produce an open-access, easy-to-consult, and reliable source of information and guidance about telepsychiatry and COVID-19 using an evidence-based approach.
   Methods: We systematically searched existing English language guidelines and websites for information on telepsychiatry in the context of COVID-19 up to and including May 2020. We used broad search criteria and included pre-COVID-19 guidelines and other digital mental health topics where relevant. We summarized the data we extracted as answers to specific clinical questions.
   Results: Findings from this study are presented as both a short practical checklist for clinicians and detailed textboxes with a full summary of all the guidelines. The summary textboxes are also available on an open-access webpage, which is regularly updated. These findings reflected the strong evidence base for the use of telepsychiatry and included guidelines for many of the common concerns expressed by clinicians about practical implementation, technology, information governance, and safety. Guidelines across countries differ significantly, with UK guidelines more conservative and focused on practical implementation and US guidelines more expansive and detailed. Guidelines on possible combinations with other digital technologies such as apps (eg, from the US Food and Drug Administration, the National Health Service Apps Library, and the National Institute for Health and Care Excellence) are less detailed. Several key areas were not represented. Although some special populations such as child and adolescent, and older adult, and cultural issues are specifically included, important populations such as learning disabilities, psychosis, personality disorder, and eating disorders, which may present particular challenges for telepsychiatry, are not. In addition, the initial consultation and follow-up sessions are not clearly distinguished. Finally, a hybrid model of care (combining telepsychiatry with other technologies and in-person care) is not explicitly covered by the existing guidelines.
   Conclusions: We produced a comprehensive synthesis of guidance answering a wide range of clinical questions in telepsychiatry. This meets the urgent need for practical information for both clinicians and health care organizations who are rapidly adapting to the pandemic and implementing remote consultation. It reflects variations across countries and can be used as a basis for organizational change in the short- and long-term. Providing easily accessible guidance is a first step but will need cultural change to implement as clinicians start to view telepsychiatry not just as a replacement but as a parallel and complementary form of delivering therapy with its own advantages and benefits as well as restrictions. A combination or hybrid approach can be the most successful approach in the new world of mental health post-COVID-19, and guidance will need to expand to encompass the use of telepsychiatry in conjunction with other in-person and digital technologies, and its use across all psychiatric disorders, not just those who are the first to access and engage with remote treatment.
C1 [Smith, Katharine; Ostinelli, Edoardo; Cipriani, Andrea] Univ Oxford, Dept Psychiat, Oxford, England.
   [Macdonald, Orla] Oxford Hlth Natl Hlth Serv Fdn Trust, Oxford, England.
RP Cipriani, A (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.
EM andrea.cipriani@psych.ox.ac.uk
RI Cipriani, Andrea/P-6944-2015
OI Cipriani, Andrea/0000-0001-5179-8321
FU National Institute for Health Research (NIHR) Oxford Cognitive Health
   Clinical Research FacilityNational Institute for Health Research (NIHR);
   NIHR Research Professorship [RP-2017-08-ST2-006]; NIHR Oxford and Thames
   Valley Applied Research Collaboration; NIHR Oxford Health Biomedical
   Research Centre [BRC-1215-20005]
FX KS, EO, and AC are supported by the National Institute for Health
   Research (NIHR) Oxford Cognitive Health Clinical Research Facility. AC
   is also supported by an NIHR Research Professorship (grant
   RP-2017-08-ST2-006), the NIHR Oxford and Thames Valley Applied Research
   Collaboration, and the NIHR Oxford Health Biomedical Research Centre
   (grant BRC-1215-20005). The views expressed are those of the authors and
   not necessarily those of the UK NHS, the NIHR, or the UK Department of
   Health.
CR [Anonymous], DIG HLTH INN ACT PLA
   [Anonymous], 2020, COVID 19 MEDICINES I
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Cowan KE, 2019, MAYO CLIN PROC, V94, P2510, DOI 10.1016/j.mayocp.2019.04.018
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Goodday SM, 2020, J MED INTERNET RES, V22, DOI 10.2196/15188
   GRATZER D, 2020, JAMA PSYCHIAT, P35179, DOI DOI 10.1001/JAMAPSYCHIATRY.2020.1640
   Greenhalgh T, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m998
   Hilty D, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/12229
   Hilty DM, 2018, ACAD PSYCHIATR, V42, P818, DOI 10.1007/s40596-018-0992-5
   Hoffman L, 2020, J PSYCHIATR PRACT, V26, P80, DOI 10.1097/PRA.0000000000000450
   Leigh S, 2015, EVID-BASED MENT HEAL, V18, P97, DOI 10.1136/eb-2015-102203
   Linardon J, 2019, WORLD PSYCHIATRY, V18, P325, DOI 10.1002/wps.20673
   McConnochie KM, 2019, TELEMED E-HEALTH, V25, P1007, DOI 10.1089/tmj.2018.0274
   NICE, EV STAND FRAM DIG HL
   Reinhardt I, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1054-8
   Rogers JP, 2020, LANCET PSYCHIAT, V7, P611, DOI 10.1016/S2215-0366(20)30203-0
   Shore JH, 2020, JAMA PSYCHIAT, V77, P1211, DOI 10.1001/jamapsychiatry.2020.1643
   Shore JH, 2020, JAMA PSYCHIAT, V77, P541, DOI 10.1001/jamapsychiatry.2020.0139
   Smith K, 2020, EVID-BASED MENT HEAL, V23, P45, DOI 10.1136/ebmental-2020-300155
   Sucala M, 2012, J MED INTERNET RES, V14, P175, DOI 10.2196/jmir.2084
   Torous J, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/18848
NR 23
TC 3
Z9 3
U1 5
U2 5
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2368-7959
J9 JMIR MENT HEALTH
JI JMIR Ment. Health
PD AUG 28
PY 2020
VL 7
IS 8
AR e21108
DI 10.2196/21108
PG 19
WC Psychiatry
SC Psychiatry
GA NG1RM
UT WOS:000563764400001
PM 32658857
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Elkin, E
   Viele, C
   Schumacher, K
   Boberg, M
   Cunningham, M
   Liu, LR
   Miaskowski, C
AF Elkin, Emmika
   Viele, Carol
   Schumacher, Karen
   Boberg, Maureen
   Cunningham, Mari
   Liu, Lauren
   Miaskowski, Christine
TI A COVID-19 screening tool for oncology telephone triage
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article; Early Access
DE COVID-19; Cancer; Telephone triage; Screening; Symptoms
AB Purpose Symptoms associated with COVID-19 infection have made the assessment and triage of cancer patients extremely complicated. The purpose of this paper is to describe the development and implementation of a COVID-19 screening tool for oncology telephone triage. Methods An Ambulatory Oncology Clinical Nurse Educator and three faculty members worked on the development of an oncology specific triage tool based on the challenges that oncology nurses were having with the generic COVID triage tool. A thorough search of the published literature, as well as pertinent websites, verified that no screening tool for oncology patients was available. Results The screening tool met a number of essential criteria: (1) simple and easy to use, (2) included the most common signs and symptoms as knowledge of COVID-19 infection changed, (3) was congruent with the overall screening procedures of the medical center, (4) included questions about risk factors for and environmental exposures related to COVID-19, and (5) assessed patient's current cancer history and treatment status. Over a period of 3 weeks, the content and specific questions on the tool were modified based on information obtained from a variety of sources and feedback from the triage nurses. Conclusion Within 1 month, the tool was developed and implemented in clinical practice. Oncology clinicians can modify this tool to triage patients as well as to screen patients in a variety of outpatient settings (e.g., chemotherapy infusion units, radiation therapy departments). The tool will require updates and modifications based on available resources and individual health care organizations' policies and procedures.
C1 [Elkin, Emmika; Boberg, Maureen; Cunningham, Mari; Liu, Lauren; Miaskowski, Christine] Univ Calif San Francisco, Dept Nursing, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
   [Viele, Carol; Schumacher, Karen; Miaskowski, Christine] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA.
   [Miaskowski, Christine] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, Sch Med, San Francisco, CA 94143 USA.
   [Miaskowski, Christine] Univ Calif San Francisco, Pain & Addict Res Ctr, San Francisco, CA 94143 USA.
RP Elkin, E (corresponding author), Univ Calif San Francisco, Dept Nursing, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
EM emmika.elkin@ucsf.edu
OI Miaskowski, Christine/0000-0001-5170-2027
CR Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   Allday E, 2020, BAY AREA ORDERS SHEL
   Allday E., 2020, SAN FRANCISCO CHRONI
   Centers for Disease Control and Prevention, 2020, EV TEST PERS COR DIS
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hickey M, 2019, TELEPHONE TRIAGE ONC
   Judson TJ, 2020, J AM MED INFORM ASSN, V27, P860, DOI 10.1093/jamia/ocaa051
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Miaskowski C, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12437
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Moon S, 2020, CNN
   Papachristou N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36973-1
   Renzi C, 2019, NAT REV CLIN ONCOL, V16, P746, DOI 10.1038/s41571-019-0249-6
   Ritchie CS, 2017, CANCER-AM CANCER SOC, V123, P3835, DOI 10.1002/cncr.30801
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Yang F, 2020, J MED VIROL, V92, P2067, DOI 10.1002/jmv.25972
NR 19
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
DI 10.1007/s00520-020-05713-5
EA AUG 2020
PG 6
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA NH8YV
UT WOS:000564949800001
PM 32856214
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rahmani, H
   Davoudi-Monfared, E
   Nourian, A
   Nabiee, M
   Sadeghi, S
   Khalili, H
   Abbasian, L
   Ghiasvand, F
   Seifi, A
   Hasannezhad, M
   Ghaderkhani, S
   Mohammadi, M
   Yekaninejad, MS
AF Rahmani, Hamid
   Davoudi-Monfared, Effat
   Nourian, Anahid
   Nabiee, Morteza
   Sadeghi, Setayesh
   Khalili, Hossein
   Abbasian, Ladan
   Ghiasvand, Fereshteh
   Seifi, Arash
   Hasannezhad, Malihe
   Ghaderkhani, Sara
   Mohammadi, Mostafa
   Yekaninejad, Mir Saeed
TI Comparing outcomes of hospitalized patients with moderate and severe
   COVID-19 following treatment with hydroxychloroquine plus
   atazanavir/ritonavir
SO DARU-JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE COVID-19; Hydroxychloroquine; Atazanavir; ritonavir; Outcomes
ID LIVER-INJURY
AB Background The role of the antiviral therapy in treatment of COVID-19 is still a matter to be investigated. Also efficacy and safety of antiviral regimens were not compared according severity of the disease. In this study the efficacy and safety of hydroxychloroquine plus atazanavir/ritonavir was compared in patients with moderate and severe COVID-19.
   Methods We prospectively evaluated the clinical outcomes of 213 patients with COVID-19 during the hospitalization course and up to 56 days after the hospital discharge. The disease was categorized to moderate and severe based on the severity of pneumonia and peripheral oxygen saturation (SpO2). The patients received the national treatment protocol containing hydroxychloroquine (400 mg BD in first day and then 200 mg BD) plus atazanavir/ritonavir (300/100 mg daily) for 7 days. Main outcomes included discharge rates at day 7, 14 and 28, 28-day mortality, rate of intensive care unit (ICU) admission and intubation, length of hospital and ICU stay and incidence of adverse events.
   Results The mean (SD) age of patients was 60(14) years and 53% were male. According to WHO definition, 51.64% and 48.36% of the patients had moderate (SpO2 >= 90%) and severe disease (SpO2 < 90%) at baseline, respectively. The discharge rate of the moderate group was significantly higher than the severe group at day 7, 14 and 28 (HR = 0.49; 95% CI: 0.35-0.69, p = < 0.001 at day 7, HR = 0.48; 95% CI: 0.35-0.66, p = < 0.001 at day 14 and HR = 0.49; 95% CI: 0.36-0.67, p = < 0.001at day 28). The 28-day mortality of the severe group was six times higher than the moderate group (HR = 6.00; 95% CI: 2.50-14.44), p = < 0.001). The need of admission in ICU for the severe group and the moderate group was 37.86% and 18.18% of the patients. Length of hospital stay was significantly shorter in the moderate group in comparison with the severe group (5 +/- 4 vs. 8 +/- 6 days,p < 0.001). Patients in the moderate group experienced the serious adverse events and complications less than the severe group. The discharged patients were followed up to 56 days after discharge. Some of the patients complained of symptoms such as exertional dyspnea, weakness and new-onset hair loss.
   Conclusion Our study did not support the use of hydroxychloroquine plus atazanavir/ritonavir in patients who had SpO(2) < 90% at the time of hospital admission. SpO2 was the only predictor of clinical outcomes (duration of hospital stay, discharge from the hospital and mortality) in patients treated with hydroxychloroquine plus atazanavir/ritonavir.
C1 [Rahmani, Hamid; Davoudi-Monfared, Effat; Nourian, Anahid; Nabiee, Morteza; Sadeghi, Setayesh; Khalili, Hossein] Univ Tehran Med Sci, Dept Pharmacotherapy, Imam Khomeini Hosp Complex, Tehran, Iran.
   [Abbasian, Ladan; Ghiasvand, Fereshteh; Seifi, Arash; Hasannezhad, Malihe; Ghaderkhani, Sara] Univ Tehran Med Sci, Dept Infect Dis, Imam Khomeini Hosp Complex, Tehran, Iran.
   [Mohammadi, Mostafa] Univ Tehran Med Sci, Dept Intens Care Unit, Imam Khomeini Hosp Complex, Fac Med, Tehran, Iran.
   [Yekaninejad, Mir Saeed] Univ Tehran Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Tehran, Iran.
RP Khalili, H (corresponding author), Univ Tehran Med Sci, Dept Pharmacotherapy, Imam Khomeini Hosp Complex, Tehran, Iran.
EM hmdrahmani89@gmail.com; edavudimonfared@gmail.com;
   anahid.nourian@gmail.com; m1450nabiee@gmail.com;
   sadeghi.setayesh@gmail.com; khalilih@tums.ac.ir; la.abbasian@gmail.com;
   ghiasvand_62@yahoo.com; dr.seifi@email.com; malihehasannezhad@yahoo.com;
   sghaderkhani@gmail.com; mohammady_mm@tums.ac.ir; yekaninejad@yahoo.com
RI Seifi, Arash/K-2336-2019
OI Seifi, Arash/0000-0002-6174-0315
FU Office of Vice-Chancellor for Research of Tehran University of Medical
   Sciences, Tehran, Iran
FX Office of Vice-Chancellor for Research of Tehran University of Medical
   Sciences, Tehran, Iran supported this work. We would like to thank the
   nurses of Imam Khomeini Hospital Complex for their kind supports and
   also Ms. Ava Khalili for English proofreading the manuscript.
CR Argenziano MG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1996
   Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Fu L., 2020, INFLUENCE FACTORS DE, DOI [10. 1101/2020.03.13.20035329., DOI 10.1101/2020.03.13.20035329]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2021436, DOI 10.1056/NEJM0A2021436]
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Lagier JC, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101791
   Lai LX, 2020, ENERGIES, V13, DOI 10.3390/en13040803
   Lescot T, 2012, ANESTHESIOLOGY, V117, P898, DOI 10.1097/ALN.0b013e318266c6df
   Lu S., EFFECTIVENESS SAFETY, DOI [10.1101/2020.04.17.20064469, DOI 10.1101/2020.04.17.20064469]
   McMichael TM, 2020, MMWR-MORBID MORTAL W, V69, P339, DOI 10.15585/mmwr.mm6912e1
   National Institutes of Health, COVID 19 TREATM GUID
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Phadke M, 2020, DRUG DEVELOP RES, V81, P541, DOI 10.1002/ddr.21666
   Pisani L, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0327-9
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Shao Z., CLIN EFFICACY INTRAV, DOI [10.1101/2020.04.11.20061739, DOI 10.1101/2020.04.11.20061739]
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Srinivasa Amar, 2017, J Rheumatol, V44, P398, DOI 10.3899/jrheum.161063
   Truche AS, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0467-6
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang D, 2020, NO CLEAR BENEFIT USE, DOI [10.1101/2020.04.21.20066258., DOI 10.1101/2020.04.21.20066258, 10.1101/2020.04.21.20066258]
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization (WHO), 2020, NOV COR CHIN
   Wu J, 2020, CLIN INFECT DIS, V71, P706, DOI 10.1093/cid/ciaa199
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang GQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104364
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 37
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
EI 2008-2231
J9 DARU
JI DARU
PD DEC
PY 2020
VL 28
IS 2
BP 625
EP 634
DI 10.1007/s40199-020-00369-2
EA AUG 2020
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ3QF
UT WOS:000563604700001
PM 32857301
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Xia, P
   Dubrovska, A
AF Xia, Pu
   Dubrovska, Anna
TI Tumor markers as an entry for SARS-CoV-2 infection?
SO FEBS JOURNAL
LA English
DT Article
DE Basigin; CD147; COVID-19; Emmprin; SARS-CoV-2; spike protein
ID COVID-19
AB Coronavirus disease 2019 (COVID-19), the highly contagious illness caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread across the globe, becoming one of the most challenging public health crisis of our times. SARS-CoV-2 can cause severe disease associated with multiple organ damage. Cancer patients have a higher risk of SARS-CoV-2 infection and death. While the virus uses angiotensin-converting enzyme 2 (ACE2) as the primary entry receptor, the recent experimental and clinical findings suggest that some tumor markers, including CD147 (basigin), can provide an additional entry for SARS-CoV-2 infection through binding to the viral spike (S) protein. In the absence of specific viral drugs, blocking of CD147 might be a way to prevent virus invasion. Identifying other target proteins is of high importance as targeting the alternative receptors for SARS-CoV-2 might open up a promising avenue for the treatment of COVID-19 patients, including those who have cancer.
C1 [Xia, Pu; Dubrovska, Anna] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Helmholtz Zentrum Dresden Rossendorf, OncoRay Natl Ctr Radiat Res Oncol,Fac Med, Dresden, Germany.
   [Dubrovska, Anna] Helmholtz Zentrum Dresden Rossendorf HZDR, Inst Radiooncol OncoRay, Dresden, Germany.
   [Dubrovska, Anna] German Canc Consortium DKTK, Partner Site Dresden, Dresden, Germany.
   [Dubrovska, Anna] German Canc Res Ctr, Heidelberg, Germany.
   [Dubrovska, Anna] Natl Ctr Tumor Dis NCT, Partner Site Dresden, Dresden, Germany.
RP Xia, P; Dubrovska, A (corresponding author), Tech Univ Dresden, OncoRay Natl Ctr Radiat Res Oncol, Fac Med, Fetscherstr 74, D-01307 Dresden, Germany.; Xia, P; Dubrovska, A (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Fetscherstr 74, D-01307 Dresden, Germany.
EM Pu.Xia@uniklinikum-dresden.de; anna.dubrovska@oncoray.de
OI Dubrovska, Anna/0000-0002-3375-1500
FU Projekt DEAL
FX Open access funding enabled and organized by Projekt DEAL.
CR Addeo A, 2020, CANCER TREAT REV, V88, DOI 10.1016/j.ctrv.2020.102041
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Bian H, 2020, MEPLAZUMAB TREATS CO
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Ellul MA, 2020, LANCET NEUROL
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Kong Q, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01209-2
   Landras A, 2019, CANCERS, V11, DOI 10.3390/cancers11111803
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Macindoe G, 2010, NUCLEIC ACIDS RES, V38, pW445, DOI 10.1093/nar/gkq311
   Magnani C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103452
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Radzikowska U, 2020, ALLERGY, V75, P2829, DOI 10.1111/all.14429
   Ritchie DW, 2008, BIOINFORMATICS, V24, P1865, DOI 10.1093/bioinformatics/btn334
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Sigrist CJA, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104759
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   Woolf SH, 2020, JAMA-J AM MED ASSOC, V324, P510, DOI 10.1001/jama.2020.11787
   World Health Organization, COR DIS COVID 2019 S
   Wu J, 2020, SSRN ELECT J
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang LL, 2020, CLIN TRANSL MED, V10, P28, DOI 10.1002/ctm2.17
   Zheng Y, 2020, J MED VIROL, DOI 10.1002/jmv.26218
NR 28
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD SEP
PY 2020
VL 287
IS 17
BP 3677
EP 3680
DI 10.1111/febs.15499
EA AUG 2020
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NK6MS
UT WOS:000563894600001
PM 32738184
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU da Silva, JTA
   Tsigaris, P
   Erfanmanesh, M
AF Teixeira da Silva, Jaime A.
   Tsigaris, Panagiotis
   Erfanmanesh, Mohammadamin
TI Publishing volumes in major databases related to Covid-19
SO SCIENTOMETRICS
LA English
DT Article; Early Access
DE Acceptance and rejection; Biomedicine; Correction of the literature;
   Peer review; Open access; Preprints; Retractions; SARS-CoV-2 virus
ID GOOGLE-SCHOLAR; SCIENCE; SCOPUS; WEB
AB The SARS-CoV-2 virus, which causes Covid-19, induced a global pandemic for which an effective cure, either in the form of a drug or vaccine, has yet to be discovered. In the few brief months that the world has known Covid-19, there has been an unprecedented volume of papers published related to this disease, either in a bid to find solutions, or to discuss applied or related aspects. Data from Clarivate Analytics' Web of Science, and Elsevier's Scopus, which do not index preprints, were assessed. Our estimates indicate that 23,634 unique documents, 9960 of which were in common to both databases, were published between January 1 and June 30, 2020. Publications include research articles, letters, editorials, notes and reviews. As one example, amongst the 21,542 documents in Scopus, 47.6% were research articles, 22.4% were letters, and the rest were reviews, editorials, notes and other. Based on both databases, the top three countries, ranked by volume of published papers, are the USA, China, and Italy whileBMJ,Journal of Medical VirologyandThe Lancetpublished the largest number of Covid-19-related papers. This paper provides one snapshot of how the publishing landscape has evolved in the first six months of 2020 in response to this pandemic and discusses the risks associated with the speed of publications.
C1 [Teixeira da Silva, Jaime A.] POB 7,Miki Cho Post Off,Ikenobe 3011-2, Miki, Kagawa 7610799, Japan.
   [Tsigaris, Panagiotis] Thompson Rivers Univ, Dept Econ, 805 TRU Way, Kamloops, BC V2C 0C8, Canada.
   [Erfanmanesh, Mohammadamin] Univ Malaya, Dept Lib & Informat Sci, Fac Comp Sci & Informat Technol, Kuala Lumpur, Malaysia.
RP da Silva, JTA (corresponding author), POB 7,Miki Cho Post Off,Ikenobe 3011-2, Miki, Kagawa 7610799, Japan.; Tsigaris, P (corresponding author), Thompson Rivers Univ, Dept Econ, 805 TRU Way, Kamloops, BC V2C 0C8, Canada.; Erfanmanesh, M (corresponding author), Univ Malaya, Dept Lib & Informat Sci, Fac Comp Sci & Informat Technol, Kuala Lumpur, Malaysia.
EM jaimetex@yahoo.com; ptsigaris@tru.ca; amin.erfanmanesh@gmail.com
RI Erfanmanesh, Mohammadamin/G-4512-2017
CR Chen QY, 2020, NATURE, V579, P193, DOI 10.1038/d41586-020-00694-1
   da Silva JAT, 2020, J ACAD LIBR, V46, DOI 10.1016/j.acalib.2020.102187
   da Silva JAT, 2020, PUBLISH RES Q, V36, P254, DOI 10.1007/s12109-020-09725-1
   Falagas ME, 2008, FASEB J, V22, P338, DOI 10.1096/fj.07-9492LSF
   Fraser N, 2020, PREPRINTING PANDEMIC, DOI [10.1101/2020.05.22.111294, DOI 10.1101/2020.05.22.111294]
   Hussain I, 2017, KNOWL ENG REV, V32, pe22, DOI [10.1017/S0269888917000182, DOI 10.1017/S0269888917000182]
   Ioannidis JPA, 2020, EUR J CLIN INVEST, V50, DOI [10.1111/eci.13222, 10.1111/eci.13223]
   Martin-Martin A, 2018, J INFORMETR, V12, P1160, DOI 10.1016/j.joi.2018.09.002
   Mongeon P, 2016, SCIENTOMETRICS, V106, P213, DOI 10.1007/s11192-015-1765-5
   Vera-Baceta MA, 2019, SCIENTOMETRICS, V121, P1803, DOI 10.1007/s11192-019-03264-z
NR 10
TC 3
Z9 3
U1 6
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0138-9130
EI 1588-2861
J9 SCIENTOMETRICS
JI Scientometrics
DI 10.1007/s11192-020-03675-3
EA AUG 2020
PG 12
WC Computer Science, Interdisciplinary Applications; Information Science &
   Library Science
SC Computer Science; Information Science & Library Science
GA NG2IS
UT WOS:000563809200002
PM 32904414
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Dansana, D
   Kumar, R
   Bhattacharjee, A
   Hemanth, DJ
   Gupta, D
   Khanna, A
   Castillo, O
AF Dansana, Debabrata
   Kumar, Raghvendra
   Bhattacharjee, Aishik
   Hemanth, D. Jude
   Gupta, Deepak
   Khanna, Ashish
   Castillo, Oscar
TI Early diagnosis of COVID-19-affected patients based on X-ray and
   computed tomography images using deep learning algorithm
SO SOFT COMPUTING
LA English
DT Article; Early Access
DE COVID-19; X-ray images; CT scan; CNN; VGG-16; Inception_V2; Decision
   tree
ID NEURAL-NETWORKS; FUZZY-SYSTEMS; PNEUMONIA
AB The novel coronavirus infection (COVID-19) that was first identified in China in December 2019 has spread across the globe rapidly infecting over ten million people. The World Health Organization (WHO) declared it as a pandemic on March 11, 2020. What makes it even more critical is the lack of vaccines available to control the disease, although many pharmaceutical companies and research institutions all over the world are working toward developing effective solutions to battle this life-threatening disease. X-ray and computed tomography (CT) images scanning is one of the most encouraging exploration zones; it can help in finding and providing early diagnosis to diseases and gives both quick and precise outcomes. In this study, convolution neural networks method is used for binary classification pneumonia-based conversion of VGG-19, Inception_V2 and decision tree model on X-ray and CT scan images dataset, which contains 360 images. It can infer that fine-tuned version VGG-19, Inception_V2 and decision tree model show highly satisfactory performance with a rate of increase in training and validation accuracy (91%) other than Inception_V2 (78%) and decision tree (60%) models.
C1 [Dansana, Debabrata; Kumar, Raghvendra; Bhattacharjee, Aishik] GIET Univ, Dept Comp Sci & Engn, Gunupur, Odisha, India.
   [Hemanth, D. Jude] Karunya Inst Technol & Sci, Dept ECE, Coimbatore, Tamil Nadu, India.
   [Gupta, Deepak; Khanna, Ashish] Maharaja Agrasen Inst Technol, Dept CSE, Delhi, India.
   [Castillo, Oscar] Tijuana Inst Technol, Tijuana, Mexico.
RP Gupta, D (corresponding author), Maharaja Agrasen Inst Technol, Dept CSE, Delhi, India.
EM debabratadansana07@gmail.com; raghvendraagrawa17@gmail.com;
   aishikbhattacharjee98@gmail.com; judehemanth@karunya.edu;
   deepakgupta@mait.ac.in; ashishkhanna@mait.ac.in; ocastillo@tectijuana.mx
RI Castillo, Oscar/I-5578-2019; Gupta, Deepak/AAV-2728-2020; DANSANA,
   DEBABRATA/ABG-2734-2020
OI Castillo, Oscar/0000-0002-7385-5689; Gupta, Deepak/0000-0002-3019-7161;
   DANSANA, DEBABRATA/0000-0002-8818-7652; Khanna,
   Ashish/0000-0002-8418-3929
CR Ayan E., 2019, P 2019 SCI M EL EL B, V7, P1
   Basu S, 2020, DEEP LEARNING SCREEN, P1, DOI [10.1101/2020.05.04.20090423, DOI 10.1101/2020.05.04.20090423]
   Behzadi-khormouji H, 2020, COMPUT METH PROG BIO, V185, DOI 10.1016/j.cmpb.2019.105162
   Bhandary A, 2020, PATTERN RECOGN LETT, V129, P271, DOI 10.1016/j.patrec.2019.11.013
   Blum A., 2001, P 18 INT C MACH LEAR, P19, DOI DOI 10.1184/R1/6606860.V1
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Hamimi A, 2016, EGYPT J RADIOL NUC M, V47, P95, DOI 10.1016/j.ejrnm.2015.11.004
   Jaiswal AK, 2019, MEASUREMENT, V145, P511, DOI 10.1016/j.measurement.2019.05.076
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Li JJ, 2019, IEEE T CYBERNETICS, V49, P2144, DOI 10.1109/TCYB.2018.2820174
   Melin P, 2018, EXPERT SYST APPL, V107, P146, DOI 10.1016/j.eswa.2018.04.023
   Miramontes I, 2018, ALGORITHMS, V11, DOI 10.3390/a11120206
   Ozkaya U, 2020, ARXIV200403698, P1
   Pavithra R, 2015, INT J SCI RES PUBL, V5, P1
   Rajpurkar P, 2017, CHEXNET RADIOLOGIST, P1
   Ramirez E, 2019, EXPERT SYST APPL, V126, P295, DOI 10.1016/j.eswa.2019.02.035
   Santos SV, 2020, CLASSIFICATION XRAY, V2020, P237
   Shan F., 2020, ARXIV200304655
   Sharfstein JM, 2020, JAMA-J AM MED ASSOC, V323, P1437, DOI 10.1001/jama.2020.3864
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Sirazitdinov I, 2019, COMPUT ELECTR ENG, V78, P388, DOI 10.1016/j.compeleceng.2019.08.004
   Stephen O, 2019, J HEALTHC ENG, V2019, DOI 10.1155/2019/4180949
   Szegedy C, 2015, PROC CVPR IEEE, P1, DOI 10.1109/CVPR.2015.7298594
   Toacar M, 2019, IRBM, V40, P286, DOI [10.1016/j.irbm.2019.05.003, DOI 10.1016/J.IRBM.2019.05.003]
   Tolga AC, 2020, ENG APPL ARTIF INTEL, V87, DOI 10.1016/j.engappai.2019.103352
   Varshni D., 2019, P 2019 IEEE INT C EL, P1
   Wang LF, 2006, EMERG INFECT DIS, V12, P1834
   Wang XS, 2017, PROC CVPR IEEE, P3462, DOI 10.1109/CVPR.2017.369
   Xie X, 2006, MINING XRAY IMAGES S, P282, DOI [10.1007/11677437_22, DOI 10.1007/11677437_22]
   Xu X., 2020, ARXIV200209334
   Yang Y, 2018, DEEP NEURAL DECISION, P1
   Zisserman A, 2019, ARXIV14091556
NR 33
TC 3
Z9 3
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1432-7643
EI 1433-7479
J9 SOFT COMPUT
JI Soft Comput.
DI 10.1007/s00500-020-05275-y
EA AUG 2020
PG 9
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications
SC Computer Science
GA NG2ED
UT WOS:000563797300005
PM 32904395
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lebow, JL
AF Lebow, Jay L.
TI COVID-19, Families, and Family Therapy: Shining Light into the Darkness
SO FAMILY PROCESS
LA English
DT Article
ID RESILIENCE; INTERVENTION; REFLECTION; FRAMEWORK; ILLNESS; COUPLE; ART
C1 [Lebow, Jay L.] Family Inst Northwestern, Family Proc, Evanston, IL 60201 USA.
RP Lebow, JL (corresponding author), Family Inst Northwestern, 618 Lib Pl, Evanston, IL 60201 USA.
EM j-lebow@northwestern.edu
CR ALGER I, 1967, AM J PSYCHIAT, V123, P1425, DOI 10.1176/ajp.123.11.1425
   Anderson RE, 2019, FAM PROCESS, V58, P53, DOI 10.1111/famp.12412
   [Anonymous], 2020, J PSYCHOTHERAPY INTE, V30, P155
   Behar-Zusman V, 2020, FAM PROCESS, V59, P1045, DOI 10.1111/famp.12579
   Bowen M, 1978, FAMILY THERAPY CLIN
   Brock RL, 2020, FAM PROCESS, V59, P1007, DOI 10.1111/famp.12582
   Burgoyne N., 2020, FAMILY PROCESS, V59
   Connolly SL, 2020, CLIN PSYCHOL-SCI PR, V27, DOI 10.1111/cpsp.12311
   Gordon KC, 2020, FAM PROCESS, V59, P956, DOI 10.1111/famp.12576
   Dickerson VC, 2020, FAM PROCESS, V59, P1034, DOI 10.1111/famp.12583
   Falicov C, 2020, FAM PROCESS, V59, P865, DOI 10.1111/famp.12578
   Fraenkel P, 2020, FAM PROCESS, V59, P847, DOI 10.1111/famp.12570
   Fraenkel P, 2019, FAM PROCESS, V58, P569, DOI 10.1111/famp.12474
   Frankl V. E., 1963, MANS SEARCH MEANING
   Salivar EGJ, 2020, FAM PROCESS, V59, P66, DOI 10.1111/famp.12414
   Gunther-Bel C., 2020, COUPLE FAMILY RELATI
   Imber-Black E, 2006, FAM PROCESS, V45, P273, DOI 10.1111/j.1545-5300.2006.00169.x
   Imber-Black E, 2020, FAM PROCESS, V59, P912, DOI 10.1111/famp.12581
   Imber-Black E, 2014, FAM PROCESS, V53, P371, DOI 10.1111/famp.12091
   Imber-Black E, 2011, FAM PROCESS, V50, P267, DOI 10.1111/j.1545-5300.2011.01367.x
   Lebow J. L., 2019, TREATING DIFFICULT D
   Lebow JL, 2020, FAM PROCESS, V59, P967, DOI 10.1111/famp.12574
   Lebow JL, 2020, FAM PROCESS, V59, P309, DOI 10.1111/famp.12543
   Lebow JL, 2019, FAM PROCESS, V58, P610, DOI 10.1111/famp.12473
   Lee WY, 2020, FAM PROCESS, V59, P1018, DOI 10.1111/famp.12577
   May R., 1989, CURRENT PSYCHOTHERAP, P363
   McDowell T, 2019, FAM PROCESS, V58, P9, DOI 10.1111/famp.12383
   Mcfarlane WR, 2016, FAM PROCESS, V55, P460, DOI 10.1111/famp.12235
   Messer S. B., 1984, PSYCHOANALYTIC THERA, P63, DOI DOI 10.1007/978-1-4613-2733-2_5
   Miklowitz DJ, 2016, FAM PROCESS, V55, P483, DOI 10.1111/famp.12237
   Nadan Y, 2020, FAM PROCESS, V59, P997, DOI 10.1111/famp.12573
   Pickens JC, 2020, J MARITAL FAM THER, V46, P186, DOI 10.1111/jmft.12417
   Rivett M, 2020, FAM PROCESS, V59, P1024, DOI 10.1111/famp.12571
   Roddy MK, 2017, FAM PROCESS, V56, P835, DOI 10.1111/famp.12262
   Rolland J. S., 2020, FAMILY PROCESS, V59
   Rolland JS, 2017, FAM PROCESS, V56, P799, DOI 10.1111/famp.12316
   Rolland JS, 2005, FAM PROCESS, V44, P3, DOI 10.1111/j.1545-5300.2005.00039.x
   ROLLAND JS, 1987, FAM PROCESS, V26, P203, DOI 10.1111/j.1545-5300.1987.00203.x
   Sahebi B., 2020, FAMILY PROCESS, V59
   Stanley SM, 2020, FAM PROCESS, V59, P937, DOI 10.1111/famp.12575
   Walsh D, 2020, RHEUMATOLOGY, V59
   Walsh F, 2003, FAM PROCESS, V42, P1, DOI 10.1111/j.1545-5300.2003.00001.x
   Walsh F, 1996, FAM PROCESS, V35, P261, DOI 10.1111/j.1545-5300.1996.00261.x
   Walsh F, 2016, FAM PROCESS, V55, P616, DOI 10.1111/famp.12260
   Watson MF, 2020, FAM PROCESS, V59, P832, DOI 10.1111/famp.12572
   Watson MF, 2019, FAM PROCESS, V58, P23, DOI 10.1111/famp.12427
   Watzlawick P., 1977, INTERACTIONAL VIEW S
   Weingarten K, 2020, FAM PROCESS, V59, P883, DOI 10.1111/famp.12580
   Weingarten K, 2018, FAM PROCESS, V57, P572, DOI 10.1111/famp.12347
   Weingarten K, 2016, FAM PROCESS, V55, P195, DOI 10.1111/famp.12158
   Weingarten K, 2013, FAM PROCESS, V52, P83, DOI 10.1111/famp.12017
   Weingarten K, 2012, FAM PROCESS, V51, P440, DOI 10.1111/j.1545-5300.2012.01412.x
   Weingarten K, 2010, FAM PROCESS, V49, P5, DOI 10.1111/j.1545-5300.2010.01305.x
NR 53
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-7370
EI 1545-5300
J9 FAM PROCESS
JI Fam. Process
PD SEP
PY 2020
VL 59
IS 3
BP 825
EP 831
DI 10.1111/famp.12590
EA AUG 2020
PG 7
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA NL5AR
UT WOS:000563269900001
PM 32856753
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lobatoa, SD
   Perales, JMC
   Inigo, JMA
AF Diaz Lobatoa, Salvador
   Carratala Perales, Jose Manuel
   Alonso Inigo, Jose Miguel
TI Can we use noninvasive respiratory therapies in COVID-19 pandemic?
SO MEDICINA CLINICA
LA Spanish
DT Letter
C1 [Diaz Lobatoa, Salvador] Hosp HLA Univ Moncloa, Unidad Neumol, Madrid, Spain.
   [Diaz Lobatoa, Salvador] Univ Europea, Madrid, Spain.
   [Diaz Lobatoa, Salvador] Nippon Gases Healthcare, Madrid, Spain.
   [Carratala Perales, Jose Manuel] Hosp Gen Univ Alicante, Serv Urgencias, Unidad Corta Estancia, Alicante, Spain.
   [Alonso Inigo, Jose Miguel] Hosp Univ Politecn La Fe, Serv Anestesiol Reanimac & Tratamiento Dolor, Valencia, Spain.
RP Lobatoa, SD (corresponding author), Hosp HLA Univ Moncloa, Unidad Neumol, Madrid, Spain.; Lobatoa, SD (corresponding author), Univ Europea, Madrid, Spain.; Lobatoa, SD (corresponding author), Nippon Gases Healthcare, Madrid, Spain.
EM sdiazlobato@gmail.com
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Namendys-Silva SA, 2020, LANCET RESP MED, V8, pE18, DOI 10.1016/S2213-2600(20)30110-7
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Singh A, 2008, EUR RESPIR J, V31, P280, DOI DOI 10.1183/09031936.00052208.3
   Wang K, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00653-z
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER ESPANA SLU
PI BARCELONA
PA AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
SN 0025-7753
EI 1578-8989
J9 MED CLIN-BARCELONA
JI Med. Clin.
PD AUG 28
PY 2020
VL 155
IS 4
BP 183
EP 183
DI 10.1016/j.medcli.2020.05.011
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA MY8NU
UT WOS:000558675100011
PM 32564931
OA Green Published
DA 2021-01-01
ER

PT J
AU Dinnon, KH
   Leist, SR
   Schafer, A
   Edwards, CE
   Martinez, DR
   Montgomery, SA
   West, A
   Yount, BL
   Hou, YXJ
   Adams, LE
   Gully, KL
   Brown, AJ
   Huang, E
   Bryant, MD
   Choong, IC
   Glenn, JS
   Gralinski, LE
   Sheahan, TP
   Baric, RS
AF Dinnon, Kenneth H., III
   Leist, Sarah R.
   Schafer, Alexandra
   Edwards, Caitlin E.
   Martinez, David R.
   Montgomery, Stephanie A.
   West, Ande
   Yount, Boyd L., Jr.
   Hou, Yixuan J.
   Adams, Lily E.
   Gully, Kendra L.
   Brown, Ariane J.
   Huang, Emily
   Bryant, Matthew D.
   Choong, Ingrid C.
   Glenn, Jeffrey S.
   Gralinski, Lisa E.
   Sheahan, Timothy P.
   Baric, Ralph S.
TI A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
SO NATURE
LA English
DT Article; Early Access
ID ACUTE RESPIRATORY SYNDROME; LENGTH INFECTIOUS CDNA; RANDOMIZED PHASE 2B;
   REVERSE GENETICS; CORONAVIRUS; SARS; LAMBDA; IFN; TRANSMISSION;
   PROTECTION
AB A model in mouse using a species-adapted virus recapitulates features of SARS-CoV-2 infection and age-related disease pathogenesis in humans, and provides a model system for rapid evaluation of medical countermeasures against coronavirus disease 2019 (COVID-19).
   Coronaviruses are prone to transmission to new host species, as recently demonstrated by the spread to humans of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic(1). Small animal models that recapitulate SARS-CoV-2 disease are needed urgently for rapid evaluation of medical countermeasures(2,3). SARS-CoV-2 cannot infect wild-type laboratory mice owing to inefficient interactions between the viral spike protein and the mouse orthologue of the human receptor, angiotensin-converting enzyme 2 (ACE2)(4). Here we used reverse genetics(5)to remodel the interaction between SARS-CoV-2 spike protein and mouse ACE2 and designed mouse-adapted SARS-CoV-2 (SARS-CoV-2 MA), a recombinant virus that can use mouse ACE2 for entry into cells. SARS-CoV-2 MA was able to replicate in the upper and lower airways of both young adult and aged BALB/c mice. SARS-CoV-2 MA caused more severe disease in aged mice, and exhibited more clinically relevant phenotypes than those seen inHfh4-ACE2transgenic mice, which express human ACE2 under the control of theHfh4(also known asFoxj1) promoter. We demonstrate the utility of this model using vaccine-challenge studies in immune-competent mice with native expression of mouse ACE2. Finally, we show that the clinical candidate interferon-lambda 1a (IFN-lambda 1a) potently inhibits SARS-CoV-2 replication in primary human airway epithelial cells in vitro-both prophylactic and therapeutic administration of IFN-lambda 1a diminished SARS-CoV-2 replication in mice. In summary, the mouse-adapted SARS-CoV-2 MA model demonstrates age-related disease pathogenesis and supports the clinical use of pegylated IFN-lambda 1a as a treatment for human COVID-19(6).
C1 [Dinnon, Kenneth H., III; Adams, Lily E.; Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA.
   [Leist, Sarah R.; Schafer, Alexandra; Edwards, Caitlin E.; Martinez, David R.; West, Ande; Yount, Boyd L., Jr.; Hou, Yixuan J.; Gully, Kendra L.; Brown, Ariane J.; Huang, Emily; Gralinski, Lisa E.; Sheahan, Timothy P.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.
   [Montgomery, Stephanie A.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA.
   [Bryant, Matthew D.; Choong, Ingrid C.] Eiger BioPharmaceut, Palo Alto, CA USA.
   [Glenn, Jeffrey S.] Stanford Univ, Dept Med & Microbiol & Immunobiol, Stanford, CA 94305 USA.
   [Glenn, Jeffrey S.] Palo Alto Vet Adm, Palo Alto, CA USA.
   [Baric, Ralph S.] Univ N Carolina, Rapidly Emerging Antiviral Drug Discovery Initiat, Chapel Hill, NC 27515 USA.
RP Baric, RS (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA.; Baric, RS (corresponding author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.; Baric, RS (corresponding author), Univ N Carolina, Rapidly Emerging Antiviral Drug Discovery Initiat, Chapel Hill, NC 27515 USA.
EM rbaric@email.unc.edu
RI Hou, Yixuan/P-6443-2019
OI Hou, Yixuan/0000-0002-8323-7243; Dinnon, Kenneth/0000-0002-8942-1551
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human Service [1U19
   AI142759, 5R01AI132178]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [DK065988,
   HHSN272201700036I]; North Carolina Policy Collaboratory at the
   University of North Carolina at Chapel Hill; North Carolina Coronavirus
   Relief Fund; NIH NIAIDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [T32 AI007151, T32 AI007419];
   Burroughs Wellcome Fund Postdoctoral Enrichment Program AwardBurroughs
   Wellcome Fund; Cystic Fibrosis Foundation [BOUCHE15RO]; NCI Center Core
   Support Grant [5P30CA016086-41]
FX This project was funded in part by the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health, Department of Health
   and Human Service award: 1U19 AI142759 (Antiviral Drug Discovery and
   Development Center awarded to R.S.B.); 5R01AI132178 (partnership grant
   awarded to T.P.S. and R.S.B.) and an animal models contract from the NIH
   (HHSN272201700036I). This project was supported in part by the North
   Carolina Policy Collaboratory at the University of North Carolina at
   Chapel Hill with funding from the North Carolina Coronavirus Relief Fund
   established and appropriated by the North Carolina General Assembly.
   K.H.D. is funded by an NIH NIAID T32 AI007419. D.R.M. is funded by an
   NIH NIAID T32 AI007151 and a Burroughs Wellcome Fund Postdoctoral
   Enrichment Program Award. The Marsico Lung Institute Tissue Procurement
   and Cell Culture Core is supported by NIH grant DK065988 and Cystic
   Fibrosis Foundation grant BOUCHE15RO. Animal histopathology service was
   performed by D. Hilliard and L. Wang in the Animal Histopathology and
   Laboratory Medicine Core at the University of North Carolina, which is
   supported in part by an NCI Center Core Support Grant (5P30CA016086-41)
   to the UNC Lineberger Comprehensive Cancer Center.
CR Abdi K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03812-w
   Agnihothram S, 2018, J VIROL, V92, DOI [10.1128/JVI.00027-18, 10.1128/jvi.00027-18]
   Andreakos E, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012465
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Chan HLY, 2016, J HEPATOL, V64, P1011, DOI 10.1016/j.jhep.2015.12.018
   Corbett Kizzmekia S, 2020, Nature, V586, P567, DOI 10.1038/s41586-020-2622-0
   Davidson S, 2016, EMBO MOL MED, V8, P1099, DOI 10.15252/emmm.201606413
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Elazar M, 2017, CURR OPIN VIROL, V24, P55, DOI 10.1016/j.coviro.2017.04.004
   Felgenhauer U, 2020, J BIOL CHEM, V295, P13958, DOI 10.1074/jbc.AC120.013788
   Fulcher M Leslie, 2005, Methods Mol Med, V107, P183
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042
   Humeniuk R, 2020, CTS-CLIN TRANSL SCI, V13, P896, DOI 10.1111/cts.12840
   Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI [10.1073/pnas.2009799117/-/DCSupplemental., 10.1073/pnas.2009799117]
   Israelow B, 2020, J EXP MED, V217
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li L, 2017, ANTIVIR RES, V140, P76, DOI 10.1016/j.antiviral.2017.01.012
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Menachery VD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131451
   Mordstein M, 2010, J VIROL, V84, P5670, DOI 10.1128/JVI.00272-10
   Muir AJ, 2014, J HEPATOL, V61, P1238, DOI 10.1016/j.jhep.2014.07.022
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Ostrowski LE, 2003, MOL THER, V8, P637, DOI 10.1016/S1525-0016(03)00221-1
   Roberts A, 2005, J VIROL, V79, P5833, DOI 10.1128/JVI.79.9.5833-5838.2005
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Sui JH, 2014, J VIROL, V88, P13769, DOI 10.1128/JVI.02232-14
   Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010
   Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Yu Pin, 2020, Animal Model Exp Med, V3, P93, DOI 10.1002/ame2.12108
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zost SJ, 2020, NATURE, DOI 10.1038/s41586-020-2548-6
NR 48
TC 10
Z9 8
U1 13
U2 13
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
DI 10.1038/s41586-020-2708-8
EA AUG 2020
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ7QO
UT WOS:000577298700001
PM 32854108
OA Bronze
DA 2021-01-01
ER

PT J
AU Michel, CJ
   Mayer, C
   Poch, O
   Thompson, JD
AF Michel, Christian Jean
   Mayer, Claudine
   Poch, Olivier
   Thompson, Julie Dawn
TI Characterization of accessory genes in coronavirus genomes
SO VIROLOGY JOURNAL
LA English
DT Article
DE COVID-19; SARS-CoV-2; SARS-CoV; Coronavirus; Accessory genes; ORF
   prediction; Circular code motifs
ID RESPIRATORY SYNDROME CORONAVIRUS; CIRCULAR CODE MOTIFS; PROTEINS;
   REPLICATION; PNEUMONIA; 9B
AB Background The Covid19 infection is caused by the SARS-CoV-2 virus, a novel member of the coronavirus (CoV) family. CoV genomes code for a ORF1a / ORF1ab polyprotein and four structural proteins widely studied as major drug targets. The genomes also contain a variable number of open reading frames (ORFs) coding for accessory proteins that are not essential for virus replication, but appear to have a role in pathogenesis. The accessory proteins have been less well characterized and are difficult to predict by classical bioinformatics methods. Methods We propose a computational tool GOFIX to characterize potential ORFs in virus genomes. In particular, ORF coding potential is estimated by searching for enrichment in motifs of theXcircular code, that is known to be over-represented in the reading frames of viral genes. Results We applied GOFIX to study the SARS-CoV-2 and related genomes including SARS-CoV and SARS-like viruses from bat, civet and pangolin hosts, focusing on the accessory proteins. Our analysis provides evidence supporting the presence of overlapping ORFs 7b, 9b and 9c in all the genomes and thus helps to resolve some differences in current genome annotations. In contrast, we predict that ORF3b is not functional in all genomes. Novel putative ORFs were also predicted, including a truncated form of the ORF10 previously identified in SARS-CoV-2 and a little known ORF overlapping the Spike protein in Civet-CoV and SARS-CoV. Conclusions Our findings contribute to characterizing sequence properties of accessory genes of SARS coronaviruses, and especially the newly acquired genes making use of overlapping reading frames.
C1 [Michel, Christian Jean; Mayer, Claudine; Poch, Olivier; Thompson, Julie Dawn] Univ Strasbourg, CNRS, Dept Comp Sci, Lab ICube, F-67412 Strasbourg, France.
   [Mayer, Claudine] Inst Pasteur, CNRS, Unite Microbiol Struct, UMR 3528, F-75724 Paris 15, France.
   [Mayer, Claudine] Univ Paris Diderot, Sorbonne Paris Cite, F-75724 Paris 15, France.
RP Thompson, JD (corresponding author), Univ Strasbourg, CNRS, Dept Comp Sci, Lab ICube, F-67412 Strasbourg, France.
EM thompson@unistra.fr
FU Institut Francais de Bioinformatique (IFB) [ANR-11-INBS-0013]; ANRFrench
   National Research Agency (ANR) [GA-676559, ANR-18-RAR3-0006-02]; French
   Centre National de la Recherche ScientifiqueCentre National de la
   Recherche Scientifique (CNRS); University of Strasbourg
FX This work was supported by the Institut Francais de Bioinformatique
   (IFB), ANR-11-INBS-0013, the ANR projects Elixir-Excelerate: GA-676559
   and RAinRARE: ANR-18-RAR3-0006-02, and institute funds from the French
   Centre National de la Recherche Scientifique and the University of
   Strasbourg.
CR Arques DG, 1996, J THEOR BIOL, V182, P45, DOI 10.1006/jtbi.1996.0142
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Cagliani R, 2020, J VIROL, V94, DOI 10.1128/JVI.00411-20
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen CY, 2007, J INFECT DIS, V196, P405, DOI 10.1086/519166
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dila G, 2019, RNA, V25, P1714, DOI 10.1261/rna.072074.119
   El Soufi K, 2017, BIOSYSTEMS, V153, P45, DOI 10.1016/j.biosystems.2017.02.001
   El Soufi K, 2016, J THEOR BIOL, V408, P198, DOI 10.1016/j.jtbi.2016.07.022
   Firth AE, 2014, NUCLEIC ACIDS RES, V42, P12425, DOI 10.1093/nar/gku981
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Hussain M, 2020, J MED VIROL, V92, P1580, DOI 10.1002/jmv.25832
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Liu DX, 2014, ANTIVIR RES, V109, P97, DOI 10.1016/j.antiviral.2014.06.013
   McBride R, 2012, VIRUSES-BASEL, V4, P2902, DOI 10.3390/v4112902
   Michel Christian J, 2017, Life (Basel), V7, DOI 10.3390/life7020020
   Michel CJ, 2012, COMPUT BIOL CHEM, V37, P24, DOI 10.1016/j.compbiolchem.2011.10.002
   Oostra M, 2007, J VIROL, V81, P13876, DOI 10.1128/JVI.01631-07
   Pavesi A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202513
   Schaecher SR, 2009, MOL BIOL SARS CORONA, V22, P153
   Schlub TE, 2018, MOL BIOL EVOL, V35, P2572, DOI 10.1093/molbev/msy155
   Shukla A, 2015, VIRUS GENES, V50, P29, DOI 10.1007/s11262-014-1139-8
   Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360
   Su Y. C. F., 2020, BIORXIV, DOI [10.1101/2020.03.11.987222, DOI 10.1101/2020.03.11.987222]
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Xu K, 2009, VIROLOGY, V388, P279, DOI 10.1016/j.virol.2009.03.032
   Yang XL, 2016, J VIROL, V90, P3253, DOI 10.1128/JVI.02582-15
   Yount B, 2005, J VIROL, V79, P14909, DOI 10.1128/JVI.79.23.14909-14922.2005
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zhang KY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00184
   Zhang T, 2020, CURR BIOL, V30, P1578, DOI 10.1016/j.cub.2020.03.063
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 40
TC 2
Z9 2
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD AUG 27
PY 2020
VL 17
IS 1
AR 131
DI 10.1186/s12985-020-01402-1
PG 13
WC Virology
SC Virology
GA NR4TM
UT WOS:000571556700001
PM 32854725
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Spuch, C
   Lopez-Garcia, M
   Rivera-Baltanas, T
   Rodrigues-Amorim, D
   Olivares, JM
AF Spuch, Carlos
   Lopez-Garcia, Marta
   Rivera-Baltanas, Tania
   Rodrigues-Amorim, Daniela
   Olivares, Jose M.
TI Does Lithium Deserve a Place in the Treatment Against COVID-19? A
   Preliminary Observational Study in Six Patients, Case Report
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; lithium carbonate; case report; inflammation
ID CHLORIDE; VIRUS; REPLICATION; THERAPY
AB Lithium has shown the capacity to: a) inhibit the replication of several types of viruses, some of which are similar to the SARS-CoV-2 virus, b) increase the immune response by reducing lymphopenia, and c) reduce inflammation by preventing or reducing the cytokine storm. In the present study, we have treated six patients with severe COVID-19 infection with lithium carbonate. We found that lithium carbonate significantly reduced plasma reactive C-Protein levels, increased lymphocyte numbers and decreased the neutrophil-lymphocyte ratio, improving both inflammatory activity and the immune response in these patients. We propose that lithium carbonate may deserve a place in the treatment against COVID-19.
C1 [Spuch, Carlos; Rivera-Baltanas, Tania; Rodrigues-Amorim, Daniela] CIBERSAM, Galicia Hlth Res Inst IISGS, Translat Neurosci Res Grp, Vigo, Spain.
   [Lopez-Garcia, Marta] CIBERSAM, Galicia Hlth Res Inst IISGS, Translat Neurosci Res Grp, Dept Psychiat,Hosp Alvaro Cunqueiro, Vigo, Spain.
   [Olivares, Jose M.] Hosp Alvaro Cunqueiro, Dept Psychiat, Vigo, Spain.
   [Olivares, Jose M.] CIBERSAM, Galicia Hlth Res Inst IISGS, Neurosci Res Area, Vigo, Spain.
RP Olivares, JM (corresponding author), Hosp Alvaro Cunqueiro, Dept Psychiat, Vigo, Spain.; Olivares, JM (corresponding author), CIBERSAM, Galicia Hlth Res Inst IISGS, Neurosci Res Area, Vigo, Spain.
EM jose.manuel.olivares.diez@sergas.es
RI Rodrigues-Amorim, Daniela/ABH-6289-2020
OI Rodrigues-Amorim, Daniela/0000-0002-0469-0534
FU Foundation for Science and Technology (FCT, Fundacao para a Ciencia e
   Tecnologia) [SFRH/BD/135623/2018]; Carlos III Health Institute (ISCIII,
   Instituto Carlos III) [P16/00405]; Ministry of Health, Equality, and
   Social Policy (Ministerio de Sanidad, Servicios Sociales e Igualdad) -
   Government Delegation for the National Plan on Drugs (Delegacion del
   Gobierno para el Plan Nacional sobre Drogas) [2017I054]; Consolidation
   and structure programme of competitive research units (Consolidacion y
   estructuracion de unidades de investigacion competitivas) [IN607B]
FX This research was financially backed by the Foundation for Science and
   Technology (FCT, Fundacao para a Ciencia e Tecnologia) within the
   framework of grant SFRH/BD/135623/2018 awarded to DR-A. Our research was
   further supported by the Carlos III Health Institute (ISCIII, Instituto
   Carlos III) through grant P16/00405, and the Ministry of Health,
   Equality, and Social Policy (Ministerio de Sanidad, Servicios Sociales e
   Igualdad) - Government Delegation for the National Plan on Drugs
   (Delegacion del Gobierno para el Plan Nacional sobre Drogas) through
   grant number 2017I054 awarded to JO. Finally, this work was also
   supported by the Consolidation and structure programme of competitive
   research units (Consolidacion y estructuracion de unidades de
   investigacion competitivas); through grant number IN607B 2018/17.
CR Anand Amit, 2016, Mol Neuropsychiatry, V2, P115
   BACH RO, 1987, MED HYPOTHESES, V23, P157, DOI 10.1016/0306-9877(87)90152-6
   Baldessarini RJ, 2003, J CLIN PSYCHIAT, V64, P44
   Briggs KT, 2016, BIOPHYS J, V111, P294, DOI 10.1016/j.bpj.2016.06.015
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen ZY, 2015, BRIT J CANCER, V112, P1088, DOI 10.1038/bjc.2015.61
   Cui J, 2015, ANTIVIR THER, V20, P565, DOI 10.3851/IMP2924
   Harrison SM, 2007, AVIAN PATHOL, V36, P109, DOI 10.1080/03079450601156083
   Jellusova J, 2017, NAT IMMUNOL, V18, P303, DOI 10.1038/ni.3664
   Kibirige D, 2013, THYROID RES, V6, DOI 10.1186/1756-6614-6-3
   Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1733, DOI 10.1002/jmv.25819
   Leucht S, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003834.pub3
   LIEB J, 1981, MED HYPOTHESES, V7, P885, DOI 10.1016/0306-9877(81)90043-8
   LIEB J, 1979, NEW ENGL J MED, V301, P942
   Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002
   Nassar A, 2014, ACS CHEM NEUROSCI, V5, P451, DOI 10.1021/cn500038f
   Pietruczuk K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21769-0
   Qu R, 2020, J MED VIROL, V92, P1533, DOI 10.1002/jmv.25767
   Shorter E, 2009, BIPOLAR DISORD, V11, P4, DOI 10.1111/j.1399-5618.2009.00706.x
   Sinha Neeraj, 2020, Postgrad Med J, V96, P550, DOI 10.1136/postgradmedj-2020-137785
   SKINNER GRB, 1980, MED MICROBIOL IMMUN, V168, P139, DOI 10.1007/BF02121762
   Stower Hannah, 2020, Nat Med, V26, P465, DOI 10.1038/s41591-020-0849-9
   Tan CC, 2020, J MED VIROL, V92, P856, DOI 10.1002/jmv.25871
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Tyrer S. P., 1994, NEUROPSYCHOPHARMACOL, P234, DOI [10.1016/0924-977X(94)90060-4, DOI 10.1016/0924-977X(94)90060-4]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang L, 2020, MED MALADIES INFECT, V50, P332, DOI 10.1016/j.medmal.2020.03.007
   Wu HX, 2015, ARCH VIROL, V160, P2935, DOI 10.1007/s00705-015-2534-8
   Zhai XF, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8030144
   Zhao YX, 2020, MICROB PATHOGENESIS, V144, DOI 10.1016/j.micpath.2020.104169
NR 30
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 27
PY 2020
VL 11
AR 557629
DI 10.3389/fphar.2020.557629
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NQ2ZD
UT WOS:000570733000001
PM 32973537
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Noy-Porat, T
   Makdasi, E
   Alcalay, R
   Mechaly, A
   Levy, Y
   Bercovich-Kinori, A
   Zauberman, A
   Tamir, H
   Yahalom-Ronen, Y
   Israeli, M
   Epstein, E
   Achdout, H
   Melamed, S
   Chitlaru, T
   Weiss, S
   Peretz, E
   Rosen, O
   Paran, N
   Yitzhaki, S
   Shapira, SC
   Israely, T
   Mazor, O
   Rosenfeld, R
AF Noy-Porat, Tal
   Makdasi, Efi
   Alcalay, Ron
   Mechaly, Adva
   Levy, Yinon
   Bercovich-Kinori, Adi
   Zauberman, Ayelet
   Tamir, Hadas
   Yahalom-Ronen, Yfat
   Israeli, Ma'ayan
   Epstein, Eyal
   Achdout, Hagit
   Melamed, Sharon
   Chitlaru, Theodor
   Weiss, Shay
   Peretz, Eldar
   Rosen, Osnat
   Paran, Nir
   Yitzhaki, Shmuel
   Shapira, Shmuel C.
   Israely, Tomer
   Mazor, Ohad
   Rosenfeld, Ronit
TI A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at
   multiple epitopes
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; STRUCTURAL BASIS; ANTIBODIES; PROTEIN
AB The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically targeting this emerging virus. Here we report the isolation and characterization of a panel of human neutralizing monoclonal antibodies targeting the SARS-CoV-2 receptor binding domain (RBD). These antibodies were selected from a phage display library constructed using peripheral circulatory lymphocytes collected from patients at the acute phase of the disease. These neutralizing antibodies are shown to recognize distinct epitopes on the viral spike RBD. A subset of the antibodies exert their inhibitory activity by abrogating binding of the RBD to the human ACE2 receptor. The human monoclonal antibodies described here represent a promising basis for the design of efficient combined post-exposure therapy for SARS-CoV-2 infection. Here, Noy-Porat, Makdasi et al. report the isolation of a panel of neutralizing mAbs selected against SARS-CoV-2 receptor-binding domain (RBD) from a phage display library constructed based on patient samples collected in the acute phase of the disease, which show efficient neutralizing activities against authentic virus in vitro.
C1 [Noy-Porat, Tal; Makdasi, Efi; Alcalay, Ron; Mechaly, Adva; Levy, Yinon; Bercovich-Kinori, Adi; Zauberman, Ayelet; Tamir, Hadas; Yahalom-Ronen, Yfat; Israeli, Ma'ayan; Epstein, Eyal; Achdout, Hagit; Melamed, Sharon; Chitlaru, Theodor; Weiss, Shay; Peretz, Eldar; Rosen, Osnat; Paran, Nir; Yitzhaki, Shmuel; Shapira, Shmuel C.; Israely, Tomer; Mazor, Ohad; Rosenfeld, Ronit] Israel Inst Biol Res, Ness Ziona, Israel.
RP Mazor, O; Rosenfeld, R (corresponding author), Israel Inst Biol Res, Ness Ziona, Israel.
EM ohadm@iibr.gov.il; ronitr@iibr.gov.il
CR Abdiche YN, 2009, ANAL BIOCHEM, V386, P172, DOI 10.1016/j.ab.2008.11.038
   Abdiche YN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092451
   Azriel-Rosenfeld R, 2004, J MOL BIOL, V335, P177, DOI 10.1016/j.jmb.2003.10.053
   Benhar I, 2002, CURRENT PROTOCOLS IM, V48, p1019B1, DOI [10.1002/0471142735.im1019bs48, DOI 10.1002/0471142735.IM1019BS48]
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Eyal O, 2005, J VIROL METHODS, V130, P15, DOI 10.1016/j.jviromet.2005.05.027
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P545, DOI 10.1016/j.it.2020.04.008
   Mechaly A, 2016, ANAL BIOCHEM, V506, P22, DOI 10.1016/j.ab.2016.04.018
   Noy-Porat T, 2017, TOXICON, V127, P100, DOI 10.1016/j.toxicon.2017.01.009
   Noy-Porat T, 2016, TOXINS, V8, DOI 10.3390/toxins8030064
   Noy-Porat T, 2015, BIOCONJUGATE CHEM, V26, P1753, DOI 10.1021/acs.bioconjchem.5b00305
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Prabakaran P, 2009, EXPERT OPIN BIOL TH, V9, P355, DOI 10.1517/14712590902763755 
   Reguera J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002859
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Saphire EO, 2018, NAT IMMUNOL, V19, P1169, DOI 10.1038/s41590-018-0233-9
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382
   Ying TL, 2014, J VIROL, V88, P7796, DOI 10.1128/JVI.00912-14
   Yoo DW, 2001, CLIN DIAGN LAB IMMUN, V8, P297, DOI 10.1128/CDLI.8.2.297-302.2001
   Yu Xiang, 2015, BRAND MARKETING, V5, pp9, DOI DOI 10.1038/srep13133
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhou HX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10897-4
NR 33
TC 1
Z9 1
U1 2
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 27
PY 2020
VL 11
IS 1
AR 4303
DI 10.1038/s41467-020-18159-4
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NM2LG
UT WOS:000567932900002
PM 32855401
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vuong, W
   Khan, MB
   Fischer, C
   Arutyunova, E
   Lamer, T
   Shields, J
   Saffran, HA
   McKay, RT
   van Belkum, MJ
   Joyce, MA
   Young, HS
   Tyrrell, DL
   Vederas, JC
   Lemieux, MJ
AF Vuong, Wayne
   Khan, Muhammad Bashir
   Fischer, Conrad
   Arutyunova, Elena
   Lamer, Tess
   Shields, Justin
   Saffran, Holly A.
   McKay, Ryan T.
   van Belkum, Marco J.
   Joyce, Michael A.
   Young, Howard S.
   Tyrrell, D. Lorne
   Vederas, John C.
   Lemieux, M. Joanne
TI Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and
   blocks virus replication
SO NATURE COMMUNICATIONS
LA English
DT Article
ID 3C-LIKE PROTEASES; 3C
AB The main protease, M-pro (or 3CL(pro)) in SARS-CoV-2 is a viable drug target because of its essential role in the cleavage of the virus polypeptide. Feline infectious peritonitis, a fatal coronavirus infection in cats, was successfully treated previously with a prodrug GC376, a dipeptide-based protease inhibitor. Here, we show the prodrug and its parent GC373, are effective inhibitors of the M-pro from both SARS-CoV and SARS-CoV-2 with IC50 values in the nanomolar range. Crystal structures of SARS-CoV-2 M-pro with these inhibitors have a covalent modification of the nucleophilic Cys145. NMR analysis reveals that inhibition proceeds via reversible formation of a hemithioacetal. GC373 and GC376 are potent inhibitors of SARS-CoV-2 replication in cell culture. They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals. The work here lays the framework for their use in human trials for the treatment of COVID-19. Coronavirus main protease is essential for viral polyprotein processing and replication. Here Vuong et al. report efficient inhibition of SARS-CoV-2 replication by the dipeptide-based protease inhibitor GC376 and its parent GC373, which were originally used to treat feline coronavirus infection.
C1 [Vuong, Wayne; Fischer, Conrad; Lamer, Tess; McKay, Ryan T.; van Belkum, Marco J.; Vederas, John C.] Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.
   [Khan, Muhammad Bashir; Arutyunova, Elena; Young, Howard S.; Lemieux, M. Joanne] Univ Alberta, Membrane Prot Dis Res Grp, Dept Biochem, Edmonton, AB T6G 2R3, Canada.
   [Shields, Justin; Saffran, Holly A.; Joyce, Michael A.; Tyrrell, D. Lorne] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2R3, Canada.
   [Shields, Justin; Saffran, Holly A.; Joyce, Michael A.; Tyrrell, D. Lorne] Univ Alberta, Li Ka Shing Inst Virol, Edmonton, AB T6G 2E1, Canada.
RP Vederas, JC (corresponding author), Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.; Lemieux, MJ (corresponding author), Univ Alberta, Membrane Prot Dis Res Grp, Dept Biochem, Edmonton, AB T6G 2R3, Canada.; Tyrrell, DL (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2R3, Canada.; Tyrrell, DL (corresponding author), Univ Alberta, Li Ka Shing Inst Virol, Edmonton, AB T6G 2E1, Canada.
EM lorne.tyrrell@ualberta.ca; john.vederas@ualberta.ca;
   mlemieux@ualberta.ca
RI ; Fischer, Conrad/O-3263-2017
OI McKay, Ryan/0000-0002-0255-159X; Khan, Muhammad
   Bashir/0000-0002-4164-9573; Joyce, Michael A./0000-0002-9173-7299;
   Vuong, Wayne/0000-0002-3439-8788; Fischer, Conrad/0000-0002-2289-010X
FU CIHRCanadian Institutes of Health Research (CIHR); NSERCNatural Sciences
   and Engineering Research Council of Canada [COVID-19 SOF-5492972019]; Li
   Ka Shing Institute of Virology; GSK Chair in Virology; Alberta Innovates
   Graduate Scholarship; CIHR CGSM ScholarshipCanadian Institutes of Health
   Research (CIHR); US Department of Energy, Office of Science, Office of
   Basic Energy SciencesUnited States Department of Energy (DOE)
   [DEAC02-76SF00515]; DOE Office of Biological and Environmental
   ResearchUnited States Department of Energy (DOE); National Institutes of
   Health, National Institute of General Medical SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [P41GM103393]
FX We would like to thank the staff at the Stanford Synchrotron Light
   Source, in particular Dr. Silvia Russi and Lisa Dunn. We greatly thank
   Dr. Randy Whittal and Bela Reiz for their help in the acquisition and
   interpretation of mass spectrometry data. M.J.L, J.C.V., and D.L.T.
   acknowledge funding from CIHR and NSERC (COVID-19 SOF-5492972019).
   D.L.T. acknowledges support from Li Ka Shing Institute of Virology and
   the GSK Chair in Virology. W.V. was supported by an Alberta Innovates
   Graduate Scholarship and T.L. by a CIHR CGSM Scholarship. Use of the
   Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator
   Laboratory, is supported by the US Department of Energy, Office of
   Science, Office of Basic Energy Sciences under contract no.
   DEAC02-76SF00515. The SSRL Structural Molecular Biology Program is
   supported by the DOE Office of Biological and Environmental Research,
   and by the National Institutes of Health, National Institute of General
   Medical Sciences (P41GM103393). The contents of this publication are
   solely the responsibility of the authors and do not necessarily
   represent the official views of NIGMS or NIH.
CR Biswas A, 2020, CRIT REV MICROBIOL, V46, P182, DOI 10.1080/1040841X.2020.1739001
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Chang KO, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020197
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Deng X, 2014, J VIROL, V88, P11886, DOI 10.1128/JVI.01528-14
   Drag M, 2010, NAT REV DRUG DISCOV, V9, P690, DOI 10.1038/nrd3053
   Flexner C, 2005, NAT REV DRUG DISCOV, V4, P955, DOI 10.1038/nrd1907
   Gonzalez A, 2008, J APPL CRYSTALLOGR, V41, P176, DOI 10.1107/S0021889807057822
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hu TC, 2009, VIROLOGY, V388, P324, DOI 10.1016/j.virol.2009.03.034
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Kankanamalage ACG, 2018, EUR J MED CHEM, V150, P334, DOI 10.1016/j.ejmech.2018.03.004
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Kim Y, 2015, J VIROL, V89, P4942, DOI 10.1128/JVI.03688-14
   Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   MALCOLM BA, 1995, BIOCHEMISTRY-US, V34, P8172, DOI 10.1021/bi00025a024
   Menendez-Arias L, 2013, ANTIVIR RES, V98, P93, DOI 10.1016/j.antiviral.2013.01.007
   Otto HH, 1997, CHEM REV, V97, P133, DOI 10.1021/cr950025u
   Pedersen NC, 2018, J FELINE MED SURG, V20, P378, DOI 10.1177/1098612X17729626
   Perera KD, 2018, ANTIVIR RES, V160, P79, DOI 10.1016/j.antiviral.2018.10.015
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Shi JH, 2008, J VIROL, V82, P4620, DOI 10.1128/JVI.02680-07
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Yin JA, 2007, J MOL BIOL, V371, P1060, DOI 10.1016/j.jmb.2007.06.001
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhong N, 2009, PROTEIN SCI, V18, P839, DOI 10.1002/pro.76
NR 30
TC 6
Z9 6
U1 12
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 27
PY 2020
VL 11
IS 1
AR 4282
DI 10.1038/s41467-020-18096-2
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NM2KB
UT WOS:000567929800005
PM 32855413
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Niriella, MA
   Ediriweera, DS
   De Silva, AP
   Premarathne, R
   Balasooriya, P
   Duminda, KD
   Malavige, NG
   Wanigasuriya, K
   Lekamwasam, S
   Kularathne, SA
   Siribaddana, S
   de Silva, HJ
   Jayasinghe, S
AF Niriella, Madunil A.
   Ediriweera, Dileepa S.
   De Silva, Arjuna P.
   Premarathne, Ranjan
   Balasooriya, Priyantha
   Duminda, Kaluthanthri D.
   Malavige, Neelika G.
   Wanigasuriya, Kamani
   Lekamwasam, Sarath
   Kularathne, Senanayake A.
   Siribaddana, Sisira
   de Silva, Hithanadura J.
   Jayasinghe, Saroj
TI Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval
   personnel in Sri Lanka: study protocol for a randomized, controlled
   trial
SO TRIALS
LA English
DT Article
DE Randomized controlled trial; COVID-19; SARS-CoV-2; Prophylaxis;
   Post-exposure; Hydroxychloroquine; HCQ; Sri Lanka
ID EFFICACY
AB Background: The first case of a coronavirus 2019 (COVID-19) infection in a Sri Lankan was reported on March 11, 2020. The situation in Sri Lanka changed with the rapid increase of personnel contracting COVID-19 in a naval base camp that housed more than 4000 people. This provided a unique opportunity to study the effectiveness of hydroxychloroquine (HCQ) for post-exposure prophylaxis (PEP), while taking stringent, non-pharmacologic, public health measures to prevent spread. Our aim is to study the effectiveness and safety of HCQ for PEP among naval personnel with exposure to COVID-19-positive patients.
   Methods/design: This is a placebo-controlled, randomized, clinical trial carried out in the naval base camp and quarantine centers of the Sri Lanka Navy, Ministry of Defense, Sri Lanka. Navy personnel who are exposed to a patient with confirmed COVID-19 infection but test negative for the virus on reverse real-time polymerase chain reaction (rRT-PCR) at recruitment will be randomized, 200 to each arm, to receive HCQ or placebo and monitored for the development of symptoms or rRT-PCR positivity for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus for 14 days.
   Discussion: This trial will provide high-quality evidence of the effectiveness and safety of HCQ as PEP for COVID-19. The study design is unique due to the circumstances of the outbreak in a confined area among otherwise healthy adults, at a relatively early stage of its spread.
C1 [Niriella, Madunil A.; Ediriweera, Dileepa S.; De Silva, Arjuna P.; Premarathne, Ranjan; de Silva, Hithanadura J.] Univ Kelaniya, Fac Med, Ragama, Sri Lanka.
   [Balasooriya, Priyantha] Navy Hosp, Welisara, Sri Lanka.
   [Duminda, Kaluthanthri D.] Army Hosp, Narahenpita, Sri Lanka.
   [Malavige, Neelika G.; Wanigasuriya, Kamani] Univ Sri Jayawardenapura, Fac Med Sci, Nugegoda, Sri Lanka.
   [Lekamwasam, Sarath] Univ Ruhuna, Fac Med, Galle, Sri Lanka.
   [Kularathne, Senanayake A.] Univ Peradeniya, Fac Med, Kandy, Sri Lanka.
   [Siribaddana, Sisira] Rajarata Univ Sri Lanka, Fac Med & Allied Sci, Anuradhapura, Sri Lanka.
   [Jayasinghe, Saroj] Univ Colombo, Fac Med, Colombo, Sri Lanka.
RP Niriella, MA (corresponding author), Univ Kelaniya, Fac Med, Ragama, Sri Lanka.
EM madunil.niriella@kln.ac.lk
RI Siribaddana, Sisira/I-2295-2016; Lekamwasam, Sarath/ABG-4986-2020;
   Niriella, Madunil/G-7803-2016
OI Siribaddana, Sisira/0000-0001-5821-2557; Niriella,
   Madunil/0000-0002-7213-5858
CR [Anonymous], 2020, ADVISORY USE HYDROXY
   Cevik M, 2020, CLIN MICROBIOL INFEC, V26, P842, DOI 10.1016/j.cmi.2020.04.023
   Das SK, 2007, CURR MED RES OPIN, V23, P2227, DOI 10.1185/030079907X219634
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shelar J, 2020, BMC TRY OUT HYDROXYC
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, LAB TEST COR DIS COV
NR 9
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 27
PY 2020
VL 21
IS 1
AR 748
DI 10.1186/s13063-020-04659-7
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NK8FF
UT WOS:000566966000002
PM 32854751
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, SP
   Zhu, QG
   Zhan, C
   Cheng, W
   Xiao, MF
   Fang, M
   Fang, L
AF Zhang, Shuaipan
   Zhu, Qingguang
   Zhan, Chao
   Cheng, Wei
   Xiao Mingfang
   Fang, Min
   Fang, Lei
TI Acupressure therapy and Liu Zi Jue Qigong for pulmonary function and
   quality of life in patients with severe novel coronavirus pneumonia
   (COVID-19): a study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Acupressure therapy; Liu Zi Jue Qigong; Traditional Chinese
   medicine rehabilitation; Randomized controlled trial; Study protocol
ID CLINICAL CHARACTERISTICS; MENTAL-HEALTH; DISEASE; EXERCISE; DYSPNEA;
   OUTBREAK; SARS; CARE
AB Background: In December 2019, pneumonia associated with the 2019 novel coronavirus (COVID-19) emerged in Wuhan, China. The number of cases has increased rapidly. Patients with severe disease have a poor prognosis, and there are no effective therapies for COVID-19. Only rapid advice guidelines for symptomatic supportive care have been used. A traditional Chinese medicine rehabilitation (TCMR) program consisting of acupressure therapy and Liu Zi Jue Qigong can be used as a complementary therapy for COVID-19. Hence, we designed a randomized trial to evaluate the efficacy and advantages of TCMR for treating patients with severe COVID-19.
   Methods/design: This is a parallel-design, two-arm, analyst assessor-blinded, randomized controlled trial. A total of 128 patients with COVID-19 aged from 20 to 80 years will be recruited and assigned randomly into a guideline therapy group and a guideline therapy plus TCMR group at a 1:1 ratio. Patients in both groups will receive guideline therapy. The patients in the intervention group will perform acupressure therapy and Liu Zi Jue Qigong exercises in addition to conventional treatments twice a day and will be persistent from admission to discharge. The primary outcome will be measured with the Modified Medical Research Council Dyspnea Scale, and the secondary outcomes will include the Activities of Daily Living Barthel Index Scale, Patient Health Questionnaire-9 Scale, and the Respiratory Symptoms Scale. The assessments of the clinical scales will be performed at three points (before treatment, the 7th day during hospitalization, and the discharge day). Adverse events will be noted and recorded for the safety evaluation.
   Discussion: This trial will provide high-quality evidence of the value of TCMR, which consists of acupressure therapy and Liu Zi Jue Qigong exercises, for treating patients with severe COVID-19.
C1 [Zhang, Shuaipan; Zhu, Qingguang; Fang, Min; Fang, Lei] Shanghai Univ Tradit Chinese Med, Yue Yang Hosp Integrated Tradit Chinese & Western, Shanghai 200437, Peoples R China.
   [Zhan, Chao; Cheng, Wei; Xiao Mingfang] Huangshi Hosp Tradit Chinese Med, Huangshi 435000, Hubei, Peoples R China.
   [Fang, Min] Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Shanghai 201203, Peoples R China.
   [Fang, Lei] Shanghai Univ Tradit Chinese Med, Sch Rehabil Sci, Shanghai 201203, Peoples R China.
RP Fang, M; Fang, L (corresponding author), Shanghai Univ Tradit Chinese Med, Yue Yang Hosp Integrated Tradit Chinese & Western, Shanghai 200437, Peoples R China.; Fang, M (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Shanghai 201203, Peoples R China.; Fang, L (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Rehabil Sci, Shanghai 201203, Peoples R China.
EM fangmin19650510@163.com; fanglei586@126.com
FU project of Emergency Scientific Research Project for prevention and
   control of new coronavirus (COVID-19) by Shanghai University of
   Traditional Chinese Medicine (first batch); High-Level Innovation Team
   of "Peak and Plateau Discipline" in Traditional Chinese Medicine
   [30304114316]; Shanghai University of Traditional Chinese Medicine;
   Shanghai Government [ZY (2018-2020)-CCCX-2004-02, ZY
   (2018-2020)-FWTX-2005]; Shanghai Municipal Government; Yueyang
   Integrated Traditional Chinese and Western Medicine Hospital
FX This study is supported financially by the project of Emergency
   Scientific Research Project for prevention and control of new
   coronavirus (COVID-19) by Shanghai University of Traditional Chinese
   Medicine (first batch) (no fund number) and High-Level Innovation Team
   of "Peak and Plateau Discipline" in Traditional Chinese Medicine
   (30304114316). These two projects are funded by the Shanghai University
   of Traditional Chinese Medicine. The Shanghai further accelerates the
   3-year action plan for the development of Chinese medicine (ZY
   (2018-2020)-CCCX-2004-02), and the National Key Clinical Difficult
   Diseases Clinical Collaborative Pilot Construction Project
   Osteoarticular Degenerative Disease (ZY (2018-2020)-FWTX-2005) is funded
   by the Shanghai Government. The funders had no role in the design of the
   study; analysis, collection, and interpretation of the data; or the
   writing and decision for publication of the manuscript. This funding
   relates to a wider group of projects and applies to this study. The
   trial sponsor is the Shanghai Municipal Government and Shanghai
   University of Traditional Chinese Medicine. The final fund management is
   performed by the Yueyang Integrated Traditional Chinese and Western
   Medicine Hospital affiliated to Shanghai University of Traditional
   Chinese Medicine. The public contact email is yykyc2004@163.com.
CR Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581
   Buscemi J, 2015, CONTEMP CLIN TRIALS, V42, P98, DOI 10.1016/j.cct.2015.03.014
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng FK, 2015, J BODYW MOV THER, V19, P138, DOI 10.1016/j.jbmt.2014.11.001
   Dalusung-Angosta A, 2011, J AM ACAD NURSE PRAC, V23, P376, DOI 10.1111/j.1745-7599.2011.00597.x
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dogan Nurhan, 2020, Altern Ther Health Med, V26, P49
   Dong YR, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-222
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Eekhout I, 2014, J CLIN EPIDEMIOL, V67, P335, DOI 10.1016/j.jclinepi.2013.09.009
   He C, 2020, PSYCHOTHER PSYCHOSOM, V89, P25, DOI 10.1159/000502294
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jinglin R, 2019, CHIN J TRADIT CHIN M, V37, P2004
   Junfang J, 2019, CHIN MOD DOCT, V57, P100
   Li PJ, 2018, CLIN INTERV AGING, V13, P1391, DOI 10.2147/CIA.S169671
   Li ZM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010022
   MAHLER DA, 1988, CHEST, V93, P580, DOI 10.1378/chest.93.3.580
   Marcellus Lenora, 2004, Can J Nurs Res, V36, P82
   Marciniuk DD, 2011, CAN RESPIR J, V18, P69, DOI 10.1155/2011/745047
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   Mlinac ME, 2016, ARCH CLIN NEUROPSYCH, V31, P506, DOI 10.1093/arclin/acw049
   de Araujo CLP, 2015, J REHABIL MED, V47, P957, DOI 10.2340/16501977-2008
   Shiyan Y, 2020, WORLD SCI TECHNOL MO, V22, P823
   Spahija J, 2005, CHEST, V128, P640, DOI 10.1378/chest.128.2.640
   Tan JY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132989
   Tang J, 2019, ANN OTO RHINOL LARYN, V128, P654, DOI 10.1177/0003489419837265
   Uemura Y, 2018, CIRC J, V82, P2793, DOI 10.1253/circj.CJ-18-0279
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI DOI 10.1001/JAMA.2013.281053
   Wu JJ, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015776
   Wu L, 2019, CHIN J TRADIT CHIN M, V34, P5700
   Wu WB, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/2361962
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   Xiao C, 2020, EMERG MICROBES INFEC, V9, P378, DOI 10.1080/22221751.2020.1727299
   Xiao CM, 2015, J AM GERIATR SOC, V63, P1420, DOI 10.1111/jgs.13478
   Xin XY, 2017, J CLIN NEUROPHYSIOL, V34, P162, DOI 10.1097/WNP.0000000000000341
   Yang Bin, 2013, Zhongguo Zhen Jiu, V33, P299
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yorke J, 2015, SUPPORT CARE CANCER, V23, P3373, DOI 10.1007/s00520-015-2810-x
   Zan J, 2017, CELL PHYSIOL BIOCHEM, V44, P607, DOI 10.1159/000485116
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 41
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 27
PY 2020
VL 21
IS 1
AR 751
DI 10.1186/s13063-020-04693-5
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NK8FF
UT WOS:000566966000005
PM 32854761
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Meng, FP
   Xu, RN
   Wang, SY
   Xu, Z
   Zhang, C
   Li, YY
   Yang, T
   Shi, L
   Fu, JL
   Jiang, TJ
   Huang, L
   Zhao, P
   Yuan, X
   Fan, X
   Zhang, JY
   Song, JW
   Zhang, DW
   Jiao, YM
   Liu, LM
   Zhou, CB
   Maeurer, M
   Zumla, A
   Shi, M
   Wang, FS
AF Meng, Fanping
   Xu, Ruonan
   Wang, Siyu
   Xu, Zhe
   Zhang, Chao
   Li, Yuanyuan
   Yang, Tao
   Shi, Lei
   Fu, Junliang
   Jiang, Tianjun
   Huang, Lei
   Zhao, Peng
   Yuan, Xin
   Fan, Xing
   Zhang, Ji-Yuan
   Song, Jinwen
   Zhang, Dawei
   Jiao, Yanmei
   Liu, Limin
   Zhou, Chunbao
   Maeurer, Markus
   Zumla, Alimuddin
   Shi, Ming
   Wang, Fu-Sheng
TI Human umbilical cord-derived mesenchymal stem cell therapy in patients
   with COVID-19: a phase 1 clinical trial
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Article
ID STROMAL CELLS; REDUCING MORTALITY; TRANSPLANTATION; IMPROVES
AB No effective drug treatments are available for coronavirus disease 2019 (COVID-19). Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage, death, or long-term functional disability in survivors require clinical evaluation. We performed a parallel assigned controlled, non-randomized, phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease. The study enrolled 18 hospitalized patients with COVID-19 (n = 9 for each group). The treatment group received three cycles of intravenous infusion of UC-MSCs (3 x 10(7)cells per infusion) on days 0, 3, and 6. Both groups received standard COVID-treatment regimens. Adverse events, duration of clinical symptoms, laboratory parameters, length of hospitalization, serial chest computed tomography (CT) images, the PaO2/FiO(2)ratio, dynamics of cytokines, and IgG and IgM anti-SARS-CoV-2 antibodies were analyzed. No serious UC-MSCs infusion-associated adverse events were observed. Two patients receiving UC-MSCs developed transient facial flushing and fever, and one patient developed transient hypoxia at 12 h post UC-MSCs transfusion. Mechanical ventilation was required in one patient in the treatment group compared with four in the control group. All patients recovered and were discharged. Our data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated. Phase 2/3 randomized, controlled, double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC-MSCs to reduce deaths and improve long-term treatment outcomes in patients with serious COVID-19.
C1 [Meng, Fanping; Xu, Ruonan; Wang, Siyu; Xu, Zhe; Zhang, Chao; Li, Yuanyuan; Yang, Tao; Shi, Lei; Fu, Junliang; Jiang, Tianjun; Huang, Lei; Zhao, Peng; Yuan, Xin; Fan, Xing; Zhang, Ji-Yuan; Song, Jinwen; Zhang, Dawei; Jiao, Yanmei; Liu, Limin; Zhou, Chunbao; Shi, Ming; Wang, Fu-Sheng] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Infect Dis, Med Ctr 5, Dept Infect Dis, Beijing, Peoples R China.
   [Maeurer, Markus] Champalimaud Ctr Unknown, Immunotherapy Programme, Lisbon, Portugal.
   [Maeurer, Markus] Johannes Gutenberg Univ Mainz, Med Clin 1, Mainz, Germany.
   [Zumla, Alimuddin] UCL, Dept Infect, Div Infect & Immun, London, England.
   [Zumla, Alimuddin] Univ Coll London Hosp NHS Fdn Trust, Natl Inst Hlth Res, Biomed Res Ctr, London, England.
RP Shi, M; Wang, FS (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Infect Dis, Med Ctr 5, Dept Infect Dis, Beijing, Peoples R China.
EM shiming302@sina.com; fswang302@163.com
RI ZUMLA, Alimuddin/ABA-8208-2020
OI Zumla, Professor Sir Alimuddin/0000-0002-5111-5735; Maeurer,
   Markus/0000-0002-8436-8077; Wang, Fu-Sheng/0000-0002-8043-6685
FU National Key R&D Program of China [2020YFC0841900, 2020YFC0844000];
   Innovation Groups of the National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81721002];
   National Science and Technology Major Project [2017YFA0105703]; Military
   Emergency Research Project for COVID-19 [BWS20J006]; Project for
   Innovation of Military Medicine of China [16CXZ045]; European and
   Developing Countries Clinical Trials Partnership; National Institutes of
   Health Research senior investigator awardUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
FX This work was supported by The National Key R&D Program of China
   (2020YFC0841900, 2020YFC0844000), The Innovation Groups of the National
   Natural Science Foundation of China (81721002), The National Science and
   Technology Major Project (2017YFA0105703), The Military Emergency
   Research Project for COVID-19 (BWS20J006), and The Project for
   Innovation of Military Medicine of China (16CXZ045). Sir Zumla is co-PI
   of the Pan-African Network on Emerging and ReEmerging Infections
   (PANDORA-ID-NET -https://www.pandora-id.net/) awarded by the European
   and Developing Countries Clinical Trials Partnership. Z.A. is in receipt
   of a National Institutes of Health Research senior investigator award.
   W.F.S., Z.C., M.M., and Z.A. are founder members of the Global Cancer
   and Infectious Diseases consortium for Host-directed therapies: Weblink:
   https://www.fchampalimaud.org/covid19/aci/.
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Ball LM, 2013, BRIT J HAEMATOL, V163, P501, DOI 10.1111/bjh.12545
   Behnke J, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030682
   Bian XW, 2020, NATL SCI REV, V7, P1414, DOI 10.1093/nsr/nwaa123
   Chen B, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0190-2
   Chuang HM, 2018, CELL TRANSPLANT, V27, P1581, DOI 10.1177/0963689718787501
   Dienz O, 2012, MUCOSAL IMMUNOL, V5, P258, DOI 10.1038/mi.2012.2
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fan HY, 2012, CELL MOL IMMUNOL, V9, P473, DOI 10.1038/cmi.2012.40
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Lohan P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01626
   Mangalmurti N, 2020, IMMUNITY, V28, P30272
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Shi M, 2012, STEM CELL TRANSL MED, V1, P725, DOI 10.5966/sctm.2012-0034
   Song JW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17240-2
   Thompson Mary, 2020, EClinicalMedicine, V19, P100249, DOI 10.1016/j.eclinm.2019.100249
   Wang LM, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9165267
   WHO, 2020, COR DIS COVID 19 SIT
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004
   Zhang Z, 2013, AIDS, V27, P1283, DOI 10.1097/QAD.0b013e32835fab77
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zumla A, 2020, INT J INFECT DIS, V96, P431, DOI 10.1016/j.ijid.2020.05.040
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 30
TC 5
Z9 5
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD AUG 27
PY 2020
VL 5
IS 1
AR 172
DI 10.1038/s41392-020-00286-5
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NK7WT
UT WOS:000566943900001
PM 32855385
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Podlasin, RB
   Kowalska, JD
   Pihowicz, A
   Wojtycha-Kwasnica, B
   Thompson, M
   Dyda, T
   Czeszko-Paprocka, H
   Horban, A
AF Podlasin, Regina B.
   Kowalska, Justyna D.
   Pihowicz, Andrzej
   Wojtycha-Kwasnica, Beata
   Thompson, Magdalena
   Dyda, Tomasz
   Czeszko-Paprocka, Hanna
   Horban, Andrzej
TI How to follow-up a patient who received tocilizumab in severe COVID-19:
   a case report
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article
DE SARS-CoV-2; COVID-19; Tocilizumab; Chloroquine; ARDS; Cytokine storm
AB Background COVID-19 is characterized by fast deterioration in the mechanism of cytokine storm. Therefore, treatment with immunomodulating agents should be initiated as soon as hyperinflammation is established. Evidence for the use of tocilizumab (TCZ) in COVID-19 is emerging, but the drug in this setting is used "off label" with limited data on both effectiveness and safety. Therefore, Hospital for Infectious Diseases in Warsaw established a Standard Operating Procedure (SOP) for the use of TCZ in severe COVID-19 cases. Case presentation Here, we present a case of 27-year-old, otherwise healthy man, who was successfully treated with chloroquine, azithromycin, tocilizumab and a standard of care. Initially the magnitude of lung devastation, clinical deterioration and the need for mechanical ventilation suggested unfavorable prognosis. However, we observed complete regression in radiological changes and rapid clinical improvement. Irrespective of this, patient's serum interleukin 6 and aminotransferases remained elevated even after a month from treatment. Conclusions An overlapping effect of hyperinflammation, hypoxic organ injury and drug-related toxicity warrants a long-term follow-up for COVID-19 survivors. In addition, residual IL-6 receptors blockage may mask new infections. A standardized approach to follow-up for COVID-19 survivors is urgently needed. Current and future research should also investigate the impact of experimental therapies on lung tissue healing and regeneration, as well as long-term treatment toxicities.
C1 [Podlasin, Regina B.; Thompson, Magdalena] Hosp Infect Dis, Dept 4, Warsaw, Poland.
   [Kowalska, Justyna D.; Horban, Andrzej] Med Univ Warsaw, Dept Adults Infect Dis, Warsaw, Poland.
   [Pihowicz, Andrzej] Hosp Infect Dis Warsaw, Intens Care Unit, Warsaw, Poland.
   [Wojtycha-Kwasnica, Beata] Hosp Infect Dis Warsaw, Dept Diagnost Imaging, Warsaw, Poland.
   [Dyda, Tomasz] Hosp Infect Dis Warsaw, Mol Diagnost Lab, Warsaw, Poland.
   [Czeszko-Paprocka, Hanna] Hosp Infect Dis Warsaw, Cent Analyt Lab, Warsaw, Poland.
RP Kowalska, JD (corresponding author), Med Univ Warsaw, Dept Adults Infect Dis, Warsaw, Poland.
EM jdkowalska@gmail.com
CR Atal S, 2020, PHARM MED, V34, P223, DOI 10.1007/s40290-020-00342-z
   Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009
   Coomes EA, INTERLEUKIN 6 COVID, DOI DOI 10.1101/2020.03.30.20048058V1
   Eimer J, 2020, J INTERN MED, DOI 10.1111/joim.13162
   Emery P, 2008, ANN RHEUM DIS, V67, P1516, DOI 10.1136/ard.2008.092932
   Flisiak R, 2020, POL ARCH INTERN MED, V130, P352, DOI 10.20452/pamw.15270
   Flynn MG, 2019, AGING DIS, V10, P147, DOI 10.14336/AD.2018.0326
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kewan Tariq, 2020, EClinicalMedicine, V24, P100418, DOI 10.1016/j.eclinm.2020.100418
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC
   Schiff MH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3455
   Shu SQ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030207
   Tomasiewicz K, 2020, EXPERT REV ANTI-INFE, DOI 10.1080/14787210.2020.1800453
   Waseem N, 2016, J CLIN TRANSL HEPATO, V4, P263, DOI 10.14218/JCTH.2016.00022
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zheng Z, 2020, J MED VIROL, V92, P2412, DOI 10.1002/jmv.25994
NR 22
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD AUG 27
PY 2020
VL 25
IS 1
AR 37
DI 10.1186/s40001-020-00438-x
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NJ7ZE
UT WOS:000566260600001
PM 32854774
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ferri, C
   Giuggioli, D
   Raimondo, V
   L'Andolina, M
   Tavoni, A
   Cecchetti, R
   Guiducci, S
   Ursini, F
   Caminiti, M
   Varcasia, G
   Gigliotti, P
   Pellegrini, R
   Olivo, D
   Colaci, M
   Murdaca, G
   Brittelli, R
   Mariano, GP
   Spinella, A
   Bellando-Randone, S
   Aiello, V
   Bilia, S
   Giannini, D
   Ferrari, T
   Caminiti, R
   Brusi, V
   Meliconi, R
   Fallahi, P
   Antonelli, A
AF Ferri, Clodoveo
   Giuggioli, Dilia
   Raimondo, Vincenzo
   L'Andolina, Massimo
   Tavoni, Antonio
   Cecchetti, Riccardo
   Guiducci, Serena
   Ursini, Francesco
   Caminiti, Maurizio
   Varcasia, Giuseppe
   Gigliotti, Pietro
   Pellegrini, Roberta
   Olivo, Domenico
   Colaci, Michele
   Murdaca, Giuseppe
   Brittelli, Raffaele
   Mariano, Giuseppa Pagano
   Spinella, Amelia
   Bellando-Randone, Silvia
   Aiello, Vincenzo
   Bilia, Silvia
   Giannini, Daiana
   Ferrari, Tommaso
   Caminiti, Rodolfo
   Brusi, Veronica
   Meliconi, Riccardo
   Fallahi, Poupak
   Antonelli, Alessandro
CA COVID-19 & ASD Italian Study Grp
TI COVID-19 and rheumatic autoimmune systemic diseases: report of a large
   Italian patients series
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Arthritis; Autoimmune systemic diseases; Connective tissue diseases;
   COVID-19; Rheumatic diseases; SARS-CoV-2
ID CLINICAL-COURSE; CORONAVIRUS; INFECTION; SCLEROSIS
AB Introduction Covid-19 infection poses a serious challenge for immune-compromised patients with inflammatory autoimmune systemic diseases. We investigated the clinical-epidemiological findings of 1641 autoimmune systemic disease Italian patients during the Covid-19 pandemic.
   Method This observational multicenter study included 1641 unselected patients with autoimmune systemic diseases from three Italian geographical areas with different prevalence of Covid-19 [high in north (Emilia Romagna), medium in central (Tuscany), and low in south (Calabria)] by means of telephone 6-week survey. Covid-19 was classified as (1)definite diagnosis of Covid-19 disease: presence of symptomatic Covid-19 infection, confirmed by positive oral/nasopharyngeal swabs; (2)highly suspected Covid-19 disease: presence of highly suggestive symptoms, in absence of a swab test.
   Results A significantly higher prevalence of patients with definite diagnosis of Covid-19 disease,or with highly suspected Covid-19 disease, or both the conditions together, was observed in the whole autoimmune systemic disease series, compared to "Italian general population" (p = .030,p = .001,p = .000, respectively); and for definite + highly suspected diagnosis of Covid-19 disease, in patients with autoimmune systemic diseases of the three regions (p = .000, for all comparisons with the respective regional general population). Moreover, significantly higher prevalence of definite + highly suspected diagnosis of Covid-19 disease was found either in patients with various "connective tissue diseases" compared to "inflammatory arthritis group" (p < .000), or in patients without ongoing conventional synthetic disease-modifying anti-rheumatic drugs treatments (p = .011).
   Conclusions The finding of a higher prevalence of Covid-19 in patients with autoimmune systemic diseases is particularly important, suggesting the need to develop valuable prevention/management strategies, and stimulates in-depth investigations to verify the possible interactions between Covid-19 infection and impaired immune-system of autoimmune systemic diseases.
C1 [Ferri, Clodoveo; Giuggioli, Dilia; Spinella, Amelia] Univ Modena & RE, Sch Med, Rheumatol Unit, Modena, Italy.
   [Ferri, Clodoveo; Raimondo, Vincenzo; Brittelli, Raffaele; Aiello, Vincenzo; Caminiti, Rodolfo] Rheumatol Clin Madonna dello Scoglio Cotronei, Crotone, Italy.
   [L'Andolina, Massimo] ASP Vibo Valentia Tropea Hosp, Rheumatol Outpatient Clin, Tropea, Italy.
   [Tavoni, Antonio; Bilia, Silvia; Giannini, Daiana] Univ Pisa, Clin Immunol Unit, Pisa, Italy.
   [Cecchetti, Riccardo] Osped Portoferraio, Livorno, Italy.
   [Guiducci, Serena; Bellando-Randone, Silvia] Univ Florence, Rheumatol Unit, Florence, Italy.
   [Ursini, Francesco; Brusi, Veronica; Meliconi, Riccardo] Univ Bologna, Rizzoli Orthopaed Inst Bologna, Bologna, Italy.
   [Caminiti, Maurizio; Mariano, Giuseppa Pagano] Grande Osped Metropolitano, UOD Reumatol, Reggio Di Calabria, Italy.
   [Varcasia, Giuseppe; Ferrari, Tommaso] Osped Castrovillari, UOS Reumatol, Cosenza, Italy.
   [Gigliotti, Pietro] UOT Specialist Ambulatoriale Asp 201, Cosenza, Italy.
   [Pellegrini, Roberta] UOC Med Interna M Valentini PO Annunziata, Cosenza, Italy.
   [Olivo, Domenico] San Giovanni di Dio Hosp, Rheumatol Outpatient Clin, Crotone, Italy.
   [Colaci, Michele] Univ Catania, Rheumatol Unit, Catania, Italy.
   [Murdaca, Giuseppe] Univ Genoa, San Martino Policlin Hosp, Dept Internal Med, Genoa, Italy.
   [Fallahi, Poupak] Univ Pisa, Sch Med, Dept Translat Res & New Technol Med & Surg, Pisa, Italy.
   [Antonelli, Alessandro] Univ Pisa, Sch Med, Dept Clin & Expt Med, Lab Primary Human Cells,Immunoendocrine Sect Inte, Via Savi 10, I-56126 Pisa, Italy.
RP Ferri, C (corresponding author), Univ Modena & RE, Sch Med, Rheumatol Unit, Modena, Italy.; Ferri, C (corresponding author), Rheumatol Clin Madonna dello Scoglio Cotronei, Crotone, Italy.; Antonelli, A (corresponding author), Univ Pisa, Sch Med, Dept Clin & Expt Med, Lab Primary Human Cells,Immunoendocrine Sect Inte, Via Savi 10, I-56126 Pisa, Italy.
EM clferri@unimore.it; alessandro.antonelli@med.unipi.it
FU Universita di Pisa within the CRUI-CARE Agreement
FX Open access funding provided by Universita di Pisa within the CRUI-CARE
   Agreement.
CR [Anonymous], 2020, CHINESE MED J-PEKING, V133, P1087, DOI 10.1097/CM9.0000000000000819
   [Anonymous], 2020, 51 WHO
   Antonelli A, 2020, CURR GENOMICS, V21, P157, DOI 10.2174/1389202921999200427133052
   Beydon M, 2020, ANN RHEUM DIS, V2020, DOI [10.1136/annrheumdis-2020-217549, DOI 10.1136/ANNRHEUMDIS-2020-217549]
   Bijlsma JWJ, 2018, EULAR TXB RHEUMATIC
   Cassione EB, 2020, ANN RHEUM DIS, V79, P1382, DOI 10.1136/annrheumdis-2020-217717
   Cheng CF, 2020, CLIN RHEUMATOL, V39, P2025, DOI 10.1007/s10067-020-05160-x
   Conticini Edoardo, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217681, 10.1136/annrheumdis-2020-218761]
   Del Papa N, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102558
   Emmi G, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102575
   Favalli Ennio Giulio, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217615, 10.1136/annrheumdis-2020-217787]
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guilpain Philippe, 2021, Ann Rheum Dis, V80, pe10, DOI 10.1136/annrheumdis-2020-217549
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Lu CY, 2020, ANN RHEUM DIS, V79, P737, DOI 10.1136/annrheumdis-2020-217460
   Marotto D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102539
   Mathian A, 2020, ANN RHEUM DIS, V79, P837, DOI 10.1136/annrheumdis-2020-217566
   Matucci-Cerinic M, 2020, ANN RHEUM DIS, V79, P724, DOI 10.1136/annrheumdis-2020-217407
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Memoli MJ, 2014, CLIN INFECT DIS, V58, P214, DOI 10.1093/cid/cit725
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Quartuccio L, 2020, JOINT BONE SPINE, V87, P439, DOI 10.1016/j.jbspin.2020.05.003
   Riccardo F, 2020, INTEGRATED SURVEILLA
   Tomelleri A, 2020, ANN RHEUM DIS, V79, P1252, DOI 10.1136/annrheumdis-2020-217600
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071
   Zen M, 2020, J AUTOIMMUN, V112, DOI 10.1016/j.jaut.2020.102502
NR 35
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD NOV
PY 2020
VL 39
IS 11
BP 3195
EP 3204
DI 10.1007/s10067-020-05334-7
EA AUG 2020
PG 10
WC Rheumatology
SC Rheumatology
GA OA8ZQ
UT WOS:000564968600001
PM 32852623
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ran, JJ
   Song, Y
   Zhuang, ZA
   Han, LF
   Zhao, S
   Cao, PH
   Geng, Y
   Xu, L
   Qin, J
   He, DH
   Wu, FF
   Yang, L
AF Ran, Jinjun
   Song, Ying
   Zhuang, Zian
   Han, Lefei
   Zhao, Shi
   Cao, Peihua
   Geng, Yan
   Xu, Lin
   Qin, Jing
   He, Daihai
   Wu, Fengfu
   Yang, Lin
TI Blood pressure control and adverse outcomes of COVID-19 infection in
   patients with concomitant hypertension in Wuhan, China
SO HYPERTENSION RESEARCH
LA English
DT Article
DE COVID-19; Hypertension; Heart failure; Intensive care unit; Mortality
ID VISIT-TO-VISIT; SARS CORONAVIRUS; RECEPTOR; ACE2; VARIABILITY
AB Hypertension is a common comorbidity in hospitalized patients with COVID-19 infection. This study aimed to estimate the risks of adverse events associated with in-hospital blood pressure (BP) control and the effects of angiotensin II receptor blocker (ARB) prescription in COVID-19 patients with concomitant hypertension. In this retrospective cohort study, the anonymized medical records of COVID-19 patients were retrieved from an acute field hospital in Wuhan, China. Clinical data, drug prescriptions, and laboratory investigations were collected for individual patients with diagnosed hypertension on admission. Cox proportional hazards models were used to estimate the risks of adverse outcomes associated with BP control during the hospital stay. Of 803 hypertensive patients, 67 (8.3%) were admitted to the ICU, 30 (3.7%) had respiratory failure, 26 (3.2%) had heart failure, and 35 (4.8%) died. After adjustment for confounders, the significant predictors of heart failure were average systolic blood pressure (SBP) (hazard ratio (HR) per 10 mmHg 1.89, 95% confidence interval (CI): 1.15, 3.13) and pulse pressure (HR per 10 mmHg 2.71, 95% CI: 1.39, 5.29). The standard deviations of SBP and diastolic BP were independently associated with mortality and ICU admission. The risk estimates of poor BP control were comparable between patients receiving ARBs and those not receiving ARBs, with the only exception of a high risk of heart failure in the non-ARB group. Poor BP control was independently associated with higher risks of adverse outcomes of COVID-19. ARB drugs did not increase the risks of adverse events in hypertensive patients.
C1 [Ran, Jinjun] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China.
   [Ran, Jinjun] Shanghai Jiao Tong Univ, Sch Publ Hlth, Sch Med, Shanghai, Peoples R China.
   [Song, Ying; Wu, Fengfu] Huoshenshan Hosp, Dept Med Affairs, Wuhan, Peoples R China.
   [Song, Ying; Wu, Fengfu] 923 Hosp Joint Serv Supporting Force, Nanning, Peoples R China.
   [Zhuang, Zian; He, Daihai] Hong Kong Polytech Univ, Dept Appl Math, Hong Kong, Peoples R China.
   [Han, Lefei; Qin, Jing; Yang, Lin] Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Peoples R China.
   [Zhao, Shi] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China.
   [Cao, Peihua] Southern Med Univ, Zhujiang Hosp, Clin Res Ctr, Guangzhou, Peoples R China.
   [Geng, Yan] Huoshenshan Hosp, Dept Infect Dis, Wuhan, Peoples R China.
   [Geng, Yan] 923 Hosp Joint Serv Supporting Force, Dept Gastroenterol, Nanning, Peoples R China.
   [Xu, Lin] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China.
RP Wu, FF (corresponding author), Huoshenshan Hosp, Dept Med Affairs, Wuhan, Peoples R China.; Wu, FF (corresponding author), 923 Hosp Joint Serv Supporting Force, Nanning, Peoples R China.; Yang, L (corresponding author), Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Peoples R China.
EM 24632513@qq.com; l.yang@polyu.edu.hk
FU Alibaba (China)-Hong Kong Polytechnic University Collaborative Research
   Fund [P0031768]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81903406]
FX LY and DH are supported by the Alibaba (China)-Hong Kong Polytechnic
   University Collaborative Research Fund (P0031768). PC is supported by
   the National Natural Science Foundation of China (No. 81903406).
CR Benetos A, 2002, ARCH INTERN MED, V162, P577, DOI 10.1001/archinte.162.5.577
   Chang TI, 2017, HYPERTENSION, V70, P751, DOI 10.1161/HYPERTENSIONAHA.117.09788
   Clark CE, COVID 19 HYPERTENSIO
   Diaz KM, 2012, HYPERTENS RES, V35, P55, DOI 10.1038/hr.2011.135
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Nagai M, 2011, J AM SOC HYPERTENS, V5, P184, DOI 10.1016/j.jash.2011.03.001
   National Health Commission of China, NTR
   Nicin L, 2020, EUR HEART J, V41, P1804, DOI 10.1093/eurheartj/ehaa311
   Parati G, 2013, NAT REV CARDIOL, V10, P143, DOI 10.1038/nrcardio.2013.1
   Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   Unger T, 2020, HYPERTENSION, V75, P1334, DOI 10.1161/HYPERTENSIONAHA.120.15026
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang MQ, 2019, HYPERTENS RES, V42, P1701, DOI 10.1038/s41440-019-0274-y
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 33
TC 2
Z9 2
U1 1
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0916-9636
EI 1348-4214
J9 HYPERTENS RES
JI Hypertens. Res.
PD NOV
PY 2020
VL 43
IS 11
BP 1267
EP 1276
DI 10.1038/s41440-020-00541-w
EA AUG 2020
PG 10
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA OC9EQ
UT WOS:000564936200001
PM 32855527
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Cojutti, PG
   Londero, A
   Della Siega, P
   Givone, F
   Fabris, M
   Biasizzo, J
   Tascini, C
   Pea, F
AF Cojutti, Pier Giorgio
   Londero, Angela
   Della Siega, Paola
   Givone, Filippo
   Fabris, Martina
   Biasizzo, Jessica
   Tascini, Carlo
   Pea, Federico
TI Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2
   Patients vs. HIV Patients: The Role of Interleukin-6
SO CLINICAL PHARMACOKINETICS
LA English
DT Article
ID FIXED-DOSE COMBINATION; DISEASE; TOCILIZUMAB; COVID-19
AB Background Darunavir is an anti-HIV protease inhibitor repurposed for SARS-CoV-2 treatment. Objective The aim of this study was to assess the population pharmacokinetics of darunavir in SARS-CoV-2 patients compared with HIV patients. Methods Two separate models were created by means of a nonlinear mixed-effect approach. The influence of clinical covariates on each basic model was tested and the association of significant covariates with darunavir parameters was assessed at multivariate regression and classification and regression tree (CART) analyses. Monte Carlo simulation assessed the influence of covariates on the darunavir concentration versus time profile. Results A one-compartment model well-described darunavir concentrations in both groups. In SARS-CoV-2 patients (n = 30), interleukin (IL)-6 and body surface area were covariates associated with darunavir oral clearance (CL/F) and volume of distribution (V-d), respectively; no covariates were identified in HIV patients (n = 25). Darunavir CL/F was significantly lower in SARS-CoV-2 patients compared with HIV patients (4.1 vs. 10.3 L/h;p < 0.001). CART analysis found that an IL-6 level of 18 pg/mL may split the SARS-CoV-2 population in patients with low versus high darunavir CL/F (mean +/- standard deviation 3.47 +/- 1.90 vs. 8.03 +/- 3.24 L/h; proportion of reduction in error = 0.46). Median (interquartile range) darunavir CL/F was significantly lower in SARS-CoV-2 patients with IL-6 levels >= 18 pg/mL than in SARS-CoV-2 patients with IL-6 levels < 18 pg/mL or HIV patients (2.78 [2.16-4.47] vs. 7.24 [5.88-10.38] vs. 9.75 [8.45-13.79] L/h, respectively;p < 0.0001). Increasing IL-6 levels affected darunavir concentration versus time simulated profiles. We hypothesized that increases in IL-6 levels associated with severe SARS-CoV-2 disease may downregulate the cytochrome P450 (CYP) 3A4-mediated metabolism of darunavir. Conclusions This is a proof-of-concept of SARS-CoV-2 disease-drug interactions, and may support the need for optimal dose selection of sensitive CYP3A4 substrates in severe SARS-CoV-2 patients.
C1 [Cojutti, Pier Giorgio; Pea, Federico] Univ Udine, Dept Med, Udine, Italy.
   [Cojutti, Pier Giorgio; Pea, Federico] Santa Maria della Misericordia Univ Hosp Udine, ASUFC, Inst Clin Pharmacol, Ple S Maria della Misericordia 3, I-33100 Udine, Italy.
   [Londero, Angela; Della Siega, Paola; Givone, Filippo; Tascini, Carlo] Santa Maria della Misericordia Univ Hosp Udine, Clin Infect Dis, ASUFC, Udine, Italy.
   [Fabris, Martina; Biasizzo, Jessica] Santa Maria della Misericordia Univ Hosp Udine, Inst Clin Pathol, ASUFC, Udine, Italy.
RP Pea, F (corresponding author), Univ Udine, Dept Med, Udine, Italy.; Pea, F (corresponding author), Santa Maria della Misericordia Univ Hosp Udine, ASUFC, Inst Clin Pharmacol, Ple S Maria della Misericordia 3, I-33100 Udine, Italy.
EM federico.pea@uniud.it
OI Pea, Federico/0000-0002-6966-7167
FU Universita degli Studi di Udine within the CRUI-CARE Agreement
FX Open access funding provided by Universita degli Studi di Udine within
   the CRUI-CARE Agreement. This research received no external funding.
CR Aitken AE, 2006, ANNU REV PHARMACOL, V46, P123, DOI 10.1146/annurev.pharmtox.46.120604.141059
   Baker EH, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14416
   Baldelli S, 2020, J ANTIMICROB CHEMOTH, DOI [10.1093/jac/dkaa1907239103, DOI 10.1093/JAC/DKAA1907239103]
   Borges AH, 2015, J INFECT DIS, V212, P585, DOI 10.1093/infdis/jiv123
   Uysal BB, 2020, J MED VIROL, V92, P2648, DOI 10.1002/jmv.26111
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Cattaneo D, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104898
   Chromsystems Instruments & Chemicals GmbH, 2014, MASSTOX TDM SER A
   Daskapan A, 2019, THER DRUG MONIT, V41, P59, DOI 10.1097/FTD.0000000000000576
   Dickinson L, 2020, J ANTIMICROB CHEMOTH, V75, P628, DOI 10.1093/jac/dkz479
   Evers R, 2013, DRUG METAB DISPOS, V41, P1598, DOI 10.1124/dmd.113.052225
   Gregoire M, 2020, J ANTIMICROB CHEMOTH, DOI [10.1093/jac/dkaa1957313987, DOI 10.1093/JAC/DKAA1957313987]
   Kakuda TN, 2014, J CLIN PHARMACOL, V54, P949, DOI 10.1002/jcph.290
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Machavaram KK, 2013, CLIN PHARMACOL THER, V94, P260, DOI 10.1038/clpt.2013.79
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Morgan ET, 2009, CLIN PHARMACOL THER, V85, P434, DOI 10.1038/clpt.2008.302
   Navarro J, 2016, HIV AIDS-RES PALLIAT, V8, P175, DOI 10.2147/HIV.S56158
   Peck RW, 2020, CLIN PHARMACOL THER, V108, P921, DOI 10.1002/cpt.1922
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Renton KW, 2004, CURR DRUG METAB, V5, P235, DOI 10.2174/1389200043335559
   Rilinger J, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04447-3
   Schmitt C, 2011, CLIN PHARMACOL THER, V89, P735, DOI 10.1038/clpt.2011.35
   Schoergenhofer C, 2020, ANN INTERN MED, DOI [10.7326/m20-15507236891, DOI 10.7326/M20-15507236891]
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Smith PF, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14314
   WHO, 2020, COR DIS COVID 19 SIT
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 29
TC 1
Z9 1
U1 4
U2 4
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0312-5963
EI 1179-1926
J9 CLIN PHARMACOKINET
JI Clin. Pharmacokinet.
PD OCT
PY 2020
VL 59
IS 10
BP 1251
EP 1260
DI 10.1007/s40262-020-00933-8
EA AUG 2020
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OC8DQ
UT WOS:000564939800002
PM 32856282
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gattinger, P
   Borochova, K
   Dorofeeva, Y
   Henning, R
   Kiss, R
   Kratzer, B
   Muhl, B
   Perkmann, T
   Trapin, D
   Trella, M
   Ettel, P
   Tulaeva, I
   Pickl, WF
   Valenta, R
AF Gattinger, Pia
   Borochova, Kristina
   Dorofeeva, Yulia
   Henning, Rainer
   Kiss, Renata
   Kratzer, Bernhard
   Muehl, Bernhard
   Perkmann, Thomas
   Trapin, Doris
   Trella, Martina
   Ettel, Paul
   Tulaeva, Inna
   Pickl, Winfried F.
   Valenta, Rudolf
TI Antibodies in serum of convalescent patients following mild COVID-19 do
   not always prevent virus-receptor binding
SO ALLERGY
LA English
DT Letter; Early Access
DE COVID-19; immune complex; molecular interaction assay; protective
   antibodies; SARS-CoV-2; vaccine
ID SARS CORONAVIRUS
C1 [Gattinger, Pia; Borochova, Kristina; Dorofeeva, Yulia; Tulaeva, Inna; Valenta, Rudolf] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Div Immunopathol, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.
   [Henning, Rainer; Kiss, Renata] Viravaxx, Vienna, Austria.
   [Kratzer, Bernhard; Trapin, Doris; Ettel, Paul; Pickl, Winfried F.] Med Univ Vienna, Inst Immunol, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.
   [Muehl, Bernhard] Labors At, Vienna, Austria.
   [Perkmann, Thomas; Trella, Martina] Med Univ Vienna, Dept Lab Med, Vienna, Austria.
   [Tulaeva, Inna; Valenta, Rudolf] Sechenov First Moscow State Med Univ, Dept Clin Immunol & Allergy, Immunopathol Lab, Moscow, Russia.
   [Valenta, Rudolf] NRC Inst Immunol FMBA Russia, Moscow, Russia.
   [Valenta, Rudolf] Karl Landsteiner Univ Hlth Sci, Krems, Austria.
RP Valenta, R (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM rudolf.valenta@meduniwien.ac.at
RI Tulaeva, Inna/ABA-8281-2020
OI Tulaeva, Inna/0000-0002-5825-2687; Kratzer,
   Bernhard/0000-0003-1091-4327; Gattinger, Pia/0000-0001-6724-8543
FU Viravaxx, Vienna, Austria
FX This study was supported by a grant from Viravaxx, Vienna, Austria. The
   funders had no role in study design, data collection and analysis,
   decision to publish or preparation of the manuscript.
CR Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364
   de Alwis R, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102768
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Liu YC, 2020, BIOMED J, V19, P2319
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Niespodziana K, 2012, FASEB J, V26, P1001, DOI 10.1096/fj.11-193557
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
NR 9
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
DI 10.1111/all.14523
EA AUG 2020
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA NE7AU
UT WOS:000562754200001
PM 32734595
OA Other Gold
DA 2021-01-01
ER

PT J
AU Calina, D
   Hartung, T
   Docea, AO
   Spandidos, DA
   Egorov, AM
   Shtilman, MI
   Carvalho, F
   Tsatsakis, A
AF Calina, Daniela
   Hartung, Thomas
   Docea, Anca Oana
   Spandidos, Demetrios A.
   Egorov, Alex M.
   Shtilman, Michael, I
   Carvalho, Felix
   Tsatsakis, Aristidis
TI COVID-19 vaccines: ethical framework concerning human challenge studies
SO DARU-JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE COVID-19 vaccines; Risk taking; Human challenge studies; Randomized
   clinical trials
ID HEALTHY-VOLUNTEERS
AB Background The pandemic associated with the new SARS-CoV-2 coronavirus continues to spread worldwide. The most favorable epidemic control scenario, which provides long-term protection against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine. The need to develop a new COVID-19 vaccine is pressing; however, it is likely to take a long time, possibly several years. This is due to the time required to demonstrate the safety and efficacy of the proposed vaccine. and the time required to manufacture and distribute millions of doses. Objectives To accelerate this development and associated safety testing, the deliberate infection of healthy volunteers has been suggested. The purpose of this short communication is to describe the ethical aspects of this type of testing, Results Deliberate infection of volunteers with a dangerous virus such as SARS-CoV-2 was initially considered unethical by researchers; but the current pandemic is so different from previous ones that these studies are considered ethical if certain criteria are met. Participants in human challenge studies must be relatively young, in good health and must receive the highest quality medical care, with frequent monitoring. Tests should also be performed with great caution and specialized medical supervision. Besides, the fact that obtaining vaccines faster through deliberate infection studies of healthy people has greater benefits than risks, has been demonstrated by obtaining other vaccines in other historical pandemics such as: smallpox, influenza, malaria, typhoid fever, Dengue fever and Zika. Conclusions One possibility to shorten the time required for the development of COVID-19 vaccines is to reduce clinical phases II and III by using human challenge studies through eliberate infection of healthy volunteers with SARS-CoV-2 after administration of the candidate vaccine. Accelerating the development of a COVID-19 vaccine even for a few weeks or months would have a great beneficial impact on public health by saving many lives.
C1 [Calina, Daniela] Univ Med & Pharm Craiova, Dept Clin Pharm, Craiova 200349, Romania.
   [Hartung, Thomas] CAAT Europe Univ Konstanz, D-78457 Constance, Germany.
   [Hartung, Thomas] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, CAAT, Baltimore, MD 21287 USA.
   [Docea, Anca Oana] Univ Med & Pharm Craiova, Dept Toxicol, Craiova 200349, Romania.
   [Spandidos, Demetrios A.] Univ Crete, Med Sch, Lab Clin Virol, Iraklion 71409, Greece.
   [Egorov, Alex M.] Russian Acad Sci, FSBSI Chumakov Fed Sci Ctr Res & Dev Immune & Bio, Moscow 108819, Russia.
   [Egorov, Alex M.; Tsatsakis, Aristidis] Russian Acad Sci, Moscow, Russia.
   [Shtilman, Michael, I] DI Mendeleyev Univ Chem Technol, Moscow 125047, Russia.
   [Carvalho, Felix] Univ Porto, Fac Pharm, Dept Biol Sci, REQUIMTE,Lab Toxicol,UCIBIO, P-4050313 Porto, Portugal.
   [Tsatsakis, Aristidis] Sechenov Univ, Dept Analyt & Forens Med Toxicol, Moscow 119991, Russia.
   [Tsatsakis, Aristidis] Univ Crete, Fac Med, Dept Forens Sci & Toxicol, Iraklion 71003, Greece.
   [Tsatsakis, Aristidis] Univ Crete, Med Sch, Lab Toxicol, Iraklion 70013, Greece.
RP Calina, D (corresponding author), Univ Med & Pharm Craiova, Dept Clin Pharm, Craiova 200349, Romania.; Tsatsakis, A (corresponding author), Russian Acad Sci, Moscow, Russia.; Tsatsakis, A (corresponding author), Sechenov Univ, Dept Analyt & Forens Med Toxicol, Moscow 119991, Russia.; Tsatsakis, A (corresponding author), Univ Crete, Fac Med, Dept Forens Sci & Toxicol, Iraklion 71003, Greece.; Tsatsakis, A (corresponding author), Univ Crete, Med Sch, Lab Toxicol, Iraklion 70013, Greece.
EM calinadaniela@gmail.com; tsatsaka@uoc.gr
RI Calina, Daniela/M-6679-2019; Calina, Daniela/I-5509-2017; Docea, Anca
   Oana/P-5807-2019; Tsatsakis, Aristidis M./H-2890-2013
OI Calina, Daniela/0000-0002-1523-9116; Docea, Anca
   Oana/0000-0002-8162-5955; Tsatsakis, Aristidis M./0000-0003-3824-2462
CR Arsene AL, 2020, FARMACIA, V68, P185, DOI 10.31925/farmacia.2020.2.1
   Bambery B, 2016, PUBLIC HEALTH ETH-UK, V9, P92, DOI 10.1093/phe/phv026
   Bompart F, 2019, CAMB Q HEALTHC ETHIC, V28, P134, DOI 10.1017/S0963180118000476
   Bullen C Korin, 2020, ALTEX, V37, P665, DOI 10.14573/altex.2006111
   Busquet F, 2020, ARCH TOXICOL, V94, P2263, DOI 10.1007/s00204-020-02787-2
   Calina D, 2020, INT J MOL MED, V46, P3, DOI 10.3892/ijmm.2020.4596
   CDC, CDC SEAS FLU VACC EF
   Delany I, 2014, EMBO MOL MED, V6, P708, DOI 10.1002/emmm.201403876
   Docea AO, 2020, INT J MOL MED, V45, P1631, DOI 10.3892/ijmm.2020.4555
   Docea AO, 2016, FARMACIA, V64, P605
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Gerlich WH, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-239
   Jamrozik E, 2020, LANCET INFECT DIS, V20, pE198, DOI 10.1016/S1473-3099(20)30438-2
   Lakdawala SS, 2020, SCIENCE, V368, P942, DOI 10.1126/science.abc6141
   Meagher KM, 2020, MAYO CLIN PROC, V95, P1119, DOI 10.1016/j.mayocp.2020.04.019
   Movert E, 2013, J INFECT DIS, V208, P2025, DOI 10.1093/infdis/jit359
   Nitulescu GM, 2020, INT J MOL MED, V46, P467, DOI 10.3892/ijmm.2020.4608
   Offit PA, 2005, HEALTH AFFAIR, V24, P622, DOI 10.1377/hlthaff.24.3.622
   Plotkin SA, 2020, VACCINE, V38, P3987, DOI 10.1016/j.vaccine.2020.04.039
   Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755
   Resnik DB, 2012, THEOR MED BIOETH, V33, P137, DOI 10.1007/s11017-011-9201-1
   Rostami-Nejad Mohammad, 2020, Iranian Biomedical Journal, V24, P1, DOI 10.29252/ibj.24.1.1
   Schaefer GO, 2020, VACCINE, V38, P5085, DOI 10.1016/j.vaccine.2020.06.007
   Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2
   Islam MT, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00281
   Tsatsakis A, 2020, FOOD CHEM TOXICOL, V141, DOI 10.1016/j.fct.2020.111418
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   World Health Organization, 2020, WHO DRAFT LANDSC COV
NR 28
TC 3
Z9 3
U1 3
U2 3
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
EI 2008-2231
J9 DARU
JI DARU
PD DEC
PY 2020
VL 28
IS 2
BP 807
EP 812
DI 10.1007/s40199-020-00371-8
EA AUG 2020
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ3QF
UT WOS:000562942300001
PM 32851596
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lindahl, U
   Li, JP
AF Lindahl, Ulf
   Li, Jin-Ping
TI Heparin - An old drug with multiple potential targets in Covid-19
   therapy
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Letter
C1 [Lindahl, Ulf; Li, Jin-Ping] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden.
RP Li, JP (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden.
EM Jin-ping.Li@imbim.uu.se
FU Swedish Research CouncilSwedish Research Council
FX The research work of the authors is supported by the Swedish Research
   Council.
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Cassinelli G, 2020, ADV EXP MED BIOL, V1221, P493, DOI 10.1007/978-3-030-34521-1_20
   Farrugia BL, 2018, J HISTOCHEM CYTOCHEM, V66, P321, DOI 10.1369/0022155417740881
   Lillicrap D, 2020, J THROMB HAEMOST, V18, P786, DOI 10.1111/jth.14781
   LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551
   Lindahl U, 2009, INT REV CEL MOL BIO, V276, P105, DOI 10.1016/S1937-6448(09)76003-4
   Mycroft-West CJ, 2020, BIORXIV2020202002297
   Shi C, 2020, MEDRXIV2020202003282
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
NR 9
TC 11
Z9 12
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD SEP
PY 2020
VL 18
IS 9
BP 2422
EP 2424
DI 10.1111/jth.14898
EA AUG 2020
PG 3
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA NG4TN
UT WOS:000562945900001
PM 32426897
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Abbas, AM
   AbouBakr, A
   Bahaa, N
   Michael, S
   Ghobrial, M
   AbuElmagd, ME
   Ahmed, OA
   AbdelWahab, RA
   Shaltout, AS
AF Abbas, Ahmed M.
   AbouBakr, Asmaa
   Bahaa, Nermeen
   Michael, Sherry
   Ghobrial, Marco
   AbuElmagd, Mai E.
   Ahmed, Omar A.
   AbdelWahab, Radwa A.
   Shaltout, Asmaa S.
TI The effect of BCG vaccine in the era of COVID-19 pandemic
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Letter
C1 [Abbas, Ahmed M.] Assiut Univ, Fac Med, Dept Obstet & Gynecol, Assiut, Egypt.
   [Abbas, Ahmed M.; AbouBakr, Asmaa; Bahaa, Nermeen; Michael, Sherry; AbuElmagd, Mai E.] Assiut Univ, COvid19 Res, Assoc CORAUNA Grp, Assiut, Egypt.
   [AbouBakr, Asmaa; Bahaa, Nermeen; Michael, Sherry; AbuElmagd, Mai E.] Assiut Univ, Fac Med, Assiut, Egypt.
   [Ghobrial, Marco] Queen Elizabeth Univ Hosp, Glasgow, Lanark, Scotland.
   [Ahmed, Omar A.] Assiut Univ, Dept Pathol, Fac Med, Assiut, Egypt.
   [AbdelWahab, Radwa A.; Shaltout, Asmaa S.] Assiut Univ, Dept Med Microbiol & Immunol, Fac Med, Assiut, Egypt.
RP Abbas, AM (corresponding author), Assiut Univ, Women Hlth Hosp, Dept Obstet & Gynecol, Assiut 71511, Egypt.
EM bmr90@hotmail.com
RI Ahmed, Omar/ABE-8383-2020
OI Ahmed, Omar/0000-0002-5901-180X; AbuElmagd, Mai/0000-0002-6433-6844
CR Ayoub BM, 2020, PHARMAZIE, V75, P159, DOI 10.1691/ph.2020.0444
   Berg MK, 2020, MANDATED BACILLUS CA
   Covian C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02806
   Gursel M, 2020, ALLERGY, V75, P1815, DOI 10.1111/all.14345
   Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Kumar J, 2020, INDIAN PEDIATR, V57, P588
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Miyasaka M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012661
   Ozdemir C, 2020, ALLERGY, V75, P1824, DOI 10.1111/all.14344
   Redelman-Sidi G, 2020, NAT REV UROL, V17, P316, DOI 10.1038/s41585-020-0325-9
   Sharquie IK, 2020, ELECT J GEN MED, V17, pem229
   Smith SG, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00644
NR 13
TC 0
Z9 0
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD DEC
PY 2020
VL 92
IS 6
AR e12947
DI 10.1111/sji.12947
EA AUG 2020
PG 2
WC Immunology
SC Immunology
GA PA6TY
UT WOS:000562893000001
PM 32698247
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Atala, A
   Henn, A
   Lundberg, M
   Ahsan, T
   Greenberg, J
   Krukin, J
   Lynum, S
   Lutz, C
   Cetrulo, K
   Albanna, M
   Pereira, T
   Eaker, S
   Hunsberger, J
AF Atala, Anthony
   Henn, Alicia
   Lundberg, Martha
   Ahsan, Taby
   Greenberg, Jordan
   Krukin, Jeff
   Lynum, Steven
   Lutz, Cat
   Cetrulo, Kyle
   Albanna, Mohammad
   Pereira, Taciana
   Eaker, Shannon
   Hunsberger, Joshua
TI Regen med therapeutic opportunities for fightingCOVID-19
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article; Early Access
DE animal models; COVID-19; mesenchymal stromal; stem cells; organoids;
   regenerative medicine; SARS-CoV-2
ID BACTERIAL CLEARANCE; CELLS; CORONAVIRUS; COVID-19; SURVIVAL; OUTBREAK;
   DISEASE
AB This perspective from a Regenerative Medicine Manufacturing Society working group highlights regenerative medicine therapeutic opportunities for fighting COVID-19. This article addresses why SARS-CoV-2 is so different from other viruses and how regenerative medicine is poised to deliver new therapeutic opportunities to battle COVID-19. We describe animal models that depict the mechanism of action for COVID-19 and that may help identify new treatments. Additionally, organoid platforms that can recapitulate some of the physiological properties of human organ systems, such as the lungs and the heart, are discussed as potential platforms that may prove useful in rapidly screening new drugs and identifying at-risk patients. This article critically evaluates some of the promising regenerative medicine-based therapies for treating COVID-19 and presents some of the collective technologies and resources that the scientific community currently has available to confront this pandemic.
C1 [Atala, Anthony] Wake Forest Inst Regenerat Med, Winston Salem, NC USA.
   [Henn, Alicia] Biospherix, Lacona, NY USA.
   [Lundberg, Martha] NHLBI, Bethesda, MD 20892 USA.
   [Ahsan, Taby] RoosterBio, Frederick, MD USA.
   [Greenberg, Jordan] Organabio, Miami, FL USA.
   [Krukin, Jeff] Orbital Transports, Chicago, IL USA.
   [Lynum, Steven] PHC Grp, Livingston, NJ USA.
   [Lutz, Cat] Jackson Labs, Mt Desert Isl, ME USA.
   [Cetrulo, Kyle] Int Perinatal Stem Cell Soc Inc, Westport, CT USA.
   [Albanna, Mohammad] Humabiol Inc, Phoenix, AZ USA.
   [Pereira, Taciana] Allevi, Philadelphia, PA USA.
   [Eaker, Shannon] Cytiva, Marlborough, MA USA.
   [Hunsberger, Joshua] Regenerat Med Mfg Soc, Winston Salem, NC USA.
RP Hunsberger, J (corresponding author), Wake Forest Univ, Wake Forest Sch Med, Wake Forest Baptist Hlth, Wake Forest Inst Regenerat Med, 391 Technol Way, Winston Salem, NC 27101 USA.
EM joshua.hunsberger@regenmedmanufacturing.org
OI Greenberg, Jordan/0000-0002-4138-2477
FU U.S. Department of Health and Human Services; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA
FX U.S. Department of Health and Human Services; National Institutes of
   Health
CR Agarwal S, 2020, CANCER DISCOV, V10, P775, DOI 10.1158/2159-8290.CD-20-0473
   [Anonymous], 2020, REUTERS
   [Anonymous], 2020, BUSINESSWIRE
   [Anonymous], LANCET
   [Anonymous], 2020, FOC DEV CELL THER TR
   [Anonymous], ATLANTIC
   Ball RS, 2006, ILAR J, V47, P348, DOI 10.1093/ilar.47.4.348
   BioCentury, COVID 19 RES CTR INF
   CellTrials.org, 2020, COVID 19 CLIN TRIALS
   Center for Disease Control and Prevention, GET FACTS COR
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Chen YX, 2007, J EXP MED, V204, P2529, DOI 10.1084/jem.20070462
   Chinese Center for Disease Control and Prevention (China CDC), WEEKLY REPORTS
   Conarck B., 2020, MIAMI HERALD
   COVID-19 Treatment Guidelines Panel, 2019, COR DIS 2019 COVID 1
   COVID-evidence, 2020, FIND EV INT COVID 19
   Eva Garland Consulting LLC, 2020, COVID 19 FUND OPP
   GatesNotes, 2020, BLOG BILL GATES
   Horby P, 2020, N ENGL J MED
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui KPY, 2018, LANCET RESP MED, V6, P846, DOI 10.1016/S2213-2600(18)30236-4
   Johns Hopkins University of Medicine, COVID 19 DAT MOT
   Khoury M, 2020, CYTOTHERAPY
   Lakdawala SS, 2020, SCIENCE, V368, P942, DOI 10.1126/science.abc6141
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li Y, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/5847876
   Licciardi F, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-1711
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   McIntyre LA, 2018, AM J RESP CRIT CARE, V197, P337, DOI 10.1164/rccm.201705-1006OC
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mei SHJ, 2010, AM J RESP CRIT CARE, V182, P1047, DOI 10.1164/rccm.201001-0010OC
   Miao JX, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02329
   Mills RJ, 2019, CELL STEM CELL, V24, P895, DOI 10.1016/j.stem.2019.03.009
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   National Institutes of Health, NAT CTR ADV TRANSL S
   Patterson BK, 2020, ISRUPTION CCL5 RANTE
   Petrilli CM, 2020, FACTORS ASS HOSPITAL, DOI [10.1101/2020.04.08.20057794, DOI 10.1101/2020.04.08.20057794]
   Pluristem Therapeutics Inc, PLUR REP PREL DAT IT
   Purwada A, 2017, NAT PROTOC, V12, DOI 10.1038/nprot.2016.157
   Qu WC, 2020, STEM CELL TRANSL MED, V9, P1007, DOI 10.1002/sctm.20-0146
   Raciti P, 2020, MODERN PATHOL, V33, P2058, DOI 10.1038/s41379-020-0551-y
   Riegman PHJ, 2019, NEW BIOTECHNOL, V53, P35, DOI 10.1016/j.nbt.2019.06.007
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   Ronconi G, 2020, J BIOL REGUL HOMEOST
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shieber J., 2020, TECH CRUNCH     0402
   Si L, 2020, BIORXIV
   Skardal A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08879-x
   Terry Mark, 2020, BIOSPACE
   The New England Journal of Medicine, 2020, COR COVID 19 COLL
   U.S. Food and Drug Administration, 2020, COR DIS 2019 COVID 1
   U.S. Food & Drug Administration, EM US AUTH MED DEV
   US Food and Drug Administration, COR TREATM ACC PROGR
   van der Leest P, 2020, CANCERS, V12, DOI 10.3390/cancers12051222
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wahl-Jensen V, 2012, VIRUSES-BASEL, V4, P3754, DOI 10.3390/v4123754
   WHO, COR DIS COVID 19 PAN
   Wilson JW, 2007, P NATL ACAD SCI USA, V104, P16299, DOI 10.1073/pnas.0707155104
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yun HD, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111968
   Zea L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164359
   Zhang Y, 2020, ENGINEERING BEIJING
   Zhao B, 2020, PROTEIN CELL, V11, P771, DOI 10.1007/s13238-020-00718-6
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu YN, 2017, STEM CELLS DEV, V26, P1054, DOI 10.1089/scd.2016.0329
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 68
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
DI 10.1002/sctm.20-0245
EA AUG 2020
PG 9
WC Cell & Tissue Engineering
SC Cell Biology
GA NE9US
UT WOS:000562950000001
PM 32856432
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Trifiro, G
   Massari, M
   Da Cas, R
   Ippolito, FM
   Sultana, J
   Crisafulli, S
   Rossi, PG
   Marino, M
   Zorzi, M
   Bovo, E
   Leoni, O
   Ludergnani, M
   Alegiani, SS
AF Trifiro, Gianluca
   Massari, Marco
   Da Cas, Roberto
   Ippolito, Francesca Menniti
   Sultana, Janet
   Crisafulli, Salvatore
   Rossi, Paolo Giorgi
   Marino, Massimiliano
   Zorzi, Manuel
   Bovo, Emanuela
   Leoni, Olivia
   Ludergnani, Monica
   Alegiani, Stefania Spila
CA ITA-COVID-19 RAAS Inhibitor Grp
TI Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in
   Patients Hospitalised with COVID-19: A Retrospective Italian Cohort
   Study of 43,000 Patients
SO DRUG SAFETY
LA English
DT Article
ID ACE2
AB Introduction The epidemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been spreading globally, raising increasing concerns. There are several controversial hypotheses on the potentially harmful or beneficial effects of antihypertensive drugs acting on the renin-angiotensin-aldosterone system (RAAS) in coronavirus disease 2019 (COVID-19). Furthermore, there is accumulating evidence, based on several observational studies, that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) do not increase the risk of contracting SARS-CoV-2 infection. On the other hand, conflicting findings regarding the role of ACEIs/ARBs as prognosis modifiers in COVID-19 hospitalised patients have been reported. Objective The aim of this large-scale, retrospective cohort study was to investigate whether prior exposure to ACEIs and/or ARBs was associated with all-cause mortality among over 40,000 hospitalised COVID-19 patients compared with calcium channel blockers (CCBs), a potential therapeutic alternative. Methods This study was conducted using COVID-19 registries linked to claims databases from Lombardy, Veneto and Reggio Emilia (overall, 25% of Italian population). Overall, 42,926 patients hospitalised between 21 February and 21 April 2020 with a diagnosis of COVID-19 confirmed by real-time polymerase chain reaction tests were included in this study. All-cause mortality occurring in or out of hospital, as reported in the COVID-19 registry, was estimated. Using Cox models, adjusted hazard ratios (HRs) of all-cause mortality (along with 95% confidence intervals [CIs]) were estimated separately for ACEIs/ARBs and other antihypertensives versus CCBs and non-use. Results Overall, 11,205 in- and out-of-hospital deaths occurred over a median of 24 days of follow-up after hospital admission due to COVID-19. Compared with CCBs, adjusted analyses showed no difference in the risk of death among ACEI (HR 0.97, 95% CI 0.89-1.06) or ARB (HR 0.98, 95% CI 0.89-1.06) users. When non-use of antihypertensives was considered as a comparator, a modest statistically significant increase in mortality risk was observed for any antihypertensive use. However, when restricting to drugs with antihypertensive indications only, these marginal increases disappeared. Sensitivity and subgroup analyses confirmed our main findings. Conclusions ACEI/ARB use is not associated with either an increased or decreased risk of all-cause mortality, compared with CCB use, in the largest cohort of hospitalised COVID-19 patients exposed to these drugs studied to date. The use of these drugs therefore does not affect the prognosis of COVID-19. This finding strengthens recommendations of international regulatory agencies about not withdrawing/switching ACEI/ARB treatments to modify COVID-19 prognosis.
C1 [Trifiro, Gianluca; Sultana, Janet; Crisafulli, Salvatore] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy.
   [Trifiro, Gianluca; Sultana, Janet; Crisafulli, Salvatore] Italian Soc Pharmacol, Milan, Italy.
   [Massari, Marco; Da Cas, Roberto; Ippolito, Francesca Menniti; Alegiani, Stefania Spila] Ist Super Sanita, Pharmacoepidemiol Unit, Natl Ctr Drug Res & Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.
   [Rossi, Paolo Giorgi; Marino, Massimiliano] IRCCS, Azienda Unita Sanitaria Locale, Reggio Emilia, Italy.
   [Zorzi, Manuel; Bovo, Emanuela] Azienda Zero, Dept Hlth Veneto Reg, Padua, Italy.
   [Leoni, Olivia; Ludergnani, Monica] Epidemiol Observ, Dept Hlth Lombardy Reg, Milan, Italy.
RP Alegiani, SS (corresponding author), Ist Super Sanita, Pharmacoepidemiol Unit, Natl Ctr Drug Res & Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.
EM stefania.spila@iss.it
RI Rossi, Paolo Giorgi/K-6367-2016
OI Rossi, Paolo Giorgi/0000-0001-9703-2460
CR [Anonymous], 2020, CLIN INFECT DIS, V71, P899, DOI 10.1093/cid/ciaa492
   Conversano A, 2020, HYPERTENSION, V76, pe10, DOI [10.1161/HYPERTENSIONAHA.120.15312, DOI 10.1161/HYPERTENSIONAHA.120.15312]
   de Abajo FJ, 2020, LANCET, V395, P1705, DOI 10.1016/S0140-6736(20)31030-8
   European Centre for Disease Prevention and Control, 2020, LAT SIT UPD EP CURV
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC
   Ferrario CM, 2005, KIDNEY INT, V68, P2189, DOI 10.1111/j.1523-1755.2005.00675.x
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Fosbol EL, 2020, JAMA-J AM MED ASSOC, V324, P168, DOI 10.1001/jama.2020.11301
   Gao C, 2020, EUR HEART J, V41, P2058, DOI 10.1093/eurheartj/ehaa433
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Ip Andrew KParikh, 2020, HYPERTENSION RENIN A, DOI [10.1101/2020.04.24.20077388, DOI 10.1101/2020.04.24.20077388, 10.1101/2020.04.24.20077388.]
   Italian Ministry of Health, 2020, COVID 19 SIT IT
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Pirola CJ, 2020, J INFECTION, V81, P276, DOI 10.1016/j.jinf.2020.05.052
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Rubin EJ, 2020, NEW ENGL J MED, V382, P2464, DOI 10.1056/NEJMe2020822
   Selcuk M, 2020, CLIN EXP HYPERTENS, V42, P738, DOI 10.1080/10641963.2020.1783549
   Trifiro G, 2019, DRUG SAFETY, V42, P347, DOI 10.1007/s40264-018-0732-5
   Watkins J, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m810
   Yang G, 2020, HYPERTENSION, V76, P51, DOI 10.1161/HYPERTENSIONAHA.120.15143
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang X, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104927
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 30
TC 3
Z9 3
U1 2
U2 2
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD DEC
PY 2020
VL 43
IS 12
BP 1297
EP 1308
DI 10.1007/s40264-020-00994-5
EA AUG 2020
PG 12
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA OW1DX
UT WOS:000563241000001
PM 32852721
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Santoliquido, A
   Porfidia, A
   Nesci, A
   De Matteis, G
   Marrone, G
   Porceddu, E
   Camma, G
   Giarretta, I
   Fantoni, M
   Landi, F
   Gasbarrini, A
   Pola, R
   D'Alfonso, ME
   Lo Monaco, MR
AF Santoliquido, Angelo
   Porfidia, Angelo
   Nesci, Antonio
   De Matteis, Giuseppe
   Marrone, Giuseppe
   Porceddu, Enrica
   Camma, Giulia
   Giarretta, Igor
   Fantoni, Massimo
   Landi, Francesco
   Gasbarrini, Antonio
   Pola, Roberto
   D'Alfonso, Maria E.
   Lo Monaco, Maria R.
CA GEMELLI AGAINST COVID-19 Grp
TI Incidence of deep vein thrombosis among non-ICU patients hospitalized
   for COVID-19 despite pharmacological thromboprophylaxis
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE COVID-19; deep vein thrombosis; thromboprophylaxis; venous
   thromboembolism
ID MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM; PREVENTION;
   ENOXAPARIN; PLACEBO
AB Background A remarkably high incidence of venous thromboembolism (VTE) has been reported among critically ill patients with COVID-19 assisted in the intensive care unit (ICU). However, VTE burden among non-ICU patients hospitalized for COVID-19 that receive guideline-recommended thromboprophylaxis is unknown. Objectives To determine the incidence of VTE among non-ICU patients hospitalized for COVID-19 that receive pharmacological thromboprophylaxis. Methods We performed a systematic screening for the diagnosis of deep vein thrombosis (DVT) by lower limb vein compression ultrasonography (CUS) in consecutive non-ICU patients hospitalized for COVID-19, independent of the presence of signs or symptoms of DVT. All patients were receiving pharmacological thromboprophylaxis with either enoxaparin or fondaparinux. Results The population that we screened consisted of 84 consecutive patients, with a mean age of 67.6 +/- 13.5 years and a mean Padua Prediction Score of 5.1 +/- 1.6. Seventy-two patients (85.7%) had respiratory insufficiency, required oxygen supplementation, and had reduced mobility or were bedridden. In this cohort, we found 10 cases of DVT, with an incidence of 11.9% (95% confidence interval [CI] 4.98-18.82). Of these, 2 were proximal DVT (incidence rate 2.4%, 95% CI -0.87-5.67) and 8 were distal DVT (incidence rate 9.5%, 95% CI 3.23-5.77). Significant differences between subjects with and without DVT were D-dimer > 3000 mu g/L (P < .05), current or previous cancer (P < .05), and need of high flow nasal oxygen therapy and/or non-invasive ventilation (P < .01). Conclusions DVT may occur among non-ICU patients hospitalized for COVID-19, despite guideline-recommended thromboprophylaxis.
C1 [Santoliquido, Angelo; Nesci, Antonio; Pola, Roberto] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Dept Cardiovasc Sci, Sch Med, Rome, Italy.
   [Porfidia, Angelo; De Matteis, Giuseppe] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Div Internal Med, Sch Med, Rome, Italy.
   [Marrone, Giuseppe; Porceddu, Enrica; Camma, Giulia; Giarretta, Igor; Gasbarrini, Antonio] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Dept Translat Med & Surg, Sch Med, Rome, Italy.
   [Fantoni, Massimo] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Div Infect Dis, Sch Med, Rome, Italy.
   [Landi, Francesco] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Div Geriatr, Sch Med, Rome, Italy.
RP Pola, R (corresponding author), Policlin A Gemelli, Ist Med Interna & Geriatria, 9th Floor,C Wing,Room C907,Lgo A Gemelli 8, I-00168 Rome, Italy.
EM roberto.pola@unicatt.it
RI caruso, cristiano/AAR-9502-2020; Porfidia, Angelo/U-1558-2019; sarnari,
   caterina/AAX-5886-2020; Miele, Luca/C-2255-2015; De matteis,
   Giuseppe/AAY-6427-2020; Perniola, Simone/AAU-7158-2020; Rumi,
   Gabriele/M-8291-2018
OI caruso, cristiano/0000-0001-7631-029X; Porfidia,
   Angelo/0000-0003-4915-2892; Miele, Luca/0000-0003-3464-0068; De matteis,
   Giuseppe/0000-0003-2982-3951; Perniola, Simone/0000-0001-6918-4731;
   Giarretta, Igor/0000-0001-5380-0843; Rumi, Gabriele/0000-0001-5990-9129;
   Vetrone, Lorenzo Maria/0000-0002-9845-0004; Natalello,
   Gerlando/0000-0001-7333-371X; Bruno, Dario/0000-0002-6647-9208
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Agarwal PP, 2009, AM J ROENTGENOL, V193, P1488, DOI 10.2214/AJR.09.3599
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Avnon LS, 2015, EUR J INTERN MED, V26, P596, DOI 10.1016/j.ejim.2015.08.017
   Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x
   Bunce PE, 2011, CLIN INFECT DIS, V52, pE14, DOI 10.1093/cid/ciq125
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Demelo-Rodriguez P, 2020, THROMB RES, V192, P23, DOI 10.1016/j.thromres.2020.05.018
   Harenberg J, 1996, HAEMOSTASIS, V26, P127
   Harms PW, 2010, AM J CLIN PATHOL, V134, P27, DOI 10.1309/AJCP35KOZSAVNQZW
   Helmy YA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041225
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   KELLER F, 1995, THROMB HAEMOSTASIS, V73, P1106
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Porfidia A, 2020, J THROMB THROMBOLYS, V50, P68, DOI 10.1007/s11239-020-02125-4
   Righini M, 2009, J THROMB HAEMOST, V7, P406, DOI 10.1111/j.1538-7836.2008.03264.x
   Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103
   Schaller T, 2020, JAMA-J AM MED ASSOC, V323, P2518, DOI 10.1001/jama.2020.8907
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Wichmann D, 2020, ANN INTERN MED, V6, P20
   Yi XH, 2010, AM J RESP CRIT CARE, V182, P436
   Zhai ZG, 2020, THROMB HAEMOSTASIS, V120, P937, DOI 10.1055/s-0040-1710019
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 25
TC 10
Z9 10
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD SEP
PY 2020
VL 18
IS 9
BP 2358
EP 2363
DI 10.1111/jth.14992
EA AUG 2020
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA NG4TN
UT WOS:000562869500001
PM 32633068
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Westmark, CJ
   Kiso, M
   Halfmann, P
   Westmark, PR
   Kawaoka, Y
AF Westmark, Cara J.
   Kiso, Maki
   Halfmann, Peter
   Westmark, Pamela R.
   Kawaoka, Yoshihiro
TI Repurposing Fragile X Drugs to Inhibit SARS-CoV-2 Viral Reproduction
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE coronavirus; COVID-19; fragile X mental retardation protein;
   metabotropic glutamate receptor 5; protein synthesis
ID MENTAL-RETARDATION PROTEIN; IMMUNE-MEDIATED DISORDERS;
   GLUTAMATE-RECEPTOR 5; MESSENGER-RNAS; MOUSE MODEL; IDENTIFICATION; FMR1;
   CORONAVIRUSES; TRANSLATION; PROFILES
AB The COVID-19 pandemic is a global health crisis that requires the application of interdisciplinary research to address numerous knowledge gaps including molecular strategies to prevent viral reproduction in affected individuals. In response to the Frontiers Research Topic, "Coronavirus disease (COVID-19): Pathophysiology, Epidemiology, Clinical Management, and Public Health Response," this Hypothesis article proposes a novel therapeutic strategy to repurpose metabotropic glutamate 5 receptor (mGluR(5)) inhibitors to interfere with viral hijacking of the host protein synthesis machinery. We review pertinent background on SARS-CoV-2, fragile X syndrome (FXS) and metabotropic glutamate receptor 5 (mGluR(5)) and provide a mechanistic-based hypothesis and preliminary data to support testing mGluR(5)inhibitors in COVID-19 research.
C1 [Westmark, Cara J.; Westmark, Pamela R.] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA.
   [Kiso, Maki; Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol, Tokyo, Japan.
   [Halfmann, Peter; Kawaoka, Yoshihiro] Univ Wisconsin, Influenza Res Inst, Sch Vet Med, Dept Pathobiol Sci, Madison, WI USA.
   [Kawaoka, Yoshihiro] Univ Tokyo, Int Res Ctr Infect Dis, Inst Med Sci, Dept Special Pathogens, Tokyo, Japan.
RP Westmark, CJ (corresponding author), Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA.
EM westmark@wisc.edu
FU USDAUnited States Department of Agriculture (USDA) [2018-67001-28266];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R03 HD097067]; Center for Research on
   Influenza Pathogenesis - National Institute of Allergy and Infectious
   Diseases [HHSN272201400008C]; Japan Agency for Medical Research and
   Development (AMED)Japan Agency for Medical Research and Development
   (AMED) [19fk0108113]
FX CW was funded by USDA grant number 2018-67001-28266 and NIH grant number
   R03 HD097067. YK was funded by a grant (HHSN272201400008C) from the
   Center for Research on Influenza Pathogenesis, funded by the National
   Institute of Allergy and Infectious Diseases, and by a Research Program
   on Emerging and Re-emerging Infectious Disease grant (19fk0108113) from
   the Japan Agency for Medical Research and Development (AMED).
CR Adinolfi S, 1999, RNA, V5, P1248, DOI 10.1017/S1355838299990647
   Agostini F, 2013, BIOINFORMATICS, V29, P2928, DOI 10.1093/bioinformatics/btt495
   Ashwood P, 2010, BRAIN BEHAV IMMUN, V24, P898, DOI 10.1016/j.bbi.2010.01.008
   Bagni C, 2005, NAT REV NEUROSCI, V6, P376, DOI 10.1038/nrn1667
   Bear MF, 2004, TRENDS NEUROSCI, V27, P370, DOI 10.1016/j.tins.2004.04.009
   Bellucci M, 2011, NAT METHODS, V8, P444, DOI 10.1038/nmeth.1611
   Berry-Kravis EM, 2018, NAT REV DRUG DISCOV, V17, P280, DOI 10.1038/nrd.2017.221
   Berthoux L, 2020, VIROL SIN, V35, P363, DOI 10.1007/s12250-020-00208-3
   Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2
   Careaga M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-110
   Careaga M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094475
   Cirillo D, 2013, RNA, V19, P129, DOI 10.1261/rna.034777.112
   Darnell JC, 2005, GENE DEV, V19, P903, DOI 10.1101/gad.1276805
   Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9
   Darnell JC, 2011, CELL, V146, P247, DOI 10.1016/j.cell.2011.06.013
   Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Feng Y, 1997, J NEUROSCI, V17, P1539
   Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X
   Gravius A, 2010, CURR TOP MED CHEM, V10, P187, DOI 10.2174/156802610790411018
   Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009
   Hagerman R. J., 2002, PHYS BEHAV PHENOTYPE
   Hanak TJ, 2019, EXP NEUROL, V311, P194, DOI 10.1016/j.expneurol.2018.10.006
   He JH, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040428
   Hodges SL, 2020, PHYSIOL BEHAV, V215, DOI 10.1016/j.physbeh.2019.112776
   Irigoyen N, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005473
   Jalnapurkar I, 2015, AM J MED GENET A, V167, P190, DOI 10.1002/ajmg.a.36748
   Kelly E, 2018, NEUROPSYCHOPHARMACOL, V43, P1457, DOI 10.1038/npp.2017.295
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Laggerbauer B, 2001, HUM MOL GENET, V10, P329, DOI 10.1093/hmg/10.4.329
   Lai AS, 2020, TRAFFIC, V21, P454, DOI 10.1111/tra.12733
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li ZZ, 2001, NUCLEIC ACIDS RES, V29, P2276, DOI 10.1093/nar/29.11.2276
   Lindemann L, 2011, J PHARMACOL EXP THER, V339, P474, DOI 10.1124/jpet.111.185660
   Lisik MZ, 2015, NEURODEGENER DIS, V15, P45, DOI 10.1159/000369215
   Maranon DG, 2020, WIRES RNA, V11, DOI 10.1002/wrna.1614
   Mazeaud C, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00595
   Mazroui R, 2002, HUM MOL GENET, V11, P3007, DOI 10.1093/hmg/11.24.3007
   Michalon A, 2012, NEURON, V74, P49, DOI 10.1016/j.neuron.2012.03.009
   Miyashiro KY, 2003, NEURON, V37, P417, DOI 10.1016/S0896-6273(03)00034-5
   O'Connor RM, 2017, J CELL BIOL, V216, P595, DOI 10.1083/jcb.201607093
   Osterweil EK, 2010, J NEUROSCI, V30, P15616, DOI 10.1523/JNEUROSCI.3888-10.2010
   Scharf SH, 2015, CURR OPIN PHARMACOL, V20, P124, DOI 10.1016/j.coph.2014.11.004
   Shah A, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-52
   SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1
   Soto-Acosta R, 2018, ELIFE, V7, DOI 10.7554/eLife.39023
   Stoppel L. J., 2017, FRAGILE X SYNDROME G
   Taha MS, 2020, FEBS J, DOI 10.1111/febs.15443
   Tison F, 2016, MOVEMENT DISORD, V31, P1373, DOI 10.1002/mds.26659
   Van Dijck A, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01715-2
   VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395
   Westmark C., 2014, METABOTROPIC GLUTAMA
   Winarni TI, 2012, AM J MED GENET A, V158A, P2473, DOI 10.1002/ajmg.a.35569
   Wu HY, 2010, P NATL ACAD SCI USA, V107, P12257, DOI 10.1073/pnas.1000378107
   Yu KH, 2020, EUR J NEUROL, V27, P590, DOI 10.1111/ene.14146
   Yuskaitis CJ, 2010, BBA-MOL BASIS DIS, V1802, P1006, DOI 10.1016/j.bbadis.2010.06.015
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 60
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD AUG 26
PY 2020
VL 8
AR 856
DI 10.3389/fcell.2020.00856
PG 10
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA NQ0TK
UT WOS:000570581000001
PM 32984339
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Thames, AH
   Wolniak, KL
   Stupp, SI
   Jewett, MC
AF Thames, Ariel H.
   Wolniak, Kristy L.
   Stupp, Samuel, I
   Jewett, Michael C.
TI Principles Learned from the International Race to Develop a Safe and
   Effective COVID-19 Vaccine
SO ACS CENTRAL SCIENCE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS SARS-COV; ANTIBODY-DEPENDENT
   ENHANCEMENT; RECEPTOR-BINDING DOMAIN; T-CELL RESPONSES; NUCLEOCAPSID
   PROTEIN; VIRUS; INFECTION; PROTECTION; PNEUMONIA
AB Vaccines against COVID-19 have the potential to protect people before they are exposed to the infective form of the virus. However, because of the involvement of pathogenic immune processes in many severe presentations of COVID-19, eliciting an immune response with a vaccine must strike a delicate balance to achieve viral clearance without also inducing immune-mediated harm. This Outlook synthesizes current laboratory findings to define which parts of the immune system help with recovery from and protection against the virus and which can lead to adverse outcomes. To inform our understanding, we analyze research about the immune mechanisms implicated in SARS-CoV, from the 2003 outbreak, and SARS-CoV-2, the virus causing COVID-19. The impact of how innate immunity, humoral immunity, and cell-mediated immunity play a role in a harmful versus helpful response is discussed, establishing principles to guide the development and evaluation of a safe but effective COVID-19 vaccine. The principles derived include (i) targeting the appropriate specificity and effector function of the humoral response, (ii) eliciting a T cell response, especially a cytotoxic T cell response, to achieve safe, yet effective, immune protection from COVID-19, and (iii) monitoring for the possibility of acute lung injury during SARS-CoV-2 infection post-vaccination in preclinical and clinical studies. These principles can not only guide efforts toward a safe and effective COVID-19 vaccine, but also the development of effective vaccines for viral pandemics to come.
C1 [Thames, Ariel H.; Jewett, Michael C.] Northwestern Univ, Med Scientist Training Program, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Thames, Ariel H.] Northwestern Univ, Ctr Synthet Biol, Evanston, IL 60208 USA.
   [Thames, Ariel H.] Northwestern Univ, Interdisciplinary Biol Sci Program, Evanston, IL 60208 USA.
   [Wolniak, Kristy L.] Northwestern Univ, Dept Pathol, Div Hematopathol, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Stupp, Samuel, I] Northwestern Univ, Dept Chem, Dept Biomed Engn, Simpson Querrey Inst, Chicago, IL 60611 USA.
   [Stupp, Samuel, I] Northwestern Univ, Dept Mat Sci & Engn, Chicago, IL 60611 USA.
   [Stupp, Samuel, I] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Jewett, Michael C.] Northwestern Univ, Interdisciplinary Biol Sci Program, Ctr Synthet Biol, Simpson Querrey Inst, Evanston, IL 60208 USA.
   [Jewett, Michael C.] Northwestern Univ, Dept Chem & Biol Engn, Evanston, IL 60208 USA.
RP Jewett, MC (corresponding author), Northwestern Univ, Med Scientist Training Program, Feinberg Sch Med, Chicago, IL 60611 USA.; Jewett, MC (corresponding author), Northwestern Univ, Interdisciplinary Biol Sci Program, Ctr Synthet Biol, Simpson Querrey Inst, Evanston, IL 60208 USA.; Jewett, MC (corresponding author), Northwestern Univ, Dept Chem & Biol Engn, Evanston, IL 60208 USA.
EM m-jewett@northwestern.edu
RI Jewett, Michael C/E-3506-2010; Stupp, Samuel/B-6737-2009
OI Thames, Ariel/0000-0001-5418-6048; Jewett, Michael/0000-0003-2948-6211
FU Defense Threat Reduction AgencyUnited States Department of
   DefenseDefense Threat Reduction Agency [HDTRA1-15-10052/P00001];
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1U19AI142780-01]
FX We would like the acknowledge the Defense Threat Reduction Agency Grant
   HDTRA1-15-10052/P00001, the National Institutes of Health Grant
   1U19AI142780-01, the David and Lucile Packard Foundation, the Camille
   Dreyfus TeacherScholar Program, and the Center for Regenerative
   Nanomedicine at the Simpson Querrey Institute. We also thank Ashty Karim
   for figure development, and we are grateful to some colleagues who
   wished to remain anonymous and the reviewers for their input during
   review.
CR Cao Y., 2020, CELL, V12
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chen X., 2020, RESTORATION LEUKOMON, DOI [10.1101/2020.03.03.20030437, DOI 10.1101/2020.03.03.20030437]
   Clay C, 2012, J VIROL, V86, P4234, DOI 10.1128/JVI.06791-11
   Corbett K. S., 2020, BIORXIV
   Dahlke C, 2020, DISTINCT EARLY IGA P, DOI [10.1101/2020.04.14.20059733, DOI 10.1101/2020.04.14.20059733]
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Du LY, 2008, J IMMUNOL, V180, P948, DOI 10.4049/jimmunol.180.2.948
   Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Duan K, 2020, FEASIBILITY CONVALES
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0
   Haslwanter D, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006643
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang J., 2020, LANCET INFECT DIS
   Jiang H.-W., 2020, GLOBAL PROFILING SAR, DOI [10.1101/2020.03.20.20039495, DOI 10.1101/2020.03.20.20039495]
   Kim KD, 2007, NAT MED, V13, P1248, DOI 10.1038/nm1633
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   OCHIAI H, 1992, J MED VIROL, V36, P217, DOI 10.1002/jmv.1890360312
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shi W, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3546089, DOI 10.2139/SSRN.3546089, 10.2139/ssrn.3546089.]
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Song C. Y., 2020, COVID 19 EARLY WARNI, V2020, DOI [10.1101/ 2020.03.05.20031906., DOI 10.1101/2020.03.05.20031906.]
   Takada A, 2003, REV MED VIROL, V13, P387, DOI 10.1002/rmv.405
   Takada A, 2003, J VIROL, V77, P7539, DOI 10.1128/JVI.77.13.7539-7544.2003
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195
   Venkatraman N, 2019, J INFECT DIS, V219, P1187, DOI 10.1093/infdis/jiy639
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Xu Z., 2020, LANCET INFECT DIS
   Yang LT, 2006, CLIN IMMUNOL, V120, P171, DOI 10.1016/j.clim.2006.05.002
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zheng Y, 2020, STUDY LYMPHOCYTE CHA, DOI [10.1101/2020.02.19.20024885, DOI 10.1101/2020.02.19.20024885]
   Zost S.J., 2020, RAPID ISOLATION PROF
NR 45
TC 1
Z9 1
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2374-7943
EI 2374-7951
J9 ACS CENTRAL SCI
JI ACS Central Sci.
PD AUG 26
PY 2020
VL 6
IS 8
BP 1341
EP 1347
DI 10.1021/acscentsci.0c00644
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA NK3XY
UT WOS:000566668400013
PM 32868999
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Maskin, LP
   Olarte, GL
   Palizas, F
   Velo, AE
   Lurbet, MF
   Bonelli, I
   Baredes, ND
   Rodriguez, PO
AF Patricio Maskin, Luis
   Leonardo Olarte, Gabriel
   Palizas Jr, Fernando
   Velo, Agostina E.
   Fernanda Lurbet, Maria
   Bonelli, Ignacio
   Baredes, Natalio D.
   Oscar Rodriguez, Pablo
TI High dose dexamethasone treatment for Acute Respiratory Distress
   Syndrome secondary to COVID-19: a structured summary of a study protocol
   for a randomised controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Dexamethasone; Acute Respiratory Distress Syndrome; Randomised
   controlled trial; protocol; Steroids
AB ObjectivesThe aim of this study is to explore the effectiveness and safety of high dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to SARS-Cov-2 pneumonia.Trial designMulticentre, randomized clinical trial, controlled, open label, parallel group, to evaluate the effectiveness and safety of high dose dexamethasone in adult patients with confirmed COVID-19, with Acute Respiratory Distress Syndrome.ParticipantsWe will include patients with SARS-Cov-2 pneumonia who develop acute respiratory distress syndrome, in several intensive care units (ICU) in Buenos Aires, Argentina (CEMIC, Clinica Bazterrica, Sanatorio Sagrado Corazon)Inclusion criteria: Men and women, age >= 18 years old.Confirmed diagnosis of SARS-CoV-2 infection, by RT-PCR.Diagnosis of Acute Respiratory Distress Syndrome (hypoxemic respiratory failure not explained by cardiac disease + PaO2/FiO2 ratio < 300 with a Positive End-Expiratory Pressure <greater than or equal to> 5 cm H2O + bilateral pulmonary infiltrates)Length of mechanical ventilation of at least 72 hoursInformed consent (next of kin / legal guardian)Exclusion criteria: Pregnant or breast-feeding women.Terminal disease (advanced cancer; under palliative care; cardiovascular, respiratory, or renal disease with a life expectancy less <= 1 year).Therapeutic limitation (advance directives or do not resuscitate order)Severe immunosuppression (HIV infection, long-term use of immunosuppressive agents, active cancer).Patients under chronic treatment with glucocorticoids for other diseases (>= 8 mg prednisone, or equivalent)Participation in another randomized clinical trial.Intervention and comparatorEligible patients will be randomized to receive standard ICU patient care (group 1) or standard ICU patient care plus high dose dexamethasone (group 2). Group 1: dexamethasone up to 6 mg/24 hours for up to 10 days + ventilatory, hemodynamic, nutritional, and antimicrobial support according to international guidelines.Group 2: dexamethasone 16 mg/24 hours for 5 days followed by dexamethasone 8 mg/24 hours for 5 days + ventilatory, hemodynamic, nutritional, and antimicrobial support according to international guidelines.Main outcomeThe main result is ventilator-free days at 28 days (Days without ventilator support in the first 28 days following randomization). Secondary outcomes are 28-days and 90-days mortality, frequency of nosocomial infections in the first 28 days after randomization, Sequential Organ Failure Assessment (SOFA) score variation and prone position in the first 10-days, viral shedding 28-days after randomization, and delirium and muscle weakness at ICU discharge.RandomisationTreatment will be assigned according to site stratified randomization by permuted random blocks sequence 1:1 generated with a table in R language concealed in a randomization tool in REDCap (Research Electronic Data CAPture) platform.Blinding (masking)This is an open trial, so no masking of treatment assignment will be used.Numbers to be randomised (sample size)Assuming a 3 days difference in ventilator-free days between treatment groups, with a mean of 9 days, and a standard deviation of 9 days; the necessary sample size would be 284 subjects (142 per group), with a power of 80% and a two-tailed alpha error of 0.05.Trial StatusThe protocol with code 1264, version 3.0 on date: May 13, 2020 is approved by the local Ethics Committee. The trial is in the recruitment phase. Recruitment began May 22, 2020 and is anticipated to be complete by the end of December 2021.
   Trial registrationThe trial was registered under the title "Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial" with ClinicalTrials number NCT04395105, https://clinicaltrials.gov/ct2/show/NCT04395105, registered on 20 May 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Patricio Maskin, Luis; Velo, Agostina E.; Fernanda Lurbet, Maria; Bonelli, Ignacio; Oscar Rodriguez, Pablo] CEMIC, Intens Care Unit, Buenos Aires, DF, Argentina.
   [Patricio Maskin, Luis; Oscar Rodriguez, Pablo] CEMIC, Pulm Sect, Internal Med Dept, Buenos Aires, DF, Argentina.
   [Leonardo Olarte, Gabriel; Baredes, Natalio D.] Sanatorio Sagrad Corazon, Intens Care Unit, Buenos Aires, DF, Argentina.
   [Palizas Jr, Fernando] Clin Bazterr, Intens Care Unit, Buenos Aires, DF, Argentina.
RP Maskin, LP (corresponding author), CEMIC, Intens Care Unit, Buenos Aires, DF, Argentina.; Maskin, LP (corresponding author), CEMIC, Pulm Sect, Internal Med Dept, Buenos Aires, DF, Argentina.
EM pmaskin@cemic.edu.ar; prodriguez@cemic.edu.ar
NR 0
TC 0
Z9 0
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 26
PY 2020
VL 21
IS 1
AR 743
DI 10.1186/s13063-020-04646-y
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NK9TV
UT WOS:000567071800003
PM 32843098
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Johansson, PI
   Bestle, M
   Soe-Jensen, P
   Kristiansen, KT
   Stensballe, J
   Clausen, NE
   Perner, A
AF Johansson, Par Ingemar
   Bestle, Morten
   Soe-Jensen, Peter
   Kristiansen, Klaus Tjelle
   Stensballe, Jakob
   Clausen, Niels Erikstrup
   Perner, Anders
TI The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min
   for 72 hours compared to placebo in mechanically ventilated patients
   with COVID-19: A structured summary of a study protocol for a randomized
   controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Randomised controlled trial; protocol; mechanical ventilation;
   endotheliopathy; thrombomodulin; prostacyclin
AB Objectives: To investigate the effect of continuous infusion of the potential endothelial cytoprotective agent prostacyclin (Iloprost) 1 ng/kg/min vs. placebo for 72 hours on pulmonary endotheliopathy in mechanically ventilated COVID-19 patients.
   Trial design: A multicenter, randomized (1:1, active: placebo), blinded, parallel group exploratory trial
   Participants: Inclusion criteria are: Adult patients (>18 years); Confirmed COVID-19 infection; Need for mechanical interventions; Endothelial biomarker soluble thrombomodulin >4ng/ml. Exclusion criteria: Withdrawal from active therapy; Pregnancy (non-pregnancy confirmed by patient being postmenopausal (age 60 or above) or having a negative urine- or plasma-hCG); Known hypersensitivity to iloprost or to any of the other ingredients; Previously included in this trial or a prostacyclin trial within 30 days; Consent cannot be obtained; Life-threatening bleeding defined by the treating physician; Known severe heart failure (NYHA class IV); Suspected acute coronary syndrome The study is conducted at five intensive care units in the Capital Region of Denmark at Rigshospitalet, Herlev Hospital, Hvidovre Hospital, Bispebjerg Hospital, Nordsj AE llands Hospital.
   Intervention and comparator: The patients are randomized to 72-hours continuous infusion of either prostacyclin (Iloprost/Ilomedin) at a dose of 1 ng/kg/min or Placebo (normal saline).
   Main outcomes: Primary endpoint: Days alive without mechanical ventilation in the intensive care units within 28 days
   Randomisation: The randomisation sequence is performed in permuted blocks of variable sizes stratified for trial site using centralised, concealed allocation. The randomisation sequence is generated 1:1 (active/placebo) using the online randomisation software 'Sealed Envelope' (). Once generated the randomisation sequence is formatted and uploaded into Research Electronic Data Capture system (REDCap) to facilitate centralised, web-based allocation according to local written instruction.
   Blinding (masking): The following are blinded: all clinicians, patients, investigators, and those assessing the outcomes including the statisticians.
   Numbers to be randomised (sample size): Forty patients are planned to be randomized to each group, with a total sample size of 80 patients.
   Trial Status: Protocol version 1.4 dated May 25, 2020. Recruitment is ongoing. The recruitment was started June 15, 2020 and the anticipated finish of recruitment is February 28, 2021 with 90 days follow up hereafter.
   Trial registration: Trial registration at clinicaltrialregisters.eu; EudraCT no. 2020-001296-33 on 3 April 2020 and at ClinicalTrials.gov Identifier: NCT04420741 on 9 June 2020
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file1).In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Johansson, Par Ingemar] Rigshosp, Dept Clin Immunol, Copenhagen, Denmark.
   [Bestle, Morten] Nordsjaellands Hosp, Dept Intens Care, Hillerod, Denmark.
   [Soe-Jensen, Peter] Herlev Hosp, Dept Intens Care, Herlev, Denmark.
   [Kristiansen, Klaus Tjelle] Hvidovre Univ Hosp, Dept Intens Care, Hvidovre, Denmark.
   [Stensballe, Jakob] Rigshosp, Dept Anaesthesiol, Copenhagen, Denmark.
   [Clausen, Niels Erikstrup] Bispebjerg Hosp, Dept Intens Care, Copenhagen, Denmark.
   [Perner, Anders] Rigshosp, Dept Intens Care 4131, Copenhagen, Denmark.
RP Johansson, PI (corresponding author), Rigshosp, Dept Clin Immunol, Copenhagen, Denmark.
EM per.johansson@regionh.dk
OI Johansson, Par Ingemar/0000-0001-9778-5964
FU Innovation Fund Denmark Grand Solutions [0208-00015B]
FX The trial has received funding from Innovation Fund Denmark Grand
   Solutions no. 0208-00015B. The funder has no role in the design of the
   study and collection, analysis, and interpretation of data and in
   writing the manuscript.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 26
PY 2020
VL 21
IS 1
AR 746
DI 10.1186/s13063-020-04696-2
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NK9UE
UT WOS:000567072700002
PM 32847626
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Faqihi, F
   Alharthy, A
   Alshaya, R
   Papanikolaou, J
   Kutsogiannis, DJ
   Brindley, PG
   Karakitsos, D
AF Faqihi, Fahad
   Alharthy, Abdulrahman
   Alshaya, Rayan
   Papanikolaou, John
   Kutsogiannis, Demetrios J.
   Brindley, Peter G.
   Karakitsos, Dimitrios
TI Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with
   cytokine release syndrome and resolution following therapeutic plasma
   exchange: a case-report
SO BMC CARDIOVASCULAR DISORDERS
LA English
DT Article
DE COVID-19; Reverse takotsubo cardiomyopathy; Echocardiography;
   Cardiogenic shock; Cytokine release syndrome; Therapeutic plasma
   exchange; Case-report
ID TAKO-TSUBO SYNDROME; SUBARACHNOID HEMORRHAGE; SEPTIC SHOCK; OUTCOMES;
   ECHOCARDIOGRAPHY; MORTALITY; ESMOLOL
AB Background Fulminant (life-threatening) COVID-19 can be associated with acute respiratory failure (ARF), multi-system organ failure and cytokine release syndrome (CRS). We present a rare case of fulminant COVID-19 associated with reverse-takotsubo-cardiomyopathy (RTCC) that improved with therapeutic plasma exchange (TPE). Case presentation A 40 year old previous healthy male presented in the emergency room with 4 days of dry cough, chest pain, myalgias and fatigue. He progressed to ARF requiring high-flow-nasal-cannula (flow: 60 L/minute, fraction of inspired oxygen: 40%). Real-Time-Polymerase-Chain-Reaction (RT-PCR) assay confirmed COVID-19 and chest X-ray showed interstitial infiltrates. Biochemistry suggested CRS: increased C-reactive protein, lactate dehydrogenase, ferritin and interleukin-6. Renal function was normal but lactate levels were elevated. Electrocardiogram demonstrated non-specific changes and troponin-I levels were slightly elevated. Echocardiography revealed left ventricular (LV) basal and midventricular akinesia with apex sparing (LV ejection fraction: 30%) and depressed cardiac output (2.8 L/min) consistent with a rare variant of stress-related cardiomyopathy: RTCC. His ratio of partial arterial pressure of oxygen to fractional inspired concentration of oxygen was < 120. He was admitted to the intensive care unit (ICU) for mechanical ventilation and vasopressors, plus antivirals (lopinavir/ritonavir), and prophylactic anticoagulation. Infusion of milrinone failed to improve his cardiogenic shock (day-1). Thus, rescue TPE was performed using the Spectra Optia (TM) Apheresis System equipped with the Depuro D2000 Adsorption Cartridge (Terumo BCT Inc., USA) without protective antibodies. Over 5 days he received daily TPE (each lasting 4 hours). His lactate levels, oxygenation, and LV function normalized and he was weaned off vasopressors. His inflammation markers improved, and he was extubated on day-7. RT-PCR was negative on day-17. He was discharged to home isolation in good condition. Conclusion Stress-cardiomyopathy may complicate the course of fulminant COVID-19 with associated CRS. If inotropic therapy fails, TPE without protective antibodies may help rescue the critically ill patient.
C1 [Faqihi, Fahad; Alharthy, Abdulrahman; Alshaya, Rayan; Papanikolaou, John; Karakitsos, Dimitrios] King Saud Med City, Crit Care Dept, Riyadh, Saudi Arabia.
   [Faqihi, Fahad] Al Imam Abdulrahman Al Feisal Hosp, Crit Care Dept, Riyadh, Saudi Arabia.
   [Papanikolaou, John; Karakitsos, Dimitrios] Univ South Carolina, Sch Med, Dept Med, Columbia, SC 29208 USA.
   [Kutsogiannis, Demetrios J.; Brindley, Peter G.] Univ Alberta, Fac Med & Dent, Dept Crit Care, Edmonton, AB, Canada.
   [Karakitsos, Dimitrios] USC, Crit Care Dept, Keck Med Sch, Los Angeles, CA 90089 USA.
RP Karakitsos, D (corresponding author), King Saud Med City, Crit Care Dept, Riyadh, Saudi Arabia.; Karakitsos, D (corresponding author), Univ South Carolina, Sch Med, Dept Med, Columbia, SC 29208 USA.; Karakitsos, D (corresponding author), USC, Crit Care Dept, Keck Med Sch, Los Angeles, CA 90089 USA.
EM karakitsosdimitrios@gmail.com
FU King Saud Medical
FX The study is funded by King Saud Medical
CR Akhmerov A, 2020, CIRC RES, V126, P1443, DOI 10.1161/CIRCRESAHA.120.317055
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364
   Belliveau D, 2016, ECHOCARDIOGR-J CARD, V33, P1089, DOI 10.1111/echo.13219
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Buchholz S, 2010, MAYO CLIN PROC, V85, P863, DOI 10.4065/mcp.2010.0231
   Bybee KA, 2008, CIRCULATION, V118, P397, DOI 10.1161/CIRCULATIONAHA.106.677625
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carenzo A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081828
   Chadha S, 2020, QJM-INT J MED, V113, P488, DOI 10.1093/qjmed/hcaa135
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   De Backer O, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-147
   Dellinger RP, 2018, JAMA-J AM MED ASSOC, V320, P1455, DOI 10.1001/jama.2018.14618
   Deng Y, 2020, CHINESE MED J-PEKING, V133, P1261, DOI 10.1097/CM9.0000000000000824
   Deshpande C, 2020, ANN INTERN MED, V173, P394, DOI 10.7326/M20-3255
   Douglas Pamela S, 2007, J Am Coll Cardiol, V50, P187, DOI 10.1016/j.jacc.2007.05.003
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Elkayam U, 2014, CIRCULATION, V129, P1695, DOI 10.1161/CIRCULATIONAHA.113.002054
   Faqihi F, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04454-4
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Fraisse M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03025-y
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guzik TJ, 2020, CARDIOVASC RES, V116, pcvaa106
   Hekimian G, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02931-5
   Ibanez B, 2006, EUR HEART J, V27, P1509, DOI 10.1093/eurheartj/ehl091
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Isogai T, 2016, HEART, V102, P1029, DOI 10.1136/heartjnl-2015-308712
   Klein DJ, 2018, INTENS CARE MED, V44, P2205, DOI 10.1007/s00134-018-5463-7
   Knaup H, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2220-9
   Kochi AN, 2020, J CARDIOVASC ELECTR, V31, P1003, DOI 10.1111/jce.14479
   Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Lyon AR, 2008, NAT CLIN PRACT CARD, V5, P22, DOI 10.1038/ncpcardio1066
   Madias JE, 2015, CARDIOLOGY, V130, P162, DOI 10.1159/000370029
   Masuda T, 2002, STROKE, V33, P1671, DOI 10.1161/01.STR.0000016327.74392.02
   Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134
   Meyer P, 2020, EUR HEART J, V41, P1860, DOI 10.1093/eurheartj/ehaa306
   Minhas Anum S, 2020, JACC Case Rep, V2, P1321, DOI 10.1016/j.jaccas.2020.04.023
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Morelli A, 2013, JAMA-J AM MED ASSOC, V310, P1683, DOI 10.1001/jama.2013.278477
   Mrozek S, 2016, HEART LUNG, V45, P406, DOI 10.1016/j.hrtlng.2016.06.007
   NGUYEN DP, 2020, TETRAHEDRON LETT, V61
   Nojima Y, 2010, J AM COLL CARDIOL, V55, P956, DOI 10.1016/j.jacc.2009.10.035
   Noritomi DT, 2010, SHOCK, V34, P59, DOI 10.1097/SHK.0b013e3181e7e8ed
   Nunez-Gil IJ, 2016, EUR HEART J-ACUTE CA, V5, P308, DOI 10.1177/2048872615589512
   Papanikolaou J, 2014, INT J CARDIOL, V176, P1435, DOI 10.1016/j.ijcard.2014.08.039
   Patel P, 2011, PEDIATR CRIT CARE ME, V12, pE87, DOI 10.1097/PCC.0b013e3181e2a569
   Paur H, 2012, CIRCULATION, V126, P697, DOI 10.1161/CIRCULATIONAHA.112.111591
   Puja M, 2020, LANCET, V395, P1033, DOI DOI 10.1016/S0140-6736(20)30628-0
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Sala S, 2020, EUR HEART J, V41, P1861, DOI 10.1093/eurheartj/ehaa286
   Santoro F, 2019, JAMA CARDIOL, V4, P892, DOI 10.1001/jamacardio.2019.2597
   Santoro F, 2016, CARDIOVASC THER, V34, P161, DOI 10.1111/1755-5922.12182
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Templin C, 2015, NEW ENGL J MED, V373, P929, DOI 10.1056/NEJMoa1406761
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Wang AYM, 2019, KIDNEY INT REP, V4, P1523, DOI 10.1016/j.ekir.2019.09.007
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zeng JH, 2020, INFECTION, V48, P773, DOI 10.1007/s15010-020-01424-5
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhao R, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa523, DOI 10.1093/CID/CIAA523]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 72
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2261
J9 BMC CARDIOVASC DISOR
JI BMC Cardiovasc. Disord.
PD AUG 26
PY 2020
VL 20
IS 1
AR 389
DI 10.1186/s12872-020-01665-0
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NJ3WA
UT WOS:000565976600001
PM 32842957
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Maheshwari, N
   Jain, A
AF Maheshwari, Nidhi
   Jain, Ayush
TI Is There a Rationale for UsingBacillusCalmette-Guerin Vaccine in
   Coronavirus Infection?
SO VIRAL IMMUNOLOGY
LA English
DT Article; Early Access
DE coronavirus; BCG vaccine; COVID-19
ID BCG VACCINATION; CHILDREN
AB Coronavirus disease 2019 (COVID-19) has become a global pandemic in 2020. The pathogen responsible for the COVID-19 has been found to be coronavirus (2019-nCoV) with human transmission through droplets, airway secretions, and even direct contact with host. Currently multiple drugs and their combinations are being tried for the treatment of the COVID-19 disease, but none approved. In absence of definitive and approved treatment, it is imperative that prevention of COVID-19 infection is of utmost importance. For the same, face masks, hand hygiene, isolation, and quarantine are being practiced all over the world. However much successful these methods be, they cannot be used for a very long time. Thus, it becomes necessary that a vaccine be developed for the disease so that the further spread could be halted. Some reports suggest the use ofBacillusCalmette-Guerin (BCG) vaccine as the prophylaxis for coronavirus. BCG vaccine is a live attenuated vaccine, used for prophylaxis ofMycobacterium tuberculosisand is present in the essential list of the World Health Organization as well as immunization programs of many countries. Immunostimulatory antiviral effects of BCG vaccine are well known. At present, there are no published evidence available to support the use of BCG vaccine for the prevention of coronavirus infection. However, there have been speculations on enhanced immunity with BCG vaccine, which might be useful in prevention of coronavirus infection. Results from the clinical studies of BCG vaccine in vulnerable population are required to confirm this hypothesis.
C1 [Maheshwari, Nidhi; Jain, Ayush] Maulana Azad Med Coll, Dept Pharmacol, Room 151,Pathol Block, New Delhi 110002, India.
RP Jain, A (corresponding author), Maulana Azad Med Coll, Dept Pharmacol, Room 151,Pathol Block, New Delhi 110002, India.
EM ayushucms@gmail.com
CR Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240
   American Society for Microbiology, 2019, 2019 NOV COR 2019 NC
   Angelidou A, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00332
   [Anonymous], 1996, MMWR Recomm Rep, V45, P1
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Ayoub BM, 2020, PHARMAZIE, V75, P159, DOI 10.1691/ph.2020.0444
   Butkeviciute E, 2018, FUTURE MICROBIOL, V13, P1193, DOI 10.2217/fmb-2018-0026
   Cascella M, 2020, STATPEARLS
   Castro MJ, 2016, CLIN INFECT DIS, V60, P1611
   Centres for Disease Control and Prevention, 2020, MOD MORT REP MMWR
   Cirovic B, 2020, CELL HOST MICROBE, pS1931
   Covian C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02806
   Fuge O, 2015, RES REP UROL, V7, P65, DOI 10.2147/RRU.S63447
   Goodridge HS, 2016, NAT REV IMMUNOL, V16, P392, DOI 10.1038/nri.2016.43
   Indian Council of Medical Research, 2020, ADV US HYDR CHLOR PR
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Leentjens J, 2015, J INFECT DIS, V212, P1930, DOI 10.1093/infdis/jiv332
   Mathurin KS, 2009, J VIROL, V83, P3528, DOI 10.1128/JVI.02393-08
   Miller A, 2020, CORRELATION UNIVERSA, DOI [/10.1101/2020.03.24.20042937v1., DOI 10.1101/2020.03.24.20042937V1]
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Ramesh S, 2020, 100 YEAR OLD TB VACC
   Ritz N, 2013, VACCINE, V31, P3098, DOI 10.1016/j.vaccine.2013.03.059
   Salem A, 2013, PEDIATR DERMATOL, V30, P60, DOI 10.1111/j.1525-1470.2012.01848.x
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Sparrow A, 2020, FP NEWS         0324
   Stensballe LG, 2005, VACCINE, V23, P1251, DOI 10.1016/j.vaccine.2004.09.006
   Vetskova Evelina K, 2013, Folia Med (Plovdiv), V55, P49
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Wardhana, 2011, Acta Med Indones, V43, P185
   WHO, 2020, Q A COR COVID 19
   WHO Expert Committee on Biological Standards, 2011, REC ASS QUAL SAF EFF
   World Health Organization, 2020, COR COVID 19 PAND
   World Health Organization, 2020, RAT US PERS PROT EQ
   Yamazaki-Nakashimada MA, 2020, HUM VACC IMMUNOTHER, V16, P1841, DOI 10.1080/21645515.2019.1706930
NR 34
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0882-8245
EI 1557-8976
J9 VIRAL IMMUNOL
JI Viral Immunol.
DI 10.1089/vim.2020.0079
EA AUG 2020
PG 7
WC Immunology; Virology
SC Immunology; Virology
GA NJ4MQ
UT WOS:000566019800001
PM 32857679
OA Bronze
DA 2021-01-01
ER

PT J
AU Rao, PY
   Shukla, A
   Parmar, P
   Rawal, RM
   Patel, BV
   Saraf, M
   Goswami, D
AF Rao, Priyashi
   Shukla, Arpit
   Parmar, Paritosh
   Rawal, Rakesh M.
   Patel, Baldev V.
   Saraf, Meenu
   Goswami, Dweipayan
TI Proposing a fungal metabolite-flaviolin as a potential inhibitor of
   3CL(pro)of novel coronavirus SARS-CoV-2 identified using docking and
   molecular dynamics
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE 3-chymotrypsin like protease (3CLpro; ); SARS-CoV-2 novel corona virus;
   Fungal metabolites; docking; Molecular dynamics
ID ACHILLES-HEEL; MAIN PROTEASE; GROMACS; DESIGN
AB The novel SARS-CoV-2 is the etiological agent causing the Coronavirus disease 2019 (COVID-19), which continues to become an inevitable pandemic outbreak. Over a short span of time, the structures of therapeutic target proteins for SARS-CoV-2 were identified based on the homology modelled structure of similar virus, SARS-CoV that transmitted rapidly in 2003. Since the outset of the disease, the research community has been looking for a potential drug lead. Out of all the known resolved structures related to SARS-CoV-2; 3-chymotrypsin (3 C) like protease (3CL(pro)) is considered as an attractive anti-viral drug compound on the grounds of its role in viral replication and probable non-interactive competency to bind to any viral host protein. To the best of our knowledge, till date only one compound has been identified and testedin-vitroas a potent inhibitor of 3CL(pro)protein, addressed as N3 (PubChem Compound CID: 6323191) and is known to bind irreversibly to 3CL(pro)suppressing its activity. Using computational approach, we intend to identify a probable natural fungal metabolite to interact and inhibit 3CL(pro). Here after performing docking and molecular dynamics of various small molecules derived as a secondary metabolite from fungi, we propose Flaviolin as potent inhibitor of 3CL(pro)of novel Coronavirus SARS-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Rao, Priyashi; Rawal, Rakesh M.] Gujarat Univ, Univ Sch Sci, Dept Biochem & Forens Sci, Ahmadabad, Gujarat, India.
   [Shukla, Arpit; Parmar, Paritosh; Patel, Baldev V.; Saraf, Meenu; Goswami, Dweipayan] Gujarat Univ, Univ Sch Sci, Dept Microbiol & Biotechnol, Ahmadabad 380009, Gujarat, India.
RP Goswami, D (corresponding author), Gujarat Univ, Univ Sch Sci, Dept Microbiol & Biotechnol, Ahmadabad 380009, Gujarat, India.
EM dweipayan.goswami@gujaratuniversity.ac.in
OI Saraf, Meenu/0000-0003-4964-9452; Parmar, Paritosh/0000-0001-6463-8124;
   Rawal, Rakesh/0000-0002-7985-1187; Goswami,
   Dweipayan/0000-0003-0165-0294; Rao, Priyashi/0000-0002-7203-8249
CR Arya R., 2020, POTENTIAL INHIBITORS, DOI [10.26434/chemrxiv.11860011.v2, DOI 10.26434/CHEMRXIV.11860011.V2]
   BEKKER H, 1993, PHYSICS COMPUTING '92, P252
   Berendsen HJC, 1981, INTERMOLECULAR FORCE, V1981, P331, DOI [10.1007/978-94-015-7658-1_21, DOI 10.1007/978-94-015-7658-1_21]
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0602, DOI DOI https://doi.org/10.1080/07391102.2020.1772109
   BORKOTOKY S, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1774419
   Cui W, 2019, BIOCHEM BIOPH RES CO, V511, P794, DOI 10.1016/j.bbrc.2019.02.105
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   GASTEIGER J, 1979, J CHEM INF COMP SCI, V19, P43, DOI 10.1021/ci60017a011
   GHOSH R, 2020, J BIOMOL STRUCT 0620, DOI DOI https://doi.org/10.1080/07391102.2020.1779818
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kong Ren, 2020, Bioinformatics, V36, P5109, DOI 10.1093/bioinformatics/btaa645
   Krivov GG, 2009, PROTEINS, V77, P778, DOI 10.1002/prot.22488
   Kumar A, 2019, CURR ALZHEIMER RES, V16, P116, DOI 10.2174/1567205016666181212155147
   LINNAKOSKI R, 2018, FRONT MICROBIOL, V9, DOI DOI https://doi.org/10.3389/fmicb.2018.02325
   Macchiagodena M., 2020, ARXIV09937
   Parmar P, 2020, BIOORG CHEM, V99, DOI 10.1016/j.bioorg.2020.103823
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Rao P, 2020, BIOPHYS CHEM, V264, DOI 10.1016/j.bpc.2020.106425
   Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3
   Shukla A, 2020, CURR MICROBIOL, V77, P1800, DOI 10.1007/s00284-020-01997-2
   St John SE, 2015, BIOORGAN MED CHEM, V23, P6036, DOI 10.1016/j.bmc.2015.06.039
   Huynh T, 2020, J PHYS CHEM LETT, V11, P4413, DOI 10.1021/acs.jpclett.0c00994
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Turner P., 2005, XMGRACE VERSION 5 1
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   WANG JM, 2001, ABSTR PAP AM CHEM 1, V222
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Yang HT, 2006, CURR PHARM DESIGN, V12, P4573, DOI 10.2174/138161206779010369
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 42
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1813202
EA AUG 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NI0HM
UT WOS:000565039900001
PM 32875950
OA Bronze
DA 2021-01-01
ER

PT J
AU Leipe, J
   Hoyer, BF
   Iking-Konert, C
   Schulze-Koops, H
   Specker, C
   Kruger, K
AF Leipe, J.
   Hoyer, B. F.
   Iking-Konert, C.
   Schulze-Koops, H.
   Specker, C.
   Krueger, K.
TI SARS-CoV-2 & rheumatic disease Consequences of the SARS-CoV-2 pandemic
   for patients with inflammatory rheumatic diseases. A comparison of the
   recommendations for action of rheumatological societies and risk
   assessment of different antirheumatic treatments
SO ZEITSCHRIFT FUR RHEUMATOLOGIE
LA German
DT Article; Early Access
DE COVID-19; Management; Recommendations; Inflammatory rheumatic diseases;
   DMARD
AB The recommendations of the German Society of Rheumatology (DGRh) update, which update and expand the guidance on the management of patients with inflammatory rheumatic diseases in view of SARS-CoV-2 created at the beginning of the COVID-19 pandemic, correspond in many points with the recommendations for action of the American (ACR) and European (EULAR) societies, but also differ in some points. Therefore, this article discusses the core recommendations of the DGRh update on the prevention of SARS-CoV-2/COVID-19, the risk assessment for inflammatory rheumatic diseases and the use of antirheumatic treatments in the context and in comparison to the ACR and EULAR recommendations, and provides an overview of the risk assessment of individual antirheumatic drugs.
C1 [Leipe, J.] Univ Klinikum Mannheim, Sekt Rheumatol, Med Klin 5, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
   [Leipe, J.; Schulze-Koops, H.] Ludwig Maximilians Univ Munchen, Sekt Rheumatol & Klin Immunol, Med Klin & Poliklin 4, Munich, Germany.
   [Hoyer, B. F.] Univ Krankenhaus Schleswig Holstein, Abt Rheumatol, Med Klin 1, Campus Kiel, Kiel, Germany.
   [Iking-Konert, C.] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin 3, Sekt Rheumatol, Hamburg, Germany.
   [Specker, C.] Kliniken Essen Mitte, Klin Rheumatol & Klin Immunol, Essen, Germany.
   [Krueger, K.] Rheumatol Praxiszentrum Munchen, Munich, Germany.
RP Leipe, J (corresponding author), Univ Klinikum Mannheim, Sekt Rheumatol, Med Klin 5, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM jan.leipe@umm.de
FU Projekt DEAL
FX Open Access funding provided by Projekt DEAL.
CR Aries Peer, 2020, Ann Rheum Dis, DOI 10.1136/annrheumdis-2020-218400
   Bundesministerium fur Gesundheit, 2020, REG NACH DTSCH EINR
   Cortegiani A, 2021, Pulmonology, V27, P52, DOI 10.1016/j.pulmoe.2020.07.003
   D'Silva KM, 2020, ANN RHEUM DIS, V79, P1156, DOI [10.1136/annrheumdis-2020-217888, 10.1136/annrheumdis-2020-218196, 10.1136/annrheumdis-2020-218179, 10.1136/annrheumdis-2020-218431]
   Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Landewe RBM, 2020, ANN RHEUM DIS, V79, P851, DOI [10.1136/annrheumdis-2020-216999, 10.1136/annrheumdis-2020-217877]
   Michelena X, 2020, SEMIN ARTHRITIS RHEU, V50, P564, DOI 10.1016/j.semarthrit.2020.05.001
   Mikuls TR, 2020, ARTHRITIS RHEUMATOL, V72, P1241, DOI 10.1002/art.41301
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Pablos JL, 2020, ANN RHEUM DIS, V79, P1544, DOI [10.1136/annrheumdis-2020-217763, 10.1136/annrheumdis-2020-218296]
   Robert-Koch-Institut-RKI, 2020, SARS COV 2 STECKBR C
   Roche, 2020, ROCH UPD PHAS 3 COVA
   Schulze-Koops H, 2020, Z RHEUMATOL, V79, P385, DOI 10.1007/s00393-020-00799-y
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
NR 17
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-1855
EI 1435-1250
J9 Z RHEUMATOL
JI Z. Rheumatol.
DI 10.1007/s00393-020-00878-0
EA AUG 2020
PG 6
WC Rheumatology
SC Rheumatology
GA NH9VM
UT WOS:000565008700002
PM 32845393
OA Other Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Liu, G
   Carter, B
   Bricken, T
   Jain, S
   Viard, M
   Carrington, M
   Gifford, DK
AF Liu, Ge
   Carter, Brandon
   Bricken, Trenton
   Jain, Siddhartha
   Viard, Mathias
   Carrington, Mary
   Gifford, David K.
TI Computationally Optimized SARS-CoV-2 MHC Class I and II Vaccine
   Formulations Predicted to Target Human Haplotype Distributions
SO CELL SYSTEMS
LA English
DT Article
ID T-CELL EPITOPES; BINDING; SELECTION; AFFINITY
AB We present a combinatorial machine learning method to evaluate and optimize peptide vaccine formulations for SARS-CoV-2. Our approach optimizes the presentation likelihood of a diverse set of vaccine peptides conditioned on a target human-population HLA haplotype distribution and expected epitope drift. Our proposed SARS-CoV-2 MHC class I vaccine formulations provide 93.21% predicted population coverage with at least five vaccine peptide-HLA average hits per person 1 peptide (>= 1 peptide 99.91%) with all vaccine peptides perfectly conserved across 4,690 geographically sampled SARS-CoV-2 genomes. Our proposed MHC class II vaccine formulations provide 97.21 % predicted coverage with at least five vaccine peptide-HLA average hits per person with all peptides having an observed mutation probability of <= 0.001. We provide an open-source implementation of our design methods (OptiVax), vaccine evaluation tool (EvalVax), as well as the data used in our design efforts here: https://github.com/gifford-lab/optivax.
C1 [Liu, Ge; Carter, Brandon; Jain, Siddhartha; Gifford, David K.] MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Liu, Ge; Carter, Brandon; Gifford, David K.] MIT, Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Gifford, David K.] MIT, Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Bricken, Trenton] Duke Univ, Durham, NC USA.
   [Viard, Mathias; Carrington, Mary] Frederick Natl Lab Canc Res, Basic Sci Program, Frederick, MD USA.
   [Viard, Mathias; Carrington, Mary] MIT & Harvard Univ, Massachusetts Gen Hosp, Ragon Inst, Cambridge, MA USA.
RP Gifford, DK (corresponding author), MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Gifford, DK (corresponding author), MIT, Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Gifford, DK (corresponding author), MIT, Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM gifford@mit.edu
FU Schmidt Futures; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01CA218094];
   Frederick National Laboratory for Cancer Research [HHSN261200800001E];
   Intramural Research Program of the NIH, Frederick National Lab, Center
   for Cancer Research
FX Michael Birnbaum, Brooke Huisman, and Jonathan Krog provided helpful
   discussions. Viral sequences are from GISAID (see Table S4: GISAID
   acknowledgements). This work was supported in part by Schmidt Futures
   and NIH grant R01CA218094 to D.K.G.; HLA haplotype frequencies were
   generated from previously published NGS data generated in the Carrington
   lab and we thank our many collaborators. This project was funded in part
   with federal funds from the Frederick National Laboratory for Cancer
   Research, under contract no. HHSN261200800001E. The content of this
   publication does not necessarily reflect the views or policies of the
   Department of Health and Human Services, nor does mention of trade
   names, commercial products, or organizations imply endorsement by the
   U.S. Government. This Research was supported in part by the Intramural
   Research Program of the NIH, Frederick National Lab, Center for Cancer
   Research. The views expressed in this article do not necessarily reflect
   the official policy or position of the National Institutes of Health,
   the Department of the Navy, the Department of Defense, or any other
   agency of the US Government.
CR Abdelmageed MI, 2020, DESIGN MULTIEPITOPE, DOI [10.1101/2020.02.04.934232, DOI 10.1101/2020.02.04.934232]
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Akhand M. R. N., 2020, GENOME BASED EVOLUTI, DOI [10.1101/2020.04.15.036285, DOI 10.1101/2020.04.15.036285]
   Banerjee A., 2020, ENERGETICS BASED EPI, DOI [10.1101/2020.04.02.021725, DOI 10.1101/2020.04.02.021725, 10.1101/2020.04.02.021725.]
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Buus S, 2003, TISSUE ANTIGENS, V62, P378, DOI 10.1034/j.1399-0039.2003.00112.x
   CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Croft NP, 2019, P NATL ACAD SCI USA, V116, P3112, DOI 10.1073/pnas.1815239116
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921
   Fast E, 2020, POTENTIAL T CELL B C, DOI [10.1101/2020.02.19.955484, DOI 10.1101/2020.02.19.955484]
   Finkel Y, 2020, CODING CAPACITY SARS, DOI [10.1101/2020.05.07.082909, DOI 10.1101/2020.05.07.082909]
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Gupta E., 2020, IDENTIFICATION POTEN, DOI [10.1101/2020.04.13.039198, DOI 10.1101/2020.04.13.039198]
   Gupta R., 2004, PREDICTION N GLYCOSY
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Helmberg W, 2004, NUCLEIC ACIDS RES, V32, pW173, DOI 10.1093/nar/gkh424
   Herst CV, 2020, VACCINE, V38, P4464, DOI 10.1016/j.vaccine.2020.04.034
   Hyun-Jung Lee Chloe, 2020, F1000Res, V9, P145, DOI 10.12688/f1000research.22507.1
   Ismail S., 2020, IMMUNO INFORM CHARAC, DOI [10.1101/2020.04.05.026005, DOI 10.1101/2020.04.05.026005]
   Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Khan A., 2020, DESIGN EPITOPE BASED, DOI [10.1101/2020.05.03.074930, DOI 10.1101/2020.05.03.074930]
   Mitra D., 2020, MULTIEPITOPE BASED P, DOI [10.1101/2020.04.23.055467, DOI 10.1101/2020.04.23.055467]
   Moise L, 2015, HUM VACC IMMUNOTHER, V11, P2312, DOI 10.1080/21645515.2015.1061159
   Nerli Santrupti, 2020, bioRxiv, DOI 10.1101/2020.03.23.004176
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   O'Donnell TJ, 2018, CELL SYST, V7, P129, DOI 10.1016/j.cels.2018.05.014
   ODonnell T., 2020, MODEL ANTIGEN PROCES, DOI [10.1101/2020.03.28.013714., DOI 10.1101/2020.03.28.013714]
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825
   Peters B, 2020, ANNU REV IMMUNOL, V38, P123, DOI 10.1146/annurev-immunol-082119-124838
   Poran A., 2020, BIORXIV, DOI [10.1101/2020.04.06.027805, DOI 10.1101/2020.04.06.027805]
   Prachar M., 2020, COVID 19 VACCINE CAN, DOI [10.1101/2020.03.20.000794, DOI 10.1101/2020.03.20.000794]
   Ramaiah A., 2020, INSIGHTS CROSS SPECI, DOI [10.1101/2020.01.29.925867, DOI 10.1101/2020.01.29.925867]
   Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379
   Reynisson B, 2020, J PROTEOME RES, V19, P2304, DOI 10.1021/acs.jproteome.9b00874
   Rist MJ, 2013, J IMMUNOL, V191, P561, DOI 10.4049/jimmunol.1300292
   Saha R., 2020, SILICO APPROACH DESI, DOI [10.1101/2020.03.31.017459, DOI 10.1101/2020.03.31.017459]
   SETTE A, 1994, J IMMUNOL, V153, P5586
   Singh A., 2020, DESIGNING MULTIEPITE, DOI [10.1101/2020.04.15.040618, DOI 10.1101/2020.04.15.040618]
   Srivastava S., 2020, STRUCTURAL BASIS DES, DOI [10.1101/2020.04.01.019299, DOI 10.1101/2020.04.01.019299]
   Trolle T, 2016, J IMMUNOL, V196, P1480, DOI 10.4049/jimmunol.1501721
   ul Qamar M.T., 2020, DESIGNING NEXT GENER, DOI [10.1101/2020.02.28.970343, DOI 10.1101/2020.02.28.970343]
   Vashi Y., 2020, UNDERSTANDING B T CE, DOI [10.1101/2020.04.08.013516., DOI 10.1101/2020.04.08.013516, 10.1101/2020.04.08.013516]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang Q, 2020, VIROL SIN, V20, P1
   Wolfert MA, 2013, NAT CHEM BIOL, V9, P776, DOI [10.1038/NCHEMBIO.1403, 10.1038/nchembio.1403]
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yarmarkovich M., 2020, CELL REP MED, V1
   Yazdani Z., 2020, DESIGN EFFICIENT MUL, DOI [10.1101/2020.04.20.051557., DOI 10.1101/2020.04.20.051557, 10.1101/2020.04.20.051557]
   Zeng HY, 2019, CELL SYST, V9, P159, DOI 10.1016/j.cels.2019.05.004
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang Y., 2020, SITE SPECIFIC N GLYC, DOI [10.1101/ 2020.03.28.013276, DOI 10.1101/2020.03.28.013276, 10.1101/2020.03.28.013276.]
NR 59
TC 2
Z9 2
U1 0
U2 0
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2405-4712
EI 2405-4720
J9 CELL SYST
JI Cell Syst.
PD AUG 26
PY 2020
VL 11
IS 2
BP 131
EP +
DI 10.1016/j.cels.2020.06.009
PG 20
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NF2DZ
UT WOS:000563112000003
PM 32721383
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Klemm, T
   Ebert, G
   Calleja, DJ
   Allison, CC
   Richardson, LW
   Bernardini, JP
   Lu, BGC
   Kuchel, NW
   Grohmann, C
   Shibata, Y
   Gan, ZY
   Cooney, JP
   Doerflinger, M
   Au, AE
   Blackmore, TR
   van Noort, GJV
   Geurink, PP
   Ovaa, H
   Newman, J
   Riboldi-Tunnicliffe, A
   Czabotar, PE
   Mitchell, JP
   Feltham, R
   Lechtenberg, BC
   Lowes, KN
   Dewson, G
   Pellegrini, M
   Lessene, G
   Komander, D
AF Klemm, Theresa
   Ebert, Gregor
   Calleja, Dale J.
   Allison, Cody C.
   Richardson, Lachlan W.
   Bernardini, Jonathan P.
   Lu, Bernadine G. C.
   Kuchel, Nathan W.
   Grohmann, Christoph
   Shibata, Yuri
   Gan, Zhong Yan
   Cooney, James P.
   Doerflinger, Marcel
   Au, Amanda E.
   Blackmore, Timothy R.
   van Noort, Gerbrand J. van der Heden
   Geurink, Paul P.
   Ovaa, Huib
   Newman, Janet
   Riboldi-Tunnicliffe, Alan
   Czabotar, Peter E.
   Mitchell, Jeffrey P.
   Feltham, Rebecca
   Lechtenberg, Bernhard C.
   Lowes, Kym N.
   Dewson, Grant
   Pellegrini, Marc
   Lessene, Guillaume
   Komander, David
TI Mechanism and inhibition of the papain-like protease, PLpro, of
   SARS-CoV-2
SO EMBO JOURNAL
LA English
DT Article; Early Access
DE COVID-19; ISG15; papain-like protease; small molecule inhibitor;
   ubiquitin
ID RESPIRATORY-SYNDROME-CORONAVIRUS; UBIQUITIN RECOGNITION;
   CROSS-REACTIVITY; STRUCTURAL BASIS; MOLECULAR-BASIS; SPECIFICITY;
   ENZYMES; POTENT; ISG15
AB The SARS-CoV-2 coronavirus encodes an essential papain-like protease domain as part of its non-structural protein (nsp)-3, namely SARS2 PLpro, that cleaves the viral polyprotein, but also removes ubiquitin-like ISG15 protein modifications as well as, with lower activity, Lys48-linked polyubiquitin. Structures of PLpro bound to ubiquitin and ISG15 reveal that the S1 ubiquitin-binding site is responsible for high ISG15 activity, while the S2 binding site provides Lys48 chain specificity and cleavage efficiency. To identify PLpro inhibitors in a repurposing approach, screening of 3,727 unique approved drugs and clinical compounds against SARS2 PLpro identified no compounds that inhibited PLpro consistently or that could be validated in counterscreens. More promisingly, non-covalent small molecule SARS PLpro inhibitors also target SARS2 PLpro, prevent self-processing of nsp3 in cells and display high potency and excellent antiviral activity in a SARS-CoV-2 infection model.
C1 [Klemm, Theresa; Ebert, Gregor; Calleja, Dale J.; Allison, Cody C.; Richardson, Lachlan W.; Bernardini, Jonathan P.; Lu, Bernadine G. C.; Kuchel, Nathan W.; Grohmann, Christoph; Shibata, Yuri; Gan, Zhong Yan; Cooney, James P.; Doerflinger, Marcel; Au, Amanda E.; Blackmore, Timothy R.; Czabotar, Peter E.; Mitchell, Jeffrey P.; Feltham, Rebecca; Lechtenberg, Bernhard C.; Lowes, Kym N.; Dewson, Grant; Pellegrini, Marc; Lessene, Guillaume; Komander, David] Univ Melbourne, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia.
   [Klemm, Theresa; Ebert, Gregor; Calleja, Dale J.; Allison, Cody C.; Richardson, Lachlan W.; Bernardini, Jonathan P.; Lu, Bernadine G. C.; Kuchel, Nathan W.; Grohmann, Christoph; Shibata, Yuri; Gan, Zhong Yan; Cooney, James P.; Doerflinger, Marcel; Au, Amanda E.; Blackmore, Timothy R.; Czabotar, Peter E.; Mitchell, Jeffrey P.; Feltham, Rebecca; Lechtenberg, Bernhard C.; Lowes, Kym N.; Dewson, Grant; Pellegrini, Marc; Lessene, Guillaume; Komander, David] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia.
   [Bernardini, Jonathan P.] Univ British Columbia, Dept Biochem & Mol Biol, Michael Smith Labs, Vancouver, BC, Canada.
   [van Noort, Gerbrand J. van der Heden; Geurink, Paul P.; Ovaa, Huib] Leiden Univ, Med Ctr, Oncode Inst, Leiden, Netherlands.
   [van Noort, Gerbrand J. van der Heden; Geurink, Paul P.; Ovaa, Huib] Leiden Univ, Med Ctr, Dept Cell & Chem Biol, Leiden, Netherlands.
   [Newman, Janet] Commonwealth Sci & Ind Res Org CSIRO, Biomed Program, Parkville, Vic, Australia.
   [Riboldi-Tunnicliffe, Alan] ANSTO, Australian Synchrotron, Clayton, Vic, Australia.
   [Lessene, Guillaume] Univ Melbourne, Pharmacol & Therapeut Dept, Melbourne, Vic, Australia.
RP Pellegrini, M; Lessene, G; Komander, D (corresponding author), Univ Melbourne, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia.; Pellegrini, M; Lessene, G; Komander, D (corresponding author), Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia.
EM pellegrini@wehi.edu.au; glessene@wehi.edu.au; dk@wehi.edu.au
RI van der Heden van Noort, Gerbrand/AAZ-9848-2020; Newman,
   Janet/D-1857-2011
OI van der Heden van Noort, Gerbrand/0000-0001-5955-6431; Richardson,
   Lachlan/0000-0001-8877-1376; Lechtenberg, Bernhard
   Clemens/0000-0002-5674-6894; Newman, Janet/0000-0003-2666-3219; Calleja,
   Dale/0000-0002-8306-0900
FU Walter and Eliza Hall Institute of Medical Research; NHMRC/MRFF "VirDUB"
   grant [MRF2002119]; NWO (VIDI)Netherlands Organization for Scientific
   Research (NWO); NHMRCNational Health and Medical Research Council of
   Australia [GNT1178122, GNT0637350, GNT1117089]; NHMRC Independent
   Research Institutes Infrastructure Support Scheme grantNational Health
   and Medical Research Council of Australia [361646]; Victorian State
   Government Operational Infrastructure Support grant
FX We would like to thank Kanta Subbarao (Peter Doherty Institute,
   Melbourne) for live SARS-CoV-2 virus, Frederick P. (Fritz) Roth
   (University of Toronto) for providing the SARS2 nsp3 pENTRY plasmid,
   Thibault Major (University of British Columbia, Vancouver) for vectors
   and for supporting J. Bernardini, Sandra Nicholson, Peter Colman, Ian
   Wicks and Thomas Cotton (WEHI) for sharing expertise and reagents, and
   Jonathan O'Connell (FORMA Therapeutics) for advice on high-throughput
   assays. This work was funded by The Walter and Eliza Hall Institute of
   Medical Research, an NHMRC/MRFF "VirDUB" grant MRF2002119 (to DK, GL,
   MP, PEC), NWO (VIDI-grant and Off-road grant) to GJvdHvN, NHMRC
   Investigator Grants and Fellowships (GNT1178122 to DK, GNT0637350 to MP,
   and GNT1117089 to GL), NHMRC Independent Research Institutes
   Infrastructure Support Scheme grant (361646) and Victorian State
   Government Operational Infrastructure Support grant, and a generous
   donation by Hengyi Pacific Pty Ltd to support COVID-19 research.
CR Adams PD, 2011, METHODS, V55, P94, DOI 10.1016/j.ymeth.2011.07.005
   Akutsu M, 2011, P NATL ACAD SCI USA, V108, P2228, DOI 10.1073/pnas.1015287108
   Aragao D, 2018, J SYNCHROTRON RADIAT, V25, P885, DOI 10.1107/S1600577518003120
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Bailey-Elkin BA, 2017, J MOL BIOL, V429, P3441, DOI 10.1016/j.jmb.2017.06.010
   Bailey-Elkin BA, 2014, J BIOL CHEM, V289, P34667, DOI 10.1074/jbc.M114.609644
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Bekes M, 2016, MOL CELL, V62, P572, DOI 10.1016/j.molcel.2016.04.016
   Bekes M, 2015, BIOCHEM J, V468, P215, DOI 10.1042/BJ20141170
   Berlin David A, 2020, N Engl J Med, V383, P2451, DOI 10.1056/NEJMcp2009575
   Berrow NS, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm047
   Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Chou CY, 2014, ACTA CRYSTALLOGR D, V70, P572, DOI 10.1107/S1399004713031040
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Clasman JR, 2020, ANTIVIR RES, V174, DOI 10.1016/j.antiviral.2019.104661
   Clementz MA, 2010, J VIROL, V84, P4619, DOI 10.1128/JVI.02406-09
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Daczkowski CM, 2017, J VIROL, V91, DOI 10.1128/JVI.01067-17
   Daczkowski CM, 2017, J MOL BIOL, V429, P1661, DOI 10.1016/j.jmb.2017.04.011
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dzimianski JV, 2019, J MOL BIOL, V431, P4203, DOI 10.1016/j.jmb.2019.03.013
   Ebner P, 2017, CRIT REV BIOCHEM MOL, V52, P425, DOI 10.1080/10409238.2017.1325829
   Ekkebus R, 2013, J AM CHEM SOC, V135, P2867, DOI 10.1021/ja309802n
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Flierman D, 2016, CELL CHEM BIOL, V23, P472, DOI 10.1016/j.chembiol.2016.03.009
   Freitas BT, 2020, ACS INFECT DIS, V6, P2099, DOI 10.1021/acsinfecdis.0c00168
   Frias-Staheli N, 2007, CELL HOST MICROBE, V2, P404, DOI 10.1016/j.chom.2007.09.014
   Gersch M, 2017, NAT STRUCT MOL BIOL, V510, P370
   Geurink PP, 2019, METHOD ENZYMOL, V618, P357, DOI 10.1016/bs.mie.2018.12.037
   Geurink PP, 2012, CHEMBIOCHEM, V13, P293, DOI 10.1002/cbic.201100706
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Heaton SM, 2016, J EXP MED, V213, P1, DOI 10.1084/jem.20151531
   Isaacson MK, 2009, CELL HOST MICROBE, V5, P559, DOI 10.1016/j.chom.2009.05.012
   Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581
   James TW, 2011, P NATL ACAD SCI USA, V108, P2222, DOI 10.1073/pnas.1013388108
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   KIM JC, 1995, VIROLOGY, V208, P1, DOI 10.1006/viro.1995.1123
   Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830
   Lee H, 2015, ACS CHEM BIOL, V10, P1456, DOI 10.1021/cb500917m
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Lindner HA, 2007, ARCH BIOCHEM BIOPHYS, V466, P8, DOI 10.1016/j.abb.2007.07.006
   Magis C, 2014, METHODS MOL BIOL, V1079, P117, DOI 10.1007/978-1-62703-646-7_7
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Mevissen TET, 2017, ANNU REV BIOCHEM, V86, P159, DOI 10.1146/annurev-biochem-061516-044916
   Mevissen TET, 2013, CELL, V154, P169, DOI 10.1016/j.cell.2013.05.046
   Michel MA, 2018, METHODS MOL BIOL, V1844, P73, DOI 10.1007/978-1-4939-8706-1_6
   Perng YC, 2018, NAT REV MICROBIOL, V16, P423, DOI 10.1038/s41579-018-0020-5
   Pruijssers AJ, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107940
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Rut Wioletta, 2020, bioRxiv, DOI 10.1101/2020.04.29.068890
   Shin D, 2020, NATURE, DOI 10.1038/s41586-020-2601-5
   Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048
   Swatek KN, 2018, P NATL ACAD SCI USA, V115, P2371, DOI 10.1073/pnas.1710617115
   Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39
   Turnbull AP, 2017, NATURE, V550, P481, DOI 10.1038/nature24451
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wilkinson KD, 2005, METHOD ENZYMOL, V399, P37, DOI 10.1016/S0076-6879(05)99003-4
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yau R, 2016, NAT CELL BIOL, V18, P579, DOI 10.1038/ncb3358
   Ye Y, 2011, EMBO REP, V12, P350, DOI 10.1038/embor.2011.17
   Zhang X, 2017, MOL CELL, V65, P1
NR 70
TC 1
Z9 1
U1 20
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
AR e106275
DI 10.15252/embj.2020106275
EA AUG 2020
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NE2ZJ
UT WOS:000562465900001
PM 32845033
OA Green Published
DA 2021-01-01
ER

PT J
AU Rolta, R
   Yadav, R
   Salaria, D
   Trivedi, S
   Imran, M
   Sourirajan, A
   Baumler, DJ
   Dev, K
AF Rolta, Rajan
   Yadav, Rohitash
   Salaria, Deeksha
   Trivedi, Shubham
   Imran, Mohammad
   Sourirajan, Anuradha
   Baumler, David J.
   Dev, Kamal
TI In silicoscreening of hundred phytocompounds of ten medicinal plants as
   potential inhibitors of nucleocapsid phosphoproteinof COVID-19:an
   approach to prevent virus assembly
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE RNA binding domain of nucleocapsid phosphoprotein; COVID-19; Molecular
   docking; Phytocompounds; antiviral and toxicity; Active site prediction
   and MD simulation
ID N-TERMINAL DOMAIN; RNA-BINDING; CORONAVIRUS; PROTEIN; SEQUENCE; SPIKE
AB Currently, there is no specific treatment to cure COVID-19. Many medicinal plants have antiviral, antioxidant, antibacterial, antifungal, anticancer, wound healing etc. Therefore, the aim of the current study was to screen for potent inhibitors of N-terminal domain (NTD) of nucleocapsid phosphoprotein of SARS-CoV-2. The structure of NTD of RNA binding domain of nucleocapsid phosphoprotein of SARS coronavirus 2 was retrieved from the Protein Data Bank (PDB 6VYO) and the structures of 100 different phytocompounds were retrieved from Pubchem. The receptor protein and ligands were prepared using Schrodinger's Protein Preparation Wizard. Molecular docking was done by using the Schrodinger's maestro 12.0 software. Drug likeness and toxicity of active phytocompounds was predicted by using Swiss adme, admetSAR and protox II online servers. Molecular dynamic simulation of the best three protein- ligand complexes (alizarin, aloe-emodin and anthrarufin) was performed to study the interaction stability. We have identified three potential active sites (named as A, B, C) on receptor protein for efficient binding of the phytocompounds. We found that, among 100 phytocompounds, emodin, aloe-emodin, anthrarufin, alizarine, and dantron ofRheum emodishowed good binding affinity at all the three active sites of RNA binding domain of nucleocapsid phosphoprotein of COVID-19.The binding energies of emodin, aloe-emodin, anthrarufin, alizarine, and dantron were -8.299, -8.508, -8.456, -8.441, and -8.322 Kcal mol(-1)respectively (site A), -7.714, -6.433, -6.354, -6.598, and -6.99 Kcal mol(-1)respectively (site B), and -8.299, 8.508, 8.538, 8.841, and 8.322 Kcal mol(-1)respectively (site C). All the active phytocompounds follows the drug likeness properties, non-carcinogenic, and non-toxic. Theses phytocompounds (alone or in combination) could be developed into effective therapy against COVID-19. From MD simulation data, we found that all three complexes of 6VYO with alizarin, aloe-emodin and anthrarufin were stable up to 50 ns. These phytocompounds can be tested further forin vitroorin vivoand used as a potential drug to cure SARS-CoV-2 infection. Communicated by Ramaswamy H. Sarma
C1 [Rolta, Rajan; Salaria, Deeksha; Sourirajan, Anuradha; Dev, Kamal] Shoolini Univ Biotechnol & Management Sci, Fac Appl Sci & Biotechnol, Bajhol, Himachal Prades, India.
   [Yadav, Rohitash] All India Inst Med Sci, Dept Pharmacol, Rishikesh, Uttarakhand, India.
   [Trivedi, Shubham] Integral Univ Lucknow, Dept Bioengn, Lucknow, Uttar Pradesh, India.
   [Imran, Mohammad] Shaqra Univ, Dept Pharmacol, Shaqra, Saudi Arabia.
   [Baumler, David J.] Univ Minnesota Twin Cities, Dept Food Sci & Nutr, St Paul, MN USA.
RP Dev, K (corresponding author), Shoolini Univ Biotechnol & Management Sci, Fac Appl Sci & Biotechnol, Solan Hp 173229, Bajhol, India.
EM kamaldevbhardwaj1969@gmail.com
OI Dev, Kamal/0000-0002-2076-9023
FU Yeast Biology Laboratory, School of Biotechnology, Shoolini University,
   Solan, India
FX The authors acknowledge Shoolini University, Solan (India) for providing
   infrastructure support to conduct the research work. Authors also
   acknowledge the support provided by Yeast Biology Laboratory, School of
   Biotechnology, Shoolini University, Solan, India. Authors are thankful
   to the Department of Pharmacology, AIIMS, Rishikesh, Dr. Prajwal
   Nandekar, Dr. Vinod and Schrodinger team; Dheeraj Kumar Chaurasia from
   Supercomputing facility for Bioinformatics and Computational Biology,
   IIT Delhi for their help.
CR Aja P. M., 2014, AM J PHYTOMED CLIN T, V2
   Baloch I. I., 2020, TRAVEL MED, V27
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988
   Ben-Shabat S, 2020, DRUG DELIV TRANSL RE, V10, P354, DOI 10.1007/s13346-019-00691-6
   Chen IJ, 2013, BBA-PROTEINS PROTEOM, V1834, P1054, DOI 10.1016/j.bbapap.2013.03.003
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   Davidson AD, 2020, BIORXIV, DOI [10.1101/2020.03.22.002204, DOI 10.1101/2020.03.22.002204]
   Dev K., 2017, US Patent, Patent No. 201711028454
   FENWICK GR, 1985, VET REC, V116, P28, DOI 10.1136/vr.116.1.28
   Ganjhu Rajesh Kumar, 2015, VirusDisease, V26, P225, DOI 10.1007/s13337-015-0276-6
   Georgiev V., 2005, JOURNEES EQUATIONS D, DOI [10.5802/jedp.17, DOI 10.5802/JEDP.17]
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Grossoehme NE, 2009, J MOL BIOL, V394, P544, DOI 10.1016/j.jmb.2009.09.040
   Gupta E., 2020, ETHNOPHARMACOLOGICAL
   Gutierrez C, 2019, I C DEPEND SYS NETWO, P9, DOI 10.1109/DSN-Industry.2019.00009
   Ho TY, 2007, ANTIVIR RES, V74, P92, DOI 10.1016/j.antiviral.2006.04.014
   Jaric S, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/101978
   Kalyaanamoorthy S, 2011, DRUG DISCOV TODAY, V16, P831, DOI 10.1016/j.drudis.2011.07.006
   Kang Yuan-Lin, 2020, bioRxiv, DOI 10.1101/2020.04.21.053058
   Lanka G, 2019, J RECEPT SIG TRANSD, V39, P253, DOI 10.1080/10799893.2019.1660897
   Latha N., 2020, SILICO STUDIES REVEA, DOI [10.21203/rs.3.rs-22687/v1, DOI 10.21203/RS.3.RS-22687/V1]
   Lionta E, 2014, CURR TOP MED CHEM, V14, P1923, DOI 10.2174/1568026614666140929124445
   Lo YS, 2013, FEBS LETT, V587, P120, DOI 10.1016/j.febslet.2012.11.016
   Masters P. S., 1990, ADV EXPT MED BIOL, V276, DOI [10.1007/978-1-4684-5823-7_32, DOI 10.1007/978-1-4684-5823-7_32]
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Meng Y., 1993, VIROL SIN, V8
   Nai-Lan G., 1993, CHIN MED J, V106
   Nandekar PP, 2013, MED CHEM RES, V22, P3728, DOI 10.1007/s00044-012-0364-8
   Nelson GW, 2000, J GEN VIROL, V81, P181, DOI 10.1099/0022-1317-81-1-181
   Oladeji O., 2019, SCI AFRICAN, V6, DOI 10.1016/j.sciaf.2019.e00137
   Pal S. K., 1995, ANCIENT SCI LIFE, V14
   Potdar D, 2012, FITOTERAPIA, V83, P817, DOI 10.1016/j.fitote.2012.04.012
   Ramajayam R, 2011, BIOCHEM SOC T, V39, P1371, DOI 10.1042/BST0391371
   Ramatenki V, 2015, J RECEPT SIG TRANSD, V35, P536, DOI 10.3109/10799893.2014.969375
   RATHI K, 2020, CHEM BIOL LETT, V7
   Rolta R., 2018, MED PLANT, V8
   Rolta R, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112867
   Saikatendu KS, 2007, J VIROL, V81, P3913, DOI 10.1128/JVI.02236-06
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Schwarz S, 2011, ANTIVIR RES, V90, P64, DOI 10.1016/j.antiviral.2011.02.008
   Sharma N, 2020, J ETHNOPHARMACOL, V255, DOI 10.1016/j.jep.2020.112736
   Singh M, 2017, PAC ASIA J ASSOC INF, V9, P1
   Takooree H, 2019, CRIT REV FOOD SCI, V59, pS210, DOI 10.1080/10408398.2019.1565489
   Tan YW, 2006, NUCLEIC ACIDS RES, V34, P4816, DOI 10.1093/nar/gkl650
   Tatar G., 2020, INVESTIGATION N TERM, DOI [10.14293/S2199-1006.1.SOR-.PPPT99I.v1, DOI 10.14293/S2199-1006.1.SOR-.PPPT99I.V1]
   Tripathi SK, 2013, J THEOR BIOL, V334, P87, DOI 10.1016/j.jtbi.2013.05.014
   TSAI Y, 1985, PLANTA MED, V51, P460, DOI 10.1055/s-2007-969553
   Ubani A., 2020, BIORXIV, DOI 10.1101/2020.03.31.017657
   WEBER ND, 1992, PLANTA MED, V58, P417, DOI 10.1055/s-2006-961504
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yadav R., 2020, J BIOMOLECULAR STRUC, V20
NR 52
TC 1
Z9 1
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1804457
EA AUG 2020
PG 18
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NF5UW
UT WOS:000563363100001
PM 32851912
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Shree, P
   Mishra, P
   Selvaraj, C
   Singh, SK
   Chaube, R
   Garg, N
   Tripathi, YB
AF Shree, Priya
   Mishra, Priyanka
   Selvaraj, Chandrabose
   Singh, Sanjeev Kumar
   Chaube, Radha
   Garg, Neha
   Tripathi, Yamini Bhusan
TI Targeting COVID-19 (SARS-CoV-2) main protease through active
   phytochemicals of ayurvedic medicinal plants -Withania
   somnifera(Ashwagandha),Tinospora cordifolia(Giloy) andOcimum
   sanctum(Tulsi) - a molecular docking study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19 (SARS-CoV-2) M-pro; molecular docking; MD simulation; ayurveda;
   medicinal plants; ADMET; drug-likeness
ID DISCOVERY
AB COVID-19 (Coronavirus disease 2019) is a transmissible disease initiated and propagated through a new virus strain SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) since 31(st)December 2019 in Wuhan city of China and the infection has outspread globally influencing millions of people. Here, an attempt was made to recognize natural phytochemicals from medicinal plants, in order to reutilize them against COVID-19 by the virtue of molecular docking and molecular dynamics (MD) simulation study. Molecular docking study showed six probable inhibitors against SARS-CoV-2 M-pro(Main protease), two fromWithania somnifera(Ashwagandha) (Withanoside V [10.32 kcal/mol] and Somniferine [9.62 kcal/mol]), one fromTinospora cordifolia(Giloy) (Tinocordiside [8.10 kcal/mol]) and three fromOcimum sanctum(Tulsi) (Vicenin [8.97 kcal/mol], Isorientin 4 '-O-glucoside 2 ''-O-p-hydroxybenzoagte [8.55 kcal/mol] and Ursolic acid [8.52 kcal/mol]). ADMET profile prediction showed that the best docked phytochemicals from present work were safe and possesses drug-like properties. Further MD simulation study was performed to assess the constancy of docked complexes and found stable. Hence from present study it could be suggested that active phytochemicals from medicinal plants could potentially inhibit M(pro)of SARS-CoV-2 and further equip the management strategy against COVID-19-a global contagion.
C1 [Shree, Priya; Mishra, Priyanka; Garg, Neha; Tripathi, Yamini Bhusan] Banaras Hindu Univ, Inst Med Sci, Dept Med Chem, Varanasi, Uttar Pradesh, India.
   [Selvaraj, Chandrabose; Singh, Sanjeev Kumar] Alagappa Univ, Dept Bioinformat, Comp Aided Drug Design & Mol Modeling Lab, Sci Block, Karaikkudi, Tamil Nadu, India.
   [Chaube, Radha] Banaras Hindu Univ, Inst Sci, Dept Zool, Varanasi, Uttar Pradesh, India.
RP Garg, N; Tripathi, YB (corresponding author), Banaras Hindu Univ, Inst Med Sci, Dept Med Chem, Varanasi, Uttar Pradesh, India.
EM nehagarg@bhu.ac.in; yamini30@gmail.com
RI Tripathi, Yamini Bhusan/Q-6160-2019; Garg, Neha/AAG-5180-2020; Selvaraj,
   Chandrabose/F-4168-2012
OI Tripathi, Yamini Bhusan/0000-0002-8093-1109; Garg,
   Neha/0000-0003-2227-8292; Selvaraj, Chandrabose/0000-0002-8115-0486;
   mishra, priyanka/0000-0002-4490-9844; Shree, Priya/0000-0002-8899-1499
FU RUSA-Phase 2.0 Policy (TNmulti-Gen), Dept. of Edn, Govt. of India
   [F.24-51/2014-U]
FX BHU administration, Center for Bioinformatics, School of Biotechnology,
   Department of Biotechnology, ISc, BHU, Varanasi, for the use of YASARA
   software. We are thankful to Manish Kumar Tripathi, Research associate,
   Department of Biophysics, AIIMS, New Delhi, for help in image
   visualization. CS and SKS thankfully acknowledge RUSA-Phase 2.0 Policy
   (TNmulti-Gen), Dept. of Edn, Govt. of India (Grant No: F.24-51/2014-U).
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], COR COVID 19 2019 NC
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Chan JFW, 2012, J INFECTION, V65, P477, DOI 10.1016/j.jinf.2012.10.002
   Chaudhary A, 2020, J FOOD SCI TECH MYS, V57, P3852, DOI 10.1007/s13197-020-04417-2
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Chow E., 2008, DESMOND PERFORMANCE
   de Oliveira OV, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772885
   Dhar RS, 2006, PHYTOCHEMISTRY, V67, P2269, DOI 10.1016/j.phytochem.2006.07.014
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Ganguly B, 2018, J GINSENG RES, V42, P463, DOI 10.1016/j.jgr.2017.05.002
   Ghosal S, 1997, J NAT PROD, V60, P839, DOI 10.1021/np970169z
   Hindustan Times, 2020, HINDUSTAN TIMES
   Jamshidi N, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/9217567
   Jayaram B, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S17-S7
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Kapoor L.D., 1990, CRC HDB AYURVEDIC ME
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Krieger E, 2014, BIOINFORMATICS, V30, P2981, DOI 10.1093/bioinformatics/btu426
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Matsuda H, 2001, BIOORGAN MED CHEM, V9, P1499, DOI 10.1016/S0968-0896(01)00024-4
   Maurya D. K., 2020, EVALUATION TRADITION, DOI [10.26434/chemrxiv.12110214.v1, DOI 10.26434/CHEMRXIV.12110214.V1]
   Mengist HM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0178-y
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Mothay Dipti, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00585-z
   Mukherjee R, 2005, RES VET SCI, V79, P37, DOI 10.1016/j.rvsc.2004.11.001
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Murthy M. R. Ven, 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P238
   Nadkarni K. M., 1954, KM NADKARNIS INDIAN
   Panchabhai TS, 2008, PHYTOTHER RES, V22, P425, DOI 10.1002/ptr.2347
   Prakash P., 2005, INDIAN J PHYSL PHARM
   RJPP, 2010, TRAD IND HERB PLANTS
   Selvaraj C, 2018, FOOD CHEM TOXICOL, V112, P495, DOI 10.1016/j.fct.2017.08.028
   Sharma P, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02437
   Sharma P, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/643847
   Sharma S., 1999, J SCI IND RES, V58
   Sharma U, 2012, J ETHNOPHARMACOL, V141, P918, DOI 10.1016/j.jep.2012.03.027
   Singh R, 2008, BIOGERONTOLOGY, V9, P369, DOI 10.1007/s10522-008-9185-z
   Thatte U. M., 1992, J POSTGRADUATE MED, V38
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Varshney A., 2020, VIROL J, DOI [10.21203/rs.3.rs-17806/v1, DOI 10.21203/RS.3.RS-17806/V1]
   Varshney K. K., 2020, MOL MODELING ISOLATE
   Vyas Vivek K., 2011, Journal of Natural Remedies, V11, P1
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Williamson E. M., 2002, MAJOR HERBS AYURVEDA
   World Health Organization, 2020, WHO WELC PREL RES DE
   World Health Organization (WHO), 2020, DAT REC WHO NAT AUTH
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yadav R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2019.1709546
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Yuan SG, 2017, WIRES COMPUT MOL SCI, V7, DOI 10.1002/wcms.1298
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 56
TC 1
Z9 1
U1 6
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1810778
EA AUG 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NF5YK
UT WOS:000563372400001
PM 32851919
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Shea, LM
AF Shea, Lynne-Marie
TI The Courage to Be: Using DBT Skills to Choose Who to Be in Uncertainty
SO JOURNAL OF HUMANISTIC PSYCHOLOGY
LA English
DT Article; Early Access
DE existential psychology; humanistic psychology; dialectical behavior
   therapy; critical pedagogy
ID SELF; MECHANISMS
AB The COVID-19 pandemic has presented a unique set of circumstances in which most of us are struggling with the same sort of existential questions across our unique contexts and subjective experiences. As we work to answer these questions within the uncertainty of the pandemic, dialectical behavior therapy (DBT) provides tools through which to consider and make meaning of these existential questions. DBT skills, which are aimed at increasing our capacity to practice mindfulness, regulate emotions, tolerate distress, think dialectically, and interact interpersonally, provide practical strategies to increase our senses of agency as we consider who we are in our own lives and in our relationship with others. With increased agency, we are more able to respond to the existential questions inherent in a global crisis by building the kind of courage needed to choose who to be.
C1 [Shea, Lynne-Marie] Suffolk Univ, Psychol, Boston, MA 02114 USA.
RP Shea, LM (corresponding author), Suffolk Univ, 73 Tremont St, Boston, MA 02114 USA.
EM lshea@su.suffolk.edu
OI Shea, Lynne-Marie/0000-0003-2501-0523
CR Basseches M., 1984, DIALECTICAL THINKING
   Baumeister RF, 2006, J PERS, V74, P1773, DOI 10.1111/j.1467-6494.2006.00428.x
   Bohart AC, 2001, AM PSYCHOL, V56, P81, DOI 10.1037/0003-066X.56.1.81
   Bonavitacola L, 2019, COGN BEHAV PRACT, V26, P547, DOI 10.1016/j.cbpra.2018.11.003
   Brace K., 1992, HUMANISTIC PSYCHOL, V20, P41, DOI 10.1080/08873267.1992.9986778
   Buber M., 1965, KNOWLEDGE MAN PHILOS
   Bugental J. F., 1992, ART PSYCHOTHERAPIST
   Bugental J. F. T., 1992, HUMANISTIC PSYCHOL, V20, P273, DOI [10.1080/08873267.1992.9986795, DOI 10.1080/08873267.1992.9986795]
   Bunting K, 2008, EXISTENTIAL-INTEGRATIVE PSYCHOTHERAPY: GUIDEPOSTS TO THE CORE OF PRACTICE, P217
   CACIOPPO JT, 1994, PSYCHOL BULL, V115, P401, DOI 10.1037/0033-2909.115.3.401
   Carver C. S., 2001, SELF REGULATION BEHA
   Chaffins B. J., 2002, ANN CONV AM PSYCH AS
   Christakis N. A., 2009, CONNECTED SURPRISING
   Comas-Diaz L, 2012, PSYCHOTHERAPY, V49, P437, DOI 10.1037/a0027126
   Cooper M, 2016, J HUMANIST PSYCHOL, V56, P581, DOI 10.1177/0022167816659755
   Cunningham RJ, 2007, J HUMANIST PSYCHOL, V47, P73, DOI 10.1177/0022167806293004
   Elliot AJ, 2006, MOTIV EMOTION, V30, P111, DOI 10.1007/s11031-006-9028-7
   Feliu-Soler A, 2014, CLIN PSYCHOL PSYCHOT, V21, P363, DOI 10.1002/cpp.1837
   FIRESTONE RW, 1987, AM J PSYCHOANAL, V47, P210, DOI 10.1007/BF01250340
   Frankl V., 1962, J RELIG HLTH, V1, P93, DOI DOI 10.1007/BF01532076
   Freire P., 1972, PEDAGOGY OPPRESSED
   FRICK WB, 1987, J HUMANIST PSYCHOL, V27, P406, DOI 10.1177/0022167887274003
   Holzel BK, 2011, PERSPECT PSYCHOL SCI, V6, P537, DOI 10.1177/1745691611419671
   Hoffman BA, 2014, WORLD BANK LEGAL REVIEW, VOL 5: FOSTERING DEVELOPMENT THROUGH OPPORTUNITY, INCLUSION, AND EQUITY, P41
   Hoffman L., 2019, WILEY WORLD HDB EXIS, P290, DOI [10.1002/9781119167198.ch18, DOI 10.1002/9781119167198.CH18]
   Hoffman L, 2009, J HUMANIST PSYCHOL, V49, P135, DOI 10.1177/0022167808324880
   Kincheloe J. L., 2008, CRITICAL PEDAGOGY PR, V1
   Linehan M., 1993, COGNITIVE BEHAV TREA, DOI [10.1037/10169-020, DOI 10.1037/10169-020]
   Linehan M. M., 1993, SKILLS TRAINING MANU
   Linehan M. M., 1995, THEORIES BEHAV THERA, P553, DOI 10.1037/10169-020
   Lynch TR, 2006, J CLIN PSYCHOL, V62, P459, DOI 10.1002/jclp.20243
   MacLean KA, 2010, PSYCHOL SCI, V21, P829, DOI 10.1177/0956797610371339
   May R., 1985, COURAGE CREATE
   Miller AL, 2006, DIALECTICAL BEHAV TH
   Morton K. W., 2019, GETTING OUT YOUTH GA
   Pitts S. E, 1978, M BUBERS I THOU CONC
   Pyszczynski T, 2006, PSYCHOL INQ, V17, P328, DOI 10.1080/10478400701369542
   Rathus J., 2014, DBT SKILLS MANUAL AD
   Richert AJ, 1999, J PSYCHOTHER INTEGR, V9, P257, DOI 10.1023/A:1023248122756
   Robbins B. D., 2018, MED BODY ANESTHETIC, P301
   Rockwell D., 2014, HUMANIST PSYCHOL, V42, P114
   Schneider K., 1999, PARADOXICAL SELF UND
   Schneider K. J., 2010, HUMANISTIC PSYCHOL, V38, P1, DOI [10.1080/08873261003635815, DOI 10.1080/08873261003635815]
   Seitz Andrew C., 2016, International Pacific Halibut Commission Scientific Report, V86, P1
   SOLOMON S, 1991, ADV EXP SOC PSYCHOL, V24, P93
   Tillich P, 1952, COURAGE BE
   Toews J. E., 1985, HEGELIANISM PATH DIA
   van den Bos K, 2009, PSYCHOL INQ, V20, P197, DOI 10.1080/10478400903333411
   Watson J. C., 2016, APA HDB CLIN PSYCHOL, P117, DOI [10.1037/14773-005, DOI 10.1037/14773-005]
NR 49
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-1678
EI 1552-650X
J9 J HUMANIST PSYCHOL
JI J. Humanist. Psychol.
AR 0022167820950887
DI 10.1177/0022167820950887
EA AUG 2020
PG 15
WC Psychology, Multidisciplinary
SC Psychology
GA NF7OJ
UT WOS:000563483500001
DA 2021-01-01
ER

PT J
AU Saha, S
   Samanta, GP
   Nieto, JJ
AF Saha, Sangeeta
   Samanta, G. P.
   Nieto, Juan J.
TI Epidemic model of COVID-19 outbreak by inducing behavioural response in
   population
SO NONLINEAR DYNAMICS
LA English
DT Article
DE COVID-19; Epidemic model; Behavioural response; Optimal control
ID INFECTIOUS-DISEASES
AB COVID-19 has spread around the world since December 2019, creating one of the greatest pandemics ever witnessed. According to the current reports, this is a situation when people need to be more careful and take the precaution measures more seriously, unless the condition may become even worse. Maintaining social distances and proper hygiene, staying at isolation or adopting the self-quarantine method are some of the common practices that people should use to avoid the infection. And the growing information regarding COVID-19 and its symptoms help the people to take proper precautions. In this present study, we consider an SEIRS epidemiological model on COVID-19 transmission which accounts for the effect of an individual's behavioural response due to the information regarding proper precautions. Our results indicate that if people respond to the growing information regarding awareness at a higher rate and start to take the protective measures, then the infected population decreases significantly. The disease fatality can be controlled only if a large proportion of individuals become immune, either by natural immunity or by a proper vaccine. In order to apply the latter option, we need to wait until a safe and proper vaccine is developed and it is a time-taking process. Hence, in the latter part of the work, an optimal control problem is considered by implementing control strategies to reduce the disease burden. Numerical figures show that the control denoting behavioural response works with higher intensity immediately after implementation and then gradually decreases with time. Further, the control policy denoting hospitalisation of infected individuals works with its maximum intensity for quite a long time period following a sudden decrease. As, the implementation of the control strategies reduce the infected population and increase the recovered population, so, it may help to reduce the disease transmission at this current epidemic situation.
C1 [Saha, Sangeeta; Samanta, G. P.] Indian Inst Engn Sci & Technol, Dept Math, Sibpur 711103, Howrah, India.
   [Nieto, Juan J.] Univ Santiago de Compostela, Inst Matemat, Santiago De Compostela 15782, Spain.
RP Samanta, GP (corresponding author), Indian Inst Engn Sci & Technol, Dept Math, Sibpur 711103, Howrah, India.
EM sangeetasaha629@gmail.com; g_p_samanta@yahoo.co.uk;
   juanjose.nieto.roig@usc.es
OI Nieto, Juan J./0000-0001-8202-6578
FU University Grants Commission, IndiaUniversity Grants Commission, India;
   Agencia Estatal de Investigacion (AEI) of Spain; European Fund for
   Regional Development (FEDER)European Union (EU) [MTM201675140-P]; Xunta
   deGaliciaXunta de Galicia [ED431C 2019/02]
FX The authors are grateful to the anonymous referees, Dr. Jun Ma,
   Associate Editor, for their careful reading, valuable comments and
   helpful suggestions, which have helped them to improve the presentation
   of this work significantly. The first author (Sangeeta Saha) is thankful
   to the University Grants Commission, India for providing SRF. The
   research of J.J. Nieto has been partially supported by the Agencia
   Estatal de Investigacion (AEI) of Spain, cofinanced by the European Fund
   for Regional Development (FEDER) corresponding to the 2014-2020
   multiyear financial framework, Project MTM201675140-P; and byXunta
   deGalicia under Grant ED431C 2019/02.
CR [Anonymous], 2020, CORONAVIRUS COVID 19
   Arriola L., LECT NOTES FORWARD A
   Behncke H, 2000, OPTIM CONTR APPL MET, V21, P269, DOI 10.1002/oca.678
   Buonomo B, 2012, APPL MATH LETT, V25, P1056, DOI 10.1016/j.aml.2012.03.016
   Castilho C, 2006, ELECTRON J DIFFER EQ
   CDC Director, 25 PERC INF PEOPL MA
   Centers for Disease Control and Prevention, 2019, 2019 NOV COR, P2020
   Chakravarthi VP, 2020, DATA BRIEF, V30, DOI 10.1016/j.dib.2020.105405
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coddington E. A., 1955, THEORY ORDINARY DIFF
   Das M., 2020, FRACTIONAL ORDER COV
   Dorigatti I, 2020, REPORT 4 SEVERITY 20
   Famulare M., 2020, 2019 NCOV PRELIMINAR
   Ferguson N, 2020, REPORT 9 IMPACT NONP
   Fleming W., 1975, DETERMINISTIC STOCHA
   Gaff H, 2009, MATH BIOSCI ENG, V6, P469, DOI 10.3934/mbe.2009.6.469
   Gaythorpe K., 2020, REPORT 8 SYMPTOM PRO, P10
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hale J., 1977, THEORY FUNCTIONAL DI
   Joshi HR, 2006, CONTEMP MATH, V410, P187
   Juan D., 2020, WUHAN WET MARKET CLO
   Kassa SM, 2015, J MATH BIOL, V70, P213, DOI 10.1007/s00285-014-0761-3
   Kirk D. E., 2012, OPTIMAL CONTROL THEO
   LaSalle J. P., 1976, STABILITY DYNAMICAL
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Ndairou F, 2020, SOLITONS FRACTALS, DOI 10.1016/j.chaos.2020.109846
   Pontryagin L. S., 1987, MATH THEORY OPTIMAL
   Quilty BJ, 2020, EUROSURVEILLANCE, V25, P4, DOI 10.2807/1560-7917.ES.2020.25.5.2000080
   Richman D.D., 2016, CLIN VIROLOGY
   Secon H., 2020, PEOPLE COULD GET NOV
   Shen M, 2020, MODELLING EPIDEMIC T, DOI [10.1101/2020.01.23.916726, DOI 10.1101/2020.01.23.916726, 10.1101/2020.01.23.916726.]
   Singh R., 2020, ARXIV200312055
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 40
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0924-090X
EI 1573-269X
J9 NONLINEAR DYNAM
JI Nonlinear Dyn.
PD SEP
PY 2020
VL 102
IS 1
BP 455
EP 487
DI 10.1007/s11071-020-05896-w
EA AUG 2020
PG 33
WC Engineering, Mechanical; Mechanics
SC Engineering; Mechanics
GA OG5NP
UT WOS:000562674600001
PM 32863581
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, XW
   Chen, XF
   Tang, F
   Luo, WJ
   Fang, J
   Qi, C
   Sun, H
   Xiao, H
   Peng, XH
   Shao, JB
AF Wang, Xiaowen
   Chen, Xingfeng
   Tang, Feng
   Luo, Wanjun
   Fang, Jian
   Qi, Chang
   Sun, Hua
   Xiao, Han
   Peng, Xuehua
   Shao, Jianbo
TI Be aware of acute kidney injury in critically ill children with COVID-19
SO PEDIATRIC NEPHROLOGY
LA English
DT Article
DE COVID-19; AKI; Plasmapheresis; CKRT
ID IMPAIRMENT
AB Background Acute kidney injury (AKI) is a common complication of critically ill adult patients with COVID-19. However, currently, no studies investigate kidney impairment in children with COVID-19. We investigated incidence and treatment of AKI in pediatric patients with COVID-19 in Wuhan Children's Hospital during the early stages of the COVID-19 pandemic and discuss possible mechanisms of AKI related to SARS-CoV-2 infection. Methods By extracting data from electronic medical records, we conducted a retrospective observational study of kidney involvement in confirmed pediatric COVID-19 cases in Wuhan Children's Hospital during the coronavirus outbreak, from January 24 to March 20, 2020. Clinical presentations, clinical courses, laboratory findings, and medical interventions are described below. Results Among 238 confirmed COVID-19 cases, only three were critically ill and needed intensive care unit (ICU) admission. All three developed AKI, but AKI was not detected in any non-critically ill patients outside the ICU. Two of the three patients with AKI had prodromal gastrointestinal symptoms. Significantly elevated interleukin-6 (IL-6) levels and complement activation were observed in these patients with AKI. The three patients with AKI were treated with plasma exchange (PE) and continuous kidney replacement therapy (CKRT), resulting in one complete recovery, one partial recovery, and one mortality due to critical illness. Conclusions Critically ill children with COVID-19 may develop AKI, especially following prodromal gastrointestinal symptoms. An inflammatory storm and complement-mediated injury may underlie AKI development in children with COVID-19. Our study supports implantation of PE and CKRT in management of critically ill patients with AKI.
C1 [Wang, Xiaowen; Fang, Jian; Qi, Chang] Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Wuhan Maternal & Child Healthcare Hosp, Tongji Med Coll,Dept Nephrol, Wuhan 430000, Peoples R China.
   [Chen, Xingfeng; Shao, Jianbo] Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Wuhan Maternal & Child Healthcare Hosp, Tongji Med Coll,Intens Care Unit, Wuhan 430000, Peoples R China.
   [Tang, Feng] Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Wuhan Maternal & Child Healthcare Hosp, Tongji Med Coll,Dept Lab Med, Wuhan 430000, Peoples R China.
   [Luo, Wanjun] Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Wuhan Maternal & Child Healthcare Hosp, Tongji Med Coll,Hosp Acquired Infect Control Dept, Wuhan 430000, Peoples R China.
   [Sun, Hua] Harvard Med Sch, Boston Childrens Hosp, Dept Nephrol, Boston, MA 02115 USA.
   [Xiao, Han] Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Tongji Med Coll, Wuhan Maternal & Child Healthcare Hosp,Inst Mater, Wuhan 430000, Peoples R China.
   [Peng, Xuehua; Shao, Jianbo] Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Tongji Med Coll, Wuhan Maternal & Child Healthcare Hosp,Med Imagin, Wuhan 430000, Peoples R China.
   [Shao, Jianbo] Wuhan Childrens Hosp, Wuhan Maternal & Child Healthcare Hosp, Inst Maternal & Child Hlth, 100 Hongkong Rd, Wuhan 430000, Peoples R China.
RP Shao, JB (corresponding author), Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Wuhan Maternal & Child Healthcare Hosp, Tongji Med Coll,Intens Care Unit, Wuhan 430000, Peoples R China.; Shao, JB (corresponding author), Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Tongji Med Coll, Wuhan Maternal & Child Healthcare Hosp,Med Imagin, Wuhan 430000, Peoples R China.; Shao, JB (corresponding author), Wuhan Childrens Hosp, Wuhan Maternal & Child Healthcare Hosp, Inst Maternal & Child Hlth, 100 Hongkong Rd, Wuhan 430000, Peoples R China.
EM shaojb2002@sina.com
FU Natural Science Foundation of Hubei ProvinceNatural Science Foundation
   of Hubei Province [2016CFC728]; Key Projects of Scientific Research
   Program of Wuhan Health Commission [WX16A07]; Projects of Healthy
   Commission of Hubei Province [WJ2019M011]; Projects of Centers for
   Disease Control and Prevention of WuhanUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [WHCDCIRB-K-2020007]
FX All phases of this study were supported by the Natural Science
   Foundation of Hubei Province (2016CFC728), Key Projects of Scientific
   Research Program of Wuhan Health Commission (WX16A07), Projects of
   Healthy Commission of Hubei Province (WJ2019M011), and Projects of
   Centers for Disease Control and Prevention of Wuhan
   (WHCDCIRB-K-2020007).
CR Benoit SW, 2018, PEDIATR NEPHROL, V33, P779, DOI 10.1007/s00467-017-3695-3
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Ciccia E, 2017, INT J NEPHROL RENOV, V10, P77, DOI 10.2147/IJNRD.S103785
   Deng YY, 2020, CHINESE MED J-PEKING, V133, P1129, DOI 10.1097/CM9.0000000000000783
   Diao B, 2020, HUMAN KIDNEY IS TARG, DOI [10.1101/2020.03.04.20031120medRxiv, DOI 10.1101/2020.03.04.20031120MEDRXIV]
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Fayad AI, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010613.pub2
   Kaddourah A, 2017, NEW ENGL J MED, V376, P11, DOI 10.1056/NEJMoa1611391
   Lameire N, 2017, PEDIATR NEPHROL, V32, P1301, DOI 10.1007/s00467-016-3433-2
   Li Z, 2020, CAUTION KIDNEY DYSFU, DOI [10.1101/2020.02.08.20021212%JmedRxiv, DOI 10.1101/2020.02.08.20021212%JMEDRXIV]
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Ma J, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108408
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   McCullough JW, 2013, SEMIN NEPHROL, V33, P543, DOI 10.1016/j.semnephrol.2013.08.005
   Mulay SR, 2016, SEMIN NEPHROL, V36, P17, DOI 10.1016/j.semnephrol.2016.01.006
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Perico Luca, 2020, Nephron, V144, P213, DOI 10.1159/000507305
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Rismanbaf A, 2020, ARCH ACAD EMERG MED, V8
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Sutherland SM, 2017, ADV CHRONIC KIDNEY D, V24, P380, DOI 10.1053/j.ackd.2017.09.007
   Tveito Kari, 2020, Tidsskr Nor Laegeforen, V140, DOI 10.4045/tidsskr.20.0239
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu X, 2018, CLIN J AM SOC NEPHRO, V13, P1791, DOI 10.2215/CJN.00800118
   Xu X, 2018, J AM SOC NEPHROL, V29, P2432, DOI 10.1681/ASN.2018010090
   Yang X H, 2020, Zhonghua Yi Xue Za Zhi, V100, P1205, DOI 10.3760/cma.j.cn112137-20200229-00520
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JX, 2018, BLOOD PURIFICAT, V46, P326, DOI 10.1159/000492026
   Zilberman-Itskovich S, 2019, RENAL FAILURE, V41, P967, DOI 10.1080/0886022X.2019.1677248
NR 34
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0931-041X
EI 1432-198X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD JAN
PY 2021
VL 36
IS 1
BP 163
EP 169
DI 10.1007/s00467-020-04715-z
EA AUG 2020
PG 7
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA OZ4NF
UT WOS:000562991500003
PM 32844290
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Dursun, R
   Temiz, SA
   Ozer, I
   Daye, M
   Ataseven, A
AF Dursun, Recep
   Temiz, Selami A.
   Ozer, Ilkay
   Daye, Munise
   Ataseven, Arzu
TI Management of patients with Behcet's disease during theCOVID-19 pandemic
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE anti-TNF agents; azathioprine; Behcet's disease; colchicine; COVID-19;
   immunosuppressive drugs
AB Behcet's disease is a disease characterized by chronic inflammatory vasculitis. In the clinical symptoms of Behcet's disease, many immunosuppressive and immunomodulatory drugs are used. The suspicion that drugs used in chronic disease treatments such as Behcet's disease during pandemic will increase the risk of transmission of COVID-19 disease, and that the disease may progress more lethally in these patients after the infection caused clinicians to worry. As far as we know, there is no study in the literature about the management of patients with Behcet's disease in the pandemic period. Fifty-four patients with Behcet's disease who were admitted to the dermatology outpatient clinic between 11 March and July 14, 2020 were retrospectively analyzed. In this pandemic period, 44 of 54 patients were recommended to continue their previous treatment. While the dose of medication used by 7 patients was reduced, it was decided to change the treatment of 3 patients. No life-threatening activation was observed. None of the patients developed COVID-19 disease. This article is important in terms of being the first study in the literature examining the treatment of patients with Behcet's disease during the COVID-19. In this period, we know that the treatment practices in chronic diseases change frequently daily, and in this respect, we hope that our study will provide a perspective to other dermatology clinics in terms of the treatment of Behcet's disease during the pandemic.
C1 [Dursun, Recep; Temiz, Selami A.; Ozer, Ilkay; Daye, Munise; Ataseven, Arzu] Necmettin Erbakan Univ, Meram Med Fac, Dept Dermatol, Konya, Turkey.
RP Dursun, R (corresponding author), Necmettin Erbakan Univ, Meram Med Fac, Dept Dermatol, TR-42080 Meram Konya, Konya, Turkey.
EM recepdursun@gmail.com
RI Dursun, Recep/ABI-1641-2020; Temiz, Selami Aykut/AAI-1181-2020
OI Dursun, Recep/0000-0002-1279-574X; Temiz, Selami
   Aykut/0000-0003-4878-0045; Ataseven, Arzu/0000-0001-5372-0712; ozer,
   ilkay/0000-0001-6170-0930
CR Alpsoy E, 2007, BRIT J DERMATOL, V157, P901, DOI 10.1111/j.1365-2133.2007.08116.x
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Caliskan M, 2008, INT J CARDIOL, V125, P428, DOI 10.1016/j.ijcard.2007.01.057
   Cure MC, 2020, CLIN RHEUMATOL, V39, P2101, DOI 10.1007/s10067-020-05144-x
   Dursun R, 2007, INT J PSYCHIAT CLIN, V11, P16, DOI 10.1080/13651500600811438
   Elmas OF, 2020, DERMATOL THER, DOI 10.1111/dth.13858
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Farouk A, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109768
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hatemi G, 2018, ANN RHEUM DIS, V77, P808, DOI 10.1136/annrheumdis-2018-213225
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Karadag AS, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13686
   Kutlu O, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13581
   Long B, 2020, AM J EMERG MED, V38, P1504, DOI 10.1016/j.ajem.2020.04.048
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Parra-Medina R, 2020, CLIN RHEUMATOL, V39, P2485, DOI 10.1007/s10067-020-05247-5
   Temiz SA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13642
   Uzun S, 2003, J DERMATOL, V30, P499, DOI 10.1111/j.1346-8138.2003.tb00423.x
   YAZICI H, 1990, NEW ENGL J MED, V322, P281, DOI 10.1056/NEJM199002013220501
NR 21
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e14063
DI 10.1111/dth.14063
EA AUG 2020
PG 5
WC Dermatology
SC Dermatology
GA NE3UY
UT WOS:000562525300001
PM 32710599
OA Bronze
DA 2021-01-01
ER

PT J
AU Moodley, K
   Rennie, S
   Behets, F
   Obasa, AE
   Yemesi, R
   Ravez, L
   Kayembe, P
   Makindu, D
   Mwinga, A
   Jaoko, W
AF Moodley, Keymanthri
   Rennie, Stuart
   Behets, Frieda
   Obasa, Adetayo Emmanuel
   Yemesi, Robert
   Ravez, Laurent
   Kayembe, Patrick
   Makindu, Darius
   Mwinga, Alwyn
   Jaoko, Walter
TI Allocation of scarce resources in Africa during COVID-19: Utility and
   justice for the bottom of the pyramid?
SO DEVELOPING WORLD BIOETHICS
LA English
DT Article; Early Access
DE COVID-19; scarce resources; Africa
ID VACCINE
AB The COVID-19 pandemic has raised important universal public health challenges. Conceiving ethical responses to these challenges is a public health imperative but must take context into account. This is particularly important in sub-Saharan Africa (SSA). In this paper, we examine how some of the ethical recommendations offered so far in high-income countries might appear from a SSA perspective. We also reflect on some of the key ethical challenges raised by the COVID-19 pandemic in low-income countries suffering from chronic shortages in health care resources, and chronic high morbidity and mortality from non-COVID-19 causes. A parallel is drawn between the distribution of severity of COVID-19 disease and the classic "Fortune at the bottom of the pyramid" model that is relevant in SSA. Focusing allocation of resources during COVID-19 on the 'thick' part of the pyramid in Low-to-Middle Income Countries (LMICs) could be ethically justified on utilitarian and social justice grounds, since it prioritizes a large number of persons who have been economically and socially marginalized. During the pandemic, importing allocation frameworks focused on the apex of the pyramid from the global north may therefore not always be appropriate. In a post-COVID-19 world, we need to think strategically about how health care systems can be financed and structured to ensure broad access to adequate health care for all who need it. The root problems underlying health inequity, exposed by COVID-19, must be addressed, not just to prepare for the next pandemic, but to care for people in resource poor settings in non-pandemic times.
C1 [Moodley, Keymanthri] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Med, Cape Town, South Africa.
   [Moodley, Keymanthri] Stellenbosch Univ, Fac Med & Hlth Sci, Ctr Med Eth & Law, Cape Town, South Africa.
   [Moodley, Keymanthri] Univ North Carolina Chapel Hill, Dept Social Med, Chapel Hill, NC USA.
   [Rennie, Stuart] Univ North Carolina Chapel Hill, Ctr Bioeth, Dept Social Med, Chapel Hill, NC USA.
   [Rennie, Stuart] Univ North Carolina Chapel Hill, Ctr Bioeth, Core Fac, Chapel Hill, NC USA.
   [Behets, Frieda] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA.
   [Obasa, Adetayo Emmanuel] Stellenbosch Univ, Dept Med, Ctr Med Eth & Law, Cape Town, South Africa.
   [Yemesi, Robert] Univ Sci & Technol Lodja, Lodja, DEM REP CONGO.
   [Yemesi, Robert; Makindu, Darius] Kinshasa Sch Publ Hlth, Ctr Interdisciplinaire Bioeth Afrique Francophone, Kinshasa, DEM REP CONGO.
   [Yemesi, Robert] Natl Eth Comm CNES, Paris, France.
   [Ravez, Laurent] Univ Namur, Fac Med, Bioeth, Namur, Belgium.
   [Ravez, Laurent] Univ Namur, Fac Med, Ctr Bioeth, Namur, Belgium.
   [Ravez, Laurent] Univ Namur, Fac Sci, Namur, Belgium.
   [Kayembe, Patrick] Kinshasa Sch Publ Hlth KSPH, Kinshasa, DEM REP CONGO.
   [Kayembe, Patrick] KSPH Res Eth Comm, Kinshasa, DEM REP CONGO.
   [Kayembe, Patrick] Fogarty NIH Bioeth Project Strengthening Bioeth C, Kinshasa, DEM REP CONGO.
   [Makindu, Darius] Univ Pedag Natl, Dept Sci Polit & Adm, Kinshasa, DEM REP CONGO.
   [Mwinga, Alwyn] Zambia AIDS Related TB Project Zambart, Lusaka, Zambia.
   [Mwinga, Alwyn] Cdc Zambia, Lusaka, Zambia.
   [Jaoko, Walter] Univ Nairobi, Med Microbiol & Trop Med, Nairobi, Kenya.
   [Jaoko, Walter] Univ Nairobi, KAVI, Nairobi, Kenya.
   [Jaoko, Walter] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya.
   [Jaoko, Walter] Stellenbosch Univ, Dept Med, Cape Town, South Africa.
RP Moodley, K (corresponding author), Stellenbosch Univ, Fac Med & Hlth Sci, Ctr Med Eth & Law, Dept Med, Cape Town, South Africa.
EM km@sun.ac.za
OI Moodley, Keymanthri/0000-0003-3404-4901; Jaoko,
   Walter/0000-0002-7134-6581; Obasa, Adetayo/0000-0003-0934-9586
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [D43-TW01511-01, R25-TW007098]
FX NIH D43-TW01511-01 and R25-TW007098
CR Abrams E. M., 2020, LANCET RESP MED, V2019, P2019, DOI [10.1016/S2213-2600(20)30234-4, DOI 10.1016/S2213-2600(20)30234-4;]
   Baker T, 2020, LANCET, V395, P1253, DOI 10.1016/S0140-6736(20)30793-5
   Biddison ELD, 2018, CHEST, V153, P187, DOI 10.1016/j.chest.2017.08.001
   Cain M.C., 2020, THE NEW YORK TIMES
   Cash R, 2020, LANCET, V395, P1687, DOI 10.1016/S0140-6736(20)31089-8
   Christen M., 2015, FILOS UNISINOS, V16, DOI [10.4013/fsu.2015.162.07, DOI 10.4013/FSU.2015.162.07]
   Cotterill J., 2020, S AFRICAS MASS SCREE
   Dizolele MP, 2010, J DEMOCR, V21, P143
   Dubler N.N., 2020, COVID 19 ETHICAL ISS
   Emanuel E, 2020, NEW ENGL J MED, V4, P1, DOI DOI 10.1056/NEJMSB2005114.2IBID
   Fischkoff K., 2020, COVID 19 ETHICAL DIL
   Fisher JA, 2013, KENNEDY INST ETHIC J, V23, P355, DOI 10.1353/ken.2013.0018
   Gattinoni L, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1750-x
   Halpern SD, 2020, ANN INTERN MED, V173, P302, DOI 10.7326/M20-2071
   Jecker NS, 2020, HASTINGS CENT REP, V50, P35, DOI 10.1002/hast.1100
   Kavanagh MM, 2020, LANCET, V395, P1735, DOI 10.1016/S0140-6736(20)31093-X
   Maclean R., 2020, NEW YORK TIMES
   McLachlan HV, 2012, J MED ETHICS, V38, P317, DOI 10.1136/medethics-2011-100031
   Murthy S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116949
   Ntusi N., 2019, S AFR MED J, P2
   Owen W.F., 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.6547, DOI 10.1001/JAMA.2020.6547;]
   Prahalad C.K., 2001, FORTUNE BOTTOM PYRAM
   Riley Taylor, 2020, Int Perspect Sex Reprod Health, V46, P73, DOI 10.1363/46e9020
   Scheunemann LP, 2011, CHEST, V140, P1625, DOI 10.1378/chest.11-0622
   Schweda M., 2017, PLANNING LATER LIFE
   The World Bank Data, 2020, WORLD BANK DATA
   van den Heever A., 2020, S AFRICA NEEDS POSTL
   van den Heever A., 2020, PROJECTIONS SA HLTH
   Wadhera R.K., 2020, JAMA J AM MED ASS, P29
   Wardrope A, 2012, J MED ETHICS, V38, P765, DOI 10.1136/medethics-2012-100750
   White DB, 2009, ANN INTERN MED, V150, P132, DOI 10.7326/0003-4819-150-2-200901200-00011
   Williams D.R., 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.8051, DOI 10.1001/JAMA.2020.8051;]
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Zimmerman RK, 2007, VACCINE, V25, P2019, DOI 10.1016/j.vaccine.2006.11.045
NR 34
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1471-8731
EI 1471-8847
J9 DEV WORLD BIOETH
JI Dev. World Bioeth.
DI 10.1111/dewb.12280
EA AUG 2020
PG 8
WC Ethics; Medical Ethics
SC Social Sciences - Other Topics; Medical Ethics
GA NE3ZA
UT WOS:000562535900001
PM 32845575
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Nasher, O
   Sutcliffe, JR
   Stewart, RJ
AF Nasher, Omar
   Sutcliffe, Jonathan Richard
   Stewart, Richard James
TI Pediatric Surgery during the COVID-19 Pandemic: An International Survey
   of Current Practice
SO EUROPEAN JOURNAL OF PEDIATRIC SURGERY
LA English
DT Article; Early Access
DE COVID-19; pediatric surgery; infectivity; asymptomatic carriage; testing
AB Introduction Understanding the challenges experienced by pediatric surgeons in the early phases of the pandemic may help identify key issues and focus research. Materials and Methods Two pediatric surgeons from each of the 10 countries most affected by COVID-19 were surveyed over a 10-day period. Data were obtained regarding service provision, infection control, specific surgical conditions, and the surgical workforce. Results Twenty pediatric surgeons responded. All centers had postponed non-emergency surgery and clinics for nonurgent conditions with virtual consultations being undertaken in 90% of centers. A majority (65%) of centers had not yet knowingly operated on a positive patient. Minimal access surgery was performed in 75% centers but a further 75% had reduced or stopped upper gastrointestinal endoscopy. The management of simple appendicitis was unchanged in 70% centers, patients with intussusception were being referred for radiological reduction in all centers and definitive pull-through surgery for Hirschsprung patients was performed by 95% where washouts were successful. Timing of surgery for reducible neonatal inguinal hernias had changed in 55% of centers and the management of urgent feeding gastrostomy referrals and of inflammatory bowel disease patients failing with biological therapy varied considerably. Conclusion Service provision has been severely affected by COVID-19 leading to an inevitable increase in untreated surgical pathology. Better understanding of extrapulmonary infectivity, the risk of asymptomatic carriage in children, and the reliability of testing for surgical scenarios may allow appropriate use of conventional surgery, including laparoscopy and endoscopy, and rational development of the novel care pathways needed during the pandemic.
C1 [Nasher, Omar; Sutcliffe, Jonathan Richard] Leeds Teaching Hosp NHS Trust, Dept Paediat Surg, Leeds, W Yorkshire, England.
   [Stewart, Richard James] Nottingham Univ Hosp NHS Trust, Dept Paediat Surg, Nottingham, England.
RP Nasher, O (corresponding author), Leeds Teaching Hosp NHS Trust, Dept Paediat Surg, Leeds, W Yorkshire, England.
EM omar.nasher@nhs.net
CR Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1070, DOI 10.1515/cclm-2020-0285
   Long CQ, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108961
   Ma X, 2020, J MICROBIOL IMMUNOL, V53, P373, DOI 10.1016/j.jmii.2020.03.010
   Tan YP, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104353
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Xing YH, 2020, J MICROBIOL IMMUNOL, V53, P473, DOI 10.1016/j.jmii.2020.03.021
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zhang TQ, 2020, J MED VIROL, V92, P909, DOI 10.1002/jmv.25795
NR 11
TC 0
Z9 0
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0939-7248
EI 1439-359X
J9 EUR J PEDIATR SURG
JI Eur. J. Pediatr. Surg.
DI 10.1055/s-0040-1714714
EA AUG 2020
PG 7
WC Pediatrics; Surgery
SC Pediatrics; Surgery
GA NE7GC
UT WOS:000562768500001
PM 32851612
OA Bronze
DA 2021-01-01
ER

PT J
AU Popkin, BM
   Du, SF
   Green, WD
   Beck, MA
   Algaith, T
   Herbst, CH
   Alsukait, RF
   Alluhidan, M
   Alazemi, N
   Shekar, M
AF Popkin, Barry M.
   Du, Shufa
   Green, William D.
   Beck, Melinda A.
   Algaith, Taghred
   Herbst, Christopher H.
   Alsukait, Reem F.
   Alluhidan, Mohammed
   Alazemi, Nahar
   Shekar, Meera
TI Individuals with obesity and COVID-19: A global perspective on the
   epidemiology and biological relationships
SO OBESITY REVIEWS
LA English
DT Article
DE COVID-19; individuals with obesity; meta-analysis; vaccination
ID POLYUNSATURATED FATTY-ACIDS; BODY-MASS INDEX; WAIST CIRCUMFERENCE;
   T-CELLS; SOCIOECONOMIC-STATUS; DEVELOPING-COUNTRIES; FOOD-CONSUMPTION;
   ADIPOSE-TISSUE; CORONAVIRUS; OVERWEIGHT
AB The linkage of individuals with obesity and COVID-19 is controversial and lacks systematic reviews. After a systematic search of the Chinese and English language literature on COVID-19, 75 studies were used to conduct a series of meta-analyses on the relationship of individuals with obesity-COVID-19 over the full spectrum from risk to mortality. A systematic review of the mechanistic pathways for COVID-19 and individuals with obesity is presented. Pooled analysis show individuals with obesity were more at risk for COVID-19 positive, >46.0% higher (OR = 1.46; 95% CI, 1.30-1.65;p< 0.0001); for hospitalization, 113% higher (OR = 2.13; 95% CI, 1.74-2.60;p< 0.0001); for ICU admission, 74% higher (OR = 1.74; 95% CI, 1.46-2.08); and for mortality, 48% increase in deaths (OR = 1.48; 95% CI, 1.22-1.80;p< 0.001). Mechanistic pathways for individuals with obesity are presented in depth for factors linked with COVID-19 risk, severity and their potential for diminished therapeutic and prophylactic treatments among these individuals. Individuals with obesity are linked with large significant increases in morbidity and mortality from COVID-19. There are many mechanisms that jointly explain this impact. A major concern is that vaccines will be less effective for the individuals with obesity.
C1 [Popkin, Barry M.; Herbst, Christopher H.; Alsukait, Reem F.; Shekar, Meera] World Bank, Nutr & Populat Global Practice, Washington, DC USA.
   [Popkin, Barry M.; Du, Shufa; Green, William D.; Beck, Melinda A.] Univ N Carolina, Dept Nutr, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27516 USA.
   [Popkin, Barry M.] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27516 USA.
   [Algaith, Taghred; Alluhidan, Mohammed; Alazemi, Nahar] Saudi Hlth Council, Riyadh, Saudi Arabia.
   [Alsukait, Reem F.] King Saud Univ, Community Hlth Sci, Riyadh, Saudi Arabia.
RP Popkin, BM (corresponding author), Univ N Carolina, Nutr Carolina Populat Ctr, 123 W Franklin St,Carolina Sq, Chapel Hill, NC 27516 USA.
EM popkin@unc.edu
OI popkin, barry/0000-0001-9495-9324; Alsukait, Reem/0000-0003-0797-0643;
   Alluhidan, Mohammed/0000-0003-3824-2059; Green,
   William/0000-0001-7472-8756
FU Bloomberg Philanthropies; Carolina Population Center [CPC P2C HD050924];
   World BankThe World Bank India; Saudi Health Council
FX Bloomberg Philanthropies and the Carolina Population Center, Grant/Award
   Number: CPC P2C HD050924; World Bank; Saudi Health Council
CR ABDULAI I, 2020, CELL, V181, DOI DOI 10.1016/J.AGSY.2020.102812
   Adjibade M, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1312-y
   Afshin A, 2017, NEW ENGL J MED, V377, P13, DOI 10.1056/NEJMoa1614362
   Al-Sabah SK, 2020, COVID 19 IMPACT OBES
   Alam MR, 2020, COMORBIDITIES MIGHT
   Albrecht SS, 2015, EUR J CLIN NUTR, V69, P1306, DOI 10.1038/ejcn.2015.71
   Albrecht SS, 2014, AM J HUM BIOL, V26, P627, DOI 10.1002/ajhb.22573
   Altmann DM, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6160
   [Anonymous], 2018, DIET NUTR PHYS ACT C
   Antonio-Villa NE, 2020, HLTH CARE WORKERS CO
   Antwi-Amoabeng D, 2020, SOCIODEMOGRAPHIC PRE
   Argenziano MG, 2020, CHARACTERIZATION CLI
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Baqui PO, 2020, ETHNIC REGIONAL VARI
   BelloChavolla OY, 2020, PREDICTING MORTALITY
   Berumen J, 2020, RISK INFECT HOSP COV
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bixby H, 2019, NATURE, V569, P260, DOI 10.1038/s41586-019-1171-x
   Borobia AM, 2020, COHORT PATIENTS COVI
   Braun J., 2020, PRESENCE SARS COV 2
   Burn E, 2020, NATURAL HIST SYMPTOM
   Cai QX, 2020, DIABETES CARE, V43, P1392, DOI 10.2337/dc20-0576
   Calder PC, 2006, PROSTAG LEUKOTR ESS, V75, P197, DOI 10.1016/j.plefa.2006.05.012
   Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S
   Carrillo-Vega MF, 2020, EARLY ESTIMATION RIS
   Caussy C, 2020, LANCET DIABETES ENDO, V8, P562, DOI [10.1016/S2213-8587(20)30160-0, 10.1016/S2213-8587(20)30160-1]
   Caussy C, 2020, OBESITY, V28, P1175, DOI 10.1002/oby.22842
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Cho ER, 2020, SMOKING RISK COVID 1
   Cohen PG, 2008, MED HYPOTHESES, V70, P358, DOI 10.1016/j.mehy.2007.05.020
   Corvalan C, 2019, OBES REV, V20, P367, DOI 10.1111/obr.12802
   Costa CS, 2019, NUTR METAB CARDIOVAS, V29, P177, DOI 10.1016/j.numecd.2018.11.003
   Crouch M, 2020, MOL NUTR FOOD RES, DOI 10.1002/mnfr.201900924
   Cunha DB, 2018, NUTR DIABETES, V8, DOI 10.1038/s41387-018-0043-z
   Cure E, 2020, DIABETES METAB SYND, V14, P349, DOI 10.1016/j.dsx.2020.04.019
   Darling AL, 2020, VITAMIN D STATUS BOD
   DAVEY K, 2020, AM J EMERG MED, V13, DOI DOI 10.1016/J.AJEM.2020.04.035
   Mendonca RD, 2017, AM J HYPERTENS, V30, P358, DOI 10.1093/ajh/hpw137
   Mendonca RD, 2016, AM J CLIN NUTR, V104, P1433, DOI 10.3945/ajcn.116.135004
   de Lusignan S, 2020, LANCET INFECT DIS, V20, P1034, DOI 10.1016/S1473-3099(20)30371-6
   Denova-Gutierrez E, 2020, OBESITY, V28, P1826, DOI 10.1002/oby.22946
   Di Cesare M, 2016, LANCET, V387, P1377, DOI 10.1016/S0140-6736(16)30054-X
   Di Renzo L, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02399-5
   Docherty AB, 2020, FEATURES 16749 HOSP
   Ebinger JE, 2020, PREEXISTING CHARACTE
   Eliakim A, 2006, AUTOIMMUNITY, V39, P137, DOI 10.1080/08916930600597326
   Endevelt R, 2017, PUBLIC HLTH PANORAMA, V3, P567
   Euromonitor Passport, 2020, EUR PASSP IMP COR PA
   Fanelli Vito, 2015, Ann Am Thorac Soc, V12 Suppl 1, pS3, DOI 10.1513/AnnalsATS.201407-340MG
   Fehr AR, 2017, ANNU REV MED, V68, P387, DOI 10.1146/annurev-med-051215-031152
   Feuth T, 2020, IS SLEEP APNOEA RISK
   Fiolet T, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k322
   Gaibazzi N, 2020, LUNG DIS SEVERITY CO
   Ganeshan K, 2014, ANNU REV IMMUNOL, V32, P609, DOI 10.1146/annurev-immunol-032713-120236
   Gao F, 2020, DIABETES CARE, V43, pE72, DOI 10.2337/dc20-0682
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gerotziafas G, 2020, DERIVATION VALIDATIO
   Giacomelli A, 2020, 30 DAY MORTALITY PAT
   Giannouchos T, 2020, CHARACTERISTICS RISK
   Glende J, 2008, VIROLOGY, V381, P215, DOI 10.1016/j.virol.2008.08.026
   Gomez-Donoso C, 2020, EUR J NUTR, V59, P1093, DOI 10.1007/s00394-019-01970-1
   Gong MN, 2010, THORAX, V65, P44, DOI 10.1136/thx.2009.117572
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Gu T, 2020, COVID 19 OUTCOMES RI
   Hajifathalian K, 2020, OBESITY, V28, P1606, DOI 10.1002/oby.22923
   Halasz G, 2020, EUR J PREV CARDIOL, DOI 10.1177/2047487320939675
   Hall KD, 2019, CELL METAB, V30, P67, DOI 10.1016/j.cmet.2019.05.008
   Hamer M, 2020, LIFESTYLE RISK FACTO
   Han JM, 2014, J IMMUNOL, V192, P623, DOI 10.4049/jimmunol.1302181
   Hernandez-Garduno E, 2020, OBES RES CLIN PRACT, V14, P375, DOI 10.1016/j.orcp.2020.06.001
   Hilgenfeld R, 2013, ANTIVIR RES, V100, P286, DOI 10.1016/j.antiviral.2013.08.015
   Ho FK, 2020, MODIFIABLE NONMODIFI
   Horby P, 2020, EFFECT DEXAMETHASONE
   Hu L., 2020, CLIN INFECT DIS, V52, DOI [10.1093/cid/ciaa539, DOI 10.1093/CID/CIAA539]
   Huttunen R, 2013, INT J OBESITY, V37, P333, DOI 10.1038/ijo.2012.62
   Huttunen R, 2010, LANCET INFECT DIS, V10, P442, DOI 10.1016/S1473-3099(10)70103-1
   ICNARC, 2020, ICNARC REP COVID 19
   Independent Expert Group of the Global Nutrition Report, 2020, 2020 GLOBAL NUTR REP, P172
   Ip B, 2016, OBESITY, V24, P102, DOI 10.1002/oby.21243
   Jaacks LM, 2015, J NUTR, V145, P352, DOI 10.3945/jn.114.203562
   Jagannathan-Bogdan M, 2011, J IMMUNOL, V186, P1162, DOI 10.4049/jimmunol.1002615
   Johnson RM, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2648
   Jones-Smith JC, 2012, INT J OBESITY, V36, P1114, DOI 10.1038/ijo.2011.179
   Jones-Smith JC, 2011, AM J EPIDEMIOL, V173, P667, DOI 10.1093/aje/kwq428
   Kaeuffer C, SSRN ELECT J, DOI [10.2139/ssrn.3586679, DOI 10.2139/SSRN.3586679]
   Kalligeros M, 2020, OBESITY, V28, P1200, DOI 10.1002/oby.22859
   Kantar, 2020, COV 19 WAV 2 27 30 M
   Kanter R, 2020, AM J PUBLIC HEALTH, V110, P971, DOI 10.2105/AJPH.2020.305711
   Karlsson EA, 2019, MECHANISMS AND MANIFESTATIONS OF OBESITY IN LUNG DISEASE, P227, DOI 10.1016/B978-0-12-813553-2.00010-5
   Karlsson EA, 2016, MBIO, V7, DOI 10.1128/mBio.01144-16
   Kebisek Julianna, 2020, MSMR, V27, P50
   Khawaja AP, 2020, ASS COVID 19 HOSP 40
   Kim H, 2019, PUBLIC HEALTH NUTR, V22, P1777, DOI [10.1017/s1368980018003890, 10.1017/S1368980018003890]
   Kim L, 2020, INTERIM ANAL RISK FA
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Kris-Etherton PM, 2000, AM J CLIN NUTR, V71, p179S, DOI 10.1093/ajcn/71.1.179S
   Kruglikov IL, 2020, OBESITY, V28, P1187, DOI 10.1002/oby.22856
   Lawrence MA, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l2289
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Leal FE, 2020, PRIMARY CARE APPROAC
   Lee JS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd1554
   Leung NY, 2020, PREDICTORS COVID 19
   Li T, 2020, EUR J CLIN NUTR, V74, P871, DOI 10.1038/s41430-020-0642-3
   Liao XC, 2020, CRITICAL CARE SEVERE
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Liu H, 2005, CYTOKINE, V31, P251, DOI 10.1016/j.cyto.2004.12.008
   Liu M, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE016, DOI [10.3760/cma.j.issn.1001-0939.2020.03.014, 10.3760/cma.j.issn.1001-0939.2020.0016]
   Louie JK, 2011, CLIN INFECT DIS, V52, P301, DOI 10.1093/cid/ciq152
   McLaughlin T, 2017, J CLIN INVEST, V127, P5, DOI 10.1172/JCI88876
   McLaughlin T, 2014, ARTERIOSCL THROM VAS, V34, P2637, DOI 10.1161/ATVBAHA.114.304636
   Mendy A, 2020, FACTORS ASS HOSP DIS
   Merzon E, 2020, LOW PLASMA 25 OH VIT
   Milner JJ, 2013, J IMMUNOL, V191, P2474, DOI 10.4049/jimmunol.1202429
   Misumi I, 2019, CELL REP, V27, P514, DOI 10.1016/j.celrep.2019.03.030
   Monteiro CA, 2004, B WORLD HEALTH ORGAN, V82, P940
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Murillo-Zamora E, 2020, SURVIVAL ADULT INPAT
   Neidich SD, 2017, INT J OBESITY, V41, P1324, DOI 10.1038/ijo.2017.131
   Nicholas DA, 2019, CELL METAB, V30, P447, DOI 10.1016/j.cmet.2019.07.004
   Norris PC, 2012, P NATL ACAD SCI USA, V109, P8517, DOI 10.1073/pnas.1200189109
   NYC Department of Health and Mental Hygiene, 2020, IND OB
   Ortiz-Brizuela E, 2020, REV INVESTIGACION CL, V72
   Paich HA, 2013, OBESITY, V21, P2377, DOI 10.1002/oby.20383
   Painter SD, 2015, VACCINE, V33, P4422, DOI 10.1016/j.vaccine.2015.06.101
   Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262
   Pantea Stoian A, 2020, DEATH SARS COV2 A RO
   Paquette SG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038214
   Peng Y D, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P450, DOI 10.3760/cma.j.cn112148-20200220-00105
   Petrilli CM, 2020, FACTORS ASS HOSPITAL, DOI [10.1101/2020.04.08.20057794, DOI 10.1101/2020.04.08.20057794]
   Pettit NN, 2020, OBESITY, V28, P1806, DOI 10.1002/oby.22941
   Pongpirul WA, 2020, CLIN COURSE POTENTIA
   Popkin BM, 2013, OBES REV, V14, P11, DOI 10.1111/obr.12102
   Popkin BM, 2020, LANCET, V395, P65, DOI 10.1016/S0140-6736(19)32497-3
   Popkin BM, 2010, AM J CLIN NUTR, V91, p284S, DOI 10.3945/ajcn.2009.28473C
   Popkin BM, 1998, NUTR REV, V56, P106
   Prats-Uribe A, 2020, ETHNICITY COMORBIDIT
   Pries AM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122962
   Qi D, 2020, EPIDEMIOLOGICAL CLIN
   Raisi-Estabragh Z, 2020, NONWHITE ETHNICITY M
   Rasouli N, 2008, J CLIN ENDOCR METAB, V93, pS64, DOI 10.1210/jc.2008-1613
   Rauber F, 2015, NUTR METAB CARDIOVAS, V25, P116, DOI 10.1016/j.numecd.2014.08.001
   Rauber F, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050587
   Regina J, 2020, EPIDEMIOLOGY RISK FA
   Reilev M, 2020, CHARACTERISTICS PRED
   Reyes Gil M, 2020, CORRELATION COAGULAT
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rico-Campa A, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1949
   Robinson DP, 2014, J VIROL, V88, P4711, DOI 10.1128/JVI.02081-13
   Rohatgi KW, 2017, PEERJ, V5, DOI 10.7717/peerj.4091
   Rossi A, 2020, OBESITY RISK FACTOR
   Roth J, 2016, MOL MED, V22, P873, DOI 10.2119/molmed.2016.00211
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Rundle AG, 2020, OBESITY, V28, P1008, DOI 10.1002/oby.22813
   Ryan PM, 2020, OBESITY, V28, P1191, DOI 10.1002/oby.22843
   Sainaghi P, 2020, FATALITY RATE PREDIC
   Sandoval-Insausti H, 2020, J GERONTOL A-BIOL, V75, P1126, DOI 10.1093/gerona/glz140
   Sapey E, 2020, ETHNICITY RISK DEATH
   Sattar N, 2020, CIRCULATION, V142, P4, DOI 10.1161/CIRCULATIONAHA.120.047659
   Saucillo DC, 2014, J IMMUNOL, V192, P136, DOI 10.4049/jimmunol.1301158
   Schnabel L, 2019, JAMA INTERN MED, V179, P490, DOI 10.1001/jamainternmed.2018.7289
   SCHNEIDER G, 1979, J CLIN ENDOCR METAB, V48, P633, DOI 10.1210/jcem-48-4-633
   Seow J., 2020, LONGITUDINAL EVALUAT
   Shah P, 2020, ANN MED, V52, P354, DOI 10.1080/07853890.2020.1791356
   Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579
   Shekar M, 2020, OBESITY HLTH EC CONS
   Sheridan PA, 2012, INT J OBESITY, V36, P1072, DOI 10.1038/ijo.2011.208
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Singh S, 2020, OUTCOMES COVID 19 PA
   Singla P, 2010, WORLD J DIABETES, V1, P76, DOI 10.4239/wjd.v1.i3.76
   Siso-Almirall A, 2020, PROGNOSTIC FACTORS S
   Souza FSH, 2020, PREDICTING DIS OUTCO
   Srour B, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1451
   StataCorp LLC, 2019, STATA 16
   Stefan N, 2020, NAT REV ENDOCRINOL, V16, P341, DOI 10.1038/s41574-020-0364-6
   Steinberg E, 2020, WEST J EMERG MED, V21, P752, DOI 10.5811/westjem.2020.5.47972
   Stern D, 2014, INT J OBESITY, V38, P1503, DOI 10.1038/ijo.2014.74
   Subramanian SV, 2011, AM J CLIN NUTR, V93, P413, DOI 10.3945/ajcn.110.004820
   Suleyman G, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.12270
   Taillie LS, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003015
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Trecarichi EM, 2020, CHARACTERISTICS OUTC
   Tsai S, 2018, CELL METAB, V28, P922, DOI 10.1016/j.cmet.2018.08.003
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   van der Weerd K, 2012, DIABETES, V61, P401, DOI 10.2337/db11-1065
   Vandevijvere S, 2019, OBES REV, V20, P10, DOI 10.1111/obr.12860
   Vaquero LM, 2020, C REACTIVE PROTEIN S
   Wang B, 2020, TERTIARY CTR EXPERIE
   WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1
   Wollenstein-Betech S, 2020, PERSONALIZED PREDICT
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yanover C., 2020, WHAT FACTORS INCREAS, V6
   Zheng KI, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154244
   Zhi G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163677
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 200
TC 10
Z9 10
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1467-7881
EI 1467-789X
J9 OBES REV
JI Obes. Rev.
PD NOV
PY 2020
VL 21
IS 11
DI 10.1111/obr.13128
EA AUG 2020
PG 17
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NZ4RV
UT WOS:000562510600001
PM 32845580
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shanmugarajan, D
   Prabitha, P
   Kumar, BRP
   Suresh, B
AF Shanmugarajan, Dhivya
   Prabitha, P.
   Kumar, B. R. Prashantha
   Suresh, B.
TI Curcumin to inhibit binding of spike glycoprotein to ACE2 receptors:
   computational modelling, simulations, and ADMET studies to explore
   curcuminoids against novel SARS-CoV-2 targets
SO RSC ADVANCES
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; PROTEIN; INFECTION; PATHWAY; VIRUS
AB The recent emergence of the novel coronavirus (SARS-CoV-2) has raised global concern as it is declared a pandemic by the WHO. However, to date, there is no current regimen to mitigate the molecular pathogenesis of SARS-CoV-2 virus. Curcuminoids, bioactive ingredients present inCurcuma longa(turmeric), are known to exhibit diverse pharmacological properties. To the best of our understanding to date, SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) for the host cellular entry. This is mediatedviaproteins of SARS-CoV-2, especially the spike glycoprotein receptor binding domain. Accordingly, our primary objective is to thwart virus replication and binding to the host system, leading us to probe curcuminoids efficiency towards key surface drug target proteins using the computational biology paradigm approach. Specifically, fourteen natural curcuminoids were studied for their possibility of inhibiting SARS-CoV-2. We studied theirin silicoproperties towards SARS-CoV-2 target proteins by homology modelling, ADME, drug-likeness, toxicity predictions, docking molecular dynamics simulations and MM-PBSA free energy estimation. Among the curcuminoids docked to the receptor binding domain of SARS-CoV-2 spike glycoprotein, the keto and enol forms of curcumin form strong hydrogen bond interactions with ACE2 binding residues Q493, T501, Y505, Y489 and Q498. Molecular dynamics simulations, free energy binding and interaction energy validated the interaction and stability of the docked keto and enol forms of curcumin.
C1 [Shanmugarajan, Dhivya; Prabitha, P.; Kumar, B. R. Prashantha] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmaceut Chem, Mysuru 570015, India.
   [Suresh, B.] JSS Acad Higher Educ & Res, Mysuru 570015, India.
RP Kumar, BRP (corresponding author), JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmaceut Chem, Mysuru 570015, India.
EM brprashanthkumar@jssuni.edu.in
OI Kumar B R, Prashantha/0000-0001-9503-741X
CR Allen M. P., 1987, COMPUTER SIMULATION
   Anggakusuma, 2014, GUT, V63, P1137, DOI 10.1136/gutjnl-2012-304299
   [Anonymous], 2011, J CLIN HYPERTENSI S1, V13, pA155
   Balasubramanian A, 2019, ANTIVIR RES, V162, P71, DOI 10.1016/j.antiviral.2018.12.002
   Barret R., 2018, MED CHEM FUNDAMENTAL, P89
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Chattopadhyay I, 2004, CURR SCI INDIA, V87, P44
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dandapat J., 2020, INSIGHTS COMPUTATION
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   Dhivya S., 2019, LIPID BILAYERS PROPE, P203
   Dhivya S, 2018, J BIOMOL STRUCT DYN, V36, P2361, DOI 10.1080/07391102.2017.1354783
   Dongling Z., 2014, INT J MOL SCI, V15, P17284
   Eke-Okoro UJ, 2018, J CLIN PHARM THER, V43, P460, DOI 10.1111/jcpt.12703
   Florian Z., 2020, FRONT CARDIOVASC MED, V7, P71
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114
   Hogue B. G., 2008, IMPORTANCE CONSERVED, P179
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jimenez-Guardeno JM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004320
   Kim MK, 2012, NAT PROD COMMUN, V7, P57
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   MACARTHUR MW, 1994, CURR OPIN STRUC BIOL, V4, P731, DOI 10.1016/S0959-440X(94)90172-4
   Minassi A, 2013, J NAT PROD, V76, P1105, DOI 10.1021/np400148e
   Mounce BC, 2017, ANTIVIR RES, V142, P148, DOI 10.1016/j.antiviral.2017.03.014
   Praditya D, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00912
   Priyadarsini KI, 2014, MOLECULES, V19, P20091, DOI 10.3390/molecules191220091
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ruch TR, 2011, J VIROL, V85, P675, DOI 10.1128/JVI.01570-10
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   Spassov VZ, 2008, PROTEIN ENG DES SEL, V21, P91, DOI 10.1093/protein/gzm083
   Studer G, 2014, BIOINFORMATICS, V30, pI505, DOI 10.1093/bioinformatics/btu457
   Tirado-Rives J, 2006, J MED CHEM, V49, P5880, DOI 10.1021/jm060763i
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Waghela BN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117526
   Webb B, 2014, METHODS MOL BIOL, V1137, P1, DOI 10.1007/978-1-4939-0366-5_1
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang HS, 2011, J CELL PHYSIOL, V226, P3385, DOI 10.1002/jcp.22691
NR 47
TC 0
Z9 0
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD AUG 25
PY 2020
VL 10
IS 52
BP 31385
EP 31399
DI 10.1039/d0ra03167d
PG 15
WC Chemistry, Multidisciplinary
SC Chemistry
GA NK2PS
UT WOS:000566579400038
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Al-Jehani, H
   John, S
   Hussain, SI
   Al Hashmi, A
   Alhamid, MA
   Amr, D
   Ozdemir, AO
   Shuaib, A
   Alhazzani, A
   Ghorbani, M
   Mansour, O
   Saqqur, M
AF Al-Jehani, Hosam
   John, Seby
   Hussain, Syed Irteza
   Al Hashmi, Amal
   Alhamid, May Adel
   Amr, Dareen
   Ozdemir, Atilla Ozcan
   Shuaib, Ashfaq
   Alhazzani, Adel
   Ghorbani, Mohammad
   Mansour, Ossama
   Saqqur, Maher
CA MENA-SINO Grp
TI MENA-SINO Consensus Statement on Implementing Care Pathways for Acute
   Neurovascular Emergencies During the COVID-19 Pandemic
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE COVID; endovascular therapy; recommendation; MENA; acute ischemic
   stroke; subarachnoid hemorrhage
ID CORONAVIRUS
AB In the unprecedented current era of the COVID-19 pandemic, challenges have arisen in the management and interventional care of patients with acute stroke and large vessel occlusion, aneurysmal subarachnoid hemorrhage, and ruptured vascular malformations. There are several challenges facing endovascular therapy for stroke, including shortages of medical staff who may be deployed for COVID-19 coverage or who may have contracted the infection and are thus quarantined, patients avoiding early medical care, a lack of personal protective equipment, delays in door-to-puncture time, anesthesia challenges, and a lack of high-intensity intensive care unit and stroke ward beds. As a leading regional neurovascular organization, the Middle East North Africa Stroke and Interventional Neurotherapies Organization (MENA-SINO) has established a task force composed of medical staff and physicians from different disciplines to establish guiding recommendations for the implementation of acute care pathways for various neurovascular emergencies during the current COVID-19 pandemic. This consensus recommendation was achieved through a series of meetings to finalize the recommendation.
C1 [Al-Jehani, Hosam] Imam Abdulrahman Bin Faisal Univ, King Fahad Hosp Univ, Dept Neurosurg & Intervent Radiol, Dammam, Saudi Arabia.
   [Al-Jehani, Hosam] McGill Univ, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, Montreal, PQ, Canada.
   [John, Seby; Hussain, Syed Irteza] Cleveland Clin Abu Dhabi, Neurol Inst, Abu Dhabi, U Arab Emirates.
   [Al Hashmi, Amal] Minist Hlth Oman, Khoula Hosp, Cent Stroke Unit, Muscat, Oman.
   [Alhamid, May Adel] Imam Abdulrahman Bin Faisal Univ, King Fahad Hosp Univ, Dept Neurol & Intervent Radiol, Dammam, Saudi Arabia.
   [Amr, Dareen; Mansour, Ossama] Alexandria Univ, Dept Neurol, Stroke & Neurointervent Unit, Sch Med, Alexandria, Egypt.
   [Ozdemir, Atilla Ozcan] Eskisehir Osmangazi Univ, Dept Neurol, Neurocrit Care, Eskisehir, Turkey.
   [Ozdemir, Atilla Ozcan] Stroke Ctr, Dept Neurol, Eskisehir, Turkey.
   [Shuaib, Ashfaq; Saqqur, Maher] Univ Alberta, Div Neurol, Dept Med, Edmonton, AB, Canada.
   [Alhazzani, Adel] King Saud Univ, Div Neurol, Dept Med, Coll Med, Riyadh, Saudi Arabia.
   [Ghorbani, Mohammad] Iran Univ Med Sci, Firoozgar Hosp, Div Vasc & Endovasc Neurosurg, Tehran, Iran.
   [Saqqur, Maher] Univ Toronto, Trillium Hosp, Mississauga, ON, Canada.
RP Al-Jehani, H (corresponding author), Imam Abdulrahman Bin Faisal Univ, King Fahad Hosp Univ, Dept Neurosurg & Intervent Radiol, Dammam, Saudi Arabia.; Al-Jehani, H (corresponding author), McGill Univ, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, Montreal, PQ, Canada.
EM hjehani@iau.edu.sa
CR ACR, GUID COVID 19 MR US
   Aggour M, 2020, J NEUROINTERV SURG, V12, P542, DOI 10.1136/neurintsurg-2020-016137
   Bajunaid Khalid, 2020, Neurosciences (Riyadh), V25, P148, DOI 10.17712/nsj.2020.2.20200054
   Bauchner H, 2020, JAMA-J AM MED ASSOC, V323, P1912, DOI 10.1001/jama.2020.4770
   Burrer SL, 2020, CHARACTERISTICS HLTH
   Canelli R, 2020, NEW ENGL J MED, V382, P1957, DOI 10.1056/NEJMc2007589
   Couper K, 2013, CURR OPIN CRIT CARE, V19, P188, DOI 10.1097/MCC.0b013e32835f58aa
   Fargen KM, 2020, J NEUROINTERV SURG, DOI [10.1136/neurintsurg-2020-SNIS.10, DOI 10.1136/NEURINTSURG-2020-SNIS.10]
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Griffin E, 2020, J NEUROINTERV SURG, V12, P1166, DOI 10.1136/neurintsurg-2019-015667
   Khosravani H, 2020, STROKE, V51, pE156, DOI 10.1161/STROKEAHA.120.030243
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Morelli N, 2020, EUR NEUROL, V83, P213, DOI 10.1159/000507666
   Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211
   World Health Organization, 2020, COR DIS COVID 19 DAT
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 19
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD AUG 25
PY 2020
VL 11
AR 928
DI 10.3389/fneur.2020.00928
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NQ1FP
UT WOS:000570612900001
PM 32982938
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chen, BY
   Kessi, M
   Chen, SM
   Xiong, J
   Wu, LW
   Deng, XL
   Yang, LF
   He, F
   Yin, F
   Peng, J
AF Chen, Baiyu
   Kessi, Miriam
   Chen, Shimeng
   Xiong, Juan
   Wu, Liwen
   Deng, Xiaolu
   Yang, Lifen
   He, Fang
   Yin, Fei
   Peng, Jing
TI The Recommendations for the Management of Chinese Children With Epilepsy
   During the COVID-19 Outbreak
SO FRONTIERS IN PEDIATRICS
LA English
DT Article
DE COVID-19; SARS-CoV2; epilepsy; children; management recommendations
AB The coronavirus disease (COVID-19) is the most severe public health problem facing the world currently. Social distancing and avoidance of unnecessary movements are preventive strategies that are being advocated to prevent the spread of the causative virus [severe acute respiratory syndrome (SARS)-CoV2]. It is known that epileptic children need long term treatments (antiepileptic drugs and/or immunosuppressive agents) as well as close follow up due to the nature of the disease. In addition, it is clear that epilepsy can concur with other chronic illnesses which can lower body immunity. As a result, epileptic children have high risk of acquiring this novel disease due to weak/immature immune system. Of concern, the management of children with epilepsy has become more challenging during this outbreak due to the prevention measures that are being taken. Although children with controlled seizures can be managed at home, it is challenging for pediatricians when it comes to cases with uncontrolled seizures/severe cases. To this end, we provide recommendations for the management of epileptic children at home, outpatient and inpatient settings.
C1 [Chen, Baiyu; Kessi, Miriam; Chen, Shimeng; Xiong, Juan; Wu, Liwen; Deng, Xiaolu; Yang, Lifen; He, Fang; Yin, Fei; Peng, Jing] Cent South Univ, Xiangya Hosp, Dept Pediat, Changsha, Peoples R China.
   [Chen, Baiyu; Kessi, Miriam; Chen, Shimeng; Xiong, Juan; Wu, Liwen; Deng, Xiaolu; Yang, Lifen; He, Fang; Yin, Fei; Peng, Jing] Hunan Intellectual & Dev Disabil Res Ctr, Changsha, Peoples R China.
RP Yin, F; Peng, J (corresponding author), Cent South Univ, Xiangya Hosp, Dept Pediat, Changsha, Peoples R China.; Yin, F; Peng, J (corresponding author), Hunan Intellectual & Dev Disabil Res Ctr, Changsha, Peoples R China.
EM yf2323@hotmail.com; pengjing4346@163.com
FU Pediatric Discipline Construction Funds
FX This work was supported by the Pediatric Discipline Construction Funds.
CR Aaberg KM, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0921
   Chen Zhimin, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P139, DOI 10.3785/j.issn.1008-9292.2020.02.01
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Cross JH, 2019, EPILEPSIA, V60, pS39, DOI 10.1111/epi.16334
   D'Alonzo R, 2018, CLIN DRUG INVEST, V38, P113, DOI 10.1007/s40261-017-0595-z
   French JA, 2020, NEUROLOGY, V94, P1032, DOI 10.1212/WNL.0000000000009632
   Grinspan ZM, 2020, ANN NEUROL, V88, P215, DOI 10.1002/ana.25792
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hani AJ, 2016, SEMIN PEDIATR NEUROL, V23, P180, DOI 10.1016/j.spen.2016.06.001
   Hong H, 2020, PEDIATR NEONATOL, V61, P131, DOI 10.1016/j.pedneo.2020.03.001
   Johns Hopkins University, 2020, NOV COR COVID 19 201
   Kuroda N, 2020, EPILEPSY BEHAV, V108, DOI 10.1016/j.yebeh.2020.107122
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Mirro EA, 2020, NEUROSURGERY, V87, pE409, DOI 10.1093/neuros/nyaa244
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Peng Jing, 2020, Zhongguo Dang Dai Er Ke Za Zhi, V22, P100
   Perucca E, 2014, EPILEPSIA, V55, P1326, DOI 10.1111/epi.12725
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sethi NK, 2020, CLIN NEUROPHYSIOL, V131, P1462, DOI 10.1016/j.clinph.2020.04.007
   Singhal Nilika Shah, 2014, ISRN Neurol, V2014, P619079, DOI 10.1155/2014/619079
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Sorbello M, 2020, ANAESTHESIA, V75, P724, DOI 10.1111/anae.15049
   Verrotti A, 2018, SEIZURE-EUR J EPILEP, V63, P17, DOI 10.1016/j.seizure.2018.10.016
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Zhu HP, 2020, TRANSL PEDIATR, V9, P51, DOI 10.21037/tp.2020.02.06
NR 28
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2360
J9 FRONT PEDIATR
JI Front. Pediatr.
PD AUG 25
PY 2020
VL 8
AR 495
DI 10.3389/fped.2020.00495
PG 6
WC Pediatrics
SC Pediatrics
GA NP7XB
UT WOS:000570384700001
PM 32984209
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhao, HJ
   To, KKW
   Sze, KH
   Yung, TTM
   Bian, MJ
   Lam, HY
   Yeung, ML
   Li, C
   Chu, H
   Yuen, KY
AF Zhao, Hanjun
   To, Kelvin K. W.
   Sze, Kong-Hung
   Yung, Timothy Tin-Mong
   Bian, Mingjie
   Lam, Hoiyan
   Yeung, Man Lung
   Li, Cun
   Chu, Hin
   Yuen, Kwok-Yung
TI A broad-spectrum virus- and host-targeting peptide against respiratory
   viruses including influenza virus and SARS-CoV-2
SO NATURE COMMUNICATIONS
LA English
DT Article
ID SYNDROME CORONAVIRUS; CHLOROQUINE; INFECTION; ENTRY; DRUG; DYNAMICS;
   DESIGN; FUSION; MICE; H5N1
AB The 2019 novel respiratory virus (SARS-CoV-2) causes COVID-19 with rapid global socioeconomic disruptions and disease burden to healthcare. The COVID-19 and previous emerging virus outbreaks highlight the urgent need for broad-spectrum antivirals. Here, we show that a defensin-like peptide P9R exhibited potent antiviral activity against pH-dependent viruses that require endosomal acidification for virus infection, including the enveloped pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, coronaviruses (SARS-CoV-2, MERS-CoV and SARS-CoV), and the non-enveloped rhinovirus. P9R can significantly protect mice from lethal challenge by A(H1N1)pdm09 virus and shows low possibility to cause drug-resistant virus. Mechanistic studies indicate that the antiviral activity of P9R depends on the direct binding to viruses and the inhibition of virus-host endosomal acidification, which provides a proof of concept that virus-binding alkaline peptides can broadly inhibit pH-dependent viruses. These results suggest that the dual-functional virus- and host-targeting P9R can be a promising candidate for combating pH-dependent respiratory viruses.
C1 [Zhao, Hanjun; To, Kelvin K. W.; Sze, Kong-Hung; Yeung, Man Lung; Chu, Hin; Yuen, Kwok-Yung] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Pokfulam, Hong Kong, Peoples R China.
   [Zhao, Hanjun; To, Kelvin K. W.; Sze, Kong-Hung; Yung, Timothy Tin-Mong; Lam, Hoiyan; Yeung, Man Lung; Li, Cun; Chu, Hin; Yuen, Kwok-Yung] Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China.
   [Zhao, Hanjun; To, Kelvin K. W.; Yung, Timothy Tin-Mong; Lam, Hoiyan; Yeung, Man Lung; Li, Cun; Chu, Hin; Yuen, Kwok-Yung] Univ Hong Kong, Ctr Virol Vaccinol & Therapeut, Hlth InnoHK, Hong Kong, Peoples R China.
   [To, Kelvin K. W.; Yuen, Kwok-Yung] Univ Hong Kong, Li Ka Shing Fac Med, Carol Yu Ctr Infect, Pokfulam, Hong Kong, Peoples R China.
   [To, Kelvin K. W.; Yeung, Man Lung; Yuen, Kwok-Yung] Univ Hong Kong, Shenzhen Hosp, Shenzhen, Guangdong, Peoples R China.
   [Bian, Mingjie] Anhui Normal Univ, Sch Life Sci, Wuhu, Anhui, Peoples R China.
RP Yuen, KY (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Pokfulam, Hong Kong, Peoples R China.; Yuen, KY (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China.; Yuen, KY (corresponding author), Univ Hong Kong, Ctr Virol Vaccinol & Therapeut, Hlth InnoHK, Hong Kong, Peoples R China.; Yuen, KY (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Carol Yu Ctr Infect, Pokfulam, Hong Kong, Peoples R China.; Yuen, KY (corresponding author), Univ Hong Kong, Shenzhen Hosp, Shenzhen, Guangdong, Peoples R China.
EM kyyuen@hku.hk
RI Li, Cun/ABD-9346-2020
OI Bian, Mingjie/0000-0003-0496-0909
FU Health@InnoHK (Centre for Virology, Vaccinology and Therapeutics);
   Innovation and Technology Commission; Government of the Hong Kong
   Special Administrative Region of the People's Republic of China;
   National Program on Key Research Project of China [2020YFA0707500,
   2020YFA0707504]
FX This study was partly supported by the donations of Richard Yu and Carol
   Yu, Michael Seak-Kan Tong, May Tam Mak Mei Yin, the Shaw Foundation Hong
   Kong, Respiratory Viral Research Foundation Limited, Hui Ming, Hui Hoy
   and Chow Sin Lan Charity Fund Limited, Chan Yin Chuen Memorial
   Charitable Foundation, Marina Man-Wai Lee, the Hong Kong Hainan
   Commercial Association South China Microbiology Research Fund, the
   Jessie & George Ho Charitable Foundation, Perfect Shape Medical Limited,
   and Kai Chong Tong; and funding from Health@InnoHK (Centre for Virology,
   Vaccinology and Therapeutics), Innovation and Technology Commission, The
   Government of the Hong Kong Special Administrative Region of the
   People's Republic of China, and the National Program on Key Research
   Project of China (grant no. 2020YFA0707500 and 2020YFA0707504). The
   funding sources had no role in the study design, data collection,
   analysis, interpretation, or writing of the report.
CR Brice DC, 2020, CURR MED CHEM, V27, P1420, DOI 10.2174/0929867326666190805151654
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chandrababu KB, 2009, BIOCHEMISTRY-US, V48, P6052, DOI 10.1021/bi900154f
   Cheng VCC, 2012, CLIN MICROBIOL REV, V25, P223, DOI 10.1128/CMR.05012-11
   Cheung MS, 2010, J MAGN RESON, V202, P223, DOI 10.1016/j.jmr.2009.11.008
   Falzarano D, 2015, EMERG INFECT DIS, V21, P1065, DOI 10.3201/eid2106.150176
   Gomes B, 2018, BIOTECHNOL ADV, V36, P415, DOI 10.1016/j.biotechadv.2018.01.004
   Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041
   Hayden FG, 2018, NEW ENGL J MED, V379, P913, DOI 10.1056/NEJMoa1716197
   Holthausen DJ, 2017, IMMUNITY, V46, P587, DOI 10.1016/j.immuni.2017.03.018
   Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286
   Jurgeit A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002976
   Kao JC, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006715
   Klotman ME, 2006, NAT REV IMMUNOL, V6, P447, DOI 10.1038/nri1860
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Leikina E, 2005, NAT IMMUNOL, V6, P995, DOI 10.1038/ni1248
   Li CF, 2017, EBIOMEDICINE, V24, P189, DOI 10.1016/j.ebiom.2017.09.034
   Li FF, 2019, J BIOL CHEM, V294, P182, DOI 10.1074/jbc.RA118.005015
   Li QL, 2011, PEPTIDES, V32, P1518, DOI 10.1016/j.peptides.2011.05.015
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu SP, 2008, CHEMBIOCHEM, V9, P964, DOI 10.1002/cbic.200700560
   Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M411141200
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   Michen B, 2010, J APPL MICROBIOL, V109, P388, DOI 10.1111/j.1365-2672.2010.04663.x
   Moscona A, 2005, J CLIN INVEST, V115, P1688, DOI 10.1172/JCI25669
   Nakano S, 2015, SCI REP-UK, V5, DOI 10.1038/srep13836
   Paton NI, 2011, LANCET INFECT DIS, V11, P677, DOI 10.1016/S1473-3099(11)70065-2
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rajendran L, 2010, NAT REV DRUG DISCOV, V9, P29, DOI 10.1038/nrd2897
   Rieping W, 2007, BIOINFORMATICS, V23, P381, DOI 10.1093/bioinformatics/btl589
   Sample CJ, 2013, PEPTIDES, V48, P96, DOI 10.1016/j.peptides.2013.07.014
   Seppala J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136969
   Skinner SP, 2016, J BIOMOL NMR, V66, P111, DOI 10.1007/s10858-016-0060-y
   Smith JG, 2008, CELL HOST MICROBE, V3, P11, DOI 10.1016/j.chom.2007.12.001
   Swanson MD, 2015, CELL, V163, P746, DOI 10.1016/j.cell.2015.09.056
   Tan YW, 2018, ANTIVIR RES, V149, P143, DOI 10.1016/j.antiviral.2017.11.017
   To KKW, 2016, J CLIN VIROL, V77, P85, DOI 10.1016/j.jcv.2016.02.014
   To KKW, 2013, LANCET INFECT DIS, V13, P809, DOI 10.1016/S1473-3099(13)70167-1
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
   Vigant F, 2015, NAT REV MICROBIOL, V13, P426, DOI 10.1038/nrmicro3475
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Woo PCY, 2004, LANCET, V363, P841, DOI 10.1016/S0140-6736(04)15729-2
   Yan N, 2012, NAT IMMUNOL, V13, P214, DOI 10.1038/ni.2229
   Yeung ML, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.4, 10.1038/nmicrobiol.2016.4]
   Yu YF, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15672
   Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x
   Zhao HJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04792-7
   Zhao HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22008
   Zheng BJ, 2008, P NATL ACAD SCI USA, V105, P8091, DOI 10.1073/pnas.0711942105
NR 52
TC 0
Z9 0
U1 2
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 25
PY 2020
VL 11
IS 1
AR 4252
DI 10.1038/s41467-020-17986-9
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NL6QI
UT WOS:000567537300011
PM 32843628
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Crooke, SN
   Ovsyannikova, IG
   Kennedy, RB
   Poland, GA
AF Crooke, Stephen N.
   Ovsyannikova, Inna G.
   Kennedy, Richard B.
   Poland, Gregory A.
TI Immunoinformatic identification of B cell and T cell epitopes in the
   SARS-CoV-2 proteome
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; CLASS-I BINDING; SARS CORONAVIRUS;
   NEUTRALIZING EPITOPES; PROTECTIVE IMMUNITY; ANTIBODY-RESPONSES;
   RECEPTOR-BINDING; SPIKE PROTEIN; VACCINE; PREDICTION
AB A novel coronavirus (SARS-CoV-2) emerged from China in late 2019 and rapidly spread across the globe, infecting millions of people and generating societal disruption on a level not seen since the 1918 influenza pandemic. A safe and effective vaccine is desperately needed to prevent the continued spread of SARS-CoV-2; yet, rational vaccine design efforts are currently hampered by the lack of knowledge regarding viral epitopes targeted during an immune response, and the need for more in-depth knowledge on betacoronavirus immunology. To that end, we developed a computational workflow using a series of open-source algorithms and webtools to analyze the proteome of SARS-CoV-2 and identify putative T cell and B cell epitopes. Utilizing a set of stringent selection criteria to filter peptide epitopes, we identified 41 T cell epitopes (5 HLA class I, 36 HLA class II) and 6 B cell epitopes that could serve as promising targets for peptide-based vaccine development against this emerging global pathogen. To our knowledge, this is the first study to comprehensively analyze all 10 (structural, non-structural and accessory) proteins from SARS-CoV-2 using predictive algorithms to identify potential targets for vaccine development.
C1 [Crooke, Stephen N.; Ovsyannikova, Inna G.; Kennedy, Richard B.; Poland, Gregory A.] Mayo Clin, Mayo Clin Vaccine Res Grp, Guggenheim Bldg 611C,200 First St SW, Rochester, MN 55905 USA.
RP Poland, GA (corresponding author), Mayo Clin, Mayo Clin Vaccine Res Grp, Guggenheim Bldg 611C,200 First St SW, Rochester, MN 55905 USA.
EM poland.gregory@mayo.edu
OI Crooke, Stephen/0000-0002-4711-5767
CR Andersen PH, 2006, PROTEIN SCI, V15, P2558, DOI 10.1110/ps.062405906
   Backert L, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0245-0
   Berry JD, 2010, MABS-AUSTIN, V2, P53, DOI 10.4161/mabs.2.1.10788
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Braun J., 2020, PRESENCE SARS COV 2, DOI [10.1101/2020.04.17.20061440, 10.1101/2020.04.17.20061440., DOI 10.1101/2020.04.17.20061440]
   Brune KD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19234
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Doud MB, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006271
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Doytchinova IA, 2007, VACCINE, V25, P856, DOI 10.1016/j.vaccine.2006.09.032
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Ellis JM, 2000, HUM IMMUNOL, V61, P334, DOI 10.1016/S0198-8859(99)00155-X
   Fast E, 2020, POTENTIAL T CELL B C, DOI [10.1101/2020.02.19.955484, DOI 10.1101/2020.02.19.955484]
   Feng Y.-E, 2019, PREPRINT, DOI [10.1101/2020.03.03.962332, DOI 10.1101/2020.03.03]
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   He YX, 2006, VACCINE, V24, P5498, DOI 10.1016/j.vaccine.2006.04.054
   Henriques HR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002330
   Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang LR, 2004, J MED VIROL, V73, P338, DOI 10.1002/jmv.20096
   Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889
   Johnson KL, 2009, VACCINE, V28, P38, DOI 10.1016/j.vaccine.2009.09.126
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Keck ML, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01194
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Larsen MV, 2005, EUR J IMMUNOL, V35, P2295, DOI 10.1002/eji.200425811
   Lee H, 2015, NUCLEIC ACIDS RES, V43, pW431, DOI 10.1093/nar/gkv495
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Lorente E, 2016, MOL CELL PROTEOMICS, V15, P2141, DOI 10.1074/mcp.M115.057356
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Maurer-Stroh S, 2019, BIOINFORMATICS, V35, P3020, DOI 10.1093/bioinformatics/btz029
   McCarthy DP, 2014, WIRES NANOMED NANOBI, V6, P298, DOI 10.1002/wnan.1263
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Nguyen A., 2020, HUMAN LEUKOCYTE ANTI, DOI [10.1101/2020.03.22.20040600, DOI 10.1101/2020.03.22.20040600]
   Nielsen M, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0288-x
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Peng P, 2014, MOL THER, V22, P881, DOI 10.1038/mt.2013.287
   Peng Yanchun, 2020, bioRxiv, DOI 10.1101/2020.06.05.134551
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Poland GA, 2020, VACCINE, V38, P4219, DOI 10.1016/j.vaccine.2020.04.073
   Qiu MF, 2005, MICROBES INFECT, V7, P882, DOI 10.1016/j.micinf.2005.02.006
   Roder G, 2008, ACTA CRYSTALLOGR F, V64, P459, DOI 10.1107/S1744309108012396
   Roder G, 2006, ACTA CRYSTALLOGR D, V62, P1300, DOI 10.1107/S0907444906027636
   Seema M, 2020, PREPRINT
   SETTE A, 1994, J IMMUNOL, V153, P5586
   Srivastava S., 2020, STRUCTURAL BASIS DES, DOI [10.1101/2020.04.01.019299, DOI 10.1101/2020.04.01.019299]
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tomar Namrata, 2014, Methods Mol Biol, V1184, P23, DOI 10.1007/978-1-4939-1115-8_3
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Weston S, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00203-20
   WHO, 2020, COR DIS COVID 19 SIT
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zeng FY, 2006, FEBS LETT, V580, P5612, DOI 10.1016/j.febslet.2006.08.085
   Zhai LK, 2017, ANTIVIR RES, V147, P116, DOI 10.1016/j.antiviral.2017.09.012
   Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102
   Zhang LJ, 2017, ACS CHEM BIOL, V12, P539, DOI 10.1021/acschembio.6b00994
   Zhang Y, 2004, PROTEINS, V57, P702, DOI 10.1002/prot.20264
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 82
TC 2
Z9 2
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 25
PY 2020
VL 10
IS 1
AR 14179
DI 10.1038/s41598-020-70864-8
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NK9PX
UT WOS:000567061600020
PM 32843695
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Qiao, BF
   de la Cruz, MO
AF Qiao, Baofu
   de la Cruz, Monica Olvera
TI Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal
   Polybasic Cleavage Sites
SO ACS NANO
LA English
DT Article
DE COVID-19; SARS-CoV-2; polybasic cleavage sites; peptide inhibitor;
   molecular dynamics simulations
ID LINEAR CONSTRAINT SOLVER; PARTICLE MESH EWALD; DYNAMICS; SOLUBILITY;
   PEPTIDES; LINCS
AB The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein plays a crucial role in binding the human cell receptor ACE2 that is required for viral entry. Many studies have been conducted to target the structures of RBD-ACE2 binding and to design RBD-targeting vaccines and drugs. Nevertheless, mutations distal from the SARS-CoV-2 RBD also impact its transmissibility and antibody can target non-RBD regions, suggesting the incomplete role of the RBD region in the spike protein-ACE2 binding. Here, in order to elucidate distant binding mechanisms, we analyze complexes of ACE2 with the wild-type spike protein and with key mutants via large-scale all-atom explicit solvent molecular dynamics simulations. We find that though distributed approximately 10 nm away from the RBD, the SARS-CoV-2 polybasic cleavage sites enhance, via electrostatic interactions and hydration, the RBD-ACE2 binding affinity. A negatively charged tetrapeptide (GluGluLeuGlu) is then designed to neutralize the positively charged arginine on the polybasic cleavage sites. We find that the tetrapeptide GluGluLeuGlu binds to one of the three polybasic cleavage sites of the SARS-CoV-2 spike protein lessening by 34% the RBD-ACE2 binding strength. This significant binding energy reduction demonstrates the feasibility to neutralize RBD-ACE2 binding by targeting this specific polybasic cleavage site. Our work enhances understanding of the binding mechanism of SARS-CoV-2 to ACE2, which may aid the design of therapeutics for COVID-19 infection.
C1 [Qiao, Baofu] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA.
   [de la Cruz, Monica Olvera] Northwestern Univ, Dept Chem & Biol Engn, Dept Chem, Dept Mat Sci & Engn, Evanston, IL 60208 USA.
   [de la Cruz, Monica Olvera] Northwestern Univ, Dept Phys & Astron, Evanston, IL 60208 USA.
RP de la Cruz, MO (corresponding author), Northwestern Univ, Dept Chem & Biol Engn, Dept Chem, Dept Mat Sci & Engn, Evanston, IL 60208 USA.; de la Cruz, MO (corresponding author), Northwestern Univ, Dept Phys & Astron, Evanston, IL 60208 USA.
EM m-olver@northwestern.edu
RI de la Cruz, Monica Olvera/X-2039-2019; Olvera de la Cruz,
   Monica/N-6359-2018
OI Olvera de la Cruz, Monica/0000-0002-9802-3627
FU U.S. Department of Energy (DOE), Office of Science, Office of Basic
   Energy SciencesUnited States Department of Energy (DOE)
   [DE-FG02-08ER46539]; Sherman Fairchild Foundation; Center for
   Computation and Theory of Soft Materials at Northwestern University
FX This work was supported by the U.S. Department of Energy (DOE), Office
   of Science, Office of Basic Energy Sciences, under Award No.
   DE-FG02-08ER46539, the Sherman Fairchild Foundation, and the Center for
   Computation and Theory of Soft Materials at Northwestern University. We
   thank Yang Li for assistance in generating Figure
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Blum AP, 2016, CHEM SCI, V7, P989, DOI [10.1039/C5SC03417E, 10.1039/c5sc03417e]
   Blum AP, 2014, J AM CHEM SOC, V136, P15422, DOI 10.1021/ja5088216
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Chipot C, 2014, WIRES COMPUT MOL SCI, V4, P71, DOI 10.1002/wcms.1157
   Chong SH, 2014, ANGEW CHEM INT EDIT, V53, P3961, DOI 10.1002/anie.201309317
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Jong DH, 2013, J CHEM THEORY COMPUT, V9, P687, DOI 10.1021/ct300646g
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003
   Fumagalli L, 2018, SCIENCE, V360, P1339, DOI 10.1126/science.aat4191
   Golovanov AP, 2004, J AM CHEM SOC, V126, P8933, DOI 10.1021/ja049297h
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P116, DOI 10.1021/ct700200b
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Huang J, 2017, NAT METHODS, V14, P71, DOI [10.1038/NMETH.4067, 10.1038/nmeth.4067]
   Jiang T, 2020, NATURE, V577, P216, DOI 10.1038/s41586-019-1881-0
   Jimenez-Angeles F, 2019, ACS CENTRAL SCI, V5, P688, DOI 10.1021/acscentsci.9b00084
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kramer RM, 2012, BIOPHYS J, V102, P1907, DOI 10.1016/j.bpj.2012.01.060
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lau JL, 2018, BIOORGAN MED CHEM, V26, P2700, DOI 10.1016/j.bmc.2017.06.052
   Lee J, 2016, J CHEM THEORY COMPUT, V12, P405, DOI 10.1021/acs.jctc.5b00935
   Li Ying, 2020, Chinese Medical Sciences Journal, V35, P1, DOI 10.24920/003712
   LUZAR A, 1993, J CHEM PHYS, V98, P8160, DOI 10.1063/1.464521
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805
   Panganiban B, 2018, SCIENCE, V359, P1239, DOI 10.1126/science.aao0335
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Periole X, 2009, J CHEM THEORY COMPUT, V5, P2531, DOI 10.1021/ct9002114
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Qiao BF, 2019, P NATL ACAD SCI USA, V116, P19274, DOI 10.1073/pnas.1910225116
   Qiao BF, 2019, J PHYS CHEM B, V123, P3907, DOI 10.1021/acs.jpcb.9b01394
   Qiao B, 2014, J PHYS CHEM LETT, V5, P1440, DOI 10.1021/jz500495p
   Sato K, 2018, CHEM SOC REV, V47, P7539, DOI 10.1039/c7cs00735c
   Schlaich A, 2016, PHYS REV LETT, V117, DOI 10.1103/PhysRevLett.117.048001
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sun C, 2018, P NATL ACAD SCI USA, V115, P8883, DOI 10.1073/pnas.1809383115
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wong KH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020381
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang CX, 2020, J PROTEOME RES, V19, P1351, DOI 10.1021/acs.jproteome.0c00129
   Zhang G., 2020, INVESTIGATION ACE2 N, DOI [10.1101/2020.03.19.999318, DOI 10.1101/2020.03.19.999318]
   Zheng W, 2019, PROTEINS, V87, P1149, DOI 10.1002/prot.25792
NR 53
TC 4
Z9 4
U1 3
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD AUG 25
PY 2020
VL 14
IS 8
BP 10616
EP 10623
DI 10.1021/acsnano.0c04798
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA NJ9CF
UT WOS:000566341000123
PM 32806067
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Pinana, JL
   Martino, R
   Garcia-Garcia, I
   Parody, R
   Morales, MD
   Benzo, G
   Gomez-Catalan, I
   Coll, R
   De la Fuente, I
   Luna, A
   Merchan, B
   Chinea, A
   de Miguel, D
   Serrano, A
   Perez, C
   Diaz, C
   Lopez, JL
   Saez, AJ
   Bailen, R
   Zudaire, T
   Martinez, D
   Jurado, M
   Calbacho, M
   Vazquez, L
   Garcia-Cadenas, I
   Fox, L
   Pimentel, AI
   Bautista, G
   Nieto, A
   Fernandez, P
   Vallejo, JC
   Solano, C
   Valero, M
   Espigado, I
   Saldana, R
   Sisinni, L
   Ribera, JM
   Jimenez, MJ
   Trabazo, M
   Gonzalez-Vicent, M
   Fernandez, N
   Talarn, C
   Montoya, MC
   Cedillo, A
   Sureda, A
AF Pinana, Jose Luis
   Martino, Rodrigo
   Garcia-Garcia, Irene
   Parody, Rocio
   Morales, Maria Dolores
   Benzo, Gonzalo
   Gomez-Catalan, Irene
   Coll, Rosa
   De la Fuente, Ignacio
   Luna, Alejandro
   Merchan, Beatriz
   Chinea, Anabelle
   de Miguel, Dunia
   Serrano, Ana
   Perez, Carmen
   Diaz, Carola
   Lopez, Jose Luis
   Saez, Adolfo Jesus
   Bailen, Rebeca
   Zudaire, Teresa
   Martinez, Diana
   Jurado, Manuel
   Calbacho, Maria
   Vazquez, Lourdes
   Garcia-Cadenas, Irene
   Fox, Laura
   Pimentel, Ana I.
   Bautista, Guiomar
   Nieto, Agustin
   Fernandez, Pascual
   Vallejo, Juan Carlos
   Solano, Carlos
   Valero, Marta
   Espigado, Ildefonso
   Saldana, Raquel
   Sisinni, Luisa
   Ribera, Josep Maria
   Jimenez, Maria Jose
   Trabazo, Maria
   Gonzalez-Vicent, Marta
   Fernandez, Noemi
   Talarn, Carme
   Montoya, Maria Carmen
   Cedillo, Angel
   Sureda, Anna
CA Spanish Hematopoietic Stem Cell Tr
TI Risk factors and outcome of COVID-19 in patients with hematological
   malignancies
SO EXPERIMENTAL HEMATOLOGY & ONCOLOGY
LA English
DT Article
ID RECOMMENDATIONS; MANAGEMENT; CRITERIA
AB Background Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined. Patients and methods This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective observational study, which included a large cohort of blood cancer patients with laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020. Results We included 367 pediatric and adult patients with hematological malignancies, including recipients of autologous (ASCT) (n = 58) or allogeneic stem cell transplantation (allo-SCT) (n = 65) from 41 hospitals in Spain. Median age of patients was 64 years (range 1-93.8). Recipients of ASCT and allo-SCT showed lower mortality rates (17% and 18%, respectively) compared to non-SCT patients (31%) (p = 0.02). Prognostic factors identified for day 45 overall mortality (OM) by logistic regression multivariate analysis included age > 70 years [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2-3.8, p = 0.011]; uncontrolled hematological malignancy (OR 2.9, 95% CI 1.6-5.2, p < 0.0001); ECOG 3-4 (OR, 2.56, 95% CI 1.4-4.7, p = 0.003); neutropenia (< 0.5 x 10(9)/L) (OR 2.8, 95% CI 1.3-6.1, p = 0.01); and a C-reactive protein (CRP) > 20 mg/dL (OR 3.3, 95% CI 1.7-6.4, p < 0.0001). In multivariate analysis of 216 patients with very severe COVID-19, treatment with azithromycin or low dose corticosteroids was associated with lower OM (OR 0.42, 95% CI 0.2-0.89 and OR 0.31, 95% CI 0.11-0.87, respectively, p = 0.02) whereas the use of hidroxycloroquine did not show significant improvement in OM (OR 0.64, 95% CI 0.37-1.1, P = 0.1). Conclusions In most patients with hematological malignancies COVID-19 mortality was directly driven by older age, disease status, performance status, as well as by immune (neutropenia) parameters and level of inflammation (high CRP). Use of azithromycin and low dose corticosteroids may be of value in very severe COVID-19.
C1 [Pinana, Jose Luis] Hosp Univ & Politecn La Fe, Inst Invest Sanit La Fe, Hematol Div, Valencia, Spain.
   [Pinana, Jose Luis] Inst Carlos III, CIBERONC, Madrid, Spain.
   [Pinana, Jose Luis; Martino, Rodrigo; Garcia-Cadenas, Irene] Hosp Santa Creu Sant & Pau, Hematol Div, Barcelona, Spain.
   [Garcia-Garcia, Irene; Luna, Alejandro; Chinea, Anabelle; Saez, Adolfo Jesus] Hosp Ramon & Cajal, Hematol Div, Madrid, Spain.
   [Parody, Rocio; Sureda, Anna] Hosp Duran & Reynals, Hematol Div, Inst Catala Oncol, Barcelona, Spain.
   [Pinana, Jose Luis; Morales, Maria Dolores; Merchan, Beatriz; de Miguel, Dunia] Hosp Guadalajara, Hematol Div, Guadalajara, Spain.
   [Benzo, Gonzalo] Hosp La Princesa, Hematol Div, Madrid, Spain.
   [Gomez-Catalan, Irene; Serrano, Ana; Montoya, Maria Carmen] Hosp Albacete, Hematol Div, Albacete, Spain.
   [Coll, Rosa] Hosp Josep Trueta, Hematol Div, Inst Catala Oncol, Girona, Spain.
   [De la Fuente, Ignacio; Perez, Carmen] Hosp Clin Valladolid, Hematol Div, Valladolid, Spain.
   [Diaz, Carola] Hosp Carlos Haya, Hematol Div, Malaga, Spain.
   [Lopez, Jose Luis] Hosp Fdn Jimenez Diaz, Hematol Div, Madrid, Spain.
   [Bailen, Rebeca] Hosp Gregorio Maranon, Hematol Div, Madrid, Spain.
   [Zudaire, Teresa] Hosp Navarra, Hematol Div, Navarra, Spain.
   [Martinez, Diana] Hosp Coruna, Hematol Div, Coruna, Spain.
   [Jurado, Manuel] Hosp Virgen Nieves, Hematol Div, Granada, Spain.
   [Calbacho, Maria] Hosp 12 Octubre, Hematol Div, Madrid, Spain.
   [Vazquez, Lourdes] Hosp Univ Salamanca, Hematol Div, Salamanca, Spain.
   [Fox, Laura] Hosp Valle De Hebron, Hematol Div, Barcelona, Spain.
   [Pimentel, Ana I.] Hosp Clin Univ Lozano Blesa, IIS Aragon, Hematol Div, Zaragoza, Spain.
   [Bautista, Guiomar] Hosp Puerta Hierro, Hematol Div, Madrid, Spain.
   [Nieto, Agustin] Hosp Vigo, Hematol Div, Vigo, Spain.
   [Fernandez, Pascual] Hosp Gen Alicante, Hematol Div, Alicante, Spain.
   [Vallejo, Juan Carlos] Hosp Donostia, Hematol Div, Donostia San Sebastian, Spain.
   [Solano, Carlos] Hosp Clin Univ Valencia, Hematol Div, Valencia, Spain.
   [Valero, Marta] Hosp Arnau Vilanova, Hematol Div, Valencia, Spain.
   [Espigado, Ildefonso] Univ Seville, CSIC, Univ Hosp Virgen Rocio, Dept Hematol,Inst Biomed Sevilla, Seville, Spain.
   [Saldana, Raquel] Hosp Jerez, Hematol Div, Jerez de la Frontera, Spain.
   [Sisinni, Luisa] Hosp Paz, Pediat Hematol Oncol Div, Madrid, Spain.
   [Ribera, Josep Maria; Jimenez, Maria Jose] Hosp Badalona Germans Trias & Pujol, Josep Carreras Res Inst, ICO, Hematol Div, Badalona, Spain.
   [Trabazo, Maria] Hosp Santa Creu & Sant Pau, Pediat Div, Barcelona, Spain.
   [Gonzalez-Vicent, Marta] Hosp Nino Jesus, Pediat Div, Madrid, Spain.
   [Fernandez, Noemi] Hosp Marques Valdecilla, Hematol Div, Santander, Spain.
   [Talarn, Carme] Hosp Joan 23, Hematol Div, Tarragona, Spain.
   [Cedillo, Angel] Hematopoiet Stem Cell Transplantat & Cell Therapy, Madrid, Spain.
   [Pinana, Jose Luis] Hosp Univ Fe Valencia, Div Clin Hematol, Avda Fernando Abril Martorell 106, Valencia 46026, Spain.
RP Pinana, JL (corresponding author), Hosp Univ Fe Valencia, Div Clin Hematol, Avda Fernando Abril Martorell 106, Valencia 46026, Spain.
EM jlpinana@gmail.com
RI ESPIGADO, ILDEFONSO/C-9304-2015
OI ESPIGADO, ILDEFONSO/0000-0002-4043-6613; Trabazo del Castillo,
   Maria/0000-0002-4515-4279
FU Vanderbilt Institute for Clinical and Translational Research; Spanish
   Society of Hematology (SEHH)
FX REDCap is developed and supported by Vanderbilt Institute for Clinical
   and Translational Research. We thank the Spanish Society of Hematology
   (SEHH) for its support on patients' recruitment.
CR [Anonymous], 2020, RANDOMISED EVALUATIO
   [Anonymous], 2020, ENFERMEDAD CORONAVIR
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Bhargava A, 2020, CLIN INFECT DIS, V71, P1962, DOI 10.1093/cid/ciaa674
   Chen W, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00362-2
   Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800
   Chien JW, 2003, AM J RESP CRIT CARE, V168, P208, DOI 10.1164/rccm.200212-1468OC
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Division of Risk Assessment and International Cooperation, 2020, UPD COVID 19 KOR APR
   Dohner H, 2017, BLOOD, V129, P424, DOI 10.1182/blood-2016-08-733196
   Erard V, 2006, J INFECT DIS, V193, P1619, DOI 10.1086/504268
   Fadel Raef, 2020, Clin Infect Dis, V71, P2114, DOI 10.1093/cid/ciaa601
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hao SR, 2020, J INFECT DIS, V222, P367, DOI 10.1093/infdis/jiaa311
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kolilekas L, 2020, J MED VIROL, V92, P2866, DOI 10.1002/jmv.26165
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6
   Lapostolle F, 2020, INTERN EMERG MED, V15, P813, DOI 10.1007/s11739-020-02379-z
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Pinana JL, 2020, BONE MARROW TRANSPL, V55, P431, DOI 10.1038/s41409-019-0698-7
   Malard F, 2020, BONE MARROW TRANSPL, V55, P2180, DOI 10.1038/s41409-020-0931-4
   Martin-Moro F, 2020, BRIT J HAEMATOL, V190, pE16, DOI 10.1111/bjh.16801
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Scarfo L, 2020, LEUKEMIA, V34, P2354, DOI 10.1038/s41375-020-0959-x
   Shah DP, 2012, AM J BLOOD RES, V2, P203
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   So C, 2020, RESPIROL CASE REP, V8, DOI 10.1002/rcr2.596
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang B, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00934-x
   Wang YS, 2020, J MED VIROL, V92, P1401, DOI 10.1002/jmv.25990
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Yuan Mingli, 2020, Shock, V54, P638, DOI 10.1097/SHK.0000000000001574
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 46
TC 3
Z9 3
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2162-3619
J9 EXP HEMATOL ONCOL
JI Exp. Hematol. Oncol.
PD AUG 25
PY 2020
VL 9
IS 1
AR 21
DI 10.1186/s40164-020-00177-z
PG 16
WC Oncology; Hematology
SC Oncology; Hematology
GA NJ7VS
UT WOS:000566251400001
PM 32864192
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alonso-Fernandez, A
   Toledo-Pons, N
   Cosio, BG
   Millan, A
   Calvo, N
   Ramon, L
   de Mendoza, SH
   Morell-Garcia, D
   Bauca-Rossello, JM
   Nunez, B
   Pons, J
   Palmer, JA
   Martin, L
   Penaranda, M
   Pou, JA
   Sauleda, J
   Sala-LlinaS, E
AF Alonso-Fernandez, Alberto
   Toledo-Pons, Nuria
   Cosio, Borja G.
   Millan, Aina
   Calvo, Nestor
   Ramon, Luisa
   Hermoso de Mendoza, Sara
   Morell-Garcia, Daniel
   Miquel Bauca-Rossello, Josep
   Nunez, Belen
   Pons, Jaume
   Palmer, Juan A.
   Martin, Luisa
   Penaranda, Maria
   Pou, Joan A.
   Sauleda, Jaume
   Sala-LlinaS, Ernest
TI Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and
   high D-dimer values: A prospective study
SO PLOS ONE
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; VENOUS THROMBOEMBOLISM; COAGULATION;
   OBSTRUCTION; PREVENTION; ENOXAPARIN; SEVERITY; INDEX; CT
AB Introduction Coronavirus disease 2019 (COVID-19) pneumonia is associated to systemic hyper-inflammation and abnormal coagulation profile. D-dimer elevation is particularly frequent, and values higher than 1 mu g/mL have been associated with disease severity and in-hospital mortality. Previous retrospective studies found a high pulmonary embolism (PE) prevalence, however, it should be highlighted that diagnoses were only completed when PE was clinically suspected. Material and methods Single-center prospective cohort study. Between April 6(th)and April 17(th)2020, consecutive confirmed cases of COVID-19 pneumonia with D-dimer >1 mu g/mL underwent computed tomography pulmonary angiography (CTPA) to investigate the presence and magnitude of PE. Demographic and laboratory data, comorbidities, CTPA scores, administered treatments, and, clinical outcomes were analysed and compared between patients with and without PE. Results Thirty consecutive patients (11 women) were included. PE was diagnosed in 15 patients (50%). In patients with PE, emboli were located mainly in segmental arteries (86%) and bilaterally (60%). Patients with PE were significantly older (median age 67.0 (IQR 63.0-73.0) vs. 57.0 (IQR 48.0-69.0) years, p = .048) and did not differ in sex or risk factors for thromboembolic disease from the non-PE group. D-dimer, platelet count, and, C reactive protein values were significantly higher among PE patients. D-dimer values correlated with the radiologic magnitude of PE (p<0.001). Conclusions Patients with COVID-19 pneumonia and D-dimer values higher than 1 mu g/mL presented a high prevalence of PE, regardless of clinical suspicion. We consider that these findings could contribute to improve the prognosis of patients with COVID-19 pneumonia, by initiating anticoagulant therapy when a PE is found.
C1 [Alonso-Fernandez, Alberto; Toledo-Pons, Nuria; Cosio, Borja G.; Ramon, Luisa; Hermoso de Mendoza, Sara; Nunez, Belen; Sauleda, Jaume; Sala-LlinaS, Ernest] Univ Hosp Son Espases, Dept Pneumol, Palma De Mallorca, Spain.
   [Alonso-Fernandez, Alberto; Cosio, Borja G.; Sauleda, Jaume; Sala-LlinaS, Ernest] CIBER Enfermedades Resp, Madrid, Spain.
   [Alonso-Fernandez, Alberto; Toledo-Pons, Nuria; Cosio, Borja G.; Millan, Aina; Morell-Garcia, Daniel; Nunez, Belen; Sauleda, Jaume; Sala-LlinaS, Ernest] Univ Hosp Son Espases, Inst Invest Sanitaria Illes Balears IdISBa, Palma De Mallorca, Spain.
   [Calvo, Nestor; Palmer, Juan A.] Univ Hosp Son Espases, Radiodiagnost Dept, Palma De Mallorca, Spain.
   [Morell-Garcia, Daniel; Miquel Bauca-Rossello, Josep] Univ Hosp Son Espases, Dept Lab Med, Palma De Mallorca, Spain.
   [Pons, Jaume] Univ Hosp Son Espases, Cardiol Dept, Palma De Mallorca, Spain.
   [Martin, Luisa; Penaranda, Maria; Pou, Joan A.] Univ Hosp Son Espases, Dept Internal Med, Palma De Mallorca, Spain.
RP Alonso-Fernandez, A (corresponding author), Univ Hosp Son Espases, Dept Pneumol, Palma De Mallorca, Spain.; Alonso-Fernandez, A (corresponding author), CIBER Enfermedades Resp, Madrid, Spain.; Alonso-Fernandez, A (corresponding author), Univ Hosp Son Espases, Inst Invest Sanitaria Illes Balears IdISBa, Palma De Mallorca, Spain.
EM alberto.alonso@ssib.es
OI Pou Goyanes, J. Albert/0000-0003-0584-0116; ,
   Alonso-Fernandez/0000-0002-0802-8871
FU  [IdISBa COVID-19/22]
FX This work was supported by IdISBa COVID-19/22 to AAF.
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bruggemann R, 2020, THROMB RES, V191, P153, DOI 10.1016/j.thromres.2020.04.046
   Castro DJ, 2001, RESPIRATION, V68, P371
   Ciceri F, 2020, CRITICAL CARE RESUSC
   Demelo-Rodriguez P, 2020, THROMB RES, V192, P23, DOI 10.1016/j.thromres.2020.05.018
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Frasson S, 2016, J THROMB THROMBOLYS, V41, P404, DOI 10.1007/s11239-015-1242-2
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Jeebun V, 2010, QJM-INT J MED, V103, P91, DOI 10.1093/qjmed/hcp162
   Kleber FX, 2003, AM HEART J, V145, P614, DOI 10.1067/mhj.2003.189
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Konstantinides SV, 2020, EUR HEART J, V41, P543, DOI 10.1093/eurheartj/ehz405
   Leonard-Lorant I, 2020, RADIOLOGY, V296, pE189, DOI 10.1148/radiol.2020201561
   Levi M, 2017, THROMB RES, V149, P38, DOI 10.1016/j.thromres.2016.11.007
   Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Milbrandt EB, 2009, MOL MED, V15, P438, DOI 10.2119/molmed.2009.00091
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Qanadli SD, 2001, AM J ROENTGENOL, V176, P1415, DOI 10.2214/ajr.176.6.1761415
   Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103
   Thachil J, 2020, SEMINARS THROMBOSIS
   Uresandi F, 2013, ARCH BRONCONEUMOL, V49, P534, DOI 10.1016/j.arbres.2013.07.008
   van der Meer RW, 2005, RADIOLOGY, V235, P798, DOI 10.1148/radiol.2353040593
   WHO, 2020, WHO2019NCOVCLINICAL2
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   World Health Organization, COR DIS COVID 19 OUT
   Xiong TY, 2020, EUR HEART J, V41, P1798, DOI 10.1093/eurheartj/ehaa231
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Zhang YF, 2016, J THROMB THROMBOLYS, V41, P619, DOI 10.1007/s11239-015-1275-6
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 35
TC 1
Z9 1
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 25
PY 2020
VL 15
IS 8
AR e0238216
DI 10.1371/journal.pone.0238216
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NI7UF
UT WOS:000565553400037
PM 32841275
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Elnadoury, O
   Beattie, J
   Lubinsky, AS
AF Elnadoury, Ola
   Beattie, Jason
   Lubinsky, Anthony S.
TI Uninterrupted Continuous and Intermittent Nebulizer Therapy in a
   COVID-19 Patient Using Sequential Vibratory Mesh Nebulizers: A Case
   Report
SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY
LA English
DT Article
DE COVID-19; epoprostenol; mucolytics; nebulized antibiotics
ID ACUTE LUNG INJURY
AB Interruptions in continuous nebulized pulmonary vasodilators, such as epoprostenol, can potentially result in clinical deterioration in respiratory status. Coadministration of other intermittent nebulized therapies may require opening the ventilator circuit to facilitate administration. However, in patients with SARS-CoV2 infection, it is preferred to avoid opening the circuit whenever feasible to prevent aerosolization of the virus and exposure of health care workers. In this study, we describe a unique method of administering continuous epoprostenol nebulization and intermittent nebulized antibiotics, mucolytics, and bronchodilators, using Aerogen vibrating mesh nebulizers without interruptions in epoprostenol or opening the ventilator circuit. This technique set up consisted of stacking two Aerogen nebulizer cups, each with its own controller. This approach was successful in allowing concomitant delivery of intermittent and continuous nebulized therapy without interruptions. To our knowledge, this method has not been previously described in the literature and may be helpful to bedside clinicians facing a similar clinical scenario.
C1 [Elnadoury, Ola] NYU, Langone Hosp Brooklyn, Dept Pharm, 150 55th St, Brooklyn, NY 11220 USA.
   [Beattie, Jason] Mem Sloan Kettering Canc Ctr, Dept Med Pulm, 1275 York Ave, New York, NY 10021 USA.
   [Lubinsky, Anthony S.] NYU Langone Hlth, Dept Med, Div Pulm & Crit Care Med, New York, NY USA.
RP Elnadoury, O (corresponding author), NYU, Langone Hosp Brooklyn, Dept Pharm, 150 55th St, Brooklyn, NY 11220 USA.
EM ola.elnadoury@nyulangone.org
CR Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Buckley MS, 2019, J PHARM PRACT, V32, P347, DOI 10.1177/0897190019830504
   Dzierba AL, 2014, PHARMACOTHERAPY, V34, P279, DOI 10.1002/phar.1365
   Jung SY, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1916-6
   Lu Q, 2012, ANESTHESIOLOGY, V117, P1335, DOI 10.1097/ALN.0b013e31827515de
   Moss M, 2019, NEW ENGL J MED, V380, P1997, DOI 10.1056/NEJMoa1901686
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   Respiratory Care Committee of Chinese Thoracic Society, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P288, DOI 10.3760/cma.j.cn112147-20200304-00239
   Tsuji BT, 2019, PHARMACOTHERAPY, V39, P10, DOI 10.1002/phar.2209
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 10
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1941-2711
EI 1941-2703
J9 J AEROSOL MED PULM D
JI J. Aerosol Med. Pulm. Drug Deliv.
PD DEC 1
PY 2020
VL 33
IS 6
BP 357
EP 360
DI 10.1089/jamp.2020.1636
EA AUG 2020
PG 4
WC Respiratory System
SC Respiratory System
GA PF0CH
UT WOS:000565950200001
PM 32852238
OA Bronze
DA 2021-01-01
ER

PT J
AU Schlegl, S
   Maier, J
   Meule, A
   Voderholzer, U
AF Schlegl, Sandra
   Maier, Julia
   Meule, Adrian
   Voderholzer, Ulrich
TI Eating disorders in times of theCOVID-19 pandemic-Results from an online
   survey of patients with anorexia nervosa
SO INTERNATIONAL JOURNAL OF EATING DISORDERS
LA English
DT Article
DE anorexia nervosa; coping strategies; COVID-19 pandemic; health care
   utilization; symptoms worsening
ID UNCERTAINTY; INTOLERANCE; LONELINESS; COVID-19; ACCURACY; ANXIETY
AB Objective The COVID-19 pandemic and the resulting public restrictions pose a psychological burden for humans worldwide and may be particularly detrimental for individuals with mental disorders. Therefore, the current study explored effects of the COVID-19 pandemic on eating disorder (ED) symptoms and other psychological aspects in former inpatients with anorexia nervosa (AN). Method One-hundred and fifty-nine patients with AN-discharged from inpatient treatment in 2019-completed an online survey on contact history with COVID-19, changes in ED symptoms and other psychological aspects, health care utilization, and strategies patients employed to cope during the pandemic. Results Approximately 70% of patients reported that eating, shape and weight concerns, drive for physical activity, loneliness, sadness, and inner restlessness increased during the pandemic. Access to in-person psychotherapies and visits at the general practitioner (including weight checks) decreased by 37% and 46%, respectively. Videoconference therapy was used by 26% and telephone contacts by 35% of patients. Patients experienced daily routines, day planning and enjoyable activities as the most helpful among the most used coping strategies. Discussion The COVID-19 pandemic poses great challenges to patients with AN. ED-related thoughts and behaviors may be used as dysfunctional coping mechanisms to regain control over the current circumstances. E-mental health interventions appear to be promising for supporting AN patients during these hard times. Furthermore, interventions addressing symptoms of depression and anxiety, as well as intolerance of uncertainty might help them manage their ED symptoms.
C1 [Schlegl, Sandra; Maier, Julia; Meule, Adrian; Voderholzer, Ulrich] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany.
   [Meule, Adrian; Voderholzer, Ulrich] Schoen Clin Roseneck, Prien Am Chiemsee, Germany.
   [Voderholzer, Ulrich] Univ Hosp Freiburg, Dept Psychiat & Psychotherapy, Freiburg, Germany.
RP Schlegl, S (corresponding author), Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany.
EM sandra.schlegl@med.uni-muenchen.de
RI Meule, Adrian/W-5150-2017
OI Meule, Adrian/0000-0002-6639-8977; Voderholzer Prof.,
   Ulrich/0000-0003-0261-3145
FU Projekt DEAL
FX Open access funding enabled and organized by Projekt DEAL.
CR Brown M, 2017, EUR EAT DISORD REV, V25, P329, DOI 10.1002/erv.2523
   Cacioppo JT, 2006, PSYCHOL AGING, V21, P140, DOI 10.1037/0882-7974.21.1.140
   Cohen J., 1988, STAT POWER ANAL BEHA
   Cooper M, 2020, EAT DISORD, DOI 10.1080/10640266.2020.1790271
   Diamond R, 2020, BRIT J PSYCHIAT, V217, P408, DOI 10.1192/bjp.2020.91
   Fairburn C. G., 2008, COGNITIVE BEHAV THER
   Fairburn CG, 1999, BEHAV RES THER, V37, P1, DOI 10.1016/S0005-7967(98)00102-8
   Fernandez-Aranda F, 2020, EUR EAT DISORD REV, V28, P239, DOI 10.1002/erv.2738
   Fitzpatrick KM, 2020, DEPRESS ANXIETY, V37, P957, DOI 10.1002/da.23080
   Frank GKW, 2012, INT J EAT DISORDER, V45, P227, DOI 10.1002/eat.20929
   Hayes SC, 1999, ACCEPTANCE COMMITMEN
   Hempel R, 2018, EAT DISORD, V26, P92, DOI 10.1080/10640266.2018.1418268
   Holland G, 2016, BODY IMAGE, V17, P100, DOI 10.1016/j.bodyim.2016.02.008
   Kesby A, 2017, CLIN PSYCHOL REV, V56, P94, DOI 10.1016/j.cpr.2017.07.002
   Killgore WDS, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113117
   Kraemer H. C., 2015, ENCY CLIN PSYCHOL
   Kraemer HC, 2020, INT J EAT DISORDER, V53, P302, DOI 10.1002/eat.23216
   Li JF, 2020, WORLD PSYCHIATRY, V19, P249, DOI 10.1002/wps.20758
   Linardon J, 2020, INT J EAT DISORDER, V53, P907, DOI 10.1002/eat.23268
   Mahoney Alison E. J., 2012, Cognitive Behaviour Therapy, V41, P212, DOI 10.1080/16506073.2011.622130
   Matheson BE, 2020, INT J EAT DISORDER, V53, P1142, DOI 10.1002/eat.23326
   McCabe RE, 2001, INT J EAT DISORDER, V29, P59, DOI 10.1002/1098-108X(200101)29:1&lt;59::AID-EAT9&gt;3.0.CO;2-#
   Meyer C, 2011, EUR EAT DISORD REV, V19, P174, DOI 10.1002/erv.1122
   Meyer C, 2009, EUR EAT DISORD REV, V17, P366, DOI 10.1002/erv.950
   Murphy R, 2020, COGN BEH THER, V13, DOI 10.1017/S1754470X20000161
   Naumann E, 2014, PSYCHIAT RES, V215, P711, DOI 10.1016/j.psychres.2013.12.043
   Stein Aliza T, 2020, Psychol Med, P1, DOI 10.1017/S0033291720000239
   Taylor CB, 2020, INT J EAT DISORDER, V53, P1155, DOI 10.1002/eat.23300
   Torous J, 2020, JAMA PSYCHIAT, V77, P1205, DOI 10.1001/jamapsychiatry.2020.1640
   Touyz S, 2020, J EAT DISORD, V8, DOI 10.1186/s40337-020-00295-3
   Waller G, 2020, INT J EAT DISORDER, V53, P1132, DOI 10.1002/eat.23289
   Weissman RS, 2020, INT J EAT DISORDER, V53, P369, DOI 10.1002/eat.23279
   Wind TR, 2020, INTERNET INTERV, V20, DOI 10.1016/j.invent.2020.100317
NR 33
TC 2
Z9 2
U1 7
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0276-3478
EI 1098-108X
J9 INT J EAT DISORDER
JI Int. J. Eating Disord.
PD NOV
PY 2020
VL 53
IS 11
BP 1791
EP 1800
DI 10.1002/eat.23374
EA AUG 2020
PG 10
WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology
SC Psychology; Nutrition & Dietetics; Psychiatry
GA OQ2UO
UT WOS:000563985400001
PM 32841413
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Biernacka, EK
   Kosior, DA
   Zienciuk-Krajka, A
   Miszczak-Knecht, M
   Kempa, M
   Przybylski, A
AF Biernacka, Elzbieta K.
   Kosior, Dariusz A.
   Zienciuk-Krajka, Agnieszka
   Miszczak-Knecht, Maria
   Kempa, Maciej
   Przybylski, Andrzej
TI Predictors of arrhythmia other than QT interval prolongation and the use
   of beta-blocker therapy in the coronavirus disease 2019 pandemic Reply
SO KARDIOLOGIA POLSKA
LA English
DT Letter
C1 [Biernacka, Elzbieta K.] Cardinal Stefan Wyszynski Natl Inst Cardiol, Dept Congenital Heart Dis, Ul Alpejska 42, PL-04628 Warsaw, Poland.
   [Kosior, Dariusz A.] Cent Res Hosp, Minist Interior & Adm, Dept Cardiol & Hypertens, Electrophysiol Lab, Warsaw, Poland.
   [Kosior, Dariusz A.] Polish Acad Sci, Mossakowski Med Res Ctr, Warsaw, Poland.
   [Zienciuk-Krajka, Agnieszka; Kempa, Maciej] Med Univ Gdansk, Dept Cardiol & Electrotherapy, Gdansk, Poland.
   [Miszczak-Knecht, Maria] Childrens Memorial Hlth Inst, Dept Cardiol, Warsaw, Poland.
   [Przybylski, Andrzej] Univ Rzeszow, Med Coll, Rzeszow, Poland.
   [Przybylski, Andrzej] Clin Prov Hosp 2, Acute Coronary Syndromes Subdiv, Cardiol Dept, Rzeszow, Poland.
RP Biernacka, EK (corresponding author), Cardinal Stefan Wyszynski Natl Inst Cardiol, Dept Congenital Heart Dis, Ul Alpejska 42, PL-04628 Warsaw, Poland.
EM k.biernacka@ikard.pl
OI Przybylski, Andrzej/0000-0002-8136-7589
CR Ahmad K, 2020, EUROPACE, piv16
   Mazzanti A, 2018, J AM COLL CARDIOL, V71, P1663, DOI 10.1016/j.jacc.2018.01.078
   Shenthar J, 2017, INDIAN HEART J, V69, P707, DOI 10.1016/j.ihj.2017.05.024
   Yoshiga Y, 2002, CIRC J, V66, P1024, DOI 10.1253/circj.66.1024
NR 4
TC 0
Z9 0
U1 1
U2 1
PU POLSKIE TOWARZYSTOWO KARDIOLOGICZNE
PI WARSZAWA
PA UL STAWKI 3 A LOK 1-2, WARSZAWA, POLAND
SN 0022-9032
EI 1897-4279
J9 KARDIOL POL
JI Kardiol. Pol.
PD AUG 25
PY 2020
VL 78
IS 7-8
BP 796
EP 797
DI 10.33963/KP.15564
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NE7RM
UT WOS:000562800100035
PM 32844612
OA Bronze
DA 2021-01-01
ER

PT J
AU Tolunay, H
AF Tolunay, Hatice
TI Predictors of arrhythmia other than QT interval prolongation and the use
   of beta-blocker therapy in the coronavirus disease 2019 pandemic
SO KARDIOLOGIA POLSKA
LA English
DT Letter
C1 [Tolunay, Hatice] Gulhane Educ & Res Hosp, Dept Cardiol, Gen Dr Tevfik Saglam St 1, TR-06010 Ankara, Turkey.
RP Tolunay, H (corresponding author), Gulhane Educ & Res Hosp, Dept Cardiol, Gen Dr Tevfik Saglam St 1, TR-06010 Ankara, Turkey.
EM drhaticearslan@gmail.com
CR Biernacka EK, 2020, KARDIOL POL, V78, P493, DOI 10.33963/KP.15354
   Chadha S, 2020, QJM-INT J MED, V113, P488, DOI 10.1093/qjmed/hcaa135
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 5
TC 0
Z9 0
U1 1
U2 1
PU POLSKIE TOWARZYSTOWO KARDIOLOGICZNE
PI WARSZAWA
PA UL STAWKI 3 A LOK 1-2, WARSZAWA, POLAND
SN 0022-9032
EI 1897-4279
J9 KARDIOL POL
JI Kardiol. Pol.
PD AUG 25
PY 2020
VL 78
IS 7-8
BP 796
EP 796
DI 10.33963/KP.15563
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NE7RM
UT WOS:000562800100034
PM 32844613
OA Bronze
DA 2021-01-01
ER

PT J
AU Jankowska, EA
   Sierpinski, R
   Tkaczyszyn, M
   Drozd, M
   Szachniewicz, J
   Duda-Sikula, M
   Knysz, B
   Simon, K
   Szenborn, L
   Ponikowski, P
AF Jankowska, Ewa A.
   Sierpinski, Radoslaw
   Tkaczyszyn, Michal
   Drozd, Marcin
   Szachniewicz, Joanna
   Duda-Sikula, Marta
   Knysz, Brygida
   Simon, Krzysztof
   Szenborn, Leszek
   Ponikowski, Piotr
TI Chloroquine and hydroxychloroquine for the prevention and therapy of
   coronavirus disease 2019: new hopes and old cardiovascular concerns
SO KARDIOLOGIA POLSKA
LA English
DT Article
DE chloroquine; hydroxychloroquine; coronavirus disease 2019; QT
   prolongation; ventricular arrhythmia
C1 [Jankowska, Ewa A.; Tkaczyszyn, Michal; Drozd, Marcin; Ponikowski, Piotr] Wroclaw Med Univ, Dept Heart Dis, Wroclaw, Poland.
   [Jankowska, Ewa A.; Tkaczyszyn, Michal; Drozd, Marcin; Ponikowski, Piotr] Univ Hosp, Ctr Heart Dis, Wroclaw, Poland.
   [Sierpinski, Radoslaw] Med Res Agcy, Warsaw, Poland.
   [Szachniewicz, Joanna] Univ Hosp, Dept Clin Trials Cardiovasc Dis, Wroclaw, Poland.
   [Duda-Sikula, Marta] Wroclaw Med Univ, Int Sci Projects Sect, Wroclaw, Poland.
   [Knysz, Brygida] Wroclaw Med Univ, Dept Infect Dis Liver Dis & Acquired Immune Defic, Wroclaw, Poland.
   [Simon, Krzysztof] Wroclaw Med Univ, Dept Infect Dis & Hepatol, Wroclaw, Poland.
   [Szenborn, Leszek] Wroclaw Med Univ, Dept Pediat Infect Dis, Wroclaw, Poland.
RP Jankowska, EA (corresponding author), Wroclaw Med Univ, Lab Appl Res Cardiovasc Syst, Dept Heart Dis, Ctr Heart Dis,Univ Hosp, Ul Borowska 213, PL-50556 Wroclaw, Poland.
EM ewa.jankowska@umed.wroc.pl
RI Sierpinski, Radoslaw/ABA-7673-2020
FU Medical Research Agency, Warsaw, Poland [2020/ABM/SARS/3]
FX This research was financially supported by the Medical Research Agency,
   Warsaw, Poland (grant no. 2020/ABM/SARS/3).
CR Adamed, 2020, AR PHARM REP
   Al-Khatib SM, 2003, JAMA-J AM MED ASSOC, V289, P2120, DOI 10.1001/jama.289.16.2120
   Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2020.02.033, 10.1016/j.jiph.2019.02.033]
   Bertolo R, 2020, INT J UROL, V27, P914, DOI 10.1111/iju.14334
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boulware D.R., 2020, N ENGL J MED
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Flisiak R, 2020, POL ARCH INTERN MED, V130, P557, DOI 10.20452/pamw.15424
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Griffith KS, 2007, JAMA-J AM MED ASSOC, V297, P2264, DOI 10.1001/jama.297.20.2264
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Haeusler IL, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1188-2
   Kamp TJ, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016887
   Khan S, 2020, J CLIN MICROBIOL, V58, DOI [10.1128/JCM.01297-20, 10.1128/JCM.00187-20]
   Liu D, 2018, DRUG DES DEV THER, V12, P1685, DOI 10.2147/DDDT.S166893
   Mazzanti A, 2020, CIRCULATION
   Mercuro NJ, 2020, JAMA CARDIOL
   Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9
   Nguyen LS, 2020, CIRCULATION, V142, P303, DOI 10.1161/CIRCULATIONAHA.120.048238
   Painvin B, 2020, INTENS CARE MED, V46, P1772, DOI 10.1007/s00134-020-06142-y
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Ramireddy A, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017144
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Sanders JM, 2020, JAMA
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Tang W, BMJ, V369, pm1849
   Taylor WRJ, 2004, DRUG SAFETY, V27, P25, DOI 10.2165/00002018-200427010-00003
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
   Zulfiqar H, 2020, AMEBIASIS
NR 41
TC 0
Z9 0
U1 1
U2 1
PU POLSKIE TOWARZYSTOWO KARDIOLOGICZNE
PI WARSZAWA
PA UL STAWKI 3 A LOK 1-2, WARSZAWA, POLAND
SN 0022-9032
EI 1897-4279
J9 KARDIOL POL
JI Kardiol. Pol.
PD AUG 25
PY 2020
VL 78
IS 7-8
BP 811
EP 817
DI 10.33963/KP.15511
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NE7RM
UT WOS:000562800100045
PM 32687267
OA Bronze
DA 2021-01-01
ER

PT J
AU Dodt, C
   Schneider, N
AF Dodt, C.
   Schneider, N.
TI Emergency and intensive care medicine aspects of COVID-19 infections
SO RADIOLOGE
LA German
DT Article
DE SARS-CoV-2; Pandemic; COVID-19 pneumonia; Organ failure; Respiration;
   artificial
ID ACUTE RESPIRATORY-FAILURE; HIGH-FLOW OXYGEN; SOCIETY
AB Clinical issue The COVID 19 pandemic led to a profound adaptation of the German healthcare system in preparation of a massive increase of SARS-CoV-2-associated diseases. While general practitioners care for COVID patients who are less severely ill, hospitals are focused on the care of severely ill COVID-19 patients. Standard treatment The role of emergency medicine (EM) is to rapidly detect the virus, to classify disease severity, and to initiate therapy. In addition, the flow of patients into the hospital must be directed in such a way that optimal care is provided without risk of infecting health care personnel and patients. Despite optimal intensive care treatment, the mortality of patients remains high if organ failure develops, especially in patients who are older or have pre-existing conditions. Treatment innovations Rapid diagnosis of patients with SARS-CoV-2 infection together with assessment of disease severity and awareness of organ failure are the mainstays of emergency care. Intensive care is needed for the treatment of SARS-CoV-2-induced organ failure, whereby lung failure in these patients requires differentiated ventilation therapies. Diagnostic work-up The polymerase chain reaction (PCR) test is performed to diagnose SARS-CoV-2 infection. Adjunctive diagnostic measures which enhance diagnostic specificity are lung ultrasound, x-ray, and computed tomography of the lungs. This also allows categorization of the type of COVID-19 pneumonia. Practical recommendations For early detection and appropriate treatment of SARS-CoV-2 infection, PCR is needed. Adjunctive sonographic and radiological examinations allow the treatment of COVID-19 patients to be tailored according to the specific type of pneumonia.
C1 [Dodt, C.] Munchen Klin Bogenhausen, Notfallzentrum, Englschalkingerstr 77, D-81925 Munich, Germany.
   [Schneider, N.] Munchen Klin Schwabing, Munich, Germany.
RP Dodt, C (corresponding author), Munchen Klin Bogenhausen, Notfallzentrum, Englschalkingerstr 77, D-81925 Munich, Germany.
EM christoph.dodt@muenchen-klinik.de
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   [Anonymous], 2020, CHIEF INVESTIGATORS
   [Anonymous], 2020, MULT AD RAND TRIAL S
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Batlle D, 2020, J AM SOC NEPHROL, V31, P1380, DOI 10.1681/ASN.2020040419
   Beigel JH, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2021436, DOI 10.1056/NEJMOA2021436]
   Byambasuren O, 2020, ESTIMATING EXTENT AS, DOI [10.1101/2020.05.1020097543, DOI 10.1101/2020.05.1020097543]
   Cheng HY, 2020, JAMA INTERN MED, V180, P1156, DOI 10.1001/jamainternmed.2020.2020
   Coppo A, 2020, LANCET RESP MED, V8, P765, DOI 10.1016/S2213-2600(20)30268-X
   Ferioli M, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0068-2020
   Fernandez-Rodriguez A, 2020, SPAN J LEG MED, DOI [10.1016/j.remle.2020.05.007, DOI 10.1016/J.REMLE.2020.05.007]
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Garcia-Castrillo L, 2020, EUR J EMERG MED, V27, P174, DOI 10.1097/MEJ.0000000000000701
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   German Resuscitation Council, 2020, COVID 19 LEITL EUR R
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Guerin C, 2014, INTENS CARE MED, V40, P1634, DOI 10.1007/s00134-014-3500-8
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Karagiannidis C, 2020, LANCET RESP MED, V8, P853, DOI 10.1016/S2213-2600(20)30316-7
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kluge S, 2020, MED KLIN-INTENSIVMED, V115, P175, DOI 10.1007/s00063-020-00674-3
   Koehler P, 2020, MYCOSES, V63, P528, DOI 10.1111/myc.13096
   Kucirka LM, 2020, ANN INTERN MED, V173, P262, DOI 10.7326/M20-1495
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Leisman DE, 2020, INTENS CARE MED, V46, P1105, DOI 10.1007/s00134-020-06059-6
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Li H, 2020, LEUKEMIA, V34, P1503, DOI 10.1038/s41375-020-0848-3
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Robert Koch Institut, 2020, FLUSSSCH MA NAHM TES
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Shang Y, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00689-1
   Tachil J, 2020, JTH, V18, P1023, DOI DOI 10.1111/jth.14810
   The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CDC WKLY, V2, P10
   Wachs C, 2020, DEUT MED WOCHENSCHR, V145, P693, DOI 10.1055/a-0948-8505
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wei WE, 2020, MMWR-MORBID MORTAL W, V69, p411e5, DOI DOI 10.15585/mmwr.mm6914e1
   Westhoff M, 2015, PNEUMOLOGIE, V69, P719, DOI 10.1055/s-0034-1393309
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wiersinga JW, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.12839, DOI 10.1001/JAMA.2020.12839]
   Williamson Brandi N, 2020, bioRxiv, DOI 10.1101/2020.04.15.043166
   Xie JF, 2020, INTENS CARE MED, V46, P837, DOI 10.1007/s00134-020-05979-7
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 50
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0033-832X
EI 1432-2102
J9 RADIOLOGE
JI Radiologe
PD OCT
PY 2020
VL 60
IS 10
SI SI
BP 899
EP 907
DI 10.1007/s00117-020-00742-x
EA AUG 2020
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA NU7LP
UT WOS:000562666500001
PM 32840663
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Dongala, T
   Katari, NK
   Palakurthi, AK
   Katakam, LNR
   Marisetti, VM
AF Dongala, Thirupathi
   Katari, Naresh Kumar
   Palakurthi, Ashok Kumar
   Katakam, Lakshmi Narasimha Rao
   Marisetti, Vishnu Murthy
TI Stability Indicating LC Method Development for Hydroxychloroquine
   Sulfate Impurities as Available for Treatment of COVID-19 and Evaluation
   of Risk Assessment Prior to Method Validation by Quality by Design
   Approach
SO CHROMATOGRAPHIA
LA English
DT Article
DE Hydroxychloroquine sulfate; Quality by design; Design of experiments;
   HPLC; Validation
ID LIQUID-CHROMATOGRAPHY; CHLOROQUINE; DESETHYLCHLOROQUINE; PLASMA; BLOOD;
   SERUM; QUANTIFICATION; IDENTIFICATION; QUININE; HPLC
AB A quality by design-based stability indicating HPLC method has been developed for hydroxychloroquine sulfate impurities. The optimized HPLC method can detect and quantify the hydroxychloroquine sulfate and related organic impurities in pharmaceutical solid oral dosage forms. Nowadays, for the quantification of impurities in drug products demands more comprehensive way of analytical method development. The quality by design approach allows the assessment of different analytical parameters and their effects with minimum number of experiments. A highly sensitive and stability indicating RP-HPLC method was developed and evaluated the risk assessment prior to method validation. The chromatographic separation was achieved with X-terra phenyl column (250 x 4.6 mm, 5 mu m) using phosphate buffer (0.3 M and pH 2.5). The gradient method flow rate was 1.5 mL min(-1)and UV detection was made at 220 nm. The calibration curve of hydroxychloroquine sulfate and related impurities were linear from LOQ to 150% and correlation coefficient was found more than 0.999. The precision and intermediate precision % RSD values were found less than 2.0. In all forced degradation conditions, the purity angle of HCQ was found less than purity threshold. The optimized method found to be specific, accurate, rugged, and robust for determination of hydroxychloroquine sulfate impurities in the solid oral dosage forms. Finally, the method was applied successfully in quality control lab for stability analysis.
C1 [Dongala, Thirupathi; Palakurthi, Ashok Kumar] Aurex Labs LLC, Analyt Res & Dev, 10 Lake Dr, East Windsor, NJ 08520 USA.
   [Dongala, Thirupathi; Katari, Naresh Kumar] GITAM Univ, Dept Chem, Hyderabad 502329, Telangana, India.
   [Katakam, Lakshmi Narasimha Rao] Saptalis Pharmaceut LLC, Analyt Dev, Hauppauge, NY 11788 USA.
   [Marisetti, Vishnu Murthy] ScieGen Pharmaceut Inc, Analyt Res & Dev, 89 Arkay Dr, Hauppauge, NY 11788 USA.
RP Dongala, T (corresponding author), Aurex Labs LLC, Analyt Res & Dev, 10 Lake Dr, East Windsor, NJ 08520 USA.; Dongala, T (corresponding author), GITAM Univ, Dept Chem, Hyderabad 502329, Telangana, India.
EM thirupathi2009@gmail.com
RI Dongala, Thirupathi/E-1610-2019
OI Dongala, Thirupathi/0000-0001-8251-5005
CR AKINTONWA A, 1983, J LIQ CHROMATOGR, V6, P1513, DOI 10.1080/01483918308064868
   Arguelho MLPM, 2003, J PHARMACEUT BIOMED, V32, P269, DOI 10.1016/S0731-7085(02)00669-6
   Blessy M, 2014, J Pharm Anal, V4, P159, DOI 10.1016/j.jpha.2013.09.003
   Boccardvi G, 2005, OXIDATIVE SUSCEPTIBI, P220
   BROWN RR, 1986, J CHROMATOGR, V377, P454, DOI 10.1016/S0378-4347(00)80809-9
   CARR GP, 1990, J PHARMACEUT BIOMED, V8, P613, DOI 10.1016/0731-7085(90)80090-C
   CHAULET JF, 1993, J CHROMATOGR-BIOMED, V613, P303, DOI 10.1016/0378-4347(93)80146-U
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   CROES K, 1994, J ANAL TOXICOL, V18, P255, DOI 10.1093/jat/18.5.255
   Dongala T, 2020, RES SQ, DOI [10.21203/rs.3.pex-880/v1, DOI 10.21203/RS.3.PEX-880/V1]
   Dongre VG, 2009, J PHARMACEUT BIOMED, V49, P873, DOI 10.1016/j.jpba.2009.01.013
   Fuzery AK, 2013, CLIN CHIM ACTA, V421, P79, DOI 10.1016/j.cca.2013.02.018
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   ICH, 2006, INT C HARM GEN
   ICH guidelines, INT C HARM
   Jenke DR, 1996, J LIQ CHROMATOGR R T, V19, P737, DOI 10.1080/10826079608005534
   Jordan P, 1999, J TOXICOL-CLIN TOXIC, V37, P861, DOI 10.1081/CLT-100102466
   Katakam LNR, 2020, SEP SCI PLUS, V3, P276, DOI 10.1002/sscp.202000023
   Kats M, 2005, BIOPHARM INT, V18, P32
   Kumar PA, 2020, PRACT LAB MED, DOI [10.1016/j.plabm.2020.e00169, DOI 10.1016/J.PLABM.2020.E00169]
   Maheswaran R, 2012, PHARM TECHNOL, V36, P73
   MORRIS RG, 1985, J CHROMATOGR, V338, P422, DOI 10.1016/0378-4347(85)80115-8
   Qiu FH, 2007, J LIQ CHROMATOGR R T, V30, P877, DOI 10.1080/10826070701191151
   Reynolds D, 2002, PHARM TECHNOL, P48
   Saini B, 2013, J PHARMACEUT BIOMED, V84, P224, DOI 10.1016/j.jpba.2013.06.014
   Singh R., 2012, J PHARM ED RES, V3, P54
   TONNESEN HH, 1988, INT J PHARM, V43, P215, DOI 10.1016/0378-5173(88)90276-1
   VOLIN P, 1995, J CHROMATOGR B, V666, P347, DOI 10.1016/0378-4347(94)00584-R
   Wang LZ, 2012, J PHARMACEUT BIOMED, V61, P86, DOI 10.1016/j.jpba.2011.11.034
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zuluaga-Idarraga L, 2014, J PHARMACEUT BIOMED, V95, P200, DOI 10.1016/j.jpba.2014.03.006
NR 32
TC 1
Z9 1
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0009-5893
EI 1612-1112
J9 CHROMATOGRAPHIA
JI Chromatographia
PD OCT
PY 2020
VL 83
IS 10
BP 1269
EP 1281
DI 10.1007/s10337-020-03945-5
EA AUG 2020
PG 13
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA NN9HT
UT WOS:000562727100001
PM 32863397
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Razeghian-Jahromi, I
   Zibaeenezhad, MJ
   Lu, ZB
   Zahra, E
   Mahboobeh, R
   Lionetti, V
AF Razeghian-Jahromi, Iman
   Zibaeenezhad, Mohammad Javad
   Lu, Zhibing
   Zahra, Elyaspour
   Mahboobeh, Razmkhah
   Lionetti, Vicenzo
TI Angiotensin-converting enzyme 2: a double-edged sword in COVID-19
   patients with an increased risk of heart failure
SO HEART FAILURE REVIEWS
LA English
DT Article; Early Access
DE ACE2; Angiotensin II; RAS inhibitors; COVID-19; Heart failure;
   SARS-CoV-2
ID RECEPTOR BLOCKER; ENDOTHELIAL DYSFUNCTION; BLOOD-PRESSURE; CORONAVIRUS;
   EXPRESSION; BRADYKININ; ACE2; SYSTEM; SPIKE; INHIBITORS
AB The coronavirus disease (COVID-19) pandemic is a global health priority. Given that cardiovascular diseases (CVD) are the leading cause of morbidity around the world and that several trials have reported severe cardiovascular damage in patients infected with SARS-CoV-2, a substantial number of COVID-19 patients with underlying cardiovascular diseases need to continue their medications in order to improve myocardial contractility and to prevent the onset of major adverse cardiovascular events (MACEs), including heart failure. Some of the current life-saving medications may actually simultaneously expose patients to a higher risk of severe COVID-19. Angiotensin-converting enzyme 2 (ACE2), a key counter regulator of the renin-angiotensin system (RAS), is the main entry gate of SARS-CoV-2 into human host cells and an established drug target to prevent heart failure. In fact, ACE inhibitors, angiotensin II receptor blockers, and mineralocorticoid antagonists may augment ACE2 levels to protect organs from angiotensin II overload. Elevated ACE2 expression on the host cell surface might facilitate viral entrance, at the same time sudden nonadherence to these medications triggers MACEs. Hence, safety issues in the use of RAS inhibitors in COVID-19 patients with cardiac dysfunction remain an unsolved dilemma and need paramount attention. Although ACE2 generally plays an adaptive role in both healthy subjects and patients with systolic and/or diastolic dysfunction, we conducted a literature appraisal on its maladaptive role. Understanding the exact role of ACE2 in COVID-19 patients at risk of heart failure is needed to safely manage RAS inhibitors in frail and non-frail critically ill patients.
C1 [Razeghian-Jahromi, Iman; Zibaeenezhad, Mohammad Javad; Zahra, Elyaspour] Shiraz Univ Med Sci, Cardiovasc Res Ctr, Shiraz, Iran.
   [Lu, Zhibing] Wuhan Univ, Dept Cardiol, Zhongnan Hosp, Wuhan, Peoples R China.
   [Mahboobeh, Razmkhah] Shiraz Univ Med Sci, Shiraz Inst Canc Res, Shiraz, Iran.
   [Lionetti, Vicenzo] Scuola Super Sant Anna, Unit Translat Crit Care Med, Inst Life Sci, Pisa, Italy.
   [Lionetti, Vicenzo] Fdn Toscana G Monasterio, UOS Anesthesiol & Intens Care Med, Pisa, Italy.
RP Razeghian-Jahromi, I (corresponding author), Shiraz Univ Med Sci, Cardiovasc Res Ctr, Shiraz, Iran.; Lionetti, V (corresponding author), Scuola Super Sant Anna, Unit Translat Crit Care Med, Inst Life Sci, Pisa, Italy.; Lionetti, V (corresponding author), Fdn Toscana G Monasterio, UOS Anesthesiol & Intens Care Med, Pisa, Italy.
EM razejahromi@yahoo.com; vincenzo.lionetti@santannapisa.it
FU Scuola Superiore Sant'Anna, Pisa, Italy
FX Internal funds, Scuola Superiore Sant'Anna, Pisa, Italy (V.L.).
CR Agata J, 2006, HYPERTENS RES, V29, P865, DOI 10.1291/hypres.29.865
   Al Suwaidi J, 2000, CIRCULATION, V101, P948, DOI 10.1161/01.CIR.101.9.948
   Alasady M, 2011, HEART RHYTHM, V8, P955, DOI 10.1016/j.hrthm.2011.02.016
   Bai F, 2016, LIFE SCI, V153, P141, DOI 10.1016/j.lfs.2016.04.013
   Bozkurt B, 2020, J CARD FAIL, V26, P370, DOI 10.1016/j.cardfail.2020.04.013
   Brojakowska A, 2020, J AM COLL CARDIOL, V75, P3085, DOI 10.1016/j.jacc.2020.04.028
   Byrd JB, 2008, HYPERTENSION, V51, P141, DOI 10.1161/HYPERTENSIONAHA.107.096552
   Ceconi C, 2007, EUR J PHARMACOL, V577, P1, DOI 10.1016/j.ejphar.2007.07.061
   Chandran S, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005868
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Clancy P, 2014, ATHEROSCLEROSIS, V236, P108, DOI 10.1016/j.atherosclerosis.2014.06.011
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Crowley SD, 2005, J CLIN INVEST, V115, P1092, DOI 10.1172/JCI200523378
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   de Gasparo Marc, 2002, Heart Fail Rev, V7, P347
   Doerschug KC, 2010, CRIT CARE, V14, DOI 10.1186/cc8887
   Dushpanova A, 2016, SCI REP-UK, V6, DOI 10.1038/srep30048
   EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012
   Epelman S, 2008, J AM COLL CARDIOL, V52, P750, DOI 10.1016/j.jacc.2008.02.088
   Escobales N, 2019, AM J PHYSIOL-HEART C, V316, pH1426, DOI 10.1152/ajpheart.00772.2018
   Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600
   Fattah C, 2016, J AM COLL CARDIOL, V68, P2652, DOI 10.1016/j.jacc.2016.09.946
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Ferrario CM, 2005, AM J PHYSIOL-HEART C, V289, pH2281, DOI 10.1152/ajpheart.00618.2005
   Fukuta H, 2020, HEART FAIL REV, P1
   Gallagher PE, 2008, AM J PHYSIOL-HEART C, V295, pH2373, DOI 10.1152/ajpheart.00426.2008
   Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z
   Guo JY, 2020, J CELL PHYSIOL, V235, P9884, DOI 10.1002/jcp.29802
   Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105
   HEDNER T, 1992, BRIT MED J, V304, P941, DOI 10.1136/bmj.304.6832.941
   Hemnes AR, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02638-2017
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Igase M, 2005, AM J PHYSIOL-HEART C, V289, pH1013, DOI 10.1152/ajpheart.00068.2005
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Inciardi RM, 2020, EUR HEART J, V41, P1821, DOI 10.1093/eurheartj/ehaa388
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Iwata M, 2005, AM J PHYSIOL-HEART C, V289, pH2356, DOI 10.1152/ajpheart.00317.2005
   Iyer SN, 1998, HYPERTENSION, V31, P699, DOI 10.1161/01.HYP.31.2.699
   Keidar S, 2005, CIRC RES, V97, P946, DOI 10.1161/01.RES.0000187500.24964.7A
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Kiya Y, 2010, CLIN EXP HYPERTENS, V32, P129, DOI 10.3109/10641960903254430
   Kostis WJ, 2018, CURR HYPERTENS REP, V20, DOI 10.1007/s11906-018-0859-x
   Kreutz R, 2020, CARDIOVASC RES, V116, P1688, DOI 10.1093/cvr/cvaa097
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Landmesser U, 2007, ARTERIOSCL THROM VAS, V27, P943, DOI 10.1161/01.ATV.0000258415.32883.bf
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li XT, 2020, HEART, V106, P1142, DOI 10.1136/heartjnl-2020-317062
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Lin RY, 2005, ANN ALLERG ASTHMA IM, V95, P159, DOI 10.1016/S1081-1206(10)61206-9
   Lionetti V, 2016, SIMULTANEOUS EXPOSUR
   Lionetti V, 2020, MINERVA ANESTESIOL, V86, P445, DOI 10.23736/S0375-9393.19.13848-5
   Lionetti V, 2010, HEART FAIL REV, V15, P531, DOI 10.1007/s10741-010-9165-7
   Markousis-Mavrogenis G, 2019, EUR J HEART FAIL, V21, P965, DOI 10.1002/ejhf.1482
   Mazak I, 2004, CIRCULATION, V109, P2792, DOI 10.1161/01.CIR.0000131860.80444.AB
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Moccia F, 2020, GEROSCIENCE, V42, P1021, DOI 10.1007/s11357-020-00198-w
   Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X
   Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820
   Oudit GY, 2010, J CARD FAIL, V16, pS16, DOI 10.1016/j.cardfail.2010.06.054
   Pagliaro P, 2005, CARDIOVASC DRUG THER, V19, P77, DOI 10.1007/s10557-005-6900-8
   Pang XF, 2019, J CELL PHYSIOL, V234, P5988, DOI 10.1002/jcp.27147
   Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pugliese NR, 2020, HEART FAIL REV, V25, P31, DOI 10.1007/s10741-019-09855-5
   Rahimi F, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101677
   Russo V, 2020, J CARDIOVASC PHARM, V76, P138, DOI 10.1097/FJC.0000000000000854
   Sama IE, 2020, EUR HEART J, V41, P1810, DOI 10.1093/eurheartj/ehaa373
   Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Silva ACSE, 2013, BRIT J PHARMACOL, V169, P477, DOI 10.1111/bph.12159
   SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Taddei S, 2002, DRUGS, V62, P265, DOI 10.2165/00003495-200262020-00003
   Taddei S, 2016, AM J CARDIOVASC DRUG, V16, P309, DOI 10.1007/s40256-016-0173-4
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang DZ, 1997, HYPERTENSION, V29, P488, DOI 10.1161/01.HYP.29.1.488
   Wang J, 2017, MOL MED REP, V16, P1973, DOI 10.3892/mmr.2017.6848
   Wang Y, 2020, THEOR BIOL MED MODEL, V17, DOI 10.1186/s12976-020-00120-z
   Wenz M, 2000, INTENS CARE MED, V26, P292, DOI 10.1007/s001340051152
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yamakawa K, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2587-2
   Yang CZ, 2020, JAMA CARDIOL, V5, P743, DOI 10.1001/jamacardio.2020.0934
   Ye RS, 2020, EXP MOL PATHOL, V113, DOI 10.1016/j.yexmp.2019.104350
   Zhou LL, 2020, OCUL SURF, V18, P537, DOI 10.1016/j.jtos.2020.06.007
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 93
TC 1
Z9 1
U1 3
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1382-4147
EI 1573-7322
J9 HEART FAIL REV
JI Heart Fail. Rev.
DI 10.1007/s10741-020-10016-2
EA AUG 2020
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NE5RG
UT WOS:000562657600001
PM 32844337
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gong, Y
   Guan, L
   Jin, Z
   Chen, SX
   Xiang, GM
   Gao, BA
AF Gong, Yuan
   Guan, Li
   Jin, Zhu
   Chen, Shixiong
   Xiang, Guangming
   Gao, Baoan
TI Effects of methylprednisolone use on viral genomic nucleic acid negative
   conversion and CT imaging lesion absorption in COVID-19 patients under
   50 years old
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE COVID-19; CT image lesion; methylprednisolone; treatment; virus nucleic
   acid
ID SARS
AB The use of corticosteroids has been controversial in viral pneumonia. In most cases, application of methylprednisolone in severe and critical viral pneumonia patients can quickly alleviate the symptoms of dyspnea and prevent disease progression. However, some scholars have confirmed that corticosteroids delayed the body's clearance of the virus. In our retrospective non-randomized study, 34 patients under 50 years old and diagnosed with coronavirus disease 2019 (COVID-19) were included. According to the given methylprednisolone treatment (n = 18) or not (n = 16), they were separated into two groups. By comparing the clinical data we concluded that corticosteroids therapy can effectively release COVID-19 symptoms such as persistent fever and difficult in breathing, improve oxygenation, and prevent disease progression. However, it can prolong the negative conversion of nucleic acids.
C1 [Gong, Yuan; Guan, Li; Jin, Zhu; Chen, Shixiong; Xiang, Guangming; Gao, Baoan] Three Gorges Univ, Dept Med & Resp, Clin Med Coll 1, Yi Chang Cent Peoples Hosp,Inst Resp Dis, Yichang 443003, Hubei, Peoples R China.
RP Gao, BA (corresponding author), Three Gorges Univ, Dept Med & Resp, Clin Med Coll 1, Yi Chang Cent Peoples Hosp,Inst Resp Dis, Yichang 443003, Hubei, Peoples R China.
EM 222xiaozhao@163.com
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Brun-Buisson C, 2011, AM J RESP CRIT CARE, V183, P1200, DOI 10.1164/rccm.201101-0135OC
   Caplan A, 2017, J AM ACAD DERMATOL, V76, P191, DOI 10.1016/j.jaad.2016.02.1240
   Chai Z, 2019, HUM GENE THER, V30, P829, DOI 10.1089/hum.2018.233
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Liu HJ, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016839
   Liu P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11110979
   Ronchetti S, 2018, CLIN SCI, V132, P1529, DOI 10.1042/CS20171505
   Tanaka Hirotoshi, 2013, Nihon Rinsho, V71, P1261
   Tu GW, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1284-7
   Ye Z, 2020, CAN MED ASS J
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 15
TC 4
Z9 4
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2551
EP 2555
DI 10.1002/jmv.26052
EA AUG 2020
PG 5
WC Virology
SC Virology
GA NU0EN
UT WOS:000562234900001
PM 32441786
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Cox, S
AF Cox, Shereen
TI To dispense or not to dispense: Lessons to be learnt from ethical
   challenges faced by pharmacists in theCOVID-19 pandemic
SO DEVELOPING WORLD BIOETHICS
LA English
DT Article; Early Access
DE COVID-19 pandemic; pharmacist; hydroxychloroquine; off-label; ethical
   challenges; moral distress
AB The year 2020 is facing one of the worst public health situations in decades. The world is experiencing a pandemic that has triggered significant challenges to healthcare systems in both high and low-middle income countries (LMICs). Government policymakers and healthcare personnel are experiencing real-life ethical dilemmas and are pressed to respond to these situations. Many possible treatments are being investigated, one of which is the use of hydroxychloroquine or chloroquine. These drugs are approved for use by patients with systemic lupus erythematosus (SLE), rheumatoid arthritis, and malaria. The demand for these products has increased, and the stocks are depleting for the patient population for whom the drugs are intended initially. Although both innovator and generic pharmaceutical manufacturers are making plans for increased production, there are challenges with global supply chains disruption and the retention of supplies for local markets. This may cause countries that rely on the importation of pharmaceuticals to be out of stock of supplies for an extended period. There are allegations of off-label prescribing and hoarding. Pharmacists are the custodians and dispensers of medications and are faced with the task of assessing prescriptions and making decisions about the allocation of these products. This paper seeks to 1) highlight some of the ethical challenges of dispensing hydroxychloroquine by pharmacists during theCOVID-19 pandemic, 2) identify some of the responses to these issues from various regulatory authorities in theUSA, and 3) recommend approaches to assist pharmacists in their decision-making process, especially inLMICs.
C1 [Cox, Shereen] Univ Oslo, Ctr Med Eth, Oslo, Norway.
RP Cox, S (corresponding author), Univ Oslo, Ctr Med Eth, Oslo, Norway.
EM shereen.cox@medisin.uio.no
CR Academy of Managed Care Pharmacy, 2019, DRUG UT REV
   American Cancer Society, 2020, COMP DRUG US
   American Medical Association, 2020, BOARDS PHARM OTH ACT
   [Anonymous], 2020, EMERGENCY USE AUTHOR
   Astbury JL, 2020, RES SOC ADMIN PHARM, V16, P321, DOI 10.1016/j.sapharm.2019.05.019
   Balfour H., 2020, COVID 19 UPDATE CORO
   Bebinger M, 2020, NPR
   Boseley S., 2020, GUARDIAN
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Campbell SM, 2016, AM J BIOETHICS, V16, P2, DOI 10.1080/15265161.2016.1239782
   Cortez Michelle F., 2020, BLOOMBERG NEWS
   Ducharme Jamie, 2020, TIME
   Duffull SB, 2018, RES SOC ADMIN PHARM, V14, P309, DOI 10.1016/j.sapharm.2017.04.049
   European Medicines Agency, 2020, COVID 19 CHLOR HYDR
   FDA, 2020, RIGHT TRY
   FDA, 2020, FDA CAUT US HYDR CHL
   FDA, 1998, OFF LAB INV US MARK
   FDA, 2020, COR COVID 19 UPD FDA
   FIP, 2014, FIP STAT PROF STAND
   Furey Katrina, 2016, AMA J Ethics, V18, P587, DOI 10.1001/journalofethics.2016.18.6.ecas3-1606
   Gabler E., 2020, CHICAGO TRIBUNE
   Gautret P, 2020, HYDROXYCHLOROQUINE A, DOI [10.1101/2020.03.16.20037135, DOI 10.1101/2020.03.16.20037135]
   Hibbert K., 2020, COVID 19 DEMAND MAKE
   Knoer S., 2020, PHARMACISTS PATIENTS
   Lenk C, 2014, THER CLIN RISK MANAG, V10, P537, DOI 10.2147/TCRM.S40232
   Lupkin S., 2020, NPR
   Lynch H., 2020, HEALTH AFFAIR, DOI [10.1377/hblog20200330.265604/full, DOI 10.1377/HBLOG20200330.265604/FULL/]
   Mehra M.R., 2020, LANCET, DOI [10.1016/s0140-6736(20)31324, DOI 10.1016/S0140-6736(20)31324]
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mohan S., 2020, NOVARTIS
   Murphy J., 2020, PHARM TIMES
   Murray S., 2020, PHARM TIMES
   National Alliance of State Pharmacy Associations, 2020, COVID 19 HYDR CHLOR
   Rowland C., 2020, WASHINGTON POST
   Rushton Cynda Hylton, 2016, J Clin Ethics, V27, P214
   Russell P., 2020, PM COVID 19 WORST PU
   Schiff GD, 2016, NEW ENGL J MED, V375, P306, DOI 10.1056/NEJMp1603964
   Tessman L, 2020, MED HEALTH CARE PHIL, V23, P165, DOI 10.1007/s11019-020-09942-7
   Ulrich CM, 2018, MORAL DISTRESS HLTH
   US National Library of Medicine, 2020, COVID 19 LIST RES
   Volansky R., 2020, RHEUMATOLOGISTS PHAR
   Wong J.C., 2020, GUARDIAN
   World Health Organization, 2020, SOL CLIN TRIAL COVID
   World Health Organization, 2012, PURS RESP US MED SHA
NR 44
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1471-8731
EI 1471-8847
J9 DEV WORLD BIOETH
JI Dev. World Bioeth.
DI 10.1111/dewb.12284
EA AUG 2020
PG 8
WC Ethics; Medical Ethics
SC Social Sciences - Other Topics; Medical Ethics
GA NE1UH
UT WOS:000562382500001
PM 32844516
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tizabi, Y
   Getachew, B
   Copeland, RL
   Aschner, M
AF Tizabi, Yousef
   Getachew, Bruk
   Copeland, Robert L.
   Aschner, Michael
TI Nicotine and the nicotinic cholinergic system in COVID-19
SO FEBS JOURNAL
LA English
DT Article
DE ACE2; allosteric modulators; COVID-19; inflammation; nAChR; nicotine;
   SARS-CoV-2; smoking
ID RENIN-ANGIOTENSIN SYSTEM; CYTOKINE STORM; RECEPTOR; ALPHA-7; SEVERITY;
   SMOKING; DEFICIENCY; EXPRESSION; INCREASE; MOOD
AB There is an urgent need to address the devastating pandemic, COVID-19, caused by SARS-CoV-2. The efforts to understand the details of this disease in hope of providing effective treatments are commendable. It is clear now that the virus can cause far more damage in patients with comorbid conditions-particularly in those with respiratory, cardiovascular, or immune-compromised system-than in patients without such comorbidities. Drug use can further exacerbate the condition. In this regard, the ill effects of smoking are amply documented, and no doubt can be a confounding factor in COVID-19 progression. Although conflicting hypotheses on the potential role of nicotine in COVID-19 pathology have recently been offered, we believe that nicotine itself, through its interaction with the nicotinic cholinergic system, as well as ACE2, may not only be of use in a variety of neuropsychiatric and neurodegenerative diseases, but may also be of potential use in COVID-19. Thus, on one hand, while we strongly support smoking cessation as a means of harm reduction associated with COVID-19, on the other hand, we support a potential therapeutic role for nicotine, nicotinic agonists, or positive allosteric modulators of nicotinic cholinergic receptors in COVID-19, owing to their varied effects including mood regulation, anti-inflammatory, and purported interference with SARS-CoV-2 entry and/or replication.
C1 [Tizabi, Yousef; Getachew, Bruk; Copeland, Robert L.] Howard Univ, Dept Pharmacol, Coll Med, Washington, DC 20059 USA.
   [Aschner, Michael] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA.
RP Tizabi, Y (corresponding author), Howard Univ, Pharmacol, Coll Med, 520 W St NW, Washington, DC 20059 USA.
EM ytizabi@howard.edu
OI Tizabi, Yousef/0000-0003-1703-1842
FU NIH/NIAAAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse
   & Alcoholism (NIAAA) [R03AA022479]; NIH/NIEHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Environmental Health Sciences (NIEHS) [R01ES10563,
   R01ES07331]
FX The study was supported by NIH/NIAAA R03AA022479 (YT) and NIH/NIEHS
   R01ES10563 and R01ES07331 (MA).
CR Alam SB, 2020, EUR J NEUROL, V27, P2348, DOI 10.1111/ene.14442
   Alexandre J, 2020, ANN ENDOCRINOL-PARIS, V81, P63, DOI 10.1016/j.ando.2020.04.005
   Alifano M, 2020, BIOCHIMIE, V174, P30, DOI 10.1016/j.biochi.2020.04.008
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Azimi M, 2020, PSYCHOPHARMACOLOGY, V237, P997, DOI 10.1007/s00213-019-05430-w
   Bagdas D, 2018, CURR NEUROPHARMACOL, V16, P415, DOI 10.2174/1570159X15666170818102108
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bennett JA, 2019, J PHARMACOL EXP THER, V369, P182, DOI 10.1124/jpet.118.253583
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cattaruzza Maria Sofia, 2020, Acta Biomed, V91, P106, DOI 10.23750/abm.v91i2.9698
   Changeux JP, 2020, CR BIOL, V343, P33, DOI 10.5802/crbiol.8
   Changeux JP, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0174
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Ciaglia E, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00206
   Conti AA, 2020, NEUROSCI BIOBEHAV R, V115, P48, DOI 10.1016/j.neubiorev.2020.04.018
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Dani JA, 2015, INT REV NEUROBIOL, V124, P3, DOI 10.1016/bs.irn.2015.07.001
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Desforges M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010014
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dhillon P, 2020, FEBS J, V287, P3612, DOI 10.1111/febs.15442
   Echeverria V, 2016, CURR PHARM DESIGN, V22, P1324, DOI 10.2174/138161282210160304112511
   Farsalinos K, 2020, MOL MODELLING DOCKIN, DOI [10.20944/preprints202005.0365.v1, DOI 10.20944/PREPRINTS202005.0365.V1]
   Farsalinos K, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320935765
   Farsalinos K, 2020, EUR RESPIR J, V56, DOI [10.1183/13993003.01589-2020, 10.1183/13223003.01589-2020]
   Farsalinos K, 2020, INTERN EMERG MED, V15, P845, DOI 10.1007/s11739-020-02355-7
   Farsalinos Konstantinos, 2020, Toxicol Rep, V7, P658, DOI 10.1016/j.toxrep.2020.04.012
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Ferrari MFR, 2008, J MOL NEUROSCI, V35, P151, DOI 10.1007/s12031-007-9025-7
   Gallus S, 2020, EUR J INTERN MED, V77, P33, DOI 10.1016/j.ejim.2020.06.014
   Gandelman JA, 2018, NEUROSCI BIOBEHAV R, V84, P289, DOI 10.1016/j.neubiorev.2017.08.018
   Georgiev T, 2020, RHEUMATOL INT, V40, P825, DOI 10.1007/s00296-020-04570-z
   Gomes JP, 2018, PHARMACOL RES, V128, P101, DOI 10.1016/j.phrs.2017.10.005
   Gonzalez-Rubio J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01359
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Hamer M, 2020, 2020050920096438 MED
   Hom S, 2016, PLATELETS, V27, P694, DOI 10.3109/09537104.2016.1158403
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jordan CJ, 2018, EXPERT OPIN DRUG DIS, V13, P671, DOI 10.1080/17460441.2018.1458090
   Kabbani N, 2020, MOL PHARMACOL, V97, P351, DOI 10.1124/molpharm.120.000014
   Kalamida D, 2007, FEBS J, V274, P3799, DOI 10.1111/j.1742-4658.2007.05935.x
   Khani MA, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109871
   Kloc M, 2020, IMMUNOL LETT, V224, P28, DOI 10.1016/j.imlet.2020.06.002
   Ko JK, 2014, CURR PHARM DESIGN, V20, P1082, DOI 10.2174/13816128113199990416
   Kooijman S, 2015, J THROMB HAEMOST, V13, P126, DOI 10.1111/jth.12765
   Koukouli F, 2020, TRENDS NEUROSCI, VS0166-2236, P30125
   Krause RM, 1998, MOL PHARMACOL, V53, P283
   Lanza K, 2020, CLIN SCI, V134, P1259, DOI 10.1042/CS20200492
   Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020
   Li Q, 2011, CELL PHYSIOL BIOCHEM, V27, P605, DOI 10.1159/000329982
   Lippi G, 2020, EUR J INTERN MED, V75, P107, DOI 10.1016/j.ejim.2020.03.014
   Lunney PC, 2012, ALIMENT PHARM THER, V36, P997, DOI 10.1111/apt.12086
   Mabley J, 2011, INFLAMMATION, V34, P231, DOI 10.1007/s10753-010-9228-x
   Manji H, 2020, J NEUROL NEUROSUR PS, V91, P568, DOI 10.1136/jnnp-2020-323414
   Manni L, 2020, CONTRIBUTION HYPOTHE
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moein ST, 2020, INT FORUM ALLERGY RH, V10, P953, DOI 10.1002/alr.22638
   Nalleballe K, 2020, BRAIN BEHAV IMMUN, V88, P71, DOI 10.1016/j.bbi.2020.06.020
   National Institute of Alcohol Abuse and Alcoholism, 2020, ALC POS DIFF CHALL C
   National Institute on Drug Abuse, 2020, COVID 19 POT IMPL IN
   Ni YF, 2011, RESPIRATION, V81, P39, DOI 10.1159/000319151
   Oakes JM, 2018, AM J PHYSIOL-REG I, V315, pR895, DOI 10.1152/ajpregu.00099.2018
   Olds JL, 2020, FEBS J, V287, P3651, DOI 10.1111/febs.15303
   Papke RL, 2020, NEUROPHARMACOLOGY, V168, DOI 10.1016/j.neuropharm.2020.108021
   Patanavanich R, 2020, NICOTINE TOB RES, V22, P1653, DOI 10.1093/ntr/ntaa082
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Romero-Sanchez CM, 2020, NEUROLOGY, V95, pE1060, DOI 10.1212/WNL.0000000000009937
   Russo P, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01116-2020
   Ruszkiewicz JA, 2020, FOOD CHEM TOXICOL, V138, DOI 10.1016/j.fct.2020.111245
   Rutherford AI, 2018, ANN RHEUM DIS, V77, P905, DOI 10.1136/annrheumdis-2017-212825
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Smith JC, 2020, DEV CELL, V53, P514, DOI 10.1016/j.devcel.2020.05.012
   Sorensen LT, 2012, ANN SURG, V255, P1069, DOI 10.1097/SLA.0b013e31824f632d
   Steardo L, 2020, ACTA PHYSIOL, V229, DOI 10.1111/apha.13473
   Tindle HA, 2020, NICOTINE TOB RES, V22, P1669, DOI 10.1093/ntr/ntaa077
   Tizabi Y, 2019, PROG MOL BIOL TRANSL, V167, P1, DOI 10.1016/bs.pmbts.2019.06.004
   Tizabi Yousef, 2017, Clin Pharmacol Transl Med, V1, P14
   Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321
   Ulloa L, 2005, NAT REV DRUG DISCOV, V4, P673, DOI 10.1038/nrd1797
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Valentine G, 2018, CURR NEUROPHARMACOL, V16, P403, DOI 10.2174/1570159X15666171103152136
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339
   Yang J, 2019, NEUROTOXICOLOGY, V73, P175, DOI 10.1016/j.neuro.2019.02.008
   Yue XP, 2018, ANN AM THORAC SOC, V15, pS126, DOI 10.1513/AnnalsATS.201706-464MG
NR 89
TC 2
Z9 2
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD SEP
PY 2020
VL 287
IS 17
BP 3656
EP 3663
DI 10.1111/febs.15521
EA AUG 2020
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NK6MS
UT WOS:000562749200001
PM 32790936
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Braidotti, R
AF Braidotti, R.
TI "We" Are InThisTogether, But We Are Not One and the Same
SO JOURNAL OF BIOETHICAL INQUIRY
LA English
DT Article
DE COVID-19; Anthropocene; Posthumanism; Postcolonialism; Feminism;
   Intersectionality; Indigenous theories
AB The COVID-19 pandemic is a man-made disaster, caused by undue interference in the ecological balance and the lives of multiple species. Paradoxically, the contagion has resulted in increased use of technology and digital mediation, as well as enhanced hopes for vaccines and biomedical solutions. It has thereby intensified humans' reliance on the very high-tech economy of cognitive capitalism that caused the problems in the first place. This combination of ambivalent elements in relation to the Fourth Industrial revolution and the Sixth Extinction is the trademark of the posthuman condition. This essay explores this condition further, offering both critical and affirmative propositions for moving forward.
C1 [Braidotti, R.] Univ Utrecht, Achter Dom 20, NL-3512 JP Utrecht, Netherlands.
RP Braidotti, R (corresponding author), Univ Utrecht, Achter Dom 20, NL-3512 JP Utrecht, Netherlands.
EM r.braidotti@uu.nl
CR Braidotti R, 2013, POSTHUMAN
   Braidotti R., 2019, POSTHUMAN KNOWLEDGE
   Braidotti R., 2018, POSTHUMAN GLOSSARY
   Gibson K., 2015, MANIFESTO LIVING ANT
   Piccinini P, 2020, EMBRACING FUTURE
NR 5
TC 1
Z9 1
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1176-7529
EI 1872-4353
J9 J BIOETHIC INQ
JI J. Bioethical Inq.
PD DEC
PY 2020
VL 17
IS 4
SI SI
BP 465
EP 469
DI 10.1007/s11673-020-10017-8
EA AUG 2020
PG 5
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA PF0QB
UT WOS:000562745200017
PM 32840844
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lipworth, W
   Gentgall, M
   Kerridge, I
   Stewart, C
AF Lipworth, Wendy
   Gentgall, Melanie
   Kerridge, Ian
   Stewart, Cameron
TI Science at Warp Speed: Medical Research, Publication, and Translation
   During the COVID-19 Pandemic
SO JOURNAL OF BIOETHICAL INQUIRY
LA English
DT Article
DE COVID-19; Pandemic; Research quality; Research governance; Research
   integrity; Biomedical publication
ID BIG DATA; ETHICS; HEALTH
AB In response to the COVID-19 pandemic, there has been a rapid growth in research focused on developing vaccines and therapies. In this context, the need for speed is taken for granted, and the scientific process has adapted to accommodate this. On the surface, attempts to speed up the research enterprise appear to be a good thing. It is, however, important to consider what, if anything, might be lost when biomedical innovation is sped up. In this article we use the case of a study recently retracted from theLancetto illustrate the potential risks and harms associated with speeding up science. We then argue that, with appropriate governance mechanisms in place (and adequately resourced), it should be quite possible to both speed up science and remain attentive to scientific quality and integrity.
C1 [Lipworth, Wendy] Univ Sydney, Fac Med & Hlth, Sydney Hlth Eth, Med Fdn Bldg K25, Sydney, NSW 2006, Australia.
   [Gentgall, Melanie] PRAXIS Australia Ltd, Adelaide, SA, Australia.
   [Kerridge, Ian] Univ Sydney, Fac Med & Hlth, Sydney Hlth Eth, Sydney, NSW, Australia.
   [Kerridge, Ian] Royal North Shore Hosp, Sydney, NSW, Australia.
   [Stewart, Cameron] Univ Sydney, Sydney Law Sch, Sydney, NSW, Australia.
RP Lipworth, W (corresponding author), Univ Sydney, Fac Med & Hlth, Sydney Hlth Eth, Med Fdn Bldg K25, Sydney, NSW 2006, Australia.
EM wendy.lipworth@sydney.edu.au
RI Stewart, Cameron/AAZ-4288-2020
OI Stewart, Cameron/0000-0003-3625-0899
FU National Health and Medical Research CouncilNational Health and Medical
   Research Council of Australia [APP1141943] Funding Source: Medline
CR [Anonymous], 2020, LANCET, V395, pE102, DOI 10.1016/S0140-6736(20)31290-3
   Callaway E, 2020, NATURE, V582, P167, DOI 10.1038/d41586-020-01520-4
   Chan TE, 2013, MED LAW REV, V21, P92, DOI 10.1093/medlaw/fws025
   Chin-Yee B, 2019, PERSPECT BIOL MED, V62, P237, DOI 10.1353/pbm.2019.0012
   da Silva JAT, 2017, SCIENTOMETRICS, V110, P365, DOI 10.1007/s11192-016-2178-9
   Davey M., 2020, GUARDIAN
   European Medicines Agency, 2020, EMA IN ACC DEV SUPP
   Godlee F, 2003, PEER REV HLTH SCI
   Kaiser J, 2017, SCIENCE, V357, P1344, DOI 10.1126/science.357.6358.1344
   Komesaroff PA, 2020, CONVERSATION
   Ledford H., 2020, NATURE
   Lipworth W, 2019, ASIAN BIOETHICS REV, V11, P289, DOI 10.1007/s41649-019-00095-1
   Lipworth W, 2017, J BIOETHIC INQ, V14, P485, DOI 10.1007/s11673-017-9815-8
   Lipworth W, 2011, J LAW MED, V18, P724
   Lock S., 1985, DIFFICULT BALANCE ED
   London AJ, 2020, SCIENCE, V368, P476, DOI 10.1126/science.abc1731
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1166
   Markar SR, 2020, ANN SURG, V272, pE170, DOI 10.1097/SLA.0000000000004000
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Morris ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/jrsm.2011.110180
   Park A., 2020, TIME
   Surgisphere, 2020, RESP WID REACT REC L
   Taylor Patrick L, 2013, Yale J Health Policy Law Ethics, V13, P135
   Watson J., 2020, HYDROXYCHLOROQUINE C
NR 25
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1176-7529
EI 1872-4353
J9 J BIOETHIC INQ
JI J. Bioethical Inq.
PD DEC
PY 2020
VL 17
IS 4
SI SI
BP 555
EP 561
DI 10.1007/s11673-020-10013-y
EA AUG 2020
PG 7
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA PF0QB
UT WOS:000562745200022
PM 32840838
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Jamrozik, E
   Heriot, GS
   Selgelid, MJ
AF Jamrozik, Euzebiusz
   Heriot, George S.
   Selgelid, Michael J.
TI Coronavirus Human Infection Challenge Studies: Assessing Potential
   Benefits and Risks
SO JOURNAL OF BIOETHICAL INQUIRY
LA English
DT Article
DE Infectious disease; Human challenge studies; Controlled human infection
   model; Research Ethics; Risk; Background risk; Modelling; Coronavirus;
   COVID-19
ID EFFICACY; VACCINE
AB Human infection challenge studies (HCS) have been proposed as a means to accelerate SARS-CoV2 vaccine development and thereby help to mitigate a prolonged global public health crisis. A key criterion for the ethical acceptability of SARS-CoV2 HCS is that potential benefits outweigh risks. Although the assessment of risks and benefits is meant to be a standard part of research ethics review, systematic comparisons are particularly important in the context of SARS-CoV2 HCS in light of the significant potential benefits and harms at stake as well as the need to preserve public trust in research and vaccines. In this paper we explore several considerations that should inform systematic assessment of SARS-CoV-2 HCS. First, we detail key potential benefits of SARS-CoV-2 HCS including, but not limited to, those related to the acceleration of vaccine development. Second, we identify where modelling is needed to inform risk-benefit (and thus ethical) assessments. Modelling will be particularly useful in (i) comparing potential benefits and risks of HCS with those of vaccine field trials under different epidemiological conditions and (ii) estimating marginal risks to HCS participants in light of the background probabilities of infection in their local community. We highlight interactions between public health policy and research priorities, including situations in which research ethics assessments may need to strike a balance between competing considerations.
C1 [Jamrozik, Euzebiusz; Selgelid, Michael J.] Monash Univ, Monash Bioeth Ctr, Melbourne, Vic, Australia.
   [Jamrozik, Euzebiusz] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic, Australia.
   [Heriot, George S.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.
RP Jamrozik, E (corresponding author), Monash Univ, Monash Bioeth Ctr, Melbourne, Vic, Australia.
EM zeb.jamrozik@monash.edu
RI Jamrozik, Euzebiusz/AAF-4512-2020
OI Jamrozik, Euzebiusz/0000-0001-5940-602X
CR [Anonymous], 2018, NAT STAT ETH COND HU
   Bambery B, 2016, PUBLIC HEALTH ETH-UK, V9, P92, DOI 10.1093/phe/phv026
   Bandaranayake D., 2010, FW10057 I ENV SCI RE
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Cohen J., 2020, SCI MAGAZINE
   Eyal N., 2020, ETHICAL COMPARATORS
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Heriot G.S., 2020, TENSIONS PUBLIC HLTH
   Hilding D A, 1994, Ear Nose Throat J, V73, P639
   Hope T, 2004, J MED ETHICS, V30, P110, DOI 10.1136/jme.2003.004440
   Jamrozik E, 2020, HUMAN CHALLENGE STUD
   Jamrozik E, 2020, BIOETHICS, DOI 10.1111/bioe.12802
   Jamrozik E, 2020, LANCET INFECT DIS, V20, pE198, DOI 10.1016/S1473-3099(20)30438-2
   Jin C, 2017, LANCET, V390, P2472, DOI 10.1016/S0140-6736(17)32149-9
   Kahn R, 2019, AM J EPIDEMIOL, V188, P467, DOI 10.1093/aje/kwy239
   KRZYZANOWSKI M, 1990, AM J EPIDEMIOL, V131, P412, DOI 10.1093/oxfordjournals.aje.a115516
   Lederer Susan E., 2008, OXFORD TXB CLIN RES, P9
   Lipsitch M, 2020, NAT MED, V26, P818, DOI 10.1038/s41591-020-0887-3
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Memoli MJ, 2016, MBIO, V7, DOI 10.1128/mBio.00417-16
   Phelan AL, 2020, LANCET, V395, P1595, DOI 10.1016/S0140-6736(20)31034-5
   Plotkin SA, 2020, VACCINE, V38, P3987, DOI 10.1016/j.vaccine.2020.04.039
   Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517
   Schaefer G., 2020, COVID 19 VACCINE DEV, DOI [10.2139/ssrn.3568981, DOI 10.2139/SSRN.3568981]
   Tacket CO, 1999, INFECT IMMUN, V67, P6341
   Thombre AC, 2017, INT CONF COMPUT
   Vannice KS, 2019, VACCINE, V37, P863, DOI 10.1016/j.vaccine.2018.12.040
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wenner D.M., 2018, PALGRAVE HDB PHILOS, P563
   World Health Organization, KEY CRIT ETH ACC COV
NR 31
TC 1
Z9 1
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1176-7529
EI 1872-4353
J9 J BIOETHIC INQ
JI J. Bioethical Inq.
PD DEC
PY 2020
VL 17
IS 4
SI SI
BP 709
EP 715
DI 10.1007/s11673-020-10030-x
EA AUG 2020
PG 7
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA PF0QB
UT WOS:000562745200027
PM 32840856
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Murphy, EJ
   Masterson, C
   Rezoagli, E
   O'Toole, D
   Major, I
   Stack, GD
   Lynch, M
   Laffey, JG
   Rowan, NJ
AF Murphy, Emma J.
   Masterson, Claire
   Rezoagli, Emanuele
   O'Toole, Daniel
   Major, Ian
   Stack, Gary D.
   Lynch, Mark
   Laffey, John G.
   Rowan, Neil J.
TI S-Glucan extracts from the same edible shiitake mushroom Lentinus edodes
   produce differential in -vitro immunomodulatory and pulmonary
   cytoprotective effects ? Implications for coronavirus disease (COVID-19)
   immunotherapies
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Article
ID MEDICINAL MUSHROOMS; IMMUNE RECOGNITION; CANCER-THERAPY; CYTOKINE STORM
C1 [Murphy, Emma J.; Stack, Gary D.; Lynch, Mark; Rowan, Neil J.] Athlone Inst Technol, Biosci Res Inst, Dublin Rd, Athlone, Ireland.
   [Masterson, Claire; Rezoagli, Emanuele; O'Toole, Daniel; Laffey, John G.] Natl Univ Ireland Galway, Regenerat Med Inst, Lung Biol Grp, CURAM Ctr Med Devices, Galway, Ireland.
   [Rezoagli, Emanuele; Laffey, John G.] Univ Hosp Galway, Anaesthesia & Intens Care Med, Galway, Ireland.
   [Rezoagli, Emanuele] Univ Milano Bicocca, Dept Med & Surg, Monza, MB, Italy.
   [Major, Ian] Athlone Inst Technol, Mat Res Inst, Athlone, Ireland.
   [Rowan, Neil J.] Athlone Inst Technol, Ctr Disinfect Sterilizat & Biosecur, Athlone, Ireland.
RP Murphy, EJ (corresponding author), Athlone Inst Technol, Biosci Res Inst, Dublin Rd, Athlone, Ireland.
EM emurphy@ait.ie
RI ; Major, Ian/E-7608-2013
OI Masterson, Claire/0000-0002-9863-5324; Major, Ian/0000-0002-0538-9786;
   Rezoagli, Emanuele/0000-0002-4506-7212; Lynch, Mark/0000-0002-8476-4854
FU Health Research Board Project, Republic of Ireland
   [HRB-HRA-POR-2014-664]; Athlone Institute of Technology Doctoral
   Scholarship, Republic of Ireland [AIT0614]
FX The authors acknowledge funding support from the Health Research Board
   Project [grant number HRB-HRA-POR-2014-664], Republic of Ireland, and
   Athlone Institute of Technology Doctoral Scholarship [grant number
   AIT0614], Republic of Ireland.
CR Akramiene D., 2006, MED KAUNAS LITHUANIA, V43, P597, DOI [10.3390/medicina43080076., DOI 10.3390/medicina43080076]
   Bak WC, 2014, MYCOBIOLOGY, V42, P301, DOI 10.5941/MYCO.2014.42.3.301
   Bellani G, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1443-x
   Brown GD, 2005, CELL MICROBIOL, V7, P471, DOI 10.1111/j.1462-5822.2005.00505.x
   Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620
   Carballo C, 2019, FISH SHELLFISH IMMUN, V92, P31, DOI 10.1016/j.fsi.2019.05.044
   Carty M.F., 2020, PROG CARDIOVASC DIS, DOI [10.1016/j.pcad.202.02.007availableonline., DOI 10.1016/J.PCAD.202.02.007]
   Chaichian S, 2020, J OVARIAN RES, V13, DOI 10.1186/s13048-020-00626-7
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Farrell H, 2011, J MICROBIOL METH, V84, P317, DOI 10.1016/j.mimet.2010.12.021
   Gil-Ramirez A., 2011, P 7 INT C MUSHR BIOL
   Herre J, 2004, BLOOD, V104, P4038, DOI 10.1182/blood-2004-03-1140
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kaur R, 2020, FIBERS, V8, DOI 10.3390/fib8010001
   Kouhpayeh S., 2020, MOL STORY COVID 19 N, DOI [10.20944/preprints202003.0346.v1, DOI 10.20944/PREPRINTS202003.0346.V1]
   Kumar K., 2015, S ASIAN J FOOD TECHN, V1, P211
   Laffey JG, 2017, AM J RESP CRIT CARE, V196, P266, DOI 10.1164/rccm.201701-0107CP
   Liu RM, 2008, ANTIOXID REDOX SIGN, V10, P303, DOI 10.1089/ars.2007.1903
   Marwick JA, 2007, EXPERT OPIN THER TAR, V11, P745, DOI 10.1517/14728222.11.6.745
   Masterson CH, 2019, AM J RESP CRIT CARE, V199
   Morales D., 2019, CARBOHYD POLYM, DOI [10.1016/j.carbpol.2019.115521, DOI 10.1016/J.CARBP0L.2019.115521]
   Netea MG, 2008, NAT REV MICROBIOL, V6, P67, DOI 10.1038/nrmicro1815
   Pelizon AC, 2005, PHYSIOL RES, V54, P557
   Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x
   Rezoagli E, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.62
   Rowan NJ, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138532
   Ruan Z, 2005, INT IMMUNOPHARMACOL, V5, P811, DOI 10.1016/j.intimp.2004.11.011
   Smith JE, 2002, BIOTECHNOL LETT, V24, P1839, DOI 10.1023/A:1020994628109
   Stone BA, 2009, CHEMISTRY, BIOCHEMISTRY, AND BIOLOGY OF (1-->3)-BETA-GLUCANS AND RELATED POLYSACCHARIDES, P5
   Sullivan R, 2006, PERSPECT BIOL MED, V49, P159, DOI 10.1353/pbm.2006.0034
   Taufek N.M., 2020, EMBRYO, V17, DOI [10.1016/j.aqrep.2020.100322, DOI 10.1016/J.AQREP.2020.100322]
   Vaclav V., 2013, AM J IMMUNOL, DOI 10.3844/ajisp.2013.88.93.
   Vermes I, 2000, J IMMUNOL METHODS, V243, P167, DOI 10.1016/S0022-1759(00)00233-7
   Willment JA, 2003, J IMMUNOL, V171, P4569, DOI 10.4049/jimmunol.171.9.4569
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang YY, 2011, FOOD HYDROCOLLOID, V25, P196, DOI 10.1016/j.foodhyd.2010.02.001
   Zhu FM, 2015, J FOOD COMPOS ANAL, V41, P165, DOI 10.1016/j.jfca.2015.01.019
   Zi Y., 2019, J COSMET DERMATOL, DOI [10.1111/jocd.13005., DOI 10.1111/J0CD.13005]
NR 40
TC 9
Z9 9
U1 28
U2 35
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD AUG 25
PY 2020
VL 732
AR 139330
DI 10.1016/j.scitotenv.2020.139330
PG 10
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA LX7JB
UT WOS:000540002500009
PM 32413619
OA Green Published
DA 2021-01-01
ER

PT J
AU Wei, LJ
   Gao, X
   Chen, SH
   Zeng, WJ
   Wu, JL
   Lin, XG
   Zhang, HT
   Sharifu, LM
   Chen, L
   Feng, L
   Wang, SS
AF Wei, Lijie
   Gao, Xuan
   Chen, Suhua
   Zeng, Wanjiang
   Wu, Jianli
   Lin, Xingguang
   Zhang, Huiting
   Sharifu, Lali Mwamaka
   Chen, Ling
   Feng, Ling
   Wang, Shaoshuai
TI Clinical Characteristics and Outcomes of Childbearing-Age Women With
   COVID-19 in Wuhan: Retrospective, Single-Center Study
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; childbearing age; pregnancy; clinical
   characteristics; outcomes; women; health information; epidemiology;
   diagnosis; symptom
ID RESPIRATORY SYNDROME; CORONAVIRUS; PREGNANCY; INFLUENZA; PNEUMONIA
AB Background: Since December 2019, an outbreak of the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly in Wuhan and worldwide. However, previous studies on pregnant patients were limited.
   Objective: The aim of this study is to evaluate the clinical characteristics and outcomes of pregnant and nonpregnant women with COVID-19.
   Methods: This study retrospectively collected epidemiological, clinical, laboratory, imaging, management, and outcome data of 43 childbearing-age women patients (including 17 pregnant and 26 nonpregnant patients) who presented with laboratory-confirmed COVID-19 in Tongji Hospital, Wuhan, China from January 19 to March 2, 2020. Clinical outcomes were followed up to March 28, 2020.
   Results: Of the 43 childbearing-age women in this study, none developed a severe adverse illness or died. The median ages of pregnant and nonpregnant women were 33.0 and 33.5 years, respectively. Pregnant women had a markedly higher proportion of history exposure to hospitals within 2 weeks before onset compared to nonpregnant women (9/17, 53% vs 5/26, 19%, P=.02) and a lower proportion of other family members affected (4/17, 24% vs 19/26, 73%, P=.004). Fever (8/17, 47% vs 18/26, 69%) and cough (9/17, 53% vs 12/26, 46%) were common onsets of symptoms for the two groups. Abdominal pain (n=4, 24%), vaginal bleeding (n=1, 6%), reduced fetal movement (n=1, 6%), and increased fetal movement (n=2, 13%) were observed at onset in the 17 pregnant patients. Higher neutrophil and lower lymphocyte percent were observed in the pregnant group compared to the nonpregnant group (79% vs 56%, P<.001; 15% vs 33%, P<.001, respectively). In both groups, we observed an elevated concentration of high-sensitivity C-reactive protein, erythrocyte sedimentation rate, aminotransferase, and lactate dehydrogenase. Concentrations of alkaline phosphatase and D-dimer in the pregnant group were significantly higher than those of the nonpregnant group (119.0 vs 48.0 U/L, P<.001; 2.1 vs 0.3 mu g/mL, P<.001, respectively). Both pregnant (4/10, 40%) and nonpregnant (8/15, 53%) women tested positive for influenza A virus. A majority of pregnant and nonpregnant groups received antiviral (13/17, 76% vs 25/26, 96%) and antibiotic (13/17, 76% vs 23/26, 88%) therapy. Additionally, both pregnant (2/11, 18%) and nonpregnant (2/19, 11%) recovered women redetected positive for SARS-CoV-2 after discharge.
   Conclusions: The epidemiology and clinical and laboratory features of pregnant women with COVID-19 were diverse and atypical, which increased the difficulty of diagnosis. Most pregnant women with COVID-19 were mild and moderate, and rarely developed severe pneumonia or severe adverse outcomes.
C1 [Wei, Lijie; Gao, Xuan; Chen, Suhua; Zeng, Wanjiang; Wu, Jianli; Lin, Xingguang; Zhang, Huiting; Sharifu, Lali Mwamaka; Feng, Ling; Wang, Shaoshuai] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Obstet & Gynecol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
   [Chen, Ling] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China.
RP Wang, SS (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Obstet & Gynecol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
EM colombo2008@sina.com
OI Wei, Lijie/0000-0003-1693-9779
FU National Key Research and Development Program of China [2018YFC1002900,
   2020YFC0846300]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [2020kfyXGYJ00]
FX We thank all the patients involved in this study and the nurses and
   clinical staff who provided care for the patients. This work was
   supported by the research grants from the National Key Research and
   Development Program of China (grant numbers 2018YFC1002900,
   2020YFC0846300) and the Fundamental Research Funds for the Central
   Universities (grant number 2020kfyXGYJ00).
CR [Anonymous], 2019, REP CLUST PNEUM UNKN
   [Anonymous], 2020, DIAGN TREATM PROT CO
   Assiri A, 2016, CLIN INFECT DIS, V63, P951, DOI 10.1093/cid/ciw412
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harris JW, 1919, J AMER MED ASSOC, V72, P978, DOI 10.1001/jama.1919.02610140008002
   Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638, DOI 10.3201/eid1211.060152
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Lam CM, 2004, BJOG-INT J OBSTET GY, V111, P771, DOI 10.1111/j.1471-0528.2004.00199.x
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Office of Health Emergency, 2020, NAT HLTH COMM PEOPL
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   WEINBERGER SE, 1980, AM REV RESPIR DIS, V121, P559, DOI 10.1164/arrd.1980.121.3.559
   WHO, 2020, CLIN MAN SEV AC RESP
   Wong SF, 2004, AM J OBSTET GYNECOL, V191, P292, DOI 10.1016/j.ajog.2003.11.019
   World Health Organization, 2020, WHO COR DIS COVID 19
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Yu N, 2020, LANCET INFECT DIS, V20, P559, DOI 10.1016/S1473-3099(20)30176-6
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang L, 2020, Zhonghua Fu Chan Ke Za Zhi, V55, P166, DOI 10.3760/cma.j.cn112141-20200218-00111
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 26
TC 0
Z9 0
U1 1
U2 1
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD AUG 24
PY 2020
VL 22
IS 8
AR e19642
DI 10.2196/19642
PG 12
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA NW5ME
UT WOS:000575055200003
PM 32750000
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Marcus, TS
   Heese, J
   Scheibe, A
   Shelly, S
   Lalla, SX
   Hugo, JF
AF Marcus, Tessa S.
   Heese, Jan
   Scheibe, Andrew
   Shelly, Shaun
   Lalla, Sasha X.
   Hugo, Jannie F.
TI Harm reduction in an emergency response to homelessness during South
   Africa's COVID-19 lockdown
SO HARM REDUCTION JOURNAL
LA English
DT Article
DE COVID-19; Harm reduction; Homelessness; Opioid substitution therapy;
   National state of disaster lockdown; Emergency shelter
AB Background Caledonian Stadium, the main mass temporary shelter for homeless people in the City of Tshwane, was created as a local response to the imperatives of the novel coronavirus disease (COVID-19) National State of Disaster lockdown in South Africa. This is a case study of the coordinated emergency healthcare response provided by the University of Pretoria's Department of Family Medicine between 24 March and 6 April 2020. Methods This study uses a narrative approach to restory situated, transient, partial and provisional knowledge. Analysis is based on documented data and iteratively triangulated interviews on the operational experiences of selected healthcare first responders directly involved in the shelter. Results The impending lockdown generated intense interactions by UP-DFM to prepare for the provision of COVID-19 and essential generalist primary with partners involved in the Community Oriented Substance Use Programme (COSUP). With approximately 2000 people at the shelter at its peak, the numbers exceeded expectations. Throughout, while government officials tried to secure bedding, food and toilets, the shelter was poorly equipped and without onsite management. The COSUP clinical team prioritised opioid substitution therapy using methadone and COVID-19 screening over generalist healthcare to manage withdrawal and contain tension and anxiety. COSUP and its partners helped the city plan and implement the safe re-sheltering of all Caledonian residents. Conclusion The Caledonian shelter is an account of organisational resilience in the face of homelessness and substance use emergencies triggered by lockdown. Through community-oriented, bottom-up self-organisation, a clinically led team navigated a response to the immediate needs of people who are homeless and/or use drugs that evolved into a more sustainable intervention. Key lessons learnt were the importance of communicating with people directly affected by emergencies, the value of using methadone to reduce harms during emergencies and the imperative of including OST in essential primary healthcare.
C1 [Marcus, Tessa S.; Heese, Jan; Hugo, Jannie F.] Univ Pretoria, Fac Hlth Sci, Dept Family Med, COPC Res Unit,Sch Med, P Bag x323, ZA-0007 City Of Tshwane, South Africa.
   [Scheibe, Andrew; Shelly, Shaun; Lalla, Sasha X.] Univ Pretoria, Fac Hlth Sci, Community Oriented Subst Use Programme, Dept Family Med,COPC Res Unit,Sch Med, P Bag x323, ZA-0007 City Of Tshwane, South Africa.
RP Marcus, TS (corresponding author), Univ Pretoria, Fac Hlth Sci, Dept Family Med, COPC Res Unit,Sch Med, P Bag x323, ZA-0007 City Of Tshwane, South Africa.
EM tessa.marcus@up.ac.za
OI Shelly, Shaun/0000-0002-8199-876X; marcus, Tessa/0000-0002-7218-0376
FU Tshwane Metropolitan Municipality, Republic of South Africa
FX Tshwane Metropolitan Municipality, Republic of South Africa.
CR [Anonymous], 2020, WHO TIM COVID 19 8 A
   [Anonymous], 2020, MAPP PHYS SHOPP BEH
   [Anonymous], 2020, PRES RAM ANN NAT LOC
   [Anonymous], 2020, E COMMUNICATION 0331
   Axelsson R, 2006, INT J HEALTH PLAN M, V21, P75, DOI 10.1002/hpm.826
   Center for Substance Abuse Treatment, 2006, TREATMENT IMPROVEMEN
   Department of Family Medicine, 2020, DFM DAIL M NOT UNPUB
   Emden C, 1998, Collegian, V5, P34, DOI 10.1016/S1322-7696(08)60299-1
   Greenhalgh T, 2005, QUAL SAF HEALTH CARE, V14, P443, DOI 10.1136/qshc.2005.014712
   Heese J, 2020, E COMMUNICATION 0402
   Heese J, 2020, COMMUNICA UNPUB 0426
   Heese J, 2020, E COMMUNICATION 0328
   Hugo JFM, 2020, EMERGENCY CARE UNPUB
   JFM Hugo, 2000, E COMMUNICATION 0402
   Kroukamp L, 2020, DFM SHELTERS S UNPUB
   Lalla SX, 2020, COMMUNICA UNPUB 0426
   Lalla SX, 2020, E COMMUNICATION 0402
   Lenfesty K, EDRM600 COL STAT U
   Marcus T, 2017, HDB FAMILY MED, P334
   Mitchell M, 2003, REV NARRATIVE METHOD, P1, DOI DOI 10.1037/E426492005-001
   Ndlazi S, 2019, PRETORIA NEWS
   Ndlazi S, 2020, COVID 19 WE WANT DRU
   Nonyano D, 2020, COMMUNICA UNPUB 0426
   Renkin W, 2020, E COMMUNICATION 0328
   Scheibe A, 2020, AFR J PRIM HEALTH CA, V12, DOI 10.4102/phcfm.v12i1.2285
   WHO Regional Office for Africa, 2020, COVID 19
   Zebrowski C, 2019, SECUR DIALOGUE, V50, P148, DOI 10.1177/0967010618817422
NR 27
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7517
J9 HARM REDUCT J
JI Harm Reduct. J.
PD AUG 24
PY 2020
VL 17
IS 1
AR 60
DI 10.1186/s12954-020-00404-0
PG 8
WC Substance Abuse
SC Substance Abuse
GA NL0HB
UT WOS:000567106200003
PM 32831083
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sterne, JAC
   Diaz, J
   Villar, J
   Murthy, S
   Slutsky, AS
   Perner, A
   Juni, P
   Angus, DC
   Annane, D
   Azevedo, LCP
   Du, B
   Dequin, PF
   Gordon, AC
   Green, C
   Higgins, JPT
   Horby, P
   Landray, MJ
   Lapadula, G
   Le Gouge, A
   Leclerc, M
   Savovic, J
   Tomazini, B
   Venkatesh, B
   Webb, S
   Marshall, JC
AF Sterne, Jonathan A. C.
   Diaz, Janet
   Villar, Jesus
   Murthy, Srinivas
   Slutsky, Arthur S.
   Perner, Anders
   Juni, Peter
   Angus, Derek C.
   Annane, Djillali
   Pontes Azevedo, Luciano Cesar
   Du, Bin
   Dequin, Pierre-Francois
   Gordon, Anthony C.
   Green, Cameron
   Higgins, Julian P. T.
   Horby, Peter
   Landray, Martin J.
   Lapadula, Giuseppe
   Le Gouge, Amelie
   Leclerc, Marie
   Savovic, Jelena
   Tomazini, Bruno
   Venkatesh, Balasubramanian
   Webb, Steve
   Marshall, John C.
CA WHO COVID-19 Clinical Management
TI Corticosteroid therapy for critically ill patients with COVID-19: A
   structured summary of a study protocol for a prospective meta-analysis
   of randomized trials
SO TRIALS
LA English
DT Article
DE COVID-19; Randomised controlled trial; Systematic Review;
   Corticosteroid; Dexamethasone; Hydrocortisone; Methylprednisolone;
   Mortality; Meta-analysis
AB Objectives: Primary objective: To estimate the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization. Secondary objectives: To examine whether the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization varies between subgroups related to treatment characteristics, disease severity at the time of randomization, patient characteristics, or risk of bias. To examine the effect of corticosteroids compared with usual care or placebo on serious adverse events.
   Study design: Prospective meta-analysis of randomized controlled trials. Both placebo-controlled and open-label trials are eligible.
   Participants: Hospitalised, critically ill patients with suspected or confirmed COVID-19.
   Intervention and comparator: Intervention groups will have received therapeutic doses of a steroid (dexamethasone, hydrocortisone or methylprednisolone) with IV or oral administration immediately after randomization.
   The comparator groups will have received standard of care or usual care or placebo.
   Main outcome: All-cause mortality up to 28 days after randomization.
   Search methods: Systematic searching of, EudraCT, the WHO ISRCTN registry, and the Chinese clinical trials registry. Additionally, research and WHO networks will be asked for relevant trials.
   Risk of bias assessments: These will be based on the Cochrane RoB 2 tool, and will use structured information provided by the trial investigators on a form designed for this prospective meta-analysis.
   Summary of findings: We will use GRADE to assess the certainty of the evidence.
   Statistical analyses: Trial investigators will provide data on the numbers of participants who did and did not experience each outcome according to intervention group, overall and in specified subgroups. We will conduct fixed-effect (primary analysis) and random-effects (Paule-Mandel estimate of heterogeneity and Hartung-Knapp adjustment) meta-analyses. We will quantify inconsistency in effects between trials using I(2)statistics. Evidence for subgroup effects will be quantified by ratios of odds ratios comparing effects in the subgroups, and corresponding interaction p-values. Comparisons between subgroups defined by trial characteristics will be made using random-effects meta-regression. Comparisons between subgroups defined by patient characteristics will be made by estimating trial-specific ratios of odds ratios comparing intervention effects between subgroups then combining these using random-effects meta-analysis. Steroid interventions will be classified as high or low dose according to whether the dose is greater or less than or equal to 400 mg hydrocortisone per day or equivalent. We will use network meta-analysis methods to make comparisons between the effects of high and low dose steroid interventions (because one trial randomized participants to both low and high dose steroid arms).
   PROSPERO registration number CRD42020197242
   Full protocol: The full protocol for this prospective meta-analysis is attached as an additional file, accessible from the Trials website (Additional file1). To expedite dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol for the systematic review.
C1 [Sterne, Jonathan A. C.; Higgins, Julian P. T.; Savovic, Jelena] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England.
   [Sterne, Jonathan A. C.; Higgins, Julian P. T.] NIHR Bristol Biomed Res Ctr, Bristol, Avon, England.
   [Diaz, Janet] WHO, Clin Unit, Hlth Emergencies Programme, Geneva, Switzerland.
   [Villar, Jesus] Hosp Univ Dr Negrin Las Palmas de Gran Canaria, Res Unit, Las Palmas Gran Canaria, Spain.
   [Villar, Jesus] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
   [Murthy, Srinivas] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada.
   [Slutsky, Arthur S.; Juni, Peter] Univ Toronto, Appl Hlth Res Ctr, Li Ka Shing Knowledge Inst, St Michaels Hosp,Dept Med, Toronto, ON, Canada.
   [Perner, Anders] Rigshosp, Dept Intens Care, Copenhagen, Denmark.
   [Angus, Derek C.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA.
   [Annane, Djillali] Univ Paris Saclay UVSQ, Raymond Poincare Hosp, AP HP, Dept Intens Care,Sch Med Simone Vei, Paris, France.
   [Pontes Azevedo, Luciano Cesar; Tomazini, Bruno] Hosp Sirio Libanes, Crit Care & Emergency Med, Sao Paulo, Brazil.
   [Du, Bin] Peking Union Med Coll Hosp, Beijing, Peoples R China.
   [Dequin, Pierre-Francois] CHRU Tours, Med Intens Reanimat, INSERM, CIC1415, Tours, France.
   [Dequin, Pierre-Francois] Univ Tours, Ctr Etud Pathol Resp, CRICS TriGGERSep Network, Tours, France.
   [Gordon, Anthony C.] Imperial Coll London, Div Anaesthet Pain Med & Intens Care, London, England.
   [Green, Cameron; Webb, Steve] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.
   [Higgins, Julian P. T.; Savovic, Jelena] Univ Hosp Bristol & Weston NHS Fdn Trust, NIHR Appl Res Collaborat ARC West, Bristol, Avon, England.
   [Horby, Peter] Univ Oxford, Nuffield Dept Med, Oxford, England.
   [Landray, Martin J.] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England.
   [Landray, Martin J.] Univ Oxford, MRC, Populat Hlth Res Unit, Oxford, England.
   [Landray, Martin J.] Oxford Univ Hosp NHS Fdn Trust, NIHR Oxford Biomed Res Ctr, Oxford, England.
   [Lapadula, Giuseppe] ASST Monza, Div Infect Dis, San Gerardo Hosp, Monza, Italy.
   [Le Gouge, Amelie] CHRU Tours, Hop Bretonneau, CIC INSERM 1415, Tours, France.
   [Leclerc, Marie] CHRU Tours, Delegat Rech Clin & Innovat, Tours, France.
   [Venkatesh, Balasubramanian] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia.
   [Marshall, John C.] Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada.
RP Sterne, JAC (corresponding author), Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England.; Sterne, JAC (corresponding author), NIHR Bristol Biomed Res Ctr, Bristol, Avon, England.
EM jonathan.sterne@bristol.ac.uk
RI Savovic, Jelena/O-4107-2019; Villar, Jesus/R-4526-2019; Tomazini,
   Bruno/AAZ-6149-2020; Higgins, Julian/H-4008-2011
OI Savovic, Jelena/0000-0002-2861-0578; Villar, Jesus/0000-0001-5687-3562;
   Sterne, Jonathan/0000-0001-8496-6053; Higgins,
   Julian/0000-0002-8323-2514
FU World Health OrganisationWorld Health Organization
FX Funding for administrative and communications support was provided by
   the World Health Organisation. No other specific funding for the
   prospective meta-analysis was received. Dr Diaz contributed to the
   design of the study. World Health Organisation staff contacted trial
   investigators to request their participation in this prospective
   meta-analysis and that they share outcome data.
NR 0
TC 3
Z9 3
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 24
PY 2020
VL 21
IS 1
AR 734
DI 10.1186/s13063-020-04641-3
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NL1LU
UT WOS:000567186100001
PM 32831155
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, ZY
   Fu, SZ
   Xu, L
   Li, SS
   Qian, KJ
   He, XD
   Zhu, GC
   Li, LH
   Zhang, J
   Li, WF
   Qin, BY
   Zhou, CL
   Ma, PL
AF Wang, Zong-Yu
   Fu, Shou-Zhi
   Xu, Liang
   Li, Shu-Sheng
   Qian, Ke-Jian
   He, Xian-Di
   Zhu, Guo-Chao
   Li, Liang-Hai
   Zhang, Jun
   Li, Wen-Fang
   Qin, Bing-Yu
   Zhou, Chen-Liang
   Ma, Peng-Lin
TI Impact of Shenfu injection on a composite of organ dysfunction
   development in critically ill patients with coronavirus disease 2019
   (COVID-19): A structured summary of a study protocol for a randomized
   controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Shenfu injection; randomised controlled trial; protocol
AB Objectives: This study aims to determine the protection provided by Shenfu injection (a traditional Chinese medicine) against development of organ dysfunction in critically ill patients with coronavirus disease 2019 (COVID-19).
   Trial design: This study is a multicenter, randomized, controlled, open-label, two-arm ratio 1:1, parallel group clinical trial.
   Participants: The patients, who are aged from 18 to 75 years old, with a confirmed or suspected diagnosis of severe or critical COVID-19, will be consecutively recruited in the study, according to the guideline on diagnosis and treatment of COVID-19 (the 7(th)version) issued by National Health Commission of the People's Republic of China.
   Exclusion criteria include pregnant and breastfeeding women, atopy or allergies to Shenfu Injection (SFI), severe underlying disease (malignant tumor with multiple metastases, uncontrolled hemopathy, cachexia, severe malnutrition, HIV), active bleeding, obstructive pneumonia caused by lung tumor, severe pulmonary interstitial fibrosis, alveolar proteinosis and allergic alveolitis, continuous use of immunosuppressive drugs in last 6 months, organ transplantation, expected death within 48 hours, the patients considered unsuitable for this study by researchers. The study is conducted in 11 ICUs of designated hospitals for COVID-19, located in 5 cities of China.
   Intervention and comparator: The enrolled patients will randomly receive 100 ml SFI (study group) or identical volume of saline (control group) twice a day for seven consecutive days. Patients in the both groups will be given usual care and the necessary supportive therapies as recommended by the latest edition of the management guidelines for COVID-19 (the 7(th)version so far).
   Main outcomes: The primary endpoint is a composite of newly developed or exacerbated organ dysfunction. This is defined as an increase in the sequential organ failure assessment (SOFA) score of two or more, indicating sepsis and involvement of at least one organ. The SOFA score will be measured for the 14 days after enrolment from the baseline (the score at randomization).
   The secondary endpoints are shown below:
   SOFA score in total
   Pneumonia severity index score
   Dosage of vasoactive drugs
   Ventilation free days within 28 days
   Length of stay in intensive care unit
   Total hospital costs to treat the patient
   28-day mortality
   The incidence of adverse drug events related to SFI
   Randomisation: The block randomization codes were generated by SAS V.9.1 for allocation of participants in this study. The ratio of random distribution is 1:1. The sealed envelope method is used for allocation concealment.
   Blinding (masking): The patients and statistical personnel analyzing study data are both blinded. The blinding of group assignment is not adopted for the medical staff.
   Numbers to be randomised (sample size): This study is expected to recruit 300 patients with COVID-19, (150 in each group).
   Trial Status: Protocol version 2.0, February 15, 2020. Patient recruitment started on February 25, and will end on August 31, 2020.
   Trial registration: Chinese Clinical Trial Registry: ChiCTR2000030043. Registered February 21, 2020, http://www.chictr.org. cn/showprojen.aspx?proj=49866
   Full protocol: The full protocol is attached as an additional file, accessible from theTrialswebsite (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
C1 [Wang, Zong-Yu; Ma, Peng-Lin] Peking Univ Third Hosp, Dept Intens Care, 49 North Garden Rd, Beijing 100191, Peoples R China.
   [Fu, Shou-Zhi] Wuhan Univ, Wuhan Hosp 3, Dept Intens Care Unit Emergency, Wuhan, Hubei, Peoples R China.
   [Xu, Liang] Wuchang Hosp, Dept Crit Care Med, Wuhan, Hubei, Peoples R China.
   [Li, Shu-Sheng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Emergency & Crit Care Med, Wuhan, Hubei, Peoples R China.
   [Qian, Ke-Jian] Nanchang Univ, Dept Crit Care Med, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
   [He, Xian-Di] Bengbu Med Coll, Dept Intens Care Unit, Affiliated Hosp 1, Bengbu, Anhui, Peoples R China.
   [Zhu, Guo-Chao] Jianghan Univ, Dept Crit Care Med, Affiliated Hosp, Wuhan, Hubei, Peoples R China.
   [Li, Liang-Hai] Yangtze Univ, Jingzhou Cent Hosp, Clin Med Coll 2, Dept Intens Care Unit, Jingzhou, Hubei, Peoples R China.
   [Zhang, Jun] Wuhan Hosp Tradit Chinese Med, Dept Crit Care Med, Wuhan, Hubei, Peoples R China.
   [Li, Wen-Fang] Naval Med Univ, Changzheng Hosp, Dept Emergency & Crit Care, Shanghai, Peoples R China.
   [Qin, Bing-Yu] Henan Prov Peoples Hosp, Dept Crit Care Med, Zhengzhou, Henan, Peoples R China.
   [Zhou, Chen-Liang] Wuhan Univ, Intens Care Med, Renmin Hosp, Eastern Campus, Wuhan, Hubei, Peoples R China.
RP Ma, PL (corresponding author), Peking Univ Third Hosp, Dept Intens Care, 49 North Garden Rd, Beijing 100191, Peoples R China.
EM mapenglin1@163.com
FU Bethune Charitable Foundation [B-0301-H-20200304]
FX This study has received support from Bethune Charitable Foundation
   (identifier B-0301-H-20200304), which is not involved in the design of
   the study and collection, analysis, and interpretation of data and in
   writing the manuscript.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 24
PY 2020
VL 21
IS 1
AR 738
DI 10.1186/s13063-020-04677-5
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NL1LU
UT WOS:000567186100005
PM 32831151
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Singh, N
   Chaput, L
   Villoutreix, BO
AF Singh, Natesh
   Chaput, Ludovic
   Villoutreix, Bruno O.
TI Fast Rescoring Protocols to Improve the Performance of Structure-Based
   Virtual Screening Performed on Protein-Protein Interfaces
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID CYCLIC PEPTIDE ANTAGONIST; ACCESSIBLE SURFACE-AREA; STRUCTURE-BASED
   DESIGN; DRUG DISCOVERY; INTERACTION MODULATORS; SCORING FUNCTIONS;
   BINDING-AFFINITY; IN-SILICO; INTERACTION INHIBITORS; DUAL INHIBITORS
AB Protein-protein interactions (PPIs) are attractive targets for drug design because of their essential role in numerous cellular processes and disease pathways. However, in general, PPIs display exposed binding pockets at the interface, and as such, have been largely unexploited for therapeutic interventions with low-molecular weight compounds. Here, we used docking and various rescoring strategies in an attempt to recover PPI inhibitors from a set of active and inactive molecules for 11 targets collected in ChEMBL and PubChem. Our focus is on the screening power of the various developed protocols and on using fast approaches so as to be able to apply such a strategy to the screening of ultralarge libraries in the future. First, we docked compounds into each target using the fast "pscreen" mode of the structure-based virtual screening (VS) package Surflex. Subsequently, the docking poses were postprocessed to derive a set of 3D topological descriptors: (i) shape similarity and (ii) interaction fingerprint similarity with a co-crystallized inhibitor, (iii) solvent-accessible surface area, and (iv) extent of deviation from the geometric center of a reference inhibitor. The derivatized descriptors, together with descriptor-scaled scoring functions, were utilized to investigate possible impacts on VS performance metrics. Moreover, four standalone scoring functions, RF-Score-VS (machine-learning), DLIGAND2 (knowledge-based), Vinardo (empirical), and X-SCORE (empirical), were employed to rescore the PPI compounds. Collectively, the results indicate that the topological scoring algorithms could be valuable both at a global level, with up to 79% increase in areas under the receiver operating characteristic curve for some targets, and in early stages, with up to a 4-fold increase in enrichment factors at 1% of the screened collections. Outstandingly, DLIGAND2 emerged as the best scoring function on this data set, outperforming all rescoring techniques in terms of VS metrics. The described methodology could help in the rational design of small-molecule PPI inhibitors and has direct applications in many therapeutic areas, including cancer, CNS, and infectious diseases such as COVID-19.
C1 [Singh, Natesh; Chaput, Ludovic; Villoutreix, Bruno O.] Univ Lille, INSERM, Inst Pasteur Lille, U1177 Drugs & Mol Living Syst, F-59000 Lille, France.
RP Villoutreix, BO (corresponding author), Univ Lille, INSERM, Inst Pasteur Lille, U1177 Drugs & Mol Living Syst, F-59000 Lille, France.
EM bruno.villoutreix@inserm.fr
OI Villoutreix, Bruno/0000-0002-6456-7730
FU INSERMInstitut National de la Sante et de la Recherche Medicale
   (Inserm); I-Site Universite Lille Nord Europe; Region Hauts-de-France,
   program STaRS
FX This work was supported by INSERM, I-Site Universite Lille Nord Europe,
   and Region Hauts-de-France, program STaRS (to B.O.V.).
CR [Anonymous], 2015, SCHROD REL 2015 1 CA
   [Anonymous], 2015, SCHROD REL 2015 1 PR
   [Anonymous], 2015, SCHROD REL 2015 1 PH
   [Anonymous], 2015, SCHROD REL 2015 1 MA
   [Anonymous], 2015, SCHROD REL 2015 1 QI
   [Anonymous], 2015, SCHROD SUIT 2015 PRO
   [Anonymous], 2015, SCHROD REL 2015 1 SI
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bajorath F, 2002, NAT REV DRUG DISCOV, V1, P882, DOI 10.1038/nrd941
   Ballester PJ, 2014, J CHEM INF MODEL, V54, P944, DOI 10.1021/ci500091r
   Ballester PJ, 2010, BIOINFORMATICS, V26, P1169, DOI 10.1093/bioinformatics/btq112
   Basse MJ, 2013, NUCLEIC ACIDS RES, V41, pD824, DOI 10.1093/nar/gks1002
   Belkin S, 2018, J COMPUT AID MOL DES, V32, P769, DOI 10.1007/s10822-018-0124-z
   Berthold MR, 2008, STUD CLASS DATA ANAL, P319, DOI 10.1145/1656274.1656280
   Bewersdorf J.P., 2020, HAEMATOLOGICA, DOI [10.3324/haematol.2019.242826, DOI 10.3324/HAEMATOL.2019.242826]
   Bissantz C, 2000, J MED CHEM, V43, P4759, DOI 10.1021/jm001044l
   Blazer LL, 2009, NEUROPSYCHOPHARMACOL, V34, P126, DOI 10.1038/npp.2008.151
   Borkin D, 2016, J MED CHEM, V59, P892, DOI 10.1021/acs.jmedchem.5b01305
   Bosc N, 2020, ACS CHEM BIOL, V15, P1566, DOI 10.1021/acschembio.0c00179
   Bosch Jurgen, 2017, Drug Discov Today Technol, V24, P3, DOI 10.1016/j.ddtec.2017.10.004
   Bourgeas R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009598
   Boyles F, 2020, BIOINFORMATICS, V36, P758, DOI 10.1093/bioinformatics/btz665
   Bruncko M, 2007, J MED CHEM, V50, P641, DOI 10.1021/jm061152t
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD520, DOI 10.1093/nar/gky949
   Caraus I, 2015, BRIEF BIOINFORM, V16, P974, DOI 10.1093/bib/bbv004
   Carro L, 2018, BEILSTEIN J ORG CHEM, V14, P2881, DOI 10.3762/bjoc.14.267
   Chaput L, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/s13321-016-0167-x
   Chen DQ, 2019, EUR J MED CHEM, V163, P597, DOI 10.1016/j.ejmech.2018.12.018
   Chen P, 2019, J CHEMINFORMATICS, V11, DOI 10.1186/s13321-019-0373-4
   Chene P, 2006, CHEMMEDCHEM, V1, P400, DOI 10.1002/cmdc.200600004
   Cheng HM, 2018, J MED CHEM, V61, P7573, DOI 10.1021/acs.jmedchem.8b00040
   Cheng TJ, 2012, AAPS J, V14, P133, DOI 10.1208/s12248-012-9322-0
   Chessari G, 2015, J MED CHEM, V58, P6574, DOI 10.1021/acs.jmedchem.5b00706
   Cleves AE, 2020, J CHEM INF MODEL, V60, P4296, DOI 10.1021/acs.jcim.0c00115
   Cleves AE, 2019, J COMPUT AID MOL DES, V33, P865, DOI 10.1007/s10822-019-00236-6
   Cleves AE, 2017, J COMPUT AID MOL DES, V31, P419, DOI 10.1007/s10822-017-0015-8
   Cossar PJ, 2020, MED RES REV, V40, P469, DOI 10.1002/med.21519
   Crawford TD, 2016, J MED CHEM, V59, P10549, DOI 10.1021/acs.jmedchem.6b01022
   Davies JW, 2006, CURR OPIN CHEM BIOL, V10, P343, DOI 10.1016/j.cbpa.2006.06.022
   Deeks ED, 2016, DRUGS, V76, P979, DOI 10.1007/s40265-016-0596-x
   DeLano WL, 2008, PYMOL MOL GRAPHICS S
   Deng Z, 2004, J MED CHEM, V47, P337, DOI 10.1021/jm030331x
   Dennis ML, 2019, STRUCT DYN-US, V6, DOI 10.1063/1.5122849
   Diaz-Eufracio BI, 2018, ADV PROTEIN CHEM STR, V110, P65, DOI 10.1016/bs.apcsb.2017.06.002
   Divakaran A, 2019, ACCOUNTS CHEM RES, V52, P3407, DOI 10.1021/acs.accounts.9b00377
   Dixon SL, 2006, CHEM BIOL DRUG DES, V67, P370, DOI 10.1111/j.1747-0285.2006.00384.x
   Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822-006-9087-6
   Drouin L, 2015, J MED CHEM, V58, P2553, DOI 10.1021/jm501963e
   Drwal Malgorzata N, 2013, Drug Discov Today Technol, V10, pe395, DOI 10.1016/j.ddtec.2013.02.002
   Empereur-mot C, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0100-8
   Falchi F, 2014, FUTURE MED CHEM, V6, P343, DOI 10.4155/fmc.13.204
   Feher M, 2006, DRUG DISCOV TODAY, V11, P421, DOI 10.1016/j.drudis.2006.03.009
   Fry DC, 2008, CURR PROTEIN PEPT SC, V9, P240, DOI 10.2174/138920308784533989
   Fry D, 2013, CHEMMEDCHEM, V8, P726, DOI 10.1002/cmdc.201200540
   Fry DC, 2015, METHODS MOL BIOL, V1278, P93, DOI 10.1007/978-1-4939-2425-7_6
   Fuller JC, 2009, DRUG DISCOV TODAY, V14, P155, DOI 10.1016/j.drudis.2008.10.009
   Gable JE, 2016, CHEMMEDCHEM, V11, P862, DOI 10.1002/cmdc.201500526
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Ghosh S, 2006, CURR OPIN CHEM BIOL, V10, P194, DOI 10.1016/j.cbpa.2006.04.002
   Gimeno A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061375
   Gonzalez AZ, 2014, J MED CHEM, V57, P2963, DOI 10.1021/jm401911v
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gorgulla C, 2020, NATURE, V580, P663, DOI 10.1038/s41586-020-2117-z
   Gowthaman R, 2013, J CHEM INF MODEL, V53, P2073, DOI 10.1021/ci4002316
   Guedes IA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01089
   Guitierrez-de-Teran H, 2012, METHODS MOL BIOL, V819, P305, DOI 10.1007/978-1-61779-465-0_20
   Higueruelo AP, 2013, CURR OPIN PHARMACOL, V13, P791, DOI 10.1016/j.coph.2013.05.009
   Huang SY, 2015, DRUG DISCOV TODAY, V20, P969, DOI 10.1016/j.drudis.2015.03.007
   Hugle M, 2016, J MED CHEM, V59, P1518, DOI 10.1021/acs.jmedchem.5b01267
   Jacobsson M, 2006, J CHEM INF MODEL, V46, P1334, DOI 10.1021/ci050407t
   Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h
   Johannes JW, 2017, ACS MED CHEM LETT, V8, P239, DOI 10.1021/acsmedchemlett.6b00464
   Jullien M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030717
   Kamada Y, 2017, J MED CHEM, V60, P4358, DOI 10.1021/acs.jmedchem.7b00313
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Koes DR, 2013, J CHEM INF MODEL, V53, P1893, DOI 10.1021/ci300604z
   Koutsoukas A, 2013, J CHEM INF MODEL, V53, P1957, DOI 10.1021/ci300435j
   Kruger DM, 2012, J CHEM INF MODEL, V52, P2807, DOI 10.1021/ci3003599
   Kuenemann MA, 2014, J CHEM INF MODEL, V54, P3067, DOI 10.1021/ci500487q
   Kurkinen ST, 2019, J CHEM INF MODEL, V59, P3584, DOI 10.1021/acs.jcim.9b00383
   Lagorce D, 2017, SCI REP-UK, V7, DOI 10.1038/srep46277
   Lamberto I, 2014, ACS CHEM BIOL, V9, P2787, DOI 10.1021/cb500677x
   Lee EF, 2009, J BIOL CHEM, V284, P30508, DOI 10.1074/jbc.M109.040725
   Li HJ, 2015, MOL INFORM, V34, P115, DOI 10.1002/minf.201400132
   Li J, 2019, INTERDISCIP SCI, V11, P320, DOI 10.1007/s12539-019-00327-w
   Lyne PD, 2002, DRUG DISCOV TODAY, V7, P1047, DOI 10.1016/S1359-6446(02)02483-2
   Lyu J, 2019, NATURE, V566, P224, DOI 10.1038/s41586-019-0917-9
   Ma DL, 2013, CHEM SOC REV, V42, P2130, DOI 10.1039/c2cs35357a
   Mabonga Lloyd, 2019, Biophys Rev, V11, P559, DOI 10.1007/s12551-019-00570-x
   Macarron R, 2011, NAT REV DRUG DISCOV, V10, P188, DOI 10.1038/nrd3368
   Mackey MD, 2009, J CHEM INF MODEL, V49, P1154, DOI 10.1021/ci8003978
   Melagraki G, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005372
   Milhas S, 2016, ACS CHEM BIOL, V11, P2140, DOI 10.1021/acschembio.6b00286
   Mysinger MM, 2010, J CHEM INF MODEL, V50, P1561, DOI 10.1021/ci100214a
   Nero TL, 2014, NAT REV CANCER, V14, P248, DOI 10.1038/nrc3690
   Nogueira MS, 2019, J CHEM INF MODEL, V59, P1238, DOI 10.1021/acs.jcim.8b00773
   Nshogoza G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133230
   Nunez S, 2010, J CHEM INF MODEL, V50, P480, DOI 10.1021/ci9004628
   Olson EJ, 2016, ACS MED CHEM LETT, V7, P841, DOI 10.1021/acsmedchemlett.6b00132
   Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k
   Oprea TI, 2004, CURR OPIN CHEM BIOL, V8, P349, DOI 10.1016/j.cbpa.2004.06.008
   Pan Y., 2003, J CHEM INF COMP SCI, V43, P272
   Paquet E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/183918
   Peat TS, 2014, J COMPUT AID MOL DES, V28, P347, DOI 10.1007/s10822-014-9721-7
   Pelz NF, 2016, J MED CHEM, V59, P2054, DOI 10.1021/acs.jmedchem.5b01660
   Plewczynski D, 2011, J COMPUT CHEM, V32, P742, DOI 10.1002/jcc.21643
   Pollyea DA, 2019, BLOOD ADV, V3, P4326, DOI 10.1182/bloodadvances.2019000937
   Quiroga R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155183
   R Core Team, 2018, R LANG ENV STAT COMP
   Ran X, 2018, CURR OPIN CHEM BIOL, V44, P75, DOI 10.1016/j.cbpa.2018.06.004
   Refolo G, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00008
   Rodrigues T, 2019, PROG CHEM ORG NAT PR, V110, P73, DOI 10.1007/978-3-030-14632-0_3
   Rognan D, 2017, PHARMACOL THERAPEUT, V175, P47, DOI 10.1016/j.pharmthera.2017.02.034
   Ruppert J, 1997, PROTEIN SCI, V6, P524
   Sastry GM, 2011, J CHEM INF MODEL, V51, P2455, DOI 10.1021/ci2002704
   Schneider G, 2010, NAT REV DRUG DISCOV, V9, P273, DOI 10.1038/nrd3139
   Scior T, 2012, J CHEM INF MODEL, V52, P867, DOI 10.1021/ci200528d
   Shen Chao, 2020, Brief Bioinform, DOI 10.1093/bib/bbz173
   Sheridan RP, 2002, DRUG DISCOV TODAY, V7, P903, DOI 10.1016/S1359-6446(02)02411-X
   Shoichet BK, 2004, NATURE, V432, P862, DOI 10.1038/nature03197
   Sidorov P, 2015, J COMPUT AID MOL DES, V29, P1087, DOI 10.1007/s10822-015-9882-z
   Sieg J, 2019, J CHEM INF MODEL, V59, P947, DOI 10.1021/acs.jcim.8b00712
   Singh J, 2006, CHEM BIOL DRUG DES, V67, P5, DOI 10.1111/j.1747-0285.2005.00323.x
   Slater O, 2019, EXPERT OPIN DRUG DIS, V14, P619, DOI 10.1080/17460441.2019.1604677
   Smith MC, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/erm.2012.10
   Soler D, 2019, J COMPUT AID MOL DES, V33, P613, DOI 10.1007/s10822-019-00212-0
   Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048
   Sperandio O, 2010, DRUG DISCOV TODAY, V15, P220, DOI 10.1016/j.drudis.2009.11.007
   Spitzer R, 2012, J COMPUT AID MOL DES, V26, P687, DOI 10.1007/s10822-011-9533-y
   Spyrakis F, 2015, ARCH BIOCHEM BIOPHYS, V583, P105, DOI 10.1016/j.abb.2015.08.002
   Surmiak E, 2016, ACS CHEM BIOL, V11, P3310, DOI 10.1021/acschembio.6b00596
   Tanaka Y, 2013, J MED CHEM, V56, P9635, DOI 10.1021/jm401170c
   Torres PHM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184574
   Triballeau N, 2005, J MED CHEM, V48, P2534, DOI 10.1021/jm049092j
   Trisciuzzi D, 2019, DRUG DISCOV TODAY, V24, P551, DOI 10.1016/j.drudis.2018.11.013
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Truchon JF, 2007, J CHEM INF MODEL, V47, P488, DOI 10.1021/ci600426e
   Unzue A, 2016, J MED CHEM, V59, P3087, DOI 10.1021/acs.jmedchem.5b01757
   Venkatraman V, 2010, J CHEM INF MODEL, V50, P2079, DOI 10.1021/ci100263p
   Tran-Nguyen VK, 2019, J CHEM INF MODEL, V59, P573, DOI 10.1021/acs.jcim.8b00684
   Villoutreix BO, 2014, MOL INFORM, V33, P414, DOI 10.1002/minf.201400040
   Voter AF, 2018, ADV PROTEIN CHEM STR, V111, P197, DOI 10.1016/bs.apcsb.2017.07.005
   Walters WP, 1998, DRUG DISCOV TODAY, V3, P160, DOI 10.1016/S1359-6446(97)01163-X
   Wang GM, 2016, FUTURE MED CHEM, V8, DOI 10.4155/fmc-2016-0143
   Wang RX, 2001, J CHEM INF COMP SCI, V41, P1422, DOI 10.1021/ci010025x
   Wang RX, 2002, J COMPUT AID MOL DES, V16, P11, DOI 10.1023/A:1016357811882
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wang Z, 2018, J PHYS CHEM B, V122, P2544, DOI 10.1021/acs.jpcb.7b12658
   WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216
   Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526
   Weydert C, 2016, CURR TOP MED CHEM, V16, P1167, DOI 10.2174/1568026615666150901115106
   Whitty A, 2006, NAT CHEM BIOL, V2, P112, DOI 10.1038/nchembio0306-112
   Wieder M, 2017, J CHEM INF MODEL, V57, P365, DOI 10.1021/acs.jcim.6b00674
   Wieder M, 2016, BIOCHEM BIOPH RES CO, V470, P685, DOI 10.1016/j.bbrc.2016.01.081
   Wingert BM, 2018, CURR OPIN CHEM BIOL, V44, P87, DOI 10.1016/j.cbpa.2018.06.006
   WODAK SJ, 1980, P NATL ACAD SCI USA, V77, P1736, DOI 10.1073/pnas.77.4.1736
   Wojcikowski M, 2017, SCI REP-UK, V7, DOI 10.1038/srep46710
   Xu SL, 2018, ANGEW CHEM INT EDIT, V57, P1601, DOI 10.1002/anie.201711828
   Xu WJ, 2015, J MOL GRAPH MODEL, V57, P76, DOI 10.1016/j.jmgm.2015.01.009
   Yang JC, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00069
   Zhenin M, 2018, J COMPUT AID MOL DES, V32, P877, DOI 10.1007/s10822-018-0155-5
   Zhong MQ, 2019, CURR OPIN CHEM BIOL, V50, P55, DOI 10.1016/j.cbpa.2019.02.012
   Zhong SJ, 2008, J THEOR COMPUT CHEM, V7, P833, DOI 10.1142/S0219633608004155
   Zhong SJ, 2010, CURR OPIN DRUG DISC, V13, P326
   Zhou M, 2016, CHEMMEDCHEM, V11, P738, DOI 10.1002/cmdc.201500495
   Zhu J, 2018, ACS MED CHEM LETT, V9, P929, DOI 10.1021/acsmedchemlett.8b00286
NR 167
TC 2
Z9 2
U1 12
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
EI 1549-960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD AUG 24
PY 2020
VL 60
IS 8
BP 3910
EP 3934
DI 10.1021/acs.jcim.0c00545
PG 25
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA NG2BY
UT WOS:000563791600021
PM 32786511
DA 2021-01-01
ER

PT J
AU Tanguturi, VK
   Lindman, BR
   Pibarot, P
   Passeri, JJ
   Kapadia, S
   Mack, MJ
   Inglessis, I
   Langer, NB
   Sundt, TM
   Hung, J
   Elmariah, S
AF Tanguturi, Varsha K.
   Lindman, Brian R.
   Pibarot, Philippe
   Passeri, Jonathan J.
   Kapadia, Samir
   Mack, Michael J.
   Inglessis, Ignacio
   Langer, Nathan B.
   Sundt, Thoralf M.
   Hung, Judy
   Elmariah, Sammy
TI Managing Severe Aortic Stenosis in the COVID-19 Era
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE aortic stenosis; COVID-19; SAVR; TAVR
ID VALVE-REPLACEMENT; HEART-DISEASE; TRANSCATHETER; MANAGEMENT
AB The novel coronavirus disease-2019 (COVID-19) pandemic has created uncertainty in the management of patients with severe aortic stenosis. This population experiences high mortality from delays in treatment of valve disease but is largely overlapping with the population of highest mortality from COVID-19. The authors present strategies for managing patients with severe aortic stenosis in the COVID-19 era. The authors suggest transitions to virtual assessments and consultation, careful pruning and planning of necessary testing, and fewer and shorter hospital admissions. These strategies center on minimizing patient exposure to COVID-19 and expenditure of human and health care resources without significant sacrifice to patient outcomes during this public health emergency. Areas of innovation to improve care during this time include increased use of wearable and remote devices to assess patient performance and vital signs, devices for facile cardiac assessment, and widespread use of clinical protocols for expedient discharge with virtual physical therapy and cardiac rehabilitation options. (C) 2020 by the American College of Cardiology Foundation.
C1 [Tanguturi, Varsha K.; Passeri, Jonathan J.; Inglessis, Ignacio; Hung, Judy; Elmariah, Sammy] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Cardiol Div, Boston, MA 02115 USA.
   [Lindman, Brian R.] Vanderbilt Univ, Sch Med, Struct Heart & Valve Ctr, Nashville, TN 37212 USA.
   [Pibarot, Philippe] Quebec Heart & Lung Inst, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada.
   [Kapadia, Samir] Cleveland Clin, Dept Med, Cleveland, OH 44106 USA.
   [Mack, Michael J.] Baylor Scott & White Hlth, Dallas, TX USA.
   [Langer, Nathan B.; Sundt, Thoralf M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Div Cardiac Surg, Boston, MA 02115 USA.
RP Tanguturi, VK (corresponding author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 5B, Boston, MA 02114 USA.; Elmariah, S (corresponding author), Massachusetts Gen Hosp, 55 Fruit St,Bigelow 800, Boston, MA 02114 USA.
EM vtanguturi@mgh.harvard.edu; selmariah@mgh.harvard.edu
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01 HL151838, R01 HL141917] Funding Source: Medline
CR American College of Cardiology, GEN GUID DEF NON CV
   Arora S, 2018, CIRC-CARDIOVASC INTE, V11, DOI 10.1161/CIRCINTERVENTIONS.118.006929
   Asgar AW, 2016, CAN J CARDIOL, V32, DOI 10.1016/j.cjca.2015.11.008
   Bettger JP, 2020, J BONE JOINT SURG AM, V102, P101, DOI 10.2106/JBJS.19.00695
   Bialek S, 2020, SEVERE OUTCOMES PATI
   Butala N, 2020, J AM COLL CARDIOL, V75, P1428
   Carroll JD, 2013, J AM COLL CARDIOL, V62, P1026, DOI 10.1016/j.jacc.2013.03.060
   Chang D, 2020, LANCET RESP MED, V8, pE13, DOI 10.1016/S2213-2600(20)30066-7
   Chung CJ, 2020, J AM COLL CARDIOL, V75, P2974, DOI 10.1016/j.jacc.2020.04.009
   Elbaz-Greener G, 2018, CIRCULATION, V138, P483, DOI 10.1161/CIRCULATIONAHA.117.033432
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Engelman DT, 2019, JAMA SURG, V154, P755, DOI 10.1001/jamasurg.2019.1153
   Funahashi T, SAVING LIVES VIRTUAL
   Gray LC, 2016, J AM GERIATR SOC, V64, P1347, DOI 10.1111/jgs.14139
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Kirkpatrick JN, 2020, J AM COLL CARDIOL, V75, P3078, DOI 10.1016/j.jacc.2020.04.002
   Kolte D, 2019, J AM COLL CARDIOL, V74, P1532, DOI 10.1016/j.jacc.2019.06.076
   Kucirka LM, 2020, ANN INTERN MED
   Leon MB, 2016, NEW ENGL J MED, V374, P1609, DOI 10.1056/NEJMoa1514616
   Leon MB, 2010, NEW ENGL J MED, V363, P1597, DOI 10.1056/NEJMoa1008232
   Malaisrie SC, 2014, ANN THORAC SURG, V98, P1564, DOI 10.1016/j.athoracsur.2014.06.040
   Nishimura RA, 2014, CIRCULATION, V129, pE521, DOI 10.1161/CIR.0000000000000031
   Rodes-Cabau J, 2019, J AM COLL CARDIOL, V74, P1086, DOI 10.1016/j.jacc.2019.07.014
   Shah PB, 2020, JACC-CARDIOVASC INTE, V13, P1484, DOI 10.1016/j.jcin.2020.04.001
   Siddiqui S., CMS ADULT ELECTIVE S
   TURINA J, 1987, EUR HEART J, V8, P471, DOI 10.1093/oxfordjournals.eurheartj.a062307
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wood DA, 2019, JACC-CARDIOVASC INTE, V12, P459, DOI 10.1016/j.jcin.2018.12.020
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 29
TC 6
Z9 6
U1 5
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936-8798
EI 1876-7605
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD AUG 24
PY 2020
VL 13
IS 16
BP 1937
EP 1944
DI 10.1016/j.jcin.2020.05.045
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NF1VZ
UT WOS:000563091200001
PM 32484159
OA Green Published
DA 2021-01-01
ER

PT J
AU dell'Omo, R
   Filippelli, M
   Semeraro, F
   Avitabile, T
   Giansanti, F
   Parmeggiani, F
   Romano, MR
   Strianese, D
   Romano, V
   Virgili, G
   Costagliola, C
AF dell'Omo, Roberto
   Filippelli, Mariaelena
   Semeraro, Francesco
   Avitabile, Teresio
   Giansanti, Fabrizio
   Parmeggiani, Francesco
   Romano, Mario R.
   Strianese, Diego
   Romano, Vito
   Virgili, Gianni
   Costagliola, Ciro
TI Effects of the first month of lockdown for COVID-19 in Italy: A
   preliminary analysis on the eyecare system from six centers
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article; Early Access
DE COVID-19; coronavirus outbreak; pars plana vitrectomy;
   phacoemulsification
ID DURATION; REPAIR
AB Purpose: To compare the number of eye surgical procedures performed in Italy during the first month of lockdown with those performed in the same period in 2019. Methods: Review of the surgical procedures performed from 10 March to 9 April 2019 and from 10 March to 9 April 2020 (the first month of lockdown because of the COVID-19 outbreak) at six academic institutional centers of Italy. A distinction was made between urgent procedures: any trauma repairment, trabeculectomy/drainage implant for glaucoma, any operation for rhegmatogenous retinal detachment (RRD) repair, pars plana vitrectomy (PPV) for vitreous hemorrhage (VH), macular hole, or retained lens fragments; elective procedures: corneal transplant, phacoemulsification for cataract extraction, silicone oil removal, and PPV for epiretinal membrane; and intravitreal injections (either anti-vascular endothelial growth factor [VEGF] or dexamethasone) to treat exudative maculopathies. The main outcome measure was the rate of reduction in urgent and elective surgeries performed. Results: Overall, 3624 and 844 surgical procedures were performed from 10 March to 9 April 2019 and from 10 March to 10 April 2020, respectively (-76.7% in 2020 compared to 2019,p < 0.0001). Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections). Conclusion: A significant reduction in the rate of urgent and elective surgeries and intravitreal injections was recorded during the first month of lockdown compared to the same period in 2019. With this analysis, the authors hope to provide some preliminary insights about the consequences of lockdown for the eyecare system in Italy.
C1 [dell'Omo, Roberto; Filippelli, Mariaelena; Costagliola, Ciro] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Via Francesco De Sanctis 1, I-86100 Campobasso, Italy.
   [Semeraro, Francesco] Univ Brescia, Dept Neurol & Vis Sci, Eye Clin, Brescia, Italy.
   [Avitabile, Teresio] Univ Catania, Dept Ophthalmol, Catania, Italy.
   [Giansanti, Fabrizio; Virgili, Gianni] Univ Florence, Dept Ophthalmol, Florence, Italy.
   [Parmeggiani, Francesco] Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy.
   [Romano, Mario R.] Humanitas Gavazzeni Castelli, Dept Ophthalmol, Bergamo, Italy.
   [Strianese, Diego] King Khalid Eye Specialist Hosp, CME Dept, Orbital Unit, Riyadh, Saudi Arabia.
   [Romano, Vito] Univ Liverpool, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
RP Filippelli, M (corresponding author), Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Via Francesco De Sanctis 1, I-86100 Campobasso, Italy.
EM oftelena@gmail.com
RI ; SEMERARO, Francesco/K-8667-2016
OI strianese, diego/0000-0002-6140-7539; SEMERARO,
   Francesco/0000-0002-2275-4917
CR American Academy of Ophthalmology, LIST URG EM OPHT PRO
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   GIUFFRE G, 1994, INT OPHTHALMOL, V18, P363, DOI 10.1007/BF00930317
   Hassan TS, 2002, OPHTHALMOLOGY, V109, P146, DOI 10.1016/S0161-6420(01)00886-7
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kim JD, 2013, RETINA-J RET VIT DIS, V33, P1931, DOI 10.1097/IAE.0b013e3182877a27
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   PATERLINI M, 2020, BMJ-BRIT MED J, V368, P47365, DOI DOI 10.1136/BMJ.M1065
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ross WH, 1998, OPHTHALMOLOGY, V105, P2149, DOI 10.1016/S0161-6420(98)91142-3
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
NR 11
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
AR 1120672120953074
DI 10.1177/1120672120953074
EA AUG 2020
PG 7
WC Ophthalmology
SC Ophthalmology
GA NF0UR
UT WOS:000563019200001
PM 32838559
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Chandel, V
   Sharma, PP
   Raj, S
   Choudhari, R
   Rathi, B
   Kumar, D
AF Chandel, Vaishali
   Sharma, Prem Prakash
   Raj, Sibi
   Choudhari, Ramesh
   Rathi, Brijesh
   Kumar, Dhruv
TI Structure-based drug repurposing for targeting Nsp9 replicase and spike
   proteins of severe acute respiratory syndrome coronavirus 2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; Nsp9 replicase; spike proteins; molecular docking; drug
   designing; drug repurposing
ID VIRUS
AB Drug re-purposing might be a fast and efficient way of drug development against the novel coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We applied a bioinformatics approach using molecular dynamics and docking to identify FDA-approved drugs that can be re-purposed to potentially inhibit the non-structural protein 9 (Nsp9) replicase and spike proteins in SARS-CoV-2. We performed virtual screening of FDA-approved compounds, including antiviral, anti-malarial, anti-parasitic, anti-fungal, anti-tuberculosis, and active phytochemicals against the Nsp9 replicase and spike proteins. Selected hit compounds were identified based on their highest binding energy and favorable absorption, distribution, metabolism and excretion (ADME) profile. Conivaptan, an arginine vasopressin antagonist drug exhibited the highest binding energy (-8.4 Kcal/mol) and maximum stability with the amino acid residues present at the active site of the Nsp9 replicase. Tegobuvir, a non-nucleoside inhibitor of the hepatitis C virus, also exhibited maximum stability along with the highest binding energy (-8.1 Kcal/mol) at the active site of the spike proteins. Molecular docking scores were further validated by molecular dynamics using Schrodinger, which supported the strong stability of ligands with the proteins at their active sites through water bridges, hydrophobic interactions, and H-bonding. Our findings suggest Conivaptan and Tegobuvir as potential therapeutic agents against SARS-CoV-2. Furtherin vitroandin vivovalidation and evaluation are warranted to establish how these drug compounds target the Nsp9 replicase and spike proteins.
C1 [Chandel, Vaishali; Raj, Sibi; Kumar, Dhruv] Amity Univ Uttar Pradesh, Amity Inst Mol Med & Stem Cell Res AIMMSCR, Sec 125, Noida 201313, India.
   [Sharma, Prem Prakash; Rathi, Brijesh] Univ Delhi, Hansraj Coll, Dept Chem, Lab Translat Chem & Drug Discovery, Delhi, India.
   [Choudhari, Ramesh] Texas Tech Univ, Hlth Sci Ctr, Dept Mol & Translat Med, Paul L Foster Sch Med,Ctr Emphasis Canc, El Paso, TX USA.
   [Choudhari, Ramesh] BLDE Deemed Univ, Hosp & Res Ctr, Shri BM Patil Med Coll, Vijayapura, India.
   [Rathi, Brijesh] South Ural State Univ, Lab Computat Modelling Drugs, Chelyabinsk, Russia.
RP Kumar, D (corresponding author), Amity Univ Uttar Pradesh, Amity Inst Mol Med & Stem Cell Res AIMMSCR, Sec 125, Noida 201313, India.
EM dhruvbhu@gmail.com
FU Department of Science & Technology-Science and Engineering Research
   Board (DST-SERB), Govt. of India [ECR/2016/001489]
FX Department of Science & Technology-Science and Engineering Research
   Board (DST-SERB) funded research grant (ECR/2016/001489), Govt. of
   India.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2020, SCHROD REL 2020 1 DE
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chandel V., 2020, CHEM BIOL LETT, V7, P47
   Chaudhuri S, 2018, ANTIVIR RES, V155, P76, DOI 10.1016/j.antiviral.2018.05.005
   Chopra S, 2020, BIORESOUR BIOPROCESS, V7, DOI 10.1186/s40643-020-0297-x
   Chu M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/263630
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   de Brito MA, 2011, BRAZ J PHARM SCI, V47, P797, DOI 10.1590/S1984-82502011000400017
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Ghali JK, 2009, DRUG DES DEV THER, V3, P253
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767691
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kamal A, 2015, BIOORG MED CHEM LETT, V25, P3867, DOI 10.1016/j.bmcl.2015.07.057
   Kato F, 2016, ANTIVIR RES, V131, P141, DOI 10.1016/j.antiviral.2016.04.014
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Lenard J., 2008, ENCY VVIROLOGY, DOI [10.1016/B978-012374410-4.00530-6, DOI 10.1016/B978-012374410-4.00530-6]
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lim KP, 2000, J VIROL, V74, P1674, DOI 10.1128/JVI.74.4.1674-1685.2000
   Littler DR, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101258
   Mahanta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768902
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Miura S, 2011, J RENIN-ANGIO-ALDO S, V12, P1, DOI 10.1177/1470320310370852
   Mohanraj K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22631-z
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Mukherjee S, 2020, ROUT INT HANDB, P3
   Nakagawa K, 2016, ADV VIRUS RES, V96, P165, DOI 10.1016/bs.aivir.2016.08.001
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Pagadala Nataraj S, 2017, Biophys Rev, V9, P91, DOI 10.1007/s12551-016-0247-1
   Raj S., 2020, CORONAVIRUSES, V1
   Robson B, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103749
   Schrodinger Release 2020-1: Maestro, 2020, SCHROD REL 2020 1 MA
   Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822-010-9352-6
   Sutton G, 2004, STRUCTURE, V12, P341, DOI 10.1016/j.str.2004.01.016
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Vliegen I, 2015, ANTIVIR RES, V120, P112, DOI 10.1016/j.antiviral.2015.05.011
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Young J. P., 2019, NNATURE SSTRUCTURAL, V26, DOI [10.1038/s41594-019-0334-7, DOI 10.1038/S41594-019-0334-7]
NR 42
TC 1
Z9 1
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1811773
EA AUG 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA ND9HX
UT WOS:000562212600001
PM 32838660
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kluge, S
   Janssens, U
   Welte, T
   Weber-Carstens, S
   Schalte, G
   Salzberger, B
   Gastmeier, P
   Langer, F
   Wepler, M
   Westhoff, M
   Pfeifer, M
   Hoffmann, F
   Bottiger, BW
   Marx, G
   Karagiannidis, C
AF Kluge, S.
   Janssens, U.
   Welte, T.
   Weber-Carstens, S.
   Schaelte, G.
   Salzberger, B.
   Gastmeier, P.
   Langer, F.
   Wepler, M.
   Westhoff, M.
   Pfeifer, M.
   Hoffmann, F.
   Boettiger, B. W.
   Marx, G.
   Karagiannidis, C.
TI Recommendations for intensive care Therapy of Patients with COVID-19-3rd
   Version
SO ANAESTHESIST
LA German
DT Article
ID NONINVASIVE VENTILATION; OXYGEN-THERAPY; INTUBATION; INFECTION;
   MANAGEMENT; DISPERSION; 2019-NCOV; EPIDEMIC; OUTCOMES; FAILURE
AB ZusammenfassungSeit Dezember 2019 verbreitet sich das neuartige Coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome - Corona Virus-2) rasch im Sinne einer weltweiten Pandemie. Dies stellt Kliniker und Krankenhauser vor gro ss e Herausforderungen und belastet die Gesundheitssysteme vieler Lander in einem nie dagewesenen Ausma ss. Die Mehrheit der Patienten zeigt lediglich milde Symptome der sogenannten Coronavirus Disease 2019 (COVID-19). Dennoch benotigen etwa 5-8% eine intensivmedizinische Behandlung. Die akute hypoxamische respiratorische Insuffizienz mit Dyspnoe und hoher Atemfrequenz (>30/Min) fuhrt in der Regel zur Aufnahme auf die Intensivstation. Oft finden sich dann bereits bilaterale pulmonale Infiltrate/Konsolidierungen oder auch Lungenembolien in der Bildgebung. Im weiteren Verlauf entwickeln viele Patienten ein Acute Respiratory Distress Syndrome (ARDS). Eine klinische Wirksamkeit einer medikamentosen Therapie bei schwerer COVID-Erkrankung (hospitalisierte Patienten) ist bisher fur Remdesivir und Dexamethason nachgewiesen. Das Hauptziel der supportiven Therapie ist es eine ausreichende Oxygenierung sicherzustellen. Die invasive Beatmung und wiederholte Bauchlagerung sind dabei wichtige Elemente in der Behandlung von schwer hypoxamischen COVID-19 Patienten. Die strikte Einhaltung der Basishygiene, einschlie ss lich der Handehygiene, sowie das korrekte Tragen von adaquater personlicher Schutzausrustung sind im Umgang mit den Patienten unabdingbar. Prozeduren, die zur Aerosolbildung fuhren konnten, sollten falls notig, mit au ss erster Sorgfalt und Vorbereitung durchgefuhrt werden.
C1 [Kluge, S.; Janssens, U.; Welte, T.; Karagiannidis, C.] Deutsch Gesell Internist Intens Med & Notfallmed, Berlin, Germany.
   [Kluge, S.; Janssens, U.; Weber-Carstens, S.; Hoffmann, F.; Boettiger, B. W.; Marx, G.; Karagiannidis, C.] Deutsch Interdisziplinare Vereinigung Intens & No, Berlin, Germany.
   [Kluge, S.; Welte, T.; Westhoff, M.; Pfeifer, M.; Karagiannidis, C.] Deutsch Gesell Pneumol & Beatmungsmed DGP, Berlin, Germany.
   [Weber-Carstens, S.; Schaelte, G.; Wepler, M.; Marx, G.] Deutsch Gesell Anasthesiol & Intens Med DGAI, Nurnberg, Germany.
   [Salzberger, B.] Deutsch Gesell Infektiol DGI, Munich, Germany.
   [Gastmeier, P.] Deutsch Gesell Hyg & Mikrobiol DGHM, Munster, Germany.
   [Langer, F.] Gesell Thrombose & Hamostaseforsch GTH, Cologne, Germany.
   [Hoffmann, F.] Deutsch Gesell Kinder & Jugendmed DGKJ, Berlin, Germany.
   [Boettiger, B. W.] Deutsch Rat Wiederbelebung, German Resuscitat Council, GRC, Ulm, Germany.
   [Kluge, S.; Janssens, U.; Welte, T.; Weber-Carstens, S.; Marx, G.; Karagiannidis, C.] ARDS Netzwerk Deutschland, Berlin, Germany.
   [Kluge, S.] Univ Klinikum Hamburg Eppendorf, Klin Intens Med, Martinistr 52, D-20246 Hamburg, Germany.
RP Kluge, S (corresponding author), Univ Klinikum Hamburg Eppendorf, Klin Intens Med, Martinistr 52, D-20246 Hamburg, Germany.
EM skluge@uke.de
RI Hoffmann, Florian/A-4486-2017
OI Hoffmann, Florian/0000-0002-2713-2455
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Antoch G, 2020, ROFO-FORTSCHR RONTG, V192, P418, DOI 10.1055/a-1149-3625
   AWMF, 2017, S3 LEITL INV BEATM E
   Begley JL, 2020, PATIENTS SITU SIMUL, DOI [10.1111/anae.15115, DOI 10.1111/ANAE.15115]
   Beigel JH, 2020, NEW ENGL J MED, V383, P994, DOI 10.1056/NEJMc2022236
   Bellani G, 2017, AM J RESP CRIT CARE, V195, P67, DOI 10.1164/rccm.201606-1306OC
   Bottiger BW, 2019, CHEST, V156, P1035, DOI 10.1016/j.chest.2019.08.1922
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Brunkhorst FM, 2020, MED KLIN-INTENSIVMED, DOI 10.1007/s00063-020-00685-0
   Cabrini L, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30359-7
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Caputo KM, 2006, CAN J ANAESTH, V53, P122, DOI 10.1007/BF03021815
   Carteaux G, 2016, CRIT CARE MED, V44, P282, DOI 10.1097/CCM.0000000000001379
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Chen ZHJ, 2020, CLIN TRIAL MEDRXIV, DOI [10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Dalli J, 2020, BRIT J ANAESTH, V125, pE293, DOI 10.1016/j.bja.2020.05.006
   Darwiche K, 2020, PNEUMOLOGIE, V74, P260, DOI 10.1055/a-1154-1814
   Deutsche Gesellschaft fur Palliativmedizin, 2020, PALL 2020
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dutzmann J, ENTSCHEIDUNGEN ZUTEI
   Elkbuli A, 2019, AM SURGEON, V85, P370
   Empfehlungen des International Liaison Committee on Resuscitation (ILCOR), CPR BEI PAT COVID 19
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Fowler RA, 2004, AM J RESP CRIT CARE, V169, P1198, DOI 10.1164/rccm.200305-715OC
   Gattinoni L, 2020, INTENSIVE CARE MED
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Greenland JR, 2020, ANESTHESIOLOGY, V132, P1346, DOI 10.1097/ALN.0000000000003303
   Griffiths RD, 2010, CRIT CARE MED, V38, P779, DOI 10.1097/CCM.0b013e3181cc4b53
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Guan WJ, 2020, NEW ENGL J MED, DOI [10.1101/2020.02.06.200209747121484, DOI 10.1101/2020.02.06.200209747121484]
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Hosokawa K, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1138-8
   Huang C, 2020, LANCET, V395, P496, DOI 10.1016/S0140-6736(20)30252-X
   Hui DS, 2006, CHEST, V130, P730, DOI 10.1378/chest.130.3.730
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Hui DS, 2009, CHEST, V136, P998, DOI 10.1378/chest.09-0434
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Janssens U, 2012, DIVI, V3, P103
   Kluge S, 2020, MED KLIN-INTENSIVMED, V115, P175, DOI 10.1007/s00063-020-00674-3
   Langer F, 2020, HAMOSTASEOLOGIE, V40, P264, DOI 10.1055/a-1178-3551
   Leonard S, 2020, CHEST, DOI [10.1016/j.chest.2020.03.0437130245, DOI 10.1016/J.CHEST.2020.03.0437130245]
   Liao XL, 2020, INTENS CARE MED, V46, P357, DOI 10.1007/s00134-020-05954-2
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   McGrath BA, 2020, LANCET RESP MED, V8, P717, DOI 10.1016/S2213-2600(20)30230-7
   Orser BA, 2020, ANESTH ANALG, V130, P1109, DOI 10.1213/ANE.0000000000004803
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Patel NA, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2020.102573
   Peng PWH, 2020, BRIT J ANAESTH, V124, P497, DOI 10.1016/j.bja.2020.02.008
   Pfeifer M, 2020, PNEUMOLOGIE, V74, P337, DOI 10.1055/a-1157-9976
   Piepho TCE, 2015, ATEMWEGSMANAGEMENT
   Ramcharan T, 2020, PEDIATR CARDIOL, V41, P1391, DOI 10.1007/s00246-020-02391-2
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Robert Koch Institut, EMPF ROB KOCH I HYG
   Robert Koch Institut, HINW TEST PAT INF NE
   Robert Koch Institut, SARS COV 2 STECKBR C
   Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Schalte G, 2020, ANASTH INTENSIVMED, V61, pS132, DOI 10.19224/ai2020.S132
   Schwarz K, 2015, J AEROSOL MED PULM D, V28, P52, DOI 10.1089/jamp.2013.1104
   Shao F, 2020, RESUSCITATION, V151, P18, DOI 10.1016/j.resuscitation.2020.04.005
   Simonds AK, 2010, HEALTH TECHNOL ASSES, V14, P131, DOI 10.3310/hta14460-02
   Tagarro A, 2020, SCREENING, DOI [10.1001/jamapediatrics.2020.1346, DOI 10.1001/JAMAPEDIATRICS.2020.1346]
   Valk SJ, 2020, COCHRANE DB SYST REV, V5, DOI DOI 10.1002/14651858.CD013600/FULL.32406927
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wachs C, 2020, DEUT MED WOCHENSCHR, V145, P693, DOI 10.1055/a-0948-8505
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang RH, 2019, HEART LUNG, V48, P46, DOI 10.1016/j.hrtlng.2018.09.005
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Westhoff M, 2015, PNEUMOLOGIE, V69, P719, DOI 10.1055/s-0034-1393309
   Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   World Health Organization, 2020, CLIN MAN COVID 19
   Wu Z, 2019, CHARACTERISTICS IMPO
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhu YY, 2020, BIOMETRICAL J, V62, P1371, DOI 10.1002/bimj.201900112
NR 87
TC 2
Z9 2
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0003-2417
EI 1432-055X
J9 ANAESTHESIST
JI Anaesthesist
PD SEP
PY 2020
VL 69
IS 9
SI SI
BP 653
EP 664
DI 10.1007/s00101-020-00833-3
EA AUG 2020
PG 12
WC Anesthesiology
SC Anesthesiology
GA NI2RE
UT WOS:000562329800002
PM 32833080
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Dadhich, R
   Kapoor, S
AF Dadhich, Ruchika
   Kapoor, Shobhna
TI Various Facets of Pathogenic Lipids in Infectious Diseases: Exploring
   Virulent Lipid-Host Interactome and Their Druggability
SO JOURNAL OF MEMBRANE BIOLOGY
LA English
DT Article
DE Host-pathogen interactions; Virulence-associated lipids; Lipid rafts;
   Lipid biosynthesis; Membrane organization; Drug development
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; MYCOBACTERIAL
   OUTER-MEMBRANE; GIANT UNILAMELLAR VESICLES; SARS-CORONAVIRUS;
   PLASMA-MEMBRANE; SULFOLIPID-1 BIOSYNTHESIS; ENTEROVIRUS REPLICATION;
   LATERAL ORGANIZATION; ANTIVIRAL AGENT
AB Lipids form an integral, structural, and functional part of all life forms. They play a significant role in various cellular processes such as membrane fusion, fission, endocytosis, protein trafficking, and protein functions. Interestingly, recent studies have revealed their more impactful and critical involvement in infectious diseases, starting with the manipulation of the host membrane to facilitate pathogenic entry. Thereafter, pathogens recruit specific host lipids for the maintenance of favorable intracellular niche to augment their survival and proliferation. In this review, we showcase the lipid-mediated host pathogen interplay in context of life-threatening viral and bacterial diseases including the recent SARS-CoV-2 infection. We evaluate the emergent lipid-centric approaches adopted by these pathogens, while delineating the alterations in the composition and organization of the cell membrane within the host, as well as the pathogen. Lastly, crucial nexus points in their interaction landscape for therapeutic interventions are identified.
   Graphic Abstract
   [GRAPHICS]
   Lipids act as critical determinants of bacterial and viral pathogenesis by altering the host cell membrane structure and functions.
C1 [Dadhich, Ruchika; Kapoor, Shobhna] Indian Inst Technol, Dept Chem, Mumbai 400076, Maharashtra, India.
   [Kapoor, Shobhna] Indian Inst Technol, Wadhwani Res Ctr Bioengn, Mumbai 400076, Maharashtra, India.
RP Dadhich, R; Kapoor, S (corresponding author), Indian Inst Technol, Dept Chem, Mumbai 400076, Maharashtra, India.; Kapoor, S (corresponding author), Indian Inst Technol, Wadhwani Res Ctr Bioengn, Mumbai 400076, Maharashtra, India.
EM ruchikadadhich@iitb.ac.in; shobhnakapoor@chem.iitb.ac.in
OI Kapoor, Shobhna/0000-0003-3684-4312
FU DST-Woman Scientist Scheme, India [WOS-A/CS-16/2018]; DST-SERBDepartment
   of Science & Technology (India)Science Engineering Research Board
   (SERB), India [EMR/2016/005414]; BRNSDepartment of Atomic Energy
   (DAE)Board of Research in Nuclear Sciences (BRNS) [201805BRE01RP04922];
   DBT Ramalingaswami Fellowship; DST-Inspire Faculty Award; Wadhwani
   Research Centre for Bioengineering (WRCB)
FX RD acknowledges DST-Woman Scientist Scheme WOS-A/CS-16/2018, India for
   research funding. Work in our lab is supported by DST-SERB Grant
   EMR/2016/005414, BRNS Grant 201805BRE01RP04922, Wadhwani Research Centre
   for Bioengineering (WRCB), DBT Ramalingaswami Fellowship, and
   DST-Inspire Faculty Award. We acknowledge BEI Resources, NIAID, NIH for
   purified mycobacterial lipids and antibodies supporting our work.
CR Adhyapak P, 2020, BIOPHYS J, V118, P1279, DOI 10.1016/j.bpj.2020.01.027
   Agrawal H, 2016, SCI REP-UK, V6, DOI 10.1038/srep25412
   Al-Kuraishy HM, 2018, J LAB PHYS, V10, P271, DOI 10.4103/JLP.JLP_170_17
   Albulescu L, 2017, ANTIVIR RES, V140, P37, DOI 10.1016/j.antiviral.2017.01.008
   Albulescu L, 2015, ANTIVIR RES, V117, P110, DOI 10.1016/j.antiviral.2015.02.013
   Amara A, 2015, NAT REV MICROBIOL, V13, P461, DOI 10.1038/nrmicro3469
   Angelini MM, 2013, MBIO, V4, DOI 10.1128/mBio.00524-13
   Astarie-Dequeker C, 2010, DRUG DISCOV TODAY DI, V7, pe33, DOI DOI 10.1016/j.ddmec.2010.09.003
   Astarie-Dequeker C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000289
   Augenstreich J, 2020, BIORXIV, DOI [10.1101/2020.05.13.092585, DOI 10.1101/2020.05.13.092585]
   Augenstreich J, 2019, P NATL ACAD SCI USA, V116, P25649, DOI 10.1073/pnas.1910368116
   Augenstreich J, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12726
   Baglivo Mirko, 2020, Acta Biomed, V91, P161, DOI 10.23750/abm.v91i1.9402
   Bahl N, 2011, J BIOL CHEM, V286, P37793, DOI 10.1074/jbc.M111.245472
   Balsalobre C, 2006, MOL MICROBIOL, V59, P99, DOI 10.1111/j.1365-2958.2005.04938.x
   Bansal-Mutalik R, 2014, P NATL ACAD SCI USA, V111, P4958, DOI 10.1073/pnas.1403078111
   Barry CE, 2009, NAT REV MICROBIOL, V7, P845, DOI 10.1038/nrmicro2236
   Bauwens A, 2013, CELL MOL LIFE SCI, V70, P425, DOI 10.1007/s00018-012-1060-z
   Bergman P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024394
   Blanc L, 2017, P NATL ACAD SCI USA, V114, P11205, DOI 10.1073/pnas.1707840114
   Blenkiron C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160440
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   BRANDENBURG K, 1990, EUR J BIOCHEM, V191, P229, DOI 10.1111/j.1432-1033.1990.tb19114.x
   BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Burlaka I, 2013, J AM SOC NEPHROL, V24, P1413, DOI 10.1681/ASN.2012101044
   Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200
   Catron DM, 2004, INFECT IMMUN, V72, P1036, DOI 10.1128/IAI.72.2.1036-1042.2004
   Chahar HS, 2015, VIRUSES-BASEL, V7, P3204, DOI 10.3390/v7062770
   Chan R, 2008, J VIROL, V82, P11228, DOI 10.1128/JVI.00981-08
   Charlier L, 2014, BIOPHYS J, V106, P577, DOI 10.1016/j.bpj.2013.12.019
   Chen LC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07006-2
   Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455
   Cheshenko N, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006766
   Cheung W, 2010, J VIROL, V84, P6782, DOI 10.1128/JVI.01757-09
   Choi KS, 2005, J VIROL, V79, P9862, DOI 10.1128/JVI.79.15.9862-9871.2005
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Clements A, 2012, GUT MICROBES, V3, P71, DOI 10.4161/gmic.19182
   Colpitts CC, 2013, J VIROL, V87, P3640, DOI 10.1128/JVI.02882-12
   Corbin-Lickfett K, 2010, CHEM BIOL DEFENSE SC
   Dadhich R, 2020, ACS CHEM BIOL, V15, P740, DOI 10.1021/acschembio.9b00991
   Dadhich R, 2019, BBA-BIOMEMBRANES, V1861, P1213, DOI 10.1016/j.bbamem.2019.04.004
   Dahmane S, 2019, NANOSCALE, V11, P6036, DOI 10.1039/c8nr07269h
   Di Lorenzo F, 2019, FEMS MICROBIOL REV, V43, P257, DOI 10.1093/femsre/fuz002
   Domenech P, 2004, J BIOL CHEM, V279, P21257, DOI 10.1074/jbc.M400324200
   Donnenberg MS, 2001, J CLIN INVEST, V107, P539, DOI 10.1172/JCI12404
   Dowhan W, 2009, ANNU REV BIOCHEM, V78, P515, DOI 10.1146/annurev.biochem.77.060806.091251
   Dumas F, 2017, BBA-BIOMEMBRANES, V1859, P1636, DOI 10.1016/j.bbamem.2017.05.007
   Duncan MJ, 2004, J BIOL CHEM, V279, P18944, DOI 10.1074/jbc.M400769200
   Ernst JD, 1998, INFECT IMMUN, V66, P1277, DOI 10.1128/IAI.66.4.1277-1281.1998
   Erridge C, 2002, MICROBES INFECT, V4, P837, DOI 10.1016/S1286-4579(02)01604-0
   Filipe A, 2015, TRENDS MOL MED, V21, P34, DOI 10.1016/j.molmed.2014.11.003
   Finzi A, 2007, J VIROL, V81, P7476, DOI 10.1128/JVI.00308-07
   Forrellad MA, 2013, VIRULENCE, V4, P3, DOI 10.4161/viru.22329
   Fratti RA, 2003, P NATL ACAD SCI USA, V100, P5437, DOI 10.1073/pnas.0737613100
   Garcia-Saez AJ, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706162200
   Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647
   Ge M, 2009, BIOPHYS J, V96, P4925, DOI 10.1016/j.bpj.2009.04.015
   Ghosal A, 2015, MICROBIOLOGYOPEN, V4, P252, DOI 10.1002/mbo3.235
   Gill S, 2019, FEMS MICROBIOL REV, V43, P273, DOI 10.1093/femsre/fuy042
   Gilmore SA, 2012, ACS CHEM BIOL, V7, P863, DOI 10.1021/cb200311s
   Glende J, 2008, VIROLOGY, V381, P215, DOI 10.1016/j.virol.2008.08.026
   Godbole AA, 2015, ANTIMICROB AGENTS CH, V59, P1554, DOI 10.1128/AAC.04516-14
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Grigorov B, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-28
   Hagemeijer MC, 2014, VIROLOGY, V458, P125, DOI 10.1016/j.virol.2014.04.027
   Hagemeijer MC, 2012, VIRUSES-BASEL, V4, P3245, DOI 10.3390/v4113245
   Hagemeijer MC, 2011, J VIROL, V85, P4572, DOI 10.1128/JVI.00042-11
   Hagemeijer MC, 2010, J VIROL, V84, P2134, DOI 10.1128/JVI.01716-09
   Harada S, 2005, BIOCHEM J, V392, P191, DOI 10.1042/BJ20051069
   Harrison SC, 2015, VIROLOGY, V479, P498, DOI 10.1016/j.virol.2015.03.043
   Heaton NS, 2011, TRENDS MICROBIOL, V19, P368, DOI 10.1016/j.tim.2011.03.007
   Hoffmann C, 2008, P NATL ACAD SCI USA, V105, P3963, DOI 10.1073/pnas.0709530105
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu CMJ, 2013, NAT NANOTECHNOL, V8, P933, DOI [10.1038/nnano.2013.254, 10.1038/NNANO.2013.254]
   Huang FC, 2011, CELL IMMUNOL, V271, P480, DOI 10.1016/j.cellimm.2011.08.018
   Huarte N, 2016, SCI REP-UK, V6, DOI 10.1038/srep34190
   Hunt JM, 2010, CLIN LAB MED, V30, P21, DOI 10.1016/j.cll.2009.11.001
   Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780
   Ishikawa E, 2017, TRENDS IMMUNOL, V38, P66, DOI 10.1016/j.it.2016.10.009
   Ishikawa E, 2009, J EXP MED, V206, P2879, DOI 10.1084/jem.20091750
   Izquierdo-Useros N, 2007, J VIROL, V81, P7559, DOI 10.1128/JVI.02572-06
   Izquierdo-Useros N, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001315
   Jerwood S, 2008, J ANTIMICROB CHEMOTH, V61, P362, DOI 10.1093/jac/dkm496
   Jolly C, 2007, J VIROL, V81, P7873, DOI 10.1128/JVI.01845-06
   Jouvenet N, 2009, P NATL ACAD SCI USA, V106, P19114, DOI 10.1073/pnas.0907364106
   Jozefowski S, 2008, BIOESSAYS, V30, P943, DOI 10.1002/bies.20815
   Karpman D, 1998, INFECT IMMUN, V66, P636, DOI 10.1128/IAI.66.2.636-644.1998
   Kaul D, 2004, MOL CELL BIOCHEM, V258, P219, DOI 10.1023/B:MCBI.0000012851.42642.be
   Ketter E, 2019, ANNU REV VIROL, V6, P319, DOI 10.1146/annurev-virology-092818-015748
   Khan I, 2014, J VIROL, V88, P12276, DOI 10.1128/JVI.00970-14
   Kliger Y, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471-2180-3-20
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x
   Kouokam JC, 2006, INFECT IMMUN, V74, P2022, DOI 10.1128/IAI.74.4.2022-2030.2006
   Kovbasnjuk O, 2001, J CELL SCI, V114, P4025
   Kreutzberger AJB, 2017, BIOPHYS J, V113, P1912, DOI 10.1016/j.bpj.2017.09.014
   Krishnakumari V, 2020, ACS OMEGA, V5, P6366, DOI 10.1021/acsomega.9b03770
   Kubiak J, 2011, BIOPHYS J, V100, P978, DOI 10.1016/j.bpj.2011.01.012
   Kulkarni R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14817-8
   Kutluay SB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001200
   Lai AL, 2017, J MOL BIOL, V429, P3875, DOI 10.1016/j.jmb.2017.10.017
   Lai AL, 2012, J MOL BIOL, V418, P3, DOI 10.1016/j.jmb.2012.02.010
   Larrouy-Maumus G, 2019, CURR MED CHEM, V26, P1924, DOI 10.2174/0929867325666180904120029
   Layre E, 2011, CHEM BIOL, V18, P1537, DOI 10.1016/j.chembiol.2011.10.013
   Legros N, 2018, J LIPID RES, V59, P1383, DOI 10.1194/jlr.M083048
   Li GM, 2007, MICROBES INFECT, V9, P96, DOI 10.1016/j.micinf.2006.10.015
   Lingwood CA, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004788
   Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545
   LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254
   Lorizate M, 2013, CELL MICROBIOL, V15, P292, DOI 10.1111/cmi.12101
   Lu YN, 2008, BIOCHEM BIOPH RES CO, V369, P344, DOI 10.1016/j.bbrc.2008.02.023
   Lugo-Villarino G, 2011, EUR J MICROBIOL IMMU, V1, P25, DOI 10.1556/EuJMI.1.2011.1.6
   Madison MN, 2015, VIRUSES-BASEL, V7, P4093, DOI 10.3390/v7072810
   Maeshima N, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00003
   Martens S, 2008, NAT REV MOL CELL BIO, V9, P543, DOI 10.1038/nrm2417
   Martin-Acebes MA, 2016, J LIPID RES, V57, P422, DOI 10.1194/jlr.M064212
   Martin-Acebes MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069479
   McLauchlan J, 2009, BBA-MOL CELL BIOL L, V1791, P552, DOI 10.1016/j.bbalip.2008.12.012
   Meher G, 2019, J MEMBRANE BIOL, V252, P261, DOI 10.1007/s00232-019-00064-7
   Melikyan GB, 2010, P NATL ACAD SCI USA, V107, P17069, DOI 10.1073/pnas.1012748107
   Melton-Celsa AR, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.EHEC-0024-2013
   Miller S, 2008, NAT REV MICROBIOL, V6, P363, DOI 10.1038/nrmicro1890
   Millet JK, 2018, VIROLOGY, V517, P3, DOI 10.1016/j.virol.2017.12.015
   Mishra A, 2017, MOL IMMUNOL, V87, P240, DOI 10.1016/j.molimm.2017.05.001
   Mishra AK, 2011, FEMS MICROBIOL REV, V35, P1126, DOI 10.1111/j.1574-6976.2011.00276.x
   Mishra M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49343-2
   Moriel-Carretero M, 2020, TRAFFIC, V21, P545, DOI 10.1111/tra.12738
   Mortaz E, 2015, J CLIN IMMUNOL, V35, P1, DOI 10.1007/s10875-014-0103-7
   Muller C, 2018, J VIROL, V92, DOI 10.1128/JVI.01463-17
   Mullineaux CW, 2006, J BACTERIOL, V188, P3442, DOI 10.1128/JB.188.10.3442-3448.2006
   Nagata S, 2020, CURR OPIN IMMUNOL, V62, P31, DOI 10.1016/j.coi.2019.11.009
   Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003
   Nomura R, 2004, J VIROL, V78, P8701, DOI 10.1128/JVI.78.16.8701-8708.2004
   Ono A, 2004, P NATL ACAD SCI USA, V101, P14889, DOI 10.1073/pnas.0405596101
   Parihar SP, 2014, J INFECT DIS, V209, P754, DOI 10.1093/infdis/jit550
   Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830
   Popik W, 2002, J VIROL, V76, P4709, DOI 10.1128/JVI.76.10.4709-4722.2002
   Queval CJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02284
   Quigley J, 2017, MBIO, V8, DOI 10.1128/mBio.00148-17
   RAETZ CRH, 1990, J BIOL CHEM, V265, P1235
   Rahman SA, 2014, J VIROL, V88, P7904, DOI 10.1128/JVI.00431-14
   Rao L, 2020, ACS NANO, V14, P2569, DOI 10.1021/acsnano.0c01665
   Riff JD, 2005, INFECT IMMUN, V73, P7113, DOI 10.1128/IAI.73.11.7113-7125.2005
   Rogers TJ, 2012, INFECT IMMUN, V80, P2858, DOI 10.1128/IAI.00336-12
   Rowlett VW, 2017, J BACTERIOL, V199, DOI 10.1128/JB.00849-16
   Saez-Cirion A, 2002, J BIOL CHEM, V277, P21776, DOI 10.1074/jbc.M202255200
   Samsa MM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000632
   Sani M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000794
   Sartain MJ, 2011, J LIPID RES, V52, P861, DOI 10.1194/jlr.M010363
   Seeliger JC, 2012, J BIOL CHEM, V287, P7990, DOI 10.1074/jbc.M111.315473
   SEYDEL U, 1993, J STRUCT BIOL, V110, P232, DOI 10.1006/jsbi.1993.1026
   Shrivastava R, 2019, J BIOL CHEM, V294, P14175, DOI 10.1074/jbc.AW119.008139
   Siegel DP, 1997, BIOPHYS J, V73, P3089, DOI 10.1016/S0006-3495(97)78336-X
   Silhavy TJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000414
   Smith I, 2003, CLIN MICROBIOL REV, V16, P463, DOI 10.1128/CMR.16.3.463-496.2003
   Soares MM, 2008, NAT MED, V14, P1357, DOI 10.1038/nm.1885
   SPARGO BJ, 1991, P NATL ACAD SCI USA, V88, P737, DOI 10.1073/pnas.88.3.737
   Speerstra S, 2018, ANTIVIR RES, V149, P164, DOI 10.1016/j.antiviral.2017.11.018
   St Vincent MR, 2010, P NATL ACAD SCI USA, V107, P17339, DOI 10.1073/pnas.1010026107
   Stahl AL, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004619
   Stancu C, 2001, J CELL MOL MED, V5, P378, DOI 10.1111/j.1582-4934.2001.tb00172.x
   Strating JRPM, 2015, CELL REP, V10, P600, DOI 10.1016/j.celrep.2014.12.054
   Straus MR, 2020, J VIROL, V94, DOI 10.1128/JVI.00426-20
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   Thomas A, 2015, J VIROL, V89, P8162, DOI 10.1128/JVI.00469-15
   Turnbull WB, 2004, ANGEW CHEM INT EDIT, V43, P3918, DOI 10.1002/anie.200454119
   Turner J, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty026
   Veiga AS, 2007, FEBS J, V274, P5096, DOI 10.1111/j.1742-4658.2007.06029.x
   Vergne I, 2003, J EXP MED, V198, P653, DOI 10.1084/jem.20030527
   Vigant F, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003297
   Villysson A, 2017, TOXINS, V9, DOI 10.3390/toxins9110376
   Vincent N, 2002, BBA-BIOMEMBRANES, V1567, P157, DOI 10.1016/S0005-2736(02)00611-9
   Viswanathan G, 2018, CHEM PHYS LIPIDS, V213, P25, DOI 10.1016/j.chemphyslip.2018.03.004
   Viswanathan G, 2015, CHEM PHYS LIPIDS, V189, P19, DOI 10.1016/j.chemphyslip.2015.05.006
   Waheed AA, 2009, VIRUS RES, V143, P162, DOI 10.1016/j.virusres.2009.04.007
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Warner FJ, 2005, J BIOL CHEM, V280, P39353, DOI 10.1074/jbc.M508914200
   Wilkinson SG, 1996, PROG LIPID RES, V35, P283, DOI 10.1016/S0163-7827(96)00004-5
   Wojcechowskyj JA, 2010, VIRUSES-BASEL, V2, P1106, DOI 10.3390/v2051106
   Wolf MC, 2010, P NATL ACAD SCI USA, V107, P3157, DOI 10.1073/pnas.0909587107
   Wu EL, 2013, BIOPHYS J, V105, P1444, DOI 10.1016/j.bpj.2013.08.002
   Yan BP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010073
   Yandrapalli N, 2016, SCI REP-UK, V6, DOI 10.1038/srep39332
   Yang ST, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11401
   Yang ST, 2015, NAT CHEM BIOL, V11, P424, DOI [10.1038/NCHEMBIO.1800, 10.1038/nchembio.1800]
   Yaron S, 2000, APPL ENVIRON MICROB, V66, P4414, DOI 10.1128/AEM.66.10.4414-4420.2000
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Yonekawa A, 2014, IMMUNITY, V41, P402, DOI 10.1016/j.immuni.2014.08.005
   Zhang WB, 2019, CHEM PHYS LETT, V717, P34, DOI 10.1016/j.cplett.2018.12.041
   Zhang XW, 2004, J MOL STRUC-THEOCHEM, V677, P73, DOI 10.1016/j.theochem.2004.02.018
   Zick M, 2014, ELIFE, V3, DOI 10.7554/eLife.01879
   Zuber B, 2008, J BACTERIOL, V190, P5672, DOI 10.1128/JB.01919-07
NR 194
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0022-2631
EI 1432-1424
J9 J MEMBRANE BIOL
JI J. Membr. Biol.
PD OCT
PY 2020
VL 253
IS 5
SI SI
BP 399
EP 423
DI 10.1007/s00232-020-00135-0
EA AUG 2020
PG 25
WC Biochemistry & Molecular Biology; Cell Biology; Physiology
SC Biochemistry & Molecular Biology; Cell Biology; Physiology
GA NT9MX
UT WOS:000562335600001
PM 32833058
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ozturk, S
   Elcin, AE
   Koca, A
   Elcin, YM
AF Ozturk, Selcuk
   Elcin, Ayse Eser
   Koca, Ayca
   Elcin, Yasar Murat
TI Therapeutic Applications of Stem Cells and Extracellular Vesicles in
   Emergency Care: Futuristic Perspectives
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article; Early Access
DE Stem cell therapy; Extracellular vesicle therapy; Acute emergency care;
   Trauma and critical care medicine
ID TRAUMATIC BRAIN-INJURY; RESPIRATORY-DISTRESS-SYNDROME; MESENCHYMAL
   STROMAL CELLS; UMBILICAL-CORD BLOOD; ACUTE LUNG INJURY; BONE-MARROW;
   CELLULAR THERAPIES; LOCOMOTOR RECOVERY; PROTEOMIC ANALYSIS;
   RADIATION-INJURY
AB Regenerative medicine (RM) is an interdisciplinary field that aims to repair, replace or regenerate damaged or missing tissue or organs to function as close as possible to its physiological architecture and functions. Stem cells, which are undifferentiated cells retaining self-renewal potential, excessive proliferation and differentiation capacity into offspring or daughter cells that form different lineage cells of an organism, are considered as an important part of the RM approaches. They have been widely investigated in preclinical and clinical studies for therapeutic purposes. Extracellular vesicles (EVs) are the vital mediators that regulate the therapeutic effects of stem cells. Besides, they carry various types of cargo between cells which make them a significant contributor of intercellular communication. Given their role in physiological and pathological conditions in living cells, EVs are considered as a new therapeutic alternative solution for a variety of diseases in which there is a high unmet clinical need. This review aims to summarize and identify therapeutic potential of stem cells and EVs in diseases requiring acute emergency care such as trauma, heart diseases, stroke, acute respiratory distress syndrome and burn injury. Diseases that affect militaries or societies including acute radiation syndrome, sepsis and viral pandemics such as novel coronavirus disease 2019 are also discussed. Additionally, featuring and problematic issues that hamper clinical translation of stem cells and EVs are debated in a comparative manner with a futuristic perspective.
C1 [Ozturk, Selcuk; Elcin, Ayse Eser; Elcin, Yasar Murat] Ankara Univ, Tissue Engn Biomat & Nanobiotechnol Lab, Fac Sci, Ankara, Turkey.
   [Elcin, Ayse Eser; Elcin, Yasar Murat] Ankara Univ, Grad Sch Hlth Sci, Interdisciplinary Dept Stem Cell & Regenerat Med, Ankara, Turkey.
   [Koca, Ayca] Ankara Univ, Sch Med, Dept Emergency Med, Ankara, Turkey.
   [Elcin, Yasar Murat] Biovalda Hlth Technol Inc, Ankara, Turkey.
   [Elcin, Yasar Murat] Ankara Univ, Fac Sci, Biochem Div, TR-06100 Ankara, Turkey.
RP Elcin, YM (corresponding author), Ankara Univ, Tissue Engn Biomat & Nanobiotechnol Lab, Fac Sci, Ankara, Turkey.; Elcin, YM (corresponding author), Ankara Univ, Grad Sch Hlth Sci, Interdisciplinary Dept Stem Cell & Regenerat Med, Ankara, Turkey.; Elcin, YM (corresponding author), Biovalda Hlth Technol Inc, Ankara, Turkey.; Elcin, YM (corresponding author), Ankara Univ, Fac Sci, Biochem Div, TR-06100 Ankara, Turkey.
EM elcin@ankara.edu.tr
CR Adamiak M, 2018, CIRC RES, V122, P296, DOI 10.1161/CIRCRESAHA.117.311769
   Al-Mayah AHJ, 2012, RADIAT RES, V177, P539, DOI 10.1667/RR2868.1
   Ambrosy AP, 2014, J AM COLL CARDIOL, V63, P1123, DOI 10.1016/j.jacc.2013.11.053
   Amosse Jeremy, 2017, Stem Cell Investig, V4, P102, DOI 10.21037/sci.2017.11.07
   Arno A, 2011, PHARMACEUTICALS, V4, P1355, DOI 10.3390/ph4101355
   Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460
   Bari E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040924
   Barile Lucio, 2017, Stem Cell Investig, V4, P93, DOI 10.21037/sci.2017.11.06
   Baulch JE, 2016, P NATL ACAD SCI USA, V113, P4836, DOI 10.1073/pnas.1521668113
   Bein T, 2016, INTENS CARE MED, V42, P699, DOI 10.1007/s00134-016-4325-4
   Besalti O, 2016, J VET MED SCI, V78, P1465, DOI 10.1292/jvms.15-0571
   Bey E, 2010, WOUND REPAIR REGEN, V18, P50, DOI 10.1111/j.1524-475X.2009.00562.x
   Bogatcheva NV, 2019, BIOCHEMISTRY-MOSCOW+, V84, P1375, DOI 10.1134/S0006297919110129
   Bogin V., 2015, REGEN MED, P33
   Borlongan CV, 2019, STEM CELL TRANSL MED, V8, P983, DOI 10.1002/sctm.19-0076
   Calfee CS, 2007, CHEST, V131, P913, DOI 10.1378/chest.06-1743
   Cambria E, 2017, NPJ REGEN MED, V2, DOI 10.1038/s41536-017-0024-1
   Cancio LC, 2005, J BURN CARE REHABIL, V26, P151, DOI 10.1097/01.BCR.0000155540.31879.FB
   Chang Y, 2014, J KOREAN MED SCI, V29, P438, DOI 10.3346/jkms.2014.29.3.438
   Chaubey S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0903-4
   Chen JL, 2018, STROKE, V49, P1083, DOI 10.1161/STROKEAHA.117.018292
   Chen JL, 2017, TRANSL STROKE RES, V8, P374, DOI 10.1007/s12975-017-0520-z
   Christopherson GT, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt81
   Cibelli J, 2013, CELL STEM CELL, V12, P271, DOI 10.1016/j.stem.2013.01.004
   Cofano F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112698
   Coleman CN, 2009, ANN EMERG MED, V53, P213, DOI 10.1016/j.annemergmed.2007.12.021
   Correa Bruna Lima, 2020, Cardiovasc Res, DOI 10.1093/cvr/cvaa028
   Cossu G, 2018, LANCET, V391, P883, DOI 10.1016/S0140-6736(17)31366-1
   Cox CS, 2017, STEM CELLS, V35, P1065, DOI 10.1002/stem.2538
   Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c
   Cruz FF, 2016, EXPERT OPIN BIOL TH, V16, P1353, DOI 10.1080/14712598.2016.1218845
   Cruz FF, 2015, STEM CELL TRANSL MED, V4, P1302, DOI 10.5966/sctm.2014-0280
   Curley GF, 2013, ANESTHESIOLOGY, V118, P924, DOI 10.1097/ALN.0b013e318287ba08
   Cyranoski D., 2017, NATURE, V10, P1038
   Das S, 2015, CARDIOVASC PATHOL, V24, P199, DOI 10.1016/j.carpath.2015.04.007
   De Meyer J, 2018, INT J CRITICAL CARE, V4
   Ortuno-Costela MD, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246305
   Diamandis T, 2015, STROKE, V46, P588, DOI 10.1161/STROKEAHA.114.007105
   DiCarlo AL, 2017, RADIAT RES, V188, pE54, DOI 10.1667/RR14810.1
   Doeppner TR, 2015, STEM CELL TRANSL MED, V4, P1131, DOI 10.5966/sctm.2015-0078
   Dogan A, 2017, CURR PHARM DESIGN, V23, P903, DOI 10.2174/1381612823666161111141954
   Dogan A, 2016, STEM CELL REV REP, V12, P202, DOI 10.1007/s12015-015-9641-5
   Eding JEC, 2015, CIRC RES, V116, P80, DOI 10.1161/CIRCRESAHA.116.304872
   Eirin A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174303
   Eirin A, 2016, SCI REP-UK, V6, DOI 10.1038/srep36120
   Eirin A, 2014, GENE, V551, P55, DOI 10.1016/j.gene.2014.08.041
   El Harane N, 2018, EUR HEART J, V39, P1835, DOI 10.1093/eurheartj/ehy012
   Ela S, 2013, DRUG DISCOVERY, V12, P347
   Emmerich Christoph H, 2020, Handb Exp Pharmacol, V257, P177, DOI 10.1007/164_2019_284
   Escudier B, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-10
   Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253
   Frantz S, 2012, NAT BIOTECHNOL, V30, P12, DOI 10.1038/nbt0112-12
   Gaberman E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066549
   Galstyan G, 2018, INT J BLOOD RES DISO, V5
   Gardiner C, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.32945
   Glicksman MA, 2018, CLIN THER, V40, P1060, DOI 10.1016/j.clinthera.2018.06.004
   Glotzbach JP, 2011, CURR PROB SURG, V48, P148, DOI 10.1067/j.cpsurg.2010.11.002
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Gourmelon P, 2010, HEALTH PHYS, V98, P825, DOI 10.1097/HP.0b013e3181ce64d4
   Hao ZC, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12359
   Hare JM, 2017, J AM COLL CARDIOL, V69, P526, DOI 10.1016/j.jacc.2016.11.009
   Hare JM, 2012, JAMA-J AM MED ASSOC, V308, P2369, DOI 10.1001/jama.2012.25321
   Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158
   Hayes M, 2012, CRIT CARE, V16, DOI 10.1186/cc10570
   Henderson SJ, 2018, J THROMB HAEMOST, V16, P1932, DOI 10.1111/jth.14215
   Heslet L, 2012, INT J GEN MED, V5, P105, DOI 10.2147/IJGM.S22177
   Hess DC, 2017, LANCET NEUROL, V16, P360, DOI 10.1016/S1474-4422(17)30046-7
   Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552
   Hu CX, 2018, J CELL MOL MED, V22, P1428, DOI 10.1111/jcmm.13492
   Hu KX, 2010, BRIT J RADIOL, V83, P52, DOI 10.1259/bjr/61042310
   Hu P, 2019, BURNS TRAUMA, V7, DOI 10.1186/s41038-019-0178-8
   Huang S, 2015, CELL TRANSPLANT, V24, P2643, DOI 10.3727/096368915X687219
   Jansen SJ, 2014, EUR J CLIN INVEST, V44, P892, DOI 10.1111/eci.12299
   Joo HS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030727
   Jung JH, 2017, CIRC RES, V120, P407, DOI 10.1161/CIRCRESAHA.116.309307
   Kabat M, 2020, STEM CELL TRANSL MED, V9, P17, DOI 10.1002/sctm.19-0202
   Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005-0342
   Kervadec A, 2016, J HEART LUNG TRANSPL, V35, P795, DOI 10.1016/j.healun.2016.01.013
   Kim HS, 2012, J PROTEOME RES, V11, P839, DOI 10.1021/pr200682z
   Kink JA, 2019, BIOL BLOOD MARROW TR, V25, P2124, DOI 10.1016/j.bbmt.2019.07.026
   Konoshenko MY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8545347
   Kordelas L, 2014, LEUKEMIA, V28, P970, DOI 10.1038/leu.2014.41
   Kuravi SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183640
   Kusuma GD, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01199
   Lackland DT, 2014, STROKE, V45, P315, DOI 10.1161/01.str.0000437068.30550.cf
   Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003
   Lalegul-Ulker O, 2019, ARTIF CELL NANOMED B, V47, P10, DOI 10.1080/21691401.2018.1540426
   Lalu M. M., 2019, TRANSLATIONAL STROKE, V11, P345
   Lange C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014486
   Laroye C, 2017, STEM CELLS, V35, P2331, DOI 10.1002/stem.2695
   Lee JH, 2019, TRANSFUSION, V59, P876, DOI 10.1111/trf.14838
   Lees JS, 2012, INT J STROKE, V7, P582, DOI 10.1111/j.1747-4949.2012.00797.x
   Lener T, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.30087
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li X, 2014, AM J RESP CELL MOL, V51, P455, DOI 10.1165/rcmb.2013-0529OC
   Liang B, 2020, MEDICINE, V99
   Liao GP, 2015, PEDIATR CRIT CARE ME, V16, P245, DOI 10.1097/PCC.0000000000000324
   Liu AR, 2020, EXPERT OPIN BIOL TH, V20, P125, DOI 10.1080/14712598.2020.1689954
   Lopes-Pacheco M, 2020, CELL BIOL TOXICOL, V36, P83, DOI 10.1007/s10565-019-09493-5
   Lowthian JA, 2012, MED J AUSTRALIA, V196, P128, DOI 10.5694/mja11.10955
   Lu HY, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/7537589
   Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482
   Mahla RS., 2016, INT J CELL BIOL, V2016
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Marks PW, 2017, NEW ENGL J MED, V376, P1007, DOI 10.1056/NEJMp1613723
   Mason C, 2008, REGEN MED, V3, P1, DOI 10.2217/17460751.3.1.1
   Mathur A, 2017, EUR HEART J, V38, P2930, DOI 10.1093/eurheartj/ehw640
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Melling GE, 2019, EUR J PHARM BIOPHARM, V144, P50, DOI 10.1016/j.ejpb.2019.08.009
   Menasche P, 2018, NAT REV CARDIOL, V15, P659, DOI 10.1038/s41569-018-0013-0
   Menasche P, 2018, J AM COLL CARDIOL, V71, P429, DOI 10.1016/j.jacc.2017.11.047
   Meng WR, 2020, DRUG DELIV, V27, P585, DOI 10.1080/10717544.2020.1748758
   Meng Y, 2018, DIABETOL METAB SYNDR, P10
   Mettler FA, 2007, HEALTH PHYS, V93, P462, DOI 10.1097/01.HP.0000278843.27969.74
   Moghaddam AS, 2019, ATHEROSCLEROSIS, V285, P1, DOI 10.1016/j.atherosclerosis.2019.03.016
   Monsel A, 2015, AM J RESP CRIT CARE, V192, P324, DOI 10.1164/rccm.201410-1765OC
   Moon GJ, 2019, TRANSL STROKE RES, V10, P509, DOI 10.1007/s12975-018-0668-1
   Morse MA, 2005, J TRANSL MED, V3
   Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446
   Murry CE, 2020, SCIENCE, V367, P854, DOI 10.1126/science.aaz3650
   Nassar Wael, 2016, Biomater Res, V20, P21, DOI 10.1186/s40824-016-0068-0
   Nowbar AN, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2688
   Ojeh N, 2015, INT J MOL SCI, V16, P25476, DOI 10.3390/ijms161025476
   Oliveri RS, 2014, NEUROBIOL DIS, V62, P338, DOI 10.1016/j.nbd.2013.10.014
   Osborne N, 2018, EMBO REP, V19, DOI 10.15252/embr.201846069
   Ozturk S, 2018, CURR PHARM DESIGN, V24, P3101, DOI 10.2174/1381612824666180903123817
   Parmaksiz M, 2017, J TISSUE ENG REGEN M, V11, P1754, DOI 10.1002/term.2071
   Pati S, 2015, SHOCK, V44, P505, DOI 10.1097/SHK.0000000000000482
   Pelizzo G, 2018, REGEN MED, V13, P385, DOI 10.2217/rme-2018-0001
   Peng WJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0034-0
   Petrenko Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61167-z
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Raghavendran K, 2008, CURR MED CHEM, V15, P1911, DOI 10.2174/092986708785132942
   Rastogi S, 2018, MOL BIOL CELL, V29, P2228, DOI 10.1091/mbc.E18-02-0130
   Rezaie J, 2019, J CELL PHYSIOL, V234, P21732, DOI 10.1002/jcp.28894
   Rios C, 2017, RADIAT RES, V188, P242, DOI 10.1667/RR14835.1
   Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Romagnuolo R, 2019, STEM CELL REP, V12, P967, DOI 10.1016/j.stemcr.2019.04.005
   Ross JS, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000144
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Saha Bitan, 2018, Med J Armed Forces India, V74, P313, DOI 10.1016/j.mjafi.2018.03.005
   Schneider C. M., 2019, PRINCIPLES REGENERAT, P369
   Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344
   Shah TG, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0242-9
   Shao LB, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/4150705
   Shetty AK, 2020, AGING DIS, V11, P462, DOI 10.14336/AD.2020.0301
   Shimokawa H, 2015, EUR J HEART FAIL, V17, P884, DOI 10.1002/ejhf.319
   Shpichka A, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1203-3
   Silva PL, 2020, EXPERT OPIN INV DRUG, V29, P49, DOI 10.1080/13543784.2020.1699531
   Silvestre JS, 2015, EBIOMEDICINE, V2, P1871, DOI 10.1016/j.ebiom.2015.11.010
   Simonson OE, 2015, STEM CELL TRANSL MED, V4, P1199, DOI 10.5966/sctm.2015-0021
   Singh VK, 2012, RADIAT RES, V177, P781, DOI 10.1667/RR2894.1
   Stonesifer C, 2017, PROG NEUROBIOL, V158, P94, DOI 10.1016/j.pneurobio.2017.07.004
   Sun XY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01730-7
   Szatmari T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00347
   Sze SK, 2007, MOL CELL PROTEOMICS, V6, P1680, DOI 10.1074/mcp.M600393-MCP200
   Tanriverdi AK, 2020, EUR J TRAUMA EMERG S, V46, P53, DOI 10.1007/s00068-019-01101-9
   Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Thurairajah K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030577
   Tian CL, 2013, EXP CLIN TRANSPLANT, V11, P176, DOI 10.6002/ect.2012.0053
   Tian T, 2018, BIOMATERIALS, V150, P137, DOI 10.1016/j.biomaterials.2017.10.012
   Tisherman SA, 2018, CRIT CARE MED, V46, P1991, DOI 10.1097/CCM.0000000000003407
   Tisherman SA, 2015, ANN SURG, V261, P586, DOI 10.1097/SLA.0000000000000837
   Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007
   Ude CC, 2018, MILITARY MED RES, V5, DOI 10.1186/s40779-018-0154-9
   van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245
   Van Roosbroeck K, 2017, ADV CANCER RES, V135, P119, DOI 10.1016/bs.acr.2017.06.002
   Vivo C, 2016, MED INTENSIVA, V40, P49, DOI 10.1016/j.medin.2015.11.010
   Weber B, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2052-7
   Weisdorf D, 2007, BIOL BLOOD MARROW TR, V13, P103, DOI 10.1016/j.bbmt.2006.10.002
   Weston NM, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0812-z
   Wiklander OPB, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav8521
   Wiklander OPB, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26316
   Willing AE, 2020, CNS NEUROSCI THER, V26, P616, DOI 10.1111/cns.13300
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Witwer KW, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1648167
   Wu JJ, 2017, BBA-MOL BASIS DIS, V1863, P292, DOI 10.1016/j.bbadis.2016.10.024
   Wu PP, 2018, CYTOTHERAPY, V20, P291, DOI 10.1016/j.jcyt.2017.11.002
   Yang JL, 2017, MOL THER-NUCL ACIDS, V7, P278, DOI 10.1016/j.omtn.2017.04.010
   Yang PC, 2018, CIRC RES, V122, P661, DOI 10.1161/CIRCRESAHA.118.312657
   Yang X, 2012, ADV HEMATOLOGY, V2012
   Yates AG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02723
   Zhang LL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2182-0
   Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003
   Zhang ZG, 2019, NAT REV NEUROL, V15, P193, DOI 10.1038/s41582-018-0126-4
   Zhang ZG, 2016, J CLIN INVEST, V126, P1190, DOI 10.1172/JCI81133
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zhu Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0510-9
   Zipkin M, 2019, NAT BIOTECHNOL, V37, P1395, DOI 10.1038/s41587-019-0326-5
NR 192
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
DI 10.1007/s12015-020-10029-2
EA AUG 2020
PG 21
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA NE1FI
UT WOS:000562342300001
PM 32839921
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Alves, VM
   Bobrowski, T
   Melo, CC
   Korn, D
   Auerbach, S
   Schmitt, C
   Muratov, EN
   Tropsha, A
AF Alves, Vinicius M.
   Bobrowski, Tesia
   Melo-Filho, Cleber C.
   Korn, Daniel
   Auerbach, Scott
   Schmitt, Charles
   Muratov, Eugene N.
   Tropsha, Alexander
TI QSAR Modeling of SARS-CoV M(pro)Inhibitors Identifies Sufugolix,
   Cenicriviroc, Proglumetacin, and Other Drugs as Candidates for
   Repurposing against SARS-CoV-2
SO MOLECULAR INFORMATICS
LA English
DT Article; Early Access
DE SARS-CoV-2; drug repurposing; cheminformatics; virtual screening;
   SARS-CoV-2 M-pro
ID PROTEASE INHIBITOR; CORONAVIRUS; VIRUS; LOPINAVIR/RITONAVIR;
   CHEMINFORMATICS; NITROAROMATICS; POLYPROTEINS; REPLICATION; PROTEINASE;
   TOXICITY
AB The main protease (M-pro) of the SARS-CoV-2 has been proposed as one of the major drug targets for COVID-19. We have identified the experimental data on the inhibitory activity of compounds tested against the closely related (96 % sequence identity, 100 % active site conservation) M(pro)of SARS-CoV. We developed QSAR models of these inhibitors and employed these models for virtual screening of all drugs in the DrugBank database. Similarity searching and molecular docking were explored in parallel, but docking failed to correctly discriminate between experimentally active and inactive compounds, so it was not relied upon for prospective virtual screening. Forty-two compounds were identified by our models as consensus computational hits. Subsequent to our computational studies, NCATS reported the results of experimental screening of their drug collection in SARS-CoV-2 cytopathic effect assay (https://opendata.ncats.nih.gov/covid19/). Coincidentally, NCATS tested 11 of our 42 hits, and three of them, cenicriviroc (AC(50)of 8.9 mu M), proglumetacin (tested twice independently, with AC(50)of 8.9 mu M and 12.5 mu M), and sufugolix (AC(50)12.6 mu M), were shown to be active. These observations support the value of our modeling approaches and models for guiding the experimental investigations of putative anti-COVID-19 drug candidates. All data and models used in this study are publicly available via Supplementary Materials, GitHub (https://github.com/alvesvm/sars-cov-mpro), and Chembench web portal (https://chembench.mml.unc.edu/).
C1 [Alves, Vinicius M.; Schmitt, Charles] NIEHS, Off Data Sci, Natl Toxicol Program, Morrisville, NC 27560 USA.
   [Bobrowski, Tesia; Melo-Filho, Cleber C.; Korn, Daniel; Muratov, Eugene N.; Tropsha, Alexander] Univ N Carolina, UNC Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Beard Hall, Chapel Hill, NC 27599 USA.
   [Korn, Daniel] Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27599 USA.
   [Auerbach, Scott] NIEHS, Toxinformat Grp, Natl Toxicol Program, Morrisville, NC 27560 USA.
   [Muratov, Eugene N.] Univ Fed Paraiba, Dept Pharmaceut Sci, Joao Pessoa, Paraiba, Brazil.
RP Muratov, EN; Tropsha, A (corresponding author), Univ N Carolina, UNC Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Beard Hall, Chapel Hill, NC 27599 USA.; Muratov, EN (corresponding author), Univ Fed Paraiba, Dept Pharmaceut Sci, Joao Pessoa, Paraiba, Brazil.
EM murik@email.unc.edu; alex_tropsha@unc.edu
RI Muratov, Eugene/C-4454-2014; Camilo Melo-Filho, Cleber/V-1119-2018
OI Muratov, Eugene/0000-0003-4616-7036; Camilo Melo-Filho,
   Cleber/0000-0003-0056-6971
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1R01 GM114015, 1U01CA207160]
FX This study was inspired by "Calling all coronavirus researchers" Nature
   editorial.[27]. It was supported in part by NIH grants 1R01 GM114015 and
   1U01CA207160.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Artemenko AG, 2011, SAR QSAR ENVIRON RES, V22, P575, DOI 10.1080/1062936X.2011.569950
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Beasley D., 2020, COMP OUTBREAKS NEW V
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bologa C, 2005, J COMPUT AID MOL DES, V19, P625, DOI 10.1007/s10822-005-9020-4
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Capuzzi SJ, 2017, J CHEM INF MODEL, V57, P105, DOI 10.1021/acs.jcim.6b00462
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   ChEMBL, TARG REP CARD CHEMBL
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Deng X, 2014, J VIROL, V88, P11886, DOI 10.1128/JVI.01528-14
   Donnelly CA, 2019, EMERG INFECT DIS, V25, P1758, DOI 10.3201/eid2509.190143
   Ekins S, 2020, DRUG DISCOV TODAY, V25, P928, DOI 10.1016/j.drudis.2020.03.019
   Fang SG, 2008, VIROLOGY, V379, P175, DOI 10.1016/j.virol.2008.06.038
   FDA-Food and Drug Administration, 2020, REMD EUA LETT AUTH
   FIGUERAS J, 1993, J CHEM INF COMP SCI, V33, P717, DOI 10.1021/ci00015a009
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1
   Golbraikh A, 2014, J CHEM INF MODEL, V54, P1, DOI 10.1021/ci400572x
   Heusipp G, 1997, J GEN VIROL, V78, P2789, DOI 10.1099/0022-1317-78-11-2789
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kempf DJ, 2001, J VIROL, V75, P7462, DOI 10.1128/JVI.75.16.7462-7469.2001
   Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P747, DOI 10.1007/s10822-008-9211-x
   Kuz'min VE, 2009, QSAR COMB SCI, V28, P664, DOI 10.1002/qsar.200860117
   Lagunin AA, 2019, J CHEM INF MODEL, V59, P713, DOI 10.1021/acs.jcim.8b00617
   Lau H, 2020, J MICROBIOL IMMUNOL, V53, P454, DOI 10.1016/j.jmii.2020.03.013
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Mallapaty S, 2020, NATURE, V582, P467, DOI 10.1038/d41586-020-01738-2
   Muratov EN, 2020, CHEM SOC REV, V49, P3525, DOI 10.1039/d0cs00098a
   Muratov EN, 2010, FUTURE MED CHEM, V2, P1205, DOI 10.4155/FMC.10.194
   NCATS, NCGC CURVEFIT
   NCATS, 2020, SARS COV 2 CYT EFF C
   NCBI, 2020, SARS COV 2 SEV AC RE
   NIH, NIH CLIN TRIAL SHOWS
   RDKit, 2020, MORG FING
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   Svetnik V, 2005, J CHEM INF MODEL, V45, P786, DOI 10.1021/ci0500379
   Todeschini R, 2009, HDB MOL DESCRIPTORS
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang XS, 2008, J CHEM INF MODEL, V48, P997, DOI 10.1021/ci700404c
   WHO. Statement on the second meeting of the International Health Regulations, 2005, 2 M INT HLTH REG 200
   World Health Organization, NAM COR DIS COVID 19
   Zakharov AV, 2019, J CHEM INF MODEL, V59, P4613, DOI 10.1021/acs.jcim.9b00526
   Zhu H, 2008, J CHEM INF MODEL, V48, P766, DOI 10.1021/ci700443v
   Ziebuhr J, 1999, J VIROL, V73, P177, DOI 10.1128/JVI.73.1.177-185.1999
NR 58
TC 1
Z9 1
U1 2
U2 2
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1868-1743
EI 1868-1751
J9 MOL INFORM
JI Mol. Inf.
DI 10.1002/minf.202000113
EA AUG 2020
PG 11
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications;
   Mathematical & Computational Biology
SC Pharmacology & Pharmacy; Computer Science; Mathematical & Computational
   Biology
GA ND4LF
UT WOS:000561872500001
OA Bronze
DA 2021-01-01
ER

PT J
AU Pesavento, R
   Ceccato, D
   Pasquetto, G
   Monticelli, J
   Leone, L
   Frigo, A
   Gorgi, D
   Postal, A
   Marchese, GM
   Cipriani, A
   Saller, A
   Sarais, C
   Criveller, P
   Gemelli, M
   Capone, F
   Fioretto, P
   Pagano, C
   Rossato, M
   Avogaro, A
   Simioni, P
   Prandoni, P
   Vettor, R
AF Pesavento, Raffaele
   Ceccato, Davide
   Pasquetto, Giampaolo
   Monticelli, Jacopo
   Leone, Lucia
   Frigo, Annachiara
   Gorgi, Davide
   Postal, Anna
   Marchese, Giuseppe Maria
   Cipriani, Alberto
   Saller, Alois
   Sarais, Cristiano
   Criveller, Pietro
   Gemelli, Marco
   Capone, Federico
   Fioretto, Paola
   Pagano, Claudio
   Rossato, Marco
   Avogaro, Angelo
   Simioni, Paolo
   Prandoni, Paolo
   Vettor, Roberto
TI The hazard of (sub)therapeutic doses of anticoagulants in non-critically
   ill patients with Covid-19: The Padua province experience
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE anticoagulants; bleeding; coronavirus 2019; COVID-19; venous
   thromboembolism
ID ANTITHROMBOTIC THERAPY; DISEASE; VTE
AB Background Coronavirus Disease 2019 (COVID-19) is responsible for a worldwide pandemic, with a high rate of morbidity and mortality. The increasing evidence of an associated relevant prothrombotic coagulopathy has resulted in an increasing use of antithrombotic doses higher than usual in COVID-19 patients. Information on the benefit/risk ratio of this approach is still lacking. Objective To assess the incidence of relevant bleeding complications in association with the antithrombotic strategy and its relationship with the amount of drug. Methods Consecutive COVID-19 patients admitted between February and April 2020 were included in a retrospective analysis. Major bleedings (MB) and clinically relevant non-major bleeding (CRNMB) were obtained from patient medical records and were adjudicated by an independent committee. Results Of the 324 patients who were recruited, 240 had been treated with prophylactic doses and 84 with higher doses of anticoagulants. The rate of the composite endpoint of MB or CRNMB was 6.9 per 100-person/months in patients who had been given prophylactic doses, and 26.4 per 100-person/months in those who had been prescribed higher doses (hazard ratio, 3.89; 95% confidence interval, 1.90-7.97). The corresponding rates for overall mortality were 12.2 and 20.1 per 100-person/months, respectively. Conclusions The rate of relevant bleeding events was high in patients treated with (sub)therapeutic doses of anticoagulants. In the latter group, overall mortality did not differ from that of patients treated with standard prophylactic doses and was even higher. Our result does not support a strategy of giving (sub)therapeutic doses of anticoagulants in non-critically ill patients with COVID-19.
C1 [Pesavento, Raffaele; Ceccato, Davide; Gorgi, Davide; Postal, Anna; Saller, Alois; Capone, Federico; Fioretto, Paola; Pagano, Claudio; Rossato, Marco; Avogaro, Angelo; Simioni, Paolo; Vettor, Roberto] Univ Padua, Dept Med, Padua, Italy.
   [Pasquetto, Giampaolo; Marchese, Giuseppe Maria] Osped Riuniti Padova Sud, Div Cardiol, Monselice, Italy.
   [Monticelli, Jacopo] Osped Riuniti Padova Sud, Hosp Direct, Monselice, Italy.
   [Leone, Lucia; Criveller, Pietro; Gemelli, Marco] Osped Riuniti Padova Sud, Div Gen Med, Monselice, Italy.
   [Frigo, Annachiara; Cipriani, Alberto; Sarais, Cristiano] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Padua, Italy.
   [Prandoni, Paolo] Arianna Fdn Anticoagulat, Bologna, Italy.
RP Pesavento, R (corresponding author), Azienda Osped Univ Padova, Clin Med 3, Padua, Italy.
EM raffaele@pesavento.eu
RI Cipriani, Alberto/B-6495-2018; Pesavento, Raffaele/J-1643-2014
OI Cipriani, Alberto/0000-0001-7842-6202; Gemelli,
   Marco/0000-0003-2902-7947; criveller, pietro/0000-0002-9776-0553;
   Pesavento, Raffaele/0000-0001-9578-3455
CR Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Casini Alessandro, 2020, Swiss Med Wkly, V150, pw20247, DOI 10.4414/smw.2020.20247
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kaatz S, 2015, J THROMB HAEMOST, V13, P2119, DOI 10.1111/jth.13140
   Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296
   Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026
   Khan IH, 2020, J VASC SURG, V72, P799, DOI 10.1016/j.jvs.2020.05.015
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2020, CLIN MAN SEV AC RESP
   Yang X, 2020, LANCET RESP MED, V8, pE26
   Yin SJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1745281
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 33
TC 7
Z9 7
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD OCT
PY 2020
VL 18
IS 10
BP 2629
EP 2635
DI 10.1111/jth.15022
EA AUG 2020
PG 7
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA NU9GL
UT WOS:000561770800001
PM 32692874
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Patell, R
   Bogue, T
   Bindal, P
   Koshy, A
   Merrill, M
   Aird, WC
   Bauer, KA
   Zwicker, JI
AF Patell, Rushad
   Bogue, Thomas
   Bindal, Poorva
   Koshy, Anita
   Merrill, Mwanasha
   Aird, William C.
   Bauer, Kenneth A.
   Zwicker, Jeffrey I.
TI Incidence of thrombosis and hemorrhage in hospitalized cancer patients
   with COVID-19
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE anticoagulation; cancer; COVID-19; hemorrhage; venous thromboembolism
ID DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; MEDICAL PATIENTS;
   RISK-FACTORS; COMPLICATIONS; PNEUMONIA; DISEASE; RATES
AB Background Coronavirus disease-2019 (COVID-19) is a recognized prothrombotic state. Patients hospitalized with active cancer are predisposed to thrombosis but whether active cancer further amplifies thrombotic risk with COVID-19 is not known. Objectives To evaluate cumulative incidences of thrombotic and hemorrhagic events in hospitalized COVID-19 patients with and without active cancer at 28 days. Methods A retrospective cohort analysis of consecutive adults hospitalized with COVID-19 was performed. Active cancer required cancer-directed therapy within previous 6 months. The cumulative incidences of thrombosis or hemorrhage were estimated considering death as a competing risk. Results Patients without cancer (n = 353) and active cancer (n = 45) were comparable in terms of age, sex, antibiotics administered, length of hospitalization, and critical care. The most common malignancies were lymphoid (17.8%), gastrointestinal (15.6%), lung (13.3%), and genitourinary (13.3%). At day 28, the cumulative incidence of thrombotic events was 18.2% (95% confidence interval [CI], 10.2%-27.9%) in the non-cancer cohort and 14.2% (95% CI, 4.7%-28.7%) in the cancer cohort. The cumulative incidence of major and fatal bleeding at day 28 was 20.8% (95% CI, 12.1%-31.0%) in the non-cancer group and 19.5% (95% CI, 5.5%-39.8%) in the cancer cohort. Three patients experienced fatal bleeds, all of whom were in the non-cancer cohort. Survival was significantly shorter in the group with active cancer (P = .038). Conclusions We observed a similarly high incidence of thrombosis and bleeding among patients admitted with COVID-19 with or without active cancer.
C1 [Patell, Rushad; Bogue, Thomas; Bindal, Poorva; Koshy, Anita; Aird, William C.; Bauer, Kenneth A.; Zwicker, Jeffrey I.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Hematol, Boston, MA 02115 USA.
   [Merrill, Mwanasha] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA.
RP Zwicker, JI (corresponding author), Beth Israel Deaconess Med Ctr, Dept Hematol, 330 Brookline Ave, Boston, MA 02215 USA.
EM jzwicker@bidmc.harvard.edu
OI Zwicker, Jeffrey/0000-0001-5810-6893
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [U01HL143365]
FX National Heart, Lung, and Blood Institute, Grant/Award Number:
   U01HL143365
CR Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520
   Alikhan R, 2004, ARCH INTERN MED, V164, P963, DOI 10.1001/archinte.164.9.963
   Alikhan R, 2003, BLOOD COAGUL FIBRIN, V14, P341, DOI 10.1097/00001721-200306000-00004
   [Anonymous], 2020, MED JHUA
   Barbui T, 2013, BLOOD, V122, P2176, DOI 10.1182/blood-2013-03-460154
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Brenner B, 2018, AM J MED, V131, P1095, DOI 10.1016/j.amjmed.2018.04.037
   Campigotto F, 2012, J THROMB HAEMOST, V10, P1449, DOI 10.1111/j.1538-7836.2012.04766.x
   Cao W, 2020, CELL RES, V30, P367, DOI 10.1038/s41422-020-0327-4
   Caruso V, 2010, BLOOD, V115, P5322, DOI 10.1182/blood-2010-01-258624
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cohen AT, 2007, VASC MED, V12, P123, DOI 10.1177/1358863x07079017
   Cohoon KP, 2020, RES PRACT THROMB HAE, V4, DOI 10.1002/rth2.12358
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Decousus H, 2011, CHEST, V139, P69, DOI 10.1378/chest.09-3081
   Demelo-Rodriguez P, 2020, THROMB RES, V192, P23, DOI 10.1016/j.thromres.2020.05.018
   Falanga A, 2009, J CLIN ONCOL, V27, P4848, DOI 10.1200/JCO.2009.22.8197
   Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809
   Hutten BA, 2000, J CLIN ONCOL, V18, P3078, DOI 10.1200/JCO.2000.18.17.3078
   Kaatz S, 2015, J THROMB HAEMOST, V13, P2119, DOI 10.1111/jth.13140
   Khorana AA, 2006, J CLIN ONCOL, V24, P484, DOI 10.1200/JCO.2005.03.8877
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Nahum J, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10478
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Patell R, 2017, AM J HEMATOL, V92, P501, DOI 10.1002/ajh.24700
   Sidaway P, 2020, NAT REV CLIN ONCOL, DOI 10.1038/s41571-020-0366-2
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang F, 2020, J MED VIROL, V92, P2067, DOI 10.1002/jmv.25972
   Zhang L, 2020, CIRCULATION, V142, P114, DOI 10.1161/CIRCULATIONAHA.120.046702
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 37
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD SEP
PY 2020
VL 18
IS 9
BP 2349
EP 2357
DI 10.1111/jth.15018
EA AUG 2020
PG 9
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA NG4TN
UT WOS:000561753500001
PM 32692862
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Surmelioglu, N
   Yalcin, N
   Kuscu, F
   Candevir, A
   Inal, AS
   Komur, S
   Kurtaran, B
   Demirkan, K
   Tasova, Y
AF Surmelioglu, Nursel
   Yalcin, Nadir
   Kuscu, Ferit
   Candevir, Aslihan
   Inal, Ayse Seza
   Komur, Suheyla
   Kurtaran, Behice
   Demirkan, Kutay
   Tasova, Yesim
TI Physicians' knowledge of potential covid-19 drug-drug interactions: An
   online survey in turkey
SO POSTGRADUATE MEDICINE
LA English
DT Article; Early Access
DE COVID-19; drug-drug interactions; physicians; approach; awareness
ID PRESCRIBERS
AB Objectives Given the many medications used to treat novel coronavirus disease (COVID-19) and its comorbidities and complications, the risk of drug-drug interactions (DDIs) and resulting patient harm is concerning. This study aimed to shed light on physicians' knowledge of potential DDIs related to COVID-19 treatment, to determine the effect of an information brief about these DDIs on their correct response rates, and to identify factors associated with higher levels of knowledge about these DDIs. Methods The knowledge of physicians regarding the clinical significance and intervention of 7 common potential DDIs during COVID-19 treatment was evaluated via an online survey. Using a pretest-posttest design, the physicians completed a multiple-choice questionnaire first using their existing knowledge, then received an information brief about the DDIs and completed the same questionnaire again. Pretest and posttest scores were evaluated and factors affecting correct response rates were determined using correlation, regression, and post-hoc analyzes. Results A total of 244 physicians participated in the survey, 147 (60.2%) of whom were involved in the treatment of COVID-19 patients. After the information brief, there were significant increases in the number of correct responses for both clinical significance and interventions (p< 0.0001). In comparisons of pretest knowledge, physicians involved in the treatment of COVID-19 patients showed significantly higher correct response rate for interventions compared to physicians who had not treated COVID-19 patients (p= 0.003). Post-hoc analysis to compare pretest correct intervention responses among all medical specialties revealed significant differences between infectious diseases and family practice (mean difference: 1.059;p= 0.005) and between internal medicine and family practice (mean difference: 1.771;p< 0.0001). Conclusion Physicians involved in the treatment of COVID-19 patients had more knowledge regarding clinical significance and appropriate management of potential DDIs than those not involved. Therefore, it may be beneficial to organize trainings and issue guidelines about potential DDIs for physicians during the COVID-19 pandemic.
C1 [Surmelioglu, Nursel] Cukurova Univ, Dept Clin Pharm, Fac Pharm, Adana, Turkey.
   [Yalcin, Nadir; Demirkan, Kutay] Hacettepe Univ, Dept Clin Pharm, Fac Pharm, TR-06230 Ankara, Turkey.
   [Kuscu, Ferit; Candevir, Aslihan; Inal, Ayse Seza; Komur, Suheyla; Kurtaran, Behice; Tasova, Yesim] Cukurova Univ, Dept Infect Dis & Clin Microbiol, Fac Med, Adana, Turkey.
RP Yalcin, N (corresponding author), Hacettepe Univ, Dept Clin Pharm, Fac Pharm, TR-06230 Ankara, Turkey.
EM nadir.yalcin@hotmail.com
RI Yalcin, Nadir/AAJ-9513-2020; Candevir Ulu, Aslihan/A-8016-2015
OI Candevir Ulu, Aslihan/0000-0001-9340-516X; Demirkan,
   Kutay/0000-0002-6427-5826
CR Al-Quteimat OM, 2020, RES SOCIAL ADM PHARM
   Back D, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14358
   Bartiromo M, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13286
   Ko Y, 2008, DRUG SAFETY, V31, P525, DOI 10.2165/00002018-200831060-00007
   Ko Y, 2008, RES SOC ADMIN PHARM, V4, P355, DOI 10.1016/j.sapharm.2007.10.004
   Kretchy Irene A, 2021, Res Social Adm Pharm, V17, P2023, DOI 10.1016/j.sapharm.2020.04.007
   Li Huibo, 2021, Res Social Adm Pharm, V17, P1813, DOI 10.1016/j.sapharm.2020.04.003
   Liu S, 2020, INT J CLIN PHARM-NET, V42, P299, DOI 10.1007/s11096-020-01017-0
   Lverpool Drug Interactions Group, INT COVID 19 THER
   Malone DC, 2013, J MANAGE CARE PHARM, V19, P549, DOI 10.18553/jmcp.2013.19.7.549
   Nabovati E, 2017, INT J CLIN PHARM-NET, V39, P560, DOI 10.1007/s11096-017-0453-3
   Pirnejad H, 2019, INT J MED INFORM, V127, P18, DOI 10.1016/j.ijmedinf.2019.04.006
   RISMANBAF A, 2020, ARCH ACAD EMERG MED, V8
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sarayani Amir, 2021, Res Social Adm Pharm, V17, P483, DOI 10.1016/j.sapharm.2020.04.016
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Song Zaiwei, 2021, Res Social Adm Pharm, V17, P2027, DOI 10.1016/j.sapharm.2020.03.027
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 119 WHO
   Ying Wang, 2021, Res Social Adm Pharm, V17, P1978, DOI 10.1016/j.sapharm.2020.04.001
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 22
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0032-5481
EI 1941-9260
J9 POSTGRAD MED
JI Postgrad. Med.
DI 10.1080/00325481.2020.1807809
EA AUG 2020
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NE4XQ
UT WOS:000562603400001
PM 32780961
DA 2021-01-01
ER

PT J
AU Zellweger, RM
   Wartel, TA
   Marks, F
   Song, MK
   Kim, JH
AF Zellweger, Raphael M.
   Wartel, T. Anh
   Marks, Florian
   Song, Manki
   Kim, Jerome H.
TI Vaccination against SARS-CoV-2 and disease enhancement - knowns and
   unknowns
SO EXPERT REVIEW OF VACCINES
LA English
DT Article
DE Coronavirus; SARS-CoV-2; COVID-19; disease enhancement; vaccine safety
ID RESPIRATORY SYNDROME CORONAVIRUS; PARAINFLUENZA VIRUS-VACCINE; T-CELL
   RESPONSES; SARS-COV; FIELD-EVALUATION; ANIMAL-MODELS; DELTA INULIN;
   IMMUNIZATION; PROTECTION; CHALLENGE
AB Introduction The world is currently fighting a COVID-19 pandemic, perhaps the most disruptive infectious disease outbreak since the 1918 Spanish influenza. Governments have taken drastic measures to curb the spread of SARS-CoV-2, and the development of safe and efficacious vaccine candidates is being accelerated. The possibility of vaccine-mediated disease enhancement with coronavirus vaccines has been flagged as a potential safety concern, and, despite the urgent need, should be thoroughly assessed as vaccines against SARS-CoV-2 are being tested. Area covered We review the in vivo evidence suggesting a theoretical risk of disease enhancement after vaccination with SARS-CoV and MERS-CoV vaccine candidates. We also identify knowledge gaps that need to be filled to maximize the chance of developing a safe vaccine and minimize the risk of encountering disease enhancement in vaccinated individuals after exposure to SARS-CoV-2. Expert opinion We compile and propose avenues to investigate the risk of vaccine-mediated disease enhancement both during pre-clinical and early clinical development. While the pressing need for a vaccine against COVID-19 (and future epidemic coronaviruses) cannot be ignored, we advocate to keep safety at the center of the debate. Protecting individuals with effective and safe vaccines should be a priority, even during extraordinary times like the COVID-19 pandemic.
C1 [Zellweger, Raphael M.; Wartel, T. Anh; Marks, Florian; Kim, Jerome H.] Int Vaccine Inst, Epidemiol Publ Hlth Impact & Clin Dev Unit, Seoul, South Korea.
   [Song, Manki] Int Vaccine Inst, Sci Unit, Seoul, South Korea.
RP Zellweger, RM (corresponding author), Int Vaccine Inst, Seoul, South Korea.
EM raphael.zellweger@ivi.int
OI Kim, Jerome/0000-0003-0461-6438
CR Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Callaway Ewen, 2020, Nature, V579, P183, DOI 10.1038/d41586-020-00698-x
   CEPI/BC, 2020, CONS CONS ASS RISK D
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   CHIN J, 1969, AM J EPIDEMIOL, V89, P449, DOI 10.1093/oxfordjournals.aje.a120957
   Chiotos K, 2020, J PEDIAT INF DIS SOC, V9, P393, DOI 10.1093/jpids/piaa069
   Czub M, 2005, VACCINE, V23, P2273, DOI 10.1016/j.vaccine.2005.01.033
   Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Diamond MS, 2020, CELL HOST MICROBE, V27, P699, DOI 10.1016/j.chom.2020.04.021
   Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031
   FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Gretebeck LM, 2015, CURR OPIN VIROL, V13, P123, DOI 10.1016/j.coviro.2015.06.009
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   HALSTEAD SB, 1982, PROG ALLERGY, V31, P301
   Hashem AM, 2019, J INFECT DIS, V220, P1558, DOI 10.1093/infdis/jiz137
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0323-4
   Huisman W, 2009, VACCINE, V27, P505, DOI 10.1016/j.vaccine.2008.10.087
   ICMRA, 2020, GLOB REG WORKSH COVI
   Iwata-Yoshikawa N, 2014, J VIROL, V88, P8597, DOI 10.1128/JVI.00983-14
   JHU, 2020, COVID 19 GLOB CAS CT
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Lamirande EW, 2008, J VIROL, V82, P7721, DOI 10.1128/JVI.00304-08
   Larson HJ, 2020, HUM VACC IMMUNOTHER, V16, P2577, DOI 10.1080/21645515.2019.1628510
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   LSHTM, 2020, COVID 19 VACC DEV PI
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lv H, 2020, CELL REP, V107725:1-6
   Moorthy V, 2020, B WORLD HEALTH ORGAN, V98, P150, DOI 10.2471/BLT.20.251561
   Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462
   Organization WH, 2019, 10 THREATS GLOB HLTH
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Petrovsky N, 2015, VACCINE, V33, P5920, DOI 10.1016/j.vaccine.2015.09.030
   Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781
   Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Roberts A, 2010, VIRAL IMMUNOL, V23, P509, DOI 10.1089/vim.2010.0028
   Ruckwardt TJ, 2019, IMMUNITY, V51, P429, DOI 10.1016/j.immuni.2019.08.007
   See RH, 2008, J GEN VIROL, V89, P2136, DOI 10.1099/vir.0.2008/001891-0
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Sutton TC, 2015, VIROLOGY, V479, P247, DOI 10.1016/j.virol.2015.02.030
   Thomas SJ, 2019, HUM VACC IMMUNOTHER, V15, P2295, DOI 10.1080/21645515.2019.1658503
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Wang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8712
   WEIBEL RE, 1967, AM REV RESPIR DIS, V96, P724
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Word Health Organization (WHO), 2018, ANN REV DIS PRIOR RE
   World Health Organization, 2020, WHO R D BLUEPR NOV C
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Yang Y, 2020, J INTELL FUZZY SYST, V39, P2581, DOI [10.3233/JIFS-190156, 10.1017/S0021932020000164]
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
NR 67
TC 1
Z9 1
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-0584
EI 1744-8395
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD AUG 2
PY 2020
VL 19
IS 8
BP 691
EP 698
DI 10.1080/14760584.2020.1800463
EA AUG 2020
PG 8
WC Immunology
SC Immunology
GA NU1DQ
UT WOS:000562245100001
PM 32838605
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Liu, M
   Zhu, HQ
   Xiong, Q
   Zeng, ZL
   Xu, XL
   Ye, M
   Zeng, YL
   Hu, XD
   Zhu, Y
AF Liu, Min
   Zhu, Hongqiu
   Xiong, Qian
   Zeng, Zhulan
   Xu, Xinlei
   Ye, Min
   Zeng, Yanling
   Hu, Xiaodan
   Zhu, Ying
TI The efficacy and safety of fire needle therapy for COVID-19 Protocol for
   a systematic review and meta-analysis
SO MEDICINE
LA English
DT Article
DE coronavirus disease 2019; COVID-19; fire needle; protocol; systematic
AB Background: Coronavirus disease 2019 (COVID-19), a new type of coronavirus, first reported in Wuhan, China at the end of December 2019. As a result of the worldwide outbreak, the number of patients continues to increase. With multiple therapeutic interventions, more and more patients are recovering. Fire needle is used as an alternative therapy. At present, there are no relevant articles for systematic review and meta-analysis, so this study will evaluate the efficacy and safety of fire needle in the treatment of COVID-19 pneumonia. Methods: The following electronic bibliographic databases will be searched to identify relevant studies from December 2019 to December 2020: MEDLINE, PubMed, Embase, Cochrane library, Web of Science, China National Knowledge Infrastructure (CNKI), Chinese Technical Periodicals (VIP), Wan-fang data, Chinese Biological Medicine Database (CBM), and other databases. All included articles were randomized controlled trial without any language restrictions. Two reviewers will independently conduct cations retrieval, de-duplication, filtering, quality assessment, and data analysis by the Review Manager (V.5.3). Meta-analysis, subgroup analysis and/or descriptive analysis were performed on the included data. Discussion: This study will investigate the application of fire needle in the treatment or prevention of COVID-19, and provide a high-quality synthesis to evaluate whether fire needle is an effective and safe intervention for COVID-19. Systematic review registration: PROSPERO registration number: CRD 42020193703.
C1 [Liu, Min; Xiong, Qian; Zeng, Zhulan; Xu, Xinlei; Ye, Min; Zeng, Yanling; Hu, Xiaodan; Zhu, Ying] Chengdu Univ Tradit Chinese Med, Affiliated Hosp, Chengdu, Sichuan, Peoples R China.
   [Zhu, Hongqiu] Chengdu Univ Tradit Chinese Med, Chengdu Univ Tradit Chinese, Dept Gynecol, Reprod & Women Children Hosp,Sch Med & Life Sci, Chengdu, Sichuan, Peoples R China.
RP Zhu, HQ (corresponding author), Chengdu Univ Tradit Chinese Med, Chengdu Univ Tradit Chinese, Dept Gynecol, Reprod & Women Children Hosp,Sch Med & Life Sci, Chengdu, Sichuan, Peoples R China.
EM zhuhongqiu@cdutcm.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81873335]; General Project of Sichuan
   Science and Technology Department [2020YJ0376]; Chengdu University of
   Traditional Chinese Medicine science and Technology Development Fund
   Hospital special key project [2017-EL-13]
FX This work was supported by (The National Natural Science Foundation of
   China) grant number (No. 81873335), (General Project of Sichuan Science
   and Technology Department) grant number (No. 2020YJ0376), and (Chengdu
   University of Traditional Chinese Medicine science and Technology
   Development Fund Hospital special key project) grant number (No.
   2017-EL-13).
CR AN YT, 2020, CHIN ACUPUNCT MOXIBU, V40, P3571, DOI DOI 10.5846/STXB201906111236
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Bulut C, 2020, TURK J MED SCI, V50, P563, DOI 10.3906/sag-2004-172
   Cao Y, 2020, ELECTRON RES ARCH, V28, P27, DOI 10.3934/era.2020003
   Chinese Health Commission, 2020, CHIN MED, V15, P801
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li JZ, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.198043
   Li Y, 2019, CHIN ACUPUNCT MOXIB, V39, P296
   Lin Y, 2020, CHIN ACUPUNCT MOXIB, V40, P693
   Liu WH, 2020, WORLD J ACUPUNCT-MOX, V30, P1, DOI 10.1016/j.wjam.2020.03.005
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.i4086, 10.1136/bmj.g7647]
   Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008
   Shi X, 2020, CHIN ACUPUNCT MOXIB, V40, P462
   WHO, 2020, WHO DIR GEN REM MED
   Worldometer, 2020, COVID 19 COR PAND
NR 16
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG 21
PY 2020
VL 99
IS 34
DI 10.1097/MD.0000000000021873
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC9DS
UT WOS:000579455900096
PM 32846842
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, JX
   Hang, XF
   Wei, B
   Li, DC
   Chen, FY
   Liu, W
   Yang, CJ
   Miao, XH
   Han, L
AF Wang, Junxue
   Hang, Xiaofeng
   Wei, Bo
   Li, Dingchen
   Chen, Fangyan
   Liu, Wei
   Yang, Chaojie
   Miao, Xiaohui
   Han, Li
TI Persistent SARS-COV-2 RNA positivity in a patient for 92 days after
   disease onset A case report
SO MEDICINE
LA English
DT Article
DE antiviral therapy; COVID-19; quarantine; SARS-CoV-2 nucleic acids
AB Rationale: Recently, patients with COVID-19 who showed persistently positive SARS-CoV-2 nucleic acid test results despite resolved clinical symptoms have attracted a lot of attention. We report the case of a patient with mild symptoms of coronavirus disease (COVID-19), who achieved clinical recovery but showed persistently positive SARS-CoV-2 nucleic acid test results until Day 92 after disease onset. Patient concerns: The patient is a 50-year-old man with mild symptoms of coronavirus disease (COVID-19). Diagnoses: COVID-19 pneumonia. Interventions: The patient was quarantined for 105 days. Of these, inpatient quarantine lasted for 75 days. When the nucleic acid test results were negative for 3 consecutive days, the patient was discharged at Day 75 after disease onset. During this period, multiple samples were collected from the patient's body surface, the surrounding environment, and physical surfaces, but none of these tested positive for SARS-CoV-2. These samples included those from anal swabs, hands, inner surface of mask, cell phone, bed rails, floor around the bed, and toilet bowl surface. However, nucleic acid retest results on Day 80 and Day 92 after disease onset were positive for SARS-CoV-2 nucleic acids. Outcomes: The patient continued with quarantine and observation at home. After the test results on Days 101 and 105 after disease onset were negative, quarantine was terminated at last. Lessons: Per our knowledge, this is the longest known time that a patient has tested positive for SARS-CoV-2 nucleic acids. No symptoms were observed during follow-up. During hospitalization, the SARS-CoV-2 nucleic acid positivity was not observed in samples from the body surface and surrounding environment, and no verified transmission event occurred during the quarantine at home. After undergoing clinical recovery a minority of patients with COVID-19 have shown long-term positive results for the presence of the SARS-CoV-2 nucleic acid. This has provided new understanding and research directions for coronavirus infection. Long-term follow-up and quarantine measures have been employed for such patients. Further studies are required to analyze potential infectivity in such patients and determine whether more effective antiviral drugs or regimens to enable these patients to completely clear viral infection should be researched.
C1 [Wang, Junxue; Hang, Xiaofeng; Wei, Bo; Miao, Xiaohui] Second Mil Med Univ, Changzheng Hosp, Dept Infect Dis, Shanghai 200003, Peoples R China.
   [Li, Dingchen; Chen, Fangyan; Liu, Wei; Yang, Chaojie; Han, Li] China PLA Inst Dis Control & Prevent, Beijing 100071, Peoples R China.
RP Wang, JX (corresponding author), Second Mil Med Univ, Changzheng Hosp, Dept Infect Dis, Shanghai 200003, Peoples R China.; Han, L (corresponding author), China PLA Inst Dis Control & Prevent, Beijing 100071, Peoples R China.
EM docd1@sina.com; hanlicdc@163.com
FU Shanghai Committee of Science and Technology, ChinaShanghai Science &
   Technology Committee [17411972300]; General Program of the Huoshenshan
   Hospital, Wuhan, China [2020185]; Major Infectious Diseases Such as AIDS
   and Viral Hepatitis Prevention and Control Technology Major Projects
   [2018ZX10712, 2018ZX10732401]
FX This work is supported by the Shanghai Committee of Science and
   Technology, China (Grant No. 17411972300); General Program of the
   Huoshenshan Hospital, Wuhan, China (Grant No. 2020185); the Major
   Infectious Diseases Such as AIDS and Viral Hepatitis Prevention and
   Control Technology Major Projects (Grant No. 2018ZX10712;
   2018ZX10732401).
CR An J., 2020, CLIN CHARACTERISTICS
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   National Institutes of Health, NIH CLIN TRIAL SHOWS
   Tan L., 2020, SPECIAL CASE COVID 1, V2020
   Yao H, 2020, PATIENT DERIVED MUTA
   Yao XH, 2020, CELL RES, V30, P541, DOI 10.1038/s41422-020-0318-5
   Zhang Z, 2020, EARLY VIRAL CLEARANC
NR 9
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG 21
PY 2020
VL 99
IS 34
DI 10.1097/MD.0000000000021865
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC9DS
UT WOS:000579455900093
PM 32846839
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhou, H
   Huang, HB
   Xie, XL
   Gao, JD
   Wu, J
   Zhu, Y
   He, W
   Liu, JY
   Li, A
   Xu, Y
AF Zhou, Hua
   Huang, Huibin
   Xie, Xiaolei
   Gao, Jiandong
   Wu, Ji
   Zhu, Yan
   He, Wei
   Liu, Jingyuan
   Li, Ang
   Xu, Yuan
TI Development of early warning and rapid response system for patients with
   novel coronavirus pneumonia (COVID-19) A research protocol
SO MEDICINE
LA English
DT Article
DE cohort study; COVID-19; critically ill; deterioration; early warning;
   rapid response
ID INFLUENZA-A H1N1; RISK; READMISSION; FAILURE; DEATH
AB Background: Coronavirus disease 2019 (COVID-19) has caused serious damage to public health. COVID-19 has no vaccine or specific therapy; its mortality rate increases significantly once patients deteriorate. Furthermore, intensive monitoring of COVID-19 is limited by insufficient medical resources and increased risks of exposure to medical staff. We therefore aim to build an early warning and rapid response system (EWRRS) to address these problems. Method: The research is designed as a prospective cohort study, to verify a dynamic and interactive evaluation system; it includes patient self-reporting, active monitoring, early alarming and treatment recommendations. Adult patients diagnosed with COVID-19 will be recruited from Sept 2020 to Aug 2021 at a tertiary contagious hospital. Patients with life expectancy <48 hours, pregnant or lactating, in immunosuppression states or end-stage diseases will be excluded. The intervention is implementation of EWRRS to detect early signs of clinical deterioration of COVID-19 patients, to provide timely and efficient treatment suggestions by the system. EWRRS can determine the classification and interactive evaluation of patient information; the determination is based on the application of 3 different scenario modules, separately driven by patients, nurses, and physicians. The primary outcome is change in disease severity category after treatment. Secondary outcomes include the proportion of patients with different disease severity types; critical deterioration events; patients who had unplanned transfers to an intensive care unit (ICU) and required critical care interventions; intervals from warning to implementation of clinical interventions; hospital mortality; length of ICU and hospital stay; workload of medical staff and risks of exposure to COVID-19. Discussion: Our hypothesis is that EWRRS provides an example of an early identification, warning, and response system for COVID-19. In addition, EWRRS can potentially be extended to use as a grading metric for general critically ill patients in an ICU setting.
C1 [Zhou, Hua; Huang, Huibin; Zhu, Yan; Xu, Yuan] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Crit Care Med, Beijing 102218, Peoples R China.
   [Xie, Xiaolei] Tsinghua Univ, Ctr Healthcare Serv Res, Dept Ind Engn, Beijing, Peoples R China.
   [Gao, Jiandong] Tsinghua Univ, Inst Precis Med, Ctr Big Data & Clin Res, Beijing, Peoples R China.
   [Wu, Ji] Tsinghua Univ, Dept Elect Engn, Beijing, Peoples R China.
   [He, Wei] Capital Med Univ, Beijing Tongren Hosp, Dept Crit Care Med, Beijing, Peoples R China.
   [Liu, Jingyuan; Li, Ang] Capital Med Univ, Beijing Ditan Hosp, Dept Crit Care Med, Beijing 100011, Peoples R China.
RP Xu, Y (corresponding author), Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Crit Care Med, Beijing 102218, Peoples R China.; Li, A (corresponding author), Capital Med Univ, Beijing Ditan Hosp, Dept Crit Care Med, Beijing 100011, Peoples R China.
EM dtyyicu@163.com; xya01200@btch.edu.cn
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [71872093]
FX This research was funded by the National Natural Science Foundation of
   China (NSFC), under Grant 71872093.
CR Amarasingham R, 2010, MED CARE, V48, P981, DOI 10.1097/MLR.0b013e3181ef60d9
   Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Chan AW, 2015, REV PANAM SALUD PUBL, V38, P506
   Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010
   Fan Z, 2020, CLIN GASTROENTEROL H
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252
   Richardson S., 2020, JAMA
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang PJ, 2013, CHINESE MED J-PEKING, V126, P2222, DOI 10.3760/cma.j.issn.0366-6999.20130871
NR 13
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG 21
PY 2020
VL 99
IS 34
DI 10.1097/MD.0000000000021874
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC9DS
UT WOS:000579455900097
PM 32846843
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gates, LE
   Hamed, AA
AF Gates, Lyndsey Elaine
   Hamed, Ahmed Abdeen
TI The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the
   CovidX Network Algorithm for Drug Repurposing Recommendation
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE health; informatics; COVID-19 treatment; drug repurposing; network
   algorithm; ranking; drug; biomedical; antiviral; COVID-19
ID GENE ONTOLOGY
AB Background: Driven by the COVID-19 pandemic and the dire need to discover an antiviral drug, we explored the landscape of the SARS-CoV-2 biomedical publications to identify potential treatments.
   Objective: The aims of this study are to identify off-label drugs that may have benefits for the coronavirus disease pandemic, present a novel ranking algorithm called CovidX to recommend existing drugs for potential repurposing, and validate the literature-based outcome with drug knowledge available in clinical trials.
   Methods: To achieve such objectives, we applied natural language processing techniques to identify drugs and linked entities (eg, disease, gene, protein, chemical compounds). When such entities are linked, they form a map that can be further explored using network science tools. The CovidX algorithm was based upon a notion that we called "diversity." A diversity score for a given drug was calculated by measuring how "diverse" a drug is calculated using various biological entities (regardless of the cardinality of actual instances in each category). The algorithm validates the ranking and awards those drugs that are currently being investigated in open clinical trials. The rationale behind the open clinical trial is to provide a validating mechanism of the PubMed results. This ensures providing up to date evidence of the fast development of this disease.
   Results: From the analyzed biomedical literature, the algorithm identified 30 possible drug candidates for repurposing, ranked them accordingly, and validated the ranking outcomes against evidence from clinical trials. The top 10 candidates according to our algorithm are hydroxychloroquine, azithromycin, chloroquine, ritonavir, losartan, remdesivir, favipiravir, methylprednisolone, rapamycin, and tilorone dihydrochloride.
   Conclusions: The ranking shows both consistency and promise in identifying drugs that can be repurposed. We believe, however, the full treatment to be a multifaceted, adjuvant approach where multiple drugs may need to be taken at the same time.
C1 [Gates, Lyndsey Elaine] Norwich Univ, Sch Nursing, Northfield, VT 05663 USA.
   [Hamed, Ahmed Abdeen] Norwich Univ, Sch Cybersecur Data Sci & Comp, 158 Harmon Dr, Northfield, VT 05663 USA.
RP Hamed, AA (corresponding author), Norwich Univ, Sch Cybersecur Data Sci & Comp, 158 Harmon Dr, Northfield, VT 05663 USA.
EM ahamed@norwich.edu
RI Hamed, Ahmed Abdeen/AAF-4658-2020
OI Gates, Lyndsey/0000-0003-1402-2270
FU Norwich University Applied Research Institute
FX This research is partly supported by Norwich University Applied Research
   Institute. The authors wish to thank Osama Harraz, Yomna Gohar, Tamer
   Fandy, and Page Spiess for their input from a pharmaceutical and
   biochemistry point of view, and Laila Hamed for her inspiring ideas
   related to some figures in this work.
CR Andronis C, 2011, BRIEF BIOINFORM, V12, P357, DOI 10.1093/bib/bbr005
   [Anonymous], PLAQUENIL R HYDR SUL
   [Anonymous], NETWORKX NETW AN PYT
   [Anonymous], METH TABL
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Balakin KV, 2009, PHARM DATA MINING AP
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Blake JA, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI 10.1093/nar/gku1179
   Buonaguro FM, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02333-9
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Centers for Disease Control and Prevention, INT CLIN GUID MAN PA
   Chen H, 2005, MED INFORM KNOWLEDGE
   Cheng FX, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002503
   Christopher M, 1999, FDN STAT NATURAL LAN
   Cohut M., 2020, MED NEWS TODAY
   Deftereos SN, 2011, WIRES SYST BIOL MED, V3, P323, DOI 10.1002/wsbm.147
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Ekins S, 2020, PHARM RES-DORDR, V37, DOI 10.1007/s11095-020-02799-8
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Guastalegname M, 2020, CLIN INFECT DIS, V71, P888, DOI 10.1093/cid/ciaa321
   Hamed A, 2019, INT C ADV MACH LEARN, DOI [10.1007/978-3-030-14118-9_16], DOI 10.1007/978-3-030-14118-9_16]
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036
   He RY, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104361
   Ho JSY, 2020, CARDIOVASC DRUG THER, V34, P585, DOI 10.1007/s10557-020-06985-z
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Issa NT, 2013, CURR TOP MED CHEM, V13, P2328, DOI 10.2174/15680266113136660163
   Karatzas E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12849-8
   Katragkou A, 2016, EXPERT OPIN PHARMACO, V17, P1179, DOI 10.1080/14656566.2016.1186647
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Li J, 2016, BRIEF BIOINFORM, V17, P2, DOI 10.1093/bib/bbv020
   Loging W., 2011, DRUG DISCOV TODAY TH, V8, P109, DOI DOI 10.1016/J.DDSTR.2011.06.004
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Luo HM, 2018, BIOINFORMATICS, V34, P1904, DOI 10.1093/bioinformatics/bty013
   Mishra PM, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109790
   Muller HM, 2004, PLOS BIOL, V2, P1984, DOI 10.1371/journal.pbio.0020309
   Nabirotchkin S, 2020, CURR OPIN PHARMACOL, V51, P78, DOI 10.1016/j.coph.2019.12.004
   Nadeau D, 2007, LINGUIST INVESTIG, V30, P3
   Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189
   Pasquau Liano Juan, 2008, Enferm Infecc Microbiol Clin, V26 Suppl 10, P3
   Rotzinger DC, 2020, THROMB RES, V190, P58, DOI 10.1016/j.thromres.2020.04.011
   Sadeghi Seyedeh Shaghayegh, 2019, IEEE/ACM Trans Comput Biol Bioinform, VPP, DOI 10.1109/TCBB.2019.2933825
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Sanseau P, 2011, BRIEF BIOINFORM, V12, P301, DOI 10.1093/bib/bbr047
   Sargiacomo C, 2020, AGING-US, V12, P6511, DOI 10.18632/aging.103001
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Sree GNSH, 2019, BIOMED PHARMACOTHER, V110, P700, DOI 10.1016/j.biopha.2018.11.127
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Testa S, 2020, INTERN EMERG MED, V15, P751, DOI 10.1007/s11739-020-02331-1
   Tobaiqy M, 2020, INFECT PREVENTION PR, V100061, DOI [10.1016/j.infpip.2020.100061, DOI 10.1016/J.INFPIP.2020.100061]
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Worldometer, COVID 19 COR PAND
   Wu C, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-S5-S6
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu HY, 2020, CLIN PHARMACOL THER, V107, P886, DOI 10.1002/cpt.1745
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zheng S, 2019, TEXT MINING DRUG DIS, P231
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 62
TC 0
Z9 0
U1 0
U2 0
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD AUG 21
PY 2020
VL 22
IS 8
AR e21169
DI 10.2196/21169
PG 17
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA NW5MJ
UT WOS:000575055700005
PM 32735546
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Grohskopf, LA
   Alyanak, E
   Broder, KR
   Blanton, LH
   Fry, AM
   Jernigan, DB
   Atmar, RL
AF Grohskopf, Lisa A.
   Alyanak, Elif
   Broder, Karen R.
   Blanton, Lenee H.
   Fry, Alicia M.
   Jernigan, Daniel B.
   Atmar, Robert L.
TI Prevention and Control of Seasonal Influenza with Vaccines:
   Recommendations of the Advisory Committee on Immunization Practices -
   United States, 2020-21 Influenza Season
SO MMWR RECOMMENDATIONS AND REPORTS
LA English
DT Article
ID LABORATORY-CONFIRMED INFLUENZA; PNEUMOCOCCAL CONJUGATE VACCINE;
   PREGNANCY BIRTH-DEFECTS; ADULTS 65 YEARS; SPONTANEOUS-ABORTION;
   OLDER-ADULTS; ACELLULAR PERTUSSIS; PROSPECTIVE COHORT; PRETERM DELIVERY;
   RISK-FACTORS
AB This report updates the 2019-20 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2019;68[No. RR-31). Routine annual influenza vaccination is recommended for all persons aged >= 6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Most influenza vaccines available for the 2020-21 season will be quadrivalent, with the exception of MF59-adjuvanted IIV, which is expected to be available in both quadrivalent and trivalent formulations.
   Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 23, 2019; February 26, 2020; and June 24,2020. Primary updates to this report include the following two items. First, the composition of 2020-21 U.S. influenza vaccines includes updates to the influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B/Victoria lineage components. Second, recent licensures of two new influenza vaccines, Fluzone High-Dose Quadrivalent and Fluad Quadrivalent, are discussed. Both new vaccines are licensed for persons aged >= 65 years. Additional changes include updated discussion of contraindications and precautions to influenza vaccination and the accompanying Table, updated discussion concerning use of LAIV4 in the setting of influenza antiviral medication use, and updated recommendations concerning vaccination of persons with egg allergy who receive either cell culture-based IIV4 (ccIIV4) or RIV4.
   The 2020-21 influenza season will coincide with the continued or recurrent circulation of SARSCoV-2 (the novel coronavirus associated with coronavirus disease 2019 [COVID-19]). Influenza vaccination of persons aged >= 6 months to reduce prevalence of illness caused by influenza will reduce symptoms that might be confused with those of COVID-19. Prevention of and reduction in the severity of influenza illness and reduction of outpatient illnesses, hospitalizations, and intensive care unit admissions through influenza vaccination also could alleviate stress on the U.S. health care system. Guidance for vaccine planning during the pandemic is available at https://www.cdc.gov/vaccines/pandemic-guidance/index.html.
   This report focuses on recommendations for the use of vaccines for the prevention and control of seasonal influenza during the 2020-21 season in the United States. A brief summary of the recommendations and a link to the most recent Background Document containing additional information are available at https://www.cdc.gov/vaccines/hcp/acip-ircs/vacc-specific/flu.html. These recommendations apply to U.S.-licensed influenza vaccines used within Food and Drug Administration (FDA)-licensed indications. Updates and other information are available from CDC's influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check this site periodically for additional information.
C1 [Grohskopf, Lisa A.; Alyanak, Elif; Blanton, Lenee H.; Fry, Alicia M.; Jernigan, Daniel B.] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Alyanak, Elif] Battelle Mem Inst, Atlanta, GA USA.
   [Broder, Karen R.] CDC, Immunizat Safety Off, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
   [Atmar, Robert L.] Baylor Coll Med, Houston, TX 77030 USA.
RP Grohskopf, LA (corresponding author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
EM Lgrohskopf@cdc.gov
OI Jernigan, Daniel/0000-0002-0653-2433
CR Ahmed F., 2013, ACIP HDB DEV EV BAS
   Allison MA, 2006, J PEDIATR-US, V149, P755, DOI 10.1016/j.jpeds.2006.06.036
   [Anonymous], 2018, Obstet Gynecol, V131, pe214, DOI 10.1097/AOG.0000000000002662
   [Anonymous], 2018, Obstet Gynecol, V131, pe109, DOI 10.1097/AOG.0000000000002588
   [Anonymous], 2020, FLUMIST QUADRIVALENT
   [Anonymous], 2018, XOFLUZA BALOXAVIR MA
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, AFLURIA QUADRIVALENT
   [Anonymous], 2020, FLUARIX QUADRIVALENT
   [Anonymous], 2017, RAPIVAB
   [Anonymous], 2020, FLUAD QUADRIVALENT
   [Anonymous], 2020, FLUBLOK QUADRIVALENT
   [Anonymous], 2020, FLUZONE HIGH DOSE
   [Anonymous], 2017, HEPLISAV B PACKAGE I
   [Anonymous], 2020, FLUZONE HIGH DOSE QU
   [Anonymous], 2017, SHINGRIX PACKAGE INS
   [Anonymous], 2020, FLUZONE QUADRIVALENT
   [Anonymous], 2020, FLUCELVAX QUADRIVALE
   [Anonymous], 2020, FLUAD PACKAGE INSERT
   [Anonymous], 2020, FLULAVAL QUADRIVALEN
   BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052
   BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761
   Belongia EA, 2015, VACCINE, V33, P246, DOI 10.1016/j.vaccine.2014.06.052
   Bratton KN, 2015, CLIN INFECT DIS, V60, pE11, DOI 10.1093/cid/ciu915
   Castilla J, 2013, EUROSURVEILLANCE, V18, P17
   CDC, 2015, FLU SEAS
   CDC, 2011, MMWR RECOMM REP, V60
   CDC, FLU VACC EFF EFF MEA
   CDC, INFL ANT MED SUMM CL
   Chambers CD, 2016, VACCINE, V34, P4443, DOI 10.1016/j.vaccine.2016.06.054
   Chambers CD, 2013, VACCINE, V31, P5026, DOI 10.1016/j.vaccine.2013.08.097
   Chang LJ, 2019, VACCINE, V37, P5825, DOI 10.1016/j.vaccine.2019.08.016
   Coleman BL, 2018, INFLUENZA OTHER RESP, V12, P22, DOI 10.1111/irv.12504
   DiazGranados CA, 2015, VACCINE, V33, P4988, DOI 10.1016/j.vaccine.2015.07.006
   DiazGranados CA, 2015, VACCINE, V33, P4565, DOI 10.1016/j.vaccine.2015.07.003
   DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727
   Donahue JG, 2019, VACCINE, V37, P6673, DOI 10.1016/j.vaccine.2019.09.035
   Donahue JG, 2017, VACCINE, V35, P5314, DOI 10.1016/j.vaccine.2017.06.069
   Duffy J, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0320
   Dunkle LM, 2017, NEW ENGL J MED, V376, P2427, DOI [10.1056/nejmoa1608862, 10.1056/NEJMoa1608862]
   Eisenberg KW, 2008, PEDIATRICS, V122, P911, DOI 10.1542/peds.2007-3304
   Essink B, 2020, VACCINE, V38, P242, DOI 10.1016/j.vaccine.2019.10.021
   Ezeanolue EHK, GEN BEST PRACTICE GU
   Falsey AR, 2009, J INFECT DIS, V200, P172, DOI 10.1086/599790
   Ferdinands JM, 2020, CLIN INFECT DIS, V70, P1550, DOI 10.1093/cid/ciz452
   Ferdinands JM, 2017, CLIN INFECT DIS, V64, P544, DOI 10.1093/cid/ciw816
   Fiore AE, 2010, MMWR RECOMM REP, V59
   Food and Drug Administration, 2003, GUID IND BIOAV BIOEQ
   Food and Drug Administration, 2014, CLIN REV FLUZ HIGH D
   Food and Drug Administration, 2015, CLIN REV FLUAD
   Food and Drug Administration, 2020, CLIN REV FLUAD QUADR
   Fragaszy EB, 2018, INFLUENZA OTHER RESP, V12, P171, DOI 10.1111/irv.12506
   Frenck RW, 2012, CLIN VACCINE IMMUNOL, V19, P1296, DOI 10.1128/CVI.00176-12
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gravenstein S, 2017, LANCET RESP MED, V5, P738, DOI 10.1016/S2213-2600(17)30235-7
   Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1
   Health Resources and Services Administration, 2019, WHAT YOU NEED KNOW N
   Heikkinen T, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.07.007
   Huang WT, 2014, VACCINE, V32, P6463, DOI 10.1016/j.vaccine.2014.09.054
   Irving SA, 2013, OBSTET GYNECOL, V121, P159, DOI [10.1097/AOG.0b013e318279f56f, http://10.1097/AOG.0b013e318279f56f]
   Izurieta HS, 2015, LANCET INFECT DIS, V15, P293, DOI 10.1016/S1473-3099(14)71087-4
   Kerzner B, 2007, J AM GERIATR SOC, V55, P1499, DOI 10.1111/j.1532-5415.2007.01397.x
   Kissling E, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.16.30201
   Lapi F, 2019, EXPERT REV VACCINES, V18, P663, DOI 10.1080/14760584.2019.1622418
   Lee JKH, 2018, EXPERT REV VACCINES, V17, P435, DOI 10.1080/14760584.2018.1471989
   Levin MJ, 2018, VACCINE, V36, P179, DOI 10.1016/j.vaccine.2017.08.029
   Li RX, 2016, PHARMACOEPIDEM DR S, V25, P928, DOI 10.1002/pds.3996
   Lum LCS, 2010, VACCINE, V28, P1566, DOI 10.1016/j.vaccine.2009.11.054
   Ma FB, 2014, CLIN VACCINE IMMUNOL, V21, P1282, DOI 10.1128/CVI.00375-14
   Mannino S, 2012, AM J EPIDEMIOL, V176, P527, DOI 10.1093/aje/kws313
   McMillan M, 2015, VACCINE, V33, P2108, DOI 10.1016/j.vaccine.2015.02.068
   McNeil SA, 2007, VACCINE, V25, P3464, DOI 10.1016/j.vaccine.2006.12.047
   Millman AJ, 2015, J TRAVEL MED, V22, P306, DOI 10.1111/jtm.12215
   Mullooly JP, 2007, VACCINE, V25, P846, DOI 10.1016/j.vaccine.2006.09.041
   Mutsch M, 2005, CLIN INFECT DIS, V40, P1282, DOI 10.1086/429243
   Nakashima K, 2018, HUM VACC IMMUNOTHER, V14, P1923, DOI 10.1080/21645515.2018.1455476
   Neuzil KM, 2006, J INFECT DIS, V194, P1032, DOI 10.1086/507309
   Nolan T, 2008, VACCINE, V26, P6383, DOI 10.1016/j.vaccine.2008.08.046
   Oppermann M, 2012, VACCINE, V30, P4445, DOI 10.1016/j.vaccine.2012.04.081
   Pasternak B, 2012, BMJ-BRIT MED J, V344, pe2794, DOI DOI 10.1136/BMJ.E2794
   Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1
   Patterson JL, 2013, PEDIATR ANN, V42, pE258, DOI 10.3928/00904481-20131122-09
   Pearson ML, 2006, MMWR RECOMM REP, V55
   Pebody RG, 2013, EUROSURVEILLANCE, V18, P25
   Petrie JG, 2016, J INFECT DIS, V214, P1142, DOI 10.1093/infdis/jiw105
   Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869
   Poehling KA, 2013, PEDIATRICS, V131, P207, DOI 10.1542/peds.2012-1255
   Puig-Barbera J, 2017, VACCINE, V35, P5799, DOI 10.1016/j.vaccine.2017.09.035
   Radin JM, 2016, VACCINE, V34, P3907, DOI 10.1016/j.vaccine.2016.05.034
   Ratnam I, 2013, J CLIN VIROL, V57, P54, DOI 10.1016/j.jcv.2013.01.008
   Ray GT, 2019, CLIN INFECT DIS, V68, P1623, DOI 10.1093/cid/ciy770
   Richardson DM, 2015, CLIN INFECT DIS, V61, P171, DOI 10.1093/cid/civ261
   Ritzwoller DP, 2005, PEDIATRICS, V116, P153, DOI 10.1542/peds.2005-0049
   Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075
   Rolfes MA, 2018, INFLUENZA OTHER RESP, V12, P132, DOI 10.1111/irv.12486
   Sammon CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051734
   Schwarz TF, 2011, VACCINE, V29, P5195, DOI 10.1016/j.vaccine.2011.05.031
   Schwarz TF, 2017, J INFECT DIS, V216, P1352, DOI 10.1093/infdis/jix481
   Shay DK, 2017, J INFECT DIS, V215, P510, DOI 10.1093/infdis/jiw641
   Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479
   Song JY, 2015, VACCINE, V33, P4647, DOI 10.1016/j.vaccine.2015.05.003
   Stockwell MS, 2014, JAMA PEDIATR, V168, P211, DOI 10.1001/jamapediatrics.2013.4469
   Sukumaran L, 2015, OBSTET GYNECOL, V126, P1069, DOI 10.1097/AOG.0000000000001066
   Uyeki TM, 2003, CLIN INFECT DIS, V36, P1095, DOI 10.1086/374053
   Valenciano M, 2013, EUROSURVEILLANCE, V18, P12
   Van Buynder PG, 2013, VACCINE, V31, P6122, DOI 10.1016/j.vaccine.2013.07.059
   Van Wormer JJ, 2017, J OCCUP ENVIRON MED, V59, P1135, DOI [10.1097/JOM.0000000000001120, 10.1097/jom.0000000000001120]
   Walter EB, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-1909
   Willis GA, 2019, INFLUENZA OTHER RESP, V13, P18, DOI 10.1111/irv.12604
   Young-Xu YN, 2018, J INFECT DIS, V217, P1718, DOI 10.1093/infdis/jiy088
NR 110
TC 11
Z9 11
U1 4
U2 4
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1057-5987
EI 1545-8601
J9 MMWR RECOMM REP
JI MMWR Recomm. Rep.
PD AUG 21
PY 2020
VL 69
IS 8
BP 1
EP 24
DI 10.15585/mmwr.rr6908a1
PG 24
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NW6DT
UT WOS:000575104700001
PM 32820746
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Javed, B
AF Javed, Bilal
TI Bioactive Virus-Mimicking Nanovesicles From Dendrimersomes: A Novel
   Approach to Understanding SARS-CoV-2 Host-Interactions to Better Design
   Therapeutics
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE COVID-19; dendrimers; immune response; pseudoviruses; surface
   modifications; therapeutic carriers; vaccine
ID PROGRAMMABLE GLYCAN PRESENTATION; GLYCODENDRIMERSOMES
C1 [Javed, Bilal] Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA.
   [Javed, Bilal] PMAS Arid Agr Univ, Fac Sci, Rawalpindi, Pakistan.
RP Javed, B (corresponding author), Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA.; Javed, B (corresponding author), PMAS Arid Agr Univ, Fac Sci, Rawalpindi, Pakistan.
EM javedbilal87@gmail.com
OI Javed, Bilal/0000-0002-9566-1498
CR Brockmeier E. K., 2020, PENN TODAY
   Dings RPM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030905
   Kopitz J, 2017, ANGEW CHEM INT EDIT, V56, P14677, DOI 10.1002/anie.201708237
   Li QQ, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1963
   Li SD, 2020, ACS NANO, V14, P7398, DOI 10.1021/acsnano.0c02912
   Rodriguez-Emmenegger C, 2019, P NATL ACAD SCI USA, V116, P5376, DOI 10.1073/pnas.1821924116
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Sherman SE, 2017, CHEM REV, V117, P6538, DOI 10.1021/acs.chemrev.7b00097
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Xiao Q, 2020, P NATL ACAD SCI USA, V117, P11931, DOI 10.1073/pnas.2003938117
   Xiao Q, 2018, P NATL ACAD SCI USA, V115, pE2509, DOI 10.1073/pnas.1720055115
   Xiao Q, 2016, P NATL ACAD SCI USA, V113, pE1134, DOI 10.1073/pnas.1525589113
   Xiao Q, 2016, P NATL ACAD SCI USA, V113, P1162, DOI 10.1073/pnas.1524976113
   Yadavalli SS, 2019, P NATL ACAD SCI USA, V116, P744, DOI 10.1073/pnas.1811307116
   Zhang SD, 2015, P NATL ACAD SCI USA, V112, P5585, DOI 10.1073/pnas.1506220112
   Zhang SD, 2015, ANGEW CHEM INT EDIT, V54, P4036, DOI 10.1002/anie.201410882
NR 16
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD AUG 21
PY 2020
VL 7
AR 188
DI 10.3389/fmolb.2020.00188
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NO9ZZ
UT WOS:000569845300001
PM 32974384
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ejemel, M
   Li, Q
   Hou, SR
   Schiller, ZA
   Tree, JA
   Wallace, A
   Amcheslavsky, A
   Yilmaz, NK
   Buttigieg, KR
   Elmore, MJ
   Godwin, K
   Coombes, N
   Toomey, JR
   Schneider, R
   Ramchetty, AS
   Close, BJ
   Chen, DY
   Conway, HL
   Saeed, M
   Ganesa, C
   Carroll, MW
   Cavacini, LA
   Klempner, MS
   Schiffer, CA
   Wang, Y
AF Ejemel, Monir
   Li, Qi
   Hou, Shurong
   Schiller, Zachary A.
   Tree, Julia A.
   Wallace, Aaron
   Amcheslavsky, Alla
   Yilmaz, Nese Kurt
   Buttigieg, Karen R.
   Elmore, Michael J.
   Godwin, Kerry
   Coombes, Naomi
   Toomey, Jacqueline R.
   Schneider, Ryan
   Ramchetty, Anudeep S.
   Close, Brianna J.
   Chen, Da-Yuan
   Conway, Hasahn L.
   Saeed, Mohsan
   Ganesa, Chandrashekar
   Carroll, Miles W.
   Cavacini, Lisa A.
   Klempner, Mark S.
   Schiffer, Celia A.
   Wang, Yang
TI A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2
   spike-ACE2 interaction
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RECEPTOR-BINDING DOMAIN; SARS CORONAVIRUS; PNEUMONIA OUTBREAK; PROTEIN;
   NEUTRALIZATION; DISEASE
AB COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks ACE2 receptor binding, by overlapping the ACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in 293 cells expressing ACE2. When converted to secretory IgA, MAb326 also neutralizes authentic SARS-CoV-2 virus while the IgG isotype shows no neutralization. Our results suggest that SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine. Here, Ejemel et al. report the identification and characterization of a cross-neutralizing human IgA monoclonal antibody, named MAb362, that binds the receptor-binding domain of SARS-CoV-2 Spike, blocking its interaction with the ACE2 host receptor.
C1 [Ejemel, Monir; Li, Qi; Schiller, Zachary A.; Wallace, Aaron; Amcheslavsky, Alla; Toomey, Jacqueline R.; Schneider, Ryan; Ramchetty, Anudeep S.; Ganesa, Chandrashekar; Cavacini, Lisa A.; Klempner, Mark S.; Wang, Yang] Univ Massachusetts, Med Sch, MassBiol, Boston, MA 02125 USA.
   [Hou, Shurong; Yilmaz, Nese Kurt; Schiffer, Celia A.] Univ Massachusetts, Med Sch, Biochem & Mol Pharmacol, Boston, MA 02125 USA.
   [Tree, Julia A.; Buttigieg, Karen R.; Elmore, Michael J.; Godwin, Kerry; Coombes, Naomi; Carroll, Miles W.] Publ Hlth England, Natl Infect Serv, Salisbury, Wilts, England.
   [Close, Brianna J.; Chen, Da-Yuan; Conway, Hasahn L.; Saeed, Mohsan] Boston Univ, Natl Emerging Infect Dis Labs, Boston, MA 02215 USA.
RP Cavacini, LA; Klempner, MS; Wang, Y (corresponding author), Univ Massachusetts, Med Sch, MassBiol, Boston, MA 02125 USA.; Schiffer, CA (corresponding author), Univ Massachusetts, Med Sch, Biochem & Mol Pharmacol, Boston, MA 02125 USA.
EM Lisa.Cavacini@umassmed.edu; Mark.Klempner@umassmed.edu;
   Celia.Schiffer@umassmed.edu; Yang.Wang@umassmed.edu
OI Schiller, Zachary/0000-0002-4185-2416; Toomey,
   Jacqueline/0000-0002-3629-1896
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U24AI126683, NO1-AI-65315,
   R01AI150478]; Bill & Melinda Gates FoundationBill & Melinda Gates
   Foundation
FX We thank Dr. Robert Finberg at UMMS for helpful advice on functional
   assays. The initial mouse immunization work in 2005 was supported by NIH
   Contract NO1-AI-65315. S.H., N.Y.K., and C.A.S. were supported by NIH
   R01AI150478. The production of stabilized ectodomain trimer was
   supported by NIH contract U24AI126683. The dIgA and sIgA expression
   platform was supported by Bill & Melinda Gates Foundation.
CR Bakema JE, 2011, MABS-AUSTIN, V3, P352, DOI 10.4161/mabs.3.4.16092
   Becker MM, 2008, P NATL ACAD SCI USA, V105, P19944, DOI 10.1073/pnas.0808116105
   Boehm MK, 1999, J MOL BIOL, V286, P1421, DOI 10.1006/jmbi.1998.2556
   Czub M, 2005, VACCINE, V23, P2273, DOI 10.1016/j.vaccine.2005.01.033
   Dougherty R., 1964, TECHNIQUES EXPT VIRO, P169
   Du LY, 2008, J IMMUNOL, V180, P948, DOI 10.4049/jimmunol.180.2.948
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Finney, 1971, J PHARM SCI, V60, P1432, DOI DOI 10.1002/JPS.2600600940
   Giuntini S, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00355-18
   Greenough TC, 2005, J INFECT DIS, V191, P507, DOI 10.1086/427242
   Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hou SR, 2019, J CHEM THEORY COMPUT, V15, P637, DOI 10.1021/acs.jctc.8b00545
   Hu Y, 2020, J PHARM SCI-US, V109, P407, DOI 10.1016/j.xphs.2019.07.018
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Johnson RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054092
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Juarez P, 2016, PLANT BIOTECHNOL J, V14, P1791, DOI 10.1111/pbi.12541
   Leidner F, 2018, J CHEM THEORY COMPUT, V14, P2784, DOI 10.1021/acs.jctc.8b00097
   Letko M, 2020, FUNCTIONAL ASSESSMEN
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Muramatsu M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085582
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Roberts A, 2006, J INFECT DIS, V193, P685, DOI 10.1086/500143
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Stoppato M, 2020, VACCINE, V38, P2333, DOI 10.1016/j.vaccine.2020.01.064
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Tudor D, 2012, P NATL ACAD SCI USA, V109, P12680, DOI 10.1073/pnas.1200024109
   Virdi V, 2016, CELL MOL LIFE SCI, V73, P535, DOI 10.1007/s00018-015-2074-0
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Woof JM, 2004, NAT REV IMMUNOL, V4, P89, DOI 10.1038/nri1266
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Yu XC, 2013, J IMMUNOL, V190, P205, DOI 10.4049/jimmunol.1201469
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 47
TC 7
Z9 7
U1 3
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 21
PY 2020
VL 11
IS 1
AR 4198
DI 10.1038/s41467-020-18058-8
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NO8VR
UT WOS:000569766000024
PM 32826914
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Feng, LQ
   Wang, Q
   Shan, C
   Yang, CC
   Feng, Y
   Wu, J
   Liu, XL
   Zhou, YW
   Jiang, RD
   Hu, PY
   Liu, XL
   Zhang, F
   Li, PC
   Niu, XF
   Liu, YC
   Zheng, XH
   Luo, J
   Sun, J
   Gu, YY
   Liu, B
   Xu, YC
   Li, CF
   Pan, WQ
   Zhao, JC
   Ke, CW
   Chen, XW
   Xu, T
   Zhong, NS
   Guan, SH
   Yuan, ZM
   Chen, L
AF Feng, Liqiang
   Wang, Qian
   Shan, Chao
   Yang, Chenchen
   Feng, Ying
   Wu, Jia
   Liu, Xiaolin
   Zhou, Yiwu
   Jiang, Rendi
   Hu, Peiyu
   Liu, Xinglong
   Zhang, Fan
   Li, Pingchao
   Niu, Xuefeng
   Liu, Yichu
   Zheng, Xuehua
   Luo, Jia
   Sun, Jing
   Gu, Yingying
   Liu, Bo
   Xu, Yongcun
   Li, Chufang
   Pan, Weiqi
   Zhao, Jincun
   Ke, Changwen
   Chen, Xinwen
   Xu, Tao
   Zhong, Nanshan
   Guan, Suhua
   Yuan, Zhiming
   Chen, Ling
TI An adenovirus-vectored COVID-19 vaccine confers protection from
   SARS-COV-2 challenge in rhesus macaques
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; SPIKE PROTEIN; SARS-COV; ANTIBODIES;
   IMMUNIZATION; INFECTION; DELIVERY; HUMANS; TARGET
AB The rapid spread of coronavirus SARS-CoV-2 greatly threatens global public health but no prophylactic vaccine is available. Here, we report the generation of a replication-incompetent recombinant serotype 5 adenovirus, Ad5-S-nb2, carrying a codon-optimized gene encoding Spike protein (S). In mice and rhesus macaques, intramuscular injection with Ad5-S-nb2 elicits systemic S-specific antibody and cell-mediated immune (CMI) responses. Intranasal inoculation elicits both systemic and pulmonary antibody responses but weaker CMI response. At 30 days after a single vaccination with Ad5-S-nb2 either intramuscularly or intranasally, macaques are protected against SARS-CoV-2 challenge. A subsequent challenge reveals that macaques vaccinated with a 10-fold lower vaccine dosage (1x10(10) viral particles) are also protected, demonstrating the effectiveness of Ad5-S-nb2 and the possibility of offering more vaccine dosages within a shorter timeframe. Thus, Ad5-S-nb2 is a promising candidate vaccine and warrants further clinical evaluation. A vaccine protecting from SARS-CoV-2 infection is needed. Here the authors generate a replication-incompetent adenovirus based vaccine expressing SARS-CoV-2 spike, show protection from infection in non-human primates, and analyze the immune response after intramuscular and intranasal vaccination.
C1 [Feng, Liqiang; Wang, Qian; Hu, Peiyu; Liu, Xinglong; Zhang, Fan; Li, Pingchao; Liu, Yichu; Zheng, Xuehua; Luo, Jia; Chen, Xinwen; Xu, Tao; Chen, Ling] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Bioland Lab GRMH GDL, Guangzhou, Peoples R China.
   [Feng, Liqiang; Feng, Ying; Niu, Xuefeng; Sun, Jing; Gu, Yingying; Li, Chufang; Pan, Weiqi; Zhao, Jincun; Zhong, Nanshan; Chen, Ling] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China.
   [Wang, Qian] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Shan, Chao; Wu, Jia; Jiang, Rendi; Yuan, Zhiming] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Key Lab Special Pathogens & Biosafety, Wuhan, Peoples R China.
   [Yang, Chenchen; Liu, Xiaolin; Liu, Bo; Xu, Yongcun; Guan, Suhua; Chen, Ling] Guangzhou nBiomed Ltd, Guangzhou, Peoples R China.
   [Zhou, Yiwu] Huazhong Univ Sci & Technol, Dept Forens Med, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Ke, Changwen] Guangdong Prov Ctr Dis Control & Prevent, Guangzhou, Peoples R China.
RP Chen, L (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Bioland Lab GRMH GDL, Guangzhou, Peoples R China.; Chen, L (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China.; Yuan, ZM (corresponding author), Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Key Lab Special Pathogens & Biosafety, Wuhan, Peoples R China.; Guan, SH; Chen, L (corresponding author), Guangzhou nBiomed Ltd, Guangzhou, Peoples R China.
EM guan_suhua@gznbio.com; yzm@wh.iov.cn; chen_ling@gibh.ac.cn
OI Shan, Chao/0000-0002-3953-3782
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82041014]; Strategic Priority Research
   Program of the Chinese Academy of SciencesChinese Academy of Sciences
   [XDB29050701]; China Evergrande Group [2020GIRHHMS22]; Guangzhou Health
   Care and Cooperative Innovation Major Project
FX We are particularly grateful to the running team of the Key Laboratory
   of Special Pathogens and Biosafety, Wuhan Institute of Virology for
   their assistance in testing vaccine efficacy. We thank the staff at the
   Animal Center of GIBH and Guangdong Landau Biotechnology Co. Ltd. for
   their excellent technical assistance. This work was partly supported by
   the National Natural Science Foundation of China for SARS-CoV-2
   (82041014), the Strategic Priority Research Program of the Chinese
   Academy of Sciences (XDB29050701), China Evergrande Group funding for
   SARS-CoV-2 (2020GIRHHMS22), and Guangzhou Health Care and Cooperative
   Innovation Major Project.
CR Almazan F, 2013, MBIO, V4, DOI 10.1128/mBio.00650-13
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen X, 2013, NEUROBIOL AGING, V34, P2248, DOI 10.1016/j.neurobiolaging.2013.03.028
   Croyle MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003548
   Czerkinsky C, 2010, MUCOSAL IMMUNOL, V3, P545, DOI 10.1038/mi.2010.55
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haagmans BL, 2016, SCIENCE, V351, P77, DOI 10.1126/science.aad1283
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Patel A, 2007, J INFECT DIS, V196, pS413, DOI 10.1086/520603
   Qu D, 2005, VACCINE, V23, P924, DOI 10.1016/j.vaccine.2004.07.031
   Richardson JS, 2013, J VIROL, V87, P3668, DOI 10.1128/JVI.02864-12
   Schindewolf C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010074
   Sun CJ, 2011, VACCINE, V29, P3837, DOI 10.1016/j.vaccine.2011.03.042
   Tai WB, 2017, J VIROL, V91, DOI 10.1128/JVI.01651-16
   Ura T, 2014, VACCINES, V2, P624, DOI 10.3390/vaccines2030624
   Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008
   Wang YR, 2020, J INFECT DIS, V221, P1770, DOI 10.1093/infdis/jiaa119
   Widjaja I, 2019, EMERG MICROBES INFEC, V8, P516, DOI 10.1080/22221751.2019.1597644
   World Health Organization, 2020, 184 WHO
   Xiang ZQ, 2006, EMERG INFECT DIS, V12, P1596, DOI 10.3201/eid1210.060078
   Ying TL, 2014, J VIROL, V88, P7796, DOI 10.1128/JVI.00912-14
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010060
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zhu FC, 2017, LANCET, V389, P621, DOI [10.1016/S0140-6736(16)32617-4, 10.1016/s0140-6736(16)32617-4]
   Zhu FC, 2015, LANCET, V385, P2272, DOI 10.1016/S0140-6736(15)60553-0
   Zhu XJ, 2013, J THORAC DIS, V5, pS142, DOI 10.3978/j.issn.2072-1439.2013.06.06
NR 39
TC 4
Z9 4
U1 3
U2 3
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 21
PY 2020
VL 11
IS 1
AR 4207
DI 10.1038/s41467-020-18077-5
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NO8VR
UT WOS:000569766000033
PM 32826924
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, XY
   Zuo, CC
   Lu, WJ
   Zou, Y
   Xu, Q
   Li, XY
   Lv, QZ
AF Li, Xiaoye
   Zuo, Chengchun
   Lu, Wenjing
   Zou, Ye
   Xu, Qing
   Li, Xiaoyu
   Lv, Qianzhou
TI Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric
   Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the
   COVID-19 Pandemic
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE rivaroxaban; nonvalvular atrial fibrillation; corona virus disease 2019;
   remote medication management; pharmacist-led education; follow-up
   service
ID PRIMARY-CARE; THERAPY; PREVENTION; PROGRAM
AB Objective This study was designed to evaluate the efficacy of remote medication management of rivaroxaban by pharmacists for geriatric patients with nonvalvular atrial fibrillation during the COVID-19 pandemic. Methods A single-site, prospective cohort study was conducted among patients with non-valvular atrial fibrillation who received rivaroxaban therapy from July 2019 to December 2019. Patients in the pharmacist-led education and follow-up service (PEFS) group were managed remotely by a pharmacist. In contrast, those in the usual care (UC) group were managed by other providers. Data of routine blood tests, coagulation function tests, which also included cardiac function parameters were collected. The number and type of provider encounters, interventions related to rivaroxaban therapy, the occurrence of thromboembolism or bleeding, and the time of the first outpatient visit after discharge were recorded. Results A total of 600 patients were recruited, and results of 381 patients were analyzed in the end, of which 179 patients were from the PEFS group and 202 were from the UC group. There was no significant difference between the two groups in terms of the occurrence ratio of systemic thrombosis, heart failure (LVEF < 40%), and left atrial dilation, which was defined as enlargement of left atrial diameter (LAD) > 40 mm. The cumulative incidences of bleeding complications, such as gastrointestinal tract and skin ecchymosis, were significantly higher in the UC group (12.4% vs. 6.1%, P=0.038; 4.5% vs. 0.6%, P=0.018). There was no significant difference after pharmacist intervention in terms of thrombosis occurrence ratio between the two groups (P = 0.338, HR: 0.722, 95% CI: 0.372-1.405). Remote instruction by a pharmacist reduced outpatient service frequency within the first 30 days after discharge (23.7% vs. 1.1%, P < 0.001). However, more patients in the PEFS group presented for the first outpatient revisit later than 40 days post-discharge (12.8% vs. 21.3%, P < 0.001). Conclusion Remote pharmacist-led medication instruction of rivaroxaban could reduce bleeding complications of the gastrointestinal tract and skin ecchymosis and postpone the first outpatient revisit after discharge.
C1 [Li, Xiaoye; Zuo, Chengchun; Lu, Wenjing; Zou, Ye; Xu, Qing; Li, Xiaoyu; Lv, Qianzhou] Fudan Univ, Zhongshan Hosp, Dept Pharm, Shanghai, Peoples R China.
RP Li, XY; Lv, QZ (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Pharm, Shanghai, Peoples R China.
EM li.xiaoyu@zs-hospital.sh.cn; 13916088938@163.com
FU Project of Shanghai Municipal health planning commission [2016ZB0301]
FX This study was supported by the Project of Shanghai Municipal health
   planning commission (NO. 2016ZB0301).
CR Aidit S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00637
   Ashjian E, 2017, AM J HEALTH-SYST PH, V74, P483, DOI 10.2146/ajhp151026
   Conti Alberto, 2020, Crit Pathw Cardiol, V19, P131, DOI 10.1097/HPC.0000000000000205
   DiRenzo BM, 2018, ACAD EMERG MED, V25, P634, DOI 10.1111/acem.13311
   Fogg Angela, 2012, Int J Pharm Pract, V20, P294, DOI 10.1111/j.2042-7174.2012.00207.x
   Goto M, 2016, INT J CARDIOL, V220, P602, DOI 10.1016/j.ijcard.2016.06.212
   Hawes EM, 2018, AM J HEALTH-SYST PH, V75, P901, DOI 10.2146/ajhp170174
   January CT, 2014, CIRCULATION, V130, P2071, DOI 10.1161/CIR.0000000000000040
   Kim HM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211766
   Kirchhof P, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.118.009530
   Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang JB, 2020, INT J PHARM PRACT, V28, P97, DOI 10.1111/ijpp.12584
   Limone BL, 2013, THROMB RES, V132, P420, DOI 10.1016/j.thromres.2013.08.003
   Linkins LA, 2012, CHEST, V141, pE495S, DOI 10.1378/chest.11-2303
   Mielke N, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-1430-6
   Mifsud EM, 2019, INT J CLIN PHARM-NET, V41, P741, DOI 10.1007/s11096-019-00824-4
   Motulsky Aude, 2021, Res Social Adm Pharm, V17, P428, DOI 10.1016/j.sapharm.2020.03.001
   Lobato SM, 2018, FUTUR CARDIOL, V14, P17, DOI 10.2217/fca-2018-0022
   Nielsen PB, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j510
   Niessen F, 2008, NATURE, V452, P654, DOI 10.1038/nature06663
   Perlman A, 2019, ISR J HEALTH POLICY, V8, DOI 10.1186/s13584-019-0285-9
   Perzborn E, 2011, NAT REV DRUG DISCOV, V10, P61, DOI 10.1038/nrd3185
   Pickett JD, 2019, CRIT CARE NURSE, V39, P54, DOI 10.4037/ccn2019292
   Qian X, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00650-1
   Roseau C, 2020, INT J CLIN PHARM-NET, V42, P685, DOI 10.1007/s11096-020-00964-y
   Shore S, 2014, AM HEART J, V167, P810, DOI 10.1016/j.ahj.2014.03.023
   Silverio Angelo, 2019, Eur Heart J Cardiovasc Pharmacother, DOI 10.1093/ehjcvp/pvz073
   Sinigoj P, 2020, INT J CLIN PHARM-NET, V42, P445, DOI 10.1007/s11096-020-01008-1
   Tsuyuki RT, 2016, J AM COLL CARDIOL, V67, P2846, DOI 10.1016/j.jacc.2016.03.528
   Turner A, 2012, DRUG AGING, V29, P741, DOI 10.1007/s40266-012-0007-2
   Turpie AGG, 2014, THER CLIN RISK MANAG, V10, P197, DOI 10.2147/TCRM.S30159
   Valencia DN, 2020, CUREUS, V12, DOI 10.7759/cureus.7386
   Virdee MS, 2017, INT J CLIN PHARM-NET, V39, P173, DOI 10.1007/s11096-016-0419-x
NR 34
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 21
PY 2020
VL 11
AR 1275
DI 10.3389/fphar.2020.01275
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NM7KO
UT WOS:000568273600001
PM 32973511
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bouchard, S
   Allard, M
   Robillard, G
   Dumoulin, S
   Guitard, T
   Loranger, C
   Green-Demers, I
   Marchand, A
   Renaud, P
   Cournoyer, LG
   Corno, G
AF Bouchard, Stephane
   Allard, Micheline
   Robillard, Genevieve
   Dumoulin, Stephanie
   Guitard, Tanya
   Loranger, Claudie
   Green-Demers, Isabelle
   Marchand, Andre
   Renaud, Patrice
   Cournoyer, Louis-Georges
   Corno, Giulia
TI Videoconferencing Psychotherapy for Panic Disorder and Agoraphobia:
   Outcome and Treatment Processes From a Non-randomized Non-inferiority
   Trial
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE telepsychotherapy; telehealth; videoconference psychotherapy; panic
   disorder and agoraphobia; working alliance; self-efficacy; treatment
   outcome; treatment processes
ID COGNITIVE-BEHAVIORAL THERAPY; FACE-TO-FACE; SELF-DETERMINATION;
   EFFICACY; ALLIANCE
AB Background In the context of the COVID-19 pandemic, legislations are being modified around the world to allow patients to receive mental health services through telehealth. Unfortunately, there are no large clinical trial available to reliably document the efficacy of delivering videoconferencing psychotherapy (VCP) for people with panic disorder and agoraphobia (PDA) and whether basic psychotherapeutic processes are altered. Methods This 2-arm intent-to-treat non-inferiority study reports on a clinical trial on VCP and documents how therapeutic working alliance and motivation toward psychotherapy are associated to treatment outcome. We hypothesized that VCP would not be inferior to standard face-to-face (FF) cognitive behavior therapy for PDA. No specific hypothesis was stated to address working alliance and treatment mechanisms. VCP was compared to a gold-standard psychotherapy treatment for PDA, which was delivered either in person or in videoconference, with a strict tolerance criterion of about 2 points on the primary outcome measure. Seventy one adult patients were recruited. Measures of working alliance were collected after the first, fifth, and last session. Motivation toward therapy at pre-treatment and working alliance after the fifth therapy session were used as predictors of treatment outcome and compared with change in dysfunctional beliefs toward bodily sensations. Results Panic disorder, agoraphobia, fear of sensations and depressed mood all showed significant improvements and large effect-sizes from pre to post-treatment. Gains were maintained at follow-up. No significant differences were found between VCP and FF, and effect sizes were trivial for three of the four outcome measures. Non-inferiority tests confirmed that VCP was no less effective than FF therapy on the primary outcome measure and two of the three secondary outcome measures. Working alliance was very strong in VCP and did not statistically differ from FF. Working alliance and motivation did not predict treatment outcome, which was significantly predicted by the reduction in dysfunctional beliefs. The strength of the therapeutic bond was correlated with change in dysfunctional beliefs. Conclusion Mental health professionals can use VCP to provide services to patients with PDA. Building and maintaining a sound working alliance should not be a source concern. Practical recommendations are formulated.
C1 [Bouchard, Stephane; Allard, Micheline; Robillard, Genevieve; Dumoulin, Stephanie; Guitard, Tanya; Loranger, Claudie; Green-Demers, Isabelle; Renaud, Patrice; Corno, Giulia] Univ Quebec Outaouais, Cyberpsychol Lab, Gatineau, PQ, Canada.
   [Bouchard, Stephane; Loranger, Claudie] Ctr Integre Sante & Serv Sociaux Outaouais, Gatineau, PQ, Canada.
   [Dumoulin, Stephanie; Guitard, Tanya; Marchand, Andre] Univ Quebec Montreal, Dept Psychol, Montreal, PQ, Canada.
   [Cournoyer, Louis-Georges] Univ Montreal, Sch Criminol, Montreal, PQ, Canada.
RP Bouchard, S (corresponding author), Univ Quebec Outaouais, Cyberpsychol Lab, Gatineau, PQ, Canada.; Bouchard, S (corresponding author), Ctr Integre Sante & Serv Sociaux Outaouais, Gatineau, PQ, Canada.
EM stephane.bouchard@uqo.ca
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [MOP53366]; Canada Research ChairsCanada Research
   ChairsCGIAR [210762, 231039]
FX The study was conducted with the financial support of research grants
   from the Canadian Institutes of Health Research (#MOP53366) and the
   Canada Research Chairs (#210762 and 231039).
CR Allard M., 2007, REV QUEBECOISE PSYCH, V28, P43
   American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT
   Ardito RB, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00270
   Bachelor A, 2000, J Psychother Pract Res, V9, P39
   Backhaus A, 2012, PSYCHOL SERV, V9, P111, DOI 10.1037/a0027924
   BANDELOW B, 1995, INT CLIN PSYCHOPHARM, V10, P73, DOI 10.1097/00004850-199506000-00003
   Barlow D. H., 1988, ANXIETY ITS DISORDER
   Barlow D. H., 1998, PSYCHOL TREATMENT PA
   Barsky AJ, 1999, PSYCHOSOMATICS, V40, P50, DOI 10.1016/S0033-3182(99)71271-5
   Beck AT, 1996, MANUAL BECK DEPRESSI
   Berryhill MB, 2019, FAM PRACT, V36, P53, DOI 10.1093/fampra/cmy072
   Bhatia Manjeet Singh, 2020, Prim Care Companion CNS Disord, V22, DOI 10.4088/PCC.20l02626
   Bordin E. S., 1979, PSYCHOTHERAPY THEORY, V16, P252, DOI [10.1037/h0085885, DOI 10.1037/H0085885]
   Bouchard S, 2004, TELEMED J E-HEALTH, V10, P13, DOI 10.1089/153056204773644535
   Bouchard S, 2000, CYBERPSYCHOL BEHAV, V3, P999, DOI 10.1089/109493100452264
   Bouchard S, 1997, J ANXIETY DISORD, V11, P89, DOI 10.1016/S0887-6185(96)00037-0
   Bouchard S, 1996, BEHAV RES THER, V34, P213, DOI 10.1016/0005-7967(95)00077-1
   Bouchard S, 2007, J BEHAV THER EXP PSY, V38, P275, DOI 10.1016/j.jbtep.2006.08.002
   Bouchard S, 2011, ANN REV CYBERTHERAPY, V9, P104
   Buchholz JL, 2020, J ANXIETY DISORD, V70, DOI 10.1016/j.janxdis.2020.102194
   Carpenter JK, 2018, DEPRESS ANXIETY, V35, P502, DOI 10.1002/da.22728
   CHAMBLESS DL, 1985, BEHAV RES THER, V23, P35, DOI 10.1016/0005-7967(85)90140-8
   CHAMBLESS DL, 1984, J CONSULT CLIN PSYCH, V52, P1090, DOI 10.1037/0022-006X.52.6.1090
   Chang HM, 2019, J PSYCHOSOM RES, V125, DOI 10.1016/j.jpsychores.2019.109815
   Clark D. M., 1987, COGNITIVE TREATMENT
   CLARK DM, 1986, BEHAV RES THER, V24, P461, DOI 10.1016/0005-7967(86)90011-2
   Connolly SL, 2020, CLIN PSYCHOL-SCI PR, V27, DOI 10.1111/cpsp.12311
   Cowain T, 2001, AUST NZ J PSYCHIAT, V35, P62, DOI 10.1046/j.1440-1614.2001.00853.x
   Deci EL, 2000, PSYCHOL INQ, V11, P227, DOI 10.1207/S15327965PLI1104_01
   Draper JV, 1998, HUM FACTORS, V40, P354, DOI 10.1518/001872098779591386
   First MB, 1997, STRUCTURED CLIN INTE
   Gallagher MW, 2013, BEHAV RES THER, V51, P767, DOI 10.1016/j.brat.2013.09.001
   Germain V, 2010, CYBERPSYCH BEH SOC N, V13, P29, DOI 10.1089/cyber.2009.0139
   Grondin F, 2019, CLIN PSYCHOL-SCI PR, DOI 10.1111/cpsp.12298
   Haddouk L, 2018, ANN REV CYBERTHERAPY, V16, P118
   Hofmann SG, 2012, COGNITIVE THER RES, V36, P427, DOI 10.1007/s10608-012-9476-1
   HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223
   Katzman MA, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-S1-S1
   Lindner D, 2014, CLIN CASE STUD, V13, P146, DOI 10.1177/1534650113504292
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Marmar C. R., 1986, PSYCHOTHERAPEUTIC PR
   Mauri L, 2017, NEW ENGL J MED, V377, P1357, DOI 10.1056/NEJMra1510063
   Mitchell JE, 2008, BEHAV RES THER, V46, P581, DOI 10.1016/j.brat.2008.02.004
   MONCHER FJ, 1991, CLIN PSYCHOL REV, V11, P247, DOI 10.1016/0272-7358(91)90103-2
   Nelson EL, 2015, COGN BEHAV PRACT, V22, P269, DOI 10.1016/j.cbpra.2015.03.001
   Norwood C, 2018, CLIN PSYCHOL PSYCHOT, V25, P797, DOI 10.1002/cpp.2315
   Orlinsky D. E., 1994, HDB PSYCHOTHERAPY BE, P270
   Pelletier LG, 1997, J PERS ASSESS, V68, P414, DOI 10.1207/s15327752jpa6802_11
   Powers John H, 2013, Clin Investig (Lond), V3, P215
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Rees CS, 2015, AUST PSYCHOL, V50, P259, DOI 10.1111/ap.12122
   Rees CS, 2005, PROF PSYCHOL-RES PR, V36, P649, DOI 10.1037/0735-7028.36.6.649
   Richardson LK, 2009, CLIN PSYCHOL-SCI PR, V16, P323, DOI 10.1111/j.1468-2850.2009.01170.x
   Ryan RM, 2008, CAN PSYCHOL, V49, P186, DOI 10.1037/a0012753
   Sanchez-Meca J, 2010, CLIN PSYCHOL REV, V30, P37, DOI 10.1016/j.cpr.2009.08.011
   Smits JAJ, 2012, J CONSULT CLIN PSYCH, V80, P624, DOI 10.1037/a0028957
   Taylor S., 2007, PSYCHIATRY, V6, P188, DOI [10.1016/j.mppsy.2007.02.004, DOI 10.1016/J.MPPSY.2007.02.004]
   Teismann T, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1894-5
   Tracey T.J., 1989, PSYCHOL ASSESSMENT J, V1, DOI [10.1037/1040-3590.1.3.207, DOI 10.1037/1040-3590.1.3.207]
   Wellek S., 2010, TESTING STAT HYPOTHE
NR 60
TC 0
Z9 0
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD AUG 21
PY 2020
VL 11
AR 2164
DI 10.3389/fpsyg.2020.02164
PG 13
WC Psychology, Multidisciplinary
SC Psychology
GA NM7DJ
UT WOS:000568254600001
PM 32973638
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Idda, ML
   Soru, D
   Floris, M
AF Idda, Maria Laura
   Soru, Dorian
   Floris, Matteo
TI Overview of the First 6 Months of Clinical Trials for COVID-19
   Pharmacotherapy: The Most Studied Drugs
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE clinical trial (2; 172); COVID-19; coronavirus (2019-nCoV); COVID-19
   (condition); COVID-19 infection
ID CORONAVIRUS
AB SARS-CoV-2 rapidly spread from China until it was defined a pandemic by WHO in March 2020. Related scientific papers have rapidly extended information regarding the diagnosis, treatment and epidemiology of COVID-19 infection. To date, no vaccine or definitive treatment is available to defeat the virus and therapies are mainly based on existing drugs used to treat other conditions. Existing therapies used in several clinical trials work by affecting the biology of COVID-19 and/or counteracting the harmful host excessive immune response. Here, we have reviewed 526 ongoing clinical trials for COVID-19 to provide a perspective on the first 6 months of global efforts to identify an effective therapy. The drugs most actively tested in various centers include hydroxychloroquine, ritonavir, azithromycin, tocilizumab, lopinavir chloroquine and ivermectin. Our analysis shows that most clinical trials focus on a small number of candidate drugs (namely hydroxychloroquine and chloroquine representing 25% of total clinical trials) while underestimating the potential of other promising drugs. A global coordination in clinical trial management could avoid duplications and increase the effectiveness of the response to the global challenge.
C1 [Idda, Maria Laura; Floris, Matteo] CNR, Inst Genet & Biomed Res, Sassari, Italy.
   [Floris, Matteo] Univ Sassari, Dept Biomed Sci, Sassari, Italy.
RP Floris, M (corresponding author), CNR, Inst Genet & Biomed Res, Sassari, Italy.; Floris, M (corresponding author), Univ Sassari, Dept Biomed Sci, Sassari, Italy.
EM mfloris@uniss.it
RI Floris, Matteo/ABH-1274-2020
OI Floris, Matteo/0000-0003-4385-9336
CR Barlow A, 2020, PHARMACOTHERAPY, V40, P416, DOI 10.1002/phar.2398
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   CHORIN E, 2020, NAT MED 0424, DOI DOI 10.1101/2020.04.02.20047050
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041
   Gillenwater S, 2020, NEW ENGL J MED, V383, P992, DOI 10.1056/NEJMc2022236
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gu JY, 2020, GASTROENTEROLOGY, V158, P1518, DOI 10.1053/j.gastro.2020.02.054
   Haladyj Ewa, 2018, Reumatologia (Warsaw), V56, P164, DOI 10.5114/reum.2018.76904
   Heidary F, 2020, J ANTIBIOT, V73, P593, DOI 10.1038/s41429-020-0336-z
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hussain M, 2020, J MED VIROL, V92, P1580, DOI 10.1002/jmv.25832
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Luk HKH, 2019, INFECT GENET EVOL, V71, P21, DOI 10.1016/j.meegid.2019.03.001
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Vaira LA, 2020, LARYNGOSCOPE, V130, P1787, DOI 10.1002/lary.28692
   Wang B, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.101300
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
NR 37
TC 1
Z9 1
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD AUG 21
PY 2020
VL 8
AR 497
DI 10.3389/fpubh.2020.00497
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NM7MF
UT WOS:000568278000001
PM 32974268
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rojek, AM
   Martin, GE
   Horby, PW
AF Rojek, Amanda M.
   Martin, Genevieve E.
   Horby, Peter W.
TI Compassionate drug (mis)use during pandemics: lessons for COVID-19 from
   2009
SO BMC MEDICINE
LA English
DT Article
DE Pandemic; Clinical trial; Influenza; Systematic review
ID OSELTAMIVIR TREATMENT; CLINICAL MANAGEMENT; INFLUENZA; ADULTS; TRIAL;
   PHARMACOKINETICS; MULTICENTER; OUTBREAK
AB Background New emerging infections have no known treatment. Assessing potential drugs for safety and efficacy enables clinicians to make evidence-based treatment decisions and contributes to overall outbreak control. However, it is difficult to launch clinical trials in the unpredictable environment of an outbreak. We conducted a bibliometric systematic review for the 2009 influenza pandemic to determine the speed and quality of evidence generation for treatments. This informs approaches to high-quality evidence generation in this and future pandemics. Methods We searched PubMed for all clinical data (including clinical trial, observational and case series) describing treatment for patients with influenza A(H1N1)pdm09 and ClinicalTrials.gov for research that aimed to enrol patients with the disease. Results Thirty-three thousand eight hundred sixty-nine treatment courses for patients hospitalised with A(H1N1)pdm09 were detailed in 160 publications. Most were retrospective observational studies or case series. Five hundred ninety-two patients received treatment (or placebo) as participants in a registered interventional clinical trial with results publicly available. None of these registered trial results was available during the timeframe of the pandemic, and the median date of publication was 213 days after the Public Health Emergency of International Concern ended. Conclusion Patients were frequently treated for pandemic influenza with drugs not registered for this indication, but rarely under circumstances of high-quality data capture. The result was a reliance on use under compassionate circumstances, resulting in continued uncertainty regarding the potential benefits and harms of anti-viral treatment. Rapid scaling of clinical trials is critical for generating a quality evidence base during pandemics.
C1 [Rojek, Amanda M.; Horby, Peter W.] Univ Oxford, Epidem Dis Res Grp Oxford Ergo, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Old Rd Campus,Roosevelt Dr, Oxford OX3 7FZ, England.
   [Rojek, Amanda M.] Royal Melbourne Hosp, Emergency Dept, Melbourne, Vic, Australia.
   [Rojek, Amanda M.] Univ Melbourne, Ctr Integrated Crit Care, Melbourne, Vic, Australia.
   [Martin, Genevieve E.] Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia.
RP Rojek, AM; Horby, PW (corresponding author), Univ Oxford, Epidem Dis Res Grp Oxford Ergo, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Old Rd Campus,Roosevelt Dr, Oxford OX3 7FZ, England.; Rojek, AM (corresponding author), Royal Melbourne Hosp, Emergency Dept, Melbourne, Vic, Australia.; Rojek, AM (corresponding author), Univ Melbourne, Ctr Integrated Crit Care, Melbourne, Vic, Australia.
EM amanda.rojek@mh.org.au; peter.horby@ndm.ox.ac.uk
OI Martin, Genevieve Elizabeth/0000-0001-5142-7440
FU Wellcome TrustWellcome Trust [107834/Z/15/Z, 106491/Z/14/Z]
FX This work was supported by the Wellcome Trust[grant numbers
   107834/Z/15/Z and 106491/Z/14/Z]. AR is supported by Open
   Philanthropies.
CR [Anonymous], 2015, LANCET, V385, P578, DOI 10.1016/S0140-6736(15)60218-5
   Button Katherine S, 2016, BMC Psychol, V4, P59
   Cheng VCC, 2013, ANTIVIR RES, V100, P407, DOI 10.1016/j.antiviral.2013.08.016
   DeAngelis CD, 2004, JAMA-J AM MED ASSOC, V292, P1363, DOI 10.1001/jama.292.11.1363
   Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1
   Dunning J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162199
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grein J, 2020, NEW ENGL J MED, V382
   Group RC, 2020, N ENGL J MED
   Gubareva LV, 2000, LANCET, V355, P827, DOI 10.1016/S0140-6736(99)11433-8
   Hayden FG, 2014, LANCET INFECT DIS, V14, P544, DOI 10.1016/S1473-3099(14)70793-5
   Hung IEN, 2013, CHEST, V144, P464, DOI 10.1378/chest.12-2907
   Ioannidis JPA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028346
   Ison MG, 2014, ANTIVIR THER, V19, P349, DOI 10.3851/IMP2680
   Johansson MA, 2020, NATURE, V579, P29, DOI [10.1038/d41586-020-00613-4, 10.1038/d41586-020-00614-3]
   Kayem ND, 2019, EMERG INFECT DIS, V25, P2084, DOI 10.3201/eid2511.180628
   Kimberlin DW, 2013, J INFECT DIS, V207, P709, DOI 10.1093/infdis/jis765
   Kupferschmidt K, 2020, SCIENCE, V367, P963, DOI 10.1126/science.367.6481.963
   Lee N, 2013, CLIN INFECT DIS, V57, P1511, DOI 10.1093/cid/cit597
   Lipsitch M, 2009, NEW ENGL J MED, V361, P112, DOI 10.1056/NEJMp0904380
   Marty FM, 2014, J INFECT DIS, V209, P542, DOI 10.1093/infdis/jit467
   Moorthy VS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001819
   National Academies of Sciences Engineering and Medicine Health and Medicine Division; Board on Health Sciences Policy Board on Global Health, 2017, INT CLIN RES EP RESP
   Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4
   Rishu AH, 2017, J CRIT CARE, V40, P7, DOI 10.1016/j.jcrc.2017.02.009
   Rojek AM, 2018, CLIN INFECT DIS, V66, P1454, DOI 10.1093/cid/cix1061
   Rojek AM, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0294
   Rojek AM, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0760-x
   South East Asia Infectious Disease Clinical Research Network, 2013, BMJ, V346, pf3039, DOI 10.1136/bmj.f3039
   Tran TH, 2009, LANCET, V373, P2085, DOI 10.1016/S0140-6736(09)61131-4
   Wang CH, 2014, CRIT CARE MED, V42, P313, DOI 10.1097/CCM.0b013e3182a2727d
   Wang XL, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-32
   Wellcome Trust and The Academy of Medical Sciences, 2015, US NEUR INH INFL 201
   Woodcock J, 2017, NEW ENGL J MED, V377, P62, DOI 10.1056/NEJMra1510062
   Xing WJ, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000272
   Zambon M, 2014, CURR OPIN INFECT DIS, V27, P560, DOI 10.1097/QCO.0000000000000113
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 37
TC 3
Z9 3
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD AUG 21
PY 2020
VL 18
IS 1
AR 265
DI 10.1186/s12916-020-01732-5
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA NK8SH
UT WOS:000567000000001
PM 32825816
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Thomford, NE
   Yahaya, ES
   Ekor, M
   Awortwe, C
AF Thomford, Nicholas Ekow
   Yahaya, Ewura Seidu
   Ekor, Martins
   Awortwe, Charles
TI Turning Up the Volume for Precision Herbal Medicine in Africa in an Era
   of COVID-19 and Planetary Biodiversity Loss
SO OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
LA English
DT Article
DE precision herbal medicine; COVID-19; African traditional herbal
   medicine; biodiversity; planetary health; drug discovery
AB What would it take in terms of the structural reforms in science, technology, and culture to cultivate sustainable therapeutic and preventive medicine innovations against zoonotic infections such as coronavirus disease 2019 (COVID-19) in the 21st century? In May 2019, the Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services warned that "around one million animal and plant species are now threatened with extinction." Biodiversity is essential for drug discovery and development. We are currently facing a dual challenge in therapeutics innovation with COVID-19 and loss in planetary biodiversity. Hence, there is an urgent need for new ideas and strategies for drug discovery as well as repurposed drugs for the COVID-19 pandemic. To these ends, the existing scholarship in, and the field of precision herbal medicine provide an alternative source for discovery of novel therapeutics against the novel coronavirus. We propose that the application of precision herbal medicine in Africa could usefully contribute to current efforts for therapeutics innovation for the COVID-19 pandemic, and beyond. The pandemic calls for interdisciplinary dialogue and turning up the volume for precision herbal medicine in Africa, and importantly, in ways informed by robust systems science as well as broad public engagement to codesign medicines in the 21st century.
C1 [Thomford, Nicholas Ekow] Univ Cape Town, Fac Hlth Sci, Dept Pathol, Div Human Genet, Anzio Rd, ZA-7925 Cape Town, South Africa.
   [Thomford, Nicholas Ekow] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Anzio Rd, ZA-7925 Cape Town, South Africa.
   [Thomford, Nicholas Ekow] Univ Cape Coast, Coll Hlth & Allied Sci, Sch Med Sci, Dept Med Biochem, Cape Coast, Ghana.
   [Yahaya, Ewura Seidu; Ekor, Martins] Univ Cape Coast, Coll Hlth & Allied Sci, Sch Med Sci, Dept Pharmacol, Cape Coast, Ghana.
   [Awortwe, Charles] Univ Hosp Schleswig Holstein, Inst Expt & Clin Pharmacol, Kiel, Germany.
   [Awortwe, Charles] Univ Stellenbosch, Fac Med & Hlth Sci, Div Clin Pharmacol, Cape Town, South Africa.
RP Thomford, NE (corresponding author), Univ Cape Town, Fac Hlth Sci, Dept Pathol, Div Human Genet, Anzio Rd, ZA-7925 Cape Town, South Africa.; Thomford, NE (corresponding author), Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Anzio Rd, ZA-7925 Cape Town, South Africa.
EM nicholas.thomford@uct.ac.za
RI Yahaya, Ewura/F-2303-2018; THOMFORD, NICHOLAS EKOW/Q-7621-2018
OI Yahaya, Ewura/0000-0002-5003-9662; THOMFORD, NICHOLAS
   EKOW/0000-0002-3152-5817
FU National Research Foundation (NRF) of South AfricaNational Research
   Foundation - South Africa; International Foundation of Science (IFS),
   SwedenInternational Foundation for Science
FX This article received no funding. Dr. Nicholas Thomford's research is
   supported by the National Research Foundation (NRF) of South Africa
   through the rated researcher's incentive funding and the International
   Foundation of Science (IFS), Sweden.
CR Akar I, 2020, OMICS, V24, P515, DOI 10.1089/omi.2020.0111
   Brabazon H., 2020, ACAD MATTERS
   Bull JW, 2020, NAT ECOL EVOL, V4, P4, DOI 10.1038/s41559-019-1022-z
   CDC, 2020, COR DIS 2019 COVID 1
   Cheong DHJ, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104901
   Diaz S, 2019, PROJECT REPORT
   Florindo HF, 2020, NAT NANOTECHNOL, V15, P630, DOI 10.1038/s41565-020-0732-3
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Kickbusch I, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1336
   Loembe MM, 2020, NAT MED, V26, P999, DOI 10.1038/s41591-020-0961-x
   Neergheen-Bhujun V, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020304
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Ozdemir V, 2015, OMICS, V19, P579, DOI 10.1089/omi.2015.0133
   Pirih N, 2018, OMICS, V22, P337, DOI 10.1089/omi.2017.0186
   Sardas S, 2020, OMICS, V24, P124, DOI 10.1089/omi.2020.0008
   Thomford NE, 2018, OMICS, V22, P375, DOI 10.1089/omi.2018.0074
   Thomford NE, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061578
   Woolhouse MEJ, 2005, EMERG INFECT DIS, V11, P1842, DOI 10.3201/eid1112.050997
   Xu J, 2020, COMPLEMENT THER CLIN, V39, DOI 10.1016/j.ctcp.2020.101165
   Yacoub K, 2014, BIODIVERSITY MED PLA, P1
   Zheng Y, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104821
NR 21
TC 1
Z9 1
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1536-2310
EI 1557-8100
J9 OMICS
JI OMICS
PD DEC 1
PY 2020
VL 24
IS 12
BP 682
EP 684
DI 10.1089/omi.2020.0150
EA AUG 2020
PG 3
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA PA3II
UT WOS:000566013400001
PM 32833598
OA Bronze
DA 2021-01-01
ER

PT J
AU Braun, M
   Sharon, E
   Unterman, I
   Miller, M
   Shtern, AM
   Benenson, S
   Vainstein, A
   Tabach, Y
AF Braun, Maya
   Sharon, Elad
   Unterman, Irene
   Miller, Maya
   Shtern, Anna Mellul
   Benenson, Shmuel
   Vainstein, Alexander
   Tabach, Yuval
TI ACE2 Co-evolutionary Pattern Suggests Targets for Pharmaceutical
   Intervention in the COVID-19 Pandemic
SO ISCIENCE
LA English
DT Article
ID SEARCH
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spillover infection in December 2019 has caused an unprecedented pandemic. SARS-CoV-2, as other coronaviruses, binds its target cells through the angiotensin-con-verting enzyme 2 (ACE2) receptor. Accordingly, this makes ACE2 research essen-tial for understanding the zoonotic nature of coronaviruses and identifying novel drugs. Here we present a systematic analysis of the ACE2 conservation and co -evolution protein network across 1,671 eukaryotes, revealing an unexpected conservation pattern in specific metazoans, plants, fungi, and protists. We iden-tified the co-evolved protein network and pinpointed a list of drugs that target this network by using data integration from different sources. Our computational analysis found widely used drugs such as nonsteroidal anti-inflammatory drugs and vasodilators. These drugs are expected to perturb the ACE2 network affecting infectivity as well as the pathophysiology of the disease.
C1 [Braun, Maya; Sharon, Elad; Unterman, Irene; Miller, Maya; Shtern, Anna Mellul; Tabach, Yuval] Hebrew Univ Jerusalem, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-9112102 Jerusalem, Israel.
   [Benenson, Shmuel] Hadassah Hebrew Univ, Dept Clin Microbiol & Infect Dis, Med Ctr, Jerusalem, Israel.
   [Sharon, Elad; Vainstein, Alexander] Hebrew Univ Jerusalem, Robert H Smith Fac Agr Food & Environm, IL-76100 Rehovot, Israel.
RP Tabach, Y (corresponding author), Hebrew Univ Jerusalem, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-9112102 Jerusalem, Israel.
EM yuvaltab@ekmd.huji.ac.il
FU Israel Science FoundationIsrael Science Foundation [1591/19]; Israel
   Innovation Authority under the R&D Plans of Industrial Products for the
   Prevention and Treatment of the COVID-19 [70273]
FX Funding was received from the Israel Science Foundation (grant agreement
   1591/19), and the Israel Innovation Authority under the R&D Plans of
   Industrial Products for the Prevention and Treatment of the COVID-19
   (grant agreement 70273). The graphical abstract was created by
   BioRender.com.
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Anthony SJ, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex012
   Arkadir D, 2019, ANN CLIN TRANSL NEUR, V6, P106, DOI 10.1002/acn3.684
   BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592
   Bauer M, 2019, CURR NEUROL NEUROSCI, V19, DOI 10.1007/s11910-019-0986-z
   Belinky Frida, 2015, Database (Oxford), V2015, DOI 10.1093/database/bav006
   Ben-Ari Fuchs S, 2016, OMICS, V20, P139, DOI 10.1089/omi.2015.0168
   Bloch I., 2020, BIOINFORMATICS, DOI [10.1093/bioinformatics/btaa281., DOI 10.1093/BI0INFORMATICS/BTAA281]
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Chen CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018910
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   Omar I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31428-z
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285
   Pizzorno A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00531
   Pont LMEB, 2015, GENE THER, V22, P947, DOI 10.1038/gt.2015.72
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Rappaport N, 2017, NUCLEIC ACIDS RES, V45, pD877, DOI 10.1093/nar/gkw1012
   Sadreyev IR, 2015, NUCLEIC ACIDS RES, V43, pW154, DOI 10.1093/nar/gkv452
   Sayers EW, 2020, NUCLEIC ACIDS RES, V48, pD9, DOI 10.1093/nar/gkz899
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen W., 2019, TAXONKIT CROSS PLATF, DOI [10.1101/513523, DOI 10.1101/513523, 10.1101/513523.]
   Sherill-Rofe D, 2019, GENOME RES, V29, P439, DOI 10.1101/gr.241414.118
   Sinha S., 2020, SYSTEMATIC CELL LINE, V97, P84, DOI [10.20944/preprints202003.0446.v1, DOI 10.20944/PREPRINTS202003.0446.V1]
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Strittmatter SM, 2014, NAT MED, V20, P590, DOI 10.1038/nm.3595
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tabach Y, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.50
   Tabach Y, 2013, NATURE, V493, P694, DOI 10.1038/nature11779
   Thackray LB, 2018, CELL REP, V22, P3440, DOI 10.1016/j.celrep.2018.03.001
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xue C, 2018, ARTERIOSCL THROM VAS, V38, P986, DOI 10.1161/ATVBAHA.117.310661
   Yates AD, 2020, NUCLEIC ACIDS RES, V48, pD682, DOI 10.1093/nar/gkz966
   Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 46
TC 2
Z9 2
U1 2
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2589-0042
J9 ISCIENCE
JI iScience
PD AUG 21
PY 2020
VL 23
IS 8
AR 101384
DI 10.1016/j.isci.2020.101384
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NG7II
UT WOS:000564153700003
PM 32738617
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rogers, TF
   Zhao, FZ
   Huang, DL
   Beutler, N
   Burns, A
   He, WT
   Limbo, O
   Smith, C
   Song, G
   Woehl, J
   Yang, LL
   Abbott, RK
   Callaghan, S
   Garcia, E
   Hurtado, J
   Parren, M
   Peng, LH
   Ramirez, S
   Ricketts, J
   Ricciardi, MJ
   Rawlings, SA
   Wu, NC
   Yuan, M
   Smith, DM
   Nemazee, D
   Teijaro, JR
   Voss, JE
   Wilson, IA
   Andrabi, R
   Briney, B
   Landais, E
   Sok, D
   Jardine, JG
   Burton, DR
AF Rogers, Thomas F.
   Zhao, Fangzhu
   Huang, Deli
   Beutler, Nathan
   Burns, Alison
   He, Wan-Ting
   Limbo, Oliver
   Smith, Chloe
   Song, Ge
   Woehl, Jordan
   Yang, Linlin
   Abbott, Robert K.
   Callaghan, Sean
   Garcia, Elijah
   Hurtado, Jonathan
   Parren, Mara
   Peng, Linghang
   Ramirez, Sydney
   Ricketts, James
   Ricciardi, Michael J.
   Rawlings, Stephen A.
   Wu, Nicholas C.
   Yuan, Meng
   Smith, Davey M.
   Nemazee, David
   Teijaro, John R.
   Voss, James E.
   Wilson, Ian A.
   Andrabi, Raiees
   Briney, Bryan
   Landais, Elise
   Sok, Devin
   Jardine, Joseph G.
   Burton, Dennis R.
TI Isolation of potent SARS-CoV-2 neutralizing antibodies and protection
   from disease in a small animal model
SO SCIENCE
LA English
DT Article
ID MONOCLONAL-ANTIBODIES; VIRUS-INFECTION; SPIKE; DESIGN
AB Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-recovered participants, developed neutralization assays to investigate antibody responses, adapted our high-throughput antibody generation pipeline to rapidly screen more than 1800 antibodies, and established an animal model to test protection. We isolated potent neutralizing antibodies (nAbs) to two epitopes on the receptor binding domain (RBD) and to distinct non-RBD epitopes on the spike (S) protein. As indicated by maintained weight and low lung viral titers in treated animals, the passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs also define protective epitopes to guide vaccine design.
C1 [Rogers, Thomas F.; Zhao, Fangzhu; Huang, Deli; Beutler, Nathan; Burns, Alison; He, Wan-Ting; Smith, Chloe; Song, Ge; Yang, Linlin; Callaghan, Sean; Garcia, Elijah; Hurtado, Jonathan; Parren, Mara; Peng, Linghang; Ricketts, James; Nemazee, David; Teijaro, John R.; Voss, James E.; Andrabi, Raiees; Briney, Bryan; Landais, Elise; Sok, Devin; Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.
   [Rogers, Thomas F.; Rawlings, Stephen A.; Smith, Davey M.] Univ Calif San Diego, Dept Med, Div Infect Dis, La Jolla, CA 92037 USA.
   [Zhao, Fangzhu; Burns, Alison; He, Wan-Ting; Limbo, Oliver; Smith, Chloe; Song, Ge; Woehl, Jordan; Callaghan, Sean; Wilson, Ian A.; Andrabi, Raiees; Landais, Elise; Sok, Devin; Jardine, Joseph G.; Burton, Dennis R.] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.
   [Zhao, Fangzhu; Burns, Alison; He, Wan-Ting; Song, Ge; Abbott, Robert K.; Callaghan, Sean; Hurtado, Jonathan; Wilson, Ian A.; Andrabi, Raiees; Briney, Bryan; Landais, Elise; Sok, Devin; Burton, Dennis R.] Scripps Res Inst, Consortium HIV AIDS Vaccine Dev CHAVD, La Jolla, CA 92037 USA.
   [Limbo, Oliver; Woehl, Jordan; Landais, Elise; Sok, Devin; Jardine, Joseph G.] IAVI, New York, NY 10004 USA.
   [Abbott, Robert K.; Ramirez, Sydney] La Jolla Inst Immunol LJI, Ctr Infect Dis & Vaccine Res, La Jolla, CA 92037 USA.
   [Hurtado, Jonathan; Briney, Bryan] Scripps Res Inst, Ctr Viral Syst Biol, La Jolla, CA 92037 USA.
   [Ricciardi, Michael J.] George Washington Univ, Dept Pathol, Washington, DC 20052 USA.
   [Wu, Nicholas C.; Yuan, Meng; Wilson, Ian A.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
   [Burton, Dennis R.] MIT, Ragon Inst, Massachusetts Gen Hosp, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Burton, Dennis R.] Harvard Univ, Cambridge, MA 02139 USA.
RP Sok, D; Burton, DR (corresponding author), Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.; Sok, D; Jardine, JG; Burton, DR (corresponding author), Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.; Sok, D; Burton, DR (corresponding author), Scripps Res Inst, Consortium HIV AIDS Vaccine Dev CHAVD, La Jolla, CA 92037 USA.; Sok, D; Jardine, JG (corresponding author), IAVI, New York, NY 10004 USA.; Burton, DR (corresponding author), MIT, Ragon Inst, Massachusetts Gen Hosp, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Burton, DR (corresponding author), Harvard Univ, Cambridge, MA 02139 USA.
EM dsok@iavi.org; jjardine@iavi.org; burton@seripps.edu
RI Rawlings, Stephen/ABA-6797-2020
OI Rawlings, Stephen/0000-0003-3637-1447; Yang, Linlin/0000-0001-5602-4157;
   Huang, Deli/0000-0002-6989-639X; He, Wanting/0000-0003-4692-3516;
   Ricketts, James/0000-0002-9057-5937; Song, Ge/0000-0001-7306-3510;
   Parren, Mara/0000-0003-0067-0154; Limbo, Oliver/0000-0003-1686-1414;
   Smith, Chloe/0000-0003-3531-1119; Beutler, Nathan/0000-0003-3240-9524;
   Zhao, Fangzhu/0000-0002-3172-1340
FU NIH CHAVD awardUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [UM1 AI144462];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI132317, AI073148, AI145762]; IAVI
   Neutralizing Antibody Center; Bill and Melinda Gates FoundationBill &
   Melinda Gates Foundation [OPP 1170236, OPP 1183956,
   OPP1196345/INV-008813]; John and Mary Tu Foundation; Pendleton Trust
FX This work was supported by the NIH CHAVD (UM1 AI144462 to I.A.W., B.B.,
   D.S., and D.R.B.), R01 (AI132317 and AI073148 to D.N.), and K99
   (AI145762 to R.K.A.) awards; the IAVI Neutralizing Antibody Center; and
   the Bill and Melinda Gates Foundation (OPP 1170236 to I.A.W. and D.R.B.,
   OPP 1183956 to J.E.V., and OPP1196345/INV-008813 to D.S. and D.R.B.).
   This work was also supported by the John and Mary Tu Foundation and the
   Pendleton Trust.
CR Burton DR, 2020, CELL HOST MICROBE, V27, P695, DOI 10.1016/j.chom.2020.04.022
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Corti D, 2016, SCIENCE, V351, P1339, DOI 10.1126/science.aad5224
   Davis CW, 2019, CELL, V177, P1566, DOI 10.1016/j.cell.2019.04.036
   Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036
   Giroglou T, 2004, J VIROL, V78, P9007, DOI 10.1128/JVI.78.17.9007-9015.2004
   Goodwin E, 2018, IMMUNITY, V48, P339, DOI 10.1016/j.immuni.2018.01.005
   Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014
   Jain T, 2017, P NATL ACAD SCI USA, V114, P944, DOI 10.1073/pnas.1616408114
   Jardine JG, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005815
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Lefranc MP, 2009, NUCLEIC ACIDS RES, V37, pD1006, DOI 10.1093/nar/gkn838
   McBride CE, 2007, J VIROL, V81, P2418, DOI 10.1128/JVI.02146-06
   Misasi J, 2016, SCIENCE, V351, P1343, DOI 10.1126/science.aad6117
   Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531
   Parren PWHI, 2001, ADV IMMUNOL, V77, P195, DOI 10.1016/S0065-2776(01)77018-6
   Quinlan B. D., 2020, MICROBIOLOGY
   Quinlan B. D., 2020, BIORXIV, DOI [10.1101/2020.04.10.036418, DOI 10.1101/2020.04.10.036418]
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   Sok D, 2014, P NATL ACAD SCI USA, V111, P17624, DOI 10.1073/pnas.1415789111
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Walker LM, 2018, NAT REV IMMUNOL, V18, P297, DOI 10.1038/nri.2017.148
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Wec AZ, 2020, P NATL ACAD SCI USA, V117, P6675, DOI 10.1073/pnas.1921388117
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Ying TL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9223
NR 27
TC 79
Z9 77
U1 23
U2 25
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 21
PY 2020
VL 369
IS 6506
SI SI
BP 956
EP +
DI 10.1126/science.abc7520
PG 47
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NE2OL
UT WOS:000562436800044
PM 32540903
OA Other Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Gur, M
   Taka, E
   Yilmaz, SZ
   Kilinc, C
   Aktas, U
   Golcuk, M
AF Gur, Mert
   Taka, Elhan
   Yilmaz, Sema Zeynep
   Kilinc, Ceren
   Aktas, Umut
   Golcuk, Mert
TI Conformational transition of SARS-CoV-2 spike glycoprotein between its
   closed and open states
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article
ID STEERED MOLECULAR-DYNAMICS; CORONAVIRUS; PROTEIN; ENTRY
AB In 2020, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people worldwide and caused the coronavirus disease 2019 (COVID-19). Spike (S) glycoproteins on the viral membrane bind to ACE2 receptors on the host cell membrane and initiate fusion, and S protein is currently among the primary drug target to inhibit viral entry. The S protein can be in a receptor inaccessible (closed) or accessible (open) state based on down and up positions of its receptor-binding domain (RBD), respectively. However, conformational dynamics and the transition pathway between closed to open states remain unexplored. Here, we performed all-atom molecular dynamics (MD) simulations starting from closed and open states of the S protein trimer in the presence of explicit water and ions. MD simulations showed that RBD forms a higher number of interdomain interactions and exhibits lower mobility in its down position than its up position. MD simulations starting from intermediate conformations between the open and closed states indicated that RBD switches to the up position through a semi-open intermediate that potentially reduces the free energy barrier between the closed and open states. Free energy landscapes were constructed, and a minimum energy pathway connecting the closed and open states was proposed. Because RBD-ACE2 binding is compatible with the semi-open state, but not with the closed state of the S protein, we propose that the formation of the intermediate state is a prerequisite for the host cell recognition.
C1 [Gur, Mert; Taka, Elhan; Yilmaz, Sema Zeynep; Kilinc, Ceren; Aktas, Umut; Golcuk, Mert] Istanbul Tech Univ ITU, Fac Mech Engn, Dept Mech Engn, Suite 445 Inonu Caddesi,65 Gumussuyu, TR-34437 Istanbul, Turkey.
   [Gur, Mert] Istanbul Tech Univ ITU, Natl Ctr High Performance Comp, Istanbul, Turkey.
RP Gur, M (corresponding author), Istanbul Tech Univ ITU, Fac Mech Engn, Dept Mech Engn, Suite 445 Inonu Caddesi,65 Gumussuyu, TR-34437 Istanbul, Turkey.; Gur, M (corresponding author), Istanbul Tech Univ ITU, Natl Ctr High Performance Comp, Istanbul, Turkey.
EM gurme@itu.edu.tr
RI Gur, Mert/O-5304-2015; YILMAZ, SEMA ZEYNEP/ABB-8414-2020
OI Gur, Mert/0000-0003-0983-4397; YILMAZ, SEMA ZEYNEP/0000-0002-4839-3777;
   AKTAS, UMUT/0000-0002-1795-9782; Kilinc, Ceren/0000-0003-0570-9222
FU National Center of High Performance Computing (UHeM) at ITU; COVID-19
   HPC Consortium [TG-MCB200070]; Extreme Science and Engineering Discovery
   Environment (XSEDE)
FX We thank Kadir Diri for his technical support at UHeM and Ahmet Yildiz
   (UC Berkeley) for scientific discussions. We gratefully acknowledge the
   support of the National Center of High Performance Computing (UHeM) at
   ITU, the COVID-19 HPC Consortium (Grant No. TG-MCB200070), and The
   Extreme Science and Engineering Discovery Environment (XSEDE).
CR [Anonymous], 2016, NUCLEIC ACIDS RES, V44, pD7, DOI 10.1093/nar/gkv1189
   Beckstein O, 2009, J MOL BIOL, V394, P160, DOI 10.1016/j.jmb.2009.09.009
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Eskici G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066178
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Gur M, 2013, J CHEM PHYS, V139, DOI 10.1063/1.4816375
   Gur M, 2018, J CHEM PHYS, V148, DOI 10.1063/1.5019457
   Han Y, 2020, J MED VIROL, V92, P639, DOI 10.1002/jmv.25749
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI 10.1038/s41594-020-0469-6
   Isralewitz B, 2001, CURR OPIN STRUC BIOL, V11, P224, DOI 10.1016/S0959-440X(00)00194-9
   Izrailev S, 1999, BIOPHYS J, V77, P1753, DOI 10.1016/S0006-3495(99)77022-0
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   NCBI Resource Coordinators, 2018, NUCLEIC ACIDS RES, V46, pD8
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113
   Peng C., 2020, CHEMRXIV11877492V1
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Pullara F, 2019, TURK J CHEM, V43, P394, DOI 10.3906/kim-1808-1
   Rossen JWA, 1998, J VIROL, V72, P497, DOI 10.1128/JVI.72.1.497-503.1998
   Shah M., 2020, RES SQ, DOI [10.21203/rs.3.rs-16932/v1., DOI 10.21203/RS.3.RS-16932/V1]
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   Urbach, 2011, CAHIERS JUDAISME, V35, P5, DOI DOI 10.1016/J.JMGM.2011.07.008
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Wang K, 2018, SCI REP, V8, P1, DOI DOI 10.1038/s41598-018-36918-8
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiong XL, 2018, J VIROL, V92
   Yang XL, 2016, J VIROL, V90, P3253, DOI 10.1128/JVI.02582-15
   Zhang G., 2020, 1 IN CLASS PEPTIDE B
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 46
TC 2
Z9 2
U1 6
U2 6
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0021-9606
EI 1089-7690
J9 J CHEM PHYS
JI J. Chem. Phys.
PD AUG 21
PY 2020
VL 153
IS 7
AR 075101
DI 10.1063/5.0011141
PG 13
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA NG3TJ
UT WOS:000563908200001
PM 32828084
DA 2021-01-01
ER

PT J
AU Sallard, E
   Halloy, J
   Casane, D
   van Helden, J
   Decroly, E
AF Sallard, Erwan
   Halloy, Jose
   Casane, Didier
   van Helden, Jacques
   Decroly, Etienne
TI Tracing the origins of SARS-COV-2 in coronavirus phylogenies
SO M S-MEDECINE SCIENCES
LA French
DT Article
ID ACUTE RESPIRATORY SYNDROME; SARS CORONAVIRUS; CLEAVAGE SITE; SPIKE;
   RECOMBINATION; MECHANISMS; PNEUMONIA; PROTEIN; VIRUS
AB SARS-CoV-2 is a new human coronavirus (CoV), which emerged in People's Republic of China at the end of 2019 and is responsible for the global Covid-19 pandemic that caused more than 540 000 deaths in six months, Understanding the origin of this virus is an important issue and it is necessary to determine the mechanisms of its dissemination in order to be able to contain new epidemics, Based on phylogenetic inferences, sequence analysis and structure-function relationships of coronavirus proteins, informed by the knowledge currently available, we discuss the different scenarios evoked to account for the origin - natural or synthetic - of the virus, On the basis of currently available data, it is impossible to determine whether SARS-CoV-2 is the result of a natural zoonotic emergence or an accidental escape from experimental strains, Regardless of its origin, the study of the evolution of the molecular mechanisms involved in the emergence of this pandemic virus is essential to develop therapeutic and vaccine strategies.
C1 [Sallard, Erwan] Ecole Normale Super Paris, 45 Rue Ulm, F-75005 Paris, France.
   [Halloy, Jose] Univ Paris, CNRS, LIED UMR 8236, 85 Bd St Germain, F-75006 Paris, France.
   [Casane, Didier] Univ Paris Saclay, CNRS, IRD, UMR Evolut Genomes Comportement & Ecol, F-91198 Gif Sur Yvette, France.
   [Casane, Didier] Univ Paris, UFR Sci Vivant, F-75013 Paris, France.
   [van Helden, Jacques] CNRS, Inst Francais Bioinformat, IFB Core, UMS 3601, Evry, France.
   [van Helden, Jacques] Aix Marseille Univ, INSERM, Lab Theory & Approaches Genome Complex TAGC, Marseille, France.
   [Decroly, Etienne] Aix Marseille Univ, AFMB, CNRS, UMR 7257, Case 925,163 Ave Luminy, F-13288 Marseille 09, France.
RP van Helden, J (corresponding author), CNRS, Inst Francais Bioinformat, IFB Core, UMS 3601, Evry, France.; van Helden, J (corresponding author), Aix Marseille Univ, INSERM, Lab Theory & Approaches Genome Complex TAGC, Marseille, France.
EM Jacques.von-Helden@univ-amu.fr; etienne.decroly@afmb.univ-amu.fr
OI Halloy, Jose/0000-0003-1555-2484; Sallard, Erwan/0000-0002-2324-3633
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Burki T, 2018, LANCET INFECT DIS, V18, P148, DOI 10.1016/S1473-3099(18)30006-9
   CASANE D, 2019, M S MED SCI, V35, P245, DOI DOI 10.1051/MEDSCI/2019030
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Committee on Science T Affairs P and G Sciences B on L, 2013, OFF STAT
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Enserink M, 2003, SCIENCE, V301, P1824
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Follis KE, 2006, VIROLOGY, V350, P358, DOI 10.1016/j.virol.2006.02.003
   Ge XY, 2016, VIROL SIN, V31, P31, DOI 10.1007/s12250-016-3713-9
   Gibbs AJ, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-207
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Gu H, 2020, BIORXIV
   Hassanin A., 2020, BIORXIV
   Henkel RD, 2012, APPL BIOSAFETY
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Hua LS, 2015, ZOOKEYS, P99, DOI 10.3897/zookeys.507.6970
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai M, 2012, NATURE, V486, P420, DOI 10.1038/nature10831
   Iseni F, 2020, M S-MED SCI, V36, P797, DOI 10.1051/medsci/2020124
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lau SY, 2020, EMERG MICROBES INFEC, V9, P837, DOI 10.1080/22221751.2020.1756700
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Liu P, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008421
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luis AD, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2753
   Luk HKH, 2019, INFECT GENET EVOL, V71, P21, DOI 10.1016/j.meegid.2019.03.001
   Matsuyama S, 2018, J VIROL, V92, DOI 10.1128/JVI.00683-18
   Menachery VD, 2020, J VIROL, V94, DOI 10.1128/JVI.01774-19
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Moulard M, 2000, BBA-REV BIOMEMBRANES, V1469, P121, DOI 10.1016/S0304-4157(00)00014-9
   Ni L, 2020, IMMUNITY
   NIH, 2015, STAT FUND PAUS CERT
   Normile D, 2004, SCIENCE, V304, P1223
   Pradhan P, 2020, BIORXIV
   Ren W, 2008, J VIROL, V82, P1899, DOI 10.1128/JVI.01085-07
   Russell CA, 2012, SCIENCE, V336, P1541, DOI 10.1126/science.1222526
   Sabir JSM, 2016, SCIENCE, V351, P81, DOI 10.1126/science.aac8608
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Sun XJ, 2010, J VIROL, V84, P8683, DOI 10.1128/JVI.00797-10
   Thao TTN, 2020, NATURE, V582, P561, DOI 10.1038/s41586-020-2294-9
   Van Boeckel TP, ARXIV13123283QBIO
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiao K, 2020, NATURE, P1, DOI DOI 10.24252/NATURE.V7I1A1
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zeng LP, 2016, J VIROL, V90, P6573, DOI 10.1128/JVI.03079-15
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhou H, 2020, CURR BIOL, V30, P2196, DOI 10.1016/j.cub.2020.05.023
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 58
TC 2
Z9 2
U1 4
U2 4
PU EDP SCIENCES S A
PI LES ULIS CEDEX A
PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A,
   FRANCE
SN 0767-0974
EI 1958-5381
J9 M S-MED SCI
JI M S-Med. Sci.
PD AUG 21
PY 2020
VL 36
IS 8-9
BP 783
EP 796
DI 10.1051/medsci/2020123
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NF8IZ
UT WOS:000563537800018
PM 32773024
OA Other Gold
DA 2021-01-01
ER

PT J
AU Blackall, D
   Wulff, S
   Roettger, T
   Jacobs, L
   Lacasse, A
   Patri, M
   Zinser, P
   Pherez, F
   Jamkhana, Z
   Frey, SE
   Smith, L
   Goel, R
   Katz, L
AF Blackall, Douglas
   Wulff, Shephali
   Roettger, Timothy
   Jacobs, Lauren
   Lacasse, Alexandre
   Patri, Manokiran
   Zinser, Phillip
   Pherez, Francisco
   Jamkhana, Zafar
   Frey, Sharon E.
   Smith, Linda
   Goel, Ruchika
   Katz, Louis
TI Rapid establishment of aCOVID-19 convalescent plasma program in a
   regional health care delivery network
SO TRANSFUSION
LA English
DT Article
ID DISEASE
AB Background COVID-19 convalescent plasma (CCP) represents an appealing approach to the treatment of patients with infections due to SARS-CoV-2. We endeavored to quickly establish a sustainable CCP transfusion program for a regional network of health care facilities. Study design and methods A regional collaborative group was activated to address the issues necessary to implementing a CCP transfusion program and making the program sustainable. A wide range of health care providers including physicians (critical care, infectious disease, transfusion medicine), nurses, pharmacists, laboratorians, and information technology (IT) specialists were required to make the program a success. Results The CCP implementation team initially consisted of four members but quickly grew to a group of nearly 20 participants based on different issues related to program implementation. Overall, six major implementation "themes" were addressed: (a) registration of individual hospitals and principal investigators with a national investigational new drug research protocol; (b) collaboration with a regional blood donor center; (c) targeted recruitment of convalesced donors; (d) IT issues related to all aspects of CCP ordering, distribution, and transfusion; (e) prioritization of patients to receive CCP; and (f) evaluation of CCP products including antibody characteristics and patient response to therapy. Conclusion Within 4 weeks of initiation, CCP was successfully transfused at multiple hospitals in our regional health care delivery system. A program infrastructure was established that will make this program sustainable into the future. This approach has broader implications for the success of multi-institutional programs requiring rapid implementation.
C1 [Blackall, Douglas] St Louis Univ, Dept Pathol, Sch Med, 1402 South Grand Blvd, St Louis, MO 63104 USA.
   [Wulff, Shephali] SSM Hlth St Joseph Hosp, St Charles, MO USA.
   [Roettger, Timothy; Jacobs, Lauren] SSM STL Pharm, St Louis, MO USA.
   [Lacasse, Alexandre] SSM Hlth St Marys Hosp, St Louis, MO USA.
   [Patri, Manokiran; Zinser, Phillip] SSM Hlth DePaul Hosp, Bridgeton, MO USA.
   [Pherez, Francisco] SSM Hlth St Clare Hosp, Fenton, MO USA.
   [Jamkhana, Zafar; Frey, Sharon E.] St Louis Univ, Dept Internal Med, Sch Med, St Louis, MO 63104 USA.
   [Smith, Linda] SSM STL Lab, St Louis, MO USA.
   [Goel, Ruchika; Katz, Louis] Mississippi Valley Reg Blood Ctr, Springfield, IL USA.
RP Blackall, D (corresponding author), St Louis Univ, Dept Pathol, Sch Med, 1402 South Grand Blvd, St Louis, MO 63104 USA.
EM douglas.blackall@health.slu.edu
OI Blackall, Douglas/0000-0003-1031-8816
CR Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Dzik S, 2020, TRANSFUS MED REV, V34, P141, DOI 10.1016/j.tmrv.2020.04.002
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Fleming AB, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104388
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Johns Hopkins University and Medicine, NEW CAS COVID 19 WOR
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Mayo Clinic, COVID 19 EXP AC PROG
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991
   Sullivan HC, 2020, TRANSFUS MED REV, V34, P145, DOI 10.1016/j.tmrv.2020.04.001
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Zhang Y, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104854
NR 15
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD OCT
PY 2020
VL 60
IS 10
BP 2203
EP 2209
DI 10.1111/trf.16026
EA AUG 2020
PG 7
WC Hematology
SC Hematology
GA OA2BZ
UT WOS:000563943400001
PM 32748963
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Patel, RH
   Acharya, A
   Mohan, M
   Byrareddy, SN
AF Patel, Raj H.
   Acharya, Arpan
   Mohan, Mahesh
   Byrareddy, Siddappa N.
TI COVID-19 and AIDS: Outcomes from the coexistence of two global pandemics
   and the importance of chronic antiretroviral therapy
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter; Early Access
ID HIV
C1 [Patel, Raj H.] Edward Via Coll Osteopath Med, Monroe, LA USA.
   [Acharya, Arpan; Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Mohan, Mahesh] Southwest Natl Primate Res Ctr, Texas Biomed Res Inst, San Antonio, TX USA.
   [Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA.
   [Byrareddy, Siddappa N.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA.
RP Byrareddy, SN (corresponding author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
EM sid.byrareddy@unmc.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 AI129745];
   Frances E. Lageschulte and Evelyn B. Weese New Frontiers in Medical
   Research Fund;  [R01DA042524];  [R01DA050169];  [P51OD011133]
FX Research reported in this publication was partially supported by
   National Institutes of Health R01 AI129745 and Frances E. Lageschulte
   and Evelyn B. Weese New Frontiers in Medical Research Fund to SNB and
   R01DA042524, R01DA050169, P51OD011133 to M.M. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the NIH.
CR Benkovic S, 2020, J MED VIROL, V92, P2338, DOI 10.1002/jmv.26029
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chen JX, 2020, J MED VIROL, V92, P1774, DOI 10.1002/jmv.25879
   COVID-19 Treatment Guidelines Panel, COVID 19 TREATM GUID
   Dauby N, 2020, AIDS, V34, P1255, DOI 10.1097/QAD.0000000000002555
   De Groot AS, 2003, VACCINE, V21, P4095, DOI 10.1016/S0264-410X(03)00489-4
   del Amo J, 2020, ANN INTERN MED, V173, P536, DOI 10.7326/M20-3689
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Gervasoni Cristina, 2020, Clin Infect Dis, V71, P2276, DOI 10.1093/cid/ciaa579
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Harter G, 2020, INFECTION, V48, P681, DOI 10.1007/s15010-020-01438-z
   Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019
   Lesko Catherine R, 2020, Am J Epidemiol, DOI 10.1093/aje/kwaa158
   Marimuthu J, 2020, J MED VIROL, DOI 10.1002/jmv.26271
   Shalev Noga, 2020, Clin Infect Dis, V71, P2294, DOI 10.1093/cid/ciaa635
   Singu S, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00406
   Siordia JA, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104357
   Suwanwongse K, 2020, J MED VIROL, V92, P2387, DOI 10.1002/jmv.26077
   Vizcarra P, 2020, LANCET HIV
   Wu QJ, 2020, J MED VIROL, V92, P2325, DOI 10.1002/jmv.26006
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
NR 23
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26416
EA AUG 2020
PG 3
WC Virology
SC Virology
GA NC5XM
UT WOS:000561290900001
PM 32779740
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Grande, R
   Fiori, G
   Russo, G
   Fioramonti, P
   Campagnol, M
   di Marzo, L
AF Grande, Raffaele
   Fiori, Giulia
   Russo, Giulia
   Fioramonti, Paolo
   Campagnol, Monica
   di Marzo, Luca
TI A multistage combined approach to promote diabetic wound healing in
   COVID-19 era
SO INTERNATIONAL WOUND JOURNAL
LA English
DT Article
DE CLI; diabetes mellitus; non-healing ulcers; NPWT; PRP
ID PLATELET-RICH PLASMA; OZONE-THERAPY; SURGICAL REVASCULARIZATION; LEG
   ULCERS; FOOT; METALLOPROTEINASES; EFFICACY; CARE
AB When diabetes mellitus is not properly controlled with drugs and a healthy lifestyle, it exposes patients with advanced peripheral arterial disease or critical limb ischaemia (CLI) to the most serious complications, in particular lower limb ulcers. Surgical or endovascular treatments represent the first line of intervention; in addition, the adequate management of ulcers can guarantee not only a faster wound healing but also the improvement of the patient's prognosis. To speed up this process, negative pressure wound therapy (NPWT), platelet-rich plasma (PRP), and other advanced moist wound dressing have been proposed. During Coronavirus disease 2019 (COVID-19) pandemic, many patients with CLI and diabetes mellitus had difficult access to advanced treatments with a significant reduction in life expectancy. We report the cases of patients with non-healing ulcers and CLI treated with an empiric multistage approach after successful endovascular revascularisation; the postoperative course was eventful in all patients, and foot ulcers are currently in an advanced state of healing. The association between adequate revascularisation, systemic anti-inflammatory, and antibiotic therapy with the multistage advanced medications ensures healing of ulcers, limb salvage, and improvement of patient prognosis.
C1 [Grande, Raffaele; Fiori, Giulia; Russo, Giulia; Fioramonti, Paolo; Campagnol, Monica; di Marzo, Luca] Sapienza Univ Rome, Dept Surg Pietro Valdoni, Rome, Italy.
RP Grande, R (corresponding author), Sapienza Univ Rome, Dept Surg Pietro Valdoni, Policlin Umberto I, Viale Policlin 151, I-00161 Rome, Italy.
EM raffaele.eia@alice.it
CR Ammendola M, 2017, INT WOUND J, V14, P9, DOI 10.1111/iwj.12682
   Antunes MB, 2019, DIABETES METAB SYND, V13, P644, DOI 10.1016/j.dsx.2018.11.032
   Blume P, 2018, WOUNDS, V30, P29
   Bocci V, 1999, BRIT J BIOMED SCI, V56, P270
   Bocci V, 2009, MED RES REV, V29, P646, DOI 10.1002/med.20150
   Cavanagh PR, 2005, LANCET, V366, P1725, DOI 10.1016/S0140-6736(05)67699-4
   Conte MS, 2019, EUR J VASC ENDOVASC, V58, pS1, DOI 10.1016/j.ejvs.2019.05.006
   De Caridi G, 2016, INT WOUND J, V13, P493, DOI 10.1111/iwj.12464
   De Caridi G, 2016, INT WOUND J, V13, P336, DOI 10.1111/iwj.12301
   de Franciscis S, 2015, INT WOUND J, V12, P250, DOI 10.1111/iwj.12085
   Deng W, 2016, J WOUND CARE, V25, P393, DOI 10.12968/jowc.2016.25.7.393
   Galle F, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16050701
   Grande R, 2020, INT WOUND J, V17, P149, DOI 10.1111/iwj.13249
   Hall ME, 2020, J CARD FAIL, V26, P462, DOI 10.1016/j.cardfail.2020.05.005
   Hingorani A, 2016, J VASC SURG, V63, p3S, DOI 10.1016/j.jvs.2015.10.003
   Ielapi Nicola, 2020, Biomark Med, V14, P713, DOI 10.2217/bmm-2020-0201
   Izadi M, 2019, DIABETES METAB SYND, V13, P822, DOI 10.1016/j.dsx.2018.11.060
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
   Ma H, 2016, SURG INFECT, V17, P378, DOI 10.1089/sur.2015.253
   Martinez-Sanchez G, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050389
   Massara M, 2015, SEMIN VASC SURG, V28, P195, DOI 10.1053/j.semvascsurg.2016.01.002
   Melissano G, 2020, J VASC SURG, V72, P4, DOI 10.1016/j.jvs.2020.04.481
   Mii S, 2017, ANN VASC SURG, V41, P196, DOI 10.1016/j.avsg.2016.09.024
   Provenzano M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010154
   Sapienza P, 2019, INT WOUND J, V16, P1034, DOI 10.1111/iwj.13154
   Sapienza P, 2019, ANN VASC SURG, V60, P293, DOI 10.1016/j.avsg.2019.02.029
   Sapienza P, 2019, INT WOUND J, V16, P716, DOI 10.1111/iwj.13086
   Sapienza P, 2018, ANN VASC SURG, V47, P162, DOI 10.1016/j.avsg.2017.08.023
   Serra R, 2014, ACTA PHLEBOL, V15, P129
   Serra R, 2017, INT WOUND J, V14, P149, DOI 10.1111/iwj.12575
   Serra R, 2016, INT WOUND J, V13, P53, DOI 10.1111/iwj.12225
   Serra R, 2015, INT WOUND J, V12, P555, DOI 10.1111/iwj.12162
   Serra R, 2015, EXPERT REV ANTI-INFE, V13, P605, DOI 10.1586/14787210.2015.1023291
   Serra R, 2013, INT WOUND J, V10, P612, DOI 10.1111/iwj.12052
   Sterpetti AV, 2011, ANN VASC SURG, V25, P766, DOI 10.1016/j.avsg.2011.01.006
   Weinstein J, 2011, DIABETES TECHNOL THE, V13, P1255, DOI 10.1089/dia.2011.0018
   Zeng JR, 2018, INT IMMUNOPHARMACOL, V56, P235, DOI 10.1016/j.intimp.2018.01.040
   Zhang WH, 2019, TISSUE ENG PART B-RE, V25, P225, DOI [10.1089/ten.teb.2018.0309, 10.1089/ten.TEB.2018.0309]
NR 38
TC 1
Z9 1
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-4801
EI 1742-481X
J9 INT WOUND J
JI Int. Wound J.
PD DEC
PY 2020
VL 17
IS 6
BP 1863
EP 1870
DI 10.1111/iwj.13476
EA AUG 2020
PG 8
WC Dermatology; Surgery
SC Dermatology; Surgery
GA PE3BU
UT WOS:000561059400001
PM 32820598
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Pettit, NN
   Nguyen, CT
   Mutlu, GM
   Wu, D
   Kimmig, L
   Pitrak, D
   Pursell, K
AF Pettit, Natasha N.
   Nguyen, Cynthia T.
   Mutlu, Gokhan M.
   Wu, David
   Kimmig, Lucas
   Pitrak, David
   Pursell, Kenneth
TI Late onset infectious complications and safety of tocilizumab in the
   management of COVID-19
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE coronavirus; cytokine; chemokine; immune responses; Il-6 inhibition;
   SARS coronavirus; tocilizumab
AB Background Tocilizumab (TCZ) has been used in the management of COVID-19-related cytokine release syndrome (CRS). Concerns exist regarding the risk of infections and drug-related toxicities. We sought to evaluate the incidence of these TCZ complications among COVID-19 patients. Methods All adult inpatients with COVID-19 between 1 March and 25 April 2020 that received TCZ were included. We compared the rate of late-onset infections (>48 hours following admission) to a control group matched according to intensive care unit admission and mechanical ventilation requirement. Post-TCZ toxicities evaluated included: elevated liver function tests (LFTs), GI perforation, diverticulitis, neutropenia, hypertension, allergic reactions, and infusion-related reactions. Results Seventy-four patients were included in each group. Seventeen infections in the TCZ group (23%) and 6 (8%) infections in the control group occurred >48 hours after admission (P = .013). Most infections were bacterial with pneumonia being the most common manifestation. Among patients receiving TCZ, LFT elevations were observed in 51%, neutropenia in 1.4%, and hypertension in 8%. The mortality rate among those that received TCZ was greater than the control (39% versus 23%,P = .03). Conclusion Late onset infections were significantly more common among those receiving TCZ. Combining infections and TCZ-related toxicities, 61% of patients had a possible post-TCZ complication. While awaiting clinical trial results to establish the efficacy of TCZ for COVID-19 related CRS, the potential for infections and TCZ related toxicities should be carefully weighed when considering use.
C1 [Pettit, Natasha N.; Nguyen, Cynthia T.] Univ Chicago Med, Dept Pharm, 5841 S Maryland Ave,MC0010, Chicago, IL 60637 USA.
   [Mutlu, Gokhan M.; Wu, David; Kimmig, Lucas] Univ Chicago Med, Dept Med, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA.
   [Pitrak, David; Pursell, Kenneth] Univ Chicago Med, Dept Med, Sect Infect Dis & Global Hlth, Chicago, IL 60637 USA.
RP Pettit, NN (corresponding author), Univ Chicago Med, Dept Pharm, 5841 S Maryland Ave,MC0010, Chicago, IL 60637 USA.
EM natasha.pettit@uchospitals.edu
OI Pettit, Natasha/0000-0002-8937-8039; Kimmig, Lucas/0000-0001-8297-0278
CR [Anonymous], 2012, LIVERTOX CLIN RES IN
   [Anonymous], 2013, TOC ACT PRESCR INF
   Antinori S, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102564
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   Dastan F, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106043
   Feng G, 2020, J CLIN TRANSL HEPATO, V8, P18, DOI 10.14218/JCTH.2020.00018
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Morena V, 2020, EUR J INTERN MED, V76, P36, DOI 10.1016/j.ejim.2020.05.011
   National Center for Immunization and Respiratory Disease (NCIRD), EV US UPD LIST UND M
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sheppard M, 2017, HUM VACC IMMUNOTHER, V13, P1972, DOI 10.1080/21645515.2017.1316909
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Van Enckevort FHJ, 1999, MED MYCOL, V37, P419, DOI 10.1046/j.1365-280X.1999.00247.x
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 25
TC 4
Z9 4
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26429
EA AUG 2020
PG 6
WC Virology
SC Virology
GA NC5XT
UT WOS:000561291600001
PM 32790075
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Shafiee, A
   Moradi, L
   Lim, M
   Brown, J
AF Shafiee, Abbas
   Moradi, Lida
   Lim, Mayasari
   Brown, Jason
TI Coronavirus disease 2019: A tissue engineering and regenerative medicine
   perspective
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article; Early Access
DE acute respiratory distress syndrome; biomaterial; cell processing;
   clinical trials; mesenchymal stem cell
ID MESENCHYMAL STEM-CELLS; ACUTE LUNG INJURY; STROMAL CELLS; IN-VIVO;
   MICROCARRIERS; SUSPENSION; COVID-19; SYSTEM; SCALE; ARDS
AB Current therapies for novel coronavirus disease (COVID-19) are generally used to manage rather than cure this highly infective disease. Therefore, there is a significant unmet medical need for a safe and effective treatment for COVID-19. Inflammation is the driving force behind coronavirus infections, and the majority of deaths caused by COVID-19 are the result of acute respiratory distress syndrome (ARDS). It is crucial to control the inflammation as early as possible. To date, numerous studies have been conducted to evaluate the safety and efficacy of tissue engineering and regenerative medicine (TERM) products, including mesenchymal stem cells (MSCs), and their derivatives (eg, exosomes) for coronavirus infections, which could be applied for the COVID-19. In this review, first, the impacts of COVID-19 pandemic in the present and future of TERM research and products are briefly presented. Then, the recent clinical trials and the therapeutic benefits of MSCs in coronavirus-induced ARDS are critically reviewed. Last, the recent advances in the field of tissue engineering relevant to the coronavirus infections, including three-dimensional platforms to study the disease progression and test the effects of antiviral agents are described. Moreover, the application of biomaterials for vaccine technology, and drug delivery are highlighted. Despite promising results in the preclinical and clinical applications of MSC therapy for coronavirus infections, the controversy still exists, and thus further investigation is required to understand the efficacy of these therapies.
C1 [Shafiee, Abbas; Brown, Jason] Metro North Hosp & Hlth Serv, Herston Biofabricat Inst, Brisbane, Qld, Australia.
   [Shafiee, Abbas; Brown, Jason] Royal Brisbane & Womens Hosp, Metro North Hosp & Hlth Serv, Brisbane, Qld, Australia.
   [Shafiee, Abbas] Univ Queensland, UQ Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia.
   [Moradi, Lida] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA.
   [Moradi, Lida] NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY USA.
   [Lim, Mayasari] RoosterBio, Frederick, MD USA.
RP Shafiee, A (corresponding author), Royal Brisbane & Womens Hosp, Div Surg, Level 8,Ned Hanlon Bldg,Butterfield St, Brisbane, Qld 4029, Australia.
EM abbas.shafiee@health.qld.gov.au
RI Shafiee, Abbas/H-9230-2019
OI Shafiee, Abbas/0000-0002-8885-9025
CR Abo-Aziza Faten A M, 2017, Int J Hematol Oncol Stem Cell Res, V11, P121
   Abraham A, 2020, STEM CELL TRANSL MED, V9, P28, DOI 10.1002/sctm.19-0205
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   Ali Omar A, 2011, Biomatter, V1, P66, DOI 10.4161/biom.1.1.16277
   Ali OA, 2011, PHARM RES-DORDR, V28, P1074, DOI 10.1007/s11095-010-0361-x
   Ali OA, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000359
   Bellingan G, 2019, AM J RESP CRIT CARE, V201, pA7353
   Broxmeyer HE, 2020, STEM CELLS DEV, V29, P625, DOI 10.1089/scd.2020.0064
   Chan MCW, 2016, P NATL ACAD SCI USA, V113, P3621, DOI 10.1073/pnas.1601911113
   Chang Y, 2014, J KOREAN MED SCI, V29, P438, DOI 10.3346/jkms.2014.29.3.438
   Chen J., 2020, ENGINEERING
   Clevers H, 2020, NAT REV MOL CELL BIO, V21, P355, DOI 10.1038/s41580-020-0258-4
   Dinh PUC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14344-7
   Ghorbani F, 2017, TISSUE ENG PART B-RE, V23, P118, DOI [10.1089/ten.teb.2016.0254, 10.1089/ten.TEB.2016.0254]
   Grivel JC, 2009, NAT PROTOC, V4, P256, DOI 10.1038/nprot.2008.245
   Hanley PJ, 2014, CYTOTHERAPY, V16, P1048, DOI 10.1016/j.jcyt.2014.01.417
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jain A, 2018, CLIN PHARMACOL THER, V103, P332, DOI 10.1002/cpt.742
   Jang KJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax5516
   Kamguyan K, 2017, BIOMATER SCI-UK, V6, P189, DOI 10.1039/c7bm00733g
   Kehoe D, 2012, BIOPHARM INT, V25, P28
   Khoury M, 2020, CYTOTHERAPY
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   Kim J, 2015, NAT BIOTECHNOL, V33, P64, DOI 10.1038/nbt.3071
   Kirian RD, 2019, CYTOTHERAPY, V21, pS71, DOI 10.1016/j.jcyt.2019.03.464
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Lechanteur C, 2014, J STEM CELL RES THER, V4
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li Y, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0395-z
   Liang B, 2020, CLIN REMISSION CRITI, V2, pv1
   Ling TY, 2006, P NATL ACAD SCI USA, V103, P9530, DOI 10.1073/pnas.0510232103
   Liu KD, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0022-z
   Mao AS, 2015, P NATL ACAD SCI USA, V112, P14452, DOI 10.1073/pnas.1508520112
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Matthay MA, 2017, LANCET RESP MED, V5, P524, DOI 10.1016/S2213-2600(17)30188-1
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   OFFEN D, 2019, CYTOTHERAPY S, V21, pE6
   Olsen TR, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00178
   Rafiq QA, 2013, BIOTECHNOL LETT, V35, P1233, DOI 10.1007/s10529-013-1211-9
   Ramani S, 2018, CURR OPIN VIROL, V29, P79, DOI 10.1016/j.coviro.2018.04.001
   Rowley JA, 2012, BIOPROCESS INT, V10, P7
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sengupta V, 2020, STEM CELLS DEV, V29, P747, DOI 10.1089/scd.2020.0080
   Shafiee A, 2020, TISSUE ENG PT A, V26, P305, DOI [10.1089/ten.tea.2019.0278, 10.1089/ten.TEA.2019.0278]
   Shafiee A, 2015, STEM CELL TRANSL MED, V4, P419, DOI 10.5966/sctm.2014-0224
   Shander A, 2020, ANESTH ANALG, V131, P74, DOI 10.1213/ANE.0000000000004844
   Shetty AK, 2020, AGING DIS, V11, P462, DOI 10.14336/AD.2020.0301
   Si L, 2020, BIORXIV
   Simonson OE, 2015, STEM CELL TRANSL MED, V4, P1199, DOI 10.5966/sctm.2015-0021
   Suderman MT, 2006, NASATP2006213723
   Szer J, 2020, BONE MARROW TRANSPL, V55, P2043, DOI 10.1038/s41409-020-0873-x
   Tatara AM, 2020, TISSUE ENG PT A, V26, P468, DOI [10.1089/ten.tea.2020.0094, 10.1089/ten.TEA.2020.0094]
   van den Berg A, 2019, LAB CHIP, V19, P198, DOI 10.1039/c8lc00827b
   Vang B, 2020, J BIOL METHODS, V7, pe130
   Vishwakarma A, 2016, TRENDS BIOTECHNOL, V34, P470, DOI 10.1016/j.tibtech.2016.03.009
   Willis GR, 2018, AM J RESP CRIT CARE, V197, P104, DOI 10.1164/rccm.201705-0925OC
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Wu YB, 2012, BIOMATERIALS, V33, P2351, DOI 10.1016/j.biomaterials.2011.11.068
   Yip HK, 2020, CRIT CARE MED, V48, pE391, DOI 10.1097/CCM.0000000000004285
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zhou J, 2020, NAT MED, V26, P1077, DOI 10.1038/s41591-020-0912-6
NR 65
TC 0
Z9 0
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
DI 10.1002/sctm.20-0197
EA AUG 2020
PG 12
WC Cell & Tissue Engineering
SC Cell Biology
GA NC2YD
UT WOS:000561081100001
PM 32820868
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Coppola, A
   Annunziata, A
   Carannante, N
   Di Spirito, V
   Fiorentino, G
AF Coppola, Antonietta
   Annunziata, Anna
   Carannante, Novella
   Di Spirito, Valentina
   Fiorentino, Giuseppe
TI Late Reactivation of SARS-CoV-2: A Case Report
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID 19; reactivation; naso pharingheal swab; IGM SARS-CoV2; IGG
   SARS-CoV2
AB SARS-CoV-2 is a betacoronavirus that belongs to the family Coronaviridae and the order Nidovirales (1). During December 2019, a series of pneumonia cases caused by a SARS-CoV-2 outbreak was identified in Wuhan, Hubei, China, and rapidly spread across the world. The spectrum of SARS-CoV-2 disease (COVID 19) varies from asymptomatic or paucisymptomatic forms to clinical conditions characterized by respiratory failure that necessitate mechanical ventilation and support in an intensive care unit (ICU), multiorgan and systemic manifestations, and, in terms of sepsis, septic shock, and multiple organ dysfunction syndromes (MODS) (2). Whilst many reports have characterized the clinical, epidemiological, laboratory, and radiological features, as well as treatment and clinical outcomes of patients with COVID-19 pneumonia, information on SARS-CoV-2 reactivation remains unreported. Curative and eradicative therapy for COVID-19 is not currently available (3). We report a case of a patient with PCR-confirmed COVID-19 pneumonia who experienced reactivation after 43 days and negative PCR sampling.
C1 [Coppola, Antonietta; Annunziata, Anna; Di Spirito, Valentina; Fiorentino, Giuseppe] Monaldi Cotugno Hosp, Dept Resp Pathophysiol, Naples, Italy.
   [Carannante, Novella] Cotugno Hosp, Div Infect Dis 1, Naples, Italy.
RP Coppola, A (corresponding author), Monaldi Cotugno Hosp, Dept Resp Pathophysiol, Naples, Italy.
EM antonietta.coppola84@gmail.com
CR Cascella M, 2020, STATPEARLS
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Ravioli S, 2020, J INFECTION, V81, pE72, DOI 10.1016/j.jinf.2020.05.008
   Richman D.D., 2016, CLIN VIROLOGY
   Ye GM, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.001
NR 5
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD AUG 20
PY 2020
VL 7
AR 531
DI 10.3389/fmed.2020.00531
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA NP4UU
UT WOS:000570173500001
PM 32974374
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alonso, AM
   Diambra, L
AF Alonso, Andres Mariano
   Diambra, Luis
TI SARS-CoV-2 Codon Usage Bias Downregulates Host Expressed Genes With
   Similar Codon Usage
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE SARS-CoV-2; codon usage bias; codon optimality; translational control;
   pathogeny; vaccine design
ID MATRIX GLA PROTEIN; SARS CORONAVIRUS; NUCLEOCAPSID PROTEIN;
   INTERFERON-GAMMA; VIRUS; EFFICIENCY; SELECTION; COMPLEX; GENOME;
   FIBRONECTIN
AB Severe acute respiratory syndrome has spread quickly throughout the world and was declared a pandemic by the World Health Organization (WHO). The pathogenic agent is a new coronavirus (SARS-CoV-2) that infects pulmonary cells with great effectiveness. In this study we focus on the codon composition for the viral protein synthesis and its relationship with the protein synthesis of the host. Our analysis reveals that SARS-CoV-2 preferred codons have poor representation of G or C nucleotides in the third position, a characteristic which could result in an unbalance in the tRNAs pools of the infected cells with serious implications in host protein synthesis. By integrating this observation with proteomic data from infected cells, we observe a reduced translation rate of host proteins associated with highly expressed genes and that they share the codon usage bias of the virus. The functional analysis of these genes suggests that this mechanism of epistasis can contribute to understanding how this virus evades the immune response and the etiology of some deleterious collateral effect as a result of the viral replication. In this manner, our finding contributes to the understanding of the SARS-CoV-2 pathogeny and could be useful for the design of a vaccine based on the live attenuated strategy.
C1 [Alonso, Andres Mariano] Univ Nacl San Martin, InTech, Chascomus, Argentina.
   [Alonso, Andres Mariano; Diambra, Luis] Consejo Nacl Invest Cient & Tecn, Chascomus, Argentina.
   [Diambra, Luis] Univ Nacl La Plata, CREG, La Plata, Argentina.
RP Diambra, L (corresponding author), Consejo Nacl Invest Cient & Tecn, Chascomus, Argentina.; Diambra, L (corresponding author), Univ Nacl La Plata, CREG, La Plata, Argentina.
EM ldiambra@gmail.com
RI Diambra, Luis/F-6319-2015
OI Diambra, Luis/0000-0001-8052-4880
CR Bataille V, 2020, DIAGNOSTIC VALUE SKI, DOI [10.1101/2020.07.10.20150656, DOI 10.1101/2020.07.10.20150656]
   BERNIER GM, 1980, VOX SANG, V38, P323, DOI 10.1111/j.1423-0410.1980.tb04500.x
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Buhr F, 2016, MOL CELL, V61, P341, DOI 10.1016/j.molcel.2016.01.008
   Cameron MJ, 2007, J VIROL, V81, P8692, DOI 10.1128/JVI.00527-07
   Cater JH, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5410657
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Chen F, 2020, NAT ECOL EVOL, V4, P589, DOI 10.1038/s41559-020-1124-7
   Coleman JR, 2008, SCIENCE, V320, P1784, DOI 10.1126/science.1155761
   Dana A, 2014, NUCLEIC ACIDS RES, V42, P9171, DOI 10.1093/nar/gku646
   Dhindsa RS, 2020, AM J HUM GENET, V107, P83, DOI 10.1016/j.ajhg.2020.05.011
   Diambra LA, 2017, PEERJ, V5, DOI 10.7717/peerj.3081
   Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793
   Frumkin I, 2018, P NATL ACAD SCI USA, V115, pE4940, DOI 10.1073/pnas.1719375115
   Gingold H, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.14
   Girard JP, 1996, J BIOL CHEM, V271, P4511
   GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7
   Gu WJ, 2004, VIRUS RES, V101, P155, DOI 10.1016/j.virusres.2004.01.006
   Haase M, 2016, GENE, V575, P171, DOI 10.1016/j.gene.2015.08.063
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hulpke S, 2013, TRENDS BIOCHEM SCI, V38, P412, DOI 10.1016/j.tibs.2013.06.003
   Hunt RC, 2014, TRENDS GENET, V30, P308, DOI 10.1016/j.tig.2014.04.006
   Hussain T, 2017, AMINO ACIDS, V49, P1457, DOI 10.1007/s00726-017-2447-9
   Kandeel M, 2020, J MED VIROL, V92, P660, DOI 10.1002/jmv.25754
   Kenney SP, 2015, VIRUS RES, V204, P31, DOI 10.1016/j.virusres.2015.04.004
   Khosroshahi HE, 2014, AM J MED GENET A, V164, P2849, DOI 10.1002/ajmg.a.36699
   Kim A, 2020, BRAIN, V143, P2027, DOI 10.1093/brain/awaa152
   Kirchner S, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2000779
   Kwan T, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a032672
   Le Nouen C, 2014, P NATL ACAD SCI USA, V111, P13169, DOI 10.1073/pnas.1411290111
   Lee KN, 2005, IMMUNITY, V22, P195, DOI 10.1016/j.immuni.2004.12.012
   Maruyama T, 2007, CLIN EXP IMMUNOL, V147, P164, DOI 10.1111/j.1365-2249.2006.03249.x
   McCarthy C, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3609-6
   Munroe PB, 1999, NAT GENET, V21, P142, DOI 10.1038/5102
   Nicholson P, 2010, CELL MOL LIFE SCI, V67, P677, DOI 10.1007/s00018-009-0177-1
   Nikolich-Zugich J, 2020, GEROSCIENCE, V42, P505, DOI 10.1007/s11357-020-00186-0
   Pan A, 1998, GENE, V215, P405, DOI 10.1016/S0378-1119(98)00257-1
   Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059
   Perez-Cano FJ, 2003, CELL IMMUNOL, V226, P86, DOI 10.1016/j.cellimm.2003.09.009
   Piovesan A, 2013, GENOMICS, V101, P282, DOI 10.1016/j.ygeno.2013.02.009
   Plotkin JB, 2011, NAT REV GENET, V12, P32, DOI 10.1038/nrg2899
   Quax TEF, 2015, MOL CELL, V59, P149, DOI 10.1016/j.molcel.2015.05.035
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Shackelton LA, 2006, J MOL EVOL, V62, P551, DOI 10.1007/s00239-005-0221-1
   Shah P, 2011, P NATL ACAD SCI USA, V108, P10231, DOI 10.1073/pnas.1016719108
   Shen B, 2020, CELL, V182, P59, DOI 10.1016/j.cell.2020.05.032
   Surjit M, 2004, BIOCHEM J, V383, P13, DOI 10.1042/BJ20040984
   Thoms M, 2020, SCIENCE, V369, P1249, DOI 10.1126/science.abc8665
   Tsai CJ, 2008, J MOL BIOL, V383, P281, DOI 10.1016/j.jmb.2008.08.012
   Tuller T, 2010, CELL, V141, P344, DOI 10.1016/j.cell.2010.03.031
   Tuller T, 2010, P NATL ACAD SCI USA, V107, P3645, DOI 10.1073/pnas.0909910107
   von Herrmann KM, 2018, NPJ PARKINSON DIS, V4, DOI 10.1038/s41531-018-0061-5
   Wang YM, 2016, CELL MOL LIFE SCI, V73, P3265, DOI 10.1007/s00018-016-2225-y
   White MP, 2015, J MOL CELL CARDIOL, V84, P13, DOI 10.1016/j.yjmcc.2015.04.006
   Xia C, 2016, J VIROL, V90, P2403, DOI 10.1128/JVI.02749-15
   Zhou T, 2009, MOL BIOL EVOL, V26, P1571, DOI 10.1093/molbev/msp070
NR 58
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD AUG 20
PY 2020
VL 8
AR 831
DI 10.3389/fcell.2020.00831
PG 8
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA NM1XV
UT WOS:000567898000001
PM 32974353
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Asgharpour, M
   Mehdinezhad, H
   Bayani, M
   Zavareh, MSH
   Hamidi, SH
   Akbari, R
   Ghadimi, R
   Bijani, A
   Mouodi, S
AF Asgharpour, Masoumeh
   Mehdinezhad, Hamed
   Bayani, Masoumeh
   Zavareh, Mahmoud Sadeghi Haddad
   Hamidi, Seyed Hossein
   Akbari, Roghayeh
   Ghadimi, Reza
   Bijani, Ali
   Mouodi, Simin
TI Effectiveness of extracorporeal blood purification (hemoadsorption) in
   patients with severe coronavirus disease 2019 (COVID-19)
SO BMC NEPHROLOGY
LA English
DT Article
DE Coronavirus infection; Extracorporeal dialysis; Critical illness
ID CYTOKINE STORM
AB BackgroundExtracorporeal blood purification has been proposed as one of the therapeutic approaches in patients with coronavirus infection, because of its beneficial impact on elimination of inflammatory cytokines.MethodsThis controlled trial has been conducted on critically ill COVID-19 patients admitted in the state hospital affiliated to Babol University of Medical Sciences, Iran who received different antiviral and antibacterial drugs, and different modalities of respiratory treatments and did not have positive clinical improvement. No randomization and blindness was considered. All of the participants underwent three sessions of resin-directed hemoperfusion using continuous renal replacement therapy with a mode of continuous venovenous hemofiltration (CVVH).ResultsFive men and five women with a mean age of 57.3018.07years have been enrolled in the study; and six of them have improved after the intervention. Peripheral capillary oxygen saturation (SpO2) changed after each session. Mean SpO2 before the three sessions of hemoperfusion was 89.60%3.94% and increased to 92.13%+/- 3.28% after them (p <0.001). Serum IL-6 showed a reduction from 139.70<plus/minus>105.62 to 72.06 +/- 65.87pg/mL (p =0.073); and c-reactive protein decreased from 136.25 +/- 84.39 to 78.25 +/- 38.67mg/L (P =0.016).Conclusions Extracorporeal hemoadsorption could improve the general condition in most of recruited patients with severe coronavirus disease; however, large prospective multicenter trials in carefully selected patients are needed to definitely evaluate the efficacy of hemoperfusion in COVID-19 patients.Trial registration The research protocol has been registered in the website of Iranian Registry of Clinical Trials with the reference number IRCT20150704023055N2.
C1 [Asgharpour, Masoumeh; Mehdinezhad, Hamed] Babol Univ Med Sci, Rouhani Hosp, Dept Internal Med, Babol, Iran.
   [Bayani, Masoumeh; Zavareh, Mahmoud Sadeghi Haddad] Babol Univ Med Sci, Infect Dis & Trop Med Res Ctr, Hlth Res Inst, Babol, Iran.
   [Hamidi, Seyed Hossein] Babol Univ Med Sci, Sch Med, Dept Anesthesiol, Babol, Iran.
   [Akbari, Roghayeh] Babol Univ Med Sci, Dept Internal Med, Babol, Iran.
   [Ghadimi, Reza; Bijani, Ali; Mouodi, Simin] Babol Univ Med Sci, Social Determinants Hlth Res Ctr, Hlth Res Inst, Ganjafrooz St, Babol, Iran.
RP Mouodi, S (corresponding author), Babol Univ Med Sci, Social Determinants Hlth Res Ctr, Hlth Res Inst, Ganjafrooz St, Babol, Iran.
EM dr.mouodi@gmail.com
RI Bijani, Ali/B-1718-2017
OI Bijani, Ali/0000-0003-2233-8726
FU Babol University of Medical Sciences, Babol, Iran [724132940]
FX The authors declare receipt of the financial support ([2020]
   No.724132940) for this research from Babol University of Medical
   Sciences, Babol, Iran. The funder supported the initiation of this study
   and organization of a multidisciplinary team for conducting the
   intervention.
CR [Anonymous], 2020, COR DIS 2019 COVID 1
   Argani H, 2018, IRAN RED CRESCENT ME, V20, DOI 10.5812/ircmj.62674
   Cascella M, 2020, FEATURES EVALUATION
   Chan KW, 2019, AM J CHINESE MED, V2020, P1
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Epstein SK, 2018, WEANING MECH VENTILA
   Garg SK, 2014, INDIAN J CRIT CARE M, V18, P399, DOI 10.4103/0972-5229.133939
   Griffiths MJD, 2019, BMJ OPEN RESPIR RES, V6, DOI 10.1136/bmjresp-2019-000420
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Harm S, 2020, BLOOD PURIFICAT, V49, P33, DOI 10.1159/000502680
   Honore PM, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0491-1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Juneja D, 2012, INDIAN J CRIT CARE M, V16, P231, DOI 10.4103/0972-5229.106511
   Kellum JA, 2016, PITTSBURGH CRITICAL, DOI [10.1093/med/9780190225537.001.0001., DOI 10.1093/MED/9780190225537.001.0001]
   Ma J, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108408
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monard C, 2019, BLOOD PURIFICAT, V47, P2, DOI 10.1159/000499520
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Schadler D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187015
   Wang L, 2020, MED MALADIES INFECT, V50, P332, DOI 10.1016/j.medmal.2020.03.007
   World Health Organization, 2020, COR HLTH TOP WHO
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang Yimin, 2020, Engineering (Beijing), DOI 10.1016/j.eng.2020.03.006
NR 28
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD AUG 20
PY 2020
VL 21
IS 1
AR 356
DI 10.1186/s12882-020-02020-3
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA NJ8AP
UT WOS:000566264400004
PM 32819292
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Arvin, AM
   Fink, K
   Schmid, MA
   Cathcart, A
   Spreafico, R
   Havenar-Daughton, C
   Lanzavecchia, A
   Corti, D
   Virgin, HW
AF Arvin, Ann M.
   Fink, Katja
   Schmid, Michael A.
   Cathcart, Andrea
   Spreafico, Roberto
   Havenar-Daughton, Colin
   Lanzavecchia, Antonio
   Corti, Davide
   Virgin, Herbert W.
TI A perspective on potential antibody-dependent enhancement of SARS-CoV-2
SO NATURE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; HUMAN MONOCLONAL-ANTIBODY;
   PARAINFLUENZA VIRUS-VACCINE; SARS-CORONAVIRUS; CONVALESCENT PLASMA;
   EFFECTOR FUNCTIONS; PROTECTIVE EFFICACY; SPIKE GLYCOPROTEIN;
   IMMUNE-RESPONSE; INFECTION
AB Antibody-dependent enhancement (ADE) of disease is a general concern for the development of vaccines and antibody therapies because the mechanisms that underlie antibody protection against any virus have a theoretical potential to amplify the infection or trigger harmful immunopathology. This possibility requires careful consideration at this critical point in the pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we review observations relevant to the risks of ADE of disease, and their potential implications for SARS-CoV-2 infection. At present, there are no known clinical findings, immunological assays or biomarkers that can differentiate any severe viral infection from immune-enhanced disease, whether by measuring antibodies, T cells or intrinsic host responses. In vitro systems and animal models do not predict the risk of ADE of disease, in part because protective and potentially detrimental antibody-mediated mechanisms are the same and designing animal models depends on understanding how antiviral host responses may become harmful in humans. The implications of our lack of knowledge are twofold. First, comprehensive studies are urgently needed to define clinical correlates of protective immunity against SARS-CoV-2. Second, because ADE of disease cannot be reliably predicted after either vaccination or treatment with antibodies-regardless of what virus is the causative agent-it will be essential to depend on careful analysis of safety in humans as immune interventions for COVID-19 move forward.
C1 [Arvin, Ann M.; Fink, Katja; Cathcart, Andrea; Spreafico, Roberto; Havenar-Daughton, Colin; Lanzavecchia, Antonio; Corti, Davide; Virgin, Herbert W.] Vir Biotechnol, San Francisco, CA USA.
   [Arvin, Ann M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
   [Fink, Katja; Schmid, Michael A.; Lanzavecchia, Antonio; Corti, Davide] Humabs Biomed SA, Bellinzona, Switzerland.
   [Virgin, Herbert W.] Washington Univ, Sch Med, St Louis, MO USA.
RP Arvin, AM; Virgin, HW (corresponding author), Vir Biotechnol, San Francisco, CA USA.; Arvin, AM (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.; Virgin, HW (corresponding author), Washington Univ, Sch Med, St Louis, MO USA.
EM aarvin@vir.bio; svirgin@vir.bio
OI Virgin, Herbert/0000-0001-8580-7628; Corti, Davide/0000-0002-5797-1364
CR [Anonymous], 2019, VACCINE, V37, P4848, DOI 10.1016/j.vaccine.2018.09.063
   Aranda SS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01006
   Atkinson J. P., 2019, CLIN IMMUNOL, DOI [10.1016/B978-0-7020-6896-6.00021-1, DOI 10.1016/B978-0-7020-6896-6.00021-1]
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Bergtold A, 2005, IMMUNITY, V23, P503, DOI 10.1016/j.immuni.2005.09.013
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Bournazos S, 2017, IMMUNITY, V47, P224, DOI 10.1016/j.immuni.2017.07.009
   Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023
   Braun J, 2020, PREPRINT, DOI [10.1101/2020.04.17.20061440v1, DOI 10.1101/2020.04.17.20061440V1]
   Browne SK, 2020, VACCINE, V38, P101, DOI 10.1016/j.vaccine.2019.10.048
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974
   Chan KH, 2005, CLIN DIAGN LAB IMMUN, V12, P1317, DOI 10.1128/CDLI.12.11.1317-1321.2005
   Chan KR, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.164, 10.1038/nmicrobiol.2016.164]
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen Z, 2017, J INFECT DIS, V215, P1807, DOI 10.1093/infdis/jix209
   Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   CHIN J, 1969, AM J EPIDEMIOL, V89, P449, DOI 10.1093/oxfordjournals.aje.a120957
   Monsalvo AC, 2011, NAT MED, V17, P195, DOI 10.1038/nm.2262
   Clay C, 2012, J VIROL, V86, P4234, DOI 10.1128/JVI.06791-11
   Co MDT, 2014, VIRAL IMMUNOL, V27, P375, DOI 10.1089/vim.2014.0061
   Corbett KS, 2020, PREPRINT, DOI [10.1101/2020.06.11.145920v1, DOI 10.1101/2020.06.11.145920V1]
   Corti D, 2015, P NATL ACAD SCI USA, V112, P10473, DOI 10.1073/pnas.1510199112
   Corti D, 2013, ANNU REV IMMUNOL, V31, P705, DOI 10.1146/annurev-immunol-032712-095916
   Crowley AR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00697
   Czub M, 2005, VACCINE, V23, P2273, DOI 10.1016/j.vaccine.2005.01.033
   de Alwis R, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102768
   de Alwis R, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004386
   de Wit E, 2019, ANTIVIR RES, V163, P70, DOI 10.1016/j.antiviral.2019.01.016
   de Wit E, 2018, ANTIVIR RES, V156, P64, DOI 10.1016/j.antiviral.2018.06.006
   Dekkers G, 2017, MABS-AUSTIN, V9, P767, DOI 10.1080/19420862.2017.1323159
   DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443
   Domachowske JB, 2018, PEDIATR INFECT DIS J, V37, P886, DOI [10.1097/inf.0000000000001916, 10.1097/INF.0000000000001916]
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Fett C, 2013, J VIROL, V87, P6551, DOI 10.1128/JVI.00087-13
   Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894
   FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956
   Galeotti C, 2017, INT IMMUNOL, V29, P491, DOI 10.1093/intimm/dxx039
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Gunn BM, 2018, CELL HOST MICROBE, V24, P221, DOI 10.1016/j.chom.2018.07.009
   Guo X., 2020, PREPRINT, DOI [10.1101/2020.02.12.20021386v1, DOI 10.1101/2020.02.12.20021386V1]
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   Ho MS, 2005, EMERG INFECT DIS, V11, P1730, DOI 10.3201/eid1111.040659
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0323-4
   Huang A., 2020, PREPRINT, DOI [10.1101/2020.04.14.20065771v1, DOI 10.1101/2020.04.14.20065771V1]
   Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Johnson RF, 2016, VIROLOGY, V490, P49, DOI 10.1016/j.virol.2016.01.004
   Joyner MJ, 2020, MAYO CLIN PROC, V95, P1888, DOI 10.1016/j.mayocp.2020.06.028
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Khurana S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006366
   KIM HW, 1976, PEDIATR RES, V10, P75, DOI 10.1203/00006450-197601000-00015
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Kong Hong, 2010, CLIN INFECT DIS, V51, P1184
   Lam JH, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94500
   Lan JM, 2015, EBIOMEDICINE, V2, P1438, DOI 10.1016/j.ebiom.2015.08.031
   Lansbury LE, 2017, VACCINE, V35, P1996, DOI 10.1016/j.vaccine.2017.02.059
   Lau Y L, 2012, Hong Kong Med J, V18 Suppl 3, P28
   Lavezzo E, 2020, NATURE, V584, P425, DOI 10.1038/s41586-020-2488-1
   Lee N, 2006, J CLIN VIROL, V35, P179, DOI 10.1016/j.jcv.2005.07.005
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Li SW, 2020, ECOTOX ENVIRON SAFE, V201, DOI 10.1016/j.ecoenv.2020.110801
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lu LL, 2018, NAT REV IMMUNOL, V18, P46, DOI 10.1038/nri.2017.106
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Martines RB, 2020, EMERG INFECT DIS, V26, P2005, DOI 10.3201/eid2609.202095
   Miyoshi-Akiyama T, 2011, J INFECT DIS, V203, P1574, DOI 10.1093/infdis/jir084
   Munster VJ, 2020, PREPRINT, DOI [10.1101/2020.03.21.001628v1, DOI 10.1101/2020.03.21.001628V1]
   MURPHY BR, 1986, J CLIN MICROBIOL, V24, P197, DOI 10.1128/JCM.24.2.197-202.1986
   Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462
   Muus C., 2020, INTEGRATED ANAL SING, DOI [10.1101/2020.04.19.049254v2, DOI 10.1101/2020.04.19.049254V2]
   Ng K., 2020, PREPRINT, DOI [10.1101/2020.05.14.095414v1, DOI 10.1101/2020.05.14.095414V1]
   Ng S, 2019, NAT MED, V25, P962, DOI 10.1038/s41591-019-0463-x
   Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Pedersen NC, 2014, VET J, V201, P123, DOI 10.1016/j.tvjl.2014.04.017
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Polack FP, 2003, NAT MED, V9, P1209, DOI 10.1038/nm918
   Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781
   Pyzik M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01540
   Qin E, 2006, VACCINE, V24, P1028, DOI 10.1016/j.vaccine.2005.06.038
   Quinlan BD, 2020, SARS COV 2 RECEPTOR, DOI DOI 10.1101/2020.04.10.036418V1
   Ramcharan T, 2020, PEDIATR CARDIOL, V41, P1391, DOI 10.1007/s00246-020-02391-2
   REED SE, 1984, J MED VIROL, V13, P179, DOI 10.1002/jmv.1890130208
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rodriguez-Barraquer I, 2019, SCIENCE, V363, P607, DOI 10.1126/science.aav6618
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Ruckwardt TJ, 2019, IMMUNITY, V51, P429, DOI 10.1016/j.immuni.2019.08.007
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Skowronski DM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000258
   Smith P, 2012, P NATL ACAD SCI USA, V109, P6181, DOI 10.1073/pnas.1203954109
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9
   Thomas SJ, 2019, HUM VACC IMMUNOTHER, V15, P2295, DOI 10.1080/21645515.2019.1658503
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Tynell J, 2016, J GEN VIROL, V97, P344, DOI 10.1099/jgv.0.000351
   van der Hoek L, 2006, FEMS MICROBIOL REV, V30, P760, DOI 10.1111/j.1574-6976.2006.00032.x
   van Doremalen N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba8399
   van Erp EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00548
   VanBlargan LA, 2016, MICROBIOL MOL BIOL R, V80, DOI 10.1128/MMBR.00024-15
   Walker LM, 2018, NAT REV IMMUNOL, V18, P297, DOI 10.1038/nri.2017.148
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wellcome Sanger Institute, HUM CELL ATL CHAN ZU
   Winarski KL, 2019, P NATL ACAD SCI USA, V116, P15194, DOI 10.1073/pnas.1821317116
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Yasui F, 2014, VIROLOGY, V454, P157, DOI 10.1016/j.virol.2014.02.005
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Yilla M, 2005, VIRUS RES, V107, P93, DOI 10.1016/j.virusres.2004.09.004
   Yip M S, 2016, Hong Kong Med J, V22, P25
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zandman-Goddard G, 2005, CLIN REV ALLERG IMMU, V29, P219, DOI 10.1385/CRIAI:29:3:219
   Zhang LQ, 2006, J MED VIROL, V78, P1, DOI 10.1002/jmv.20499
   Zhou J, 2005, VACCINE, V23, P3202, DOI 10.1016/j.vaccine.2004.11.075
   Zhou J, 2014, J INFECT DIS, V209, P1331, DOI 10.1093/infdis/jit504
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zost S. J., 2020, PREPRINT, DOI [10.1101/2020.05.22.111005v1, DOI 10.1101/2020.05.22.111005V1]
NR 137
TC 28
Z9 27
U1 10
U2 10
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD AUG 20
PY 2020
VL 584
IS 7821
BP 353
EP 363
DI 10.1038/s41586-020-2538-8
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NG4DR
UT WOS:000563935100008
PM 32659783
OA Bronze
DA 2021-01-01
ER

PT J
AU Robbiani, DF
   Gaebler, C
   Muecksch, F
   Lorenzi, JCC
   Wang, ZJ
   Cho, A
   Agudelo, M
   Barnes, CO
   Gazumyan, A
   Finkin, S
   Hagglof, T
   Oliveira, TY
   Viant, C
   Hurley, A
   Hoffmann, HH
   Millard, KG
   Kost, RG
   Cipolla, M
   Gordon, K
   Bianchini, F
   Chen, ST
   Ramos, V
   Patel, R
   Dizon, J
   Shimeliovich, I
   Mendoza, P
   Hartweger, H
   Nogueira, L
   Pack, M
   Horowitz, J
   Schmidt, F
   Weisblum, Y
   Michailidis, E
   Ashbrook, AW
   Waltari, E
   Pak, JE
   Huey-Tubman, KE
   Koranda, N
   Hoffman, PR
   West, AP
   Rice, CM
   Hatziioannou, T
   Bjorkman, PJ
   Bieniasz, PD
   Caskey, M
   Nussenzweig, MC
AF Robbiani, Davide F.
   Gaebler, Christian
   Muecksch, Frauke
   Lorenzi, Julio C. C.
   Wang, Zijun
   Cho, Alice
   Agudelo, Marianna
   Barnes, Christopher O.
   Gazumyan, Anna
   Finkin, Shlomo
   Hagglof, Thomas
   Oliveira, Thiago Y.
   Viant, Charlotte
   Hurley, Arlene
   Hoffmann, Hans-Heinrich
   Millard, Katrina G.
   Kost, Rhonda G.
   Cipolla, Melissa
   Gordon, Kristie
   Bianchini, Filippo
   Chen, Spencer T.
   Ramos, Victor
   Patel, Roshni
   Dizon, Juan
   Shimeliovich, Irina
   Mendoza, Pilar
   Hartweger, Harald
   Nogueira, Lilian
   Pack, Maggi
   Horowitz, Jill
   Schmidt, Fabian
   Weisblum, Yiska
   Michailidis, Eleftherios
   Ashbrook, Alison W.
   Waltari, Eric
   Pak, John E.
   Huey-Tubman, Kathryn E.
   Koranda, Nicholas
   Hoffman, Pauline R.
   West, Anthony P., Jr.
   Rice, Charles M.
   Hatziioannou, Theodora
   Bjorkman, Pamela J.
   Bieniasz, Paul D.
   Caskey, Marina
   Nussenzweig, Michel C.
TI Convergent antibody responses to SARS-CoV-2 in convalescent individuals
SO NATURE
LA English
DT Article
ID NEUTRALIZING ANTIBODIES; SARS CORONAVIRUS; B-CELLS; VIRUS; BROAD;
   SEQUENCE
AB During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2(1-5). Here we report on 149 COVID-19-convalescent individuals. Plasma samples collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres; titres were less than 50 in 33% of samples, below 1,000 in 79% of samples and only 1% of samples had titres above 5,000. Antibody sequencing revealed the expansion of clones of RBD-specific memory B cells that expressed closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutralized the virus with half-maximal inhibitory concentrations (IC50 values) as low as 2 ng ml(-1). In conclusion, most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
C1 [Robbiani, Davide F.; Gaebler, Christian; Lorenzi, Julio C. C.; Wang, Zijun; Cho, Alice; Agudelo, Marianna; Gazumyan, Anna; Finkin, Shlomo; Hagglof, Thomas; Oliveira, Thiago Y.; Viant, Charlotte; Millard, Katrina G.; Cipolla, Melissa; Gordon, Kristie; Bianchini, Filippo; Chen, Spencer T.; Ramos, Victor; Patel, Roshni; Dizon, Juan; Shimeliovich, Irina; Mendoza, Pilar; Hartweger, Harald; Nogueira, Lilian; Pack, Maggi; Horowitz, Jill; Caskey, Marina; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.
   [Muecksch, Frauke; Barnes, Christopher O.; Schmidt, Fabian; Weisblum, Yiska; Hatziioannou, Theodora; Bieniasz, Paul D.] Rockefeller Univ, Lab Retrovirol, 1230 York Ave, New York, NY 10021 USA.
   [Huey-Tubman, Kathryn E.; Koranda, Nicholas; Hoffman, Pauline R.; West, Anthony P., Jr.; Bjorkman, Pamela J.] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA.
   [Hurley, Arlene] Rockefeller Univ, Hosp Program Direct, 1230 York Ave, New York, NY 10021 USA.
   [Hoffmann, Hans-Heinrich; Michailidis, Eleftherios; Ashbrook, Alison W.; Rice, Charles M.] Rockefeller Univ, Lab Virol & Infect Dis, 1230 York Ave, New York, NY 10021 USA.
   [Kost, Rhonda G.] Rockefeller Univ, Ctr Clin Translat Sci, 1230 York Ave, New York, NY 10021 USA.
   [Waltari, Eric; Pak, John E.] Chan Zuckerberg Biohub, San Francisco, CA USA.
   [Bieniasz, Paul D.; Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.
   [Robbiani, Davide F.] Univ Svizzera italiana, Inst Res Biomed, Bellinzona, Switzerland.
RP Robbiani, DF; Caskey, M; Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.; Bieniasz, PD (corresponding author), Rockefeller Univ, Lab Retrovirol, 1230 York Ave, New York, NY 10021 USA.; Bjorkman, PJ (corresponding author), CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA.; Bieniasz, PD; Nussenzweig, MC (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.; Robbiani, DF (corresponding author), Univ Svizzera italiana, Inst Res Biomed, Bellinzona, Switzerland.
EM drobbiani@irb.usi.ch; bjorkman@caltech.edu; pbieniasz@rockefeller.edu;
   mcaskey@rockefeller.edu; nussen@rockefeller.edu
RI Robbiani, Davide F./AAF-7662-2019; Oliveira, Thiago Yukio
   Kikuchi/ABF-5186-2020; Cetrulo Lorenzi, Julio Cesar/B-5264-2008
OI Robbiani, Davide F./0000-0001-7379-3484; Oliveira, Thiago Yukio
   Kikuchi/0000-0002-2654-0879; Cetrulo Lorenzi, Julio
   Cesar/0000-0003-2492-3961; Ashbrook, Alison/0000-0003-1114-1426;
   Cipolla, Melissa/0000-0001-8156-2512; Michailidis,
   Eleftherios/0000-0002-9907-4346; Wang, Zijun/0000-0002-2095-2151;
   Gaebler, Christian/0000-0001-7295-8128; Mendoza Daroca,
   Pilar/0000-0003-2957-1811
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P01-AI138398-S1, 2U19AI111825];
   Caltech Merkin Institute for Translational Research; George Mason
   University Fast Grants; European ATAC consortium EC [101003650]; G.
   Harold and Leila Y. Mathers Charitable Foundation; Robert S. Wennett
   Post-Doctoral Fellowship; National Center for Advancing Translational
   Sciences (National Institutes of Health Clinical and Translational
   Science Award programme) [UL1 TR001866]; Shapiro-Silverberg Fund for the
   Advancement of Translational Research;  [P50 AI150464]; 
   [R01-AI091707-10S1];  [R37-AI64003];  [R01AI78788]
FX We thank all study participants who devoted time to our research; B.
   Coller and S. Schlesinger, the Rockefeller University Hospital Clinical
   Research Support Office and nursing staff; J. L. DeRisi for facilitating
   interactions with the Chan Zuckerberg Biohub; all members of the M.C.N.
   laboratory for discussions; A. Escolano, G. Breton and B. Reis; M.
   Jankovic for laboratory support; and J. Vielmetter and the Protein
   Expression Center in the Beckman Institute at Caltech. This work was
   supported by NIH grant P01-AI138398-S1 (M.C.N., C.M.R. and P.J.B.) and
   2U19AI111825 (M.C.N. and C.M.R.); the Caltech Merkin Institute for
   Translational Research and P50 AI150464 (P.J.B.), George Mason
   University Fast Grants (D.F.R. and P.J.B.) and the European ATAC
   consortium EC 101003650 (D.F.R.); R01-AI091707-10S1 to C.M.R.;
   R37-AI64003 to P.D.B.; R01AI78788 to T. Hatziioannou; The G. Harold and
   Leila Y. Mathers Charitable Foundation to C.M.R. Electron microscopy was
   performed in the Caltech Beckman Institute Resource Center for
   Transmission Electron Microscopy (directors: S. Chen and A. Malyutin).
   C.G. was supported by the Robert S. Wennett Post-Doctoral Fellowship, in
   part by the National Center for Advancing Translational Sciences
   (National Institutes of Health Clinical and Translational Science Award
   programme, grant UL1 TR001866) and by the Shapiro-Silverberg Fund for
   the Advancement of Translational Research. P.D.B. and M.C.N. are
   investigators of the Howard Hughes Medical Institute.
CR ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Barnes CO, 2020, CELL, V182, P828, DOI 10.1016/j.cell.2020.06.025
   Bournazos S, 2017, IMMUNOL REV, V275, P285, DOI 10.1111/imr.12482
   Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   DeWitt WS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160853
   Ehrhardt SA, 2019, NAT MED, V25, P1589, DOI 10.1038/s41591-019-0602-4
   Feinberg MB, 2017, SCIENCE, V358, P865, DOI 10.1126/science.aaq0215
   Goddard TD, 2007, J STRUCT BIOL, V157, P281, DOI 10.1016/j.jsb.2006.06.010
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gralinski LE, 2015, J PATHOL, V235, P185, DOI 10.1002/path.4454
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359
   GUY HR, 1985, BIOPHYS J, V47, P61, DOI 10.1016/S0006-3495(85)83877-7
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Kane M, 2016, CELL HOST MICROBE, V20, P392, DOI 10.1016/j.chom.2016.08.005
   Klein F, 2014, J EXP MED, V211, P2361, DOI 10.1084/jem.20141050
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   Murugan R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8029
   Pappas L, 2014, NATURE, V516, P418, DOI 10.1038/nature13764
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024
   Rubelt F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049774
   Salazar G, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0019-3
   Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227
   Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930
   Schmidt F, 2020, J EXP MED, V217, DOI 10.1084/jem.20201181
   Schoofs T, 2019, IMMUNITY, V50, P1513, DOI 10.1016/j.immuni.2019.04.014
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Tiller T, 2007, IMMUNITY, V26, P205, DOI 10.1016/j.immuni.2007.01.009
   Van Rompay KKA, 2020, P NATL ACAD SCI USA, V117, P7981, DOI 10.1073/pnas.2000414117
   von Boehmer L, 2016, NAT PROTOC, V11, P1908, DOI 10.1038/nprot.2016.102
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wang Q, 2020, CELL HOST MICROBE, V28, P335, DOI 10.1016/j.chom.2020.05.010
   Wang ZJ, 2020, J IMMUNOL METHODS, V478, DOI 10.1016/j.jim.2019.112734
   Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 47
TC 120
Z9 119
U1 16
U2 20
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD AUG 20
PY 2020
VL 584
IS 7821
BP 437
EP +
DI 10.1038/s41586-020-2456-9
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NG4DR
UT WOS:000563935100023
PM 32555388
OA Green Accepted, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Shook, NJ
   Sevi, B
   Lee, J
   Oosterhoff, B
   Fitzgerald, HN
AF Shook, Natalie J.
   Sevi, Baris
   Lee, Jerin
   Oosterhoff, Benjamin
   Fitzgerald, Holly N.
TI Disease avoidance in the time of COVID-19: The behavioral immune system
   is associated with concern and preventative health behaviors
SO PLOS ONE
LA English
DT Article
ID INDIVIDUAL-DIFFERENCES; PATHOGEN PREVALENCE; VULNERABILITY; PERSONALITY;
   DOMAINS
AB The coronavirus disease 2019 (COVID-19) poses a serious global health threat. Without a vaccine, behavior change is the most effective means of reducing disease transmission. Identifying psychological factors that may encourage engagement in preventative health behaviors is crucial. The behavioral immune system (BIS) represents a set of psychological processes thought to promote health by encouraging disease avoidance behaviors. This study examined whether individual differences in BIS reactivity (germ aversion, pathogen disgust sensitivity) were associated with concern about COVID-19 and engagement in recommended preventative health behaviors (social distancing, handwashing, cleaning/disinfecting, avoiding touching face, wearing facemasks). From March 20 to 23, 2020, a US national sample (N= 1019) completed an online survey. Germ aversion and pathogen disgust sensitivity were the two variables most consistently associated with COVID-19 concern and preventative health behaviors, while accounting for demographic, health, and psychosocial covariates. Findings have implications for the development of interventions intended to increase preventative health behaviors.
C1 [Shook, Natalie J.; Sevi, Baris; Lee, Jerin; Fitzgerald, Holly N.] Univ Connecticut, Storrs, CT 06269 USA.
   [Oosterhoff, Benjamin] Montana State Univ, Bozeman, MT 59717 USA.
RP Shook, NJ (corresponding author), Univ Connecticut, Storrs, CT 06269 USA.
EM natalie.shook@uconn.edu
OI Sevi, Baris/0000-0001-9663-4339
FU RAPID grant from the National Science Foundation [BCS-2027027]
FX This work was supported by a RAPID grant from the National Science
   Foundation under Award ID BCS-2027027 (PI Shook). The funding
   organization was not involved in designing the study, collecting and
   analyzing the data, or preparing the manuscript.
CR Ahrenfeldt LJ, 2018, PUBLIC HEALTH, V165, P74, DOI 10.1016/j.puhe.2018.09.009
   Centers for diasease control and prevention, 2020, PROT YOURS
   Centers for Disease Control and Prevention, 2020, PEOPL WHO NEED TAK E
   Centers for Disease Control and Prevention, 2020, REC REG US CLOTH FAC
   Diaz R, 2020, PREPRINT, DOI [10.31234/osf.io/5zrqx, DOI 10.31234/OSF.IO/5ZRQX]
   Duncan LA, 2009, PERS INDIV DIFFER, V47, P541, DOI 10.1016/j.paid.2009.05.001
   Fincher CL, 2008, P ROY SOC B-BIOL SCI, V275, P1279, DOI 10.1098/rspb.2008.0094
   Fincher CL, 2012, BEHAV BRAIN SCI, V35, P99, DOI 10.1017/S0140525X11001774
   Friedman HS, 2019, PERSONAL DISORD, V10, P25, DOI 10.1037/per0000274
   Gadarian Shana Kushner, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3562796, DOI 10.2139/SSRN.3562796]
   Gassen J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203961
   Goh JX, 2020, PREPRINT, DOI [10.31234/osf.io/52bw4, DOI 10.31234/OSF.IO/52BW4]
   HAIDT J, 1994, PERS INDIV DIFFER, V16, P701, DOI 10.1016/0191-8869(94)90212-7
   Hill SE, 2016, ADAPT HUM BEHAV PHYS, V2, P116, DOI 10.1007/s40750-015-0040-6
   Miller SL, 2011, PSYCHOL SCI, V22, P1467, DOI 10.1177/0956797611420166
   Murray DR, 2014, J CROSS CULT PSYCHOL, V45, P971, DOI 10.1177/0022022114532356
   Oosterhoff B, 2018, J RES PERS, V77, P47, DOI 10.1016/j.jrp.2018.09.008
   Rammstedt B, 2007, J RES PERS, V41, P203, DOI 10.1016/j.jrp.2006.02.001
   Schaller M., 2007, OXFORD HDB EVOLUTION, P491, DOI DOI 10.1093/OXFORDHB/9780198568308.013.0033
   Schaller M, 2007, SYD SYM SOC PSYCHOL, P293
   Schaller M, 2006, PSYCHOL INQ, V17, P96
   Schaller M, 2011, CURR DIR PSYCHOL SCI, V20, P99, DOI 10.1177/0963721411402596
   Shook NJ, 2019, PERS INDIV DIFFER, V150, DOI 10.1016/j.paid.2019.05.063
   Stamatoulakis KK, 2013, PROCD SOC BEHV, V82, P830, DOI 10.1016/j.sbspro.2013.06.357
   Strickhouser JE, 2017, HEALTH PSYCHOL, V36, P797, DOI 10.1037/hea0000475
   Terrizzi JA, 2013, EVOL HUM BEHAV, V34, P99, DOI 10.1016/j.evolhumbehav.2012.10.003
   Thiruchselvam R, 2017, SOC COGN AFFECT NEUR, V12, P956, DOI 10.1093/scan/nsx023
   Trump DJ, 2020, PROCLAMATION DECLARI
   TYBUR JM, 2014, EVOL BEHAV SCI, V8, P274, DOI DOI 10.1037/EBS0000017)
   Tybur JM, 2009, J PERS SOC PSYCHOL, V97, P103, DOI 10.1037/a0015474
   West R, 2020, NAT HUM BEHAV, DOI 10.1038/s41562-020-0887-9
   WHO, 2020, COR DIS COVID 19 PAN
   WHO, 2020, DIR GEN OP REM MED B
   World Health Organization, 2020, COR DIS COVID 19 ADV
NR 34
TC 0
Z9 0
U1 8
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 20
PY 2020
VL 15
IS 8
AR e0238015
DI 10.1371/journal.pone.0238015
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NG9QD
UT WOS:000564315600091
PM 32817714
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bookani, KR
   Minga, I
   Chander, M
   Hankewych, K
   Plassmeier, M
   Tafur, A
AF Bookani, Kaveh Rezaei
   Minga, Iva
   Chander, Manisha
   Hankewych, Ksenia
   Plassmeier, Matthew
   Tafur, Alfonso
TI Drive-Through Model for Anticoagulation Clinics During the COVID-19
   Pandemic
SO CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
LA English
DT Article
DE COVID-19; anticoagulation; drive-through clinic
ID CARE
AB The coronavirus disease of 2019 (COVID-19) has posed a major challenge for providers and patients. A large number of patients with atrial fibrillation, venous thromboembolism, or valvular heart disease are chronically anticoagulated with vitamin K antagonists and rely on frequent follow ups at anticoagulation clinics for management of their anticoagulation therapy. The need for isolation during COVID-19 pandemic can potentially limit access to health care including anticoagulation clinics and directly affect the care of patients on chronic anticoagulation. Therefore, we created a drive-through clinic to bridge the gap of continuation of care and preservation of social distancing precautions. In this manuscript, we report the steps in implementing such initiative which can be applied to other clinics during a pandemic.
C1 [Bookani, Kaveh Rezaei] Northshore Univ Hlth Syst, Dept Med, Div Cardiovasc Med, Evanston, IL 60201 USA.
   [Bookani, Kaveh Rezaei; Minga, Iva; Tafur, Alfonso] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
   [Minga, Iva] Northshore Univ Hlth Syst, Dept Med, Evanston, IL 60201 USA.
   [Chander, Manisha; Hankewych, Ksenia; Plassmeier, Matthew] Northshore Univ Hlth Syst, Dept Pharm, Skokie, IL USA.
   [Tafur, Alfonso] Northshore Univ Hlth Syst, Dept Med, Div Vasc Med, Evanston, IL 60201 USA.
RP Bookani, KR (corresponding author), Northshore Univ Hlth Syst, Div Cardiovasc Med, 2650 Ridge Ave,Suite 1304, Evanston, IL 60201 USA.
EM KRezaeiBookani@northshore.org
OI Rezaei Bookani, Kaveh/0000-0002-8476-5005
CR Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Brigden ML, 1996, POSTGRAD MED, V99, P81
   Chiquette E, 1998, ARCH INTERN MED, V158, P1641, DOI 10.1001/archinte.158.15.1641
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Fineberg HV, 2014, NEW ENGL J MED, V370, P1335, DOI 10.1056/NEJMra1208802
   Gill James M, 2002, Jt Comm J Qual Improv, V28, P625
   Gupta A, 2013, SIMUL MODEL PRACT TH, V37, P99, DOI 10.1016/j.simpat.2013.06.004
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Meijer P, 2006, AM J CLIN PATHOL, V126, P756, DOI 10.1309/6Q8DY5J1THA8BQG3
   Michel-Kerjan E, 2010, MORE DANGEROUS WORLD, P1
   Rossiter Jennifer, 2013, Int J Family Med, V2013, P691454, DOI 10.1155/2013/691454
NR 11
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1076-0296
EI 1938-2723
J9 CLIN APPL THROMB-HEM
JI Clin. Appl. Thromb.-Hemost.
PD AUG 20
PY 2020
VL 26
AR 1076029620947476
DI 10.1177/1076029620947476
PG 5
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA NF7VV
UT WOS:000563503200001
PM 32822220
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Maurya, AK
   Mishra, N
AF Maurya, Akhilesh Kumar
   Mishra, Nidhi
TI In silicovalidation of coumarin derivatives as potential inhibitors
   against Main Protease, NSP10/NSP16-Methyltransferase, Phosphatase and
   Endoribonuclease of SARS CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS CoV-2; docking; ADME; T; binding free energy; MD simulation;
   inhibitor
ID CORONAVIRUS; SOLUBILITY; DYNAMICS
AB Coronavirus Disease (COVID-19) is recently declared pandemic (WHO) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The virus was named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), (Coronavirus Disease 2019). Currently, there is no specific drug for the therapy of COVID-19. So, there is a need to develop or find out the new drug from the existing to cure the COVID-19. Identification of a potent inhibitor of Methyltransferase, Endoribonuclease, Phosphatase and Main Protease enzymes of SARS CoV-2 by coumarin derivatives usinginsilicoapproach. Thein silicostudies were performed on maestro 12.0 software (Schrodinger LLC 2019, USA). Two thousand seven hundred fifty-five biologically active coumarin derivative was docked with above receptor proteins of SARS CoV-2. The molecular dynamic simulation of the top one ligand of respected proteins was performed. Top five ligands of each protein were taken for study. Coumarin derivatives actively interact with taken receptors and showed good docking results for Methyltransferase, Endoribonuclease, Phosphatase and Main Protease and top five compounds of each have docking score from -9.00 to -7.97, -8.42 to -6.80, -8.63 to -7.48 and -7.30 to -6.01 kcal/mol, respectively. The docked compounds were showed RMSD and binding stability of simulated ligands are show the potency of ligands against the SARS CoV-2. Our study provides information on drugs that may be a potent inhibitor of COVID-19 infection. Drug repurposing of the available drugs would be great help in the treatment of COVID-19 infection. The combination therapy of the finding may improve inhibitory activity. Communicated by Ramaswamy H. Sarma
C1 [Maurya, Akhilesh Kumar; Mishra, Nidhi] Indian Inst Informat Technol Allahabad, Dept Appl Sci, Chem Lab, Prayagraj 211012, UP, India.
RP Mishra, N (corresponding author), Indian Inst Informat Technol Allahabad, Dept Appl Sci, Chem Lab, Prayagraj 211012, UP, India.
EM nidhimishra@iiita.ac.in
RI Maurya, Akhilesh Kumar/AAY-3479-2020
OI Maurya, Akhilesh Kumar/0000-0003-3281-532X
FU Ministry of Human Resource Development
FX The authors are grateful to the Ministry of Human Resource Development
   for funding as research fellowship.
CR [Anonymous], 2006, ADV VIRUS RES, V66
   Berendsen H. J. C., 1981, INTERMOLECULAR FORCE, V33
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Bezergiannidou-Baloucts C., 1993, LIEBIGS ANN CHEM, V1993, P1175, DOI DOI 10.1002/JLAC.1993199301190
   Deng XF, 2019, J VIROL, V93, DOI [10.1128/JVI.02000-18, 10.1128/jvi.02000-18]
   Deng XF, 2018, VIROLOGY, V517, P157, DOI 10.1016/j.virol.2017.12.024
   Egan D, 1997, CANCER LETT, V118, P201, DOI 10.1016/S0304-3835(97)00331-5
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hwu JR, 2008, ANTIVIR RES, V77, P157, DOI 10.1016/j.antiviral.2007.09.003
   Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X
   Joseph JS, 2007, J VIROL, V81, P6700, DOI 10.1128/JVI.02817-06
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   Ligprep M., 2011, QIKPROP
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   Maurya SK, 2020, J RECEPT SIG TRANSD, V40, P605, DOI 10.1080/10799893.2020.1772298
   Murray R. D., 2002, FORTSCHRITTE CHEMIEO, V83
   Nicolaides DN, 1996, J HETEROCYCLIC CHEM, V33, P967, DOI 10.1002/jhet.5570330367
   Olomola TO, 2013, BIOORGAN MED CHEM, V21, P1964, DOI 10.1016/j.bmc.2013.01.025
   Ou XY, 2016, J VIROL, V90, P5586, DOI 10.1128/JVI.00015-16
   Pavurala S, 2018, SYNTHETIC COMMUN, V48, P1494, DOI 10.1080/00397911.2018.1455871
   Pawar AY, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105984
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Senanayake S. L., 2020, FUTURE DRUG DISCOVER, V2, pFDD40, DOI [10.4155/fdd-2020-0010, DOI 10.4155/FDD-2020-0010]
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Vanommeslaeghe K, 2012, J CHEM INF MODEL, V52, P3144, DOI 10.1021/ci300363c
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Wizard P. P., 2009, JAGUAR GLIDE
   World Health Organization, 2020, WHO COR DIS COVID 19
NR 33
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1808075
EA AUG 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA ND9QU
UT WOS:000562235700001
PM 32835632
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Barnes, CO
   West, AP
   Huey-Tubman, KE
   Hoffmann, MAG
   Sharaf, NG
   Hoffman, PR
   Koranda, N
   Gristick, HB
   Gaebler, C
   Muecksch, F
   Lorenzi, JCC
   Finkin, S
   Hagglof, T
   Hurley, A
   Millard, KG
   Weisblum, Y
   Schmidt, F
   Hatziioannou, T
   Bieniasz, PD
   Caskey, M
   Robbiani, DF
   Nussenzweig, MC
   Bjorkman, PJ
AF Barnes, Christopher O.
   West, Anthony P., Jr.
   Huey-Tubman, Kathryn E.
   Hoffmann, Magnus A. G.
   Sharaf, Naima G.
   Hoffman, Pauline R.
   Koranda, Nicholas
   Gristick, Harry B.
   Gaebler, Christian
   Muecksch, Frauke
   Lorenzi, Julio C. Cetrulo
   Finkin, Shlomo
   Hagglof, Thomas
   Hurley, Arlene
   Millard, Katrina G.
   Weisblum, Yiska
   Schmidt, Fabian
   Hatziioannou, Theodora
   Bieniasz, Paul D.
   Caskey, Marina
   Robbiani, Davide F.
   Nussenzweig, Michel C.
   Bjorkman, Pamela J.
TI Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common
   Epitopes and Recurrent Features of Antibodies
SO CELL
LA English
DT Article
ID POTENT NEUTRALIZING ANTIBODIES; CRYO-EM STRUCTURE; FUNCTIONAL RECEPTOR;
   MONOCLONAL-ANTIBODY; CORONAVIRUS; PROTECTION; HIV-1; SARS; PERFORMANCE;
   VALIDATION
AB Neutralizing antibody responses to coronaviruses mainly target the receptor-binding domain (RBD) of the trimeric spike. Here, we characterized polyclonal immunoglobulin Gs (IgGs) and Fabs from COVID-19 convalescent individuals for recognition of coronavirus spikes. Plasma IgGs differed in their focus on RBD epitopes, recognition of alpha- and beta-coronaviruses, and contributions of avidity to increased binding/neutralization of IgGs over Fabs. Using electron microscopy, we examined specificities of polyclonal plasma Fabs, revealing recognition of both S1(A) and RBD epitopes on SARS-CoV-2 spike. Moreover, a 3.4 A cryo-electron microscopy (cryo-EM) structure of a neutralizing monoclonal Fab-spike complex revealed an epitope that blocks ACE2 receptor binding. Modeling based on these structures suggested different potentials for inter-spike crosslinking by IgGs on viruses, and characterized IgGs would not be affected by identified SARS-CoV-2 spike mutations. Overall, our studies structurally define a recurrent anti-SARS-CoV-2 antibody class derived from VH3-53/VH3-66 and similarity to a SARS-CoV VH3-30 antibody, providing criteria for evaluating vaccine-elicited antibodies.
C1 [Barnes, Christopher O.; West, Anthony P., Jr.; Huey-Tubman, Kathryn E.; Hoffmann, Magnus A. G.; Hoffman, Pauline R.; Koranda, Nicholas; Gristick, Harry B.; Bjorkman, Pamela J.] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA.
   [Sharaf, Naima G.] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.
   [Gaebler, Christian; Lorenzi, Julio C. Cetrulo; Finkin, Shlomo; Hagglof, Thomas; Millard, Katrina G.; Caskey, Marina; Robbiani, Davide F.; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.
   [Muecksch, Frauke; Weisblum, Yiska; Schmidt, Fabian; Hatziioannou, Theodora; Bieniasz, Paul D.] Rockefeller Univ, Lab Retrovirol, 1230 York Ave, New York, NY 10021 USA.
   [Hurley, Arlene] Rockefeller Univ, Hosp Program Direct, 1230 York Ave, New York, NY 10021 USA.
   [Bieniasz, Paul D.; Nussenzweig, Michel C.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
   [Robbiani, Davide F.] Univ Svizzera Italiana, Inst Res Biomed, Bellinzona, Switzerland.
RP Bjorkman, PJ (corresponding author), CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA.; Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.; Nussenzweig, MC (corresponding author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
EM nussen@mail.rockefeller.edu; bjorkman@caltech.edu
OI Robbiani, Davide F./0000-0001-7379-3484
FU U.S. Department of Energy, Office of Science, Office of Basic Energy
   SciencesUnited States Department of Energy (DOE) [DE-AC02-76SF00515];
   DOE Office of Biological and Environmental ResearchUnited States
   Department of Energy (DOE); NIH, National Institute of General Medical
   SciencesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [P41GM103393]; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [P01-AI138938-S1, P50 8 P50 AI150464-13, 2U19AI111825]; Caltech Merkin
   Institute for Translational Research; George Mason University Fast
   Grants; Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine
   Discovery (CAVD) [INV-002143]; Hanna Gray Fellowship Program from the
   Howard Hughes Medical Institute; Postdoctoral Enrichment Program from
   the Burroughs Wellcome Fund; National Center for Advancing Translational
   Sciences (NCATS, National Institutes of Health Clinical and
   Translational Science Award [CTSA] program) [UL1 TR001866];
   Shapiro-Silverberg Fund for the Advancement of Translational Research
FX We gratefully acknowledge all labs and authors for making SARS-CoV-2
   genome sequence data available for this research. We thank all study
   participants who devoted time to our research, Drs. Barry Coller and
   Sarah Schlesinger, and the Rockefeller University Hospital Clinical
   Research Support Office and nursing staff. We thank the Global
   Initiative on Sharing Avian Influenza Data (GISAID) and the originating
   and submitting laboratories for sharing the SARS-CoV-2 genome sequences;
   see Table S4 for a list of sequence contributors. We thank members of
   the Bjorkman, Nussenzweig, and Bienasz laboratories for helpful
   discussions, Drs. John Pak (Chan Zuckerberg Biohub) and Florian Krammer
   (Icahn School of Medicine at Mount Sinai) for CoV expression plasmids,
   Drs. Songye Chen and Andrey Malyutin (Caltech) for maintaining electron
   microscopes, Dr. Jost Vielmetter and the Protein Expression Center in
   the Beckman Institute at Caltech for expression assistance, and Ms.
   Marta Murphy for help with figures. Electron microscopy was performed in
   the Caltech Beckman Institute Resource Center for Transmission Electron
   Microscopy. We thank the Gordon and Betty Moore and Beckman Foundations
   for gifts to Caltech to support the Molecular Observatory (Dr. Jens
   Kaiser, director), and Drs. Silvia Russi, Aina Cohen, and Clyde Smith
   and the beamline staff at SSRL for data collection assistance. Use of
   the Stanford Synchrotron Radiation Lightsource, SLAC National
   Accelerator Laboratory is supported by the U.S. Department of Energy,
   Office of Science, Office of Basic Energy Sciences (DE-AC02-76SF00515).
   The SSRL Structural Molecular Biology Program is supported by the DOE
   Office of Biological and Environmental Research, and by the NIH,
   National Institute of General Medical Sciences (P41GM103393). The
   contents of this publication are solely the responsibility of the
   authors and do not necessarily represent the official views of NIGMS or
   NIH. This work was supported by NIH (P01-AI138938-S1 to P.J.B. and
   M.C.N., P50 8 P50 AI150464-13 to P.J.B., and 2U19AI111825 to M.C.N.),
   the Caltech Merkin Institute for Translational Research (to P.J.B.),
   George Mason University Fast Grants (to P.J.B. and D.F.R.), and the Bill
   and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery
   (CAVD) (INV-002143 to P.J.B. and M.C.N.). C.O.B was supported by the
   Hanna Gray Fellowship Program from the Howard Hughes Medical Institute
   and the Postdoctoral Enrichment Program from the Burroughs Wellcome
   Fund. C.G. is a fellow of the Robert S. Wennett and Mario Cader-Frech
   Foundation and was supported in part by the National Center for
   Advancing Translational Sciences (NCATS, National Institutes of Health
   Clinical and Translational Science Award [CTSA] program) (UL1 TR001866),
   and by the Shapiro-Silverberg Fund for the Advancement of Translational
   Research. P.D.B. and M.C.N. are Howard Hughes Medical Institute
   Investigators.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Bell JM, 2016, METHODS, V100, P25, DOI 10.1016/j.ymeth.2016.02.018
   Bianchi M, 2018, IMMUNITY, V49, P288, DOI 10.1016/j.immuni.2018.07.009
   Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dunbar J, 2014, NUCLEIC ACIDS RES, V42, pD1140, DOI 10.1093/nar/gkt1043
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Goddard TD, 2007, J STRUCT BIOL, V157, P281, DOI 10.1016/j.jsb.2006.06.010
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gralinski LE, 2015, J PATHOL, V235, P185, DOI 10.1002/path.4454
   Gristick HB, 2016, NAT STRUCT MOL BIOL, V23, P906, DOI 10.1038/nsmb.3291
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Harris LJ, 1998, J MOL BIOL, V275, P861, DOI 10.1006/jmbi.1997.1508
   HARRIS LJ, 1992, NATURE, V360, P369, DOI 10.1038/360369a0
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Kane M, 2016, CELL HOST MICROBE, V20, P392, DOI 10.1016/j.chom.2016.08.005
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kirchdoerfer R.N., 2020, BIORXIV, DOI [10.1101/2020.02.18.955195, DOI 10.1101/2020.02.18.955195]
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Klein JS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000908
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370
   Lefranc MP, 2015, NUCLEIC ACIDS RES, V43, pD413, DOI 10.1093/nar/gku1056
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li ZJ, 2019, ELIFE, V8, DOI 10.7554/eLife.51230
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Nogal B, 2020, CELL REP, V30, P3755, DOI 10.1016/j.celrep.2020.02.061
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Plotkin SA, 2001, PEDIATR INFECT DIS J, V20, P63, DOI 10.1097/00006454-200101000-00013
   Plotkin SA, 2008, CLIN INFECT DIS, V47, P401, DOI 10.1086/589862
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   Price M.N., 2010, FASTTREE 2 APPROXIMA
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Quinlan B. D., 2020, BIORXIV, DOI [10.1101/2020.04.10.036418, DOI 10.1101/2020.04.10.036418]
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reguera J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002859
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008
   Sandin S, 2004, STRUCTURE, V12, P409, DOI 10.1016/j.str.2004.02.011
   Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692
   Scharf L, 2015, CELL, V162, P1379, DOI 10.1016/j.cell.2015.08.035
   Schoofs T, 2019, IMMUNITY, V50, P1513, DOI 10.1016/j.immuni.2019.04.014
   Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shang J, 2018, J VIROL, V92, DOI 10.1128/JVI.01556-17
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Terwilliger TC, 2018, NAT METHODS, V15, P905, DOI 10.1038/s41592-018-0173-1
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8712
   Widjaja I, 2019, EMERG MICROBES INFEC, V8, P516, DOI 10.1080/22221751.2019.1597644
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wrapp D, 2019, J VIROL, V93, DOI 10.1128/JVI.00923-19
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu H, 2005, J MOL BIOL, V350, P126, DOI 10.1016/j.jmb.2005.04.049
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xiong H-L, 2020, BIORXIV, DOI [10.1101/2020.04.08.026948, DOI 10.1101/2020.04.08.026948]
   Xiong XL, 2018, J VIROL, V92
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zost Seth J, 2020, bioRxiv, DOI 10.1101/2020.05.12.091462
NR 98
TC 35
Z9 33
U1 12
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 20
PY 2020
VL 182
IS 4
BP 828
EP +
DI 10.1016/j.cell.2020.06.025
PG 31
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NC8UU
UT WOS:000561488500007
PM 32645326
OA Green Accepted, Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Kreer, C
   Zehner, M
   Weber, T
   Ercanoglu, MS
   Gieselmann, L
   Rohde, C
   Halwe, S
   Korenkov, M
   Schommers, P
   Vanshylla, K
   Di Cristanziano, V
   Janicki, H
   Brinker, R
   Ashurov, A
   Krahling, V
   Kupke, A
   Cohen-Dvashi, H
   Koch, M
   Eckert, JM
   Lederer, S
   Pfeifer, N
   Wolf, T
   Vehreschild, MJGT
   Wendtner, C
   Diskin, R
   Gruell, H
   Becker, S
   Klein, F
AF Kreer, Christoph
   Zehner, Matthias
   Weber, Timm
   Ercanoglu, Meryem S.
   Gieselmann, Lutz
   Rohde, Cornelius
   Halwe, Sandro
   Korenkov, Michael
   Schommers, Philipp
   Vanshylla, Kanika
   Di Cristanziano, Veronica
   Janicki, Hanna
   Brinker, Reinhild
   Ashurov, Artem
   Kraehling, Verena
   Kupke, Alexandra
   Cohen-Dvashi, Hadas
   Koch, Manuel
   Eckert, Jan Mathis
   Lederer, Simone
   Pfeifer, Nico
   Wolf, Timo
   Vehreschild, Maria J. G. T.
   Wendtner, Clemens
   Diskin, Ron
   Gruell, Henning
   Becker, Stephan
   Klein, Florian
TI Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing
   Antibodies from COVID-19 Patients
SO CELL
LA English
DT Article
ID NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODIES; B-CELLS; VACCINE; HIV;
   BROAD; GENERATION; SEQUENCE; DESIGN
AB The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and the world economy. Because approved drugs and vaccines are limited or not available, new options for COVID-19 treatment and prevention are in high demand. To identify SARS-CoV-2-neutralizing antibodies, we analyzed the antibody response of 12 COVID-19 patients from 8 to 69 days after diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days after diagnosis. Of these, 28 potently neutralized authentic SARS-CoV-2 with IC100 as low as 0.04 mu g/mL, showing a broad spectrum of variable (V) genes and low levels of somatic mutations. Interestingly, potential precursor sequences were identified in naive B cell repertoires from 48 healthy individuals who were sampled before the COVID-19 pandemic. Our results demonstrate that SARS-CoV-2-neutralizing antibodies are readily generated from a diverse pool of precursors, fostering hope for rapid induction of a protective immune response upon vaccination.
C1 [Kreer, Christoph; Zehner, Matthias; Weber, Timm; Ercanoglu, Meryem S.; Gieselmann, Lutz; Korenkov, Michael; Schommers, Philipp; Vanshylla, Kanika; Janicki, Hanna; Ashurov, Artem; Gruell, Henning; Klein, Florian] Univ Cologne, Fac Med, Inst Virol, Lab Expt Immunol, D-50931 Cologne, Germany.
   [Kreer, Christoph; Zehner, Matthias; Weber, Timm; Ercanoglu, Meryem S.; Gieselmann, Lutz; Korenkov, Michael; Schommers, Philipp; Vanshylla, Kanika; Di Cristanziano, Veronica; Janicki, Hanna; Ashurov, Artem; Gruell, Henning; Klein, Florian] Univ Cologne, Univ Hosp Cologne, D-50931 Cologne, Germany.
   [Rohde, Cornelius; Halwe, Sandro; Kraehling, Verena; Kupke, Alexandra; Becker, Stephan] Philipps Univ Marburg, Fac Med, Inst Virol, D-35043 Marburg, Germany.
   [Rohde, Cornelius; Halwe, Sandro; Kraehling, Verena; Kupke, Alexandra; Becker, Stephan] German Ctr Infect Res, Partner Site Giessen Marburg Langen, D-35043 Marburg, Germany.
   [Schommers, Philipp; Gruell, Henning; Klein, Florian] German Ctr Infect Res, Partner Site Bonn Cologne, D-50931 Cologne, Germany.
   [Schommers, Philipp] Univ Cologne, Fac Med, Dept Internal Med 1, D-50937 Cologne, Germany.
   [Di Cristanziano, Veronica] Univ Cologne, Fac Med, Inst Virol, D-50935 Cologne, Germany.
   [Brinker, Reinhild] Univ Cologne, Univ Hosp Cologne, Ctr Integrated Oncol CIO Aachen Bonn Cologne Duss, Dept Internal Med 1, D-50937 Cologne, Germany.
   [Brinker, Reinhild] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-50931 Cologne, Germany.
   [Cohen-Dvashi, Hadas; Diskin, Ron] Weizmann Inst Sci, Dept Struct Biol, IL-76100 Rehovot, Israel.
   [Koch, Manuel] Univ Cologne, Inst Dent Res & Oral Musculoskeletal Biol, D-50931 Cologne, Germany.
   [Koch, Manuel] Univ Cologne, Ctr Biochem, D-50931 Cologne, Germany.
   [Koch, Manuel; Klein, Florian] Univ Cologne, Ctr Mol Med Cologne CMMC, D-50931 Cologne, Germany.
   [Eckert, Jan Mathis] Univ Wurzburg, Fac Med, D-97080 Wurzburg, Germany.
   [Lederer, Simone] Univ Hosp Tubingen, Inst Translat Bioinformat, D-72076 Tubingen, Germany.
   [Lederer, Simone] Univ Tubingen, D-72076 Tubingen, Germany.
   [Pfeifer, Nico] Univ Tubingen, Fac Med, D-72076 Tubingen, Germany.
   [Pfeifer, Nico] Univ Tubingen, Dept Comp Sci, Methods Med Informat, D-72076 Tubingen, Germany.
   [Pfeifer, Nico] German Ctr Infect Res, Partner Site Tubingen, D-72076 Tubingen, Germany.
   [Wolf, Timo; Vehreschild, Maria J. G. T.] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Internal Med, Infect Dis, D-60590 Frankfurt, Germany.
   [Wendtner, Clemens] Ludwig Maximilians Univ Munchen, Acad Teaching Hosp, Dept Infect Dis & Trop Med, Munich Clin Schwabing, D-80804 Munich, Germany.
RP Klein, F (corresponding author), Univ Cologne, Fac Med, Inst Virol, Lab Expt Immunol, D-50931 Cologne, Germany.; Klein, F (corresponding author), Univ Cologne, Univ Hosp Cologne, D-50931 Cologne, Germany.; Klein, F (corresponding author), German Ctr Infect Res, Partner Site Bonn Cologne, D-50931 Cologne, Germany.; Klein, F (corresponding author), Univ Cologne, Ctr Mol Med Cologne CMMC, D-50931 Cologne, Germany.
EM florian.klein@uk-koeln.de
RI Zehner, Matthias/AAV-9709-2020
OI Schommers, Philipp/0000-0003-3375-6800; Grull,
   Henning/0000-0002-0725-7138
FU Klein Laboratory; Becker Laboratory; German Center for Infection
   Research (DZIF); German Research Foundation (DFG)German Research
   Foundation (DFG) [CRC 1279, CRC 1310, FOR2722, EXC 2064/1, 390727645];
   European Research CouncilEuropean Research Council (ERC)
   [ERC-StG639961]; German Federal Ministry of Education and Research
   (BMBF) within the Medical Informatics Initiative (DIFUTURE)Federal
   Ministry of Education & Research (BMBF) [01ZZ1804D]; Ben B. and Joyce E.
   Eisenberg Foundation; Ernst I. Ascher Foundation
FX We thank all study participants who devoted time to our research;
   members of the Klein and Becker Laboratories for continuous support and
   helpful discussions; Jason McLellan, Nianshuang Wang, and Daniel Wrapp
   for sharing the SARS-CoV-2 S ectodomain plasmid; Florian Krammer for
   sharing the RBD plasmid; Simon Popsel and Robert Hansel-Hertsch for
   helpful discussions and technical support; Daniela Weiland and Nadine
   Henn for lab management and assistance; Birgit Gathof and Sabine Adam of
   the Institute of Transfusion Medicine of the University Hospital of
   Cologne for providing blood samples for NGS analysis; as well as Heidrun
   Schossler and Ralf Ortmanns of the health department of Heinsberg for
   support with patient recruitment. This work was funded by grants from
   the German Center for Infection Research (DZIF) to F.K. and S.B., the
   German Research Foundation (DFG) (CRC 1279 and CRC 1310 to F.K., FOR2722
   to M.K.; EXC 2064/1, project no. 390727645 to N.P.), the European
   Research Council (ERC-StG639961 to F.K.), the German Federal Ministry of
   Education and Research (BMBF) within the Medical Informatics Initiative
   (DIFUTURE) (reference 01ZZ1804D to S.L. and N.P.), the Ben B. and Joyce
   E. Eisenberg Foundation to R.D., the Ernst I. Ascher Foundation and
   Natan Sharansky to R.D.
CR Andreano E., 2020, IDENTIFICATION NEUTR, DOI [10.1101/2020.05.05.078154, DOI 10.1101/2020.05.05.078154]
   Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Braun J., 2020, PRESENCE SARS COV 2, DOI [10.1101/2020.04.17.20061440, 10.1101/2020.04.17.20061440., DOI 10.1101/2020.04.17.20061440]
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Burton DR, 2020, CELL HOST MICROBE, V27, P695, DOI 10.1016/j.chom.2020.04.022
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669
   Davis CW, 2019, CELL, V177, P1566, DOI 10.1016/j.cell.2019.04.036
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Edler D., 2019, RAXMLGUI 2 0 BETA GR, DOI [10.1101/2020.05.05.078154., DOI 10.1101/2020.05.05.078154]
   Ehrhardt SA, 2019, NAT MED, V25, P1589, DOI 10.1038/s41591-019-0602-4
   EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7
   Fauci AS, 2015, SCIENCE, V349, P386, DOI 10.1126/science.aac6300
   Flyak AI, 2016, CELL, V164, P392, DOI 10.1016/j.cell.2015.12.022
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang JH, 2016, IMMUNITY, V45, P1108, DOI 10.1016/j.immuni.2016.10.027
   Huang YX, 2016, CELL, V165, P1621, DOI 10.1016/j.cell.2016.05.024
   Joyce MG, 2016, CELL, V166, P609, DOI 10.1016/j.cell.2016.06.043
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kallewaard NL, 2016, CELL, V166, P596, DOI 10.1016/j.cell.2016.05.073
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Koch T, 2020, LANCET INFECT DIS, V20, P827, DOI 10.1016/S1473-3099(20)30248-6
   Koff WC, 2013, SCIENCE, V340, DOI 10.1126/science.1232910
   Kowarz E, 2015, BIOTECHNOL J, V10, P647, DOI 10.1002/biot.201400821
   Kreer C, 2020, J IMMUNOL METHODS, V480
   Kreer C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010013
   Kwakkenbos MJ, 2010, NAT MED, V16, P123, DOI 10.1038/nm.2071
   Li Wei, 2020, bioRxiv, DOI 10.1101/2020.05.13.093088
   Liu Lihong, 2020, bioRxiv, DOI 10.1101/2020.06.17.153486
   Liu X., 2020, PREPRINT, DOI [10.1101/2020.05.03.074914., DOI 10.1101/2020.05.03.074914]
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Mascola JR, 2010, ANNU REV IMMUNOL, V28, P413, DOI 10.1146/annurev-immunol-030409-101256
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   ROBBIANI DF, 2020, NATURE, DOI DOI 10.1101/2020.05.13.092619
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Saphire EO, 2018, CELL, V174, P938, DOI 10.1016/j.cell.2018.07.033
   Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227
   Schommers P, 2020, CELL, V180, P471, DOI 10.1016/j.cell.2020.01.010
   Sempowski GD, 2020, CELL, V181, P1458, DOI 10.1016/j.cell.2020.05.041
   Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Vander Heiden JA, 2014, BIOINFORMATICS, V30, P1930, DOI 10.1093/bioinformatics/btu138
   von Boehmer L, 2016, NAT PROTOC, V11, P1908, DOI 10.1038/nprot.2016.102
   Walker LM, 2018, NAT REV IMMUNOL, V18, P297, DOI 10.1038/nri.2017.148
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang P, 2020, PREPRINT, DOI [10.1101/2020.06.13.150250, DOI 10.1101/2020.06.13.150250]
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Wec AZ, 2020, P NATL ACAD SCI USA, V117, P6675, DOI 10.1073/pnas.1921388117
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Wu Y., 2020, SCIENCE, DOI [10.1126/eabc2241, DOI 10.1126/EABC2241]
   Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382
   Yuan A.Q., 2020, BIORXIV, DOI [10.1101/2020.05.19.104281, DOI 10.1101/2020.05.19.104281]
   Zeng X., 2020, BLOCKING ANTIBODIES, DOI [10.1101/2020.04.19.049643, DOI 10.1101/2020.04.19.049643]
   Zhang Y, 2013, J EXP MED, V210, P457, DOI 10.1084/jem.20120150
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zolla-Pazner S, 2019, CURR OPIN HIV AIDS, V14, P309, DOI 10.1097/COH.0000000000000551
   Zost S.J., 2020, BIORXIV, DOI [10.1101/2020.04.19.049643, DOI 10.1101/2020.04.19.049643]
NR 72
TC 14
Z9 14
U1 6
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 20
PY 2020
VL 182
IS 4
BP 843
EP +
DI 10.1016/j.cell.2020.06.044
PG 24
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NC8UU
UT WOS:000561488500008
PM 32673567
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Houston, BL
   Lawler, PR
   Goligher, EC
   Farkouh, ME
   Bradbury, C
   Carrier, M
   Dzavik, V
   Fergusson, DA
   Fowler, RA
   Galanaud, JP
   Gross, PL
   McDonald, EG
   Husain, M
   Kahn, SR
   Kumar, A
   Marshall, J
   Murthy, S
   Slutsky, AS
   Turgeon, AF
   Berry, SM
   Rosenson, RS
   Escobedo, J
   Nicolau, JC
   Bond, L
   Kirwan, BA
   de Brouwer, S
   Zarychanski, R
AF Houston, Brett L.
   Lawler, Patrick R.
   Goligher, Ewan C.
   Farkouh, Michael E.
   Bradbury, Charlotte
   Carrier, Marc
   Dzavik, Vlad
   Fergusson, Dean A.
   Fowler, Robert A.
   Galanaud, Jean-Phillippe
   Gross, Peter L.
   McDonald, Emily G.
   Husain, Mansoor
   Kahn, Susan R.
   Kumar, Anand
   Marshall, John
   Murthy, Srinivas
   Slutsky, Arthur S.
   Turgeon, Alexis F.
   Berry, Scott M.
   Rosenson, Robert S.
   Escobedo, Jorge
   Nicolau, Jose C.
   Bond, Lindsay
   Kirwan, Bridget-Anne
   de Brouwer, Sophie
   Zarychanski, Ryan
TI Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19
   (ATTACC): Study design and methodology for an international, adaptive
   Bayesian randomized controlled trial
SO CLINICAL TRIALS
LA English
DT Article
DE Heparin; thrombosis; COVID-19; adaptive clinical trial; protocol
ID MOLECULAR-WEIGHT HEPARIN; SEPSIS; METAANALYSIS; CORONAVIRUS; EFFICACY;
   SAFETY
AB Background: Mortality from COVID-19 is high among hospitalized patients and effective therapeutics are lacking. Hypercoagulability, thrombosis and hyperinflammation occur in COVID-19 and may contribute to severe complications. Therapeutic anticoagulation may improve clinical outcomes through anti-thrombotic, anti-inflammatory and anti-viral mechanisms. Our primary objective is to evaluate whether therapeutic-dose anticoagulation with low-molecular-weight heparin or unfractionated heparin prevents mechanical ventilation and/or death in patients hospitalized with COVID-19 compared to usual care. Methods: An international, open-label, adaptive randomized controlled trial. Using a Bayesian framework, the trial will declare results as soon as pre-specified posterior probabilities for superiority, futility, or harm are reached. The trial uses response-adaptive randomization to maximize the probability that patients will receive the more beneficial treatment approach, as treatment effect information accumulates within the trial. By leveraging a common data safety monitoring board and pooling data with a second similar international Bayesian adaptive trial (REMAP-COVID anticoagulation domain), treatment efficacy and safety will be evaluated as efficiently as possible. The primary outcome is an ordinal endpoint with three possible outcomes based on the worst status of each patient through day 30: no requirement for invasive mechanical ventilation, invasive mechanical ventilation or death. Conclusion: Using an adaptive trial design, the Anti-Thrombotic Therapy To Ameliorate Complications of COVID-19 trial will establish whether therapeutic anticoagulation can reduce mortality and/or avoid the need for mechanical ventilation in patients hospitalized with COVID-19. Leveraging existing networks to recruit sites will increase enrollment and mitigate enrollment risk in sites with declining COVID-19 cases.
C1 [Houston, Brett L.; Kumar, Anand; Zarychanski, Ryan] Univ Manitoba, Max Rady Coll Med, Max Rady Fac Hlth Sci, Dept Internal Med, Winnipeg, MB, Canada.
   [Lawler, Patrick R.; Farkouh, Michael E.; Dzavik, Vlad; Husain, Mansoor] Univ Hlth Network, Peter Munk Cardiac Ctr, Toronto, ON, Canada.
   [Lawler, Patrick R.; Farkouh, Michael E.; Dzavik, Vlad; Fowler, Robert A.; Galanaud, Jean-Phillippe; Husain, Mansoor; Marshall, John] Univ Toronto, Toronto, ON, Canada.
   [Lawler, Patrick R.; Goligher, Ewan C.] Toronto Gen Hosp Res Inst, Toronto, ON, Canada.
   [Lawler, Patrick R.; Goligher, Ewan C.] Univ Toronto, InterDept Div Crit Care Med, Toronto, ON, Canada.
   [Goligher, Ewan C.] Univ Hlth Network, Dept Med, Div Respirol, Toronto, ON, Canada.
   [Bradbury, Charlotte] Univ Bristol, Fac Hlth Sciences, Bristol, Avon, England.
   [Carrier, Marc; Fergusson, Dean A.] Ottawa Hosp Res Inst, Clin Epidmiol Program, Ottawa, ON, Canada.
   [Fowler, Robert A.; Galanaud, Jean-Phillippe] Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON, Canada.
   [Gross, Peter L.] McMaster Univ, Atherosclerosis Res Inst, Dept Med, Hamilton, ON, Canada.
   [Gross, Peter L.] Hamilton Hlth Sci, Hamilton, ON, Canada.
   [McDonald, Emily G.] McGill Univ Hlth Centre, Dept Med, Clin Practice Assessment Unit, Montreal, PQ, Canada.
   [Kahn, Susan R.] McGill Univ, Ctr Clin Epidemiol, Div Internal Med, Jewish Gen Hosp,Lady Davis Inst,Dept Med, Montreal, PQ, Canada.
   [Marshall, John] St Michaels Hosp, Dept Surg, Toronto, ON, Canada.
   [Murthy, Srinivas] Univ British Columbia, Vancouver, BC, Canada.
   [Slutsky, Arthur S.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada.
   [Slutsky, Arthur S.] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Slutsky, Arthur S.] Univ Toronto, Dept Surg, Toronto, ON, Canada.
   [Slutsky, Arthur S.] Univ Toronto, Dept Biomed Engn, Toronto, ON, Canada.
   [Turgeon, Alexis F.] Univ Laval, Fac Med, Div Crit Care Med, Dept Anesthesiol & Crit Care Med, Quebec City, PQ, Canada.
   [Turgeon, Alexis F.] Univ Laval, Trauma Emergency Crit Care Med, Populat Hlth & Optimal Hlth Practices Res Unit, CHU Quebec,Res Ctr, Quebec City, PQ, Canada.
   [Berry, Scott M.] Berry Consultants LLC, Austin, TX USA.
   [Rosenson, Robert S.] Icahn Sch Med Mt Sinai, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, Mt Sinai Hosp, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA.
   [Escobedo, Jorge] Mexican Social Secur Inst, Med Res Unit Clin Epidmiol, Mexico City, DF, Mexico.
   [Nicolau, Jose C.] Univ Sao Paulo, Hosp Clin HCFMUSP, Instituto Coracao InCor, Fac Med, Sao Paulo, Brazil.
   [Bond, Lindsay] Ozmosis Res Inc, Toronto, ON, Canada.
   [Kirwan, Bridget-Anne; de Brouwer, Sophie] SOCAR Res SA, Dept Clin Res, Nyon, Switzerland.
   [Kirwan, Bridget-Anne] London Sch Hyg & Trop Med, Fac Epidemiol & Publ Hlth, London, England.
   [Zarychanski, Ryan] CancerCare Manitoba, Res Inst Oncol & Hematol, Winnipeg, MB, Canada.
RP Zarychanski, R (corresponding author), Univ Manitoba, Dept Internal Med, Max Rady Coll Med, Max Rady Fac Hlth Sci,CancerCare Manitoba, ON 2051-675 McDermot Ave, Winnipeg, MB R3E OV9, Canada.
EM rzarychanski@cancercare.mb.ca
OI Houston, Brett/0000-0002-8776-4083
FU FastGrants COVID-19 fund/Thistledown Foundation (Canada); Peter Munk
   Cardiac Centre (Toronto, Canada); Research Manitoba (Winnipeg, Canada)
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: The ATTACC
   trial is funded by FastGrants COVID-19 fund/Thistledown Foundation
   (Canada), the Peter Munk Cardiac Centre (Toronto, Canada) and Research
   Manitoba (Winnipeg, Canada).
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bhatt DL, 2016, NEW ENGL J MED, V375, P65, DOI 10.1056/NEJMra1510061
   Cornet AD, 2007, THROMB HAEMOSTASIS, V98, P579, DOI 10.1160/TH07-01-0006
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   de Haan CAM, 2005, J VIROL, V79, P14451, DOI 10.1128/JVI.79.22.14451-14456.2005
   Fan Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep25984
   Food Drug Administration, 2006, HEP SOD INJ USP PROD
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Iorio A, 2003, J THROMB HAEMOST, V1, P1906, DOI 10.1046/j.1538-7836.2003.00364.x
   Lever R, 2000, BRIT J PHARMACOL, V129, P533, DOI 10.1038/sj.bjp.0703099
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Mummery RS, 2000, J IMMUNOL, V165, P5671, DOI 10.4049/jimmunol.165.10.5671
   Mycroft-West C., 2020, BIORXIV, P1, DOI [10.1101/2020.02.29.971093, DOI 10.1101/2020.02.29.971093]
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Polderman KH, 2004, LANCET, V363, P1721, DOI 10.1016/S0140-6736(04)16259-4
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   REMAP-CAP, RAND EMB MULT AD PLA
   Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x
   Vicenzi E, 2004, EMERG INFECT DIS, V10, P413, DOI 10.3201/eid1003.030683
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zarychanski R, 2008, CRIT CARE MED, V36, P2973, DOI 10.1097/CCM.0b013e31818b8c6b
   Zarychanski R, 2015, CRIT CARE MED, V43, P511, DOI 10.1097/CCM.0000000000000763
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 27
TC 1
Z9 1
U1 4
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
EI 1740-7753
J9 CLIN TRIALS
JI Clin. Trials
PD OCT
PY 2020
VL 17
IS 5
BP 491
EP 500
AR 1740774520943846
DI 10.1177/1740774520943846
EA AUG 2020
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NU8GJ
UT WOS:000561686100001
PM 32815416
DA 2021-01-01
ER

PT J
AU Luchting, B
AF Luchting, Benjamin
TI Interdisciplinary multimodal pain therapy under the protective measures
   of the COVID-19 pandemic Analysis and progress report
SO SCHMERZ
LA German
DT Article
DE Multimodal pain therapy; Covid-19; Corona; Protective measures;
   Infection
AB Due to the COVID-19 pandemic, elective medical services have had to be reduced to a minimum, which has also affected care in pain medicine. Following these drastic cutbacks, a cautious resumption of elective care is planned. This also applies to the delivery of inpatient and day-care interdisciplinary multimodal pain therapy (IMPT). Since the majority of pain medicine centers have been closed to date, the question has arisen as to whether a resumption of regular care can be easily provided under the required protective measures. To answer this question, the authors conducted a survey among patients that were in a position to make a direct comparison between IMPT under normal conditions as well as under the currently required protective measures. The survey recorded the level of disruption caused by the different protective measures in the various treatment modules. An evaluation of the questionnaires, which were completed by two patient groups and all therapists involved, revealed that interdisciplinary multimodal pain therapy is possible without significant impairments even under the required protective measures. In particular, wearing protective masks proved to be the protective measure with the greatest negative impact. However, options like the use of protective visors or relocating treatment modules to the outdoors offer practicable alternative solutions for protection. Both patient and therapist satisfaction was high despite these constraints, and personal concern regarding possible infection low.
C1 [Luchting, Benjamin] Klinikum Landsberg Lech, Interdisziplinares Schmerzzentrum, Bgm Dr Hartmann Str 50, D-86899 Landsberg, Germany.
RP Luchting, B (corresponding author), Klinikum Landsberg Lech, Interdisziplinares Schmerzzentrum, Bgm Dr Hartmann Str 50, D-86899 Landsberg, Germany.
EM benjamin.luchting@klinikum-landsberg.de
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Arnold B, 2009, SCHMERZ, V23, P112, DOI 10.1007/s00482-008-0741-x
   Bundesgesundheitsministerium, 2020, BESCHL GES 27 04 202
   BVSD, 2020, BVSD HYG TEIL VOLL V
   BVSD, 2020, UMFR BER ARZT PSYCH
   Deer T, 2020, ANESTH ANALG, V10, P1213
   Feng Y, 2020, J AEROSOL SCI, V147, DOI 10.1016/j.jaerosci.2020.105585
   Pfingsten M, 2019, SCHMERZ, V33, P191, DOI 10.1007/s00482-019-0374-2
NR 7
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-433X
EI 1432-2129
J9 SCHMERZ
JI Schmerz
PD OCT
PY 2020
VL 34
IS 5
BP 431
EP 434
DI 10.1007/s00482-020-00491-9
EA AUG 2020
PG 4
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA NR8UX
UT WOS:000561235500001
PM 32820359
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gordon, KC
   Mitchell, EA
AF Coop Gordon, Kristina
   Mitchell, Erica A.
TI Infidelity in the Time of COVID-19
SO FAMILY PROCESS
LA English
DT Article
DE Infidelity; Affair Recovery; Pandemic; Clinical Recommendations; Couples
ID UNDERSTANDING INFIDELITY; SEXUAL ACTIVITIES; PREDICTORS; SATISFACTION;
   FORGIVENESS; ATTACHMENT; CONFLICT; MARRIAGE; CHILDREN; REASONS
AB Infidelity occurs in approximately 25% of marriages and is associated with various negative consequences for individuals (e.g., depression, anxiety, and post-traumatic stress), the couple relationship (e.g., financial loss, increased conflict, and aggression), and the couple's children (e.g., internalizing and externalizing behaviors). Infidelity is also one of the most frequently cited reasons for divorce. The increased stress brought on by the pandemic may be putting couples at an increased risk for experiencing infidelity, and data collected during the pandemic have shown that people across the United States are engaging in behaviors that are associated with a high likelihood of experiencing infidelity. The negative consequences of infidelity are also likely to be exacerbated for couples during the pandemic due to the intersection with the social, emotional, and financial consequences of COVID-19. Furthermore, couples are likely to experience disruptions and delays to the affair recovery process during the pandemic, which can negatively impact their ability to heal. Therefore, recommendations for navigating affair recovery during the pandemic, including adaptations for therapy, are also discussed.
C1 [Coop Gordon, Kristina; Mitchell, Erica A.] Univ Tennessee, 1404 Circle Dr,Suite 310B, Knoxville, TN 37996 USA.
RP Gordon, KC (corresponding author), Univ Tennessee, 1404 Circle Dr,Suite 310B, Knoxville, TN 37996 USA.
EM kgordon1@utk.edu
CR Ablow JC, 2009, J FAM PSYCHOL, V23, P485, DOI 10.1037/a0015894
   Abrahamson I, 2012, J FAM ISSUES, V33, P1494, DOI 10.1177/0192513X11424257
   Allen ES, 2005, CLIN PSYCHOL-SCI PR, V12, P101, DOI 10.1093/clipsy/bpi014
   Amato PR, 2003, J FAM ISSUES, V24, P602, DOI 10.1177/0192513X03254507
   [Anonymous], 2020, NEWS WISE       0429
   Atkins DC, 2001, J FAM PSYCHOL, V15, P735, DOI 10.1037/0893-3200.15.4.735
   Bird MH, 2007, J COUPLE RELATSH THE, V6, P1, DOI 10.1300/J398v06n04_01
   Blow AJ, 2005, J MARITAL FAM THER, V31, P183, DOI 10.1111/j.1752-0606.2005.tb01555.x
   Bodenmann G, 2007, PERS RELATIONSHIP, V14, P551, DOI 10.1111/j.1475-6811.2007.00171.x
   Campbell AM, 2020, FORENSIC SCI INT REP, V2, DOI [10.1016/j.fsir.2020.100089, DOI 10.1016/J.FSIR.2020.100089]
   Cano A, 2000, J CONSULT CLIN PSYCH, V68, P774, DOI 10.1037/0022-006X.68.5.774
   Centers for Disease Control and Prevention, 2020, COP STRESS
   Couch LL, 2017, CURR PSYCHOL, V36, P504, DOI 10.1007/s12144-016-9438-y
   Crouch E, 2016, INT J SOCIOL SOC POL, V36, P53, DOI 10.1108/IJSSP-03-2015-0032
   Emmers-Sommer TM, 2010, MARRIAGE FAM REV, V46, P420, DOI 10.1080/01494929.2010.528707
   Epstein N. B., 2002, ENHANCED COGNITIVE B
   Fife ST, 2013, J FAM THER, V35, P343, DOI 10.1111/j.146`-6427.2011.00561.x
   Gordon KC, 2004, J MARITAL FAM THER, V30, P213, DOI 10.1111/j.1752-0606.2004.tb01235.x
   Gordon KC, 1998, FAM PROCESS, V37, P425, DOI 10.1111/j.1545-5300.1998.00425.x
   Grov C, 2011, ARCH SEX BEHAV, V40, P429, DOI 10.1007/s10508-010-9598-z
   Harper JM, 2000, AM J FAM THER, V28, P1, DOI 10.1080/019261800261770
   Hunyady O, 2008, SELF IDENTITY, V7, P278, DOI 10.1080/15298860701620227
   Johns KN, 2015, MINDFULNESS, V6, P1462, DOI 10.1007/s12671-015-0427-2
   Laumann E. O., 1994, SOCIAL ORG SEXUALITY
   Lehmiller J, 2020, SEX PSYCHOL     0506
   Linehan M. M., 2015, DBT SKILLS TRAINING
   Lusterman DD, 2005, J CLIN PSYCHOL, V61, P1439, DOI 10.1002/jclp.20193
   Manning JC, 2006, SEX ADDICT COMPULS, V13, P131, DOI 10.1080/10720160600870711
   Mayer K, 2020, HUMAN RESOURCE EXECU
   McAlister AR, 2005, BRIT J PSYCHOL, V96, P331, DOI 10.1348/000712605X47936
   Neff LA, 2004, PERS SOC PSYCHOL B, V30, P134, DOI 10.1177/0146167203255984
   Negash S, 2016, CONTEMP FAM THER, V38, P198, DOI 10.1007/s10591-015-9364-4
   Nemeth JM, 2012, J WOMENS HEALTH, V21, P942, DOI 10.1089/jwh.2011.3328
   O'Connor T., 2009, INT J MASS EMERGENCI, V27, P26
   Olson MM, 2002, J MARITAL FAM THER, V28, P423, DOI 10.1111/j.1752-0606.2002.tb00367.x
   Panchal N, 2020, IMPLICATIONS COVID 1
   Parker K., 2020, HALF LOWER INCOME AM
   Peluso PR, 2008, FAM J, V16, P324, DOI 10.1177/1066480708323282
   Platt RAL, 2008, AM J FAM THER, V36, P149, DOI 10.1080/01926180701236258
   Previti D, 2004, J SOC PERS RELAT, V21, P217, DOI 10.1177/0265407504041384
   Revenson TA., 2005, DECADE BEHAV COUPLES, P33, DOI DOI 10.1037/11031-002
   Serrata JVA, 2019, UNDERSTANDING IMPACT
   Shaw AMM, 2013, J SEX RES, V50, P598, DOI 10.1080/00224499.2012.666816
   Snyder D. K., 2007, GETTING AFFAIR COPE
   Takahashi D., 2020, VENTURE BEAT    0328
   Timm T. M., 2018, QUICKIES HDB BRIEF S, P115
   Waite LJ, 2001, J MARRIAGE FAM, V63, P247, DOI 10.1111/j.1741-3737.2001.00247.x
   Wang CCDC, 2012, J COLL COUNS, V15, P101, DOI 10.1002/j.2161-1882.2012.00009.x
   Warren T., 2020, VERGE           0331
   Weeks G. R., 2001, COUPLES TREATMENT TE
   Weiner-Davis M, 2020, PSYCHOL TODAY
NR 51
TC 2
Z9 2
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-7370
EI 1545-5300
J9 FAM PROCESS
JI Fam. Process
PD SEP
PY 2020
VL 59
IS 3
BP 956
EP 966
DI 10.1111/famp.12576
EA AUG 2020
PG 11
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA NL5AR
UT WOS:000560807400001
PM 32621371
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Fujita, R
   Hino, M
   Ebihara, T
   Nagasato, T
   Masuda, A
   Lee, JM
   Fujii, T
   Mon, H
   Kakino, K
   Nagai, R
   Tanaka, M
   Tonooka, Y
   Moriyama, T
   Kusakabe, T
AF Fujita, Ryosuke
   Hino, Masato
   Ebihara, Takeru
   Nagasato, Takumi
   Masuda, Akitsu
   Lee, Jae Man
   Fujii, Tsuguru
   Mon, Hiroaki
   Kakino, Kohei
   Nagai, Ryo
   Tanaka, Miyu
   Tonooka, Yoshino
   Moriyama, Takato
   Kusakabe, Takahiro
TI Efficient production of recombinant SARS-CoV-2 spike protein using the
   baculovirus-silkworm system
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Silkworm-BmNPV expression system; SARS-CoV-2; Spike protein
ID EXPRESSION; VACCINE; VIRUS
AB In the case of a new viral disease outbreak, an immediate development of virus detection kits and vaccines is required. For COVID-19, we established a rapid production procedure for SARS-CoV-2 spike protein (S protein) by using the baculovirus-silkworm expression system. The baculovirus vector-derived S proteins were successfully secreted to silkworm serum, whereas those formed insoluble structure in the larval fat body and the pupal cells. The ectodomain of S protein with the native sequence was cleaved by the host furin-protease, resulting in less recombinant protein production. The S protein modified in furin protease-target site was efficiently secreted to silkworm serum and was purified as oligomers, which showed immunoreactivity for anti-SARS-CoV-2 S2 antibody. By using the direct transfection of recombinant bacmid to silkworms, we achieved the efficient production of SARS-CoV-2 S protein as fetal bovine serum (FBS)-free system. The resultant purified S protein would be useful tools for the development of immunodetection kits, antigen for immunization for immunoglobulin production, and vaccines. (C) 2020 Published by Elsevier Inc.
C1 [Fujita, Ryosuke; Hino, Masato] Kyushu Univ, Fac Agr, Lab Sanit Entomol, Nishi Ku, Motooka 744, Fukuoka 8190395, Japan.
   [Ebihara, Takeru; Nagasato, Takumi; Masuda, Akitsu; Kakino, Kohei; Nagai, Ryo; Tanaka, Miyu; Tonooka, Yoshino; Moriyama, Takato] Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Lab Insect Genome Sci, Nishi Ku, Motooka 744, Fukuoka 8190395, Japan.
   [Lee, Jae Man; Fujii, Tsuguru] Kyushu Univ, Fac Agr, Lab Creat Sci Insect Ind, Nishi Ku, Motooka 744, Fukuoka 8190395, Japan.
   [Mon, Hiroaki; Kusakabe, Takahiro] Kyushu Univ, Fac Agr, Lab Insect Genome Sci, Nishi Ku, Motooka 744, Fukuoka 8190395, Japan.
RP Fujita, R (corresponding author), Kyushu Univ, Fac Agr, Lab Sanit Entomol, Nishi Ku, Motooka 744, Fukuoka 8190395, Japan.
EM r-fujita@agr.kyushu-u.ac.jp
OI Masuda, Akitsu/0000-0001-9402-924X
CR Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cui ZF, 2020, BIO-DES MANUF, V3, P83, DOI 10.1007/s42242-020-00075-7
   Diamond MS, 2020, CELL HOST MICROBE, V27, P699, DOI 10.1016/j.chom.2020.04.021
   Harakuni T, 2016, VACCINE, V34, P3184, DOI 10.1016/j.vaccine.2016.04.005
   Jaimes JA, 2020, J MOL BIOL, V432, P3309, DOI 10.1016/j.jmb.2020.04.009
   Kinoshita Y, 2019, PROTEIN EXPRES PURIF, V159, P69, DOI 10.1016/j.pep.2019.03.010
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Maesaki R, 2014, SCI REP-UK, V4, DOI 10.1038/srep06016
   Masuda A, 2018, J GEN VIROL, V99, P917, DOI 10.1099/jgv.0.001087
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yamashita M, 2017, MOL BIOTECHNOL, V59, P221, DOI 10.1007/s12033-017-0008-9
   Yano T, 2019, J ASIA-PAC ENTOMOL, V22, P453, DOI 10.1016/j.aspen.2019.02.008
   Zhao R, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa523, DOI 10.1093/CID/CIAA523]
NR 21
TC 0
Z9 0
U1 22
U2 22
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 20
PY 2020
VL 529
IS 2
BP 257
EP 262
DI 10.1016/j.bbrc.2020.06.020
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MP0AC
UT WOS:000551875700021
PM 32703420
OA Green Published
DA 2021-01-01
ER

PT J
AU Irham, LM
   Chou, WH
   Calkins, MJ
   Adikusuma, W
   Hsieh, SL
   Chang, WC
AF Irham, Lalu Muhammad
   Chou, Wan-Hsuan
   Calkins, Marcus J.
   Adikusuma, Wirawan
   Hsieh, Shie-Liang
   Chang, Wei-Chiao
TI Genetic variants that influence SARS-CoV-2 receptor TMPRSS2 expression
   among population cohorts from multiple continents
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE SARS-CoV-2; COVID-19; TMPRSS2; Variant gene
ID INFECTION; VIRUS; H7N9
AB The World Health Organization recently announced that pandemic status has been achieved for coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Exponential increases in patient numbers have been reported around the world, along with proportional increases in the number of COVID-19-related deaths. The SARS-CoV-2 infection rate in a population is expected to be influenced by social practices, availability of vaccines or prophylactics, and the prevalence of susceptibility genes in the population. Previous work revealed that cellular uptake of SARS-CoV-2 requires Angiotensin Converting Enzyme 2 (ACE-2) and a cellular protease. The spike (S) protein on SARS-CoV-2 binds ACE-2, which functions as an entry receptor. Following receptor binding, transmembrane protease serine 2 (encoded by TMPRSS2) primes the S protein to allow cellular uptake. Therefore, individual expression of TMPRSS2 may be a crucial determinant of SARS-CoV-2 infection susceptibility. Here, we utilized multiple large genome databases, including the GTEx portal, SNP nexus, and Ensembl genome project, to identify gene expression profiles for TMPRSS2 and its important expression quantitative trait loci. Our results show that four variants (rs464397, rs469390, rs2070788 and rs383510) affect expression of TMPRSS2 in lung tissue. The allele frequency of each variant was then assessed in regional populations, including African, American, European, and three Asian cohorts (China, Japan and Taiwan). Interestingly, our data shows that TMPRSS2-upregulating variants are at higher frequencies in European and American populations than in the Asian populations, which implies that these populations might be relatively susceptible to SARS-CoV-2 infection. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Irham, Lalu Muhammad; Chou, Wan-Hsuan; Adikusuma, Wirawan; Chang, Wei-Chiao] Taipei Med Univ, Coll Pharm, Sch Pharm, Dept Clin Pharm, Taipei 11031, Taiwan.
   [Chou, Wan-Hsuan; Chang, Wei-Chiao] Taipei Med Univ, Sch Pharm, Master Program Clin Pharmacogen & Pharmacoprote, Taipei 11031, Taiwan.
   [Irham, Lalu Muhammad] Univ Ahmad Dahlan, Fac Pharm, Yogyakarta 55164, Indonesia.
   [Calkins, Marcus J.] Acad Sinica, Inst Cellular & Organism Biol, Taipei 11529, Taiwan.
   [Hsieh, Shie-Liang] Acad Sinica, Genom Res Ctr, Taipei 11529, Taiwan.
   [Chang, Wei-Chiao] Taipei Med Univ Taipei, Wan Fang Hosp, Integrat Res Ctr Crit Care, Taipei 11696, Taiwan.
   [Chang, Wei-Chiao] Taipei Med Univ, Shuang Ho Hosp, Dept Med Res, New Taipei 23561, Taiwan.
RP Chang, WC (corresponding author), Taipei Med Univ, Coll Pharm, Sch Pharm, Dept Clin Pharm, Taipei 11031, Taiwan.
EM wcc@tmu.edu.tw
RI Irham, Lalu Muhammad/ABH-5191-2020; Adikusuma, Wirawan/AAI-2258-2019
OI Irham, Lalu Muhammad/0000-0002-0091-4887; Adikusuma,
   Wirawan/0000-0001-9165-690X; Chou, Wan-Hsuan/0000-0002-7693-5959
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [105-2628-B-038-001-MY4, 108-2314-B-038-027]; Taipei
   Medical University [106-5807-001-400]
FX This work was supported by the grants from Ministry of Science and
   Technology, Taiwan (105-2628-B-038-001-MY4; 108-2314-B-038-027) and
   Taipei Medical University (106-5807-001-400; Yusuke Nakamura Chair
   Professorship, 2020). Part of the data were extracted from the
   Genotype-Tissue Expression (GTEx) Portal on 03/20/2020.
CR Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cheng ZS, 2015, J INFECT DIS, V212, P1214, DOI 10.1093/infdis/jiv246
   Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758
   Garcia-Alvarez M, 2017, SCI REP-UK, V7, DOI 10.1038/srep41516
   Ghinai I., 2020, LANCET LONDON ENGLAN
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Laporte M, 2017, CURR OPIN VIROL, V24, P16, DOI 10.1016/j.coviro.2017.03.018
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu YC, 2020, NEW ENGL J MED, V382, P1070, DOI 10.1056/NEJMc2001573
   Matsuyama S., 2020, ENHANCED ISOLATION S
   Sakai K, 2014, J VIROL, V88, P5608, DOI 10.1128/JVI.03677-13
   Tarnow C, 2014, J VIROL, V88, P4744, DOI 10.1128/JVI.03799-13
   World Health Organization, 2020, NAM COR DIS COVID 19
   Zhao Y, 2020, SINGLE CELL RNA EXPR
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 21
TC 2
Z9 2
U1 5
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 20
PY 2020
VL 529
IS 2
BP 263
EP 269
DI 10.1016/j.bbrc.2020.05.179
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MP0AC
UT WOS:000551875700022
PM 32703421
DA 2021-01-01
ER

PT J
AU Reale, ML
   Bironzo, P
   Bertaglia, V
   Palesandro, E
   Leone, G
   Tabbo, F
   Bungaro, M
   Audisio, M
   Mariniello, A
   Rapetti, SG
   Di Stefano, RF
   Artusio, E
   Capelletto, E
   Sperone, P
   Boccuzzi, A
   Calandri, M
   Perboni, A
   Malapelle, U
   Passiglia, F
   Novello, S
AF Reale, Maria Lucia
   Bironzo, Paolo
   Bertaglia, Valentina
   Palesandro, Erica
   Leone, Gianmarco
   Tabbo, Fabrizio
   Bungaro, Maristella
   Audisio, Marco
   Mariniello, Annapaola
   Rapetti, Simonetta G.
   Di Stefano, Rosario F.
   Artusio, Elisa
   Capelletto, Enrica
   Sperone, Paola
   Boccuzzi, Adriana
   Calandri, Marco
   Perboni, Alberto
   Malapelle, Umberto
   Passiglia, Francesco
   Novello, Silvia
TI SARS-CoV-2 Infection in Cancer Patients: A Picture of an
   ItalianOnco-CovidUnit
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE COVID-19; lung cancer; cancer patients; asymptomatic patients; Italian
   retrospective study
ID COVID-19
AB Background:The world, and Italy on the front lines, has experienced a major medical emergency due to the novel coronavirus outbreak. Cancer patients are one of the potentially most vulnerable cohorts of people, but data about their management are still few. Patients and Methods:In this monocentric retrospective study we included all SARS-CoV-2 oncological patients accepted, between March 27th and April 19th 2020, at the Onco-COVID Unit at San Luigi Gonzaga Hospital, one of the few Italian oncological-COVID wards. Data were obtained from medical records. Results:Eighteen cancer patients with COVID-19 were included. The mean (+/- SD) age of patients was 67 +/- 14 years, 89% were men. Seven (39%) developed infection in communities and 11 (61%) during hospitalization. Lung cancer was the most frequent type of cancer (10, 56%). Seven patients (39%) were symptomatic for COVID-19 at the time of diagnosis and symptoms began 2 (+/- 2) days before. The most common were shortness of breath and diarrhea. Fever was present in 5 patients (28%). Among the 11 asymptomatic patients, 8 (73%) became symptomatic during the hospitalization (mean time of symptoms onset 4 days +/- 4). Six patients (33%) were on active anti-tumor treatment: 2 (33%) received anti-tumor therapy within 2 weeks before the infection diagnosis and 2 (33%) continued oncological treatment after SARS-CoV-2 positivity. Eight (44%) patients died within a mean of 12 days (+/- 8) from the infection diagnosis. Conclusions:Our series confirms the high mortality among cancer patients with COVID-19. The presence of asymptomatic cases evidences that typical symptoms and fever are not the only parameters to suspect the infection. The Onco-Covid unit suggests the importance of a tailored and holistic approach, even in this difficult situation.
C1 [Reale, Maria Lucia; Bironzo, Paolo; Bertaglia, Valentina; Palesandro, Erica; Leone, Gianmarco; Tabbo, Fabrizio; Bungaro, Maristella; Audisio, Marco; Mariniello, Annapaola; Rapetti, Simonetta G.; Di Stefano, Rosario F.; Artusio, Elisa; Capelletto, Enrica; Sperone, Paola; Passiglia, Francesco; Novello, Silvia] Univ Turin, Dept Oncol, San Luigi Gonzaga Hosp, Turin, Italy.
   [Boccuzzi, Adriana] San Luigi Gonzaga Hosp, Emergency Med, Turin, Italy.
   [Calandri, Marco] Univ Turin, San Luigi Gonzaga Hosp, Dept Oncol, Radiol Unit, Turin, Italy.
   [Perboni, Alberto] San Luigi Gonzaga Hosp, Pneumol, Turin, Italy.
   [Malapelle, Umberto] Univ Naples Federico II, Dept Publ Hlth, Naples, Italy.
RP Bironzo, P; Novello, S (corresponding author), Univ Turin, Dept Oncol, San Luigi Gonzaga Hosp, Turin, Italy.
EM pbironzo@gmail.com; silvia.novello@unito.it
CR American Society of Clinical Oncology (ASCO), COVID 19 PROV PRACT
   [Anonymous], 2020, INFEZ MED, V28, P143
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   European Medicines Agency, COVID 19 REM RISKS C
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Istituto Superiore di Sanita, COVID 19 INT SURV KE
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lambertini M, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000759
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Societa Italiana di Malattie Infettive e Tropicali (SIMET), 2020, SEZ REG LOMB LIN GUI
   Statistiche Coronavirus, 2020, STAT COR PIEM, V395, P1919, DOI [10.1016/S0140-6736(20)31173-9, DOI 10.1016/S0140-6736(20)31173-9]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, COR DIS COVID 19 PAN
   World Health Organization, COR DIS COVID 19 TEC
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 20
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 19
PY 2020
VL 10
AR 1722
DI 10.3389/fonc.2020.01722
PG 8
WC Oncology
SC Oncology
GA NM1KJ
UT WOS:000567862600001
PM 32974210
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sauvat, A
   Ciccosanti, F
   Colavita, F
   Di Rienzo, M
   Castilletti, C
   Capobianchi, MR
   Kepp, O
   Zitvogel, L
   Fimia, GM
   Piacentini, M
   Kroemer, G
AF Sauvat, Allan
   Ciccosanti, Fabiola
   Colavita, Francesca
   Di Rienzo, Martina
   Castilletti, Concetta
   Capobianchi, Maria Rosaria
   Kepp, Oliver
   Zitvogel, Laurence
   Fimia, Gian Maria
   Piacentini, Mauro
   Kroemer, Guido
TI On-target versus off-target effects of drugs inhibiting the replication
   of SARS-CoV-2
SO CELL DEATH & DISEASE
LA English
DT Article
ID MEMBRANE PERMEABILIZATION; CELL; CHLORPROMAZINE; AUTOPHAGY; EFFICACY;
   COVID-19; THERAPY
AB The current epidemic of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) calls for the development of inhibitors of viral replication. Here, we performed a bioinformatic analysis of published and purported SARS-CoV-2 antivirals including imatinib mesylate that we found to suppress SARS-CoV-2 replication on Vero E6 cells and that, according to the published literature on other coronaviruses is likely to act on-target, as a tyrosine kinase inhibitor. We identified a cluster of SARS-CoV-2 antivirals with characteristics of lysosomotropic agents, meaning that they are lipophilic weak bases capable of penetrating into cells. These agents include cepharentine, chloroquine, chlorpromazine, clemastine, cloperastine, emetine, hydroxychloroquine, haloperidol, ML240, PB28, ponatinib, siramesine, and zotatifin (eFT226) all of which are likely to inhibit SARS-CoV-2 replication by non-specific (off-target) effects, meaning that they probably do not act on their 'official' pharmacological targets, but rather interfere with viral replication through non-specific effects on acidophilic organelles including autophagosomes, endosomes, and lysosomes. Imatinib mesylate did not fall into this cluster. In conclusion, we propose a tentative classification of SARS-CoV-2 antivirals into specific (on-target) versus non-specific (off-target) agents based on their physicochemical characteristics.
C1 [Sauvat, Allan; Kepp, Oliver; Kroemer, Guido] Sorbonne Univ, Univ Paris, Equipe Labellisee Ligue Canc, Ctr Rech Cordeliers,INSERM,UMR1138, Paris, France.
   [Sauvat, Allan; Kepp, Oliver; Kroemer, Guido] Gustave Roussy, Metabol & Cell Biol Platforms, Villejuif, France.
   [Ciccosanti, Fabiola; Colavita, Francesca; Di Rienzo, Martina; Castilletti, Concetta; Capobianchi, Maria Rosaria; Fimia, Gian Maria; Piacentini, Mauro] IRCCS, Natl Inst Infect Dis L Spallanzani, Dept Epidemiol Preclin Res & Adv Diagnost, Rome, Italy.
   [Fimia, Gian Maria] Sapienza Univ Rome, Dept Mol Med, Rome, Italy.
   [Piacentini, Mauro] Univ Roma Tor Vergata, Dept Biol, Rome, Italy.
   [Zitvogel, Laurence] Gustave Roussy Comprehens Canc Inst, Villejuif, France.
   [Zitvogel, Laurence] INSERM, U1015, Villejuif, France.
   [Zitvogel, Laurence] Ctr Clin Invest Biotherapies Canc CICBT, F-1428 Villejuif, France.
   [Zitvogel, Laurence] Univ Paris Saclay, Fac Med, Le Kremlin Bicetre, France.
   [Zitvogel, Laurence] Univ Paris Sud, Paris Saclay, Fac Med, Le Kremlin Bicetre, France.
   [Zitvogel, Laurence; Kroemer, Guido] Chinese Acad Med Sci, Suzhou Inst Syst Med, Suzhou, Peoples R China.
   [Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France.
   [Kroemer, Guido] Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, Stockholm, Sweden.
RP Kroemer, G (corresponding author), Sorbonne Univ, Univ Paris, Equipe Labellisee Ligue Canc, Ctr Rech Cordeliers,INSERM,UMR1138, Paris, France.; Kroemer, G (corresponding author), Gustave Roussy, Metabol & Cell Biol Platforms, Villejuif, France.; Piacentini, M (corresponding author), IRCCS, Natl Inst Infect Dis L Spallanzani, Dept Epidemiol Preclin Res & Adv Diagnost, Rome, Italy.; Piacentini, M (corresponding author), Univ Roma Tor Vergata, Dept Biol, Rome, Italy.; Kroemer, G (corresponding author), Chinese Acad Med Sci, Suzhou Inst Syst Med, Suzhou, Peoples R China.; Kroemer, G (corresponding author), Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France.; Kroemer, G (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, Stockholm, Sweden.
EM mauro.piacentini@uniroma2.it; kroemer@orange.fr
RI Kepp, Oliver/N-2763-2017; Fimia, Gian Maria/K-3232-2016
OI Kepp, Oliver/0000-0002-6081-9558; Fimia, Gian Maria/0000-0003-4438-3325
FU Ligue contre le Cancer (equipe labellisee); Agence National de la
   Recherche (ANR) - Projets blancsFrench National Research Agency (ANR);
   ANRFrench National Research Agency (ANR); AMMICa US23/CNRS [UMS3655];
   Association pour la recherche sur le cancer (ARC)Fondation ARC pour la
   Recherche sur le Cancer; Association "Le Cancer du Sein, Parlons-en!";
   Canceropole Ile-de-FranceRegion Ile-de-France; Chancelerie des
   universites de Paris (Legs Poix); Fondation pour la Recherche Medicale
   (FRM)Fondation pour la Recherche Medicale; European Research Area
   Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy
   Odyssea; European Union Horizon 2020 Project Oncobiome; Fondation
   Carrefour; High-end Foreign Expert Program in China [GDW20171100085];
   Institut National du Cancer (INCa)Institut National du Cancer (INCA)
   France; Inserm (HTE); Institut Universitaire de France; LeDucq
   FoundationLeducq Foundation; LabEx ImmunoOncology [ANR-18-IDEX-0001];
   RHU Torino Lumiere; Seerave Foundation; SIRIC Stratified Oncology Cell
   DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research
   and Personalized Medicine (CARPEM)
FX G.K. is supported by the Ligue contre le Cancer (equipe labellisee);
   Agence National de la Recherche (ANR) - Projets blancs; ANR under the
   frame of E-Rare2, the ERA-Net for Research on Rare Diseases; AMMICa
   US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC);
   Association "Le Cancer du Sein, Parlons-en!"; Canceropole Ile-de-France;
   Chancelerie des universites de Paris (Legs Poix), Fondation pour la
   Recherche Medicale (FRM); a donation by Elior; European Research Area
   Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy
   Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation
   Carrefour; High-end Foreign Expert Program in China (GDW20171100085),
   Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire
   de France; LeDucq Foundation; the LabEx ImmunoOncology
   (ANR-18-IDEX-0001); the RHU Torino Lumiere; the Seerave Foundation; the
   SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination
   (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine
   (CARPEM).
CR Abate C, 2011, J MED CHEM, V54, P5858, DOI 10.1021/jm200591t
   Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Apolloni S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0658-8
   Ashoor R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082481
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622
   BRIGGS I, 1987, NEUROPHARMACOLOGY, V26, P469, DOI 10.1016/0028-3908(87)90029-3
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Campleman SL, 2020, CLIN TOXICOL, DOI 10.1080/15563650.2020.1746330
   Canfran-Duque A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030404
   Cao Y, 2008, BIOINFORMATICS, V24, P1733, DOI 10.1093/bioinformatics/btn307
   Cesen MH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.361
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Gorkin L, 2016, NAT REV CLIN ONCOL, V13, P270, DOI 10.1038/nrclinonc.2016.59
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guha R, 2007, J STAT SOFTW, V18
   Huang JS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041131
   Joensuu H, 2012, ANNU REV MED, V63, P247, DOI 10.1146/annurev-med-043010-091813
   KOVACS J, 1974, VIRCHOWS ARCH B, V15, P209
   Li CC, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01342-w
   Li Y, 2016, PHARMACOL RES, V110, P35, DOI 10.1016/j.phrs.2016.05.004
   Liu W, 2020, CAN MED ASSOC J, V192, pE734, DOI 10.1503/cmaj.200647
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   MORGAN DJ, 1986, J PHARM PHARMACOL, V38, P557, DOI 10.1111/j.2042-7158.1986.tb04640.x
   Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269
   Park J, 2012, NEUROSCIENCE, V209, P64, DOI 10.1016/j.neuroscience.2012.02.035
   Park SJ, 2020, MBIO, V11, DOI 10.1128/mBio.01114-20
   Plaze M, 2020, ENCEPHALE, V46, pS35, DOI 10.1016/j.encep.2020.04.010
   Raoult D, 2020, CELL STRESS, V4, P66, DOI 10.15698/cst2020.04.216
   Rogado J, 2020, CLIN TRANSL ONCOL, V22, P2364, DOI 10.1007/s12094-020-02381-z
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Strachan EM, 2004, EUR J CLIN PHARMACOL, V60, P541, DOI 10.1007/s00228-004-0811-7
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Tang ZH, 2018, CANCER LETT, V412, P1, DOI 10.1016/j.canlet.2017.10.001
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yuan SF, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104960
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zitvogel L, 2016, NAT REV CLIN ONCOL, V13, P431, DOI 10.1038/nrclinonc.2016.41
NR 51
TC 0
Z9 0
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG 19
PY 2020
VL 11
IS 8
AR 656
DI 10.1038/s41419-020-02842-x
PG 11
WC Cell Biology
SC Cell Biology
GA NJ7RZ
UT WOS:000566241700001
PM 32814759
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shenoy, N
   Luchtel, R
   Gulani, P
AF Shenoy, Niraj
   Luchtel, Rebecca
   Gulani, Perminder
TI Considerations for target oxygen saturation in COVID-19 patients: are we
   under-shooting?
SO BMC MEDICINE
LA English
DT Article
DE SARS-CoV-2; COVID-19; Hypoxemia; Hypoxia; ACE2
ID ARTERY SMOOTH-MUSCLE; NOCTURNAL HYPOXEMIA; SARS CORONAVIRUS; ACE2;
   THERAPY; EXPRESSION; MORTALITY; RECEPTOR; EVENTS
AB Background The current target oxygen saturation range for patients with COVID-19 recommended by the National Institutes of Health is 92-96%. Main body This article critically examines the evidence guiding current target oxygen saturation recommendation for COVID-19 patients, and raises important concerns in the extrapolation of data from the two studies stated to be guiding the recommendation. Next, it examines the influence of hypoxia on upregulation of ACE2 (target receptor for SARS-CoV-2 entry) expression, with supporting transcriptomic analysis of a publicly available gene expression profile dataset of human renal proximal tubular epithelial cells cultured in normoxic or hypoxic conditions. Finally, it discusses potential implications of specific clinical observations and considerations in COVID-19 patients on target oxygen saturation, such as diffuse systemic endothelitis and microthrombi playing an important pathogenic role in the wide range of systemic manifestations, exacerbation of hypoxic pulmonary vasoconstriction in the setting of pulmonary vascular endothelitis/microthrombi, the phenomenon of "silent hypoxemia" with some patients presenting to the hospital with severe hypoxemia disproportional to symptoms, and overburdened health systems and public health resources in many parts of the world with adverse implications on outpatient monitoring and early institution of oxygen supplementation. Conclusions The above factors and analyses, put together, call for an urgent exploration and re-evaluation of target oxygen saturation in COVID-19 patients, both in the inpatient and outpatient settings. Until data from such trials become available, where possible, it may be prudent to target an oxygen saturation at least at the upper end of the recommended 92-96% range in COVID-19 patients both in the inpatient and outpatient settings (in patients that are normoxemic at pre-COVID baseline). Home pulse oximetry, tele-monitoring, and earlier institution of oxygen supplementation for hypoxemic COVID-19 outpatients could be beneficial, where public health resources allow for their implementation.
C1 [Shenoy, Niraj; Luchtel, Rebecca] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med Oncol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
   [Gulani, Perminder] Albert Einstein Coll Med, Jacobi Med Ctr, Dept Med Crit Care Med, Bronx, NY 10461 USA.
RP Shenoy, N (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med Oncol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM niraj.shenoy@einsteinmed.org
OI Shenoy, Niraj/0000-0003-2074-1108
FU Albert Einstein Cancer Center core grant [2P30CA013330-47]
FX Dr. Shenoy's research is supported by the Albert Einstein Cancer Center
   core grant (2P30CA013330-47).
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Barrot L, 2020, NEW ENGL J MED, V382, P999, DOI 10.1056/NEJMoa1916431
   Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Gries RE, 1996, CHEST, V110, P1489, DOI 10.1378/chest.110.6.1489
   Gu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19840
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Horby P, 2020, EFFECT DEXAMETHASONE
   Hu HH, 2020, EUR REV MED PHARMACO, V24, P3968, DOI 10.26355/eurrev_202004_20867
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jouffroy R, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03036-9
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lumb AB, 2015, ANESTHESIOLOGY, V122, P932, DOI 10.1097/ALN.0000000000000569
   Majumdar SR, 2011, CLIN INFECT DIS, V52, P325, DOI 10.1093/cid/ciq076
   Mitra AR, 2020, CAN MED ASSOC J, V192, pE694, DOI 10.1503/cmaj.200794
   Morrell NW, 1999, AM J PHYSIOL-LUNG C, V277, pL440
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Rafanan AL, 2001, CHEST, V120, P894, DOI 10.1378/chest.120.3.894
   Richardson S., 2020, JAMA
   Santos RAS, 2008, EXP PHYSIOL, V93, P519, DOI 10.1113/expphysiol.2008.042002
   Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254
   Shenoy V, 2011, CURR OPIN PHARMACOL, V11, P150, DOI 10.1016/j.coph.2010.12.002
   Shved N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08492-y
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Spiezia L, 2020, THROMB HAEMOST
   Sylvester JT, 2012, PHYSIOL REV, V92, P367, DOI 10.1152/physrev.00041.2010
   Tobin MJ, 2020, AM J RESP CRIT CARE, V202, P356, DOI 10.1164/rccm.202006-2157CP
   Varga Z, 2020, LANCET
   vonEiff M, 1996, INTENS CARE MED, V22, P174, DOI 10.1007/BF01720726
   Wang RQ, 1999, AM J PHYSIOL-LUNG C, V276, pL885
   Wilkerson RG, 2020, AM J EMERG MED
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   Wrapp D, 2020, CRYO EM STRUCTURE 20
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang RF, 2009, AM J PHYSIOL-LUNG C, V297, pL631, DOI 10.1152/ajplung.90415.2008
NR 37
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD AUG 19
PY 2020
VL 18
IS 1
AR 260
DI 10.1186/s12916-020-01735-2
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA NI3SX
UT WOS:000565277100002
PM 32814566
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rathnayake, AD
   Zheng, J
   Kim, Y
   Perera, KD
   Mackin, S
   Meyerholz, DK
   Kashipathy, MM
   Battaile, KP
   Lovell, S
   Perlman, S
   Groutas, WC
   Chang, KO
AF Rathnayake, Athri D.
   Zheng, Jian
   Kim, Yunjeong
   Perera, Krishani Dinali
   Mackin, Samantha
   Meyerholz, David K.
   Kashipathy, Maithri M.
   Battaile, Kevin P.
   Lovell, Scott
   Perlman, Stanley
   Groutas, William C.
   Chang, Kyeong-Ok
TI 3C-like protease inhibitors block coronavirus replication in vitro and
   improve survival in MERS-CoV-infected mice
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID NOROVIRUS 3CL PROTEASE; FELINE CORONAVIRUSES; POTENT INHIBITION; MOUSE
   MODEL; DESIGN; GENERATION; EFFICACY; DISEASE
AB Pathogenic coronaviruses are a major threat to global public health, as exemplified by severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and the newly emerged SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). We describe herein the structure-guided optimization of a series of inhibitors of the coronavirus 3C-like protease (3CLpro), an enzyme essential for viral replication. The optimized compounds were effective against several human coronaviruses including MERS-CoV, SARS-CoV, and SARS-CoV-2 in an enzyme assay and in cell-based assays using Huh-7 and Vero E6 cell lines. Two selected compounds showed antiviral effects against SARS-CoV-2 in cultured primary human airway epithelial cells. In a mouse model of MERS-CoV infection, administration of a lead compound 1 day after virus infection increased survival from 0 to 100% and reduced lung viral titers and lung histopathology. These results suggest that this series of compounds has the potential to be developed further as antiviral drugs against human coronaviruses.
C1 [Rathnayake, Athri D.; Groutas, William C.] Wichita State Univ, Dept Chem, Wichita, KS 67260 USA.
   [Zheng, Jian; Mackin, Samantha; Perlman, Stanley] Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA 52242 USA.
   [Kim, Yunjeong; Perera, Krishani Dinali; Chang, Kyeong-Ok] Kansas State Univ, Coll Vet Med, Dept Diagnost Med & Pathobiol, Manhattan, KS 66506 USA.
   [Meyerholz, David K.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA.
   [Kashipathy, Maithri M.; Lovell, Scott] Univ Kansas, Prot Struct Lab, Lawrence, KS 66045 USA.
   [Battaile, Kevin P.] New York Struct Biol Ctr, NYX, Upton, NY 11973 USA.
RP Groutas, WC (corresponding author), Wichita State Univ, Dept Chem, Wichita, KS 67260 USA.; Perlman, S (corresponding author), Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA 52242 USA.; Chang, KO (corresponding author), Kansas State Univ, Coll Vet Med, Dept Diagnost Med & Pathobiol, Manhattan, KS 66506 USA.
EM stanley-perlman@uiowa.edu; bill.groutas@wichita.edu; kchang@vet.ksu.edu
RI Meyerholz, David/J-8131-2019
OI Meyerholz, David/0000-0003-1552-3253; Battaile,
   Kevin/0000-0003-0833-3259; Lovell, Scott/0000-0002-3215-4472; Mackin,
   Samantha/0000-0003-4518-1274; Kim, Yunjeong/0000-0002-2977-4400; Perera,
   Krishani Dinali/0000-0002-3778-4975; Thennakoon Mudiyansleage, Athri
   Dewmina Rathnayake/0000-0003-2588-7624
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 AI109039, P01 AI060699, R01
   AI129269]; National Institute of General Medical Sciences of the
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [P30GM110761]; Industrial Macromolecular
   Crystallography Association; Hauptman-Woodward Medical Research
   Institute; U.S. Department of Energy, Office of Science, Office of Basic
   Energy SciencesUnited States Department of Energy (DOE)
   [DE-AC02-06CH11357]
FX This research was supported in part by grants from the NIH (R01 AI109039
   to K.-O.C. and P01 AI060699 and R01 AI129269 to S.P.). Use of the
   University of Kansas Protein Structure Laboratory was supported by a
   grant from the National Institute of General Medical Sciences
   (P30GM110761) of the NIH. Use of the IMCA-CAT beamline 17-ID at the
   Advanced Photon Source was supported by the companies of the Industrial
   Macromolecular Crystallography Association through a contract with
   Hauptman-Woodward Medical Research Institute. Use of the Advanced Photon
   Source was supported by the U.S. Department of Energy, Office of
   Science, Office of Basic Energy Sciences under contract no.
   DE-AC02-06CH11357.
CR Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308
   Agrawal AS, 2015, J VIROL, V89, P3659, DOI 10.1128/JVI.03427-14
   Bonanno J.B., 2003, N Y TIMES WEB, pC2
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269
   Dragovich PS, 1999, J MED CHEM, V42, P1213, DOI 10.1021/jm9805384
   DYALL J, 2017, DRUGS, V77, P1935, DOI [10.1007/s40265-017-0830-1, DOI 10.1007/S40265-017-0830-1]
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693
   Evans P, 2012, SCIENCE, V336, P986, DOI 10.1126/science.1222162
   Evans PR, 2011, ACTA CRYSTALLOGR D, V67, P282, DOI 10.1107/S090744491003982X
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Homes K. V., 2001, CORONAVIRUSES, P1187
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Kankanamalage ACG, 2018, EUR J MED CHEM, V150, P334, DOI 10.1016/j.ejmech.2018.03.004
   Kankanamalage ACG, 2017, EUR J MED CHEM, V126, P502, DOI 10.1016/j.ejmech.2016.11.027
   Kankanamalage ACG, 2015, J MED CHEM, V58, P3144, DOI 10.1021/jm5019934
   Karp Philip H, 2002, Methods Mol Biol, V188, P115
   Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.1218231, 10.1126/science.121823]
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Kim Y, 2015, J VIROL, V89, P4942, DOI 10.1128/JVI.03688-14
   Kim Y, 2013, ANTIVIR RES, V97, P161, DOI 10.1016/j.antiviral.2012.11.005
   Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12
   Kjell DP, 1999, J ORG CHEM, V64, P5722, DOI 10.1021/jo990543v
   Li K, 2017, P NATL ACAD SCI USA, V114, pE3119, DOI 10.1073/pnas.1619109114
   Li K, 2016, J INFECT DIS, V213, P712, DOI 10.1093/infdis/jiv499
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mandadapu SR, 2013, BIOORG MED CHEM LETT, V23, P62, DOI 10.1016/j.bmcl.2012.11.026
   Mandadapu SR, 2012, BIOORG MED CHEM LETT, V22, P4820, DOI 10.1016/j.bmcl.2012.05.055
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Meyerholz DK, 2018, LAB INVEST, V98, P844, DOI 10.1038/s41374-018-0057-0
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Needle D, 2015, ACTA CRYSTALLOGR D, V71, P1102, DOI 10.1107/S1399004715003521
   Ng DL, 2016, AM J PATHOL, V186, P652, DOI 10.1016/j.ajpath.2015.10.024
   Pedersen NC, 2018, J FELINE MED SURG, V20, P378, DOI 10.1177/1098612X17729626
   Perera KD, 2018, ANTIVIR RES, V160, P79, DOI 10.1016/j.antiviral.2018.10.015
   Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716
   Prior AM, 2013, BIOORG MED CHEM LETT, V23, P6317, DOI 10.1016/j.bmcl.2013.09.070
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Skariyachan S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00569
   Tian QP, 2001, TETRAHEDRON LETT, V42, P6807, DOI 10.1016/S0040-4039(01)01416-2
   Totura AL, 2019, EXPERT OPIN DRUG DIS, V14, P397, DOI 10.1080/17460441.2019.1581171
   Vonrhein C, 2011, ACTA CRYSTALLOGR D, V67, P293, DOI 10.1107/S0907444911007773
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Weiss MS, 2001, J APPL CRYSTALLOGR, V34, P130, DOI 10.1107/S0021889800018227
   Wu AD, 2015, VIRUS RES, V208, P56, DOI 10.1016/j.virusres.2015.05.018
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 55
TC 4
Z9 4
U1 4
U2 4
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD AUG 19
PY 2020
VL 12
IS 557
AR eabc5332
DI 10.1126/scitranslmed.abc5332
PG 11
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA NF0TJ
UT WOS:000563015800006
PM 32747425
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jayaseelan, VP
   Paramasivam, A
AF Jayaseelan, Vijayashree Priyadharsini
   Paramasivam, Arumugam
TI Repurposing calcium channel blockers as antiviral drugs
SO JOURNAL OF CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE CCB; Calcium homeostasis; Calcium channels; SARs; Virus; Verapamil
AB The current pandemic caused by the SARS-CoV-2 has claimed over a half a million lives within a very short span of time. A therapeutic drug which could prevent the entry and propagation of the virus is the need of the hour. Several lines of evidence collected from experimental studies older than three decades have pointed out the fact that inhibiting calcium entry into cells can affect vital steps in the lifecycle of viruses. Hence, calcium channel blockers may be considered as an effective measure in the containment of the viruses. This commentary throws light two scientific papers although with divergent facts converging at a point by suggesting a promising treatment option for CoVID-19 (Fang et al. Lancet Respir Med 8:e21,2020; Straus et al. J Virol 94:e00426,2020).
C1 [Jayaseelan, Vijayashree Priyadharsini; Paramasivam, Arumugam] Saveetha Univ, BRULAC DRC, Saveetha Dent Coll & Hosp, Saveetha Inst Med & Tech Sci SIMATS, Poonamallee High Rd, Chennai 600077, Tamil Nadu, India.
RP Jayaseelan, VP (corresponding author), Saveetha Univ, BRULAC DRC, Saveetha Dent Coll & Hosp, Saveetha Inst Med & Tech Sci SIMATS, Poonamallee High Rd, Chennai 600077, Tamil Nadu, India.
EM vijayashreej.sdc@saveetha.com
OI Jayaseelan, Dr. Vijayashree Priyadharsini/0000-0001-7884-5466
FU Science and Engineering Research Board [CRG/2019/003756] Funding Source:
   Medline
CR Chang-Graham AL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46856-8
   CHEN XS, 2019, FRONT PLANT SCI, V9, P1, DOI DOI 10.1680/jstbu.18.00053
   Dobson SJ, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104819
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Kai H, 2020, HYPERTENS RES, V43, P648, DOI 10.1038/s41440-020-0455-8
   Li G, 2020, HYPERTENS RES, V43, P588, DOI 10.1038/s41440-020-0433-1
   Long D, 2016, GENES IMMUN, V17, P298, DOI 10.1038/gene.2016.21
   Nathan L, 2020, ACS INFECT DIS, V6, P250, DOI 10.1021/acsinfecdis.9b00296
   Omar S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171681
   Paramasivam A, 2020, HYPERTENS RES, V43, P729, DOI 10.1038/s41440-020-0461-x
   Straus MR, 2020, J VIROL, V94, DOI 10.1128/JVI.00426-20
NR 11
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1873-9601
EI 1873-961X
J9 J CELL COMMUN SIGNAL
JI J. Cell Commun. Signal
PD DEC
PY 2020
VL 14
IS 4
BP 467
EP 468
DI 10.1007/s12079-020-00579-y
EA AUG 2020
PG 2
WC Cell Biology
SC Cell Biology
GA OM9PU
UT WOS:000561479000001
PM 32815099
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bui, TQ
   Loan, HTP
   My, TTA
   Quang, DT
   Thuy, BTP
   Nhan, VD
   Quy, PT
   Tat, PV
   Dao, DQ
   Trung, NT
   Huynh, LK
   Nhung, NTA
AF Bui, Thanh Q.
   Huynh Thi Phuong Loan
   Tran Thi Ai My
   Duong Tuan Quang
   Bui Thi Phuong Thuy
   Vo Duy Nhan
   Phan Tu Quy
   Pham Van Tat
   Duy Quang Dao
   Nguyen Tien Trung
   Huynh, Lam K.
   Nguyen Thi Ai Nhung
TI A density functional theory study on silver and bis-silver complexes
   with lighter tetrylene: are silver and bis-silver carbenes candidates
   for SARS-CoV-2 inhibition? Insight from molecular docking simulation
SO RSC ADVANCES
LA English
DT Article
ID N-HETEROCYCLIC CARBENE; MAIN-GROUP ELEMENTS; ELECTRONIC-STRUCTURE;
   BASIS-SETS; ANTICANCER; DISCOVERY; LIGANDS; GOLD; AG
AB Ribavirin and remdesivir have been preclinically reported as potential drugs for the treatment of SARS-CoV-2 infection, while light silver tetrylene complexes (NHEPh-AgCl and (NHEPh-AgCl)(2)with E = C, Si, and Ge) have gained significant interest due to their promising applicability on the cytological scale. Firstly, the structures and bonding states of silver-tetrylene complexes (NHE-Ag) and bis-silver-tetrylene complexes (NHE-Ag-bis) were investigated using density functional theory (DFT) at the BP86 level with the def2-SVP and def2-TZVPP basis sets. Secondly, the inhibitory capabilities of the carbene complexes (NHC-AgandNHC-Ag-bis) and the two potential drugs (ribavirin and remdesivir) on human-protein ACE2 and SARS-CoV-2 protease PDB6LU7 were evaluated using molecular docking simulation. The carbene ligandNHCbonds in a head-on configuration with AgCl and (AgCl)(2), whereas, the otherNHE(E = Si and Ge) tetrylene ligands bond in a side-on mode to the metal fragments. The bond dissociation energy (BDE) of the NHE-Ag bond in the complex families follows the order ofNHC-Ag>NHSi-Ag>NHGe-AgandNHSi-Ag-bis>NHGe-Ag-bis>NHC-Ag-bis. The natural bond orbital analysis implies that the [NHEPh -> AgCl] and [(NHEPh)(2)->(AgCl)(2)] donations are derived mainly from the sigma- and pi-contributions of the ligands. The docking results indicate that both the ACE2 and PDB6LU7 proteins are strongly inhibited by silver-carbeneNHC-Ag, bis-silver-carbeneNHC-Ag-bis, ribavirin, and remdesivir with the docking score energy values varying from -17.5 to -16.5 kcal mol(-1)and -16.9 to -16.6 kcal mol(-1), respectively. The root-mean-square deviation values were recorded to be less than 2 angstrom in all the calculated systems. Thus, the present study suggests that silver-carbeneNHC-Agand bis-silver-carbeneNHC-Ag-biscomplexes are potential candidates to inhibit ACE2 and PDB6LU7, and thus potentially conducive to prevent infection caused by the SARS-CoV-2 virus.
C1 [Bui, Thanh Q.; Huynh Thi Phuong Loan; Tran Thi Ai My; Nguyen Thi Ai Nhung] Hue Univ, Univ Sci, Dept Chem, Hue City 530000, Vietnam.
   [Duong Tuan Quang] Hue Univ, Univ Educ, Dept Chem, Hue City 530000, Vietnam.
   [Bui Thi Phuong Thuy] Van Lang Univ, Fac Fundamental Sci, Ho Chi Minh City 700000, Vietnam.
   [Vo Duy Nhan] Nam Can Tho Univ, Fac Pharm, Ninh Kieu 94000, Can Tho, Vietnam.
   [Phan Tu Quy] Tay Nguyen Univ, Dept Nat Sci & Technol, Buon Ma Thuot City 630000, Vietnam.
   [Pham Van Tat] Hoa Sen Univ, Inst Dev & Appl Econ, Ho Chi Minh City 700000, Vietnam.
   [Duy Quang Dao] Duy Tan Univ, Inst Res & Dev, Da Nang 550000, Vietnam.
   [Nguyen Tien Trung] Quy Nhon Univ, Fac Nat Sci, Lab Computat Chem & Modeling, Quy Nhon City 590000, Vietnam.
   [Huynh, Lam K.] Int Univ, Dept Chem Engn, Ho Chi Minh City 700000, Vietnam.
RP Loan, HTP; Nhung, NTA (corresponding author), Hue Univ, Univ Sci, Dept Chem, Hue City 530000, Vietnam.; Thuy, BTP (corresponding author), Van Lang Univ, Fac Fundamental Sci, Ho Chi Minh City 700000, Vietnam.
EM phuongloan.thptnct@tayninh.edu.vn; buithiphuongthuy@vanlanguni.edu.vn;
   ntanhung@hueuni.edu.vn
RI Phong, KHCN-HTQT/AAJ-5480-2020; DAO, DUY QUANG/R-5515-2018
OI Loan, Huynh Thi Phuong/0000-0002-3659-4571; DAO, DUY
   QUANG/0000-0003-0896-5168; Quang, Duong Tuan/0000-0002-4926-0271
FU Vietnam National Foundation for Science and Technology Development
   (NAFOSTED)National Foundation for Science & Technology Development
   (NAFOSTED) [104.06-2017.303]
FX Nguyen Thi Ai Nhung thanks Prof. Dr Gernot Frenking for allowing the
   continuous use of her own resources within Frenking's group. The
   programs used in the studies were run via the Erwin/Annemarie clusters
   operated by Reuti (Thomas Reuter) at the Philipps-Universitat Marburg,
   Germany. This research is funded by the Vietnam National Foundation for
   Science and Technology Development (NAFOSTED) under grant number
   104.06-2017.303.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   AHLRICHS R, 1989, CHEM PHYS LETT, V162, P165, DOI 10.1016/0009-2614(89)85118-8
   ALALLAF TAK, 1990, J INORG BIOCHEM, V38, P47, DOI 10.1016/0162-0134(90)85006-I
   ARDUENGO AJ, 1991, J AM CHEM SOC, V113, P361, DOI 10.1021/ja00001a054
   ARDUENGO AJ, 1993, ORGANOMETALLICS, V12, P3405, DOI 10.1021/om00033a009
   Arduengo AJ, 1999, ACCOUNTS CHEM RES, V32, P913, DOI 10.1021/ar980126p
   Babu TMC, 2017, RSC ADV, V7, P18277, DOI 10.1039/c6ra27872h
   Banti CN, 2013, METALLOMICS, V5, P569, DOI 10.1039/c3mt00046j
   BECKE AD, 1986, J CHEM PHYS, V84, P4524, DOI 10.1063/1.450025
   Benhamou L, 2011, CHEM REV, V111, P2705, DOI 10.1021/cr100328e
   Boehme C, 1998, ORGANOMETALLICS, V17, P5801, DOI 10.1021/om980394r
   Bourissou D, 2000, CHEM REV, V100, P39, DOI 10.1021/cr940472u
   Budagumpi S, 2013, EUR J INORG CHEM, V2013, P4367, DOI 10.1002/ejic.201300483
   Cannon CL, 2009, ANTIMICROB AGENTS CH, V53, P3285, DOI 10.1128/AAC.00314-09
   Catalano VJ, 2004, INORG CHEM, V43, P5714, DOI 10.1021/ic049604k
   Cohen DT, 2012, CHEM SCI, V3, P53, DOI 10.1039/c1sc00621e
   Cordes M, 2009, CHEM SOC REV, V38, P892, DOI 10.1039/b805743p
   Eloy L, 2012, CHEMMEDCHEM, V7, P805, DOI 10.1002/cmdc.201200055
   Fackler JP, 2002, INORG CHEM, V41, P6959, DOI 10.1021/ic025734m
   Fischer J., 2012, ANALOGUE BASED DRUG
   Frisch M.J, 2009, GAUSSIAN 09 REV B 01
   Garrison JC, 2005, CHEM REV, V105, P3978, DOI 10.1021/cr050004s
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Hague RA, 2014, INORG CHEM COMMUN, V44, P128, DOI 10.1016/j.inoche.2014.03.016
   HERRMANN WA, 1994, J ORGANOMET CHEM, V480, pC7, DOI 10.1016/0022-328X(94)87130-2
   Herrmann WA, 2001, ADV ORGANOMET CHEM, V48, P1
   Hindi KM, 2009, CHEM REV, V109, P3859, DOI 10.1021/cr800500u
   Kascatan-Nebioglu A, 2007, COORDIN CHEM REV, V251, P884, DOI 10.1016/j.ccr.2006.08.019
   Thai KM, 2015, J THEOR BIOL, V385, P31, DOI 10.1016/j.jtbi.2015.08.019
   Khalili JS, 2020, J MED VIROL, V92, P740, DOI 10.1002/jmv.25798
   KHARKYANEN VN, 1978, J THEOR BIOL, V73, P29, DOI 10.1016/0022-5193(78)90178-9
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Lee MT, 2004, ORGANOMETALLICS, V23, P976, DOI 10.1021/om0341451
   Liu AL, 2008, INORG CHEM COMMUN, V11, P1128, DOI 10.1016/j.inoche.2008.06.015
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Lukovits I, 2001, CORROSION, V57, P3, DOI 10.5006/1.3290328
   Lv K, 2008, ORGANOMETALLICS, V27, P5438, DOI 10.1021/om800801k
   Melaiye A, 2004, J MED CHEM, V47, P973, DOI 10.1021/jm030262m
   Metz B, 2000, J CHEM PHYS, V113, P2563, DOI 10.1063/1.1305880
   Narkhede R. R., 2020, EURASIAN J MED ONCOL, V4, P185, DOI [https://doi.org/10.14744/ejmo.2020.31503, 10.14744/ejmo.2020.31503, DOI 10.14744/EJM0.2020.31503]
   Nemcsok D, 2004, ORGANOMETALLICS, V23, P3640, DOI 10.1021/om049802j
   Nguyen T. A. N., 2014, VIETNAM ENV, V6, P142
   Ozdemir I, 2010, MOLECULES, V15, P2499, DOI 10.3390/molecules15042499
   Ray S, 2007, J AM CHEM SOC, V129, P15042, DOI 10.1021/ja075889z
   REED AE, 1985, J CHEM PHYS, V83, P735, DOI 10.1063/1.449486
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Roland S, 2011, CHEM-EUR J, V17, P1442, DOI 10.1002/chem.201002812
   ROSENBERG B, 1962, NATURE, V193, P364, DOI 10.1038/193364a0
   SCHAFER A, 1992, J CHEM PHYS, V97, P2571, DOI 10.1063/1.463096
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Streciwilk W, 2014, J ORGANOMET CHEM, V749, P88, DOI 10.1016/j.jorganchem.2013.09.033
   Tarasova O, 2018, MOLECULES, V23, DOI 10.3390/molecules23051233
   Teyssot ML, 2009, DALTON T, P6894, DOI 10.1039/b906308k
   Tran TD, 2016, APPL SCI-BASEL, V6, DOI 10.3390/app6070198
   Nguyen TAN, 2017, Z PHYS CHEM, V231, P1467, DOI 10.1515/zpch-2016-0786
   Nguyen TAN, 2017, Z ANORG ALLG CHEM, V643, P826, DOI 10.1002/zaac.201700093
   Thi ANN, 2012, CHEM-EUR J, V18, P12733, DOI 10.1002/chem.201200741
   Tikellis Chris, 2012, Int J Pept, V2012, P256294, DOI 10.1155/2012/256294
   Ngo TD, 2016, MOL DIVERS, V20, P945, DOI 10.1007/s11030-016-9688-5
   Vu T. H. M., 2017, MEDPHARMRES, V1, P26
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weigend F, 2005, PHYS CHEM CHEM PHYS, V7, P3297, DOI 10.1039/b508541a
   WHO, 2019, WHO MOD LIST ESS MED
   Youngs WJ, 2012, DALTON T, V41, P327, DOI 10.1039/c1dt11100k
   Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 67
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD AUG 19
PY 2020
VL 10
IS 51
BP 30961
EP 30974
DI 10.1039/d0ra05159d
PG 14
WC Chemistry, Multidisciplinary
SC Chemistry
GA NC6RG
UT WOS:000561344000060
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Chiaravalloti, ND
   Amato, MP
   Brichetto, G
   Chataway, J
   Dalgas, U
   DeLuca, J
   Meza, C
   Moore, NB
   Feys, P
   Filippi, M
   Freeman, J
   Inglese, M
   Motl, R
   Rocca, MA
   Sandroff, BM
   Salter, A
   Cutter, G
   Feinstein, A
AF Chiaravalloti, Nancy D.
   Amato, Maria Pia
   Brichetto, Giampaolo
   Chataway, Jeremy
   Dalgas, Ulrik
   DeLuca, John
   Meza, Cecilia
   Moore, Nancy B.
   Feys, Peter
   Filippi, Massimo
   Freeman, Jennifer
   Inglese, Matilde
   Motl, Rob
   Rocca, Maria Assunta
   Sandroff, Brian M.
   Salter, Amber
   Cutter, Gary
   Feinstein, Anthony
CA CogEx Res Team
TI The emotional impact of the COVID-19 pandemic on individuals with
   progressive multiple sclerosis
SO JOURNAL OF NEUROLOGY
LA English
DT Article; Early Access
DE COVID-19; Depression; Anxiety; Progressive multiple sclerosis; Quality
   of life
ID HOSPITAL ANXIETY; DEPRESSION SCALE; VALIDATION; MSIS-29
AB Objective Individuals with pre-existing chronic illness have shown increased anxiety and depression due to COVID-19. Here, we examine the impact of the COVID-19 pandemic on emotional symptomatology and quality of life in individuals with Progressive Multiple Sclerosis (PMS). Methods Data were obtained during a randomized clinical trial on rehabilitation taking place at 11 centers in North America and Europe. Participants included 131 individuals with PMS. Study procedures were interrupted in accordance with governmental restrictions as COVID-19 spread. During study closure, aCOVID Impact Surveywas administered via telephone or email to all participants, along with measures of depressive symptoms, anxiety symptoms, quality of life, and MS symptomatology that were previously administered pre-pandemic. Results 4% of respondents reported COVID-19 infection. No significant changes were noted in anxiety, quality of life, or the impact of MS symptomatology on daily life from baseline to lockdown. While total HADS-depression scores increased significantly at follow-up, this did not translate into more participants scoring above the HADS threshold for clinically significant depression. No significant relationships were noted between disease duration, processing speed ability or EDSS, and changes in symptoms of depression or anxiety. Most participants reported the impact of the virus on their psychological well-being, with a little impact on financial well-being. The perceived impact of the pandemic on physical and psychological well-being was correlated with the impact of MS symptomatology on daily life, as well as changes in depression. Conclusions Overall, little change was noted in symptoms of depression or anxiety or overall quality of life.
C1 [Chiaravalloti, Nancy D.; DeLuca, John; Moore, Nancy B.; Sandroff, Brian M.] Kessler Fdn, 120 Eagle Rock Ave,Suite 100, E Hanover, NJ 07936 USA.
   [Chiaravalloti, Nancy D.; DeLuca, John] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA.
   [Amato, Maria Pia] Univ Florence, Dept NEUROFARBA, Sect Neurosci, Largo Brambilla 3, I-50134 Florence, Italy.
   [Amato, Maria Pia] IRCCS Fdn Don Carlo Gnocchi, Florence, Italy.
   [Brichetto, Giampaolo] Italian Multiple Sclerosis Fdn FISM, Sci Res Area, Via Operai 40, I-16149 Genoa, Italy.
   [Brichetto, Giampaolo] Italian Multiple Sclerosis Soc, AISM Rehabil Serv, Genoa, Italy.
   [Chataway, Jeremy] UCL, Fac Brain Sci, Queen Sq Multiple Sclerosis Ctr, Dept Neuroinflammat,UCL Queen Sq Inst Neurol, London WC1B 5EH, England.
   [Chataway, Jeremy] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England.
   [Dalgas, Ulrik] Aarhus Univ, Dept Publ Hlth, Exercise Biol, Dalgas Ave 4, DK-8000 Aarhus, Denmark.
   [Meza, Cecilia; Feinstein, Anthony] Univ Toronto, Dept Psychiat, Toronto, ON M5R 3B6, Canada.
   [Meza, Cecilia; Feinstein, Anthony] Sunnybrook Hlth Sci Ctr, Toronto, ON M5R 3B6, Canada.
   [Feys, Peter] Hasselt Univ, Fac Rehabil Sci, REVAL, Diepenbeek, Belgium.
   [Filippi, Massimo; Rocca, Maria Assunta] Univ Vita Salute San Raffaele, Div Neurosci, Neuroimaging Res Unit, Inst Expt Neurol,IRCSS San Raffaele Sci Inst, Via Olgettina 60, I-20132 Milan, Italy.
   [Filippi, Massimo; Rocca, Maria Assunta] IRCSS San Raffaele Sci Inst, Neurol Unit, Milan, Italy.
   [Filippi, Massimo] IRCSS San Raffaele Sci Inst, Neurophysiol Unit, Milan, Italy.
   [Filippi, Massimo] Univ Vita Salute San Raffaele, Milan, Italy.
   [Freeman, Jennifer] Univ Plymouth, Fac Hlth, Sch Hlth Profess, Plymouth, Devon, England.
   [Inglese, Matilde] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
   [Inglese, Matilde] Univ Genoa, Ctr Excellence Biomed Res, Genoa, Italy.
   [Inglese, Matilde] IRCCS, Osped Policlin San Martino, Genoa, Italy.
   [Motl, Rob; Sandroff, Brian M.] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL USA.
   [Salter, Amber] Washington Univ, Sch Med, Div Biostat, St Louis, MO USA.
   [Cutter, Gary] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL USA.
RP Chiaravalloti, ND (corresponding author), Kessler Fdn, 120 Eagle Rock Ave,Suite 100, E Hanover, NJ 07936 USA.; Chiaravalloti, ND (corresponding author), Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA.
EM nchiaravalloti@kesslerfoundation.org
RI Brichetto, Giampaolo/D-2497-2011; Brichetto, Giampaolo/ABB-4188-2020;
   Filippi, Massimo/K-1755-2018
OI Brichetto, Giampaolo/0000-0003-2026-3572; Brichetto,
   Giampaolo/0000-0003-2026-3572; Filippi, Massimo/0000-0002-5485-0479;
   Dalgas, Ulrik/0000-0003-4132-2789; Chiaravalloti,
   Nancy/0000-0003-2943-7567; Sandroff, Brian/0000-0002-2013-7632
FU MS Society of Canada [EGID3185]
FX Supported by the MS Society of Canada (Grant #EGID3185).
CR Akhoundia FH, 2020, MULT SCLER RELAT DIS, V41, P102
   Annunziata MA, 2011, ANN ONCOL, V22, P2330, DOI 10.1093/annonc/mdq750
   BADRFAM R, 2020, ASIAN J PSYCHIATR, V50, DOI DOI 10.1016/J.AJP.2020.1019907315943
   Balestroni Gianluigi, 2012, Monaldi Arch Chest Dis, V78, P155
   Bao YP, 2020, LANCET, V395, pE37, DOI 10.1016/S0140-6736(20)30309-3
   Barzegar M, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000753
   Beck A., 1996, MANUAL BECK DEPRESSI
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   Borriello G, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102165
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Drageset J, 2013, SCAND J CARING SCI, V27, P872, DOI 10.1111/j.1471-6712.2012.01095.x
   Feinstein A, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01772-7
   Hall RCW, 2008, GEN HOSP PSYCHIAT, V30, P446, DOI 10.1016/j.genhosppsych.2008.05.003
   Hatch R, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2223-6
   Herman C, 2020, NEUROLOGY, DOI [10.1212/WNL, DOI 10.1212/WNL]
   Hobart J, 2001, BRAIN, V124, P962, DOI 10.1093/brain/124.5.962
   Hobart JC, 2005, J NEUROL NEUROSUR PS, V76, P1539, DOI 10.1136/jnnp.2005.064584
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Honarmand K, 2009, MULT SCLER J, V15, P1518, DOI 10.1177/1352458509347150
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Iani L, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-84
   Liu D., 2020, LANCET PSYCHIAT, DOI [10.2139/ssrn.3551415, DOI 10.2139/SSRN.3551415]
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Matthews T, 2016, SOC PSYCH PSYCH EPID, V51, P339, DOI 10.1007/s00127-016-1178-7
   Moghanibashi-Mansourieh A, 2020, ASIAN J PSYCHIATR, DOI [10.1016/j.ajp.2020.1020767165107, DOI 10.1016/J.AJP.2020.1020767165107]
   Ozamiz-Etxebarria N, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311X00054020, 10.1590/0102-311x00054020]
   Salari N, 2020, GLOBALIZATION HEALTH, V16, DOI 10.1186/s12992-020-00589-w
   Shigemura J, 2020, PSYCHIAT CLIN NEUROS, V74, P281, DOI 10.1111/pcn.12988
   Taylor HO, 2018, J AGING HEALTH, V30, P229, DOI 10.1177/0898264316673511
   Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang YN, 2020, PSYCHOL HEALTH MED, DOI 10.1080/13548506.2020.1746817
   World Health Organisation, MENT HLTH PSYCH CONS
   Zhou SJ, 2020, EUR CHILD ADOLES PSY, V29, P749, DOI 10.1007/s00787-020-01541-4
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 36
TC 1
Z9 1
U1 3
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
DI 10.1007/s00415-020-10160-7
EA AUG 2020
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA NC2PR
UT WOS:000561058200003
PM 32813051
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Vannucchi, AM
   Sordi, B
   Morettini, A
   Nozzoli, C
   Poggesi, L
   Pieralli, F
   Bartoloni, A
   Atanasio, A
   Miselli, F
   Paoli, C
   Loscocco, GG
   Fanelli, A
   Para, O
   Berni, A
   Tassinari, I
   Zammarchi, L
   Maggi, L
   Mazzoni, A
   Scotti, V
   Falchetti, G
   Malandrino, D
   Luise, F
   Millotti, G
   Bencini, S
   Capone, M
   Piccinni, MP
   Annunziato, F
   Guglielmelli, P
AF Vannucchi, Alessandro M.
   Sordi, Benedetta
   Morettini, Alessandro
   Nozzoli, Carlo
   Poggesi, Loredana
   Pieralli, Filippo
   Bartoloni, Alessandro
   Atanasio, Alessandro
   Miselli, Filippo
   Paoli, Chiara
   Loscocco, Giuseppe G.
   Fanelli, Andrea
   Para, Ombretta
   Berni, Andrea
   Tassinari, Irene
   Zammarchi, Lorenzo
   Maggi, Laura
   Mazzoni, Alessio
   Scotti, Valentina
   Falchetti, Giorgia
   Malandrino, Danilo
   Luise, Fabio
   Millotti, Giovanni
   Bencini, Sara
   Capone, Manuela
   Piccinni, Marie Pierre
   Annunziato, Francesco
   Guglielmelli, Paola
CA RUXO-COVID Study Grp
TI Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a
   prospective observational study
SO LEUKEMIA
LA English
DT Article; Early Access
ID RESPIRATORY-DISTRESS-SYNDROME; CORTICOSTEROID TREATMENT; THERAPY; LABEL;
   SCORE
AB Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-use protocol. Patients had severe pulmonary disease defined by pulmonary infiltrates on imaging and an oxygen saturation <= 93% in air and/or PaO2/FiO2 ratio <= 300 mmHg. Median age was 80.5 years, and 85.3% had >= 2 comorbidities. Median exposure time to ruxolitinib was 13 days, median dose intensity was 20 mg/day. Overall survival by day 28 was 94.1%. Cumulative incidence of clinical improvement of >= 2 points in the ordinal scale was 82.4% (95% confidence interval, 71-93). Clinical improvement was not affected by low-flow versus high-flow oxygen support but was less frequent in patients with PaO2/FiO2 < 200 mmHg. The most frequent adverse events were anemia, urinary tract infections, and thrombocytopenia. Improvement of inflammatory cytokine profile and activated lymphocyte subsets was observed at day 14. In this prospective cohort of aged and high-risk comorbidity patients with severe COVID-19, compassionate-use ruxolitinib was safe and was associated with improvement of pulmonary function and discharge home in 85.3%. Controlled clinical trials are necessary to establish efficacy of ruxolitinib in COVID-19.
C1 [Vannucchi, Alessandro M.; Sordi, Benedetta; Atanasio, Alessandro; Miselli, Filippo; Paoli, Chiara; Loscocco, Giuseppe G.; Guglielmelli, Paola] Univ Florence, Ctr Res Innovat Myeloproliferat Neoplasms CRIMM, SOD Hematol, Florence, Italy.
   [Vannucchi, Alessandro M.; Sordi, Benedetta; Atanasio, Alessandro; Miselli, Filippo; Paoli, Chiara; Loscocco, Giuseppe G.; Guglielmelli, Paola] AOU Careggi, Florence, Italy.
   [Morettini, Alessandro; Fanelli, Andrea; Scotti, Valentina; Falchetti, Giorgia] AOU Careggi, Internal Med Unit 2, Florence, Italy.
   [Nozzoli, Carlo; Para, Ombretta] AOU Careggi, Internal Med Unit 1, Florence, Italy.
   [Poggesi, Loredana; Berni, Andrea; Malandrino, Danilo] AOU Careggi, Internal Med Unit 3, Florence, Italy.
   [Pieralli, Filippo; Tassinari, Irene; Luise, Fabio] AOU Careggi, Intermediate Care Unit COVID 19, Florence, Italy.
   [Bartoloni, Alessandro; Zammarchi, Lorenzo; Millotti, Giovanni] AOU Careggi, Infect & Trop Dis Unit, Florence, Italy.
   [Maggi, Laura; Mazzoni, Alessio; Capone, Manuela; Piccinni, Marie Pierre; Annunziato, Francesco] Univ Florence, Dept Clin & Expt Med, Florence, Italy.
   [Bencini, Sara; Annunziato, Francesco] AOU Careggi, Cytometry & Immunotherapy Diagnost Ctr CDCI, Florence, Italy.
RP Vannucchi, AM (corresponding author), Univ Florence, Ctr Res Innovat Myeloproliferat Neoplasms CRIMM, SOD Hematol, Florence, Italy.; Vannucchi, AM (corresponding author), AOU Careggi, Florence, Italy.
EM amvannucchi@unifi.it
RI Mazzoni, Alessio/AAB-4311-2019
OI Mazzoni, Alessio/0000-0001-7768-3805; vannucchi, alessandro
   maria/0000-0001-5755-0730; Salvati, Lorenzo/0000-0001-5831-0392;
   Morettini, Alessandro/0000-0002-7101-9599
FU Associazione Italiana per la Ricerca sul Cancro (AIRC), Milano, as part
   of the Progetto 5 per Mille "Mynerva"Associazione Italiana per la
   Ricerca sul Cancro (AIRC) [21267]; Italian Ministry of Education,
   University and ResearchMinistry of Education, Universities and Research
   (MIUR)
FX The study was financed by Associazione Italiana per la Ricerca sul
   Cancro (AIRC), Milano, as part of the Progetto 5 per Mille "Mynerva",
   no.21267. Also supported by funds of Italian Ministry of Education,
   University and Research, "Excellence Departments 2018-2022 Project" to
   the Department of Experimental and Clinical Medicine, University of
   Florence. Financial supporters had no role in study design and
   interpretation. The study was developed in part in the setting of
   Laboratorio Congiunto per le Malattie Mieloproliferative, University of
   Florence.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Ahmed A, 2019, LANCET HAEMATOL, V6, pE630, DOI 10.1016/S2352-3026(19)30156-5
   Al-Ani F, 2020, THROMB RES, V192, P152, DOI 10.1016/j.thromres.2020.05.039
   [Anonymous], 2020, COVID 19 THER TRIAL
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao Y, 2020, J ALLERGY CLIN IMMUN, V146, P137, DOI 10.1016/j.jaci.2020.05.019
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Centers for Disease Control and Prevention, 2020, SEV OUTC PAT COR DIS
   CHEN L, 2020, LEUKEMIA 0616, DOI DOI 10.1038/S41375-020-0911-0
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cossarizza A, 2019, EUR J IMMUNOL, V49, P1457, DOI 10.1002/eji.201970107
   CTCAE, 2020, COMM TERM CRIT ADV E
   Cucinotta D, 2020, ACTA BIOMED, V91, P157, DOI [10.23750/abm.v91i1.9397, DOI 10.23750/ABM.V91I1.9397]
   Das S, 2020, CLIN DRUG INVEST, V40, P591, DOI 10.1007/s40261-020-00927-1
   Dolin Raphael, 2020, N Engl J Med, V383, P1886, DOI 10.1056/NEJMe2018715
   Fang XW, 2020, J INFECTION, V81, P147, DOI 10.1016/j.jinf.2020.03.039
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Gale RP, 2020, BRIT J HAEMATOL, V190, P358, DOI 10.1111/bjh.16905
   Gaspari V, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106023
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Harrison C, 2012, NEW ENGL J MED, V366, P787, DOI 10.1056/NEJMoa1110556
   Health USNIo, 2020, INT COVID 19 TREATM
   Heidel F, 2020, LEUKEMIA, V34, P1723, DOI 10.1038/s41375-020-0898-6
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kiladjian JJ, 2020, LANCET HAEMATOL, V7, pE226, DOI 10.1016/S2352-3026(19)30207-8
   La Rosee F, 2020, LEUKEMIA, V34, P1799
   Ledee N, 2008, HUM REPROD, V23, P2001, DOI 10.1093/humrep/den192
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Mazzoni A, 2020, J CLIN INVEST, V130, P4694, DOI [10.1172/JCI138554, 10.1172/JCI138554.]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moores LK, 2020, CHEST
   Morena V, 2020, EUR J INTERN MED, V76, P36, DOI 10.1016/j.ejim.2020.05.011
   Neubauer A, 2020, LEUKEMIA, V34, P2276, DOI 10.1038/s41375-020-0907-9
   Passamonti F, 2017, LANCET ONCOL, V18, P88, DOI 10.1016/S1470-2045(16)30558-7
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Soares A, 2010, J IMMUNOL METHODS, V362, P43, DOI 10.1016/j.jim.2010.08.007
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Vannucchi AM, 2015, NEW ENGL J MED, V372, P426, DOI 10.1056/NEJMoa1409002
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu Z, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.2648.7149375, DOI 10.1001/JAMA.2020.2648.7149375]
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Zeiser R, 2020, NEW ENGL J MED, V382, P1800, DOI 10.1056/NEJMoa1917635
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 60
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
DI 10.1038/s41375-020-01018-y
EA AUG 2020
PG 13
WC Oncology; Hematology
SC Oncology; Hematology
GA NC1XW
UT WOS:000561008300001
PM 32814839
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lokhande, KB
   Doiphode, S
   Vyas, R
   Swamy, KV
AF Lokhande, Kiran Bharat
   Doiphode, Sayali
   Vyas, Renu
   Swamy, K. Venkateswara
TI Molecular docking and simulation studies on SARS-CoV-2 M-pro reveals
   Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs
   against COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2 main protease (Mpro); drug repurposing; molecular docking;
   molecular dynamic simulation
AB The outbreak of novel coronavirus (COVID-19), which began from Wuhan City, Hubei, China, and declared as a Public Health Emergency of International Concern by World Health Organization (WHO) on 30(th)January 2020. The present study describes how the available drug candidates can be used as a potential SARS-CoV-2 M(pro)inhibitor by molecular docking and molecular dynamic simulation studies. Drug repurposing strategy is applied by using the library of antiviral and FDA approved drugs retrieved from the Selleckchem Inc. (Houston, TX,) and DrugBank database respectively. Computational methods like molecular docking and molecular dynamics simulation were used. The molecular docking calculations were performed using LeadIT FlexX software. The molecular dynamics simulations of 100 ns were performed to study conformational stability for all complex systems. Mitoxantrone and Leucovorin from FDA approved drug library and Birinapant and Dynasore from anti-viral drug libraries interact with SARS-CoV-2 M(pro)at higher efficiency as a result of the improved steric and hydrophobic environment in the binding cavity to make stable complex. Also, the molecular dynamics simulations of 100 ns revealed the mean RMSD value of 2.25 angstrom for all the complex systems. This shows that lead compounds bound tightly within the M(pro)cavity and thus having conformational stability. Glutamic acid (Glu166) of M(pro)is a key residue to hold and form a stable complex of reported lead compounds by forming hydrogen bonds and salt bridge. Our findings suggest that Mitoxantrone, Leucovorin, Birinapant, and Dynasore represents potential inhibitors of SARS-CoV-2 M-pro.
   [GRAPHICS]
   .
C1 [Lokhande, Kiran Bharat; Doiphode, Sayali; Swamy, K. Venkateswara] Dr DY Patil Vidyapeeth, Dr DY Patil Biotechnol & Bioinformat Inst, Bioinformat Res Lab, Pune, Maharashtra, India.
   [Vyas, Renu; Swamy, K. Venkateswara] MIT ADT Univ, MIT Sch Bioengn Sci & Res, Bioinformat Res Grp, Pune 412201, Maharashtra, India.
RP Swamy, KV (corresponding author), MIT ADT Univ, MIT Sch Bioengn Sci & Res, Bioinformat Res Grp, Pune 412201, Maharashtra, India.
EM venkateswara.swamy@gmail.com
RI Lokhande, Kiran/X-5688-2019; Kakumani, Venkateswara Swamy/P-6186-2019
OI Lokhande, Kiran/0000-0001-6945-8288; Kakumani, Venkateswara
   Swamy/0000-0001-8198-3042
FU Department of Science and Technology Science and Engineering Research
   Board (DST-SERB), Govt. of India, New Delhi [YSS/2015/002035]; Indian
   Council of Medical Research, New DelhiIndian Council of Medical Research
   (ICMR) [2019-3458, ISRM/11(54)/2019]
FX The authors are thankful to Dr. D. Y. Patil Biotechnology and
   Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune for the
   physical infrastructure and Department of Science and Technology Science
   and Engineering Research Board (DST-SERB), Govt. of India, New Delhi,
   (File Number: YSS/2015/002035) for utilizing an Optimized Supercomputer
   for docking and dynamics calculations. Senior Research Fellowship
   awarded to Kiran Bharat Lokhande (Project ID: 2019-3458; File No.:
   ISRM/11(54)/2019) by the Indian Council of Medical Research, New Delhi
   is also acknowledged. Authors also acknowledge Ms. Shweta Ashok More,
   Ph.D. Scholar, Y.B. Chavan College of Pharmacy, Aurangabad, India for
   technical help during MM/GBSA calculation for this study.
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Agic D, 2019, J BIOMOL STRUCT DYN, V37, P3596, DOI 10.1080/07391102.2018.1521343
   Ailenberg M, 2015, BRIT J PHARMACOL, V172, P3748, DOI 10.1111/bph.13162
   Alonso S, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0726-2
   Beck S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040338
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Bursulaya BD, 2003, J COMPUT AID MOL DES, V17, P755, DOI 10.1023/B:JCAM.0000017496.76572.6f
   Bzowka M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093099
   Carro AC, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006685
   Cascella M, 2020, FEATURES EVALUATION
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   De Vivo M, 2016, J MED CHEM, V59, P4035, DOI 10.1021/acs.jmedchem.5b01684
   Ebert G, 2015, P NATL ACAD SCI USA, V112, P5803, DOI 10.1073/pnas.1502400112
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   He F, 2020, J MED VIROL, V92, P719, DOI [10.1002/jmv.25766, 10.3171/2020.3.JNS193202]
   Huang Q, 2019, BMC MICROBIOL, V19, DOI 10.1186/s12866-019-1639-8
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Kollar J, 2018, J MOL MODEL, V24, DOI 10.1007/s00894-017-3537-z
   Lu SN, 2020, NUCLEIC ACIDS RES, V48, pD265, DOI 10.1093/nar/gkz991
   Malakar S, 2018, VIRUS RES, V255, P171, DOI 10.1016/j.virusres.2018.07.018
   NCBI Taxonomy Browser, 2020, SEV AC RESP SYNDR CO, V2
   Preta G, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0102-1
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477
   Simsek M, 2018, DRUG DISCOV TODAY, V23, P17, DOI 10.1016/j.drudis.2017.08.008
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wang GM, 2016, FUTURE MED CHEM, V8, DOI 10.4155/fmc-2016-0143
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World Health Organization, 2020, WHO COR DIS COVID 19
   World Health Organization, 2020, NAM COR DIS COVID 19
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
NR 38
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1805019
EA AUG 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NB9VO
UT WOS:000560862900001
PM 32815481
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Dequin, PF
   Le Gouge, A
   Tavernier, E
   Giraudeau, B
   Zohar, S
AF Dequin, Pierre-Francois
   Le Gouge, Amelie
   Tavernier, Elsa
   Giraudeau, Bruno
   Zohar, Sarah
TI Embedding a COVID-19 Group Sequential Clinical Trial Within an Ongoing
   Trial: Lessons From an Unusual Experience
SO STATISTICS IN BIOPHARMACEUTICAL RESEARCH
LA English
DT Article
DE Adaptive design; Group-sequential designs; SARS-CoV-2 virus
AB The Cape-Covid trial is an embedded clinical trial within the ongoing Cape-Cod trial. The Covid-19 pandemic appeared while we were conducting a randomized trial assessing the effectiveness of corticosteroids in severe community-acquired pneumonia. We took advantage of this ongoing trial to embed a sub-trial assessing hydrocortisone in SARS-CoV-2 infected patients. In this article, we wish to share our experience when we needed to make fast and robust methodological decisions during the Covid-19 pandemic in a two weeks period of time.for this article are available online.
C1 [Dequin, Pierre-Francois] CHRU Tours, Serv Med Intens Reanimat, Tours, France.
   [Dequin, Pierre-Francois] Univ Tours, Ctr Etud Pathol Resp, INSERM U1100, Tours, France.
   [Le Gouge, Amelie; Tavernier, Elsa; Giraudeau, Bruno] CHRU Tours, INSERM CIC1415, Tours, France.
   [Giraudeau, Bruno] Univ Tours, Univ Nantes, SPHERE U1246, INSERM, Tours, France.
   [Zohar, Sarah] Univ Paris, Sorbonne Univ, Ctr Rech Cordeliers, INSERM, Paris, France.
RP Zohar, S (corresponding author), Univ Paris, Sorbonne Univ, Ctr Rech Cordeliers, INSERM, Paris, France.
EM sarah.zohar@inserm.fr
CR Dean NE, 2020, NEW ENGL J MED, V382, P1366, DOI 10.1056/NEJMsb1905390
   Eichler HG, 2020, CLIN PHARMACOL THER, V108, P730, DOI 10.1002/cpt.1891
   European Medicines Agency, 2020, GUID MAN CLIN TRIALS
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   KIM K, 1987, BIOMETRICS, V43, P857, DOI 10.2307/2531539
   LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502
   London AJ, 2020, SCIENCE, V368, P476, DOI 10.1126/science.abc1731
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191
   RECOVERY Trial, 2020, RES REL
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Schuler S, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0387-4
   WHITEHEAD J, 1983, BIOMETRICS, V39, P227, DOI 10.2307/2530822
NR 15
TC 3
Z9 3
U1 2
U2 2
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA
SN 1946-6315
J9 STAT BIOPHARM RES
JI Stat. Biopharm. Res.
PD OCT 1
PY 2020
VL 12
IS 4
BP 478
EP 482
DI 10.1080/19466315.2020.1800509
EA AUG 2020
PG 5
WC Mathematical & Computational Biology; Statistics & Probability
SC Mathematical & Computational Biology; Mathematics
GA OK5GB
UT WOS:000560846100001
OA Bronze
DA 2021-01-01
ER

PT J
AU Hung, M
   Lauren, E
   Hon, ES
   Birmingham, WC
   Xu, J
   Su, S
   Hon, SD
   Park, J
   Dang, P
   Lipsky, MS
AF Hung, Man
   Lauren, Evelyn
   Hon, Eric S.
   Birmingham, Wendy C.
   Xu, Julie
   Su, Sharon
   Hon, Shirley D.
   Park, Jungweon
   Dang, Peter
   Lipsky, Martin S.
TI Social Network Analysis of COVID-19 Sentiments: Application of
   Artificial Intelligence
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE COVID-19; coronavirus; sentiment; social network; Twitter;
   infodemiology; infodemic; pandemic; crisis; public health; business
   economy; artificial intelligence
ID QUARANTINE; SUPPORT; VACCINE; STRESS
AB Background: The coronavirus disease (COVID-19) pandemic led to substantial public discussion. Understanding these discussions can help institutions, governments, and individuals navigate the pandemic.
   Objective: The aim of this study is to analyze discussions on Twitter related to COVID-19 and to investigate the sentiments toward COVID-19.
   Methods: This study applied machine learning methods in the field of artificial intelligence to analyze data collected from Twitter. Using tweets originating exclusively in the United States and written in English during the 1-month period from March 20 to April 19, 2020, the study examined COVID-19-related discussions. Social network and sentiment analyses were also conducted to determine the social network of dominant topics and whether the tweets expressed positive, neutral, or negative sentiments. Geographic analysis of the tweets was also conducted.
   Results: There were a total of 14,180,603 likes, 863,411 replies, 3,087,812 retweets, and 641,381 mentions in tweets during the study timeframe. Out of 902,138 tweets analyzed, sentiment analysis classified 434,254 (48.2%) tweets as having a positive sentiment, 187,042 (20.7%) as neutral, and 280,842 (31.1%) as negative. The study identified 5 dominant themes among COVID-19-related tweets: health care environment, emotional support, business economy, social change, and psychological stress. Alaska, Wyoming, New Mexico, Pennsylvania, and Florida were the states expressing the most negative sentiment while Vermont, North Dakota, Utah, Colorado, Tennessee, and North Carolina conveyed the most positive sentiment.
   Conclusions: This study identified 5 prevalent themes of COVID-19 discussion with sentiments ranging from positive to negative. These themes and sentiments can clarify the public's response to COVID-19 and help officials navigate the pandemic.
C1 [Hung, Man; Su, Sharon; Park, Jungweon; Dang, Peter; Lipsky, Martin S.] Roseman Univ Hlth Sci, Coll Dent Med, 10894 South River Front Pkwy, South Jordan, UT 84095 USA.
   [Hung, Man] Univ Utah, Dept Orthopaed, Salt Lake City, UT USA.
   [Hung, Man] George E Wahlen Dept Vet Affairs Med Ctr, Salt Lake City, UT USA.
   [Hung, Man] Towson Univ, Dept Occupat Therapy & Occupat Sci, Towson, MD USA.
   [Hung, Man] Univ Utah, David Eccles Sch Business, Salt Lake City, UT USA.
   [Hung, Man] Univ Utah, Dept Educ Psychol, Salt Lake City, UT 84112 USA.
   [Hung, Man] Univ Utah, Div Publ Hlth, Salt Lake City, UT USA.
   [Lauren, Evelyn] Boston Univ, Dept Biostat, Boston, MA 02215 USA.
   [Hon, Eric S.] Univ Chicago, Dept Econ, Chicago, IL 60637 USA.
   [Birmingham, Wendy C.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA.
   [Xu, Julie] Univ Utah, Coll Nursing, Salt Lake City, UT 84112 USA.
   [Hon, Shirley D.] Univ Utah, Dept Elect & Comp Engn, Salt Lake City, UT USA.
   [Hon, Shirley D.] Univ Utah, Sch Comp, Salt Lake City, UT USA.
   [Hon, Shirley D.] IBM Corp, Poughkeepsie, NY USA.
RP Hung, M (corresponding author), Roseman Univ Hlth Sci, Coll Dent Med, 10894 South River Front Pkwy, South Jordan, UT 84095 USA.
EM mhung@roseman.edu
OI Lipsky, Martin/0000-0003-1749-8477; Lauren, Evelyn/0000-0002-0333-110X;
   Hung, Man/0000-0003-2827-3740
FU Clinical Outcomes Research and Education at Roseman University of Health
   Sciences College of Dental Medicine
FX The authors would like to thank the Clinical Outcomes Research and
   Education at Roseman University of Health Sciences College of Dental
   Medicine for supporting this study.
CR [Anonymous], 2020, WIKIPEDIA
   [Anonymous], 2020, COR DIS 2019 COVID 1
   [Anonymous], 2020, NY TIMES
   [Anonymous], 2019, COR DIS COVID 19 SIT
   BALLROKEACH SJ, 1976, COMMUN RES, V3, P3, DOI 10.1177/009365027600300101
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Cascella M, 2020, FEATURES EVALUATION
   Cava MA, 2005, J NURS SCHOLARSHIP, V37, P343, DOI 10.1111/j.1547-5069.2005.00059.x
   Chunara R, 2012, AM J TROP MED HYG, V86, P39, DOI 10.4269/ajtmh.2012.11-0597
   COBB S, 1976, PSYCHOSOM MED, V38, P300, DOI 10.1097/00006842-197609000-00003
   COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310
   Congressional Research Service (CRS), 2020, GLOB EC EFF COVID 19
   Cori L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093114
   Cornwall W., 2020, SCIENCE, DOI [10.1126/science.abd6018., DOI 10.1126/SCIENCE.ABD6018]
   Delgado D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082798
   Dhanuthai K, 2018, MED ORAL PATOL ORAL, V23, pE23, DOI 10.4317/medoral.21999
   Duggan M, 2014, SOCIAL MEDIA UPDATE
   Gesualdo F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082489
   Gore RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133505
   Hawkins JB, 2016, BMJ QUAL SAF, V25, P404, DOI 10.1136/bmjqs-2015-004309
   Hawryluck L, 2004, EMERG INFECT DIS, V10, P1206, DOI 10.3201/eid1007.030703
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043
   Liu HB, 2012, J BIOMED SEMANT, V3, DOI 10.1186/2041-1480-3-3
   McFadden SM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231808
   Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477
   Padilla JJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198857
   Pershad Y, 2018, J CLIN MED, V28, P7, DOI DOI 10.3390/JCM7060121]
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI [10.1016/j.tmaid.2020.101623, DOI 10.1016/J.TMAID.2020.101623]
   Salathe M, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002616
   Serido J, 2004, J HEALTH SOC BEHAV, V45, P17, DOI 10.1177/002214650404500102
   Signorini A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019467
   Smith A, 2012, TWITTER USE 2012
   Studdert DM, 2020, NEW ENGL J MED, V383, P102, DOI 10.1056/NEJMp2007637
   Wang P, 2020, CLIN CHEM, V66, P644, DOI 10.1093/clinchem/hvaa080
   WHO, 2020, DIR GEN OP REM MED B
   Wong Q., 2020, CNET
   Ye GM, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.001
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 40
TC 4
Z9 4
U1 6
U2 6
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD AUG 18
PY 2020
VL 22
IS 8
AR e22590
DI 10.2196/22590
PG 13
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA NW5LR
UT WOS:000575053900001
PM 32750001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Weill, JA
   Stigler, M
   Deschenes, O
   Springborn, MR
AF Weill, Joakim A.
   Stigler, Matthieu
   Deschenes, Olivier
   Springborn, Michael R.
TI Social distancing responses to COVID-19 emergency declarations strongly
   differentiated by income
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE inequalities; COVID-19; social distancing
ID INEQUALITY
AB In the absence of a vaccine, social distancing measures are one of the primary tools to reduce the transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which causes coronavirus disease 2019 (COVID-19). We show that social distancing following US state-level emergency declarations substantially varies by income. Using mobility measures derived from mobile device location pings, we find that wealthier areas decreased mobility significantly more than poorer areas, and this general pattern holds across income quantiles, data sources, and mobility measures. Using an event study design focusing on behavior subsequent to state emergency orders, we docu-ment a reversal in the ordering of social distancing by income: Wealthy areas went from most mobile before the pandemic to least mobile, while, for multiple measures, the poorest areas went from least mobile to most. Previous research has shown that lower income communities have higher levels of preexisting health conditions and lower access to healthcare. Combining this with our core finding-that lower income communities exhibit less social distancing-suggests a double burden of the COVID-19 pandemic with stark distributional implications.
C1 [Weill, Joakim A.] Univ Calif Davis, Agr & Resource Econ, Davis, CA 95616 USA.
   [Stigler, Matthieu] Stanford Univ, Ctr Food Secur & Environm, Stanford, CA 94305 USA.
   [Deschenes, Olivier] Univ Calif Santa Barbara, Dept Econ, Santa Barbara, CA 93106 USA.
   [Springborn, Michael R.] Univ Calif Davis, Environm Sci & Policy, Davis, CA 95616 USA.
RP Weill, JA (corresponding author), Univ Calif Davis, Agr & Resource Econ, Davis, CA 95616 USA.
EM jweill@ucdavis.edu
OI Stigler, Matthieu/0000-0002-6802-4290; Weill,
   Joakim/0000-0002-3796-858X; Springborn, Michael/0000-0003-3476-8758
FU California Breast Cancer Research Program of the University of
   California [R00RG2419]
FX We thank SafeGraph, PlaceIQ, and Google Mobility for making data
   publicly available, and Arnon Erba for technical assistance. This
   research was supported by the California Breast Cancer Research Program
   of the University of California, Grant R00RG2419.
CR Aizer A, 2014, SCIENCE, V344, P856, DOI 10.1126/science.1251872
   Beatty TKM, 2019, J ASSOC ENVIRON RESO, V6, P633, DOI 10.1086/703379
   Bento AI, 2020, P NATL ACAD SCI USA, V117, P11220, DOI 10.1073/pnas.2005335117
   Berchick ER, 2019, HLTH INSURANCE COVER
   Bitler M., 2020, MILBANK Q OPINI 0430, DOI [10.1599/mqop.2020.0401, DOI 10.1599/MQOP.2020.0401]
   Centers for Disease Control and Prevention, COVID 19 RAC ETHN MI
   Couture V., EXPOSURE INDICES DER
   Deschenes O, 2017, AM ECON REV, V107, P2958, DOI 10.1257/aer.20131002
   Downey L, 2008, SOCIOL PERSPECT, V51, P759, DOI 10.1525/sop.2008.51.4.759
   Feldman S, 2014, POLIT PSYCHOL, V35, P337, DOI 10.1111/pops.12055
   Machina M. J., 1990, CHOICE UNCERTAINTY P
   Norms P., 2001, DIGITAL DIVIDE CIVIC
   Orhun AY, 2019, J MARKETING RES, V56, P1, DOI 10.1177/0022243718821660
   Springborn M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-014-0691-0
   Weill J. A., 2020, SOCIAL DISTANCING RE
   Yesuf M, 2009, AM J AGR ECON, V91, P1022, DOI 10.1111/j.1467-8276.2009.01307.x
NR 16
TC 11
Z9 11
U1 3
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 18
PY 2020
VL 117
IS 33
BP 19658
EP 19660
DI 10.1073/pnas.2009412117
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NP6TL
UT WOS:000570306900015
PM 32727905
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU van Gerwen, M
   Alsen, M
   Little, C
   Barlow, J
   Naymagon, L
   Tremblay, D
   Sinclair, CF
   Genden, E
AF van Gerwen, Maaike
   Alsen, Mathilda
   Little, Christine
   Barlow, Joshua
   Naymagon, Leonard
   Tremblay, Douglas
   Sinclair, Catherine F.
   Genden, Eric
TI Outcomes of Patients With Hypothyroidism and COVID-19: A Retrospective
   Cohort Study
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE COVID-19; hypothyroidism; survival; outcomes; epidemiology; cohort
AB Coronavirus diseases (COVID-19) is associated with high rates of morbidity and mortality and worse outcomes have been reported for various morbidities. The impact of pre-existing hypothyroidism on COVID-19 outcomes remains unknown. The aim of the present study was to identify a possible association between hypothyroidism and outcomes related to COVID-19 including hospitalization, need for mechanical ventilation, and all-cause mortality. All patients with a laboratory confirmed COVID-19 diagnosis in March 2020 in a large New York City health system were reviewed. Of the 3703 COVID-19 positive patients included in present study, 251 patients (6.8%) had pre-existing hypothyroidism and received thyroid hormone therapy. Hypothyroidism was not associated with increased risk of hospitalization [Adjusted Odds Ratio (ORadj): 1.23 (95% Confidence Interval (CI): 0.88- 1.70)], mechanical ventilation [ORadj: 1.17 (95% CI: 0.81-1.69)] nor death [ORadj: 1.07 (95% CI: 0.75-1.54)]. This study provides insight into the role of hypothyroidism on the outcomes of COVID-19 positive patients, indicating that no additional precautions or consultations are needed. However, future research into the potential complications of COVID-19 on the thyroid gland and function is warranted.
C1 [van Gerwen, Maaike; Alsen, Mathilda; Little, Christine; Barlow, Joshua; Sinclair, Catherine F.; Genden, Eric] Icahn Sch Med Mt Sinai, Dept Otolaryngol Head & Neck Surg, New York, NY 10029 USA.
   [van Gerwen, Maaike] Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA.
   [Naymagon, Leonard; Tremblay, Douglas] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA.
RP van Gerwen, M; Sinclair, CF (corresponding author), Icahn Sch Med Mt Sinai, Dept Otolaryngol Head & Neck Surg, New York, NY 10029 USA.; van Gerwen, M (corresponding author), Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA.
EM maaike.vangerwen@mountsinai.org; catherine.sinclair@mountsinai.org
CR Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480
   Bourgonje AR, 2020, J PATHOL, V251, P228, DOI 10.1002/path.5471
   Centers for Disease Control and Prevention, BOD MASS IND BMI
   Chrousos GP, 2005, CLIN ENDOCRINOL, V63, P363, DOI 10.1111/j.1365-2265.2005.02361.x
   CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244
   Devaux CA, 2020, J MICROBIOL IMMUNOL, V53, P425, DOI 10.1016/j.jmii.2020.04.015
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Jonklaas J, 2014, THYROID, V24, P1670, DOI 10.1089/thy.2014.0028
   Leow MKS, 2005, CLIN ENDOCRINOL, V63, P197, DOI 10.1111/j.1365-2265.2005.02325.x
   Mammen JS, 2015, THYROID, V25, P979, DOI 10.1089/thy.2015.0180
   Mayer D, 1997, EXP CLIN ENDOCR DIAB, V105, P80, DOI 10.1055/s-0029-1211942
   Pal R, 2020, J ENDOCRINOL INVEST, V43, P1027, DOI 10.1007/s40618-020-01276-8
   SCHOENFELD PS, 1995, SOUTHERN MED J, V88, P347, DOI 10.1097/00007611-199503000-00019
   van Gerwen M, 2020, J MED VIROL, DOI 10.1002/jmv.26337
   Wei L, 2007, HUM PATHOL, V38, P95, DOI 10.1016/j.humpath.2006.06.011
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 19
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD AUG 18
PY 2020
VL 11
AR 565
DI 10.3389/fendo.2020.00565
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NM8NI
UT WOS:000568349200001
PM 33013686
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sharma, A
   Goyal, S
   Yadav, AK
   Kumar, P
   Gupta, L
AF Sharma, Aniket
   Goyal, Shubham
   Yadav, Arvind Kumar
   Kumar, Pawan
   Gupta, Lovely
TI In-silicoscreening of plant-derived antivirals against main protease,
   3CL(pro)and endoribonuclease, NSP15 proteins of SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; docking; plant-derived compounds; 3CL(pro);
   endoribonuclease
ID TRADITIONAL CHINESE MEDICINES; MOLECULAR-DYNAMICS; VIRUS-INFECTION;
   CORONAVIRUS; CURCUMIN; CHIKUNGUNYA; INTERFERON; SYSTEM
AB Novel Coronavirus or SARS-CoV-2 outbreak has developed a pandemic condition all over the world. The virus is highly infectious and spreads by human to human local transmission mode. Till date, there is no vaccination or drugs been approved for the treatment by the World Health Organisation. Henceforth, the discovery of the potential drugs is an urgent and utmost requirement for the medical fraternity. Since, the side effects of plant-derived compounds will be lower compared to synthetic/chemical drugs. The Main protease (3CL(pro)or NSP5) and endoribonuclease (NSP15) proteins are necessity for viral replication and its survival in the host cell. In the present study,in-silicoapproach of drug development was used to search for potential antiviral plant-derived compounds as inhibitors against SARS-CoV-2 replication proteins. Eight plant-derived compounds of which the antiviral activity was known and available, and two reported drugs against SARS-CoV-2 selected for the molecular docking analysis. The docking results suggested that bisdemethoxycurcumin, demethoxycurcumin, scutellarin, quercetin and myricetin showed least binding energy,i.e.,greater than -6.5 Kcal/mol against 3CL(pro)and endoribonuclease of SARS-CoV-2. Further studies of ADME-Tox and bioavailability of drugs were also performed that exhibited efficient parameters of drug likeness. Molecular dynamics simulation calculations were performed for the most negative binding affinity of the compound to evaluate the dynamic behavior,and stability of protein-ligand complex. Our findings suggest that these compounds could be potential inhibitors of SARS-CoV-2 main protease and endoribonuclease. However, furtherin-vitroand pre-clinical experiments would validate the potential inhibitors of SARS-CoV-2 proteins.
C1 [Sharma, Aniket; Goyal, Shubham; Gupta, Lovely] Amity Univ, Amity Inst Biotechnol, Noida 201301, Uttar Pradesh, India.
   [Yadav, Arvind Kumar] Jaypee Univ Informat Technol, Dept Biotechnol & Bioinformat, Solan, Himachal Prades, India.
   [Kumar, Pawan] Natl Inst Immunol, Bioinformat Ctr, New Delhi, India.
RP Gupta, L (corresponding author), Amity Univ, Amity Inst Biotechnol, Noida 201301, Uttar Pradesh, India.
EM lgupta@amity.edu
OI Kumar, Pawan/0000-0002-8801-644X
FU DBT Project
FX The authors would like to thank Amity University Uttar Pradesh, India
   for providing facilities to carry out this work. The authors also would
   like to thank the researchers who generated and shared the sequencing
   and protein data of main protease (3CLpro) and endoribonuclease (NSP15)
   proteins of SARS-CoV-2 in Protein Data Bank website
   (https://www.rcsb.org/).The authors would like to acknowledge Ms. Sapna
   Ratnakar, Ph.D. Scholar, School of Life Sciences, JNU for providing her
   support to carry out MDS. P.K. would like to thank DBT Project for
   supporting the research work and also thank Dr. Debabsisa Mohanty for
   providing the NII computational facility to carry out the simulation
   analysis.
CR Akula SM, 2002, AM J VET RES, V63, P1124, DOI 10.2460/ajvr.2002.63.1124
   Baikerikar S, 2017, PHARMACOGN RES, V9, pS15, DOI 10.4103/pr.pr_30_17
   Benet LZ, 2016, ADV DRUG DELIVER REV, V101, P89, DOI 10.1016/j.addr.2016.05.007
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chandel V., 2020, SILICO IDENTIFICATIO, DOI [10.20944/preprints202003.0349.v1, DOI 10.20944/PREPRINTS202003.0349.V1]
   Cheng J, 2013, J MICROBIOL BIOTECHN, V23, P1076, DOI 10.4014/jmb.1303.03074
   Deng XF, 2017, P NATL ACAD SCI USA, V114, pE4251, DOI 10.1073/pnas.1618310114
   Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00028-20
   Dorman G, 2016, NUTRACEUTICALS EFFIC, P263, DOI DOI 10.1016/B978-0-12-802147-7.00021-8
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Gajula MP., 2016, BIOPROTOCOL, V6, pe2051, DOI [10.21769/BioProtoc.2051, DOI https://doi.org/10.21769/BioProtoc.2051]
   Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Hackbart M, 2020, P NATL ACAD SCI USA, V117, P8094, DOI 10.1073/pnas.1921485117
   Hoda S, 2019, J PURE APPL MICROBIO, V13, P1207, DOI 10.22207/JPAM.13.2.61
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   KHAN SA, 2020, J BIOMOL STRUCT 0411, DOI DOI https://doi.org/10.1080/07391102.2020.1751298
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Kitazato K, 2007, DRUG DISCOV THER, V1, P14
   Kutluay SB, 2008, VIROLOGY, V373, P239, DOI 10.1016/j.virol.2007.11.028
   Lim KP, 2000, J VIROL, V74, P1674, DOI 10.1128/JVI.74.4.1674-1685.2000
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu XR, 2019, MOL IMMUNOL, V114, P100, DOI 10.1016/j.molimm.2019.07.003
   LOBOGALO N, 2020, J BIOMOL STRUCT 0513, DOI DOI https://doi.org/10.1080/07391102.2020.1764393
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mounce BC, 2017, ANTIVIR RES, V142, P148, DOI 10.1016/j.antiviral.2017.03.014
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   POLANSKY H, 2020, INT J ANTIMICROB AG, V55, DOI DOI https://doi.org/10.1016/j.ijantimicag.2020.105971
   Rajtar B, 2017, FOOD CHEM TOXICOL, V109, P1026, DOI 10.1016/j.fct.2017.05.011
   Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Salem MM, 2006, J NAT PROD, V69, P43, DOI 10.1021/np0502600
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Shikishima Y, 2001, CHEM PHARM BULL, V49, P877, DOI 10.1248/cpb.49.877
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Sun N, 2015, BIOTECHNOL BIOPROC E, V20, P180, DOI 10.1007/s12257-014-0520-8
   Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129
   VECKENSTEDT A, 1987, ANTIVIR RES, V7, P169, DOI 10.1016/0166-3542(87)90005-2
   von Rhein C, 2016, ANTIVIR RES, V125, P51, DOI 10.1016/j.antiviral.2015.11.007
   Wang F. H., 2016, SCI REP UK, V6, DOI DOI https://doi.org/10.1038/srep22677
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Zhou J, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep001
NR 58
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1808077
EA AUG 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NL1PB
UT WOS:000567194700001
PM 32896226
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Schultheiss, C
   Paschold, L
   Simnica, D
   Mohme, M
   Willscher, E
   von Wenserski, L
   Scholz, R
   Wieters, I
   Dahlke, C
   Tolosa, E
   Sedding, DG
   Ciesek, S
   Addo, M
   Binder, M
AF Schultheiss, Christoph
   Paschold, Lisa
   Simnica, Donjete
   Mohme, Malte
   Willscher, Edith
   von Wenserski, Lisa
   Scholz, Rebekka
   Wieters, Imke
   Dahlke, Christine
   Tolosa, Eva
   Sedding, Daniel G.
   Ciesek, Sandra
   Addo, Marylyn
   Binder, Mascha
TI Next-Generation Sequencing of T and B Cell Receptor Repertoires from
   COVID-19 Patients Showed Signatures Associated with Severity of Disease
SO IMMUNITY
LA English
DT Article
ID CORONAVIRUS; HETEROGENEITY; EXPRESSION; ANTIBODIES; SYSTEM
AB We profiled adaptive immunity in COVID-19 patients with active infection or after recovery and created a repository of currently >14 million B and T cell receptor (BCR and TCR) sequences from the blood of these patients. The B cell response showed converging IGHV3-driven BCR clusters closely associated with SARS-CoV-2 antibodies. Clonality and skewing of TCR repertoires were associated with interferon type I and III responses, early CD4(+) and CD8(+) T cell activation, and counterregulation by the co-receptors BTLA, Tim-3, PD-1, TIGIT, and CD73. Tfh, Th17-like, and nonconventional (but not classical antiviral) Th1 cell polarizations were induced. SARS-CoV-2-specific T cell responses were driven by TCR clusters shared between patients with a characteristic trajectory of clonotypes and traceability over the disease course. Our data provide fundamental insight into adaptive immunity to SARS-CoV-2 with the actively updated repository providing a resource for the scientific community urgently needed to inform therapeutic concepts and vaccine development.
C1 [Schultheiss, Christoph; Paschold, Lisa; Simnica, Donjete; Willscher, Edith; von Wenserski, Lisa; Scholz, Rebekka; Binder, Mascha] Martin Luther Univ Halle Wittenberg, Dept Internal Med 4, Oncol Hematol, D-06120 Halle, Saale, Germany.
   [Mohme, Malte] Univ Med Ctr Hamburg Eppendorf UKE, Dept Neurosurg, D-20246 Hamburg, Germany.
   [Wieters, Imke] Univ Hosp Frankfurt, Dept Internal Med 2, Infect Dis, D-60596 Frankfurt, Germany.
   [Dahlke, Christine; Addo, Marylyn] Univ Med Ctr Hamburg Eppendorf, Div Infect Dis, Dept Med 1, D-20246 Hamburg, Germany.
   [Dahlke, Christine; Addo, Marylyn] Bernhard Nocht Inst Trop Med, Dept Clin Immunol Infect Dis, D-20359 Hamburg, Germany.
   [Tolosa, Eva] Univ Med Ctr Hamburg Eppendorf, Dept Immunol, D-20246 Hamburg, Germany.
   [Sedding, Daniel G.] Martin Luther Univ Halle Wittenberg, Univ Hosp, Dept Cardiol & Intens Care Med, Mid German Heart Ctr, D-06120 Halle, Saale, Germany.
   [Ciesek, Sandra] Goethe Univ Frankfurt, Univ Hosp, Inst Med Virol, D-60596 Frankfurt, Germany.
   [Ciesek, Sandra] Fraunhofer Inst Mol Biol & Appl Ecol IME, Branch Translat Med & Pharmacol, D-60596 Frankfurt, Germany.
   [Ciesek, Sandra] German Ctr Infect Res DZIF, External Partner Site Frankfurt, D-60596 Frankfurt, Germany.
RP Binder, M (corresponding author), Martin Luther Univ Halle Wittenberg, Dept Internal Med 4, Oncol Hematol, D-06120 Halle, Saale, Germany.
EM mascha.binder@uk-halle.de
OI von Wenserski, Lisa/0000-0003-1963-0398; Scholz,
   Rebekka/0000-0003-2077-0718; Addo, Marylyn/0000-0003-2836-9224; Binder,
   Mascha/0000-0003-0663-3004; Simnica, Donjete/0000-0003-2286-1381;
   Schultheiss, Christoph/0000-0001-9789-5776
FU German Research FoundationGerman Research Foundation (DFG) [CRC 841];
   Martin-Luther-University, Halle (Saale)
FX We thank the following investigators and advisors for contributing
   patients and samples, technical assistance, supporting lab facilities,
   biobanking, ethical, and other input: Nuray Akyuez, Samiya Al-Robaiy,
   Wolfgang Altermann, Herrmann Behre, Mildred Borrmann, Johanna Brandner,
   Christine Dierks, Jochen Dutzmann, Johann Fabian Eberhardt, Stephan
   Eisenmann, Lena Engels, Laura Glau, Katrin Hoffmann, Mareike Holz, Petra
   Hubner, Ulla Kasten-Pisula, Katharina Kolbe, Kerstin Korber-Fehrl,
   Katrin Lamszus, Beatrice Ludwig-Kraus, Cecile L. Maire, Sabine Matutat,
   Lutz P. M_uller, Undine Musielinsky, Alexander Navarrete Santos and the
   FACS Core Facility Halle, Sebastian Nuding, Gerald Schlaf, Henning
   Seismann, Marta Siedlecki, Alexander Stein, Maria Vehreschild, Maxi
   Wass, Christoph Wosiek, Tanja Zeller, and Andela Zic. Moreover, we thank
   all of the patients and donors after recovery from COVID-19 for donating
   their blood for this project. This project was partially funded by the
   CRC 841 of the German Research Foundation (to M.B.) and by the
   Martin-Luther-University, Halle (Saale).
CR Aeffner F, 2015, AM J PHYSIOL-LUNG C, V309, pL1313, DOI 10.1152/ajplung.00130.2015
   Aloui C, 2014, INT J MOL SCI, V15, P22342, DOI 10.3390/ijms151222342
   Becattini S, 2015, SCIENCE, V347, P400, DOI 10.1126/science.1260668
   Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364
   Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316
   Bruggemann M, 2019, LEUKEMIA, V33, P2241, DOI 10.1038/s41375-019-0496-7
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Corrie BD, 2018, IMMUNOL REV, V284, P24, DOI 10.1111/imr.12666
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Elhanati Y, 2018, IMMUNOL REV, V284, P167, DOI 10.1111/imr.12665
   Gautreau G, 2017, BIOINFORMATICS, V33, P779, DOI 10.1093/bioinformatics/btw708
   Gil A, 2015, J VIROL, V89, P4102, DOI 10.1128/JVI.03020-14
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Han MV, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-356
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou H, 2020, CLIN EXP IMMUNOL, V201, P76, DOI 10.1111/cei.13450
   Huang H, 2020, NAT BIOTECHNOL, V38, P1194, DOI 10.1038/s41587-020-0505-4
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Ko JH, 2017, DIAGN MICR INFEC DIS, V89, P106, DOI 10.1016/j.diagmicrobio.2017.07.006
   Kreuzaler M, 2012, J IMMUNOL, V188, P497, DOI 10.4049/jimmunol.1102321
   Lee N, 2006, J CLIN VIROL, V35, P179, DOI 10.1016/j.jcv.2005.07.005
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Mackay F, 2009, NAT REV IMMUNOL, V9, P491, DOI 10.1038/nri2572
   Marraco SAF, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00310
   McKechnie JL, 2020, CELL HOST MICROBE, V27, P863, DOI 10.1016/j.chom.2020.05.009
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Messaoudi I, 2002, SCIENCE, V298, P1797, DOI 10.1126/science.1076064
   Minervina A.A., 2020, BIORXIV, DOI DOI 10.1101/2020.05.18.100545
   Minervina AA, 2020, ELIFE, V9, DOI 10.7554/eLife.53704
   Nielsen S.C.A., 2020, BIORXIV, DOI DOI 10.21203/RS.3.RS-27220/V1
   O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Price DA, 2004, IMMUNITY, V21, P793, DOI 10.1016/j.immuni.2004.10.010
   Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sallusto F, 2016, ANNU REV IMMUNOL, V34, P317, DOI 10.1146/annurev-immunol-032414-112056
   Sethna Z, 2019, BIOINFORMATICS, V35, P2974, DOI 10.1093/bioinformatics/btz035
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shubin NJ, 2012, J LEUKOCYTE BIOL, V92, P593, DOI 10.1189/jlb.1211641
   Simnica D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01897
   Simnica D, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1644110
   Sjostrand M, 2016, J IMMUNOL, V196, P91, DOI 10.4049/jimmunol.1501061
   Speranza E, 2018, J INFECT DIS, V218, pS508, DOI 10.1093/infdis/jiy352
   Tan W, 2020, VIRAL KINETICS ANTIB, DOI [10.1101/2020.03.24.20042382, DOI 10.1101/2020.03.24.20042382]
   Tangye SG, 2002, J IMMUNOL, V169, P4298, DOI 10.4049/jimmunol.169.8.4298
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202
   VanDuijn MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01286
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 60
TC 7
Z9 7
U1 2
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD AUG 18
PY 2020
VL 53
IS 2
BP 442
EP +
DI 10.1016/j.immuni.2020.06.024
PG 18
WC Immunology
SC Immunology
GA NC4NX
UT WOS:000561190600020
PM 32668194
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Shu, L
   Niu, CM
   Li, RY
   Huang, TR
   Wang, Y
   Huang, M
   Ji, NF
   Zheng, Y
   Chen, XL
   Shi, L
   Wu, MJ
   Deng, KL
   Wei, J
   Wang, XL
   Cao, Y
   Yan, JX
   Feng, GZ
AF Shu, Lei
   Niu, Changming
   Li, Ruyou
   Huang, Tingrong
   Wang, Yan
   Huang, Mao
   Ji, Ningfei
   Zheng, You
   Chen, Xiaolin
   Shi, Lei
   Wu, Mingjing
   Deng, Kaili
   Wei, Jing
   Wang, Xueli
   Cao, Yang
   Yan, Jiaxin
   Feng, Ganzhu
TI Treatment of severe COVID-19 with human umbilical cord mesenchymal stem
   cells
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Coronavirus disease-19 (COVID-19); Clinical characteristics; Coronavirus
   pneumonia; Human umbilical cord mesenchymal stem cells
ID STROMAL CELLS; TRANSPLANTATION; THERAPY; SAFETY
AB Background: COVID-19 is a highly infectious respiratory disease. No therapeutics have yet been proven effective for treating severe COVID-19.
   Objectives: To determine whether human umbilical cord mesenchymal stem cell infusion may be effective and safe for the treatment of severe COVID-19.
   Methods: Patients with severe COVID-19 were randomly divided into 2 groups: the standard treatment group and the standard treatment plus hUC-MSC infusion group. The incidence of progression from severe to critical illness, 28-day mortality, clinical symptom improvement, time to clinical symptom improvement, hematologic indicators including C-reactive protein, lymphocyte number, and interleukin 6, and imaging changes were observed and compared between the two groups.
   Measurements and main results: The incidence of progression from severe to critical illness and the 28-day mortality rate were 0 in the hUC-MSC treatment group, while 4 patients in the control group deteriorated to critical condition and received invasive ventilation; 3 of them died, and the 28-day mortality rate was 10.34%. In the hUC-MSC treatment group, the time to clinical improvement was shorter than that in the control group. Clinical symptoms of weakness and fatigue, shortness of breath, and low oxygen saturation obviously improved beginning on the third day of stem cell infusion and reached a significant difference on day 7. CRP and IL-6 levels were significantly lower from day 3 of infusion, the time for the lymphocyte count to return to the normal range was significantly faster, and lung inflammation absorption was significantly shorter on CT imaging in the hUC-MSC group than in the control group.
   Conclusions: Intravenous transplantation of hUC-MSCs is a safe and effective method that can be considered a salvage and priority treatment option for severe COVID-19.
C1 [Shu, Lei; Chen, Xiaolin; Shi, Lei; Wu, Mingjing; Deng, Kaili; Wei, Jing; Wang, Xueli; Cao, Yang; Yan, Jiaxin] Nanjing Med Univ, Sir Run Run Hosp, Dept Resp Med, Nanjing 211166, Jiangsu, Peoples R China.
   [Shu, Lei] Nanjing Med Univ, Clin Med Sch 2, Dept Resp Med, Nanjing 210011, Jiangsu, Peoples R China.
   [Niu, Changming] Nanjing Med Univ, Affiliated Hosp 2, Dept Crit Care Med, Nanjing 210011, Jiangsu, Peoples R China.
   [Li, Ruyou] Huangshi Cent Hosp, Dept Resp Med, Hangshi 435000, Hubei, Peoples R China.
   [Huang, Tingrong; Zheng, You] Huangshi Hosp Tradit Chinese Med, Dept Nephrol, Hangshi 435000, Hubei, Peoples R China.
   [Wang, Yan] Jiangsu Cell Tech Med Res Inst, Nanjing 211166, Jiangsu, Peoples R China.
   [Huang, Mao; Ji, Ningfei] Nanjing Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Nanjing 210029, Jiangsu, Peoples R China.
   [Feng, Ganzhu] Nanjing Med Univ, Affiliated Hosp 2, Dept Pulm & Crit Care Med, 121 Jiangjiayuan Rd, Nanjing 210011, Jiangsu, Peoples R China.
RP Feng, GZ (corresponding author), Nanjing Med Univ, Affiliated Hosp 2, Dept Pulm & Crit Care Med, 121 Jiangjiayuan Rd, Nanjing 210011, Jiangsu, Peoples R China.
EM fenggz163@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81670013]; Key Research and Development
   Project of Jiangsu Province [BE2020616]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (81670013) and the Key Research and Development
   Project of Jiangsu Province (BE2020616).
CR [Anonymous], 2020, NEW CORONAVIRUS PNEU
   [Anonymous], 2020, WHO CHAR COVID 19 PA
   [Anonymous], 2020, COR DIS COVID 19 SIT
   Cai JQ, 2016, DIABETES CARE, V39, P149, DOI 10.2337/dc15-0171
   Carlsson PO, 2015, DIABETES, V64, P587, DOI 10.2337/db14-0656
   Chang YC, 2005, RADIOLOGY, V236, P1067, DOI 10.1148/radiol.2363040958
   Chen P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11997-1
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Geng LY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00233
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Harrell CR, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4236973
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jagiello J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184561
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7
   Leng Z, 2020, AGING DIS, V216, P228
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Li T, 2015, EXPERT OPIN BIOL TH, V15, P1293, DOI 10.1517/14712598.2015.1051528
   Liu M, 2020, J OPER RES SOC, V71, P748, DOI 10.1080/01605682.2019.1582589
   Liu XB, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt446
   Loy H, 2019, J INFECT DIS, V219, P186, DOI 10.1093/infdis/jiy478
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   McIntyre LA, 2018, AM J RESP CRIT CARE, V197, P337, DOI 10.1164/rccm.201705-1006OC
   Naji A, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1158-4
   Naji A, 2017, STEM CELL TRANSL MED, V6, P713, DOI 10.5966/sctm.2016-0289
   Royal College of Physicians, 2017, NAT EARL WARN SCOR N
   Sauler M, 2019, ANNU REV PHYSIOL, V81, P375, DOI 10.1146/annurev-physiol-020518-114320
   Schoen K, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4592-0
   Sinclair KA, 2016, STEM CELLS, V34, P2548, DOI 10.1002/stem.2419
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, J INFECT DIS, V221, P1688, DOI 10.1093/infdis/jiz656
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu C, 2020, JAMA INTERN MED, V395, P1054
   Wu MJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23396-1
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yan XR, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/2654910
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 43
TC 3
Z9 3
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD AUG 18
PY 2020
VL 11
IS 1
AR 361
DI 10.1186/s13287-020-01875-5
PG 11
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA NI6IT
UT WOS:000565455500002
PM 32811531
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yang, Y
   Du, Y
   Kaltashov, IA
AF Yang, Yang
   Du, Yi
   Kaltashov, Igor A.
TI The Utility of Native MS for Understanding the Mechanism of Action of
   Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the
   SARS-CoV-2 Interaction with Its Host Cell Receptor
SO ANALYTICAL CHEMISTRY
LA English
DT Article
AB The emergence and rapid proliferation of the novel coronavirus (SARS-CoV-2) resulted in a global pandemic, with over 6,000,000 cases and nearly 400,000 deaths reported worldwide by the end of May 2020. A rush to find a cure prompted re-evaluation of a range of existing therapeutics vis-a-vis their potential role in treating COVID-19, placing a premium on analytical tools capable of supporting such efforts. Native mass spectrometry (MS) has long been a tool of choice in supporting the mechanistic studies of drug/therapeutic target interactions, but its applications remain limited in the cases that involve systems with a high level of structural heterogeneity. Both SARS-CoV-2 spike protein (S-protein), a critical element of the viral entry to the host cell, and ACE2, its docking site on the host cell surface, are extensively glycosylated, making them challenging targets for native MS. However, supplementing native MS with a gas-phase ion manipulation technique (limited charge reduction) allows meaningful information to be obtained on the noncovalent complexes formed by ACE2 and the receptor-binding domain (RBD) of the S-protein. Using this technique in combination with molecular modeling also allows the role of heparin in destabilizing the ACE2/RBD association to be studied, providing critical information for understanding the molecular mechanism of its interference with the virus docking to the host cell receptor. Both short (pentasaccharide) and relatively long (eicosasaccharide) heparin oligomers form 1:1 complexes with RBD, indicating the presence of a single binding site. This association alters the protein conformation (to maximize the contiguous patch of the positive charge on the RBD surface), resulting in a notable decrease in its ability to associate with ACE2. The destabilizing effect of heparin is more pronounced in the case of the longer chains due to the electrostatic repulsion between the low-pI ACE2 and the heparin segments not accommodated on the RBD surface. In addition to providing important mechanistic information on attenuation of the ACE2/RBD association by heparin, the study demonstrates the yet untapped potential of native MS coupled to gas-phase ion chemistry as a means of facilitating rational repurposing of the existing medicines for treating COVID-19.
C1 [Yang, Yang; Du, Yi; Kaltashov, Igor A.] Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.
RP Kaltashov, IA (corresponding author), Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.
EM kaltashov@chem.umass.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 GM112666];
   National Science FoundationNational Science Foundation (NSF)
   [CHE-1709552]
FX This work was supported by grants from the National Institutes of Health
   (R01 GM112666) and the National Science Foundation (CHE-1709552). MS
   instrumentation used in this work is part of the Mass Spectrometry Core
   Facility at UMass-Amherst.
CR Abzalimov RR, 2010, ANAL CHEM, V82, P7523, DOI 10.1021/ac101848z
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Freed JS, 2020, ANN GLOB HEALTH, V86, DOI 10.5334/aogh.2894
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Hannah VV, 2010, FUTURE MED CHEM, V2, P35, DOI [10.4155/FMC.09.141, 10.4155/fmc.09.141]
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Kaltashov IA, 2018, METHODS, V144, P14, DOI 10.1016/j.ymeth.2018.04.019
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Leverence R, 2010, P NATL ACAD SCI USA, V107, P8123, DOI 10.1073/pnas.0914898107
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lindahl U, 2020, J THROMB HAEMOST, V18, P2422, DOI 10.1111/jth.14898
   Liu X., 2020, HEPARIN INDUCED THRO, DOI [10.1101/2020.04.23.20076851, DOI 10.1101/2020.04.23.20076851]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Menzella F., 2020, DRUGS CONTEXT, V9, P2020
   Menzella F., 2020, DRUGS CONTEXT, V9, P2026
   Mycroft-West C., 2020, BIORXIV, P1, DOI [10.1101/2020.02.29.971093, DOI 10.1101/2020.02.29.971093]
   Mycroft-West C.J., 2020, BIORXIV, DOI [10.1101/2020.04.28.066761, DOI 10.1101/2020.04.28.066761]
   Niu CD, 2020, BIOPHYS J, V119, P1371, DOI 10.1016/j.bpj.2020.04.012
   Niu CD, 2020, ANAL CHEM, V92, P7565, DOI 10.1021/acs.analchem.0c00115
   Rauova L, 2005, BLOOD, V105, P131, DOI 10.1182/blood-2004-04-1544
   Shajahan Asif, 2020, Glycobiology, V30, P981, DOI 10.1093/glycob/cwaa042
   Shin HS, 2020, INFECT CHEMOTHER, V52, P217, DOI 10.3947/ic.2020.52.2.217
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Tong WJ, 2018, METHODS, V144, P3, DOI 10.1016/j.ymeth.2018.04.025
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan Y, 2020, J VIROL, V94
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Young E, 2008, THROMB RES, V122, P743, DOI 10.1016/j.thromres.2006.10.026
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhao YL, 2016, ANAL CHEM, V88, P1711, DOI 10.1021/acs.analchem.5b03792
   Zhou H, 2020, BRIT J PHARMACOL, V177, P3147, DOI 10.1111/bph.15092
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 33
TC 1
Z9 1
U1 11
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD AUG 18
PY 2020
VL 92
IS 16
BP 10930
EP 10934
DI 10.1021/acs.analchem.0c02449
PG 5
WC Chemistry, Analytical
SC Chemistry
GA NF1FN
UT WOS:000563047900010
PM 32678978
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tan, AS
   Nerurkar, SN
   Tan, WCC
   Goh, D
   Lai, CPT
   Yeong, JPS
AF Tan, An Sen
   Nerurkar, Sanjna Nilesh
   Tan, Wei Chang Colin
   Goh, Denise
   Lai, Chi Peng Timothy
   Poh Sheng Yeong, Joe
TI The Virological, Immunological, and Imaging Approaches for COVID-19
   Diagnosis and Research
SO SLAS TECHNOLOGY
LA English
DT Article
DE COVID-19; immunology; pathology; diagnostics; specific T cells
ID ACUTE RESPIRATORY SYNDROME; SYNDROME CORONAVIRUS; SEROLOGICAL ASSAYS;
   CELL RESPONSES; HEALTH; VIRUS; EXPRESSION; INFECTION; ELISPOT; PROTEIN
AB In 2019, a novel coronavirus (SARS-CoV-2) was found to cause a highly contagious disease characterized by pneumonia. The disease (COVID-19) quickly spread around the globe, escalating to a global pandemic. In this review, we discuss the virological, immunological, and imaging approaches harnessed for COVID-19 diagnosis and research. COVID-19 shares many clinical characteristics with other respiratory illnesses.
   Accurate and early detection of the infection is pivotal to controlling the outbreak, as this enables case identification, isolation, and contact tracing. We summarize the available literature on current laboratory and point-of-care diagnostics, highlight their strengths and limitations, and describe the emerging diagnostic approaches on the horizon.
   We also discuss the various research techniques that are being used to evaluate host immunity in laboratory-confirmed patients. Additionally, pathological imaging of tissue samples from affected patients has a critical role in guiding investigations on this disease. Conventional techniques, such as immunohistochemistry and immunofluorescence, have been frequently used to characterize the immune microenvironment in COVID-19. We also outline the emerging imaging techniques, such as the RNAscope, which might also aid in our understanding of the significance of COVID-19-specific biomarkers, such as the angiotensin-converting enzyme 2 (ACE2) cellular receptor.
   Overall, great progress has been made in COVID-19 research in a short period. Extensive, global collation of our current knowledge of SARS-CoV-2 will provide insights into novel treatment modalities, such as monoclonal antibodies, and support the development of a SARS-CoV-2 vaccine.
C1 [Tan, An Sen; Lai, Chi Peng Timothy] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Nerurkar, Sanjna Nilesh; Tan, Wei Chang Colin] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Goh, Denise; Poh Sheng Yeong, Joe] ASTAR, Inst Mol Cell Biol IMCB, 20 Coll Rd,Level 7,Diagnost Tower, Singapore 169856, Singapore.
   [Poh Sheng Yeong, Joe] Singapore Gen Hosp, Dept Anat Pathol, Singapore, Singapore.
RP Yeong, JPS (corresponding author), ASTAR, Inst Mol Cell Biol IMCB, 20 Coll Rd,Level 7,Diagnost Tower, Singapore 169856, Singapore.
EM yeongps@imcb.a-star.edu.sg
CR Ackermann M, 2020, N ENGL J MED
   Adachi T, 2020, CANCER IMAGING, V20, DOI 10.1186/s40644-020-00325-y
   Adams E.R., 2020, ANTIBODY TESTING COV, DOI [10.1101/2020.04.15.20066407, DOI 10.1101/2020.04.15.20066407, 10.1101/2020.04.15.20066407.]
   Alshukairi AN, 2016, EMERG INFECT DIS, V22, P1113, DOI 10.3201/eid2206.160010
   Altmann DM, 2020, LANCET, V395, P1527, DOI 10.1016/S0140-6736(20)30985-5
   Baek YH, 2020, EMERG MICROBES INFEC, V9, P998, DOI 10.1080/22221751.2020.1756698
   Barton L., 2020, AM J CLIN PATHOL, V153
   Bradley B. T., 2020, HISTOPATHOLOGY ULTRA, DOI [10.1101/2020.04.17.20058545, DOI 10.1101/2020.04.17.20058545]
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Broughton J. P., 2020, NAT BIOTECHNOL
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Buja LM, 2020, CARDIOVASC PATHOL, V48, DOI 10.1016/j.carpath.2020.107233
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Carsana L, 2020, LANCET INFECT DIS
   Cassaniti I, 2020, J MED VIROL, V92, P1724, DOI 10.1002/jmv.25800
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cobb B, 2017, EXPERT REV MOL DIAGN, V17, P167, DOI 10.1080/14737159.2017.1275962
   Colaco S., 2020, 200404935V1 ARXIV
   Cripps K., 2020, CNN, V21
   De Simone M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01638
   Del Valle D. M., 2020, INFLAMMATORY CYTOKIN
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Edler C, 2020, INT J LEGAL MED, V134, P1275, DOI 10.1007/s00414-020-02317-w
   Engstrom-Melnyk J, 2015, METHOD MICROBIOL, V42, P161, DOI 10.1016/bs.mim.2015.04.005
   Fan Z, 2020, CLIN GASTROENTEROL H
   Feng Z, 2020, NOVEL SEVERE ACUTE R, DOI [10.1101/2020.03.27.20045427, DOI 10.1101/2020.03.27.20045427]
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Gao Y., 2020, J MED VIROL
   Giamarellos-Bourboulis E. J., 2020, CELL HOST MICROBE
   Gootenberg JS, 2017, SCIENCE, V356, P438, DOI 10.1126/science.aam9321
   Green K., MOL ANTIBODY POINT T
   Grifoni A., 2020, CELL
   Grimes Z, 2020, CARDIOVASC PATHOL, V48, DOI 10.1016/j.carpath.2020.107227
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo L., 2020, CLIN INFECT DIS
   Hagen J, 2015, CELLS-BASEL, V4, P84, DOI 10.3390/cells4010084
   Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ikram A, 2020, METALS-BASEL, V10, DOI 10.3390/met10030418
   Johns Hopkins Center for Health Security, GLOB PROGR COVID 19
   Kellner MJ, 2019, NAT PROTOC, V14, P2986, DOI 10.1038/s41596-019-0210-2
   Kontou PI, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050319
   Kothari H., 2020, IDENTIFICATION HUMAN, DOI [10.1101/2020.04.19.047274, DOI 10.1101/2020.04.19.047274]
   Lan L, 2020, JAMA
   Larsen CP, 2020, KIDNEY INT REP, V5, P935, DOI 10.1016/j.ekir.2020.04.002
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li MM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230295
   Li YF, 2020, J MED VIROL, V92, P903, DOI 10.1002/jmv.25786
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Liu J., 2020, JCI INSIGHT
   Liu Y., 2020, DIAGNOSTIC INDEXES R, V2020, DOI [10.1101/2020.03.26.20044883, DOI 10.1101/2020.03.26.20044883]
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lu RF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082826
   Luo W., 2020, CLIN PATHOLOGY CRITI
   Mathur G., 2020, AM J CLIN PATHOL
   Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134
   Mertens P, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00225
   Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018
   Ni L., 2020, IMMUNITY
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Nisreen M. A. O., 2020, EMERG INFECT DIS J, P26
   Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P9293, DOI 10.1073/pnas.96.16.9293
   Oetjen KA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.124928
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Ouyang Y., 2020, CLIN INFECT DIS
   Pan XB, 2020, IRISH J MED SCI, V189, P1145, DOI 10.1007/s11845-020-02215-5
   Peaper DR, 2014, HAND CLINIC, V123, P123, DOI 10.1016/B978-0-444-53488-0.00005-5
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421
   Petherick A, 2020, LANCET, V395, P1101, DOI 10.1016/S0140-6736(20)30788-1
   Qin C, 2020, CLIN INFECT DIS
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Riley RS, 2016, LAB MED, V47, P90, DOI 10.1093/labmed/lmw001
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shen MZ, 2020, J PHARM ANAL, V10, P97, DOI 10.1016/j.jpha.2020.02.010
   Shi S, 2020, JAMA CARDIOL
   Si YJ, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13322
   Siota M, 2011, EXPERT REV VACCINES, V10, P299, DOI [10.1586/erv.10.169, 10.1586/ERV.10.169]
   Spicuzza L., 2020, J INFECTION
   Stawiski EW, 2020, BIORXIV, DOI [10.1101/2020.04.07.024752, DOI 10.1101/2020.04.07.024752]
   Su H, 2020, KIDNEY INT
   Sun B., 2020, EMERG MICROBES INFEC, P1
   Tan MK, 2020, IMMUNOLOGY, V160, P261, DOI 10.1111/imm.13223
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Tang YW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00512-20
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Vabret N, 2020, IMMUNITY
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002
   Wang K, 2020, SARS COV 2 INVADES H, V3, P14, DOI DOI 10.1101/2020.03.14.988345
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Wang WJ, 2020, CELL MOL IMMUNOL, V17, P650, DOI 10.1038/s41423-020-0447-2
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang XL, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-020-0424-9
   Watanabe K, 2020, SOC SCI COMPUT REV, DOI 10.1177/0894439320907027
   Wee YTF, 2018, ANN DIAGN PATHOL, V37, P12, DOI 10.1016/j.anndiagpath.2018.09.002
   Wei L., 2020, SSRN ELECT J
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9
   WHO, REP WHO CHIN JOINT M
   Wichmann D, 2020, ANN INTERN MED
   Winichakoon P, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00297-20
   World Health Organization, 162 WHO
   World Health Organization, 2002, SUMM PROB SARS CAS O
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao SY, 2020, J MED VIROL, V92, P464, DOI 10.1002/jmv.25702
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan C., 2020, CLIN MICROBIOL INFEC
   Yan L., 2020, ARCH PATHOL LAB MED
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Yao XH, 2020, CELL RES, V30, P541, DOI 10.1038/s41422-020-0318-5
   Yong SEF, 2020, LANCET INFECT DIS, V20, P809, DOI 10.1016/S1473-3099(20)30273-5
   Zhang H, 2020, GUT, V69, P1010, DOI 10.1136/gutjnl-2020-320953
   Zhang L., 2020, J THROMB HAEMOST
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhang Y, 2020, ADV MATER INTERFACES, V7, DOI 10.1002/admi.201902011
   Zhao JC, 2011, J CLIN INVEST, V121, P4921, DOI 10.1172/JCI59777
   Zhao S, 2020, INFECT DIS-NOR, V52, P284, DOI 10.1080/23744235.2020.1717598
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 131
TC 1
Z9 1
U1 3
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2472-6303
EI 2472-6311
J9 SLAS TECHNOL
JI SLAS Technol.
PD DEC
PY 2020
VL 25
IS 6
BP 522
EP 544
AR 2472630320950248
DI 10.1177/2472630320950248
EA AUG 2020
PG 23
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA OT8JL
UT WOS:000561984200001
PM 32808850
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Tan, L
   Kovoor, JG
   Williamson, P
   Tivey, DR
   Babidge, WJ
   Collinson, TG
   Hewett, PJ
   Hugh, TJ
   Padbury, RTA
   Langley, SJ
   Maddern, GJ
AF Tan, Lorwai
   Kovoor, Joshua G.
   Williamson, Penny
   Tivey, David R.
   Babidge, Wendy J.
   Collinson, Trevor G.
   Hewett, Peter J.
   Hugh, Thomas J.
   Padbury, Robert T. A.
   Langley, Sally J.
   Maddern, Guy J.
TI Personal protective equipment and evidence-based advice for surgical
   departments duringCOVID-19
SO ANZ JOURNAL OF SURGERY
LA English
DT Article
DE COVID-19; healthcare worker; personal protective equipment; SARS-CoV-2;
   surgery
ID HEALTH-CARE WORKERS; ACUTE RESPIRATORY SYNDROME; RANDOMIZED
   CLINICAL-TRIAL; FULL SYSTEMATIC REVIEWS; N95 RESPIRATORS; SARS
   TRANSMISSION; INFECTION-CONTROL; MEDICAL MASKS; PRECAUTIONS; BLOOD
AB Background Inconsistencies regarding the use of appropriate personal protective equipment (PPE) have raised concerns for the safety of surgical staff during the coronavirus disease 2019 (COVID-19) pandemic. This rapid review synthesizes the literature and includes input from clinical experts to provide evidence-based guidance for surgical services. Methods The rapid review comprised of targeted searches in PubMed and grey literature. Pertinent findings were discussed by a working group of clinical experts, and consensus recommendations, consistent with Australian and New Zealand Government guidelines, were formulated. Results There was a paucity of high-quality primary studies specifically investigating appropriate surgical PPE for healthcare workers treating patients possibly infected with COVID-19. SARS-CoV-2 is capable of aerosol, droplet and fomite transmission, making it essential to augment standard infection control measures with appropriate PPE, especially during surgical emergencies and aerosol-generating procedures. All biological material should be treated a potential source of SARS-COV-2. Staff must have formal training in the use of PPE and should be supervised by a colleague during donning and doffing. Patients with suspected or confirmed COVID-19 should wear a surgical mask during transfer to and from theatre. Potential solutions exist in the literature to extend the use of surgical P2/N95 respirators in situations of limited supply. Conclusion PPE is advised for all high-risk procedures and when a patient's COVID-19 status is unknown. Surgical departments should facilitate staggered rostering, remote meeting attendance, and self-isolation of symptomatic staff. Vulnerable surgical staff should be identified and excluded from operations with a high risk of COVID-19 infection.
C1 [Tan, Lorwai; Williamson, Penny; Tivey, David R.; Babidge, Wendy J.; Maddern, Guy J.] Royal Australasian Coll Surg, Res Audit & Acad Surg, Adelaide, SA, Australia.
   [Kovoor, Joshua G.] Univ Adelaide, Adelaide, SA, Australia.
   [Tivey, David R.; Babidge, Wendy J.; Hewett, Peter J.; Maddern, Guy J.] Univ Adelaide, Queen Elizabeth Hosp, Discipline Surg, Adelaide, SA, Australia.
   [Collinson, Trevor G.] Gen Surg Australia, Adelaide, SA, Australia.
   [Hugh, Thomas J.] Univ Sydney, Northern Clin Sch, Sydney, NSW, Australia.
   [Hugh, Thomas J.] Royal North Shore Hosp, Surg Educ Res & Training Inst, Sydney, NSW, Australia.
   [Padbury, Robert T. A.] Flinders Univ S Australia, Adelaide, SA, Australia.
   [Padbury, Robert T. A.] Flinders Med Ctr, Div Surg & Perioperat Med, Adelaide, SA, Australia.
   [Langley, Sally J.] Christchurch Hosp, Plast & Reconstruct Surg Dept, Christchurch, New Zealand.
RP Maddern, GJ (corresponding author), Royal Australasian Coll Surg, 199 Ward St, Adelaide, SA 5006, Australia.
EM guy.maddern@adelaide.edu.au
RI ; Tivey, David/A-6354-2017
OI Hugh, Thomas J/0000-0001-6690-342X; Tan, Lorwai/0000-0001-8434-2988;
   Tivey, David/0000-0003-2213-2576; Kovoor, Joshua/0000-0002-3880-3840;
   Maddern, Guy/0000-0003-2064-181X
CR [Anonymous], US PERS PROT EQ PPE
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Australian and New Zealand College of Anaesthetists and the Faculty of Pain Medicine, 2020, ANZCA STAT PERS PROT
   Australian Commission on Safety and Quality in Health Care, 2019, AUSTR GUID PREV CONT, P2019
   [Australian Government Department of Health], 2020, GUID US PERS PROT EQ, P1
   Australian Government Department of Health, INT ADV NON CAR PERS
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Balazy A, 2006, AM J INFECT CONTROL, V34, P51, DOI 10.1016/j.ajic.2005.08.018
   Beam EL, 2011, AM J INFECT CONTROL, V39, P415, DOI 10.1016/j.ajic.2010.07.009
   Brindle ME, 2020, ANN SURG, V272, pE1, DOI 10.1097/SLA.0000000000003923
   Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1045
   Chang D, 2020, LANCET RESP MED, V8, pE13, DOI 10.1016/S2213-2600(20)30066-7
   Chen YC, 2004, EMERG INFECT DIS, V10, P895, DOI 10.3201/eid1005.030777
   Cho KJ, 2010, ANN OCCUP HYG, V54, P68, DOI 10.1093/annhyg/mep062
   Chughtai AA, 2018, AM J INFECT CONTROL, V46, P1329, DOI 10.1016/j.ajic.2018.06.003
   Coffey CC, 2004, J OCCUP ENVIRON HYG, V1, P262, DOI 10.1080/15459620490433799
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Evans HL, 2020, SURG INFECT, V21, P671, DOI 10.1089/sur.2020.140
   Forrester JD, 2020, J AM COLL SURGEONS, V230, P1098, DOI 10.1016/j.jamcollsurg.2020.03.030
   GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506
   Gralton J, 2010, CRIT CARE MED, V38, P657, DOI 10.1097/CCM.0b013e3181b9e8b3
   Johnson Richard M, 2020, PDA J Pharm Sci Technol, V74, P170, DOI 10.5731/pdajpst.2019.001118
   Khangura S, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-10
   Kwon JH, 2017, INFECT CONT HOSP EP, V38, P1077, DOI 10.1017/ice.2017.121
   Lau JTF, 2004, EMERG INFECT DIS, V10, P280, DOI 10.3201/eid1002.030534
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1070, DOI 10.1515/cclm-2020-0285
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Livingston E, 2020, JAMA-J AM MED ASSOC, V323, P1912, DOI 10.1001/jama.2020.5317
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MacIntyre CR, 2014, PREV MED, V62, P1, DOI 10.1016/j.ypmed.2014.01.015
   MacIntyre CR, 2013, AM J RESP CRIT CARE, V187, P960, DOI 10.1164/rccm.201207-1164OC
   MacIntyre CR, 2011, INFLUENZA OTHER RESP, V5, P170, DOI 10.1111/j.1750-2659.2011.00198.x
   Ministry of Health New Zealand, CAS DEF COVID 19 INF
   Nagao M, 2009, AM J INFECT CONTROL, V37, P541, DOI 10.1016/j.ajic.2009.01.009
   National Institute for Occupational Safety and Health, 2019, PROC TEB APR STP 005
   Newman M, 2020, COVID 19 DOCTORS LEA
   Ofner-Agostini M, 2006, INFECT CONT HOSP EP, V27, P473, DOI 10.1086/504363
   PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533
   Patel R, 2020, MBIO, V11, DOI 10.1128/mBio.00722-20
   Royal Australasian College of Surgeons, GUID PERS PROT EQ
   Royal Australasian College of Surgeons, GUID PERS PROT EQ RA
   Sharfstein JM, 2020, JAMA-J AM MED ASSOC, V323, P1437, DOI 10.1001/jama.2020.3864
   Shigayeva A, 2007, INFECT CONT HOSP EP, V28, P1275, DOI 10.1086/521661
   Siegel JD, 2007, AM J INFECT CONTROL, V35, pS65, DOI 10.1016/j.ajic.2007.10.007
   Sinkule EJ, 2013, ANN OCCUP HYG, V57, P384, DOI 10.1093/annhyg/mes068
   Standards Australia, 2015, AUSTR STAND SINGL US
   Standards Australia Limited/Standards New Zealand, 2012, 17162012 ASNSZ
   Standards Australia Limited/Standards New Zealand, 2009, 17152009 ASNSZ
   STOBBE TJ, 1988, AM IND HYG ASSOC J, V49, P199
   Swerdlow DL, 2020, NEW ENGL J MED, V382, P1869, DOI 10.1056/NEJMc2005157
   Ti LK, 2020, CAN J ANESTH, V67, P756, DOI 10.1007/s12630-020-01617-4
   Tomas ME, 2015, JAMA INTERN MED, V175, P1904, DOI 10.1001/jamainternmed.2015.4535
   Tseng CC, 2007, J OCCUP ENVIRON HYG, V4, P400, DOI 10.1080/15459620701329012
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Verbeek JH, 2020, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011621.pub4, 10.1002/14651858.CD011621.pub5]
   Vo E, 2009, APPL ENVIRON MICROB, V75, P7303, DOI 10.1128/AEM.00799-09
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Watt A, 2008, ANZ J SURG, V78, P1037, DOI 10.1111/j.1445-2197.2008.04730.x
   Watt A, 2008, INT J TECHNOL ASSESS, V24, P133, DOI 10.1017/S0266462308080185
   WHO, 2020, DIS OUTBREAK NE 0208
   Wong J, 2020, CAN J ANESTH, V67, P732, DOI 10.1007/s12630-020-01620-9
   World Health Organization, 2020, RAT US PERS PROT EQ
   World Health Organization, 2020, LAB TEST COR DIS 201
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Zaman S, 2020, MED J AUSTRALIA, DOI 10.5694/mja2.50714
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 71
TC 3
Z9 3
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1445-1433
EI 1445-2197
J9 ANZ J SURG
JI ANZ J. Surg.
PD SEP
PY 2020
VL 90
IS 9
BP 1566
EP 1572
DI 10.1111/ans.16194
EA AUG 2020
PG 7
WC Surgery
SC Surgery
GA NN7SR
UT WOS:000560912900001
PM 32671968
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Moreau, VH
AF Moreau, Vitor Hugo
TI Forecast predictions for the COVID-19 pandemic in Brazil by statistical
   modeling using the Weibull distribution for daily new cases and deaths
SO BRAZILIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE COVID-19; Forecast predictions; Weibull distribution; Brazil; Death toll
AB COVID-19 has killed more than 500,000 people worldwide and more than 60,000 in Brazil. Since there are no specific drugs or vaccines, the available tools against COVID-19 are preventive, such as the use of personal protective equipment, social distancing, lockdowns, and mass testing. Such measures are hindered in Brazil due to a restrict budget, low educational level of the population, and misleading attitudes from the federal authorities. Predictions for COVID-19 are of pivotal importance to subsidize and mobilize health authorities' efforts in applying the necessary preventive strategies. The Weibull distribution was used to model the forecast prediction of COVID-19, in four scenarios, based on the curve of daily new deaths as a function of time. The date in which the number of daily new deaths will fall below the rate of 3 deaths per million - the average level in which some countries start to relax the stay-at-home measures - was estimated. If the daily new deaths curve was bending today (i.e., about 1250 deaths per day), the predicted date would be on July 5. Forecast predictions allowed the estimation of overall death toll at the end of the outbreak. Our results suggest that each additional day that lasts to bend the daily new deaths curve may correspond to additional 1685 deaths at the end of COVID-19 outbreak in Brazil (R-2 = 0.9890). Predictions of the outbreak can be used to guide Brazilian health authorities in the decision-making to properly fight COVID-19 pandemic.
C1 [Moreau, Vitor Hugo] Fed Univ Bahia UFBA, Inst Hlth Sci ICS, Dept Biotechnol DBTEC, Salvador, BA, Brazil.
RP Moreau, VH (corresponding author), Fed Univ Bahia UFBA, Inst Hlth Sci ICS, Dept Biotechnol DBTEC, Salvador, BA, Brazil.
EM vitorhmc@ufba.br
RI Moreau, Vitor Hugo/J-4829-2015
OI Moreau, Vitor Hugo/0000-0002-5393-0645
CR Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Beltekian D, 2018, EXTREME POVERTY IS F
   Bhatia S, 2020, SHORT TERM FORECASTS
   Bong CL, 2020, ANESTH ANALG, V131, P86, DOI 10.1213/ANE.0000000000004846
   Burki T, 2020, LANCET INFECT DIS, V20, P547, DOI 10.1016/S1473-3099(20)30303-0
   Choi JY, 2020, POSTGRAD MED J, V96, P399, DOI 10.1136/postgradmedj-2020-137738
   Ciufolini I, 2020, EUR PHYS J PLUS, V135, DOI 10.1140/epjp/s13360-020-00383-y
   Gupta S, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138860
   Hopman J, 2020, JAMA-J AM MED ASSOC, V323, P1549, DOI 10.1001/jama.2020.4169
   IMF, 2020, WORLD EC DAT
   Khan SA, 2018, LIFETIME DATA ANAL, V24, P328, DOI 10.1007/s10985-017-9394-3
   Kim S, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020026
   Lau H, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa037
   Lawless JF, 2003, STAT MODELS METHODS, P1
   Li LX, 2020, INFECT DIS MODEL, V5, P282, DOI 10.1016/j.idm.2020.03.002
   Londono E., 2020, NY TIMES
   Marcel S, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20225
   MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030
   Mitja O, 2020, LANCET, V395, P1193, DOI 10.1016/S0140-6736(20)30753-4
   Moreau VH, 2020, PROJECTION DAI UNPUB
   Peto Julian, 2020, BMJ, V368, pm1163, DOI 10.1136/bmj.m1163
   Phillips D, 2020, GUARDIAN
   Rawson T, 2020, END COVID 19 LOCKDOW, DOI [10.1101/2020.04.29.20084517, DOI 10.1101/2020.04.29.20084517]
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Roser M., 2020, CORONAVIRUS PANDEMIC
   Saez M, 2020, SCI TOTAL ENVIRON, V727, DOI 10.1016/j.scitotenv.2020.138761
   Sjodin H, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.13.2000280
   Toginho Filho DO, 2009, CATALOGO EXPT LAB IN
   Verma V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233074
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
NR 30
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1517-8382
EI 1678-4405
J9 BRAZ J MICROBIOL
JI Braz. J. Microbiol.
PD SEP
PY 2020
VL 51
IS 3
BP 1109
EP 1115
DI 10.1007/s42770-020-00331-z
EA AUG 2020
PG 7
WC Microbiology
SC Microbiology
GA NF8EM
UT WOS:000560617700001
PM 32809115
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Janda, A
   Schuetz, C
   Heeg, M
   Minden, K
   Hedrich, CM
   Kallinich, T
   Hinze, C
   Schulz, A
   Speth, F
AF Janda, A.
   Schuetz, C.
   Heeg, M.
   Minden, K.
   Hedrich, C. M.
   Kallinich, T.
   Hinze, C.
   Schulz, A.
   Speth, F.
TI COVID-19: treatment strategies of German-speaking pediatric
   rheumatologists Results of an online survey
SO ZEITSCHRIFT FUR RHEUMATOLOGIE
LA German
DT Article; Early Access
DE Children; Rheumatic diseases; COVID-19; Therapy; SARS-CoV-2
ID INTENSIFIED IMMUNOSUPPRESSION; CHILDREN
AB Background Reliable data on the course and treatment of pediatric COVID-19 ("corona virus disease 2019") in immunosuppressed patients with rheumatic diseases are missing. Aim Delineation of individual strategies of the members of the Society for Pediatric Rheumatology (GKJR) in cases of COVID-19. Methods In May 2020 all GKJR members were invited to take part in an online survey. Opinion data regarding an approach using disease-modifying anti-rheumatic drugs (DMARD) in cases of COVID-19 as well as the readiness to use new therapeutic agents in patients in different stages of the disease were collected. Results A total of 71 respondents (27.3% of all contacted pediatric rheumatologists) took part in the survey. Of these 28.2% had treated patients with COVID-19. Over 95% of the respondents did not support a preventive adaptation of the anti-rheumatic treatment during the SARS-CoV-2 pandemic. In the case of outpatients under immunosuppression with proven COVID-19 more than 50% of the respondents would refrain from administering intravenous high-dose steroids, cyclophosphamide, anti-CD20 antibodies as well as BAFF, CTLA-4 and TNF-alpha blockades. Conversely, >70% of the respondents would continue the treatment with nonsteroidal anti-inflammatory drugs, hydroxychloroquine (HCQ), oral steroids, mycophenolate, IL-1 blockade and immunoglobulins (Ig). In the case of inpatients 74.6% of respondents would consider targeted COVID-19 treatment. In stable patients with oxygen treatment (stage I) HCQ (18.3%), azithromycin (16.9%) and Ig (9.9%) were most frequently used. In cases of early signs (stage II) or a manifest cytokine storm (stage III) anakinra (40.8% for stage II and 46.5% for stage III), tocilizumab (26.8% and 40.8%, respectively), steroids (25.4% and 33.8%, respectively) and remdesivir (29.6% and 38.0%, respectively) were most frequently used. The need for a personalized approach based on the current clinical situation was emphasized by many respondents. Conclusion The currently low prevalence of COVID-19 in Germany limits the general clinical experience. Therefore, the presented results have to be interpreted with caution and mostly as hypothetical treatment considerations. It is to be expected that there will always be a limited amount of evidence on pediatric COVID-19; therefore, a continuous and critical exchange of expert opinions on the treatment strategies is important.
C1 [Janda, A.; Schulz, A.] Univ Klinikum Ulm, Klin Kinder & Jugendmed, Eythstr 24, D-89075 Ulm, Germany.
   [Schuetz, C.] Techn Univ Dresden, Univ Klinikum Carl Gustav Carus, Klin & Poliklin Kinder & Jugendmed, Dresden, Germany.
   [Heeg, M.] Univ Klinikum Freiburg, Inst Immundefizienz, Freiburg, Germany.
   [Heeg, M.] Univ Klinikum Freiburg, Zentrum Kinder & Jugendmed, Freiburg, Germany.
   [Minden, K.; Kallinich, T.] Charite Univ Med Berlin, Berlin, Germany.
   [Minden, K.; Kallinich, T.] Deutsch Rheuma Forschungszentrum Berlin, Berlin, Germany.
   [Hedrich, C. M.] Univ Liverpool, Inst Life Course & Med Sci, Dept Womens & Childrens Hlth, Liverpool, Merseyside, England.
   [Hedrich, C. M.] Alder Hey Childrens NHS Fdn Trust Hosp, Dept Paediat Rheumatol, Liverpool, Merseyside, England.
   [Hinze, C.] Univ Klinikum Munster, Klin Padiatr Rheumatol & Immunol, Munster, Germany.
   [Speth, F.] Univ Klinikum Hamburg Eppendorf, Abt Kinderrheumatol, Zentrum Geburtshilfe Kinder & Jugendmed, Sekt Padiatr Stammzelltransplantat & Immunol, Hamburg, Germany.
RP Janda, A (corresponding author), Univ Klinikum Ulm, Klin Kinder & Jugendmed, Eythstr 24, D-89075 Ulm, Germany.
EM ales.janda@uniklinik-ulm.de
FU Projekt DEAL
FX Open Access funding provided by Projekt DEAL.
CR American Academy of Pediatrics, 2020, CRIT UPD COVID 19
   [Anonymous], 2020, Drug Ther Bull, V58, P69, DOI 10.1136/dtb.2020.000021
   API, 2020, NEUART COR
   Armann JP, 2020, DTSCH ARZTEBL INT, V117, P373, DOI 10.3238/arztebl.2020.0373
   Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467
   COVID-19 Treatment Guidelines Panel, 2020, COR DIS 2019 COVID 1
   Deutsche Gesellschaft fur Kinder- und Jugendmedizin e.V, 2020, COVID 19 MED THER KI
   Deutsche Gesellschaft fur Rheumatologie, 2020, EMPF WAHR SARS COV 2
   DGPI: Deutsche Gesellschaft fur Padiatrische Infektiologie, 2020, COVID 19 SURV UPD KW
   DGPI: Deutsche Gesellschaft fur Padiatrische Infektiologie, 2020, STELL DGPI GPP API G
   European Centre for Disease Prevention and Control (ECDC), 2020, PAED INFL MULT SYNDR
   Fajgenbaum DC, 2020, INFECT DIS THER, V9, P435, DOI 10.1007/s40121-020-00303-8
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Franzetti M, 2020, INT J INFECT DIS, V97, P215, DOI 10.1016/j.ijid.2020.05.050
   Gao Y, 2020, J INFECTION, V81, pE93, DOI 10.1016/j.jinf.2020.05.017
   Gesellschaft fur Kinder- und Jugendrheumatologie, 2020, HANDL GES KIND UND J
   Goldbach-Mansky R, 2006, NEW ENGL J MED, V355, P581, DOI 10.1056/NEJMoa055137
   Hedrich CM, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108420
   Konig MF, 2020, ANN RHEUM DIS, V79, P1386, DOI 10.1136/annrheumdis-2020-217690
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Minotti C, 2020, J INFECTION, V81, pE61, DOI 10.1016/j.jinf.2020.04.026
   Nationale Plattform fur geographische Daten (NPGEO), 2020, CORONA
   Ortiz-Alvarez O, 2004, J RHEUMATOL, V31, P2501
   Paediatric Rheumatology European Society, 2020, UPD PRES REC COR OUT
   Pain CE, 2020, LANCET RHEUMATOL, V2, pE376, DOI 10.1016/S2665-9913(20)30137-5
   Roche Group Media Relations, 2020, ROCH IN PHAS 3 CLIN
   Speth F, 2013, Z RHEUMATOL, V72, P896, DOI 10.1007/s00393-013-1203-0
   Speth F, 2013, Z RHEUMATOL, V72, P814, DOI 10.1007/s00393-013-1200-3
   Streng A, 2020, MONATSSCHR KINDERH, V168, P615, DOI 10.1007/s00112-020-00919-7
   Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369
NR 31
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-1855
EI 1435-1250
J9 Z RHEUMATOL
JI Z. Rheumatol.
DI 10.1007/s00393-020-00854-8
EA AUG 2020
PG 8
WC Rheumatology
SC Rheumatology
GA NC1DP
UT WOS:000560954200001
PM 32809050
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pandey, AK
   Verma, S
AF Pandey, Anand Kumar
   Verma, Shalja
TI An in-silico evaluation of dietary components for structural inhibition
   of SARS-Cov-2 main protease
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Covid-19; SARS-CoV-2 main protease; natural antioxidants; molecular
   docking; pharmacophore modeling
ID AUTOMATED DOCKING; PROTEINS
AB The main protease (M-pro) of SARS-CoV-2 is responsible for the cleavage of viral replicase polyproteins 1a and 1ab into their mature form and is highly specific and exclusive in its activity. Many studies have targeted this enzyme by small molecule inhibitors to develop therapeutics against the highly infectious disease Covid-19. Our diet contains many natural antioxidants which along with providing support for proper growth and functioning of the body, pose additional health benefits. Present in-silico analysis depicted that natural antioxidants like sesamin, ellagic acid, capsaisin, and epicatechin along with galangin, exhibited significant binding at the catalytic site of the M(pro)enzyme. They interacted with excellent efficiency with the chief active site residue Cys145 and thus seem to possess the remarkable potential to act as drug candidates for the treatment of Covid-19. Such dietary compounds can be easily administered orally with least toxicity related concern and thus yell for urgent exhaustive research to develop into efficient therapies. Communicated by Ramaswamy H. Sarma
C1 [Pandey, Anand Kumar; Verma, Shalja] Bundelkhand Univ, Inst Engn & Technol, Dept Biotechnol Engn, Jhansi 284128, Uttar Pradesh, India.
   [Verma, Shalja] Indian Inst Technol, Dept Biochem Engn & Biotechnol, New Delhi, India.
RP Pandey, AK (corresponding author), Bundelkhand Univ, Inst Engn & Technol, Dept Biotechnol Engn, Jhansi 284128, Uttar Pradesh, India.
EM pandayanandkumar@gmail.com
CR da Costa KS, 2019, ACS OMEGA, V4, P22475, DOI 10.1021/acsomega.9b03157
   do Nascimento LD, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10070988
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334
   Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498
   Pandurangan AP, 2017, NUCLEIC ACIDS RES, V45, pW229, DOI 10.1093/nar/gkx439
   Pathak Niti, 2014, Pharmacogn Rev, V8, P147, DOI 10.4103/0973-7847.134249
   Pinto VD, 2019, PHARMACEUTICALS-BASE, V12, DOI 10.3390/ph12010036
   Ramos RS, 2020, J BIOMOL STRUCT DYN, V38, P4687, DOI 10.1080/07391102.2019.1688192
   Rosa A, 2002, J AGR FOOD CHEM, V50, P7396, DOI 10.1021/jf020431w
   Schneidman-Duhovny D, 2008, J COMPUT BIOL, V15, P737, DOI 10.1089/cmb.2007.0130
   Schneidman-Duhovny D, 2008, NUCLEIC ACIDS RES, V36, pW223, DOI 10.1093/nar/gkn187
   Tsao R, 2010, NUTRIENTS, V2, P1231, DOI 10.3390/nu2121231
   Vale VV, 2020, MED CHEM RES, V29, P487, DOI 10.1007/s00044-019-02498-z
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 21
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1809522
EA AUG 2020
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NB4IS
UT WOS:000560478500001
PM 32811367
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Janardhan, V
   Janardhan, V
   Kalousek, V
AF Janardhan, Vallabh
   Janardhan, Vikram
   Kalousek, Vladimir
TI COVID-19 as a Blood Clotting Disorder Masquerading as a Respiratory
   Illness: A Cerebrovascular Perspective and Therapeutic Implications for
   Stroke Thrombectomy
SO JOURNAL OF NEUROIMAGING
LA English
DT Article
DE Antiphospholipid antibodies; blood clots; COVID-19; stroke; thrombectomy
ID ISCHEMIC-STROKE; CORONAVIRUS; RECEPTOR; ACE2
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the name suggests was initially thought to only cause a respiratory illness. However, several reports have been published of patients with ischemic strokes in the setting of coronavirus disease 2019 (COVID-19). The mechanisms of how SARS-CoV-2 results in blood clots and large vessel strokes need to be defined as it has therapeutic implications. SARS-CoV-2 enters the blood stream by breaching the blood-air barrier via the lung capillary adjacent to the alveolus, and then attaches to the angiotensin-converting enzyme II receptors on the endothelial cells. Once SARS-CoV-2 enters the blood stream, a cascade of events (Steps 1-8) unfolds including accumulation of angiotensin II, reactive oxygen species, endothelial dysfunction, oxidation of beta 2 glycoprotein 1, formation of antiphospholipid antibody complexes promoting platelet aggregation, coagulation cascade, and formation of cross-linked fibrin blood clots, leading to pulmonary emboli (PE) and large vessel strokes seen on angiographic imaging studies. There is emerging evidence for COVID-19 being a blood clotting disorder and SARS-CoV-2 using the respiratory route to enter the blood stream. As the blood-air barrier is breached, varying degrees of collateral damage occur. Although antiviral and immune therapies are studied, the role of blood thinners in the prevention, and management of blood clots in Covid-19 need evaluation. In addition to ventilators and blood thinners, continuous aspiration and clot retrieval devices (approved in Europe, cleared in the United States) or cyclical aspiration devices (approved in Europe) need to be considered for the emergent management of life-threatening clots including PE and large vessel strokes.
C1 [Janardhan, Vallabh] Med Ctr Plano, Stroke & Intervent Neurol, Plano, TX USA.
   [Janardhan, Vallabh; Janardhan, Vikram] Insera Therapeut Inc, Dallas, TX USA.
   [Kalousek, Vladimir] Clin Hosp Ctr Sestre Milosrdnice, Dept Radiol, Zagreb, Croatia.
RP Janardhan, V (corresponding author), Med Ctr Plano, Stroke & Intervent Neurol, 3901 W 15th St, Dallas, TX 75075 USA.
EM drvallabh@yahoo.com
RI Janardhan, Vallabh/ABG-3655-2020
OI Janardhan, Vallabh/0000-0003-3137-9626
FU National Science Foundation (NSF)National Science Foundation (NSF)
   [1819491]
FX Dr Vallabh Janardhan reports grants from National Science Foundation,
   other from Insera Therapeutics, Inc, and other from Society of Vascular
   & Interventional Neurology (SVIN), outside the submitted work. In
   addition, Dr Janardhan has patents with the United States Patent and
   Trademark Office (USPTO), over 20+ patents pending, and 65+ USPTO and
   worldwide patents issued. Dr Vikram Janardhan reports grants from
   National Science Foundation and other from Insera Therapeutics, Inc,
   outside the submitted work. In addition, Dr Janardhan has over 20+
   patents pending and 65+ USPTO and worldwide patents issued. Dr Vladimir
   Kalousek reports consultancy from Balt and other from
   MicroventionTerumo, outside the submitted work. The preclinical testing
   was funded in part by the National Science Foundation (NSF Award:
   1819491, Principal Investigator: Vallabh Janardhan).
CR Arai D, 2016, J NEUROINTERV SURG, V8, P992, DOI 10.1136/neurintsurg-2015-011968
   Arslanian RA, 2019, J NEUROINTERV SURG, V11, P931, DOI 10.1136/neurintsurg-2018-014625
   Avula A, 2020, BRAIN BEHAV IMMUN, V87, P115, DOI 10.1016/j.bbi.2020.04.077
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Bellosta Raffaello, 2020, J Vasc Surg, V72, P1864, DOI 10.1016/j.jvs.2020.04.483
   Beyrouti R, 2020, J NEUROL NEUROSUR PS, V91, P889, DOI 10.1136/jnnp-2020-323586
   Bowles L, 2020, NEW ENGL J MED, V383, P288, DOI 10.1056/NEJMc2013656
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P465, DOI 10.15585/mmwr.mm6915e4
   El-Assaad F, 2016, THROMB J, V14, DOI 10.1186/s12959-016-0115-z
   Escalard S, 2020, STROKE, V51, P2540, DOI 10.1161/STROKEAHA.120.030574
   Fara MG, 2020, J THROMB HAEMOST, V18, P2031, DOI 10.1111/jth.14938
   Garrido AM, 2009, MOL CELL ENDOCRINOL, V302, P148, DOI 10.1016/j.mce.2008.11.003
   Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Hess DC, 2020, TRANSL STROKE RES, V11, P322, DOI 10.1007/s12975-020-00818-9
   Ho YC, 2016, ANTIBODIES, V5, DOI 10.3390/antib5020012
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jackson SP, 2019, BLOOD, V133, P906, DOI 10.1182/blood-2018-11-882993
   Janardhan V, 2004, STROKE, V35, P736, DOI 10.1161/01.STR.0000117575.48205.2D
   Janardhan V, 2014, STROKE S1, V45, pAWMP8
   Ciampi-Dopazo JJ, 2018, J VASC INTERV RADIOL, V29, P101, DOI 10.1016/j.jvir.2017.08.010
   Kadirvel R, 2019, 12 ANN M SOC VASC IN
   Kansagra AP, 2020, NEW ENGL J MED, V383, P400, DOI 10.1056/NEJMc2014816
   Katz JM, 2020, INTERV NEUROL, V8, P206, DOI 10.1159/000501080
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Marijon E, 2020, LANCET PUBLIC HEALTH, V5, pE437, DOI 10.1016/S2468-2667(20)30117-1
   Mehrpour M, 2020, INT J STROKE, DOI 10.1177/1747493020937397
   Merkler AE, 2020, JAMA NEUROL, DOI [10.1101/2020.05.18.20105494, DOI 10.1101/2020.05.18.20105494]
   Mohamud A Y, 2020, AJNR Am J Neuroradiol, V41, P1677, DOI 10.3174/ajnr.A6674
   Morassi M, 2020, J NEUROL, V267, P2185, DOI 10.1007/s00415-020-09885-2
   Nguyen TN, 2020, STROKE, V51, P1896, DOI 10.1161/STROKEAHA.120.030100
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Pandey AS, 2020, NEUROSURGERY, V87, pE397, DOI 10.1093/neuros/nyaa252
   Peschillo S, 2017, J NEUROINTERV SURG, V9, P743, DOI 10.1136/neurintsurg-2016-012533
   Phipps MS, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6983
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sahu KK, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-2793
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shams T, 2016, INTERV NEUROL, V5, P1, DOI 10.1159/000443617
   South K, 2020, INT J STROKE, V15, P722, DOI 10.1177/1747493020943815
   Stefanini GG, 2020, CIRCULATION, V141, P2113, DOI 10.1161/CIRCULATIONAHA.120.047525
   Sweid A, 2020, WORLD NEUROSURG, V140, P491, DOI 10.1016/j.wneu.2020.06.053
   Sweid A, 2020, INT J STROKE, V15, P733, DOI 10.1177/1747493020937189
   Sweid A, 2020, NEUROSURGERY, V87, pE400, DOI 10.1093/neuros/nyaa254
   Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0
   Townsley MI, 2012, COMPR PHYSIOL, V2, P675, DOI 10.1002/cphy.c100081
   Umapathi T, 2004, J NEUROL, V251, P1227, DOI 10.1007/s00415-004-0519-8
   Valderrama EV, 2020, STROKE, V51, pE124, DOI 10.1161/STROKEAHA.120.030153
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wang AR, 2020, J NEUROINTERV SURG, V12, P648, DOI [10.1136/neurintsurg-2020-016220, 10.1136/neurintsurg-2019-015702]
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yaeger KA, 2020, AM J NEURORADIOL, V41, P1357, DOI 10.3174/ajnr.A6652
   Yaghi S, 2020, STROKE, V51, P2002, DOI 10.1161/STROKEAHA.120.030335
   Zaidat OO, 2018, STROKE, V49, P660, DOI 10.1161/STROKEAHA.117.020315
   Zayet S, 2020, EMERG INFECT DIS, V26, P2258, DOI 10.3201/eid2609.201791
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 61
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1051-2284
EI 1552-6569
J9 J NEUROIMAGING
JI J. Neuroimaging
PD SEP
PY 2020
VL 30
IS 5
BP 555
EP 561
DI 10.1111/jon.12770
EA AUG 2020
PG 7
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA NU0EO
UT WOS:000560320700001
PM 32776617
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Leung, MST
   Lin, SG
   Chow, J
   Harky, A
AF Leung, Marco Shiu Tsun
   Lin, Shangzhe George
   Chow, Jason
   Harky, Amer
TI COVID-19 and Oncology: Service transformation during pandemic
SO CANCER MEDICINE
LA English
DT Article
DE chemotherapy; COVID-19; oncology service; SARS-CoV-2; systemic
   anticancer therapy; telemedicine
ID EVOLUTION
AB Background The COVID-19 pandemic has challenged healthcare systems around the world, where resources have refocused on increasing critical bed capacity to prepare for the peak in incidence of COVID-19. Oncology faces an unprecedented challenge as patients require multidisciplinary care and are more likely to be immunosuppressed. Services in oncology have been transformed using minimal resources over a short period of time. This transformation continues and telemedicine is playing a key role. Aims We explore how services in oncology have transformed to deliver services including consultations, systemic anticancer therapy, and surgery for patients, while shielding them from contracting COVID-19. We assess the risks and benefits of the service transformation in the immediate, interim, and long term, and how telemedicine supports the process. Methods We performed a comprehensive review of the literature using suitable keywords on the search engines of PubMed, SCOPUS, Google Scholar, and latest official data from May to June 2020. Results Through the published literature on this topic, we discuss the transformations in oncology and the impact on patients and healthcare workers due to the COVID-19 pandemic. We reflect on the lessions from COVID-19 and assess the role of telemedicine in the future of oncology services. Conclusion Transformation of services in oncology effectively shields patients from COVID-19 infections, and telemedicine plays a role in virtual consultations. The long-term effects are yet to be seen, such as safety of home-based treatment, and effectiveness of virtual communication on patient care. As oncology requires a multidisciplinary approach, telemedicine will play a key role to improve patient-centered cancer care in the future.
C1 [Leung, Marco Shiu Tsun; Lin, Shangzhe George; Chow, Jason] St Georges Univ Hosp NHS Fdn Trust, Dept Med Oncol, London, England.
   [Leung, Marco Shiu Tsun; Lin, Shangzhe George] St George Hosp, Fac Med, Med Sch, London, England.
   [Harky, Amer] Liverpool Heart & Chest Hosp, Dept Cardiothorac Surg, Thomas Dr, Liverpool L14 3PE, Merseyside, England.
   [Harky, Amer] Univ Liverpool, Fac Life Sci, Dept Integrat Biol, Liverpool, Merseyside, England.
RP Harky, A (corresponding author), Liverpool Heart & Chest Hosp, Dept Cardiothorac Surg, Thomas Dr, Liverpool L14 3PE, Merseyside, England.
EM aaharky@gmail.com
CR Adam S, 2020, ACTA CARDIOL, DOI 10.1080/00015385.2020.1787636
   Akhlaghi HAH, 2002, CLIN RES, V3
   [Anonymous], 2020, COVID19 GOV ANNOUNC
   [Anonymous], 2020, NG161 COVID19 RAP GU
   [Anonymous], 2020, CLIN GUD MAN NONC PA
   [Anonymous], 2020, COMMUNICATION
   [Anonymous], 2020, STAY ALERT SAFE SOC
   [Anonymous], 2020, COR COVID19 LIST NOT
   [Anonymous], 2020, GUID HEALTHC PROV HE
   [Anonymous], 2020, NG161 COVID19 RAP GU
   [Anonymous], 2020, COR COVID19 UK
   [Anonymous], 2020, DEPL CLIN NON CLIN O
   [Anonymous], 2020, NG161 COVID19 RAP GU
   ASCO, 2020, ASCO SPEC REP GUID C
   BBC, 2020, BBC
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa008
   Boseley S., 2020, GUARDIAN
   Bow EJ, 1998, J ANTIMICROB CHEMOTH, V41, P1, DOI 10.1093/jac/41.suppl_4.1
   Cally Palmer PJ, 2020, ADVICE MAINTAINING C
   Cheung KS, 2020, GASTROENTEROLOGY
   Colpan AM, 2020, ROUT INT STUD BUS HI, P3
   Du Toit A, 2020, NAT REV MICROBIOL, V18, P3, DOI 10.1038/s41579-019-0305-3
   Greenberg N, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1211
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harky A, 2020, J CARDIAC SURG, V35, P2364, DOI 10.1111/jocs.14783
   Harky A, 2020, CANCER CELL, V37, P749, DOI 10.1016/j.ccell.2020.05.006
   Health Do, 2020, INTER TREATM CHANG O, P1
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IACOBUCCI G, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1318
   Lechien JR, 2020, ANN INTERN MED
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Litz BT, 2009, CLIN PSYCHOL REV, V29, P695, DOI 10.1016/j.cpr.2009.07.003
   Meechan D, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X654551
   Shafi AMA, 2020, J CARDIAC SURG, V35, P1295, DOI 10.1111/jocs.14631
   NCCN Best Practices Committee Infusion Efficiency Workgroup, 2020, NCCN BEST PRACT COMM
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   SAYBURN A, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1297
   Shirke MM, 2020, TRENDS CANCER, V6, P547, DOI 10.1016/j.trecan.2020.05.013
   Simon Stevens AP, 2020, URGENT NEXT STEPS NH
   Spinato G, 2020, JAMA-J AM MED ASSOC, V323, P2089, DOI 10.1001/jama.2020.6771
   Sun JM, 2020, TRENDS MOL MED, V26, P483, DOI 10.1016/j.molmed.2020.02.008
   Treon SP, 2020, BLOOD, V135, P1912, DOI 10.1182/blood.2020006288
   UK Government, 2020, OUR PLAN REB UK GOV
   Usher K, 2020, J CLIN NURS, V29, P2756, DOI 10.1111/jocn.15290
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Watters C, 1997, Prof Nurse, V12, P367
   WHO, 2003, SUMM PROB SARS CAS O
   WHO, 2020, DIR GEN OPEN REM MED
   WHO, 2020, 136 WHO COR DIS COVI
   WHO, 2020, 52 WHO COR DIS 2019
   Cuan-Baltazar JY, 2020, JMIR PUBLIC HLTH SUR, V6, P176, DOI 10.2196/18444
NR 53
TC 4
Z9 4
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD OCT
PY 2020
VL 9
IS 19
BP 7161
EP 7171
DI 10.1002/cam4.3384
EA AUG 2020
PG 11
WC Oncology
SC Oncology
GA NX4DS
UT WOS:000560183900001
PM 32810386
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Narayanan, N
   Nair, DT
AF Narayanan, Naveen
   Nair, Deepak T.
TI VitaminB12may inhibitRNA-dependent-RNApolymerase activity of nsp12 from
   theSARS-CoV-2 virus
SO IUBMB LIFE
LA English
DT Article
DE inhibitor; nsp12; RNA-dependent-RNA polymerase; SARS-CoV-2; vitamin B12
ID STRUCTURAL BASIS; CEFOPERAZONE
AB SARS-CoV-2 is the causative agent for the ongoing COVID19 pandemic, and this virus belongs to the Coronaviridae family. Like other members of this family, the virus possesses a positive-sense single-stranded RNA genome. The genome encodes for the nsp12 protein, which houses the RNA-dependent-RNA polymerase (RdRP) activity responsible for the replication of the viral genome. A homology model of nsp12 was prepared using the structure of the SARS nsp12 (6NUR) as a model. The model was used to carry out in silico screening to identify molecules among natural products, or Food and Drug Administration-approved drugs that can potentially inhibit the activity of nsp12. This exercise showed that vitamin B12 (methylcobalamin) may bind to the active site of the nsp12 protein. A model of the nsp12 in complex with substrate RNA and incoming NTP showed that vitamin B12 binding site overlaps with that of the incoming nucleotide. A comparison of the calculated energies of binding for RNA plus NTP and methylcobalamin suggested that the vitamin may bind to the active site of nsp12 with significant affinity. It is, therefore, possible that methylcobalamin binding may prevent association with RNA and NTP and thus inhibit the RdRP activity of nsp12. Overall, our computational studies suggest that methylcobalamin form of vitamin B12 may serve as an effective inhibitor of the nsp12 protein.
C1 [Narayanan, Naveen; Nair, Deepak T.] NCR Biotech Sci Cluster, Lab Genom Integr & Evolut, Reg Ctr Biotechnol, 3rd Milestone,Faridabad Gurgaon Expressway, Faridabad, India.
   [Narayanan, Naveen] Manipal Acad Higher Educ, Manipal, India.
RP Nair, DT (corresponding author), Reg Ctr Biotechnol, Lab Genom Integr & Evolut, 5 NCR Biotech Sci Cluster,3rd Milestone, Faridabad 121001, Haryana, India.
EM deepak@rcb.res.in
OI Nair, Deepak/0000-0002-0677-9444
FU Regional Centre for BiotechnologyDepartment of Biotechnology (DBT) India
FX Regional Centre for Biotechnology, Grant/Award Number: Intramural Grant
CR Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   CARLBERG H, 1982, J ANTIMICROB CHEMOTH, V10, P483, DOI 10.1093/jac/10.6.483
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Graham RL, 2008, VIRUS RES, V133, P88, DOI 10.1016/j.virusres.2007.02.017
   Halgren T, 2007, CHEM BIOL DRUG DES, V69, P146, DOI 10.1111/j.1747-0285.2007.00483.x
   Holm L, 2016, NUCLEIC ACIDS RES, V44, pW351, DOI 10.1093/nar/gkw357
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kottur J, 2018, NUCLEIC ACIDS RES, V46, P5875, DOI 10.1093/nar/gky402
   Koutmos M, 2011, J BIOL CHEM, V286, P29780, DOI 10.1074/jbc.M111.261370
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Modrow S., 2013, MOL VIROLOGY, P185, DOI DOI 10.1007/978-3-642-20718-1_14
   NORRBY SR, 1987, DRUGS, V34, P105, DOI 10.2165/00003495-198700342-00009
   Ozen IO, 2008, ACTA CHIR BELG, V108, P777, DOI 10.1080/00015458.2008.11680339
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Selleckchem.com, INH EXP INH COMP LIB
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Strom BL, 1999, PHARMACOEPIDEM DR S, V8, P81, DOI 10.1002/(SICI)1099-1557(199903/04)8:2<81::AID-PDS411>3.0.CO;2-G
   Takeshita D, 2012, NAT STRUCT MOL BIOL, V19, P229, DOI 10.1038/nsmb.2204
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
NR 24
TC 0
Z9 0
U1 8
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1521-6543
EI 1521-6551
J9 IUBMB LIFE
JI IUBMB Life
PD OCT
PY 2020
VL 72
IS 10
BP 2112
EP 2120
DI 10.1002/iub.2359
EA AUG 2020
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NR1UM
UT WOS:000560352600001
PM 32812340
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bhatti, JS
   Bhatti, GK
   Khullar, N
   Reddy, AP
   Reddy, PH
AF Bhatti, Jasvinder Singh
   Bhatti, Gurjit Kaur
   Khullar, Naina
   Reddy, Arubala P.
   Reddy, P. Hemachandra
TI Therapeutic Strategies in the Development of Anti-viral Drugs and
   Vaccines Against SARS-CoV-2 Infection
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Novel coronavirus disease; COVID-19; SARS-CoV-2; Anti-viral drugs;
   Vaccine; Clinical trials
ID FUNCTIONAL RECEPTOR; VIRAL-INFECTIONS; CORONAVIRUS; CHLOROQUINE;
   MICRORNAS; BIOMARKERS; REMDESIVIR; PNEUMONIA; DISEASE; KIR2DL5
AB The whole world is currently facing a pandemic of an infectious disease known as novel coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) . This outbreak emerged unexpectedly and imposed a potential threat to humans, associated with the social and economic burden on the individual and federal governments. COVID-19, which initially started in Wuhan City of China and then spread to the whole world, has been declared a Public Health Emergency of International Concern. The continuous increase in the number of confirmed cases leads to high mortality across the world. Growing evidence indicates that the mortality rate is very predominant in elderly people and those with preexisting health conditions. However, the potential pathogenesis of SARS-CoV-2 infection in humans is still unknown. The dysregulated/exuberant immune response may have substantially contributed to the SARS-CoV-2-mediated pathology. Nevertheless, there is no clinically approved drug/vaccine currently available that can restrict its pathogenesis. However, several drugs are currently shown to provide some therapeutic benefits for COVID-19 patients, including antiviral drugs that might have a significant role in restricting the current pandemic of COVID-19. In this article, we highlighted the pharmacological treatment strategies for COVID-19 and purposed the therapeutic targets for the development of vaccines or anti-viral drug molecules against SARS-CoV-2 infection in humans.
C1 [Bhatti, Jasvinder Singh] Cent Univ Punjab, Sch Hlth Sci, Dept Human Genet & Mol Med, Bathinda, India.
   [Bhatti, Gurjit Kaur] Chandigarh Univ, Univ Inst Appl Hlth Sci, Dept Med Lab Technol, Mohali, Punjab, India.
   [Khullar, Naina] Mata Gujri Coll, Dept Zool, Fatehgarh Sahib, Punjab, India.
   [Reddy, Arubala P.] Texas Tech Univ, Nutr Sci Dept, Lubbock, TX 79409 USA.
   [Reddy, P. Hemachandra] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Lubbock, TX 79430 USA.
   [Reddy, P. Hemachandra] Texas Tech Univ, Hlth Sci Ctr, Neurosci & Pharmacol, Lubbock, TX 79430 USA.
   [Reddy, P. Hemachandra] Texas Tech Univ, Sch Med, Neurol Dept, Hlth Sci Ctr, Lubbock, TX 79430 USA.
   [Reddy, P. Hemachandra] Texas Tech Univ, Grad Sch Biomed Sci, Publ Hlth Dept, Hlth Sci Ctr, Lubbock, TX 79430 USA.
   [Reddy, P. Hemachandra] Texas Tech Univ, Sch Hlth Profess, Dept Speech Language & Hearing Sci, Hlth Sci Ctr, 3601 4th St, Lubbock, TX 79430 USA.
RP Reddy, PH (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Lubbock, TX 79430 USA.; Reddy, PH (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Neurosci & Pharmacol, Lubbock, TX 79430 USA.; Reddy, PH (corresponding author), Texas Tech Univ, Sch Med, Neurol Dept, Hlth Sci Ctr, Lubbock, TX 79430 USA.; Reddy, PH (corresponding author), Texas Tech Univ, Sch Hlth Profess, Dept Speech Language & Hearing Sci, Hlth Sci Ctr, 3601 4th St, Lubbock, TX 79430 USA.
EM jasvinder.bhatti@cup.edu.in; bhattigk@yahoo.com; naina306@gmail.com;
   arubala.reddy@ttuhsc.edu; hemachandra.reddy@ttuhsc.edu
OI Reddy, P. Hemachandra/0000-0002-9560-9948; Reis,
   AlessanRSS/0000-0001-8486-7469
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [AG042178,
   AG047812, NS105473, AG060767, AG069333]; Alzheimer's Association New
   Investigator Research Grant [2016-NIRG-39787]; Center of Excellence for
   Translational Neuroscience and Therapeutics [PN-CTNT20115-AR];
   Alzheimer's Association through a SAGA grant; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [AG063162]; Central University of Punjab, Bathinda, India
FX The research presented in this article was supported by the National
   Institutes of Health (NIH) grants AG042178, AG047812, NS105473,
   AG060767, and AG069333 (to PHR). This research was also supported by the
   Alzheimer's Association New Investigator Research Grant 2016-NIRG-39787,
   the Center of Excellence for Translational Neuroscience and Therapeutics
   (PN-CTNT20115-AR), Alzheimer's Association through a SAGA grant, and NIH
   grant AG063162 (to AR). We acknowledge support from the Central
   University of Punjab, Bathinda, India. We thank all the doctors, nurses,
   health workers, and research scientists who are working day and night to
   fight against the COVID-19 pandemic. The figures were assembled using
   dynamic BioRender assets.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Aguiar ACC, 2018, INT J PARASITOL-DRUG, V8, P459, DOI 10.1016/j.ijpddr.2018.10.002
   [Anonymous], INT J ANTIMICROB AG, DOI [10.1016/j.ijantimicag.2020.105982, DOI 10.1016/J.IJANTIMICAG.2020.105982]
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao Qinghua, 2019, FASEB Bioadv, V1, P375, DOI 10.1096/fba.2018-00064
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen JL, 2020, MICROBES INFECT, V22, P69, DOI 10.1016/j.micinf.2020.01.004
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Cunningham L, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102563
   da Silva JC, 2013, CLINICS, V68, P766, DOI 10.6061/clinics/2013(06)07
   Dawson Patrick, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa799
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dickinson BA, 2013, EUR J HEART FAIL, V15, P650, DOI 10.1093/eurjhf/hft018
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du Z, 2008, GENES IMMUN, V9, P470, DOI 10.1038/gene.2008.39
   Estefania E, 2007, J IMMUNOL, V178, P4402, DOI 10.4049/jimmunol.178.7.4402
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Gautier JF, 2020, OBESITY, V28, P848, DOI 10.1002/oby.22809
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gladman DD, 1998, J RHEUMATOL, V25, P983
   Golden EB, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.12.FOCUS14748
   Gosain R, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-00934-7
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Guastalegname M, 2020, CLIN INFECT DIS, V71, P888, DOI 10.1093/cid/ciaa321
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hull MW, 2011, ANN MED, V43, P375, DOI 10.3109/07853890.2011.572905
   Jackson Richard J, 2007, Sci STKE, V2007, pre1, DOI 10.1126/stke.3672007re1
   Kato M, 2015, ANN NY ACAD SCI, V1353, P72, DOI 10.1111/nyas.12758
   Kato M, 2014, NAT REV NEPHROL, V10, P517, DOI 10.1038/nrneph.2014.116
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lan J, 2020, CRYSTAL STRUCTURE 20
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Lim J, 2020, J KOREAN MED SCI, V35, P6, DOI DOI 10.3346/JKMS.2020.35.E797025910
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lopalco L, 2010, VIRUSES-BASEL, V2, P574, DOI 10.3390/v2020574
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Montgomery RL, 2011, CIRCULATION, V124, P1537, DOI 10.1161/CIRCULATIONAHA.111.030932
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   National Institutes of Health, 2020, COR COVID 19
   Passarelli PC, 2020, AM J DENT, V33, P135
   Pinti MV, 2017, AM J PHYSIOL-HEART C, V312, pH33, DOI 10.1152/ajpheart.00341.2016
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Shaikh S, 2020, INDIANS NOT HAVE GEN
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Song R, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121475
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Taylor Jason K, 2011, J Miss State Med Assoc, V52, P39
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   World Health Organization, 2020, COR DIS 2019 COVID 1, P194
   World Health Organization, 2004, WHO GUID GLOB SURV S
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yazdany J, 2020, ANN INTERN MED, V172, P754, DOI 10.7326/M20-1334
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zavascki AP, 2020, NEW ENGL J MED, V382, P1859, DOI 10.1056/NEJMc2005203
   Zhang Y, 2017, ENDOCR REV, V38, P145, DOI 10.1210/er.2016-1122
   Zhu L, 2020, CELL METAB, V31, P1077
NR 80
TC 4
Z9 4
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD NOV
PY 2020
VL 57
IS 11
BP 4856
EP 4877
DI 10.1007/s12035-020-02074-2
EA AUG 2020
PG 22
WC Neurosciences
SC Neurosciences & Neurology
GA NS9CD
UT WOS:000560278800001
PM 32808122
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Uzuncakmak, TK
   Bayazit, S
   Askin, O
   Engin, B
   Kutlubay, Z
AF Uzuncakmak, Tugba Kevser
   Bayazit, Samet
   Askin, Ozge
   Engin, Burhan
   Kutlubay, Zekayi
TI Inpatient dermatology consultations during COVID 19 pandemic in a
   tertiary referral center
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE consultation; coronavirus; COVID-19; dermatology; drug eruption;
   hospitalized patient; pandemic; urticaria
ID HOSPITALIZED-PATIENTS; CARE
AB Since the COVID-19 infection first appeared in December 2019, patient profile of outpatient and inpatient clinics has changed. Various cutaneous findings associated with COVID-19 have been reported in the literature. The main objective of this study was to describe and analyze the profile of the consultations requested from dermatology department during the COVID pandemic. Retrospective, cohort study. In this study, we observed the dermatology consultations of the hospitalized patients over a period of 2 months, corresponding to the peak of COVID outbreak in a tertiary care hospital in Turkey. We reviewed the inpatient dermatology consult database retrospectively. Both pediatric and adult dermatology inpatient consultations were evaluated. A total of 166 inpatient dermatology consultations were requested from dermatology department during March-May, 2020. The mean age of the patients was 53.12 (1-89) years. Almost 32.5% (n = 54) of dermatology consultations were requested from the COVID wards and the COVID intensive care unit. The second most common consultations were requested from internal medicine departments (n = 46, 27.7%). The most common indications for the consultations were cutaneous infections (36%), followed by inflammatory disorders (32%), and urticaria (11%). Dermatology consultations have an essential role on the management of hospitalized patients, especially at that pandemic time. Careful dermatological examination improves diagnostic accuracy in skin disorders and skin manifestations of COVID-19 infection that provides an early diagnosis and treatment, helps to improve the quality of the patient care and management.
C1 [Uzuncakmak, Tugba Kevser; Bayazit, Samet; Askin, Ozge; Engin, Burhan; Kutlubay, Zekayi] Istanbul Univ, Cerrahpasa Med Fac, Dept Dermatol, Istanbul, Turkey.
RP Uzuncakmak, TK (corresponding author), Istanbul Univ, Cerrahpasa Med Fac, Dept Dermatol, Istanbul, Turkey.
EM drtugbakevser@gmail.com
RI askin, ozge/ABA-1933-2020
OI Altunkalem, Rozerin Neval/0000-0002-9216-6686
CR Fayne R, 2020, J EUR ACAD DERMATOL, V34, P2120, DOI 10.1111/jdv.16565
   Galimberti F, 2016, INT J DERMATOL, V55, pE547, DOI 10.1111/ijd.13327
   Casas CG, 2020, BRIT J DERMATOL, V183, P71, DOI 10.1111/bjd.19163
   Milani-Nejad N, 2017, JAMA DERMATOL, V153, P523, DOI 10.1001/jamadermatol.2016.6130
   Rubegni P, 2015, J EUR ACAD DERMATOL, V29, P164, DOI 10.1111/jdv.12513
   Temiz SA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13642
   Wollina U, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13549
NR 7
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e13883
DI 10.1111/dth.13883
EA AUG 2020
PG 5
WC Dermatology
SC Dermatology
GA NB1AM
UT WOS:000560246700001
PM 32578309
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Susek, KH
   Gran, C
   Ljunggren, HG
   Alici, E
   Nahi, H
AF Susek, Katharina Helene
   Gran, Charlotte
   Ljunggren, Hans-Gustaf
   Alici, Evren
   Nahi, Hareth
TI Outcome of COVID-19 in multiple myeloma patients in relation to
   treatment
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE infectious diseases; immunology; multiple myeloma; plasma cell neoplasms
AB COVID-19 has emerged as a global pandemic. Cancer patients have been reported to be at higher risk for adverse outcome of COVID-19. Studies are ongoing to decipher the risk factors and risk groups among cancer patients as well as strategies to refine treatment approaches. Here, we report eight patients with multiple myeloma that underwent immunomodulatory therapies with daratumumab or lenalidomide-based combination treatments and one patient with smoldering multiple myeloma, all of which presented with symptomatic COVID-19. We report that patients that succumbed to COVID-19 presented with either progressive tumor disease under daratumumab treatment or were in remission under lenalidomide-dexamethasone treatment.
C1 [Susek, Katharina Helene; Gran, Charlotte; Alici, Evren; Nahi, Hareth] Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med, Alfred Nobels Allee 8, S-14186 Stockholm, Sweden.
   [Gran, Charlotte] Karolinska Univ Lab, Dept Clin Chem, Stockholm, Sweden.
   [Ljunggren, Hans-Gustaf] Karolinska Inst, Ctr Infect Med, Dept Med, Stockholm, Sweden.
   [Alici, Evren; Nahi, Hareth] Karolinska Univ Hosp, Hematol Ctr, Stockholm, Sweden.
RP Susek, KH (corresponding author), Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med, Alfred Nobels Allee 8, S-14186 Stockholm, Sweden.
EM katharina.susek@ki.se
RI Gran, Charlotte/AAI-3242-2020
OI Gran, Charlotte/0000-0002-6069-6615; nahi, hareth/0000-0003-4711-5094
FU CancerfondenSwedish Cancer Society [190190 Pj01]; VINNOVAVinnova
   [2019-00056]
FX Cancerfonden, Grant/Award Number: 190190 Pj01; VINNOVA, Grant/Award
   Number: 2019-00056
CR Blimark C, 2015, HAEMATOLOGICA, V100, P107, DOI 10.3324/haematol.2014.107714
   Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010
   Cook G, 2020, BRIT J HAEMATOL, V190, pE83, DOI 10.1111/bjh.16874
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Heaney JLJ, 2018, LEUKEMIA, V32, P1727, DOI 10.1038/s41375-018-0163-4
   Hultcrantz M, 2020, COVID 19 INFECT OUTC
   Kastritis E, 2014, LEUKEMIA, V28, P2075, DOI 10.1038/leu.2014.110
   Kazandjian D, 2016, SEMIN ONCOL, V43, P676, DOI 10.1053/j.seminoncol.2016.11.004
   Nahi H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211927
   Sorrig R, 2019, EUR J HAEMATOL, V102, P182, DOI 10.1111/ejh.13190
   Terpos E, 2020, LEUKEMIA, V34, P2000, DOI 10.1038/s41375-020-0876-z
   Wang B, 2020, TERTIARY CTR EXPERIE
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
NR 14
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-4441
EI 1600-0609
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD DEC
PY 2020
VL 105
IS 6
BP 751
EP 754
DI 10.1111/ejh.13502
EA AUG 2020
PG 4
WC Hematology
SC Hematology
GA OJ1ZC
UT WOS:000560034900001
PM 32745304
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU NaveenKumar, SK
   Hemshekhar, M
   Jagadish, S
   Manikanta, K
   Vishalakshi, GJ
   Kemparaju, K
   Girish, KS
AF NaveenKumar, Somanathapura K.
   Hemshekhar, Mahadevappa
   Jagadish, Swamy
   Manikanta, Kurnegala
   Vishalakshi, Gopalapura J.
   Kemparaju, Kempaiah
   Girish, Kesturu S.
TI Melatonin restores neutrophil functions and prevents apoptosis amid
   dysfunctional glutathione redox system
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Article
DE 2-AAPA; BSO; glutathione; glutathione reductase; melatonin; NETosis;
   neutrophil apoptosis; neutrophil functions
ID INDUCED OXIDATIVE STRESS; NADPH OXIDASE ACTIVITY; IMMUNE-PINEAL AXIS;
   DOUBLE-EDGED-SWORD; EXTRACELLULAR TRAPS; EXOGENOUS MELATONIN;
   ANTIOXIDANT ENZYMES; INNATE IMMUNITY; HOST-DEFENSE; BACTERIAL
AB Melatonin is a chronobiotic hormone, which can regulate human diseases like cancer, atherosclerosis, respiratory disorders, and microbial infections by regulating redox system. Melatonin exhibits innate immunomodulation by communicating with immune system and influencing neutrophils to fight infections and inflammation. However, sustaining redox homeostasis and reactive oxygen species (ROS) generation in neutrophils are critical during chemotaxis, oxidative burst, phagocytosis, and neutrophil extracellular trap (NET) formation. Therefore, endogenous antioxidant glutathione (GSH) redox cycle is highly vital in regulating neutrophil functions. Reduced intracellular GSH levels and glutathione reductase (GR) activity in the neutrophils during clinical conditions like autoimmune disorders, neurological disorders, diabetes, and microbial infections lead to dysfunctional neutrophils. Therefore, we hypothesized that redox modulators like melatonin can protect neutrophil health and functions under GSH and GR activity-deficient conditions. We demonstrate the dual role of melatonin, wherein it protects neutrophils from oxidative stress-induced apoptosis by reducing ROS generation; in contrast, it restores neutrophil functions like phagocytosis, degranulation, and NETosis in GSH and GR activity-deficient neutrophils by regulating ROS levels both in vitro and in vivo. Melatonin mitigates LPS-induced neutrophil dysfunctions by rejuvenating GSH redox system, specifically GR activity by acting as a parallel redox system. Our results indicate that melatonin could be a potential auxiliary therapy to treat immune dysfunction and microbial infections, including virus, under chronic disease conditions by restoring neutrophil functions. Further, melatonin could be a promising immune system booster to fight unprecedented pandemics like the current COVID-19. However, further studies are indispensable to address the clinical usage of melatonin.
C1 [NaveenKumar, Somanathapura K.; Hemshekhar, Mahadevappa; Jagadish, Swamy; Manikanta, Kurnegala; Vishalakshi, Gopalapura J.; Kemparaju, Kempaiah; Girish, Kesturu S.] Univ Mysore, Dept Studies Biochem, Mysore 570006, Karnataka, India.
   [Girish, Kesturu S.] Tumkur Univ, Dept Studies & Res Biochem, Tumakuru 572103, India.
RP Kemparaju, K (corresponding author), Univ Mysore, Dept Studies Biochem, Mysore 570006, Karnataka, India.; Girish, KS (corresponding author), Tumkur Univ, Dept Studies & Res Biochem, Tumakuru 572103, India.
EM kemparajuom@gmail.com; ksgbaboo@gmail.com
OI KS, Girish/0000-0002-7284-3707
FU DST-SERBDepartment of Science & Technology (India)Science Engineering
   Research Board (SERB), India [EEQ/2016/000280, EEQ/2016/000193]
FX DST-SERB, Grant/Award Number: EEQ/2016/000280 and EEQ/2016/000193
CR Abid MR, 2007, J BIOL CHEM, V282, P35373, DOI 10.1074/jbc.M702175200
   Allen M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00508
   ALLEN RC, 1981, J INFECT DIS, V144, P344, DOI 10.1093/infdis/144.4.344
   Anderson G, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2109
   Anisimov VN, 2003, TOXICOL PATHOL, V31, P589, DOI 10.1080/01926230390257885
   Aquilano K, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00196
   Arendt J, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00391
   Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476
   Ballatori N, 2009, BIOL CHEM, V390, P191, DOI 10.1515/BC.2009.033
   Biancatelli RMLC, 2020, J THORAC DIS, V12, pS54, DOI 10.21037/jtd.2019.12.85
   Brazao V, 2015, J PINEAL RES, V59, P488, DOI 10.1111/jpi.12280
   Brechard S, 2013, ANTIOXID REDOX SIGN, V18, P661, DOI 10.1089/ars.2012.4773
   CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x
   Calvo JR, 2013, J PINEAL RES, V55, P103, DOI 10.1111/jpi.12075
   Carrillo-Vico A, 2013, INT J MOL SCI, V14, P8638, DOI 10.3390/ijms14048638
   Carvalho-Sousa CE, 2020, J PINEAL RES, V68, DOI 10.1111/jpi.12636
   Chakraborty Subhankari Prasad, 2012, ISRN Pharmacol, V2012, P435214, DOI 10.5402/2012/435214
   Chanchamroen S, 2009, INFECT IMMUN, V77, P456, DOI 10.1128/IAI.00503-08
   Ciz M, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/181295
   Couto N, 2016, FREE RADICAL BIO MED, V95, P27, DOI 10.1016/j.freeradbiomed.2016.02.028
   Couto-Moraes R, 2009, ANN NY ACAD SCI, V1153, P193, DOI 10.1111/j.1749-6632.2008.03978.x
   Cruz-Machado SD, 2010, J PINEAL RES, V49, P183, DOI 10.1111/j.1600-079X.2010.00785.x
   Dalle-Donne I, 2003, FREE RADICAL BIO MED, V34, P23, DOI 10.1016/S0891-5849(02)01182-6
   DeLeo FR, 1999, J IMMUNOL, V163, P6732
   Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031
   Espinosa-Diez C, 2015, REDOX BIOL, V6, P183, DOI 10.1016/j.redox.2015.07.008
   Favero G, 2017, INT J ENDOCRINOL, V2017, DOI 10.1155/2017/1835195
   Favero G, 2014, MOL CELL ENDOCRINOL, V382, P926, DOI 10.1016/j.mce.2013.11.016
   Gallogly MM, 2007, CURR OPIN PHARMACOL, V7, P381, DOI 10.1016/j.coph.2007.06.003
   Gao L, 2016, J PINEAL RES, V61, P340, DOI 10.1111/jpi.12351
   Ghezzi P, 2011, INT J GEN MED, V4, P105, DOI 10.2147/IJGM.S15618
   Guerra BA, 2012, DIABETES RES CLIN PR, V98, P108, DOI 10.1016/j.diabres.2012.07.004
   Guo Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09943-2
   Habtemariam S, 2017, CURR TOP MED CHEM, V17, P467, DOI 10.2174/1568026616666160824120338
   Hardeland R, 2012, J PINEAL RES, V52, P139, DOI 10.1111/j.1600-079X.2011.00934.x
   Hu W, 2017, BRIT J PHARMACOL, V174, P754, DOI 10.1111/bph.13751
   Kalogeris T, 2014, REDOX BIOL, V2, P702, DOI 10.1016/j.redox.2014.05.006
   Katkar GD, 2014, J PINEAL RES, V56, P295, DOI 10.1111/jpi.12123
   Katkar GD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11361
   Khan MA, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00019
   Kristoffersen AW, 2011, PEDIATR INFECT DIS J, V30, P279, DOI 10.1097/INF.0b013e3181fcb159
   Lassing I, 2007, J MOL BIOL, V370, P331, DOI 10.1016/j.jmb.2007.04.056
   Li H, 2016, J PINEAL RES, V60, P206, DOI 10.1111/jpi.12304
   Lim HD, 2012, J PINEAL RES, V53, P225, DOI 10.1111/j.1600-079X.2012.00991.x
   Liugan M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092102
   Lotufo CMC, 2006, EUR J PHARMACOL, V534, P258, DOI 10.1016/j.ejphar.2006.01.050
   Lotufo CMC, 2001, EUR J PHARMACOL, V430, P351, DOI 10.1016/S0014-2999(01)01369-3
   Lushchak Volodymyr I, 2012, J Amino Acids, V2012, P736837, DOI 10.1155/2012/736837
   Majidinia M, 2018, AGEING RES REV, V47, P198, DOI 10.1016/j.arr.2018.07.010
   Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267
   Mariana JK, 2012, J IMMUNOL, V189, P2689
   Markus RP, 2018, BRIT J PHARMACOL, V175, P3239, DOI 10.1111/bph.14083
   MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5
   Moradkhani F, 2020, J CELL PHYSIOL, V235, P745, DOI 10.1002/jcp.29036
   Morris D, 2013, BBA-GEN SUBJECTS, V1830, P3329, DOI 10.1016/j.bbagen.2012.10.012
   Mortezaee K, 2019, LIFE SCI, V238, DOI 10.1016/j.lfs.2019.116960
   NaveenKumar SK, 2015, SCI REP-UK, V5, DOI 10.1038/srep15045
   Negi G, 2011, J PINEAL RES, V50, P124, DOI 10.1111/j.1600-079X.2010.00821.x
   Nguyen GT, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00373
   Pan JS, 2009, WORLD J GASTROENTERO, V15, P1702, DOI 10.3748/wjg.15.1702
   Panday A, 2015, CELL MOL IMMUNOL, V12, DOI 10.1038/cmi.2014.89
   Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105
   Paul M, 2019, FREE RADICAL BIO MED, V130, P196, DOI 10.1016/j.freeradbiomed.2018.10.453
   Reiter RJ, 2003, ACTA BIOCHIM POL, V50, P1129
   Reiter RJ, 2016, J PINEAL RES, V61, P253, DOI 10.1111/jpi.12360
   Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x
   Sakai J, 2012, IMMUNITY, V37, P1037, DOI 10.1016/j.immuni.2012.08.017
   Saravanan KS, 2007, J PINEAL RES, V42, P247, DOI 10.1111/j.1600-079X.2006.00412.x
   Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4
   Seefeldt T, 2009, J BIOL CHEM, V284, P2729, DOI 10.1074/jbc.M802683200
   Sener A, 2005, J BIOCHEM MOL BIOL, V38, P343
   Sener G, 2004, J PINEAL RES, V36, P232, DOI 10.1111/j.1600-079X.2004.00113.x
   Shao DM, 2010, INT J BIOCHEM CELL B, V42, P1736, DOI 10.1016/j.biocel.2010.07.009
   Shao S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00746
   Sharma RD, 2017, ACTA TROP, V169, P14, DOI 10.1016/j.actatropica.2017.01.004
   Sharma RD, 2015, J PINEAL RES, V59, P240, DOI 10.1111/jpi.12256
   Shen YQ, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12461
   Shi HT, 2015, J PINEAL RES, V59, P102, DOI 10.1111/jpi.12244
   Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X
   Sies H, 2020, NAT REV MOL CELL BIO, DOI 10.1038/s41580-020-0230-3
   Sohn HY, 2003, CARDIOVASC RES, V57, P804, DOI 10.1016/S0008-6363(02)00786-1
   Srinivasan V, 2012, RECENT PATENTS ENDOC, V6, P30, DOI 10.2174/187221412799015317
   Stephan A, 2015, EXP DERMATOL, V24, P161, DOI 10.1111/exd.12599
   Stojkov D, 2017, J CELL BIOL, V216, P4073, DOI 10.1083/jcb.201611168
   Su SC, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12370
   Sung PH, 2018, ONCOTARGET, V9, P3531, DOI 10.18632/oncotarget.23180
   Suzuki M, 2003, J ALLERGY CLIN IMMUN, V112, P126, DOI 10.1067/mai.2003.1515
   Tian W, 2008, BLOOD, V112, P3867, DOI 10.1182/blood-2007-11-126029
   Tomas-Zapico C, 2005, J PINEAL RES, V39, P99, DOI 10.1111/j.1600-079X.2005.00248.x
   Venketaraman V, 2003, INFECT IMMUN, V71, P1864, DOI 10.1128/IAI.71.4.1864-1871.2003
   Vida C, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01974
   Wen XP, 2019, FEBS J, V286, P678, DOI 10.1111/febs.14753
   Winiarska K, 2006, J PINEAL RES, V40, P168, DOI 10.1111/j.1600-079X.2005.00295.x
   Wu SY, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008096
   Xu L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01371
   Yan J, 2013, FREE RADICAL BIO MED, V61, P320, DOI 10.1016/j.freeradbiomed.2013.04.015
   Yan J, 2012, J IMMUNOL, V188, P2316, DOI 10.4049/jimmunol.1102683
   Yipp BG, 2012, NAT MED, V18, P1386, DOI 10.1038/nm.2847
   Yu GM, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8597159
   Yu GM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178525
   Zeng MY, 2019, MOL ORAL MICROBIOL, V34, P27, DOI 10.1111/omi.12252
   Zhai ME, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12419
   Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162
   Zhang HM, 2011, J PINEAL RES, V50, P78, DOI 10.1111/j.1600-079X.2010.00815.x
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
   Zhao CN, 2019, CYTOKINE GROWTH F R, V48, P1, DOI 10.1016/j.cytogfr.2019.07.002
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 107
TC 1
Z9 1
U1 14
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3098
EI 1600-079X
J9 J PINEAL RES
JI J. Pineal Res.
PD OCT
PY 2020
VL 69
IS 3
AR e12676
DI 10.1111/jpi.12676
EA AUG 2020
PG 24
WC Endocrinology & Metabolism; Neurosciences; Physiology
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA NV9SB
UT WOS:000560128500001
PM 32597503
DA 2021-01-01
ER

PT J
AU Cavasotto, CN
   Di Filippo, JI
AF Cavasotto, Claudio N.
   Di Filippo, Juan I.
TI In silicoDrug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins
   through Docking and Consensus Ranking
SO MOLECULAR INFORMATICS
LA English
DT Article; Early Access
DE Molecular Docking; Consensus Scoring; Quantum Mechanical Scoring;
   COVID-19; SARS-CoV-2; Drug Repurposing
ID PAPAIN-LIKE PROTEASE; LIGAND DOCKING; NDDO APPROXIMATIONS; COUPLED
   RECEPTOR; OPTIMIZATION; FLEXIBILITY; PARAMETERS; DISCOVERY
AB In December 2019, an infectious disease caused by the coronavirus SARS-CoV-2 appeared in Wuhan, China. This disease (COVID-19) spread rapidly worldwide, and on March 2020 was declared a pandemic by the World Health Organization (WHO). Today, over 21 million people have been infected, with more than 750.000 casualties. Today, no vaccine or antiviral drug is available. While the development of a vaccine might take at least a year, and for a novel drug, even longer; finding a new use to an old drug (drug repurposing) could be the most effective strategy. We present a docking-based screening using a quantum mechanical scoring of a library built from approved drugs and compounds undergoing clinical trials, against three SARS-CoV-2 target proteins: the spike or S-protein, and two proteases, the main protease and the papain-like protease. The S-protein binds directly to the Angiotensin Converting Enzyme 2 receptor of the human host cell surface, while the two proteases process viral polyproteins. Following the analysis of our structure-based compound screening, we propose several structurally diverse compounds (either FDA-approved or in clinical trials) that could display antiviral activity against SARS-CoV-2. Clearly, these compounds should be further evaluated in experimental assays and clinical trials to confirm their actual activity against the disease. We hope that these findings may contribute to the rational drug design against COVID-19.
C1 [Cavasotto, Claudio N.; Di Filippo, Juan I.] Univ Austral, CONICET, Translat Med Res Inst IIMT, Computat Drug Design & Biomed Informat Lab, Pilar, Buenos Aires, Argentina.
   [Cavasotto, Claudio N.] Univ Austral, Fac Ciencias Biomed, Pilar, Buenos Aires, Argentina.
   [Cavasotto, Claudio N.] Univ Austral, Fac Ingn, Pilar, Buenos Aires, Argentina.
   [Cavasotto, Claudio N.] Austral Inst Appl Artificial Intelligence, Pilar, Buenos Aires, Argentina.
RP Cavasotto, CN (corresponding author), Univ Austral, CONICET, Translat Med Res Inst IIMT, Computat Drug Design & Biomed Informat Lab, Pilar, Buenos Aires, Argentina.; Cavasotto, CN (corresponding author), Univ Austral, Fac Ciencias Biomed, Pilar, Buenos Aires, Argentina.; Cavasotto, CN (corresponding author), Univ Austral, Fac Ingn, Pilar, Buenos Aires, Argentina.; Cavasotto, CN (corresponding author), Austral Inst Appl Artificial Intelligence, Pilar, Buenos Aires, Argentina.
EM CCavasotto@austral.edu.ar
RI Cavasotto, Claudio/AAK-9867-2020
OI Cavasotto, Claudio/0000-0002-1372-0379
FU National Agency for the Promotion of Science and Technology
   (ANPCyT)ANPCyT [PICT-2014-3599, PICT-2017-3767]
FX The Authors thank Dr. Julian Maggini, Dr. Mariano Nunez, and Dr. Ventura
   Simonovich for helful discussions. This work was supported by the
   National Agency for the Promotion of Science and Technology (ANPCyT)
   (PICT-2014-3599 and PICT-2017-3767). CNC thanks Molsoft LLC (San Diego,
   CA) for providing an academic license for the ICM program. The authors
   are grateful to the National System of High Performance Computing
   (Sistemas Nacionales de Computacion de Alto Rendimiento, SNCAD), and the
   Centro de Calculo de Alto Desempeno (Universidad Nacional de Cordoba)
   for granting use of their computational resources.
CR ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052
   ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Aucar M Gabriela, 2020, Methods Mol Biol, V2114, P269, DOI 10.1007/978-1-0716-0282-9_17
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Cavasotto CN, 2008, CURR COMPUT-AID DRUG, V4, P221, DOI 10.2174/157340908785747474
   Cavasotto CN, 2008, J MED CHEM, V51, P581, DOI 10.1021/jm070759m
   Cavasotto CN, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00246
   Cavasotto CN, 2019, INT J QUANTUM CHEM, V119, DOI 10.1002/qua.25678
   Cavasotto CN, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00188
   Cavasotto CN, 2015, CHEM COMMUN, V51, P13576, DOI 10.1039/c5cc05050b
   Cavasotto CN, 2005, J AM CHEM SOC, V127, P9632, DOI 10.1021/ja042260c
   Cavasotto CN, 2004, J MOL BIOL, V337, P209, DOI 10.1016/j.jmb.2004.01.003
   Chen H., 2020, MEDRXIV
   Contini A., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.11847381.v11847381, DOI 10.26434/CHEMRXIV.11847381.V11847381]
   Fischer A., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.11923239.v11923232, DOI 10.26434/CHEMRXIV.11923239.V11923232]
   Gaulton A, 2017, NUCLEIC ACIDS RES, V45, pD945, DOI 10.1093/nar/gkw1074
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Khaerunnisa S., 2020, PREPRINTS, DOI [10.20944/preprints202003.200226.v202001, DOI 10.20944/PREPRINTS202003.200226.V202001]
   KLAMT A, 1993, J CHEM SOC PERK T 2, P799, DOI 10.1039/p29930000799
   Ledford H, 2020, NATURE, V581, P247, DOI 10.1038/d41586-020-01367-9
   Lee H, 2015, ACS CHEM BIOL, V10, P1456, DOI 10.1021/cb500917m
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lim WS, 2019, RESPIRATORY MEDICINE, 3RD EDITION, P393
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Palacio-Rodriguez K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41594-3
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Phatak SS, 2010, J CHEM INF MODEL, V50, P2119, DOI 10.1021/ci100285f
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Rut W., 2020, BIORXIV
   Smith M., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.11871402.v11871404, DOI 10.26434/CHEMRXIV.11871402.V11871404]
   Spyrakis F, 2015, ARCH BIOCHEM BIOPHYS, V583, P105, DOI 10.1016/j.abb.2015.08.002
   Stewart J. J. P., 2016, MOPAC2016
   Stewart JJP, 2007, J MOL MODEL, V13, P1173, DOI 10.1007/s00894-007-0233-4
   Stewart JJP, 2013, J MOL MODEL, V19, P1, DOI 10.1007/s00894-012-1667-x
   Stewart JJP, 1996, INT J QUANTUM CHEM, V58, P133, DOI 10.1002/(SICI)1097-461X(1996)58:2<133::AID-QUA2>3.0.CO;2-Z
   Sulimov A. V., 2017, Advances in Bioinformatics, V2017, P7167691, DOI 10.1155/2017/7167691
   Sulimov AV, 2017, J MOL GRAPH MODEL, V78, P139, DOI 10.1016/j.jmgm.2017.10.007
   Totrov M., 1999, RECOMB 99 P 3 ANN IN, P37
   Totrov M, 2008, CURR OPIN STRUC BIOL, V18, P178, DOI 10.1016/j.sbi.2008.01.004
   Ursu O, 2017, NUCLEIC ACIDS RES, V45, pD932, DOI 10.1093/nar/gkw993
   Wang J., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.11875446.v11875441, DOI 10.26434/CHEMRXIV.11875446.V11875441]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World Health Organization (WHO), 2020, 156 WHO
   Xu Z., 2020, BIORXIV, DOI [10.1101/2020.1101.1127.921627, DOI 10.1101/2020.1101.1127.921627]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 52
TC 1
Z9 1
U1 1
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1868-1743
EI 1868-1751
J9 MOL INFORM
JI Mol. Inf.
DI 10.1002/minf.202000115
EA AUG 2020
PG 9
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications;
   Mathematical & Computational Biology
SC Pharmacology & Pharmacy; Computer Science; Mathematical & Computational
   Biology
GA NA9IF
UT WOS:000560129700001
PM 32722864
OA Bronze
DA 2021-01-01
ER

PT J
AU Michelson, M
   Chow, T
   Martin, NA
   Ross, M
   Ying, ATQ
   Minton, S
AF Michelson, Matthew
   Chow, Tiffany
   Martin, Neil A.
   Ross, Mike
   Ying, Amelia Tee Qiao
   Minton, Steven
TI Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocular
   Toxicity of Hydroxychloroquine
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE meta-analysis; rapid meta-analysis; artificial intelligence; drug;
   analysis; hydroxychloroquine; toxic; COVID-19; treatment; side effect;
   ocular; eye
ID RETINAL TOXICITY
AB Background: Rapid access to evidence is crucial in times of an evolving clinical crisis. To that end, we propose a novel approach to answer clinical queries, termed rapid meta-analysis (RMA). Unlike traditional meta-analysis, RMA balances a quick time to production with reasonable data quality assurances, leveraging artificial intelligence (AI) to strike this balance.
   Objective: We aimed to evaluate whether RMA can generate meaningful clinical insights, but crucially, in a much faster processing time than traditional meta-analysis, using a relevant, real-world example.
   Methods: The development of our RMA approach was motivated by a currently relevant clinical question: is ocular toxicity and vision compromise a side effect of hydroxychloroquine therapy? At the time of designing this study, hydroxychloroquine was a leading candidate in the treatment of coronavirus disease (COVID-19). We then leveraged AI to pull and screen articles, automatically extract their results, review the studies, and analyze the data with standard statistical methods.
   Results: By combining AI with human analysis in our RMA, we generated a meaningful, clinical result in less than 30 minutes. The RMA identified 11 studies considering ocular toxicity as a side effect of hydroxychloroquine and estimated the incidence to be 3.4% (95% CI 1.11%-9.96%). The heterogeneity across individual study findings was high, which should be taken into account in interpretation of the result.
   Conclusions: We demonstrate that a novel approach to meta-analysis using AI can generate meaningful clinical insights in a much shorter time period than traditional meta-analysis.
C1 [Michelson, Matthew; Chow, Tiffany; Ross, Mike; Ying, Amelia Tee Qiao] Evid Sci, 2361 Rosencrans Ave Ste 348, El Segundo, CA 90245 USA.
   [Michelson, Matthew; Minton, Steven] InferLink, El Segundo, CA USA.
   [Martin, Neil A.] Providence St Johns Hlth Ctr, Pacific Neurosci Inst, Santa Monica, CA USA.
RP Michelson, M (corresponding author), Evid Sci, 2361 Rosencrans Ave Ste 348, El Segundo, CA 90245 USA.
EM mmichelson@evidscience.com
CR Bastian H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000326
   Chiu SY, 2018, CLIN OPHTHALMOL, V12, P2261, DOI 10.2147/OPTH.S170789
   Cabral RTD, 2019, ARQ BRAS OFTALMOL, V82, P12, DOI 10.5935/0004-2749.20190002
   Espandar Goldis, 2016, Med Hypothesis Discov Innov Ophthalmol, V5, P41
   Jover JA, 2012, CLIN EXP RHEUMATOL, V30, P380
   LOUGHLIN EH, 1952, ANTIBIOT CHEMOTHER, V2, P171
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Marshall IJ, 2017, PROCEEDINGS OF THE 55TH ANNUAL MEETING OF THE ASSOCIATION FOR COMPUTATIONAL LINGUISTICS (ACL 2017): SYSTEM DEMONSTRATIONS, P7, DOI 10.18653/v1/P17-4002
   Maturi RK, 2004, ARCH OPHTHALMOL-CHIC, V122, P973, DOI 10.1001/archopht.122.7.973
   Mavrikakis I, 2003, OPHTHALMOLOGY, V110, P1321, DOI 10.1016/S0161-6420(03)00409-3
   Michelson M, 2019, VALUE HEALTH, V22, pS34, DOI 10.1016/j.jval.2019.04.006
   Michelson M., 2014, AAAI FALL S EXP BOUN
   Navajas EV, 2015, CAN J OPHTHALMOL, V50, P442, DOI 10.1016/j.jcjo.2015.08.003
   Neubauer AS, 2003, BRIT J OPHTHALMOL, V87, P902, DOI 10.1136/bjo.87.7.902
   Przybyla P, 2018, RES SYNTH METHODS, V9, P470, DOI 10.1002/jrsm.1311
   Sackett D. L., 2000, EVIDENCE BASED MED P
   Scells H, 2017, 2017 NOV 06 ACM C IN
   scibert, GITHUB
   Shojania KG, 2007, ANN INTERN MED, V147, P224, DOI 10.7326/0003-4819-147-4-200708210-00179
   Singh DK, 2019, RHEUMATOL ADV PRACT, V3, P9
   Spinelli FR, 2018, LUPUS, V27, P1616, DOI 10.1177/0961203318781008
   Tsafnat G, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-74
   Tzekov RT, 2004, DOC OPHTHALMOL, V108, P87, DOI 10.1023/B:DOOP.0000018410.08802.d3
   Wallace BC, 2016, J MACH LEARN RES, V17
NR 24
TC 0
Z9 0
U1 1
U2 1
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD AUG 17
PY 2020
VL 22
IS 8
AR e20007
DI 10.2196/20007
PG 10
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA NW5MH
UT WOS:000575055500003
PM 32804086
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cavalleri, M
   Brambati, M
   Starace, V
   Capone, L
   Nadin, F
   Pederzolli, M
   Gorgoni, F
   Di Biase, C
   Corbelli, E
   Battista, M
   Moretti, AG
   Grosso, D
   Bandello, F
AF Cavalleri, Michele
   Brambati, Maria
   Starace, Vincenzo
   Capone, Luigi
   Nadin, Francesco
   Pederzolli, Matteo
   Gorgoni, Francesca
   Di Biase, Carlo
   Corbelli, Eleonora
   Battista, Marco
   Grazioli Moretti, Alessio
   Grosso, Domenico
   Bandello, Francesco
TI Ocular Features and Associated Systemic Findings in SARS-CoV-2 Infection
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Article
DE COVID-19; SARS-CoV-2; conjunctivitis; RT-PCR
AB Purposes To describe the prevalence of ocular features among COVID-19 patients and their relationship with clinical data, inflammatory markers and respiratory support therapy (including CPAP); to investigate SARS-CoV-2 in ocular secretions of symptomatic patients. Methods 172 COVID-19 patients were evaluated for presence of ocular manifestations. Clinical and laboratory data were also reviewed. Conjunctival swabs were analyzed for SARS-CoV-2 by RT-PCR. Results Forty-five patients (26.2%) reported ocular manifestations. Patients treated with CPAP were more likely to have ocular abnormalities (p<.01). The presence of ocular symptoms was not associated with more significant alterations on blood tests. Conjunctival swabs from patients with suspect conjunctivitis yielded negative results for SARS-CoV-2. Conclusions Ocular features are not infrequent in COVID-19 patients, but the presence of SARS-CoV-2 in ocular secretions is low. Ocular manifestations in hospitalized COVID-19 patients can also be a consequence of respiratory support therapy. Prevention of possible transmission through ocular secretions is still recommended.
C1 [Cavalleri, Michele; Brambati, Maria; Starace, Vincenzo; Capone, Luigi; Nadin, Francesco; Pederzolli, Matteo; Gorgoni, Francesca; Di Biase, Carlo; Corbelli, Eleonora; Battista, Marco; Grazioli Moretti, Alessio; Grosso, Domenico; Bandello, Francesco] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
RP Cavalleri, M (corresponding author), Univ Vita Salute, IRCCS, Dept Ophthalmol, I-20132 Milan, Italy.
EM cavalleri.michele@hsr.it
OI bandello, francesco/0000-0003-3238-9682; Cavalleri,
   Michele/0000-0001-5308-1201; Battista, Marco/0000-0001-5940-6177
CR American Academy of Ophthalmology, 2020, IMP COR UPD OPHTH
   Borrelli E, 2020, EYE, V34, P1175, DOI 10.1038/s41433-020-0880-6
   Chen L, 2020, BRIT J OPHTHALMOL, V104, P748, DOI 10.1136/bjophthalmol-2020-316304
   Colavita F, 2020, ANN INTERN MED, V173, P242, DOI 10.7326/M20-1176
   Karaca EE, 2016, TURK OFTALMOL DERG, V46, P104, DOI 10.4274/tjo.57778
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Marinho PM, 2020, LANCET, V395, P1610, DOI 10.1016/S0140-6736(20)31014-X
   Seah I, 2020, OCUL IMMUNOL INFLAMM, V28, P391, DOI 10.1080/09273948.2020.1738501
   Seah IYJ, 2019, OPHTHALMOLOGY, VS0161-6420, P30311
   Stefanelli P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.13.2000305
   Tan CC, 2020, J MED VIROL, V92, P856, DOI 10.1002/jmv.25871
   Vitacca M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00632-2020
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu P, 2020, JAMA OPHTHALMOL, V138, P575, DOI 10.1001/jamaophthalmol.2020.1291
   Xia JH, 2020, J MED VIROL, V92, P589, DOI 10.1002/jmv.25725
   Zhou YY, 2020, OPHTHALMOLOGY, V127, P982, DOI 10.1016/j.ophtha.2020.04.028
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 17
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD AUG 17
PY 2020
VL 28
IS 6
BP 916
EP 921
DI 10.1080/09273948.2020.1781198
PG 6
WC Ophthalmology
SC Ophthalmology
GA NH8BN
UT WOS:000564889200015
PM 32870738
DA 2021-01-01
ER

PT J
AU Trezza, A
   Iovinelli, D
   Santucci, A
   Prischi, F
   Spiga, O
AF Trezza, Alfonso
   Iovinelli, Daniele
   Santucci, Annalisa
   Prischi, Filippo
   Spiga, Ottavia
TI An integrated drug repurposing strategy for the rapid identification of
   potential SARS-CoV-2 viral inhibitors
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MOLECULAR-DYNAMICS; DISCOVERY; DOCKING; SARS
AB The Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). The virus has rapidly spread in humans, causing the ongoing Coronavirus pandemic. Recent studies have shown that, similarly to SARS-CoV, SARS-CoV-2 utilises the Spike glycoprotein on the envelope to recognise and bind the human receptor ACE2. This event initiates the fusion of viral and host cell membranes and then the viral entry into the host cell. Despite several ongoing clinical studies, there are currently no approved vaccines or drugs that specifically target SARS-CoV-2. Until an effective vaccine is available, repurposing FDA approved drugs could significantly shorten the time and reduce the cost compared to de novo drug discovery. In this study we attempted to overcome the limitation of in silico virtual screening by applying a robust in silico drug repurposing strategy. We combined and integrated docking simulations, with molecular dynamics (MD), Supervised MD (SuMD) and Steered MD (SMD) simulations to identify a Spike protein - ACE2 interaction inhibitor. Our data showed that Simeprevir and Lumacaftor bind the receptor-binding domain of the Spike protein with high affinity and prevent ACE2 interaction.
C1 [Trezza, Alfonso; Iovinelli, Daniele; Santucci, Annalisa; Spiga, Ottavia] Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy.
   [Prischi, Filippo] Univ Essex, Sch Life Sci, Colchester CO4 3SQ, Essex, England.
RP Spiga, O (corresponding author), Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy.; Prischi, F (corresponding author), Univ Essex, Sch Life Sci, Colchester CO4 3SQ, Essex, England.
EM fprischi@essex.ac.uk; ottavia.spiga@unisi.it
RI Santucci, Annalisa/K-1932-2018; Trezza, Alfonso/ABH-3773-2020; Prischi,
   Filippo/I-4844-2019
OI Santucci, Annalisa/0000-0001-6976-9086; Prischi,
   Filippo/0000-0003-2107-938X
FU Leverhulme TrustLeverhulme Trust [RPG-2018-230]
FX F.P. received funding from Leverhulme Trust Grant RPG-2018-230. We
   acknowledge the Department of Biotechnology, Chemistry and Pharmacy
   (Department of Excellence 2018-2022) at the University of Siena for
   providing access to the high performance computing cluster used for the
   simulations.
CR Alamri M. A., 2020, PHARMACOINFORMATICS, DOI [10.20944/preprints202002.0308.v1., DOI 10.20944/PREPRINTS202002.0308.V1]
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Bongini P, 2020, BIOCHEM BIOPH RES CO, V528, P35, DOI 10.1016/j.bbrc.2020.04.007
   Brady GP, 2000, J COMPUT AID MOL DES, V14, P383, DOI 10.1023/A:1008124202956
   Calligari P, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040445
   Elfiky AA, 2017, J MED VIROL, V89, P1040, DOI 10.1002/jmv.24736
   Eyrisch S, 2009, J COMPUT AID MOL DES, V23, P73, DOI 10.1007/s10822-008-9239-y
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hutter MC, 2018, FUTURE MED CHEM, V10, P1623, DOI 10.4155/fmc-2017-0303
   Janson G, 2017, BIOINFORMATICS, V33, P444, DOI 10.1093/bioinformatics/btw638
   Jenwitheesuk E, 2008, TRENDS PHARMACOL SCI, V29, P62, DOI 10.1016/j.tips.2007.11.007
   Kim MK, 2011, EUR J MED CHEM, DOI [10.1016/j.ejmech.2011.09.0057115508, DOI 10.1016/J.EJMECH.2011.09.0057115508]
   Koebel MR, 2016, VINA J CHEMINFORM, DOI [10.1186/s13321-016-0139-14870740, DOI 10.1186/S13321-016-0139-14870740]
   Krainer G, 2020, J BIOL CHEM, V295, P1985, DOI 10.1074/jbc.AC119.011360
   Lai CC, 2020, INT J ANTIMICROB AG, DOI [10.1016/j.ijantimicag.2020.1059247377685, DOI 10.1016/J.IJANTIMICAG.2020.1059247377685]
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lavecchia A, 2013, CURR MED CHEM, V20, P2839, DOI 10.2174/09298673113209990001
   Li F, 2005, SCIENCE, DOI [10.1126/science.11164803175767, DOI 10.1126/SCIENCE.11164803175767]
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li Z, 2019, ANTIVIR RES, V172, DOI 10.1016/j.antiviral.2019.104607
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Onat Kadioglu MSHJGTE, 2020, B WORLD HLTH ORG, DOI [10.2471/BLT.20.251561, DOI 10.2471/BLT.20.251561]
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Peterson L., 2020, SSRN ELECT J, DOI [10.26434/CHEMRXIV.12155523.V1, DOI 10.26434/CHEMRXIV.12155523.V1, 10.26434/chemrxiv.12155523.v1]
   Sabbadin D, 2018, METHODS MOL BIOL, V1824, P287, DOI 10.1007/978-1-4939-8630-9_17
   Sacks D, 2018, J VASC INTERV RADIOL, V29, P441, DOI 10.1016/j.jvir.2017.11.026
   Saravanan K, 2017, J BIOMOL STRUCT DYN, V35, P3627, DOI 10.1080/07391102.2016.1264891
   Senathilake K., 2020, PREPRINTS, DOI [10.20944/preprints202003.0042.v1., DOI 10.20944/PREPRINTS202003.0042.V1, 10.20944/preprints202003.0042.v1]
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v3, DOI 10.26434/CHEMRXIV.11871402.V3]
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Venditti V, 2007, BIOCHEM BIOPH RES CO, V356, P114, DOI 10.1016/j.bbrc.2007.02.094
   Wagner JR, 2017, J CHEM THEORY COMPUT, V13, P4584, DOI 10.1021/acs.jctc.7b00500
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wrapp D, 2020, SCIENCE, DOI [10.1126/science.aax09027299279, DOI 10.1126/SCIENCE.AAX09027299279]
   Wu C., 2020, ACTA PHARM SIN B, DOI [10.1016/j.apsb.2020.02.0087332810, DOI 10.1016/J.APSB.2020.02.0087332810]
   Xin M., 2017, J BIOL CHEM, DOI [10.1074/jbc.M116.7515375766925, DOI 10.1074/JBC.M116.7515375766925]
   Yan R., 2020, SCIENCE, DOI [10.1126/science.abb276232571838, DOI 10.1126/SCIENCE.ABB276232571838]
   Zhang XQ, 2016, ACTA PHARM SIN B, V6, P26, DOI 10.1016/j.apsb.2015.09.008
   Zheng BJ, 2005, ANTIVIR THER, V10, P393
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 51
TC 3
Z9 3
U1 3
U2 3
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 17
PY 2020
VL 10
IS 1
AR 13866
DI 10.1038/s41598-020-70863-9
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NF8JF
UT WOS:000563538400016
PM 32807895
OA DOAJ Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Busani, S
   Tosi, M
   Mighali, P
   Vandelli, P
   D'Amico, R
   Marietta, M
   Forfori, F
   Donati, A
   Cinnella, G
   De Monte, A
   Pasero, D
   Bellani, G
   Tascini, C
   Foti, G
   Ranieri, M
   Girardis, M
AF Busani, Stefano
   Tosi, Martina
   Mighali, Pasquale
   Vandelli, Paola
   D'Amico, Roberto
   Marietta, Marco
   Forfori, Francesco
   Donati, Abele
   Cinnella, Gilda
   De Monte, Amato
   Pasero, Daniela
   Bellani, Giacomo
   Tascini, Carlo
   Foti, Giuseppe
   Ranieri, Marco
   Girardis, Massimo
TI Multi-centre, three arm, randomized controlled trial on the use of
   methylprednisolone and unfractionated heparin in critically ill
   ventilated patients with pneumonia from SARS-CoV-2 infection: A
   structured summary of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomized controlled trial; Protocol; Low-molecular weight
   heparin; Unfractionated heparin; Methylprednisolone; Mechanical
   ventilation; SARS-CoV-2 Pneumonia
AB Objectives: To assess the hypothesis that an adjunctive therapy with methylprednisolone and unfractionated heparin (UFH) or with methylprednisolone and low molecular weight heparin (LMWH) are more effective in reducing any-cause mortality in critically-ill ventilated patients with pneumonia from SARS-CoV-2 infection compared to LMWH alone.
   Trial design: The study is designed as a multi-centre, interventional, parallel group, superiority, randomized, investigator sponsored, three arms study. Patients, who satisfy all inclusion criteria and no exclusion criteria, will be randomly assigned to one of the three treatment groups in a ratio 1:1:1.
   Participants: Inpatients will be recruited from 8 Italian Academic and non-Academic Intensive Care Units
   Inclusion Criteria (all required): 1. Positive SARS-CoV-2 diagnostic (on pharyngeal swab of deep airways material)
   2. Positive pressure ventilation (either non-invasive or invasive) from > 24 hours
   3. Invasive mechanical ventilation from < 96 hours
   4. PaO2/FiO(2) ratio lower than 150 mmHg
   5. D-dimer level > 6 times the upper limit of normal reference range
   6. C-reactive Protein > 6-fold upper the limit of normal reference range
   Exclusion Criteria
   1. Age < 18 years
   2. On-going treatment with anticoagulant drugs
   3. Platelet count < 100.000/mm(3)
   4. History of heparin-induced thrombocytopenia
   5. Allergy to sodium enoxaparin or other LMWH, UFH or methylprednisolone
   6. Active bleeding or on-going clinical condition deemed at high risk of bleeding contraindicating anticoagulant treatment
   7. Recent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery
   8. Chronic assumption or oral corticosteroids
   9. Pregnancy or breastfeeding or positive pregnancy test. In childbearing age women, before inclusion, a pregnancy test will be performed if not available
   10. Clinical decision to withhold life-sustaining treatment or "too sick to benefit"
   11. Presence of other severe diseases impairing life expectancy (e.g. patients are not expected to survive 28 days given their pre-existing medical condition)
   12. Lack or withdrawal of informed consent
   Intervention and comparator center dot LMWH group: patients in this group will be administered enoxaparin at standard prophylactic dosage.
   center dot LMWH + steroid group: patients in this group will receive enoxaparin at standard prophylactic dosage and methylprednisolone.
   center dot UFH + steroid group: patients in this group will receive UFH at therapeutic dosages and methylprednisolone.UFH will be administered intravenously in UFH + steroid group at therapeutic doses. The infusion will be started at an infusion rate of 18 UI/kg/hour and then modified to obtain aPTT Ratio in between the range of 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with UFH will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician.
   Enoxaparin will be administered in both LMWH group and LMWH + steroid group at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered subcutaneously once a day up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
   Methylprednisolone will be administered in both LMWH + steroid group and UHF + steroid group intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
   Main Outcomes
   Primary Efficacy Endpoint:
   All-cause mortality at day 28
   Secondary Efficacy Endpoints:
   - Ventilation free days (VFDs) at day 28, defined as the total number of days that patient is alive and free of ventilation (either invasive or non-invasive) between randomization and day 28 (censored at hospital discharge).
   - Need of rescue administration of high-dose steroids or immune-modulatory drugs;- Occurrence of switch from non-invasive to invasive mechanical ventilation during ICU stay;
   - Delay from start of non-invasive ventilation to switch to invasive ventilation;
   - All-cause mortality at ICU discharge and hospital discharge;
   - ICU free days (IFDs) at day 28, defined as the total number of days between ICU discharge and day 28.- Occurrence of new infections from randomization to day 28; including infections by Candida, Aspergillus, Adenovirus, Herpes Virus e Cytomegalovirus- Occurrence of new organ dysfunction and grade of dysfunction during ICU stay.
   - Objectively confirmed venous thromboembolism, stroke or myocardial infarction;
   Safety endpoints:
   - Occurrence of major bleeding, defined as transfusion of 2 or more units of packed red blood cells in a day, bleeding that occurs in at least one of the following critical sites [intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal], bleeding that necessitates surgical intervention and bleeding that is fatal (defined as a bleeding event that was the primary cause of death or contributed directly to death);
   - Occurrence of clinically relevant non-major bleeding, defined ad acute clinically overt bleeding that does not meet the criteria for major and consists of any bleeding compromising hemodynamic; spontaneous hematoma larger than 25 cm(2), intramuscular hematoma documented by ultrasonography, haematuria that was macroscopic and was spontaneous or lasted for more than 24 hours after invasive procedures; haemoptysis, hematemesis or spontaneous rectal bleeding requiring endoscopy or other medical intervention or any other bleeding requiring temporary cessation of a study drug.
   Randomization A block randomisation will be used with variable block sizes (block size 4-6-8), stratified by 3 factors: Centre, BMI (<30/>= 30) and Age (<75/>= 75). Central randomisation will be performed using a secure, web-based, randomisation system with an allocation ratio of 1:1:1. The allocation sequence will be generated by the study statistician using computer generated random numbers.Blinding (masking) Participants to the study will be blinded to group assignment.
   Numbers to be randomised (sample size)The target sample size is based on the hypothesis that the combined use of UHF and steroid versus the LMWH group will significantly reduce the risk of death at day 28. The overall sample size in this study is expected to be 210 with a randomization 1:1:1 and seventy patients in each group. Assuming an alpha of 2.5% (two tailed) and mortality rate in LMWH group of 50%, as indicated from initial studies of ICU patients, the study will have an 80% power to detect at least a 25 % absolute reduction in the risk of death between: a) LMHW + steroid group and LMWH group or b) UHF + steroid group and LMWH group. The study has not been sized to assess the difference between LMHW + steroid group and UHF + steroid group, therefore the results obtained from this comparison will need to be interpreted with caution and will need further adequately sized studies confirm the effect.On the basis of a conservative estimation, that 8 participating sites admit an average of 3 eligible patients per month per centre (24 patients/month). Assuming that 80 % of eligible patients are enrolled, recruitment of 210 participants will be completed in approximately 10 months.
   Trial Status Protocol version 1.1 of April 26(th), 2020.
   Recruitment start (expected): September 1(st), 2020
   Recruitment finish (expected): June 30(th), 2021Trial registrationEudraCT number 2020-001921-30, registered on April 15(th), 2020AIFA approval on May 4(th), 2020
   Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Busani, Stefano; Tosi, Martina; Girardis, Massimo] Azienda Osped Univ Modena, Osped Policlin, Anaesthesia & Intens Care Unit, Terapia Intens Polivalente,Policlin Modena, Via Pozzo 71, I-41124 Modena, Italy.
   [Mighali, Pasquale; Vandelli, Paola] Azienda Osped Univ Modena, Osped Policlin, Serv Formaz Ric & Innovaz, Modena, Italy.
   [D'Amico, Roberto] Univ Modena & Reggio Emilia, Dipartimento Sci Med & Chirurg Maternoinfantili &, Cattedra Stat Med, Modena, Italy.
   [Marietta, Marco] Azienda Osped Univ Modena, Osped Policlin, Haematol Unit, Modena, Italy.
   [Forfori, Francesco] Azienda Osped Univ Pisana, Dipartimento Anestesia & Terapia Intens, Pisa, Italy.
   [Donati, Abele] Univ Politecn Marche, Dept Biomed Sci & Publ Hlth, Anaesthesia & Intens Care Unit, Torrette Di Ancona, Italy.
   [Cinnella, Gilda] Univ Foggia, OO Riuniti Hosp, Dept Anesthesia & Intens Care, Foggia, Italy.
   [De Monte, Amato] Azienda Sanit Univ Integrata Udine, Dept Anesthesia & Intens Care, Anesthesiol & Intens Care 1, Udine, Italy.
   [Pasero, Daniela] Univ Sassari, Dept Med Surg & Expt Sci, Sassari, Italy.
   [Bellani, Giacomo] San Gerardo Hosp, Dept Emergency & Intens Care, Monza, Italy.
   [Tascini, Carlo] Azienda Sanit Univ Friuli Cent, Clin Malattie Infett, Udine, Italy.
   [Foti, Giuseppe] San Gerardo Hosp, Dept Emergency Med, Monza, Italy.
   [Foti, Giuseppe] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy.
   [Ranieri, Marco] Univ Bologna, Alma Mater Studiorum, Univ Hosp Bologna St Orsola, Anesthesia & Intens Care Med, Bologna, Italy.
RP Busani, S (corresponding author), Azienda Osped Univ Modena, Osped Policlin, Anaesthesia & Intens Care Unit, Terapia Intens Polivalente,Policlin Modena, Via Pozzo 71, I-41124 Modena, Italy.
EM stefano.busani@unimore.it
OI Busani, Stefano/0000-0003-0150-4967
FU Azienda Ospedaliero Universitaria di Modena, Italy
FX Funded by Azienda Ospedaliero Universitaria di Modena, Italy. The
   funding body had no role in the study design of the study and
   collection, analysis and interpretation of data and in writing the
   manuscript.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 17
PY 2020
VL 21
IS 1
AR 724
DI 10.1186/s13063-020-04645-z
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NF8AW
UT WOS:000563516500007
PM 32807241
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hinks, TSC
   Barber, VS
   Black, J
   Dutton, SJ
   Jabeen, M
   Melhorn, J
   Rahman, NM
   Richards, D
   Lasserson, D
   Pavord, ID
   Bafadhel, M
AF Hinks, Timothy S. C.
   Barber, Vicki S.
   Black, Joanna
   Dutton, Susan J.
   Jabeen, Maisha
   Melhorn, James
   Rahman, Najib M.
   Richards, Duncan
   Lasserson, Daniel
   Pavord, Ian D.
   Bafadhel, Mona
TI A multi-centre open-label two-arm randomised superiority clinical trial
   of azithromycin versus usual care in ambulatory COVID-19: study protocol
   for the ATOMIC2 trial
SO TRIALS
LA English
DT Article
DE COVID-19; Coronavirus; SAR-CoV-2; Azithromycin; Macrolide; Randomised
   controlled trial; Respiratory failure; Mortality; Trial
ID MACROLIDE ANTIBIOTICS; DIFFUSE PANBRONCHIOLITIS; ASTHMA; EXACERBATIONS;
   PROLONGATION; INFECTIONS; MECHANISMS; EXPRESSION; CYTOKINES; RECEPTOR
AB BackgroundAzithromycin is an orally active synthetic macrolide antibiotic with a wide range of anti-bacterial, anti-inflammatory and antiviral properties. It is a safe, inexpensive, generic licenced drug available worldwide and manufactured to scale and is a potential candidate therapy for pandemic coronavirus disease 2019 (COVID-19). Azithromycin was widely used to treat severe SARS-CoV and MERS-CoV, but to date, no randomised data are available in any coronavirus infections.Other ongoing trials are exploring short courses of azithromycin either in early disease, within the first 7days of symptoms, when azithromycin's antiviral properties may be important, or late in disease when anti-bacterial properties may reduce the risk of secondary bacterial infection. However, the molecule's anti-inflammatory properties, including suppression of pulmonary macrophage-derived pro-inflammatory cytokines such as interleukins-1 beta, -6, -8, and -18 and cytokines G-CSF and GM-CSF may provide a distinct therapeutic benefit if given in as a prolonged course during the period of progression from moderate to severe disease.MethodsATOMIC2 is a phase II/III, multi-centre, prospective, open-label, two-arm randomised superiority clinical trial of azithromycin versus standard care for adults presenting to hospital with COVID-19 symptoms who are not admitted at initial presentation. We will enrol adults, >= 18years of age assessed in acute hospitals in the UK with clinical diagnosis of COVID-19 infection where management on an ambulatory care pathway is deemed appropriate. Participants will be randomised in a 1:1 ratio to usual care or to azithromycin 500mg orally daily for 14days with telephone follow-up at days 14 and 28. The primary objective is to compare the proportion with either death or respiratory failure requiring invasive or non-invasive mechanical ventilation over 28days from randomisation. Secondary objectives include mortality/respiratory failure in those with a PCR-confirmed diagnosis; all-cause mortality; progression to pneumonia; progression to severe pneumonia; peak severity of illness and mechanistic analysis of blood and nasal biomarkers.DiscussionThis trial will determine the clinical utility of azithromycin in patients with moderately severe, clinically diagnosed COVID-19 and could be rapidly applicable worldwide.Trial registrationClinicalTrials.gov NCT04381962. Registered on 11 May 2020. EudraCT identifier 2020-001740-26. Opened for accrual on 29 May 2020.
C1 [Hinks, Timothy S. C.; Jabeen, Maisha; Rahman, Najib M.; Pavord, Ian D.; Bafadhel, Mona] Univ Oxford, Nuffield Dept Med Expt Med, Oxford Biomed Res Ctr BRC, Resp Med Unit, Oxford OX3 9DU, Oxon, England.
   [Hinks, Timothy S. C.; Jabeen, Maisha; Rahman, Najib M.; Pavord, Ian D.; Bafadhel, Mona] Univ Oxford, Nuffield Dept Med Expt Med, Oxford Biomed Res Ctr BRC, Natl Inst Hlth Res NIHR, Oxford OX3 9DU, Oxon, England.
   [Barber, Vicki S.; Black, Joanna; Dutton, Susan J.; Richards, Duncan] Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford Clin Trials Res Unit, Oxford, England.
   [Melhorn, James] Univ Hosp Llandough, Cardiff CF64 2XX, Wales.
   [Lasserson, Daniel] Univ Oxford, Nuffield Dept Med, Oxford, Wales.
   [Lasserson, Daniel] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.
RP Hinks, TSC (corresponding author), Univ Oxford, Nuffield Dept Med Expt Med, Oxford Biomed Res Ctr BRC, Resp Med Unit, Oxford OX3 9DU, Oxon, England.; Hinks, TSC (corresponding author), Univ Oxford, Nuffield Dept Med Expt Med, Oxford Biomed Res Ctr BRC, Natl Inst Hlth Res NIHR, Oxford OX3 9DU, Oxon, England.
EM timothy.hinks@ndm.ox.ac.uk
OI Hinks, Timothy/0000-0003-0699-2373
FU National Institute for Health Research (NIHR) Oxford Biomedical Research
   Centre (BRC)National Institute for Health Research (NIHR); University of
   Oxford; Pfizer Inc.Pfizer; Wellcome TrustWellcome Trust [211050/Z/18/z];
   NIHR Applied Research Collaboration (ARC) West Midlands
FX This research is funded by the National Institute for Health Research
   (NIHR) Oxford Biomedical Research Centre (BRC), by the University of
   Oxford and by an unrestricted research grant from Pfizer Inc. TSCH is
   supported by a fellowship from the Wellcome Trust (211050/Z/18/z). This
   research is supported by the NIHR Applied Research Collaboration (ARC)
   West Midlands through funding to DSL. The views expressed are those of
   the authors and not necessarily those of the NHS, the NIHR or the
   Department of Health and Social Care. The funders played no role in the
   study design.
CR Altenburg J, 2011, RESPIRATION, V81, P67, DOI 10.1159/000320319
   Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Arabi YM, 2019, INT J INFECT DIS, V81, P184, DOI 10.1016/j.ijid.2019.01.041
   Baden LR, 2020, NEW ENGL J MED, V382, P1851, DOI 10.1056/NEJMe2005477
   Banjanac M, 2012, PHARMACOL RES, V66, P357, DOI 10.1016/j.phrs.2012.06.011
   Belhadi D, 2020, BRIEF REV ANTIVIRAL, DOI [10.1101/2020.03.18.20038190, DOI 10.1101/2020.03.18.20038190]
   Bosnar M, 2011, INT IMMUNOPHARMACOL, V11, P424, DOI 10.1016/j.intimp.2010.12.010
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cheng YJ, 2015, J AM COLL CARDIOL, V66, P2173, DOI 10.1016/j.jacc.2015.09.029
   Doan Thuy, 2020, Clin Infect Dis, V71, P2282, DOI 10.1093/cid/ciaa606
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gibson PG, 2017, LANCET, V390, P659, DOI 10.1016/S0140-6736(17)31281-3
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   Hansen MP, 2019, CURATORIAL CHALLENGE, P1
   Hodge S, 2008, AM J RESP CRIT CARE, V178, P139, DOI 10.1164/rccm.200711-1666OC
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui D, 2013, J THORAC DIS, V5, P613, DOI 10.3978/j.issn.2072-1439.2013.09.01
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601
   Kanoh S, 2010, CLIN MICROBIOL REV, V23, P590, DOI 10.1128/CMR.00078-09
   Kawamura K, 2018, INT J ANTIMICROB AG, V51, P918, DOI 10.1016/j.ijantimicag.2018.02.009
   Kezerashvili A, 2007, J INTERV CARD ELECTR, V18, P243, DOI 10.1007/s10840-007-9124-y
   Khan AA, 1999, INT J ANTIMICROB AG, V11, P121, DOI 10.1016/S0924-8579(98)00091-0
   Kouznetsova J, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.88
   Kudoh S, 1998, AM J RESP CRIT CARE, V157, P1829, DOI 10.1164/ajrccm.157.6.9710075
   Lee N, 2017, ANTIVIR RES, V144, P48, DOI 10.1016/j.antiviral.2017.05.008
   Legssyer R, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-134
   Li CF, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00394-19
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Marjanovic N, 2011, PHARMACOL RES, V63, P389, DOI 10.1016/j.phrs.2011.02.001
   Meyer M, 2009, AM J RESP CELL MOL, V41, P590, DOI 10.1165/rcmb.2008-0155OC
   Milberg P, 2002, J PHARMACOL EXP THER, V303, P218, DOI 10.1124/jpet.102.037911
   Murphy BS, 2008, J ANTIMICROB CHEMOTH, V61, P554, DOI 10.1093/jac/dkn007
   Nabirotchkin S., 2020, FOCUSING UNFOLDED PR, DOI DOI 10.20944/PREPRINTS202003.0302.V1
   NAGAI H, 1991, RESPIRATION, V58, P145, DOI 10.1159/000195915
   Parnham MJ, 2014, PHARMACOL THERAPEUT, V143, P225, DOI 10.1016/j.pharmthera.2014.03.003
   Polgreen LA, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008074
   Porter JD, 2016, J ANTIMICROB CHEMOTH, V71, P2767, DOI 10.1093/jac/dkw222
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schogler A, 2015, EUR RESPIR J, V45, P428, DOI 10.1183/09031936.00102014
   Serisier DJ, 2013, LANCET RESP MED, V1, P262, DOI 10.1016/S2213-2600(13)70038-9
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Shinkai M, 2006, AM J PHYSIOL-LUNG C, V290, pL75, DOI 10.1152/ajplung.00093.2005
   Touret F., 2020, IN VITRO SCREENING F, DOI [10.1101/2020.04.03.023846., DOI 10.1101/2020.04.03.023846]
   Weng D, 2019, BIOMED PHARMACOTHER, V110, P440, DOI 10.1016/j.biopha.2018.11.090
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yamauchi K, 2009, INT J BIOL SCI, V5, P667
   Zeng SN, 2019, INT J ANTIMICROB AG, V53, P362, DOI 10.1016/j.ijantimicag.2018.12.009
   Zhou Y, 2020, BIORXIV, DOI [10.1101/2020.02.12.945576, DOI 10.1101/2020.02.12.945576]
NR 55
TC 2
Z9 2
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 17
PY 2020
VL 21
IS 1
AR 718
DI 10.1186/s13063-020-04593-8
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NF8AW
UT WOS:000563516500001
PM 32807209
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Palamenghi, L
   Barello, S
   Boccia, S
   Graffigna, G
AF Palamenghi, Lorenzo
   Barello, Serena
   Boccia, Stefania
   Graffigna, Guendalina
TI Mistrust in biomedical research and vaccine hesitancy: the forefront
   challenge in the battle against COVID-19 in Italy
SO EUROPEAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Covid-19; Vaccine hesitancy; Trust in science; Vaccine effectiveness;
   Trust in vaccine
ID SCIENCE
AB Researchers have been working quickly and collaboratively for the development of vaccines against the COVID-19 virus. The effort of the scientific community in searching a vaccine for COVID-19 may be hampered by a diffused vaccine hesitancy. Two waves of data collection on representative samples of the Italian population (during the "first" and "second" phase of the Italian Covid-19 mitigation strategy) were conducted to understand citizens' perceptions and behaviors about preventive behaviors willingness to vaccine for COVID-19. Our study shows that willingness to COVID-19 vaccine is correlated to trust in research and in vaccines, which decreased between phase 1 and phase 2 of the Italian pandemic. According to the results of our study, the proportion of citizens that seem to be intentioned to get the Covid-19 vaccine is probably too small to effectively stop the spreading of the disease. This requires to foster a climate of respectful mutual trust between science and society, where scientific knowledge is not only preached but also cultivated and sustained thanks to the emphatic understanding of citizens worries, needs of reassurance and health expectations.
C1 [Palamenghi, Lorenzo; Barello, Serena; Graffigna, Guendalina] Univ Cattolica Sacro Cuore, Dept Psychol, EngageMinds HUB Consumer, Food & Hlth Engagement Res Ctr, Milan, Italy.
   [Boccia, Stefania] Univ Cattolica Sacro Cuore, Univ Dept Hlth Sci & Publ Hlth, Sect Hyg, Rome, Italy.
   [Boccia, Stefania] Fdn Policlin Univ A Gemelli IRCCS, Publ Hlth Area, Dept Woman & Child Hlth & Publ Hlth, Rome, Italy.
RP Graffigna, G (corresponding author), Univ Cattolica Sacro Cuore, Dept Psychol, EngageMinds HUB Consumer, Food & Hlth Engagement Res Ctr, Milan, Italy.
EM guendalina.graffigna@unicatt.it
RI Barello, Serena/ABD-6168-2020; Palamenghi, Lorenzo/ABB-6320-2020
OI Barello, Serena/0000-0002-8514-2563; Palamenghi,
   Lorenzo/0000-0002-8222-3915
FU Fondazione Cariplo & Regione LombardiaFondazione CariploRegione
   Lombardia
FX This work was conducted within the CRemona Agri-Food Technologies
   (CRAFT) project, supported by Fondazione Cariplo & Regione Lombardia
CR Bela G, 2016, CONSERV BIOL, V30, P990, DOI 10.1111/cobi.12762
   Chakraborty I, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138882
   Dubey S, 2020, DIABETES METAB SYND, V14, P779, DOI 10.1016/j.dsx.2020.05.035
   Gadarian Shana Kushner, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3562796, DOI 10.2139/SSRN.3562796]
   Garfin DR, 2020, HEALTH PSYCHOL, V39, P355, DOI 10.1037/hea0000875
   Garnier-Crussard A, 2020, J AM GERIATR SOC, V68, P939, DOI 10.1111/jgs.16407
   Giambi C, 2018, VACCINE, V36, P779, DOI 10.1016/j.vaccine.2017.12.074
   Goldenberg Maya J., 2016, Perspectives on Science, V24, P552, DOI 10.1162/POSC_a_00223
   Goodman JL, 2020, JAMA-J AM MED ASSOC, V323, P1899, DOI 10.1001/jama.2020.6434
   Guerrini CJ, 2018, SCIENCE, V361, P134, DOI 10.1126/science.aar8379
   Harper CA, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00281-5
   Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3
   Jones DS, 2020, NEW ENGL J MED, V382, P1681, DOI 10.1056/NEJMp2004361
   Ministero della Salute, DAT COP VACC
   Paakkari L, 2020, LANCET PUBLIC HEALTH, V5, pE249, DOI 10.1016/S2468-2667(20)30086-4
   Provenzi L, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00282
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
NR 20
TC 1
Z9 1
U1 9
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0393-2990
EI 1573-7284
J9 EUR J EPIDEMIOL
JI Eur. J. Epidemiol.
PD AUG
PY 2020
VL 35
IS 8
BP 785
EP 788
DI 10.1007/s10654-020-00675-8
EA AUG 2020
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NM3LR
UT WOS:000560874900001
PM 32808095
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tamai, M
   Maekawa, A
   Goto, N
   Ge, LD
   Nishida, T
   Iwahashi, H
   Yokomi, A
AF Tamai, Masakazu
   Maekawa, Aya
   Goto, Noriko
   Ge, Lindun
   Nishida, Tsutomu
   Iwahashi, Hiromi
   Yokomi, Akinori
TI Three cases of COVID-19 patients presenting with erythema
SO JOURNAL OF DERMATOLOGY
LA English
DT Article
DE COVID-19; cutaneous manifestations; eruption; erythema; rash
AB Individuals infected with the novel coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) who develop coronavirus disease 2019 (COVID-19) experience many symptoms; however, cutaneous manifestations are relatively rare. The authors encountered three patients with COVID-19 who presented with erythema and suspected viral rash. In all cases, erythema appeared after the onset of the initial symptoms of COVID-19. Erythema was considered to be caused by COVID-19 and not a drug-induced eruption because, in all cases, erythema was relieved merely by external medicine and oral antihistamines, without discontinuing the original medication. The authors' hospital accepted 69 COVID-19 patients between 22 February 2020 and 31 May 2020 and, of these, three (4.3%) exhibited eruptions, and all cases presented erythema. Except for seven patients who exhibited positive nasopharyngeal swab tests for SARS-CoV-2 RNA but no symptoms, three (4.8%) of the remaining 62 patients exhibited erythema. Although various types of eruptions have been reported in patients with COVID-19, erythema was the only type in our patients. Erythema in the three patients exhibited many similarities to that previously reported in COVID-19 patients, particularly in the manner it appeared and disappeared. For these reasons, these three cases were considered typical examples of erythema in patients with COVID-19. Considering previous studies and the three cases reported here, there is a high probability that SARS-CoV-2 can cause erythema.
C1 [Tamai, Masakazu; Maekawa, Aya; Goto, Noriko; Yokomi, Akinori] Toyonaka City Hosp, Dept Dermatol, Toyonaka, Osaka, Japan.
   [Ge, Lindun] Toyonaka City Hosp, Dept Neurol, Toyonaka, Osaka, Japan.
   [Nishida, Tsutomu] Toyonaka City Hosp, Dept Gastroenterol, Toyonaka, Osaka, Japan.
   [Iwahashi, Hiromi] Toyonaka City Hosp, Dept Internal Med, Toyonaka, Osaka, Japan.
RP Tamai, M (corresponding author), Toyonaka City Hosp, 4-14-1 Shibahara, Toyonaka, Osaka 5608565, Japan.
EM king.plus.1.well@gmail.coms
RI Nishida, Tsutomu/M-5744-2017
OI Nishida, Tsutomu/0000-0003-4037-9003
CR Ahouach B, 2020, BRIT J DERMATOL, V183, pE31, DOI 10.1111/bjd.19168
   Amatore F, 2020, J EUR ACAD DERMATOL, V34, pE304, DOI 10.1111/jdv.16528
   Casas CG, 2020, BRIT J DERMATOL, V183, P71, DOI 10.1111/bjd.19163
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hedou M, 2020, J EUR ACAD DERMATOL, V34, pE299, DOI 10.1111/jdv.16519
   Jimenez-Cauhe J, 2020, CLIN EXP DERMATOL, V45, P892, DOI 10.1111/ced.14281
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Mahe A, 2020, J EUR ACAD DERMATOL, V34, pE246, DOI 10.1111/jdv.16471
   Morey-Olive M, 2020, AN PEDIATR, V92, P374, DOI [10.1016/j.anpedi.2020.04.013, 10.1016/j.anpede.2020.04.002]
   Paolino G, 2020, INT J DERMATOL, V59, P874, DOI 10.1111/ijd.14919
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Rivera-Oyola Ryan, 2020, JAAD Case Rep, V6, P537, DOI 10.1016/j.jdcr.2020.04.027
   Sachdeva M, 2020, J DERMATOL SCI, V98, P75, DOI 10.1016/j.jdermsci.2020.04.011
   Zengarini C, 2020, J EUR ACAD DERMATOL, V34, pE453, DOI 10.1111/jdv.16569
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
NR 15
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0385-2407
EI 1346-8138
J9 J DERMATOL
JI J. Dermatol.
PD OCT
PY 2020
VL 47
IS 10
BP 1175
EP 1178
DI 10.1111/1346-8138.15532
EA AUG 2020
PG 4
WC Dermatology
SC Dermatology
GA NW6MI
UT WOS:000560913900001
PM 32881072
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hachim, A
   Kavian, N
   Cohen, CA
   Chin, AWH
   Chu, DKW
   Mok, CKP
   Tsang, OTY
   Yeung, YC
   Perera, RAPM
   Poon, LLM
   Peiris, JSM
   Valkenburg, SA
AF Hachim, Asmaa
   Kavian, Niloufar
   Cohen, Carolyn A.
   Chin, Alex W. H.
   Chu, Daniel K. W.
   Mok, Chris K. P.
   Tsang, Owen T. Y.
   Yeung, Yiu Cheong
   Perera, Ranawaka A. P. M.
   Poon, Leo L. M.
   Peiris, J. S. Malik
   Valkenburg, Sophie A.
TI ORF8 and ORF3b antibodies are accurate serological markers of early and
   late SARS-CoV-2 infection
SO NATURE IMMUNOLOGY
LA English
DT Article
AB Accurate serology testing is urgently needed to help diagnose SARS-CoV-2 infection. Here Valkenburg and colleagues use a luciferase immunoprecipitation system to assess the antibody responses to 15 different SARS-CoV-2 antigens in patients with COVID-19 and find ORF8 and ORF3b antibodies, taken together as a cluster of points, identified 96.5% of COVID-19 samples at early and late time points of disease with 99.5% specificity
   The SARS-CoV-2 virus emerged in December 2019 and has caused a worldwide pandemic due to the lack of any pre-existing immunity. Accurate serology testing is urgently needed to help diagnose infection, determine past exposure of populations and assess the response to a future vaccine. The landscape of antibody responses to SARS-CoV-2 is unknown. In this study, we utilized the luciferase immunoprecipitation system to assess the antibody responses to 15 different SARS-CoV-2 antigens in patients with COVID-19. We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses. ORF8 and ORF3b antibodies, taken together as a cluster of points, identified 96.5% of COVID-19 samples at early and late time points of disease with 99.5% specificity. Our findings could be used to develop second-generation diagnostic tests to improve serological assays for COVID-19 and are important in understanding pathogenicity.
C1 [Hachim, Asmaa; Kavian, Niloufar; Cohen, Carolyn A.; Mok, Chris K. P.; Poon, Leo L. M.; Peiris, J. S. Malik; Valkenburg, Sophie A.] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, HKU Pasteur Res Pole, Hong Kong, Peoples R China.
   [Kavian, Niloufar] Univ Paris 05, Ctr Hosp Univ Cochin, AP HP, Fac Med,Sorbonne Paris Cite,Hop Univ Paris Ctr, Paris, France.
   [Kavian, Niloufar] Univ Paris 05, Inst Cochin, INSERM U1016, Sorbonne Paris Cite, Paris, France.
   [Chin, Alex W. H.; Chu, Daniel K. W.; Perera, Ranawaka A. P. M.; Poon, Leo L. M.; Peiris, J. S. Malik] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Div Publ Hlth Lab Sci, Hong Kong, Peoples R China.
   [Tsang, Owen T. Y.; Yeung, Yiu Cheong] Princess Margaret Hosp, Hosp Author Hong Kong, Infect Dis Ctr, Hong Kong, Peoples R China.
RP Kavian, N; Valkenburg, SA (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, HKU Pasteur Res Pole, Hong Kong, Peoples R China.; Kavian, N (corresponding author), Univ Paris 05, Ctr Hosp Univ Cochin, AP HP, Fac Med,Sorbonne Paris Cite,Hop Univ Paris Ctr, Paris, France.; Kavian, N (corresponding author), Univ Paris 05, Inst Cochin, INSERM U1016, Sorbonne Paris Cite, Paris, France.
EM niloufar@hku.hk; sophiev@hku.hk
RI Poon, Leo/AAP-6887-2020; Dr, Ranawaka A.P.M Perera -/N-8263-2015
OI Dr, Ranawaka A.P.M Perera -/0000-0003-3936-1535; Kavian,
   Niloufar/0000-0003-2829-3311
FU Research Grants Scheme [GRF 17113718]; Health and Medical Research Fund
   [HMRF COVID190115]; Hong Kong Health and Medical Research Fund
   [COVID190115]; General Research Fund [17113718]
FX This study was partly supported by the Research Grants Scheme (GRF
   17113718) and Health and Medical Research Fund (HMRF COVID190115). We
   thank L.-F. Wang (Duke NUS, Singapore) for technical advice for
   establishing the LIPS assay. We thank J.T. Wu and K. Leung for providing
   access to the blood donor plasma as controls. The authors thank O.
   Kavian and H. Hagen for their help with the ConTeXt software used in
   Figs. 3f and 4d. This project was supported by the Hong Kong Health and
   Medical Research Fund (COVID190115, from S.A.V.) and General Research
   Fund (17113718, from S.A.V.). The study of the patients with COVID-19
   was approved by the Institutional Review Board of the Hong Kong West
   Cluster of the Hospital Authority of Hong Kong (approval no. UW20-169).
   The collection of plasma from blood donors serving as controls was
   approved by the Institutional Review Board of The Hong Kong University
   and the Hong Kong Island West Cluster (reference no. UW16-254).
CR Burbelo PD, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-22
   Burbelo PD, 2019, DIAGNOSTICS, V9, DOI 10.3390/diagnostics9030089
   Burbelo PD, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0545-y
   Burbelo Peter D, 2009, J Vis Exp, DOI 10.3791/1549
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7
   Juno JA, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0995-0
   Keng CT, 2006, VIROLOGY, V354, P132, DOI 10.1016/j.virol.2006.06.026
   Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725
   McBride R, 2012, VIRUSES-BASEL, V4, P2902, DOI 10.3390/v4112902
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Su Y. C. F, 2020, MBIO, DOI [10.1128/mBio.01610-20, DOI 10.1128/MBI0.01610-20]
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang H., 2020, SARS COV 2 PROTEOME, P1, DOI [10.1101/2020.03.26.994756, DOI 10.1101/2020.03.26.994756]
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Weissleder R, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc1931
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yong SEF, 2020, LANCET INFECT DIS, V20, P809, DOI 10.1016/S1473-3099(20)30273-5
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zeng WH, 2020, BIOCHEM BIOPH RES CO, V527, P618, DOI 10.1016/j.bbrc.2020.04.136
   Zhang CX, 2020, J PROTEOME RES, V19, P1351, DOI 10.1021/acs.jproteome.0c00129
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   ZHANG Y, 2020, P ASM INT DES ENG
NR 28
TC 6
Z9 6
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
EI 1529-2916
J9 NAT IMMUNOL
JI Nat. Immunol.
PD OCT
PY 2020
VL 21
IS 10
BP 1293
EP +
DI 10.1038/s41590-020-0773-7
EA AUG 2020
PG 18
WC Immunology
SC Immunology
GA NR0OB
UT WOS:000561014100001
PM 32807944
OA Bronze
DA 2021-01-01
ER

PT J
AU Lu, J
   Lu, GL
   Tan, SD
   Xia, J
   Xiong, HL
   Yu, XF
   Qi, QQ
   Yu, X
   Li, L
   Yu, H
   Xia, NS
   Zhang, TY
   Xu, YJ
   Lin, JZ
AF Lu, Jing
   Lu, Guoliang
   Tan, Shudan
   Xia, Jia
   Xiong, Hualong
   Yu, Xiaofei
   Qi, Qingqing
   Yu, Xiang
   Li, Li
   Yu, Hang
   Xia, Ningshao
   Zhang, Tianying
   Xu, Yingjie
   Lin, Jinzhong
TI A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces
   a strong antiviral-like immune response in mice
SO CELL RESEARCH
LA English
DT Letter
ID RESPIRATORY SYNDROME CORONAVIRUS; STRUCTURAL PROTEINS
C1 [Lu, Jing; Lu, Guoliang; Tan, Shudan; Li, Li; Lin, Jinzhong] Fudan Univ, Sch Life Sci, Zhongshan Hosp, State Key Lab Genet Engn, Shanghai 200438, Peoples R China.
   [Xia, Jia] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Urol, Sch Med, Shanghai 200092, Peoples R China.
   [Xiong, Hualong; Xia, Ningshao; Zhang, Tianying] Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Natl Inst Diagnost & Vaccine Dev Infect Dis, Sch Life Sci, Xiamen 361102, Fujian, Peoples R China.
   [Xiong, Hualong; Xia, Ningshao; Zhang, Tianying] Xiamen Univ, Sch Publ Hlth, Xiamen 361102, Fujian, Peoples R China.
   [Yu, Xiaofei; Qi, Qingqing] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200438, Peoples R China.
   [Yu, Xiang; Xu, Yingjie] Shanghai Jiao Tong Univ, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, Sch Med, Shanghai 200025, Peoples R China.
   [Yu, Hang] Shanghai RNACure Biopharma Co Ltd, Shanghai 200438, Peoples R China.
RP Lin, JZ (corresponding author), Fudan Univ, Sch Life Sci, Zhongshan Hosp, State Key Lab Genet Engn, Shanghai 200438, Peoples R China.; Zhang, TY (corresponding author), Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Natl Inst Diagnost & Vaccine Dev Infect Dis, Sch Life Sci, Xiamen 361102, Fujian, Peoples R China.; Zhang, TY (corresponding author), Xiamen Univ, Sch Publ Hlth, Xiamen 361102, Fujian, Peoples R China.; Xu, YJ (corresponding author), Shanghai Jiao Tong Univ, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, Sch Med, Shanghai 200025, Peoples R China.
EM tyzhang1003@163.com; xuyingjie@shsmu.edu.cn; linjinzhong@fudan.edu.cn
FU Fudan University; Shanghai Municipal Science and Technology Major
   Project [2017SHZDZX01]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81991495];
   Shanghai RNACure Biopharma; Shanghai Jiao Tong University
FX This work was supported by the Fudan University Special Funds for
   COVID-19 and the Shanghai Municipal Science and Technology Major Project
   (2017SHZDZX01) to J. Lin, Shanghai Jiao Tong University Special Funds
   for COVID-19 to Y.X., the National Natural Science Foundation of China
   (81991495) to T.Z., and the Shanghai RNACure Biopharma. We thank Dr. Wei
   Yu, Dr. Jin Li, Dr. Shangyu Hong, and Dr. Jiaxue Wu for assistance in
   animal experiments. We also thank Dr. Xi Zhu for assistance in LNP
   formulations, and Professors Li Jin and Xinhua Lin for reading our
   manuscript and providing insightful suggestions.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Chroboczek J, 2014, ACTA BIOCHIM POL, V61, P531
   Nakauchi M, 2008, MICROBIOL IMMUNOL, V52, P625, DOI 10.1111/j.1348-0421.2008.00079.x
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08
   Wang C, 2017, ONCOTARGET, V8, P12686, DOI 10.18632/oncotarget.8475
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 8
TC 3
Z9 2
U1 9
U2 9
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD OCT
PY 2020
VL 30
IS 10
BP 936
EP 939
DI 10.1038/s41422-020-00392-7
EA AUG 2020
PG 4
WC Cell Biology
SC Cell Biology
GA NV6DH
UT WOS:000560319600001
PM 32801356
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Perks, B
   Cluver, LD
AF Perks, Benjamin
   Cluver, Lucie D.
TI The parenting 'vaccine'
SO NATURE HUMAN BEHAVIOUR
LA English
DT Letter
ID ABUSE
AB The world is waiting for a vaccine against SARS-CoV-2. In anticipation of successful trial results, preparations are being made for an unprecedented effort to achieve universal coverage and protection. But the interim measures to mitigate COVID-19 have brought their own severe and negative aftershocks. Global lockdowns and closures of schools and protective services have shone light on the vulnerability of children. Challenges of parenting under the strain of the epidemic are near-universal, and most harsh parenting is not malicious, but triggered by stress, poverty and mental health distress. In the extreme, the situation of fragile families affected by violence and neglect has worsened(1), abusers have had increased impunity and victims have been cut off from supportive teachers, social workers and friends. The looming economic fallout and uncertainty is adding yet more pressure onto such family settings, with lifetime and intergenerational consequences for the children affected. But there is a cost-effective and scalable response.
C1 [Perks, Benjamin] UNICEF, New York, NY USA.
   [Perks, Benjamin] Univ Birmingham, Jubilee Ctr, Birmingham, W Midlands, England.
   [Cluver, Lucie D.] Univ Oxford, Dept Social Policy & Intervent, Oxford, England.
   [Cluver, Lucie D.] Univ Cape Town, Dept Psychiat & Mental Hlth, Cape Town, South Africa.
RP Cluver, LD (corresponding author), Univ Oxford, Dept Social Policy & Intervent, Oxford, England.; Cluver, LD (corresponding author), Univ Cape Town, Dept Psychiat & Mental Hlth, Cape Town, South Africa.
EM lucie.cluver@spi.ox.ac.uk
OI Cluver, Lucie/0000-0002-0418-835X
CR Anda RF, 2006, EUR ARCH PSY CLIN N, V256, P174, DOI 10.1007/s00406-005-0624-4
   Cluver L, 2020, LANCET, V395, pE64, DOI 10.1016/S0140-6736(20)30736-4
   Cluver LD, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000539
   Fore H.H., 2020, JOINT LEADERS STATEM
   Hillis S, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-4079
   Nemeroff CB, 2016, NEURON, V89, P892, DOI 10.1016/j.neuron.2016.01.019
   Pereznieto P., 2014, COSTS EC IMP VIOL CH
   Puffer ES, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172611
   Ward CL, 2020, J CHILD PSYCHOL PSYC, V61, P503, DOI 10.1111/jcpp.13129
   World Health Organization (WHO), 2016, INSPIRE 7 STRAT END
NR 10
TC 0
Z9 0
U1 4
U2 4
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2397-3374
J9 NAT HUM BEHAV
JI Nat. Hum. Behav.
PD OCT
PY 2020
VL 4
IS 10
BP 985
EP 985
DI 10.1038/s41562-020-0932-8
EA AUG 2020
PG 1
WC Psychology, Biological; Multidisciplinary Sciences; Neurosciences;
   Psychology, Experimental
SC Psychology; Science & Technology - Other Topics; Neurosciences &
   Neurology
GA OB1KE
UT WOS:000560287600001
PM 32807939
OA Bronze
DA 2021-01-01
ER

PT J
AU Sharif-Askari, NS
   Sharif-Askari, FS
   Mdkhana, B
   Al Heialy, S
   Ratemi, E
   Alghamdi, M
   Abusnana, S
   Kashour, T
   Hamid, Q
   Halwani, R
AF Sharif-Askari, Narjes Saheb
   Sharif-Askari, Fatemeh Saheb
   Mdkhana, Bushra
   Al Heialy, Saba
   Ratemi, Elaref
   Alghamdi, Malak
   Abusnana, Salah
   Kashour, Tarek
   Hamid, Qutayba
   Halwani, Rabih
TI Effect of common medications on the expression of SARS-CoV-2 entry
   receptors in liver tissue
SO ARCHIVES OF TOXICOLOGY
LA English
DT Article
DE ACE2; TMPRSS2; SARS-CoV-2; COVID-19; Liver; Medications; Metformin;
   Acetaminophen; Nsaids; Hepatocyte
ID CORONAVIRUS; TMPRSS2; ACE2
AB Besides lung drastic involvement, SARS-CoV-2 severely affected other systems including liver. Emerging epidemiological studies brought the attentions towards liver injury and impairment as a potential outcome of COVID19. Angiotensin-converting enzyme 2 (ACE2) and Transmembrane serine protease (TMPRSS2) are the main cell entry receptors of SARS-CoV-2. We have tested the ability of medications to regulate expression of SARS-CoV-2 receptors. Understanding that may reflect how such medications may affect the level of infectivity and permissibility of the liver following COVID-19. Using transcriptomic datasets, Toxicogenomic Project-Genomics Assisted Toxicity Evaluation System (Open TG-GATEs) and GSE30351, we have tested the ability of ninety common medications to regulate COVID-19 receptors expression in human primary hepatocytes. Most medications displayed a dose-dependent change in expression of receptors which could hint at a potentially more pronounced change with chronic use. The expression level of TMPRSS2 was increased noticeably with a number of medications such as metformin. Within the analgesics, acetaminophen revealed a dose-dependent reduction in expression of ACE2, while non-steroidal anti-inflammatory drugs had mixed effect on receptors expression. To confirm the observed effects on primary human hepatocytes, rat hepatocyte treatments data was obtained from DrugMatrix toxicogenomic database (GSE57805), which showed a similar ACE2 and TMPRSS2 expression pattern. Treatment of common co-morbidities often require chronic use of multiple medications, which may result in an additive increase in the expression of ACE2 and TMPRSS2. More research is needed to determine the effect of different medications on COVID-19 receptors.
C1 [Sharif-Askari, Narjes Saheb; Sharif-Askari, Fatemeh Saheb; Mdkhana, Bushra; Hamid, Qutayba; Halwani, Rabih] Univ Sharjah, Coll Med, Sharjah Inst Med Res, POB 27272, Sharjah, U Arab Emirates.
   [Al Heialy, Saba] Mohammed Bin Rashid Univ Med & Hlth Sci, Coll Med, Dubai, U Arab Emirates.
   [Ratemi, Elaref] Jubail Ind Coll, Dept Chem & Proc Engn Technol, Al Jubail, Saudi Arabia.
   [Alghamdi, Malak] King Saud Univ, Coll Med, Dept Pediat, Med Genet Div, Riyadh, Saudi Arabia.
   [Abusnana, Salah; Hamid, Qutayba; Halwani, Rabih] Univ Sharjah, Coll Med, Dept Clin Sci, Sharjah, U Arab Emirates.
   [Abusnana, Salah] Univ Hosp Sharjah, Diabet & Endocrinol Dept, Sharjah, U Arab Emirates.
   [Kashour, Tarek] King Saud Univ Med City, King Fahad Cardiac Ctr, Dept Cardiol, Riyadh, Saudi Arabia.
   [Al Heialy, Saba; Hamid, Qutayba] McGill Univ, Hlth Ctr, Res Inst, Meakins Christie Labs, Montreal, PQ, Canada.
   [Halwani, Rabih] King Saud Univ, Fac Med, Dept Pediat, Prince Abdullah Ben Khaled Celiac Dis Res Chair, Riyadh, Saudi Arabia.
RP Halwani, R (corresponding author), Univ Sharjah, Coll Med, Sharjah Inst Med Res, POB 27272, Sharjah, U Arab Emirates.; Halwani, R (corresponding author), Univ Sharjah, Coll Med, Dept Clin Sci, Sharjah, U Arab Emirates.; Halwani, R (corresponding author), King Saud Univ, Fac Med, Dept Pediat, Prince Abdullah Ben Khaled Celiac Dis Res Chair, Riyadh, Saudi Arabia.
EM rhalwani@sharjah.ac.ae
RI Halwani, Rabih/E-9311-2014
OI Halwani, Rabih/0000-0002-6516-7771; Saheb Sharif-Askari,
   Narjes/0000-0003-0482-6777
FU Tissue Injury and Repair (TIR) group operational grant [150317];
   COVID-19 research grant; Sandooq Al Watan Applied Research & Development
   grant; Prince Abdullah Ben Khalid Celiac Disease Research Chair, under
   the Vice Deanship of Research Chairs, King Saud University, Riyadh,
   Kingdom of Saudi Arabia;  [2001090275];  [2001090278]
FX This research has been financially supported by Tissue Injury and Repair
   (TIR) group operational grant (Grant code: 150317); COVID-19 research
   grant; seed grant (Grant code: 2001090275); and by collaborative
   research grant (Grant code: 2001090278) to RH, University of Sharjah,
   UAE; and by a Sandooq Al Watan Applied Research & Development grant to
   RH; and by Prince Abdullah Ben Khalid Celiac Disease Research Chair,
   under the Vice Deanship of Research Chairs, King Saud University,
   Riyadh, Kingdom of Saudi Arabia.
CR Alsaad KO, 2018, HISTOPATHOLOGY, V72, P516, DOI 10.1111/his.13379
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Boeckmans J, 2020, ARCH TOXICOL, V94, P1367, DOI 10.1007/s00204-020-02734-1
   Chau TN, 2004, HEPATOLOGY, V39, P302, DOI 10.1002/hep.20111
   Clarke NE, 2014, CLIN SCI, V126, P507, DOI 10.1042/CS20130291
   Dudoit S, 2002, STAT SINICA, V12, P111
   Esumi M, 2015, HEPATOLOGY, V61, P437, DOI 10.1002/hep.27426
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gusenleitner D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102579
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hughey JJ, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv229
   Igarashi Y, 2015, NUCLEIC ACIDS RES, V43, pD921, DOI 10.1093/nar/gku955
   Kossenkov AV, 2010, INT J DATA MIN BIOIN, V4, P72, DOI 10.1504/IJDMB.2010.030968
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Sharif-Askari NS, 2020, MOL THER-METH CLIN D, V18, P1, DOI 10.1016/j.omtm.2020.05.013
   Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Uehara T, 2010, MOL NUTR FOOD RES, V54, P218, DOI 10.1002/mnfr.200900169
   Wambier CG, 2020, J AM ACAD DERMATOL, V83, P308, DOI 10.1016/j.jaad.2020.04.032
   Wang YJ, 2020, J HEPATOL, V73, P807, DOI 10.1016/j.jhep.2020.05.002
   Yamamoto M, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00605
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhao B, 2020, PROTEIN CELL, V11, P771, DOI 10.1007/s13238-020-00718-6
NR 26
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5761
EI 1432-0738
J9 ARCH TOXICOL
JI Arch. Toxicol.
PD DEC
PY 2020
VL 94
IS 12
BP 4037
EP 4041
DI 10.1007/s00204-020-02869-1
EA AUG 2020
PG 5
WC Toxicology
SC Toxicology
GA OP9QL
UT WOS:000560271900001
PM 32808185
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zame, WR
   Bica, I
   Shen, C
   Curth, A
   Lee, HS
   Bailey, S
   Weatherall, J
   Wright, D
   Bretz, F
   van der Schaar, M
AF Zame, William R.
   Bica, Ioana
   Shen, Cong
   Curth, Alicia
   Lee, Hyun-Suk
   Bailey, Stuart
   Weatherall, James
   Wright, David
   Bretz, Frank
   van der Schaar, Mihaela
TI Machine Learning for Clinical Trials in the Era of COVID-19
SO STATISTICS IN BIOPHARMACEUTICAL RESEARCH
LA English
DT Article
DE Clinical trials; COVID-19; Machine learning; SARS-CoV-2; The novel
   SARS-CoV-2 virus and COVID-19; the disease it causes; have changed the
   whole world; We are facing a global health crisis-characterized as a
   pandemic by the World Health Organization (WHO)-unlike any in recent
   history; The international scientific community is struggling to
   understand both the virus and the disease; This requires efforts at an
   unprecedented level of international focus and cooperation to preserve
   clinical trial integrity during the pandemic; to develop and to identify
   treatments; and to find out under what conditions they are safe and
   effective
ID DESIGN; TOXICITY
AB The world is in the midst of a pandemic. We still know little about the disease COVID-19 or about the virus (SARS-CoV-2) that causes it. We do not have a vaccine or a treatment (aside from managing symptoms). We do not know if recovery from COVID-19 produces immunity, and if so for how long, hence we do not know if "herd immunity" will eventually reduce the risk or if a successful vaccine can be developed-and this knowledge may be a long time coming. In the meantime, the COVID-19 pandemic is presenting enormous challenges to medical research, and to clinical trials in particular. This article identifies some of those challenges and suggests ways in which machine learning (ML) can help in response to those challenges. We identify three areas of challenge: ongoing clinical trials for non-COVID-19 drugs, clinical trials for repurposing drugs to treat COVID-19, and clinical trials for new drugs to treat COVID-19. Within each of these areas, we identify aspects for which we believe ML can provide invaluable assistance.
C1 [Zame, William R.] Univ Calif Los Angeles, Dept Econ & Math, Los Angeles, CA USA.
   [Bica, Ioana] Univ Oxford, Dept Engn Sci, Oxford, England.
   [Bica, Ioana; van der Schaar, Mihaela] Alan Turing Inst, London, England.
   [Shen, Cong] Univ Virginia, Dept Elect & Comp Engn, Charlottesville, VA USA.
   [Curth, Alicia] Univ Oxford, Dept Stat, Oxford, England.
   [Lee, Hyun-Suk; van der Schaar, Mihaela] Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge CB2 1TN, England.
   [Bailey, Stuart] Novartis Pharmaceut, Cambridge, MA USA.
   [Weatherall, James; Wright, David] AstraZeneca, Cambridge, England.
   [Bretz, Frank] Novartis Pharma AG, Basel, Switzerland.
   [Bretz, Frank] Med Univ Vienna, Sect Med Stat, Vienna, Austria.
   [van der Schaar, Mihaela] Univ Calif Los Angeles, Dept Elect & Comp Engn, Los Angeles, CA USA.
RP van der Schaar, M (corresponding author), Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge CB2 1TN, England.
EM mv472@cam.ac.uk
CR Akacha M, 2020, STAT BIOPHARM RES, V12, P419, DOI 10.1080/19466315.2020.1788984
   ALAA A., 2018, P 35 INT C MACH LEAR, P129
   Alaa A. M., 2019, P 36 INT C MACH LEAR, V97, P191
   ALAA A. M., 2017, ADV NEURAL INFORM PR, V30, P3424
   Alaa A. M., 2017, INT C MACH LEARN DEE, P1
   Alaa A. M., 2020, ADJUTORIUM COVID 19
   Alaa Ahmed M, 2017, P 34 INT C MACH LEAR, V70, P60
   Alaimo S., 2018, COMPUTATIONAL METHOD, P97
   Atan Onur, 2019, P MACHINE LEARNING R, V89, P1891
   Athey S, 2016, P NATL ACAD SCI USA, V113, P7353, DOI 10.1073/pnas.1510489113
   Bekele BN, 2005, BIOMETRICS, V61, P344, DOI 10.1111/j.-1541-0420.2005.00314.x
   Berry DA, 2004, STAT SCI, V19, P175, DOI 10.1214/088342304000000044
   Bica I., 2020, 200212326 ARXIV
   Bica I., 2020, P 8 INT C LEARN REPR, P1
   Bica I, 2020, CLIN PHARMACOL THER, DOI 10.1002/cpt.1907
   Breiman L., 1984, CLASSIFICATION REGRE
   Bretz F, 2017, CLIN TRIALS, V14, P417, DOI 10.1177/1740774517699406
   Committee for Medicinal Products for Human Use (CHMP), 2020, CALL POOL EU RES RES
   Cruz-Roa A, 2017, SCI REP-UK, V7, DOI 10.1038/srep46450
   Dette H., 2019, 191008769 ARXIV
   Dodd LE, 2016, J INFECT DIS, V213, P1906, DOI 10.1093/infdis/jiw061
   EMA, 2020, GUID MAN CLIN TRIALS
   European Medicines Agency (EMA), 2020, POINTS CONS IMPL COR
   European Medicines Agency (EMA), 2020, COR DIS COVID 19
   Filipovych R, 2011, NEUROIMAGE, V54, P2185, DOI 10.1016/j.neuroimage.2010.09.074
   Food and Drug Administration (FDA) (, 2020, LETT EM US AUTH EUA
   Food and Drug Administration (FDA), 2020, GUID IND INV I REV B
   GITTINS JC, 1979, J ROY STAT SOC B MET, V41, P148
   Harrer S, 2019, TRENDS PHARMACOL SCI, V40, P577, DOI 10.1016/j.tips.2019.05.005
   Heshmati A, 2018, PERSPECT DEV MID E N, P1, DOI 10.1007/978-981-10-8126-2_1
   Hill JL, 2011, J COMPUT GRAPH STAT, V20, P217, DOI 10.1198/jcgs.2010.08162
   Hobbs BP, 2011, BIOMETRICS, V67, P1047, DOI 10.1111/j.1541-0420.2011.01564.x
   Infectious Diseases Data Observatory (IDDO), 2020, LIV SYST REV COVID 1
   Johansson U, 2018, EXPERT SYST APPL, V97, P394, DOI 10.1016/j.eswa.2017.12.041
   Kunz CU, 2020, STAT BIOPHARM RES, V12, P461, DOI 10.1080/19466315.2020.1799857
   LAI TL, 1985, ADV APPL MATH, V6, P4, DOI 10.1016/0196-8858(85)90002-8
   Lee H.-S., 2020, 200607917 ARXIV
   Lee HS, 2020, PR MACH LEARN RES, V108, P2645
   Lee JJ, 2012, STAT MED, V31, P2955, DOI 10.1002/sim.5404
   Lei J, 2018, J AM STAT ASSOC, V113, P1094, DOI 10.1080/01621459.2017.1307116
   LIM B, 2018, ADV NEUR IN, V31, P7483
   Meyer RD, 2020, STAT BIOPHARM RES, V12, P399, DOI 10.1080/19466315.2020.1779122
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Neil D., 2016, ADV NEURAL INFORM PR, V29, P3882
   Neyman J.S., 1923, ROCZNIKI NAUK ROLNIC, V10, P1
   Oxford, 2020, U OXF RECOVERY TRIAL
   Pallmann P, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1017-7
   Park JJH, 2018, CLIN EPIDEMIOL, V10, P343, DOI 10.2147/CLEP.S156708
   Printz C, 2015, CANCER-AM CANCER SOC, V121, P1529, DOI 10.1002/cncr.28994
   Proschan MA, 2016, CLIN TRIALS, V13, P39, DOI 10.1177/1740774515620145
   RUBIN DB, 1978, ANN STAT, V6, P34, DOI 10.1214/aos/1176344064
   Schmidli H, 2020, CLIN PHARMACOL THER, V107, P806, DOI 10.1002/cpt.1723
   Segar MW, 2020, EUR J HEART FAIL, V22, P148, DOI 10.1002/ejhf.1621
   Shalit U, 2017, P MACHINE LEARNING R, P3076
   Shen C., 2020, P 37 INT C MACH LEAR
   Shukla S. N., 2019, P 7 INT C LEARN REPR
   Stallard N, 2020, STAT BIOPHARM RES, V12, P483, DOI 10.1080/19466315.2020.1790415
   Su XG, 2009, J MACH LEARN RES, V10, P141
   Suo QL, 2018, IEEE T NANOBIOSCI, V17, P219, DOI 10.1109/TNB.2018.2837622
   Thompson WR, 1933, BIOMETRIKA, V25, P285, DOI 10.2307/2332286
   Tibshirani R. J., 2019, ADV NEURAL INFORM PR, V32, P2526
   Tran C, 2019, THIRTY-THIRD AAAI CONFERENCE ON ARTIFICIAL INTELLIGENCE / THIRTY-FIRST INNOVATIVE APPLICATIONS OF ARTIFICIAL INTELLIGENCE CONFERENCE / NINTH AAAI SYMPOSIUM ON EDUCATIONAL ADVANCES IN ARTIFICIAL INTELLIGENCE, P5183
   Varatharajah Y., 2018, 180900258 ARXIV
   Villar SS, 2015, STAT SCI, V30, P199, DOI 10.1214/14-STS504
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   World Health Organization, 2020, SOL CLIN TRIAL COVID
   Yin GS, 2006, BIOMETRICS, V62, P777, DOI 10.1111/j.1541-0420.2006.00534.x
   Yin K., 2019, P 2019 IEEE INT C HE, P1, DOI [10.1109/ICHI.2019.8904733, DOI 10.1109/ICHI.2019.8904733]
   Yoon J., 2018, P MACH LEARN RES P 3, P5689
   Yoon J., 2017, TIM SER WORKSH 34 IN, P1
   Yoon J, 2019, IEEE T BIO-MED ENG, V66, P1477, DOI 10.1109/TBME.2018.2874712
   Zhang W, 2006, STAT MED, V25, P2365, DOI 10.1002/sim.2325
   Zhu ZH, 2016, IEEE DATA MINING, P749, DOI [10.1109/ICDM.2016.90, 10.1109/ICDM.2016.0086]
NR 73
TC 1
Z9 1
U1 1
U2 1
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA
SN 1946-6315
J9 STAT BIOPHARM RES
JI Stat. Biopharm. Res.
PD OCT 1
PY 2020
VL 12
IS 4
BP 506
EP 517
DI 10.1080/19466315.2020.1797867
EA AUG 2020
PG 12
WC Mathematical & Computational Biology; Statistics & Probability
SC Mathematical & Computational Biology; Mathematics
GA OK5GB
UT WOS:000561843900001
OA Bronze
DA 2021-01-01
ER

PT J
AU Wells, SY
   Morland, LA
   Wilhite, ER
   Grubbs, KM
   Rauch, SAM
   Acierno, R
   McLean, CP
AF Wells, Stephanie Y.
   Morland, Leslie A.
   Wilhite, Emily R.
   Grubbs, Kathleen M.
   Rauch, Sheila A. M.
   Acierno, Ron
   McLean, Carmen P.
TI Delivering Prolonged Exposure Therapy via Videoconferencing During the
   COVID-19 Pandemic: An Overview of the Research and Special
   Considerations for Providers
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; PTSD;
   TELEHEALTH
AB Leveraging technology to provide evidence-based therapy for posttraumatic stress disorder (PTSD), such as prolonged exposure (PE), during the COVID-19 pandemic helps ensure continued access to first-line PTSD treatment. Clinical video teleconferencing (CVT) technology can be used to effectively deliver PE while reducing the risk of COVID-19 exposure during the pandemic for both providers and patients. However, provider knowledge, experience, and comfort level with delivering mental health care services, such as PE, via CVT is critical to ensure a smooth, safe, and effective transition to virtual care. Further, some of the limitations associated with the pandemic, including stay-at-home orders and physical distancing, require that providers become adept at applying principles of exposure therapy with more flexibility and creativity, such as when assigning in vivo exposures. The present paper provides the rationale and guidelines for implementing PE via CVT during COVID-19 and includes practical suggestions and clinical recommendations.
C1 [Wells, Stephanie Y.] Durham VA Hlth Care Syst, 508 Fulton St, Durham, NC 27705 USA.
   [Wells, Stephanie Y.] VISN 6 Mid Atlantic MIRECC, Durham, NC USA.
   [Wells, Stephanie Y.] Duke Univ, Dept Psychiat, Durham, NC 27706 USA.
   [Morland, Leslie A.; Wilhite, Emily R.; Grubbs, Kathleen M.] VA San Diego Healthcare Syst, San Diego, CA USA.
   [Morland, Leslie A.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
   [Morland, Leslie A.] Natl Ctr PTSD, Pacific Isl Div, Honolulu, HI USA.
   [Rauch, Sheila A. M.] VA Atlanta Healthcare Syst, Atlanta, GA USA.
   [Rauch, Sheila A. M.] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA USA.
   [Acierno, Ron] Univ Texas Hlth Sci Ctr Houston, Faillace Dept Psychiat, Houston, TX 77030 USA.
   [Acierno, Ron] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
   [McLean, Carmen P.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Palo Alto, CA USA.
   [McLean, Carmen P.] Stanford Univ, Palo Alto, CA 94304 USA.
RP Wells, SY (corresponding author), Durham VA Hlth Care Syst, 508 Fulton St, Durham, NC 27705 USA.
EM Stephanie.wells2@va.gov
CR Acierno R, 2017, BEHAV RES THER, V89, P57, DOI 10.1016/j.brat.2016.11.009
   Batten SV, 2009, PSYCHOL SERV, V6, P184, DOI 10.1037/a0015392
   Carrasquillo A., 2020, NEWSWEEK
   Centers for Disease Control and Prevention, 2020, PROT YOURS OTH
   Centers for Disease Control and Prevention, 2020, IMPL MIT STRAT COMM
   Cigrang JA, 2017, FAM SYST HEALTH, V35, P450, DOI 10.1037/fsh0000315
   Cuijpers P, 2019, JAMA PSYCHIAT, V76, P700, DOI 10.1001/jamapsychiatry.2019.0268
   Foa E., 2019, PROLONGED EXPOSURE T
   FOA EB, 1986, PSYCHOL BULL, V99, P20, DOI 10.1037/0033-2909.99.1.20
   Franklin CL, 2017, J TRAUMA DISSOCIATIO, V18, P116, DOI 10.1080/15299732.2016.1205704
   Fredman SJ, 2014, J ANXIETY DISORD, V28, P372, DOI 10.1016/j.janxdis.2014.04.001
   Gros DF, 2018, J TELEMED TELECARE, V24, P51, DOI 10.1177/1357633X16671096
   Gros DF, 2018, BEHAV COGN PSYCHOTH, V46, P35, DOI 10.1017/S135246581700039X
   Gros DF, 2011, J TELEMED TELECARE, V17, P332, DOI 10.1258/jtt.2011.101207
   Gros DF, 2011, BEHAV THER, V42, P276, DOI 10.1016/j.beth.2010.07.005
   Hernandez-Tejada MA, 2017, MIL PSYCHOL, V29, P157, DOI 10.1037/mil0000137
   Hernandez-Tejada MA, 2014, INT J PSYCHIAT MED, V48, P33, DOI 10.2190/PM.48.1.d
   Hundt NE, 2015, MIL MED, V180, P851, DOI 10.7205/MILMED-D-14-00536
   Luxton DD, 2014, INT J PSYCHIAT MED, V48, P19, DOI 10.2190/PM.48.1.c
   Meis LA, 2019, J CONSULT CLIN PSYCH, V87, P246, DOI 10.1037/ccp0000386
   Morland Leslie A, 2020, Curr Treat Options Psychiatry, P1, DOI 10.1007/s40501-020-00215-x
   Morland LA, 2020, DEPRESS ANXIETY, V37, P346, DOI 10.1002/da.22979
   Nacasch N, 2015, BEHAV THER, V46, P328, DOI 10.1016/j.beth.2014.12.002
   Ohannessian R, 2020, JMIR PUBLIC HLTH SUR, V6, P121, DOI 10.2196/18810
   Page KR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005953
   Price M, 2018, PSYCHIATRY, V81, P258, DOI 10.1080/00332747.2017.1402569
   Price M, 2013, PSYCHOL TRAUMA-US, V5, P93, DOI 10.1037/a0026244
   Rauch S, 2006, J CONTEMP PSYCHOTHER, V36, P61, DOI 10.1007/s10879-006-9008-y
   Reger GM, 2013, PSYCHOL SERV, V10, P342, DOI 10.1037/a0032774
   Sloan DM, 2018, JAMA PSYCHIAT, V75, P233, DOI 10.1001/jamapsychiatry.2017.4249
   Smith AC, 2020, J TELEMED TELECARE, V26, P309, DOI 10.1177/1357633X20916567
   Tuerk PW, 2010, J TRAUMA STRESS, V23, P116, DOI 10.1002/jts.20494
   Yuen EK, 2015, J CLIN PSYCHOL, V71, P500, DOI 10.1002/jclp.22168
   Zulman Donna M, 2019, JAMIA Open, V2, P323, DOI 10.1093/jamiaopen/ooz024
NR 34
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD AUG
PY 2020
VL 33
IS 4
BP 380
EP 390
DI 10.1002/jts.22573
EA AUG 2020
PG 11
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA NE4JK
UT WOS:000559911000001
PM 32881116
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Villar, J
   Anon, JM
   Ferrando, C
   Aguilar, G
   Munoz, T
   Ferreres, J
   Ambros, A
   Aldecoa, C
   Suarez-Sipmann, F
   Thorpe, KE
   Juni, P
   Slutsky, AS
AF Villar, Jesus
   Anon, Jose M.
   Ferrando, Carlos
   Aguilar, Gerardo
   Munoz, Tomas
   Ferreres, Jose
   Ambros, Alfonso
   Aldecoa, Cesar
   Suarez-Sipmann, Fernando
   Thorpe, Kevin E.
   Juni, Peter
   Slutsky, Arthur S.
CA DEXA-COVID19 Network
TI Efficacy of dexamethasone treatment for patients with the acute
   respiratory distress syndrome caused by COVID-19: study protocol for a
   randomized controlled superiority trial
SO TRIALS
LA English
DT Article
DE Acute respiratory distress syndrome; Coronavirus disease 19; COVID-19;
   Dexamethasone; Corticosteroids; Lung protective ventilation; Acute
   respiratory failure
ID CORTICOSTEROID TREATMENT; LUNG INJURY; SARS; MECHANISMS; PNEUMONIA;
   GUANGZHOU; SEVERITY; OUTBREAK
AB Background There are no specific generally accepted therapies for the coronavirus disease 2019 (COVID-19). The full spectrum of COVID-19 ranges from asymptomatic disease to mild respiratory tract illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multisystem organ failure, and death. The efficacy of corticosteroids in viral ARDS remains unknown. We postulated that adjunctive treatment of established ARDS caused by COVID-19 with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality. Methods/design This is a multicenter, randomized, controlled, parallel, open-label, superiority trial testing dexamethasone in 200 mechanically ventilated adult patients with established moderate-to-severe ARDS caused by confirmed SARS-CoV-2 infection. Established ARDS is defined as maintaining a PaO2/FiO(2) <= 200 mmHg on PEEP >= 10 cmH(2)O and FiO(2) >= 0.5 after 12 +/- 3 h of routine intensive care. Eligible patients will be randomly assigned to receive either dexamethasone plus standard intensive care or standard intensive care alone. Patients in the dexamethasone group will receive an intravenous dose of 20 mg once daily from day 1 to day 5, followed by 10 mg once daily from day 6 to day 10. The primary outcome is 60-day mortality. The secondary outcome is the number of ventilator-free days, defined as days alive and free from mechanical ventilation at day 28 after randomization. All analyses will be done according to the intention-to-treat principle. Discussion This study will assess the role of dexamethasone in patients with established moderate-to-severe ARDS caused by SARS-CoV-2.
C1 [Villar, Jesus; Anon, Jose M.; Ferrando, Carlos; Suarez-Sipmann, Fernando] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.
   [Villar, Jesus] Hosp Univ Dr Negrin, Res Unit, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Barranco Ballena S-N,4th Floor South Wing, Las Palmas Gran Canaria 35019, Spain.
   [Villar, Jesus; Slutsky, Arthur S.] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Anon, Jose M.] Hosp Univ La Paz, Intens Care Unit, IdIPaz, Madrid, Spain.
   [Ferrando, Carlos] Hosp Clin Barcelona, Dept Anesthesia & Crit Care, Barcelona, Spain.
   [Aguilar, Gerardo] Hosp Clin Univ, Dept Anesthesia, Valencia, Spain.
   [Munoz, Tomas] Hosp Univ Cruces, Intens Care Unit, Baracaldo, Vizcaya, Spain.
   [Ferreres, Jose] Hosp Clin Univ, Intens Care Unit, Valencia, Spain.
   [Ambros, Alfonso] Hosp Gen Univ Ciudad Real, Intens Care Unit, Ciudad Real, Spain.
   [Aldecoa, Cesar] Hosp Univ Rio Hortega, Dept Anesthesia, Valladolid, Spain.
   [Suarez-Sipmann, Fernando] Hosp Univ La Princesa, Intens Care Unit, Madrid, Spain.
   [Thorpe, Kevin E.; Juni, Peter] Li Ka Shing Knowledge Inst, Appl Hlth Res Ctr, Toronto, ON, Canada.
   [Thorpe, Kevin E.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Juni, Peter; Slutsky, Arthur S.] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Juni, Peter] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
RP Villar, J (corresponding author), Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain.; Villar, J (corresponding author), Hosp Univ Dr Negrin, Res Unit, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Barranco Ballena S-N,4th Floor South Wing, Las Palmas Gran Canaria 35019, Spain.; Villar, J (corresponding author), St Michaels Hosp, Keenan Res Ctr Biomed Sci, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
EM jesus.villar54@gmail.com
RI Villar, Jesus/R-4526-2019
OI Villar, Jesus/0000-0001-5687-3562; Badenes, Rafael/0000-0001-7017-0150;
   Castro Rebollo, Pedro/0000-0002-6118-8970; Blasco/0000-0002-9141-3198
FU Instituto de Salud Carlos III, Madrid, SpainInstituto de Salud Carlos
   III [CB06/06/1088, PI19/00141]; Asociacion Cientifica Pulmon y
   Ventilacion Mecanica, Las Palmas de Gran Canaria, Spain; Canadian
   Institute for Health Research, Ottawa, CanadaCanadian Institutes of
   Health Research (CIHR) [FDN143285, OV3-170344]
FX This investigator-initiated, academic, non-industry sponsored trial was
   funded by academic grants from the Instituto de Salud Carlos III,
   Madrid, Spain (CB06/06/1088, PI19/00141); Asociacion Cientifica Pulmon y
   Ventilacion Mecanica, Las Palmas de Gran Canaria, Spain; and the
   Canadian Institute for Health Research, Ottawa, Canada (Grants
   FDN143285, OV3-170344). Centers enrolling patients were the legal
   sponsors for the study in their own hospitals. Dexamethasone was
   provided free of cost by the Pharmacy Departments of all participating
   hospitals, with no obligation to blind the study nor to prepare any form
   of placebo. All researchers are independent of the funding bodies. None
   of the clinical investigators received any honorarium for participating
   in the trial. Study funding agencies have no role in study design;
   collection, management, analysis, and interpretation of data; writing of
   the report; and decision to submit the report for publication and no
   authority over any of these activities.
CR Angus DC, 2020, NEW ENGL J MED, V382, P1054, DOI 10.1056/NEJMe2000800
   Annane D, 2017, CRIT CARE MED, V45, P2078, DOI 10.1097/CCM.0000000000002737
   ASHBAUGH DG, 1967, LANCET, V2, P319
   Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Burnham EL, 2014, EUR RESPIR J, V43, P276, DOI 10.1183/09031936.00196412
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7
   Jefferies WM, 1998, CLIN INFECT DIS, V26, P708, DOI 10.1086/514594
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Meduri GU, 2009, CHEST, V136, P1631, DOI 10.1378/chest.08-2408
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meijvis SCA, 2011, LANCET, V377, P2023, DOI 10.1016/S0140-6736(11)60607-7
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Villar J, 2020, CRIT CARE EXPL, V2
   Villar J, 2007, AM J RESP CRIT CARE, V176, P795, DOI 10.1164/rccm.200610-1534OC
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Villar J, 2017, CURR OPIN CRIT CARE, V23, P4, DOI 10.1097/MCC.0000000000000378
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wheatland R, 2004, MED HYPOTHESES, V63, P855, DOI 10.1016/j.mehy.2004.04.009
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI DOI 10.1001/JAMA.2013.281053
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yehya N, 2019, AM J RESP CRIT CARE, V200, P828, DOI 10.1164/rccm.201810-2050CP
   Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0
NR 31
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 16
PY 2020
VL 21
IS 1
AR 717
DI 10.1186/s13063-020-04643-1
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NF8DK
UT WOS:000563523200001
PM 32799933
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Allam, AE
   Assaf, HK
   Hassan, HA
   Shimizu, K
   Elshaier, YAMM
AF Allam, Ahmed E.
   Assaf, Hamdy K.
   Hassan, Heba Ali
   Shimizu, Kuniyoshi
   Elshaier, Yaseen A. M. M.
TI Anin silicoperception for newly isolated flavonoids from peach fruit as
   privileged avenue for a countermeasure outbreak of COVID-19
SO RSC ADVANCES
LA English
DT Article
ID FLAVANONE GLYCOSIDES; INHIBITORS; DRUG; REPLICATION; CHLOROQUINE;
   DERIVATIVES; THALIDOMIDE; DESIGN
AB 3 '-Hydroxy-4 '-methoxy-chroman-7-O-beta-d-glucopyranoside4was first isolated from a natural source, together with three known compounds, the ferulic acid heptyl ester1, naringenin2, and 4,2 ',4 '-trihydroxy-6 '-methoxychalcone-4 '-O-beta-d-glucopyranoside3, which were isolated from peach [Prunus persica(L.) Batsch] fruits. These compounds were subjected to different virtual screening strategies in order to examine their activity to combat the COVID-19 outbreak. The study design composed of some major aspects: (a) docking with main protease (M-pro), (b) docking with spike protein, (c) 3D shape similarity study (Rapid Overlay Chemical Similarity-ROCS) to the clinically used drugs in COVID-19 patients, and finally, (d) the rule of five and the estimated pre-ADMT properties of the separated flavonoids. Docking study withM(pro)of SARS-CoV-2 (PDB ID:;6LU7, and ;6Y2F) showed that compound3, its aglycone part, and compound4have a strong binding mode to a protease receptor with key amino acids, especially Gln:166AA, and having a similar docking pose to co-crystalized ligands. Docking with the spike protein of SARS-CoV-2 illustrated that compounds3and4have a good binding affinity to PDB ID:;6VSBthrough the formation of HBs with Asp:;467Aand Asn:;422A. According to ROCS analysis, compounds1,3, and4displayed high similarities to drugs that prevent SARS-Co2 entry to the lung cells or block the inflammatory storm causing lung injury. Compounds3and4are good candidates for drug development especially because they showed predicted activity against SARS-CoV-2 through different mechanisms either by preventing genome replication or by blocking inflammatory storm that trigger lung injury. These compounds were isolated from peach fruit, and the study supports data and continues with the recommendation of peach fruits in controlling and managing COVID-19 cases.
C1 [Allam, Ahmed E.; Assaf, Hamdy K.] Al Azhar Univ, Fac Pharm, Dept Pharmacognosy, Assiut 71524, Egypt.
   [Hassan, Heba Ali] Deraya Univ, Fac Pharm, Dept Pharmacognosy, New Minia City 61111, Egypt.
   [Shimizu, Kuniyoshi] Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Agroenvironm Sci, Fukuoka 8190395, Japan.
   [Elshaier, Yaseen A. M. M.] Univ Sadat City, Fac Pharm, Organ & Med Chem Dept, Menoufia, Egypt.
RP Allam, AE (corresponding author), Al Azhar Univ, Fac Pharm, Dept Pharmacognosy, Assiut 71524, Egypt.; Elshaier, YAMM (corresponding author), Univ Sadat City, Fac Pharm, Organ & Med Chem Dept, Menoufia, Egypt.
RI Elshaier, Yaseen/U-8348-2019
OI Elshaier, Yaseen/0000-0003-4332-6345; Aallam, Ahmed/0000-0003-0286-581X
FU USC [15]
FX Dr Yaseen A. M. M. Elshaier, Organic& Medicinal Chemistry Department,
   Faculty of Pharmacy, University of Sadat City (USC), Egypt acknowledge
   OpenEye scientific software for providing the academic license. Also, he
   acknowledges USC (No. 15) for supporting this project.
CR Abdellatif KRA, 2019, BIOORG CHEM, V82, P86, DOI 10.1016/j.bioorg.2018.09.034
   Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Adhikari N, 2016, BIOORGAN MED CHEM, V24, P4291, DOI 10.1016/j.bmc.2016.07.023
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Amin SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1780946
   Amin SA, 2020, EUR J MED CHEM, V201, DOI 10.1016/j.ejmech.2020.112559
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Diao SB, 2019, NAT PROD RES, V33, P3021, DOI 10.1080/14786419.2018.1512995
   Ee G. C. L., 2005, M J CHEM, V7, P45
   Elbastawesy MAI, 2020, MOL DIVERS, DOI 10.1007/s11030-019-10021-0
   Fischer A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103626
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Ganbaatar C., 2015, The Open Natural Products Journal, V8, P1, DOI 10.2174/1874848101508010001
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Ghosh AK, 2009, J MED CHEM, V52, P5228, DOI 10.1021/jm900611t
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hawkins PCD, 2007, J MED CHEM, V50, P74, DOI 10.1021/jm0603365
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Islam MS, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10062170
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kang TH, 2000, J NAT PROD, V63, P680, DOI 10.1021/np990567x
   Kell DB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01221
   Kelleni M., 2020, PREPRINTS, DOI [10.20944/preprints202004.0432.v1, DOI 10.20944/PREPRINTS202004.0432.V1]
   Lamb YN, 2018, DRUGS, V78, P929, DOI 10.1007/s40265-018-0929-z
   Li HL, 2009, NAT PROD RES, V23, P122, DOI 10.1080/14786410801887664
   MARKHAM KR, 1982, TECHNIQUES FLAVONOID
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Nakagawa T, 2018, NAT PROD COMMUN, V13, P1293
   Noratto G, 2009, J AGR FOOD CHEM, V57, P5219, DOI 10.1021/jf900259m
   Nouga AB, 2016, NAT PROD RES, V30, P305, DOI 10.1080/14786419.2015.1057727
   Panda PK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8097
   Patel K, 2018, CHIN J INTEGR MED, V24, P551, DOI 10.1007/s11655-014-1960-x
   Pelletier D, 2012, NEW ENGL J MED, V366, P339, DOI 10.1056/NEJMct1101691
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ragab E. A., 2010, Journal of Natural Products (India), V3, P35
   Rayner CR, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104805
   Ritchie TJ, 2014, DRUG DISCOV TODAY, V19, P489, DOI 10.1016/j.drudis.2014.01.007
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Sayed AM, 2020, RSC ADV, V10, P19790, DOI 10.1039/d0ra04199h
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Singh VP, 1999, PHYTOCHEMISTRY, V51, P587, DOI 10.1016/S0031-9422(99)00010-2
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768149
   Sultana N, 2010, NAT PROD RES, V24, P1018, DOI 10.1080/14786410902899022
   Thi THN, 2012, BIOTECHNOL LETT, V34, P831, DOI 10.1007/s10529-011-0845-8
   Vargesson N, 2015, BIRTH DEFECTS RES C, V105, P140, DOI 10.1002/bdrc.21096
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Vladimirov YA, 2009, BIOCHEMISTRY-MOSCOW+, V74, P301, DOI 10.1134/S0006297909030092
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang SX, 2020, J INTEGR MED-JIM, V18, P275, DOI 10.1016/j.joim.2020.04.001
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760
   Zakaryan H, 2017, ARCH VIROL, V162, P2539, DOI 10.1007/s00705-017-3417-y
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu HY, 2014, INFLAMMATION, V37, P2091, DOI 10.1007/s10753-014-9943-9
NR 61
TC 0
Z9 0
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD AUG 16
PY 2020
VL 10
IS 50
BP 29983
EP 29998
DI 10.1039/d0ra05265e
PG 16
WC Chemistry, Multidisciplinary
SC Chemistry
GA ND5NN
UT WOS:000561946700042
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Ko, M
   Jeon, S
   Ryu, WS
   Kim, S
AF Ko, Meehyun
   Jeon, Sangeun
   Ryu, Wang-Shick
   Kim, Seungtaek
TI Comparative analysis of antiviral efficacy of FDA-approved drugs against
   SARS-CoV-2 in human lung cells
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE COVID-19; drug repositioning; FDA-approved drug; SARS-CoV-2
ID CORONAVIRUS; NAFAMOSTAT; PNEUMONIA
AB Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022 mu M).
C1 [Ko, Meehyun; Jeon, Sangeun; Kim, Seungtaek] Inst Pasteur Korea, Zoonot Virus Lab, Seongnam, South Korea.
   [Ryu, Wang-Shick] Inst Pasteur Korea, CEO Off, Seongnam, South Korea.
RP Kim, S (corresponding author), Inst Pasteur Korea, Zoonot Virus Lab, 16,Daewangpangyo Ro 712 Beon Gil, Seongnam Si 13488, Gyeonggi Do, South Korea.
EM seungtaek.kim@ip-korea.org
OI Jeon, Sangeun/0000-0003-3695-6357
FU National Research Foundation of KoreaNational Research Foundation of
   Korea [NRF-2017M3A9G6068245, NRF-2020M3E9A1041756]
FX National Research Foundation of Korea, Grant/Award Numbers:
   NRF-2017M3A9G6068245, NRF-2020M3E9A1041756
CR Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Jang S, 2020, INT J INFECT DIS, V96, P500, DOI 10.1016/j.ijid.2020.05.072
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Pruijssers Andrea J, 2020, bioRxiv, DOI 10.1101/2020.04.27.064279
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yamamoto M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060629
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu Y, 2010, CRIT CARE RES PRACT, DOI 10.1155/2010/394578
NR 18
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26397
EA AUG 2020
PG 6
WC Virology
SC Virology
GA NB6AA
UT WOS:000560593000001
PM 32767684
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Cavalcante, FP
   Novita, GG
   Millen, EC
   Zerwes, FP
   de Oliveira, VM
   Sousa, ALL
   Freitas, R
AF Cavalcante, Francisco Pimentel
   Novita, Guilherme Garcia
   Millen, Eduardo Camargo
   Zerwes, Felipe Pereira
   de Oliveira, Vilmar Marques
   Sousa, Ana Luiza Lima
   Freitas Junior, Ruffo
TI Management of early breast cancer during the COVID-19 pandemic in Brazil
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE COVID-19; Early breast cancer; Hormone receptor-positive tumors; Breast
   surgery
ID ENDOCRINE THERAPY; RANDOMIZED-TRIAL; CHEMOTHERAPY; RECONSTRUCTION;
   COMPLICATIONS; CONSENSUS; SURGERY
AB Purpose The COVID-19 pandemic has impacted early breast cancer (EBC) treatment worldwide. This study analyzed how Brazilian breast specialists are managing EBC. Methods An electronic survey was conducted with members of the Brazilian Society of Breast Cancer Specialists (SBM) between April 30 and May 11, 2020. Bivariate analysis was used to describe changes in how specialists managed EBC at the beginning and during the pandemic, according to breast cancer subtype and oncoplastic surgery. Results The response rate was 34.4% (503/1462 specialists). Most of the respondents (324; 64.4%) lived in a state capital city, were board-certified as breast specialists (395; 78.5%) and either worked in an academic institute or one associated with breast cancer treatment (390; 77.5%). The best response rate was from the southeast of the country (240; 47.7%) followed by the northeast (128; 25.4%). At the beginning of the pandemic, 43% changed their management approach. As the outbreak progressed, this proportion increased to 69.8% (p < 0.001). The southeast of the country (p = 0.005) and the state capital cities (p < 0.001) were associated with changes at the beginning of the pandemic, while being female (p = 0.001) was associated with changes during the pandemic. For hormone receptor-positive tumors with the best prognosis (Ki-67 < 20%), 47.9% and 17.7% of specialists would recommend neoadjuvant endocrine therapy for postmenopausal and premenopausal women, respectively. For tumors with poorer prognosis (Ki-67 > 30%), 34% and 10.9% would recommend it for postmenopausal and premenopausal women, respectively. Menopausal status significantly affected whether the specialists changed their approach (p < 0.00001). For tumors >= 1.0 cm, 42.9% of respondents would recommend neoadjuvant systemic therapy for triple-negative tumors and 39.6% for HER2 + tumors. Overall, 63.4% would recommend immediate total breast reconstruction, while only 3.4% would recommend autologous reconstruction. In breast-conserving surgery, 75% would recommend partial breast reconstruction; however, 54.1% would contraindicate mammoplasty. Furthermore, 84.9% of respondents would not recommend prophylactic mastectomy in cases of BRCA mutation. Conclusions Important changes occurred in EBC treatment, particularly for hormone receptor-positive tumors, as the outbreak progressed in each region. Systematic monitoring could assure appropriate breast cancer treatment, mitigating the impact of the pandemic.
C1 [Cavalcante, Francisco Pimentel] Fortaleza Gen Hosp HGF, Rua Avila Goularte,900, BR-60150160 Fortaleza, Ceara, Brazil.
   [Novita, Guilherme Garcia] Grp Amer, Sao Paulo, SP, Brazil.
   [Millen, Eduardo Camargo] Sao Vicente Clin, Rio De Janeiro, RJ, Brazil.
   [Zerwes, Felipe Pereira] Pontificia Univ Catolica Rio Grande do Sul, Porto Alegre, RS, Brazil.
   [de Oliveira, Vilmar Marques] Santa Casa Sao Paulo, Sch Med Sci, Sao Paulo, SP, Brazil.
   [Sousa, Ana Luiza Lima] Univ Fed Goias, Goiania, Go, Brazil.
   [Freitas Junior, Ruffo] Univ Fed Goias, Adv Ctr Diag & Treatment Breast Canc CORA, Goiania, Go, Brazil.
RP Cavalcante, FP (corresponding author), Fortaleza Gen Hosp HGF, Rua Avila Goularte,900, BR-60150160 Fortaleza, Ceara, Brazil.
EM fpimentelcavalcante@gmail.com; gui.novita@gmail.com;
   eduardomillen@gmail.com; zerwes@hotmail.com; vilmarmarques@yahoo.com.br;
   demmilima@gmail.com; ruffojr@terra.com.br
RI ; Sousa, Ana Luiza/F-2127-2010; Freitas-Junior, Ruffo/A-7595-2010
OI Novita, Guilherme/0000-0003-2983-3199; Sousa, Ana
   Luiza/0000-0002-7566-3541; Freitas-Junior, Ruffo/0000-0003-4145-8598;
   Millen, Eduardo/0000-0002-2113-6324; Pimentel Cavalcante,
   Francisco/0000-0002-7156-2890; Oliveira, Vilmar/0000-0002-9478-5616
CR Abubakar M, 2019, MODERN PATHOL, V32, P1244, DOI 10.1038/s41379-019-0270-4
   Al-Rashdan A, 2020, ADV RAD ONCOL, DOI [10.1016/j.adro.2020.03.0117194663, DOI 10.1016/J.ADRO.2020.03.0117194663]
   Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   Alba E, 2012, ANN ONCOL, V23, P3069, DOI 10.1093/annonc/mds132
   Amorim GLS, 2020, BRAZ J ONCOL, V16, P1, DOI [10.5935/2526-8732.20190024, DOI 10.5935/2526-8732.20190024]
   [Anonymous], 2020, NCCN CLIN PRACTICE G
   Bennett KG, 2018, JAMA SURG, V153, P901, DOI 10.1001/jamasurg.2018.1687
   Breast Oncology Center Dana-Farber/Brigham and Women's Cancer Center, 2020, SUGGESTED TREATMENT
   Burstein HJ, 2019, ANN ONCOL, V30, P1541, DOI 10.1093/annonc/mdz235
   Cardoso F, 2019, ANN ONCOL, V30, P1194, DOI 10.1093/annonc/mdz173
   Cavalcante FP, 2020, JCO GLOB ONCOL, V6, P238, DOI 10.1200/JGO.19.00351
   Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081
   Coates AS, 2015, ANN ONCOL, V26, P1533, DOI 10.1093/annonc/mdv221
   Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8
   Curigliano G, 2020, BREAST, V52, P8, DOI 10.1016/j.breast.2020.04.006
   Dietz JR, 2020, BREAST CANCER RES TR, V181, P487, DOI 10.1007/s10549-020-05644-z
   Dowsett M, 2019, J CLIN ONCOL, V37, P689, DOI 10.1200/JCO.18.01412
   European Society for Medical Oncology (ESMO), 2020, ESMO CLIN PRACT GUID
   Facina G, 2020, MASTOLOGY, V30, DOI [10.29289/2594539420202020200014, DOI 10.29289/2594539420202020200014]
   Fineberg HV, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMe2007263
   Gasparri ML, 2020, BREAST, V52, P110, DOI 10.1016/j.breast.2020.05.006
   Gschwantler-Kaulich D, 2018, BREAST J, V24, P957, DOI 10.1111/tbj.13113
   Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0122-z, 10.1038/s41572-019-0111-2]
   Huo JH, 2016, BREAST CANCER RES TR, V157, P373, DOI 10.1007/s10549-016-3832-x
   Hurvitz SA, 2019, J CLIN ONCOL, V37, P2206, DOI 10.1200/JCO.19.00882
   Hwang ES, 2020, J CLIN ONCOL, V38, P1284, DOI 10.1200/JCO.19.00510
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Marti C, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1027
   Massenburg BB, 2015, AESTHET PLAST SURG, V39, P902, DOI 10.1007/s00266-015-0575-8
   Masuda N, 2017, NEW ENGL J MED, V376, P2147, DOI 10.1056/NEJMoa1612645
   Meresse T, 2019, ANN CHIR PLAST ESTH, V64, P594, DOI 10.1016/j.anplas.2019.07.015
   Moberg IO, 2018, J PLAST SURG HAND SU, V52, P234, DOI 10.1080/2000656X.2018.1470093
   Ontario Health, 2020, PAND PLANN CLIN GUID
   Palmieri C, 2014, BREAST CANCER RES TR, V148, P581, DOI 10.1007/s10549-014-3183-4
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Poggio Francesca, 2020, JCO Oncol Pract, V16, pe1304, DOI 10.1200/OP.20.00297
   Ponde NF, 2019, NAT REV CLIN ONCOL, V16, P27, DOI 10.1038/s41571-018-0089-9
   Semiglazov VF, 2007, CANCER-AM CANCER SOC, V110, P244, DOI 10.1002/cncr.22789
   Sestak L, 2018, JAMA ONCOL, V4, P545, DOI 10.1001/jamaoncol.2017.5524
   Shah UA, 2020, JAMA ONCOL, DOI [10.1001/jamaoncol.2020.18487047856, DOI 10.1001/JAMAONCOL.2020.18487047856]
   Sheng JY, 2020, JCO ONCOL PRACT, V16, P665, DOI 10.1200/OP.20.00364
   Simpson AM, 2019, J PLAST RECONSTR AES, V72, P1434, DOI 10.1016/j.bjps.2019.04.002
   Siqueira Hianga Fayssa Fernandes, 2020, BMC Res Notes, V13, P223, DOI 10.1186/s13104-020-05058-6
   Tasoulis MK, 2020, EJSO-EUR J SURG ONC, V46, P1192, DOI 10.1016/j.ejso.2020.04.049
   Tolaney SM, 2019, J CLIN ONCOL, V37, P1868, DOI 10.1200/JCO.19.00066
   von Minckwitz G, 2019, NEW ENGL J MED, V380, P617, DOI 10.1056/NEJMoa1814017
   Weber WP, 2018, BREAST CANCER RES TR, V172, P523, DOI 10.1007/s10549-018-4937-1
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 50
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD NOV
PY 2020
VL 184
IS 2
BP 637
EP 647
DI 10.1007/s10549-020-05877-y
EA AUG 2020
PG 11
WC Oncology
SC Oncology
GA OI1CL
UT WOS:000559939300001
PM 32803637
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Panzuto, F
   Maccauro, M
   Campana, D
   Faggiano, A
   Massironi, S
   Pusceddu, S
   Spada, F
   Ferone, D
   Modica, R
   Grana, CM
   Ferolla, P
   Rinzivillo, M
   Badalamenti, G
   Zatelli, MC
   Gelsomino, F
   De Carlo, E
   Bartolomei, M
   Brizzi, MP
   Cingarlini, S
   Versari, A
   Fanciulli, G
   Arvat, E
   Merola, E
   Cives, M
   Tafuto, S
   Baldari, S
   Falconi, M
AF Panzuto, F.
   Maccauro, M.
   Campana, D.
   Faggiano, A.
   Massironi, S.
   Pusceddu, S.
   Spada, F.
   Ferone, D.
   Modica, R.
   Grana, C. M.
   Ferolla, P.
   Rinzivillo, M.
   Badalamenti, G.
   Zatelli, M. C.
   Gelsomino, F.
   De Carlo, E.
   Bartolomei, M.
   Brizzi, M. P.
   Cingarlini, S.
   Versari, A.
   Fanciulli, G.
   Arvat, E.
   Merola, E.
   Cives, M.
   Tafuto, S.
   Baldari, S.
   Falconi, M.
TI Impact of the SARS-CoV2 pandemic dissemination on the management of
   neuroendocrine neoplasia in Italy: a report from the Italian Association
   for Neuroendocrine Tumors (Itanet)
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV2; Pandemic; Neuroendocrine tumors; Multidisciplinary
   team; Management; Peptide receptors radionuclide therapy
AB Introduction The organization of the healthcare system has significantly changed after the recent COVID-19 outbreak, with a negative impact on the management of oncological patients. The present survey reports data collected by the Italian Association for Neuroendocrine Tumors on the management of patients with neuroendocrine neoplasia (NEN) during the pandemic dissemination.
   Methods A survey with 57 questions was sent to NEN-dedicated Italian centers regarding the management of patients in the period March 9, 2020, to May 9, 2020
   Results The main modification in the centers' activity consisted of decreases in newly diagnosed NEN patients (-76.8%), decreases in performed surgical procedures (-58%), delays to starting peptide receptor radionuclide therapy (45.5%), postponed/canceled follow-up examinations (26%), and canceled multidisciplinary teams' activity (20.8%). A low proportion of centers (<10%) reported having to withdraw systemic anti-tumor medical treatment due to concerns about the pandemic situation, whereas PRRT was withdrawn from no patients.
   Conclusion Although the COVID-19 outbreak induced the centers to reduce some important activities in the management of NEN patients, the Italian network was able to provide continuity in care without withdrawing anti-tumor treatment for the majority of patients.
C1 [Panzuto, F.; Rinzivillo, M.] St Andrea Univ Hosp, ENETS Ctr Excellence, Digest Dis Unit, Via Grottarossa 1035, I-00189 Rome, Italy.
   [Maccauro, M.] IRRCS Natl Canc Inst INT, ENETS Ctr Excellence, Nucl Med Unit, Milan, Italy.
   [Campana, D.] Azienda Osped Univ Bologna, Div Oncol, Bologna, Italy.
   [Faggiano, A.] Sapienza Univ Rome, Dept Expt Med, Endocrinol Unit, Rome, Italy.
   [Massironi, S.] Univ Milano Bicocca, Div Gastroenterol, Monza, Italy.
   [Massironi, S.] Univ Milano Bicocca, Ctr Autoimmune Liver Dis, Dept Med & Surg, Monza, Italy.
   [Massironi, S.] San Gerardo Hosp, European Reference Network Hepatol Dis ERN RARE L, Monza, Italy.
   [Pusceddu, S.] IRRCS Natl Canc Inst INT, ENETS Ctr Excellence, Oncol Unit, Milan, Italy.
   [Spada, F.] European Canc Inst IEO, ENETS Ctr Excellence, Oncol Unit, Milan, Italy.
   [Ferone, D.] Univ Genoa, Endocrinol Unit, IRCCS Osped Policlin San Martino, Genoa, Italy.
   [Ferone, D.] Univ Genoa, Dept Internal Med & Med Specialties DIMI, Endocrinol, Genoa, Italy.
   [Modica, R.] Univ Federico II, Dept Clin Med & Surg, Naples, Italy.
   [Grana, C. M.] IRCCS European Inst Oncol, Nucl Med Div, Milan, Italy.
   [Ferolla, P.] Multidisciplinary Grp Diag & Treatment Neuroendoc, Perugia, Italy.
   [Badalamenti, G.] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, Palermo, Italy.
   [Zatelli, M. C.] Univ Ferrara, Dept Med Sci, Sect Endocrinol & Internal Med, Ferrara, Italy.
   [Gelsomino, F.] Univ Hosp Modena, Dept Oncol & Hematol, Modena, Italy.
   [De Carlo, E.] Univ Padua, Dept Med, Internal Med 3, Padua, Italy.
   [Bartolomei, M.] St Anna Hosp, Nucl Med Dept, Ferrara, Italy.
   [Brizzi, M. P.] Univ Turin, San Luigi Gonzaga Hosp, Dept Oncol, Orbassano, Italy.
   [Cingarlini, S.] Univ Hosp Verona, ENETS Ctr Excellence, Oncol Unit, Verona, Italy.
   [Versari, A.] Azienda Unita Sanit Locale IRCCS Reggio Emilia, Nucl Med Unit, Reggio Emilia, Italy.
   [Fanciulli, G.] Univ Sassari, Dept Med Surg & Expt Sci, NET Unit, AOU Sassari,Endocrine Unit, Sassari, Italy.
   [Arvat, E.] Univ Turin, Dept Med Sci, Oncol Endocrinol Unit, Turin, Italy.
   [Merola, E.] Azienda Prov & Serv Sanitari Trento APSS, Dept Gastroenterol, Trento, Italy.
   [Cives, M.] Univ Bari, Dept Biomed Sci & Human Oncol, Bari, Italy.
   [Tafuto, S.] IRCCS Fdn G Pascale, Ist Nazl Tumori, SC Sarcomi & Tumori Rari, Naples, Italy.
   [Baldari, S.] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Nucl Med Unit, Messina, Italy.
   [Falconi, M.] IRCCS San Raffaele Sci Inst, Pancreas Translat & Clin Res Ctr, ENETS Ctr Excellence, Pancreat Surg, Milan, Italy.
RP Panzuto, F (corresponding author), St Andrea Univ Hosp, ENETS Ctr Excellence, Digest Dis Unit, Via Grottarossa 1035, I-00189 Rome, Italy.
EM fpanzuto@ospedalesantandrea.it
RI Faggiano, Antongiulio/ABC-4819-2020; cingarlini, sara/ABB-5280-2020;
   Panzuto, Francesco/Y-2882-2019; Zatelli, Maria Chiara/U-2649-2018;
   Faggiano, Antongiulio/K-7771-2016
OI Panzuto, Francesco/0000-0003-2789-4289; Zatelli, Maria
   Chiara/0000-0001-8408-7796; Faggiano, Antongiulio/0000-0002-9324-3946
CR Annunziata S, 2020, EUR J NUCL MED MOL I, V47, P2090, DOI 10.1007/s00259-020-04874-z
   Basuroy R, 2018, NEUROENDOCRINOLOGY, V107, P42, DOI 10.1159/000488510
   Bergsland EK, 2020, PANCREAS, V49, P723, DOI 10.1097/MPA.0000000000001561
   Chen YM, 2004, LUNG CANCER-J IASLC, V45, P39, DOI 10.1016/j.lungcan.2004.01.002
   Cives M, 2018, CA-CANCER J CLIN, V68, P471, DOI 10.3322/caac.21493
   Corsi F, 2020, BREAST J, V26, P1609, DOI 10.1111/tbj.13926
   Gill S, 2020, Curr Oncol, V27, P71, DOI 10.3747/co.27.6643
   Grimaldi F, 2014, J ENDOCRINOL INVEST, V37, P875, DOI 10.1007/s40618-014-0119-0
   Isidori AM, 2020, J ENDOCRINOL INVEST, V43, P1039, DOI 10.1007/s40618-020-01279-5
   Lambertini M, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000759
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   London Jack W, 2020, JCO Clin Cancer Inform, V4, P657, DOI 10.1200/CCI.20.00068
   Magi L, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060910
   Maida M, 2020, DIGEST LIVER DIS, V52, P808, DOI 10.1016/j.dld.2020.05.017
   Mistretta FA, 2020, CANCERS, V12, DOI 10.3390/cancers12061513
   Partelli S, 2019, NEUROENDOCRINOLOGY, V109, P165, DOI 10.1159/000499606
   Pellino G, 2020, DIS COLON RECTUM, V63, P720, DOI 10.1097/DCR.0000000000001685
   Tuech JJ, 2020, J VISC SURG, V157, pS7, DOI 10.1016/j.jviscsurg.2020.03.008
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Xu Y, 2020, THORAC CANCER, V11, P2067, DOI 10.1111/1759-7714.13498
NR 20
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0391-4097
EI 1720-8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
DI 10.1007/s40618-020-01393-4
EA AUG 2020
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NB2ZQ
UT WOS:000560382100001
PM 32803662
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Xue, HY
   Liu, Y
   Luo, P
   Liu, XL
   Qiu, L
   Liu, D
   Li, J
AF Xue, Huiying
   Liu, Yi
   Luo, Pan
   Liu, Xiulan
   Qiu, Lin
   Liu, Dong
   Li, Juan
TI Hydroxychloroquine treatment in COVID-19: A descriptive observational
   analysis of 30 cases from a single center in Wuhan, China
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE ACE2; COVID-19; cytokine storms; hydroxychloroquine; SARS-CoV-2
ID CORONAVIRUS; PNEUMONIA
AB Hydroxychloroquine (HCQ) garnered scientific attention in early February following publication of reports showing in vitro activity of chloroquine (CQ) against coronavirus disease 2019 (COVID-19). While studies are mixed on this topic, the therapeutic effect of HCQ or CQ still need more valid clinical evidence. In this descriptive observational study, we aimed to discuss the treatment response of HCQ in COVID-19 infected patients and 30 cases were included. The demographic, treatment, laboratory parameters of C-reactive protein (CRP) and interleukin-6 (IL-6) before and after HCQ therapy and clinical outcome in the 30 patients with COVID-19 were assessed. To evaluate the effect of mediation time point, we also divided these cases into two groups, patients began administrated with HCQ within 7 days hospital (defined as early delivery group) and 7 days after hospital (defined as later delivery group). We found that, the elevated IL-6, a risk factor in severe patients were reduced to normal level after HCQ treatment. More importantly, patients treated with HCQ at the time of early hospital recovered faster than those who treated later or taken as second line choose for their obvious shorter hospitalization time. In summary, early use of HCQ was better than later use and the effect of IL-6 and CRP level cannot be ruled out.
C1 [Xue, Huiying; Liu, Yi; Luo, Pan; Liu, Xiulan; Qiu, Lin; Liu, Dong; Li, Juan] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Hubei, Peoples R China.
RP Liu, D; Li, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Hubei, Peoples R China.
EM l_d2069@163.com; lijuan@tjh.tjmu.edu.cn
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Gendelman O, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102566
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang Y, 2020, LIVER INT
   Zhou D, 2020, J ANTIMICROB CHEMOTH
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 15
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2523
EP 2527
DI 10.1002/jmv.26193
EA AUG 2020
PG 5
WC Virology
SC Virology
GA NU0EN
UT WOS:000560061900001
PM 32779755
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Xu, ZH
   Wang, ZJ
   Wang, S
   Ye, YC
   Luo, D
   Wan, L
   Yu, AL
   Sun, LF
   Tesfaye, S
   Meng, QT
   Gao, L
AF Xu, Zihui
   Wang, Zhongjing
   Wang, Shuo
   Ye, Yingchun
   Luo, Deng
   Wan, Li
   Yu, Ailin
   Sun, Lifang
   Tesfaye, Solomon
   Meng, Qingtao
   Gao, Ling
TI The impact of type 2 diabetes and its management on the prognosis of
   patients with severeCOVID-19
SO JOURNAL OF DIABETES
LA English
DT Article
DE antihyperglycemic drugs; clinical status; coronavirus disease 2019
   (COVID-19); glucocorticoid; type 2 diabetes
ID CHINA; CORONAVIRUS; PNEUMONIA; COVID-19; OUTCOMES; WUHAN; SARS
AB Background Although type 2 diabetes mellitus (T2DM) patients with coronavirus disease 2019 (COVID-19) develop a more severe condition compared to those without diabetes, the mechanisms for this are unknown. Moreover, the impact of treatment with antihyperglycemic drugs and glucocorticoids is unclear. Methods From 1584 COVID-19 patients, 364 severe/critical COVID-19 patients with clinical outcome were enrolled for the final analysis, and patients without preexisting T2DM but elevated glucose levels were excluded. Epidemiological data were obtained and clinical status evaluation carried out to assess the impact of T2DM and its management on clinical outcomes. Results Of 364 enrolled severe COVID-19 inpatients, 114 (31.3%) had a history of T2DM. Twenty-seven (23.7%) T2DM patients died, who had more severe inflammation, coagulation activation, myocardia injury, hepatic injury, and kidney injury compared with non-DM patients. In severe COVID-19 patients with T2DM, we demonstrated a higher risk of all-cause fatality with glucocorticoid treatment (adjusted hazard ratio [HR], 3.61; 95% CI, 1.14-11.46;P= .029) and severe hyperglycemia (fasting plasma glucose >= 11.1 mmol/L; adjusted HR, 11.86; 95% CI, 1.21-116.44;P= .034). Conclusions T2DM status aggravated the clinical condition of COVID-19 patients and increased their critical illness risk. Poor fasting blood glucose (>= 11.1 mmol/L) and glucocorticoid treatment are associated with poor prognosis for T2DM patients with severe COVID-19.
C1 [Xu, Zihui; Wang, Shuo; Ye, Yingchun; Luo, Deng; Wan, Li; Yu, Ailin; Gao, Ling] Wuhan Univ, Dept Endocrinol & Metab, Renmin Hosp, Jiefang RD 238, Wuhan 430060, Peoples R China.
   [Wang, Zhongjing] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Dept Endocrinol, Tongji Med Coll, Wuhan, Peoples R China.
   [Sun, Lifang] Wuhan Univ, Intens Care Unit, Renmin Hosp, Wuhan, Peoples R China.
   [Tesfaye, Solomon] Royal Hallamshire Hosp, Sheffield Teaching Hosp, Diabet Res Unit, Sheffield, S Yorkshire, England.
   [Meng, Qingtao] Wuhan Univ, Anesthesiol Dept, Renmin Hosp, Wuhan, Peoples R China.
RP Gao, L (corresponding author), Wuhan Univ, Dept Endocrinol & Metab, Renmin Hosp, Jiefang RD 238, Wuhan 430060, Peoples R China.
EM ling.gao@whu.edu.cn
OI Tesfaye, Solomon/0000-0003-1190-1472; Xu, Zihui/0000-0001-7081-3195;
   Meng, Qingtao/0000-0002-1936-3050
FU China Young Scientific Talent Research Fund for diabetes [2017];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81571376]; Wuhan Young and Middle-aged
   Medical Talent Award Plan [2018]
FX China Young Scientific Talent Research Fund for diabetes, Grant/Award
   Number: 2017; National Natural Science Foundation of China, Grant/Award
   Number: 81571376; Wuhan Young and Middle-aged Medical Talent Award Plan,
   Grant/Award Number: 2018
CR Allard R, 2010, DIABETES CARE, V33, P1491, DOI 10.2337/dc09-2215
   Ascierto PA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000878
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussain A, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108142
   Li J, 2020, IEEE T NETW SCI ENG, V7, P1, DOI 10.1109/TNSE.2020.2968206
   Li YZ, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m997
   Maddaloni E, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3321
   National Health Commission of the People's Republic of China, 2020, DIAGN TREATM PROT PN
   National Institute for Viral Disease Control and Prevention, 2020, SPEC PRIM PROB DET 2
   Schmid S, 2002, DIABETOLOGIA, V45, P677, DOI 10.1007/s00125-002-0816-7
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Takeda M, 2013, DIABETES, V62, P223, DOI 10.2337/db12-0177
   van den Brand JMA, 2015, J PATHOL, V235, P175, DOI 10.1002/path.4458
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang LM, 2017, JAMA-J AM MED ASSOC, V317, P2515, DOI 10.1001/jama.2017.7596
   WHO, 182 WHO
   WHO, 2020, CLIN MAN SEV AC RESP
   Williams B, 2019, CLIN MED, V19, P94, DOI 10.7861/clinmedicine.19-1-94
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xuan XP, 2018, METABOLISM, V81, P83, DOI 10.1016/j.metabol.2017.12.003
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhou J, 2020, METABOLISM, V107, DOI 10.1016/j.metabol.2020.154216
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 37
TC 2
Z9 2
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1753-0393
EI 1753-0407
J9 J DIABETES
JI J. Diabetes
PD DEC
PY 2020
VL 12
IS 12
BP 909
EP 918
DI 10.1111/1753-0407.13084
EA AUG 2020
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OJ9CL
UT WOS:000559918700001
PM 32638507
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Donmez, A
   Rifaioglu, AS
   Acar, A
   Dogan, T
   Cetin-Atalay, R
   Atalay, V
AF Donmez, Ataberk
   Rifaioglu, Ahmet Sureyya
   Acar, Aybar
   Dogan, Tunca
   Cetin-Atalay, Rengul
   Atalay, Volkan
TI iBioProVis: interactive visualization and analysis of compound
   bioactivity space
SO BIOINFORMATICS
LA English
DT Article
ID EXPLORATION; INHIBITORS
AB iBioProVis is an interactive tool for visual analysis of the compound bioactivity space in the context of target proteins, drugs and drug candidate compounds. iBioProVis tool takes target protein identifiers and, optionally, compound SMILES as input, and uses the state-of-the-art non-linear dimensionality reduction method t-Distributed Stochastic Neighbor Embedding (t-SNE) to plot the distribution of compounds embedded in a 2D map, based on the similarity of structural properties of compounds and in the context of compounds' cognate targets. Similar compounds, which are embedded to proximate points on the 2D map, may bind the same or similar target proteins. Thus, iBioProVis can be used to easily observe the structural distribution of one or two target proteins' known ligands on the 2D compound space, and to infer new binders to the same protein, or to infer new potential target(s) for a compound of interest, based on this distribution. Principal component analysis (PCA) projection of the input compounds is also provided, Hence the user can interactively observe the same compound or a group of selected compounds which is projected by both PCA and embedded by t-SNE. iBioProVis also provides detailed information about drugs and drug candidate compounds through cross-references to widely used and well-known databases, in the form of linked table views. Two use-case studies were demonstrated, one being on angiotensin-converting enzyme 2 (ACE2) protein which is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike protein receptor. ACE2 binding compounds and seven antiviral drugs were closely embedded in which two of them have been under clinical trial for Coronavirus disease 19 (COVID-19).
C1 [Donmez, Ataberk; Rifaioglu, Ahmet Sureyya; Atalay, Volkan] METU, Dept Comp Engn, TR-06800 Ankara, Turkey.
   [Rifaioglu, Ahmet Sureyya] Iskenderun Tech Univ, Dept Comp Engn, TR-31200 Antakya, Turkey.
   [Acar, Aybar; Cetin-Atalay, Rengul] METU, Grad Sch Informat, KanSiL, Dept Hlth Informat, TR-06800 Ankara, Turkey.
   [Dogan, Tunca] Hacettepe Univ, Dept Comp Engn, TR-06800 Ankara, Turkey.
   [Dogan, Tunca] Hacettepe Univ, Inst Informat, TR-06800 Ankara, Turkey.
   [Cetin-Atalay, Rengul] Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA.
RP Atalay, V (corresponding author), METU, Dept Comp Engn, TR-06800 Ankara, Turkey.
EM vatalay@metu.edu.tr
RI Cetin-Atalay, Rengul/O-9826-2014; Dogan, Tunca/B-5274-2017; Acar, Aybar
   C./A-9981-2012
OI Cetin-Atalay, Rengul/0000-0003-2408-6606; Dogan,
   Tunca/0000-0002-1298-9763; Acar, Aybar C./0000-0001-5694-8675; Donmez,
   Ataberk/0000-0002-4817-0637; Rifaioglu, Ahmet
   Sureyya/0000-0001-6717-4767
FU Scientific and Technological Council of Turkey (TUB_ ITAK)Turkiye
   Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [EEEAG-116E930]
FX This work was supported by Scientific and Technological Council of
   Turkey (TUB_ ITAK) Grant number: EEEAG-116E930.
CR Awale M, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/s13321-016-0138-2
   Bokeh Development Team, 2019, BOK PYTH LIB INT VIS
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Deaton DN, 2008, BIOORG MED CHEM LETT, V18, P732, DOI 10.1016/j.bmcl.2007.11.048
   Gaspar HA, 2015, J CHEM INF MODEL, V55, P84, DOI 10.1021/ci500575y
   Gutlein M, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-7
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Janssen APA, 2019, J CHEM INF MODEL, V59, P1221, DOI 10.1021/acs.jcim.8b00640
   Karlov DS, 2019, RSC ADV, V9, P5151, DOI 10.1039/c8ra10182e
   Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075
   Mores A, 2008, J MED CHEM, V51, P2216, DOI 10.1021/jm701275z
   Rifaioglu AS, 2019, BRIEF BIOINFORM, V20, P1878, DOI 10.1093/bib/bby061
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   van der Maaten L, 2008, J MACH LEARN RES, V9, P2579
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
NR 16
TC 1
Z9 1
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
EI 1460-2059
J9 BIOINFORMATICS
JI Bioinformatics
PD AUG 15
PY 2020
VL 36
IS 14
BP 4227
EP 4230
DI 10.1093/bioinformatics/btaa496
PG 4
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA OJ3SU
UT WOS:000583886000025
PM 32407491
OA Green Published
DA 2021-01-01
ER

PT J
AU Flet, L
   Tching-Sin, M
   Chanat, A
   Gendre, P
   Tibi, A
AF Flet, Laurent
   Tching-Sin, Martine
   Chanat, Adeline
   Gendre, Pauline
   Tibi, Annick
TI Clinical trials: Management of investigational products during the
   COVID-19 pandemic
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Letter
DE clinical trials; COVID-19; investigational drugs
C1 [Flet, Laurent; Tching-Sin, Martine; Chanat, Adeline; Gendre, Pauline] Nantes Univ Hosp, Dept Pharm, Nantes, France.
   [Tibi, Annick] Hop Paris, Agence Gen Equipements & Prod Sante, Paris, France.
RP Flet, L (corresponding author), Nantes Univ Hosp, Dept Pharm, Nantes, France.
EM laurent.flet@chu-nantes.fr
CR Agence nationale de securite du medicament et des produits de sante, COVID 19 ESS CLIN CO
   European Medicines Agency, 2020, GUID CLIN TRIAL MAN
   Food and Drug Administration, 2020, FDA GUID COND CLIN T
   Medicines & Healthcare products Regulatory Agency, MAN CLIN TRIALS COR
NR 4
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-2082
EI 1535-2900
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD AUG 15
PY 2020
VL 77
IS 16
BP 1277
EP 1278
DI 10.1093/ajhp/zxaa146
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OH6NG
UT WOS:000582708900004
PM 32406904
OA Green Published, Bronze, Green Accepted
DA 2021-01-01
ER

PT J
AU Arthur-Holmes, F
   Akaadom, MKA
   Agyemang-Duah, W
   Busia, KA
   Peprah, P
AF Arthur-Holmes, Francis
   Akaadom, Michael Kwesi Asare
   Agyemang-Duah, Williams
   Abrefa Busia, Kwaku
   Peprah, Prince
TI Healthcare Concerns of Older Adults during the COVID-19 Outbreak in Low-
   and Middle-Income Countries: Lessons for Health Policy and Social Work
SO JOURNAL OF GERONTOLOGICAL SOCIAL WORK
LA English
DT Article; Early Access
DE COVID-19 pandemic; older adults; healthcare; health-seeking behavior;
   social workers; low- and middle-income countries
AB Older people have been identified to be one of the most vulnerable population groups to the 2019 novel coronavirus (COVID-19). At the same time, more health workers in low-and middle-income countries (LMICs) including Ghana are contracting COVID-19. This poses healthcare utilization concerns for older adults. As a result, many older adults are changing their health-seeking behavior by staying at home and resorting to informal healthcare such as the use of traditional therapies and over-the-counter medicines for self-treatment or to boost their immune system. This commentary calls for social workers to collaborate with health authorities and community pharmacists to develop social and health programs to increase older adults' access to healthcare during the COVID-19 crisis. Policies are also required to deal with the pandemic and its impact on health systems in LMICs for both short and long term. We have suggested in this commentary how governments, health institutions, and local authorities in LMICs can address the healthcare concerns of older adults during this and any future pandemic.
C1 [Arthur-Holmes, Francis] Univ Oxford, Oxford Dept Int Dev, Oxford X1 3TB, England.
   [Akaadom, Michael Kwesi Asare] Cent Univ, Sch Pharm, Accra, Ghana.
   [Agyemang-Duah, Williams] Kwame Nkrumah Univ Sci & Technol, Dept Planning, Kumasi, Ghana.
   [Abrefa Busia, Kwaku] Lingnan Univ, Dept Sociol & Social Policy, Tuen Mun, Hong Kong, Peoples R China.
   [Peprah, Prince] Univ New South Wales, Social Policy Res Ctr, Sydney, NSW, Australia.
RP Arthur-Holmes, F (corresponding author), Univ Oxford, Oxford Dept Int Dev, Oxford X1 3TB, England.
EM frarthur88@gmail.com
OI Abrefa Busia, Kwaku/0000-0003-2667-7338; Arthur-Holmes,
   Francis/0000-0002-5099-4555
CR Aboderin IAG, 2015, LANCET, V385, pE9, DOI 10.1016/S0140-6736(14)61602-0
   Abu-bashal A., 2020, ANADOLU AGENCY
   Adamu Z., 2020, CNN NEWS
   Agyemang-Duah W, 2019, J PUBLIC HEALTH-HEID, V27, P133, DOI 10.1007/s10389-018-0946-0
   Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   Arthur-Holmes F, 2020, J GERONTOL SOC WORK, DOI 10.1080/01634372.2020.1764689
   Bhasin S., 2020, NDTV
   Ruiz ME, 2010, CURR DRUG SAF, V5, P315, DOI 10.2174/157488610792245966
   Gyasi R.M., 2011, GLOBAL J HLTH SCI, V3, P2, DOI DOI 10.5539/gjhs.v3n2p40
   Gyasi RM, 2020, J GERONTOL SOC WORK, DOI 10.1080/01634372.2020.1766630
   Ifijeh M., 2020, THISDAY
   Isilow H., 2020, ANADOLU AGENCY
   Peprah P, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2476-x
   United Nations Development Programme (UNDP), 2020, COVID 19 NEW UNDP DA
NR 14
TC 0
Z9 0
U1 6
U2 6
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1540-4048
EI 0163-4372
J9 J GERONTOL SOC WORK
JI J. Gerontol. Soc. Work
DI 10.1080/01634372.2020.1800883
EA AUG 2020
PG 7
WC Geriatrics & Gerontology; Gerontology; Social Work
SC Geriatrics & Gerontology; Social Work
GA NH1OU
UT WOS:000564447300001
PM 32808585
DA 2021-01-01
ER

PT J
AU Folegatti, PM
   Ewer, KJ
   Aley, PK
   Angus, B
   Becker, S
   Belij-Rammerstorfer, S
   Bellamy, D
   Bibi, S
   Bittaye, M
   Clutterbuck, EA
   Dold, C
   Faust, SN
   Finn, A
   Flaxman, AL
   Hallis, B
   Heath, P
   Jenkin, D
   Lazarus, R
   Makinson, R
   Minassian, AM
   Pollock, KM
   Ramasamy, M
   Robinson, H
   Snape, M
   Tarrant, R
   Voysey, M
   Green, C
   Douglas, AD
   Hill, AVS
   Lambe, T
   Gilbert, SC
   Pollard, AJ
AF Folegatti, Pedro M.
   Ewer, Katie J.
   Aley, Parvinder K.
   Angus, Brian
   Becker, Stephan
   Belij-Rammerstorfer, Sandra
   Bellamy, Duncan
   Bibi, Sagida
   Bittaye, Mustapha
   Clutterbuck, Elizabeth A.
   Dold, Christina
   Faust, Saul N.
   Finn, Adam
   Flaxman, Amy L.
   Hallis, Bassam
   Heath, Paul
   Jenkin, Daniel
   Lazarus, Rajeka
   Makinson, Rebecca
   Minassian, Angela M.
   Pollock, Katrina M.
   Ramasamy, Maheshi
   Robinson, Hannah
   Snape, Matthew
   Tarrant, Richard
   Voysey, Merryn
   Green, Catherine
   Douglas, Alexander D.
   Hill, Adrian V. S.
   Lambe, Teresa
   Gilbert, Sarah C.
   Pollard, Andrew J.
CA Oxford COVID Vaccine Trial Grp
TI Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against
   SARS-CoV-2: a preliminary report of a phase 1/2, single-blind,
   randomised controlled trial
SO LANCET
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME
AB Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2.
   Methods We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. Healthy adults aged 18-55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose of 5 x 10(10) viral particles or MenACWY as a single intramuscular injection. A protocol amendment in two of the five sites allowed prophylactic paracetamol to be administered before vaccination. Ten participants assigned to a non-randomised, unblinded ChAdOx1 nCoV-19 prime-boost group received a two-dose schedule, with the booster vaccine administered 28 days after the first dose. Humoral responses at baseline and following vaccination were assessed using a standardised total IgG ELISA against trimeric SARS-CoV-2 spike protein, a muliplexed immunoassay, three live SARS-CoV-2 eutralisation assays (a 50% plaque reduction neutralisation assay [PRNT50]; a microneutralisation assay [MNA(50), MNA(80), and MNA(90)]; and Marburg VN), and a pseudovirus neutralisation assay. Cellular responses were assessed using an ex-vivo interferon-gamma enzyme-linked immunospot assay. The co-primary outcomes are to assess efficacy, as measured by cases of symptomatic virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse events. Analyses were done by group allocation in participants who received the vaccine. Safety was assessed over 28 days after vaccination. Here, we report the preliminary findings on safety, reactogenicity, and cellular and humoral immune responses. The study is ongoing, and was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.
   Findings Between April 23 and May 21, 2020, 1077 participants were enrolled and assigned to receive either ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534), ten of whom were enrolled in the non-randomised ChAdOx1 nCoV-19 prime-boost group. Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group and many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache, and malaise (all p<0.05). There were no serious adverse events related to ChAdOx1 nCoV-19. In the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked on day 14 (median 856 spot-forming cells per million peripheral blood mononuclear cells, IQR 493-1802; n=43). Anti-spike IgG responses rose by day 28 (median 157 ELISA units [EU], 96-317; n=127), and were boosted following a second dose (639 EU, 360-792; n=10). Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA 80 and in 35 (100%) participants when measured in PRNT 50. After a booster dose, all participants had neutralising activity (nine of nine in MNA 80 at day 42 and ten of ten in Marburg VN on day 56). Neutralising antibody responses correlated strongly with antibody levels measured by ELISA (R-2=0.67 by Marburg VN; p<0.001).
   Interpretation ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support largescale evaluation of this candidate vaccine in an ongoing phase 3 programme.
C1 [Folegatti, Pedro M.; Ewer, Katie J.; Belij-Rammerstorfer, Sandra; Bellamy, Duncan; Bittaye, Mustapha; Flaxman, Amy L.; Jenkin, Daniel; Lazarus, Rajeka; Minassian, Angela M.; Douglas, Alexander D.; Hill, Adrian V. S.; Lambe, Teresa; Gilbert, Sarah C.] Univ Oxford, Jenner Inst, Oxford, England.
   [Tarrant, Richard; Green, Catherine] Univ Oxford, Clin Biomanufacturing Facil, Oxford, England.
   [Angus, Brian] Univ Oxford, Nuffield Dept Med, Oxford, England.
   [Aley, Parvinder K.; Bibi, Sagida; Clutterbuck, Elizabeth A.; Dold, Christina; Ramasamy, Maheshi; Robinson, Hannah; Snape, Matthew; Voysey, Merryn; Pollard, Andrew J.] Univ Oxford, Oxford Vaccine Grp, Dept Paediat, Oxford, England.
   [Folegatti, Pedro M.; Ewer, Katie J.; Aley, Parvinder K.; Angus, Brian; Belij-Rammerstorfer, Sandra; Bellamy, Duncan; Bibi, Sagida; Bittaye, Mustapha; Clutterbuck, Elizabeth A.; Dold, Christina; Flaxman, Amy L.; Jenkin, Daniel; Makinson, Rebecca; Minassian, Angela M.; Ramasamy, Maheshi; Robinson, Hannah; Snape, Matthew; Voysey, Merryn; Douglas, Alexander D.; Hill, Adrian V. S.; Lambe, Teresa; Gilbert, Sarah C.; Pollard, Andrew J.] NIHR Oxford Biomed Res Ctr, Oxford, England.
   [Becker, Stephan] Philipps Univ Marburg, Inst Virol, Marburg, Germany.
   [Faust, Saul N.] Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Clin Res Facil, Southampton, Hants, England.
   [Faust, Saul N.] Univ Southampton, Southampton, Hants, England.
   [Finn, Adam] Univ Bristol, Sch Populat Hlth Sci, Bristol, Avon, England.
   [Hallis, Bassam] Publ Hlth England, Natl Infect Serv, Salisbury, Wilts, England.
   [Heath, Paul] St Georges Univ, Vaccine Inst, London, England.
   [Lazarus, Rajeka] Univ Hosp Bristol & Weston NHS Fdn Trust, Dept Microbiol, Bristol, Avon, England.
   [Pollock, Katrina M.] Imperial Coll London, NIHR Imperial Clin Res Facil, London, England.
RP Pollard, AJ (corresponding author), Univ Oxford, Dept Paediat, Oxford OX3 9DU, England.
EM andrew.pollard@paediatrics.ox.ac.uk
RI Morter, Richard/AAU-7115-2020; OConnor, Daniel/AAF-4903-2019; Noe,
   Andres/AAU-9612-2020; Baker, Philip/ABI-2575-2020; Ewer, Katie
   J/B-4328-2011; Pulido-Gomez, David/P-9297-2015; Munster,
   Vincent/I-7607-2018; Faust, Saul/J-9779-2014; james, william/H-4289-2013
OI Morter, Richard/0000-0002-7005-1546; OConnor,
   Daniel/0000-0002-6902-9886; Noe, Andres/0000-0002-6408-7032; Baker,
   Philip/0000-0002-4519-1563; Ewer, Katie J/0000-0001-9827-9836; Sharpe,
   Hannah/0000-0002-1194-2429; Skelly, Donal/0000-0002-2426-3097; Allen,
   Elizabeth/0000-0002-6406-4834; Taylor, Iona/0000-0002-2287-9488; Jones,
   Christine/0000-0003-1523-2368; Gorini, Giacomo/0000-0003-2872-1531;
   Flaxman, Amy/0000-0001-6460-1372; Sanchez Riera,
   Lidia/0000-0003-0774-2480; Donnellan, Francesca/0000-0002-4723-3560;
   Barrett, Jordan/0000-0003-0746-1945; Chelysheva,
   Irina/0000-0001-7802-7025; Ramos Lopez, Fernando/0000-0002-9997-7879;
   Smith, David/0000-0001-9177-4201; Mansatta, Kushal/0000-0001-8334-309X;
   Pulido-Gomez, David/0000-0003-3422-0434; Munster,
   Vincent/0000-0002-2288-3196; Mallett, Garry/0000-0001-5475-9061; Henry,
   Aaron/0000-0002-7650-0963; Faust, Saul/0000-0003-3410-7642; Owens,
   Daniel/0000-0002-8110-4252; Barnes, Eleanor/0000-0002-0860-0831; james,
   william/0000-0002-2506-1198; Jenkin, Daniel/0000-0003-3088-310X;
   Sulaiman, Sulaiman/0000-0002-5376-9636; Minassian,
   Angela/0000-0001-7832-9824; Makinson, Rebecca/0000-0001-7582-9073; Hou,
   Mimi/0000-0002-8517-9147; Frater, John/0000-0001-7163-7277; Folegatti,
   Pedro/0000-0001-5330-0240
FU UK Research and Innovation; Coalition for Epidemic Preparedness
   Innovations; National Institute for Health Research (NIHR)National
   Institute for Health Research (NIHR); NIHR Oxford Biomedical Research
   CentreNational Institute for Health Research (NIHR); Thames Valley and
   South Midland's NIHR Clinical Research Network; German Center for
   Infection Research (DZIF); Giessen-Marburg-Langen
FX UK Research and Innovation, Coalition for Epidemic Preparedness
   Innovations, National Institute for Health Research (NIHR), NIHR Oxford
   Biomedical Research Centre, Thames Valley and South Midland's NIHR
   Clinical Research Network, and the German Center for Infection Research
   (DZIF), Partner site Giessen-Marburg-Langen.
CR Bliss CM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21630-4
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Coughlan L, 2018, EBIOMEDICINE, V29, P146, DOI 10.1016/j.ebiom.2018.02.011
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385
   Ewer K, 2016, NEW ENGL J MED, V374, P1635, DOI 10.1056/NEJMoa1411627
   Fidler S, 2020, LANCET, V395, P888, DOI 10.1016/S0140-6736(19)32990-3
   Folegatti PM, 2020, LANCET INFECT DIS, V20, P816, DOI 10.1016/S1473-3099(20)30160-2
   Folegatti PM, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020040
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hanke T, 2019, EXPERT REV VACCINES, V18, P1029, DOI 10.1080/14760584.2019.1675518
   Hesse EM, 2019, MMWR-MORBID MORTAL W, V68, P91, DOI 10.15585/mmwr.mm6804a4
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Morris Susan J, 2016, Methods Mol Biol, V1349, P121, DOI 10.1007/978-1-4939-3008-1_8
   Mothe Beatriz, 2019, EClinicalMedicine, V11, P65, DOI 10.1016/j.eclinm.2019.05.009
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Sekine T, 2020, ROBUST T CELL IMMUNI, DOI [10.1101/2020.06.29.174888, DOI 10.1101/2020.06.29.174888]
   van Doremalen N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba8399
   van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195
   Wang X, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa721ciaa721, DOI 10.1093/CID/CIAA721CIAA721]
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   WHO, 2020, COR DIS COVID 19 SIT
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
NR 25
TC 126
Z9 125
U1 31
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD AUG 15
PY 2020
VL 396
IS 10249
BP 467
EP 478
DI 10.1016/S0140-6736(20)31604-4
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA ND0TT
UT WOS:000561621400016
PM 32702298
OA Green Accepted, Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhu, FC
   Guan, XH
   Li, YH
   Huang, JY
   Jiang, T
   Hou, LH
   Li, JX
   Yang, BF
   Wang, L
   Wang, WJ
   Wu, SP
   Wang, Z
   Wu, XH
   Xu, JJ
   Zhang, Z
   Jia, SY
   Wang, BS
   Hu, Y
   Liu, JJ
   Zhang, J
   Qian, XA
   Li, Q
   Pan, HX
   Jiang, HDC
   Deng, P
   Gou, JB
   Wang, XW
   Wang, XH
   Chen, W
AF Zhu, Feng-Cai
   Guan, Xu-Hua
   Li, Yu-Hua
   Huang, Jian-Ying
   Jiang, Tao
   Hou, Li-Hua
   Li, Jing-Xin
   Yang, Bei-Fang
   Wang, Ling
   Wang, Wen-Juan
   Wu, Shi-Po
   Wang, Zhao
   Wu, Xiao-Hong
   Xu, Jun-Jie
   Zhang, Zhe
   Jia, Si-Yue
   Wang, Bu-Sen
   Hu, Yi
   Liu, Jing-Jing
   Zhang, Jun
   Qian, Xiao-Ai
   Li, Qiong
   Pan, Hong-Xing
   Jiang, Hu-Dachuan
   Deng, Peng
   Gou, Jin-Bo
   Wang, Xue-Wen
   Wang, Xing-Huan
   Chen, Wei
TI Immunogenicity and safety of a recombinant adenovirus type-5-vectored
   COVID-19 vaccine in healthy adults aged 18 years or older: a randomised,
   double-blind, placebo-controlled, phase 2 trial
SO LANCET
LA English
DT Article
ID NEUTRALIZING ANTIBODIES; CHINA; IMMUNITY
AB Background This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study.
   Methods This randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China. Healthy adults aged 18 years or older, who were HIV-negative and previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-free, were eligible to participate and were randomly assigned to receive the vaccine at a dose of 1 x 10(11) viral particles per mL or 5 x 10(10) viral particles per mL, or placebo. Investigators allocated participants at a ratio of 2:1:1 to receive a single injection intramuscularly in the arm. The randomisation list (block size 4) was generated by an independent statistician. Participants, investigators, and staff undertaking laboratory analyses were masked to group allocation. The primary endpoints for immunogenicity were the geometric mean titres (GMTs) of specific ELISA antibody responses to the receptor binding domain (RBD) and neutralising antibody responses at day 28. The primary endpoint for safety evaluation was the incidence of adverse reactions within 14 days. All recruited participants who received at least one dose were included in the primary and safety analyses. This study is registered with ClinicalTrials.gov, NCT04341389.
   Findings 603 volunteers were recruited and screened for eligibility between April 11 and 16, 2020. 508 eligible participants (50% male; mean age 39.7 years, SD 12.5) consented to participate in the trial and were randomly assigned to receive the vaccine (1 x 10(11) viral particles n=253; 5 x 10(10) viral particles n=129) or placebo (n=126). In the 1 x 10(11) and 5 x 10(1)degrees viral particles dose groups, the RBD-specific ELISA antibodies peaked at 656.5 (95% CI 575.2-749.2) and 571.0 (467.6-697.3), with seroconversion rates at 96% (95% CI 93-98) and 97% (92-99), respectively, at day 28. Both doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2, with GMTs of 19.5 (95% CI 16.8-22.7) and 18.3 (14.4-23.3) in participants receiving 1 x 10(11) and 5 x 10(1)degrees viral particles, respectively. Specific interferon. enzyme-linked immunospot assay responses post vaccination were observed in 227 (90%, 95% CI 85-93) of 253 and 113 (88%, 81-92) of 129 participants in the 1 x 10(11) and 5 x 10(10) viral particles dose groups, respectively. Solicited adverse reactions were reported by 183 (72%) of 253 and 96 (74%) of 129 participants in the 1 x 10(11) and 5 x 10(10) viral particles dose groups, respectively. Severe adverse reactions were reported by 24 (9%) participants in the 1 x 10(11) viral particles dose group and one (1%) participant in the 5 x 10(10) viral particles dose group. No serious adverse reactions were documented.
   Interpretation The Ad5-vectored COVID-19 vaccine at 5 x 10(10) viral particles is safe, and induced significant immune responses in the majority of recipients after a single immunisation.
C1 [Zhu, Feng-Cai; Li, Jing-Xin; Wang, Wen-Juan; Jia, Si-Yue; Pan, Hong-Xing; Jiang, Hu-Dachuan] Jiangsu Prov Ctr Dis Control & Prevent, NHC Key Lab Enter Pathogen Microbiol, Nanjing, Peoples R China.
   [Guan, Xu-Hua; Yang, Bei-Fang; Wang, Zhao; Qian, Xiao-Ai; Li, Qiong; Deng, Peng] Hubei Prov Ctr Dis Control & Prevent, Wuhan, Peoples R China.
   [Li, Yu-Hua; Wang, Ling; Wu, Xiao-Hong; Liu, Jing-Jing] Natl Inst Food & Drug Control, Beijing, Peoples R China.
   [Huang, Jian-Ying; Wang, Xing-Huan] Wuhan Univ, Zhongnan Hosp, Clin Trial Ctr, Wuhan, Peoples R China.
   [Jiang, Tao; Hu, Yi] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.
   [Hou, Li-Hua; Wu, Shi-Po; Xu, Jun-Jie; Zhang, Zhe; Wang, Bu-Sen; Zhang, Jun; Chen, Wei] Acad Mil Med Sci, Beijing Inst Biotechnol, Beijing, Peoples R China.
   [Gou, Jin-Bo] CanSino Biol, Tianjin, Peoples R China.
   [Wang, Xue-Wen] Shanghai Canming Med Technol, Shanghai, Peoples R China.
RP Chen, W (corresponding author), Beijing Inst Biotechnol, Beijing 100071, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Zhongnan Hosp, Wuhan 430071, Peoples R China.; Zhu, FC (corresponding author), Jiangsu Prov Ctr Dis Control & Prevent, Nanjing 210009, Peoples R China.
EM jszfc@vip.sina.com; wangxinghuan@whu.edu.cn; cw0226@foxmail.com
OI wang, busen/0000-0001-9041-1919
FU National Key R&D Programme of China; National Science and Technology
   Major Project; CanSino Biologics
FX National Key R&D Programme of China, National Science and Technology
   Major Project, and CanSino Biologics.
CR Barouch DH, 2011, VACCINE, V29, P5203, DOI 10.1016/j.vaccine.2011.05.025
   Caddy S, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1790
   CEPI, 2020, CEPI FUND COVID 19 V
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng HY, 2020, JAMA INTERN MED, V180, P1156, DOI 10.1001/jamainternmed.2020.2020
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Leung K, 2020, LANCET, V395, P1382, DOI 10.1016/S0140-6736(20)30746-7
   Li JX, 2017, LANCET GLOB HEALTH, V5, pE324, DOI [10.1016/S2214-109X(16)30367-9, 10.1016/s2214-109x(16)30367-9]
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   National Medical Products Administration China, 2004, TECHN GUID CLIN TRIA
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Pilankatta R, 2010, J MED VIROL, V82, P407, DOI 10.1002/jmv.21721
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sprangers MC, 2003, J CLIN MICROBIOL, V41, P5046, DOI 10.1128/JCM.41.11.5046-5052.2003
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Thorner AR, 2006, J CLIN MICROBIOL, V44, P3781, DOI 10.1128/JCM.01249-06
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   WHO, 2020, CRIT COVID 19 VACC P
   World Health Organization, 2020, COR DIS COVID 2019 S
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Yonker LM, 2020, PEDIATR PULM, V55, P1085, DOI 10.1002/ppul.24748
   Yu B, 2012, J MED VIROL, V84, P1408, DOI 10.1002/jmv.23325
   Zhu FC, SAFETY TOLERABILITY, V395, P1845
NR 26
TC 65
Z9 64
U1 28
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD AUG 15
PY 2020
VL 396
IS 10249
BP 479
EP 488
DI 10.1016/S0140-6736(20)31605-6
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA ND0TT
UT WOS:000561621400017
PM 32702299
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Ashraf, MA
   Sherafat, A
   Pourdast, A
   Nazemi, P
   Mohraz, M
AF Ashraf, Mohammad Ali
   Sherafat, Alireza
   Pourdast, Alieh
   Nazemi, Pershang
   Mohraz, Minoo
TI The application of direct viral cytopathic hypothesis to design drug
   trials in the battle against COVID-19
SO DARU-JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Letter
DE Coronavirus disease of 2019 (COVID-19); Potential therapies; Direct
   viral cytopathy
ID ACE2; EXPRESSION
AB COVID-19 has caused many deaths worldwide. Systemic complications alongside coagulopathy, and ARDS account for the majority of COVID-19 mortalities. The pathogenesis of the disease can be explained by two theories of direct viral cytopathy and systemic inflammatory cascade of events. ACE-2 is shown to be the cellular host receptor for SARS-CoV-2. It might be the key to explain the pathogenesis of systemic complications with a focus on the direct viral cytopathic hypothesis. Different medications tend to show up in many in vitro drug screens. However, more trials are needed to translate their application into in vivo efficacy.
C1 [Ashraf, Mohammad Ali] Shiraz Univ Med Sci, Shiraz, Iran.
   [Sherafat, Alireza] Univ Cent Lancashire, Sch Med, Preston, Lancs, England.
   [Pourdast, Alieh; Mohraz, Minoo] Imam Khomeini Hosp, Iranian Res Ctr HIV AIDS IRCHA, Dist 6,Keshavarz Blvd,Nosrat St, Tehran, Tehran Province, Iran.
   [Pourdast, Alieh; Nazemi, Pershang] Univ Tehran Med Sci, Tehran, Iran.
RP Mohraz, M (corresponding author), Imam Khomeini Hosp, Iranian Res Ctr HIV AIDS IRCHA, Dist 6,Keshavarz Blvd,Nosrat St, Tehran, Tehran Province, Iran.
EM minoomohraz@gmail.com
CR Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Kim ES, 2016, J KOREAN MED SCI, V31, P1717, DOI 10.3346/jkms.2016.31.11.1717
   Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374
   Li CC, 2019, DRUG DISCOV TODAY, V24, P726, DOI 10.1016/j.drudis.2019.01.018
   Li Z, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3559601, DOI 10.2139/SSRN.3559601]
   Massimino M, 2020, ANTICANCER RES, V40, P2457, DOI 10.21873/anticanres.14215
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Ruan SG, 2020, LANCET INFECT DIS, V20, P630, DOI 10.1016/S1473-3099(20)30257-7
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Song RF, 2012, PEDIATR RES, V71, P13, DOI 10.1038/pr.2011.7
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
NR 18
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
EI 2008-2231
J9 DARU
JI DARU
PD DEC
PY 2020
VL 28
IS 2
BP 813
EP 814
DI 10.1007/s40199-020-00368-3
EA AUG 2020
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ3QF
UT WOS:000560598800004
PM 32803688
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kumar, N
   Awasthi, A
   Kumari, A
   Sood, D
   Jain, P
   Singh, T
   Sharma, N
   Grover, A
   Chandra, R
AF Kumar, Neeraj
   Awasthi, Amardeep
   Kumari, Anchala
   Sood, Damini
   Jain, Pallavi
   Singh, Taru
   Sharma, Neera
   Grover, Abhinav
   Chandra, Ramesh
TI Antitussive noscapine and antiviral drug conjugates as arsenal against
   COVID-19: a comprehensive chemoinformatics analysis
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; noscapine conjugates; main protease enzyme coronavirus;
   molecular dynamics simulation
AB Coronavirus pandemic has caused a vast number of deaths worldwide. Thus creating an urgent need to develop effective counteragents against novel coronavirus disease (COVID-19). Many antiviral drugs have been repurposed for treatment but implicated minimal recovery, which further advanced the need for clearer insights and innovation to derive effective therapeutics. Strategically, Noscapine, an approved antitussive drug with positive effects on lung linings may show favorable outcomes synergistically with antiviral drugs in trials. Hence, we have theoretically examined the combinatorial drug therapy by culminating the existing experimental results within silicoanalyses. We employed the antitussive noscapine in conjugation with antiviral drugs (Chloroquine, Umifenovir, Hydroxychloroquine, Favlplravir and Galidesivir). We found that Noscapine-Hydroxychloroquine (Nos-Hcq) conjugate has strong binding affinity for the main protease (Mpro) of SARS-CoV-2, which performs key biological function in virus infection and progression. Nos-Hcq was analyzed through molecular dynamics simulation. The MD simulation for 100 ns affirmed the stable binding of conjugation unprecedentedly through RMSD and radius of gyration plots along with critical reaction coordinate binding free energy profile. Also, dynamical residue cross-correlation map with principal component analysis depicted the stable binding of Nos-Hcq conjugate to Mpro domains with optimal secondary structure statistics of complex dynamics. Also, we reveal the drugs with stable binding to major domains of Mpro can significantly improve the work profile of reaction coordinates, drug accession and inhibitory regulation of Mpro. The designed combinatorial therapy paves way for further prioritizedin vitroandin vivoinvestigations for drug with robust binding against Mpro of SARS-CoV-2.
C1 [Kumar, Neeraj; Awasthi, Amardeep; Sood, Damini; Sharma, Neera; Chandra, Ramesh] Univ Delhi, Dept Chem, Drug Discovery & Dev Lab, Delhi 110007, India.
   [Kumari, Anchala; Grover, Abhinav] Jawaharlal Nehru Univ, Sch Biotechnol, Delhi, India.
   [Jain, Pallavi] SRM IST, Dept Chem, NCR Campus, Ghaziabad, India.
   [Singh, Taru] Univ Coll Med Sci, ICMR Natl Inst Malaria Res, Microbiol, New Delhi, India.
RP Chandra, R (corresponding author), Univ Delhi, Dept Chem, Drug Discovery & Dev Lab, Delhi 110007, India.
EM rameshchandragroup@gmail.com
FU CSIRCouncil of Scientific & Industrial Research (CSIR) - India;
   DST-INSPIREDepartment of Science & Technology (India)
FX N. K. particularly thanks CSIR for Research Associate fellowship and
   University of Delhi for Guest Assistant Professor Opportunity to conduct
   research smoothly. A. A gratefully acknowledge DST-INSPIRE for the award
   of Senior Research Fellowship.
CR Amawi H, 2020, THER DELIV, V11, P245, DOI 10.4155/tde-2020-0035
   Aneja R, 2006, BIOCHEM PHARMACOL, V72, P415, DOI 10.1016/j.bcp.2006.05.004
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Chaudhary M, 2020, J BIOMOL STRUCT DYN, V38, P1335, DOI 10.1080/07391102.2019.1604266
   Chen K, 2016, CHEM COMMUN, V52, P9125, DOI 10.1039/c6cc01135g
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cheng Feixiong, 2019, Methods Mol Biol, V1878, P243, DOI 10.1007/978-1-4939-8868-6_15
   Cheng FX, 2016, TRENDS MOL MED, V22, P919, DOI 10.1016/j.molmed.2016.09.006
   Cheng FX, 2017, BRIEF BIOINFORM, V18, P682, DOI 10.1093/bib/bbw051
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Coomes EA, 2020, J ANTIMICROB CHEMOTH, V75, P2013, DOI 10.1093/jac/dkaa171
   Ebrahimi S. A., 2003, Acta Physiologica Hungarica, V90, P147, DOI 10.1556/APhysiol.90.2003.2.7
   Ebrahimi SA, 2020, DRUG DEVELOP RES, V81, P765, DOI 10.1002/ddr.21676
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Grant BJ, 2006, BIOINFORMATICS, V22, P2695, DOI 10.1093/bioinformatics/btl461
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Han J, 2020, SCIENCE, V368, DOI 10.1126/science.abc1767
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kim DE, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110696
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779131
   Kumar N, 2020, J CHEM INF MODEL, V60, P421, DOI 10.1021/acs.jcim.9b01051
   Kumar N, 2019, ACS OMEGA, V4, P21370, DOI 10.1021/acsomega.9b03035
   Kumar N, 2018, ARTIF CELL NANOMED B, V46, P1288, DOI 10.1080/21691401.2017.1369423
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Macindoe G, 2010, NUCLEIC ACIDS RES, V38, pW445, DOI 10.1093/nar/gkq311
   Magagnoli J, 2020, MED, DOI [10.1016/j.medj.2020.06.001, DOI 10.1016/J.MEDJ.2020.06.001]
   Martin K. W., 2003, ANTIVIRAL THERAPY, V8
   McGibbon RT, 2015, BIOPHYS J, V109, P1528, DOI 10.1016/j.bpj.2015.08.015
   Mengist HM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0178-y
   MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407
   Patri A, 2020, J AM ACAD DERMATOL, V82, pE221, DOI 10.1016/j.jaad.2020.04.017
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Singh A, 2018, CURR TOP MED CHEM, V18, P2056, DOI 10.2174/1568026619666181129125524
   Singh VK, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00069
   Sood D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35384-6
   Sood Damini, 2018, Genomics & Informatics, V16, P44, DOI 10.5808/GI.2018.16.3.44
   VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V
   WHO, 2020, COR DIS COVID 19 PAN
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang Jing-Fang, 2020, Brief Bioinform, V21, P2206, DOI 10.1093/bib/bbz141
   ZHANG B, 2020, CHINESE MED J-PEKING, V134
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 49
TC 1
Z9 1
U1 8
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1808072
EA AUG 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NC3XT
UT WOS:000561148600001
PM 32815796
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Folayan, MO
   Brown, B
   Haire, B
   Babalola, CP
   Ndembi, N
AF Folayan, Morenike Oluwatoyin
   Brown, Brandon
   Haire, Bridget
   Babalola, Chinedum Peace
   Ndembi, Nicaise
TI Considerations for stakeholder engagement andCOVID-19 related clinical
   trials' conduct in sub-Saharan Africa
SO DEVELOPING WORLD BIOETHICS
LA English
DT Article; Early Access
DE SAR-COV-2; COVID-19; GPP-EP; sub-Saharan Africa; stakeholder engagement
AB The aim of this study is to determine how stakeholder engagement can be adapted for the conduct ofCOVID-19-related clinical trials in sub-Saharan Africa. Nine essential stakeholder engagement practices were reviewed: formative research; stakeholder engagement plan; communications and issues management plan; protocol development; informed consent process; standard of prevention for vaccine research and standard of care for treatment research; policies on trial-related physical, psychological, financial, and/or social harms; trial accrual, follow-up, exit trial closure and results dissemination; and post-trial access to trial products or procedures. The norms, values, and practices of collectivist societies in Sub-Saharan Africa and the low research literacy pose challenges to the conduct of clinical trials. Civil-society organizations, members of community advisory boards and ethics committees, young persons,COVID-19 survivors, researchers, government, and the private sector are assets for the implementation and translation ofCOVID-19 related clinical trials. Adapting ethics guidelines to the socio-cultural context of the region can facilitate achieving the aim of stakeholder engagement.
C1 [Folayan, Morenike Oluwatoyin] Obafemi Awolowo Univ, Dept Child Dent Hlth, Ife, Nigeria.
   [Haire, Bridget] Kirby Inst, Sydney, NSW, Australia.
   [Brown, Brandon] Univ Calif Riverside, Sch Med, Dept Social Med Populat & Publ Hlth, Riverside, CA 92521 USA.
   [Babalola, Chinedum Peace] Univ Ibadan, Pharmaceut Chem Pharmacokinet, Ibadan, Nigeria.
   [Ndembi, Nicaise] Inst Human Virol Nigeria, Lab Res, Abuja, Nigeria.
   [Ndembi, Nicaise] Kanazawa Univ, Virol, Dept Viral Infect & Int Hlth, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan.
   [Ndembi, Nicaise] Africa Ctr Dis Control & Prevent, Addis Ababa, Ethiopia.
RP Folayan, MO (corresponding author), Obafemi Awolowo Univ, Ife, Nigeria.
EM toyinukpong@yahoo.co.uk
OI Folayan, Morenike/0000-0002-9008-7730
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 Al147331-01]
FX Nicaise Ndembi is supported by the NIH R01 Al147331-01.
CR Adhikari Bipin, 2020, Glob Bioeth, V31, P1, DOI 10.1080/11287462.2019.1703504
   Afolabi MO, 2014, TROP MED INT HEALTH, V19, P625, DOI 10.1111/tmi.12288
   Africa CDC, 2020, STAT AFR CDC POT CLI
   African Union/ African CDC, 2020, COR DIS 2019 COVID 1
   Akkus B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185725
   [Anonymous], 2020, COVID 19 TRIALS RISK
   Bekker LG, 2020, SCIENCE, V368, P919, DOI 10.1126/science.abc9528
   Ceasar J, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14111422
   Centers for Disease Control and Prevention, 2020, PROT YOURS OTH
   Clinicaltrial. gov, COVID 19 VACC STUD
   Connecting Business Initiative, 2020, CONN BUS IN RESP COV
   de Bruyn G, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-S3-P195
   Dunning J, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001997
   Edwards Kathryn M, 2020, Annu Rev Virol, V7, P475, DOI 10.1146/annurev-virology-013120-013123
   Fenollar F., 2018, New Microbes and New Infections, V26, pS10, DOI 10.1016/j.nmni.2018.09.004
   Folayan M.O., 2020, PAN AFRICAN J MED
   Folayan M. O., 2018, DEV WORLD BIOETH, P1
   Folayan M. O., 2020, GLOBAL BIOETHICS
   Folayan MO, 2016, EBOLAS MESSAGE PUBLI
   Folayan MO, 2019, PAN AFR MED J, V34, DOI 10.11604/pamj.2019.34.179.18458
   Folayan Morenike Oluwatoyin, 2018, BMC Res Notes, V11, P159, DOI 10.1186/s13104-018-3263-3
   Folayan MO, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0950-8
   Gesell Sabina B, 2017, J Clin Transl Sci, V1, P121, DOI 10.1017/cts.2016.26
   Haire B, 2013, DEV WORLD BIOETH, V13, P87, DOI 10.1111/dewb.12032
   Haire BG, 2016, AM J PUBLIC HEALTH, V106, pE1, DOI 10.2105/AJPH.2016.303311
   Hasunira R., 2010, COMMUNITY INVOLVEMEN
   Healthgaps, 2019, COMM LED MON HLTH SE
   Henao-Restrepo AM, 2017, LANCET, V389, P504, DOI 10.1016/S0140-6736(16)32633-2
   Kaseje N., 2020, WHY SUB SAHARAN AFRI
   Kerasidou A, 2017, MED HEALTH CARE PHIL, V20, P43, DOI 10.1007/s11019-016-9721-6
   Kirigia Joses Muthuri, 2008, Int Arch Med, V1, P27, DOI 10.1186/1755-7682-1-27
   Lee BY, 2020, FORBES
   Lwin KM, 2014, BMC MED ETHICS, V15, DOI 10.1186/1472-6939-15-12
   Marshall P.A., 2007, ETHICAL CHALLENGES S
   Milford Cecilia, 2006, IRB, V28, P1
   Mlambo CK, 2019, BMC MED ETHICS, V20, DOI 10.1186/s12910-019-0384-8
   Mugamba S., 2020, HUMANITARIAN EXCHANG, V77, P26
   Nkengasong J, 2020, NATURE, V580, P565, DOI 10.1038/d41586-020-01265-0
   Nyirenda D., 2017, DEV WORLD BIOETH, P1, DOI DOI 10.1111/DEWB.12163
   Onvomaha Tindana Paulina, 2006, IRB, V28, P1
   Phelan AL, 2020, LANCET, V395, P1595, DOI 10.1016/S0140-6736(20)31034-5
   Philpott S, 2011, J MED ETHICS, V37, P244, DOI 10.1136/jme.2010.037176
   QuartzAfrica, 2020, AFR SCI MUST MAK SUR
   Reynolds L., 2018, CRITICAL PUBLIC HLTH, V28
   Robinson E.T., COMMUNICATIONS HDB C
   Royal Society for Public Health, 2020, ON 5 PUBL UNS GETT C
   Sissoko D, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001967
   TIMduluza T., 2007, GATEWAY BIOMEDICAL R
   Wealth Management, 2020, HUNT COVID 19 TREATM
   West Slevin K., 2008, COMMUNITY ENGAGEMENT
   World Health Organization, 2016, GOOD PART PRACT GUID
   World Health Organization. Regional Office for Africa, 2016, MAPP RISK DISTR EP W
   Zvonareva O., 2005, DEV WORLD BIOETH, V15, P8
NR 53
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1471-8731
EI 1471-8847
J9 DEV WORLD BIOETH
JI Dev. World Bioeth.
DI 10.1111/dewb.12283
EA AUG 2020
PG 7
WC Ethics; Medical Ethics
SC Social Sciences - Other Topics; Medical Ethics
GA NA2VV
UT WOS:000559673800001
PM 32798320
OA Green Published
DA 2021-01-01
ER

PT J
AU Lawrence, RJ
   O'Donoghue, G
   Kitterick, P
   O'Donoghue, K
   Hague, R
   Mitchell, L
   Lycett-Ranson, Z
   Hartley, DEH
AF Lawrence, Rachael J.
   O'Donoghue, Gerard
   Kitterick, Padraig
   O'Donoghue, Kevin
   Hague, Richard
   Mitchell, Laura
   Lycett-Ranson, Zoe
   Hartley, Douglas E. H.
TI Recommended Personal Protective Equipment for Cochlear Implant and Other
   Mastoid Surgery During theCOVID-19 Era
SO LARYNGOSCOPE
LA English
DT Article
DE COVID-19; coronavirus; otolaryngology; cochlear implant; mastoidectomy;
   ear; nose; and throat surgery; otology; personal protective equipment;
   safety
AB Objectives/Hypothesis The overall aim of this study was to evaluate personal protective equipment (PPE) that may facilitate the safe recommencement of cochlear implantation in the COVID-19 era, with the broader goal of minimizing the period of auditory deprivation in prelingually deaf children and reducing the risk of cochlear ossification in individuals following meningitis. Methods The study design comprised 1) an objective assessment of mastoid drilling-induced droplet spread conducted during simulated cochlear implant (CI) surgery and its mitigation via the use of a protective drape tent and 2) an evaluation of three PPE configurations by otologists while performing mastoid drilling on ex vivo temporal bones. The various PPE solutions were assessed in terms of their impact on communication, vital physiological parameters, visual acuity and fields, and acceptability to surgeons using a systematic risk-based approach. Results Droplet spread during simulated CI surgery extended over 2 m, a distance greater than previously reported. A drape tent significantly reduced droplet spread. The ensemble of a half-face mask and safety spoggles (foam lined safety goggles) had consistently superior performance across all aspects of clinical usability. All other PPE options were found to substantially restrict the visual field, making them unsafe for microsurgery. Conclusions The results of this preclinical study indicate that the most viable solution to enable the safe conduct of CI and other mastoid surgery is a combination of a filtering facepiece (FFP)3 mask or half-face respirator with safety spoggles as PPE. Prescription spoggles are an option for surgeons who need to wear corrective glasses to operate. A drape tent reduces droplet spread. A multicenter clinical trial to evaluate the effectiveness of PPE should be the next step toward safely performing CI surgery during the COVID-19 era. Level of Evidence 4Laryngoscope, 2020
C1 [Lawrence, Rachael J.; O'Donoghue, Gerard; Kitterick, Padraig; Hartley, Douglas E. H.] Natl Inst Hlth Res Nottingham Biomed Res Ctr, Ropewalk House,113 Ropewalk, Nottingham NG1 5DU, England.
   [Lawrence, Rachael J.; O'Donoghue, Gerard; Kitterick, Padraig; Hartley, Douglas E. H.] Univ Nottingham, Sch Med, Div Clin Neurosci, Hearing Sci, Nottingham, England.
   [Lawrence, Rachael J.; O'Donoghue, Gerard; Kitterick, Padraig; O'Donoghue, Kevin; Mitchell, Laura; Lycett-Ranson, Zoe; Hartley, Douglas E. H.] Nottingham Univ Hosp Natl Hlth Serv Trust, Nottingham, England.
   [Hague, Richard] Univ Nottingham, Ctr Addit Mfg, Nottingham, England.
RP Lawrence, RJ (corresponding author), Natl Inst Hlth Res Nottingham Biomed Res Ctr, Ropewalk House,113 Ropewalk, Nottingham NG1 5DU, England.
EM rachael.lawrence@nottingham.ac.uk
FU Medical Research CouncilMedical Research Council UK (MRC)
   [MR/R017344/1]; National Institute for Health Research Nottingham
   Biomedical Research Centre; National Institute for Health Research
   Nottingham Clinical Research Facilities
FX This work was funded by the Medical Research Council (MR/R017344/1 to
   R.J.L) and the National Institute for Health Research Nottingham
   Biomedical Research Centre, and was supported by the National Institute
   for Health Research Nottingham Clinical Research Facilities. The views
   expressed are those of the author(s) and not necessarily those of the
   National Health Service, the National Institute for Health Research, or
   the Department of Health and Social Care. The funders had no role in
   study design, data collection and analysis, decision to publish, nor
   preparation of the manuscript.
CR Boothroyd A., 1968, BRIT J AUDIOL, V2, P3, DOI [10.3109/00381796809075436, DOI 10.3109/00381796809075436]
   British Standards Institution, 1327462002 BS EN
   Canadian Society of Otolaryngology-Head & Neck Surgery, GUID HEALTHC WORK PE
   Chen JX, 2020, OTOL NEUROTOL, V41, P1230, DOI 10.1097/MAO.0000000000002765
   Clamp PJ, 2020, J LARYNGOL OTOL, V134, P739, DOI 10.1017/S0022215120001607
   Cole EC, 1998, AM J INFECT CONTROL, V26, P453, DOI 10.1016/S0196-6553(98)70046-X
   Ge HP, 2020, EUR J CLIN MICROBIOL, V39, P1011, DOI 10.1007/s10096-020-03874-z
   Hellier W, MASTOIDECTOMY COVID
   Hilal A, 2005, LARYNGOSCOPE, V115, P1873, DOI 10.1097/01.mlg.0000177459.80574.2d
   Hinds W. C., 1999, AEROSOL TECHNOLOGY
   Jones RM, 2020, AM J INFECT CONTROL, V48, P46, DOI 10.1016/j.ajic.2019.06.023
   Mick P, 2020, J OTOLARYNGOL-HEAD N, V49, DOI 10.1186/s40463-020-00424-7
   Morris LA, 271991 HLTH SAF EC
   Patel ZM, 2020, NEUROSURGERY, V87, pE66, DOI 10.1093/neuros/nyaa125
   Peek Vision Ltd, PEEK AC
   Public Health England, GUID COVID 19 EP VIR
   Smith CL, 2013, ERGONOMICS, V56, P781, DOI 10.1080/00140139.2013.777128
   Stanford Bioengineering Prakash Lab, PNEUM PROJ
   Tellier R, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3707-y
   Vukkadala N, 2020, LARYNGOSCOPE, V130, P2537, DOI 10.1002/lary.28672
   Xu Kai, 2020, World J Otorhinolaryngol Head Neck Surg, DOI 10.1016/j.wjorl.2020.03.002
   Zarocostas J, 2020, LANCET, V395, P401, DOI 10.1016/S0140-6736(20)30292-0
NR 22
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD NOV
PY 2020
VL 130
IS 11
BP 2693
EP 2699
DI 10.1002/lary.29014
EA AUG 2020
PG 7
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA OD4NC
UT WOS:000559721900001
PM 32720316
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Karzai, F
   Madan, RA
   Dahut, WL
AF Karzai, Fatima
   Madan, Ravi A.
   Dahut, William L.
TI The World of Clinical Trial Development Post COVID-19: Lessons Learned
   from a Global Pandemic
SO CLINICAL CANCER RESEARCH
LA English
DT Article
AB The novel coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a global health threat (1). Patients with cancer are one of the most vulnerable populations. During this pandemic, clinical trial accrual to NCI studies has fallen dramatically. Investigators quickly turned to regulatory bodies to simplify treatment schedules, facilitate telemedicine, and decrease required data collection. Going forward, the oncology research community must use the lessons learned to focus on redesigning studies to ensure that critical scientific questions are answered safely while expanding access and increasing partnerships with community physicians. These changes will accelerate clinical progress while protecting our patients.
C1 [Karzai, Fatima; Madan, Ravi A.; Dahut, William L.] NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Dahut, WL (corresponding author), NCI, Ctr Canc Res, Bldg 10,CRC 3-2571, Bethesda, MD 20892 USA.
EM dahutw@mail.nih.gov
CR Donne J, 1977, DEVOTIONS EMERGENT O
   Duma N, 2018, J ONCOL PRACT, V14, P35, DOI 10.1200/JOP.2017.025288
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   George SL, 1996, J CLIN ONCOL, V14, P1364, DOI 10.1200/JCO.1996.14.4.1364
   Goossens N, 2015, TRANSL CANCER RES, V4, P256, DOI 10.3978/j.issn.2218-676X.2015.06.04
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Kalos M, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-26
   Kim ES, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.73.7916
   Kim Edward S, 2016, Am Soc Clin Oncol Educ Book, V35, P83, DOI 10.14694/EDBK_155880
   Laurencin CT, 2020, J RACIAL ETHN HEALTH, V7, P398, DOI 10.1007/s40615-020-00756-0
   Pantanowitz Liron, 2018, J Pathol Inform, V9, P40, DOI 10.4103/jpi.jpi_69_18
   Patel L, 2020, J RURAL HEALTH, DOI 10.1111/jrh.12447
NR 12
TC 1
Z9 1
U1 2
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 15
PY 2020
VL 26
IS 16
BP 4198
EP 4200
DI 10.1158/1078-0432.CCR-20-1914
PG 3
WC Oncology
SC Oncology
GA MY8SH
UT WOS:000558688100006
PM 32503806
OA Bronze
DA 2021-01-01
ER

PT J
AU Maio, M
   Hamid, O
   Larkin, J
   Covre, A
   Altomonte, M
   Calabro, L
   Vardhana, SA
   Robert, C
   Ibrahim, R
   Anichini, A
   Wolchok, JD
   Di Giacomo, AM
AF Maio, Michele
   Hamid, Omid
   Larkin, James
   Covre, Alessia
   Altomonte, Maresa
   Calabro, Luana
   Vardhana, Santosh A.
   Robert, Caroline
   Ibrahim, Ramy
   Anichini, Andrea
   Wolchok, Jedd D.
   Di Giacomo, Anna Maria
TI Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
SO CLINICAL CANCER RESEARCH
LA English
DT Article
AB The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to be considered, immune checkpoint inhibitors (ICI) seem to require major attention as they may act at the crossroads between cancer treatment and COVID-19 disease, due to their profound immunomodulatory activity. On the basis of available literature evidence, we suggest guidance to consider for treating physicians, and propose areas of clinical and preclinical investigation. Comprehensively, although with the necessary caution, ICI therapy seems to remain a suitable therapeutic option for patients with cancer during the COVID-19 pandemic.
C1 [Maio, Michele; Covre, Alessia; Altomonte, Maresa; Calabro, Luana; Di Giacomo, Anna Maria] Univ Hosp Siena, Dept Oncol, Ctr Immunooncol Med Oncol & Immunotherapy, Viale Mario Bracci 16, I-53100 Siena, Italy.
   [Maio, Michele] NIBIT Fdn Onlus, Genoa, Italy.
   [Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA.
   [Larkin, James] Royal Marsden Hosp, London, England.
   [Covre, Alessia] Toscana Life Sci Fdn, Siena, Italy.
   [Vardhana, Santosh A.; Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Vardhana, Santosh A.; Wolchok, Jedd D.] Weill Cornell Med Coll, New York, NY USA.
   [Robert, Caroline] Gustave Roussy, Dept Med, Villejuif, France.
   [Robert, Caroline] Paris Saclay Univ, Villejuif, France.
   [Ibrahim, Ramy] Parker Inst Canc Immunotherapy, San Francisco, CA USA.
   [Anichini, Andrea] Ist Nazl Tumori, Fdn IRCCS, Human Tumor Immunobiol Unit, Milan, Italy.
RP Maio, M (corresponding author), Univ Hosp Siena, Dept Oncol, Ctr Immunooncol Med Oncol & Immunotherapy, Viale Mario Bracci 16, I-53100 Siena, Italy.
EM mmaiocro@gmail.com
RI Robert, Caroline/G-6157-2018; Di Giacomo, Anna Maria/AAY-5625-2020
OI Robert, Caroline/0000-0002-9493-0238; 
FU FONDAZIONE AIRC under 5 per MilleAssociazione Italiana per la Ricerca
   sul Cancro (AIRC) [2018 - ID 21073]
FX This work was supported, in part, by funding from the FONDAZIONE AIRC
   under 5 per Mille 2018 - ID 21073 program (to principal investigator M.
   Maio).
CR Calabro L, 2020, LANCET RESP MED
   Di Giacomo AM, 2020, EUR J CANCER, V133, P1, DOI 10.1016/j.ejca.2020.04.026
   El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318
   Poltronieri P, 2015, CURR GENOMICS, V16, P327, DOI 10.2174/1389202916666150707160613
   Pu D, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019013
   Rotte A, 2018, ANN ONCOL, V29, P71, DOI 10.1093/annonc/mdx686
   Shah NJ, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0771-1
   Tanaka R, 2017, J DERMATOL SCI, V86, P71, DOI 10.1016/j.jdermsci.2016.12.019
   Thevarajan I, 2020, NAT MED, V26, P450
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
NR 15
TC 6
Z9 5
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 15
PY 2020
VL 26
IS 16
BP 4201
EP 4205
DI 10.1158/1078-0432.CCR-20-1657
PG 5
WC Oncology
SC Oncology
GA MY8SH
UT WOS:000558688100007
PM 32540850
OA Bronze
DA 2021-01-01
ER

PT J
AU Serrano, MM
   Perez-Sanchez, JR
   Sanchez, SP
   De la Casa-Fages, B
   Jimeno, VM
   Tamayo, IP
   Grandas, F
AF Mas Serrano, Miguel
   Ricardo Perez-Sanchez, Javier
   Portela Sanchez, Sofia
   De la Casa-Fages, Beatriz
   Mato Jimeno, Victor
   Perez Tamayo, Isabel
   Grandas, Francisco
TI Serotonin syndrome in two COVID-19 patients treated with
   lopinavir/ritonavir
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Letter
DE Serotonin syndrome; COVID-19; Lopinavir/ritonavir; Neurological
   complication; Drug-induced disorder
C1 [Mas Serrano, Miguel; Portela Sanchez, Sofia] Hosp Gen Univ Gregorio Maranon, Dept Neurol, Madrid, Spain.
   [Ricardo Perez-Sanchez, Javier; De la Casa-Fages, Beatriz; Grandas, Francisco] Hosp Gen Univ Gregorio Maranon, Movement Disorders Unit, Dept Neurol, C Doctor Esquerdo 46, Madrid 28007, Spain.
   [Mato Jimeno, Victor; Perez Tamayo, Isabel] Hosp Gen Univ Gregorio Maranon, Dept Internal Med, Madrid, Spain.
RP Perez-Sanchez, JR (corresponding author), Hosp Gen Univ Gregorio Maranon, Movement Disorders Unit, Dept Neurol, C Doctor Esquerdo 46, Madrid 28007, Spain.
EM javierricardo.perez@salud.madrid.org
RI Sanchez, Javier Ricardo Perez/AAD-2866-2019
OI Sanchez, Javier Ricardo Perez/0000-0001-9292-9471; De la Casa-Fages,
   Beatriz/0000-0003-0486-3308; Mas Serrano, Miguel/0000-0003-1234-6896
CR Boothman LJ, 2005, NEUROREPORT, V16, P891, DOI 10.1097/00001756-200506210-00004
   Buckley NA, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1626
   Celada P, 2004, J PSYCHIATR NEUROSCI, V29, P252
   DeSilva KE, 2001, AIDS, V15, P1281, DOI 10.1097/00002030-200107060-00010
   Scotton WJ, 2019, INT J TRYPTOPHAN RES, V12, DOI 10.1177/1178646919873925
   Tao R, 2002, J PHARMACOL EXP THER, V303, P704, DOI 10.1124/jpet.102.038133
   University of Liverpool, 2020, DET REC INT EXP COVI
   Werneke U, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0616-1
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
NR 9
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD AUG 15
PY 2020
VL 415
AR 116944
DI 10.1016/j.jns.2020.116944
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA ML3SO
UT WOS:000549390100040
PM 32531579
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Medina, MT
   Moncada, S
AF Medina, Marco T.
   Moncada, Salvador
TI Hydroxychloroquine/chloroquine as a treatment choice or prophylaxis for
   Covid-19 at the primary care level in developing countries: A Primum non
   Nocere dilemma
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Letter
DE Hydroxychloroquine/chloroquine; Developing countries; Primary care;
   Bioethics; Clinical trials
AB The Food and Drug Administration (FDA) warned against the use of Hydroxychloroquine or chloroquine for Covid-19 outside of a hospital or a clinical trial setting due to the risk of QT interval prolongation, ventricular tachycardia and the increased risk of these complications when combined with some antibiotics such as azithromycin. Several studies have reported no benefit of Hydroxychloroquine or chloroquine, when used alone or with a macrolide in COVID-19 hospitalized patients.
   Despite these warnings, in several developing countries the official guidelines for treatment of Covid-19 patients at the primary care level recommend Hydroxychloroquine and azithromycin, among other treatments, as the first-choice for mild symptomatic Covid-19 patients, asymptomatic contacts or for prophylaxis. In our opinion there is a primum non nocere dilemma during this Covid-19 pandemic. In order to solve this bioethical problem, we strongly recommend that a randomized controlled trial in a primary care setting be carried out as a matter of urgency in these areas of the world.
C1 [Medina, Marco T.] Natl Autonomous Univ Honduras, Fac Med Sci, Latin Amer, Tegucigalpa, Honduras.
   [Moncada, Salvador] Univ Manchester, Manchester Canc Res Ctr, Manchester, Lancs, England.
RP Medina, MT (corresponding author), Natl Autonomous Univ Honduras, Fac Med Sci, Latin Amer, Tegucigalpa, Honduras.
EM marcotmedina@yahoo.com
CR Beigel J, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2007764, DOI 10.1056/NEJM0A2007764]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2012410, DOI 10.1056/NEJM0A2012410]
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
NR 4
TC 1
Z9 1
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD AUG 15
PY 2020
VL 415
AR 116972
DI 10.1016/j.jns.2020.116972
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA ML3SO
UT WOS:000549390100052
PM 32534369
OA Bronze
DA 2021-01-01
ER

PT J
AU Chiarini, M
   Paghera, S
   Moratto, D
   De Rossi, N
   Giacomelli, M
   Badolato, R
   Capra, R
   Imberti, L
AF Chiarini, Marco
   Paghera, Simone
   Moratto, Daniele
   De Rossi, Nicola
   Giacomelli, Mauro
   Badolato, Raffaele
   Capra, Ruggero
   Imberti, Luisa
TI Immunologic characterization of a immunosuppressed multiple sclerosis
   patient that recovered from SARS-CoV-2 infection
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE COVID-19; Fingolimod; Multiple sclerosis
ID REPERTOIRE; BLOOD
AB A multiple sclerosis patient infected by SARS-CoV-2 during fingolimod therapy was hospitalized with moderate clinical features, and recovered in 15 days. High levels of CCL5 and CCL10 chemokines and of antibody-secreting B cells were detected, while the levels other B- and T-cell subsets were comparable to that of appropriate controls. However, CD4+ and CD8+ cells were oligoclonally expanded and prone to apoptosis when stimulated in vitro. This study suggests that fingolimod-immunosuppressed patients, despite the low circulating lymphocytes, may rapidly expand antibody-secreting cells and mount an effective immune response that favors COVID-19 recovery after drug discontinuation.
C1 [Chiarini, Marco; Moratto, Daniele] ASST Spedali Civili Brescia, Flow Cytometry Lab, Diagnost Dept, Brescia, Italy.
   [Paghera, Simone; Imberti, Luisa] ASST Spedali Civili Brescia, Diagnost Dept, Ctr Ric Emato Oncol AIL CREA, Brescia, Italy.
   [De Rossi, Nicola; Capra, Ruggero] ASST Spedali Civili Brescia, Multiple Sclerosis Ctr, Brescia, Italy.
   [Giacomelli, Mauro; Badolato, Raffaele] Univ Brescia, Mol Med Inst Angelo Nocivelli, Dept Clin & Expt Sci, Brescia, Italy.
RP Imberti, L (corresponding author), ASST Spedali Civili Brescia, Diagnost Dept, CREA, Ple Spedali Civili 1, I-25123 Asst Spedali Civili Di B, Italy.
EM luisa.imberti@asst-spedalicivili.it
FU Biogen Italia; Teva Italia; Roche Italia; Merck-SeronoMerck SeronoMerck
   & Company [EMR200136-555]; GenzymeSanofiGenzyme Corporation [GZ402673]
FX Biogen Italia, Teva Italia, Roche Italia. Research funding from research
   support from Merck-Serono (ID EMR200136-555) and GenzymeSanofi
   (GZ402673).
CR Brodin P, 2017, NAT REV IMMUNOL, V17, P21, DOI 10.1038/nri.2016.125
   Chiarini M, 2015, MULT SCLER J, V21, P726, DOI 10.1177/1352458514551456
   Culley FJ, 2006, J VIROL, V80, P8151, DOI 10.1128/JVI.00496-06
   DESTEFANO N, 2020, LANCET NEUROL, DOI DOI 10.1016/S1474-4422(20)30147-2
   Ellebedy AH, 2016, NAT IMMUNOL, V17, P1226, DOI 10.1038/ni.3533
   Frau J, 2018, EUR J NEUROL, V25, P1270, DOI 10.1111/ene.13694
   Fujii C, 2016, SCI REP-UK, V6, DOI 10.1038/srep35314
   Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073
   Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215
   Grebenciucova E, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0800-8
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1131, DOI 10.1515/cclm-2020-0198
   Liu J, 2020, LONGITUDINAL CHARACT, DOI [10.1101/ 2020.02.16.20023671, DOI 10.1101/2020.02.16.20023671, 10.1101/2020.02.16.20023671]
   McElroy AK, 2015, P NATL ACAD SCI USA, V112, P4719, DOI 10.1073/pnas.1502619112
   Sica F, 2019, NEUROL THER, V8, P231, DOI 10.1007/s40120-019-00162-7
   Stefan N, 2020, NAT REV ENDOCRINOL, V16, P341, DOI 10.1038/s41574-020-0364-6
   Tessitore MV, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1169-9
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
NR 17
TC 6
Z9 6
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0165-5728
EI 1872-8421
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD AUG 15
PY 2020
VL 345
AR 577282
DI 10.1016/j.jneuroim.2020.577282
PG 5
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA MC5YG
UT WOS:000543361500015
PM 32505908
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Miserocchi, E
   Giuffre, C
   Modorati, GM
   Cimaz, R
AF Miserocchi, Elisabetta
   Giuffre, Chiara
   Modorati, Giulio M.
   Cimaz, Rolando
TI Management of Juvenile Idiopathic Arthritis-associated Uveitis during
   the COVID-19 Pandemic in a Pediatric Referral Center in Lombardy
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Letter
DE COVID-19; juvenile idiopathic arthritis; JIA-associated uveitis;
   pediatric uveitis; SARS-CoV-2
AB Italy was the first European country to be affected by the SARS-CoV-2 pandemic. In this scenario, we had to face a new clinical approach in our Pediatric Rheumatology Unit for the management of patients affected by juvenile idiopathic arthritis (JIA)-associated uveitis. During the lockdown (phase 1), the weekly outpatient clinic was discontinued and telephone consultations were set up. A toll-free telephone number was instituted for emergencies. None of our children with JIA-associated uveitis was advised to stop the ongoing immunosuppressant systemic therapy. We had no cases of COVID-19 infection and uveitis activity was under control in all but two out of 125 patients, which was comparable with the pre-COVID-19 situation. During phase 2 of the pandemic, hospital and ambulatory rearrangements were made to minimize the risk of SARS-CoV-2 infection. Overall, during the first 4 weeks of phase 2, we did not notice an increased number of patients with uveitis activity.
C1 [Miserocchi, Elisabetta; Giuffre, Chiara; Modorati, Giulio M.] Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
   [Cimaz, Rolando] ASST G Pini, Dept Pediat Rheumatol, Milan, Italy.
   [Cimaz, Rolando] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
RP Miserocchi, E (corresponding author), Univ Vita Salute, Dept Ophthalmol, I-20132 Milan, Italy.
EM miserocchi.elisabetta@hsr.it
CR Borrelli E, 2020, EYE, V34, P1175, DOI 10.1038/s41433-020-0880-6
   Costi S, 2020, PEDIATR DRUGS, V22, P263, DOI 10.1007/s40272-020-00395-2
   Cron Randy Q, 2020, J Rheumatol, DOI 10.3899/jrheum.200492
   Favalli Ennio Giulio, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217615, 10.1136/annrheumdis-2020-217787]
   Filocamo Giovanni, 2020, J Rheumatol, DOI 10.3899/jrheum.200483
   Istituto Superiore di Sanita, 2020, AGG NAZ 20 MAGG 2020
   Lai THT, 2020, GRAEF ARCH CLIN EXP, V258, P1049, DOI 10.1007/s00417-020-04641-8
   Li JPO, 2020, BRIT J OPHTHALMOL, V104, P297, DOI 10.1136/bjophthalmol-2020-315994
   Licciardi F, 2020, PEDIATR RHEUMATOL, V18, DOI 10.1186/s12969-020-00422-z
   Linee Guida e Raccomandazioni SOI, 2020, LINEE GUIDA RACCOMAN
   Lu XX, 2020, PEDIAT ALLERG IMM-UK, V31, P449, DOI 10.1111/pai.13267
   Parravano M, 2020, OPHTHALMOL THER, V9, P231, DOI 10.1007/s40123-020-00251-z
   Reviglio Victor Eduardo, 2020, Med Hypothesis Discov Innov Ophthalmol, V9, P71
   Sadhu S, 2020, OPHTHALMOL THER, V9, P231, DOI [10.1007/s40123-020-00251-z, DOI 10.1007/S40123-020-00251-Z]
   Signorelli Carlo, 2020, Acta Biomed, V91, P175, DOI 10.23750/abm.v91i3-S.9511
   Xia JH, 2020, J MED VIROL, V92, P589, DOI 10.1002/jmv.25725
NR 16
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD NOV 16
PY 2020
VL 28
IS 8
BP 1305
EP 1307
DI 10.1080/09273948.2020.1800752
EA AUG 2020
PG 3
WC Ophthalmology
SC Ophthalmology
GA OU3GT
UT WOS:000573138400001
PM 32976038
DA 2021-01-01
ER

PT J
AU Wang, Y
   Niu, Z
   Peng, JL
   Wang, HS
   Zhang, K
AF Wang, Yan
   Niu, Zhuo
   Peng, Jia-Lin
   Wang, Hui-Sheng
   Zhang, Ke
TI Case Report: Opportunities for Treatment of Severe COVID-19
   Patients-Lessons From a Death Case
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE SARS-CoV-2; COVID-19; severe; rescue; treatment
AB With the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the incidence of coronavirus disease (COVID-19) increases each day. To date, there is no specific anti-SARS-CoV-2 drug. The usual approach to treating COVID-19 is treating its symptoms. However, this approach is limited by the different conditions of each area. We treated a 57-year-old man who was initially diagnosed with a severe type of the infection, but he progressed to a critical condition and eventually died. We learned valuable lessons from this case. The first lesson is the need to use immediate invasive mechanical ventilation if there is no obvious improvement after using non-invasive ventilation for several hours, which directly affects the prognosis. Another lesson is the risk involved in transferring severe COVID-19 patients. In the process of transfer, various threats may be encountered at any time. Thus, accurate assessment of the patient's condition and strict medical conditions are highly required. During the patient's 25-day treatment, we performed cardiopulmonary resuscitation twice. Currently, many patients require invasive mechanical ventilation and transfer to a superior hospital. We hope our findings will provide some advice and help for treating severe and critical COVID-19 cases.
C1 [Wang, Yan] Peoples Hosp Liaoning Prov, Dept Resp Med, Shenyang, Peoples R China.
   [Niu, Zhuo; Zhang, Ke] China Med Univ, Dept Dev Cell Biol, Key Lab Med Cell Biol, Key Lab Cell Biol,Minist Publ Hlth,Minist Educ, Shenyang, Peoples R China.
   [Niu, Zhuo] China Med Univ, Affiliated Hosp 1, Key Lab Precis Diag & Treatment Gastrointestinal, Minist Educ,Dept Surg Oncol & Gen Surg, Shenyang, Peoples R China.
   [Peng, Jia-Lin] Nan Zhang Peoples Hosp, Dept Neurol, Xiangyang, Peoples R China.
   [Wang, Hui-Sheng] Peoples Hosp Liaoning Prov, Dept Med Serv, Shenyang, Peoples R China.
RP Zhang, K (corresponding author), China Med Univ, Dept Dev Cell Biol, Key Lab Med Cell Biol, Key Lab Cell Biol,Minist Publ Hlth,Minist Educ, Shenyang, Peoples R China.
EM kzhang@cmu.edu.cn
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chiumello D, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1304-7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Quintin L, 2016, ANAESTH INTENSIVE TH, V48, P62, DOI 10.5603/AIT.2016.0011
   Wang HF, 2020, Int J Nurs Sci, V7, P139, DOI 10.1016/j.ijnss.2020.04.001
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Winck JC, 2020, PULMONOLOGY, V26, P213, DOI 10.1016/j.pulmoe.2020.04.013
   World Health Organization, 2020, DIAGN TREATM PROT NO
NR 8
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD AUG 14
PY 2020
VL 7
AR 533
DI 10.3389/fmed.2020.00533
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NJ7OY
UT WOS:000566233700001
PM 32923450
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Eisenhut, M
   Shin, JI
AF Eisenhut, Michael
   Shin, Jae Il
TI Pathways in the Pathophysiology of Coronavirus 19 Lung Disease
   Accessible to Prevention and Treatment
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE tumor necrosis factor; conductance regulator chloride channel;
   epithelial sodium channel; Na(+); K(+); 2Cl(-) cotransporter type 1
   cystic fibrosis transmembrane; furosemide; acute respiratory distress
   syndrome; acute lung injury; pulmonary edema
ID TUMOR-NECROSIS-FACTOR; ALVEOLAR FLUID CLEARANCE; FACTOR-ALPHA;
   PULMONARY-EDEMA; CYSTIC-FIBROSIS; STATIN THERAPY; SARS-COV;
   RHEUMATOID-ARTHRITIS; TNF-ALPHA; INJURY
AB Background:In COVID 19 related lung disease, which is a leading cause of death from this disease, cytokines like tumor necrosis factor-alpha (TNF alpha) may be pivotal in the pathogenesis. TNF alpha reduces fluid absorption due to impairment of sodium and chloride transport required for building an osmotic gradient across epithelial cells, which in the airways maintains airway surface liquid helping to keep airways open and enabling bacterial clearance and aids water absorption from the alveolar spaces. TNF alpha can, through Rho-kinase, disintegrate the endothelial and epithelial cytoskeleton, and thus break up intercellular tight junctional proteins, breaching the intercellular barrier, which prevents flooding of the interstitial and alveolar spaces with fluid. Hypotheses:(1) Preservation and restoration of airway and alveolar epithelial sodium and chloride transport and the cytoskeleton dependent integrity of the cell barriers within the lung can prevent and treat COVID 19 lung disease. (2) TNF alpha is the key mediator of pulmonary edema in COVID 19 lung disease. Confirmation of hypothesis and implications:The role of a reduction in the function of epithelial sodium and chloride transport could with regards to chloride transport be tested by analysis of chloride levels in exhaled breath condensate and levels correlated with TNF alpha concentrations. Reduced levels would indicate a reduction of the function of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel and a correlation with TNF alpha levels indicative of its involvement. Anti-TNF alpha treatment with antibodies is already available and needs to be tested in randomized controlled trials of COVID 19 lung disease. TNF alpha levels could also be reduced by statins, aspirin, and curcumin. Chloride transport could be facilitated by CFTR activators, including curcumin and phosphodiesterase-5 inhibitors. Sodium and chloride transport could be further regulated to prevent accumulation of alveolar fluid by use of Na(+)/K(+)/2Cl(-) cotransporter type 1 inhibitors, which have been associated with improved outcome in adults ventilated for acute respiratory distress syndrome (ARDS) in randomized controlled trials. Primary prevention of coronavirus infection and TNF alpha release in response to it could be improved by induction of antimicrobial peptides LL-37 and human beta defensin-2 and reduction of TNF alpha production by vitamin D prophylaxis for the population as a whole.
C1 [Eisenhut, Michael] Luton & Dunstable Univ Hosp NHS Fdn Trust, Childrens & Adolescent Serv, Luton, Beds, England.
   [Shin, Jae Il] Yonsei Univ, Dept Pediat, Coll Med, Seoul, South Korea.
RP Eisenhut, M (corresponding author), Luton & Dunstable Univ Hosp NHS Fdn Trust, Childrens & Adolescent Serv, Luton, Beds, England.
EM michael_eisenhut@yahoo.com
RI SHIN, JAE IL/J-6922-2017
OI SHIN, JAE IL/0000-0003-2326-1820
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   ADERKA D, 1991, ISRAEL J MED SCI, V27, P52
   Aeffner F, 2011, AM J PHYSIOL-LUNG C, V301, pL99, DOI 10.1152/ajplung.00398.2010
   Aigner C, 2018, J HEART LUNG TRANSPL, V37, P225, DOI 10.1016/j.healun.2017.09.021
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Almog Y, 2007, CRIT CARE MED, V35, P372, DOI 10.1097/01.CCM.0000253397.42079.D5
   Becq F, 2011, J CYST FIBROS, V10, pS129, DOI 10.1016/S1569-1993(11)60018-0
   Bergman P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065835
   Birukova AA, 2004, J CELL PHYSIOL, V201, P55, DOI 10.1002/jcp.20055
   Birukova AA, 2016, AM J RESP CELL MOL, V55, P476, DOI 10.1165/rcmb.2015-0328OC
   Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275
   Braun C, 2005, J IMMUNOL, V175, P3402, DOI 10.4049/jimmunol.175.5.3402
   Calfee CS, 2018, LANCET RESP MED, V6, P691, DOI 10.1016/S2213-2600(18)30177-2
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chansrichavala P, 2009, ASIAN PAC J ALLERGY, V27, P49
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Czikora I, 2014, AM J RESP CRIT CARE, V190, P522, DOI 10.1164/rccm.201405-0833OC
   Dagenais A, 2004, AM J PHYSIOL-LUNG C, V286, pL301, DOI 10.1152/ajplung.00326.2002
   Dancer RCA, 2015, THORAX, V70, P617, DOI 10.1136/thoraxjnl-2014-206680
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   Eisenhut M, 2006, PEDIATR CRIT CARE ME, V7, P119, DOI 10.1097/01.PCC.0000200944.98424.E0
   Eisenhut M, 2011, PFLUG ARCH EUR J PHY, V461, P401, DOI 10.1007/s00424-010-0917-y
   Erlich JM, 2011, CHEST, V139, P289, DOI 10.1378/chest.10-0891
   FAIZULHASSAN, 2019, FRONT GENET, V10, DOI DOI 10.3389/FGENE.2019.00514
   Fang XH, 2006, AM J PHYSIOL-LUNG C, V290, pL242, DOI 10.1152/ajplung.00178.2005
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Feng Y, 2018, EUR REV MED PHARMACO, V22, P3190, DOI 10.26355/eurrev_201805_15080
   FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Greiller CL, 2015, NUTRIENTS, V7, P4240, DOI 10.3390/nu7064240
   Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105
   Hagemeijer MC, 2012, VIRUSES-BASEL, V4, P3245, DOI 10.3390/v4113245
   Huang H, 2005, FRONT BIOSCI-LANDMRK, V10, P192, DOI 10.2741/1521
   Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004
   Ji HL, 2009, AM J PHYSIOL-LUNG C, V296, pL372, DOI 10.1152/ajplung.90437.2008
   Kasa A, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974448
   Kern L, 2019, CANCERS, V11, DOI 10.3390/cancers11010024
   Kiemer L, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-72
   Kim J, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1035-2
   Kor DJ, 2011, CRIT CARE MED, V39, P2393, DOI 10.1097/CCM.0b013e318225757f
   Kor DJ, 2009, INTENS CARE MED, V35, P1039, DOI 10.1007/s00134-009-1421-8
   Krenn K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1795-x
   Laffon M, 1999, AM J RESP CRIT CARE, V160, P1443, DOI 10.1164/ajrccm.160.5.9901097
   Li XM, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02324-w
   Li XP, 2017, CRIT CARE MED, V45, pe1240, DOI 10.1097/CCM.0000000000002720
   Li XP, 2012, AM J PHYSIOL-LUNG C, V303, pL152, DOI 10.1152/ajplung.00116.2012
   Liu KC, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108941
   Losche Wolfgang, 2012, Thrombosis, V2012, P720254, DOI 10.1155/2012/720254
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Matthay Michael A, 2005, Proc Am Thorac Soc, V2, P206, DOI 10.1513/pats.200501-009AC
   Matthay MA, 2020, LANCET RESP MED, V8, P433, DOI 10.1016/S2213-2600(20)30127-2
   McDermott JE, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0336-6
   Minozzi S, 2016, EXPERT OPIN DRUG SAF, V15, P11, DOI 10.1080/14740338.2016.1240783
   Mutlu G, 2005, CIRC RES, V96, P999, DOI 10.1161/01.RES.0000164554.21993.AC
   NAKAMURA H, 1992, FEBS LETT, V314, P366, DOI 10.1016/0014-5793(92)81507-I
   Novack V, 2009, INTENS CARE MED, V35, P1255, DOI 10.1007/s00134-009-1429-0
   O'Neal HR, 2011, CRIT CARE MED, V39, P1343, DOI 10.1097/CCM.0b013e3182120992
   Peteranderl C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00446
   Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Rezaiguia S, 1997, J CLIN INVEST, V99, P325, DOI 10.1172/JCI119161
   Sahebkar A, 2016, PHARMACOL RES, V107, P234, DOI 10.1016/j.phrs.2016.03.026
   Shen CH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02049
   Szatmary Z, 1999, NEOPLASMA, V46, P257
   Thickett DR, 2015, BMJ OPEN RESPIR RES, V2, DOI 10.1136/bmjresp-2014-000074
   Thijs L G, 1993, Intensive Care Med, V19 Suppl 1, pS8, DOI 10.1007/BF01738944
   Toussie D, 2020, RADIOLOGY, V297, pE197, DOI 10.1148/radiol.2020201754
   VANDEUREN M, 1995, J INFECT DIS, V172, P433, DOI 10.1093/infdis/172.2.433
   Vila E, 2005, AM J PHYSIOL-HEART C, V288, pH1016, DOI 10.1152/ajpheart.00779.2004
   Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035
   Weidenfeld S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00393
   White CM, 2019, PHARMACOL RES, V146, DOI 10.1016/j.phrs.2019.104280
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
   Wolk KE, 2008, AM J RESP CRIT CARE, V178, P969, DOI 10.1164/rccm.200803-455OC
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yamagata T, 2009, RESP PHYSIOL NEUROBI, V166, P16, DOI 10.1016/j.resp.2008.12.008
   Yang Guang, 2010, J Cardiovasc Dis Res, V1, P29, DOI 10.4103/0975-3583.59983
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Ye Z, 2020, EUR RADIOL, V30, P4381, DOI 10.1007/s00330-020-06801-0
   Zacharasiewicz A, 2004, PEDIATR PULM, V37, P273, DOI 10.1002/ppul.10431
NR 82
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD AUG 14
PY 2020
VL 11
AR 872
DI 10.3389/fphys.2020.00872
PG 9
WC Physiology
SC Physiology
GA NJ6KD
UT WOS:000566151100001
PM 32922301
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zayed, H
AF Zayed, Hatem
TI Vaccine Development Against COVID-19 Prior to Pandemic Outbreaks,
   Usingin vitroEvolution and Reverse Genetics
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE VLP vaccines; COVID-19; pandemic outbreak; SARS-CoV2; integrating
   vectors; coronaviruses
ID VIRUS-LIKE PARTICLES
C1 [Zayed, Hatem] Qatar Univ, QU Hlth, Coll Hlth Sci, Dept Biomed Sci, Doha, Qatar.
RP Zayed, H (corresponding author), Qatar Univ, QU Hlth, Coll Hlth Sci, Dept Biomed Sci, Doha, Qatar.
EM hatem.zayed@qu.edu.qa
OI Zayed, Hatem/0000-0001-8838-6638
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Baranyi L, 2013, HUM GENE THER METHOD, V24, P214, DOI 10.1089/hgtb.2013.002
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wispelaere M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004081
   Fan Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030210
   Fontana D, 2016, METHODS MOL BIOL, V1403, P155, DOI 10.1007/978-1-4939-3387-7_7
   Ivics Z, 2004, CURR ISSUES MOL BIOL, V6, P43
   Kaye M, 2006, EMERG INFECT DIS, V12, P128, DOI 10.3201/eid1201.050496
   Kikuchi Miho, 2002, Methods Mol Biol, V182, P243
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   McBurney SP, 2007, VIROLOGY, V358, P334, DOI 10.1016/j.virol.2006.08.032
   Moingeon P, 2003, CURR OPIN MICROBIOL, V6, P462, DOI 10.1016/j.mib.2003.08.002
   Muratori C, 2010, METHODS MOL BIOL, V614, P111, DOI 10.1007/978-1-60761-533-0_7
   Rigouin C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10758-4
   Stobart CC, 2014, VIRUSES-BASEL, V6, P2531, DOI 10.3390/v6072531
   Thompson CM, 2016, METHODS MOL BIOL, V1350, P299, DOI 10.1007/978-1-4939-3043-2_14
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu LL, 2016, VACCINE, V34, P2627, DOI 10.1016/j.vaccine.2016.03.031
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD AUG 14
PY 2020
VL 11
AR 2051
DI 10.3389/fimmu.2020.02051
PG 3
WC Immunology
SC Immunology
GA NJ5MW
UT WOS:000566088000001
PM 32922408
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mobasheri, A
AF Mobasheri, Ali
TI COVID-19, Companion Animals, Comparative Medicine, and One Health
SO FRONTIERS IN VETERINARY SCIENCE
LA English
DT Article
DE COVID-19; SARS-CoV2; companion animal; zoo animal; One Health;
   comparative medicine; Remdesivir (RDV; GS-5734)
ID CANINE CORONAVIRUS
AB The COVID-19 pandemic in 2020 has stimulated open collaboration between different scientific and clinical disciplines like never before. Public and private partnerships continue to form in order to tackle this unprecedented global challenge. This paper highlights the importance of open collaboration and cooperation between the disciplines of medicine, veterinary medicine, and animal health sciences in the fight against COVID-19. Since the pandemic took the whole world by surprise, many existing drugs were rapidly repurposed and tested in COVID-19 clinical trials and some of the trials are revealing promising results, it is clear that the long-term solution will come in the form of vaccines. While vaccines are being developed, the antiviral agent Remdesivir (RDV, GS-5734) is being repurposed for use in human clinical trials but this is being done without acknowledging the significant efforts that went into development for treating cats with feline infectious peritonitis (FIP), a highly fatal immune-mediated vasculitis in cats which is caused by a feline coronavirus. There are many other antiviral drugs and immune modulating treatments that are currently being trialed that have animal health origins in terms of discovery and clinical development. Closer collaboration between the animal health and human health sectors is likely to accelerate progress in the fight against COVID-19. There is much that we do not yet know about COVID-19 and its causative agent SARS-CoV-2 but we will learn and progress much faster if we increase interdisciplinary collaboration and communication between human and animal health researchers and taking a genuine "One Health" approach to this and other emerging viral pathogens. Enhanced knowledge of zoonotic coronaviruses can significantly enhance our ability to fight current and future emerging coronaviruses. This article highlights the acute need for One Health and comparative medicine and the crucial importance of building on and recognizing veterinary research for addressing future human pandemics.
C1 [Mobasheri, Ali] Univ Oulu, Fac Med, Res Unit Med Imaging, Oulu, Finland.
   [Mobasheri, Ali] Ctr Innovat Med, Dept Regenerat Med, State Res Inst, Vilnius, Lithuania.
   [Mobasheri, Ali] Univ Med Ctr Utrecht, Dept Orthoped, Utrecht, Netherlands.
   [Mobasheri, Ali] Univ Med Ctr Utrecht, Dept Rheumatol, Utrecht, Netherlands.
   [Mobasheri, Ali] Univ Med Ctr Utrecht, Dept Clin Immunol, Utrecht, Netherlands.
   [Mobasheri, Ali] Queens Med Ctr, Ctr Sport Exercise & Osteoarthrit Versus Arthrit, Nottingham, England.
RP Mobasheri, A (corresponding author), Univ Oulu, Fac Med, Res Unit Med Imaging, Oulu, Finland.; Mobasheri, A (corresponding author), Ctr Innovat Med, Dept Regenerat Med, State Res Inst, Vilnius, Lithuania.; Mobasheri, A (corresponding author), Univ Med Ctr Utrecht, Dept Orthoped, Utrecht, Netherlands.; Mobasheri, A (corresponding author), Univ Med Ctr Utrecht, Dept Rheumatol, Utrecht, Netherlands.; Mobasheri, A (corresponding author), Univ Med Ctr Utrecht, Dept Clin Immunol, Utrecht, Netherlands.; Mobasheri, A (corresponding author), Queens Med Ctr, Ctr Sport Exercise & Osteoarthrit Versus Arthrit, Nottingham, England.
EM ali.mobasheri@oulu.fi
RI Mobasheri, Ali/D-5770-2011
OI Mobasheri, Ali/0000-0001-6261-1286
CR Amirian ES, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100128
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Buonavoglia C, 2006, EMERG INFECT DIS, V12, P492, DOI 10.3201/eid1203.050839
   Cagliani R, 2020, J VIROL, V94, DOI 10.1128/JVI.00411-20
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Decaro N, 2020, RES VET SCI, V131, P21, DOI 10.1016/j.rvsc.2020.04.009
   Decaro N, 2011, VET CLIN N AM-SMALL, V41, P1121, DOI 10.1016/j.cvsm.2011.07.005
   Ding Q, 2020, J MED VIROL, V92, P1549, DOI 10.1002/jmv.25781
   Eyles K, 2008, VET CLIN N AM-SMALL, V38, P815, DOI 10.1016/j.cvsm.2008.02.008
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Gollakner R, 2020, VET ITAL, V56, P11, DOI 10.12834/VetIt.2246.12523.1
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lau SKP, 2020, EMERG INFECT DIS, V26, P1542, DOI 10.3201/eid2607.200092
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Liu SL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020130
   Luan JW, 2020, J MED VIROL, V92, P1649, DOI 10.1002/jmv.25817
   Mallapaty Smriti, 2020, Nature, DOI 10.1038/d41586-020-00984-8
   Mobasheri A, 2015, FRONT VET SCI, V2, DOI 10.3389/fvets.2015.00002
   Morgan AJ, 2011, VACCINE, V29, pD152, DOI 10.1016/j.vaccine.2011.08.128
   Ntafis V, 2011, VET MICROBIOL, V151, P238, DOI 10.1016/j.vetmic.2011.03.008
   Oreshkova N, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.23.2001005
   Priestnall SL, 2006, VET MICROBIOL, V115, P43, DOI 10.1016/j.vetmic.2006.02.008
   Riedel Stefan, 2005, Proc (Bayl Univ Med Cent), V18, P21
   Sharma V, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2010
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   Tilocca B, 2020, MICROBES INFECT, V22, P218, DOI 10.1016/j.micinf.2020.03.002
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang CM, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0411-4
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu JY, 2020, J MED VIROL, V92, P1902, DOI 10.1002/jmv.25884
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 39
TC 2
Z9 2
U1 9
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2297-1769
J9 FRONT VET SCI
JI Front. Vet. Sci.
PD AUG 14
PY 2020
VL 7
AR 522
DI 10.3389/fvets.2020.00522
PG 5
WC Veterinary Sciences
SC Veterinary Sciences
GA NJ5KJ
UT WOS:000566081500001
PM 32923472
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Debnath, P
   Debnath, B
   Bhaumik, S
   Debnath, S
AF Debnath, Pradip
   Debnath, Bimal
   Bhaumik, Samhita
   Debnath, Sudhan
TI In Silico Identification of Potential Inhibitors of ADP-Ribose
   Phosphatase of SARS-CoV-2 nsP3 by Combining E-Pharmacophore- and
   Receptor-Based Virtual Screening of Database
SO CHEMISTRYSELECT
LA English
DT Article
DE Drug design; Molecular docking; MolPort database; SARS-CoV-2; Virtual
   screening
ID ACCURATE DOCKING; CORONAVIRUS; GLIDE; PNEUMONIA; OUTBREAK; PROTEIN;
   DOMAIN
AB The recently emerged 2019 Novel Coronavirus (SARS-CoV-2) and associated COVID-19 disease cause serious or even fatal respiratory tract infection. Observing the spread, illness and death caused by COVID-19, the World Health Organization (WHO) declared COVID-19 a pandemic. To date, there is no approved therapeutics or effective treatment available to combat the outbreak. This urgent situation is pressing the world to respond with development of novel vaccine or a small molecule therapeutics for SARS-CoV-2. In line with these efforts, the structure of several proteins of SARS-CoV-2 has been rapidly resolved and made publicly available to facilitate global efforts to develop novel drug candidates. In this paper, we aim to find out the small molecule inhibitors for ADP-ribose phosphatase of SARS-CoV-2. In order to identify potential inhibitors, we applied sequential E-pharmacophore and structure-based virtual screening (VS) of MolPort database containing 113687 number of commercially available natural compounds using Glide module. Six potential inhibitors having admirable XP glide score range from -11.009 to -14.684 kcal/mol and good binding affinity towards active sites were identified. All the molecules are commercially available for further characterization and development by scientific community. Thein vitroactivity of selected inhibitors can be done easily which will provide useful information for clinical treatment of novel coronavirus pneumonia.
C1 [Debnath, Pradip; Debnath, Sudhan] MBB Coll, Dept Chem, Agartala 799004, Tripura, India.
   [Debnath, Bimal] Tripura Univ, Dept Forestry & Biodivers, Agartala 799022, Tripura, India.
   [Bhaumik, Samhita] Womens Coll, Dept Chem, Agartala 799001, Tripura, India.
RP Debnath, P; Debnath, S (corresponding author), MBB Coll, Dept Chem, Agartala 799004, Tripura, India.
EM pradipchem78@gmail.com; bcsdebnath@gmail.com
CR Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], 2020, QIKPROP
   [Anonymous], 2020, SCHROD REL 20204
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Fehr AR, 2018, TRENDS MICROBIOL, V26, P598, DOI 10.1016/j.tim.2017.11.011
   Fischer A., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.11923239.v1, DOI 10.26434/CHEMRXIV.11923239.V1]
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imberta I, 2008, VIRUS RES, V133, P136, DOI 10.1016/j.virusres.2007.11.017
   Israeli Eitan, 2020, Harefuah, V159, P70
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Liu W, 2020, CURR TOP MED CHEM, V20, P603, DOI 10.2174/1568026620999200305145032
   Mohd HA, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0544-0
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Paasche A, 2014, BIOCHEMISTRY-US, V53, P5930, DOI 10.1021/bi400604t
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Salam NK, 2009, J CHEM INF MODEL, V49, P2356, DOI 10.1021/ci900212v
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   World Health Organization, NOV COR 2019 NCOV SI
   World Health Organization, INT HLTH REG EM COMM
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z., 2020, BIORXIV, DOI [10.1101/2020.01.27.921627., DOI 10.1101/2020.01.27.921627]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhang HG, 2020, IEEE T NEUR NET LEAR, V31, P4816, DOI 10.1109/TNNLS.2019.2958107
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu Z., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.11959323.v1, DOI 10.26434/CHEMRXIV.11959323.V1]
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 43
TC 0
Z9 0
U1 2
U2 2
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2365-6549
J9 CHEMISTRYSELECT
JI ChemistrySelect
PD AUG 14
PY 2020
VL 5
IS 30
BP 9388
EP 9398
DI 10.1002/slct.202001419
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA NG8JS
UT WOS:000564226500010
PM 32835090
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wu, SP
   Zhong, GX
   Zhang, J
   Shuai, L
   Zhang, Z
   Wen, ZY
   Wang, BS
   Zhao, ZH
   Song, XH
   Chen, Y
   Liu, RQ
   Fu, L
   Zhang, JL
   Guo, Q
   Wang, C
   Yang, YL
   Fang, T
   Lv, P
   Wang, JL
   Xu, JJ
   Li, JM
   Yu, CM
   Hou, LH
   Bu, ZG
   Chen, W
AF Wu, Shipo
   Zhong, Gongxun
   Zhang, Jun
   Shuai, Lei
   Zhang, Zhe
   Wen, Zhiyuan
   Wang, Busen
   Zhao, Zhenghao
   Song, Xiaohong
   Chen, Yi
   Liu, Renqiang
   Fu, Ling
   Zhang, Jinlong
   Guo, Qiang
   Wang, Chong
   Yang, Yilong
   Fang, Ting
   Lv, Peng
   Wang, Jinliang
   Xu, Junjie
   Li, Jianmin
   Yu, Changming
   Hou, Lihua
   Bu, Zhigao
   Chen, Wei
TI A single dose of an adenovirus-vectored vaccine provides protection
   against SARS-CoV-2 challenge
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ATTENUATED INFLUENZA VACCINE; DOUBLE-BLIND; HEALTHY-ADULTS; EBOLA
   VACCINE; SAFETY; IMMUNOGENICITY; EFFICACY; CHILDREN
AB The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.
C1 [Wu, Shipo; Zhang, Jun; Zhang, Zhe; Wang, Busen; Zhao, Zhenghao; Song, Xiaohong; Chen, Yi; Fu, Ling; Zhang, Jinlong; Guo, Qiang; Yang, Yilong; Fang, Ting; Lv, Peng; Xu, Junjie; Li, Jianmin; Yu, Changming; Hou, Lihua; Chen, Wei] Beijing Inst Biotechnol, Beijing, Peoples R China.
   [Zhong, Gongxun; Shuai, Lei; Wen, Zhiyuan; Liu, Renqiang; Wang, Chong; Wang, Jinliang; Bu, Zhigao] Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin, Peoples R China.
RP Hou, LH; Chen, W (corresponding author), Beijing Inst Biotechnol, Beijing, Peoples R China.; Bu, ZG (corresponding author), Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin, Peoples R China.
EM houlihua@sina.com; buzhigao@caas.cn; cw0226@foxmail.com
OI Zhong, Gongxun/0000-0002-0748-9641; ZHANG, JUN/0000-0002-9650-112X; Wen,
   Zhiyuan/0000-0003-3112-0243; shuai, lei/0000-0003-2122-8365; wang,
   busen/0000-0001-9041-1919
FU National Key Research and Development Program of China [2020YFC0841400,
   2020YFC0846500]; National Major Science & Technology Major Project
   [2016ZX10004001, 2018ZX09201005]
FX We thank CanSinoBIO Inc. for providing Ad5-nCoV vaccine for this work.
   We thank Beijing Institute of Microbiology and Epidemiology for
   providing SARS-CoV-2 strain
   (SARS-CoV-2/human/CHN/Beijing_IME-BJ01/2020). We thank the support from
   the National Key Research and Development Program of China
   (2020YFC0841400, 2020YFC0846500), the National Major Science &
   Technology Major Project (2016ZX10004001, 2018ZX09201005).
CR Broadbent A. J, 2015, MUCOSAL IMMUNOLOGY, V1, P1129, DOI [10.1016/B978-0-12-415847-4.00059-8, DOI 10.1016/B978-0-12-415847-4.00059-8]
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Choi JH, 2012, MOL PHARMACEUT, V9, P156, DOI 10.1021/mp200392g
   Croyle MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003548
   Duffy J, 2017, ANN ALLERG ASTHMA IM, V118, P439, DOI 10.1016/j.anai.2017.01.030
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Guo Q, 2018, J INFECT DIS, V218, P365, DOI 10.1093/infdis/jiy187
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Li JX, 2017, LANCET GLOB HEALTH, V5, pE324, DOI [10.1016/S2214-109X(16)30367-9, 10.1016/s2214-109x(16)30367-9]
   Liebowitz D, 2020, LANCET INFECT DIS, V20, P435, DOI 10.1016/S1473-3099(19)30584-5
   Garcia-Garcia ML, 2016, ARCH BRONCONEUMOL, V52, P269, DOI 10.1016/j.arbres.2015.11.008
   Nordin JD, 2019, VACCINE, V37, P4055, DOI 10.1016/j.vaccine.2019.05.081
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Turner PJ, 2015, J ALLERGY CLIN IMMUN, V136, P376, DOI 10.1016/j.jaci.2014.12.1925
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zens KD, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85832
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zhu FC, 2017, LANCET, V389, P621, DOI [10.1016/S0140-6736(16)32617-4, 10.1016/s0140-6736(16)32617-4]
   Zhu FC, 2015, LANCET, V385, P2272, DOI 10.1016/S0140-6736(15)60553-0
NR 21
TC 2
Z9 2
U1 7
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 14
PY 2020
VL 11
IS 1
AR 4081
DI 10.1038/s41467-020-17972-1
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NG7IO
UT WOS:000564154300003
PM 32796842
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gao, JB
   Yang, M
   Liu, L
   Guo, S
   Li, YF
   Cheng, C
AF Gao, Jinbo
   Yang, Ming
   Liu, Lian
   Guo, Shuang
   Li, Yongfeng
   Cheng, Chao
TI The aggressive surgical treatment and outcome of a colon cancer patient
   with COVID-19 in Wuhan, China
SO BMC GASTROENTEROLOGY
LA English
DT Article
DE Colon Cancer; COVID-19; SARS-CoV-2; Pathology; Case report
AB Background Cancer patients are at increased risk of novel coronavirus disease 2019 (COVID-19). Currently, surgeries for cancer patients with COVID-19 are generally suggested to be properly delayed. Case presentation We presented a 69-year-old Chinese female colon cancer patient with COVID-19, the first case accepted the surgical treatment during the pandemic in China. The patient developed a fever on January 28, 2020. After treatments with Ceftriaxone and Abidol, her fever was not moderated yet. A repeat chest computed tomography (CT) scan showed significantly exacerbated infectious lesions with a positive result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid. An abdomen CT scan indicated the tumor of ascending colon with local wrapped changes. She was diagnosed with 'Severe novel coronavirus pneumonia' and 'Incomplete bowel obstruction: Colon cancer?'. After actively anti-inflammatory and anti-viral therapies, a right colectomy with lymph node dissection was performed on March 11, followed by a pathological examination. The patient successfully recovered from COVID-19 pneumonia and incomplete bowel obstruction after surgery without any postoperative related complications and was discharged on the 9th day after operation. Significant degeneration, necrosis and slough of focal intestinal and colonic mucosal epithelial cells were observed under microscope. No surgeons, nurses or anesthetists in our team were infected with SARS-CoV-2. Conclusions It is meaningful and imperative to share our experience of protecting health care personnels from SARS-CoV-2 infection and providing references for optimizing treatment of cancer patients, at least for the operative intervention with absolute necessity or surgical emergency, during the outbreak of COVID-19.
C1 [Gao, Jinbo; Li, Yongfeng; Cheng, Chao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, 1277 Jiefang Ave, Wuhan, Hubei, Peoples R China.
   [Yang, Ming; Guo, Shuang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, Wuhan, Hubei, Peoples R China.
   [Liu, Lian] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Hubei, Peoples R China.
RP Cheng, C (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, 1277 Jiefang Ave, Wuhan, Hubei, Peoples R China.
EM chengchao0306@sina.cn
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2016YXMS250]; Natural
   Science Foundation of Hubei ProvinceNatural Science Foundation of Hubei
   Province [2016CFB228]
FX Conduction of this work and publication of this article were supported
   by the Fundamental Research Funds for the Central Universities (Grant
   No. 2016YXMS250) and Natural Science Foundation of Hubei Province (Grant
   No. 2016CFB228). The funding bodies had no roles in: the design of the
   study; collection, analysis, or interpretation of data; writing the
   manuscript; or the decision to publish the results.
CR Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Yu GY, 2020, CHIN J DENT RES, V23, P9, DOI 10.3290/j.cjdr.a44348
   Zhang HY, 2020, J THORAC ONCOL, V15, pE63, DOI 10.1016/j.jtho.2020.02.025
NR 8
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-230X
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD AUG 14
PY 2020
VL 20
IS 1
AR 269
DI 10.1186/s12876-020-01411-y
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NF6UN
UT WOS:000563431200004
PM 32799796
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, T
   Liu, Y
   Li, M
   Qian, XN
   Dai, SY
AF Li, Tom
   Liu, Yan
   Li, Man
   Qian, Xiaoning
   Dai, Susie Y.
TI Mask or no mask for COVID-19: A public health and market study
SO PLOS ONE
LA English
DT Article
ID NONPHARMACEUTICAL INTERVENTIONS; CORONAVIRUS COVID-19; FAMILY CLUSTER;
   FACE MASKS; INFLUENZA; TRANSMISSION; INFECTIONS; OUTBREAK; PREVENT;
   MODELS
AB Efficient strategies to contain the coronavirus disease 2019 (COVID-19) pandemic are peremptory to relieve the negatively impacted public health and global economy, with the full scope yet to unfold. In the absence of highly effective drugs, vaccines, and abundant medical resources, many measures are used to manage the infection rate and avoid exhausting limited hospital resources. Wearing masks is among the non-pharmaceutical intervention (NPI) measures that could be effectively implemented at a minimum cost and without dramatically disrupting social practices. The mask-wearing guidelines vary significantly across countries. Regardless of the debates in the medical community and the global mask production shortage, more countries and regions are moving forward with recommendations or mandates to wear masks in public. Our study combines mathematical modeling and existing scientific evidence to evaluate the potential impact of the utilization of normal medical masks in public to combat the COVID-19 pandemic. We consider three key factors that contribute to the effectiveness of wearing a quality mask in reducing the transmission risk, including the mask aerosol reduction rate, mask population coverage, and mask availability. We first simulate the impact of these three factors on the virus reproduction number and infection attack rate in a general population. Using the intervened viral transmission route by wearing a mask, we further model the impact of mask-wearing on the epidemic curve with increasing mask awareness and availability. Our study indicates that wearing a face mask can be effectively combined with social distancing to flatten the epidemic curve. Wearing a mask presents a rational way to implement as an NPI to combat COVID-19. We recognize our study provides a projection based only on currently available data and estimates potential probabilities. As such, our model warrants further validation studies.
C1 [Li, Tom; Li, Man; Dai, Susie Y.] Texas A&M Univ, Dept Plant Pathol & Microbiol, College Stn, TX 77843 USA.
   [Liu, Yan] Texas A&M Univ, Dept Mkt, College Stn, TX USA.
   [Qian, Xiaoning] Texas A&M Univ, Dept Elect & Comp Engn, College Stn, TX USA.
RP Dai, SY (corresponding author), Texas A&M Univ, Dept Plant Pathol & Microbiol, College Stn, TX 77843 USA.
EM sydai@tamu.edu
OI Dai, Susie/0000-0002-5747-9222
CR Abramovich MN, 2017, AM J INFECT CONTROL, V45, P272, DOI 10.1016/j.ajic.2016.10.019
   Agency EM, 1996, NOT GUID VIR VAL STU
   Bae Seongman, ANN INTERN MED, DOI [10.7326/M20-13422020.32251511, DOI 10.7326/M20-13422020.32251511]
   Bansal S, 2007, J R SOC INTERFACE, V4, P879, DOI 10.1098/rsif.2007.1100
   Benkouiten S, 2014, TRAVEL MED INFECT DI, V12, P429, DOI 10.1016/j.tmaid.2014.06.005
   Booth C. M., 2013, Journal of Hospital Infection, V84, P22, DOI 10.1016/j.jhin.2013.02.007
   Bourouiba L, 2020, JAMA-J AM MED ASSOC, V323, P1837, DOI 10.1001/jama.2020.4756
   Bridges CB, 2003, CLIN INFECT DIS, V37, P1094, DOI 10.1086/378292
   Brienen NCJ, 2010, RISK ANAL, V30, P1210, DOI 10.1111/j.1539-6924.2010.01428.x
   Carias C, 2015, CLIN INFECT DIS, V60, pS42, DOI 10.1093/cid/civ141
   Cascella M, 2020, EVALUATION TREATMENT
   Cowling BJ, 2010, EPIDEMIOL INFECT, V138, P449, DOI 10.1017/S0950268809991658
   Davies A, 2013, DISASTER MED PUBLIC, V7, P413, DOI 10.1017/dmp.2013.43
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fabian P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002691
   Feng S, 2020, LANCET RESP MED, V8, P434, DOI 10.1016/S2213-2600(20)30134-X
   Ferguson N., 2020, IMPACT NONPHARMACEUT
   Ferng YH, 2011, PUBLIC HEALTH NURS, V28, P13, DOI 10.1111/j.1525-1446.2010.00918.x
   FURUHASHI M, 1978, Bulletin of Tokyo Medical and Dental University, V25, P7
   Ganyani T, 2020, ESTIMATING GENERATIO
   Ganyani T KC, 2020, ESTIMATING GENERATIO, V2020
   Ganyani T, 2020, EUROSURVEILLANCE, V25, P12, DOI 10.2807/1560-7917.ES.2020.25.17.2000257
   Gilbert M., 2020, MINTELS PERSPECTIVE
   Haelle T., 2020, FORBES
   Han Y, 2020, J MED VIROL, V92, P639, DOI 10.1002/jmv.25749
   Hasegawa R., 2020, COVID 19 JAPANESE CO
   Henderson Max, 2020, REP JONATHAN KREISS
   HU JX, 2020, CHIN MED J, DOI DOI 10.1097/CM9.000000000000079832149768
   Huang R, 2020, LANCET INFECT DIS, V20, P534, DOI 10.1016/S1473-3099(20)30147-X
   Inouye S, 2010, JPN J INFECT DIS, V63, P197
   Jones RM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0832-0
   Joseph A., 2020, NOVEL VIRUS TIED CHI
   Jung H, 2014, AEROSOL AIR QUAL RES, V14, P991, DOI 10.4209/aaqr.2013.06.0201
   Ki M, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020007
   Kimball A, 2020, MMWR-MORBID MORTAL W, V69, P377, DOI 10.15585/mmwr.mm6913e1
   Kirkcaldy RD, 2020, JAMA-J AM MED ASSOC, V323, P2245, DOI 10.1001/jama.2020.7869
   Koo JR, 2020, LANCET INFECT DIS, V20, P678, DOI 10.1016/S1473-3099(20)30162-6
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Larson EL, 2010, PUBLIC HEALTH REP, V125, P178, DOI 10.1177/003335491012500206
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Leung K, 2020, LANCET LONDON ENGLAN, DOI [10.1016/S0140-6736(20)30746-732277878, DOI 10.1016/S0140-6736(20)30746-732277878]
   Leung NHL, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0843-2
   Liu EA, 2020, AERODYNAMIC CHARACTE, DOI [10.1101/2020.03.08.982637v1, DOI 10.1101/2020.03.08.982637V1]
   LIU Y, 2020, NATURE 0427, DOI DOI 10.1038/S41586-020-2271-3
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Liu ZQ, 2018, J ORTHOP TRANSL, V14, P57, DOI 10.1016/j.jot.2018.06.002
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MacIntyre CR, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006577
   Madbouly SA, 2020, ACS OMEGA, V5, P9977, DOI 10.1021/acsomega.0c00297
   Mallapaty Smriti, 2020, Nature, V581, P127, DOI 10.1038/d41586-020-01354-0
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Modern J. G., 2002, INFECT DIS EPIDEMIOL
   Morawska L, 2006, INDOOR AIR, V16, P335, DOI 10.1111/j.1600-0668.2006.00432.x
   Nishiura H, 2020, INT J INFECT DIS, V93, P284, DOI 10.1016/j.ijid.2020.02.060
   Pan XF, 2020, LANCET INFECT DIS, V20, P410, DOI 10.1016/S1473-3099(20)30114-6
   Puritz-Evans ASJ, 2020, MARINE PROTECTED AREAS: SCIENCE, POLICY AND MANAGEMENT, P195, DOI 10.1016/B978-0-08-102698-4.00011-3
   Rocklov J, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa030
   Santarpia JL, 2020, TRANSMISSION POTENTI, DOI [10.1101/2020.03.23.20039446, DOI 10.1101/2020.03.23.20039446]
   Shakya KM, 2017, J EXPO SCI ENV EPID, V27, P352, DOI 10.1038/jes.2016.42
   SteelFisher GK, 2012, LANCET INFECT DIS, V12, P845, DOI 10.1016/S1473-3099(12)70206-2
   Taghvaei A, 2020, FRACTIONAL SIR EPIDE, DOI [10.1101/2020.04.28.20083865, DOI 10.1101/2020.04.28.20083865]
   Taiwan C., TAIWAN TIMELY IDENTI
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Tang JW, 2009, J R SOC INTERFACE, V6, pS727, DOI 10.1098/rsif.2009.0295.focus
   Taplin N., 2020, WALL STREET J
   Tellier R, 2006, EMERG INFECT DIS, V12, P1657, DOI 10.3201/eid1211.060426
   Tellier R, 2009, J R SOC INTERFACE, V6, pS783, DOI 10.1098/rsif.2009.0302.focus
   Thaiger T., KICK FOREIGNERS NOT
   Tong ZD, 2020, EMERG INFECT DIS, V26, P1052, DOI 10.3201/eid2605.200198
   van der Sande M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002618
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Victor CWT, 2020, ECLINICAL MED, DOI [10.1016/j.eclinm.2020.10035632337502, DOI 10.1016/J.ECLINM.2020.10035632337502]
   Wang X, 2020, BIOSCI TRENDS, V14, P3, DOI 10.5582/bst.2020.01043
   Wei WE, 2020, MMWR MORB MORTAL WKL
   Wei WE, 2020, MMWR-MORBID MORTAL W, V69, P411, DOI 10.15585/mmwr.mm6914e1
   Wolf GK, 2020, J PEDIAT INF DIS SOC, V9, P362, DOI 10.1093/jpids/piaa060
   Wu Huai-Liang, 2020, EClinicalMedicine, V21, P100329, DOI 10.1016/j.eclinm.2020.100329
   Yu ITS, 2004, NEW ENGL J MED, V350, P1731, DOI 10.1056/NEJMoa032867
   Zhang LJ, 2013, EMERG INFECT DIS, V19, P1403, DOI 10.3201/eid1909.121765
   Zhang S, 2020, INT J INFECT DIS, V93, P201, DOI 10.1016/j.ijid.2020.02.033
   Zhou YR, 2020, USNEWS          0318
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 82
TC 2
Z9 2
U1 6
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 14
PY 2020
VL 15
IS 8
AR e0237691
DI 10.1371/journal.pone.0237691
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NE5WK
UT WOS:000562671300046
PM 32797067
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cantini, F
   Banci, L
   Altincekic, N
   Bains, JK
   Dhamotharan, K
   Fuks, C
   Furtig, B
   Gande, SL
   Hargittay, B
   Hengesbach, M
   Hutchison, MT
   Korn, SM
   Kubatova, N
   Kutz, F
   Linhard, V
   Lohr, F
   Meiser, N
   Pyper, DJ
   Qureshi, NS
   Richter, C
   Saxena, K
   Schlundt, A
   Schwalbe, H
   Sreeramulu, S
   Tants, JN
   Wacker, A
   Weigand, JE
   Wohnert, J
   Tsika, AC
   Fourkiotis, NK
   Spyroulias, GA
AF Cantini, F.
   Banci, L.
   Altincekic, N.
   Bains, J. K.
   Dhamotharan, K.
   Fuks, C.
   Fuertig, B.
   Gande, S. L.
   Hargittay, B.
   Hengesbach, M.
   Hutchison, M. T.
   Korn, S. M.
   Kubatova, N.
   Kutz, F.
   Linhard, V
   Loehr, F.
   Meiser, N.
   Pyper, D. J.
   Qureshi, N. S.
   Richter, C.
   Saxena, K.
   Schlundt, A.
   Schwalbe, H.
   Sreeramulu, S.
   Tants, J-N
   Wacker, A.
   Weigand, J. E.
   Woehnert, J.
   Tsika, A. C.
   Fourkiotis, N. K.
   Spyroulias, G. A.
TI H-1,C-13, and(15)N backbone chemical shift assignments of the apo and
   the ADP-ribose bound forms of the macrodomain of SARS-CoV-2
   non-structural protein 3b
SO BIOMOLECULAR NMR ASSIGNMENTS
LA English
DT Article
DE SARS-CoV-2; Non-structural protein; Macrodomain; Solution
   NMR-spectroscopy; Protein drugability; COVID19-NMR
AB The SARS-CoV-2 genome encodes for approximately 30 proteins. Within the international project COVID19-NMR, we distribute the spectroscopic analysis of the viral proteins and RNA. Here, we report NMR chemical shift assignments for the protein Nsp3b, a domain of Nsp3. The 217-kDa large Nsp3 protein contains multiple structurally independent, yet functionally related domains including the viral papain-like protease and Nsp3b, a macrodomain (MD). In general, the MDs of SARS-CoV and MERS-CoV were suggested to play a key role in viral replication by modulating the immune response of the host. The MDs are structurally conserved. They most likely remove ADP-ribose, a common posttranslational modification, from protein side chains. This de-ADP ribosylating function has potentially evolved to protect the virus from the anti-viral ADP-ribosylation catalyzed by poly-ADP-ribose polymerases (PARPs), which in turn are triggered by pathogen-associated sensing of the host immune system. This renders the SARS-CoV-2 Nsp3b a highly relevant drug target in the viral replication process. We here report the near-complete NMR backbone resonance assignment (H-1,C-13,N-15) of the putative Nsp3b MD in its apo form and in complex with ADP-ribose. Furthermore, we derive the secondary structure of Nsp3b in solution. In addition,N-15-relaxation data suggest an ordered, rigid core of the MD structure. These data will provide a basis for NMR investigations targeted at obtaining small-molecule inhibitors interfering with the catalytic activity of Nsp3b.
C1 [Cantini, F.; Banci, L.] Univ Florence, Magnet Resonance Ctr CERM, Via Luigi Sacconi 6, I-50019 Florence, Italy.
   [Cantini, F.; Banci, L.] Univ Florence, Dept Chem, Via Lastruccia 3, I-50019 Florence, Italy.
   [Altincekic, N.; Bains, J. K.; Fuks, C.; Fuertig, B.; Gande, S. L.; Hargittay, B.; Hengesbach, M.; Hutchison, M. T.; Kubatova, N.; Kutz, F.; Linhard, V; Meiser, N.; Pyper, D. J.; Qureshi, N. S.; Richter, C.; Saxena, K.; Schwalbe, H.; Sreeramulu, S.; Wacker, A.] Goethe Univ Frankfurt, Inst Organ Chem & Chem Biol, Ctr Biomol Magnet Resonance BMRZ, Max von Laue Str 7, D-60438 Frankfurt, Germany.
   [Dhamotharan, K.; Korn, S. M.; Schlundt, A.; Tants, J-N; Woehnert, J.] Goethe Univ Frankfurt, Inst Mol Biosci, Ctr Biomol Magnet Resonance BMRZ, Max von Laue Str 7, D-60438 Frankfurt, Germany.
   [Loehr, F.] Goethe Univ Frankfurt, Inst Biophys Chem, Ctr Biomol Magnet Resonance BMRZ, Max von Laue Str 7, D-60438 Frankfurt, Germany.
   [Weigand, J. E.] Tech Univ Darmstadt, Dept Biol, Schnittspahnstr 10, D-64287 Darmstadt, Germany.
   [Tsika, A. C.; Fourkiotis, N. K.; Spyroulias, G. A.] Univ Patras, Dept Pharm, Patras 26504, Greece.
RP Banci, L (corresponding author), Univ Florence, Magnet Resonance Ctr CERM, Via Luigi Sacconi 6, I-50019 Florence, Italy.; Banci, L (corresponding author), Univ Florence, Dept Chem, Via Lastruccia 3, I-50019 Florence, Italy.; Schwalbe, H (corresponding author), Goethe Univ Frankfurt, Inst Organ Chem & Chem Biol, Ctr Biomol Magnet Resonance BMRZ, Max von Laue Str 7, D-60438 Frankfurt, Germany.; Spyroulias, GA (corresponding author), Univ Patras, Dept Pharm, Patras 26504, Greece.
EM banci@cerm.unifi.it; Schwalbe@nmr.uni-frankfurt.de;
   G.A.Spyroulias@upatras.gr
RI Wacker, Anna B/A-3539-2019; Schwalbe, Harald/AAB-3143-2020; Schlundt,
   Andreas/D-2951-2017
OI Wacker, Anna B/0000-0001-5892-5661; Schwalbe,
   Harald/0000-0001-5693-7909; Weigand, Julia/0000-0003-4247-1348;
   Altincekic, Nadide/0000-0001-6370-3414; Dhamotharan,
   Karthikeyan/0000-0003-0226-7350; Schlundt, Andreas/0000-0003-2254-7560
FU Projekt DEAL; state of Hesse; Goethe Corona Funds; DFGGerman Research
   Foundation (DFG) [CRC902]; Italian Ministry for University and Research
   (FOE funding); INSPIRED - Operational Program 'Competitiveness,
   Entrepreneurship and Innovation' (NSRF 2014-2020) [MIS 5002550];
   European Union (European Regional Development Fund)European Union (EU);
   EUEuropean Union (EU) [CT-2011-285950]
FX Open Access funding provided by Projekt DEAL. Work at BMRZ is supported
   by the state of Hesse. Work in COVID19-NMR was supported by the Goethe
   Corona Funds and the DFG in CRC902: "Molecular Principles of RNA-based
   regulation." Work at CERM is supported by the Italian Ministry for
   University and Research (FOE funding) to the Italian Center (CERM,
   University of Florence) of Instruct-ERIC, an European Research
   Infrastructure, ESFRI Landmark. The work was supported by the INSPIRED
   (MIS 5002550) which is implemented under the Action 'Reinforcement of
   the Research and Innovation Infrastructure,' funded by the Operational
   Program 'Competitiveness, Entrepreneurship and Innovation' (NSRF
   2014-2020) and co-financed by Greece and the European Union (European
   Regional Development Fund). EU FP7 REGPOT CT-2011-285950 - "SEE-DRUG"
   project is acknowledged for the purchase of UPAT's 700 MHz NMR
   equipment. We thank Prof. Dr. Stefan Knapp for kindly providing the
   Nsp3b clone.
CR Favier A, 2011, J BIOMOL NMR, V49, P9, DOI 10.1007/s10858-010-9461-5
   Frick DN, 2020, BIOCHEMISTRY-US, V59, P2608, DOI 10.1021/acs.biochem.0c00309
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Laskowski RA, 1997, TRENDS BIOCHEM SCI, V22, P488, DOI 10.1016/S0968-0004(97)01140-7
   Lescop E, 2007, J MAGN RESON, V187, P163, DOI 10.1016/j.jmr.2007.04.002
   Shen Y, 2013, J BIOMOL NMR, V56, P227, DOI 10.1007/s10858-013-9741-y
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Solyom Z, 2013, J BIOMOL NMR, V55, P311, DOI 10.1007/s10858-013-9715-0
   WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777
   Yoshimoto FK, 2020, PROTEIN J, V39, P198, DOI 10.1007/s10930-020-09901-4
   Zhu G, 2000, J MAGN RESON, V143, P423, DOI 10.1006/jmre.2000.2022
NR 11
TC 1
Z9 1
U1 4
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1874-2718
EI 1874-270X
J9 BIOMOL NMR ASSIGN
JI Biomol. NMR Assign.
PD OCT
PY 2020
VL 14
IS 2
BP 339
EP 346
DI 10.1007/s12104-020-09973-4
EA AUG 2020
PG 8
WC Biophysics; Spectroscopy
SC Biophysics; Spectroscopy
GA NI2VR
UT WOS:000559668400001
PM 32803496
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Ghaleb, A
   Aouidate, A
   Ben El Ayouchia, H
   Aarjane, M
   Anane, H
   Stiriba, SE
AF Ghaleb, Adib
   Aouidate, Adnane
   Ben El Ayouchia, Hicham
   Aarjane, Mohammed
   Anane, Hafid
   Stiriba, Salah-Eddine
TI In silico molecular investigations of pyridine N-Oxide compounds as
   potential inhibitors of SARS-CoV-2: 3D QSAR, molecular docking modeling,
   and ADMET screening
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; 3D-QSAR; molecular docking; drug discovery; pyridine N-oxide
ID EXPLORATION; REACTIVITY
AB The new coronavirus SARS-CoV-2 virus is causing a severe pneumonia in human, provoking the serious outbreak epidemic CoV-2. Since its appearance in Wuhan, China on December 2019, CoV-2 becomes the biggest challenge the world is facing today, including the discovery of antiviral drug for SARS-CoV-2. In this study, the potential inhibitory of a class of human SARS inhibitors, namely pyridine N-oxide derivatives, against CoV-2 was addressed by quantitative structure-activity relationship 3 D-QSAR. The reliable CoMSIA developed model of 110 pyridine N-oxide based-antiviral compounds, showed Q(2)=0.54 and r(ext)(2). The molecular surflex-docking was applied to identify the crystal structure of CoV-2 main protease 3CLpro (PDB: 6LU7) and two potentially and largely used antiviral molecules, namely chloroquine, hydroxychloroquine. The obtained free energy affinity and ADMET properties indicate that among the series of model antiviral compounds examined, the new antiviral compound A5 could be an excellent antiviral drug inhibitor against COVID-19. The inhibition activity of pyridine N-oxyde compounds against CoV-2 was compared with the activity of two common antiviral drug, namely chloroquine (CQ) and hydroxychloroquine (HCQ). DFT method was also used to define the sites of reactivity of pyridine N-oxyde derivatives as well as CQ and HCQ.
C1 [Ghaleb, Adib; Ben El Ayouchia, Hicham; Anane, Hafid; Stiriba, Salah-Eddine] Univ Cadi Ayyad, LCAM, Fac Polydisciplinaire Safi, Safi 46000, Morocco.
   [Aouidate, Adnane] Moulay Ismail Univ, Sch Sci, MCNSL, Meknes, Morocco.
   [Aarjane, Mohammed] Univ Moulay Ismail, LCBAE, Equipe Chim Mol & Mol Bioact, Fac Sci, Meknes, Morocco.
   [Stiriba, Salah-Eddine] Univ Valencia, Inst Ciencia Mol ICMol, Valencia, Spain.
RP Ghaleb, A (corresponding author), Univ Cadi Ayyad, LCAM, Fac Polydisciplinaire Safi, Safi 46000, Morocco.
EM adib.ghaleb@gmail.com
OI ANANE, Hafid/0000-0003-3254-6203; aarjane, mohammed/0000-0002-7501-8569;
   Ben El Ayouchia, Hicham/0000-0002-4713-4837; Aouidate,
   Adnane/0000-0002-9123-5504
CR BUSH BL, 1993, J COMPUT AID MOL DES, V7, P587, DOI 10.1007/BF00124364
   CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804
   Dai WW, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070625
   Dassault Systemes BIOVIA, 2016, DISCOVERY STUDIO MOD
   Domingo LR, 2002, TETRAHEDRON, V58, P4417, DOI 10.1016/S0040-4020(02)00410-6
   Domingo LR, 2008, J ORG CHEM, V73, P4615, DOI 10.1021/jo800572a
   Domingo LR, 2016, MOLECULES, V21, DOI 10.3390/molecules21060748
   Domingo LR, 2013, RSC ADV, V3, P1486, DOI 10.1039/c2ra22886f
   Frisch M. J., 2013, GAUSSIAN 09 REVISION
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Ghaleb A, 2019, ADV PHARM BULL, V9, P84, DOI 10.15171/apb.2019.011
   Hehre M. J., 1986, AB INITIO MOL ORBITA
   Jalali-Heravi M, 2009, J PHARMACEUT BIOMED, V50, P853, DOI 10.1016/j.jpba.2009.07.009
   Jaramillo P, 2008, J MOL STRUC-THEOCHEM, V865, P68, DOI 10.1016/j.theochem.2008.06.022
   Keller TH, 2006, CURR OPIN CHEM BIOL, V10, P357, DOI 10.1016/j.cbpa.2006.06.014
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lorca M, 2018, MOLECULES, V23, DOI 10.3390/molecules23051191
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Mullard A, 2018, NAT REV DRUG DISCOV, V17, P234, DOI 10.1038/nrd.2018.41
   Parr R. G., 1989, DENSITY FUNCTIONAL T, DOI [10.1021/ja00364a005, DOI 10.1021/JA00364A005]
   Parr RG, 1999, J AM CHEM SOC, V121, P1922, DOI 10.1021/ja983494x
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   PURCELL WP, 1967, J CHEM ENG DATA, V12, P235, DOI 10.1021/je60033a020
   Siramshetty VB, 2016, NUCLEIC ACIDS RES, V44, pD1080, DOI 10.1093/nar/gkv1192
   Stahle L, 1988, Prog Med Chem, V25, P291, DOI 10.1016/S0079-6468(08)70281-9
   TRIPOS Associates Inc., 2012, SYBYL 10 MOL MOD SOF
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Vyas VK, 2013, SAR QSAR ENVIRON RES, V24, P519, DOI 10.1080/1062936X.2012.751553
   Zhao Y, 2008, THEOR CHEM ACC, V120, P215, DOI 10.1007/s00214-007-0310-x
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 31
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1808530
EA AUG 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NA5OH
UT WOS:000559865200001
PM 32799761
OA Bronze
DA 2021-01-01
ER

PT J
AU Yu, JY
   Tostanoski, LH
   Peter, L
   Mercado, NB
   McMahan, K
   Mahrokhian, SH
   Nkolola, JP
   Liu, JY
   Li, ZF
   Chandrashekar, A
   Martinez, DR
   Loos, C
   Atyeo, C
   Fischinger, S
   Burke, JS
   Slein, MD
   Chen, YZ
   Zuiani, A
   Lelis, FJN
   Travers, M
   Habibi, S
   Pessaint, L
   Van Ry, A
   Blade, K
   Brown, R
   Cook, A
   Finneyfrock, B
   Dodson, A
   Teow, E
   Velasco, J
   Zahn, R
   Wegmann, F
   Bondzie, EA
   Dagotto, G
   Gebre, MS
   He, X
   Jacob-Dolan, C
   Kirilova, M
   Kordana, N
   Lin, ZJ
   Maxfield, LF
   Nampanya, F
   Nityanandam, R
   Ventura, JD
   Wan, HH
   Cai, YF
   Chen, B
   Schmidt, AG
   Wesemann, DR
   Baric, RS
   Alter, G
   Andersen, H
   Lewis, MG
   Barouch, DH
AF Yu, Jingyou
   Tostanoski, Lisa H.
   Peter, Lauren
   Mercado, Noe B.
   McMahan, Katherine
   Mahrokhian, Shant H.
   Nkolola, Joseph P.
   Liu, Jinyan
   Li, Zhenfeng
   Chandrashekar, Abishek
   Martinez, David R.
   Loos, Carolin
   Atyeo, Caroline
   Fischinger, Stephanie
   Burke, John S.
   Slein, Matthew D.
   Chen, Yuezhou
   Zuiani, Adam
   Lelis, Felipe J. N.
   Travers, Meghan
   Habibi, Shaghayegh
   Pessaint, Laurent
   Van Ry, Alex
   Blade, Kelvin
   Brown, Renita
   Cook, Anthony
   Finneyfrock, Brad
   Dodson, Alan
   Teow, Elyse
   Velasco, Jason
   Zahn, Roland
   Wegmann, Frank
   Bondzie, Esther A.
   Dagotto, Gabriel
   Gebre, Makda S.
   He, Xuan
   Jacob-Dolan, Catherine
   Kirilova, Marinela
   Kordana, Nicole
   Lin, Zijin
   Maxfield, Lori F.
   Nampanya, Felix
   Nityanandam, Ramya
   Ventura, John D.
   Wan, Huahua
   Cai, Yongfei
   Chen, Bing
   Schmidt, Aaron G.
   Wesemann, Duane R.
   Baric, Ralph S.
   Alter, Galit
   Andersen, Hanne
   Lewis, Mark G.
   Barouch, Dan H.
TI DNA vaccine protection against SARS-CoV-2 in rhesus macaques
SO SCIENCE
LA English
DT Article
ID LENGTH INFECTIOUS CDNA; NEUTRALIZING ANTIBODY; SARS CORONAVIRUS; REVERSE
   GENETICS; IMMUNE-RESPONSES; PNEUMONIA; EFFICACY; SPIKE
AB The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV- 2 spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers at levels comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. After vaccination, all animals were challenged with SARS- CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log(10) reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with viral loads in sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates.
C1 [Yu, Jingyou; Tostanoski, Lisa H.; Peter, Lauren; Mercado, Noe B.; McMahan, Katherine; Mahrokhian, Shant H.; Nkolola, Joseph P.; Liu, Jinyan; Li, Zhenfeng; Chandrashekar, Abishek; Bondzie, Esther A.; Dagotto, Gabriel; Gebre, Makda S.; He, Xuan; Jacob-Dolan, Catherine; Kirilova, Marinela; Kordana, Nicole; Lin, Zijin; Maxfield, Lori F.; Nampanya, Felix; Nityanandam, Ramya; Ventura, John D.; Wan, Huahua; Barouch, Dan H.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.
   [Martinez, David R.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Loos, Carolin; Atyeo, Caroline; Fischinger, Stephanie; Burke, John S.; Slein, Matthew D.; Schmidt, Aaron G.; Alter, Galit; Barouch, Dan H.] MIT, Ragon Inst MGH, Cambridge, MA 02139 USA.
   [Loos, Carolin; Atyeo, Caroline; Fischinger, Stephanie; Burke, John S.; Slein, Matthew D.; Schmidt, Aaron G.; Alter, Galit; Barouch, Dan H.] Harvard, Cambridge, MA 02139 USA.
   [Chen, Yuezhou; Zuiani, Adam; Lelis, Felipe J. N.; Travers, Meghan; Habibi, Shaghayegh; Wesemann, Duane R.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Pessaint, Laurent; Van Ry, Alex; Blade, Kelvin; Brown, Renita; Cook, Anthony; Finneyfrock, Brad; Dodson, Alan; Teow, Elyse; Velasco, Jason; Andersen, Hanne; Lewis, Mark G.] Bioqual, Rockville, MD 20852 USA.
   [Zahn, Roland; Wegmann, Frank] Janssen Vaccines & Prevent BV, Leiden, Netherlands.
   [Cai, Yongfei; Chen, Bing] Childrens Hosp, Boston, MA 02115 USA.
   [Chen, Bing; Schmidt, Aaron G.; Wesemann, Duane R.; Alter, Galit; Barouch, Dan H.] Massachusetts Consortium Pathogen Readiness, Boston, MA 02215 USA.
RP Barouch, DH (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.; Barouch, DH (corresponding author), MIT, Ragon Inst MGH, Cambridge, MA 02139 USA.; Barouch, DH (corresponding author), Harvard, Cambridge, MA 02139 USA.; Barouch, DH (corresponding author), Massachusetts Consortium Pathogen Readiness, Boston, MA 02215 USA.
EM dbarouch@bidmc.harvard.edu
RI Cai, Yongfei/ABI-7748-2020; Chandrashekar, Abishek/P-2610-2019; Mercado,
   Noe/ABE-8247-2020
OI Cai, Yongfei/0000-0002-3628-3802; Chandrashekar,
   Abishek/0000-0001-7821-5552; Mercado, Noe/0000-0001-7769-7326; Slein,
   Matthew/0000-0001-8288-787X; Jacob-Dolan, Catherine/0000-0001-6641-0342;
   Wegmann, Frank/0000-0002-9821-1492; Peter, Lauren/0000-0002-2105-7503;
   Lelis, Felipe J N/0000-0002-3708-3810; Gebre, Makda/0000-0001-8520-2178;
   Ventura, John/0000-0002-4373-3242; Elyard, Hanne/0000-0003-1103-9608;
   Yu, Jingyou/0000-0002-0775-6623; Mahrokhian, Shant/0000-0003-4094-8739;
   Tostanoski, Lisa/0000-0001-9255-5684
FU Ragon Institute of MGH, MIT, and Harvard; Mark and Lisa Schwartz
   Foundation; Beth Israel Deaconess Medical Center; Massachusetts
   Consortium on Pathogen Readiness (MassCPR); Janssen Vaccines Prevention
   BV; National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [OD024917,
   AI129797, AI124377, AI128751, AI126603, AI007151, AI146779, AI121394,
   AI139538, 272201700036I-0-759301900131-1, AI100625, AI110700, AI132178,
   AI149644, AI108197]; Burroughs Wellcome Fund Postdoctoral Enrichment
   Program AwardBurroughs Wellcome Fund
FX We acknowledge support from the Ragon Institute of MGH, MIT, and
   Harvard; the Mark and Lisa Schwartz Foundation; Beth Israel Deaconess
   Medical Center; the Massachusetts Consortium on Pathogen Readiness
   (MassCPR); Janssen Vaccines & Prevention BV; and the National Institutes
   of Health (OD024917, AI129797, AI124377, AI128751, and AI126603 to
   D.H.B.; AI007151 to D.R.M.; AI146779 to A.G.S.; AI121394 and AI139538 to
   D.R.W.; and 272201700036I-0-759301900131-1, AI100625, AI110700,
   AI132178, AI149644, and AI108197 to R.S.B.). We also acknowledge a
   Burroughs Wellcome Fund Postdoctoral Enrichment Program Award to D.R.M.
CR Abbink P, 2019, SCIENCE, V365, P1029, DOI 10.1126/science.aaw8562
   Abbink P, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4163
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027
   Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Kobinger GP, 2007, VACCINE, V25, P5220, DOI 10.1016/j.vaccine.2007.04.065
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Liu RQ, 2018, ANTIVIR RES, V150, P30, DOI 10.1016/j.antiviral.2017.12.007
   Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026
   Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Tseng CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053096
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Zhou J, 2005, VACCINE, V23, P3202, DOI 10.1016/j.vaccine.2004.11.075
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 29
TC 117
Z9 109
U1 22
U2 30
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 14
PY 2020
VL 369
IS 6505
BP 806
EP +
DI 10.1126/science.abc6284
PG 37
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NA3RX
UT WOS:000559731300034
PM 32434945
OA Green Published, Other Gold
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Chandrashekar, A
   Liu, JY
   Martinot, AJ
   McMahan, K
   Mercado, NB
   Peter, L
   Tostanoski, LH
   Yu, JY
   Maliga, Z
   Nekorchuk, M
   Busman-Sahay, K
   Terry, M
   Wrijil, LM
   Ducat, S
   Martinez, DR
   Atyeo, C
   Fischinger, S
   Burke, JS
   Slein, MD
   Pessaint, L
   Van Ry, A
   Greenhouse, J
   Taylor, T
   Blade, K
   Cook, A
   Finneyfrock, B
   Brown, R
   Teow, E
   Velasco, J
   Zahn, R
   Wegmann, F
   Abbink, P
   Bondzie, EA
   Dagotto, G
   Gebre, MS
   He, X
   Jacob-Dolan, C
   Kordana, N
   Li, ZF
   Lifton, MA
   Mahrokhian, SH
   Maxfield, LF
   Nityanandam, R
   Nkolola, JP
   Schmidt, AG
   Miller, AD
   Baric, RS
   Alter, G
   Sorger, PK
   Estes, JD
   Andersen, H
   Lewis, MG
   Barouch, DH
AF Chandrashekar, Abishek
   Liu, Jinyan
   Martinot, Amanda J.
   McMahan, Katherine
   Mercado, Noe B.
   Peter, Lauren
   Tostanoski, Lisa H.
   Yu, Jingyou
   Maliga, Zoltan
   Nekorchuk, Michael
   Busman-Sahay, Kathleen
   Terry, Margaret
   Wrijil, Linda M.
   Ducat, Sarah
   Martinez, David R.
   Atyeo, Caroline
   Fischinger, Stephanie
   Burke, John S.
   Slein, Matthew D.
   Pessaint, Laurent
   Van Ry, Alex
   Greenhouse, Jack
   Taylor, Tammy
   Blade, Kelvin
   Cook, Anthony
   Finneyfrock, Brad
   Brown, Renita
   Teow, Elyse
   Velasco, Jason
   Zahn, Roland
   Wegmann, Frank
   Abbink, Peter
   Bondzie, Esther A.
   Dagotto, Gabriel
   Gebre, Makda S.
   He, Xuan
   Jacob-Dolan, Catherine
   Kordana, Nicole
   Li, Zhenfeng
   Lifton, Michelle A.
   Mahrokhian, Shant H.
   Maxfield, Lori F.
   Nityanandam, Ramya
   Nkolola, Joseph P.
   Schmidt, Aaron G.
   Miller, Andrew D.
   Baric, Ralph S.
   Alter, Galit
   Sorger, Peter K.
   Estes, Jacob D.
   Andersen, Hanne
   Lewis, Mark G.
   Barouch, Dan H.
TI SARS-CoV-2 infection protects against rechallenge in rhesus macaques
SO SCIENCE
LA English
DT Article
ID REVERSE GENETICS; CORONAVIRUS; PNEUMONIA; IMMUNITY; CDNA; SARS
AB An understanding of protective immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global coronavirus disease 2019 (COVID-19) pandemic. A key unanswered question is whether infection with SARS-CoV-2 results in protective immunity against reexposure. We developed a rhesus macaque model of SARS-CoV-2 infection and observed that macaques had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses, and pathologic evidence of viral pneumonia. After the initial viral clearance, animals were rechallenged with SARS-CoV-2 and showed 5 log(10) reductions in median viral loads in bronchoalveolar lavage and nasal mucosa compared with after the primary infection. Anamnestic immune responses after rechallenge suggested that protection was mediated by immunologic control. These data show that SARS-CoV-2 infection induced protective immunity against reexposure in nonhuman primates.
C1 [Chandrashekar, Abishek; Liu, Jinyan; Martinot, Amanda J.; McMahan, Katherine; Mercado, Noe B.; Peter, Lauren; Tostanoski, Lisa H.; Yu, Jingyou; Abbink, Peter; Bondzie, Esther A.; Dagotto, Gabriel; Gebre, Makda S.; He, Xuan; Jacob-Dolan, Catherine; Kordana, Nicole; Li, Zhenfeng; Lifton, Michelle A.; Mahrokhian, Shant H.; Maxfield, Lori F.; Nityanandam, Ramya; Nkolola, Joseph P.; Barouch, Dan H.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.
   [Martinot, Amanda J.; Wrijil, Linda M.; Ducat, Sarah] Tufts Univ, Cummings Sch Vet Med, North Grafton, MA 01536 USA.
   [Maliga, Zoltan; Atyeo, Caroline; Dagotto, Gabriel; Gebre, Makda S.; Jacob-Dolan, Catherine; Sorger, Peter K.] Harvard Med Sch, Boston, MA 02115 USA.
   [Nekorchuk, Michael; Busman-Sahay, Kathleen; Terry, Margaret; Estes, Jacob D.] Oregon Hlth & Sci Univ, Beaverton, OR 97006 USA.
   [Martinez, David R.; Baric, Ralph S.] Univ N Carolina, Chapel Hill, NC 27599 USA.
   [Atyeo, Caroline; Fischinger, Stephanie; Burke, John S.; Slein, Matthew D.; Schmidt, Aaron G.; Alter, Galit; Barouch, Dan H.] MIT, Ragon Inst MGH, Cambridge, MA 02139 USA.
   [Atyeo, Caroline; Fischinger, Stephanie; Burke, John S.; Slein, Matthew D.; Schmidt, Aaron G.; Alter, Galit; Barouch, Dan H.] Harvard, Cambridge, MA 02139 USA.
   [Pessaint, Laurent; Van Ry, Alex; Greenhouse, Jack; Taylor, Tammy; Blade, Kelvin; Cook, Anthony; Finneyfrock, Brad; Brown, Renita; Teow, Elyse; Velasco, Jason; Andersen, Hanne; Lewis, Mark G.] Bioqual, Rockville, MD 20852 USA.
   [Zahn, Roland; Wegmann, Frank] Janssen Vaccines & Prevent BV, Leiden, Netherlands.
   [Schmidt, Aaron G.; Alter, Galit; Barouch, Dan H.] Massachusetts Consortium Pathogen Readiness, Boston, MA 02215 USA.
   [Miller, Andrew D.] Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA.
RP Barouch, DH (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.; Barouch, DH (corresponding author), MIT, Ragon Inst MGH, Cambridge, MA 02139 USA.; Barouch, DH (corresponding author), Harvard, Cambridge, MA 02139 USA.; Barouch, DH (corresponding author), Massachusetts Consortium Pathogen Readiness, Boston, MA 02215 USA.
EM dbarouch@bidmc.harvard.edu
RI Mercado, Noe/ABE-8247-2020; Chandrashekar, Abishek/P-2610-2019
OI Mercado, Noe/0000-0001-7769-7326; Chandrashekar,
   Abishek/0000-0001-7821-5552; Elyard, Hanne/0000-0003-1103-9608; Gebre,
   Makda/0000-0001-8520-2178; Martinot, Amanda/0000-0001-6237-6191;
   Mahrokhian, Shant/0000-0003-4094-8739; Maliga,
   Zoltan/0000-0003-4209-7253; Wegmann, Frank/0000-0002-9821-1492; Peter,
   Lauren/0000-0002-2105-7503; Tostanoski, Lisa/0000-0001-9255-5684; Yu,
   Jingyou/0000-0002-0775-6623; Ducat, Sarah/0000-0002-5285-7642;
   Jacob-Dolan, Catherine/0000-0001-6641-0342; Slein,
   Matthew/0000-0001-8288-787X
FU Ragon Institute of MGH, MIT, and Harvard; Mark and Lisa Schwartz
   Foundation; Beth Israel Deaconess Medical Center; Massachusetts
   Consortium on Pathogen Readiness (MassCPR); Bill & Melinda Gates
   FoundationBill & Melinda Gates Foundation [INV-006131]; Janssen Vaccines
   Prevention BV; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [OD024917, AI129797, AI124377, AI128751, AI126603, AI135098, AI007387,
   AI007151, AI146779, 272201700036I-0-759301900131-1, AI100625, AI110700,
   AI132178, AI149644, AI108197, CA225088, OD011092, OD025002]; Mercatus
   Center at George Mason University; Burroughs Wellcome Fund Postdoctoral
   Enrichment Program AwardBurroughs Wellcome Fund
FX We acknowledge support from the Ragon Institute of MGH, MIT, and
   Harvard, Mark and Lisa Schwartz Foundation, Beth Israel Deaconess
   Medical Center, Massachusetts Consortium on Pathogen Readiness
   (MassCPR), Bill & Melinda Gates Foundation (INV-006131), Janssen
   Vaccines & Prevention BV, and the National Institutes of Health
   (OD024917, AI129797, AI124377, AI128751, AI126603 to D.H.B.; AI135098 to
   A.J.M.; AI007387 to L.H.T.; AI007151 to D.R.M.; AI146779 to A.G.S.;
   272201700036I-0-759301900131-1, AI100625, AI110700, AI132178, AI149644,
   AI108197 to R.S.B.; CA225088 to P.K.S.; and OD011092, OD025002 to
   J.D.E.). We also acknowledge a Fast Grant, Emergent Ventures, from the
   Mercatus Center at George Mason University, to A.J.M. and a Burroughs
   Wellcome Fund Postdoctoral Enrichment Program Award to D.R.M.
CR Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027
   Deleage C, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87065
   Deleage Claire, 2016, Pathog Immun, V1, P68
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lin JR, 2018, ELIFE, V7, DOI 10.7554/eLife.31657
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   WHO, 2020, IMM PASSP CONT COVID
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 102
Z9 98
U1 8
U2 10
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 14
PY 2020
VL 369
IS 6505
BP 812
EP +
DI 10.1126/science.abc4776
PG 37
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NA3RX
UT WOS:000559731300035
PM 32434946
OA Other Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Zhang, F
   Gan, R
   Zhen, ZQ
   Hu, XL
   Li, X
   Zhou, FX
   Liu, Y
   Chen, CE
   Xie, SY
   Zhang, BL
   Wu, XK
   Huang, ZW
AF Zhang, Fan
   Gan, Rui
   Zhen, Ziqi
   Hu, Xiaoli
   Li, Xiang
   Zhou, Fengxia
   Liu, Ying
   Chen, Chuangeng
   Xie, Shuangyu
   Zhang, Bailing
   Wu, Xiaoke
   Huang, Zhiwei
TI Adaptive immune responses to SARS-CoV-2 infection in severe versus mild
   individuals
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Article
ID PNEUMONIA; SPECIFICITY; ANTIBODIES
AB The global Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has affected more than eight million people. There is an urgent need to investigate how the adaptive immunity is established in COVID-19 patients. In this study, we profiled adaptive immune cells of PBMCs from recovered COVID-19 patients with varying disease severity using single-cell RNA and TCR/BCR V(D)J sequencing. The sequencing data revealed SARS-CoV-2-specific shuffling of adaptive immune repertories and COVID-19-induced remodeling of peripheral lymphocytes. Characterization of variations in the peripheral T and B cells from the COVID-19 patients revealed a positive correlation of humoral immune response and T-cell immune memory with disease severity. Sequencing and functional data revealed SARS-CoV-2-specific T-cell immune memory in the convalescent COVID-19 patients. Furthermore, we also identified novel antigens that are responsive in the convalescent patients. Altogether, our study reveals adaptive immune repertories underlying pathogenesis and recovery in severe versus mild COVID-19 patients, providing valuable information for potential vaccine and therapeutic development against SARS-CoV-2 infection.
C1 [Zhang, Fan; Gan, Rui; Zhen, Ziqi; Li, Xiang; Zhou, Fengxia; Chen, Chuangeng; Xie, Shuangyu; Zhang, Bailing; Huang, Zhiwei] Harbin Inst Technol, Sch Life Sci & Technol, HIT Ctr Life Sci, Harbin 150080, Peoples R China.
   [Hu, Xiaoli] Harbin Inst Technol, Heilongjiang Prov Hosp, Dept Infect Dis, Harbin 150030, Peoples R China.
   [Liu, Ying] Harbin Blood Ctr, Harbin 150056, Peoples R China.
   [Wu, Xiaoke] Harbin Inst Technol, Heilongjiang Prov Hosp, Ctr Reprod Med, Harbin 150030, Peoples R China.
   [Wu, Xiaoke] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Obstet & Gynecol, Harbin 150040, Peoples R China.
RP Huang, ZW (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, HIT Ctr Life Sci, Harbin 150080, Peoples R China.
EM huangzhiwei@hit.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31825008, 31422014, 61872117]
FX This research was funded by the National Natural Science Foundation of
   China grant no. 31825008 and 31422014 to Z.H. and grant no. 61872117 to
   F.Z.
CR Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590-018-0276-y
   Attaf M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02539
   Bryson S, 2016, J IMMUNOL, V196, P4723, DOI 10.4049/jimmunol.1402890
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Campbell Katie M, 2020, bioRxiv, DOI 10.1101/2020.03.30.016931
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chao A, 2015, ECOLOGY, V96, P1189, DOI 10.1890/14-0550.1
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Ehrhardt SA, 2019, NAT MED, V25, P1589, DOI 10.1038/s41591-019-0602-4
   Fast E, 2020, POTENTIAL T CELL B C, DOI [10.1101/2020.02.19.955484, DOI 10.1101/2020.02.19.955484]
   Fu Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12780
   Galson JD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00531
   Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359
   Hadjadj J., 2020, IMPAIRED TYPE 1 INTE, DOI [10.1101/2020.04.19.20068015, DOI 10.1101/2020.04.19.20068015]
   Hershberg U, 2008, INT IMMUNOL, V20, P683, DOI 10.1093/intimm/dxn026
   HILL MO, 1973, ECOLOGY, V54, P427, DOI 10.2307/1934352
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang L., 2020, BLOOD SINGLE CELL IM, DOI [10.1101/2020.03.15.20033472, DOI 10.1101/2020.03.15.20033472]
   Ko JH, 2016, J INFECTION, V73, P468, DOI 10.1016/j.jinf.2016.08.005
   Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0
   Li CW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15523-2
   Li TS, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000024
   Li TS, 2004, J INFECT DIS, V189, P648, DOI 10.1086/381535
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Mohn KGI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143281
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Pizzolla A, 2018, J CLIN INVEST, V128, P721, DOI 10.1172/JCI96957
   Prachar M., 2020, COVID 19 VACCINE CAN, DOI [10.1101/2020.03.20.000794, DOI 10.1101/2020.03.20.000794]
   Price DA, 2004, IMMUNITY, V21, P793, DOI 10.1016/j.immuni.2004.10.010
   Robbiani Davide F, 2020, bioRxiv, DOI 10.1101/2020.05.13.092619
   Stern JNH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008879
   Tsay GJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01064
   Ussher JE, 2018, IMMUNOL CELL BIOL, V96, P630, DOI 10.1111/imcb.12008
   Waltman L, 2013, EUR PHYS J B, V86, DOI 10.1140/epjb/e2013-40829-0
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9
   Wilk A. J., 2020, SINGLE CELL ATLAS PE, DOI [10.1101/2020.04.17.20069930, DOI 10.1101/2020.04.17.20069930]
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Yaari G, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks457
   Yu F, 2020, MICROBES INFECT, V22, P74, DOI 10.1016/j.micinf.2020.01.003
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang JQ, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S095026882000117X
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
NR 48
TC 3
Z9 3
U1 8
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD AUG 14
PY 2020
VL 5
IS 1
AR 156
DI 10.1038/s41392-020-00263-y
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NA5CO
UT WOS:000559834700001
PM 32796814
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ventura, L
   Vitali, M
   Spica, VR
AF Ventura, Luigi
   Vitali, Matteo
   Romano Spica, Vincenzo
TI Bacillus Calmette-Guerin vaccination and socioeconomic variables vs
   COVID-19 global features: Clearing up a controversial issue
SO ALLERGY
LA English
DT Letter; Early Access
DE epidemiology; infections; vaccines; virus
C1 [Ventura, Luigi] Sapienza Univ Rome, Dept Econ & Law, Rome, Italy.
   [Vitali, Matteo] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy.
   [Romano Spica, Vincenzo] Univ Rome Foro Italico, Dept Movement Human & Hlth Sci, Piazza Lauro de Bosis 6, I-00135 Rome, Italy.
RP Spica, VR (corresponding author), Univ Rome Foro Italico, Dept Movement Human & Hlth Sci, Piazza Lauro de Bosis 6, I-00135 Rome, Italy.
EM vincenzo.romanospica@uniroma4.it
RI Spica, Vincenzo Romano/V-5718-2019
CR Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4
   Fidel PL, 2020, MBIO, V11, DOI 10.1128/mBio.00907-20
   MacLean E, 2020, UNIVERSAL BCG VACCIN
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Ozdemir C, 2020, ALLERGY, V75, P1824, DOI 10.1111/all.14344
   Papke LE, 1996, J APPL ECONOM, V11, P619, DOI 10.1002/(SICI)1099-1255(199611)11:6<619::AID-JAE418>3.0.CO;2-1
   Redelman-Sidi G, 2020, NAT REV UROL, V17, P316, DOI 10.1038/s41585-020-0325-9
   Vasquez I, HUMAN FREEDOM INDEX
   World Health Organization, 2020, COR DIS 2019 COVID 1
NR 9
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
DI 10.1111/all.14524
EA AUG 2020
PG 4
WC Allergy; Immunology
SC Allergy; Immunology
GA MZ9YR
UT WOS:000559478400001
PM 32726479
OA Bronze
DA 2021-01-01
ER

PT J
AU Wassenaar, TM
   Buzard, GS
   Newman, DJ
AF Wassenaar, T. M.
   Buzard, G. S.
   Newman, D. J.
TI BCG vaccination early in life does not improve COVID-19 outcome of
   elderly populations, based on nationally reported data
SO LETTERS IN APPLIED MICROBIOLOGY
LA English
DT Article
DE BCG; Covid-19; Mycobacterium tuberculosisvaccine; Sars-CoV-2; TBC;
   trained immunity; tuberculosis
ID INFECTION
AB The reported numbers of Covid-19 cases and deaths were compared for 18 countries (14 in Western Europe, plus Australia, Brazil, Israel and the USA) to assess the effect of historic and current national BCG immunizations. In view of the high death rate for Covid-19 patients over 70 years of age, and given the fact that BCG vaccination is typically given early in life, we compared countries that had introduced BCG in the 1950s with those that had not. No effect on Covid-19 case fatality rate (CFR) or number of deaths per population could be demonstrated. Since some countries test for Covid-19 more than others, the effect of tests performed per million population on reported deaths per million was also assessed, but again did not demonstrate an effect of BCG vaccination in the 1950s. Whether countries had never used the vaccine, had historically used it but since ceased to do so, or were presently vaccinating with BCG did not correlate with national total number of deaths or CFR. We conclude that there is currently no evidence for a beneficial effect of BCG vaccination on Covid-19 reported cases or fatalities.
C1 [Wassenaar, T. M.] Mol Microbiol & Genom Consultants, Tannenstr 7, D-55576 Zotzenheim, Germany.
   [Buzard, G. S.] Ctr Dis Control & Prevent, Booz Allen Hamilton, Middletown, MD USA.
   [Newman, D. J.] NCI, Nat Prod Branch, NIH, Wayne, PA USA.
RP Wassenaar, TM (corresponding author), Mol Microbiol & Genom Consultants, Tannenstr 7, D-55576 Zotzenheim, Germany.
EM trudy@mmgc.eu
CR Aggarwal S, 2020, DIAGNOSIS, V7, P91, DOI 10.1515/dx-2020-0046
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chen J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2603-0
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Crispen R, 1989, Prog Clin Biol Res, V310, P35
   Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4
   Escobar LE, 2020, P NATL ACAD SCI USA, V117, P17720, DOI 10.1073/pnas.2008410117
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, RESPIROLOGY, V25, P898, DOI 10.1111/resp.13885
   Guo GQ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00410
   Gursel M, 2020, ALLERGY, V75, P1815, DOI 10.1111/all.14345
   Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189
   Hauer J, 2020, LEUKEMIA, V34, P2217, DOI 10.1038/s41375-020-0871-4
   Infuso A, 2006, Euro Surveill, V11, P6
   Kantor IN, 2020, MEDICINA-BUENOS AIRE, V80, P292
   Keeley AJ, 2020, THORAX, V75, P621, DOI 10.1136/thoraxjnl-2020-215337
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Kumar J, 2020, INDIAN PEDIATR, V57, P588
   Luca Simona, 2013, Maedica (Bucur), V8, P53
   Macedo A, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109816
   Madan M, 2020, PUBLIC HEALTH, V185, P91, DOI 10.1016/j.puhe.2020.05.042
   Mangalmurti N, 2020, IMMUNITY, V53, P19, DOI 10.1016/j.immuni.2020.06.017
   Meena J, 2020, INDIAN J PEDIATR, V87, P749, DOI 10.1007/s12098-020-03371-3
   Mei X, 2020, AM J INFECT CONTROL, V48, P1045, DOI 10.1016/j.ajic.2020.06.221
   Mitrani RD, 2020, HEART RHYTHM, V17, P1984, DOI 10.1016/j.hrthm.2020.06.026
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Netea MG, 2014, SEMIN IMMUNOL, V26, P512, DOI 10.1016/j.smim.2014.09.006
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Ozdemir C, 2020, ALLERGY, V75, P1824, DOI 10.1111/all.14344
   Ragab D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01446
   Ricco Matteo, 2020, Acta Biomed, V91, P207, DOI 10.23750/abm.v91i2.9700
   Sharma A, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2720-9
   Vestergaard LS, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.26.2001214
   WHO, 2020, BAC CAL GUER BCG VAC
   Zwerling A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001012
NR 37
TC 0
Z9 0
U1 7
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0266-8254
EI 1472-765X
J9 LETT APPL MICROBIOL
JI Lett. Appl. Microbiol.
PD NOV
PY 2020
VL 71
IS 5
BP 498
EP 505
DI 10.1111/lam.13365
EA AUG 2020
PG 8
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA OA2HY
UT WOS:000559444100001
PM 32734625
OA Bronze
DA 2021-01-01
ER

PT J
AU Hetherington, L
   Johnston, B
   Kotronoulas, G
   Finlay, F
   Keeley, P
   McKeown, A
AF Hetherington, Lucy
   Johnston, Bridget
   Kotronoulas, Grigorios
   Finlay, Fiona
   Keeley, Paul
   McKeown, Alistair
TI COVID-19 and Hospital Palliative Care - A service evaluation exploring
   the symptoms and outcomes of 186 patients and the impact of the pandemic
   on specialist Hospital Palliative Care
SO PALLIATIVE MEDICINE
LA English
DT Article
DE Palliative care; pandemics; terminal care; COVID-19; symptom assessment;
   inpatients
AB Background: Patients hospitalised with COVID-19 have increased morbidity and mortality, which requires extensive involvement of specialist Hospital Palliative Care Teams. Evaluating the response to the surge in demand for effective symptom management can enhance provision of Palliative Care in this patient population.
   Aim: To characterise the symptom profile, symptom management requirements and outcomes of hospitalised COVID-19 positive patients referred for Palliative Care, and to contextualise Palliative Care demands from COVID-19 against a 'typical' caseload from 2019.
   Design: Service evaluation based on a retrospective cohort review of patient records.
   Setting/participants: One large health board in Scotland. Demographic data, patient symptoms, drugs/doses for symptom control, and patient outcomes were captured for all COVID-19 positive patients referred to Hospital Palliative Care Teams between 30th March and 26th April 2020.
   Results: Our COVID-19 cohort included 186 patients (46% of all referrals). Dyspnoea and agitation were the most prevalent symptoms (median 2 symptoms per patient). 75% of patients were prescribed continuous subcutaneous infusion for symptom control, which was effective in 78.6% of patients. Compared to a 'typical' caseload, the COVID-19 cohort were on caseload for less time (median 2 vs 5 days; p < 0.001) and had a higher death rate (80.6% vs 30.3%; p < 0.001). The COVID-19 cohort replaced 'typical' caseload; overall numbers of referrals were not increased.
   Conclusions: Hospitalised COVID-19 positive patients referred for Palliative Care may have a short prognosis, differ from 'typical' caseload, and predominantly suffer from dyspnoea and agitation. Such symptoms can be effectively controlled with standard doses of opioids and benzodiazepines.
C1 [Hetherington, Lucy; Finlay, Fiona; McKeown, Alistair] NHS Greater Glasgow & Clyde, Queen Elizabeth Univ Hosp, Hosp Palliat Care Team, Glasgow, Lanark, Scotland.
   [Hetherington, Lucy] Prince & Princess Wales Hosp, Glasgow, Lanark, Scotland.
   [Johnston, Bridget; Kotronoulas, Grigorios; Keeley, Paul] Univ Glasgow, Sch Med Dent & Nursing, 57-61 Oakfield Ave, Glasgow G12 8QQ, Lanark, Scotland.
   [Johnston, Bridget] NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland.
   [Keeley, Paul] Glasgow NHS Greater Glasgow & Clyde, Glasgow Royal Infirm, Hosp Palliat Care Team, Glasgow, Lanark, Scotland.
RP Johnston, B (corresponding author), Univ Glasgow, Sch Med Dent & Nursing, 57-61 Oakfield Ave, Glasgow G12 8QQ, Lanark, Scotland.
EM Bridget.Johnston@glasgow.ac.uk
OI johnston, bridget/0000-0003-4051-3436; Keeley, Paul/0000-0002-3169-8187
CR Association for Palliative Medicine of Great Britain and Ireland, 2020, COVID 19 PALL END LI
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Etkind SN, 2020, J PAIN SYMPTOM MANAG, V60, pE31, DOI 10.1016/j.jpainsymman.2020.03.029
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jackson T, 2020, PALLIATIVE MED, V34, P1235, DOI 10.1177/0269216320935361
   Leong IYO, 2004, PALLIATIVE MED, V18, P12, DOI 10.1191/0269216304pm859oa
   Lovell N, 2020, J PAIN SYMPTOM MANAG, V60, pE77, DOI 10.1016/j.jpainsymman.2020.04.015
   McCartney G, 2012, EUR J PUBLIC HEALTH, V22, P756, DOI 10.1093/eurpub/ckr136
   Radbruch L, 2020, LANCET, V395, P1467, DOI 10.1016/S0140-6736(20)30964-8
   Scottish Palliative Care Guidelines, 2020, END LIF CAR GUID PER
   Sun H, 2020, J AM GERIATR SOC, V68, P1162, DOI 10.1111/jgs.16507
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   Turner J, J PAIN SYMPTOM MANAG, DOI [10.1016/j.jpainsymman.2020.04.031., DOI 10.1016/J.JPAINSYMMAN.2020.04.031.]
   World Health Organization (WHO), WHO DIR GEN OP REM M
NR 14
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-2163
EI 1477-030X
J9 PALLIATIVE MED
JI Palliat. Med.
PD OCT
PY 2020
VL 34
IS 9
BP 1256
EP 1262
AR 0269216320949786
DI 10.1177/0269216320949786
EA AUG 2020
PG 7
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Medicine, General & Internal
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; General & Internal Medicine
GA NO5KE
UT WOS:000559721700001
PM 32794435
OA Other Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Ren, ZG
   Luo, H
   Yu, ZJ
   Song, JC
   Liang, L
   Wang, L
   Wang, HY
   Cui, GY
   Liu, Y
   Wang, J
   Li, QQ
   Zeng, ZH
   Yang, SK
   Pei, GZ
   Zhu, YH
   Song, WB
   Yu, WQ
   Song, CJ
   Dong, LH
   Hu, CS
   Du, JF
   Chang, JB
AF Ren, Zhigang
   Luo, Hong
   Yu, Zujiang
   Song, Jingchao
   Liang, Lan
   Wang, Ling
   Wang, Haiyu
   Cui, Guangying
   Liu, Yong
   Wang, Jin
   Li, Qingquan
   Zeng, Zhaohai
   Yang, Shengkun
   Pei, Guangzhong
   Zhu, Yonghui
   Song, Wenbin
   Yu, Wenquan
   Song, Chuanjun
   Dong, Lihong
   Hu, Chuansong
   Du, Jinfa
   Chang, Junbiao
TI A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets
   in the Treatment of Mild and Common COVID-19, a Pilot Study
SO ADVANCED SCIENCE
LA English
DT Article
DE azvudine; COVID-19; SARS-CoV-2
ID NUCLEOSIDE; ANALOGS
AB Coronavirus disease 2019 (COVID-19) has spread worldwide. To date, no specific drug for COVID-19 has been developed. Thus, this randomized, open-label, controlled clinical trial (ChiCTR2000029853) was performed in China. A total of 20 mild and common COVID-19 patients were enrolled and randomly assigned to receive azvudine and symptomatic treatment (FNC group), or standard antiviral and symptomatic treatment (control group). The mean times of the first nucleic acid negative conversion (NANC) of ten patients in the FNC group and ten patients in the control group are 2.60 (SD 0.97; range 1-4) d and 5.60 (SD 3.06; range 2-13) d, respectively (p= 0.008). The mean times of the first NANC of four newly diagnosed subjects in the FNC group and ten subjects in the control group are 2.50 (SD 1.00; range 2-4) d and 9.80 (SD 4.73; range 3-19) d, respectively (starting from the initial treatment) (p= 0.01). No adverse events occur in the FNC group, while three adverse events occur in the control group (p= 0.06). The preliminary results show that FNC treatment in the mild and common COVID-19 may shorten the NANC time versus standard antiviral treatment. Therefore, clinical trials of FNC treating COVID-19 with larger sample size are warranted.
C1 [Ren, Zhigang; Yu, Zujiang; Wang, Haiyu; Cui, Guangying] Zhengzhou Univ, Dept Infect Dis, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China.
   [Ren, Zhigang; Luo, Hong; Zeng, Zhaohai; Yang, Shengkun; Pei, Guangzhong; Zhu, Yonghui; Song, Wenbin; Hu, Chuansong] Guangshan Cty Peoples Hosp, Xinyang 465450, Guangshan Count, Peoples R China.
   [Song, Jingchao; Zhu, Yonghui] Henan Prov Chest Hosp, Dept Thorac Surg, Zhengzhou 450008, Peoples R China.
   [Song, Jingchao; Li, Qingquan] Xixian Peoples Hosp, Med Dept, Xixian 464300, Xinyang, Peoples R China.
   [Liang, Lan; Chang, Junbiao] Henan Normal Univ, Sch Chem & Chem Engn, Henan Key Lab Organ Funct Mol & Drug Innovat, Xinxiang 453007, Henan, Peoples R China.
   [Wang, Ling] Henan Prov Chest Hosp, Dept Clin Lab, Zhengzhou 450008, Peoples R China.
   [Liu, Yong; Du, Jinfa] Henan Genuine Biotech Co Ltd, 10 Fuxing Rd, Pingdingshan 467036, Henan, Peoples R China.
   [Wang, Jin] Huangchuan Cty Peoples Hosp, Dept Orthoped, Xinyang 465150, Huangchuan Coun, Peoples R China.
   [Yu, Wenquan; Song, Chuanjun; Dong, Lihong; Chang, Junbiao] Zhengzhou Univ, Henan New Drug Creat & Drug Safety Evaluat Collab, Zhengzhou 450001, Peoples R China.
RP Ren, ZG (corresponding author), Zhengzhou Univ, Dept Infect Dis, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China.; Ren, ZG; Hu, CS (corresponding author), Guangshan Cty Peoples Hosp, Xinyang 465450, Guangshan Count, Peoples R China.; Chang, JB (corresponding author), Henan Normal Univ, Sch Chem & Chem Engn, Henan Key Lab Organ Funct Mol & Drug Innovat, Xinxiang 453007, Henan, Peoples R China.; Du, JF (corresponding author), Henan Genuine Biotech Co Ltd, 10 Fuxing Rd, Pingdingshan 467036, Henan, Peoples R China.; Chang, JB (corresponding author), Zhengzhou Univ, Henan New Drug Creat & Drug Safety Evaluat Collab, Zhengzhou 450001, Peoples R China.
EM fccrenzg@zzu.edu.cn; huchuansong01@163.com; dujinfa@zsswkj.net;
   changjunbiao@zzu.edu.cn
RI Yu, Wenquan/S-7342-2017
OI Yu, Wenquan/0000-0002-3711-0006
FU Henan Genuine Biotech Co., Ltd.; Henan province novel coronavirus
   control and prevention emergency science and technology tackling key
   project [201100311500]; National S&T Major Project of China
   [2018ZX10301201-008]; National Key Research and Development Program of
   China [2018YFC2000500]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [U1804283];
   Henan Province Science and Technology Project [202102310055]
FX This study was sponsored by grants from Henan Genuine Biotech Co., Ltd.,
   Henan province novel coronavirus control and prevention emergency
   science and technology tackling key project (201100311500), National S&T
   Major Project of China (2018ZX10301201-008), National Key Research and
   Development Program of China (2018YFC2000500), National Natural Science
   Foundation of China (U1804283 to J.C.), and Henan Province Science and
   Technology Project (202102310055). The authors thank all the generous
   volunteer subjects who enrolled in the study. The authors thank Bo Feng,
   Ranran Sun, Changyue Guo, and Binyuan He for their support and revision
   of the article.
CR Abreha T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002299
   [Anonymous], 2020, CORONAVIRUS DIS 2019
   Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chictr.org, 2020, RAND OP LAB CONTR CL
   ClinicalTrials.gov, 2020, DRUG SAF DOS EXPL CL
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jordheim LP, 2013, NAT REV DRUG DISCOV, V12, P447, DOI 10.1038/nrd4010
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Smith DB, 2009, J MED CHEM, V52, P2971, DOI 10.1021/jm801595c
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Tyack PL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142287
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Xu N, 2020, J VIROL, V94, DOI 10.1128/JVI.00204-20
   Zhou YB, 2012, ANTIVIR THER, V17, P1593, DOI 10.3851/IMP2292
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 19
TC 4
Z9 4
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2198-3844
J9 ADV SCI
JI Adv. Sci.
PD OCT
PY 2020
VL 7
IS 19
AR 2001435
DI 10.1002/advs.202001435
EA AUG 2020
PG 10
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA OB6WU
UT WOS:000567365500001
PM 32837847
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU De Biasi, S
   Lo Tartaro, D
   Meschiari, M
   Gibellini, L
   Bellinazzi, C
   Borella, R
   Fidanza, L
   Mattioli, M
   Paolini, A
   Gozzi, L
   Jaacoub, D
   Faltoni, M
   Volpi, S
   Milic, J
   Sita, M
   Sarti, M
   Pucillo, C
   Girardis, M
   Guaraldi, G
   Mussini, C
   Cossarizza, A
AF De Biasi, Sara
   Lo Tartaro, Domenico
   Meschiari, Marianna
   Gibellini, Lara
   Bellinazzi, Caterina
   Borella, Rebecca
   Fidanza, Lucia
   Mattioli, Marco
   Paolini, Annamaria
   Gozzi, Licia
   Jaacoub, Dina
   Faltoni, Matteo
   Volpi, Sara
   Milic, Jovana
   Sita, Marco
   Sarti, Mario
   Pucillo, Carlo
   Girardis, Massimo
   Guaraldi, Giovanni
   Mussini, Cristina
   Cossarizza, Andrea
TI Expansion of plasmablasts and loss of memory B cells in peripheral blood
   from COVID-19 patients with pneumonia
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article; Early Access
DE B cells; Coronavirus; COVID-19; plasmablasts; SARS-CoV-2;
   carboxyfluorescein succinimidyl ester CFSE; principal components (PCs);
   principal component analysis (PCA); Uniform Manifold Approximation and
   Projection (UMAP)
ID SARS CORONAVIRUS; DOWN-REGULATION; ALPHA; DIFFERENTIATION;
   PROLIFERATION; CYTOMETRY; RECEPTOR; PROTEIN; IL-6
AB Studies on the interactions between SARS-CoV-2 and humoral immunity are fundamental to elaborate effective therapies including vaccines. We used polychromatic flow cytometry, coupled with unsupervised data analysis and principal component analysis (PCA), to interrogate B cells in untreated patients with COVID-19 pneumonia. COVID-19 patients displayed normal plasma levels of the main immunoglobulin classes, of antibodies against common antigens or against antigens present in common vaccines. However, we found a decreased number of total and naive B cells, along with decreased percentages and numbers of memory switched and unswitched B cells. On the contrary, IgM(+)and IgM(-)plasmablasts were significantly increased. In vitro cell activation revealed that B lymphocytes showed a normal proliferation index and number of dividing cells per cycle. PCA indicated that B-cell number, naive and memory B cells but not plasmablasts clustered with patients who were discharged, while plasma IgM level, C-reactive protein, D-dimer, and SOFA score with those who died. In patients with pneumonia, the derangement of the B-cell compartment could be one of the causes of the immunological failure to control SARS-Cov2, have a relevant influence on several pathways, organs and systems, and must be considered to develop vaccine strategies.
C1 [De Biasi, Sara; Lo Tartaro, Domenico; Gibellini, Lara; Bellinazzi, Caterina; Borella, Rebecca; Fidanza, Lucia; Mattioli, Marco; Paolini, Annamaria; Gozzi, Licia; Cossarizza, Andrea] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Sch Med, Modena, Italy.
   [Meschiari, Marianna; Jaacoub, Dina; Faltoni, Matteo; Volpi, Sara; Milic, Jovana; Guaraldi, Giovanni; Mussini, Cristina] AOU Policlin, Infect Dis Clin, Modena, Italy.
   [Meschiari, Marianna; Jaacoub, Dina; Faltoni, Matteo; Volpi, Sara; Milic, Jovana; Sita, Marco; Girardis, Massimo; Guaraldi, Giovanni; Mussini, Cristina] Univ Modena & Reggio Emilia, Modena, Italy.
   [Sita, Marco; Girardis, Massimo] AOU Policlin, Dept Anesthesia & Intens Care, Modena, Italy.
   [Sarti, Mario] AOU Policlin, Clin Microbiol Unit, Modena, Italy.
   [Pucillo, Carlo] Univ Udine, Dept Med, Lab Immunol, Udine, Italy.
   [Cossarizza, Andrea] Natl Inst Cardiovasc Res, Bologna, Italy.
RP Cossarizza, A (corresponding author), Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Sch Med, Modena, Italy.; Cossarizza, A (corresponding author), Natl Inst Cardiovasc Res, Bologna, Italy.
EM andrea.cossarizza@unimore.it
FU Ministero della Salute, Bando Ricerca COVID-19 (2020-2021); Glem Gas SpA
   (San Cesario, MO, Italy); Sanfelice 1893 Banca Popolare (San Felice
   S.P., MO, Italy); Assicuratrice Milanese SpA; C.O.F.I.M. SPA; Biogas
   Europa Service; Pierangelo Bertoli Fans Club; Gruppo BPER; Rotary Club
   Distretto 2072 (Clubs in Modena, Modena L.A. Muratori, Carpi, Sassuolo,
   Castelvetro di Modena); Ministero della Salute, Bando Ricerca COVID-19
   [2020-2021] Funding Source: Medline
FX Sara De Biasi and Lara Gibellini are Marylou Ingram Scholar of the
   International Society for Advancement of Cytometry (ISAC) for the period
   2016-2020 and 2020-2024, respectively. This study was partially
   supported by Ministero della Salute, Bando Ricerca COVID-19 (2020-2021)
   to AC. We gratefully acknowledge Drs. Paola Paglia (ThermoFisher
   Scientific, Monza, Italy), Leonardo Beretta (Beckman Coulter, Milan,
   Italy), and Luca Cicchetti (Labospace, Milan, Italy) for their
   continuous and enthusiastic support, and for precious suggestions. Glem
   Gas SpA (San Cesario, MO, Italy), Sanfelice 1893 Banca Popolare (San
   Felice S.P., MO, Italy), Assicuratrice Milanese SpA, C.O.F.I.M. SPA &
   Gianni Gibellini, Franco Appari, Andrea Lucchi, Federica Vagnarelli,
   Angela Messerotti, Biogas Europa Service & Massimo Faccia, Pierangelo
   Bertoli Fans Club and Alberto Bertoli, Maria Santoro, Valentina
   Spezzani, Gruppo BPER and Rotary Club Distretto 2072 (Clubs in Modena,
   Modena L.A. Muratori, Carpi, Sassuolo, Castelvetro di Modena), are
   strongly acknowledged for their generous support to our research. We
   gratefully thank all the many people who are helping us with their
   precious donations. Finally, a special thanks to the patients who
   donated blood to participate to this study and to their families.
CR Blanco E, 2018, J ALLERGY CLIN IMMUN, V141, P2208, DOI 10.1016/j.jaci.2018.02.017
   Chavele KM, 2015, J IMMUNOL, V194, P2482, DOI 10.4049/jimmunol.1401190
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   Cossarizza A., 2020, CYTOMETRY A, V97
   Cossarizza A, 2020, CYTOM PART A, V97, P340, DOI 10.1002/cyto.a.24002
   Cossarizza A, 2019, EUR J IMMUNOL, V49, P1457, DOI 10.1002/eji.201970107
   De Biasi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17292-4
   Dijkman R, 2012, J GEN VIROL, V93, P1924, DOI 10.1099/vir.0.043919-0
   Frasca D, 2014, EXP GERONTOL, V54, P116, DOI 10.1016/j.exger.2014.01.004
   Frasca D, 2012, J IMMUNOL, V188, P279, DOI 10.4049/jimmunol.1003964
   Friederichs K, 2001, EUR J BIOCHEM, V268, P6401, DOI 10.1046/j.0014-2956.2001.02586.x
   Frieman M, 2008, VIRUS RES, V133, P101, DOI 10.1016/j.virusres.2007.03.015
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Guaraldi G., 2020, LANCET RHEUMATOL
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Iwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123
   Jego G, 2001, BLOOD, V97, P1817, DOI 10.1182/blood.V97.6.1817
   Lin Y, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0079-7
   Merluzzi S, 2010, BLOOD, V115, P2810, DOI 10.1182/blood-2009-10-250126
   Nasi M, 2019, J INFECT DIS, V219, P1743, DOI 10.1093/infdis/jiy730
   Nie YC, 2004, J INFECT DIS, V190, P1119, DOI 10.1086/423286
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Quah BJ, 2010, JOVE-J VIS EXP, V44, P2259, DOI DOI 10.3791/2259
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   RIECKMANN P, 1991, J IMMUNOL, V146, P3462
   Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015
   Weber LM, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0415-5
NR 29
TC 4
Z9 3
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
DI 10.1002/eji.202048838
EA AUG 2020
PG 12
WC Immunology
SC Immunology
GA NL3TB
UT WOS:000567341500001
PM 32910469
OA Bronze
DA 2021-01-01
ER

PT J
AU Okudela, K
   Hayashi, H
   Yoshimura, Y
   Sasaki, H
   Horiuchi, H
   Miyata, N
   Tachikawa, N
   Tsuchiya, Y
   Mitsui, H
   Ohashi, K
AF Okudela, Koji
   Hayashi, Hiroyuki
   Yoshimura, Yukihiro
   Sasaki, Hiroaki
   Horiuchi, Hiroshi
   Miyata, Nobuyuki
   Tachikawa, Natsuo
   Tsuchiya, Yuki
   Mitsui, Hideaki
   Ohashi, Kenichi
TI A Japanese case of COVID-19: An autopsy report
SO PATHOLOGY INTERNATIONAL
LA English
DT Article
DE COVID-19; diffuse alveolar damage; Japanese case
AB A 93-year-old woman was admitted with a 10-day history of cough and prostration. Thoracic computed tomography revealed extensive ground-glass opacities in both the lungs. The polymerase chain reaction test of sputum for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) was positive. She was treated with antiviral agents and steroid pulse therapy. However, her oxygen saturation gradually declined, and she died 10 days after hospitalization. The most important autopsy finding was fuzzily segmented diffuse alveolar damage (DAD) that expanded from the subpleural to the medial area. No remarkable changes were observed in organs other than the lungs. Therefore, pneumocytes were suggested as the primary target for SARS-CoV-2, which might explain why coronavirus infectious disease-19 is a serious condition. Thus, early treatment is essential to prevent viral replication from reaching a level that triggers DAD.
C1 [Okudela, Koji; Mitsui, Hideaki; Ohashi, Kenichi] Yokohama City Univ, Dept Pathol, Grad Sch Med, Fukuura 3-6, Yokohama, Kanagawa 236004, Japan.
   [Hayashi, Hiroyuki; Tsuchiya, Yuki] Yokohama Municipal Citizens Hosp, Div Pathol, Yokohama, Kanagawa, Japan.
   [Yoshimura, Yukihiro; Sasaki, Hiroaki; Horiuchi, Hiroshi; Miyata, Nobuyuki; Tachikawa, Natsuo] Yokohama Municipal Citizens Hosp, Div Infect Dis, Yokohama, Kanagawa, Japan.
RP Okudela, K (corresponding author), Yokohama City Univ, Dept Pathol, Grad Sch Med, Fukuura 3-6, Yokohama, Kanagawa 236004, Japan.
EM kojixok@yokohama.cu.ac.jp
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   [Anonymous], 2020, GLOBAL COVID 19 CASE
   [Anonymous], 2020, COVID 19 CORONAVIRUS
   [Anonymous], 2020, COVID 19
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Fang Y, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Karami Parisa, 2020, Travel Med Infect Dis, P101665, DOI 10.1016/j.tmaid.2020.101665
   Khafaie Morteza Abdullatif, 2020, Osong Public Health Res Perspect, V11, P74, DOI 10.24171/j.phrp.2020.11.2.03
   Konopka KE, 2020, CHEST
   Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wichmann D, 2020, ANN INTERN MED
NR 14
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1320-5463
EI 1440-1827
J9 PATHOL INT
JI Pathol. Int.
PD OCT
PY 2020
VL 70
IS 10
BP 820
EP 824
DI 10.1111/pin.13002
EA AUG 2020
PG 5
WC Pathology
SC Pathology
GA OA2ON
UT WOS:000567380000001
PM 32794245
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hur, KH
   Park, K
   Lim, Y
   Jeong, YS
   Sung, H
   Kim, MN
AF Hur, Kyu-Hwa
   Park, Kuenyoul
   Lim, Youngkuen
   Jeong, Yun Sil
   Sung, Heungsup
   Kim, Mi-Na
TI Evaluation of Four Commercial Kits for SARS-CoV-2 Real-Time
   Reverse-Transcription Polymerase Chain Reaction Approved by
   Emergency-Use-Authorization in Korea
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE severe acute respiratory syndrome coronavirus 2; coronavirus infectious
   disease 2019; emergency-use-authorization; real time; reverse
   transcription; polymerase chain reaction
ID EAST RESPIRATORY SYNDROME; CORONAVIRUS; VALIDATION; GUIDELINES;
   DIAGNOSIS; OUTBREAK; COVID-19
AB SARS-CoV-2 real-time reverse-transcription PCR (rRT-PCR) is the most effective testing system currently available to counter COVID-19 epidemics when potent treatments and vaccines are unavailable. Therefore, four SARS-CoV-2 rRT-PCR kits have been approved by the emergency-use-authorization (EUA) without clinical validation in Korea until March 15, 2020. This study evaluated the analytical and clinical performance of these kits. Allplex 2019-nCoV Real-time PCR (Seegene, Seoul, Korea), PowerChek 2019-nCoV (KogeneBiotech, Seoul), Real-Q 2019-nCoV Real-Time Detection (BioSewoom, Seoul), and StandardM nCoV Detection (SD BIOSENSOR, Osong, Korea) were evaluated. The limit of detection (LODs) of Allplex, PowerChek, and Real-Q was determined by testing the transcribed RNA of SARS-CoV-2Eand the RNA of SARS-CoV Frankfurt1. A total of 27 consecutive samples comprising 13 sputum, 12 nasopharyngeal swab (NPS), 1 urine and 1 stool sample were collected from 2 COVID-19 patients for sensitivity analysis. Precision was assessed via daily tests of positive and negative controls in each kit for 5 d. Reproducibility was examined by repeating 21 samples and 10-fold dilutions of 14 samples in pairs using Allplex. Specificity was evaluated with 24 other respiratory virus-positive samples. LOD of Allplex, PowerChek, and Real-Q were 153.9, 84.1, and 80.6 copies/mL, respectively. The degrees of association between Cts and log viral concentrations by Allplex and PowerChek was expressed as y = -3.319 log (x) + 42.039 (R = 0.96) and y = -3.392 log(x) + 43.113 (R = 0.98), respectively. One or more of the 4 kits detected 20 out of 27 clinical samples positive. Of the 20 positive samples, the detection rates of positives for Allplex, PowerChek, Real-Q, and StandardM were 90.0, 82.3, 75.0, and 100.0%, respectively, but those of PowerChek and Real-Q would be 100% if out-of-cutoff Cts were counted as positives. Precision was 100%. Interpretation of Allplex results was reproducible when Ct ofE <= 33. All 4 kits showed no cross-reactivity with other respiratory viruses. Performance of the 4 kits indicated the suitability of these for diagnosis and follow-up testing of COVID-19. Laboratory doctors who initially implement these EUA kits must be able to interpret quality control parameters.
C1 [Hur, Kyu-Hwa; Park, Kuenyoul; Lim, Youngkuen; Jeong, Yun Sil; Sung, Heungsup; Kim, Mi-Na] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Lab Med, Seoul, South Korea.
RP Kim, MN (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Lab Med, Seoul, South Korea.
EM mnkim@amc.seoul.kr
CR Abu al-Soud W, 2001, J CLIN MICROBIOL, V39, P485, DOI 10.1128/JCM.39.2.485-493.2001
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Hong KH, 2020, ANN LAB MED, V40, P351, DOI 10.3343/alm.2020.40.5.351
   Igloi Z, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104510
   Jung J, 2020, J INFECTION, V81, pE79, DOI 10.1016/j.jinf.2020.05.004
   Ki CS, 2016, ANN LAB MED, V36, P203, DOI 10.3343/alm.2016.36.3.203
   Kim M, 2020, PUBLIC HLTH WEEKLY R, V13, P800
   Kim MN, 2016, ANN LAB MED, V36, P450, DOI 10.3343/alm.2016.36.5.450
   Kim YJ, 2020, ANN LAB MED, V40, P349, DOI 10.3343/alm.2020.40.5.349
   Korea Center for Disease Control and Prevention, 2020, COVID 19 RESP GUID M
   Korea Center for Disease Control and Prevention, 2020, UPDATES COVID 19 KOR
   Lefevre J, 2003, J VIROL METHODS, V114, P135, DOI 10.1016/j.jviromet.2003.09.003
   Park B, 2017, I C INF COMM TECH CO, P555, DOI 10.1109/ICTC.2017.8191039
   Pfefferle S, 2020, EUROSURVEILLANCE, V25, P18, DOI 10.2807/1560-7917.ES.2020.25.9.2000152
   Raymaekers M, 2009, J CLIN LAB ANAL, V23, P145, DOI 10.1002/jcla.20307
   van Kasteren PB, 2020, J CLIN VIROL, V128
   World Health Organization, 2020, LAB TEST COR DIS 201
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD AUG 13
PY 2020
VL 7
AR 521
DI 10.3389/fmed.2020.00521
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA NJ7IO
UT WOS:000566217100001
PM 32903503
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Musca, SC
AF Musca, Serban C.
TI A Simple Bayesian Method for Evaluating Whether Data From Patients With
   Rheumatic Diseases Who Have Been Under Chronic Hydroxychloroquine
   Medication Since Before the COVID-19 Outbreak Can Speak to
   Hydroxychloroquine's Prophylactic Effect Against Infection With
   SARS-CoV-2
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE SARS-CoV-2; COVID-19; hydroxychloroquine; chronic medication;
   prophylactic effect; systemic lupus erythematosus; rheumatoid arthritis;
   clemastine; cloperastine
ID ARTHRITIS; PREVALENCE
AB No vaccine against infection by SARS-CoV-2 yet exists. Treatment by hydroxychloroquine (HCQ) medication, among others, has been proposed. However, prophylactic HCQ medication has been little evaluated. We propose to use data from patients with rheumatic diseases (RA, SLR) who have been chronically taking HCQ medication since before the COVID-19 outbreak (hereafter: HCQpa), in order to evaluate the potential of HCQ for preventing infection with SARS-CoV-2. This can be achieved with relative ease by considering whether COVID-19 prevalence is significantly lower in HCQpa than in the general population (i.e., all people that are not HCQpa). Even if COVID-19 prevalence is truly significantly lower in HCQpa, some HCQpa may still present with COVID-19 (lower prevalence does not mean a prevalence of zero). However, given a value for COVID-19 prevalence in the general population and a number of available HCQpa, one may compute the maximum number of HCQpa for that total number of HCQpa considered that can have COVID-19 in order to still be able to conclude a lower COVID-19 prevalence in HCQpa (i.e., if there is one more case of COVID-19 than that maximum number, the COVID-19 prevalence in the HCQpa cannot be said to be lower than in the general population). Because the COVID-19 prevalence in the general population is not known with precision, we will consider different general population prevalence values. Among these contemplated prevalence values, one is derived from the official total number of confirmed cases, others by computing the total number of cases from the number of fatal COVID-19 cases so far and considering different case fatality rates per total cases. Our analyses show that systematic testing for COVID-19 in as few as 5,000 HCQpa is all that is needed for a test of whether HCQ has a prophylactic action against COVID-19, even for a COVID-19 prevalence value as low as 250 per 100,000, provided that test sensitivity is at least equal to its specificity. For higher COVID-19 prevalence values, the number of HCQpa needed is even lower.
C1 [Musca, Serban C.] Univ Rennes 2, Campus Villejean,Pl Recteur Henri Le Moal, Rennes, France.
RP Musca, SC (corresponding author), Univ Rennes 2, Campus Villejean,Pl Recteur Henri Le Moal, Rennes, France.
EM serban-claudiu.musca@univ-rennes2.fr
CR Abramowitz M., 1972, HDB MATH FUNCTIONS
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cross M, 2014, ANN RHEUM DIS, V73, P1316, DOI 10.1136/annrheumdis-2013-204627
   Fiehn C, 2020, Z RHEUMATOL, DOI 10.1007/s00393-020-00785-4
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geffreys H, 1961, THEORY PROBABILITY
   Goehner Schweizer Katja, 2020, Praxis (Bern 1994), V109, P341, DOI 10.1024/1661-8157/a003443
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Hunter TM, 2017, RHEUMATOL INT, V37, P1551, DOI 10.1007/s00296-017-3726-1
   Jaynes ET, 1976, FDN PROBABILITY THEO, P175, DOI [DOI 10.1007/978-94-010-1436-6_6, 10.1007/978-94-010-1436-6_6.]
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Munster T, 2002, ARTHRITIS RHEUM-US, V46, P1460, DOI 10.1002/art.10307
   Myasoedova E, 2010, ARTHRITIS RHEUM-US, V62, P1576, DOI 10.1002/art.27425
   Poland GA, 2020, LANCET INFECT DIS, V20, P531, DOI 10.1016/S1473-3099(20)30250-4
   Porta M., 2008, DICT EPIDEMIOLOGY
   Rees F, 2017, RHEUMATOLOGY, V56, P1945, DOI 10.1093/rheumatology/kex260
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 18
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD AUG 13
PY 2020
VL 7
AR 490
DI 10.3389/fmed.2020.00490
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA NJ7IS
UT WOS:000566217500001
PM 32903552
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Muruato, AE
   Fontes-Garfias, CR
   Ren, P
   Garcia-Blanco, MA
   Menachery, VD
   Xie, XP
   Shi, PY
AF Muruato, Antonio E.
   Fontes-Garfias, Camila R.
   Ren, Ping
   Garcia-Blanco, Mariano A.
   Menachery, Vineet D.
   Xie, Xuping
   Shi, Pei-Yong
TI A high-throughput neutralizing antibody assay for COVID-19 diagnosis and
   vaccine evaluation
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CORONAVIRUS; ZIKA
AB Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.
C1 [Muruato, Antonio E.; Fontes-Garfias, Camila R.; Garcia-Blanco, Mariano A.; Xie, Xuping; Shi, Pei-Yong] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
   [Muruato, Antonio E.; Menachery, Vineet D.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   [Ren, Ping; Menachery, Vineet D.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Garcia-Blanco, Mariano A.] Duke NUS Med Sch, Programme Emerging Infect Dis, Singapore, Singapore.
   [Garcia-Blanco, Mariano A.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA.
   [Menachery, Vineet D.; Shi, Pei-Yong] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.
   [Shi, Pei-Yong] Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA.
   [Shi, Pei-Yong] Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA.
   [Shi, Pei-Yong] Univ Texas Med Branch, Inst Translat Sci, Galveston, TX 77555 USA.
RP Xie, XP; Shi, PY (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA.; Shi, PY (corresponding author), Univ Texas Med Branch, Inst Translat Sci, Galveston, TX 77555 USA.
EM xuxie@UTMB.edu; peshi@UTMB.edu
OI Garcia-Blanco, Mariano/0000-0001-8538-1997
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI142759, AI134907, AI145617,
   UL1TR001439, CA204806, U19AI100625, R00AG049092, R24AI120942]; Sealy &
   Smith Foundation; Kleberg Foundation; John S. Dunn Foundation; Amon G.
   Carter Foundation; Gilson Longenbaugh Foundation; Summerfield Robert
   Foundation; Vacek Distinguished Chair; University of Texas System;
   Clinical and Translational Science Award NRSA (TL1) Training Core from
   NIH [TL1TR001440]; McLaughlin Fellowship Endowment at UTMB
FX We thank colleagues at UTMB for helpful discussion during the course of
   this project. P.-Y.S. was supported by NIH grants AI142759, AI134907,
   AI145617, and UL1TR001439, and awards from the Sealy & Smith Foundation,
   Kleberg Foundation, John S. Dunn Foundation, Amon G. Carter Foundation,
   Gilson Longenbaugh Foundation, and Summerfield Robert Foundation.
   M.A.G.-B. was supported by NIH grant CA204806 and the Vacek
   Distinguished Chair. V.D.M. was supported by NIH grants U19AI100625,
   R00AG049092, R24AI120942, and STARs Award from the University of Texas
   System. A.E.M. is supported by a Clinical and Translational Science
   Award NRSA (TL1) Training Core (TL1TR001440) from NIH. C.R.F.-G. is
   supported by the predoctoral fellowship from the McLaughlin Fellowship
   Endowment at UTMB.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Geurtsvan Kessel CH, 2020, NEXT PHASE EVALUATIO, DOI [10.1101/2020.04.23.20077156, 10.1101/2020.04 .23.20077156, DOI 10.1101/2020.04.23.20077156]
   Harvala H, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.05.20.20091694, DOI 10.1101/2020.05.20.20091694]
   Huang Angkana T, 2020, medRxiv, DOI 10.1101/2020.04.14.20065771
   Khan Saahir, 2020, bioRxiv, DOI 10.1101/2020.03.24.006544
   Mulligan M. J, 2020, NATURE
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421
   Shan C, 2017, J CLIN MICROBIOL, V55, P3028, DOI [10.1128/JCM.00975-17, 10.1128/jcm.00975-17]
   Shan C, 2017, EBIOMEDICINE, V17, P157, DOI 10.1016/j.ebiom.2017.03.006
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xie Xuping, 2020, bioRxiv, DOI 10.1101/2020.06.22.165712
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 17
TC 14
Z9 13
U1 3
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 13
PY 2020
VL 11
IS 1
AR 4059
DI 10.1038/s41467-020-17892-0
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NG8RJ
UT WOS:000564247500011
PM 32792628
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Worby, CJ
   Chang, HH
AF Worby, Colin J.
   Chang, Hsiao-Han
TI Face mask use in the general population and optimal resource allocation
   during the COVID-19 pandemic
SO NATURE COMMUNICATIONS
LA English
DT Article
ID TRANSMISSION; FACEMASKS; DISEASE
AB The ongoing novel coronavirus disease (COVID-19) pandemic has already infected millions worldwide and, with no vaccine available, interventions to mitigate transmission are urgently needed. While there is broad agreement that travel restrictions and social distancing are beneficial in limiting spread, recommendations around face mask use are inconsistent. Here, we use mathematical modeling to examine the epidemiological impact of face masks, considering resource limitations and a range of supply and demand dynamics. Even with a limited protective effect, face masks can reduce total infections and deaths, and can delay the peak time of the epidemic. However, random distribution of masks is generally suboptimal; prioritized coverage of the elderly improves outcomes, while retaining resources for detected cases provides further mitigation under a range of scenarios. Face mask use, particularly for a pathogen with relatively common asymptomatic carriage, is an effective intervention strategy, while optimized distribution is important when resources are limited.
C1 [Worby, Colin J.] Broad Inst MIT & Harvard, 415 Main St, Cambridge, MA 02142 USA.
   [Chang, Hsiao-Han] Natl Tsing Hua Univ, Dept Life Sci, 101,Sect 2,Kuang Fu Rd, Hsinchu 300044, Taiwan.
   [Chang, Hsiao-Han] Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, 101,Sect 2,Kuang Fu Rd, Hsinchu 300044, Taiwan.
RP Worby, CJ (corresponding author), Broad Inst MIT & Harvard, 415 Main St, Cambridge, MA 02142 USA.; Chang, HH (corresponding author), Natl Tsing Hua Univ, Dept Life Sci, 101,Sect 2,Kuang Fu Rd, Hsinchu 300044, Taiwan.; Chang, HH (corresponding author), Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, 101,Sect 2,Kuang Fu Rd, Hsinchu 300044, Taiwan.
EM cworby@broadinstitute.org; hhchang@life.nthu.edu.tw
FU Ministry of Science and Technology in TaiwanMinistry of Science and
   Technology, Taiwan [MOST 109-2636-B-007-006]; National Institute of
   Allergy and Infectious DiseasesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U19AI110818]
FX The authors wish to acknowledge Lee Kennedy-Shaffer and Yu-Lun Liu for
   helpful discussions. This study was supported by the Ministry of Science
   and Technology in Taiwan (MOST 109-2636-B-007-006). C.J.W. received
   support from the National Institute of Allergy and Infectious Diseases
   (grant number U19AI110818). The funders had no role in preparation of
   the manuscript.
CR Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 2020, STAT DAT PLATF 3 MAJ
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bailar J., 2006, REUSABILITY FACEMASK
   Banerjee A, 2020, LANCET, V395, P1715, DOI 10.1016/S0140-6736(20)30854-0
   Barbosa MH, 2006, BRAZ J MICROBIOL, V37, P216, DOI 10.1590/S1517-83822006000300003
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Bode Bruce, 2020, J Diabetes Sci Technol, V14, P813, DOI 10.1177/1932296820924469
   Chen S, 2020, TAIWAN DONATE 10 MIL
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Cowling BJ, 2009, ANN INTERN MED, V151, P437, DOI 10.7326/0003-4819-151-7-200910060-00142
   Davies A, 2013, DISASTER MED PUBLIC, V7, P413, DOI 10.1017/dmp.2013.43
   Day M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1375
   Department for Transport United Kingdom Government, 2020, FAC COV BEC MAND PUB
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Everington K, 2020, TAIWAN NEWS
   Feng S, 2020, LANCET RESP MED, V8, P434, DOI 10.1016/S2213-2600(20)30134-X
   Greenhalgh T, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1435
   Jefferson T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3675
   Johns Hopkins University, 2020, JOHNS HOPK CSSE COV
   Kass DA, 2020, LANCET, V395, P1544, DOI 10.1016/S0140-6736(20)31024-2
   Leung CC, 2020, LANCET, V395, P945, DOI 10.1016/S0140-6736(20)30520-1
   Leung NHL, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0843-2
   Li JPO, 2020, BRIT J OPHTHALMOL, V104, P297, DOI 10.1136/bjophthalmol-2020-315994
   Maclntyre CR, 2009, EMERG INFECT DIS, V15, P233, DOI 10.3201/eid1502.081167
   Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Nierenberg A, 2020, ARE ALL MASKS
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Perrotta D, 2020, BEHAV ATTITUDES RESP, DOI [10.1101/2020.05.09.20096388, DOI 10.1101/2020.05.09.20096388]
   Qiu Jane, 2020, Nature, DOI 10.1038/d41586-020-00822-x
   R Core Team, 2019, R LANG ENV STAT COMP
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Science in Emergencies Tasking-COVID-19 (SET-C), 2020, SCI EM TASK COVID 19
   Sim SW, 2014, SINGAP MED J, V55, P160
   Soetaert K, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i09
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Stutt ROJH, 2020, P ROY SOC A-MATH PHY, V476, DOI 10.1098/rspa.2020.0376
   Tang JW, 2009, J R SOC INTERFACE, V6, pS727, DOI 10.1098/rsif.2009.0295.focus
   Tracht SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009018
   US Centers for Disease Control and Prevention, 2020, REC REG US CLOTH FAC
   Wang CJ, 2020, JAMA-J AM MED ASSOC, V323, P1341, DOI 10.1001/jama.2020.3151
   World Health Organization, 2020, ADV US MASKS CONT CO
   Wu H.-L., 2020, ECLINICALMEDICINE, V21, P100329, DOI [10.1016/j.eclinm.2020.100329, DOI 10.1101/2020.02.11.20020735]
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   2020, MMWR-MORBID MORTAL W, V69, P343
NR 46
TC 4
Z9 4
U1 7
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 13
PY 2020
VL 11
IS 1
AR 4049
DI 10.1038/s41467-020-17922-x
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NG8RJ
UT WOS:000564247500001
PM 32792562
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, FF
   Ji, CC
   Luo, JJ
   Wu, WW
   Zhang, JC
   Zhong, ZQ
   Lankford, S
   Huang, H
   Lin, F
   Wang, YG
   Mo, GX
   Hu, XS
   Jiang, TJ
   Shao, YL
   Ji, SM
   Zhang, YW
   Qin, EQ
   Mu, JS
AF Liu, Fangfang
   Ji, Chengcheng
   Luo, Jiajun
   Wu, Weiwei
   Zhang, Junchang
   Zhong, Zhiqiang
   Lankford, Seth
   Huang, Huang
   Lin, Fang
   Wang, Yonggang
   Mo, Guoxin
   Hu, Xingshuo
   Jiang, Tianjun
   Shao, Yanling
   Ji, Sumin
   Zhang, Yawei
   Qin, Enqiang
   Mu, Jinsong
TI Clinical characteristics and corticosteroids application of different
   clinical types in patients with corona virus disease 2019
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; INFLAMMATORY CYTOKINES; SARS; COV;
   PNEUMONIA; THERAPY
AB To describe the epidemiological and clinical characteristics of patients with Corona Virus Disease 2019 (COVID-19) in Beijing. To analyze the application of corticosteroids in patients with severe pneumonia. We collected information on demographic characteristics, exposure history, clinical characteristics, corticosteroids use, and outcomes of the 65 confirmed cases of COVID-19 at Fifth Medical Center of PLA General Hospital from Jan 20 to Feb 23, 2020. The final follow-up date observed was April 15th, 2020. The number of patients with mild, general, severe, and critical type were 10 (15.38%), 32 (49.23%), 8 (12.31%), and 15 (23.08%), respectively. The median incubation period was 6 days. Notable outliers were 1 patient at 16 days and 1 patient at 21 days. In lymphocyte subgroup analysis, decreases in total, T, CD4, and CD8 lymphocytes were more common as the disease worsened (All P<0.05). Methylprednisolone (mPSL) was applied to 31 (47.69%) patients with pneumonia, including 10 (31.25%) general, 8 (100%) severe, and 13 (86.67%) critical patients, respectively. Corticosteroids inhibited Interleukin-6(IL-6) production (P=0.0215) but did not affect T lymphocyte (P=0.0796). There was no significant difference between patients using lower dose (<less than or equal to>2 mg/kg day) and higher dose (>2 mg/kg day) mPSL in inhibiting IL-6 production (P=0.5856). Thirty of 31 patients (96.77%) had stopped mPSL due to improvement of pneumonia. Virus RNA clearance time lengthened with disease progression (P=0.0001). In general type, there was no significant difference in virus clearance time between patients with (15, 12-19 days) and without (14.5, 11-18 days) (P=0.7372) mPSL use. Lymphocyte, especially T lymphocyte, in severe and critical patients showed a dramatic decrease. Application of lower dose corticosteroids (<= 2 mg/kg day) could inhibit IL-6 production (a representative of cytokines) as effectively as a higher dose. Proper use corticosteroids in general type patients did not delay virus clearance.
C1 [Liu, Fangfang; Ji, Chengcheng; Zhang, Junchang; Zhong, Zhiqiang; Lin, Fang; Wang, Yonggang; Mo, Guoxin; Hu, Xingshuo; Jiang, Tianjun; Shao, Yanling; Ji, Sumin; Qin, Enqiang; Mu, Jinsong] Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China.
   [Luo, Jiajun; Huang, Huang; Zhang, Yawei] Yale Univ, Dept Environm Hlth Sci, Yale Sch Publ Hlth, New Haven, CT 06520 USA.
   [Wu, Weiwei] Shanxi Med Univ, Taiyuan, Shanxi, Peoples R China.
   [Lankford, Seth] Duke Univ, Durham, NC USA.
   [Zhang, Yawei] Yale Univ, Yale Sch Med, Dept Surg, New Haven, CT 06520 USA.
RP Qin, EQ; Mu, JS (corresponding author), Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China.; Zhang, YW (corresponding author), Yale Univ, Dept Environm Hlth Sci, Yale Sch Publ Hlth, New Haven, CT 06520 USA.; Zhang, YW (corresponding author), Yale Univ, Yale Sch Med, Dept Surg, New Haven, CT 06520 USA.
EM yawei.zhang@yale.edu; qeq2004@sina.com; jinsongmu302@163.com
FU Biosecurity Construction Plan [A3704041901-09]
FX Biosecurity Construction Plan (A3704041901-09).
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arabi YM, 2017, NEW ENGL J MED, V376, P584, DOI 10.1056/NEJMsr1408795
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Howell MD, 2018, JAMA-J AM MED ASSOC, V319, P711, DOI 10.1001/jama.2018.0307
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   LI H, 2017, VIRUSES, V11, P345, DOI DOI 10.1111/IRV.12456
   Li Q, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa20013167346765, DOI 10.1056/NEJMOA20013167346765]
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Muhovi D, 2020, LIVER INT, DOI [10.1111/liv.145167276916, DOI 10.1111/LIV.145167276916]
   Pang BS, 2003, CHINESE MED J-PEKING, V116, P1283
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhao J P, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P183, DOI 10.3760/cma.j.issn.1001-0939.2020.03.008
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
NR 31
TC 3
Z9 3
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 13
PY 2020
VL 10
IS 1
AR 13689
DI 10.1038/s41598-020-70387-2
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NF8MH
UT WOS:000563546400021
PM 32792492
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, LL
   Zhou, RH
AF Zhang, Leili
   Zhou, Ruhong
TI Structural Basis of the Potential Binding Mechanism of Remdesivir to
   SARS-CoV-2 RNA-Dependent RNA Polymerase
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID SARS-CORONAVIRUS NSP12; MOLECULAR-DYNAMICS; REPLICA-EXCHANGE;
   HEMAGGLUTININ; PERCEPTION; VIRUS
AB Starting from late 2019, the coronavirus disease 2019 (COVID-19) has emerged as a once-in-a-century pandemic with deadly consequences, which urgently calls for new treatments, cures, and supporting apparatuses. Recently, because of its positive results in clinical trials, remdesivir was approved by the Food and Drug Administration to treat COVID-19 through Emergency Use Author ization. Here, we used molecular dynamics simulations and free energy perturbation methods to study the inhibition mechanism of remdesivir to its target SARS-CoV-2 virus RNA-dependent RNA polymerase (RdRp). We first constructed the homology model of this polymerase based on a previously available structure of SARS-CoV NSP12 RdRp (with a sequence identity of 95.8%). We then built a putative preinsertion binding structure by aligning the remdesivir + RdRp complex to the ATP bound poliovirus RdRp without the RNA template. The putative binding structure was further optimized with molecular dynamics simulations. The resulting stable preinsertion state of remdesivir appeared to form hydrogen bonds with the RNA template when aligned with the newly solved cryo-EM structure of SARS-CoV-2 RdRp. The relative binding free energy between remdesivir and ATP was calculated to be -2.80 +/- 0.84 kcal/mol, where remdesivir bound much stronger to SARS-CoV-2 RdRp than the natural substrate ATP. The similar to 100-fold improvement in the K-d from remdesivir over ATP indicates an effective replacement of ATP in blocking of the RdRp preinsertion site. Key residues D618, 5549, and R555 are found to be the contributors to the binding affinity of remdesivir. These findings suggest that remdesivir can potentially act as a SARS-CoV-2 RNA-chain terminator, effectively stopping its RNA replication, with key residues also identified for future lead optimization and/or drug resistance studies.
C1 [Zhang, Leili; Zhou, Ruhong] IBM Thomas J Watson Res Ctr, Computat Biol Ctr, Yorktown Hts, NY 10598 USA.
   [Zhou, Ruhong] Zhejiang Univ, Inst Quantitat Biol, Hangzhou 310027, Peoples R China.
   [Zhou, Ruhong] Columbia Univ, Dept Chem, New York, NY 10027 USA.
RP Zhou, RH (corresponding author), IBM Thomas J Watson Res Ctr, Computat Biol Ctr, Yorktown Hts, NY 10598 USA.; Zhou, RH (corresponding author), Zhejiang Univ, Inst Quantitat Biol, Hangzhou 310027, Peoples R China.; Zhou, RH (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.
EM rz24@columbia.edu
FU W. M. Keck FoundationW.M. Keck Foundation [2019-2022]; IBM Bluegene
   Science Program [W125859, W1464125, W1464164]
FX The authors wish to acknowledge helpful discussions with Michael Levitt.
   R.Z. gratefully acknowledges the financial support from the W. M. Keck
   Foundation (2019-2022) and IBM Bluegene Science Program (W125859,
   W1464125, and W1464164).
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Ahmed R, 2019, CELL, V177, P1583, DOI 10.1016/j.cell.2019.05.007
   Ahn DG, 2012, ARCH VIROL, V157, P2095, DOI 10.1007/s00705-012-1404-x
   Baharoon S, 2019, TRAVEL MED INFECT DI, V32, DOI 10.1016/j.tmaid.2019.101520
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Ben Ouirane K, 2019, J BIOL CHEM, V294, P7573, DOI 10.1074/jbc.RA118.005209
   Chang YC, 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2., 10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572
   Cohen J, 2020, SCIENCE, V367, P962, DOI 10.1126/science.367.6481.962
   Das P, 2009, J COMPUT CHEM, V30, P1654, DOI 10.1002/jcc.21274
   DYER O, 2019, BMJ-BRIT MED J, V366, DOI DOI 10.1136/BMJ.L5140
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gao Y., 2020, BIORXIV ORG, DOI [10.1101/2020.03.16.993386v1., DOI 10.1101/2020.03.16.993386V1]
   Gong P, 2010, P NATL ACAD SCI USA, V107, P22505, DOI 10.1073/pnas.1007626107
   Gorbalenya A.E., 2020, BIORXIV, DOI [10.1101/2020.02.07.937862v1, DOI 10.1101/2020.02.07.937862V1]
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Laio A, 2002, P NATL ACAD SCI USA, V99, P12562, DOI 10.1073/pnas.202427399
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lim WS, 2019, RESPIRATORY MEDICINE, 3RD EDITION, P393
   Limongelli V, 2013, P NATL ACAD SCI USA, V110, P6358, DOI 10.1073/pnas.1303186110
   Liu P, 2005, P NATL ACAD SCI USA, V102, P13749, DOI 10.1073/pnas.0506346102
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Sgrignani J, 2012, J PHYS CHEM B, V116, P2259, DOI 10.1021/jp206475d
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shu B, 2016, P NATL ACAD SCI USA, V113, pE4005, DOI 10.1073/pnas.1602591113
   Smith RD, 2006, SOC SCI MED, V63, P3113, DOI 10.1016/j.socscimed.2006.08.004
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Sugita Y, 1999, CHEM PHYS LETT, V314, P141, DOI 10.1016/S0009-2614(99)01123-9
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Thompson AA, 2007, J MOL BIOL, V366, P1459, DOI 10.1016/j.jmb.2006.11.070
   Vanommeslaeghe K, 2012, J CHEM INF MODEL, V52, P3144, DOI 10.1021/ci300363c
   Velthuis AJWT, 2010, NUCLEIC ACIDS RES, V38, P203, DOI 10.1093/nar/gkp904
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Kaijin, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P147, DOI 10.3785/j.issn.1008-9292.2020.02.02
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zheng LQ, 2008, P NATL ACAD SCI USA, V105, P20227, DOI 10.1073/pnas.0810631106
   Zhou RH, 2008, J PHYS CHEM B, V112, P15813, DOI 10.1021/jp805529z
   Zhuang SL, 2018, J PHYS CHEM B, V122, P1176, DOI 10.1021/acs.jpcb.7b11170
NR 45
TC 6
Z9 6
U1 15
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
EI 1520-5207
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD AUG 13
PY 2020
VL 124
IS 32
BP 6955
EP 6962
DI 10.1021/acs.jpcb.0c04198
PG 8
WC Chemistry, Physical
SC Chemistry
GA NE9SB
UT WOS:000562943100002
PM 32521159
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Poran, A
   Harjanto, D
   Malloy, M
   Arieta, CM
   Rothenberg, DA
   Lenkala, D
   van Buuren, MM
   Addona, TA
   Rooney, MS
   Srinivasan, L
   Gaynor, RB
AF Poran, Asaf
   Harjanto, Dewi
   Malloy, Matthew
   Arieta, Christina M.
   Rothenberg, Daniel A.
   Lenkala, Divya
   van Buuren, Marit M.
   Addona, Terri A.
   Rooney, Michael S.
   Srinivasan, Lakshmi
   Gaynor, Richard B.
TI Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass
   spectrometry-based bioinformatics predictor identifies immunogenic T
   cell epitopes
SO GENOME MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2 T cell epitopes; Computational biology; HLA-I
   binding prediction; HLA-II binding prediction; T cell assay; Vaccine
   design
ID ACUTE RESPIRATORY SYNDROME; SARS CORONAVIRUS; PROTECTIVE IMMUNITY;
   RESPONSES; ANTIBODIES; PNEUMONIA; PROTEIN; MODEL
AB Background The ongoing COVID-19 pandemic has created an urgency to identify novel vaccine targets for protective immunity against SARS-CoV-2. Early reports identify protective roles for both humoral and cell-mediated immunity for SARS-CoV-2. Methods We leveraged our bioinformatics binding prediction tools for human leukocyte antigen (HLA)-I and HLA-II alleles that were developed using mass spectrometry-based profiling of individual HLA-I and HLA-II alleles to predict peptide binding to diverse allele sets. We applied these binding predictors to viral genomes from theCoronaviridaefamily and specifically focused on T cell epitopes from SARS-CoV-2 proteins. We assayed a subset of these epitopes in a T cell induction assay for their ability to elicit CD8(+)T cell responses. Results We first validated HLA-I and HLA-II predictions onCoronaviridaefamily epitopes deposited in the Virus Pathogen Database and Analysis Resource (ViPR) database. We then utilized our HLA-I and HLA-II predictors to identify 11,897 HLA-I and 8046 HLA-II candidate peptides which were highly ranked for binding across 13 open reading frames (ORFs) of SARS-CoV-2. These peptides are predicted to provide over 99% allele coverage for the US, European, and Asian populations. From our SARS-CoV-2-predicted peptide-HLA-I allele pairs, 374 pairs identically matched what was previously reported in the ViPR database, originating from other coronaviruses with identical sequences. Of these pairs, 333 (89%) had a positive HLA binding assay result, reinforcing the validity of our predictions. We then demonstrated that a subset of these highly predicted epitopes were immunogenic based on their recognition by specific CD8(+)T cells in healthy human donor peripheral blood mononuclear cells (PBMCs). Finally, we characterized the expression of SARS-CoV-2 proteins in virally infected cells to prioritize those which could be potential targets for T cell immunity. Conclusions Using our bioinformatics platform, we identify multiple putative epitopes that are potential targets for CD4(+)and CD8(+)T cells, whose HLA binding properties cover nearly the entire population. We also confirm that our binding predictors can predict epitopes eliciting CD8(+)T cell responses from multiple SARS-CoV-2 proteins. Protein expression and population HLA allele coverage, combined with the ability to identify T cell epitopes, should be considered in SARS-CoV-2 vaccine design strategies and immune monitoring.
C1 [Poran, Asaf; Harjanto, Dewi; Malloy, Matthew; Arieta, Christina M.; Rothenberg, Daniel A.; Lenkala, Divya; van Buuren, Marit M.; Addona, Terri A.; Rooney, Michael S.; Srinivasan, Lakshmi; Gaynor, Richard B.] BioNTech US Inc, 40 Erie St,Suite 110, Cambridge, MA 02139 USA.
RP Poran, A; Harjanto, D (corresponding author), BioNTech US Inc, 40 Erie St,Suite 110, Cambridge, MA 02139 USA.
EM asaf.poran@biontech.us; dewi.harjanto@biontech.us
FU BioNTech US
FX BioNTech US (formerly Neon Therapeutics, Inc.)
CR Abelin JG, 2019, IMMUNITY, V51, P766, DOI 10.1016/j.immuni.2019.08.012
   Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007
   Ahmed SF, 2020, NAT PROTOC, V17, P1
   Ahmed SF, 2020, VIRUSES, V25
   Ali M, 2019, NAT PROTOC, V14, P1926, DOI 10.1038/s41596-019-0170-6
   Archila LLD, 2017, METHODS MOL BIOL, V1592, P199, DOI 10.1007/978-1-4939-6925-8_16
   Bezstarosti K, 2020, BIORXIV, V2020
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chour W, 2020, SHARED ANTIGEN SPECI, DOI [10.1101/2020.05.04.20085779, DOI 10.1101/2020.05.04.20085779]
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Davidson AD, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00763-0
   Gonzalez-Galarza FF, 2015, NUCLEIC ACIDS RES, V43, pD784, DOI 10.1093/nar/gku1166
   Graham RL, 2012, NAT MED, V18, P1820, DOI 10.1038/nm.2972
   Grifoni A., 2020, CELL
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Hadrup SR, 2009, NAT METHODS, V6, P520, DOI 10.1038/nmeth.1345
   Ihling C, 2020, J PROTEOME RES, V19, P4389, DOI 10.1021/acs.jproteome.0c00280
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kim D., 2020, CELL
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563
   Liu X, 2004, CLIN DIAGN LAB IMMUN, V11, P227, DOI 10.1128/CDLI.11.1.227-228.2004
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maiers M, 2007, HUM IMMUNOL, V68, P779, DOI 10.1016/j.humimm.2007.04.005
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Ni L., 2020, IMMUNITY
   Okba NMA, 2020, EMERGING INFECT DIS, V26
   Parkhurst MR, 2019, CANCER DISCOV, V9, P1022, DOI 10.1158/2159-8290.CD-18-1494
   Paul S, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03151
   Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859
   Polveiro RC, 2020, BIORXIV
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9
   Shi YL, 2003, J CLIN MICROBIOL, V41, P5781, DOI 10.1128/JCM.41.12.5781-5782.2003
   Shomuradova AS, 2020, SARS COV 2 EPITOES R, DOI [10.1101/2020.05.20.20107813, DOI 10.1101/2020.05.20.20107813]
   Singer J, 2020, LIFE SCI
   Stronen E, 2016, SCIENCE, V352, P1337, DOI 10.1126/science.aaf2288
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Thevarajan I, 2020, NAT MED, V26, P1
   Toebes M, 2006, NAT MED, V12, P246, DOI 10.1038/nm1360
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang JQ, 2003, CLIN CHEM, V49, P1989, DOI 10.1373/clinchem.2003.023184
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   WHO, 2018, MERS COV GLOB SUMM A
   WHO, MIDDL E RESP SYNDR C
   World-Health-Organization, UPD 49 SARS CAS FAT
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xing Y, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006957
   Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001
   Yang JB, 2006, CLIN IMMUNOL, V120, P21, DOI 10.1016/j.clim.2006.03.008
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zhang LQ, 2006, J MED VIROL, V78, P1, DOI 10.1002/jmv.20499
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
   Zheng M, 2020, CELL MOL IMMUNOL, V17, P536, DOI 10.1038/s41423-020-0385-z
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zybailov B, 2006, J PROTEOME RES, V5, P2339, DOI 10.1021/pr060161n
NR 63
TC 2
Z9 2
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD AUG 13
PY 2020
VL 12
IS 1
AR 70
DI 10.1186/s13073-020-00767-w
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA NE7XP
UT WOS:000562817700001
PM 32791978
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ip, A
   Berry, DA
   Hansen, E
   Goy, AH
   Pecora, AL
   Sinclaire, BA
   Bednarz, U
   Marafelias, M
   Berry, SM
   Berry, NS
   Mathura, S
   Sawczuk, IS
   Biran, N
   Go, RC
   Sperber, S
   Piwoz, JA
   Balani, B
   Cicogna, C
   Sebti, R
   Zuckerman, J
   Rose, KM
   Tank, L
   Jacobs, L
   Korcak, J
   Timmapuri, SL
   Underwood, JP
   Sugalski, G
   Barsky, C
   Varga, DW
   Asif, A
   Landolfi, JC
   Goldberg, SL
AF Ip, Andrew
   Berry, Donald A.
   Hansen, Eric
   Goy, Andre H.
   Pecora, Andrew L.
   Sinclaire, Brittany A.
   Bednarz, Urszula
   Marafelias, Michael
   Berry, Scott M.
   Berry, Nicholas S.
   Mathura, Shivam
   Sawczuk, Ihor S.
   Biran, Noa
   Go, Ronaldo C.
   Sperber, Steven
   Piwoz, Julia A.
   Balani, Bindu
   Cicogna, Cristina
   Sebti, Rani
   Zuckerman, Jason
   Rose, Keith M.
   Tank, Lisa
   Jacobs, Laurie
   Korcak, Jason
   Timmapuri, Sarah L.
   Underwood, Joseph P.
   Sugalski, Gregory
   Barsky, Carol
   Varga, Daniel W.
   Asif, Arif
   Landolfi, Joseph C.
   Goldberg, Stuart L.
TI Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An
   observational study
SO PLOS ONE
LA English
DT Article
ID INFECTIONS
AB Hydroxychloroquine has been touted as a potential COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has also been proposed as a treatment of critically ill patients. In this retrospective observational cohort study drawn from electronic health records we sought to describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Patients were hospitalized at a 13-hospital network spanning New Jersey USA between March 1, 2020 and April 22, 2020 with positive polymerase chain reaction results for SARS-CoV-2. Follow up was through May 5, 2020. Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized. 1914 (76%) received at least one dose of hydroxychloroquine and 1473 (59%) received hydroxychloroquine with azithromycin. After adjusting for imbalances via propensity modeling, compared to receiving neither drug, there were no significant differences in associated mortality for patients receiving any hydroxychloroquine during the hospitalization (HR, 0.99 [95% CI, 0.80-1.22]), hydroxychloroquine alone (HR, 1.02 [95% CI, 0.83-1.27]), or hydroxychloroquine with azithromycin (HR, 0.98 [95% CI, 0.75-1.28]). The 30-day unadjusted mortality for patients receiving hydroxychloroquine alone, azithromycin alone, the combination or neither drug was 25%, 20%, 18%, and 20%, respectively. Among 547 evaluable ICU patients, including 134 receiving tocilizumab in the ICU, an exploratory analysis found a trend towards an improved survival association with tocilizumab treatment (adjusted HR, 0.76 [95% CI, 0.57-1.00]), with 30 day unadjusted mortality with and without tocilizumab of 46% versus 56%. This observational cohort study suggests hydroxychloroquine, either alone or in combination with azithromycin, was not associated with a survival benefit among hospitalized COVID-19 patients. Tocilizumab demonstrated a trend association towards reduced mortality among ICU patients. Our findings are limited to hospitalized patients and must be interpreted with caution while awaiting results of randomized trials. Trial Registration: Clinicaltrials.gov Identifier:
C1 [Ip, Andrew; Goldberg, Stuart L.] Hackensack Univ Med Ctr, Div Outcomes & Value Res, John Theurer Canc Ctr, Hackensack, NJ 07601 USA.
   [Berry, Donald A.; Berry, Scott M.; Berry, Nicholas S.] Berry Consultants LLC, Austin, TX USA.
   [Berry, Donald A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Hansen, Eric; Mathura, Shivam] COTA, Boston, MA USA.
   [Goy, Andre H.; Pecora, Andrew L.; Sinclaire, Brittany A.; Bednarz, Urszula; Marafelias, Michael; Biran, Noa] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
   [Sawczuk, Ihor S.; Go, Ronaldo C.; Sperber, Steven; Piwoz, Julia A.; Balani, Bindu; Cicogna, Cristina; Sebti, Rani; Zuckerman, Jason; Rose, Keith M.; Tank, Lisa; Jacobs, Laurie; Korcak, Jason; Timmapuri, Sarah L.; Underwood, Joseph P.; Sugalski, Gregory; Barsky, Carol; Varga, Daniel W.; Asif, Arif; Landolfi, Joseph C.] Hackensack Meridian Hlth, Hackensack, NJ USA.
   [Sawczuk, Ihor S.; Go, Ronaldo C.; Sperber, Steven; Piwoz, Julia A.; Balani, Bindu; Cicogna, Cristina; Sebti, Rani; Zuckerman, Jason; Rose, Keith M.; Tank, Lisa; Jacobs, Laurie; Korcak, Jason; Timmapuri, Sarah L.; Underwood, Joseph P.; Sugalski, Gregory; Barsky, Carol; Varga, Daniel W.; Asif, Arif; Landolfi, Joseph C.] Hackensack Meridian Sch Med, Nutley, NJ USA.
RP Goldberg, SL (corresponding author), Hackensack Univ Med Ctr, Div Outcomes & Value Res, John Theurer Canc Ctr, Hackensack, NJ 07601 USA.
EM Stuart.Goldberg@hackensackmeridian.org
OI Ip, Andrew/0000-0003-0456-5618
CR Anderson R N, 2001, Natl Vital Stat Rep, V49, P1
   [Anonymous], 2018, FRAM FDAS REAL WORLD
   [Anonymous], COVID 19 TREATM GUID
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480
   Cavalcanti AB, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2019014, DOI 10.1056/NEJMOA201901432706953]
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Food and Drug Administration, 2020, RE REQ EM US AUTH US
   Food and Drug Administration, 2018, US EL HLTH REC DAT C
   Food and Drug Administration, 2017, US REAL WORLD EV SUP
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.863032392282, DOI 10.1001/JAMA.2020.863032392282]
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216
   Somers EC, CLIN INFECT DIS, DOI [10.1093/cid/ciaa95432651997, DOI 10.1093/CID/CIAA95432651997]
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yao X, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa23732150618, DOI 10.1093/CID/CIAA23732150618]
NR 34
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 13
PY 2020
VL 15
IS 8
AR e0237693
DI 10.1371/journal.pone.0237693
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NE5VG
UT WOS:000562668300125
PM 32790733
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ferraz, WR
   Gomes, RA
   Novaes, ALS
   Trossini, GHG
AF Ferraz, Witor Ribeiro
   Gomes, Renan Augusto
   Novaes, Andre Luis
   Goulart Trossini, Gustavo Henrique
TI Ligand and structure-based virtual screening applied to the SARS-CoV-2
   main protease: anin silicorepurposing study
SO FUTURE MEDICINAL CHEMISTRY
LA English
DT Article
ID DOCKING; OPTIMIZATION; GENERATION; DISCOVERY; ALGORITHM
AB Aim:The identification of drugs for the coronavirus disease-19 pandemic remains urgent. In this manner, drug repurposing is a suitable strategy, saving resources and time normally spent during regular drug discovery frameworks. Essential for viral replication, the main protease has been explored as a promising target for the drug discovery process.Materials & methods:Our virtual screening pipeline relies on the known 3D properties of noncovalent ligands and features of crystalized complexes, applying consensus analyses in each step.Results:Two oral (bedaquiline and glibenclamide) and one buccal drug (miconazole) presented 3D similarity to known ligands, reasonable predicted binding modes and micromolar predicted binding affinity values.Conclusion:We identified three approved drugs as promising inhibitors of the main viral protease and suggested design insights for future studies for development of novel selective inhibitors.
C1 [Ferraz, Witor Ribeiro; Gomes, Renan Augusto; Novaes, Andre Luis; Goulart Trossini, Gustavo Henrique] Univ Sao Paulo, Fac Ciencias Farmaceut, Ave Prof Lineu Prestes 580, BR-05508000 Sao Paulo, SP, Brazil.
RP Trossini, GHG (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut, Ave Prof Lineu Prestes 580, BR-05508000 Sao Paulo, SP, Brazil.
EM trossini@usp.br
RI Trossini, Gustavo/A-5789-2013
OI Trossini, Gustavo/0000-0003-3634-2531; Gomes, Renan
   Augusto/0000-0002-4220-6838
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [436791/2018-8, 310232/2017-1]; FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2017/25543-8]; University of Sao Paulo
FX The authors thank CNPq (436791/2018-8 and 310232/2017-1) and FAPESP
   (2017/25543-8) for fellowship and financial support. We thank the
   University of Sao Paulo for financial support and infrastructure.The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Alizargar J, 2020, J FORMOS MED ASSOC, V119, P1123, DOI 10.1016/j.jfma.2020.04.013
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], PDB5R83 RCSB
   [Anonymous], PDB5R8T RCSB
   [Anonymous], PDB5RF2 RCSB
   [Anonymous], PDB5RF6 RCSB
   [Anonymous], PDB6Y84 RCSB
   [Anonymous], PDB6YB7 RCSB
   [Anonymous], PDB5RF7 RCSB
   [Anonymous], PDB5R81 RCSB
   [Anonymous], PDB5REZ RCSB
   [Anonymous], PDB5R80 RCSB
   [Anonymous], 2020, PDB5R7Y RCSB
   [Anonymous], PDB5REH RCSB
   [Anonymous], PDB5REB RCSB
   [Anonymous], PDB6M03 RCSB
   [Anonymous], PDB5RFE RCSB
   [Anonymous], PDB5R7Z RCSB
   [Anonymous], PDB5RE4 RCSB
   [Anonymous], PDB5RF1 RCSB
   [Anonymous], PDB5R84 RCSB
   [Anonymous], PDB5RF3 RCSB
   [Anonymous], PDB5R82 RCSB
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   de Magalhaes CS, 2014, INFORM SCIENCES, V289, P206, DOI 10.1016/j.ins.2014.08.002
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Discovery Studio Visualizer, DISC STUD VIS
   EON, EON
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   GraphPad Prism, GRAPHPAD PRISM
   Gurung AB, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117831
   Hawkins PCD, 2007, J MED CHEM, V50, P74, DOI 10.1021/jm0603365
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Jacobs J, 2013, J MED CHEM, V56, P534, DOI 10.1021/jm301580n
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Maggiora G, 2014, J MED CHEM, V57, P3186, DOI 10.1021/jm401411z
   Mahanta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768902
   Maia EHB, 2020, ACS OMEGA, V5, P6628, DOI 10.1021/acsomega.9b04403
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Mckee M, 2020, NAT MED, V26, P640, DOI 10.1038/s41591-020-0863-y
   Negri E. M., 2020, HEPARIN THERAPY IMPR, DOI [10.1101/2020.04.15.20067017, DOI 10.1101/2020.04.15.20067017]
   Nemec A, 2010, J ANTIMICROB CHEMOTH, V65, P367, DOI 10.1093/jac/dkp440
   OMEGA, OMEGA
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   QUACPAC, QUACPAC
   ROCS, ROCS
   Rosenberg ES, 2020, JAMA
   Santos KB, 2020, J CHEM INF MODEL, V60, P667, DOI 10.1021/acs.jcim.9b00905
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   U. S. Food and Drug Administration, 2020, COR TREATM ACC PROGR
   U. S. Food and Drug Administration, 2020, CLIN TRIAL COND COVI
   US Food and Drug Administration, 2020, COR COVID 19 UPD FDA
   US Food & Drug Administration, 2020, FDA CAUT US HYDR CHL
   Wang L, 2020, STEEL RES INT, V91, DOI 10.1002/srin.201900447
   World Health Organization, WHO COVID 19 DASHB
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu YJ, 2018, NUCLEIC ACIDS RES, V46, pW374, DOI 10.1093/nar/gky380
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 67
TC 7
Z9 7
U1 7
U2 7
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1756-8919
EI 1756-8927
J9 FUTURE MED CHEM
JI Future Med. Chem.
PD OCT
PY 2020
VL 12
IS 20
BP 1815
EP 1828
DI 10.4155/fmc-2020-0165
EA AUG 2020
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA OS0DJ
UT WOS:000561479200001
PM 32787684
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kapusta, K
   Kar, S
   Collins, JT
   Franklin, LM
   Kolodziejczyk, W
   Leszczynski, J
   Hill, GA
AF Kapusta, Karina
   Kar, Supratik
   Collins, Jasmine T.
   Franklin, Latasha M.
   Kolodziejczyk, Wojciech
   Leszczynski, Jerzy
   Hill, Glake A.
TI Protein reliability analysis and virtual screening of natural inhibitors
   for SARS-CoV-2 main protease (M-pro) through docking, molecular mechanic
   & dynamic, and ADMET profiling
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Protein reliability; docking; molecular dynamics; virtual screening;
   natural compounds; SARS-CoV-2
AB Due to an outbreak of COVID-19, the number of research papers devoted toin-silicodrug discovery of potential antiviral drugs is increasing every day exponentially. Still, there is no specific drug to prevent or treat this novel coronavirus (SARS-CoV-2) disease. Thus, the screening for a potential remedy presents a global challenge for scientists. Up to date over a hundred crystallographic structures of SARS-CoV-2 M(pro)have been deposited to Protein Data Bank. With many known proteins, the demand for a reliable target has become higher than ever, so as the choice of an efficient computational methods. Therefore, in this study comparative methods have been used for receptor-based virtual screening, targeting 9 selected structures of viral M-pro. Reliability analyses followed by re-docking of the specific co-crystallized ligand provided the best reproductivity for structures with PDB ID 6LU7, 6Y2G and 6Y2F. The influence of crystallographic water on an outcome of a virtual screening against selected targets was also investigated. Once the most reliable targets were selected, the library of easy purchasable natural compounds were retrieved from the MolPort database (10,305 compounds) and docked against the selected M(pro)proteins. To ensure the efficiency of the selected compounds, binding energies for top-15 hit ligands were calculated using Molecular Mechanics as well as their absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties were predicted. Based on predicted binding energies and toxicities, top-5 compounds were selected and subjected to Molecular Dynamics simulation and found to be stable in complex to act as possible inhibitors for SARS-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Kapusta, Karina; Kar, Supratik; Collins, Jasmine T.; Franklin, Latasha M.; Kolodziejczyk, Wojciech; Leszczynski, Jerzy; Hill, Glake A.] Jackson State Univ, Dept Chem Phys & Atmospher Sci, Interdisciplinary Ctr Nanotox, Jackson, MS 39217 USA.
RP Leszczynski, J; Hill, GA (corresponding author), Jackson State Univ, Dept Chem Phys & Atmospher Sci, Interdisciplinary Ctr Nanotox, Jackson, MS 39217 USA.
EM jerzy@icnanotox.org; glakeh@icnanotox.org
RI Voronkov, Eugene/O-1338-2019; Kapusta, Karina/AAX-5976-2020; Kar,
   Supratik/H-8868-2019; Syzochenko, Nataliia/C-5293-2016
OI Voronkov, Eugene/0000-0003-4908-7496; Kapusta,
   Karina/0000-0001-8466-4098; Kar, Supratik/0000-0002-9411-2091;
   Syzochenko, Nataliia/0000-0002-7039-7969
FU National Science FoundationNational Science Foundation (NSF) [NSF/CREST
   HRD-1547754]
FX The authors want to thank the National Science Foundation [Grant:
   NSF/CREST HRD-1547754] for financial support.
CR Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Farag A., 2020, IDENTIFICATION FDA A, DOI [10.26434/chemrxiv.12003930.v4, DOI 10.26434/CHEMRXIV.12003930.V4]
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Haider Z, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-0310-9
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joob B, 2020, J AM ACAD DERMATOL, V82, pE177, DOI 10.1016/j.jaad.2020.03.036
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Kar S, 2017, CURR DRUG METAB, V18, P1106, DOI 10.2174/1389200218666170607102104
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   Kumar Y., 2020, SILICO IDENTIFICATIO, DOI [10.26434/chemrxiv.12049590.v1, DOI 10.26434/CHEMRXIV.12049590.V1]
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Palese L. L., 2020, STRUCTURAL LANDSCAPE, DOI [10.26434/chemrxiv.12209744.v1, DOI 10.26434/CHEMRXIV.12209744.V1]
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Roos K, 2019, J CHEM THEORY COMPUT, V15, P1863, DOI 10.1021/acs.jctc.8b01026
   Sampangi-Ramaiah M. H., 2020, CURRENT SCI, V118
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Sekhar T., 2020, PREPRINTS, DOI [10.20944/ preprints202002.0418.v2, DOI 10.20944/PREPRINTS202002.0418.V2, 10.20944/preprints202002.0418.v2]
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Wong SE, 2011, EXPERT OPIN DRUG DIS, V6, P65, DOI 10.1517/17460441.2011.534452
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 30
TC 1
Z9 1
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1806930
EA AUG 2020
PG 18
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NA5NF
UT WOS:000559862400001
PM 31965914
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Park, YJ
   Farooq, J
   Cho, J
   Sadanandan, N
   Cozene, B
   Gonzales-Portillo, B
   Saft, M
   Borlongan, MC
   Borlongan, MC
   Shytle, RD
   Willing, AE
   Garbuzova-Davis, S
   Sanberg, PR
   Borlongan, CV
AF Park, You Jeong
   Farooq, Jeffrey
   Cho, Justin
   Sadanandan, Nadia
   Cozene, Blaise
   Gonzales-Portillo, Bella
   Saft, Madeline
   Borlongan, Maximillian C.
   Borlongan, Mia C.
   Shytle, R. Douglas
   Willing, Alison E.
   Garbuzova-Davis, Svitlana
   Sanberg, Paul R.
   Borlongan, Cesar, V
TI Fighting the War Against COVID-19 via Cell-Based Regenerative Medicine:
   Lessons Learned from 1918 Spanish Flu and Other Previous Pandemics
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article; Early Access
DE COVID-19; Coronavirus; Pandemics; SARS Virus; Vaccines; Antiviral Drugs;
   1918 Influenza Pandemic; Stem Cells
ID MESENCHYMAL STEM-CELLS; ACUTE RESPIRATORY SYNDROME; CORONAVIRUS SPIKE
   PROTEIN; SARS CORONAVIRUS; S2 SUBUNIT; INFLUENZA; VIRUS; LUNG; ACE2;
   RECEPTOR
AB The human population is in the midst of battling a rapidly-spreading virus- Severe Acute Respiratory Syndrome Coronavirus 2, responsible for Coronavirus disease 2019 or COVID-19. Despite the resurgences in positive cases after reopening businesses in May, the country is seeing a shift in mindset surrounding the pandemic as people have been eagerly trickling out from federally-mandated quarantine into restaurants, bars, and gyms across America. History can teach us about the past, and today's pandemic is no exception. Without a vaccine available, three lessons from the 1918 Spanish flu pandemic may arm us in our fight against COVID-19. First, those who survived the first wave developed immunity to the second wave, highlighting the potential of passive immunity-based treatments like convalescent plasma and cell-based therapy. Second, the long-term consequences of COVID-19 are unknown. Slow-progressive cases of the Spanish flu have been linked to bacterial pneumonia and neurological disorders later in life, emphasizing the need to reduce COVID-19 transmission. Third, the Spanish flu killed approximately 17 to 50 million people, and the lack of human response, overcrowding, and poor hygiene were key in promoting the spread and high mortality. Human behavior is the most important strategy for preventing the virus spread and we must adhere to proper precautions. This review will cover our current understanding of the pathology and treatment for COVID-19 and highlight similarities between past pandemics. By revisiting history, we hope to emphasize the importance of human behavior and innovative therapies as we wait for the development of a vaccine.
C1 [Park, You Jeong; Farooq, Jeffrey; Cho, Justin; Shytle, R. Douglas; Willing, Alison E.; Garbuzova-Davis, Svitlana; Sanberg, Paul R.; Borlongan, Cesar, V] Univ S Florida, Dept Neurosurg & Brain Repair, Morsani Coll Med, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.
   [Sadanandan, Nadia] Georgetown Univ, 3700 O St NW, Washington, DC 20057 USA.
   [Cozene, Blaise] Tulane Univ, 6823 St Charles Ave, New Orleans, LA 70118 USA.
   [Gonzales-Portillo, Bella] Northwestern Univ, 633 Clark St, Evanston, IL 60208 USA.
   [Saft, Madeline] Univ Michigan, 500 S State St, Ann Arbor, MI 48109 USA.
   [Borlongan, Maximillian C.] Tampa Preparatory Sch, 727 West Cass St, Tampa, FL 33606 USA.
   [Borlongan, Mia C.] Univ Calif Berkeley, Berkeley, CA 94720 USA.
RP Borlongan, CV (corresponding author), Univ S Florida, Dept Neurosurg & Brain Repair, Morsani Coll Med, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.
EM cborlong@usf.edu
OI Borlongan, Mia/0000-0003-3223-8374; Farooq, Jeffrey/0000-0002-6507-6626
FU National Institutes of Health (US)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01NS090962,
   R01NS102395, and R21NS109575] Funding Source: Medline
CR Abdel-Fattah MM, 2018, N-S ARCH PHARMACOL, V391, P1003, DOI 10.1007/s00210-018-1523-3
   Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Akhmerov A, 2020, CIRC RES, V126, P1443, DOI 10.1161/CIRCRESAHA.120.317055
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Avula A, 2020, BRAIN BEHAV IMMUN, V87, P115, DOI 10.1016/j.bbi.2020.04.077
   Baker EW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10406-x
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Barcik W, 2020, IMMUNITY, V52, P241, DOI 10.1016/j.immuni.2020.01.007
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Borlongan CV, 1998, NEUROREPORT, V9, P2837, DOI 10.1097/00001756-199808240-00028
   BORLONGAN CV, 1999, LANCET S1, V353, pS129, DOI DOI 10.1016/s0140-6736(99)90229-5
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bridwell Rachel, 2020, Am J Emerg Med, V38, DOI 10.1016/j.ajem.2020.05.024
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan PKS, 2004, J MED VIROL, V74, P1, DOI 10.1002/jmv.20138
   Chau MJ, 2018, BMC NEUROSCI, V19, DOI 10.1186/s12868-018-0418-z
   Chen J, 2020, ENGINEERING BEIJING
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Chen XY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082893
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Colombi D, 2020, RADIOLOGY, V296, pE86, DOI 10.1148/radiol.2020201433
   Corsello T, 2019, STEM CELL REV REP, V15, P900, DOI 10.1007/s12015-019-09907-1
   Dariya B, 2020, CYTOKINE GROWTH F R, V53, P43, DOI 10.1016/j.cytogfr.2020.05.001
   Docheva D, 2008, CURR RHEUMATOL REV, V4, P155, DOI 10.2174/157339708785133479
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Fan ZY, 2020, CLIN GASTROENTEROL H, V18, P1561, DOI 10.1016/j.cgh.2020.04.002
   Fantini J., 2020, INT J ANTIMICROB AG
   Farcas GA, 2005, J INFECT DIS, V191, P193, DOI 10.1086/426870
   Gao QY, 2020, J DIGEST DIS, V21, P125, DOI 10.1111/1751-2980.12851
   Garbuzova-Davis S, 2020, CELL TRANSPLANTION, V29
   Garraud O, 2016, TRANSFUS CLIN BIOL, V23, P39, DOI 10.1016/j.tracli.2015.12.003
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Goldberg M. F., 2020, AM JOUNRAL NEURORADI
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Gucciardo L, 2009, BJOG-INT J OBSTET GY, V116, P166, DOI 10.1111/j.1471-0528.2008.02005.x
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Gurusamy N, 2018, PROG MOL BIOL TRANSL, V160, P1, DOI 10.1016/bs.pmbts.2018.07.009
   Hayase Y, 1997, PSYCHIAT CLIN NEUROS, V51, P181, DOI 10.1111/j.1440-1819.1997.tb02580.x
   Hermankova B, 2019, STEM CELL REV REP, V15, P880, DOI 10.1007/s12015-019-09908-0
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Huang YB, 2020, AM J RESP CRIT CARE, V201, P1435, DOI 10.1164/rccm.202003-0572LE
   Hussain M., 2020, J MED VIROL, P1
   Ishii Tetsuya, 2014, World J Stem Cells, V6, P404, DOI 10.4252/wjsc.v6.i4.404
   Jensen S, 2012, J VIROL, V86, P2900, DOI 10.1128/JVI.05738-11
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Jia J, 2020, J DIFFER EQUATIONS, V2020, P1
   Jiang YJ, 2013, CELL TRANSPLANT, V22, P2291, DOI 10.3727/096368912X658818
   Klimpel GR, 1996, IMMUNE DEFENSES
   Kolios G, 2013, RESPIRATION, V85, P3, DOI 10.1159/000345615
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kulasekararaj A. G., 2020, BRIT J HAEMATOLOGY
   Kunal S, 2020, MONALDI ARCH CHEST D, V90, P231, DOI 10.4081/monaldi.2020.1305
   Larson AS, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016793
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lee JY, 2019, STEM CELL REV REP, V15, P690, DOI 10.1007/s12015-019-09906-2
   Lee JY, 2019, THERANOSTICS, V9, P1029, DOI 10.7150/thno.29868
   Lehmann M, 2019, STEM CELL REV REP, V15, P612, DOI 10.1007/s12015-019-09895-2
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Lenkiewicz AM, 2019, STEM CELL REV REP, V15, P391, DOI 10.1007/s12015-019-09890-7
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Li YC, 2013, J COMP NEUROL, V521, P203, DOI 10.1002/cne.23171
   Liang B., 2020, CLIN REMISSION CRITI
   Liu PP, 2020, CIRCULATION
   Liu WJ, 2018, VIROL SIN, V33, P463, DOI 10.1007/s12250-018-0079-1
   Loregian A, 2014, CELL MOL LIFE SCI, V71, P3659, DOI 10.1007/s00018-014-1615-2
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Madjid M, 2020, JAMA CARDIOLOGY, DOI [10.1001/jamacardio.2020.1286, DOI 10.1001/]
   Mallick B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007837
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Montalvan V, 2020, CLIN NEUROL NEUROSUR, V194, DOI 10.1016/j.clineuro.2020.105921
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Morabito CJ, 2020, SCIENCE, V222, P38
   Moreira A, 2020, STEM CELL TRANSL MED, V9, P221, DOI 10.1002/sctm.18-0273
   Morris DE, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01041
   Newman MB, 2005, STEM CELLS DEV, V14, P29, DOI 10.1089/scd.2005.14.29
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Park DH, 2011, STEM CELL REV REP, V7, P181, DOI 10.1007/s12015-010-9163-0
   Prabakaran P, 2004, BIOCHEM BIOPH RES CO, V314, P235, DOI 10.1016/j.bbrc.2003.12.081
   Roca-Ho H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030563
   Rogers CJ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02380-2
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Roosecelis B. M., 2020, EMERGING INFECT DIS, V26
   Samsonraj RM, 2017, STEM CELL TRANSL MED, V6, P2173, DOI 10.1002/sctm.17-0129
   Schwartz JL, 2018, AM J PUBLIC HEALTH, V108, P1455, DOI 10.2105/AJPH.2018.304581
   Sengupta V, 2020, STEM CELLS DEV, V29, P747, DOI 10.1089/scd.2020.0080
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Simsek Yavuz S, 2020, TURK J MED SCI, V50, P611, DOI 10.3906/sag-2004-145
   Smetana K, 2020, IN VIVO, V34, P1589, DOI 10.21873/invivo.11947
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Steinberg GK, 2016, STROKE, V47, P1817, DOI 10.1161/STROKEAHA.116.012995
   Sun J, 2020, LIVER INT, V40, P1278, DOI 10.1111/liv.14470
   TAGUCHI F, 1995, J VIROL, V69, P7260, DOI 10.1128/JVI.69.11.7260-7263.1995
   Taubenberger JK, 2001, PHILOS T ROY SOC B, V356, P1829, DOI 10.1098/rstb.2001.1020
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tobin MK, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.013583
   Trilla A, 2008, CLIN INFECT DIS, V47, P668, DOI 10.1086/590567
   Valk SJ, 2020, COCHRANE DB SYST REV, V5, DOI DOI 10.1002/14651858.CD013600/FULL.32406927
   Vazin T, 2010, RESTOR NEUROL NEUROS, V28, P589, DOI 10.3233/RNN-2010-0543
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Vilensky JA, 2007, PEDIATR NEUROL, V37, P79, DOI 10.1016/j.pediatrneurol.2007.04.012
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   WU JY, 2020, CLIN INFECT DIS, DOI DOI 10.1002/ANDP.202000001
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
   Xing CY, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02876-9
   Xu J, 2005, CLIN INFECT DIS, V41, P1089, DOI 10.1086/444461
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Ye QS, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04380-5
   YOO D, 1991, VIROLOGY, V180, P395, DOI 10.1016/0042-6822(91)90045-D
   Yoshida Y, 2017, CIRC RES, V120, P1958, DOI 10.1161/CIRCRESAHA.117.311080
   Yu F, 2020, CLIN INFECT DIS
   Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang PX, 2020, BONE RES, V8, DOI 10.1038/s41413-020-0084-5
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhang Y, 2020, STEM CELL RES THER, V11, P1
   Zhao JC, 2007, VIROLOGY, V359, P362, DOI 10.1016/j.virol.2006.09.022
   Zhao K, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0276-z
   Zhao Y., 2020, CLIN MICROBIOL INFEC
   Zheng D, 2012, VIRUSES-BASEL, V4, P3589, DOI 10.3390/v4123589
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 145
TC 0
Z9 0
U1 8
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
DI 10.1007/s12015-020-10026-5
EA AUG 2020
PG 24
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA MZ8WR
UT WOS:000559405600002
PM 32789802
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hu, FY
   Yin, G
   Chen, YP
   Song, JQ
   Ye, MS
   Liu, J
   Chen, CC
   Song, YL
   Tang, XJ
   Zhang, Y
AF Hu, Fuying
   Yin, Gang
   Chen, Youping
   Song, Jiangqin
   Ye, Maosong
   Liu, Jie
   Chen, Cuicui
   Song, Yuanlin
   Tang, Xinjun
   Zhang, Yong
TI Corticosteroid, oseltamivir and delayed admission are independent risk
   factors for prolonged viral shedding in patients with Coronavirus
   Disease 2019
SO CLINICAL RESPIRATORY JOURNAL
LA English
DT Article
DE characteristics; COVID-19; treatments; viral shedding
ID RESPIRATORY SYNDROME; MORTALITY; RNA
AB Introduction Coronavirus Disease 2019 (COVID-19) has spread worldwide, and it has reached to more than 14.5 million cases. Although Hubei province is the epicenter of China, little is known about epidemiological and clinical features of COVID-19 in other areas in Hubei province around Wuhan. In addition, the virological data, particularly the factors associated with viral shedding of COVID-19 has not been well described. Objective To describe the epidemiological and clinical features of patients with COVID-19 in Tianmen city, and identify risk factors associated with prolonged viral shedding of COVID-19. Methods Inpatients with COVID-19 admitted before February 9, 2020 were included. Characteristics were compared between patients with early and late viral RNA shedding. Multivariate cox regression model was used to investigate variables associated with prolonged viral shedding. Results One hundred and eighty-three patients were included. About 8.2% patients were categorized as critical degree of severity. All patients received antiviral therapy, with arbidol and interferon being the commonest. About 38.3% and 16.9% patients were treated with corticosteroid and immunoglobulin, respectively. Time from onset to admission (HR = 0.829,P < 0.001), and administration of corticosteroid (HR = 0.496,P = 0.002), arbidol (HR = 2.605,P = 0.008) and oseltamivir (HR = 0.416,P < 0.001) were independently associated with duration of viral shedding. Conclusion Symptoms of patients from Tianmen are relatively mild. Treatment should be started as early as possible, but corticosteroid and oseltamivir should be initiated with caution. In addition, clinical trials on arbidol should be conducted to demonstrate its effectiveness.
C1 [Hu, Fuying] First Peoples Hosp Tianmen, Dept Pulm & Crit Care Med, Tianmen, Peoples R China.
   [Yin, Gang] First Peoples Hosp Tianmen, Dept Gen Surg, Tianmen, Peoples R China.
   [Chen, Youping] First Peoples Hosp Tianmen, Dept Gastroenterol, Tianmen, Peoples R China.
   [Song, Jiangqin] First Peoples Hosp Tianmen, Dept Lab Med, Tianmen, Peoples R China.
   [Ye, Maosong; Liu, Jie; Chen, Cuicui; Song, Yuanlin; Tang, Xinjun; Zhang, Yong] Fudan Univ, Zhongshan Hosp, Dept Pulm & Crit Care Med, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
RP Tang, XJ; Zhang, Y (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Pulm & Crit Care Med, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM tangxj0531@126.com; zhang.yong@zs-hospital.sh.cn
OI Tang, Xinjun/0000-0002-1547-8723
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81800077]; Shanghai Municipal Key Clinical
   Specialty [shslczdzk02201]; Shanghai Top-Priority Clinical Key
   Disciplines Construction Project [2017ZZ02013]
FX National Natural Science Foundation of China, Grant/Award Number:
   81800077; Shanghai Municipal Key Clinical Specialty, Grant/Award Number:
   shslczdzk02201; Shanghai Top-Priority Clinical Key Disciplines
   Construction Project, Grant/Award Number: 2017ZZ02013
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   BENDER BS, 1992, J EXP MED, V175, P1143, DOI 10.1084/jem.175.4.1143
   Chen SM, 2020, LANCET, V395, P1305, DOI 10.1016/S0140-6736(20)30744-3
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Choi KW, 2003, ANN INTERN MED, V139, P715, DOI 10.7326/0003-4819-139-9-200311040-00005
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Dong X C, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P638, DOI 10.3760/cma.j.cn112338-20200221-00146
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Hong KH, 2018, THORAX, V73, P286, DOI 10.1136/thoraxjnl-2016-209313
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Lee N, 2009, J INFECT DIS, V200, P492, DOI 10.1086/600383
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   National Health Commission of the People's Republic of China, CHIN MAN GUID COVID
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2018, J INFECT DIS, V217, P1708, DOI 10.1093/infdis/jiy115
   World Health Organization, COR DIS COVID 19 OUT
   World Health Organization, CLIN MAN SEV AC RESP
   World Health Organization, COR DIS COVID 2019 S
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu J, 2020, CLIN INFECT DIS, V71, P706, DOI 10.1093/cid/ciaa199
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang WJ, 2020, J INFECTION, V80, P388, DOI 10.1016/j.jinf.2020.02.016
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 30
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-6981
EI 1752-699X
J9 CLIN RESPIR J
JI Clin. Respir. J.
PD NOV
PY 2020
VL 14
IS 11
BP 1067
EP 1075
DI 10.1111/crj.13243
EA AUG 2020
PG 9
WC Respiratory System
SC Respiratory System
GA OM3BK
UT WOS:000558981400001
PM 32750201
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Herman, A
   Matthews, M
   Mairlot, M
   Nobile, L
   Fameree, L
   Jacquet, LM
   Baeck, M
AF Herman, A.
   Matthews, M.
   Mairlot, M.
   Nobile, L.
   Fameree, L.
   Jacquet, L. -M.
   Baeck, M.
TI Drug reaction with eosinophilia and systemic symptoms syndrome in a
   patient with COVID-19
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Letter; Early Access
ID DRESS SYNDROME; HYDROXYCHLOROQUINE; AZITHROMYCIN
C1 [Herman, A.; Matthews, M.; Mairlot, M.; Nobile, L.; Fameree, L.; Baeck, M.] Univ Catholique Louvain UCLouvain, Clin Univ St Luc, Div Dermatol, Brussels, Belgium.
   [Jacquet, L. -M.] Univ Catholique Louvain UCLouvain, Clin Univ St Luc, Cardiac ICU Dept, Brussels, Belgium.
RP Herman, A (corresponding author), Univ Catholique Louvain UCLouvain, Clin Univ St Luc, Div Dermatol, Brussels, Belgium.
EM anne.herman@uclouvain.be
RI Herman, Anne/ABH-5814-2020
OI Herman, Anne/0000-0001-7000-1672
CR Bauer KA, 2011, PEDIATR DERMATOL, V28, P741, DOI 10.1111/j.1525-1470.2011.01558.x
   Girijala Raghavendra L, 2019, Proc (Bayl Univ Med Cent), V32, P277, DOI 10.1080/08998280.2019.1576094
   Girijala RL, 2019, J DRUGS DERMATOL, V18, P207
   Grandolfo M, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13499
   Kardaun SH, 2007, BRIT J DERMATOL, V156, P609, DOI 10.1111/j.1365-2133.2006.07704.x
   Mizukawa Y, 2019, J AM ACAD DERMATOL, V80, P670, DOI 10.1016/j.jaad.2018.08.052
   Schmutz JL, 2013, ANN DERMATOL VENER, V140, P75, DOI 10.1016/j.annder.2012.09.006
   Sriratanaviriyakul Narin, 2014, J Med Case Rep, V8, P332, DOI 10.1186/1752-1947-8-332
   Volpe A, 2008, CLIN RHEUMATOL, V27, P537, DOI 10.1007/s10067-007-0772-1
NR 9
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
EI 1468-3083
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
DI 10.1111/jdv.16838
EA AUG 2020
PG 2
WC Dermatology
SC Dermatology
GA MZ2UO
UT WOS:000558979600001
PM 32735713
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Silverman, RD
AF Silverman, Ross D.
TI The Role of Law and Ethics in Recent Preparedness and Response for
   Vaccine-Preventable Illness
SO PUBLIC HEALTH REPORTS
LA English
DT Article
DE child health; communicable diseases; COVID-19; ethics; health policy;
   infectious disease; law; legal issues; parenting; public health
   practice; SARS-CoV-2; school health; vaccines
C1 [Silverman, Ross D.] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, 1050 Wishard Blvd,RG 5126, Indianapolis, IN 46202 USA.
   [Silverman, Ross D.] Indiana Univ, Robert H McKinney Sch Law, Indianapolis, IN 46202 USA.
RP Silverman, RD (corresponding author), Indiana Univ, Richard M Fairbanks Sch Publ Hlth, 1050 Wishard Blvd,RG 5126, Indianapolis, IN 46202 USA.
EM rdsilver@iu.edu
OI Silverman, Ross D./0000-0003-4492-3096
CR American Public Health Association, 2019, ISS BRIEF PUBL HLTH
   BEAUCHAMP DE, 1985, HASTINGS CENT REP, V15, P28, DOI 10.2307/3563066
   Center for Disease Control, 1999, MMWR-MORBID MORTAL W, V48, P243
   Centers for Disease Control and Prevention, 2012, PRINC EDP PUBL HLTH
   Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P241
   Childress JF, 2002, J LAW MED ETHICS, V30, P170, DOI 10.1111/j.1748-720X.2002.tb00384.x
   Indiana Governor Eric Holcomb, 2020, EX ORD 20 02 DECL PU
   Mohanty S, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-1051
   Nuffield Council on Bioethics, 2007, PUBL HLTH ETH ISS
   Opel DJ, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-4230
   Saker A, 2019, CINCINNATI ENQUIRER
   Sisson P, 2019, LOS ANGELES TIMES
   Stanwyck C., 2007, Morbidity and Mortality Weekly Report, V56, P819
   Weixel N., 2019, HILL
   World Health Organization, 10 THREATS GLOB HLTH
   Yang YT, 2015, NEW ENGL J MED, V372, P1481, DOI 10.1056/NEJMp1501198
NR 16
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0033-3549
EI 1468-2877
J9 PUBLIC HEALTH REP
JI Public Health Rep.
PD NOV
PY 2020
VL 135
IS 6
BP 851
EP 855
AR 0033354920949532
DI 10.1177/0033354920949532
EA AUG 2020
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OK2NX
UT WOS:000559715300001
PM 32791033
OA Bronze
DA 2021-01-01
ER

PT J
AU Montero, F
   Martinez-Barrio, J
   Serrano-Benavente, B
   Gonzalez, T
   Rivera, J
   Collada, JM
   Castrejon, I
   Alvaro-Gracia, J
AF Montero, Fernando
   Martinez-Barrio, Julia
   Serrano-Benavente, Belen
   Gonzalez, Teresa
   Rivera, Javier
   Molina Collada, Juan
   Castrejon, Isabel
   alvaro-Gracia, Jose
TI Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory
   conditions: clinical characteristics of poor outcomes
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE COVID-19; Rheumatology; Autoimmune diseases; Poor outcomes
AB Objective To describe clinical characteristics of patients with rheumatic and musculoskeletal diseases (RMDs) and immunosuppressive therapies with Coronavirus disease 2019 (COVID-19) at an academic rheumatology center in Madrid and to identify baseline variables associated with a severe infection requiring hospitalization. Methods We identified SARS-CoV-2 positive cases by polymerase chain reaction performed at our center within an updated RMDs database in our clinic. Additional RMDs patients were identified when they contacted the clinic because of a positive infection. Data extraction included diagnosis, demographics, immunosuppressive treatment, comorbidities, and laboratory tests. Comparisons between patients with or without hospitalization were performed. Multivariate logistic regression was used to analyze associations between baseline variables and need for hospitalization. Results A total of 62 patients with COVID-19 and underlying RMDs were identified by April 24, 2020. Median age was 60.9 years, and 42% men. Forty-two patients required hospitalization; these were more frequently men, older and with comorbidities. There were no statistically significant between-group differences for rheumatologic diagnosis and for baseline use of immunosuppressive therapy except for glucocorticoids that were more frequent in hospitalized patients. Total deaths were 10 (16%) patients. In multivariate analysis, male sex (odds ratio [OR], 8.63;p = 0.018), previous lung disease (OR, 27.47;p = 0.042), and glucocorticoids use (> 5 mg/day) (OR, 9.95;p = 0.019) were significantly associated to hospitalization. Conclusion Neither specific RMD diagnoses or exposures to DMARDs were associated with increased odds of hospitalization. Being male, previous lung disease and exposure to glucocorticoids were associated with higher odds of hospitalization in RMDs patients.
C1 [Montero, Fernando; Martinez-Barrio, Julia; Serrano-Benavente, Belen; Gonzalez, Teresa; Rivera, Javier; Molina Collada, Juan; Castrejon, Isabel; alvaro-Gracia, Jose] Hosp Gen Univ Gregorio Maranon, Dept Rheumatol, Madrid 28007, Spain.
RP Montero, F (corresponding author), Hosp Gen Univ Gregorio Maranon, Dept Rheumatol, Madrid 28007, Spain.
EM fernandojose.montero@salud.madrid.org
RI Castrejon, Isabel/ABH-5293-2020
OI Montero, Fernando/0000-0003-4594-7663; Molina Collada,
   Juan/0000-0001-5191-7802
CR Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Conticini Edoardo, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217681, 10.1136/annrheumdis-2020-218761]
   D'Silva KM, 2020, ANN RHEUM DIS, V79, P1156, DOI [10.1136/annrheumdis-2020-217888, 10.1136/annrheumdis-2020-218196, 10.1136/annrheumdis-2020-218179, 10.1136/annrheumdis-2020-218431]
   Figueroa-Parra G, 2020, ANN RHEUM DIS, V79, P839, DOI 10.1136/annrheumdis-2020-217322
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Gobierno de Espana. Ministerio de Sanidad. Secretaria General de sanidad. Direccion General de salud publica calidad e informacion. Centro de Coordinacion de Alertas y Emergencias Sanitarias. (Government of Spain. Ministry of Health. General Secretary of Health. General Directorate of Public Health Quality and Information. Center for Coordination of Health Alerts and Emergencies), 2020, ENF COR COVID 19 COR
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Michelena X, 2020, SEMIN ARTHRITIS RHEU, V50, P564, DOI 10.1016/j.semarthrit.2020.05.001
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Pablos JL, 2020, ANN RHEUM DIS, V79, P1544, DOI [10.1136/annrheumdis-2020-217763, 10.1136/annrheumdis-2020-218296]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 19
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0172-8172
EI 1437-160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD OCT
PY 2020
VL 40
IS 10
BP 1593
EP 1598
DI 10.1007/s00296-020-04676-4
EA AUG 2020
PG 6
WC Rheumatology
SC Rheumatology
GA NF2MU
UT WOS:000559405200002
PM 32794113
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Feld, J
   Tremblay, D
   Thibaud, S
   Kessler, A
   Naymagon, L
AF Feld, Jonathan
   Tremblay, Douglas
   Thibaud, Santiago
   Kessler, Alaina
   Naymagon, Leonard
TI Ferritin levels in patients with COVID-19: A poor predictor of mortality
   and hemophagocytic lymphohistiocytosis
SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
LA English
DT Article
DE COVID-19; cytokines; ferritin; hemophagocytic lymphohistiocytosis;
   interleukin-6
AB Introduction A hyperinflammatory environment has been a hallmark of COVID-19 infection and is thought to be a key mediator of morbidity. Elevated ferritin has been observed in many patients with COVID-19. Several retrospective studies have shown ferritin levels can be correlated and predictive of poor outcomes in COVID-19, though a rigorous analysis has been lacking. Methods A retrospective analysis of 942 adult COVID-19 patients admitted in March 2020 at a large New York City health system with available ferritin levels. Results The primary outcome, all-cause mortality, was observed in 265 (28.1%) patients. Patients who died had a significantly higher median admission and maximum ferritin levels than those who did not. However, death was poorly predicted by admission and maximum ferritin levels on receiver operator curve (ROC) analysis, with AUCs of 0.677 and 0.638, respectively. AUCs increased when the cohort was limited to progressively younger patients. Ferritin levels were minimally better at predicting our secondary outcomes. These included mechanical ventilation, observed in 280 (29.7%) patients with an ROC yielding an area under the curve (AUC) of 0.769, and new renal replacement therapy, observed in 80 (8.5%) of patients with an ROC yielding an AUC of 0.787. We also performed a subset analysis on 22 patients with ferritins >20 000 ng/mL. None of the patients met HLH-2004 diagnostic criteria. Fifteen (68.2%) of these patients had suspected or confirmed bacterial infections. Conclusions Though many patients with COVID-19 present with hyperferritinemia, elevated ferritin levels are not accurate predictors of outcomes and do not appear to be indicative of hemophagocytic lymphohistiocytosis.
C1 [Feld, Jonathan; Tremblay, Douglas; Thibaud, Santiago; Kessler, Alaina; Naymagon, Leonard] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, 1 Gustave L Levy Pl,Box 1079, New York, NY 10029 USA.
RP Feld, J (corresponding author), Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, 1 Gustave L Levy Pl,Box 1079, New York, NY 10029 USA.
EM jonathan.feld@mountsinai.org
OI Kessler, Alaina/0000-0001-9058-5118; Naymagon,
   Leonard/0000-0002-6312-1307; Tremblay, Douglas/0000-0003-2584-6953
CR Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Colafrancesco S, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102573
   Dimopoulos G, 2020, CELL HOST MICROBE, V28, P117, DOI 10.1016/j.chom.2020.05.007
   Falk J, 2020, RMD OPEN, V6
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039
   Hou H, 2020, CLIN EXP IMMUNOL, V201, P76, DOI 10.1111/cei.13450
   Kernan KF, 2017, INT IMMUNOL, V29, P401, DOI 10.1093/intimm/dxx031
   Li YL, 2020, LAB INVEST, V100, P794, DOI 10.1038/s41374-020-0431-6
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   Radmanesh F, 2020, J CLIN NEUROSCI, V76, P236, DOI 10.1016/j.jocn.2020.04.054
   Ramos Garcia PC, 2007, ACTA PAEDIATR, V96, P1829, DOI 10.1111/j.1651-2227.2007.00564.x
   Rombola G, 2020, J NEPHROL, V33, P401, DOI 10.1007/s40620-020-00737-w
   Rosario C, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-185
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529
   Sun LJ, 2020, J MED VIROL, V92, P2055, DOI 10.1002/jmv.25966
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 24
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-5521
EI 1751-553X
J9 INT J LAB HEMATOL
JI Int. J. Lab. Hematol.
PD DEC
PY 2020
VL 42
IS 6
BP 773
EP 779
DI 10.1111/ijlh.13309
EA AUG 2020
PG 7
WC Hematology
SC Hematology
GA OS3BH
UT WOS:000558902400001
PM 32790918
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Yahyaoui, Y
   Ghodhbani, Z
   Hamdi, A
   Letaief, F
   Zenzri, Y
   Ben Said, A
   Blouza, I
   Mezlini, A
AF Yahyaoui, Yosra
   Ghodhbani, Zahra
   Hamdi, Adel
   Letaief, Feryel
   Zenzri, Yosr
   Ben Said, Azza
   Blouza, Imen
   Mezlini, Amel
TI Suggestion of Tunisia's medical oncologist in the management of breast
   cancer during COVID-19 pandemic
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Article
DE COVID-19; breast cancer; Tunisia; chemotherapy; medical oncology
AB Cancer patients are at higher risk to be infected with COVID-19 and to develop a more severe form. Breast cancer (BC) treatments, including chemotherapy (CT), targeted therapy and immunotherapy can weaken the immune system and possibly cause lung problems. For all these reasons Salah Azaiez Institute's department of Medical Oncology took drastic actions to protect patients. In this article we will discuss protocol adjustments taken duringthe COVID-19 pandemicfor breast cancer patients.
C1 [Yahyaoui, Yosra; Ghodhbani, Zahra; Letaief, Feryel; Zenzri, Yosr; Mezlini, Amel] Univ Tunis El Manar, Salah Azaiez Inst, Dept Med Oncol, Tunis, Tunisia.
   [Hamdi, Adel; Ben Said, Azza; Blouza, Imen] Fac Pharm Monastir, Salah Azaiez Inst, Dept Pharm, Monastir, Tunisia.
RP Ghodhbani, Z (corresponding author), Sokra Rue Ibn Neji St,01Bis, Tunis, Tunisia.
EM zahraghodhbani@gmail.com
RI Yahyaoui, Yosra/AAY-1747-2020
OI Yahyaoui, Yosra/0000-0002-8707-4613; HAMDI, Adel/0000-0002-9223-9259
CR Gligorov J, 2020, B CANCER, V107, P528, DOI 10.1016/j.bulcan.2020.03.008
NR 1
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078-1552
EI 1477-092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD OCT
PY 2020
VL 26
IS 7
BP 1732
EP 1734
AR 1078155220948943
DI 10.1177/1078155220948943
EA AUG 2020
PG 3
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA OC6XO
UT WOS:000559710100001
PM 32791938
OA Bronze
DA 2021-01-01
ER

PT J
AU Sansom-Daly, UM
   Bradford, N
AF Sansom-Daly, Ursula M.
   Bradford, Natalie
TI Grappling with the "human" problem hiding behind the technology:
   Telehealth during and beyond COVID-19
SO PSYCHO-ONCOLOGY
LA English
DT Letter
DE adolescent and young adult; COVID-19; implementation science; paediatric
   oncology; palliative care; psychological therapy; psycho-oncology;
   survivorship; telehealth; videoconferencing
ID YOUNG-ADULTS; CANCER; ADOLESCENTS; CARE
C1 [Sansom-Daly, Ursula M.] Univ New South Wales UNSW Med, UNSW Sydney, Sch Womens & Childrens Hlth, Kensington, NSW, Australia.
   [Sansom-Daly, Ursula M.] Sydney Childrens Hosp, Behav Sci Unit, Kids Canc Ctr, Level 1,South Wing,High St, Randwick, NSW 2031, Australia.
   [Sansom-Daly, Ursula M.] Prince Wales Hosp, Sydney Youth Canc Serv, Randwick, NSW, Australia.
   [Bradford, Natalie] Ctr Healthcare Transformat, Brisbane, Qld, Australia.
   [Bradford, Natalie] Ctr Childrens Hlth Res, Sch Nursing, Brisbane, Qld, Australia.
RP Sansom-Daly, UM (corresponding author), Sydney Childrens Hosp, Behav Sci Unit, Kids Canc Ctr, Level 1,South Wing,High St, Randwick, NSW 2031, Australia.
EM ursula@unsw.edu.au
RI Bradford, Natalie/ABB-9075-2020
OI Bradford, Natalie/0000-0003-1602-4544; Sansom-Daly,
   Ursula/0000-0003-4200-8900
FU Cancer Council New South WalesCancer Council New South Wales [PG16-02];
   Cancer Institute NSW [14/ECF/1-11]; Kids Cancer Alliance, Australia;
   Kids with Cancer Foundation, Australia; National Health and Medical
   Research Council AustraliaNational Health and Medical Research Council
   of Australia [APP1111800, APP1174733]; Cancer Council NSWCancer Council
   New South Wales [PG16-02]
FX Cancer Council New South Wales, Grant/Award Number: Program Grant
   PG16-02 with the support of the Est; Cancer Institute NSW, Grant/Award
   Number: 14/ECF/1-11; Kids Cancer Alliance, Australia, Grant/Award
   Number: n/a; Kids with Cancer Foundation, Australia; National Health and
   Medical Research Council Australia, Grant/Award Numbers: APP1111800,
   APP1174733; Cancer Council NSW, Grant/Award Number: PG16-02
CR Bradford NK, 2016, RURAL REMOTE HEALTH, V16
   Bradford NK, 2014, J TELEMED TELECARE, V20, P360, DOI 10.1177/1357633X14552370
   Chalmers JA, 2018, JMIR RES PROTOC, V7, DOI 10.2196/resprot.8886
   Connolly SL, 2020, CLIN PSYCHOL-SCI PR, V27, DOI 10.1111/cpsp.12311
   Holland LR, 2020, J ADOLESC YOUNG ADUL, DOI 10.1089/jayao.2020.0027
   McGill BC, 2017, J ADOLESC YOUNG ADUL, V6, P568, DOI 10.1089/jayao.2017.0001
   Orlando JF, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221848
   Sansom-Daly UM, 2019, PSYCHO-ONCOLOGY, V28, P284, DOI 10.1002/pon.4938
   Sansom-Daly UM, 2016, JMIR MENT HEALTH, V3, DOI 10.2196/mental.5481
   Sansom-Daly UM, 2015, AUST PSYCHOL, V50, P271, DOI 10.1111/ap.12112
NR 10
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD SEP
PY 2020
VL 29
IS 9
SI SI
BP 1404
EP 1408
DI 10.1002/pon.5462
EA AUG 2020
PG 5
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
   Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA NL5YW
UT WOS:000559068000001
PM 32779776
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mulligan, MJ
   Lyke, KE
   Kitchin, N
   Absalon, J
   Gurtman, A
   Lockhart, S
   Neuzil, K
   Raabe, V
   Bailey, R
   Swanson, KA
   Li, P
   Koury, K
   Kalina, W
   Cooper, D
   Fontes-Garfias, C
   Shi, PY
   Tureci, O
   Tompkins, KR
   Walsh, EE
   Frenck, R
   Falsey, AR
   Dormitzer, PR
   Gruber, WC
   Sahin, U
   Jansen, KU
AF Mulligan, Mark J.
   Lyke, Kirsten E.
   Kitchin, Nicholas
   Absalon, Judith
   Gurtman, Alejandra
   Lockhart, Stephen
   Neuzil, Kathleen
   Raabe, Vanessa
   Bailey, Ruth
   Swanson, Kena A.
   Li, Ping
   Koury, Kenneth
   Kalina, Warren
   Cooper, David
   Fontes-Garfias, Camila
   Shi, Pei-Yong
   Tuereci, Oezlem
   Tompkins, Kristin R.
   Walsh, Edward E.
   Frenck, Robert
   Falsey, Ann R.
   Dormitzer, Philip R.
   Gruber, William C.
   Sahin, Ugur
   Jansen, Kathrin U.
TI Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
SO NATURE
LA English
DT Article; Early Access
ID IMMUNOGENICITY; SAFETY; DOMAIN
AB In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(1), a pandemic. With rapidly accumulating numbers of cases and deaths reported globally(2), a vaccine is urgently needed. Here we report the available safety, tolerability and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose-escalation study (ClinicalTrials.gov identifier NCT04368728) among 45 healthy adults (18-55 years of age), who were randomized to receive 2 doses-separated by 21 days-of 10 mu g, 30 mu g or 100 mu g of BNT162b1. BNT162b1 is a lipid-nanoparticle-formulated, nucleoside-modified mRNA vaccine that encodes the trimerized receptor-binding domain (RBD) of the spike glycoprotein of SARS-CoV-2. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. A second vaccination with 100 mu g was not administered because of the increased reactogenicity and a lack of meaningfully increased immunogenicity after a single dose compared with the 30-mu g dose. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second dose. Geometric mean neutralizing titres reached 1.9-4.6-fold that of a panel of COVID-19 convalescent human sera, which were obtained at least 14 days after a positive SARS-CoV-2 PCR. These results support further evaluation of this mRNA vaccine candidate.
   In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose.
C1 [Mulligan, Mark J.; Raabe, Vanessa] NYU, Langone Vaccine Ctr, New York, NY USA.
   [Mulligan, Mark J.; Raabe, Vanessa] NYU, Grossman Sch Med, New York, NY USA.
   [Lyke, Kirsten E.; Neuzil, Kathleen] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
   [Kitchin, Nicholas; Lockhart, Stephen; Bailey, Ruth] Pfizer Inc, Vaccine Res & Dev, Hurley, England.
   [Absalon, Judith; Gurtman, Alejandra; Swanson, Kena A.; Koury, Kenneth; Kalina, Warren; Cooper, David; Tompkins, Kristin R.; Dormitzer, Philip R.; Gruber, William C.; Jansen, Kathrin U.] Pfizer Inc, Vaccine Res & Dev, Pearl River, NY 10965 USA.
   [Li, Ping] Pfizer Inc, Vaccine Res & Dev, Collegeville, PA USA.
   [Fontes-Garfias, Camila; Shi, Pei-Yong] Univ Texas Med Branch, Galveston, TX 77555 USA.
   [Tuereci, Oezlem; Sahin, Ugur] BioNTech, Mainz, Germany.
   [Walsh, Edward E.; Falsey, Ann R.] Univ Rochester, Rochester, NY USA.
   [Walsh, Edward E.; Falsey, Ann R.] Rochester Gen Hosp, Rochester, NY 14621 USA.
   [Frenck, Robert] Cincinnati Childrens Hosp, Cincinnati, OH USA.
RP Absalon, J (corresponding author), Pfizer Inc, Vaccine Res & Dev, Pearl River, NY 10965 USA.
EM judith.absalon@pfizer.com
OI Raabe, Vanessa/0000-0003-2579-1104
FU NYU CTSA grant from the National Center for Advancing Translational
   Sciences, National Institutes of Health [UL1 TR001445]; BioNTech
FX We thank C. Monahan and D. Gantt for writing and editorial support; H.
   Ma, J. Trammel and K. Challagali for statistical analysis support in the
   generation of this manuscript; all of the participants who volunteered
   for this study; A. Kottkamp, R. Herati, R. Pellet Madan, M. Olson, M.
   Samanovic-Golden, E. Cohen, A. Cornelius, L. Frye, H. Youn, B. Fran, K.
   Ballani, N. Veling, J. Erb, M. Ali, L. Zhao, S. Rettig, H. Khan, H.
   Lambert, K. Hu, J. Hyde, M. McArthur, J. Ortiz, R. Rapaka, L. Wadsworth,
   G. Cummings, T. Robinson, N. Greenberg, L. Chrisley, W. Somrajit, J.
   Marron, C. Thomas, K. Brooks, L. Turek, P. Farley, S. Eddington, P.
   Komninou, M. Reymann, K. Strauss, B. Shrestha, S. Joshi, R. Barnes, R.
   Sukhavasi, M. Lee, A. Kwon, T. Sharp, E. Pierce, M. Criddle, A. Cline,
   S. Parker, M. Dickey, K. Buschle, A. Cawein, J. L. Perez, H. Seehra, D.
   Tresnan, R. Maroko, H. Smith, S. Tweedy, A. Jones, G. Adams, R. Malick,
   E. Worobetz, E. Weaver, L. Zhang, C. Devlin, D. Boyce, E. Harkins Tull,
   M. Boaz, M. Cruz, C. Rosenbaum, C. Miculka, A. Kuhn, F. Bates, P.
   Strecker, A. Kemmer-Bruck, and the Vaccines Clinical Assay Team and
   Vaccines Assay Development Team for their assistance during this study.
   Staffing services were supported in part by an NYU CTSA grant (UL1
   TR001445) from the National Center for Advancing Translational Sciences,
   National Institutes of Health. BioNTech is the sponsor of the study.
   Pfizer was responsible for the design, data collection, data analysis,
   data interpretation and writing of the report. The corresponding authors
   had full access to all of the data in the study and had final
   responsibility for the decision to submit the data for publication. All
   study data were available to all authors.
CR Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074
   Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Coronavirus-Resources-Center, 2020, COVID 19 DASHB CTR S
   Foster GR, 2004, J IMMUNOL, V173, P1663, DOI 10.4049/jimmunol.173.3.1663
   Guthe S, 2004, J MOL BIOL, V337, P905, DOI 10.1016/j.jmb.2004.02.020
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Hopkins RJ, 2013, VACCINE, V31, P3051, DOI 10.1016/j.vaccine.2013.04.063
   Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200
   Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300
   Lai LL, 2015, JAMA-J AM MED ASSOC, V313, P1249, DOI 10.1001/jama.2015.1995
   Muruato AE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17892-0
   Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007
   Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436
   Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963
   Regules JA, 2017, NEW ENGL J MED, V376, P330, DOI 10.1056/NEJMoa1414216
   Sahin U, 2020, CONCURRENT HUMAN ANT, DOI [10.1101/2020.07.17.20140533, DOI 10.1101/2020.07.17.20140533]
   Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003
   Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278
   Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2
   Walsh Edward E, 2020, medRxiv, DOI 10.1101/2020.08.17.20176651
   World Health Organization, 2020, 154 WHO
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Zost SJ, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0998-x
NR 26
TC 32
Z9 30
U1 59
U2 59
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
DI 10.1038/s41586-020-2639-4
EA AUG 2020
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NY1CG
UT WOS:000576135500001
PM 32785213
DA 2021-01-01
ER

PT J
AU Ma, YM
   Zeng, HH
   Zhan, ZJ
   Lu, HH
   Zeng, ZH
   He, CJ
   Liu, XM
   Chen, C
   Qin, QW
   He, J
   Zhou, ZG
   Huang, P
   Jiang, MY
   Deng, DD
   Liao, X
   Xiang, Z
   Huang, XY
   Chen, Y
   Chen, P
AF Ma, Yiming
   Zeng, Huihui
   Zhan, Zijie
   Lu, Huanhuan
   Zeng, Zihang
   He, Chenjie
   Liu, Xiangming
   Chen, Chen
   Qin, Qingwu
   He, Jia
   Zhou, Zhiguo
   Huang, Peng
   Jiang, Mingyan
   Deng, Dingding
   Liao, Xin
   Xiang, Zhi
   Huang, Xiaoying
   Chen, Yan
   Chen, Ping
TI Corticosteroid Use in the Treatment of COVID-19: A Multicenter
   Retrospective Study in Hunan, China
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID-19; corticosteroid; treatment; antibiotic; viral shedding
ID ACUTE RESPIRATORY SYNDROME; CYTOKINE STORM; CORONAVIRUS; SARS; PIGS
AB Background Coronavirus disease 2019 (COVID-19) has developed into a worldwide pandemic. This study aimed to retrospectively describe the use of corticosteroids in treating COVID-19. Methods For this multicenter retrospective study, medical records from 488 symptomatic COVID-19 patients were reviewed. Patients were divided into severe and nonsevere groups. Baseline characteristics, signs and symptoms, laboratory findings, treatments, and disease outcomes were compared. Specific data for corticosteroid treatment were further analyzed. Results Four hundred fifty COVID-19 patients were included in this study, including 82 severe patients and 368 nonsevere cases. Out of the 450 patients, 126 (28.0%) received corticosteroid treatment. In the 126 patients treated with corticosteroids, the median daily dose of corticosteroid therapy was 56.6 [interquartile range (IQR): 40.0-78.4] mg and median corticosteroid therapy duration was 5.0 (IQR: 3.0-7.0) days. Among nonsevere cases, patients treated with corticosteroids were significantly older in comparison with patients who did not receive corticosteroid treatment (p<0.01); the proportion of patients receiving antibiotic therapy in the corticosteroid group was significantly higher than that in the noncorticosteroid group (p<0.001); hospitalization length and duration of viral shedding were significantly longer in patients in the corticosteroid group than in the noncorticosteroid group after adjusting for age, sex, and comorbidities (p<0.05). In severe cases, patients treated with corticosteroids were significantly older and comorbidities at admission were significantly more common in patients receiving corticosteroid treatment (p<0.05); the proportion of patients receiving antibiotic therapy in the corticosteroid group was significantly higher than that in the noncorticosteroid group (p<0.001); no significant difference in hospitalization length or viral shedding duration was found between two groups after adjusting for age, sex, and comorbidities (p>0.05). Conclusion Our study indicates that corticosteroids are regarded as one of treatments in the general clinical practice of COVID-19. However, corticosteroid use may be accompanied by increased use of antibiotics, longer hospitalization, and prolonged viral shedding.
C1 [Ma, Yiming; Zeng, Huihui; Zhan, Zijie; Lu, Huanhuan; Zeng, Zihang; He, Chenjie; Liu, Xiangming; Qin, Qingwu; Chen, Yan; Chen, Ping] Cent South Univ, Xiangya Hosp 2, Dept Resp & Crit Care Med, Changsha, Peoples R China.
   [Chen, Chen] Cent South Univ, Xiangya Hosp 2, Dept Thorac Surg, Changsha, Peoples R China.
   [He, Jia] Cent South Univ, Xiangya Hosp 2, Dept Cardiol, Changsha, Peoples R China.
   [Zhou, Zhiguo] First Hosp Changsha, Dept Resp Med, Changsha, Peoples R China.
   [Huang, Peng] Zhuzhou Cent Hosp, Dept Resp Med, Zhuzhou, Peoples R China.
   [Jiang, Mingyan] Xiangtan Cent Hosp, Dept Resp & Crit Med, Xiangtan, Peoples R China.
   [Deng, Dingding] Shaoyang Univ, Dept Resp Med, Affiliated Hosp 1, Shaoyang, Peoples R China.
   [Liao, Xin] Cent Hosp Shaoyang, Dept Resp Med, Shaoyang, Peoples R China.
   [Xiang, Zhi] Huaihua First Peoples Hosp, Dept Resp Med, Huaihua, Peoples R China.
   [Huang, Xiaoying] Loudi Cent Hosp, Dept Resp Med, Loudi, Peoples R China.
RP Chen, Y; Chen, P (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Resp & Crit Care Med, Changsha, Peoples R China.
EM chenyan99727@csu.edu.cn; pingchen0731@csu.edu.cn
FU Hunan Province's Innovative Novel Coronavirus Pneumonia Emergency Major
   Project [2020SK3013, 2020SK3014]; Emergency Project of Prevention and
   Control for COVID-19 of Central South University [502701002]
FX This project carried out with the support of Hunan Province's Innovative
   Novel Coronavirus Pneumonia Emergency Major Project (No. 2020SK3013 and
   No. 2020SK3014) and Emergency Project of Prevention and Control for
   COVID-19 of Central South University (No. 502701002).
CR Alfaraj SH, 2019, TRAVEL MED INFECT DI, V29, P48, DOI 10.1016/j.tmaid.2019.03.004
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Jang TN, 2004, J INFECTION, V48, P23, DOI 10.1016/j.jinf.2003.09.004
   Jung K, 2007, J VIROL, V81, P13681, DOI 10.1128/JVI.01702-07
   Kim ES, 2016, J KOREAN MED SCI, V31, P1717, DOI 10.3346/jkms.2016.31.11.1717
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   National Health Commission of the People's Republic of China, 2020, CHIN MAN GUID COVID
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Wang HJ, 2003, NEW ENGL J MED, V349, P507, DOI 10.1056/NEJM200307313490519
   Wang Y., 2020, EARLY LOW DOSE SHORT, DOI [10.1101/2020.03.06.20032342., DOI 10.1101/2020.03.06.20032342, 10.1101/2020.03.06. 20032342.]
   WHO, 22 WHO
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yam LYC, 2007, J INFECTION, V54, P28, DOI 10.1016/j.jinf.2006.01.005
   Zhang XS, 2008, J VIROL, V82, P4420, DOI 10.1128/JVI.02190-07
   Zhao J P, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE007, DOI 10.3760/cma.j.issn.1001-0939.2020.0007
   Zuo Y, 2020, J MED VIROL, V92, P2666, DOI 10.1002/jmv.26127
NR 27
TC 2
Z9 2
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 12
PY 2020
VL 11
AR 1198
DI 10.3389/fphar.2020.01198
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NI4UN
UT WOS:000565348900001
PM 32903363
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bhattacharjee, A
   Vishwakarma, GK
   Banerjee, S
   Shukla, S
AF Bhattacharjee, Atanu
   Vishwakarma, Gajendra K.
   Banerjee, Souvik
   Shukla, Sharvari
TI Disease progression of cancer patients during COVID-19 pandemic: a
   comprehensive analytical strategy by time-dependent modelling
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Article
DE COVID-19; Accelerated failure time; Proportional Hazard model; Bayesian;
   Auto-regression
ID SURVIVAL ANALYSIS; COMPETING RISKS; CLINICAL-TRIAL
AB Background As the whole world is experiencing the cascading effect of a new pandemic, almost every aspect of modern life has been disrupted. Because of health emergencies during this period, widespread fear has resulted in compromised patient safety, especially for patients with cancer. It is very challenging to treat such cancer patients because of the complexity of providing care and treatment, along with COVID-19. Hence, an effective treatment comparison strategy is needed. We need to have a handy tool to understand cancer progression in this unprecedented scenario. Linking different events of cancer progression is the need of the hour. It is a huge challenge for the development of new methodology. Methods This article explores the time lag effect and makes a statistical inference about the best experimental arm using Accelerated Failure Time (AFT) model and regression methods. The work is presented as the occurrence of other events as a hazard rate after the first event (relapse). The time lag effect between the events is linked and analysed. Results The results were presented as a comprehensive analytical strategy by joining all disease progression. An AFT model applied with the transition states, and the dependency structure between the gap times was used by the auto-regression model. The effects of arms were compared using the coefficient of auto-regression and accelerated failure time (AFT) models. Conclusions We provide the solutions to overcome the issue with intervals between two consecutive events in motivating head and neck cancer (HNC) data. COVID-19 is not going to leave us soon. We have to conduct several cancer clinical trials in the presence of COVID-19. A comprehensive analytical strategy to analyse cancer clinical trial data during COVID-19 pandemic is presented.
C1 [Bhattacharjee, Atanu] Tata Mem Hosp, Ctr Canc Epidemiol, Sect Biostat, Mumbai, Maharashtra, India.
   [Bhattacharjee, Atanu] Homi Bhabha Natl Inst, Mumbai, Maharashtra, India.
   [Vishwakarma, Gajendra K.; Banerjee, Souvik] Indian Inst Technol ISM, Dept Math & Comp, Dhanbad 826004, Bihar, India.
   [Shukla, Sharvari] Symbiosis Int Univ, Symbiosis Stat Inst, Pune, Maharashtra, India.
RP Vishwakarma, GK (corresponding author), Indian Inst Technol ISM, Dept Math & Comp, Dhanbad 826004, Bihar, India.
EM vishwagk@rediffmail.com
OI Vishwakarma, Gajendra/0000-0002-2804-4334
FU Science & Technology, Government of India [MSC/2020/000063]
FX Authors are thankful to the Science & Technology, Government of India,
   for providing necessary support to carry out the present research work
   through project No. MSC/2020/000063 but not for APC.
CR AKAIKE H, 1979, BIOMETRIKA, V66, P237
   AKAIKE H, 1981, J ECONOMETRICS, V16, P3, DOI 10.1016/0304-4076(81)90071-3
   Andersen P. K., 2012, STAT MODELS BASED CO
   Andersen PK, 2002, STAT METHODS MED RES, V11, P91, DOI 10.1191/0962280202SM276ra
   Ando T., 2010, BAYESIAN MODEL SELEC
   Bhattacharjee A, 2020, HEAD NECK-J SCI SPEC, V42, P1173, DOI 10.1002/hed.26196
   Bhattacharjee A, 2015, J STAT MANAG SYST, V18, P381, DOI 10.1080/09720510.2014.961770
   COX DR, 1972, J R STAT SOC B, V34, P187
   George B, 2014, J NUCL CARDIOL, V21, P686, DOI 10.1007/s12350-014-9908-2
   Hougaard P., 2012, ANAL MULTIVARIATE SU
   Kalbfleisch JD, 2011, STAT ANAL FAILURE TI
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kasza J, 2014, RESPIROLOGY, V19, P483, DOI 10.1111/resp.12281
   LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177
   Moujaess E, 2020, CRIT REV ONCOL HEMAT, V150, DOI 10.1016/j.critrevonc.2020.102972
   Poortmans PM, 2020, LANCET, V395, P1884, DOI 10.1016/S0140-6736(20)31240-X
   Pothuri B, 2020, GYNECOL ONCOL, V158, P16, DOI 10.1016/j.ygyno.2020.04.694
   Putter H, 2018, STAT METHODS MED RES, V27, P2081, DOI 10.1177/0962280216674497
   van der Linde A, 2005, STAT NEERL, V59, P45
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   WEI LJ, 1992, STAT MED, V11, P1871, DOI 10.1002/sim.4780111409
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
NR 22
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD AUG 12
PY 2020
VL 20
IS 1
AR 209
DI 10.1186/s12874-020-01090-z
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA NF8BS
UT WOS:000563518700002
PM 32787822
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cro, S
   Morris, TP
   Kahan, BC
   Cornelius, VR
   Carpenter, JR
AF Cro, Suzie
   Morris, Tim P.
   Kahan, Brennan C.
   Cornelius, Victoria R.
   Carpenter, James R.
TI A four-step strategy for handling missing outcome data in randomised
   trials affected by a pandemic
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Article
DE Missing data; Pandemic; Coronavirus SARS-CoV-2; Covid-19; Randomised
   trials; Estimands; Sensitivity analysis; Controlled multiple imputation
ID SENSITIVITY-ANALYSIS; EVENT DATA; IMPUTATION; INFERENCE; ASSUMPTION
AB Background The coronavirus pandemic (Covid-19) presents a variety of challenges for ongoing clinical trials, including an inevitably higher rate of missing outcome data, with new and non-standard reasons for missingness. International drug trial guidelines recommend trialists review plans for handling missing data in the conduct and statistical analysis, but clear recommendations are lacking. Methods We present a four-step strategy for handling missing outcome data in the analysis of randomised trials that are ongoing during a pandemic. We consider handling missing data arising due to (i) participant infection, (ii) treatment disruptions and (iii) loss to follow-up. We consider both settings where treatment effects for a 'pandemic-free world' and 'world including a pandemic' are of interest. Results In any trial, investigators should; (1) Clarify the treatment estimand of interest with respect to the occurrence of the pandemic; (2) Establish what data are missing for the chosen estimand; (3) Perform primary analysis under the most plausible missing data assumptions followed by; (4) Sensitivity analysis under alternative plausible assumptions. To obtain an estimate of the treatment effect in a 'pandemic-free world', participant data that are clinically affected by the pandemic (directly due to infection or indirectly via treatment disruptions) are not relevant and can be set to missing. For primary analysis, a missing-at-random assumption that conditions on all observed data that are expected to be associated with both the outcome and missingness may be most plausible. For the treatment effect in the 'world including a pandemic', all participant data is relevant and should be included in the analysis. For primary analysis, a missing-at-random assumption - potentially incorporating a pandemic time-period indicator and participant infection status - or a missing-not-at-random assumption with a poorer response may be most relevant, depending on the setting. In all scenarios, sensitivity analysis under credible missing-not-at-random assumptions should be used to evaluate the robustness of results. We highlight controlled multiple imputation as an accessible tool for conducting sensitivity analyses. Conclusions Missing data problems will be exacerbated for trials active during the Covid-19 pandemic. This four-step strategy will facilitate clear thinking about the appropriate analysis for relevant questions of interest.
C1 [Cro, Suzie; Cornelius, Victoria R.] Imperial Coll London, Imperial Clin Trials Unit, Stadium House,68 Wood Lane, London, England.
   [Morris, Tim P.; Kahan, Brennan C.; Carpenter, James R.] London Sch Hyg & Trop Med, Dept Med Stat, London, England.
   [Morris, Tim P.; Carpenter, James R.] UCL, MRC Clin Trials Unit, 90 High Holborn, London, England.
RP Cro, S (corresponding author), Imperial Coll London, Imperial Clin Trials Unit, Stadium House,68 Wood Lane, London, England.
EM s.cro@imperial.ac.uk
OI Morris, Tim/0000-0001-5850-3610
FU Medical Research CouncilMedical Research Council UK (MRC)
   [MC_UU_12023/21, MC_UU_12023/29]
FX We thank Professor Ian White, Dr Michelle Clements and two anonymous
   reviewers for their helpful comments on the draft manuscript. We thank
   David Charteris and the ASCOT trial team for the use of their trial as
   an example within this manuscript. We also thank all the researchers and
   trial participants who continue to be involved in ongoing trials during
   unexpected, challenging, pandemic times. Tim P. Morris, Brennan C. Kahan
   and James R. Carpenter were supported by the Medical Research Council
   (grant numbers MC_UU_12023/21 and MC_UU_12023/29). We note that
   acknowledgment does not imply endorsement.
CR Akacha M, 2016, PHARM STAT, V15, P4, DOI 10.1002/pst.1720
   [Anonymous], 2010, GUID MISS DAT CONF C
   [Anonymous], 2010, PREV TREATM MISS DAT
   [Anonymous], 2020, IMPL COR DIS COVID 1
   [Anonymous], 2020, MAN CLIN TRIALS COR
   [Anonymous], 2019, ADD EST SENS AN CLIN
   [Anonymous], 1998, STAT PRINC CLIN TRIA
   Atkinson A, 2019, PHARM STAT, V18, P645, DOI 10.1002/pst.1954
   Banerjee PJ, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1445-7
   Carpenter JR, 2013, J BIOPHARM STAT, V23, P1352, DOI 10.1080/10543406.2013.834911
   Cro S, 2020, STAT MED, V39, P2815, DOI 10.1002/sim.8569
   Cro S, 2019, J R STAT SOC A STAT, V182, P623, DOI 10.1111/rssa.12423
   Degtyarev E, 2020, STAT BIOPHARM RES, V12, P427, DOI 10.1080/19466315.2020.1785543
   Dunn G, 2007, STAT MED, V26, P4719, DOI 10.1002/sim.2891
   Dunn G, 2015, HEALTH TECHNOL ASSES, V19, DOI 10.3310/hta19930
   FDA, 2020, GUID COND CLIN TRIAL
   Gao F, 2017, PHARM STAT, V16, P424, DOI 10.1002/pst.1821
   Hernan MA, 2006, EPIDEMIOLOGY, V17, P360, DOI 10.1097/01.ede.0000222409.00878.37
   Jackson D, 2014, STAT MED, V33, P4681, DOI 10.1002/sim.6274
   Keene ON, 2014, PHARM STAT, V13, P258, DOI 10.1002/pst.1624
   Kenward M. G., 2015, Clinical Investigation, V5, P311, DOI 10.4155/cli.14.132
   Kenward MG, 2007, MISSING DATA RANDOMI, P199
   Latimer N, 2014, 16 NICE DSU
   Leacy FP, 2017, AM J EPIDEMIOL, V185, P304, DOI 10.1093/aje/kww107
   Lipkovich I, 2016, PHARM STAT, V15, P216, DOI 10.1002/pst.1738
   Lu KF, 2015, STAT BIOPHARM RES, V7, P199, DOI 10.1080/19466315.2015.1053572
   Meyer RD, 2020, STAT BIOPHARM RES, V12, P399, DOI 10.1080/19466315.2020.1779122
   Molenberghs G, 2015, HDB MISSING DATA MET, DOI [10.1201/b17622, DOI 10.1201/B17622]
   Morris TP, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-11
   Rehal S., 2018, IMPLICATIONS MISSING
   RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581
   Rubin DB, 1987, MULTIPLE IMPUTATION
   Tang YQ, 2018, STAT MED, V37, P1467, DOI 10.1002/sim.7583
   White IR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d40
   White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067
   White IR, 1999, STAT MED, V18, P2617, DOI 10.1002/(SICI)1097-0258(19991015)18:19<2617::AID-SIM187>3.0.CO;2-E
   World Health Organization, 2020, 51 WHO
NR 37
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD AUG 12
PY 2020
VL 20
IS 1
AR 208
DI 10.1186/s12874-020-01089-6
PG 12
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA NF8BS
UT WOS:000563518700001
PM 32787782
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lambkin-Williams, R
   DeVincenzo, JP
AF Lambkin-Williams, Rob
   DeVincenzo, John P.
TI A COVID-19 human viral challenge model. Learning from experience
SO INFLUENZA AND OTHER RESPIRATORY VIRUSES
LA English
DT Article
DE controlled human infection model; COVID-19; human viral challenge model;
   RSV; SARS-CoV-19
ID SYNCYTIAL VIRUS-INFECTION; ANIMAL-MODELS; VACCINE; PREVENTION; DISEASE;
   RSV
AB The controlled human infection model and specifically the human viral challenge model are not dissimilar to standard clinical trials while adding another layer of complexity and safety considerations. The models deliberately infect volunteers, with an infectious challenge agent to determine the effect of the infection and the potential benefits of the experimental interventions. The human viral challenge model studies can shorten the time to assess the efficacy of a new vaccine or treatment by combining this with the assessment of safety. The newly emerging SARS-CoV-2 virus is highly contagious, and an urgent race is on to develop a new vaccine against this virus in a timeframe never attempted before. The use of the human viral challenge model has been proposed to accelerate the development of the vaccine. In the early 2000s, the authors successfully developed a pathogenic human viral challenge model for another virus for which there was no effective treatment and established it to evaluate potential therapies and vaccines against respiratory syncytial virus. Experience gained in the development of that model can help with the development of a COVID-19 HVCM and the authors describe it here.
C1 [Lambkin-Williams, Rob] VirologyConsult Ltd, Brighton BN2 9UT, E Sussex, England.
   [DeVincenzo, John P.] Univ Tennessee, Sch Med, Memphis, TN USA.
RP Lambkin-Williams, R (corresponding author), VirologyConsult Ltd, Brighton BN2 9UT, E Sussex, England.
EM rlw@virologyconsult.com
RI Lambkin-Williams, Rob/L-2397-2019
OI Lambkin-Williams, Rob/0000-0003-2107-0174
CR Abramson JS, 2003, PEDIATRICS, V112, P1442
   Anderson EL, 2020, RISK ANAL, V40, P902, DOI 10.1111/risa.13500
   [Anonymous], 2020, LANCET, V395, P1168, DOI 10.1016/S0140-6736(20)30823-0
   Bagga B, 2018, J CLIN VIROL, V106, P1, DOI 10.1016/j.jcv.2018.06.014
   Boeckh M, 2010, AM J RESP CRIT CARE, V182, P1217, DOI 10.1164/rccm.201008-1230ED
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chen WH, 2016, CLIN INFECT DIS, V62, P1329, DOI 10.1093/cid/ciw145
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Dalan R, 2020, HORM METAB RES, V52, P257, DOI 10.1055/a-1155-0501
   DeVincenzo J., 2019, OPEN FORUM INFECT DI, V6, pS27, DOI [10.1093/ofid/ofz359.061, DOI 10.1093/OFID/OFZ359.061]
   DeVincenzo J, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01884-19
   DeVincenzo JP, 2010, AM J RESP CRIT CARE, V182, P1305, DOI 10.1164/rccm.201002-0221OC
   Doucette A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152208
   Douglas Janet L, 2004, Expert Rev Anti Infect Ther, V2, P625, DOI 10.1586/14787210.2.4.625
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   FDA, REMD EUA LETT AUTH D
   Feasey NA, 2017, LANCET, V390, P2419, DOI 10.1016/S0140-6736(17)32407-8
   Field MJ, 2004, ETHICAL CONDUCT CLIN
   Fleming DM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1218-z
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Fuentes S, 2017, SCI REP-UK, V7, DOI 10.1038/srep42428
   Galanti M, 2019, INFLUENZA OTHER RESP, V13, P226, DOI 10.1111/irv.12629
   Gbesemete D, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01670-2
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026
   Grad YH, 2014, J VIROL, V88, P7286, DOI 10.1128/JVI.00038-14
   Houng HSH, 2012, J CLIN VIROL, V53, P12, DOI 10.1016/j.jcv.2011.09.004
   Jenson AB, 2016, EXP DERMATOL, V25, P178, DOI 10.1111/exd.12925
   Jin C, 2017, LANCET, V390, P2472, DOI 10.1016/S0140-6736(17)32149-9
   KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954
   Kassir R, 2020, OBES REV, V21, DOI 10.1111/obr.13034
   Kim YI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113100
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1789, DOI 10.1002/jmv.25900
   Lambkin-Williams R, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0784-1
   Liu JY, 2020, EMERG INFECT DIS, V26, P1320, DOI 10.3201/eid2606.200239
   Luo F, 2018, VIROL SIN, V33, P201, DOI 10.1007/s12250-018-0009-2
   Mahase E., 2020, BMJ, V369, pm1438, DOI 10.1136/bmj.m1438
   McGonigle P, 2014, BIOCHEM PHARMACOL, V87, P162, DOI 10.1016/j.bcp.2013.08.006
   Moran RJ, 2020, ESTIMATING REQUIRED
   Mullard A, 2020, LANCET, V395, P1245, DOI 10.1016/S0140-6736(20)30894-1
   Pareek M, 2020, LANCET, V395, P1421, DOI 10.1016/S0140-6736(20)30922-3
   Patel MC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01646
   Rivett L, 2020, ELIFE, V9, DOI 10.7554/eLife.58728
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Singanayagam A, 2015, CLIN SCI, V129, P245, DOI 10.1042/CS20140654
   van der Laan JW, 2008, EXPERT REV VACCINES, V7, P783, DOI 10.1586/14760584.7.6.783
   Walsh EE, 2017, CLIN CHEST MED, V38, P29, DOI 10.1016/j.ccm.2016.11.010
   Walsh KB, 2014, J VIROL, V88, P6281, DOI 10.1128/JVI.00464-14
   Wang CS, 2020, INTENS CARE MED, V46, P1475, DOI 10.1007/s00134-020-06065-8
   WHO, 2020, WHO KEY CRIT ETH ACC
   Wright PF, 2014, NEW ENGL J MED, V371, P776, DOI 10.1056/NEJMe1407467
NR 52
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1750-2640
EI 1750-2659
J9 INFLUENZA OTHER RESP
JI Influenza Other Respir. Viruses
PD NOV
PY 2020
VL 14
IS 6
BP 747
EP 756
DI 10.1111/irv.12797
EA AUG 2020
PG 10
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA OE3GX
UT WOS:000563927700001
PM 32790065
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sarkar, M
   Saha, S
AF Sarkar, Manish
   Saha, Soham
TI Structural insight into the role of novel SARS-CoV-2 E protein: A
   potential target for vaccine development and other therapeutic
   strategies
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; GOLGI-COMPLEX; DOCKING; CHARMM; MODEL;
   IMMUNIZATION; MOLPROBITY; PREDICTION; CHANNEL; BUNDLE
AB The outbreak of COVID-19 across the world has posed unprecedented and global challenges on multiple fronts. Most of the vaccine and drug development has focused on the spike proteins and viral RNA-polymerases and main protease for viral replication. Using the bioinformatics and structural modelling approach, we modelled the structure of the envelope (E)-protein of novel SARS-CoV-2. The E-protein of this virus shares sequence similarity with that of SARS- CoV-1, and is highly conserved in the N-terminus regions. Incidentally, compared to spike proteins, E proteins demonstrate lower disparity and mutability among the isolated sequences. Using homology modelling, we found that the most favorable structure could function as a gated ion channel conducting H(+)ions. Combining pocket estimation and docking with water, we determined that GLU 8 and ASN 15 in the N-terminal region were in close proximity to form H-bonds which was further validated by insertion of the E protein in an ERGIC-mimic membrane. Additionally, two distinct "core" structures were visible, the hydrophobic core and the central core, which may regulate the opening/closing of the channel. We propose this as a mechanism of viral ion channeling activity which plays a critical role in viral infection and pathogenesis. In addition, it provides a structural basis and additional avenues for vaccine development and generating therapeutic interventions against the virus.
C1 [Sarkar, Manish] Bose Inst, Dept Biochem, Kolkata, India.
   [Saha, Soham] Inst Pasteur, Lab Percept & Memory, Paris, France.
   [Saha, Soham] CNRS, Unite Mixte Rech UMR 3571, Paris, France.
RP Sarkar, M (corresponding author), Bose Inst, Dept Biochem, Kolkata, India.; Saha, S (corresponding author), Inst Pasteur, Lab Percept & Memory, Paris, France.; Saha, S (corresponding author), CNRS, Unite Mixte Rech UMR 3571, Paris, France.
EM sarkarmanish2016@jcbose.ac.in; soham.saha@pasteur.fr
OI Saha, Soham/0000-0003-1173-1397
CR Acharya R, 2010, P NATL ACAD SCI USA, V107, P15075, DOI 10.1073/pnas.1007071107
   Almazan F, 2013, MBIO, V4, DOI 10.1128/mBio.00650-13
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Cohen JR, 2011, J VIROL, V85, P5794, DOI 10.1128/JVI.00060-11
   Corse E, 2000, J VIROL, V74, P4319, DOI 10.1128/JVI.74.9.4319-4326.2000
   Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216
   DeDiego ML, 2008, VIROLOGY, V376, P379, DOI 10.1016/j.virol.2008.03.005
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   DeDiego ML, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002315
   Fett C, 2013, J VIROL, V87, P6551, DOI 10.1128/JVI.00087-13
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Grosdidier A, 2011, J COMPUT CHEM, V32, P2149, DOI 10.1002/jcc.21797
   Jimenez-Guardeno JM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005215
   Jo S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000880
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   Kumar S, 2001, GENETICS, V158, P1321
   Kuo LL, 2003, J VIROL, V77, P4597, DOI 10.1128/JVI.77.8.4597-4608.2003
   Lamirande EW, 2008, J VIROL, V82, P7721, DOI 10.1128/JVI.00304-08
   Li Y, 2014, J BIOL CHEM, V289, P12535, DOI 10.1074/jbc.M114.560094
   Nieva JL, 2012, NAT REV MICROBIOL, V10, P563, DOI 10.1038/nrmicro2820
   Netland J, 2010, VIROLOGY, V399, P120, DOI 10.1016/j.virol.2010.01.004
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Nieto-Torres JL, 2011, VIROLOGY, V415, P69, DOI 10.1016/j.virol.2011.03.029
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Ortego J, 2002, J VIROL, V76, P11518, DOI 10.1128/JVI.76.22.11518-11529.2002
   Parthasarathy K, 2008, BIOPHYS J, V95, pL39, DOI 10.1529/biophysj.108.133041
   Pervushin K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000511
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Quan LJ, 2016, BIOINFORMATICS, V32, P2936, DOI 10.1093/bioinformatics/btw361
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Sievers F, 2018, PROTEIN SCI, V27, P135, DOI 10.1002/pro.3290
   Stecher G, 2020, MOL BIOL EVOL, V37, P1237, DOI 10.1093/molbev/msz312
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Surya W, 2018, BBA-BIOMEMBRANES, V1860, P1309, DOI 10.1016/j.bbamem.2018.02.017
   Tek A, 2016, NUCLEIC ACIDS RES, V44, P95, DOI 10.1093/nar/gkv1457
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Torres J, 2007, PROTEIN SCI, V16, P2065, DOI 10.1110/ps.062730007
   Torres J, 2006, BIOPHYS J, V91, P938, DOI 10.1529/biophysj.105.080119
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Venkatagopalan P, 2015, VIROLOGY, V478, P75, DOI 10.1016/j.virol.2015.02.005
   Verdia-Baguena C, 2013, BBA-BIOMEMBRANES, V1828, P2026, DOI 10.1016/j.bbamem.2013.05.008
   Verdia-Baguena C, 2012, VIROLOGY, V432, P485, DOI 10.1016/j.virol.2012.07.005
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Wilson L, 2004, VIROLOGY, V330, P322, DOI 10.1016/j.virol.2004.09.033
   World Health Organization, COR DIS COVID 2019 S
   Worldometer, 2019, COR PAND
   Wu EL, 2014, J COMPUT CHEM, V35, P1997, DOI 10.1002/jcc.23702
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
NR 53
TC 1
Z9 1
U1 6
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 12
PY 2020
VL 15
IS 8
AR e0237300
DI 10.1371/journal.pone.0237300
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ND3HD
UT WOS:000561793900024
PM 32785274
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Devaurs, D
   Antunes, DA
   Kavraki, LE
AF Devaurs, Didier
   Antunes, Dinler A.
   Kavraki, Lydia E.
TI Computational analysis of complement inhibitor compstatin using
   molecular dynamics
SO JOURNAL OF MOLECULAR MODELING
LA English
DT Article
DE Compstatin; Complement system; Complement inhibition; Molecular dynamics
ID PEPTIDE INHIBITOR; C3 ACTIVATION; FORCE-FIELD; ANALOGS; DECREASES;
   DESIGN; TARGET; MODEL
AB The complement system plays a major role in human immunity, but its abnormal activation can have severe pathological impacts. By mimicking a natural mechanism of complement regulation, the small peptidecompstatinhas proven to be a very promising complement inhibitor. Over the years, several compstatin analogs have been created, with improved inhibitory potency. A recent analog is being developed as a candidate drug against several pathological conditions, including COVID-19. However, the reasons behind its higher potency and increased binding affinity to complement proteins are not fully clear. This computational study highlights the mechanistic properties of several compstatin analogs, thus complementing previous experimental studies. We perform molecular dynamics simulations involving six analogs alone in solution and two complexes with compstatin bound to complement component 3. These simulations reveal that all the analogs we consider, except the original compstatin, naturally adopt a pre-bound conformation in solution. Interestingly, this set of analogs adopting a pre-bound conformation includes analogs that were not known to benefit from this behavior. We also show that the most recent compstatin analog (among those we consider) forms a stronger hydrogen bond network with its complement receptor than an earlier analog.
C1 [Devaurs, Didier] Univ Grenoble Alpes, LJK, Grenoble INP, INRIA,CNRS, F-38000 Grenoble, France.
   [Antunes, Dinler A.; Kavraki, Lydia E.] Rice Univ, Dept Comp Sci, 6100 Main St, Houston, TX 77005 USA.
RP Kavraki, LE (corresponding author), Rice Univ, Dept Comp Sci, 6100 Main St, Houston, TX 77005 USA.
EM kavraki@rice.edu
RI Devaurs, Didier/Y-3150-2019
OI Devaurs, Didier/0000-0002-3415-9816
FU National Science Foundation (NSF)National Science Foundation (NSF) [CCF
   1423304]; Rice University Funds; NSFNational Science Foundation (NSF)
   [OCI 0959097, CNS 0821727, CNS 1338099]; Rice University
FX This work was supported in part by the National Science Foundation (NSF)
   under Grant CCF 1423304, and by Rice University Funds. Computational
   simulations were run on equipment supported in part by the Data Analysis
   and Visualization Cyberinfrastructure funded by NSF under Grant OCI
   0959097, on equipment supported by the Cyberinfrastructure for
   Computational Research funded by NSF under Grant CNS 0821727, as well as
   on equipment supported in part by the Big-Data Private-Cloud Research
   Cyberinfrastructure MRI-award funded by NSF under grant CNS 1338099 and
   by Rice University.
CR [Anonymous], 2009, NAT REV DRUG DISCOV, V8, DOI 10.1038/nrd3064
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bjelkmar P, 2010, J CHEM THEORY COMPUT, V6, P459, DOI 10.1021/ct900549r
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Devaurs D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113406
   Devaurs D, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00013
   Devaurs Didier, 2018, International Journal of Computational Biology and Drug Design, V11, P90, DOI 10.1504/IJCBDD.2018.090834
   Ekdahl KN, 2011, ADV DRUG DELIVER REV, V63, P1042, DOI 10.1016/j.addr.2011.06.012
   Gorham RD, 2015, J MED CHEM, V58, P814, DOI 10.1021/jm501345y
   Gorham RD, 2013, EXP EYE RES, V116, P96, DOI 10.1016/j.exer.2013.07.023
   Gros P, 2008, NAT REV IMMUNOL, V8, P48, DOI 10.1038/nri2231
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200
   Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005
   Katragadda M, 2006, J MED CHEM, V49, P4616, DOI 10.1021/jm0603419
   Kocsis A, 2010, J IMMUNOL, V185, P4169, DOI 10.4049/jimmunol.1001819
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Maekawa T, 2016, J CLIN PERIODONTOL, V43, P238, DOI 10.1111/jcpe.12507
   Maekawa T, 2014, J IMMUNOL, V192, P6020, DOI 10.4049/jimmunol.1400569
   Mallik B, 2005, J MED CHEM, V48, P274, DOI 10.1021/jm0495531
   Mastaglio S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108450
   Mohan RR, 2018, ACS OMEGA, V3, P6427, DOI 10.1021/acsomega.8b00606
   Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657
   Morikis D, 1998, PROTEIN SCI, V7, P619, DOI 10.1002/pro.5560070311
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Qu HC, 2013, IMMUNOBIOLOGY, V218, P496, DOI 10.1016/j.imbio.2012.06.003
   Qu HC, 2011, MOL IMMUNOL, V48, P481, DOI 10.1016/j.molimm.2010.10.004
   Reis ES, 2015, CLIN IMMUNOL, V161, P225, DOI 10.1016/j.clim.2015.08.009
   Reis ES, 2015, IMMUNOBIOLOGY, V220, P476, DOI 10.1016/j.imbio.2014.10.026
   Ricklin D, 2016, SEMIN IMMUNOL, V28, P208, DOI 10.1016/j.smim.2016.06.001
   Risitano AM, 2014, BLOOD, V123, P2094, DOI 10.1182/blood-2013-11-536573
   Sahu A, 1996, J IMMUNOL, V157, P884
   Sfyroera G, 2015, J IMMUNOL, V194, P3305, DOI 10.4049/jimmunol.1402781
   Silasi-Mansat R, 2015, J CELL MOL MED, V19, P2549, DOI 10.1111/jcmm.12667
   Silasi-Mansat R, 2010, BLOOD, V116, P1002, DOI 10.1182/blood-2010-02-269746
   Tamamis P, 2007, J MOL GRAPH MODEL, V26, P571, DOI 10.1016/j.jmgm.2007.03.014
   Tamamis P, 2012, CHEM BIOL DRUG DES, V79, P703, DOI 10.1111/j.1747-0285.2012.01324.x
   Zhang YZ, 2015, IMMUNOBIOLOGY, V220, P993, DOI 10.1016/j.imbio.2015.04.001
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 40
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1610-2940
EI 0948-5023
J9 J MOL MODEL
JI J. Mol. Model.
PD AUG 12
PY 2020
VL 26
IS 9
AR 231
DI 10.1007/s00894-020-04472-8
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Chemistry,
   Multidisciplinary; Computer Science, Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Chemistry; Computer
   Science
GA ND5QH
UT WOS:000561953900003
PM 32789582
OA Bronze
DA 2021-01-01
ER

PT J
AU Nguyen, Y
   Corre, F
   Honsel, V
   Curac, S
   Zarrouk, V
   Burtz, CP
   Weiss, E
   Moyer, JD
   Gauss, T
   Gregory, J
   Bert, F
   Trichet, C
   Peoc'h, K
   Vilgrain, V
   Rebours, V
   Fantin, B
   Galy, A
AF Nguyen, Yann
   Corre, Felix
   Honsel, Vasco
   Curac, Sonja
   Zarrouk, Virginie
   Burtz, Catherine Paugam
   Weiss, Emmanuel
   Moyer, Jean-Denis
   Gauss, Tobias
   Gregory, Jules
   Bert, Frederic
   Trichet, Catherine
   Peoc'h, Katell
   Vilgrain, Valerie
   Rebours, Vinciane
   Fantin, Bruno
   Galy, Adrien
TI A nomogram to predict the risk of unfavourable outcome in COVID-19: a
   retrospective cohort of 279 hospitalized patients in Paris area
SO ANNALS OF MEDICINE
LA English
DT Article
DE COVID-19; risk factors; nomogram
AB Objective To identify predictive factors of unfavourable outcome among patients hospitalized for COVID-19. Methods We conducted a monocentric retrospective cohort study of COVID-19 patients hospitalized in Paris area. An unfavourable outcome was defined as the need for artificial ventilation and/or death. Characteristics at admission were analysed to identify factors predictive of unfavourable outcome using multivariable Cox proportional hazard models. Based on the results, a nomogram to predict 14-day probability of poor outcome was proposed. Results Between March 15th and April 14th, 2020, 279 COVID-19 patients were hospitalized after a median of 7 days after the first symptoms. Among them, 88 (31.5%) patients had an unfavourable outcome: 48 were admitted to the ICU for artificial ventilation, and 40 patients died without being admitted to ICU. Multivariable analyses retained age, overweight, polypnoea, fever, high C-reactive protein, elevated us troponin-I, and lymphopenia as risk factors of an unfavourable outcome. A nomogram was established with sufficient discriminatory power (C-index 0.75), and proper consistence between the prediction and the observation. Conclusion We identified seven easily available prognostic factors and proposed a simple nomogram for early detection of patients at risk of aggravation, in order to optimize clinical care and initiate specific therapies.KEY MESSAGES Since novel coronavirus disease 2019 pandemic, a minority of patients develops severe respiratory distress syndrome, leading to death despite intensive care. Tools to identify patients at risk in European populations are lacking. In our series, age, respiratory rate, overweight, temperature, C-reactive protein, troponin and lymphocyte counts were risk factors of an unfavourable outcome in hospitalized adult patients. We propose an easy-to-use nomogram to predict unfavourable outcome for hospitalized adult patients to optimize clinical care and initiate specific therapies.
C1 [Nguyen, Yann; Corre, Felix; Honsel, Vasco; Zarrouk, Virginie; Fantin, Bruno; Galy, Adrien] Univ Paris, Beaujon Hosp, AP HP Nord, Dept Internal Med, Clichy, France.
   [Nguyen, Yann] INSERM U1018, Ctr Res Epidemiol & Populat Hlth, Villejuif, France.
   [Curac, Sonja] Beaujon Hosp, AP HP Nord, Emergency Dept, Clichy, France.
   [Burtz, Catherine Paugam; Weiss, Emmanuel; Moyer, Jean-Denis; Gauss, Tobias] Univ Paris, Beaujon Hosp, AP HP Nord, Dept Anaesthesiol & Intens Care,DMU PARABOL, Clichy, France.
   [Gregory, Jules; Vilgrain, Valerie] Univ Paris, Beaujon Hosp, AP HP Nord, Dept Radiol, Clichy, France.
   [Bert, Frederic] Beaujon Hosp, AP HP Nord, Lab Microbiol, Clichy, France.
   [Trichet, Catherine] Univ Paris, Beaujon Hosp, AP HP Nord, Lab Hematol & Hemostasis, Clichy, France.
   [Peoc'h, Katell] Univ Paris, Beaujon Hosp, AP HP Nord, Lab Biochem, Clichy, France.
   [Rebours, Vinciane] Univ Paris, Beaujon Hosp, AP HP Nord, Dept Pancreatol, Clichy, France.
RP Nguyen, Y (corresponding author), Hop Beaujon, Serv Med Interne, 100 Blvd Gen Leclerc, F-92100 Clichy, France.
EM yann.nguyen2@aphp.fr
RI ; GREGORY, Jules/O-8429-2015
OI Nguyen, Yann/0000-0002-0866-3824; GREGORY, Jules/0000-0001-6081-1663
CR Austin PC, 2004, AM STAT, V58, P131, DOI 10.1198/0003130043277
   Changeux JP, 2020, CR BIOL, V343, P33, DOI 10.5802/crbiol.8
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027
   Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7
   Huang C, 2019, LANCET, V2020, P395
   Ji D, CLIN INFECT DIS
   Lechien JR, 2020, J INTERN MED, V288, P335, DOI 10.1111/joim.13089
   Li X, 2020, CHEM ENG RES DES, V158, P1, DOI 10.1016/j.cherd.2020.03.014
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mai F, 2020, J CARDIOL, V76, P453, DOI 10.1016/j.jjcc.2020.07.013
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang J, 2020, CLIN MICROBIOL INFEC, DOI [10.1093/cid/ciaa414/5818317, DOI 10.1093/CID/CIAA414/5818317]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 21
TC 1
Z9 1
U1 3
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0785-3890
EI 1365-2060
J9 ANN MED
JI Ann. Med.
PD OCT 2
PY 2020
VL 52
IS 7
BP 367
EP 375
DI 10.1080/07853890.2020.1803499
EA AUG 2020
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA NM2HY
UT WOS:000559562700001
PM 32723107
OA Bronze
DA 2021-01-01
ER

PT J
AU Dror, AA
   Eisenbach, N
   Taiber, S
   Morozov, NG
   Mizrachi, M
   Zigron, A
   Srouji, S
   Sela, E
AF Dror, Amiel A.
   Eisenbach, Netanel
   Taiber, Shahar
   Morozov, Nicole G.
   Mizrachi, Matti
   Zigron, Asaf
   Srouji, Samer
   Sela, Eyal
TI Vaccine hesitancy: the next challenge in the fight against COVID-19
SO EUROPEAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2 vaccine; Vaccine hesitancy; Healthcare staff;
   Vaccine safety; Israel
AB Vaccine hesitancy remains a barrier to full population inoculation against highly infectious diseases. Coincident with the rapid developments of COVID-19 vaccines globally, concerns about the safety of such a vaccine could contribute to vaccine hesitancy. We analyzed 1941 anonymous questionnaires completed by healthcare workers and members of the general Israeli population, regarding acceptance of a potential COVID-19 vaccine. Our results indicate that healthcare staff involved in the care of COVID-19 positive patients, and individuals considering themselves at risk of disease, were more likely to self-report acquiescence to COVID-19 vaccination if and when available. In contrast, parents, nurses, and medical workers not caring for SARS-CoV-2 positive patients expressed higher levels of vaccine hesitancy. Interventional educational campaigns targeted towards populations at risk of vaccine hesitancy are therefore urgently needed to combat misinformation and avoid low inoculation rates.
C1 [Dror, Amiel A.; Eisenbach, Netanel; Mizrachi, Matti; Sela, Eyal] Galilee Med Ctr, Dept Otolaryngol Head & Neck Surg, Nahariyya, Israel.
   [Dror, Amiel A.; Eisenbach, Netanel; Mizrachi, Matti; Zigron, Asaf; Srouji, Samer; Sela, Eyal] Bar Ilan Univ, Azrieli Fac Med, Safed, Israel.
   [Zigron, Asaf; Srouji, Samer] Galilee Med Ctr, Oral & Maxillofacial Dept, Nahariyya, Israel.
   [Taiber, Shahar; Morozov, Nicole G.] Tel Aviv Univ, Sackler Fac Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel.
RP Dror, AA (corresponding author), Galilee Med Ctr, Dept Otolaryngol Head & Neck Surg, Nahariyya, Israel.; Dror, AA (corresponding author), Bar Ilan Univ, Azrieli Fac Med, Safed, Israel.
EM amieldror@gmail.com
OI Eisenbach, Netanel/0000-0003-4513-3766; Dror, Amiel/0000-0002-7178-6771
CR Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y
   Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312
   Dean NE, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat0360
   Galbadage T, 2020, FRONT MED, DOI [10.1101/2020.05.11.20098673, DOI 10.1101/2020.05.11.20098673]
   Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Lee J, 2020, LANCET CHILD ADOLESC, V4, P421, DOI 10.1016/S2352-4642(20)30109-7
   Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477
   Rashid H, 2012, CURR OPIN INFECT DIS, V25, P243, DOI 10.1097/QCO.0b013e328352f727
NR 10
TC 3
Z9 3
U1 17
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0393-2990
EI 1573-7284
J9 EUR J EPIDEMIOL
JI Eur. J. Epidemiol.
PD AUG
PY 2020
VL 35
IS 8
BP 775
EP 779
DI 10.1007/s10654-020-00671-y
EA AUG 2020
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NM3LR
UT WOS:000559356100001
PM 32785815
OA Bronze
DA 2021-01-01
ER

PT J
AU Bidar, F
   Hekimian, G
   Martin-Toutain, I
   Lebreton, G
   Combes, A
   Frere, C
AF Bidar, Frank
   Hekimian, Guillaume
   Martin-Toutain, Isabelle
   Lebreton, Guillaume
   Combes, Alain
   Frere, Corinne
TI Heparin-induced thrombocytopenia in COVID-19 patients with severe acute
   respiratory distress syndrome requiring extracorporeal membrane
   oxygenation: two case reports
SO JOURNAL OF ARTIFICIAL ORGANS
LA English
DT Article; Early Access
DE COVID-19; Extracorporeal membrane oxygenation; Heparin-induced
   thrombocytopenia; Argatroban
AB Veno-venous (VV) extracorporeal membrane oxygenation (ECMO) is increasingly used in Coronavirus disease-19 (COVID-19) patients with the most severe forms of acute respiratory distress syndrome (ARDS). Its use is associated with a significant hemostatic challenge, especially in COVID- 19 patients who have been demonstrated to otherwise present a COVID-19-associated coagulopathy. The systematic use of unfractionated heparin therapy to prevent circuit thrombosis is warranted during ECMO support. The clinical presentation and management of heparin-induced thrombocytopenia, which is a rare but life-threatening complication of heparin therapy, has not been described in those patients yet. We report herein two cases of laboratory-confirmed HIT in COVID-19 patients with severe ARDS admitted to our intensive care unit for VV-ECMO support and the successful use of argatroban as an alternative therapy. We also provide a brief literature review of best evidence for managing such patients. The diagnosis and management of HIT is particularly challenging in COVID-19 patients receiving ECMO support. An increased awareness is warranted in those patients who already present a procoagulant state leading to higher rates of thrombotic events which can confuse the issues. Argatroban seems to be an appropriate and safe therapeutic option in COVID-19 patients with HIT while on VV-ECMO.
C1 [Bidar, Frank; Hekimian, Guillaume; Martin-Toutain, Isabelle; Lebreton, Guillaume; Combes, Alain; Frere, Corinne] Sorbonne Univ, Inst Cardiometab & Nutr, INSERM, UMRS ICAN 1166, F-75013 Paris, France.
   [Bidar, Frank; Hekimian, Guillaume; Combes, Alain] Hop La Pitie Salpetriere, AP HP, Inst Cardiol, Serv Med Intens Reanimat, F-75013 Paris, France.
   [Lebreton, Guillaume] Hop La Pitie Salpetriere, AP HP, Inst Cardiol, Serv Chirurg Thorac & Cardiovasc, F-75013 Paris, France.
   [Martin-Toutain, Isabelle; Frere, Corinne] Hop La Pitie Salpetriere, AP HP, Serv Dhematol Biol, F-75013 Paris, France.
RP Bidar, F (corresponding author), Sorbonne Univ, Inst Cardiometab & Nutr, INSERM, UMRS ICAN 1166, F-75013 Paris, France.; Bidar, F (corresponding author), Hop La Pitie Salpetriere, AP HP, Inst Cardiol, Serv Med Intens Reanimat, F-75013 Paris, France.
EM frankbidar@gmail.com
OI Bidar, Frank/0000-0003-1406-4067
CR Abrams D, 2016, INTENS CARE MED, V42, P844, DOI 10.1007/s00134-016-4312-9
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Beun R, 2020, INT J LAB HEMATOL, V42, P19, DOI 10.1111/ijlh.13230
   Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Doyle AJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00352
   Greinacher A, 2009, J THROMB HAEMOST, V7, P9, DOI 10.1111/j.1538-7836.2009.03385.x
   Iba T, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03077-0
   Kataria V, 2020, CRIT CARE MED, V48, pE82, DOI 10.1097/CCM.0000000000004090
   Kimmoun A, 2018, INTENS CARE MED, V44, P1460, DOI 10.1007/s00134-018-5346-y
   Laverdure F, 2016, INTENS CARE MED, V42, P1082, DOI 10.1007/s00134-016-4262-2
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Masi P, 2020, CIRCULATION
   Patell R, 2020, AM J HEMATOL
   Pineton de Chambrun M, 2020, J INTERN MED
   Renou A, 2020, INTENS CARE MED, V46, P1481, DOI 10.1007/s00134-020-06011-8
   Schenk S, 2006, J THORAC CARDIOVASC, V131, pe4, DOI 10.1016/j.jtcvs.2005.09.032
   Vayne C, 2019, THROMB HAEMOSTASIS, V119, P1138, DOI 10.1055/s-0039-1688827
   Yang XB, 2020, J THROMB HAEMOST, V18, P1469, DOI 10.1111/jth.14848
NR 20
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 1434-7229
EI 1619-0904
J9 J ARTIF ORGANS
JI J. Artif. Organs
DI 10.1007/s10047-020-01203-x
EA AUG 2020
PG 5
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA MZ8EF
UT WOS:000559357600001
PM 32789604
OA Bronze
DA 2021-01-01
ER

PT J
AU Katare, AK
   Singh, B
   Shukla, P
   Gupta, S
   Singh, B
   Yalamanchili, K
   Kulshrestha, N
   Bhanwaria, R
   Sharma, AK
   Sharma, S
   Sneha
   Mindala, DP
   Roy, S
   Kalgotra, R
AF Katare, Anil Kumar
   Singh, Bikarma
   Shukla, Pooja
   Gupta, Sandeep
   Singh, Bishander
   Yalamanchili, Kavya
   Kulshrestha, Nitin
   Bhanwaria, Rajendra
   Sharma, Ashok Kumar
   Sharma, Sarita
   Sneha
   Mindala, Durga Prasad
   Roy, Sumit
   Kalgotra, Rahul
TI Rapid determination and optimisation of berberine from HimalayanBerberis
   lyciumby soxhlet apparatus using CCD-RSM and its quality control as a
   potential candidate for COVID-19
SO NATURAL PRODUCT RESEARCH
LA English
DT Article; Early Access
DE Berberine; Soxhlet extraction; CCD-RSM; COVID-19
AB SARS-CoV-2 (or COVID-19) has become a global risk and scientists are attempting to investigate antiviral vaccine.Berberisare important plants due to the presence of bioactive phytochemicals, especially berberine from the protoberberine group of benzylisoquinoline and recent studies have shown its potential in treating COVID-19.B. lyciumRoyle growing in subtropical regions of Asia had wide applications in Indian system of medicine. Rapid determination and novel optimisation method for berberine extraction has been developed by Soxhlet extraction utilising central composite design-response surface methodology (CCD-RSM). Berberine was detected by high-performance liquid chromatography (HPLC), and the highest yield (13.39%) was obtained by maintaining optimal extraction conditions i.e., extraction time (7.28 hrs), ethyl alcohol (52.21%) and solvent to sample ratio (21.78 v/w). Investigation of two geographic regions (Ramnagar and Srinagar) showed high berberine content in lower altitude. This novel optimisation technique has placed berberine as a potential candidate for developing pharmaceutical products for human health care.
C1 [Katare, Anil Kumar; Yalamanchili, Kavya; Kulshrestha, Nitin; Mindala, Durga Prasad; Roy, Sumit; Kalgotra, Rahul] CSIR, Indian Inst Integrat Med, cGMP Chem Engn Div, Jammu, India.
   [Katare, Anil Kumar; Yalamanchili, Kavya; Kulshrestha, Nitin; Mindala, Durga Prasad; Roy, Sumit; Kalgotra, Rahul] CSIR, Acad Sci & Innovat Res AcSIR, Jammu, India.
   [Singh, Bikarma] CSIR, Indian Inst Integrat Med, Plant Sci Biodivers & Appl Bot Div, Jammu, India.
   [Singh, Bikarma] CSIR, Indian Inst Integrat Med, Acad Sci & Innovat Res AcSIR, Jammu, India.
   [Shukla, Pooja] CSIR, Natl Bot Res Inst, Environm Technol Div, Lucknow, Uttar Pradesh, India.
   [Gupta, Sandeep] Indra Gandhi Natl Open Univ, Reg Serv Div, Jammu, India.
   [Singh, Bishander] Veer Kunwar Singh Univ, Dept Bot, Ara, India.
   [Bhanwaria, Rajendra] CSIR, Indian Inst Integrat Med, Genet Resources & Agrotechnol Div, Jammu, India.
   [Sharma, Ashok Kumar; Sharma, Sarita] Ujjain Engn Coll, Dept Chem Engn, Ujjain, Madhya Pradesh, India.
   [Sneha] CSIR, Cent Inst Med & Aromat Plants, Informat Commun Technol, PO CIMAP, Lucknow, Uttar Pradesh, India.
RP Singh, B (corresponding author), CSIR, Indian Inst Integrat Med, Plant Sci Biodivers & Appl Bot Div, Jammu, India.; Singh, B (corresponding author), CSIR, Indian Inst Integrat Med, Acad Sci & Innovat Res AcSIR, Jammu, India.
EM drbikarma@iiim.ac.in
OI Singh, Bikarma/0000-0003-2677-3346
CR Ali H, 2015, JBAPN, V5, P295, DOI DOI 10.1080/22311866.2015.1073627
   Alothman M, 2009, FOOD CHEM, V115, P785, DOI 10.1016/j.foodchem.2008.12.005
   Andola HC, 2012, J BIOL ACTIVE PROD N, V2, P256
   Birdsall T. C., 1997, Alternative Medicine Review, V2, P94
   CHANDRA P, 1980, BIOCHEM SYST ECOL, V8, P379, DOI 10.1016/0305-1978(80)90040-X
   Hayashi K, 2007, BIOORG MED CHEM LETT, V17, P1562, DOI 10.1016/j.bmcl.2006.12.085
   Karimov A., 1993, CHEM NAT COMPD, V29, P4
   Li CY, 2006, J PHARMACEUT BIOMED, V40, P173, DOI 10.1016/j.jpba.2005.06.017
   Myer RH, 1995, RESPONSE SURFACE MET
   Narkhede RR, 2020, NAT PRODUCT BIOPROSP, V10, P297, DOI 10.1007/s13659-020-00253-1
   Niciforovic N, 2010, FOOD CHEM TOXICOL, V48, P3125, DOI 10.1016/j.fct.2010.08.007
   Sood P., 2010, Indian Journal of Natural Products and Resources, V1, P362
   Xia XA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016556
NR 13
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
DI 10.1080/14786419.2020.1806274
EA AUG 2020
PG 6
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA MZ2IP
UT WOS:000558947600001
PM 32787584
DA 2021-01-01
ER

PT J
AU Fox, TA
   Troy-Barnes, E
   Kirkwood, AA
   Chan, WY
   Day, JW
   Chavda, SJ
   Kumar, EA
   David, K
   Tomkins, O
   Sanchez, E
   Scully, M
   Khwaja, A
   Lambert, J
   Singer, M
   Roddie, C
   Morris, EC
   Yong, KL
   Thomson, KJ
   Ardeshna, KM
AF Fox, Thomas A.
   Troy-Barnes, Ethan
   Kirkwood, Amy A.
   Chan, Wei Yee
   Day, James W.
   Chavda, Selina J.
   Kumar, Emil A.
   David, Kate
   Tomkins, Oliver
   Sanchez, Emilie
   Scully, Marie
   Khwaja, Asim
   Lambert, Jonathan
   Singer, Mervyn
   Roddie, Claire
   Morris, Emma C.
   Yong, Kwee L.
   Thomson, Kirsty J.
   Ardeshna, Kirit M.
TI Clinical outcomes and risk factors for severe COVID-19 in patients with
   haematological disorders receiving chemo- or immunotherapy
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article; Early Access
DE Covid-19; chemotherapy; risk factors
ID CHEMOTHERAPY; CANCER
AB Haematology patients receiving chemo- or immunotherapy are considered to be at greater risk of COVID-19-related morbidity and mortality. We aimed to identify risk factors for COVID-19 severity and assess outcomes in patients where COVID-19 complicated the treatment of their haematological disorder. A retrospective cohort study was conducted in 55 patients with haematological disorders and COVID-19, including 52 with malignancy, two with bone marrow failure and one immune-mediated thrombotic thrombocytopenic purpura (TTP). COVID-19 diagnosis coincided with a new diagnosis of a haematological malignancy in four patients. Among patients, 82% were on systemic anti-cancer therapy (SACT) at the time of COVID-19 diagnosis. Of hospitalised patients, 37% (19/51) died while all four outpatients recovered. Risk factors for severe disease or mortality were similar to those in other published cohorts. Raised C-reactive protein at diagnosis predicted an aggressive clinical course. The majority of patients recovered from COVID-19, despite receiving recent SACT. This suggests that SACT, where urgent, should be administered despite intercurrent COVID-19 infection, which should be managed according to standard pathways. Delay or modification of therapy should be considered on an individual basis. Long-term follow-up studies in larger patient cohorts are required to assess the efficacy of treatment strategies employed during the pandemic.
C1 [Fox, Thomas A.; Troy-Barnes, Ethan; Chan, Wei Yee; Day, James W.; Chavda, Selina J.; Kumar, Emil A.; Tomkins, Oliver; Scully, Marie; Khwaja, Asim; Lambert, Jonathan; Roddie, Claire; Morris, Emma C.; Yong, Kwee L.; Thomson, Kirsty J.; Ardeshna, Kirit M.] Univ Coll London NHS Fdn Trust, Dept Haematol, London, England.
   [Fox, Thomas A.; Day, James W.; Morris, Emma C.] UCL Inst Immun & Transplantat, London, England.
   [Kirkwood, Amy A.] UCL, UCL Canc Inst, CR UK & UCL Canc Trials Ctr, London, England.
   [Chan, Wei Yee; Chavda, Selina J.; Khwaja, Asim; Roddie, Claire; Yong, Kwee L.] UCL Canc Inst, Dept Haematol, London, England.
   [Kumar, Emil A.] Queen Mary Univ London, Ctr Canc Genom & Computat Biol, Barts Canc Inst, London, England.
   [David, Kate; Sanchez, Emilie] Univ Coll London NHS Fdn Trust, Dept Clin Virol, London, England.
   [Scully, Marie; Lambert, Jonathan; Singer, Mervyn; Roddie, Claire; Morris, Emma C.; Yong, Kwee L.; Thomson, Kirsty J.; Ardeshna, Kirit M.] UCLH NIHR Biomed Res Ctr, London, England.
   [Singer, Mervyn] UCL, Bloomsbury Inst Intens Care Med, London, England.
   [Morris, Emma C.] Royal Free London Hosp NHS Fdn Trust, Dept Immunol, London, England.
RP Fox, TA (corresponding author), Univ Coll London NHS Fdn Trust, Dept Haematol, London, England.
EM t.fox@ucl.ac.uk
OI Tomkins, Oliver/0000-0002-1059-2906
CR Andrew JW, 2020, BRIT J HAEMATOL, DOI [10.1111/bjh.16962, DOI 10.1111/BJH.16962]
   Aries JA, 2020, BRIT J HAEMATOL, V190, pE64, DOI 10.1111/bjh.16852
   Booth S, 2020, EUR J HAEMATOL, V105, P476, DOI 10.1111/ejh.13469
   Brissot E, 2020, BONE MARROW TRANSPL, DOI 10.1038/s41409-020-0970-x
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Dai M, 2020, CANCER DISCOV
   DiNardo CD, 2019, BLOOD, V133, P7, DOI 10.1182/blood-2018-08-868752
   Docherty AB, 2020, FEATURES 16749 HOSP
   El-Sharkawi D, 2020, BRIT J HAEMATOL, V190, P336, DOI 10.1111/bjh.16956
   Fielding A., STUDY OLDER ADULTS A
   Gosain R, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-00934-7
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Intensive Care National Audit and Research Centre, 2020, ICNARC REP COVID 19
   Kanellopoulos A, 2020, BRIT J HAEMATOL, V190, pE67, DOI 10.1111/bjh.16856
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Martin-Moro F, 2020, BRIT J HAEMATOL, V190, pE16, DOI 10.1111/bjh.16801
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   National Cancer Research Institute, REC MAN PAT AML COVI
   National Institute for Health and Care Excellence, COVID 19 RAP GUID DE
   Perl AE, 2019, NEW ENGL J MED, V381, P1728, DOI 10.1056/NEJMoa1902688
   Shah V, 2020, BRIT J HAEMATOL, V190, pE279, DOI 10.1111/bjh.16935
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 31
TC 7
Z9 7
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
DI 10.1111/bjh.17027
EA AUG 2020
PG 13
WC Hematology
SC Hematology
GA MY7DR
UT WOS:000558574500001
PM 32678948
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Trivedi, M
   Shingada, A
   Shah, M
   Khanna, U
   Karnik, ND
   Ramachandran, R
AF Trivedi, Mayuri
   Shingada, Aakash
   Shah, Meera
   Khanna, Umesh
   Karnik, Niteen D.
   Ramachandran, Raja
TI Impact ofCOVID-19 on maintenance haemodialysis patients: The Indian
   scenario
SO NEPHROLOGY
LA English
DT Article
DE COVID-19; dialysis; renal replacement therapy
ID COVID-19; OUTCOMES
AB There is a lack of data describing the impact of the novel coronavirus 19 pandemic on the patients of chronic kidney disease stage V-dialysis (CKD V-D) from resource-limited countries. A growing body of literature describes an increased susceptibility of CKD V-D to COVID-19 with adverse outcomes in those with severe disease. In the current retrospective report, we elucidate the outcome in consecutive 37 CKD V-D patients with COVID-19 from two dialysis centres in Mumbai, India. Of the 37 patients included in the study, 56.7% of patients were asymptomatic or had mild disease and 27% presented with severe symptoms. The recovery rate was 63%, all those who presented with a severe disease succumbed to the infection. Thirty per cent of patients presented with an extended dialysis break due to various logistic and social issues. Though the overall clinical presentation and outcomes of this cohort from a limited resource setting mimic the global scenario, unique social and logistic issues are an additional burden to the patient, caregivers and the health-care facilities, which may worsen the outcomes in the future as the pandemic continues to spread.
C1 [Trivedi, Mayuri; Shah, Meera; Karnik, Niteen D.] LTMG Hosp, Dept Med, Nephrol Serv, Mumbai 400022, Maharashtra, India.
   [Shingada, Aakash; Khanna, Umesh] Kidney Associates Pvt Ltd, Dept Nephrol, Mumbai, Maharashtra, India.
   [Ramachandran, Raja] PGIMER, Dept Nephrol, Chandigarh, India.
RP Trivedi, M (corresponding author), LTMG Hosp, Dept Med, Nephrol Serv, Mumbai 400022, Maharashtra, India.
EM mayuritrivedi80@gmail.com
OI Ramachandran, Raja/0000-0002-1273-9107
CR [中华医学会肾脏病学分会专家组 Expert Team of Chinese Medical Association Nephrology Branch], 2020, [中华肾脏病杂志, Chinese Journal of Nephrology], V36, P82
   Goicoechea M, 2020, KIDNEY INT, V98, P27, DOI 10.1016/j.kint.2020.04.031
   Leung Nancy H L, 2020, Nat Med, V26, P676, DOI 10.1038/s41591-020-0843-2
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Ramachandran R, 2020, KIDNEY INT, V98, P238, DOI 10.1016/j.kint.2020.04.019
   Valeri AM, 2020, J AM SOC NEPHROL, V31, P1409, DOI 10.1681/ASN.2020040470
   Xiong F, 2020, J AM SOC NEPHROL, V31, P1387, DOI 10.1681/ASN.2020030354
NR 7
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1320-5358
EI 1440-1797
J9 NEPHROLOGY
JI Nephrology
PD DEC
PY 2020
VL 25
IS 12
BP 929
EP 932
AR e13760
DI 10.1111/nep.13760
EA AUG 2020
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA OT2OY
UT WOS:000558670800001
PM 32713060
OA Bronze
DA 2021-01-01
ER

PT J
AU Laventhal, NT
   Graham, RJ
   Rasmussen, SA
   Urion, DK
   Kang, PB
AF Laventhal, Naomi T.
   Graham, Robert J.
   Rasmussen, Sonja A.
   Urion, David K.
   Kang, Peter B.
TI Ethical decision-making for children with neuromuscular disorders in the
   COVID-19 crisis
SO NEUROLOGY
LA English
DT Article
ID DUCHENNE MUSCULAR-DYSTROPHY; CARE; MANAGEMENT; DIAGNOSIS; QUALITY;
   ILLNESS; LIFE; VENTILATION; INFLUENZA; SEVERITY
AB The sudden appearance and proliferation of coronavirus disease 2019 has forced societies and governmental authorities across the world to confront the possibility of resource constraints when critical care facilities are overwhelmed by the sheer numbers of grievously ill patients. As governments and health care systems develop and update policies and guidelines regarding the allocation of resources, patients and families affected by chronic disabilities, including many neuromuscular disorders that affect children and young adults, have become alarmed at the possibility that they may be determined to have less favorable prognoses due to their underlying diagnoses and thus be assigned to lower priority groups. It is important for health care workers, policymakers, and government officials to be aware that the long-term prognoses for children and young adults with neuromuscular disorders are often more promising than previously believed due to a better understanding of the natural history of these diseases, benefits of multidisciplinary supportive care, and novel molecular therapies that can dramatically improve the disease course. Although the realities of a global pandemic have the potential to require a shift from our usual, highly individualistic standards of care to crisis standards of care, shifting priorities should nonetheless be informed by good facts. Resource allocation guidelines with the potential to affect children and young adults with neuromuscular disorders should take into account the known trajectory of acute respiratory illness in this population and rely primarily on contemporary long-term outcome data.
C1 [Laventhal, Naomi T.] Univ Michigan, Sch Med, Dept Pediat, Div Neonatal Perinatal Med, Ann Arbor, MI USA.
   [Laventhal, Naomi T.] Univ Michigan, CS Mott Childrens Hosp, Ann Arbor, MI 48109 USA.
   [Laventhal, Naomi T.] Univ Michigan, Ctr Bioeth & Social Sci Med, Ann Arbor, MI 48109 USA.
   [Graham, Robert J.] Harvard Med Sch, Dept Anesthesiol, Boston, MA 02115 USA.
   [Graham, Robert J.] Harvard Med Sch, Boston Childrens Hosp, Crit Care & Pain Med, Boston, MA 02115 USA.
   [Graham, Robert J.] Harvard Med Sch, Dept Anaesthesia, Boston, MA 02115 USA.
   [Rasmussen, Sonja A.] Univ Florida, Coll Med, Dept Pediat, Gainesville, FL USA.
   [Rasmussen, Sonja A.] Univ Florida, Coll Med, Dept Epidemiol, Gainesville, FL USA.
   Coll Publ Hlth & Hlth Profess, Gainesville, FL USA.
   [Urion, David K.] Boston Childrens Hosp, Dept Neurol, Boston, MA USA.
   Harvard Med Sch, Boston, MA 02115 USA.
   [Kang, Peter B.] Univ Florida, Coll Med, Dept Pediat, Div Pediat Neurol, Gainesville, FL USA.
   [Kang, Peter B.] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA.
   [Kang, Peter B.] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL USA.
RP Kang, PB (corresponding author), Univ Florida, Coll Med, Dept Pediat, Div Pediat Neurol, Gainesville, FL USA.; Kang, PB (corresponding author), Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA.; Kang, PB (corresponding author), Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL USA.
EM pbkang@ufl.edu
OI Laventhal, Naomi/0000-0002-8110-7621; Kang, Peter/0000-0002-4270-7325
CR Albrecht GL, 1999, SOC SCI MED, V48, P977, DOI 10.1016/S0277-9536(98)00411-0
   Biddison ELD, 2019, CHEST, V155, P848, DOI 10.1016/j.chest.2018.09.025
   Brady AR, 2006, PEDIATRICS, V117, pE733, DOI 10.1542/peds.2005-1853
   BUSHBY KMD, 1993, J NEUROL, V240, P98, DOI 10.1007/BF00858725
   Campbell C, 2004, PEDIATRICS, V113, P811, DOI 10.1542/peds.113.4.811
   Christian MD, 2014, CHEST, V146, pE61S, DOI 10.1378/chest.14-0736
   Dondorp AM, 2020, AM J TROP MED HYG, V102, P1191, DOI 10.4269/ajtmh.20-0283
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Engel AG, 2015, LANCET NEUROL, V14, P420, DOI 10.1016/S1474-4422(14)70201-7
   Falvey JR, 2020, PHYS THER
   Finder JD, 2004, AM J RESP CRIT CARE, V170, P456, DOI 10.1164/rccm.200307-885ST
   Finkel RS, 2017, NEW ENGL J MED, V377, P1723, DOI 10.1056/NEJMoa1702752
   Finkel RS, 2018, NEUROMUSCULAR DISORD, V28, P197, DOI 10.1016/j.nmd.2017.11.004
   Finkel RS, 2014, NEUROLOGY, V83, P810, DOI 10.1212/WNL.0000000000000741
   Garg B, 2018, J MATERN-FETAL NEO M, V31, P1373, DOI 10.1080/14767058.2017.1315665
   Guidon AC, 2020, NEUROLOGY, V94, P959, DOI 10.1212/WNL.0000000000009566
   Gulla KM, 2016, INDIAN J CRIT CARE M, V20, P27, DOI 10.4103/0972-5229.173685
   Hall CA, 2019, PEDIATR PHYS THER, V31, P315, DOI 10.1097/PEP.0000000000000638
   Kang PB, 2015, NEUROLOGY, V84, P1369, DOI 10.1212/WNL.0000000000001416
   Keren R, 2005, JAMA-J AM MED ASSOC, V294, P2188, DOI 10.1001/jama.294.17.2188
   Krahn GL, 2015, AM J PUBLIC HEALTH, V105, pS198, DOI 10.2105/AJPH.2014.302182
   Mallory LA, 2009, PEDIATR NEUROL, V41, P42, DOI 10.1016/j.pediatrneurol.2009.02.017
   Meadow W, 2008, PEDIATRICS, V121, P732, DOI 10.1542/peds.2006-2797
   Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198
   Mercuri E, 2018, NEUROMUSCULAR DISORD, V28, P103, DOI 10.1016/j.nmd.2017.11.005
   MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0
   Quasney MW, 2015, PEDIATR CRIT CARE ME, V16, pS118, DOI 10.1097/PCC.0000000000000438
   Rose L, 2018, PEDIATR PULM, V53, P1378, DOI 10.1002/ppul.24145
   Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172
   Schlapbach LJ, 2018, INTENS CARE MED, V44, P179, DOI 10.1007/s00134-017-5021-8
   Simonds AK, 2010, HEALTH TECHNOL ASSES, V14, P131, DOI 10.3310/hta14460-02
   Slater Anthony, 2004, Pediatr Crit Care Med, V5, P447, DOI 10.1097/01.PCC.0000138557.31831.65
   Trenaman L, 2017, J RHEUMATOL, V44, P1899, DOI 10.3899/jrheum.161112
   Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689
   Weinstein MC, 2009, VALUE HEALTH, V12, pS5, DOI 10.1111/j.1524-4733.2009.00515.x
   White DB, 2020, JAMA-J AM MED ASSOC, V323, P1773, DOI 10.1001/jama.2020.5046
   Wilkinson D, 2009, THEOR MED BIOETH, V30, P401, DOI 10.1007/s11017-009-9120-6
   Yates K, 2004, ARCH DIS CHILD, V89, P170, DOI 10.1136/adc.2002.019562
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 40
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD AUG 11
PY 2020
VL 95
IS 6
BP 260
EP 265
DI 10.1212/WNL.0000000000009936
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA OH2AX
UT WOS:000582373300006
PM 32482844
OA Bronze
DA 2021-01-01
ER

PT J
AU Crispo, A
   Montagnese, C
   Perri, F
   Grimaldi, M
   Bimonte, S
   Augustin, LS
   Amore, A
   Celentano, E
   Di Napoli, M
   Cascella, M
   Pignata, S
AF Crispo, Anna
   Montagnese, Concetta
   Perri, Francesco
   Grimaldi, Maria
   Bimonte, Sabrina
   Augustin, Livia Silvia
   Amore, Alfonso
   Celentano, Egidio
   Di Napoli, Marilena
   Cascella, Marco
   Pignata, Sandro
TI COVID-19 Emergency and Post-Emergency in Italian Cancer Patients: How
   Can Patients Be Assisted?
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE COVID-19; coronavirus; cancer patients; telemedicine; infections
ID QUALITY-OF-LIFE; TELEMEDICINE
AB Italy and worldwide are experiencing an outbreak of a new coronavirus-related disease, named COVID-19, declared by the WHO COVID-19 a pandemic. The fragility of cancer patients is well-known, with many cases affecting aged patients or those with several comorbidities that frequently result in a loss of independency and functionality. Therefore, cancer patients have been greatly affected by this health emergency and, due to their vulnerability to COVID-19, oncologic patient visits have been often delayed or canceled leading to possible under-treatment. Different solutions can be adopted for reducing travels to cancer screening centers and the overall impact of cancer screening visits. As a consequence, it has been recommended that, when possible, the follow-up visits for cancer patients treated with oral anticancer drugs could be performed telematically. Furthermore, many patients refuse hospital visits, even if necessary, because of fear of contagion. Moreover, in some regions in Italy even the very first non-urgent visits have been postponed with the consequent delay in diagnosis, which may negatively affect disease prognosis. For these reasons, new approaches are needed such as the telemedicine tool. Throughout organized and appropriate tools, it would be possible to manage patients' visits and treatments, to avoid the dangerous extension of waiting lists when the standard activities will resume. In this context, a number of hospital visits can be substituted with visits at small local health centers, and general practitioners'office, taking in turn, advantage of well-defined telemedicine path which will be developed in the post-emergency phase.
C1 [Crispo, Anna; Montagnese, Concetta; Grimaldi, Maria; Augustin, Livia Silvia; Celentano, Egidio] IRCCS Fdn G Pascale, Epidemiol & Biostat Unit, Ist Nazl Tumori, Naples, Italy.
   [Perri, Francesco] IRCCS Fdn G Pascale, Head & Neck Med & Expt Oncol Unit, Ist Nazl Tumori, Naples, Italy.
   [Bimonte, Sabrina; Cascella, Marco] IRCCS Fdn G Pascale, Dept Anesthesia & Pain Med, Ist Nazl Tumori, Naples, Italy.
   [Amore, Alfonso; Di Napoli, Marilena; Pignata, Sandro] IRCCS Fdn G Pascale, Med Oncol Unit, Ist Nazl Tumori, Naples, Italy.
RP Crispo, A (corresponding author), IRCCS Fdn G Pascale, Epidemiol & Biostat Unit, Ist Nazl Tumori, Naples, Italy.
EM a.crispo@isttutotumori.na.it
RI Crispo, Anna/ABA-7435-2020
OI Crispo, Anna/0000-0002-8455-3328
CR AIOM, 2020, IND AIOM CIPOMO COVI
   Campi R, 2020, EUR UROL, V78, P11, DOI 10.1016/j.eururo.2020.03.054
   Checcucci Enrico, 2020, Panminerva Med, DOI 10.23736/S0031-0808.20.03958-0
   Cox A, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.6575
   Craig J, 2005, J TELEMED TELECARE, V11, P3, DOI 10.1258/1357633053430494
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Flodgren G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002098.pub2
   Gutteling JJ, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-97
   Hisada Y, 2017, BLOOD, V130, P1499, DOI 10.1182/blood-2017-03-743211
   Hoek PD, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0866-9
   Holzner B, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-126
   Istituto Superiore di Sanit, 2020, REP CHAR COVID 19 PO
   Jazieh AR, 2020, JCO GLOB ONCOL, V6, P471, DOI 10.1200/GO.20.00064
   Kruse CS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016242
   Ministero della Salute, 2012, TELEMEDICINA LIN IND
   Moletta L, 2020, INT J SURG, V79, P180, DOI 10.1016/j.ijsu.2020.05.061
   Moorthy V, 2020, B WORLD HEALTH ORGAN, V98, P150, DOI 10.2471/BLT.20.251561
   O'Gorman LD, 2016, TELEMED E-HEALTH, V22, P269, DOI 10.1089/tmj.2015.0133
   Perri F, 2020, TRANSL ONCOL, V13, P262, DOI 10.1016/j.tranon.2019.11.008
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Rajani R., 1999, Virtual Reality, V4, P243, DOI 10.1007/BF01421807
   Rogante M, 2016, ANN I SUPER SANITA, V52, P434, DOI 10.4415/ANN_16_03_16
   Sciarra Alessandro, 2020, Prostate Cancer Prostatic Dis, P1, DOI 10.1038/s41391-020-0240-4
   Taenzer P, 2000, PSYCHO-ONCOLOGY, V9, P203, DOI 10.1002/1099-1611(200005/06)9:3<203::AID-PON453>3.3.CO;2-P
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   World Health Organization (WHO), 2020, 98 WHO
   Wright EP, 2003, J CLIN ONCOL, V21, P374, DOI 10.1200/JCO.2003.11.044
   Xu XB, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20180992
   Ye Z, 2020, ZHEJIANG DA XUE XUE, V49
   Zhao Z, 2020, THORAC CANCER, V11, P1752, DOI 10.1111/1759-7714.13424
NR 30
TC 1
Z9 1
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 11
PY 2020
VL 10
AR 1571
DI 10.3389/fonc.2020.01571
PG 5
WC Oncology
SC Oncology
GA NI8IP
UT WOS:000565591100001
PM 32850461
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Meini, S
   Zanichelli, A
   Sbrojavacca, R
   Iuri, F
   Roberts, AT
   Suffritti, C
   Tascini, C
AF Meini, Simone
   Zanichelli, Andrea
   Sbrojavacca, Rodolfo
   Iuri, Federico
   Roberts, Anna Teresa
   Suffritti, Chiara
   Tascini, Carlo
TI Understanding the Pathophysiology of COVID-19: Could the Contact System
   Be the Key?
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; pathophysiology; Contact System; bradykinin; ACE;
   coagulation
ID INTRINSIC PATHWAY; C1 INHIBITOR; BRADYKININ; COAGULATION; RELEASE;
   INFLAMMATION; KALLIKREIN; ANGIOEDEMA; PROTEIN; ENZYME
AB To date the pathophysiology of COVID-19 remains unclear: this represents a factor determining the current lack of effective treatments. In this paper, we hypothesized a complex host response to SARS-CoV-2, with the Contact System (CS) playing a pivotal role in innate immune response. CS is linked with different proteolytic defense systems operating in human vasculature: the Kallikrein-Kinin (KKS), the Coagulation/Fibrinolysis and the Renin-Angiotensin (RAS) Systems. We investigated the role of the mediators involved. CS consists of Factor XII (FXII) and plasma prekallikrein (complexed to high-molecular-weight kininogen-HK). Autoactivation of FXII by contact with SARS-CoV-2 could lead to activation of intrinsic coagulation, with fibrin formation (microthrombosis), and fibrinolysis, resulting in increased D-dimer levels. Activation of kallikrein by activated FXII leads to production of bradykinin (BK) from HK. BK binds to B2-receptors, mediating vascular permeability, vasodilation and edema. B1-receptors, binding the metabolite [des-Arg(9)]-BK (DABK), are up-regulated during infections and mediate lung inflammatory responses. BK could play a relevant role in COVID-19 as already described for other viral models. Angiotensin-Converting-Enzyme (ACE) 2 displays lung protective effects: it inactivates DABK and converts Angiotensin II (Ang II) into Angiotensin-(1-7) and Angiotensin I into Angiotensin-(1-9). SARS-CoV-2 binds to ACE2 for cell entry, downregulating it: an impaired DABK inactivation could lead to an enhanced activity of B1-receptors, and the accumulation of Ang II, through a negative feedback loop, may result in decreased ACE activity, with consequent increase of BK. Therapies targeting the CS, the KKS and action of BK could be effective for the treatment of COVID-19.
C1 [Meini, Simone] Santa Maria Annunziata Hosp, Azienda USL Toscana Ctr, Internal Med Unit, Florence, Italy.
   [Zanichelli, Andrea; Suffritti, Chiara] Univ Milan, Gen Med Unit, ASST Fatebenefratelli Sacco, Osped Luigi Sacco, Milan, Italy.
   [Sbrojavacca, Rodolfo; Tascini, Carlo] Univ Udine, Santa Maria Misericordia Hosp, Infect Dis Clin, Udine, Italy.
   [Iuri, Federico] Univ Udine, Santa Maria Misericordia Hosp, Dept Emergency, Udine, Italy.
   [Roberts, Anna Teresa] Azienda USL Toscana Nord Ovest, Med Dept, Pisa, Italy.
RP Meini, S (corresponding author), Santa Maria Annunziata Hosp, Azienda USL Toscana Ctr, Internal Med Unit, Florence, Italy.
EM simonemeini2@gmail.com
OI Meini, Simone/0000-0002-8711-8305
FU CSL Behring
FX The CSL Behring funded the publishing support and journal styling
   services, but had no role in the conduct of the research, preparation of
   the article, in study design, in the collection, analysis and
   interpretation of data, in the writing of the report, and in the
   decision to submit the article for publication.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Ashar HK, 2018, AM J PATHOL, V188, P135, DOI 10.1016/j.ajpath.2017.09.014
   Baeriswyl V, 2015, ACS CHEM BIOL, V10, P1861, DOI 10.1021/acschembio.5b00103
   Broadley KJ, 2010, J PHARMACOL EXP THER, V335, P681, DOI 10.1124/jpet.110.171876
   Busse PJ, 2020, NEW ENGL J MED, V382, P1136, DOI 10.1056/NEJMra1808012
   Cai SH, 2005, J IMMUNOL, V174, P6462, DOI 10.4049/jimmunol.174.10.6462
   Cascella M, 2020, FEATURES EVALUATION
   Cha SA, 2018, KOREAN J PHYSIOL PHA, V22, P447, DOI 10.4196/kjpp.2018.22.4.447
   Cicardi M, 2005, SPRINGER SEMIN IMMUN, V27, P286, DOI 10.1007/s00281-005-0001-4
   Cicardi M, 2018, J ALLER CL IMM-PRACT, V6, P1132, DOI 10.1016/j.jaip.2018.04.022
   Clotet-Freixas S, 2018, LAB INVEST, V98, P1237, DOI 10.1038/s41374-018-0084-x
   Colarusso C, 2020, BRIT J PHARMACOL, V177, P4866, DOI 10.1111/bph.15154
   Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Deng XF, 2018, VIROLOGY, V517, P157, DOI 10.1016/j.virol.2017.12.024
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Dicpinigaitis PV, 2006, CHEST, V129, p169S, DOI 10.1378/chest.129.1_suppl.169S
   EDELMAN R, 1975, J LAB CLIN MED, V86, P410
   Endler G, 2007, J THROMB HAEMOST, V5, P1143, DOI 10.1111/j.1538-7836.2007.02530.x
   Engelmann B, 2013, NAT REV IMMUNOL, V13, P34, DOI 10.1038/nri3345
   Favresse J, 2018, CRIT REV CL LAB SCI, V55, P548, DOI 10.1080/10408363.2018.1529734
   Gailani D, 2007, ARTERIOSCL THROM VAS, V27, P2507, DOI 10.1161/ATVBAHA.107.155952
   Gershom ES, 2010, J THROMB HAEMOST, V8, P1037, DOI 10.1111/j.1538-7836.2010.03789.x
   Gheblawi M, 2020, CIRC RES, V127, pE46, DOI 10.1161/CIRCRESAHA.120.317332
   Golas A, 2013, BIOMATERIALS, V34, P607, DOI 10.1016/j.biomaterials.2012.09.034
   Grobe N, 2013, AM J PHYSIOL-CELL PH, V304, pC945, DOI 10.1152/ajpcell.00346.2012
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jang CH, 2006, RHEUMATOLOGY, V45, P703, DOI 10.1093/rheumatology/kei282
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Kannemeier C, 2007, P NATL ACAD SCI USA, V104, P6388, DOI 10.1073/pnas.0608647104
   Kaplan AP, 2014, ADV IMMUNOL, V121, P41, DOI 10.1016/B978-0-12-800100-4.00002-7
   KAPLAN AP, 1971, J EXP MED, V133, P696, DOI 10.1084/jem.133.4.696
   KLENIEWSKI J, 1992, J LAB CLIN MED, V120, P129
   LaRusch GA, 2010, BLOOD, V115, P5111, DOI 10.1182/blood-2009-08-236430
   Lazartigues E, 2007, CURR PHARM DESIGN, V13, P1231, DOI 10.2174/138161207780618911
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Long AT, 2016, J THROMB HAEMOST, V14, P427, DOI 10.1111/jth.13235
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Maas C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02046
   Maas C, 2018, BLOOD, V131, P1903, DOI 10.1182/blood-2017-04-569111
   Magnen M, 2019, AM J PHYSIOL-LUNG C, V316, pL1127, DOI 10.1152/ajplung.00379.2018
   Mailer RKW, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00076
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Marceau F, 2020, INT IMMUNOPHARMACOL, V82, DOI 10.1016/j.intimp.2020.106305
   Meini S, 2020, EUR ARCH OTO-RHINO-L, V277, P3519, DOI 10.1007/s00405-020-06102-8
   Naudin C, 2017, SEMIN THROMB HEMOST, V43, P814, DOI 10.1055/s-0036-1598003
   Oehmcke-Hecht S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00312
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   PAEGELOW I, 1995, INFLAMM RES, V44, P306, DOI 10.1007/BF02032574
   Peng QY, 2020, INTENS CARE MED, V46, P849, DOI 10.1007/s00134-020-05996-6
   Petralki CD, 2006, BIOL CHEM, V387, P653, DOI 10.1515/BC.2006.084
   Preissner KT, 2017, THROMB HAEMOSTASIS, V117, P1272, DOI 10.1160/TH-16-11-0858
   Pretorius M, 2002, HYPERTENSION, V39, P767, DOI 10.1161/hy0302.105767
   Qadri F, 2018, EXPERT OPIN THER TAR, V22, P31, DOI 10.1080/14728222.2018.1409724
   Quartuccio L, 2020, J MED VIROL, V92, P2852, DOI 10.1002/jmv.26149
   Ray S, 2012, OMICS, V16, P527, DOI 10.1089/omi.2012.0037
   Reshef A, 2015, ALLERGY, V70, P506, DOI 10.1111/all.12587
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Roche JA, 2020, FASEB J, V34, P7265, DOI 10.1096/fj.202000967
   Scangas GA, 2017, AM J RHINOL ALLERGY, V31, pE3, DOI 10.2500/ajra.2017.31.4403
   Schmaier AH, 2016, J THROMB HAEMOST, V14, P28, DOI 10.1111/jth.13194
   Slaats J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005973
   Sodhi CP, 2018, AM J PHYSIOL-LUNG C, V314, pL17, DOI 10.1152/ajplung.00498.2016
   Sparks MA, 2014, COMPR PHYSIOL, V4, P1201, DOI 10.1002/cphy.c130040
   Taddei S, 2016, AM J CARDIOVASC DRUG, V16, P309, DOI 10.1007/s40256-016-0173-4
   Taylor SL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003470
   Tong JY, 2020, OTOLARYNG HEAD NECK, V163, P3, DOI 10.1177/0194599820926473
   van de Veerdonk FL, 2020, ELIFE, V9, DOI 10.7554/eLife.57555
   Ventura PDS, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2846-3
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang GJ, 2014, ONCOL REP, V32, P1709, DOI 10.3892/or.2014.3366
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wujak L, 2015, J BIOL CHEM, V290, P7027, DOI 10.1074/jbc.M114.606343
   Wygrecka M, 2017, AM J RESP CRIT CARE, V196, P186, DOI 10.1164/rccm.201604-0712OC
   Zhu JY, 2020, J MED VIROL, V92, P891, DOI 10.1002/jmv.25910
   Zhu LP, 2010, HYPERTENSION, V56, P384, DOI 10.1161/HYPERTENSIONAHA.110.155051
NR 80
TC 1
Z9 1
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD AUG 11
PY 2020
VL 11
AR 2014
DI 10.3389/fimmu.2020.02014
PG 9
WC Immunology
SC Immunology
GA NI4OR
UT WOS:000565333700001
PM 32849666
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Santambrogio, R
   Farina, G
   D'Alessandro, V
   Iacob, G
   Gemma, M
   Zappa, MA
AF Santambrogio, Roberto
   Farina, Gabriella
   D'Alessandro, Valentina
   Iacob, Giulio
   Gemma, Marco
   Zappa, Marco Antonio
TI Guidelines Adaptation to the COVID-19 Outbreak for the Management of
   Hepatocellular Carcinoma
SO JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES
LA English
DT Article; Early Access
DE hepatocellular carcinoma; liver cirrhosis; hepatic resection; ablation
   therapies; COVID-19 pandemic
ID RESECTION; CANCER
AB Background: COVID-19 pandemic rendered the surgical approach as well as the surgical indication very complex due to the outstanding consumption of public health system' resources, especially in the intensive care subdivision. A multidisciplinary team-based strategy is necessary to adapt guidelines and medical practices to the actual situation. The aim of this study is to evaluate the changes in the therapeutic algorithm in a small group of patients with hepatocellular carcinoma (HCC) enlisted for surgery during the COVID-19 outbreak.
   Materials and Methods: A multidisciplinary strategy has been adopted to allocate HCC patients to a treatment that permitted to reduce the risk of complications and the hospital stay, thus preventing contamination by the virus. Nasopharyngeal swab and a chest radiograph were performed in all patients within 48 hours before the surgical procedure: in the suspected cases with negative COVID tests, we prudently postponed surgery and repeated the diagnostic tests after 15 days.
   Results: During the emergency state, 11 HCC patients were treated (8 laparoscopic ablations and 3 hepatic resections). We reported only 1 postoperative complication (hemothorax) and 1 death during the follow-up for COVID pneumonia. Comparing our performances with those in the same time frame in the past 4 years, we treated a similar number of HCC patients, obtaining a decrease in operative timing (P = .0409) and hospital stay (P = .0412) (Fig. 2b) with similar rates of immediate postoperative complications, without ICU admissions. FIG. 2. During the 5-year period from 2016 to 2020, annual trend shows a gradual decline of the operative time (P = .0409)(a)and hospital stays (P = .0412)(b).
   Conclusions: An adapted algorithm for the treatment of HCC to COVID outbreak permitted to manage safely these patients by identifying those most at risk of evolution of the neoplastic disease.
C1 [Santambrogio, Roberto; D'Alessandro, Valentina; Iacob, Giulio; Zappa, Marco Antonio] ASST Fatebenefratelli Sacco, UOC Chirurg Gen, Piazza Principessa Clotilde 3, I-20121 Milan, Italy.
   [Farina, Gabriella] ASST Fatebenefratelli Sacco, UOC Oncol, Milan, Italy.
   [Gemma, Marco] ASST Fatebenefratelli Sacco, UOC Anestesia & Rianimaz, Milan, Italy.
RP Santambrogio, R (corresponding author), ASST Fatebenefratelli Sacco, UOC Chirurg Gen, Piazza Principessa Clotilde 3, I-20121 Milan, Italy.
EM rsantambrogio@mclink.it
CR Aldrighetti L, 2020, UPDATES SURG, V72, P241, DOI 10.1007/s13304-020-00815-5
   Barry A, 2020, LANCET GASTROENTEROL, V5, P765, DOI 10.1016/S2468-1253(20)30182-5
   Bartlett DL, 2020, ANN SURG ONCOL, V27, P1717, DOI 10.1245/s10434-020-08461-2
   Besnier E, 2020, WORLD J SURG, V44, P1695, DOI 10.1007/s00268-020-05501-6
   Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Cabibbo GE, 2016, RACCOMANDAZIONI MULT
   Cillo U, 2019, J SURG ONCOL, V120, P956, DOI 10.1002/jso.25651
   Denys A, 2020, DIAGN INTERV IMAG, V101, P347, DOI 10.1016/j.diii.2020.04.005
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Iavarone M, 2020, J HEPATOL, V73, P1063, DOI 10.1016/j.jhep.2020.06.001
   Kudo M, 2020, HEPATOL RES, V50, P1004, DOI 10.1111/hepr.13541
   Mannelli C, 2020, J MED ETHICS, V46, P364, DOI 10.1136/medethics-2020-106227
   Mazzaferro V, 2020, ANN SURG, V272, pE84, DOI 10.1097/SLA.0000000000004005
   Morris SN, 2020, J MINIM INVAS GYN, V27, P789, DOI 10.1016/j.jmig.2020.04.002
   Nathani Piyush, 2020, Gut, DOI 10.1136/gutjnl-2020-321040
   Santambrogio R, 2020, UPDATES SURG, V72, P435, DOI 10.1007/s13304-020-00759-w
   Santambrogio R, 2020, MED ONCOL, V37, DOI 10.1007/s12032-020-1342-5
   Santambrogio R, 2018, J GASTROINTEST SURG, V22, P650, DOI 10.1007/s11605-017-3648-y
   Schrag D, 2020, JAMA-J AM MED ASSOC, V323, P2005, DOI 10.1001/jama.2020.6236
   Scorsetti M, 2020, ONCOLOGIST, V25, pE1249, DOI 10.1634/theoncologist.2020-0416
   Sharma R, 2020, LIVER INT, V40, P1823, DOI 10.1111/liv.14517
   Simons JP, 2010, CANCER-AM CANCER SOC, V116, P1733, DOI 10.1002/cncr.24904
   Tapper EB, 2020, J HEPATOL, V73, P441, DOI 10.1016/j.jhep.2020.04.005
   The Italian Board of Experts in Liver Transplantation (I-BELT) Study Group and the Italian Society of Organ Transplantation (SITO), 2020, LIVER TRANSPLANT, V26, P941
   Tuech JJ, 2020, J VISC SURG, V157, pS7, DOI 10.1016/j.jviscsurg.2020.03.008
   You B, 2020, LANCET ONCOL, V21, P619, DOI 10.1016/S1470-2045(20)30204-7
NR 30
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1092-6429
EI 1557-9034
J9 J LAPAROENDOSC ADV S
JI J. Laparoendosc. Adv. Surg. Tech.
DI 10.1089/lap.2020.0559
EA AUG 2020
PG 7
WC Surgery
SC Surgery
GA NF5KK
UT WOS:000563335100001
PM 32810426
OA Bronze
DA 2021-01-01
ER

PT J
AU Kosmidis, K
   Macheras, P
AF Kosmidis, Kosmas
   Macheras, Panos
TI A fractal kinetics SI model can explain the dynamics of COVID-19
   epidemics
SO PLOS ONE
LA English
DT Article
ID DRUG-RELEASE
AB The COVID-19 pandemic has already had a shocking impact on the lives of everybody on the planet. Here, we present a modification of the classical SI model, the Fractal Kinetics SI model which is in excellent agreement with the disease outbreak data available from the World Health Organization. The fractal kinetic approach that we propose here originates from chemical kinetics and has successfully been used in the past to describe reaction dynamics when imperfect mixing and segregation of the reactants is important and affects the dynamics of the reaction. The model introduces a novel epidemiological parameter, the "fractal" exponenthwhich is introduced in order to account for the self-organization of the societies against the pandemic through social distancing, lockdowns and flight restrictions.
C1 [Kosmidis, Kosmas] Aristotle Univ Thessaloniki, Dept Phys, Div Theoret Phys, Thessaloniki, Greece.
   [Kosmidis, Kosmas; Macheras, Panos] Res Ctr ATHENA, PharmaInformat Unit, Athens, Greece.
RP Kosmidis, K (corresponding author), Aristotle Univ Thessaloniki, Dept Phys, Div Theoret Phys, Thessaloniki, Greece.; Kosmidis, K (corresponding author), Res Ctr ATHENA, PharmaInformat Unit, Athens, Greece.
EM kosmask@auth.gr
RI Kosmidis, Kosmas/G-4812-2011
OI Kosmidis, Kosmas/0000-0002-9150-5746
FU "Athena" Research Center
FX The authors acknowledge financial support from "Athena" Research Center
   for the open access publication of this work.
CR ANDERSON R M, 1991
   Anguelova M, 2012, MATH BIOSCI, V239, P139, DOI 10.1016/j.mbs.2012.04.005
   [Anonymous], 2020, PCA IRIS DATASET
   Bank W, 2018, POPULATION
   Brauer F., 2012, MATH MODELS POPULATI, V2
   DiStefano III J., 2015, DYNAMIC SYSTEMS BIOL
   Grassly NC, 2008, NAT REV MICROBIOL, V6, P477, DOI 10.1038/nrmicro1845
   Inc WR, 2020, MATH VERS 12 1
   Jolliffe I., 2002, PRINCIPAL COMPONENT
   Karlsson J, 2012, 16 IFAC S SYST ID, V16, P941, DOI [10.3182/20120711-3-BE-2027.00381, DOI 10.3182/20120711-3-BE-2027.00381]
   KOPELMAN R, 1988, SCIENCE, V241, P1620, DOI 10.1126/science.241.4873.1620
   Kosmidis K, 2003, INT J PHARMACEUT, V254, P183, DOI 10.1016/S0378-5173(03)00030-9
   Kosmidis K, 2003, J CHEM PHYS, V119, P6373, DOI 10.1063/1.1603731
   Kosmidis K, 2003, PHARM RES-DORDR, V20, P988, DOI 10.1023/A:1024497920145
   Kucharski AJ, 2020, LANCET INFECT DIS
   Marsland S., 2015, MACHINE LEARNING ALG
   Newville M, 2014, ZENODO
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825
   Peng L, 2020, ARXIV200206563
   Raschka S., 2017, PYTHON MACHINE LEARN
   Raue A, 2014, BIOINFORMATICS, V30, P1440, DOI 10.1093/bioinformatics/btu006
   SAVAGEAU MA, 1993, J MOL RECOGNIT, V6, P149, DOI 10.1002/jmr.300060403
   SAVAGEAU MA, 1995, J THEOR BIOL, V176, P115, DOI 10.1006/jtbi.1995.0181
   Tableau, 2020, DAT COV 19 OUTBR
   Wu J, 2020, NEUROCOMPUTING, V395, P78, DOI [10.1080/17435390.2020.1831639, 10.1016/j.neucom.2020.02.017]
NR 25
TC 2
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 11
PY 2020
VL 15
IS 8
AR e0237304
DI 10.1371/journal.pone.0237304
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NE5TX
UT WOS:000562664700015
PM 32780754
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hazard, D
   Kaier, K
   von Cube, M
   Grodd, M
   Bugiera, L
   Lambert, J
   Wolkewitz, M
AF Hazard, Derek
   Kaier, Klaus
   von Cube, Maja
   Grodd, Marlon
   Bugiera, Lars
   Lambert, Jerome
   Wolkewitz, Martin
TI Joint analysis of duration of ventilation, length of intensive care, and
   mortality of COVID-19 patients: a multistate approach
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Article
DE SARS-CoV-2; Multistate model; Length of stay; Competing risks;
   Mechanical ventilation
ID TIME-DEPENDENT BIAS; MODELS
AB Background The clinical progress of patients hospitalized due to COVID-19 is often associated with severe pneumonia which may require intensive care, invasive ventilation, or extracorporeal membrane oxygenation (ECMO). The length of intensive care and the duration of these supportive therapies are clinically relevant outcomes. From the statistical perspective, these quantities are challenging to estimate due to episodes being time-dependent and potentially multiple, as well as being determined by the competing, terminal events of discharge alive and death. Methods We used multistate models to study COVID-19 patients' time-dependent progress and provide a statistical framework to estimate hazard rates and transition probabilities. These estimates can then be used to quantify average sojourn times of clinically important states such as intensive care and invasive ventilation. We have made two real data sets of COVID-19 patients (n = 24* andn = 53**) and the corresponding statistical code publically available. Results The expected lengths of intensive care unit (ICU) stay at day 28 for the two cohorts were 15.05* and 19.62** days, while expected durations of mechanical ventilation were 7.97* and 9.85** days. Predicted mortality stood at 51%* and 15%**. Patients mechanically ventilated at the start of the example studies had a longer expected duration of ventilation (12.25*, 14.57** days) compared to patients non-ventilated (4.34*, 1.41** days) after 28 days. Furthermore, initially ventilated patients had a higher risk of death (54%* and 20%** vs. 48%* and 6%**) after 4 weeks. These results are further illustrated in stacked probability plots for the two groups from time zero, as well as for the entire cohort which depicts the predicted proportions of the patients in each state over follow-up. Conclusions The multistate approach gives important insights into the progress of COVID-19 patients in terms of ventilation duration, length of ICU stay, and mortality. In addition to avoiding frequent pitfalls in survival analysis, the methodology enables active cases to be analyzed by allowing for censoring. The stacked probability plots provide extensive information in a concise manner that can be easily conveyed to decision makers regarding healthcare capacities. Furthermore, clear comparisons can be made among different baseline characteristics.
C1 [Hazard, Derek; Kaier, Klaus; von Cube, Maja; Grodd, Marlon; Bugiera, Lars; Lambert, Jerome; Wolkewitz, Martin] Univ Freiburg, Fac Med, Inst Med Biometry & Stat, Stefan Meier Str 26, D-79104 Freiburg, Germany.
   [Hazard, Derek; Kaier, Klaus; von Cube, Maja; Grodd, Marlon; Bugiera, Lars; Lambert, Jerome; Wolkewitz, Martin] Univ Freiburg, Med Ctr, Stefan Meier Str 26, D-79104 Freiburg, Germany.
   [Hazard, Derek; Kaier, Klaus; von Cube, Maja; Grodd, Marlon; Bugiera, Lars; Wolkewitz, Martin] Univ Freiburg, Freiburg Ctr Data Anal & Modeling, Ernst Zermelo Str 1, D-79104 Freiburg, Germany.
   [Lambert, Jerome] Hop St Louis, Epidemiol & Clin Stat Tumor Resp & Resuscitat Ass, INSERM, U1153,CRESS, 1 Av Claude Vellefaux, F-75010 Paris, France.
RP Hazard, D (corresponding author), Univ Freiburg, Fac Med, Inst Med Biometry & Stat, Stefan Meier Str 26, D-79104 Freiburg, Germany.; Hazard, D (corresponding author), Univ Freiburg, Med Ctr, Stefan Meier Str 26, D-79104 Freiburg, Germany.; Hazard, D (corresponding author), Univ Freiburg, Freiburg Ctr Data Anal & Modeling, Ernst Zermelo Str 1, D-79104 Freiburg, Germany.
EM hazard@imbi.uni-freiburg.de
OI Hazard, Derek/0000-0001-7874-7567; Kaier, Klaus/0000-0003-0837-6945
FU Edmond de Rothschild Foundation Medical Fellowship Program; Projekt DEAL
FX JL was supported by Edmond de Rothschild Foundation Medical Fellowship
   Program. Open access funding provided by Projekt DEAL.
CR Allignol A, 2011, J STAT SOFTW, V38, P1
   Andersen PK, 2002, STAT METHODS MED RES, V11, P91, DOI 10.1191/0962280202SM276ra
   Andersen PK, 2012, STAT MODELS BASED CO, P779
   Beyersmann J, 2011, COMPETING RISKS MULT, P249
   Beyersmann J, 2008, J CLIN EPIDEMIOL, V61, P1216, DOI 10.1016/j.jclinepi.2008.02.008
   Beyersmann J, 2014, DEMOGR RES, V30, P1681, DOI 10.4054/DemRes.2014.30.62
   Beyersmann J, 2011, BIOMETRICAL J, V53, P332, DOI 10.1002/bimj.201000146
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Lipsitch M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003846
   van Walraven C, 2004, J CLIN EPIDEMIOL, V57, P672, DOI 10.1016/j.jclinepi.2003.12.008
   von Cube M, 2020, HARMONIZING HETEROGE
   Wolkewitz M, 2017, INFECT CONT HOSP EP, V38, P953, DOI 10.1017/ice.2017.107
   Wolkewitz M, 2017, J CLIN EPIDEMIOL, V84, P121, DOI 10.1016/j.jclinepi.2017.01.008
   Wolkewitz M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160430
   Wolkewitz M, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5060
   Wu J., 2020, NEW ENGL J MED, V382, pe101, DOI [10.1056/NEJMc2015312., DOI 10.1056/NEJMC2015312]
NR 17
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD AUG 11
PY 2020
VL 20
IS 1
AR 206
DI 10.1186/s12874-020-01082-z
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA NC9NK
UT WOS:000561536900001
PM 32781984
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jain, R
   Mujwar, S
AF Jain, Rashi
   Mujwar, Somdutt
TI Repurposing metocurine as main protease inhibitor to develop novel
   antiviral therapy for COVID-19
SO STRUCTURAL CHEMISTRY
LA English
DT Article
DE Drug repurposing; Drug repositioning; SARS-CoV-2; COVID-19; Corona;
   Antiviral
ID POTENTIAL-DRUG TARGET; RIBOSWITCH; PREDICTION
AB The outbreak of severe acute respiratory syndrome coronavirus-2 is causing a serious disaster through coronavirus disease-19 (COVID-19) around the globe. A large segment of the population from every corner of the world is already infected with this dreadful pathogen with a high mortality rate. These numbers are increasing drastically causing a situation of a global pandemic. Although after the continuous scientific efforts, we are still not having any specific drug or vaccine for the SARS-CoV-2 pathogen to date and there is an urgent need to develop a newer therapy to counter the COVID-19 global pandemic. Thus, in the current study, a framework for computational drug repurposing is established, and based on their safety profile, metocurine was chosen as a safe and effective drug candidate for developing therapy against the viral Mpro enzyme of SARS-CoV-2 for the treatment of COVID-19.
C1 [Jain, Rashi; Mujwar, Somdutt] GLA Univ, Inst Pharmaceut Res, Mathura 281406, Uttar Pradesh, India.
RP Mujwar, S (corresponding author), GLA Univ, Inst Pharmaceut Res, Mathura 281406, Uttar Pradesh, India.
EM rashijainsjs@gmail.com; somduttmujwar@gmail.com
RI Mujwar, Somdutt/AAF-4635-2019
OI Mujwar, Somdutt/0000-0003-4037-5475
CR Bai Y, 2020, PRESUMED ASYMPTOMATI
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Hoffmann Markus, 2020, SARS COV 2 CELL ENTR
   Jernigan DB, 2020, MMWR-MORBID MORTAL W, V69, P216, DOI 10.15585/mmwr.mm6908e1
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Minaz N, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108897
   Mujwar S, 2019, ASSAY DRUG DEV TECHN, V17, P298, DOI 10.1089/adt.2019.944
   Mujwar Somdutt, 2015, International Journal of Computational Biology and Drug Design, V8, P326
   Mujwar S, 2015, J MED IMAG HEALTH IN, V5, P7, DOI 10.1166/jmihi.2015.1358
   Shah K, 2019, ASSAY DRUG DEV TECHN, V17, P285, DOI 10.1089/adt.2019.943
   Tyrrell D. A. J., 1996, MED MICROBIOLOGY
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   World Health Organization, 2020, COR DIS COVID 2019 S
NR 17
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1040-0400
EI 1572-9001
J9 STRUCT CHEM
JI Struct. Chem.
PD DEC
PY 2020
VL 31
IS 6
BP 2487
EP 2499
DI 10.1007/s11224-020-01605-w
EA AUG 2020
PG 13
WC Chemistry, Multidisciplinary; Chemistry, Physical; Crystallography
SC Chemistry; Crystallography
GA OE5QI
UT WOS:000559634000001
PM 32837119
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Whitfield, M
   Reed, H
   Webster, J
   Hope, V
AF Whitfield, Mark
   Reed, Howard
   Webster, Jane
   Hope, Vivian
TI Response to Marsden et al (2020): Mitigation for the impacts on needle
   and syringe programmes is needed
SO ADDICTION
LA English
DT Letter; Early Access
DE COVID-19; England; injecting drug use; interventions; needle and syringe
   programmes; risk behaviours
ID HEPATITIS-C
C1 [Hope, Vivian] Liverpool John Moores Univ, Publ Hlth Inst, Liverpool, Merseyside, England.
RP Hope, V (corresponding author), Liverpool John Moores Univ, Publ Hlth Inst, Liverpool, Merseyside, England.
EM v.d.hope@ljmu.ac.uk
OI Hope, Vivian/0000-0001-5712-5734
CR [Anonymous], HARM RED COUNTR DRUG
   European Centre for Disease Prevention and Control (ECDC) and European Monitoring Centre for Drugs and Drug Addiction, 2011, PREV CONTR INF DIS P
   Larney S, 2017, LANCET GLOB HEALTH, V5, pE1208, DOI [10.1016/S2214-109X(17)30373-X, 10.1016/s2214-109x(17)30373-x]
   Marsden J, 2020, ADDICTION, V115, P1007, DOI 10.1111/add.15080
   Turner KME, 2011, ADDICTION, V106, P1978, DOI 10.1111/j.1360-0443.2011.03515.x
   Ward Z, 2018, ADDICTION, V113, P1727, DOI 10.1111/add.14217
NR 6
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
AR 15193
DI 10.1111/add.15193
EA AUG 2020
PG 2
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA MY1LD
UT WOS:000558179300001
PM 32696539
OA Bronze
DA 2021-01-01
ER

PT J
AU Zheng, C
   Kar, I
   Chen, CK
   Sau, C
   Woodson, S
   Serra, A
   Abboud, H
AF Zheng, Crystal
   Kar, Indrani
   Chen, Claire Kaori
   Sau, Crystal
   Woodson, Sophia
   Serra, Alessandro
   Abboud, Hesham
TI Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic:
   Implications on the Risk of Infection and Future Vaccination
SO CNS DRUGS
LA English
DT Article
ID INFLUENZA VACCINE; IMMUNE-RESPONSE; ORAL TERIFLUNOMIDE;
   RANDOMIZED-TRIAL; TREATED PATIENTS; RELAPSING FORMS; INTERFERON;
   PLACEBO; OCRELIZUMAB; CLADRIBINE
AB The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic agent on the immune system is imperative during this special time. The infectious side-effect profile as well as the route and frequency of administration of each therapeutic agent should be carefully considered when selecting a new treatment or deciding on risk mitigation strategies for existing therapy. More importantly, the impact of each agent on the future severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) vaccine should be carefully considered in treatment decisions. Moreover, some multiple sclerosis therapies may have beneficial antiviral effects against SARS-CoV-2 while others may have beneficial immune-modulating effects against the cytokine storm and hyperinflammatory phase of the disease. Conventional injectables have a favorable immune profile without an increased exposure risk and therefore may be suitable for mild multiple sclerosis during the pandemic. However, moderate and highly active multiple sclerosis will continue to require treatment with oral or intravenous high-potency agents but a number of risk mitigation strategies may have to be implemented. Immune-modulating therapies such as the fumerates, sphinogosine-1P modulators, and natalizumab may be anecdotally preferred over cell-depleting immunosuppressants during the pandemic from the immune profile standpoint. Within the cell-depleting agents, selective (ocrelizumab) or preferential (cladribine) depletion of B cells may be relatively safer than non-selective depletion of lymphocytes and innate immune cells (alemtuzumab). Patients who develop severe iatrogenic or idiosyncratic lymphopenia should be advised to maintain social distancing even in areas where lockdown has been removed or ameliorated. Patients with iatrogenic hypogammaglobulinemia may require prophylactic intravenous immunoglobulin therapy in certain situations. When the future SARS-CoV-2 vaccine becomes available, patients with multiple sclerosis should be advised that certain therapies may interfere with mounting a protective immune response to the vaccine and that serological confirmation of a response may be required after vaccination. They should also be aware that most multiple sclerosis therapies are incompatible with live vaccines if a live SARS-CoV-2 vaccine is developed. In this article, we review and compare disease-modifying therapies in terms of their effect on the immune system, published infection rates, potential impact on SARS-CoV-2 susceptibility, and vaccine-related implications. We propose risk mitigation strategies and practical approaches to disease-modifying therapy during the COVID-19 pandemic.
C1 [Zheng, Crystal] Ohio Northern Univ, Raabe Coll Pharm, Ada, OH USA.
   [Kar, Indrani] Univ Hosp Cleveland, Syst Pharm Serv, Cleveland, OH 44106 USA.
   [Chen, Claire Kaori; Sau, Crystal] Univ Hosp Cleveland, Specialty Pharm, Cleveland, OH 44106 USA.
   [Sau, Crystal; Woodson, Sophia; Serra, Alessandro; Abboud, Hesham] Case Western Reserve Univ, Multiple Sclerosis & Neuroimmunol Program, Univ Hosp Cleveland, Sch Med,Cleveland Med Ctr, 5th Floor,11100 Euclid Ave, Cleveland, OH 44106 USA.
   [Serra, Alessandro] Cleveland VA Med Ctr, VA Multiple Sclerosis Ctr Excellence, Cleveland, OH USA.
RP Abboud, H (corresponding author), Case Western Reserve Univ, Multiple Sclerosis & Neuroimmunol Program, Univ Hosp Cleveland, Sch Med,Cleveland Med Ctr, 5th Floor,11100 Euclid Ave, Cleveland, OH 44106 USA.
EM Hesham.abboud@uhhospitals.org
OI Abboud, Hesham/0000-0001-5346-8254
FU US Department of Veterans Affairs, Rehabilitation Research and
   Development ServiceUS Department of Veterans Affairs [IK2RX001180];
   NovartisNovartis; GenentechRoche HoldingGenentech
FX CZ, IK, CKC, and CS report no financial disclosures. SW is a consultant
   and a speaker for Biogen, Novartis, and Sanofi-Genzyme. AS is a
   consultant and speaker for Biogen and is supported in part by Career
   Development Award #IK2RX001180 from the US Department of Veterans
   Affairs, Rehabilitation Research and Development Service. HA received
   research grants from Novartis and Genentech to conduct clinical trials.
   He received consulting fees from Biogen, Genentech, Alexion, and Viela
   Bio. He also received speaker honoraria from Biogen, Genentech, Celgene,
   Sanofi-Genzyme, Alexion, and Viela Bio.
CR AGUIRRE AE, 2020, MULT SCLER RELAT DIS, V44, DOI DOI 10.1016/J.MSARD.2020.102250
   AMEDORO A, 2020, MULT SCLER RELAT DIS, V41, DOI DOI 10.1016/J.MSARD.2020.102315
   [Anonymous], 2016, BET INT BET 1B PRESC
   [Anonymous], 2017, OCR OCR PRESCR INF
   [Anonymous], 2012, AUB TER PRESCR INF
   [Anonymous], 2012, AV INT BET LA PRESCR
   [Anonymous], 2012, GIL FING PRESCR INF
   [Anonymous], 2019, MAYZ SIP PRESCR INF
   [Anonymous], 2014, COP GLAT AC PRESCR I
   [Anonymous], 2020, ZEP OZ PRESCR INF
   [Anonymous], 2019, TYS NAT PRESCR INF
   [Anonymous], 2019, MAV CLADR PRESCR INF
   [Anonymous], 2017, LEMTR AL PRESCR INF
   [Anonymous], 2019, VUM DIR FUM PRESCR I
   Bar-Or A, 2013, NEUROLOGY, V81, P552, DOI 10.1212/WNL.0b013e31829e6fbf
   Barry B, 2019, NEUROL THER, V8, P241, DOI 10.1007/s40120-019-00160-9
   Barzegar M, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000753
   Bollo Luca, 2020, J Neurol Sci, V416, P117011, DOI 10.1016/j.jns.2020.117011
   Borriello G, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102165
   Bowen JD, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000783
   Brownlee W, 2020, NEUROLOGY, V94, P949, DOI 10.1212/WNL.0000000000009507
   Carandini T, 2020, MULT SCLER J, V26, P1268, DOI 10.1177/1352458520926459
   CDC, COR DIS 2019 COVID 1
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen XJ, 2008, ARCH IMMUNOL THER EX, V56, P77, DOI 10.1007/s00005-008-0014-5
   Chiarini M, 2020, J NEUROIMMUNOL, V345, DOI 10.1016/j.jneuroim.2020.577282
   Cohen JA, 2019, LANCET NEUROL, V18, P1021, DOI 10.1016/S1474-4422(19)30238-8
   Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839
   Confavreux C, 2014, LANCET NEUROL, V13, P247, DOI 10.1016/S1474-4422(13)70308-9
   Cross AH, 2014, J INTERN MED, V275, P350, DOI 10.1111/joim.12203
   Dalla Costa G, 2020, NEUROL SCI, V41, P1647, DOI 10.1007/s10072-020-04519-x
   Derfuss T, 2019, 2019 EUR COMM TREATM
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Diebold M, 2019, MULT SCLER J, V25, P1682, DOI 10.1177/1352458519852100
   Durand-Dubief F, 2020, MULT SCLER J, V26, P381, DOI 10.1177/1352458519828663
   Foerch C, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102180
   Fox EJ, 2019, NEUROL-CLIN PRACT, V9, P53, DOI 10.1212/CPJ.0000000000000567
   Fox RJ, 2016, NEUROL-CLIN PRACT, V6, P220, DOI 10.1212/CPJ.0000000000000238
   Fox RJ, 2012, NEW ENGL J MED, V367, P1087, DOI 10.1056/NEJMoa1206328
   Ghajarzadeh M, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102222
   Gilli F, 2017, J NEUROVIROL, V23, P825, DOI 10.1007/s13365-017-0570-8
   Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073
   Giovannoni G, 2017, NEUROTHERAPEUTICS, V14, P874, DOI 10.1007/s13311-017-0573-4
   Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533
   Gomez-Mayordomo V, 2020, J MED VIROL, DOI 10.1002/jmv.26279
   Gross CC, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000289
   Guevara Carlos, 2020, Mult Scler Relat Disord, V44, P102314, DOI 10.1016/j.msard.2020.102314
   Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277
   Hughes R, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102192
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kappos L, 2015, NEUROLOGY, V84, P872, DOI 10.1212/WNL.0000000000001302
   Kieseier BC, 2011, CNS DRUGS, V25, P491, DOI 10.2165/11591110-000000000-00000
   Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581
   Lucchini Matteo, 2020, Mult Scler Relat Disord, V44, P102323, DOI 10.1016/j.msard.2020.102323
   Maghzi AH, 2020, J NEUROL, V267, P2790, DOI 10.1007/s00415-020-09944-8
   Mantero V, 2020, J NEUROL, DOI 10.1007/s00415-020-10015-1
   Matias-Guiu Jorge, 2020, Mult Scler Relat Disord, V44, P102297, DOI 10.1016/j.msard.2020.102297
   Meca-Lallana Virginia, 2020, Mult Scler Relat Disord, V44, P102306, DOI 10.1016/j.msard.2020.102306
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Metze C, 2019, CNS NEUROSCI THER, V25, P245, DOI 10.1111/cns.13034
   Mohn N, 2020, J NEUROL, V267, P2803, DOI 10.1007/s00415-020-09921-1
   Montalban X, 2017, NEW ENGL J MED, V376, P209, DOI 10.1056/NEJMoa1606468
   Montero-Escribano P, 2020, SPAIN MULT SCLER REL, V42, DOI [10.1016/j.msard.2020.102185, DOI 10.1016/J.MSARD.2020.102185]
   MSIF, GLOB COVID 19 ADV PE
   Naismith RT, 2020, CNS DRUGS, V34, P185, DOI 10.1007/s40263-020-00700-0
   Nesbitt C, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102338
   Novi G, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.101430
   O'Connor P, 2011, NEW ENGL J MED, V365, P1293, DOI 10.1056/NEJMoa1014656
   Olberg HK, 2018, EUR J NEUROL, V25, P527, DOI 10.1111/ene.13537
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Paolicelli D, 2020, CNS DRUGS, V34, P65, DOI 10.1007/s40263-019-00691-7
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Pellegrino P, 2014, VACCINE, V32, P4730, DOI 10.1016/j.vaccine.2014.06.068
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Qin C., 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa248., DOI 10.1093/CID/CIAA248, 10.1093/cid/ciaa248]
   Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013
   Roberts DM, 2015, J AUTOIMMUN, V57, P60, DOI 10.1016/j.jaut.2014.11.009
   Ryerson LZ, 2016, J NEUROL NEUROSUR PS, V87, P885, DOI 10.1136/jnnp-2015-312940
   Safavi F, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102195
   Schwid SR, 2005, NEUROLOGY, V65, P1964, DOI 10.1212/01.wnl.0000188901.12700.e0
   Sigrist CJA, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104759
   Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Stuve O, 2019, THER ADV NEUROL DISO, V12, DOI 10.1177/1756286419854986
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Thornton Jeanine Rempe, 2020, Mult Scler Relat Disord, V44, P102341, DOI 10.1016/j.msard.2020.102341
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Vagberg M, 2012, NEUROL RES, V34, P730, DOI 10.1179/1743132812Y.0000000059
   Valencia-Sanchez C, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102182
   van Assen S, 2010, ARTHRITIS RHEUM-US, V62, P75, DOI 10.1002/art.25033
   von Hehn C, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000409
   Winkelmann A, 2014, CLIN EXP IMMUNOL, V175, P425, DOI 10.1111/cei.12226
   World Health Organization, 2020, NOV COR SIT REP 99
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
NR 98
TC 0
Z9 0
U1 3
U2 3
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1172-7047
EI 1179-1934
J9 CNS DRUGS
JI CNS Drugs
PD SEP
PY 2020
VL 34
IS 9
BP 879
EP 896
DI 10.1007/s40263-020-00756-y
EA AUG 2020
PG 18
WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA NF2IS
UT WOS:000559259000001
PM 32780300
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tarek, M
   Savarino, A
AF Tarek, Mohammad
   Savarino, Andrea
TI Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19:
   Implications for Therapy and Prevention
SO EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
LA English
DT Article
ID CHLOROQUINE; INFECTION; DRUG
AB Background and Objectives Chloroquine/hydroxychloroquine has recently been the subject of intense debate regarding its potential antiviral activity against SARS-Cov-2, the etiologic agent of COVID-19. Some report possible curative effects; others do not. Therefore, the objective of this study was to simulate possible scenarios of response to hydroxychloroquine in COVID-19 patients using mathematical modeling. Methods To shed some light on this controversial topic, we simulated hydroxychloroquine-based interventions on virus/host cell dynamics using a basic system of previously published differential equations. Mathematical modeling was implemented using Python programming language v 3.7. Results According to mathematical modeling, hydroxychloroquine may have an impact on the amplitude of the viral load peak and viral clearance if the drug is administered early enough (i.e., when the virus is still confined within the pharyngeal cavity). The effects of chloroquine/hydroxychloroquine may be fully explained only when also considering the capacity of this drug to increase the death rate of SARS-CoV-2-infected cells, in this case by enhancing the cell-mediated immune response. Conclusions These considerations may not only be applied to chloroquine/hydroxychloroquine but may have more general implications for development of anti-COVID-19 combination therapies and prevention strategies through an increased death rate of the infected cells.
C1 [Tarek, Mohammad] Armed Forces Coll Med AFCM, Bioinformat Dept, Cairo, Egypt.
   [Savarino, Andrea] Ist Super Sanita, Dept Infect Dis, Viale Regina Elena 299, I-00161 Rome, Italy.
RP Savarino, A (corresponding author), Ist Super Sanita, Dept Infect Dis, Viale Regina Elena 299, I-00161 Rome, Italy.
EM andrea.savarino@iss.it
OI Savarino, Andrea/0000-0003-0983-3693
CR Accapezzato D, 2005, J EXP MED, V202, P817, DOI 10.1084/jem.20051106
   Arnold SLM, 2020, CTS-CLIN TRANSL SCI, V13, P642, DOI 10.1111/cts.12797
   Baccam P, 2006, J VIROL, V80, P7590, DOI 10.1128/JVI.01623-05
   Best K, 2017, P NATL ACAD SCI USA, V114, P8847, DOI 10.1073/pnas.1704011114
   Boelaert JR, 2001, J CLIN VIROL, V20, P137, DOI 10.1016/S1386-6532(00)00140-2
   Borba MGS, 2020, CHLOROQUINE DIPHOSPH, DOI [10.1101/2020.04.07.20056424, DOI 10.1101/2020.04.07.20056424]
   Boulware D, POSTEXPOSURE PROPHYL
   Carlsson H, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02211-1
   Chang D, 2020, AM J RESP CRIT CARE, V201, P1150, DOI 10.1164/rccm.202003-0524LE
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Fan Jianghong, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa623
   Fong KY, 2013, FUTURE MED CHEM, V5, P1437, DOI 10.4155/fmc.13.113
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gil-Moles M, 2020, GOLD METALLODRUGS FI, DOI [10.26434/chemrxiv.12488390.v1., DOI 10.26434/CHEMRXIV.12488390.V1]
   Goncalves A, 2020, CPT-PHARMACOMET SYST, V9, P509, DOI 10.1002/psp4.12543
   Guerin V, 2020, AZITHROMYCIN HYDROXY, DOI [10.20944/preprints202005.0486.v1, DOI 10.20944/PREPRINTS202005.0486.V1]
   Huang MX, 2020, J MOL CELL BIOL, V12, P322, DOI 10.1093/jmcb/mjaa014
   Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55
   Kim KS, 2020, MODELLING SARS COV 2, DOI [10.1101/2020.03.23.20040493, DOI 10.1101/2020.03.23.20040493]
   Langtangen H.P., 2016, SCALING DIFFERENTIAL
   Lee SH, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105988
   Li CT, 2020, MATH BIOSCI ENG, V17, P2853, DOI 10.3934/mbe.2020159
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Morita S, 2016, THER DRUG MONIT, V38, P259, DOI 10.1097/FTD.0000000000000261
   Oscanoa TJ, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106078
   Pagliano P, 2020, CLIN INFECT DIS, V71, P887, DOI 10.1093/cid/ciaa320
   Perelson AS, 2012, J INFECT DIS, V205, P1642, DOI 10.1093/infdis/jis265
   Potsch WR, 1988, LEXIKON BEDEUTENDER
   PRINCIPI N, 2020, EXPERT OPIN BIO 0420, DOI DOI 10.1016/S1473-3099(20)30296-6
   PUSSARD E, 1991, ANTIMICROB AGENTS CH, V35, P406, DOI 10.1128/AAC.35.3.406
   Rong LB, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000533
   Rothan HA, 2020, VIROLOGY, V547, P7, DOI 10.1016/j.virol.2020.05.002
   Sarayani Amir, 2021, Res Social Adm Pharm, V17, P483, DOI 10.1016/j.sapharm.2020.04.016
   Savarino A, 2000, AIDS, V14, P1079, DOI 10.1097/00002030-200006160-00004
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Savarino A, 2006, EXPERT OPIN THER PAT, V16, P1269, DOI 10.1517/13543776.16.9.1269
   Shytaj IL, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-71
   Shytaj IL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002774
   Smit C, 2020, CLIN PHARMACOKINET, V59, P659, DOI 10.1007/s40262-020-00891-1
   van der Walt S, 2011, COMPUT SCI ENG, V13, P22, DOI 10.1109/MCSE.2011.37
   Virtanen P, 2020, NAT METHODS, V17, P261, DOI 10.1038/s41592-019-0686-2
   Wallace DJ, 2007, DUBOIS LUPUS ERYTHEM
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yen YT, 2006, J VIROL, V80, P2684, DOI 10.1128/JVI.80.6.2684-2693.2006
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 48
TC 1
Z9 1
U1 5
U2 5
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 0378-7966
EI 2107-0180
J9 EUR J DRUG METAB PH
JI Eur. J. Drug Metabol. Pharmacokinet.
PD DEC
PY 2020
VL 45
IS 6
BP 715
EP 723
DI 10.1007/s13318-020-00640-6
EA AUG 2020
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OT6CV
UT WOS:000559371500001
PM 32780273
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Aktas, A
   Tuzun, B
   Aslan, R
   Sayin, K
   Ataseven, H
AF Aktas, Ahmet
   Tuzun, Burak
   Aslan, Rukiye
   Sayin, Koray
   Ataseven, Hilmi
TI New anti-viral drugs for the treatment of COVID-19 instead of
   favipiravir
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID19; RNA polymerase; favipiravir; MM-PBSA; ADME
ID MOLECULAR DOCKING; SOLUBILITY; EXPRESSION; GLIDE
AB The SARS-CoV-2 virus is a major problem in the world right now. Currently, all the attention of research centers and governments globally are focused on the investigation of vaccination studies and the discovery of small molecules that inhibit the SARS-CoV-2 virus in the treatment of patients. The goal of this study was to locate small molecules to be used against COVID19 instead of favipiravir. Favipiravir analogues were selected as drug candidates from the PubChem web tool. The RNA dependent RNA polymerase (RdRp) protein was selected as the target protein as favipiravir inhibits this protein in the human body. Initially, the inhibition activity of the studied compounds against RdRp of different virus types was investigated. Then, the inhibition properties of selected drug candidates and favipiravir were examined in detail against SARS-CoV-2 RdRp proteins. It was found that 2-oxo-1H-pyrazine-3-carboxamide performed better than favipiravir in the results of molecular docking, molecular mechanics Poisson-Boltzmann surface area (MM-PSBA) calculations, and ADME analyses. Communicated by Ramaswamy H. Sarma
C1 [Aktas, Ahmet] Sivas Cumhuriyet Univ, Fac Med, Dept Internal Med, Sivas, Turkey.
   [Tuzun, Burak; Sayin, Koray] Sivas Cumhuriyet Univ, Fac Sci, Dept Chem, Sivas, Turkey.
   [Aslan, Rukiye] Sivas Cumhuriyet Univ, Vocat Sch Hlth Serv, Med Serv & Tech Dept, Sivas, Turkey.
   [Sayin, Koray] Sivas Cumhuriyet Univ, Adv Technol Res & Applicat Ctr, Sivas, Turkey.
   [Ataseven, Hilmi] Sivas Cumhuriyet Univ, Fac Med, Dept Gastroenterol, Sivas, Turkey.
   [Ataseven, Hilmi] Gen Directorate Publ Hosp, Minist Hlth Republ Turkey, Ankara, Turkey.
RP Sayin, K (corresponding author), Sivas Cumhuriyet Univ, Fac Sci, Dept Chem, Sivas, Turkey.
EM krysayin@gmail.com
OI TUZUN, BURAK/0000-0002-0420-2043
FU Scientific Research Project Fund of Sivas Cumhuriyet University
   (CUBAP)Cumhuriyet University [RGD-020]
FX This work was supported by the Scientific Research Project Fund of Sivas
   Cumhuriyet University (CUBAP) under the project number RGD-020. We thank
   all reviewers who helped improve this article.
CR Acar MF, 2019, DRUG DEVELOP RES, V80, P606, DOI 10.1002/ddr.21538
   [Anonymous], 2019, SCHROD REL 2019 4 LI
   [Anonymous], 2019, SCHROD REL 2019 4 MA
   [Anonymous], 2020, SCHROD REL 2020 1 QI
   Bcak B., 2019, BILGE INT J SCI TECH, V3, P1, DOI [https://doi.org/10.30516/bilgesci.476841, DOI 10.30516/BILGESCI.476841]
   Beylkin D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17419-6
   Bost AG, 2000, J VIROL, V74, P3379, DOI 10.1128/JVI.74.7.3379-3387.2000
   Brockway SM, 2003, J VIROL, V77, P10515, DOI 10.1128/JVI.77.19.10515-10527.2003
   Budama-Kilinc Y, 2018, J FLUORESC, V28, P1127, DOI 10.1007/s10895-018-2276-6
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Credille CV, 2019, J MED CHEM, V62, P9438, DOI 10.1021/acs.jmedchem.9b00747
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Ertas M, 2019, ARCH PHARM, V352, DOI 10.1002/ardp.201900033
   Fan HT, 2019, NATURE, V573, P287, DOI 10.1038/s41586-019-1530-7
   Fodor E, 2013, ACTA VIROL, V57, P113, DOI 10.4149/av_2013_02_113
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Fudo S, 2016, BIOCHEMISTRY-US, V55, P2646, DOI 10.1021/acs.biochem.5b01087
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Hunt R, 2020, CORONAVIRUSES COLDS
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X
   Kecel-Gunduz S, 2020, DARU, V28, P139, DOI 10.1007/s40199-019-00325-9
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Mentese E, 2019, BIOORG CHEM, V86, P151, DOI 10.1016/j.bioorg.2019.01.061
   Mermer A, 2019, J MOL STRUCT, V1181, P412, DOI 10.1016/j.molstruc.2018.12.114
   Nelson MT, 1996, INT J SUPERCOMPUT AP, V10, P251, DOI 10.1177/109434209601000401
   Nguyen M, 2003, VIRUS RES, V93, P141, DOI 10.1016/S0168-1702(03)00094-7
   Omoto S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27890-4
   Saglik BN, 2019, BIOORG CHEM, V91, DOI 10.1016/j.bioorg.2019.103153
   Saglik BN, 2019, BIOORG CHEM, V85, P97, DOI 10.1016/j.bioorg.2018.12.019
   Sari S, 2019, BIOORG CHEM, V86, P296, DOI 10.1016/j.bioorg.2019.02.015
   Singh P, 2014, MED CHEM RES, V23, P5074, DOI 10.1007/s00044-014-1090-1
   TurkishMinistryofHealth, 2020, COVID 19 SARS COV 2
   World Health Organization, 2020, COR DIS 2019 COVID 1
NR 42
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1806112
EA AUG 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MZ2LZ
UT WOS:000558956800001
PM 32783586
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ogawa, Y
   Nagata, T
   Akiyama, T
   Nishida, K
   Kumasawa, J
   Kohno, M
   Kohata, H
   Gohma, I
AF Ogawa, Yoshihiko
   Nagata, Toshihiko
   Akiyama, Taisuke
   Nishida, Koji
   Kumasawa, Junji
   Kohno, Michihiko
   Kohata, Hisakazu
   Gohma, Iwao
TI Argatroban therapy for heparin-induced thrombocytopenia in a patient
   with coronavirus disease 2019
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Letter
C1 [Ogawa, Yoshihiko] Sakai City Med Ctr, Dept Infect Dis, Ebaraji 1-1-1, Sakai, Osaka 5938304, Japan.
   [Nagata, Toshihiko; Akiyama, Taisuke; Kumasawa, Junji; Kohno, Michihiko; Kohata, Hisakazu] Sakai City Med Ctr, Dept Crit Care Med, Ebaraji 1-1-1, Sakai, Osaka 5938304, Japan.
   [Nishida, Koji; Gohma, Iwao] Sakai City Med Ctr, Dept Resp Med, Ebaraji 1-1-1, Sakai, Osaka 5938304, Japan.
RP Ogawa, Y (corresponding author), Sakai City Med Ctr, Dept Infect Dis, Ebaraji 1-1-1, Sakai, Osaka 5938304, Japan.
EM hikoichi.ogw@gmail.com
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arepally GM, 2017, BLOOD, V129, P2864, DOI 10.1182/blood-2016-11-709873
   Krauel K, 2011, BLOOD, V117, P1370, DOI 10.1182/blood-2010-08-301424
   Liu X., 2020, HEPARIN INDUCED THRO, DOI [10.1101/2020.04.23.20076851, DOI 10.1101/2020.04.23.20076851]
   Lo GK, 2006, J THROMB HAEMOST, V4, P759, DOI 10.1111/j.1538-7836.2006.01787.x
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Patell R, 2020, AM J HEMATOL, V95, pE295, DOI 10.1002/ajh.25935
   Saugel B, 2010, CRIT CARE, V14, DOI 10.1186/cc9024
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
NR 9
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD NOV
PY 2020
VL 50
IS 4
BP 1012
EP 1014
DI 10.1007/s11239-020-02248-8
EA AUG 2020
PG 3
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA OD4QN
UT WOS:000558625800001
PM 32780355
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rivinius, R
   Kaya, Z
   Schramm, R
   Boeken, U
   Provaznik, Z
   Heim, C
   Knosalla, C
   Schoenrath, F
   Rieth, A
   Berchtold-Herz, M
   Barten, MJ
   Rauschning, D
   Mucke, VT
   Heyl, S
   Pistulli, R
   Grinninger, C
   Hagl, C
   Gummert, JF
   Warnecke, G
   Schulze, PC
   Katus, HA
   Kreusser, MM
   Raake, PW
AF Rivinius, Rasmus
   Kaya, Ziya
   Schramm, Rene
   Boeken, Udo
   Provaznik, Zdenek
   Heim, Christian
   Knosalla, Christoph
   Schoenrath, Felix
   Rieth, Andreas
   Berchtold-Herz, Michael
   Barten, Markus J.
   Rauschning, Dominic
   Muecke, Victoria T.
   Heyl, Stephan
   Pistulli, Rudin
   Grinninger, Carola
   Hagl, Christian
   Gummert, Jan F.
   Warnecke, Gregor
   Schulze, P. Christian
   Katus, Hugo A.
   Kreusser, Michael M.
   Raake, Philip W.
TI COVID-19 among heart transplant recipients in Germany: a multicenter
   survey
SO CLINICAL RESEARCH IN CARDIOLOGY
LA English
DT Article
DE COVID-19; Heart transplantation; Immunosuppression; Mortality
ID REPLICATION; SENSITIVITY; FAILURE; COV
AB Aims Heart transplantation may represent a particular risk factor for severe coronavirus infectious disease 2019 (COVID-19) due to chronic immunosuppression and frequent comorbidities. We conducted a nation-wide survey of all heart transplant centers in Germany presenting the clinical characteristics of heart transplant recipients with COVID-19 during the first months of the pandemic in Germany. Methods and results A multicenter survey of all heart transplant centers in Germany evaluating the current status of COVID-19 among adult heart transplant recipients was performed. A total of 21 heart transplant patients with COVID-19 was reported to the transplant centers during the first months of the pandemic in Germany. Mean patient age was 58.6 +/- 12.3 years and 81.0% were male. Comorbidities included arterial hypertension (71.4%), dyslipidemia (71.4%), diabetes mellitus (33.3%), chronic kidney failure requiring dialysis (28.6%) and chronic-obstructive lung disease/asthma (19.0%). Most patients received an immunosuppressive drug regimen consisting of a calcineurin inhibitor (71.4%), mycophenolate mofetil (85.7%) and steroids (71.4%). Eight of 21 patients (38.1%) displayed a severe course needing invasive mechanical ventilation. Those patients showed a high mortality (87.5%) which was associated with right ventricular dysfunction (62.5% vs. 7.7%;p = 0.014), arrhythmias (50.0% vs. none;p = 0.012), and thromboembolic events (50.0% vs. none;p = 0.012). Elevated high-sensitivity cardiac troponin T- and N-terminal prohormone of brain natriuretic peptide were significantly associated with the severe form of COVID-19 (p = 0.017 andp < 0.001, respectively). Conclusion Severe course of COVID-19 was frequent in heart transplanted patients. High mortality was associated with right ventricular dysfunction, arrhythmias, thromboembolic events, and markedly elevated cardiac biomarkers.
C1 [Rivinius, Rasmus; Kaya, Ziya; Katus, Hugo A.; Kreusser, Michael M.; Raake, Philip W.] Heidelberg Univ Hosp, Dept Cardiol Angiol & Pneumol, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
   [Rivinius, Rasmus; Kaya, Ziya; Warnecke, Gregor; Katus, Hugo A.; Kreusser, Michael M.; Raake, Philip W.] German Ctr Cardiovasc Res DZHK, Partner Site Heidelberg Mannheim, Heidelberg, Germany.
   [Schramm, Rene; Gummert, Jan F.] Heart & Diabet Ctr NRW, Dept Thorac & Cardiovasc Surg, Bad Oeynhausen, Germany.
   [Boeken, Udo] Dusseldorf Univ Hosp, Dept Cardiac Surg, Dusseldorf, Germany.
   [Provaznik, Zdenek] Regensburg Univ Hosp, Dept Cardiovasc Surg, Regensburg, Germany.
   [Heim, Christian] Erlangen Univ Hosp, Dept Cardiovasc Surg, Erlangen, Germany.
   [Knosalla, Christoph; Schoenrath, Felix] German Heart Ctr Berlin, Dept Cardiothorac & Vasc Surg, Berlin, Germany.
   [Knosalla, Christoph; Schoenrath, Felix] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany.
   [Rieth, Andreas] Kerckhoff Hosp, Dept Cardiol, Bad Nauheim, Germany.
   [Berchtold-Herz, Michael] Univ Heart Ctr Freiburg Bad Krozingen, Dept Cardiovasc Surg, Freiburg, Germany.
   [Barten, Markus J.] Univ Heart & Vasc Ctr, Dept Cardiovasc Surg, Hamburg, Germany.
   [Rauschning, Dominic] Bundeswehr Cent Hosp, Dept Internal Med, Koblenz, Germany.
   [Muecke, Victoria T.] Frankfurt Univ Hosp, Dept Internal Med 1, Frankfurt, Germany.
   [Heyl, Stephan] Frankfurt Univ Hosp, Dept Internal Med 3, Frankfurt, Germany.
   [Pistulli, Rudin] Munster Univ Hosp, Dept Cardiol Coronary & Peripheral Vasc Dis 1, Heart Failure, Munster, Germany.
   [Grinninger, Carola; Hagl, Christian] Munich Univ Hosp, Dept Cardiac Surg, Munich, Germany.
   [Grinninger, Carola; Hagl, Christian] German Ctr Cardiovasc Res DZHK, Partner Site Munich, Munich, Germany.
   [Warnecke, Gregor] Heidelberg Univ Hosp, Dept Cardiac Surg, Heidelberg, Germany.
   [Schulze, P. Christian] Jena Univ Hosp, Dept Cardiol Angiol & Pneumol, Jena, Germany.
   [Kreusser, Michael M.] German Ctr Infect Res DZIF, Partner Site Heidelberg, Heidelberg, Germany.
RP Kreusser, MM (corresponding author), Heidelberg Univ Hosp, Dept Cardiol Angiol & Pneumol, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.; Kreusser, MM (corresponding author), German Ctr Cardiovasc Res DZHK, Partner Site Heidelberg Mannheim, Heidelberg, Germany.; Kreusser, MM (corresponding author), German Ctr Infect Res DZIF, Partner Site Heidelberg, Heidelberg, Germany.
EM michael.kreusser@med.uni-heidelberg.de
RI Rivinius, Rasmus/S-6820-2019
FU Projekt DEAL
FX Open Access funding provided by Projekt DEAL.
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373
   Bohm M, 2020, CLIN RES CARDIOL, V109, P1446, DOI 10.1007/s00392-020-01656-3
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cremer Paul C, 2020, Cleve Clin J Med, V87, P521, DOI 10.3949/ccjm.87a.ccc001
   Crespo-Leiro MG, 2018, EUR J HEART FAIL, V20, P1505, DOI 10.1002/ejhf.1236
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Fan L, 2020, EUR RADIOL, V30, P5214, DOI 10.1007/s00330-020-06898-3
   Fang Y., 2020, RADIOLOGY, DOI DOI 10.1148/RADI0L.2020200432
   Gao L, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01352-w
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gummert JF, 2017, EUR HEART J, V38, P3411, DOI 10.1093/eurheartj/ehx698
   Holzhauser L, 2020, AM J TRANSPLANT, V20, P2916, DOI 10.1111/ajt.15982
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kreusser MM, 2020, CLIN RES CARDIOL, V109, P700, DOI 10.1007/s00392-019-01559-y
   Latif F, 2020, JAMA CARDIOL, V5, P1165, DOI 10.1001/jamacardio.2020.2159
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Li HS, 2018, ANTIVIR RES, V155, P89, DOI 10.1016/j.antiviral.2018.05.007
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Mathies D, 2020, AM J TRANSPLANT, V20, P1925, DOI 10.1111/ajt.15932
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Muller O, 2020, DEUT MED WOCHENSCHR, V145, P670, DOI 10.1055/a-1162-1987
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Pickering JW, 2020, CLIN CHIM ACTA, V505, P15, DOI 10.1016/j.cca.2020.02.009
   Rath D, 2020, CLIN RES CARDIOL, V109, P1491, DOI 10.1007/s00392-020-01683-0
   Rattka M, 2020, CLIN RES CARDIOL, V109, P1476, DOI 10.1007/s00392-020-01681-2
   Ren ZL, 2020, J HEART LUNG TRANSPL, V39, P412, DOI 10.1016/j.healun.2020.03.008
   Rivinius R, 2020, CLIN RES CARDIOL, DOI 10.1007/s00392-020-01692-z
   Rivinius R, 2018, CLIN RES CARDIOL, V107, P138, DOI 10.1007/s00392-017-1165-3
   Schmack B, 2018, CLIN RES CARDIOL, V107, P413, DOI 10.1007/s00392-017-1200-4
   Settelmeier S, 2020, CLIN RES CARDIOL, V109, P1469, DOI 10.1007/s00392-020-01676-z
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Van Camp G, 2020, CLIN RES CARDIOL, V109, P1573, DOI 10.1007/s00392-020-01686-x
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xydakis MS, 2020, LANCET INFECT DIS, V20, P1015, DOI 10.1016/S1473-3099(20)30293-0
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 47
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1861-0684
EI 1861-0692
J9 CLIN RES CARDIOL
JI Clin. Res. Cardiol.
PD DEC
PY 2020
VL 109
IS 12
SI SI
BP 1531
EP 1539
DI 10.1007/s00392-020-01722-w
EA AUG 2020
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OX4ZR
UT WOS:000558595000001
PM 32783099
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Sanchez-Pina, JM
   Rodriguez, MR
   Quismondo, NC
   Manso, RG
   Colmenares, R
   Alos, DG
   Paciello, ML
   Zafra, D
   Garcia-Sanchez, C
   Villegas, C
   Cuellar, C
   Carreno-Tarragona, G
   Zamanillo, I
   Poza, M
   Iniguez, R
   Gutierrez, X
   Alonso, R
   Rodriguez, A
   Folgueira, MD
   Delgado, R
   Ferrari, JM
   Lizasoain, M
   Aguado, JM
   Ayala, R
   Martinez-Lopez, J
   Calbacho, M
AF Sanchez-Pina, Jose Maria
   Rodriguez Rodriguez, Mario
   Castro Quismondo, Nerea
   Gil Manso, Rodrigo
   Colmenares, Rafael
   Gil Alos, Daniel
   Paciello, Mari Liz
   Zafra, Denis
   Garcia-Sanchez, Cristina
   Villegas, Carolina
   Cuellar, Clara
   Carreno-Tarragona, Gonzalo
   Zamanillo, Irene
   Poza, Maria
   Iniguez, Rodrigo
   Gutierrez, Xabier
   Alonso, Rafael
   Rodriguez, Antonia
   Folgueira, Maria Dolores
   Delgado, Rafael
   Ferrari, Jose Miguel
   Lizasoain, Manuel
   Aguado, Jose Maria
   Ayala, Rosa
   Martinez-Lopez, Joaquin
   Calbacho, Maria
TI Clinical course and risk factors for mortality from COVID-19 in patients
   with haematological malignancies
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE cancer; COVID-19; haematology; outcome; SARS-CoV-2
ID RESPIRATORY VIRAL-INFECTIONS; STEM-CELL TRANSPLANTATION;
   VIRUS-INFECTIONS; TRACT INFECTIONS; SOLID-ORGAN; RECIPIENTS;
   CORONAVIRUS; SARS-COV-2
AB Background The impact of coronavirus disease 2019 (COVID-19) in haematological patients (HP) has not been comprehensively reported. Methods We analysed 39 patients with SARS-CoV-2 infection and haematological malignancies. Clinical characteristics and outcomes were compared to a matched control group of 53 non-cancer patients with COVID-19. Univariate and multivariate analyses were carried out to assess the risk factors associated with poor outcome. Results The most frequent haematological diseases were lymphoma (30%) and multiple myeloma (30%). Eighty-seven % HP developed moderate or severe disease. Patients with haematological malignancies had a significantly higher mortality rate compared to non-cancer patients (35.9% vs 13.2%;P = .003 (odds ratio 6.652). The worst outcome was observed in chronic lymphocytic leukaemia patients. Only age >70 years and C reactive protein >10 mg/dl at admission were associated with higher risk of death (odds ratio 34.86,P = .003 and 13.56,P = .03). Persistent viral sheddind was detected in 5 HP. Active chemotherapy, viral load at diagnosis and COVID-19 therapy were not predictors of outcome. Conclusion Mortality of COVID-19 is significantly higher in patients with haematological malignancies compared to non-cancer patients. The impact of persistent viral shedding must be considered in order to re-start therapies and maintain infectious control measures.
C1 [Sanchez-Pina, Jose Maria; Rodriguez Rodriguez, Mario; Castro Quismondo, Nerea; Gil Manso, Rodrigo; Colmenares, Rafael; Gil Alos, Daniel; Paciello, Mari Liz; Zafra, Denis; Garcia-Sanchez, Cristina; Villegas, Carolina; Cuellar, Clara; Carreno-Tarragona, Gonzalo; Zamanillo, Irene; Poza, Maria; Iniguez, Rodrigo; Gutierrez, Xabier; Alonso, Rafael; Rodriguez, Antonia; Ayala, Rosa; Martinez-Lopez, Joaquin; Calbacho, Maria] Univ Complutense Madrid, Hosp 12 Octubre imas12, Hosp Univ 12 Octubre, Dept Hematol,CNIO,CIBERONC,Inst Invest Sanitaria, Madrid, Spain.
   [Folgueira, Maria Dolores; Delgado, Rafael] Hosp 12 Octubre imas12, Inst Invest Sanitaria, Hosp Univ 12 Octubre, Dept Microbiol, Madrid, Spain.
   [Ferrari, Jose Miguel] Hosp 12 Octubre imas12, Inst Invest Sanitaria, Hosp Univ 12 Octubre, Dept Pharm, Madrid, Spain.
   [Lizasoain, Manuel; Aguado, Jose Maria] Hosp 12 Octubre imas12, Inst Invest Sanitaria, Hosp Univ 12 Octubre, Unit Infect Dis, Madrid, Spain.
RP Martinez-Lopez, J (corresponding author), Hosp Univ 12 Octubre, Dept Hematol, Ctr Actividades Ambulatorias, 3 Planta,Bloque D,Avda Cordoba S-N, Madrid 28041, Spain.
EM jmarti01@med.ucm.es
RI Delgado, Rafael/C-4910-2016
OI Delgado, Rafael/0000-0002-6912-4736; Martinez-Lopez,
   Joaquin/0000-0001-7908-0063; AYALA DIAZ, ROSA MARIA/0000-0002-2699-8353
FU Spanish Ministry of Science and Innovation, Instituto de Salud Carlos
   IIIInstituto de Salud Carlos IIISpanish Government [COV20/0018]
FX Spanish Ministry of Science and Innovation, Instituto de Salud Carlos
   III: research contract COV20/0018
CR Alzghari SK, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104380
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bhimraj A, 2020, INFECT DIS SOC AM GU
   Blimark C, 2015, HAEMATOLOGICA, V100, P107, DOI 10.3324/haematol.2014.107714
   Boulad F, 2020, ONCOL, DOI [10.1001/jamaoncol.2020.2028, DOI 10.1001/JAMAONCOL.2020.2028]
   Center for Systems Science and Engineering, 2019, COR COVID 19 GLOB CA
   Chanan-Khan A, 2008, J CLIN ONCOL, V26, P4784, DOI 10.1200/JCO.2007.14.9641
   Chemaly RF, 2006, MEDICINE, V85, P278, DOI 10.1097/01.md.0000232560.22098.4e
   D'Angelo CR, 2016, LEUKEMIA LYMPHOMA, V57, P1807, DOI 10.3109/10428194.2015.1113279
   de Lima CRA, 2014, TRANSPL INFECT DIS, V16, P165, DOI 10.1111/tid.12167
   Dignan FL, 2016, BRIT J HAEMATOL, V173, P380, DOI 10.1111/bjh.14027
   Documento tecnico, 2020, TOM TRANSP MUESTR DI
   England James T, 2020, Blood Rev, P100707, DOI 10.1016/j.blre.2020.100707
   ESMO, CANC PAT MAN COVID 1
   Falanga A, 2009, J CLIN ONCOL, V27, P4848, DOI 10.1200/JCO.2009.22.8197
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Ford ES, 2020, CURR OPIN INFECT DIS, V33, P205, DOI 10.1097/QCO.0000000000000626
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Hilal T, 2018, BLOOD REV, V32, P387, DOI 10.1016/j.blre.2018.03.004
   Kim SE, 2020, INT J INFECT DIS, V95, P441, DOI 10.1016/j.ijid.2020.04.083
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Ljungman P, 2001, BONE MARROW TRANSPL, V28, P479, DOI 10.1038/sj.bmt.1703139
   Ljungman P, 2020, BONE MARROW TRANSPL, V55, P2071, DOI 10.1038/s41409-020-0919-0
   Pinana JL, 2019, TRANSPL INFECT DIS, V21, DOI 10.1111/tid.13158
   Pinana JL, 2018, BIOL BLOOD MARROW TR, V24, P563, DOI 10.1016/j.bbmt.2017.11.001
   Macrophages PMD, 2020, NAT REV IMMUNOL, DOI [10.1038/s41577-020-0317-2, DOI 10.1038/S41577-020-0317-2]
   Magira EE, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz247
   Malard F, 2020, BONE MARROW TRANSPL, V55, P2180, DOI 10.1038/s41409-020-0931-4
   Martin-Moro F, 2020, BRIT J HAEMATOL, V190, pE16, DOI 10.1111/bjh.16801
   Martino R, 2005, BIOL BLOOD MARROW TR, V11, P781, DOI 10.1016/j.bbmt.2005.07.007
   Milano F, 2010, BLOOD, V115, P2088, DOI 10.1182/blood-2009-09-244152
   Ministerio de Sanidad Centro de Coordinacion de Alertas y Emergencias Sanitarias, DOC TECN MAN CLIN PA
   Nucci M, 2009, CLIN INFECT DIS, V49, P1211, DOI 10.1086/605664
   Palumbo A, 2008, LEUKEMIA, V22, P414, DOI 10.1038/sj.leu.2405062
   Paulsen GC, 2017, CLIN CHEST MED, V38, P707, DOI 10.1016/j.ccm.2017.07.012
   Renaud C, 2013, BIOL BLOOD MARROW TR, V19, P1220, DOI 10.1016/j.bbmt.2013.05.005
   Renaud C, 2011, CURR OPIN INFECT DIS, V24, P333, DOI 10.1097/QCO.0b013e3283480440
   Teh BW, 2018, BLOOD REV, V32, P499, DOI 10.1016/j.blre.2018.04.007
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Villegas C, 2020, ANN HEMATOL, V99, P2953, DOI 10.1007/s00277-020-04160-w
   Whimbey E, 1996, CLIN INFECT DIS, V22, P778, DOI 10.1093/clinids/22.5.778
   Whimbey Estella, 1997, American Journal of Medicine, V102, P10, DOI 10.1016/S0002-9343(97)80004-6
   World Health Organization (WHO), 2020, NOV COR CHIN
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 49
TC 3
Z9 3
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-4441
EI 1600-0609
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD NOV
PY 2020
VL 105
IS 5
BP 597
EP 607
DI 10.1111/ejh.13493
EA AUG 2020
PG 11
WC Hematology
SC Hematology
GA NW8SK
UT WOS:000557867500001
PM 32710500
OA Bronze
DA 2021-01-01
ER

PT J
AU Dave, GS
   Rakholiya, KD
   Kaneria, MJ
   Galvadiya, BP
   Vyas, SR
   Kanbi, VH
   Patel, MP
AF Dave, Gaurav S.
   Rakholiya, Kalpna D.
   Kaneria, Mital J.
   Galvadiya, Bhemji P.
   Vyas, Sudhanshu R.
   Kanbi, Vaktabhai H.
   Patel, Manubhai P.
TI High affinity interaction ofSolanum tuberosumandBrassica juncearesidue
   smoke water compounds with proteins involved in coronavirus infection
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE COVID-19; molecular docking; phytoconstituents; smoke water
ID IN-VIVO; EXTRACT; BINDING; TMPRSS2; FENFLURAMINE; SELEGILINE;
   CURCUMENOL; PRODUCTS; PYRAZOLE; RECEPTOR
AB The world is in an immediate need of treatment for coronavirus disease (COVID-19). Chronic exposure of hydroxychloroquine in the treatment of COVID-19 may have multiple adverse effects on human physiology, such as cardiac arrhythmias. Natural compounds need to be evaluated as treatment and preventive agents in coronavirus infection. A total of 30 compounds ofSolanum tuberosumandBrassica juncearesidue smoke water were selected for the virtual screening against SARS-CoV-1, SARS-CoV-2 and cellular proteins involved in the mechanism of infection. Docking analysis identified lead molecules with favorable binding energy, number of poses and hydrogen bond interactions, which indicates the effective modulation of ACE2 and TMPRSS2 receptors. Results indicated (a) curcumenol, (b)N-desmethylselegiline, (c) phentermine and (d) sphingolipid derivatives as a selective and potent candidates in comparison to hydroxychloroquine for COVID-19 treatment. Ourin silicofindings, therefore, warrant furtherin vitrovalidations of the selected compounds for the discovery of novel preventive and therapeutic drug against SARS-CoV-2 infection.
C1 [Dave, Gaurav S.; Kanbi, Vaktabhai H.] Sardarkrushinagar Dantiwada Agr Univ, Coll Basic Sci & Humanities, Dept Biochem, Sardar Krushinagar 385506, Gujarat, India.
   [Dave, Gaurav S.; Patel, Manubhai P.] Sardarkrushinagar Dantiwada Agr Univ, Pulses Res Stn, Sardar Krushinagar, India.
   [Rakholiya, Kalpna D.; Kaneria, Mital J.] Saurashtra Univ, Dept Biosci UGC CAS, Rajkot 360005, Gujarat, India.
   [Galvadiya, Bhemji P.] Sardarkrushinagar Dantiwada Agr Univ, CP Coll Agr, Dept Genet & Plant Breeding, Sardar Krushinagar, India.
   [Vyas, Sudhanshu R.] Sardarkrushinagar Dantiwada Agr Univ, Aspee Coll Home Sci & Nutr, Sardar Krushinagar, India.
   [Vyas, Sudhanshu R.; Patel, Manubhai P.] Sardarkrushinagar Dantiwada Agr Univ, Coll Basic Sci & Humanities, Sardar Krushinagar, India.
RP Dave, GS (corresponding author), Sardarkrushinagar Dantiwada Agr Univ, Coll Basic Sci & Humanities, Dept Biochem, Sardar Krushinagar 385506, Gujarat, India.
EM gsdave@sdau.edu.in
RI DAVE, GAURAV/AAZ-4619-2020
OI DAVE, GAURAV/0000-0003-2229-3492; Vyas, Sudhanshu/0000-0001-7633-9527;
   Kanbi, Vaktabhai H/0000-0002-6274-6516; Patel, Dr.
   Manubhai/0000-0002-7300-8973
FU CBSH, SDAU
FX CBSH, SDAU
CR [Anonymous], 2020, REC EMP US HYDR CHLO
   Baumann MH, 2000, SYNAPSE, V36, P102, DOI 10.1002/(SICI)1098-2396(200005)36:2<102::AID-SYN3>3.3.CO;2-R
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Bolognesi C, 2016, EFSA J, V14, DOI 10.2903/j.efsa.2016.4335
   Bontempo P, 2015, J FUNCT FOODS, V19, P584, DOI 10.1016/j.jff.2015.09.063
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Christie W. W., 2012, LIPID ANAL, P305
   Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901
   Cui L, 2018, J COSMET DERMATOL-US, V17, P1254, DOI 10.1111/jocd.12474
   Dave GS, 2018, DATA BRIEF, V21, P343, DOI 10.1016/j.dib.2018.09.117
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Ganas P, 2008, ARCH MICROBIOL, V189, P511, DOI 10.1007/s00203-007-0340-8
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Goldman M. P., 2017, SCLEROTHERAPY, P173
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Haas D. A., 2017, PHARM THERAPEUTICS D, P206
   Hamdi OAA, 2015, INT J MOL SCI, V16, P5180, DOI 10.3390/ijms16035180
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   HEINONEN EH, 1994, CLIN PHARMACOL THER, V56, P742, DOI 10.1038/clpt.1994.204
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Husain K, 1996, FUND APPL TOXICOL, V32, P278, DOI 10.1006/faat.1996.0131
   Jia HP, 2009, AM J PHYSIOL-LUNG C, V297, pL84, DOI 10.1152/ajplung.00071.2009
   Kahkeshani N, 2019, IRAN J BASIC MED SCI, V22, P225, DOI 10.22038/ijbms.2019.32806.7897
   Kalpna R, 2011, J MED PLANTS RES, V5, P63
   KALYANARAMAN B, 1994, N COMP BIOC, V28, P333
   KAMM JJ, 1969, BIOCHEM PHARMACOL, V18, P659, DOI 10.1016/0006-2952(69)90091-4
   Kelmenson A. T., 2013, OCULAR SURFACE DIS C, P117
   Kumar V, 2013, EUR J MED CHEM, V69, P735, DOI 10.1016/j.ejmech.2013.08.053
   Lee NK, 2014, J DAIRY SCI, V97, P5383, DOI 10.3168/jds.2014-8016
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li Q, 2009, MICRO NANO LETT, V4, P1, DOI 10.1049/mnl:20080036
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lo JY, 2015, FOOD FUNCT, V6, P3550, DOI 10.1039/c5fo00607d
   Mackenzie JS, 2020, MICROBIOL AUST, V41, P45, DOI 10.1071/MA20013
   Mayer J, 2010, MICROBIOL-SGM, V156, P1556, DOI 10.1099/mic.0.037580-0
   Mizuta I, 2000, BIOCHEM BIOPH RES CO, V279, P751, DOI 10.1006/bbrc.2000.4037
   Pavicic T., 2007, International Journal of Cosmetic Science, V29, P181, DOI 10.1111/j.1467-2494.2007.00378.x
   Pejo E, 2016, ANESTHESIOLOGY, V125, P943, DOI 10.1097/ALN.0000000000001304
   Qiu Y, 2020, MICROBES INFECT, V22, P221, DOI 10.1016/j.micinf.2020.03.003
   Richardson CE, 2017, J AGR FOOD CHEM, V65, P1941, DOI 10.1021/acs.jafc.6b05559
   Sakai K, 2014, J VIROL, V88, P5608, DOI 10.1128/JVI.03677-13
   Schulzke JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018107
   Sha EC, 1995, INVEST NEW DRUG, V13, P285, DOI 10.1007/BF00873134
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Sharma L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00378
   Shubhangi, 2019, J MOL STRUCT, V1195, P435, DOI 10.1016/j.molstruc.2019.05.125
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Sorensen M, 2018, MOL PLANT, V11, P95, DOI 10.1016/j.molp.2017.12.014
   Vasconcelos JF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06275-z
   Salomon MV, 2017, PLANT PHYSIOL BIOCH, V120, P1, DOI 10.1016/j.plaphy.2017.09.013
   Vijesh AM, 2013, EUR J MED CHEM, V62, P410, DOI 10.1016/j.ejmech.2012.12.057
   Virjamo V, 2010, PLANTA MED, V76, P1236
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang Q, 2019, BIORESOUR BIOPROCESS, V6, DOI 10.1186/s40643-019-0242-z
   Weiner C. P., 2019, DRUGS PREGNANT LACTA, P484
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yannai S, 2003, DICT FOOD COMPOUNDS
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   You Y, 2019, CHEM COMMUN, V55, P8478, DOI 10.1039/c9cc04057a
NR 66
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD DEC
PY 2020
VL 34
IS 12
BP 3400
EP 3410
DI 10.1002/ptr.6796
EA AUG 2020
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PC4GH
UT WOS:000557814400001
PM 32779305
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Giacobbe, DR
   Battaglini, D
   Ball, L
   Brunetti, I
   Bruzzone, B
   Codda, G
   Crea, F
   De Maria, A
   Dentone, C
   Di Biagio, A
   Icardi, G
   Magnasco, L
   Marchese, A
   Mikulska, M
   Orsi, A
   Patroniti, N
   Robba, C
   Signori, A
   Taramasso, L
   Vena, A
   Pelosi, P
   Bassetti, M
AF Giacobbe, Daniele Roberto
   Battaglini, Denise
   Ball, Lorenzo
   Brunetti, Iole
   Bruzzone, Bianca
   Codda, Giulia
   Crea, Francesca
   De Maria, Andrea
   Dentone, Chiara
   Di Biagio, Antonio
   Icardi, Giancarlo
   Magnasco, Laura
   Marchese, Anna
   Mikulska, Malgorzata
   Orsi, Andrea
   Patroniti, Nicolo
   Robba, Chiara
   Signori, Alessio
   Taramasso, Lucia
   Vena, Antonio
   Pelosi, Paolo
   Bassetti, Matteo
TI Bloodstream infections in critically ill patients with COVID-19
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE BSI; coronavirus; COVID-19; SARS-CoV-2; steroid; tocilizumab
ID INTENSIVE-CARE UNITS; RISK; PNEUMONIA; MORTALITY
AB Background Little is known about the incidence and risk of intensive care unit (ICU)-acquired bloodstream infections (BSI) in critically ill patients with coronavirus disease 2019 (COVID-19). Materials and methods This retrospective, single-centre study was conducted in Northern Italy. The primary study objectives were as follows: (a) to assess the incidence rate of ICU-acquired BSI and (b) to assess the cumulative risk of developing ICU-acquired BSI. Results Overall, 78 critically ill patients with COVID-19 were included in the study. Forty-five episodes of ICU-acquired BSI were registered in 31 patients, with an incidence rate of 47 episodes (95% confidence interval [CI] 35-63) per 1000 patient-days at risk. The estimated cumulative risk of developing at least one BSI episode was of almost 25% after 15 days at risk and possibly surpassing 50% after 30 days at risk. In multivariable analysis, anti-inflammatory treatment was independently associated with the development of BSI (cause-specific hazard ratio [csHR] 1.07 with 95% CI 0.38-3.04 for tocilizumab, csHR 3.95 with 95% CI 1.20-13.03 for methylprednisolone and csHR 10.69 with 95% CI 2.71-42.17 for methylprednisolone plus tocilizumab, with no anti-inflammatory treatment as the reference group; overallPfor the dummy variable = 0.003). Conclusions The incidence rate of BSI was high, and the cumulative risk of developing BSI increased with ICU stay. Further study will clarify if the increased risk of BSI we detected in COVID-19 patients treated with anti-inflammatory drugs is outweighed by the benefits of reducing any possible pro-inflammatory dysregulation induced by SARS-CoV-2.
C1 [Giacobbe, Daniele Roberto; De Maria, Andrea; Dentone, Chiara; Di Biagio, Antonio; Magnasco, Laura; Mikulska, Malgorzata; Taramasso, Lucia; Vena, Antonio; Bassetti, Matteo] Osped Policlin San Martino IRCCS, Infect Dis Unit, Lgo R Benzi 10, I-16132 Genoa, Italy.
   [Giacobbe, Daniele Roberto; De Maria, Andrea; Di Biagio, Antonio; Icardi, Giancarlo; Magnasco, Laura; Mikulska, Malgorzata; Orsi, Andrea; Signori, Alessio; Taramasso, Lucia; Bassetti, Matteo] Univ Genoa, Dept Hlth Sci DISSAL, Genoa, Italy.
   [Battaglini, Denise; Ball, Lorenzo; Brunetti, Iole; Patroniti, Nicolo; Robba, Chiara; Pelosi, Paolo] Osped Policlin San Martino IRCCS, Anesthesia & Intens Care, Genoa, Italy.
   [Ball, Lorenzo; Codda, Giulia; Marchese, Anna; Patroniti, Nicolo; Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost DISC, Genoa, Italy.
   [Bruzzone, Bianca; Icardi, Giancarlo; Orsi, Andrea] Osped Policlin San Martino IRCCS, Hyg Unit, Genoa, Italy.
   [Crea, Francesca; Marchese, Anna] Osped Policlin San Martino IRCCS, Microbiol Unit, Genoa, Italy.
RP Giacobbe, DR (corresponding author), Osped Policlin San Martino IRCCS, Infect Dis Unit, Lgo R Benzi 10, I-16132 Genoa, Italy.
EM daniele.roberto.giacobbe@gmail.com
RI Battaglini, Denise/X-6446-2019; Ball, Lorenzo/AAC-2786-2019; Giacobbe,
   Daniele Roberto/K-2777-2018; Di Biagio, Antonio/J-4901-2019
OI Battaglini, Denise/0000-0002-6895-6442; Ball,
   Lorenzo/0000-0002-3876-4730; Giacobbe, Daniele
   Roberto/0000-0003-2385-1759; Di Biagio, Antonio/0000-0003-1436-5089
CR AALEN OO, 1978, SCAND J STAT, V5, P141
   Bari SF, 2013, BMJ CASE REP, V2013, pbcr2013010423
   Bassetti M, 2020, CLIN MICROBIOL INFEC, V26, P880, DOI 10.1016/j.cmi.2020.04.031
   Bassetti M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13209
   Bassetti M, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2497-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   ECDC, COVID 19 SIT UPD WOR
   Elzi L, 2012, CLIN MICROBIOL INFEC, V18, pE355, DOI 10.1111/j.1469-0691.2012.03964.x
   Fardet L, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002024
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hugonnet S, 2004, EMERG INFECT DIS, V10, P76, DOI 10.3201/eid1001.030407
   Kellum JA, 2013, CRIT CARE, V17, DOI 10.1186/cc11454
   Lang VR, 2012, RHEUMATOLOGY, V51, P852, DOI 10.1093/rheumatology/ker223
   Laupland KB, 2002, CRIT CARE MED, V30, P2462, DOI 10.1097/00003246-200211000-00010
   Metersky ML, 2012, INT J INFECT DIS, V16, pE321, DOI 10.1016/j.ijid.2012.01.003
   RELLO J, 1994, INTENS CARE MED, V20, P94, DOI 10.1007/BF01707661
   Rothman K, 1979, EPIDEMIOLOGIC ANAL P
   Saravolatz LD, 2011, CLIN INFECT DIS, V52, P1156, DOI 10.1093/cid/cir147
   Simera I, 2010, EUR J CLIN INVEST, V40, P35, DOI 10.1111/j.1365-2362.2009.02234.x
   Smyk W, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13276
   STUCK AE, 1989, REV INFECT DIS, V11, P954
   Tabah A, 2012, INTENS CARE MED, V38, P1930, DOI 10.1007/s00134-012-2695-9
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
NR 27
TC 13
Z9 13
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
EI 1365-2362
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD OCT
PY 2020
VL 50
IS 10
AR e13319
DI 10.1111/eci.13319
EA AUG 2020
PG 8
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA NW6XF
UT WOS:000558053500001
PM 32535894
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Vanderslott, S
   Marks, T
AF Vanderslott, Samantha
   Marks, Tatjana
TI Travel restrictions as a disease control measure: Lessons from yellow
   fever
SO GLOBAL PUBLIC HEALTH
LA English
DT Article; Early Access
DE yellow fever; country vaccine entry requirements; travel restrictions;
   quarantine; health diplomacy
ID QUARANTINE; VACCINE; HISTORY; PLAGUE
AB Travel restrictions have become a common disease control measure during the 2019 Coronavirus disease pandemic (COVID-19). Measures have ranged from quarantines when entering a country to outright travel bans. Yet more widespread travel restrictions in the form of country vaccine entry requirements have been in place for a long time for another disease - yellow fever. We track the historical underpinnings and policy developments that have led to stringent vaccine entry requirements today. We also discuss the political issues raised by health measures imposed on borders and discuss the reasons behind some clear regional differences. Almost no European countries currently have vaccine entry requirements, while at the other end of the spectrum, the majority of countries in the African region do, making vaccine entry requirements a global south phenomenon. We argue that vaccine entry requirements should be reassessed in the future as an underused public health tool, likely to become increasingly common. Vaccine entry requirements have proved effective in controlling the international spread of yellow fever but more can be done to ensure better use of this measure. Caution is needed due to the close links between public health and politics, evident since the first travel restriction in quarantines.
C1 [Vanderslott, Samantha; Marks, Tatjana] Univ Oxford, Oxford Vaccine Grp, Oxford, England.
   [Vanderslott, Samantha] Univ Oxford, Oxford Martin Sch, Oxford, England.
RP Vanderslott, S (corresponding author), 34 Broad St, Oxford OX1 3BD, England.
EM samantha.vanderslott@paediatrics.ox.ac.uk
OI Vanderslott, Samantha/0000-0001-8685-7758
FU National Institute for Health Research (NIHR) as part of the AViD
   ProjectNational Institute for Health Research (NIHR); New Venture Fund
FX Samantha Vanderslott receives funding from the National Institute for
   Health Research (NIHR) as part of the AViD Project and the New Venture
   Fund.
CR Anderson W, 2007, J HIST MED ALL SCI, V62, P1, DOI 10.1093/jhmas/jrl014
   [Anonymous], 2020, BBC NEWS
   Barrett ADT, 2007, ANNU REV ENTOMOL, V52, P209, DOI 10.1146/annurev.ento.52.110405.091454
   Barrett ADT, 2009, CURR OPIN IMMUNOL, V21, P308, DOI 10.1016/j.coi.2009.05.018
   Bazylevych M, 2011, MED ANTHROPOL Q, V25, P436, DOI 10.1111/j.1548-1387.2011.01179.x
   Brent SE, 2018, B WORLD HEALTH ORGAN, V96, P343, DOI 10.2471/BLT.17.205658
   Brunette G. W., 2017, CDC YELLOW BOOK 2018
   Budd L, 2009, POLIT GEOGR, V28, P426, DOI 10.1016/j.polgeo.2009.10.006
   CASSAR P, 1980, B HIST MED, V54, P554
   CDC, 2020, AM SAM TRAV VIEW
   CDC, 2020, AR ZIK
   CDC, 2018, YELLOW FEVER
   Chastel C, 2003, Bull Soc Pathol Exot, V96, P250
   Chen J, 2016, BIOSCI TRENDS, V10, P158, DOI 10.5582/bst.2016.01051
   Cunha D., 2014, ATLAS OBSCURA
   Egwemi V., 2016, AFRICAN RES REV, V10, DOI [10.4314/afrrev.v10i1.10, DOI 10.4314/AFRREV.V10I1.10]
   Eritja R, 2005, BIOL INVASIONS, V7, P87, DOI 10.1007/s10530-004-9637-6
   Frierson J. Gordon, 2010, Yale Journal of Biology and Medicine, V83, P77
   Gensini GF, 2004, J INFECTION, V49, P257, DOI 10.1016/j.jinf.2004.03.002
   Gov.uk, FOR TRAV ADV
   Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433
   Harrison M, 2012, CONTAGION COMMERCE H
   Howard-Jones N., 1975, SCI BACKGROUND INT S
   Iamat.org, 2020, SAM CHIK
   Iamat.org, 2020, AM SAM DENG
   Jentes ES, 2011, LANCET INFECT DIS, V11, P622, DOI 10.1016/S1473-3099(11)70147-5
   Kamal M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0210122
   Kofler N, 2020, NATURE, V581, P379, DOI 10.1038/d41586-020-01451-0
   Maglen K, 2002, SOC HIST MED, V15, P413, DOI 10.1093/shm/15.3.413
   McKenna D., 2016, BBC NEWS
   Merriam Webster Dictionary, CONTR
   Monath TP, 2005, HUM VACCINES, V1, P207, DOI 10.4161/hv.1.5.2221
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Monath TP, 2002, CLIN INFECT DIS, V34, P1369, DOI 10.1086/340104
   Oldstone M. B., 2010, VIRUSES PLAGUES HIST
   Oliu-Barton M., 2020, ESADEECPOL POLICY IN
   Saudi Ministry of Health portal, HLTH GUID HAJJ
   Schonenberger S, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw035
   Simons H, 2016, HUM VACC IMMUNOTHER, V12, P2690, DOI 10.1080/21645515.2016.1218100
   Staples JE, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0205-6
   Tognotti E, 2013, EMERG INFECT DIS, V19, P254, DOI 10.3201/eid1902.120312
   UNICEF, 2019, EXPL MACH LEARN MAP
   UNSD, 2020, METHODOLOGY
   WHO, 2005, INT HLTH REG
   Wintour Patrick, 2020, GUARDIAN
   World Health Organization, 2018, GLOB STRAT EL YELL F
   World Health Organization (WHO), 2019, INT TRAV HLTH COUNTR
   World Health Organization (WHO), 2016, SIT REP YELL FEV
   World Health Organization (WHO), 2019, YELL FEV FACT SHEET
   World Health Organization (WHO), 2018, YELL FEV FRANC FRENC
   Yen C, 2015, LANCET INFECT DIS, V15, P340, DOI 10.1016/S1473-3099(14)70999-5
NR 51
TC 0
Z9 0
U1 2
U2 2
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1744-1692
EI 1744-1706
J9 GLOB PUBLIC HEALTH
JI Glob. Public Health
DI 10.1080/17441692.2020.1805786
EA AUG 2020
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MX3KP
UT WOS:000557624500001
PM 32772788
OA Bronze
DA 2021-01-01
ER

PT J
AU Khalifa, I
   Zhu, W
   Mohammed, HHH
   Dutta, K
   Li, CM
AF Khalifa, Ibrahim
   Zhu, Wei
   Mohammed, Hammad Hamed Hammad
   Dutta, Kunal
   Li, Chunmei
TI Tannins inhibit SARS-CoV-2 through binding with catalytic dyad residues
   of 3CL(pro): An in silico approach with 19 structural different
   hydrolysable tannins
SO JOURNAL OF FOOD BIOCHEMISTRY
LA English
DT Article
DE COVID-19; hydrolysable tannins; main 3-chymotrypsin-like cysteine
   protease; molecular docking; structural-relationship activity
ID PROANTHOCYANIDINS; PEDUNCULAGIN; PROTEASE
AB Coronavirus epidemic 2019 (COVID-19), instigated by SARS-CoV-2 virus, is recently raising worldwide and inspiring global health worries. The main 3-chymotrypsin-like cysteine protease (3CL(Pro)) enzyme of SARS-CoV-2, which operates its replication, could be used as a medication discovery point. We therefore theoretically studied and docked the effects of 19 hydrolysable tannins on SARS-CoV-2 by assembling with the catalytic dyad residues of its 3CL(pro)using molecular operating environment (MOE 09). Results discovered that pedunculagin, tercatain, and castalin intensely interacted with the receptor binding site and catalytic dyad (Cys145 and His41) of SARS-CoV-2. Our analyses estimated that the top three hits might serve as potential inhibitor of SARS-CoV-2 leading molecules for additional optimization and drug development process to combat COVID-19. This study unleashed that tannins with specific structure could be utilized as natural inhibitors against COVID-19. Practical applications The 3CL(Pro)controls SARS-CoV-2 copying and manages its life series, which was targeted in case of SARS-CoV and MERS-CoV coronavirus. About 19 hydrolysable tannins were computed against 3CL(pro)of SARS-CoV-2. Pedunculagin, tercatain, and castalin interacted with Cys145 and His41 of SARS-CoV-2-3CL(pro). Pedunculagin-SARS-CoV-2-3CL(pro)remain stable, with no obvious fluctuations. We predicted that the understandings gained in the current research may evidence valued for discovering and unindustrialized innovative natural inhibitors for COVID-19 in the nearby future.
C1 [Khalifa, Ibrahim] Benha Univ, Fac Agr, Food Technol Dept, Banha 13736, Egypt.
   [Zhu, Wei; Mohammed, Hammad Hamed Hammad; Li, Chunmei] Huazhong Agr Univ, Coll Food Sci & Technol, Key Lab Environm Correlat Food Sci, Minist Educ, Wuhan 430070, Peoples R China.
   [Mohammed, Hammad Hamed Hammad] Minist Agr & Forestry, Natl Food Res Ctr, Khartoum, Sudan.
   [Dutta, Kunal] Vidyasagar Univ, Dept Human Physiol Community Hlth, Microbiol & Immunol Lab, Midnapore, India.
RP Khalifa, I (corresponding author), Benha Univ, Fac Agr, Food Technol Dept, Banha 13736, Egypt.; Li, CM (corresponding author), Huazhong Agr Univ, Coll Food Sci & Technol, Key Lab Environm Correlat Food Sci, Minist Educ, Wuhan 430070, Peoples R China.
EM ibrahiem.khalifa@fagr.bu.edu.eg; lichmyl@mail.hzau.edu.cn
RI Dutta, Kunal/C-5447-2018
OI Dutta, Kunal/0000-0002-0818-8787; Khalifa, Ibrahim/0000-0002-7648-2961
CR Aires A., 2020, TANNINS STRUCTURAL P, P1, DOI [10.5772/intechopen.80170, DOI 10.5772/INTECHOPEN.80170]
   Buzzini P, 2008, MINI-REV MED CHEM, V8, P1179, DOI 10.2174/138955708786140990
   Chang JH, 1995, ARCH PHARM RES, V18, P396, DOI 10.1007/BF02976342
   Desai AG, 2008, CURR DRUG METAB, V9, P581, DOI 10.2174/138920008785821657
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Jia YY, 2019, FOOD BIOPROD PROCESS, V118, P67, DOI 10.1016/j.fbp.2019.08.018
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Jo S, 2019, CHEM BIOL DRUG DES, V94, P2023, DOI 10.1111/cbdd.13604
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Khan W, 2017, ADVAN LIFE SCI, V4, P113
   Kim S, 2020, INSUFFICIENT SENSITI, DOI [10.20944/preprints202002.0424.v1., DOI 10.20944/PREPRINTS202002.0424.V1, 10.20944/preprints202002.0424.v1]
   Lin LT, 2011, J VIROL, V85, P4386, DOI 10.1128/JVI.01492-10
   Liu CL, 2016, ANTIVIR RES, V134, P97, DOI 10.1016/j.antiviral.2016.08.026
   Macchiagodena M., 2020, ARXIV200209937
   Moorthy V, 2020, B WORLD HEALTH ORGAN, V98, P150, DOI 10.2471/BLT.20.251561
   Park JY, 2017, J ENZYM INHIB MED CH, V32, P504, DOI 10.1080/14756366.2016.1265519
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Rut W., 2020, BIORXIV, DOI [10.1101/2020.03.07.981928, DOI 10.1101/2020.03.07.981928]
   Serrano J, 2009, MOL NUTR FOOD RES, V53, pS310, DOI 10.1002/mnfr.200900039
   Silva RM, 2016, MUTAT RES-GEN TOX EN, V810, P40, DOI 10.1016/j.mrgentox.2016.10.001
   Smeriglio A, 2017, BRIT J PHARMACOL, V174, P1244, DOI 10.1111/bph.13630
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhu W, 2018, J BIOMOL STRUCT DYN, V36, P2862, DOI 10.1080/07391102.2017.1369163
   Zuo Guo-Ying, 2005, Antiviral Chemistry & Chemotherapy, V16, P393
NR 27
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-8884
EI 1745-4514
J9 J FOOD BIOCHEM
JI J. Food Biochem.
PD OCT
PY 2020
VL 44
IS 10
AR e13432
DI 10.1111/jfbc.13432
EA AUG 2020
PG 19
WC Biochemistry & Molecular Biology; Food Science & Technology
SC Biochemistry & Molecular Biology; Food Science & Technology
GA OH3NS
UT WOS:000558092300001
PM 32783247
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Nougier, C
   Benoit, R
   Simon, M
   Desmurs-Clavel, H
   Marcotte, G
   Argaud, L
   David, JS
   Bonnet, A
   Negrier, C
   Dargaud, Y
AF Nougier, Christophe
   Benoit, Remi
   Simon, Marie
   Desmurs-Clavel, Helene
   Marcotte, Guillaume
   Argaud, Laurent
   David, Jean Stephane
   Bonnet, Aurelie
   Negrier, Claude
   Dargaud, Yesim
TI Hypofibrinolytic state and high thrombin generation may play a major
   role in SARS-COV2 associated thrombosis
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE fibrinolysis; plasminogen activator inhibitor 1; tissue plasminogen
   activator; TAFI; thrombin generation; Covid-19
ID ACTIVATABLE FIBRINOLYSIS INHIBITOR; RISK
AB Background Thirty percent of Covid-19 patients admitted to intensive care units present with thrombotic complications despite thromboprophylaxis. Bed rest, obesity, hypoxia, coagulopathy, and acute excessive inflammation are potential mechanisms reported by previous studies. Better understanding of the underlying mechanisms leading to thrombosis is crucial for developing more appropriate prophylaxis and treatment strategies. Objective We aimed to assess fibrinolytic activity and thrombin generation in 78 Covid-19 patients. Patients and Methods Forty-eight patients admitted to the intensive care unit and 30 patients admitted to the internal medicine department were included in the study. All patients received thromboprophylaxis. We measured fibrinolytic parameters (tissue plasminogen activator, PAI-1, thrombin activatable fibrinolysis inhibitor, alpha2 anti-plasmin, and tissue plasminogen activator-modified ROTEM device), thrombin generation, and other coagulation tests (D-dimer, fibrinogen, factor VIII, antithrombin). Results and Conclusions We observed two key findings: a high thrombin generation capacity that remained within normal values despite heparin therapy and a hypofibrinolysis mainly associated with increased PAI-1 levels. A modified ROTEM is able to detect both hypercoagulability and hypofibrinolysis simultaneously in Covid-19 patients with thrombosis.
C1 [Nougier, Christophe; Benoit, Remi; Negrier, Claude; Dargaud, Yesim] Hosp Civils Lyon, Grp Hosp Est, Lab Hematol, Lyon, France.
   [Simon, Marie; Argaud, Laurent] Hop Edouard Herriot, Serv Med Intens Reanimat, Lyon, France.
   [Simon, Marie; Desmurs-Clavel, Helene; Marcotte, Guillaume; David, Jean Stephane; Bonnet, Aurelie; Dargaud, Yesim] Grp Etud Multidisciplinaire Malad Thrombot, GEMMAT, Lyon, France.
   [Desmurs-Clavel, Helene] Hop Edouard Herriot, Serv Med Interne, Lyon, France.
   [Marcotte, Guillaume] Hop Edouard Herriot, Serv Reanimat Chirurg, Lyon, France.
   [David, Jean Stephane] Ctr Hosp Lyon Sud, Serv Med Intens Reanimat, Lyon, France.
   [Bonnet, Aurelie] Hop Croix Rousse, Serv Reanimat Chirurg, Lyon, France.
   [Negrier, Claude; Dargaud, Yesim] Univ Claude Bernard Lyon 1, EA46Q9, Lyon, France.
RP Dargaud, Y (corresponding author), Hop Cardiovasc & Pneumol Louis Pradel, Unit Hemostase Clin, 28 Av Doyen Lepine, F-69500 Lyon, France.
EM ydargaud@univ-lyon1.fr
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Cattaneo M, 2020, THROMB HAEMOST
   Chen R, 2017, METAB BRAIN DIS, V32, P667, DOI 10.1007/s11011-017-0007-3
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   de Bruijne ELE, 2009, J THROMB HAEMOST, V7, P919, DOI 10.1111/j.1538-7836.2009.03350.x
   Grillet F, 2020, RADIOLOGY, V296, pE186, DOI 10.1148/radiol.2020201544
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Kuiper GJAJM, 2016, THROMB J, V14, DOI 10.1186/s12959-016-0076-2
   Meltzer ME, 2010, BLOOD, V116, P113, DOI 10.1182/blood-2010-02-267740
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Prabhakaran P, 2003, AM J PHYSIOL-LUNG C, V285, pL20, DOI 10.1152/ajplung.00312.2002
   Redlitz A, 1996, CIRCULATION, V93, P1328, DOI 10.1161/01.CIR.93.7.1328
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Tregouet DA, 2009, J THROMB HAEMOST, V7, P49, DOI 10.1111/j.1538-7836.2008.03221.x
   Whiting D, 2014, AM J HEMATOL, V89, P228, DOI 10.1002/ajh.23599
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhai ZG, 2020, THROMB HAEMOSTASIS, V120, P937, DOI 10.1055/s-0040-1710019
NR 18
TC 14
Z9 14
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD SEP
PY 2020
VL 18
IS 9
BP 2215
EP 2219
DI 10.1111/jth.15016
EA AUG 2020
PG 5
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA NG4TN
UT WOS:000557938500001
PM 32668058
OA Green Published
DA 2021-01-01
ER

PT J
AU Bernar, B
   Kropshofer, G
   Crazzolara, R
   Kapelari, K
   Griesmacher, A
   Muller, T
   Scholl-Burgi, S
AF Bernar, Benoit
   Kropshofer, Gabriele
   Crazzolara, Roman
   Kapelari, Klaus
   Griesmacher, Andrea
   Mueller, Thomas
   Scholl-Buergi, Sabine
TI SARS-CoV-2 infection in a 7-year-old girl with pancytopenia during acute
   lymphocytic leukemia maintenance therapy
SO PEDIATRIC BLOOD & CANCER
LA English
DT Letter
C1 [Bernar, Benoit; Kropshofer, Gabriele; Crazzolara, Roman; Kapelari, Klaus; Mueller, Thomas; Scholl-Buergi, Sabine] Med Univ Innsbruck, Dept Pediat 1, Innsbruck, Austria.
   [Griesmacher, Andrea] Med Univ Innsbruck, Cent Inst Clin Chem & Lab Med ZIMCL, Innsbruck, Austria.
RP Bernar, B (corresponding author), Med Univ Innsbruck, Dept Pediat 1, Innsbruck, Austria.
EM benoit.bernar@i-med.ac.at
CR [Anonymous], 2020, 51 WHO
   Centers for disease control and prevention (CDC), BURD COVID 19 EP RIS
   Le service public federal (SPF) Sante publique Securite de la Chaine alimentaire et Environnement Belgium, 2020, DEC JEUN FILL DOUZ A
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Malik YS, 2020, VET QUART, V40, P68, DOI 10.1080/01652176.2020.1727993
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Sinha IP, 2020, LANCET RESP MED, V8, P446, DOI 10.1016/S2213-2600(20)30152-1
   Statistik Austria, 2019, BUND STAT OST BEV 1
   Su L, 2020, EMERG MICROBES INFEC, V9, P707, DOI 10.1080/22221751.2020.1744483
NR 9
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD NOV
PY 2020
VL 67
IS 11
AR e28391
DI 10.1002/pbc.28391
EA AUG 2020
PG 3
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA NY3VA
UT WOS:000557921500001
PM 32779856
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hu, QC
   Zhong, ZB
   Xiong, Y
   Ye, SJ
   Wang, YF
   Ye, QF
AF Hu, Qianchao
   Zhong, Zibiao
   Xiong, Yan
   Ye, Shaojun
   Wang, Yanfeng
   Ye, Qifa
TI Management of immunosuppression in kidney transplant recipients with
   COVID-19 pneumonia: A summary of 41 confirmed cases reported worldwide
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article; Early Access
DE COVID-19; immunosuppression management; kidney transplant recipient
AB There is no consensus on immunosuppression management for kidney transplant recipients (KTRs) with SARS-CoV-2 pneumonia. Therefore, we conducted a search in English database from October 2019 to July 2020 and extracted data from cases with treatment details worldwide, and total of 41 recipients with a median age of 50 years were enrolled in this study. Most of them were males (75.8%). The most common presenting symptoms were fever (80.5%), cough (63.4%), and fatigue (41.5%). Patients were classified into three catalogs according to severity of pneumonia: 17 (41.5%) were mild, 15 (36.6%) severe, and 9 (21.9%) critical disease. Laboratory tests revealed that serum creatinine of critical patients was significantly higher than that of mild or severe patients. 68.3% received oxygen support; all patients received antiviral therapy, and 15 (36.6%) recipients were additionally treated with intravenous immunoglobulin and interferon-alpha. 19.5% of patients maintained immunosuppressive therapy; 36.6% suspended antimetabolite; and 43.9% only treated with corticosteroid. Six (14.6%) patients died (severe: 2, critical: 4); high creatinine with low lymphocyte count was the biggest challenge of immunosuppression management. In all, it is necessary to pay close attention to renal function and lymphocyte count in KTRs infected with COVID-19 and choose appropriate medication programs according to the specific situations.
C1 [Hu, Qianchao; Zhong, Zibiao; Xiong, Yan; Ye, Shaojun; Wang, Yanfeng; Ye, Qifa] Wuhan Univ, Transplant Ctr, Inst Hepatobiliary Dis, Hubei Key Lab Med Technol Transplantat,Zhongnan H, Wuhan 430071, Hubei, Peoples R China.
   [Ye, Qifa] Cent South Univ, Xiangya Hosp 3, Transplantat Med Engn & Technol Res Ctr, Natl Hlth Commiss, Changsha, Peoples R China.
RP Ye, QF (corresponding author), Wuhan Univ, Transplant Ctr, Inst Hepatobiliary Dis, Hubei Key Lab Med Technol Transplantat,Zhongnan H, Wuhan 430071, Hubei, Peoples R China.
EM yqf_china@163.com
OI Hu, Qianchao/0000-0001-5694-7461
FU Medical Science Advancement Program (Clinical Medicine) of Wuhan
   University [TFLC2018003]; National Science Foundation for Young
   Scientists of China [81700657]
FX the Medical Science Advancement Program (Clinical Medicine) of Wuhan
   University, Grant/Award Number: TFLC2018003; National Science Foundation
   for Young Scientists of China, Grant/Award Number: 81700657
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Arpali E, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13296
   Bartiromo M, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13286
   Bussalino E, 2020, AM J TRANSPLANT, V20, P1922, DOI 10.1111/ajt.15920
   Chen D, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020481
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen S, 2020, AM J TRANSPLANT, V20, P1869, DOI 10.1111/ajt.15903
   Cheng DR, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13329
   China NHCo, NEW COR PNEUM PREV C
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fung M, 2020, AM J TRANSPLANT, V20, P3225, DOI 10.1111/ajt.16079
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Kates OS, 2020, AM J TRANSPLANT, V20, P1885, DOI 10.1111/ajt.15944
   Kocak B, 2020, TRANSPL P, V52, P2663, DOI 10.1016/j.transproceed.2020.05.028
   Maritati F, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13377
   Marx D, 2020, AM J TRANSPLANT, V20, P1944, DOI 10.1111/ajt.15919
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Ning L, 2020, AM J TRANSPLANT, V20, P1864, DOI 10.1111/ajt.15897
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Seminari E, 2020, AM J TRANSPLANT, V20, P1882, DOI 10.1111/ajt.15902
   Tantisattamo E, 2020, TRANSPL INFECT DIS, DOI 10.1111/tid.13355
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang JP, 2020, EUR UROL, V77, P769, DOI 10.1016/j.eururo.2020.03.036
   World Health Organization, WHO COR DIS COVID 19
   Zhang H, 2020, EUR UROL, V77, P742, DOI 10.1016/j.eururo.2020.03.030
   Zhong ZB, 2020, AM J TRANSPLANT, V20, P1916, DOI 10.1111/ajt.15928
   Zhu L, 2020, EUR UROL, V77, P748, DOI 10.1016/j.eururo.2020.03.039
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 30
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
AR e13425
DI 10.1111/tid.13425
EA AUG 2020
PG 9
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA MX8AR
UT WOS:000557943100001
PM 32702153
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU De Flora, S
   Balansky, R
   La Maestra, S
AF De Flora, Silvio
   Balansky, Roumen
   La Maestra, Sebastiano
TI Rationale for the use ofN-acetylcysteine in both prevention and adjuvant
   therapy of COVID-19
SO FASEB JOURNAL
LA English
DT Article
DE COVID-19; glutathione; inflammation; N-acetyl-L-cysteine; oxidative
   stress
ID ACETYL-L-CYSTEINE; N-ACETYLCYSTEINE; VIRUS-REPLICATION; GLUTATHIONE
   DEPLETION; ANTIOXIDANT ACTION; INFLUENZA-VIRUS; MOUSE MODEL; PATHWAY;
   INFLAMMATION; IMPROVEMENT
AB COVID-19 may cause pneumonia, acute respiratory distress syndrome, cardiovascular alterations, and multiple organ failure, which have been ascribed to a cytokine storm, a systemic inflammatory response, and an attack by the immune system. Moreover, an oxidative stress imbalance has been demonstrated to occur in COVID-19 patients.N- Acetyl-L-cysteine (NAC) is a precursor of reduced glutathione (GSH). Due to its tolerability, this pleiotropic drug has been proposed not only as a mucolytic agent, but also as a preventive/therapeutic agent in a variety of disorders involving GSH depletion and oxidative stress. At very high doses, NAC is also used as an antidote against paracetamol intoxication. Thiols block the angiotensin-converting enzyme 2 thereby hampering penetration of SARS-CoV-2 into cells. Based on a broad range of antioxidant and anti-inflammatory mechanisms, which are herein reviewed, the oral administration of NAC is likely to attenuate the risk of developing COVID-19, as it was previously demonstrated for influenza and influenza-like illnesses. Moreover, high-dose intravenous NAC may be expected to play an adjuvant role in the treatment of severe COVID-19 cases and in the control of its lethal complications, also including pulmonary and cardiovascular adverse events.
C1 [De Flora, Silvio; La Maestra, Sebastiano] Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy.
   [Balansky, Roumen] Natl Oncol Ctr, Sofia, Bulgaria.
RP De Flora, S (corresponding author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy.
EM sdf@unige.it
CR Aldini G, 2018, FREE RADICAL RES, V52, P751, DOI 10.1080/10715762.2018.1468564
   Amatore Donatella, 2019, FASEB Bioadv, V1, P296, DOI 10.1096/fba.2018-00066
   Andreou A, 2020, IN VIVO, V34, P1567, DOI 10.21873/invivo.11946
   Arranz L, 2008, FREE RADICAL BIO MED, V45, P1252, DOI 10.1016/j.freeradbiomed.2008.07.014
   ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X
   Balansky R, 2010, INT J CANCER, V126, P1047, DOI 10.1002/ijc.24942
   Bauer Seth R, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc046
   Bazzini C, 2013, CELL PHYSIOL BIOCHEM, V32, P129, DOI 10.1159/000356633
   Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164
   BOESGAARD S, 1993, J PHARMACOL EXP THER, V265, P1239
   Cai JY, 2003, FREE RADICAL BIO MED, V34, P928, DOI 10.1016/S0891-5849(03)00023-6
   Calzetta L, 2018, EXPERT REV RESP MED, V12, P693, DOI 10.1080/17476348.2018.1495562
   Cao Min, 2020, medRxiv, DOI 10.1101/2020.03.04.20030395
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Cugno M, 2020, J ALLERGY CLIN IMMUN, V146, P215, DOI 10.1016/j.jaci.2020.05.006
   De Flora S, 2001, CARCINOGENESIS, V22, P999, DOI 10.1093/carcin/22.7.999
   DeFlora S, 1997, EUR RESPIR J, V10, P1535, DOI 10.1183/09031936.97.10071535
   DiNicolantonio JJ, MED HYPOTHESES
   Ershad M, 2020, STATPEARLS
   Fajgenbaum DC, 2020, INFECT DIS THER, V9, P435, DOI 10.1007/s40121-020-00303-8
   Garozzo A, 2007, INT J IMMUNOPATH PH, V20, P349, DOI 10.1177/039463200702000215
   Geiler J, 2010, BIOCHEM PHARMACOL, V79, P413, DOI 10.1016/j.bcp.2009.08.025
   Ghezzi P, 2004, INT J IMMUNOPATH PH, V17, P99, DOI 10.1177/039463200401700114
   Ghezzi P, 2011, INT J GEN MED, V4, P105, DOI 10.2147/IJGM.S15618
   Gould NS, 2015, TOXICOL SCI, V147, P466, DOI 10.1093/toxsci/kfv143
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   Guglielmetti G, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03060-9
   Haddad JJ, 2000, CYTOKINES CELL MOL T, V6, P177, DOI 10.1080/mccm.6.4.177.187
   Hati S, 2020, BIORXIV, DOI [10.1101/2020.05.07.083147, DOI 10.1101/2020.05.07.083147]
   HO WZ, 1992, AIDS RES HUM RETROV, V8, P1249, DOI 10.1089/aid.1992.8.1249
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hui DSC, 2013, INFLUENZA OTHER RESP, V7, P52, DOI 10.1111/irv.12171
   Istituto Superiore di Sanita, 2020, CHAR SARS COV 2 PAT
   Izzotti A, 2003, FASEB J, V17, P1127, DOI 10.1096/fj.02-0967fje
   Lai K. Y., 2015, Journal of Pulmonary and Respiratory Medicine, V5, P245
   Lang JP, 2020, AM HEART J, V226, P29, DOI 10.1016/j.ahj.2020.04.025
   Lee MF, 2013, ORAL ONCOL, V49, P129, DOI 10.1016/j.oraloncology.2012.08.003
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Liu M, 1998, CANCER RES, V58, P1723
   Loscalzo J, 2001, CIRC RES, V88, P756, DOI 10.1161/hh0801.089861
   Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005
   Maglakelidze N, 2020, PULM THER, DOI [10.1007/s41030-020-00118-5, DOI 10.1007/S41030-020-00118-5]
   Marchetti G, 1999, Cardiologia, V44, P633
   Mata M, 2011, BIOCHEM PHARMACOL, V82, P548, DOI 10.1016/j.bcp.2011.05.014
   McCarty MF, 2020, PROG CARDIOVASC DIS, V63, P383, DOI 10.1016/j.pcad.2020.02.007
   Nasi Aikaterini, 2020, Toxicol Rep, V7, P768, DOI 10.1016/j.toxrep.2020.06.003
   Nencioni L, 2003, FASEB J, V17, P758, DOI 10.1096/fj.02-0508fje
   Ong GJ, 2020, CONTEMP CLIN TRIALS, V90, DOI 10.1016/j.cct.2019.105894
   Ortolani O, 2000, SHOCK, V13, P14, DOI 10.1097/00024382-200013010-00003
   PACHT ER, 1991, CHEST, V100, P1397, DOI 10.1378/chest.100.5.1397
   Palamara AT, 1996, AIDS RES HUM RETROV, V12, P1537, DOI 10.1089/aid.1996.12.1537
   Pasupathy S, 2017, CIRCULATION, V136, P894, DOI 10.1161/CIRCULATIONAHA.117.027575
   Patel K, 2017, J HEART LUNG TRANSPL, V36, pS371
   Poe FL, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109862
   Polonikov A, 2020, ACS INFECT DIS, V6, P1558, DOI 10.1021/acsinfecdis.0c00288
   Purwanto B, 2020, ACTA MED INDONES, V44, P140
   Qi Q, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1042-x
   Rangel-Mendez JA, 2020, FUTURE MICROBIOL, V14, P959, DOI 10.2217/fmb-2020-0074
   Sadowska AM, 2012, THER ADV RESPIR DIS, V6, P127, DOI 10.1177/1753465812437563
   Salamon S, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8050111
   Soltan-Sharifi MS, 2007, HUM EXP TOXICOL, V26, P697, DOI 10.1177/0960327107083452
   Tardiolo G, 2018, MOLECULES, V23, DOI 10.3390/molecules23123305
   van der Toorn M, 2007, AM J PHYSIOL-LUNG C, V293, pL1156, DOI 10.1152/ajplung.00081.2007
   Van Schooten FJ, 2002, CANCER EPIDEM BIOMAR, V11, P167
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Wagener FADTG, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9060540
   Wang LX, 2020, REDOX BIOL, V31, DOI 10.1016/j.redox.2019.101410
   Wrotek S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041393
   Zhang RH, 2014, INT IMMUNOPHARMACOL, V22, P1, DOI 10.1016/j.intimp.2014.06.013
   Zhao N, 2018, CELL MOL LIFE SCI, V75, P3143, DOI 10.1007/s00018-018-2852-6
   Zhou Y, 2018, DRUG DES DEV THER, V12, P4117, DOI 10.2147/DDDT.S179227
   Zuin R, 2005, CLIN DRUG INVEST, V25, P401, DOI 10.2165/00044011-200525060-00005
NR 72
TC 4
Z9 4
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD OCT
PY 2020
VL 34
IS 10
BP 13185
EP 13193
DI 10.1096/fj.202001807
EA AUG 2020
PG 9
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA NY3XM
UT WOS:000558417100001
PM 32780893
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Li, GZ
   Deng, Q
   Feng, JL
   Li, F
   Xiong, N
   He, Q
AF Li, Guozhen
   Deng, Qin
   Feng, Jiali
   Li, Fang
   Xiong, Nian
   He, Qiong
TI Clinical Characteristics of Diabetic Patients with COVID-19
SO JOURNAL OF DIABETES RESEARCH
LA English
DT Article
ID RESPIRATORY SYNDROME; PREDICTORS; INFECTION; MORTALITY
AB Background. Since December 2019, novel coronavirus- (SARS-CoV-2) infected pneumonia (COVID-19) has rapidly spread throughout China. This study is aimed at describing the characteristics of COVID-19 patients in Wuhan. Methods. 199 COVID-19 patients were admitted to Wuhan Red Cross Hospital in China from January 24th to March 15th. The cases were divided into diabetic and nondiabetic groups according to the history of taking antidiabetic drugs or by plasma fasting blood glucose level at admission, and the difference between groups were compared. Results. Among 199 COVID-19 patients, 76 were diabetic and 123 were nondiabetic. Compared with nondiabetics, patients with diabetes had an older age, high levels of fasting plasma glucose (FPG), D-dimer, white blood cell, blood urea nitrogen (BUN) and total bilirubin (TBIL), lower levels of lymphocyte, albumin and oxygen saturation (SaO(2)), and higher mortality (P<0.05). The two groups showed no difference in clinical symptoms. Diabetes, higher level of D-dimer at admission, and lymphocyte count less than 0.6x10(9)/L at admission were associated with increasing odds of death. Antidiabetic drugs were associated with decreasing odds of death. Treatment with low molecular weight heparin was not related to odds of death. Conclusion. The mortality rate of COVID-19 patients with diabetes was significantly higher than those without diabetes. Diabetes, higher level of D-dimer, and lymphocyte count less than 0.6x10(9)/L at admission were the risk factors associated with in-hospital death.
C1 [Li, Guozhen; Deng, Qin; Feng, Jiali; Li, Fang; Xiong, Nian; He, Qiong] Wuhan Red Cross Hosp, Dept Gastroenterol, Wuhan 430015, Peoples R China.
   [Xiong, Nian] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430022, Peoples R China.
RP Xiong, N; He, Q (corresponding author), Wuhan Red Cross Hosp, Dept Gastroenterol, Wuhan 430015, Peoples R China.; Xiong, N (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430022, Peoples R China.
EM liguozhen426@163.com; 152315596@qq.com; 275440377@qq.com;
   596524018@qq.com; nianxiong@hust.edu.cn; 13971470191@163.com
FU National Key R&D Program of China [2016YFC1306600, 2018YFC1314700];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81873782]
FX This work was supported by grants 2016YFC1306600 (to NX) and
   2018YFC1314700 (to NX) from the National Key R&D Program of China and
   grant 81873782 (to NX) from the National Natural Science Foundation of
   China.
CR Chakrabarti SS, 2020, AGING DIS, V11, P480, DOI 10.14336/AD.2020.0402
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Choi KW, 2003, ANN INTERN MED, V139, P715, DOI 10.7326/0003-4819-139-9-200311040-00005
   Chu H, 2016, J INFECT DIS, V213, P904, DOI 10.1093/infdis/jiv380
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hong KH, 2018, THORAX, V73, P286, DOI 10.1136/thoraxjnl-2016-209313
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Joshi N, 1999, NEW ENGL J MED, V341, P1906, DOI 10.1056/NEJM199912163412507
   Klekotka Renata Barbara, 2015, Pneumonol Alergol Pol, V83, P401, DOI 10.5603/PiAP.2015.0065
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Milbrandt EB, 2009, MOL MED, V15, P438, DOI 10.2119/molmed.2009.00091
   Rodelo JR, 2012, AM J EMERG MED, V30, P1991, DOI 10.1016/j.ajem.2012.04.033
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 22
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6745
EI 2314-6753
J9 J DIABETES RES
JI J. Diabetes Res.
PD AUG 10
PY 2020
VL 2020
AR 1652403
DI 10.1155/2020/1652403
PG 5
WC Endocrinology & Metabolism; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA NI3BM
UT WOS:000565231300002
PM 32851093
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, XS
   Zeng, M
AF Wang, Xiao Shan
   Zeng, Ming
TI Challenges for a Cancer Center in the Novel Coronavirus Pneumonia
   Epidemic
SO TECHNOLOGY IN CANCER RESEARCH & TREATMENT
LA English
DT Article
DE COVID-19; cancer center; chemotherapy; radiotherapy; NCP; AIP
AB Introduction: The novel Coronavirus disease 2019 pandemic is sweeping through China, posing the greatest ever threat to its public health and economy. As a tertiary cancer center in Southwest China, we formulated and implemented an anti-infection protocol to prevent the spread of Coronavirus disease 2019 in our department. Methods: The anti-infection protocol divided patients into 3 categories, namely outpatients, inpatients, and patients receiving radiation therapy at our cancer center, and each category had a distinct anti-infection protocol to minimize the risk of Coronavirus disease 2019 transmission. In each category, the patients were classified into high-, intermediate-, and low-risk groups. Each risk group was managed differently. A survey of patient volume changes prior to and during the Coronavirus disease 2019 outbreak was performed. Results: We carried out the anti-infection protocol at our cancer center during the Coronavirus disease 2019 outbreak. We found that the total volume of both outpatient visits and inpatient treatment declined significantly depending on the conditions of each group. Radiation therapy and palliative service had the lowest and highest volume reductions at 58.3% and 100%, respectively. The decline in outpatient volumes was higher than the decline in inpatient treatment services (78.8% vs 71.8%). There was no Coronavirus disease 2019 cross-infection at our center, or Coronavirus disease 2019-related injury or death. The anti-infection protocol measures continue to be taken at the hospital even today but they have been modified depending on the prevalent local conditions. Conclusions: Challenges from the Coronavirus disease 2019 pandemic remain in our community. The anti-infection protocol implemented at our cancer center has been effective in preventing cross-infection. Whether our anti-infection protocol experience can be applied to curb the spread of the infection in other parts of the world remains to be tested.
C1 [Wang, Xiao Shan; Zeng, Ming] Hosp Univ Elect Sci & Technol China, Canc Ctr, Chengdu 610072, Sichuan, Peoples R China.
   [Wang, Xiao Shan; Zeng, Ming] Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Sichuan, Peoples R China.
   [Wang, Xiao Shan; Zeng, Ming] Univ Elect Sci & Technol China, Sch Med, Chengdu, Sichuan, Peoples R China.
RP Zeng, M (corresponding author), Hosp Univ Elect Sci & Technol China, Canc Ctr, Chengdu 610072, Sichuan, Peoples R China.; Zeng, M (corresponding author), Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Sichuan, Peoples R China.
EM miller2002@yahoo.com
FU Sichuan Academy of Medical Sciences and Provincial People's Hospital
   [30305031017P]; National Science and Technology Bureau China
   [3035031263]; Sichuan Science and Technology Office [3050410336]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by Research Grant from Sichuan Academy of Medical Sciences
   and Provincial People's Hospital (grant numbers:30305031017P); National
   Science and Technology Bureau China (grant numbers 3035031263), Sichuan
   Science and Technology Office (grant numbers 3050410336).
CR Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Phan T, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104211
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
NR 5
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-0346
EI 1533-0338
J9 TECHNOL CANCER RES T
JI Technol. Cancer Res. Treat.
PD AUG 10
PY 2020
VL 19
AR 1533033820945774
DI 10.1177/1533033820945774
PG 4
WC Oncology
SC Oncology
GA NC8WF
UT WOS:000561492200001
PM 32783511
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Infante, M
   Ricordi, C
   Alejandro, R
   Caprio, M
   Fabbri, A
AF Infante, Marco
   Ricordi, Camillo
   Alejandro, Rodolfo
   Caprio, Massimiliano
   Fabbri, Andrea
TI Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a
   rational use for prophylaxis of SARS-CoV-2 infection
SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
LA English
DT Article; Early Access
DE COVID-19; drug repositioning; hydroxychloroquine; post-exposure
   prophylaxis; pre-exposure prophylaxis; prophylaxis; remdesivir;
   SARS-CoV-2; treatment; vitamin D
ID LUPUS-ERYTHEMATOSUS; ANTIMALARIAL-DRUGS; VITAMIN-D; CHLOROQUINE;
   CORONAVIRUS; PATIENT; PROLONGATION; INHIBITION; MYOPATHY; DISEASE
AB Introduction Over the last few months, coronavirus disease 2019 (COVID-19) pandemic caused by the novel coronavirus SARS-CoV-2 has posed a serious threat to public health on a global scale. Given the current lack of an effective vaccine, several drugs have been repurposed for treatment and prophylaxis of COVID-19 in an attempt to find an effective cure. Areas covered The antimalarial drug hydroxychloroquine (HCQ) initially garnered widespread attention following the publication of preliminary results showing that this drug exerts an anti-SARS-CoV-2 activity in vitro. Expert opinion To date, clinical evidence suggests lack of benefit from HCQ use for the treatment of hospitalized patients with COVID-19. In such patients, HCQ also appears to be associated with an increased risk of QT interval prolongation and potentially lethal ventricular arrhythmias. Therefore, FDA has recently revoked the Emergency Use Authorization (EUA) for emergency use of HCQ and chloroquine to treat COVID-19. Conversely, whether HCQ use may represent an effective prophylactic strategy against COVID-19 is a separate question that still remains to be answered. In addition, relevant aspects regarding the potential risks and benefits of HCQ need to be clarified, in pursuit of a rational use of this drug in the COVID-19 pandemic era.
C1 [Infante, Marco; Fabbri, Andrea] Univ Roma Tor Vergata, Div Endocrinol, CTO Andrea Alesini Hosp, ASL Roma 2,Dept Syst Med, I-00145 Rome, Italy.
   [Infante, Marco] St Camillus Int Univ Hlth Sci, UniCamillus, Rome, Italy.
   [Infante, Marco; Fabbri, Andrea] Univ Roma Tor Vergata, Diabet Res Inst Federat DRIF, Dept Syst Med, Rome, Italy.
   [Infante, Marco] Univ Sci Educ & Res Network USERN, Network Immun Infect Malignancy & Autoimmun NIIMA, Rome, Italy.
   [Infante, Marco; Ricordi, Camillo; Alejandro, Rodolfo] Univ Miami, Miller Sch Med, Diabet Res Inst DRI, Miami, FL 33136 USA.
   [Caprio, Massimiliano] IRCCS San Raffaele Pisana, Lab Cardiovasc Endocrinol, Rome, Italy.
   [Caprio, Massimiliano] San Raffaele Roma Open Univ, Dept Human Sci & Promot Qual Life, Rome, Italy.
RP Infante, M (corresponding author), Univ Roma Tor Vergata, Div Endocrinol, CTO Andrea Alesini Hosp, ASL Roma 2,Dept Syst Med, I-00145 Rome, Italy.
EM marco.infante@uniroma2.it
RI Infante, Marco/L-1243-2019; Caprio, Massimiliano/J-3020-2012
OI Infante, Marco/0000-0003-2032-8735; Caprio,
   Massimiliano/0000-0003-0722-7163
CR Abdulai I, 2020, AGR SYST, V181, DOI 10.1016/j.agsy.2020.102812
   Afra TP, 2020, EUR J INTERN MED, DOI [10.1016/j.ejim.2020.07.00197, DOI 10.1016/J.EJIM.2020.07.00197]
   Agrawal S, 2020, MONALDI ARCH CHEST D, V90, P1, DOI DOI 10.4081/M0NALDI.2020.1289
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Al-Kofahi M, 2020, CLIN PHARMACOL THER, V108, P766, DOI 10.1002/cpt.1874
   Andersson U, 2020, MOL MED, V26, DOI 10.1186/s10020-020-00172-4
   Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323
   Aquino YSJ, 2020, J MED ETHICS, DOI [10.1136/medethics-2020-10630677, DOI 10.1136/MEDETHICS-2020-10630677]
   Aromolaran AS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208321
   Bauchner H, 2020, JAMA
   Beauverd Y, 2020, EUR J HAEMATOL, V105, P357, DOI 10.1111/ejh.13432
   Beigel JH, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa200776464, DOI 10.1056/NEJM0A200776464]
   Bessiere F., 2020, JAMA CARDIOL
   Bolanos-Meade J, 2005, AM J HEMATOL, V78, P306, DOI 10.1002/ajh.20294
   Bonow RO, 2020, JAMA CARDIOL
   Boulware DR, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa201663871, DOI 10.1056/NEJMOA201663871]
   Brufsky A, 2020, J MED VIROL, V92, P770, DOI 10.1002/jmv.25887
   Capoluongo ED, 2020, CLIN CHEM LAB MED, V58, P1162, DOI 10.1515/cclm-2020-0442
   Caprio M, 2017, EAT WEIGHT DISORD-ST, V22, P27, DOI 10.1007/s40519-016-0312-6
   Carr AC, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111211
   Casado E, 2006, ANN RHEUM DIS, V65, P385, DOI 10.1136/ard.2004.023200
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chiappetta S, 2020, INT J OBESITY, V44, P1790, DOI 10.1038/s41366-020-0597-4
   Cohen MS, 2020, NEW ENGL J MED, DOI [10.1056/ NEJMe202038872, DOI 10.1056/NEJME202038872]
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Biancatelli RMLC, 2020, EXPERT REV ANTI-INFE, V18, P99, DOI 10.1080/14787210.2020.1706483
   Cutler D J, 1988, Agents Actions Suppl, V24, P142
   Derwand R, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109815
   Diaz G, 2020, VIRT COVID 19 C 23 I
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Fabbri A, 2020, EUR REV MED PHARMACO, V24, P4038
   FDA, HYDR CHLOR LETT
   FDA Drug Safety Communication, SAF ANN
   Fung KL, 2020, J ANTIMICROB CHEMOTH, V75, P2016, DOI 10.1093/jac/dkaa169
   Furst DE, 1996, LUPUS, V5, pS11, DOI 10.1177/096120339600500104
   Galvis V, 2020, ARCH BRONCONEUMOL, DOI [10.1016/j.arbres.2020.05.00876, DOI 10.1016/J.ARBRES.2020.05.00876]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gheita TA, 2016, INT J RHEUM DIS, V19, P294, DOI 10.1111/1756-185X.12426
   Glinsky GV, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050129
   Gopel S, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04556-z
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Guastalegname M, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa321106, DOI 10.1093/CID/CIAA321106]
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hoffmann MS, 2020, LEARN INDIVID DIFFER, V78, DOI 10.1016/j.lindif.2019.101817
   Horby P, COMMUNICATION
   ICMR, 2020, REV ADV US HYDR HCQ
   Infante M, 2019, NUTRIENTS, V11, P12
   Infante M, 2020, J DIABETES, V12, P659, DOI 10.1111/1753-0407.13053
   Islam MA, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102392
   Jean SS, 2020, EXPERT REV ANTI-INFE, V18, P843, DOI 10.1080/14787210.2020.1771181
   Kalra RS, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9070546
   Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001
   Kapoor Aditya, 2020, Indian Pacing Electrophysiol J, V20, P117, DOI 10.1016/j.ipej.2020.04.003
   Khan MS, 2020, NEW ENGL J MED, P383
   Kim AHJ, 2020, ANN INTERN MED, V172, P819, DOI 10.7326/M20-1223
   Knoell DL, 2010, INT J VITAM NUTR RES, V80, P271, DOI 10.1024/0300-9831/a000034
   Kuznik A, 2011, J IMMUNOL, V186, P4794, DOI 10.4049/jimmunol.1000702
   Kwon JB, 2010, JCR-J CLIN RHEUMATOL, V16, P28, DOI 10.1097/RHU.0b013e3181c47ec8
   LANDEWE RBM, 1995, CLIN EXP IMMUNOL, V102, P144
   Lee SH, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105988
   Sisnieguez CEL, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01148-2020
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Liao W, 2008, NAT IMMUNOL, V9, P1288, DOI 10.1038/ni.1656
   Linton NM, 2020, J CLIN MED, V9, P2
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Marmor MF, 2020, AM J OPHTHALMOL, DOI [10.1016/j.ajo.2020.03.02980, DOI 10.1016/J.AJO.2020.03.02980]
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   McElhiney Linda F, 2020, Int J Pharm Compd, V24, P287
   Mercuro NJ, 2020, JAMA CARDIOL
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Mitja O., 2020, CLIN INFECT DIS
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Morgan ND, 2013, JCR-J CLIN RHEUMATOL, V19, P286, DOI 10.1097/RHU.0b013e31829d5e50
   Mvumbi DM, 2020, MED HYPOTHESES, V143
   Naghipour S, 2020, EXPERT REV ANTI-INFE, V18, P1119, DOI 10.1080/14787210.2020.1792291
   O'Laughlin JP, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/4626279
   Pablos JL, 2020, ANN RHEUM DIS, V79, P1544, DOI [10.1136/annrheumdis-2020-217763, 10.1136/annrheumdis-2020-218296]
   Pagliano P, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa32067, DOI 10.1093/CID/CIAA32067]
   Pereira BB, 2020, J TOXICOL ENV HEAL B, V23, P177, DOI 10.1080/10937404.2020.1752340
   Perricone C, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102468
   Ponticelli C, 2017, EXPERT OPIN DRUG SAF, V16, P411, DOI 10.1080/14740338.2017.1269168
   Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6
   Rathi S, 2020, LANCET INFECT DIS, DOI [10.1016/S1473-3099(20)30313-369, DOI 10.1016/S1473-3099(20)30313-369]
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Rogosnitzky Moshe, 2020, JMIR Public Health Surveill, V6, pe19199, DOI 10.2196/19199
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Rosenke K., 2020, BIORXIV
   ROTHENBERG RJ, 1987, ARTHRITIS RHEUM, V30, P221, DOI 10.1002/art.1780300214
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sapp JL, 2020, CAN J CARDIOL, V36, P948, DOI 10.1016/j.cjca.2020.04.003
   Sattar N, 2020, CIRCULATION, V142, P4, DOI 10.1161/CIRCULATIONAHA.120.047659
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Shukla S, 2019, NEUROLOGY, V92, pe742, DOI 10.1212/WNL.0000000000006914
   Spinelli FR, 2020, ANN RHEUM DIS, V79, P666, DOI [10.1136/annrheumdis-2020-217367, 10.1136/annrheumdis-2020-217557]
   Stein M, 2000, J RHEUMATOL, V27, P2927
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   Traebert M, 2004, EUR J PHARMACOL, V484, P41, DOI 10.1016/j.ejphar.2003.11.003
   vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wahie S, 2011, J INVEST DERMATOL, V131, P1981, DOI 10.1038/jid.2011.167
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yang TZ, 2020, GENET EPIDEMIOL, V44, P880, DOI 10.1002/gepi.22348
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Yusuf IH, 2017, EYE, V31, P828, DOI 10.1038/eye.2016.298
   Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 114
TC 1
Z9 1
U1 3
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-7210
EI 1744-8336
J9 EXPERT REV ANTI-INFE
JI Expert Rev. Anti-Infect. Ther.
DI 10.1080/14787210.2020.1799785
EA AUG 2020
PG 12
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NA5NL
UT WOS:000559863000001
PM 32693652
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Diamand, R
   Ploussard, G
   Roumiguie, M
   Oderda, M
   Benamran, D
   Fiard, G
   Peltier, A
   Simone, G
   Van Damme, J
   Malavaud, B
   Iselin, C
   Descotes, JL
   Roche, JB
   Quackels, T
   Roumeguere, T
   Albisinni, S
AF Diamand, Romain
   Ploussard, Guillaume
   Roumiguie, Mathieu
   Oderda, Marco
   Benamran, Daniel
   Fiard, Gaelle
   Peltier, Alexandre
   Simone, Giuseppe
   Van Damme, Julien
   Malavaud, Bernard
   Iselin, Christophe
   Descotes, Jean-Luc
   Roche, Jean-Baptiste
   Quackels, Thierry
   Roumeguere, Thierry
   Albisinni, Simone
TI Timing and delay of radical prostatectomy do not lead to adverse
   oncologic outcomes: results from a large European cohort at the times of
   COVID-19 pandemic
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article; Early Access
DE Prostate cancer; Delay; COVID-19; Biochemical recurrence; Oncologic
   outcomes
ID DECISION; CANCER; BIOPSY; MEN
AB Purpose The current COVID-19 pandemic is transforming our urologic practice and most urologic societies recommend to defer any surgical treatment for prostate cancer (PCa) patients. It is unclear whether a delay between diagnosis and surgical management (i.e., surgical delay) may have a detrimental effect on oncologic outcomes of PCa patients. The aim of the study was to assess the impact of surgical delay on oncologic outcomes. Methods Data of 926 men undergoing radical prostatectomy across Europe for intermediate and high-risk PCa according to EAU classification were identified. Multivariable analysis using binary logistic regression and Cox proportional hazard model tested association between surgical delay and upgrading on final pathology, lymph-node invasion (LNI), pathological locally advanced disease (pT3-4 and/or pN1), need for adjuvant therapy, and biochemical recurrence. Kaplan-Meier analysis was used to estimate BCR-free survival after surgery as a function of surgical delay using a 3 month cut-off. Results Median follow-up and surgical delay were 26 months (IQR 10-40) and 3 months (IQR 2-5), respectively. We did not find any significant association between surgical delay and oncologic outcomes when adjusted to pre- and post-operative variables. The lack of such association was observed across EAU risk categories. Conclusion Delay of several months did not appear to adversely impact oncologic results for intermediate and high-risk PCa, and support an attitude of deferring surgery in line with the current recommendation of urologic societies.
C1 [Diamand, Romain; Quackels, Thierry; Roumeguere, Thierry; Albisinni, Simone] Univ Libre Bruxelles, Univ Clin Brussels, Urol Dept, Hop Erasme, Route Lennik 808, B-1070 Brussels, Belgium.
   [Ploussard, Guillaume] Le Croix Sud Hosp, Urol Dept, Quint Fonsegrives, France.
   [Roumiguie, Mathieu] CHU Toulouse, Urol Dept, Toulouse, France.
   [Oderda, Marco] Univ Turin, Urol Dept, Citta Salute & Sci Torino, Turin, Italy.
   [Benamran, Daniel; Iselin, Christophe] Hop Univ Geneve, Urol Dept, Geneva, Switzerland.
   [Fiard, Gaelle; Descotes, Jean-Luc] CHU Grenoble, Urol Dept, Grenoble, France.
   [Fiard, Gaelle; Descotes, Jean-Luc] Grenoble Alpes Univ, TIMC IMAG, Grenoble INP, CNRS, Grenoble, France.
   [Peltier, Alexandre] Jules Bordet Inst, Urol Dept, Brussels, Belgium.
   [Simone, Giuseppe] IRCCS Regina Elena Natl Canc Inst, Urol Dept, Rome, Italy.
   [Van Damme, Julien] Catholic Univ Louvain, Univ Clin St Luc, Urol Dept, Brussels, Belgium.
   [Malavaud, Bernard] Inst Univ Canc Toulouse Oncopole, Urol Dept, Toulouse, France.
   [Roche, Jean-Baptiste] Clin St Augustin, Urol Dept, Bordeaux, France.
RP Diamand, R (corresponding author), Univ Libre Bruxelles, Univ Clin Brussels, Urol Dept, Hop Erasme, Route Lennik 808, B-1070 Brussels, Belgium.
EM romain.diamand@erasme.ulb.ac.be
FU Fondation de FranceFondation de France; European Urology Scholarship
   Program
FX Gaelle Fiard, M. D., Ph.D., received funding from the Fondation de
   France and the European Urology Scholarship Program.
CR Abramson Cancer Center at the University of Pennsylvania City of Hope National Cancer Center Dana-Farber/Brigham and Women's Cancer Center Duke Cancer Institute Fox Chase Cancer Center Fred Hutchinson Cancer Research Center/Seattle Cancer Care Allian and V-ICC, MAN PROST CANC COVID
   Berry DL, 2003, UROL ONCOL-SEMIN O I, V21, P93, DOI 10.1016/S1078-1439(02)00209-0
   Berry DL, 2006, CLIN GENITOURIN CANC, V5, P219, DOI 10.3816/CGC.2006.n.040
   Diamand R, 2019, WORLD J UROL, V37, P2109, DOI 10.1007/s00345-019-02634-9
   Fossati N, 2017, UROL ONCOL-SEMIN ORI, V35, DOI 10.1016/j.urolonc.2016.11.010
   Geethanath S, 2019, J MAGN RESON IMAGING, V49, pE65, DOI 10.1002/jmri.26638
   Ginsburg KB, 2020, J UROLOGY, V204, P720, DOI 10.1097/JU.0000000000001089
   Ribal MJ, EUR UROL
   Gupta N, 2019, BJU INT, V124, P268, DOI 10.1111/bju.14659
   Loeb S, 2016, SCAND J UROL, V50, P246, DOI 10.3109/21681805.2016.1166153
   Meunier ME, 2018, PROG UROL, V28, P475, DOI 10.1016/j.purol.2018.05.003
   Mottet N, EUR UROL
   Mottet N, 2017, EUR UROL, V71, P618, DOI 10.1016/j.eururo.2016.08.003
   Puliatti S, 2020, BJU INT, V125, pE7, DOI 10.1111/bju.15071
   Song LX, 2013, CANCER-AM CANCER SOC, V119, P421, DOI 10.1002/cncr.27738
   Stensland KD, 2020, EUR UROL, V77, P663, DOI 10.1016/j.eururo.2020.03.027
   Tay KJ, 2016, EUR UROL, V70, P211, DOI 10.1016/j.eururo.2015.10.041
   van den Bergh RCN, 2013, EUR UROL, V64, P204, DOI 10.1016/j.eururo.2013.02.024
   Westerman ME, 2019, INT BRAZ J UROL, V45, P468, DOI [10.1590/S1677-5538.IBJU.2018.0196, 10.1590/s1677-5538.ibju.2018.0196]
   Zanaty M, 2018, WORLD J UROL, V36, P1, DOI 10.1007/s00345-017-2105-6
NR 20
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0724-4983
EI 1433-8726
J9 WORLD J UROL
JI World J. Urol.
DI 10.1007/s00345-020-03402-w
EA AUG 2020
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA NA2DS
UT WOS:000559626700002
PM 32776243
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Goldstein, E
   Yeghiazaryan, K
   Ahmad, A
   Giordano, FA
   Frohlich, H
   Golubnitschaja, O
AF Goldstein, Elisha
   Yeghiazaryan, Kristina
   Ahmad, Ashar
   Giordano, Frank A.
   Froehlich, Holger
   Golubnitschaja, Olga
TI Optimal multiparametric set-up modelled for best survival outcomes in
   palliative treatment of liver malignancies: unsupervised machine
   learning and 3 PM recommendations
SO EPMA JOURNAL
LA English
DT Article
DE Predictive preventive personalised medicine (PPPM; 3 PM); Liver
   diseases; Liver malignancy; Palliative medicine; Unsupervised machine
   learning; Multiparametric modelling; Patient stratification;
   Hepatocellular carcinoma; Colorectal cancer; Breast cancer; Prostate
   cancer; Metastasis; Liquid biopsy; Ex vivo; Circulating leucocytes;
   Multi-omics; Biomarker patterns; Multi-level diagnostics; Survival;
   Prognosis; Metalloproteinase; Comet assay; Calgranulin A; S100;
   Catalase; Superoxide-dismutase 2; SOD-2; Profilin; Rho A; Thioredoxin;
   Scavenger; Antioxidant compounds; ROS inhibition; Selective internal
   radiation therapy (SIRT); Trans-arterial chemo-embolisation (TACE);
   Individual outcomes; Covid-19; Viral infection; Hepatitis; Hypoxia;
   Inflammation; Detoxification; Impairments; Individualised patient
   profile; Redox status; Genoprotection; Phytochemicals; Redox-based
   therapy; Risk mitigation
ID BREAST-CANCER; CLINICAL UTILITY; DISCOVERY; COVID-19; LESSONS
AB Over the last decade, a rapid rise in deaths due to liver disease has been observed especially amongst young people. Nowadays liver disease accounts for approximately 2 million deaths per year worldwide: 1 million due to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma. Besides primary liver malignancies, almost all solid tumours are capable to spread metastases to the liver, in particular, gastrointestinal cancers, breast and genitourinary cancers, lung cancer, melanomas and sarcomas. A big portion of liver malignancies undergo palliative care. To this end, the paradigm of the palliative care in the liver cancer management is evolving from "just end of the life" care to careful evaluation of all aspects relevant for the survivorship. In the presented study, an evidence-based approach has been taken to target molecular pathways and subcellular components for modelling most optimal conditions with the longest survival rates for patients diagnosed with advanced liver malignancies who underwent palliative treatments. We developed an unsupervised machine learning (UML) approach to robustly identify patient subgroups based on estimated survival curves for each individual patient and each individual potential biomarker. UML using consensus hierarchical clustering of biomarker derived risk profiles resulted into 3 stable patient subgroups. There were no significant differences in age, gender, therapy, diagnosis or comorbidities across clusters. Survival times across clusters differed significantly. Furthermore, several of the biomarkers demonstrated highly significant pairwise differences between clusters after correction for multiple testing, namely, "comet assay" patterns of classes I, III, IV and expression rates of calgranulin A (S100), SOD2 and profilin-all measured ex vivo in circulating leucocytes. Considering worst, intermediate and best survival curves with regard to identified clusters and corresponding patterns of parameters measured, clear differences were found for "comet assay" and S100 expression patterns. In conclusion, multi-faceted cancer control within the palliative care of liver malignancies is crucial for improved disease outcomes including individualised patient profiling, predictive models and implementation of corresponding cost-effective risks mitigating measures detailed in the paper. The "proof-of-principle" model is presented.
C1 [Goldstein, Elisha] Weizmann Inst Sci, Dept Bioinformat, Machine Learning Res Grp, Rehovot, Israel.
   [Goldstein, Elisha] Rheinische Friedrich Wilhelms Univ Bonn, State NRW Israel Program, Bonn, Germany.
   [Yeghiazaryan, Kristina] Rheinische Friedrich Wilhelms Univ Bonn, Univ Hosp Bonn, IT Dept, Bonn, Germany.
   [Ahmad, Ashar; Froehlich, Holger] Fraunhofer Inst Algorithms & Sci Comp SCAI, Dept Bioinformat, AI & Data Sci, D-53754 St Augustin, Germany.
   [Ahmad, Ashar; Froehlich, Holger] Rheinische Friedrich Wilhelms Univ Bonn, Bonn Aachen Int Ctr IT, D-53115 Bonn, Germany.
   [Giordano, Frank A.] Rheinische Friedrich Wilhelms Univ Bonn, Univ Hosp Bonn, Dept Radiat Oncol, Bonn, Germany.
   [Golubnitschaja, Olga] Rheinische Friedrich Wilhelms Univ Bonn, Univ Hosp Bonn, Dept Radiat Oncol, Predict Prevent & Personalised 3P Med, Venusberg Campus 1, D-53127 Bonn, Germany.
RP Frohlich, H (corresponding author), Fraunhofer Inst Algorithms & Sci Comp SCAI, Dept Bioinformat, AI & Data Sci, D-53754 St Augustin, Germany.; Frohlich, H (corresponding author), Rheinische Friedrich Wilhelms Univ Bonn, Bonn Aachen Int Ctr IT, D-53115 Bonn, Germany.; Golubnitschaja, O (corresponding author), Rheinische Friedrich Wilhelms Univ Bonn, Univ Hosp Bonn, Dept Radiat Oncol, Predict Prevent & Personalised 3P Med, Venusberg Campus 1, D-53127 Bonn, Germany.
EM holger.froehlich@scai.fraunhofer.de; Olga.Golubnitschaja@ukbonn.de
RI Frohlich, Holger/H-1976-2017; AHMAD, ASHAR/ABH-9603-2020
OI Frohlich, Holger/0000-0002-5328-1243; AHMAD, ASHAR/0000-0001-6417-4454
FU Projekt DEAL; governmental NRW(Germany)/Israeli programme for academic
   exchange, fellowship 2019
FX Open Access funding provided by Projekt DEAL. The study stay of Mr. E.
   Goldstein at 3P Medical Unit (Head -Prof. O. Golubnitschaja), Department
   of Radiation Oncology, University Hospital, Rheinische
   Friedrich-Wilhelms-Universitat Bonn, Germany, was supported by the
   governmental NRW(Germany)/Israeli programme for academic exchange,
   fellowship 2019.
CR [Anonymous], SCIENCEDAILY
   Asrani SK, 2019, J HEPATOL, V70, P151, DOI 10.1016/j.jhep.2018.09.014
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bubnov R, 2017, EPMA J, V8, P141, DOI 10.1007/s13167-017-0092-8
   Buhrmann Constanze, 2019, Nutrients, V11, DOI 10.3390/nu11122904
   Chaiswing L, 2018, ANTIOXID REDOX SIGN, V29, P1237, DOI 10.1089/ars.2017.7485
   Feng G, 2020, J CLIN TRANSL HEPATO, V8, P18, DOI 10.14218/JCTH.2020.00018
   Frohlich H, 2018, EPMA J, V9, P175, DOI 10.1007/s13167-018-0131-0
   Gerner C, 2020, MASS SPECTROM REV, V39, P442, DOI 10.1002/mas.21612
   Golubnitschaja O, 2019, MODERN HOSP PATIENTS, P403
   Golubnitschaja O, 2018, EPMA J, V9, P271, DOI 10.1007/s13167-018-0146-6
   Golubnitschaja O, 2018, AMINO ACIDS, V50, P383, DOI 10.1007/s00726-017-2524-0
   Golubnitschaja O, 2018, EPMA J, V9, P15, DOI 10.1007/s13167-018-0127-9
   Golubnitschaja O, 2017, AMINO ACIDS, V49, P273, DOI 10.1007/s00726-016-2357-2
   Golubnitschaja O, 2016, CLIN EXP METASTAS, V33, P743, DOI 10.1007/s10585-016-9816-8
   Golubnitschaja O, 2016, EPMA J, V7, DOI 10.1186/s13167-016-0072-4
   Golubnitschaja-Labudova O, 2000, CURR EYE RES, V21, P867, DOI 10.1076/ceyr.21.5.867.5534
   GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
   Hurley R., 2019, BMJ, V365, pl4424
   Jung KW, 2020, CANCER RES TREAT, V52, P351, DOI 10.4143/crt.2020.203
   Koklesova L, 2020, EPMA J, V11, P261, DOI 10.1007/s13167-020-00210-5
   Kucera R, 2020, EPMA J, V11, P399, DOI 10.1007/s13167-020-00214-1
   Lemsara A, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-3465-2
   Lu ML, 2018, EPMA J, V9, P77, DOI 10.1007/s13167-018-0128-8
   Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487
   Samec A, 2020, EPMA J, V49, P273, DOI [10.1007/s00726-016-2357-2, DOI 10.1007/S00726-016-2357-2]
   Sun J, 2020, LIVER INT, V40, P1278, DOI 10.1111/liv.14470
   Tong JF, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190452
   Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435
   Youssef M, 2020, J MED VIROL, V92, P1825, DOI 10.1002/jmv.26055
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zubor P, 2020, CANCERS, V12, DOI 10.3390/cancers12051292
NR 32
TC 1
Z9 1
U1 3
U2 3
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1878-5077
EI 1878-5085
J9 EPMA J
JI EPMA J.
PD SEP
PY 2020
VL 11
IS 3
SI SI
BP 505
EP 515
DI 10.1007/s13167-020-00221-2
EA AUG 2020
PG 11
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA ND7AK
UT WOS:000558118900001
PM 32839667
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Metcalfe, PE
AF Metcalfe, Peter E.
TI Low dose radiation therapy for COVID-19 pneumonia: brief review of the
   evidence
SO PHYSICAL AND ENGINEERING SCIENCES IN MEDICINE
LA English
DT Letter
C1 [Metcalfe, Peter E.] Univ Wollongong, Ctr Med Radiat Phys, Wollongong, NSW, Australia.
   [Metcalfe, Peter E.] Univ Wollongong, Sch Phys, Wollongong, NSW, Australia.
RP Metcalfe, PE (corresponding author), Univ Wollongong, Ctr Med Radiat Phys, Wollongong, NSW, Australia.; Metcalfe, PE (corresponding author), Univ Wollongong, Sch Phys, Wollongong, NSW, Australia.
EM metcalfe@uow.edu.au
CR Atun R, 2015, LANCET ONCOL, V16, P1153, DOI 10.1016/S1470-2045(15)00222-3
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   Dhawan G, 2020, RADIOTHER ONCOL, V147, P212, DOI 10.1016/j.radonc.2020.05.002
   Doss M, 2020, PHYS MED BIOL
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Kefayat A, 2020, RADIOTHER ONCOL, V147, P224, DOI 10.1016/j.radonc.2020.04.026
   Khan M, 2020, LOW DOSE WHOLE LUNG, DOI [10.1101/2020.06.03.20116988, DOI 10.1101/2020.06.03.20116988]
   Kirkby C, 2020, RADIOTHER ONCOL, V147, P221, DOI 10.1016/j.radonc.2020.04.004
   Marks LB, 2010, INT J RADIAT ONCOL, V76, pS10, DOI 10.1016/j.ijrobp.2009.07.1754
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mortazavi SMJ, 2020, MED PHYS, V47, P3773, DOI 10.1002/mp.14367
   Ott OJ, 2019, STRAHLENTHER ONKOL, V195, P285, DOI 10.1007/s00066-018-1412-1
   Powell EV, 1936, TEX STATE J MED, V32, P237
   Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1
   Rahnama N, 2020, ASSESSMENT LOW DOSE
   Trott KR, 2020, RADIOTHER ONCOL, V147, P210, DOI 10.1016/j.radonc.2020.05.003
   Whitaker M, 2020, PHYS ENG SCI MED, V43, P473, DOI 10.1007/s13246-020-00869-0
NR 17
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2662-4729
EI 2662-4737
J9 PHYS ENG SCI MED
JI Phys. Eng. Sci. Med.
PD SEP
PY 2020
VL 43
IS 3
BP 761
EP 763
DI 10.1007/s13246-020-00915-x
EA AUG 2020
PG 3
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA NQ9TW
UT WOS:000558940900001
PM 32776317
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Talamonti, M
   Galluzzo, M
   Chiricozzi, A
   Quaglino, P
   Fabbrocini, G
   Gisondi, P
   Marzano, AV
   Potenza, C
   Conti, A
   Parodi, A
   Fortina, AB
   Bardazzi, F
   Argenziano, G
   Rongioletti, F
   Stingeni, L
   Micali, G
   Loconsole, F
   Venturini, M
   Bongiorno, MR
   Feliciani, C
   Rubegni, P
   Amerio, P
   Fargnoli, MC
   Pigatto, P
   Savoia, P
   Nistico, SP
   Giustini, S
   Carugno, A
   Cannavo, SP
   Rech, G
   Prignano, F
   Offidani, A
   Lombardo, M
   Zalaudek, I
   Bianchi, L
   Peris, K
AF Talamonti, M.
   Galluzzo, M.
   Chiricozzi, A.
   Quaglino, P.
   Fabbrocini, G.
   Gisondi, P.
   Marzano, A. V.
   Potenza, C.
   Conti, A.
   Parodi, A.
   Belloni Fortina, A.
   Bardazzi, F.
   Argenziano, G.
   Rongioletti, F.
   Stingeni, L.
   Micali, G.
   Loconsole, F.
   Venturini, M.
   Bongiorno, M. R.
   Feliciani, C.
   Rubegni, P.
   Amerio, P.
   Fargnoli, M. C.
   Pigatto, P.
   Savoia, P.
   Nistico, S. P.
   Giustini, S.
   Carugno, A.
   Cannavo, S. P.
   Rech, G.
   Prignano, F.
   Offidani, A.
   Lombardo, M.
   Zalaudek, I.
   Bianchi, L.
   Peris, K.
CA PSO-BIO-COVID Study Grp
TI Management of biological therapies for chronic plaque psoriasis during
   COVID-19 emergency in Italy
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Letter; Early Access
C1 [Talamonti, M.; Galluzzo, M.; Bianchi, L.] Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy.
   [Chiricozzi, A.; Peris, K.] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Dermatol, Rome, Italy.
   [Chiricozzi, A.; Peris, K.] Univ Cattolica Sacro Cuore, Dermatol, Rome, Italy.
   [Quaglino, P.] Univ Turin, Dermatol Clin, Dept Med Sci, Turin, Italy.
   [Fabbrocini, G.] Univ Naples Federico II, Dept Clin Med & Surg, Dermatol Sect, Naples, Italy.
   [Gisondi, P.] Univ Verona, Dept Med, Sect Dermatol & Venereol, Verona, Italy.
   [Marzano, A. V.] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Dermatol Unit, Milan, Italy.
   [Marzano, A. V.] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.
   [Potenza, C.] Daniele Innocenzi Sapienza Univ Rome Polo Pontino, Dept Med Surg Sci & Biotechnol, Dermatol Unit, Rome, Italy.
   [Conti, A.] AOU Policlin Modena, Dept Specialized Med, Dermatol Unit, Modena, Italy.
   [Parodi, A.] Univ Genoa, Clin Dermatol DiSSal, IRCCS Genova, Osped Policlin San Martino, Genoa, Italy.
   [Belloni Fortina, A.] Univ Padua, Dept Med DIMED, Dermatol Unit, Padua, Italy.
   [Bardazzi, F.] Univ Bologna, Dept Expt Diagnost & Specialty Med, Dermatol Div, Bologna, Italy.
   [Argenziano, G.] Univ Campania Luigi Vanvitelli, Dermatol Unit, Naples, Italy.
   [Rongioletti, F.] Univ Cagliari, Dept Med Sci Publ Hlth, Sect Dermatol, Cagliari, Italy.
   [Stingeni, L.] Univ Perugia, Dept Med, Dermatol Sect, Perugia, Italy.
   [Micali, G.] Univ Catania, Dermatol Clin, Catania, Italy.
   [Loconsole, F.] Univ Bari, Unit Dermatol, Dept Biomed Sci & Human Oncol, Bari, Italy.
   [Venturini, M.] Univ Brescia, ASST Spedali Civili Brescia, Dept Dermatol, Brescia, Italy.
   [Bongiorno, M. R.] Univ Palermo, Dept Hlth Promot Maternal Infant Internal Med & S, Dermatol Sect, Palermo, Italy.
   [Feliciani, C.] Univ Parma, Dermatol Sect, Dept Med & Surg, Parma, Italy.
   [Rubegni, P.] Univ Siena, Dept Med Surg & Neurosci, Dermatol Unit, Siena, Italy.
   [Amerio, P.] Univ G dAnnunzio, Dept Med & Aging Sci, Dermatol Clin, Chieti, Italy.
   [Fargnoli, M. C.] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Dermatol, Laquila, Italy.
   [Pigatto, P.] Univ Milan, Dept Biomed Surg & Dent Sci, Dermatol Clin, IRCCS Galeazzi Orthopaed Inst, Milan, Italy.
   [Savoia, P.] Univ Piemonte Orientale, Dermatol Clin, Dept Hlth Sci, Novara, Italy.
   [Nistico, S. P.] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Dermatol Unit, Catanzaro, Italy.
   [Giustini, S.] Sapienza Univ Rome, Dept Dermatol, Rome, Italy.
   [Carugno, A.] ASST Papa Giovanni XXIII Hosp, Dermatol Unit, Bergamo, Italy.
   [Cannavo, S. P.] Univ Messina, Dept Clin & Expt Med, Dermatol, Messina, Italy.
   [Rech, G.] Santa Chiara Hosp, Div Dermatol, Trento, Italy.
   [Prignano, F.] Univ Florence, Dept Hlth Sci, Dermatol Clin, Florence, Italy.
   [Offidani, A.] Polytech Univ Marche Reg, Dept Clin & Mol Sci, Dermatol Clin, Ancona, Italy.
   [Lombardo, M.] Osped Circolo Varese, ASST Sette Laghi, Unit Dermatol Dis, Varese, Italy.
   [Zalaudek, I.] Univ Trieste, Dept Dermatol, Trieste, Italy.
RP Peris, K (corresponding author), Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Dermatol, Rome, Italy.; Peris, K (corresponding author), Univ Cattolica Sacro Cuore, Dermatol, Rome, Italy.
EM ketty.peris@unicatt.it
RI Carugno, Andrea/AAM-6118-2020; Talamonti, Marina/L-6190-2016; Amerio,
   Paolo/F-4573-2010; gualdi, giulio/L-3739-2016; Pellacani,
   Giovanni/E-8573-2011
OI Carugno, Andrea/0000-0002-8231-2205; Talamonti,
   Marina/0000-0002-3070-4071; Amerio, Paolo/0000-0003-1589-9672; gualdi,
   giulio/0000-0002-1640-6609; BIANCHI, LUCA/0000-0001-8697-6896;
   Pellacani, Giovanni/0000-0002-7222-2951; DI NUZZO,
   Sergio/0000-0003-0216-5178
CR Amerio P, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13434
   Bardazzi F, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1749545
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Carugno A, 2020, J AM ACAD DERMATOL, V83, P292, DOI 10.1016/j.jaad.2020.04.165
   Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Mahil SK, 2020, BRIT J DERMATOL, V183, P404, DOI 10.1111/bjd.19161
   Megna M, 2020, J DERMATOL TREAT, DOI [10.1080/09546634.2020.1781044, 10.1080/09546634.2020.1757605]
NR 8
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
EI 1468-3083
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
DI 10.1111/jdv.16841
EA AUG 2020
PG 3
WC Dermatology
SC Dermatology
GA MX9JH
UT WOS:000558033100001
PM 32735716
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Moss, BP
   Mahajan, KR
   Bermel, RA
   Hellisz, K
   Hua, LH
   Hudec, T
   Husak, S
   McGinley, MP
   Ontaneda, D
   Wang, ZN
   Weber, M
   Tagliani, P
   Cardenas-Robledo, S
   Zabalza, A
   Arrambide, G
   Carbonell-Mirabent, P
   Rodriguez-Barranco, M
   Sastre-Garriga, J
   Tintore, M
   Montalban, X
   Douglas, M
   Ogbuokiri, E
   Aravidis, B
   Cohen, JA
   Mowry, EM
   Fitzgerald, KC
AF Moss, Brandon P.
   Mahajan, Kedar R.
   Bermel, Robert A.
   Hellisz, Kelsey
   Hua, Le H.
   Hudec, Timothy
   Husak, Scott
   McGinley, Marisa P.
   Ontaneda, Daniel
   Wang, Zhini
   Weber, Malory
   Tagliani, Paula
   Cardenas-Robledo, Simon
   Zabalza, Ana
   Arrambide, Georgina
   Carbonell-Mirabent, Pere
   Rodriguez-Barranco, Marta
   Sastre-Garriga, Jaume
   Tintore, Mar
   Montalban, Xavier
   Douglas, Morgan
   Ogbuokiri, Esther
   Aravidis, Berna
   Cohen, Jeffrey A.
   Mowry, Ellen M.
   Fitzgerald, Kathryn C.
TI Multiple sclerosis management during the COVID-19 pandemic
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE COVID-19; SARS-CoV-2; multiple sclerosis; disease modifying therapies;
   health behaviors; healthcare delivery
AB Background: People with multiple sclerosis (MS) may be at higher risk for complications from the 2019 coronavirus (COVID-19) pandemic due to use of immunomodulatory disease modifying therapies (DMTs) and greater need for medical services.
   Objectives: To evaluate risk factors for COVID-19 susceptibility and describe the pandemic's impact on healthcare delivery.
   Methods: Surveys sent to MS patients at Cleveland Clinic, Johns Hopkins, and Vall d'Hebron-Centre d'Esclerosi Multiple de Catalunya in April and May 2020 collected information about comorbidities, DMTs, exposures, COVID-19 testing/outcomes, health behaviors, and disruptions to MS care.
   Results: There were 3028/10,816 responders. Suspected or confirmed COVID-19 cases were more likely to have a known COVID-19 contact (odds ratio (OR): 4.38; 95% confidence interval (CI): 1.04, 18.54). In multivariable-adjusted models, people who were younger, had to work on site, had a lower education level, and resided in socioeconomically disadvantaged areas were less likely to follow social distancing guidelines. 4.4% reported changes to therapy plans, primarily delays in infusions, and 15.5% a disruption to rehabilitative services.
   Conclusion: Younger people with lower socioeconomic status required to work on site may be at higher exposure risk and are potential targets for educational intervention and work restrictions to limit exposure. Providers should be mindful of potential infusion delays and MS care disruption.
C1 [Moss, Brandon P.; Mahajan, Kedar R.; Bermel, Robert A.; Hellisz, Kelsey; Hudec, Timothy; Husak, Scott; McGinley, Marisa P.; Ontaneda, Daniel; Weber, Malory; Cohen, Jeffrey A.] Cleveland Clin, Mellen Ctr Multiple Sclerosis, 9500 Euclid Ave,U-10, Cleveland, OH 44195 USA.
   [Hua, Le H.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA.
   [Wang, Zhini] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA.
   [Tagliani, Paula; Cardenas-Robledo, Simon; Zabalza, Ana; Arrambide, Georgina; Carbonell-Mirabent, Pere; Rodriguez-Barranco, Marta; Sastre-Garriga, Jaume; Tintore, Mar; Montalban, Xavier] Univ Autonoma Barcelona, Serv Neurol Neuroimmunol, Ctr Esclerosi Multiple Catalunya CEMCAT, Vall dHebron Inst Recerca,Vall dHebron Hosp Univ, Barcelona, Spain.
   [Douglas, Morgan; Ogbuokiri, Esther; Aravidis, Berna; Mowry, Ellen M.; Fitzgerald, Kathryn C.] Johns Hopkins Univ, Div Neuroimmunol & Neurol Infect, Baltimore, MA USA.
RP Moss, BP (corresponding author), Cleveland Clin, Mellen Ctr Multiple Sclerosis, 9500 Euclid Ave,U-10, Cleveland, OH 44195 USA.
EM mossb@ccf.org
RI Montalban, Xavier/J-5938-2016; Zabalza, Ana/AAX-5767-2020
OI Montalban, Xavier/0000-0002-0098-9918; Zabalza, Ana/0000-0003-3860-5251;
   Arrambide, Georgina/0000-0002-2657-5510; Hua, Le/0000-0002-0535-3978;
   Moss, Brandon/0000-0001-5319-5129; Bermel, Robert/0000-0003-2334-6883
FU NIMHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [K01 MH121582]; Career Transition Fellowship from the National MS
   Society; NIH NINDS K23 Career Development Award [1K23NS109328];
   RocheRoche Holding; BiogenBiogen; Sanofi-Genzyme; Teva; NovartisNovartis
FX The author(s) declared the following potential conflicts of interest
   with respect to the research, authorship, and/or publication of this
   article: Ms B.A. has nothing to disclose. Dr G.A. has received
   compensation for consulting services or participation in advisory boards
   from Sanofi, Merck, and Roche; research support from Novartis; travel
   expenses for scientific meetings from Novartis, Roche, Stendhal, and
   ECTRIMS; speaking honoraria from Sanofi and Merck; and is a member of
   the International Women in Multiple Sclerosis (iWiMS) network executive
   committee. https://orcid.org/0000-0002-2657-5510. Dr R.A.B. has served
   as a consultant for Biogen, EMD Serono, Genzyme/Sanofi, Genentech/Roche,
   Novartis, and Viela Bio. He receives ongoing research support directed
   to his institution from Biogen, Genentech, and Novartis. Mr P.C.-M.'s
   yearly salary is supported by a grant from Biogen to Fundacio privada
   CEMCAT toward statistical analysis, and he has received travel expenses
   from Biogen. Dr S.C.-R. is an ECTRIMS clinical fellowship awardee; he
   has received travel expenses for scientific meetings from Biogen Idec
   and Genzyme, compensation for consulting services or participation in
   advisory boards from Roche and Novartis, and speaking honoraria from
   Novartis. https://orcid.org/0000-0002-7612-3985. Dr J.A.C. received
   personal compensation for consulting for Adamas, Convelo, MedDay, and
   Mylan; and serving as an editor of Multiple Sclerosis Journal. Ms M.D.
   has nothing to disclose. Dr K.C.F. is supported by NIMH K01 MH121582 and
   a Career Transition Fellowship from the National MS Society. Ms K.H. has
   nothing to disclose. Dr L.H.H. has received speaking and consulting fees
   from Biogen, Genzyme, Genentech, Novartis, Bristol Myers Squibb, and EMD
   Serono. Mr T.H. has nothing to disclose. Mr S.H. has nothing to
   disclose. Dr K.R.M. is funded by NIH NINDS K23 Career Development Award
   1K23NS109328. Dr M.P.M. has served on scientific advisory boards for
   Genzyme and Genentech, research support from Novartis, and receives
   funding from a KL2 (KL2TR002547) grant from Clinical and Translational
   Science Collaborative of Cleveland, from the National Center for
   Advancing Translational Sciences (NCATS) component of the NIH. Dr X.M.
   received speaking honoraria and travel expenses for scientific meetings,
   has been a steering committee member of clinical trials or participated
   in advisory boards of clinical trials in the past 3 years with Actelion,
   Alexion, Bayer, Biogen, Celgene, EMD Serono, EXCEMED, Genzyme, MedDay,
   Merck, MSIF, Nervgen, NMSS, Novartis, Roche, Sanofi-Genzyme, Teva
   Pharmaceuticals, and TG Therapeutics.
   https://orcid.org/0000-0002-0098-9918. Dr B.P.M. reports research
   funding for investigator-initiated studies from Roche and is site PI for
   studies sponsored by Roche; he received speaking fees from Genzyme,
   consulting fees for Roche, and has stock in Pfizer. Dr E.L.M. reports
   research funding for investigator-initiated studies from Biogen,
   Sanofi-Genzyme, and Teva, and is site PI for studies sponsored by
   Biogen. She received royalties for editorial duties for UpToDate. Ms
   E.O. has nothing to disclose. Dr D.O. has received research support from
   the National Institutes of Health, National Multiple Sclerosis Society,
   Patient Centered Outcomes Research Institute, Race to Erase MS
   Foundation, Genentech, Genzyme, and Novartis. He has also received
   consulting fees from Biogen Idec, Genentech/Roche, Genzyme, Novartis,
   and Merck. Ms M.R.-B. has nothing to disclose. Dr J.S.-G.; has received
   compensation for participating on Advisory Boards, speaking honoraria
   and travel expenses for scientific meetings, consulting services or
   research support from Celgene, Novartis, Biogen, Teva, Merck, Almirall,
   and Genzyme. https://orcid.org/0000-0002-1589-2254. Dr P.T. is an
   ECTRIMS clinical fellowship awardee and has received travel expenses for
   scientific meetings from Roche. https://orcid.org/0000-0002-4048-7314.
   Dr M.T. has received compensation for consulting services and speaking
   honoraria from Almirall, Bayer Schering Pharma, Biogen Idec, Genzyme,
   Merck-Serono, Novartis, Roche, Sanofi-Aventis, and Teva Pharmaceuticals.
   Dr M.T. is coeditor of Multiple Sclerosis Journal-Experimental,
   Translational and Clinical. https://orcid.org/0000-0001-9999-5359. Ms
   Z.W. has nothing to disclose. Ms M.W. has nothing to disclose. Dr A.Z.
   has received travel expenses for scientific meetings from Biogen Idec,
   Novartis, and Genzyme; speaking honoraria from Eisai; and a study grant
   from Novartis. https://orcid.org/0000-0003-3860-5251.
CR Baldassari LE, 2020, MULT SCLER RELAT DIS, V38, DOI 10.1016/j.msard.2019.101525
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Jehi L, 2020, CHEST, V158, P1364, DOI 10.1016/j.chest.2020.05.580
   Kind AJH, 2014, ANN INTERN MED, V161, P765, DOI 10.7326/M13-2946
   KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
   Learmonth YC, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-37
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581
   Multiple Sclerosis International Federation, 2020, GLOB COVID 19 ADV PE
   National Multiple Sclerosis Society, 2020, MS TREATM GUID COR N
   R Core Team, 2019, R LANG ENV STAT COMP
   Sastre-Garriga J, 2020, MULT SCLER J, V26, P1153, DOI 10.1177/1352458520931785
   World Health Organization, 2020, WHO COR DIS COVID 19
   World Health Organization, 2020, COVID 19 SIGN IMP HL
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 16
TC 3
Z9 3
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD SEP
PY 2020
VL 26
IS 10
BP 1163
EP 1171
AR 1352458520948231
DI 10.1177/1352458520948231
EA AUG 2020
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NP1QZ
UT WOS:000558324900001
PM 32772807
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Unger, JP
AF Unger, Jean-Pierre
TI Comparison of COVID-19 Health Risks With Other Viral Occupational
   Hazards
SO INTERNATIONAL JOURNAL OF HEALTH SERVICES
LA English
DT Article; Early Access
DE COVID-19; occupational health; burden of disease; epidemiology
ID CASE-FATALITY; HEPATITIS; VIRUS
AB The European Commission periodically classifies viruses on their occupational hazards to define the level of protection that workers are entitled to claim. Viruses belonging to Groups 3 and 4 can cause severe human disease and hazard to workers, as well as a spreading risk to the community. However, there is no effective prophylaxis or treatment available for Group 4 viruses. European trade unions and the Commission are negotiating the classification of the COVID-19 virus along these 2 categories. This article weighs the reasons to classify it in Group 3 or 4 while comparing its risks to those of the most significant viruses classified in these 2 categories. COVID-19 characteristics justify its classification in Group 4. Contaminated workers in contact with the public play an important role in disseminating the virus. In hospitals and nursing homes, they increase the overall case fatality rate. By strongly protecting these workers and professionals, the European Union would not only improve health in work environments, but also activate a mechanism key to reducing the COVID-19 burden in the general population. Admittedly, the availability of a new vaccine or treatment would change this conclusion, which was reached in the middle of the first pandemic.
C1 [Unger, Jean-Pierre] Univ Newcastle, Inst Populat Hlth Sci, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England.
RP Unger, JP (corresponding author), Univ Newcastle, Inst Populat Hlth Sci, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England.
EM jeanpierre.unger@gmail.com
FU European Trade Unions Institute
FX The author disclosed receipt of the following financial support for the
   research, authorship and publication of this article: This work was
   supported by the European Trade Unions Institute.
CR Ajelli M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050948
   Alavi M, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3110-0
   Althaus CL, 2015, LANCET INFECT DIS, V15, P507, DOI 10.1016/S1473-3099(15)70135-0
   Althaus CL, 2015, COMMUNICATION
   [Anonymous], 2018, WHO MARBURG VIRUS DI
   [Anonymous], 2019, WHO POLIOMYELITIS FA
   [Anonymous], 2018, WHO PROGR REPORT ACC
   [Anonymous], 2019, WHO JAPANESE ENCEPHA
   [Anonymous], 2020, CORONAVIRUS DIS 2019
   [Anonymous], 2018, ECDC EPIDEMIOLOGICAL
   [Anonymous], 2017, WHO W NILE VIRUS FAC
   [Anonymous], 2019, WHO YELLOW FEVER FAC
   [Anonymous], 2013, RABIES B EUROPE
   Babu TM, 2018, J INFECT DIS, V218, P1054, DOI 10.1093/infdis/jiy291
   Bianco E, 2003, DIGEST LIVER DIS, V35, P404, DOI 10.1016/S1590-8658(03)00157-9
   CDC, 1957 1958 PAND H2N2
   CDC, NAT PROGR REP 2020 G
   CDC, 2019, HEP C QUEST ANSW HLT
   CDC, 2019, LASSA FEVER
   Centre for Evidence-Based Medicine, WILL IT BE INTR VIR
   Cohen J, 2016, INFECT DIS, V2
   Counil E, 2020, CONVERSATION
   Dean NE, 2016, CLIN INFECT DIS, V62, P1277, DOI 10.1093/cid/ciw114
   ECDC, 2020, CHIK VIR DIS
   ECDC, 2019, YELLOW FEV ANN EP RE
   ECDC, 2013, EP UPD HIGHL PATH IN
   ECDC, COVID 19 SIT UPD WOR
   ECDC and WHO, 2019, HIV AIDS SURV EUR
   Eldad E, 2020, MEDSCAPE FAMILY MED
   European Centre for Disease Prevention and Control, WEEKL UPD 2019 W NIL
   Famulare M, 2019 NCOV PRELIMINAR
   Farrar J, 2011, MANSONS TROPICAL DIS
   Fischer EAJ, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-58
   Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   House T, 2014, ELIFE, V3, DOI 10.7554/eLife.03908
   Koh D, 2020, OCCUP MED-OXFORD, V70, P3, DOI 10.1093/occmed/kqaa036
   National Institute of Allergy and Infectious Diseases, NIH CLIN TRIAL SHOWS
   New Zealand Ministry of Health, 2020, COV 19 SIGN CLUST EP
   Our World in Data, 2020, CAS FAT RAT ONG COVI
   Park SY, 2020, EMERG INFECT DIS, V26, P1666, DOI 10.3201/eid2608.201274
   Peto J, 2020, LANCET, V395, P1420, DOI 10.1016/S0140-6736(20)30936-3
   Salemi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001390
   Sciensano, 2020, COVID 19 B EP HEBD 8
   Smith JR, 2010, J ANTIMICROB CHEMOTH, V65, pII25, DOI 10.1093/jac/dkq013
   Szabo SM, 2015, ANN HEPATOL, V14, P618, DOI 10.1016/S1665-2681(19)30756-2
   Unger JP, 2019, INT J HEALTH SERV, V49, P431, DOI 10.1177/0020731419847113
   van den Driessche Pauline, 2017, Infect Dis Model, V2, P288, DOI 10.1016/j.idm.2017.06.002
   Viboud C, 2016, J INFECT DIS, V213, P738, DOI 10.1093/infdis/jiv534
   WHO, 2017, LASS FEV FACT SHEETS
   WHO, 2020, EB FACT SHEET
   WHO, 2003, AV INFL NETH DIS OUT
   WHO, 2020, DENG SEV DENG KEY FA
   WHO, FREQ ASK QUEST H5N1
   WHO, 2019, HEP B WHO EUR REG FA
   WHO, SEV AC RESP SYNDR FA
   WHO, SMALLP HLTH TOP
   WHO, MIDDL E RESP SYNDR C
   WHO, 2020, RAB FACT SHEET
   WHO, 2017, CHIK FACT SHEET
   Williams BG, 2014, ARXIV13043720QBIOQM
   World Health Organization, 2020, CUM NUMB CONF HUM CA
   World Health Organization, 2019, HIV AIDS FACT SHEET
   World Health Organization, 2018, RIFT VALL FEV FACT S
   Wu J, NY TIMES
NR 66
TC 1
Z9 1
U1 3
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0020-7314
EI 1541-4469
J9 INT J HEALTH SERV
JI Int. J. Health Serv.
AR 0020731420946590
DI 10.1177/0020731420946590
EA AUG 2020
PG 13
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA MZ0FR
UT WOS:000558800000001
PM 32772627
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Galluccio, M
   Pantanella, M
   Giudice, D
   Brescia, S
   Indiveri, C
AF Galluccio, Michele
   Pantanella, Marta
   Giudice, Deborah
   Brescia, Stefania
   Indiveri, Cesare
TI Low temperature bacterial expression of the neutral amino acid
   transporters SLC1A5 (ASCT2), and SLC6A19 (B0AT1)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Amino acid; SLC; Protein expression; B0AT1; ASCT2; COVID-19
ID ESCHERICHIA-COLI; MEMBRANE TRANSPORTERS; OVER-EXPRESSION; B(0)AT1
   SLC6A19; STRATEGIES; PROTEINS; HEALTH
AB It is well established thatEscherichia colirepresents a powerful tool for the over-expression of human proteins for structure/function studies. In many cases, such as for membrane transporters, the bacterial toxicity or the aggregation of the target protein hamper the expression limiting the application of this tool. The aim of this study was finding the appropriate conditions for the expression of reluctant proteins that is the human neutral amino acid transporters ASCT2 and B0AT1, that have great relevance to human health in cancer therapy and in COVID-19 research, respectively. The cDNAs coding for the proteins of interest were cloned in the pCOLD I vector and differentE. colistrains (BL21 codon plus RIL, and RosettaGami2) were cultured in absence or in presence of glucose (0.5-1%), at low temperature (15 degrees C), and low inducer concentrations (10-100 mu M). Cell growth and protein production were monitored by optical density measurements and western blotting assay, respectively. Even though in different conditions, the expression of both amino acid transporters was obtained.Reducing the growth rate of specificE. colistrains by lowering the temperature and the IPTG concentration, together with the addition of glucose, two reluctant human neutral amino acid transporters have been expressed inE. coli. The results have a potentially great interest in drug discovery since ASCT2 is an acknowledged target of anticancer therapy, and B0AT1 together with ACE2 is part of a receptor for the SARS-Cov-2 RBD proteins.
C1 [Galluccio, Michele; Pantanella, Marta; Giudice, Deborah; Brescia, Stefania; Indiveri, Cesare] Univ Calabria, Dept DiBEST Biol Ecol Sci Terra, Unit Biochem & Mol Biotechnol, Via Bucci 4C, I-87036 Arcavacata Di Rende, CS, Italy.
   [Indiveri, Cesare] CNR Inst Biomembranes Bioenerget & Mol Biotechnol, Via Amendola 122-O, I-70126 Bari, Italy.
RP Indiveri, C (corresponding author), Univ Calabria, Dept DiBEST Biol Ecol Sci Terra, Unit Biochem & Mol Biotechnol, Via Bucci 4C, I-87036 Arcavacata Di Rende, CS, Italy.; Indiveri, C (corresponding author), CNR Inst Biomembranes Bioenerget & Mol Biotechnol, Via Amendola 122-O, I-70126 Bari, Italy.
EM cesare.indiveri@unical.it
OI , Cesare/0000-0001-9818-6621
FU "Fondi di Ateneo" from the Universita della Calabria; MIUR (Ministry of
   Education, University and Research) ItalyMinistry of Education,
   Universities and Research (MIUR) [01_00937]
FX This work was in part supported by "Fondi di Ateneo" from the Universita
   della Calabria (to CI and MG) and in part by PON (Programma Operativo
   Nazionale) Project No. 01_00937 granted by MIUR (Ministry of Education,
   University and Research) Italy to CI.
CR Broer S, 2009, IUBMB LIFE, V61, P591, DOI 10.1002/iub.210
   Cesar-Razquin A, 2015, CELL, V162, P478, DOI 10.1016/j.cell.2015.07.022
   Chaudhary S, 2011, METHODS, V55, P273, DOI 10.1016/j.ymeth.2011.08.018
   Cheng Q, 2017, BRIT J PHARMACOL, V174, P468, DOI 10.1111/bph.13711
   Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005
   Galluccio M, 2013, PROTEIN J, V32, P442, DOI 10.1007/s10930-013-9503-4
   Garaeva AA, 2018, NAT STRUCT MOL BIOL, V25, P515, DOI 10.1038/s41594-018-0076-y
   Gonzalez-Montalban N, 2005, J BIOTECHNOL, V118, P406, DOI 10.1016/j.jbiotec.2005.05.024
   Hattab G, 2015, SCI REP-UK, V5, DOI 10.1038/srep12097
   Hediger MA, 2013, MOL ASPECTS MED, V34, P95, DOI 10.1016/j.mam.2012.12.009
   Indiveri C, 2013, MOL BIOTECHNOL, V54, P724, DOI 10.1007/s12033-012-9586-8
   Kato Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030705
   Kaur J, 2018, INT J BIOL MACROMOL, V106, P803, DOI 10.1016/j.ijbiomac.2017.08.080
   Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399
   Mitta M, 1997, MOL MICROBIOL, V26, P321, DOI 10.1046/j.1365-2958.1997.5771943.x
   Phue JN, 2008, BIOTECHNOL BIOENG, V101, P831, DOI 10.1002/bit.21973
   Pingitore P, 2013, BBA-BIOMEMBRANES, V1828, P2238, DOI 10.1016/j.bbamem.2013.05.034
   Pochini L, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00061
   Pochini L, 2014, BIOCHEM PHARMACOL, V89, P422, DOI 10.1016/j.bcp.2014.03.014
   Rebsamen M, 2015, NATURE, V519, P477, DOI 10.1038/nature14107
   Rosano GL, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00172
   Scalise M, 2017, CURR PHARM DESIGN, V23, P3871, DOI 10.2174/1381612823666170616083705
   Wagner S, 2007, MOL CELL PROTEOMICS, V6, P1527, DOI 10.1074/mcp.M600431-MCP200
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
NR 24
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD SEP
PY 2020
VL 47
IS 9
BP 7283
EP 7289
DI 10.1007/s11033-020-05717-8
EA AUG 2020
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OB1DP
UT WOS:000557735300002
PM 32772343
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Fraenkel, P
   Cho, WL
AF Fraenkel, Peter
   Cho, Wonyoung L.
TI Reaching Up, Down, In, and Around: Couple and Family Coping During the
   Coronavirus PandemicPalabras clave(sic)(sic)(sic)
SO FAMILY PROCESS
LA English
DT Article
DE Family Resilience; Religious and Spiritual Factors; Families and
   Environmental Crisis; Family and Couple Coping COVID-19 Pandemic and
   Quarantine; Families and Health Disparities
AB The worldwide coronavirus (COVID-19) has had profound effects on all aspects of life: physical health, the ability to travel locally or to more distant destinations, material and financial resources, and psychosocial wellbeing. Couples, families, and communities and individual persons in those relationships have struggled to cope with emerging depression, anxiety, and trauma, and the rise of relational conflict. In this article, we suggest that the existential nature of the pandemic's challenges requires more than just the usual psychosocial interventions. We propose a taxonomy of responses to foster coping and resilience-"Reaching Up, Down, In, and Around." "Reaching Up" includes accessing spiritual, religious, and ethical values. "Reaching Down" includes ideas and practices that foster a revised relationship with the Earth and its resources, and that engage families to participate in activities that aid the Earth's recovery from decades of human-caused damage. "Reaching In" represents a turn towards experiences available in the mind and in shared minds in relationships that provide pleasure, excitement, joy, and peace, given that external sources of these emotions are of limited availability due to quarantine. "Reaching Around" involves reframing the mandate for "social distancing" as fostering social connection and support while maintaining physical distancing. The challenges for family therapists, whose practices are confined largely to online therapy, and who are struggling with the same fears and constraints as those persons they are attempting to help, are also discussed.
C1 [Fraenkel, Peter] CUNY City Coll, Dept Psychol, New York, NY 10031 USA.
   [Cho, Wonyoung L.] Lewis & Clark Grad Sch Educ & Counseling, Marriage Couples & Family Therapy Program, Portland, OR USA.
RP Fraenkel, P (corresponding author), CUNY City Coll, 160 Convent Ave, New York, NY 10031 USA.
EM fraenkelorama@gmail.com
RI Fraenkel, Peter/AAF-8144-2020; , Polly/AAX-2742-2020
OI Fraenkel, Peter/0000-0003-0159-6304
CR Amore R. C., 2019, WORLD RELIG E TRADIT
   APM Research Lab, 2020, COL COR COVID 19 DEA
   Association for Psychological Science, 2020, PAND EFF MARR REL
   Bachelard Gaston, 1958, POETICS SPACE
   Bailey E. T., 2016, SOUND WILD SNAIL EAT
   Beach SRH, 2011, PSYCHOL RELIG SPIRIT, V3, P201, DOI 10.1037/a0022207
   Bettinger-Lopez C., 2020, DOUBLE PANDEMIC DOME
   Boyd-Franklin N., 2009, SPIRITUAL RESOURCES, P141
   Bynner W., 1944, WAY LIFE ACCORDING L
   Canagarajah S., 2002, J LANG IDENTITY EDUC, V1, P243, DOI DOI 10.1207/S15327701JLIE0104_1
   CDC, 2020, COVIDVIEW WEEKL SURV
   Chodron P., 2018, COMFORTABLE UNCERTAI
   Coalition for the Homeless, 2020, STAT HOM 2020
   Commonsensemedia.org, 2019, COMM SENS CENS MED U
   Department of Labor, 2020, UN INS WEEKL CLAIMS
   Doherty T, 2009, VINGTIEME SIECLE-REV, P215
   Doherty W. J., 1999, INTENTIONAL FAMILY S
   Doherty W. J., 2000, TAKE BACK YOUR KIDS
   Doherty W. J., 1995, SOUL SEARCHING WHY P
   Dreyfus H, 2014, SKILLFUL COPING ESSA
   Elliot M., 2009, SPIRITUAL RESOURCES, P323
   Falicov C. J., 2009, SPIRITUAL RESOURCES, P156
   Feuer A, 2020, NY TIMES
   Fincham F. D., 2014, CONTEMPORARY ISSUES, P341
   Finley R., 2013, TED C
   Fishbane MD, 1998, J MARITAL FAM THER, V24, P41, DOI 10.1111/j.1752-0606.1998.tb01062.x
   Fraenkel P, 2002, FAM PROCESS, V41, P20, DOI 10.1111/j.1545-5300.2002.40102000020.x
   Fraenkel P., 2011, SYNC YOUR RELATIONSH
   Fraenkel P., 2001, PSYCHOTHERAPY NETWOR, V25, P20
   Fraenkel P., 2019, AM FAM THER AC AFTA
   Fraenkel P., 2001, MINDING TIME FAMILY, P283
   Fraenkel P., 2001, PSYCHOTHERAPY NETWOR, V25, P22
   Fraenkel P, 2020, CLIN SOC WORK J, V48, P319, DOI 10.1007/s10615-020-00755-y
   Fraenkel P, 2019, FAM PROCESS, V58, P569, DOI 10.1111/famp.12474
   Fraenkel P, 2009, CLIN SOC WORK J, V37, P234, DOI 10.1007/s10615-009-0207-3
   Frayer L., 2020, NATL PUBLIC RADIO NP
   Goodchild C., 2015, NAKED VOICE TRANSFOR
   Gottman J. M., 2015, 7 PRINCIPLES MAKING
   Hernandez-Wolfe P, 2019, AFTA SPR BR FAM THER, P33, DOI 10.1007/978-3-030-14954-3_4
   Kagitcibasi C, 2005, J CROSS CULT PSYCHOL, V36, P403, DOI 10.1177/0022022105275959
   Kerr M., 1988, FAMILY EVALUATION
   Kluge H. H. P., 2020, COVID 19 PANDEMIC VI
   Laszloffy T. A., 2019, ECOINFORMED PRACTICE
   Lewis C. S., 1980, MERE CHRISTIANITY
   Markman H. J., 2010, FIGHTING YOUR MARRIA
   Marks L. D., 2017, RELIG FAMILIES INTRO
   Marshall G., 2014, DONT EVEN THINK IT W
   Mein SA, 2020, J GEN INTERN MED, V35, P2439, DOI 10.1007/s11606-020-05880-5
   Miller Joshua, 2001, J SOCIOLOGY SOCIAL W, V28, P23
   Minuchin S., 2014, CRAFT FAMILY THERAPY
   Nhat Hanh T., 2011, SAVOR MINDFUL EATING
   Nhat Hanh T., 2001, THICH NHAT HANH ESSE
   Novak J, 2015, CONF LASER ELECTR
   NYU Furman Center, 2020, POL MIN PROT HOUS ST
   Pietromonaco PR, 2017, AM PSYCHOL, V72, P531, DOI 10.1037/amp0000129
   Poplin M., 2014, IS REALITY SECULAR T
   Saksena M, 2018, AM EATING HABITS FOO, V196
   Seligman M. E. P., 2002, AUTHENTIC HAPPINESS
   Sigal L., 2020, ANOTHER PANDEMIC LAT
   Sire J. W., 2015, NAMING ELEPHANT WORL
   Statista, 2013, MOST POP LEIS ACT AD
   Swim J, 2009, PSYCHOL GLOBAL CLIMA
   T.H. Chan Harvard School of Public Health, 2020, COR CLIM CHANG
   Turkle S., 2015, RECLAIMING CONVERSAT
   UN Women, COVID 19 END VIOL WO
   University of Nevada Las Vegas, 2020, COMMUNICATION
   van Deurzen E., 2019, WILEY HDB EXISTENTIA
   Varda Danielle M, 2018, EGEMS (Wash DC), V6, P23, DOI 10.5334/egems.232
   Walsh F, 2016, STRENGTHENING FAMILY
   Walsh F., 2009, SPIRITUAL RESOURCES
NR 70
TC 3
Z9 3
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-7370
EI 1545-5300
J9 FAM PROCESS
JI Fam. Process
PD SEP
PY 2020
VL 59
IS 3
BP 847
EP 864
DI 10.1111/famp.12570
EA AUG 2020
PG 18
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA NL5AR
UT WOS:000557368000001
PM 32589265
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Vashishtha, VM
AF Vashishtha, Vipin M.
TI Are BCG-induced non-specific effects adequate to provide protection
   against COVID-19?
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE Coronavirus disease; SARS-CoV-2; Bacillus Calmette-Guerin (BCG) vaccine;
   nonspecific effects; trained innate immunity
ID VACCINATION; INFECTION; HEALTH
AB The world is experiencing a pandemic of Coronavirus Disease (COVID-19) caused by type-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2). Vaccination is the only option to prevent future surges of the disease. Efforts for developing an effective vaccine are underway, but the timeline for the widespread availability of safe and effective vaccines is unknown. Some ecological reports have linked regional universal use of the Bacillus Calmette-Guerin (BCG) vaccine with reduced morbidity and mortality of COVID-19. BCG protects from non-tuberculous diseases through 'non-specific' effects mediated by the modulation of innate immunity. This commentary provides details of the immunological mechanism of BCG-induced 'trained innate immunity' responsible for its nonspecific protective effects. A probable role of the BCG vaccine in the current pandemic is also examined.
C1 [Vashishtha, Vipin M.] Mangla Hosp & Res Ctr, Dept Pediat, Bijnor, Uttar Pradesh, India.
RP Vashishtha, VM (corresponding author), Mangla Hosp & Res Ctr, Bijnor 246701, Uttar Pradesh, India.
EM vipinipsita@gmail.com
OI Vashishtha, Vipin M./0000-0003-1097-117X
CR Aaby P, 2014, NAT IMMUNOL, V15, P895, DOI 10.1038/ni.2961
   Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240
   [Anonymous], 2020, COVID 19 PANDEMIC BC
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Austell J., 2020, CAN ORAL POLIO VACCI
   Biering-Sorensen S, 2012, PEDIATR INFECT DIS J, V31, P306, DOI 10.1097/INF.0b013e3182458289
   Brosch R, 2007, P NATL ACAD SCI USA, V104, P5596, DOI 10.1073/pnas.0700869104
   Ella KM, 2020, INDIAN PEDIATR, V57, P407, DOI 10.1007/s13312-020-1812-z
   Fuge O, 2015, RES REP UROL, V7, P65, DOI 10.2147/RRU.S63447
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Hindustan Times, 2020, HINDUSTAN TIMES
   Italiani P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00734
   Jensen KJ, 2015, J INFECT DIS, V211, P956, DOI 10.1093/infdis/jiu508
   de Castro MJ, 2015, CLIN INFECT DIS, V60, P1611, DOI 10.1093/cid/civ144
   Kuhtreiber WM, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0062-8
   LeThanh T, 2020, NAT REV DRUG DISCOV, P19
   Mahase E, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1679, 10.1136/bmj.m2679]
   Moliva Juan I, 2017, Front Immunol, V8, P407, DOI 10.3389/fimmu.2017.00407
   Moore TI, 2015, MOL BIOL CELL, V26
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Pollard AJ, 2017, ARCH DIS CHILD, V102, P1077, DOI 10.1136/archdischild-2015-310282
   Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086
   Shanker V, 2020, INDIAN PEDIATR, V57, P380
   Shann F, 2015, CLIN INFECT DIS, V61, P960, DOI 10.1093/cid/civ454
   Usher NT, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.12014
   Uthayakumar D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02869
   WHO, 2020, COR DIS COVID 19 PAN
   World Health Organization, 2020, SCI BRIEF       0412
   World Health Organization. SAGE working group on BCG vaccines and WHO secretariat, 2017, REP BCG VACC US PROT
   Wu Y, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.139051
   Zimmermann P, 2018, EXPERT REV VACCINES, V17, P547, DOI 10.1080/14760584.2018.1483727
NR 31
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1794219
EA AUG 2020
PG 4
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA MX2VV
UT WOS:000557585900001
PM 32762516
DA 2021-01-01
ER

PT J
AU Akram, J
   Azhar, S
   Shahzad, M
   Latif, W
   Khan, KS
AF Akram, Javed
   Azhar, Shehnoor
   Shahzad, Muhammad
   Latif, Waqas
   Khan, Khalid Saeed
TI Pakistan Randomized and Observational Trial to Evaluate Coronavirus
   Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin
   to treat newly diagnosed patients with COVID-19 infection who have no
   comorbidities like diabetes mellitus: A structured summary of a study
   protocol for a randomized controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; SARS-CoV-2;
   Hydroxychloroquine; Azithromycin; Oseltamivir; multi-center; adaptive;
   randomization
AB Objectives: To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a day for 5 days),versusoseltamivir (75 mg orally twice a day for 5 days), andversusAzithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in clearing the coronavirus (COVID-19) nucleic acid from throat and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary outcomes).
   Trial Design: An adaptive design, set within a comprehensive cohort study, to permit flexibility in this fast-changing clinical and public health scenario. The randomized study will be a multicenter, multiarm, multistage, randomized controlled trial with a parallel design. An observation only cohort will emerge from those not consenting to randomization.
   Participants: Eligible will be newly diagnosed patients, either hospitalized or in self-isolation, without any comorbidities or with controlled chronic medical conditions like diabetes mellitus and hypertension. Participants of any gender or age group having tested positive for COVID-19 on Real-Time qRT-PCR (Quantitative Reverse Transcription PCR) will be invited to take part in study at twelve centers across eight cities in Pakistan. Those pregnant or lactating, severely dyspneic or with respiratory distress, already undergoing treatment, and with serious comorbidities like liver or kidney failure will be excluded.
   Intervention and Comparator: There will be a total of seven comparator groups: Each drug (Hydroxychloroquine Phosphate/Sulfate, Oseltamivir and Azithromycin) given as monotherapy (three groups); combinations of each of two drugs (three groups); and a final group on triple drug regimen.
   Main Outcomes: The laboratory-based primary outcome will be turning the test negative for COVID-19 on qRT-PCR on day 7 of follow-up. The clinical primary outcome will be improvement from baseline of two points on a seven-category ordinal scale of clinical status on day 7 of follow-up.
   Randomization: Participants will be randomized, maintaining concealment of allocation sequence, using a computer-generated random number list of variable block size into multiple intervention groups in the allocation ratio of 1:1 for all groups.
   Blinding (masking): This is an open label study, neither physician nor participants will be blinded.
   Numbers to be randomized (sample size) This is an adaptive design and parameters for formal sample size calculation in a new disease of a previously unknown virus are not available. Thus, the final sample size will be subjected to periodic reviews at each stage of adaptive design and subsequent advice of National Data Safety & Management Board (NDSMB) notified by Drug Regulatory Authority of Pakistan.
   Trial Status: Protocol Version 1.7 dated July 5, 2020. By July 03, 2020, the trial had recruited a total of about 470 participants across 12 centers after approval from the National Bioethics Committee and Drug Regulatory Authority of Pakistan. Recruitment started on April 20, 2020. The recruitment is expected to continue for at least three months subject to review by the National Data Safety and Management Board (NDSMB) notified by Drug Regulatory Authority of Pakistan.
C1 [Akram, Javed] Univ Hlth Sci, Internal Med, Lahore, Pakistan.
   [Azhar, Shehnoor] Univ Hlth Sci, Publ Hlth, Lahore, Pakistan.
   [Shahzad, Muhammad] Univ Hlth Sci, Pharmacol, Lahore, Pakistan.
   [Latif, Waqas] Univ Hlth Sci, Lahore, Pakistan.
   [Khan, Khalid Saeed] Univ Granada, Dept Prevent Med & Publ Hlth, Granada, Spain.
RP Azhar, S (corresponding author), Univ Hlth Sci, Publ Hlth, Lahore, Pakistan.
EM shehnoor.azhar@gmail.com
FU University of Health Sciences (UHS) Lahore, Punjab, Pakistan
FX All funding was arranged by University of Health Sciences (UHS) Lahore,
   Punjab, Pakistan. First three authors of this protocol are relevant
   faculty members of UHS and investigators of the study. Mr. Waqas Latif
   is Data Analyst at UHS. Prof Khalid Saeed Khan is a Distinguished
   Investigator from University of Granada Spain and actively supported the
   study as representative of Federal task Force on Covid-19. Development
   and maintenance of the electronic data collection module was done with
   active support of IT Department at UHS Lahore. The University also
   arranged logistics to ensure provision of study medicines to all study
   centers. It also got approved the study from relevant national
   institutions upon payment of requisite processing fee. UHS will be
   responsible for future publication and data analysis as advised by
   NDSMB, along with the content at theprotect. com.pk. Shehnoor Azhar
   (Assistant Professor Public Health, UHS Lahore) trained site teams in
   Good Clinical Practices.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 8
PY 2020
VL 21
IS 1
AR 702
DI 10.1186/s13063-020-04616-4
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NC7SJ
UT WOS:000561414600001
PM 32771032
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Koshak, AE
   Koshak, EA
   Mobeireek, AF
   Badawi, MA
   Wali, SO
   Malibary, HM
   Atwah, AF
   Alhamdan, MM
   Almalki, RA
   Madani, TA
AF Koshak, Abdulrahman E.
   Koshak, Emad A.
   Mobeireek, Abdullah F.
   Badawi, Mazen A.
   Wali, Siraj O.
   Malibary, Husam M.
   Atwah, Ali F.
   Alhamdan, Meshari M.
   Almalki, Reem A.
   Madani, Tariq A.
TI Nigella sativa supplementation to treat symptomatic mild COVID-19: A
   structured summary of a protocol for a randomised, controlled, clinical
   trial
SO TRIALS
LA English
DT Letter
DE COVID-19; SARS-CoV-2; Randomised controlled trial; protocol; Nigella
   sativa; black seed; phytotherapy
AB Objectives: To investigate the potential efficacy ofNigella sativa(NS) oil supplementation on the outcomes of patients with mild Coronavirus Disease 2019 (COVID-19).
   Trial design: Prospective, two-arm, parallel-group, randomised (1:1 allocation ratio), open-label, controlled, exploratory phase II clinical trial of oral NS oil in patients with mild COVID-19.
   Participants: Inclusion Criteria:
   - Patients with mild COVID19 (defined as upper respiratory tract infection symptoms in the absence of clinical or radiological signs of pneumonia).
   - Adult (18 - 65 years old).
   - Written informed consent by the patient (or legally authorized representative) prior to initiation of any study procedures.
   - All patients should understand and agree to comply with planned study procedures.
   - Polymerase chain reaction (PCR)-confirmed infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) from throat swab.
   Exclusion Criteria:
   - Patients with pneumonia or severe illness requiring admission to intensive care unit.
   - Severe chronic kidney disease (i.e. estimated glomerular filtration rate [eGFR] < 30/) or end stage renal disease requiring dialysis
   - Severe chronic liver disease (Alanine transaminase [AlT] or Aspartate transaminase [AST] > 5 times the upper limit of normal).
   - Pregnancy or breast feeding.
   - Anticipated transfer within 72 hours to another hospital that is not a study site.
   - Allergy to the study medication
   The trial is currently conducted on patients recruited from King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
   Intervention and comparator: Intervention group:Nigella sativaoil (MARNYS (R) Cuminmar) 500 mg softgel capsules, one capsule orally twice daily for 10 days plus standard of care treatment (antipyretic, antitussive). Comparator group: standard of care treatment.
   Main outcomes: Proportion of patients who clinically recovered (defined as 3 days of no symptoms) within 14 days after randomisation.
   Randomisation: Patients will be randomly assigned to treatment or control groups in a 1:1 ratio using a computer-generated randomization scheme (Random permuted blocks of 10) developed using the web-based program:.
   Blinding (masking): No blinding.
   Numbers to be randomised (sample size) Up to 200 eligible patients will be randomly assigned to either treatment or control: groups.
   Trial Status: Protocol version 1, as of July 14, 2020. Recruitment was started on May 21, 2020. The intended completion date is December 31, 2020.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
C1 [Koshak, Abdulrahman E.] King Abdulaziz Univ, Dept Nat Prod & Alternat Med, Fac Pharm, Jeddah, Saudi Arabia.
   [Koshak, Emad A.; Badawi, Mazen A.; Wali, Siraj O.; Malibary, Husam M.; Almalki, Reem A.; Madani, Tariq A.] King Abdulaziz Univ, Dept Med, Fac Med, Jeddah, Saudi Arabia.
   [Mobeireek, Abdullah F.] King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh, Saudi Arabia.
   [Atwah, Ali F.] King Abdulaziz Univ, Dept Pediat, Fac Med, Rabigh, Saudi Arabia.
   [Alhamdan, Meshari M.] King Abdulaziz Univ, Univ Med Serv Ctr, Jeddah, Saudi Arabia.
RP Koshak, AE (corresponding author), King Abdulaziz Univ, Dept Nat Prod & Alternat Med, Fac Pharm, Jeddah, Saudi Arabia.
EM aekoshak@kau.edu.sa
RI Madani, Tariq/AAY-8909-2020; Koshak, Abdulrahman E./J-3801-2018
OI Madani, Tariq/0000-0003-2453-0623; 
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 8
PY 2020
VL 21
IS 1
AR 703
DI 10.1186/s13063-020-04647-x
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NC7SJ
UT WOS:000561414600002
PM 32771034
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nikoupour, H
   Arasteh, P
   Gholami, S
   Nikeghbalian, S
AF Nikoupour, Hamed
   Arasteh, Peyman
   Gholami, Siavash
   Nikeghbalian, Saman
TI Liver transplantation and COVID-19: a case report and cross comparison
   between two identical twins with COVID-19
SO BMC SURGERY
LA English
DT Article
DE COVID-19; Transplantation; Liver; Prognosis
AB Background To this date little information exists on the effects, clinical course and outcome of the COVID-19 among patients undergoing transplantation. Case presentation A 35 year old male referred with loss of sense of smell and taste after having close contact with his brother who was diagnosed with COVID-19 five days prior to his symptoms. The patient had undergone liver transplantation 3 years prior to his referral due to primary sclerosing cholangitis in association with ulcerative colitis and was using immunosuppressive medications. The patient referred to a local physician with mild symptoms of fatigue, cough, myalgia, dizziness, and nausea/vomiting with a fear of contracting the disease. Except for a CRP of 32 his other blood tests were normal. After 3 days of hospital admission the patient was discharged with a good condition. His brother had developed fever, chills, headache, mild dyspnea and an objective loss of sense of smell and taste and was sent home and advised to self-quarantine. Both patients had CT scans in favor of COVID-19. Conclusion Our patient who had liver transplantation and COVID-19 did not present more severe symptoms compared to his counterpart without liver transplantation and did not need to be hospitalized or be given antiviral drugs for COVID-19.
C1 [Nikoupour, Hamed; Arasteh, Peyman; Gholami, Siavash; Nikeghbalian, Saman] Shiraz Univ Med Sci, Abu Ali Sina Hosp, Shiraz Transplant Ctr, Shiraz, Iran.
RP Arasteh, P; Nikeghbalian, S (corresponding author), Shiraz Univ Med Sci, Abu Ali Sina Hosp, Shiraz Transplant Ctr, Shiraz, Iran.
EM Peyman.arasteh@yahoo.com; shiraz.livertransplantation@gmail.com
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   Fishman JA, 2007, NEW ENGL J MED, V357, P2601, DOI 10.1056/NEJMra064928
   The Transplantation Society/Transplant Infectious Disease, 2020, GUID COR DIS 2019 CO
   World Health Organization, 2020, COR DIS COVID 2019 S
NR 4
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2482
J9 BMC SURG
JI BMC Surg.
PD AUG 8
PY 2020
VL 20
IS 1
AR 181
DI 10.1186/s12893-020-00837-1
PG 3
WC Surgery
SC Surgery
GA NC4ZI
UT WOS:000561222900001
PM 32770973
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dastmalchi, DA
   Moslemkhani, S
   Bayat, M
   Balighi, K
   Abedini, R
   Mahmoudi, H
   Daneshpazhooh, M
AF Dastmalchi, Delara Amir
   Moslemkhani, Solmaz
   Bayat, Maryam
   Balighi, Kamran
   Abedini, Robabeh
   Mahmoudi, Hamidreza
   Daneshpazhooh, Maryam
TI The efficacy of rituximab in patients with mucous membrane pemphigoid
SO JOURNAL OF DERMATOLOGICAL TREATMENT
LA English
DT Article; Early Access
DE Mucous membrane pemphigoid; rituximab; therapy; IVIg; COVID-19
ID INTRAVENOUS IMMUNOGLOBULIN; COVID-19; DISEASES; THERAPY
AB Objective Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder with tendency to scarring. Long term immunosuppressive treatment may be required to minimize the consequences of the disease. Methods In this retrospective study, we investigated the efficacy of rituximab (RTX) in MMP patients and compare the beneficial effects of early versus late administration of RTX. Medical records of 24 MMP patients who were treated with 500 mg RTX on day 1, then weekly for 4 consecutive weeks were reviewed. Results Twenty-one patients (87.5%) reached disease control (DC) at the mean interval of 4.95 months (SD: 5.15; range: 1-24) after RTX. Complete remission (CR) with scarring was achieved in 45.8% (n = 11) and 33.3% (n = 8) attained CR without any residual scar (total CR with or without scar 79.1%). Two patients (8.3%) reached partial remission including persistent gingivitis. Only one patient progressed from non-cicatricial to cicatricial MMP despite receiving RTX. 47.6% (n = 10) of patients experienced relapse after achieving DC at a mean interval of 15.2 months (range: 6-30, SD: 7.0). Considerably, earlier the RTX was administered, sooner the DC was obtained (Pearsonr = 0.742,p-value < .001). Conclusions These results suggest that RTX may prevent further scarring and progression in MMP patients especially if administered early.
C1 [Dastmalchi, Delara Amir; Moslemkhani, Solmaz; Bayat, Maryam; Balighi, Kamran; Abedini, Robabeh; Mahmoudi, Hamidreza; Daneshpazhooh, Maryam] Univ Tehran Med Sci, Autoimmune Bullous Dis Res Ctr, Tehran, Iran.
RP Daneshpazhooh, M (corresponding author), Razi Hosp, Vandate Eslami Sq, Tehran 11996, Iran.
EM maryamdanesh.pj@gmail.com
CR Ahmed AR, 2003, ARCH DERMATOL, V139, P1051, DOI 10.1001/archderm.139.8.1051
   Ahmed AR, 2001, ARCH DERMATOL, V137, P1181
   Amber KT, 2018, CLIN REV ALLERG IMMU, V54, P26, DOI 10.1007/s12016-017-8633-4
   Cavallasca JA, 2015, REUMATOL CLIN, V11, P221, DOI 10.1016/j.reuma.2014.09.003
   Daneshpazhooh M, 2019, DERMATOL THER, V32, P5
   Daneshpazhooh M, 2020, J DERMATOL TREAT, V31, P446, DOI 10.1080/09546634.2020.1764472
   Foster CS, 2010, OPHTHALMOLOGY, V117, P861, DOI 10.1016/j.ophtha.2009.09.049
   Foster CS, 1999, OPHTHALMOLOGY, V106, P2136, DOI 10.1016/S0161-6420(99)90496-7
   Gurcan HM, 2009, INT IMMUNOPHARMACOL, V9, P10, DOI 10.1016/j.intimp.2008.10.004
   Hall RP, 2013, J INVEST DERMATOL, V133, P2786, DOI 10.1038/jid.2013.236
   Hammers CM, 2016, ANNU REV PATHOL-MECH, V11, P175, DOI 10.1146/annurev-pathol-012615-044313
   Heelan K, 2013, J AM ACAD DERMATOL, V69, P310, DOI 10.1016/j.jaad.2013.01.046
   Joly P, 2017, LANCET, V389, P2031, DOI 10.1016/S0140-6736(17)30070-3
   Kasperkiewicz M, 2020, J EUR ACAD DERMATOL, V34, pE302, DOI 10.1111/jdv.16525
   Lamberts A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00248
   Le Roux-Villet C, 2011, ARCH DERMATOL, V147, P843, DOI 10.1001/archdermatol.2011.54
   Letko E, 2004, CLIN IMMUNOL, V111, P303, DOI 10.1016/j.clim.2003.11.002
   Lew TT, 2012, J AM ACAD DERMATOL, V66, pAB102
   Murrell DF, 2015, J AM ACAD DERMATOL, V72, P168, DOI 10.1016/j.jaad.2014.08.024
   Neff Ann G, 2008, Ther Clin Risk Manag, V4, P617
   Price KN, 2020, J AM ACAD DERMATOL, V82, pE173, DOI 10.1016/j.jaad.2020.03.046
   Rubsam A, 2015, EXPERT OPIN BIOL TH, V15, P927, DOI 10.1517/14712598.2015.1046833
   Safavi F, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102195
   Santi CG, 2019, AN BRAS DERMATOL, V94, pS33, DOI 10.1590/abd1806-4841.2019940207
   Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4
   Shakshouk H, 2020, J AM ACAD DERMATOL, V82, pE235, DOI 10.1016/j.jaad.2020.04.005
   Sharma VK, 2016, INDIAN J DERMATOL VE, V82, P389, DOI 10.4103/0378-6323.174379
   Sitaru C, 2014, EXP DERMATOL, V23, P236, DOI 10.1111/exd.12331
   Wang HH, 2015, ACTA DERM-VENEREOL, V95, P928, DOI 10.2340/00015555-2116
   Xu Hong-Hui, 2013, Dent Clin North Am, V57, P611, DOI 10.1016/j.cden.2013.07.003
NR 30
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-6634
EI 1471-1753
J9 J DERMATOL TREAT
JI J. Dermatol. Treat.
DI 10.1080/09546634.2020.1801974
EA AUG 2020
PG 7
WC Dermatology
SC Dermatology
GA MY6RH
UT WOS:000558541400001
PM 32723108
OA Bronze
DA 2021-01-01
ER

PT J
AU Korn, SM
   Dhamotharan, K
   Furtig, B
   Hengesbach, M
   Lohr, F
   Qureshi, NS
   Richter, C
   Saxena, K
   Schwalbe, H
   Tants, JN
   Weigand, JE
   Wohnert, J
   Schlundt, A
AF Korn, Sophie M.
   Dhamotharan, Karthikeyan
   Fuertig, Boris
   Hengesbach, Martin
   Loehr, Frank
   Qureshi, Nusrat S.
   Richter, Christian
   Saxena, Krishna
   Schwalbe, Harald
   Tants, Jan-Niklas
   Weigand, Julia E.
   Woehnert, Jens
   Schlundt, Andreas
TI H-1,C-13, and(15)N backbone chemical shift assignments of the nucleic
   acid-binding domain of SARS-CoV-2 non-structural protein 3e
SO BIOMOLECULAR NMR ASSIGNMENTS
LA English
DT Article
DE SARS-CoV-2; Non-structural protein; Nucleic acid-binding domain;
   Solution NMR-spectroscopy; Protein drugability; Covid19-NMR
ID TRIPLE-RESONANCE EXPERIMENTS; NMR-SPECTROSCOPY; TROSY; C-13;
   CORONAVIRUS; RELAXATION; SOFTWARE
AB The ongoing pandemic caused by theBetacoronavirusSARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) demonstrates the urgent need of coordinated and rapid research towards inhibitors of the COVID-19 lung disease. Thecovid19-nmrconsortium seeks to support drug development by providing publicly accessible NMR data on the viral RNA elements and proteins. The SARS-CoV-2 genome encodes for approximately 30 proteins, among them are the 16 so-called non-structural proteins (Nsps) of the replication/transcription complex. The 217-kDa large Nsp3 spans one polypeptide chain, but comprises multiple independent, yet functionally related domains including the viral papain-like protease. The Nsp3e sub-moiety contains a putative nucleic acid-binding domain (NAB) with so far unknown function and consensus target sequences, which are conceived to be both viral and host RNAs and DNAs, as well as protein-protein interactions. Its NMR-suitable size renders it an attractive object to study, both for understanding the SARS-CoV-2 architecture and drugability besides the classical virus' proteases. We here report the near-complete NMR backbone chemical shifts of the putative Nsp3e NAB that reveal the secondary structure and compactness of the domain, and provide a basis for NMR-based investigations towards understanding and interfering with RNA- and small-molecule-binding by Nsp3e.
C1 [Korn, Sophie M.; Dhamotharan, Karthikeyan; Tants, Jan-Niklas; Woehnert, Jens; Schlundt, Andreas] Goethe Univ Frankfurt, Inst Mol Biosci, Max von Laue Str 9, D-60438 Frankfurt, Germany.
   [Fuertig, Boris; Hengesbach, Martin; Qureshi, Nusrat S.; Richter, Christian; Saxena, Krishna; Schwalbe, Harald] Goethe Univ Frankfurt, Inst Organ Chem & Chem Biol, Max von Laue Str 7, D-60438 Frankfurt, Germany.
   [Loehr, Frank] Goethe Univ Frankfurt, Inst Biophys Chem, Max von Laue Str 9, D-60438 Frankfurt, Germany.
   [Korn, Sophie M.; Dhamotharan, Karthikeyan; Fuertig, Boris; Hengesbach, Martin; Loehr, Frank; Qureshi, Nusrat S.; Richter, Christian; Saxena, Krishna; Schwalbe, Harald; Tants, Jan-Niklas; Woehnert, Jens; Schlundt, Andreas] Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance BMRZ, D-60438 Frankfurt, Germany.
   [Weigand, Julia E.] Tech Univ Darmstadt, Dept Biol, Schnittspahnstr 10, D-64287 Darmstadt, Germany.
RP Schlundt, A (corresponding author), Goethe Univ Frankfurt, Inst Mol Biosci, Max von Laue Str 9, D-60438 Frankfurt, Germany.; Schlundt, A (corresponding author), Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance BMRZ, D-60438 Frankfurt, Germany.
EM schlundt@bio.uni-frankfurt.de
RI Schwalbe, Harald/AAB-3143-2020; Schlundt, Andreas/D-2951-2017
OI Schwalbe, Harald/0000-0001-5693-7909; Korn, Sophie/0000-0003-3798-3277;
   Furtig, Boris/0000-0001-6443-7656; Schlundt,
   Andreas/0000-0003-2254-7560; Lohr, Frank/0000-0001-6399-9497;
   Dhamotharan, Karthikeyan/0000-0003-0226-7350; Tants,
   Jan-Niklas/0000-0002-2455-8135; Weigand, Julia/0000-0003-4247-1348
FU Projekt DEAL; Federal state of Hesse
FX Open Access funding provided by Projekt DEAL. We thank Katharina
   Targaczewski and Sabrina Tows for excellent technical support in the wet
   lab work. The Frankfurt BMRZ (Center for Biomolecular Resonance) is
   supported by the Federal state of Hesse.
CR Andersson P, 1998, J MAGN RESON, V133, P364, DOI 10.1006/jmre.1998.1492
   Czisch M, 1998, J MAGN RESON, V134, P158, DOI 10.1006/jmre.1998.1483
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Lakomek NA, 2012, J BIOMOL NMR, V53, P209, DOI 10.1007/s10858-012-9626-5
   Lee W, 2015, BIOINFORMATICS, V31, P1325, DOI 10.1093/bioinformatics/btu830
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Lescop E, 2007, J MAGN RESON, V187, P163, DOI 10.1016/j.jmr.2007.04.002
   Lohr F, 2002, J MAGN RESON, V156, P10, DOI 10.1006/jmre.2002.2539
   MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004
   Neuman BW, 2008, J VIROL, V82, P5279, DOI 10.1128/JVI.02631-07
   Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366
   PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855
   Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585
   Schanda P, 2006, J AM CHEM SOC, V128, P9042, DOI 10.1021/ja062025p
   Schulte-Herbruggen T, 2000, J MAGN RESON, V144, P123, DOI 10.1006/jmre.2000.2020
   Serrano P, 2009, J VIROL, V83, P12998, DOI 10.1128/JVI.01253-09
   Serrano P, 2008, BIOMOL NMR ASSIGN, V2, P135, DOI 10.1007/s12104-008-9104-x
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Solyom Z, 2013, J BIOMOL NMR, V55, P311, DOI 10.1007/s10858-013-9715-0
   Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449
   WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777
   WISHART DS, 1994, J BIOMOL NMR, V4, P171
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yoshimoto FK, 2020, PROTEIN J, V39, P198, DOI 10.1007/s10930-020-09901-4
   ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008
NR 25
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1874-2718
EI 1874-270X
J9 BIOMOL NMR ASSIGN
JI Biomol. NMR Assign.
PD OCT
PY 2020
VL 14
IS 2
BP 329
EP 333
DI 10.1007/s12104-020-09971-6
EA AUG 2020
PG 5
WC Biophysics; Spectroscopy
SC Biophysics; Spectroscopy
GA NI2VR
UT WOS:000557850400001
PM 32770392
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pelea, T
   Reuter, U
   Schmidt, C
   Laubinger, R
   Siegmund, R
   Walther, BW
AF Pelea, Teodor
   Reuter, Ursula
   Schmidt, Christine
   Laubinger, Raimondo
   Siegmund, Robert
   Walther, Bjoern Wito
TI SARS-CoV-2 associated Guillain-Barre syndrome
SO JOURNAL OF NEUROLOGY
LA English
DT Letter; Early Access
DE Guillain-Barre syndrome; COVID-19; SARS-CoV-2; Bilateral facial diplegia
AB Presented herein is a severe case of SARS-CoV-2 associated Guillain-Barre syndrome (GBS), showing only slight improvement despite adequate therapy. To date, only few cases of GBS associated with this infection have been described. This case report summarizes the insights gain so far to GBS with this antecedent trigger. So far, attention has mostly focused on complications of the CNS involvement. Taking into account that GBS can cause a considerable impairment of the respiratory system, clinicians dealing with SARS-CoV-2 positive-tested patients should pay attention to symptoms of the peripheral nervous system. As far as we know from this reported case and the review of the current literature, there seems to be no association with antiganglioside antibodies or a positive SARS-CoV-2 RT-PCR in CSF. An obvious frequent occurrence of a bilateral facial weakness or bilateral peripheral facial diplegia should be emphasized.
C1 [Pelea, Teodor; Reuter, Ursula; Schmidt, Christine; Walther, Bjoern Wito] SRH Zentralklinikum Suhl, Dept Neurol, Care Med, Albert Schweitzer Str 2, D-98527 Suhl, Germany.
   [Laubinger, Raimondo] SRH Zentralklinikum Suhl, Dept Anesthesiol & Intens, Care Med, Suhl, Germany.
   [Siegmund, Robert] Community Lab, Suhl, Germany.
RP Walther, BW (corresponding author), SRH Zentralklinikum Suhl, Dept Neurol, Care Med, Albert Schweitzer Str 2, D-98527 Suhl, Germany.
EM bjoern-wito.walther@srh.de
FU Projekt DEAL
FX Open Access funding provided by Projekt DEAL.Compliance with ethical
   standards
CR ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707
   Grimm A, 2016, CLIN NEUROPHYSIOL, V127, P1657, DOI 10.1016/j.clinph.2015.06.032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jacobs BC, 1998, NEUROLOGY, V51, P1110, DOI 10.1212/WNL.51.4.1110
   Mao L, 2020, NEUROLOGICAL MANIFES
   May M, 1986, FACIAL NERVE, P181
   Sedaghat Z, 2020, J CLIN NEUROSCI, V76, P233, DOI 10.1016/j.jocn.2020.04.062
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Virani A, 2020, IDCases, V20, DOI 10.1016/j.idcr.2020.e00771
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Yuki N, 2012, NEW ENGL J MED, V366, P2294, DOI 10.1056/NEJMra1114525
   Zhao H, 2020, GUILLAIN BARRE SYNDR, DOI [10.1016/S1474-4422(20)30109-5, DOI 10.1016/S1474-4422(20)30109-5]
NR 12
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
DI 10.1007/s00415-020-10133-w
EA AUG 2020
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA MW9IX
UT WOS:000557346000001
PM 32770414
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sakulkonkij, P
   Bruminhent, J
   Pankongngam, C
   Chalermphunchai, N
AF Sakulkonkij, Parichart
   Bruminhent, Jackrapong
   Pankongngam, Charan
   Chalermphunchai, Nipon
TI A family cluster of diagnosed coronavirus disease 2019 (COVID-19) kidney
   transplant recipient in Thailand
SO IMMUNITY INFLAMMATION AND DISEASE
LA English
DT Article
DE COVID-19; family cluster; pneumonia; post kidney transplant;
   transmission
ID INFECTION; VIRUS
AB Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes an ongoing outbreak of respiratory illness called coronavirus disease 2019 (COVID-19). The clinical course could be ranging from mild to severe illness especially the individuals with an immunocompromised condition such as solid organ transplant recipients.
   Method: We described a family cluster of COVID-19 patients who were admitted during 3rd April 2020 to 30th April 2020. COVID-19 was confirmed by a presence of SARS-CoV-2 ribonucleic acid in the respiratory specimens detected by a qualitative, real-time reverse transcription-polymerase chain reaction. The study focused on the clinical course and management of our cases.
   Results: A family cluster of four laboratory-confirmed COVID-19 patients, one of those carried an underlying kidney transplant (KT) receiving immunosuppressants. Clinical presentation and severity of our case series are variable depending on each individual immune status. By far, a KT recipient seems to develop more severity despite antiviral therapy, cessation of immunosuppressant, and aggressive intensive care support.
   Conclusion: Our case series plausibly affirmed a person-to-person transmission and potentially severe disease in the transplant population. Clinicians who are encountering with transplant recipients should be aware of possible transmission among family members.
C1 [Sakulkonkij, Parichart; Pankongngam, Charan; Chalermphunchai, Nipon] Lampang Hosp, Internal Med Dept, Div Infect Dis, Lampang, Thailand.
   [Bruminhent, Jackrapong] Mahidol Univ, Ramathibodi Hosp, Dept Med, Div Infect Dis,Fac Med, Bangkok, Thailand.
RP Sakulkonkij, P (corresponding author), Lampang Hosp, Internal Med Dept, Div Infect Dis, 280 Phahonyothin Rd, Amphoe Mucang 52000, Lampang, Thailand.
EM parichart1507@gmail.com
CR Ajmal S, 2018, INFECTION, V46, P555, DOI 10.1007/s15010-018-1138-0
   Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   Association ERA-EDTA, 2020, DESCARTES EXP OP REG
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bajaj Satish Kumar, 2017, Radiol Infect Dis, V4, P29, DOI 10.1016/j.jrid.2016.11.001
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Bartiromo M, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13286
   Bastola A, 2020, LANCET INFECT DIS, V20, P279, DOI 10.1016/S1473-3099(20)30067-0
   Bruminhent J, 2020, J INFECT DIS ANTIMIC, V37, P39
   Bruminhent J, 2014, J CLIN VIROL, V61, P302, DOI 10.1016/j.jcv.2014.07.004
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen S, 2020, AM J TRANSPLANT, V20, P1869, DOI 10.1111/ajt.15903
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Department of Disease Control Ministry of Public Health Thailand, 2020, GUID CLIN PRACT DIAG
   Department of Disease Control Ministry of Public Health Thailand, 2020, CAS DEF PAT INV PUIS
   Fanelli V, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02872-z
   Fishman JA, 2020, AM J TRANSPLANT, V20, P1765, DOI 10.1111/ajt.15890
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Han RB, 2020, ANIM BIOTECHNOL, DOI [10.1080/10495398.2020.1832104, 10.2214/AJR.20.22961]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang I, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00453-4
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Machado DJD, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13306
   Naesens M, 2009, CLIN J AM SOC NEPHRO, V4, P481, DOI 10.2215/CJN.04800908
   Nair V, 2020, AM J TRANSPLANT, V20, P1819, DOI 10.1111/ajt.15967
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Pongpirul WA, 2020, NEW ENGL J MED, V382, P1067, DOI 10.1056/NEJMc2001621
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Shiu EYC, 2019, CURR OPIN INFECT DIS, V32, P372, DOI 10.1097/QCO.0000000000000563
   Simpson S, 2020, RADIOLOGY, V2, pe200152, DOI [10.1148/ryct.2020200152, DOI 10.1148/RYCT.2020200152]
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tang YW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00512-20
   The Transplantation Society, 2020, GUID COR DIS 2019 CO
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang YM, 2018, J INFECT DIS, V217, P1708, DOI 10.1093/infdis/jiy115
   Wong HYF, 2020, RADIOLOGY, V296, pE72, DOI 10.1148/radiol.2020201160
   World Health Organization, 2020, WHO THAIL SIT REP 20
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xing YY, 2020, EUROSURVEILLANCE, V25, P12, DOI 10.2807/1560-7917.ES.2020.25.10.2000191
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1510, DOI 10.1001/jama.2020.4372
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu L, 2020, EUR UROL, V77, P748, DOI 10.1016/j.eururo.2020.03.039
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 53
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2050-4527
J9 IMMUN INFLAMM DIS
JI IMMUN. INFLAMM. DIS.
PD DEC
PY 2020
VL 8
IS 4
BP 534
EP 543
DI 10.1002/iid3.337
EA AUG 2020
PG 10
WC Immunology
SC Immunology
GA OP1AQ
UT WOS:000556827000001
PM 32770646
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Su, JS
   Liu, ZX
   Liu, C
   Li, XH
   Wang, Y
   Zhao, J
   Wu, QJ
   Zheng, SC
   Zhang, Y
AF Su, Jinsong
   Liu, Zixuan
   Liu, Chuan
   Li, Xuanhao
   Wang, Yi
   Zhao, Jing
   Wu, Qingjiang
   Zheng, Shichao
   Zhang, Yi
TI Network Pharmacology Integrated Molecular Docking Reveals the Mechanism
   of Anisodamine Hydrobromide Injection against Novel Coronavirus
   Pneumonia
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID IMMUNE-SYSTEM; HOST-DEFENSE; CELL; INFLAMMATION; EXPRESSION; CASPASE-3;
   CANCER; INJURY
AB Background. The Coronavirus Disease 2019 (COVID-19) outbreak in Wuhan, China, was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anisodamine hydrobromide injection (AHI), the main ingredient of which is anisodamine, is a listed drug for improving microcirculation in China. Anisodamine can improve the condition of patients with COVID-19.Materials and Methods. Protein-protein interactions obtained from the String databases were used to construct the protein interaction network (PIN) of AHI using Cytoscape. The crucial targets of AHI PIN were screened by calculating three topological parameters. Gene ontology and pathway enrichment analyses were performed. The intersection between the AHI component proteins and angiotensin-converting enzyme 2 (ACE2) coexpression proteins was analyzed. We further investigated our predictions of crucial targets by performing molecular docking studies with anisodamine.Results. The PIN of AHI, including 172 nodes and 1454 interactions, was constructed. A total of 54 crucial targets were obtained based on topological feature calculations. The results of Gene Ontology showed that AHI could regulate cell death, cytokine-mediated signaling pathways, and immune system processes. KEGG disease pathways were mainly enriched in viral infections, cancer, and immune system diseases. Between AHI targets and ACE2 coexpression proteins, 26 common proteins were obtained. The results of molecular docking showed that anisodamine bound well to all the crucial targets.Conclusion. The network pharmacological strategy integrated molecular docking to explore the mechanism of action of AHI against COVID-19. It provides protein targets associated with COVID-19 that may be further tested as therapeutic targets of anisodamine.
C1 [Su, Jinsong; Liu, Zixuan; Liu, Chuan; Li, Xuanhao; Wang, Yi; Zhang, Yi] Chengdu Univ Tradit Chinese Med, Ethn Med Acad Heritage Innovat Res Ctr, Chengdu 611137, Peoples R China.
   [Zhao, Jing] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai 200000, Peoples R China.
   [Wu, Qingjiang] Chengdu First Pharmaceut Co Ltd, Chengdu 611137, Peoples R China.
   [Zheng, Shichao] Chengdu Univ Tradit Chinese Med, Med Informat Engn Coll, Chengdu 611137, Peoples R China.
RP Zhang, Y (corresponding author), Chengdu Univ Tradit Chinese Med, Ethn Med Acad Heritage Innovat Res Ctr, Chengdu 611137, Peoples R China.; Zheng, SC (corresponding author), Chengdu Univ Tradit Chinese Med, Med Informat Engn Coll, Chengdu 611137, Peoples R China.
EM zhengshichao@cdutcm.edu.cn; zhangyi@cdutcm.edu.cn
OI Zhao, Jing/0000-0002-2439-2876
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81973573, 81703825, 21472199]; National Key
   Research and Development Program of China [2017YFC1703900]; Natural
   Science Foundation Project of Education Department of Sichuan Province
   [18ZB01869]; Chengdu First Pharmaceutical Co., Ltd.
FX This study was supported by the National Natural Science Foundation of
   China (81973573, 81703825, and 21472199), National Key Research and
   Development Program of China (2017YFC1703900), Natural Science
   Foundation Project of Education Department of Sichuan Province
   (18ZB01869), and Chengdu First Pharmaceutical Co., Ltd..
CR ALEKSEEVSKIKH YG, 1991, ARK PATOL, V53, P12
   Baumert HM, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1141-2
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   BYKOVA AV, 1982, ZH MIKROB EPID IMMUN, P81
   Chen JH, 2018, MOL MED REP, V17, P6859, DOI 10.3892/mmr.2018.8686
   Chen SL, 2014, OPT PHOTONICS NEWS, V25, P45
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Choi SM, 2013, J EXP MED, V210, P551, DOI 10.1084/jem.20120260
   Clatworthy MR, 2004, J EXP MED, V199, P717, DOI 10.1084/jem.20032197
   Du HZ, 2020, CHIN J NAT MEDICINES, V18, P206, DOI [10.3724/SP.J.1009.2019.000000, 10.1016/S1875-5364(20)30022-4]
   Duan CH, 2019, COMB CHEM HIGH T SCR, V22, P4, DOI 10.2174/1386207322666190206163409
   Duan SY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00808
   Eisenkraft A, 2016, BRIT J PHARMACOL, V173, P1719, DOI 10.1111/bph.13486
   Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5
   Hsin KY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083922
   Kolls JK, 2008, NAT REV IMMUNOL, V8, P829, DOI 10.1038/nri2433
   Komaki Y, 2005, PULM PHARMACOL THER, V18, P297, DOI 10.1016/j.pupt.2005.01.002
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   Li XG, 2020, J MED VIROL, V92, P448, DOI 10.1002/jmv.25693
   Li XH, 2020, BIOL PHARM BULL, V43, P296, DOI 10.1248/bpb.b19-00627
   [刘海波 Liu Haibo], 2012, [中草药, Chinese Traditional and Herbal Drugs], V43, P2099
   Luo L, 2009, J GASTROEN HEPATOL, V24, P1070, DOI 10.1111/j.1440-1746.2008.05756.x
   Petrache I, 2006, AM J PATHOL, V169, P1155, DOI 10.2353/ajpath.2006.060058
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Poupko JM, 2007, J APPL TOXICOL, V27, P116, DOI 10.1002/jat.1154
   Quinton LJ, 2008, AM J RESP CELL MOL, V38, P699, DOI 10.1165/rcmb.2007-0365OC
   Rao W H, 1985, Zhonghua Yi Xue Za Zhi, V65, P389
   Roux D, 2013, CRIT CARE MED, V41, pE191, DOI 10.1097/CCM.0b013e31828a25d6
   Ruggeri T, 2019, CRIT CARE MED, V47, pE28, DOI 10.1097/CCM.0000000000003466
   Sethi G, 2008, FRONT BIOSCI-LANDMRK, V13, P5094, DOI 10.2741/3066
   Shao XP, 2005, J IMMUNOL, V175, P3244, DOI 10.4049/jimmunol.175.5.3244
   Song XQ, 2020, LIFE SCI, V240, DOI 10.1016/j.lfs.2019.117063
   Swidnicka-Siergiejko AK, 2017, ONCOGENE, V36, P3149, DOI 10.1038/onc.2016.461
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Wang B. C., 2007, MODERN J INTEGRATED, V16, P4547
   Wang J, 2020, ACE2 EXPRESSION COLO, DOI [10.1101/2020.02.05.20020545, DOI 10.1101/2020.02.05.20020545]
   Wang J. W., 2018, WORLD LATEST MED INF, V18, P100
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang W, 2014, HUM EXP TOXICOL, V33, P1186, DOI 10.1177/0960327114532382
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu K., 2017, J CLIN TRANSFUSION L, V19, P592
   Xu X. Y., 2019, ELECT J CLIN MED LIT, V6, P165
   Yan Y.-M., 2020, DISCOVERY ANTI 2019, DOI [10.20944/preprints202002.0254.v1, DOI 10.20944/PREPRINTS202002.0254.V1]
   Yang Guo-dong, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P452
   Yang RC, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104820
   You QH, 2014, CYTOKINE, V66, P78, DOI 10.1016/j.cyto.2013.12.019
   You R, 2018, CANCER IMMUNOL RES, V6, P645, DOI 10.1158/2326-6066.CIR-17-0554
   Yuan XP, 2017, APOPTOSIS, V22, P1524, DOI 10.1007/s10495-017-1414-y
   Zhang H, 2011, J TRADIT CHIN MED, V31, P10, DOI 10.1016/S0254-6272(11)60003-4
   [赵静 Zhao Jing], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P829
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou CB, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7793
NR 53
TC 0
Z9 0
U1 3
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD AUG 7
PY 2020
VL 2020
AR 5818107
DI 10.1155/2020/5818107
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA NE8SE
UT WOS:000562874700005
PM 32802131
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Forster, R
   Fleige, H
   Sutter, G
AF Foerster, Reinhold
   Fleige, Henrike
   Sutter, Gerd
TI Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract
   as Promising Approach Toward Protective Immunity in the Lung
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE MVA; COVID-19; SARS-CoV-2; vaccine; lung; BALT
ID CANDIDATE TUBERCULOSIS VACCINE; ANKARA; AEROSOL; IMMUNOGENICITY;
   IMMUNIZATION; INDUCTION; SAFETY
AB The lung is the vital target organ of coronavirus disease 2019 (COVID-19) caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In the majority of patients the most active virus replication seems to be found in the upper respiratory tract, severe cases however suffer from SARS-like disease associated with virus replication in lung tissues. Due to the current lack of suitable anti-viral drugs the induction of protective immunity such as neutralizing antibodies in the lung is the key aim of the only alternative approach-the development and application of SARS-CoV-2 vaccines. However, past experience from experimental animals, livestock, and humans showed that induction of immunity in the lung is limited following application of vaccines at peripheral sides such as skin or muscles. Based on several considerations we therefore propose here to consider the application of a Modified Vaccinia virus Ankara (MVA)-based vaccine to mucosal surfaces of the respiratory tract as a favorable approach to combat COVID-19.
C1 [Foerster, Reinhold; Fleige, Henrike] Hannover Med Sch, Inst Immunol, Hannover, Germany.
   [Foerster, Reinhold] Hannover Med Sch, Cluster Excellence RESIST EXC 2155, Hannover, Germany.
   [Sutter, Gerd] Ludwig Maximilians Univ Munchen, Inst Infect Dis & Zoonoses, Div Virol, Munich, Germany.
   [Sutter, Gerd] German Ctr Infect Res, Partner Site Munich, Munich, Germany.
   [Fleige, Henrike] BioNTech SE, Mainz, Germany.
RP Forster, R (corresponding author), Hannover Med Sch, Inst Immunol, Hannover, Germany.; Forster, R (corresponding author), Hannover Med Sch, Cluster Excellence RESIST EXC 2155, Hannover, Germany.
EM foerster.reinhold@mh-hannover.de
FU Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under
   Germany's Excellence StrategyGerman Research Foundation (DFG) [EXC 2155,
   390874280, 158989968-SFB 900]
FX This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German
   Research Foundation) under Germany's Excellence Strategy-EXC
   2155-Projektnummer 390874280 and Projektnummer 158989968-SFB 900.
CR Chiu C, 2015, NAT IMMUNOL, V16, P18, DOI 10.1038/ni.3056
   Corbett M, 2008, P NATL ACAD SCI USA, V105, P2046, DOI 10.1073/pnas.0705191105
   Zajac MPD, 2017, VIRAL IMMUNOL, V30, P70, DOI 10.1089/vim.2016.0090
   Fleige H, 2018, CELL REP, V23, P783, DOI 10.1016/j.celrep.2018.03.072
   Gilbert SC, 2013, VACCINE, V31, P4241, DOI 10.1016/j.vaccine.2013.03.020
   Haagmans BL, 2016, SCIENCE, V351, P77, DOI 10.1126/science.aad1283
   Halle S, 2009, J EXP MED, V206, P2593, DOI 10.1084/jem.20091472
   Kabashima K, 2019, NAT REV IMMUNOL, V19, P19, DOI 10.1038/s41577-018-0084-5
   Koch T, 2020, LANCET INFECT DIS, V20, P827, DOI 10.1016/S1473-3099(20)30248-6
   Marlin R, 2017, J IMMUNOL, V199, P1923, DOI 10.4049/jimmunol.1700320
   Mowat AM, 2014, NAT REV IMMUNOL, V14, P667, DOI 10.1038/nri3738
   Moyron-Quiroz JE, 2004, NAT MED, V10, P927, DOI 10.1038/nm1091
   Pittman PR, 2019, NEW ENGL J MED, V381, P1897, DOI 10.1056/NEJMoa1817307
   Sanos SL, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01988
   Satti I, 2014, LANCET INFECT DIS, V14, P939, DOI 10.1016/S1473-3099(14)70845-X
   Tchilian E, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050098
   Thomas ZRM, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002790
   Tschernig T, 2000, PATHOBIOLOGY, V68, P1, DOI 10.1159/000028109
   Volz A, 2017, ADV VIRUS RES, V97, P187, DOI 10.1016/bs.aivir.2016.07.001
   White AD, 2013, CLIN VACCINE IMMUNOL, V20, P663, DOI 10.1128/CVI.00690-12
NR 20
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD AUG 7
PY 2020
VL 11
AR 1959
DI 10.3389/fimmu.2020.01959
PG 4
WC Immunology
SC Immunology
GA NF6DU
UT WOS:000563386600001
PM 32849655
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Verma, NK
   Fazil, MHUT
   Duggan, SP
   Kelleher, D
AF Verma, Navin Kumar
   Fazil, Mobashar Hussain Urf Turabe
   Duggan, Shane P.
   Kelleher, Dermot
TI Combination Therapy Using Inhalable GapmeR and Recombinant ACE2 for
   COVID-19
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE COVID-19 (2019-nCoV); GapmeR; angiotensin-converting enzyme 2; nasal
   delivery; therapy
ID RNA
AB Here we report our perspective on applying GapmeR technology in combination with recombinant angiotensin-converting enzyme 2 (ACE2) in the treatment of COVID-19 patients. GapmeR is a cell-permeating antisense single-stranded DNA molecule that can be designed to specifically target intracellular severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Once internalized into host cells, such as lung alveolar cells, GapmeR molecules can bind to the viral RNA. This RNA/DNA hybrid will then be degraded by the RNase H enzyme abundantly present in the host cells. GapmeRs can be delivered to COVID-19 patients through inhalation orvianebulization. SARS-CoV-2-targeted GapmeR can also be given to frontline healthcare workers as a prophylactic protection. The recombinant ACE2 protein, the efficacy of which is being evaluated in clinical trials, will bind to the spike (S) glycoprotein of extracellular SARS-CoV-2 and potentially block viral infectivity. We propose that combining inhalable SARS-CoV-2-targeted GapmeRs with recombinant ACE2 could provide a viable and rapidly implementable more effective therapeutic approach for eradicating SARS-CoV-2 and save millions of lives.
C1 [Verma, Navin Kumar; Fazil, Mobashar Hussain Urf Turabe; Kelleher, Dermot] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Verma, Navin Kumar; Duggan, Shane P.; Kelleher, Dermot] Univ British Columbia, Fac Med, Vancouver, BC, Canada.
RP Verma, NK (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.; Verma, NK (corresponding author), Univ British Columbia, Fac Med, Vancouver, BC, Canada.
EM nkverma@ntu.edu.sg
RI Fazil, M H U Turabe/AAA-1329-2020; Verma, Navin Kumar/B-7641-2008
OI Fazil, M H U Turabe/0000-0002-4621-8625; Verma, Navin
   Kumar/0000-0002-5940-6633
FU Singapore Ministry of Education under its Singapore Ministry of
   Education (MOE) Academic Research Fund (AcRF) Tier 2 Grant
   [MOE2017-T2-2-004]
FX NV acknowledges funding support from the Singapore Ministry of Education
   under its Singapore Ministry of Education (MOE) Academic Research Fund
   (AcRF) Tier 2 Grant (MOE2017-T2-2-004). DK and SD acknowledge Tiny
   Ventures Ltd, Canada.
CR Aartsma-Rus A, 2017, NUCLEIC ACID THER, V27, P67, DOI 10.1089/nat.2017.0665
   Drevinek P, 2020, J CYST FIBROS, V19, P99, DOI 10.1016/j.jcf.2019.05.014
   Fazil MHUT, 2016, SCI REP-UK, V6, DOI 10.1038/srep37721
   Grunweller A, 2003, NUCLEIC ACIDS RES, V31, P3185, DOI 10.1093/nar/gkg409
   Hagedorn PH, 2018, DRUG DISCOV TODAY, V23, P101, DOI 10.1016/j.drudis.2017.09.018
   Hemnes AR, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02638-2017
   Heo YA, 2020, DRUGS, V80, P329, DOI 10.1007/s40265-020-01267-2
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Kim J, 2019, MOL THER-NUCL ACIDS, V17, P714, DOI 10.1016/j.omtn.2019.07.006
   Kurreck J, 2002, NUCLEIC ACIDS RES, V30, P1911, DOI 10.1093/nar/30.9.1911
   Lenartowicz E, 2016, NUCLEIC ACID THER, V26, P277, DOI 10.1089/nat.2016.0619
   Levanova A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02151
   Ma D, 2020, EYE, V34, P1212, DOI 10.1038/s41433-020-0939-4
   Marlowe JL, 2017, NUCLEIC ACID THER, V27, P183, DOI 10.1089/nat.2017.0671
   Miwata K, 2018, MOL THER-NUCL ACIDS, V12, P698, DOI 10.1016/j.omtn.2018.07.009
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Ng B, 2019, MOL THER-NUCL ACIDS, V16, P194, DOI 10.1016/j.omtn.2019.02.013
   Ong ST, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00397
   Oudit GY, 2010, DIABETES, V59, P529, DOI 10.2337/db09-1218
   Parham JS, 2019, EXPERT OPIN PHARMACO, V20, P127, DOI 10.1080/14656566.2018.1550071
   Pedersen L, 2020, MOL THER-NUCL ACIDS, V19, P124, DOI 10.1016/j.omtn.2019.10.040
   Rodrigues FB, 2018, J HUNTINGTONS DIS, V7, P88, DOI 10.3233/JHD-189001
   Takayama K, 2020, TRENDS PHARMACOL SCI, V41, P513, DOI 10.1016/j.tips.2020.05.005
   Verma N. K., 2017, International Application Published Under the Patent Cooperation Treaty (PCT) on 26 October 2017, Patent No. [WO2017184082A1, 2017184082]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yoshida T, 2019, GENES CELLS, DOI 10.1111/gtc.12730
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 31
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD AUG 7
PY 2020
VL 7
AR 197
DI 10.3389/fmolb.2020.00197
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NF4MI
UT WOS:000563271600001
PM 32850978
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tartarone, A
   Lerose, R
AF Tartarone, Alfredo
   Lerose, Rosa
TI COVID-19 and cancer care: what do international guidelines say?
SO MEDICAL ONCOLOGY
LA English
DT Article
DE COVID-19; Pandemic; Guidelines; Cancer patients
AB Cancer patients are at particular risk from COVID-19 since they usually present multiple risk factors for this infection such as older age, immunosuppressed state, comorbidities (e.g., chronic lung disease, diabetes, cardiovascular diseases), need of frequent hospital admissions and visits. Therefore, in the COVID era, oncologists should carefully weigh risks/benefits when planning cancer therapies and follow-up appointments. Recently, several scientific associations developed specific guidelines or recommendations to help physicians in their clinical practice. This review focuses on main available guidelines/recommendations regarding the cancer patient management during the COVID-19 pandemic.
C1 [Tartarone, Alfredo] IRCCS CROB Referral Canc Ctr Basilicata, Div Med Oncol, Dept Oncohematol, Via Padre Pio 1, I-85028 Rionero In Vulture, PZ, Italy.
   [Lerose, Rosa] IRCCS CROB Referral Canc Ctr Basilicata, Hosp Pharm, Rionero In Vulture, PZ, Italy.
RP Tartarone, A (corresponding author), IRCCS CROB Referral Canc Ctr Basilicata, Div Med Oncol, Dept Oncohematol, Via Padre Pio 1, I-85028 Rionero In Vulture, PZ, Italy.
EM tarta1@virgilio.it
CR Cortiula F, 2020, ANN ONCOL, V31, P553, DOI 10.1016/j.annonc.2020.03.286
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Kuderer NM, 2020, LANCET, VS0140-6736, P31187
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Warner JL, 2020, J CLIN ONCOL, V38, pLBA110, DOI [DOI 10.1200/JCO.2020.38.18_suppl.LBA110, 10.1200/JCO.2020.38.18_suppl.LBA110, DOI 10.1200/JCO.2020.38.18_SUPPL.LBA110]
   WHISENANT JG, 2020, J CLIN ONCOL S, V38, pNIL9, DOI DOI 10.1200/JCO.2020.38.18_suppl.LBA111
   You B, 2020, LANCET ONCOL, V21, P619, DOI 10.1016/S1470-2045(20)30204-7
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 11
TC 2
Z9 2
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD AUG 7
PY 2020
VL 37
IS 9
AR 80
DI 10.1007/s12032-020-01406-5
PG 5
WC Oncology
SC Oncology
GA NC6NA
UT WOS:000561333000001
PM 32767203
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Brouwer, PJM
   Caniels, TG
   van der Straten, K
   Snitselaar, JL
   Aldon, Y
   Bangaru, S
   Torres, JL
   Okba, NMA
   Claireaux, M
   Kerster, G
   Bentlage, AEH
   van Haaren, MM
   Guerra, D
   Burger, JA
   Schermer, EE
   Verheul, KD
   van der Velde, N
   van der Kooi, A
   van Schooten, J
   van Breemen, MJ
   Bijl, TPL
   Sliepen, K
   Aartse, A
   Derking, R
   Bontjer, I
   Kootstra, NA
   Wiersinga, WJ
   Vidarsson, G
   Haagmans, BL
   Ward, AB
   de Bree, GJ
   Sanders, RW
   van Gils, MJ
AF Brouwer, Philip J. M.
   Caniels, Tom G.
   van der Straten, Karlijn
   Snitselaar, Jonne L.
   Aldon, Yoann
   Bangaru, Sandhya
   Torres, Jonathan L.
   Okba, Nisreen M. A.
   Claireaux, Mathieu
   Kerster, Gius
   Bentlage, Arthur E. H.
   van Haaren, Marlies M.
   Guerra, Denise
   Burger, Judith A.
   Schermer, Edith E.
   Verheul, Kirsten D.
   van der Velde, Niels
   van der Kooi, Alex
   van Schooten, Jelle
   van Breemen, Marielle J.
   Bijl, Tom P. L.
   Sliepen, Kwinten
   Aartse, Aafke
   Derking, Ronald
   Bontjer, Ilja
   Kootstra, Neeltje A.
   Wiersinga, W. Joost
   Vidarsson, Gestur
   Haagmans, Bart L.
   Ward, Andrew B.
   de Bree, Godelieve J.
   Sanders, Rogier W.
   van Gils, Marit J.
TI Potent neutralizing antibodies from COVID-19 patients define multiple
   targets of vulnerability
SO SCIENCE
LA English
DT Article
ID CRYO-EM STRUCTURE; MONOCLONAL-ANTIBODY; MERS-COV; CORONAVIRUS; SPIKE;
   IMMUNOGENICITY; THERAPY; SYSTEM
AB The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as (tow micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention.
C1 [Brouwer, Philip J. M.; Caniels, Tom G.; van der Straten, Karlijn; Snitselaar, Jonne L.; Aldon, Yoann; Claireaux, Mathieu; Kerster, Gius; van Haaren, Marlies M.; Guerra, Denise; Burger, Judith A.; Schermer, Edith E.; Verheul, Kirsten D.; van Schooten, Jelle; van Breemen, Marielle J.; Bijl, Tom P. L.; Sliepen, Kwinten; Aartse, Aafke; Derking, Ronald; Bontjer, Ilja; Sanders, Rogier W.; van Gils, Marit J.] Univ Amsterdam, Amsterdam Inst Infect & Immun, Dept Med Microbiol, Amsterdam UMC, NL-1105 AZ Amsterdam, Netherlands.
   [van der Straten, Karlijn; Wiersinga, W. Joost; de Bree, Godelieve J.] Univ Amsterdam, Amsterdam Inst Infect & Immun, Dept Internal Med, Amsterdam UMC, NL-1105 AZ Amsterdam, Netherlands.
   [Bangaru, Sandhya; Torres, Jonathan L.; Ward, Andrew B.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
   [Okba, Nisreen M. A.; Haagmans, Bart L.] Erasmus MC, Dept Virosci, NL-3015 GD Rotterdam, Netherlands.
   [Bentlage, Arthur E. H.; Vidarsson, Gestur] Sanquin Res, Dept Expt Immunohematol, NL-1006 AD Amsterdam, Netherlands.
   [Bentlage, Arthur E. H.; Vidarsson, Gestur] Univ Amsterdam, Landsteiner Lab, Amsterdam UMC, NL-1006 AD Amsterdam, Netherlands.
   [van der Velde, Niels; van der Kooi, Alex] IBIS Technol BV, NL-7521 PR Enschede, Netherlands.
   [Aartse, Aafke] Biomed Primate Res Ctr, Dept Virol, NL-2288 GJ Rijswijk, Netherlands.
   [Kootstra, Neeltje A.] Univ Amsterdam, Amsterdam Inst Infect & Immun, Dept Expt Immunol, Amsterdam UMC, NL-1105 AZ Amsterdam, Netherlands.
   [Sanders, Rogier W.] Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA.
RP Sanders, RW; van Gils, MJ (corresponding author), Univ Amsterdam, Amsterdam Inst Infect & Immun, Dept Med Microbiol, Amsterdam UMC, NL-1105 AZ Amsterdam, Netherlands.; de Bree, GJ (corresponding author), Univ Amsterdam, Amsterdam Inst Infect & Immun, Dept Internal Med, Amsterdam UMC, NL-1105 AZ Amsterdam, Netherlands.; Sanders, RW (corresponding author), Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA.
EM g.j.debree@amsterdamumc.nl; r.w.sanders@amsterdamumc.nl;
   m.j.vangils@amsterdamumc.nl
RI Okba, Nisreen MA/K-9984-2017; Caniels, Tom G/ABC-5922-2020; van Gils,
   Marit J./H-4791-2019; Vidarsson, Gestur/A-9909-2009
OI Okba, Nisreen MA/0000-0002-2394-1079; Caniels, Tom
   G/0000-0001-9580-157X; van Gils, Marit J./0000-0003-3422-8161;
   Vidarsson, Gestur/0000-0001-5621-003X; Brouwer,
   Philip/0000-0002-2902-7739; Haagmans, Bart/0000-0001-6221-2015; van der
   Straten, Karlijn/0000-0001-6373-9302; Aldon, Yoann/0000-0001-9831-9391;
   van Schooten, Jelle/0000-0002-5202-355X
FU Netherlands Organization for Scientific Research (NWO) Vici
   grantNetherlands Organization for Scientific Research (NWO); Bill &
   Melinda Gates Foundation through the Collaboration for AIDS Vaccine
   Discovery (CAVD) [OPP1111923, OPP1132237, INV-002022, OPP1170236];
   Fondation Dormeur, Vaduz; Health Holland PPS-allowance [LSHM20040];
   Netherlands Organisation for Health Research and Development
   (ZONMW)Netherlands Organization for Health Research and Development; AMC
   Fellowship from Amsterdam UMC; Amsterdam Institute for Infection and
   Immunity; University of Amsterdam Proof of Concept fund [200421]
FX This work was supported by a Netherlands Organization for Scientific
   Research (NWO) Vici grant (to R.W.S.); by the Bill & Melinda Gates
   Foundation through the Collaboration for AIDS Vaccine Discovery (CAVD)
   grants OPP1111923, OPP1132237, and INV-002022 to R.W.S. and grant
   OPP1170236 to A.B.W.; by the Fondation Dormeur, Vaduz (to R.W.S. and to
   M.J.v.G.) and Health Holland PPS-allowance LSHM20040 (to M.J.v.G.); and
   by the Netherlands Organisation for Health Research and Development
   (ZONMW to B.L.H). M.J.v.G. is a recipient of an AMC Fellowship from
   Amsterdam UMC and a COVID-19 grant from the Amsterdam Institute for
   Infection and Immunity. R.W.S and M.J.v.G. are recipients of support
   from the University of Amsterdam Proof of Concept fund (contract no.
   200421) as managed by Innovation Exchange Amsterdam (IXA). The funders
   had no role in study design, data collection, data analysis, data
   interpretation, or data reporting.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y
   Chen F, 2019, CURR OPIN VIROL, V34, P149, DOI 10.1016/j.coviro.2019.02.004
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7
   CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016
   de Taeye SW, 2015, CELL, V163, P1702, DOI 10.1016/j.cell.2015.11.056
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Gibson DG, 2009, NAT METHODS, V6, P343, DOI [10.1038/NMETH.1318, 10.1038/nmeth.1318]
   Gogtay NJ, 2018, CLIN INFECT DIS, V66, P387, DOI 10.1093/cid/cix791
   Goodwin E, 2018, IMMUNITY, V48, P339, DOI 10.1016/j.immuni.2018.01.005
   Grobben M, 2019, CURR OPIN VIROL, V38, P70, DOI 10.1016/j.coviro.2019.07.007
   Hershberger E, 2019, EBIOMEDICINE, V40, P574, DOI 10.1016/j.ebiom.2018.12.051
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Kulkarni R., 2020, DYNAMICS IMMUNE ACTI, P9, DOI [10.1007/978-981-15-1045-8_2, DOI 10.1007/978-981-15-1045-8_2]
   Lander GC, 2009, J STRUCT BIOL, V166, P95, DOI 10.1016/j.jsb.2009.01.002
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   McLellan JS, 2013, CURR TOP MICROBIOL, V372, P83, DOI 10.1007/978-3-642-38919-1_4
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Okba N. M., 2020, SARS COV 2 SPECIFIC
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pascal KE, 2018, J INFECT DIS, V218, pS612, DOI 10.1093/infdis/jiy285
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pinto Dora, 2020, bioRxiv, DOI 10.1101/2020.04.07.023903
   Potter CS, 1999, ULTRAMICROSCOPY, V77, P153, DOI 10.1016/S0304-3991(99)00043-1
   Robbiani Davide F, 2020, bioRxiv, DOI 10.1101/2020.05.13.092619
   Robinson JE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11544
   Rogers Thomas F, 2020, bioRxiv, DOI 10.1101/2020.05.11.088674
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Sandritter T, 1999, J Pediatr Health Care, V13, P191, DOI 10.1016/S0891-5245(99)90039-1
   Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sok D, 2014, P NATL ACAD SCI USA, V111, P17624, DOI 10.1073/pnas.1415789111
   Tan J, 2018, NAT MED, V24, P401, DOI 10.1038/nm.4513
   Tang XC, 2014, P NATL ACAD SCI USA, V111, pE2018, DOI 10.1073/pnas.1402074111
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   van Gils MJ, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.199
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Voss NR, 2009, J STRUCT BIOL, V166, P205, DOI 10.1016/j.jsb.2009.01.004
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang NS, 2019, CELL REP, V28, P3395, DOI 10.1016/j.celrep.2019.08.052
   Wang Q, 2020, CELL, Vd181, P894
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu NC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15371
   Yu L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00250
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao S, 2020, INFECT DIS-NOR, V52, P284, DOI 10.1080/23744235.2020.1717598
   Zost Seth J, 2020, bioRxiv, DOI 10.1101/2020.05.22.111005
NR 59
TC 68
Z9 65
U1 9
U2 13
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 7
PY 2020
VL 369
IS 6504
BP 643
EP +
DI 10.1126/science.abc5902
PG 39
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MZ5SN
UT WOS:000559184400037
PM 32540902
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Chi, XY
   Yan, RH
   Zhang, J
   Zhang, GY
   Zhang, YY
   Hao, M
   Zhang, Z
   Fan, PF
   Dong, YZ
   Yang, YL
   Chen, ZS
   Guo, YY
   Zhang, JL
   Li, YN
   Song, XH
   Chen, Y
   Xia, L
   Fu, L
   Hou, LH
   Xu, JJ
   Yu, CM
   Li, JM
   Zhou, Q
   Chen, W
AF Chi, Xiangyang
   Yan, Renhong
   Zhang, Jun
   Zhang, Guanying
   Zhang, Yuanyuan
   Hao, Meng
   Zhang, Zhe
   Fan, Pengfei
   Dong, Yunzhu
   Yang, Yilong
   Chen, Zhengshan
   Guo, Yingying
   Zhang, Jinlong
   Li, Yaning
   Song, Xiaohong
   Chen, Yi
   Xia, Lu
   Fu, Ling
   Hou, Lihua
   Xu, Junjie
   Yu, Changming
   Li, Jianmin
   Zhou, Qiang
   Chen, Wei
TI A neutralizing human antibody binds to the N-terminal domain of the
   Spike protein of SARS-CoV-2
SO SCIENCE
LA English
DT Article
ID CRYO-EM STRUCTURE; FUNCTIONAL RECEPTOR; CORONAVIRUS; PHYLOGENIES;
   ACTIVATION; PNEUMONIA; VACCINES; FEATURES; ENTRY; ACID
AB Developing therapeutics against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be guided by the distribution of epitopes, not only on the receptor binding domain (RBD) of the Spike (S) protein but also across the full Spike (S) protein. We isolated and characterized monoclonal antibodies (mAbs) from 10 convalescent COVID-19 patients. Three mAbs showed neutralizing activities against authentic SARS-CoV-2. One mAb, named 4A8, exhibits high neutralization potency against both authentic and pseudotyped SARS-CoV-2 but does not bind the RBD. We defined the epitope of 4A8 as the N-terminal domain (NTD) of the S protein by determining with cryo-eletron microscopy its structure in complex with the S protein to an overall resolution of 3.1 angstroms and local resolution of 3.3 angstroms for the 4A8-NTD interface. This points to the NTD as a promising target for therapeutic mAbs against COVID-19.
C1 [Chi, Xiangyang; Zhang, Jun; Zhang, Guanying; Hao, Meng; Zhang, Zhe; Fan, Pengfei; Dong, Yunzhu; Yang, Yilong; Chen, Zhengshan; Zhang, Jinlong; Song, Xiaohong; Chen, Yi; Fu, Ling; Hou, Lihua; Xu, Junjie; Yu, Changming; Li, Jianmin; Chen, Wei] Acad Mil Med Sci AMMS, Beijing Inst Biotechnol, Beijing 100071, Peoples R China.
   [Yan, Renhong; Zhang, Yuanyuan; Guo, Yingying; Xia, Lu; Zhou, Qiang] Westlake Univ, Sch Life Sci, Westlake Inst Adv Study, Inst Biol,Key Lab Struct Biol Zhejiang Prov, Hangzhou 310024, Zhejiang, Peoples R China.
   [Li, Yaning] Tsinghua Univ, Beijing Adv Innovat Ctr Struct Biol, Tsinghua Peking Joint Ctr Life Sci, Sch Life Sci, Beijing 100084, Peoples R China.
RP Li, JM; Chen, W (corresponding author), Acad Mil Med Sci AMMS, Beijing Inst Biotechnol, Beijing 100071, Peoples R China.; Zhou, Q (corresponding author), Westlake Univ, Sch Life Sci, Westlake Inst Adv Study, Inst Biol,Key Lab Struct Biol Zhejiang Prov, Hangzhou 310024, Zhejiang, Peoples R China.
EM lijmqz@126.com; zhouqiang@westlake.edu.cn; cw0226@foxmail.com
OI Yang, Yilong/0000-0003-3412-0425; , Chi/0000-0002-0580-5997; Yan,
   Renhong/0000-0002-7122-6547; Fan, Pengfei/0000-0002-7212-231X; Zhang,
   Guanying/0000-0003-3372-3355; ZHANG, JUN/0000-0002-9650-112X
FU National Key R&D Program of China [2020YFC0841400]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [31971123, 81803429, 81703048, 31900671, 81920108015, 31930059];
   Key R&D Program of Zhejiang Province [2020C04001]; SARS-CoV-2 emergency
   project of the Science and Technology Department of Zhejiang Province
   [2020C03129]; Leading Innovative and Entrepreneur Team Introduction
   Program of Hangzhou; National Science and Technology Major Project of
   the Ministry of Science and Technology of China
   [2018ZX10101003-005-007]; Special Research Program of Novel Coronavirus
   Pneumonia of Westlake University
FX This work was funded by the National Key R&D Program of China
   (2020YFC0841400), the National Natural Science Foundation of China
   (projects 31971123, 81803429, 81703048, 31900671, 81920108015, and
   31930059), the Key R&D Program of Zhejiang Province (2020C04001), the
   SARS-CoV-2 emergency project of the Science and Technology Department of
   Zhejiang Province (2020C03129), the Leading Innovative and Entrepreneur
   Team Introduction Program of Hangzhou, the National Science and
   Technology Major Project of the Ministry of Science and Technology of
   China, (2018ZX10101003-005-007), and the Special Research Program of
   Novel Coronavirus Pneumonia of Westlake University.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Burkovitz A, 2014, FEBS J, V281, P306, DOI 10.1111/febs.12597
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chen SX, 2013, ULTRAMICROSCOPY, V135, P24, DOI 10.1016/j.ultramic.2013.06.004
   Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7
   Dimitrov DS, 2003, CELL, V115, P652, DOI 10.1016/S0092-8674(03)00976-0
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Giudicelli Veronique, 2011, Cold Spring Harb Protoc, V2011, P695, DOI 10.1101/pdb.prot5633
   Grant T, 2015, ELIFE, V4, DOI 10.7554/eLife.06980
   Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ju B, 2020, POTENT HUMAN NEUTRAL, DOI [10.1101/2020.03.21.990770, DOI 10.1101/2020.03.21.990770, 10.1101/2020.03.21.990770.]
   Ju B, 2020, POTENT HUMAN NEUTRAL
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kimanius D, 2016, ELIFE, V5, DOI 10.7554/eLife.18722
   Krempl C, 1997, J VIROL, V71, P3285, DOI 10.1128/JVI.71.4.3285-3287.1997
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   KUNKEL F, 1993, VIROLOGY, V195, P195, DOI 10.1006/viro.1993.1360
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lei JL, 2005, J STRUCT BIOL, V150, P69, DOI 10.1016/j.jsb.2005.01.002
   Li QQ, 2017, VACCINE, V35, P5172, DOI 10.1016/j.vaccine.2017.07.101
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liao HX, 2009, J VIROL METHODS, V158, P171, DOI 10.1016/j.jviromet.2009.02.014
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   PRICE CG, 1994, ENVIRON GEOCHEM HLTH, V16, P27, DOI 10.1007/BF00149590
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323
   Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006
   Scheres SHW, 2012, J MOL BIOL, V415, P406, DOI 10.1016/j.jmb.2011.11.010
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Simmons G, 2013, ANTIVIR RES, V100, P605, DOI 10.1016/j.antiviral.2013.09.028
   Smith K, 2009, NAT PROTOC, V4, P372, DOI 10.1038/nprot.2009.3
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101
   Thompson JD, 2002, CURR PROTOC BIOINFOR, DOI [10.1002/0471250953.bi0203s00, DOI 10.1002/0471250953.BI0203S00]
   Trabuco LG, 2008, STRUCTURE, V16, P673, DOI 10.1016/j.str.2008.03.005
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang L, 2018, J VIROL, V92, DOI 10.1128/JVI.01060-18
   Wang LS, 2018, J VIROL, V92, DOI 10.1128/JVI.02002-17
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xu JY, 2019, EMERG MICROBES INFEC, V8, P841, DOI 10.1080/22221751.2019.1624482
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhou HX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10897-4
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 68
TC 63
Z9 60
U1 22
U2 31
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 7
PY 2020
VL 369
IS 6504
BP 650
EP +
DI 10.1126/science.abc6952
PG 49
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MZ5SN
UT WOS:000559184400038
PM 32571838
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Wec, AZ
   Wrapp, D
   Herbert, AS
   Maurer, DP
   Haslwanter, D
   Sakharkar, M
   Jangra, RK
   Dieterle, ME
   Lilov, A
   Huang, DL
   Tse, LV
   Johnson, NV
   Hsieh, CL
   Wang, NS
   Nett, JH
   Champney, E
   Burnina, I
   Brown, M
   Lin, S
   Sinclair, M
   Johnson, C
   Pudi, S
   Bortz, R
   Wirchnianski, AS
   Laudermilch, E
   Florez, C
   Fels, JM
   O'Brien, CM
   Graham, BS
   Nemazee, D
   Burton, DR
   Baric, RS
   Voss, JE
   Chandran, K
   Dye, JM
   McLellan, JS
   Walker, LM
AF Wec, Anna Z.
   Wrapp, Daniel
   Herbert, Andrew S.
   Maurer, Daniel P.
   Haslwanter, Denise
   Sakharkar, Mrunal
   Jangra, Rohit K.
   Dieterle, M. Eugenia
   Lilov, Asparouh
   Huang, Deli
   Tse, Longping, V
   Johnson, Nicole, V
   Hsieh, Ching-Lin
   Wang, Nianshuang
   Nett, Juergen H.
   Champney, Elizabeth
   Burnina, Irina
   Brown, Michael
   Lin, Shu
   Sinclair, Melanie
   Johnson, Carl
   Pudi, Sarat
   Bortz, Robert, III
   Wirchnianski, Ariel S.
   Laudermilch, Ethan
   Florez, Catalina
   Fels, J. Maximilian
   O'Brien, Cecilia M.
   Graham, Barney S.
   Nemazee, David
   Burton, Dennis R.
   Baric, Ralph S.
   Voss, James E.
   Chandran, Kartik
   Dye, John M.
   McLellan, Jason S.
   Walker, Laura M.
TI Broad neutralization of SARS-related viruses by human monoclonal
   antibodies
SO SCIENCE
LA English
DT Article
ID SPIKE
AB Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of a convalescent severe acute respiratory syndrome (SARS) donor and identified 200 SARS coronavirus 2 (SARS-CoV-2) binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the non-neutralizing antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of preexisting memory B cells elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing Si shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a target for the rational design of pan-sarbecovirus vaccines.
C1 [Wec, Anna Z.; Maurer, Daniel P.; Sakharkar, Mrunal; Lilov, Asparouh; Nett, Juergen H.; Champney, Elizabeth; Burnina, Irina; Brown, Michael; Lin, Shu; Sinclair, Melanie; Johnson, Carl; Pudi, Sarat; Walker, Laura M.] Adimab LLC, Lebanon, NH 03766 USA.
   [Wrapp, Daniel; Johnson, Nicole, V; Hsieh, Ching-Lin; Wang, Nianshuang; McLellan, Jason S.] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.
   [Herbert, Andrew S.; O'Brien, Cecilia M.; Dye, John M.] US Army Med Res, Inst Infect Dis, Frederick, MD 21702 USA.
   [Haslwanter, Denise; Jangra, Rohit K.; Dieterle, M. Eugenia; Bortz, Robert, III; Wirchnianski, Ariel S.; Laudermilch, Ethan; Florez, Catalina; Fels, J. Maximilian; Chandran, Kartik] Albert Einstein Coll Med, Dept Microbiol & Immunol, New York, NY 10462 USA.
   [Huang, Deli; Nemazee, David; Burton, Dennis R.; Voss, James E.] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.
   [Tse, Longping, V; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Graham, Barney S.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   [Burton, Dennis R.] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.
   [Burton, Dennis R.] Scripps Res Inst, Consortium HIV Aids Vaccine Dev CHAVD, La Jolla, CA 92037 USA.
   [Burton, Dennis R.] Massachusetts Gen Hosp, Ragon Inst, MIT, Cambridge, MA 02139 USA.
   [Baric, Ralph S.] Univ N Carolina, Dept Microbiol, Chapel Hill, NC 27599 USA.
   [Baric, Ralph S.] Univ N Carolina, Dept Immunol, Chapel Hill, NC 27599 USA.
RP Walker, LM (corresponding author), Adimab LLC, Lebanon, NH 03766 USA.
EM laura.walker@adimab.com
OI Wrapp, Daniel/0000-0002-0538-9647; Haslwanter,
   Denise/0000-0003-2727-0468; Maurer, Daniel/0000-0003-2074-5416; Huang,
   Deli/0000-0002-6989-639X; Johnson, Nicole/0000-0003-4351-125X; Jangra,
   Rohit K/0000-0002-3119-0869; Bortz III, Robert/0000-0003-1751-2152
FU National Institutes of Health (NIH)-NIAIDUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01-AI127521, U19 AI142777, R01AI132317, R01AI073148]; Bill and Melinda
   Gates FoundationBill & Melinda Gates Foundation [OPP 1183956]
FX This work was funded in part by National Institutes of Health
   (NIH)-NIAID grants awarded to J.S.M. (R01-AI127521) and K.C. (U19
   AI142777). D.Hu. and J.E.V. were supported by R01AI132317 and
   R01AI073148 (to D.N.). J.E.V. was also supported by the Bill and Melinda
   Gates Foundation (OPP 1183956 to J.E.V.).
CR Correia BE, 2014, NATURE, V507, P201, DOI 10.1038/nature12966
   Gietz RD, 2002, METHOD ENZYMOL, V350, P87
   Gilman MSA, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaj1879
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Kleinfelter LM, 2015, MBIO, V6, DOI 10.1128/mBio.00801-15
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022
   Shehata L, 2019, CELL REP, V28, P3300, DOI 10.1016/j.celrep.2019.08.056
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
NR 26
TC 43
Z9 41
U1 9
U2 10
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 7
PY 2020
VL 369
IS 6504
BP 731
EP +
DI 10.1126/science.abc7424
PG 36
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MZ5SN
UT WOS:000559184400053
PM 32540900
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Devi, A
   Chaitanya, NSN
AF Devi, Arpita
   Chaitanya, Nyshadham S. N.
TI In silicodesigning of multi-epitope vaccine construct against human
   coronavirus infections
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Coronavirus; spike protein; epitope; vaccine; toll-like receptor
ID COV SPIKE GLYCOPROTEIN; RESPIRATORY SYNDROME; PROTEIN-STRUCTURE; GENOME
   SEQUENCE; WEB SERVER; S PROTEIN; SARS; VIRUS; ARCHITECTURE; RECEPTOR
AB Single stranded RNA viruses were known to cause variety of diseases since many years and are gaining much importance due to pandemic after the identification of a novel corona virus (severe acute respiratory syndrome-coronavirus (SARS-CoV-2)). Seven coronaviruses (CoVs) are known to infect humans and they are OC43 CoV, NL63 CoV, HKU1 CoV, Middle East respiratory syndrome, SARS CoV, and SARS CoV-2. Virus replication weakens the immune system of host thereby altering T-cell count and much of interferon response. Although no vaccine or therapeutic treatment has been approved till now for CoV infection, trials of vaccine against SARS CoV-2 are in progress. One of the epitopes used for vaccine production is of the spike protein on the surface of virus. The work focuses on designing of multi-epitope vaccine construct for treatment of seven human CoV infections using the epitopes present on the spike protein of human CoVs. To address this, immuno-informatics techniques have been employed to design multi-epitope vaccine construct. B- and T-cell epitopes of the spike proteins have been predicted and designed into a multi-epitope vaccine construct. The tertiary structure of the vaccine construct along with the adjuvant has been modelled and the physiochemical properties have been predicted. The multi-epitope vaccine construct has antigenic and non-allergenic property. After validation, refinement and disulphide engineering of the vaccine construct, molecular docking with toll-like receptors (TLRs) have been performed. Molecular dynamics simulation in aqueous environment predicted that the vaccine-TLRs complexes were stable. The vaccine construct is predicted to be able to trigger primary immune responsein silico. Communicated by Ramaswamy H. Sarma
C1 [Devi, Arpita] Tezpur Univ, Dept Mol Biol & Biotechnol, Tezpur 784028, Assam, India.
   [Chaitanya, Nyshadham S. N.] Univ Hyderabad, Dept Anim Biol, Sch Life Sci, Hyderabad, Telangana, India.
RP Devi, A (corresponding author), Tezpur Univ, Dept Mol Biol & Biotechnol, Tezpur 784028, Assam, India.
EM arpitadevi26@gmail.com
OI Devi, Arpita/0000-0003-1718-4005
FU CSIR-SRFCouncil of Scientific & Industrial Research (CSIR) - India;
   ICMR-SRF
FX A.D. acknowledges CSIR-SRF for providing financial assistance. N.S.N.C.
   acknowledges ICMR-SRF for proving financial assistance. The authors
   acknowledge the anonymous reviewers for helping to improve the
   manuscript by providing critical suggestions.
CR Beniac DR, 2006, NAT STRUCT MOL BIOL, V13, P751, DOI 10.1038/nsmb1123
   Bhattacharya D, 2016, NUCLEIC ACIDS RES, V44, pW406, DOI 10.1093/nar/gkw336
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Brielle ES, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050497
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Coleman CM, 2014, J VIROL, V88, P5209, DOI 10.1128/JVI.03488-13
   Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Du MZ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02948
   Fehr A. R., 2015, METHODS MOL BIOL
   Gaunt ER, 2010, J CLIN MICROBIOL, V48, P2940, DOI 10.1128/JCM.00636-10
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Godeke GJ, 2000, J VIROL, V74, P1566, DOI 10.1128/JVI.74.3.1566-1571.2000
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Kar T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67749-1
   Kim LM, 2018, MICROBIOL RESOUR ANN, V6, DOI 10.1128/genomeA.00152-18
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kreil TR, 2018, TRANSFUSION, V58, P3090, DOI 10.1111/trf.15016
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Lavillette D, 2006, J BIOL CHEM, V281, P9200, DOI 10.1074/jbc.M512529200
   Lee S, 2010, EVOL BIOINFORM, V6, P47
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lim Y.X., 2016, DISEASES, V4, P26, DOI DOI 10.3390/DISEASES4030026
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu R., 2015, GENOME ANNOUNCEMENTS, V3
   Mackay IM, 2015, VIRUS RES, V202, P60, DOI 10.1016/j.virusres.2015.01.021
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   McBride CE, 2010, VIROLOGY, V405, P139, DOI 10.1016/j.virol.2010.05.031
   Naz A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01663
   Neuman BW, 2006, J VIROL, V80, P7918, DOI 10.1128/JVI.00645-06
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Sabir JSM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214337
   Samadi A, 2020, J MACROMOL SCI B, V59, P376, DOI [10.1080/00222348.2020.1730573, 10.1080/07391102.2020.1792347]
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Thorp EB, 2006, J VIROL, V80, P1280, DOI 10.1128/JVI.80.3.1280-1289.2006
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vijgen L, 2005, J VIROL, V79, P1595, DOI 10.1128/JVI.79.3.1595-1604.2005
   VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x
   WALEED M, 2020, CUREUS, V12, DOI DOI 10.3390/RS12050760
   Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568
   Wang ZY, 2011, PROTEOMICS, V11, P3786, DOI 10.1002/pmic.201100196
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Yan YM, 2020, NAT PROTOC, V15, P1829, DOI 10.1038/s41596-020-0312-x
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
   Zhou HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107606
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 56
TC 1
Z9 1
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1804460
EA AUG 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MX3KF
UT WOS:000557623500001
PM 32772892
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mukherjee, S
   Dasgupta, S
   Adhikary, T
   Adhikari, U
   Panja, SS
AF Mukherjee, Soumita
   Dasgupta, Subrata
   Adhikary, Tapasendra
   Adhikari, Utpal
   Panja, Sujit Sankar
TI Structural insight to hydroxychloroquine-3C-like proteinase complexation
   from SARS-CoV-2: inhibitor modelling study through molecular docking and
   MD-simulation study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Hydroxychloroquine; catalytic triad; conserved
   water molecule
ID DYNAMICS
AB The spread of novel coronavirus strain, Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) causes Coronavirus disease (COVID-19) has now spread worldwide and effecting the entire human race. The viral genetic material is transcripted and replicated by 3 C-like protease, as a result, it is an important drug target for COVID-19. Hydroxychloroquine (HCQ) report promising results against this drug target so, we perform molecular docking followed by MD-simulation studies of HCQ and modelled some ligand (Mod-I and Mod-II) molecules with SARS-CoV-2-main protease which reveals the structural organization of the active site residues and presence of a conserve water-mediated catalytic triad that helps in the recognition of Mod-I/II ligand molecules. The study may be helpful to gain a detailed structural insight on the presence of water-mediated catalytic triad which could be useful for inhibitor modelling. Communicated by Ramaswamy H. Sarma
C1 [Mukherjee, Soumita; Dasgupta, Subrata; Adhikari, Utpal; Panja, Sujit Sankar] Natl Inst Technol Durgapur, Dept Chem, MG Ave, Durgapur 713209, W Bengal, India.
   [Adhikary, Tapasendra] Indian Inst Technol, Dept Met & Mat Engn, Kharagpur, W Bengal, India.
RP Panja, SS (corresponding author), Natl Inst Technol Durgapur, Dept Chem, MG Ave, Durgapur 713209, W Bengal, India.
EM sujit.panja@gmail.com
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abdelli I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763199
   Peele KA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1770127
   Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Ahmad S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1775129
   Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   Amin M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1775703
   Anwar F, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1775123
   Arya A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1773929
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767211
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767210
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Basit A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768150
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Beura S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772111
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Chew CY, 2020, AUSTRALAS J DERMATOL, V61, pE150, DOI 10.1111/ajd.13168
   Choudhury C, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1771424
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   de Magalhaes CS, 2014, INFORM SCIENCES, V289, P206, DOI 10.1016/j.ins.2014.08.002
   de Oliveira OV, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772885
   Dennington R., 2009, GAUSSVIEW 5
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761881
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648
   Frisch M. J., 2009, GAUSSIAN 09 A 02
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gullingsrud J, 2001, BIOPHYS J, V80, P2074, DOI 10.1016/S0006-3495(01)76181-4
   Gupta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1776157
   Gyebi GA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764868
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Hemida MG, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100127
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772110
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767691
   Hu B, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0422-1
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kumar A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772112
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779131
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   Liu H, 2016, BIOINFORMATICS, V32, P2216, DOI 10.1093/bioinformatics/btw215
   Lobo-Galo N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764393
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Mahanta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768902
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Quimque MTJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1776639
   RYNES RI, 1988, AM J MED, V85, P18, DOI 10.1016/0002-9343(88)90357-9
   Santos KB, 2020, J CHEM INF MODEL, V60, P667, DOI 10.1021/acs.jcim.9b00905
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Sk MF, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768149
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   TANENBAUM L, 1980, ARCH DERMATOL, V116, P587, DOI 10.1001/archderm.116.5.587
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Veeramachaneni GK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1773318
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wahie S, 2013, BRIT J DERMATOL, V169, P653, DOI 10.1111/bjd.12378
   Wang LF, 2007, CURR TOP MICROBIOL, V315, P325
   WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
NR 87
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1804458
EA AUG 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MX9ES
UT WOS:000558021200001
PM 32772895
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wurm, H
   Attfield, K
   Iversen, AK
   Gold, R
   Fugger, L
   Haghikia, A
AF Wurm, Hannah
   Attfield, Kate
   Iversen, Astrid K. N.
   Gold, Ralf
   Fugger, Lars
   Haghikia, Aiden
TI Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE Multiple sclerosis (MS); rituximab; B-cell-depleting therapy; COVID-19;
   SARS-CoV-2 antibodies; cellular immune responses
AB Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for similar to 3 years. The patient was examined 5 days before the onset of coronavirus disease 2019 (COVID-19) symptoms and was admitted to the hospital 2 days after. She recovered 14 days after symptom onset despite having a 0% B lymphocyte count and not developing SARS-CoV-2 immunoglobulin G (IgG) antibodies.
C1 [Attfield, Kate; Iversen, Astrid K. N.; Fugger, Lars] John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford Ctr Neuroinflammat, Oxford OX3 9DU, England.
   [Wurm, Hannah; Gold, Ralf; Haghikia, Aiden] Ruhr Univ Bochum, St Josef Hosp Bochum, Dept Neurol, D-44801 Bochum, Germany.
   [Fugger, Lars] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford, England.
RP Fugger, L (corresponding author), John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford Ctr Neuroinflammat, Oxford OX3 9DU, England.; Haghikia, A (corresponding author), Ruhr Univ Bochum, St Josef Hosp Bochum, Dept Neurol, D-44801 Bochum, Germany.
EM lars.fugger@ndcn.ox.ac.uk; aiden.haghikia@rub.de
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Brownlee W, 2020, NEUROLOGY, V94, P949, DOI 10.1212/WNL.0000000000009507
   Hughes R, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102192
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lund FE, 2008, CURR OPIN IMMUNOL, V20, P332, DOI 10.1016/j.coi.2008.03.003
   Novi G, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.101430
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Safavi F, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102195
   Soresina A, 2020, PEDIAT ALLERGY IMMUN, V6736, P19
   Tan W, 2020, VIRAL KINETICS ANTIB, DOI [10.1101/2020.03.24.20042382, DOI 10.1101/2020.03.24.20042382]
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 13
TC 2
Z9 2
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD SEP
PY 2020
VL 26
IS 10
BP 1261
EP 1264
AR 1352458520943791
DI 10.1177/1352458520943791
EA AUG 2020
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NP1QZ
UT WOS:000557533100001
PM 32762494
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Kirkby, C
   Mackenzie, M
AF Kirkby, Charles
   Mackenzie, Marc
TI Low dose lung radiation therapy for pneumonia: an examination of
   historical dose distributions
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Monte Carlo; low dose radiation therapy; pneumonia; Covid-19;
   kilovoltage
ID MONTE-CARLO-SIMULATION; ELECTRON-TRANSPORT; RADIOTHERAPY; MECHANISMS
AB The novel coronavirus, SARS-CoV-2, that causes the COVID-19 disease currently has healthcare systems around the world dealing with unprecedented numbers of critically ill patients. One of the primary concerns associated with this illness is acute respiratory distress syndrome (ARDS) and the pneumonia that accompanies it. Historical literature dating back to the 1940s and earlier contains many reports of successful treatment of pneumonias with ionizing radiation. Although these were not randomized controlled trials, they do suggest a potential avenue for further investigation. Technical details in these reports however were limited. In this work we review the literature and identify details including nominal kilovoltage ranges, filtration, and focus-skin distances (FSDs). Using a freely available and benchmarked code, we generated spectra and used these as sources for Monte Carlo simulations using the EGSnrc software package. The approximate sources were projected through a radiologically anthropomorphic phantom to provide detailed dose distributions within a targeted lung volume (approximate right middle lobe). After accounting for the reported exposure levels, mean lung doses fell in a relatively narrow range: 30-80 cGy. Variation in patient dimensions and other details are expected to result in an uncertainty on the order of +/- 20%. This result is consistent with the dose range expected to induce anti-inflammatory effects.
C1 [Kirkby, Charles] Jack Ady Canc Ctr, Dept Med Phys, Lethbridge, AB, Canada.
   [Kirkby, Charles] Univ Calgary, Dept Oncol, Calgary, AB, Canada.
   [Kirkby, Charles] Univ Calgary, Dept Phys & Astron, Calgary, AB, Canada.
   [Mackenzie, Marc] Univ Alberta, Dept Oncol, Edmonton, AB, Canada.
RP Kirkby, C (corresponding author), Jack Ady Canc Ctr, Dept Med Phys, Lethbridge, AB, Canada.; Kirkby, C (corresponding author), Univ Calgary, Dept Oncol, Calgary, AB, Canada.; Kirkby, C (corresponding author), Univ Calgary, Dept Phys & Astron, Calgary, AB, Canada.
EM charles.kirkby@ahs.ca
CR Arenas M, 2012, STRAHLENTHER ONKOL, V188, P975, DOI 10.1007/s00066-012-0170-8
   Arenas M, 2008, RADIOTHER ONCOL, V86, P399, DOI 10.1016/j.radonc.2007.10.032
   Attix F.H., 2004, INTRO RADIOLOGICAL P
   Calabrese EJ, 2019, HUM EXP TOXICOL, V38, P888, DOI 10.1177/0960327119846925
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   Correll HL, 1943, US NAV M B, V1943, P980
   Kawrakow I, 2000, MED PHYS, V27, P499, DOI 10.1118/1.598918
   Kawrakow I, 2000, MED PHYS, V27, P485, DOI 10.1118/1.598917
   Kirkby C, 2020, RADIOTHER ONCOL, V147, P221, DOI 10.1016/j.radonc.2020.04.004
   Kramer GH, 2000, HEALTH PHYS, V78, P739, DOI 10.1097/00004032-200006000-00019
   Lara PC, 2020, CLIN TRANSL RAD ONCO, V23, P27, DOI 10.1016/j.ctro.2020.04.006
   Moldoveanu B, 2009, J INFLAMM RES, V2, P1
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Oppenheimer A, 1943, AM J ROENTGENOL RADI, V49, P635
   Oppenheimer A, 1943, J PEDIAT, V41, P404
   Powell EV, 1936, TEX STATE J MED, V32, P237
   Rodel F, 2007, INT J RADIAT BIOL, V83, P357, DOI 10.1080/09553000701317358
   Roedel F, 2012, CURR MED CHEM, V19, P1741, DOI 10.2174/092986712800099866
   Rogers D W O, 2020, PIRS0509AREVL NRCC
   ROGERS DWO, 1995, MED PHYS, V22, P503, DOI 10.1118/1.597552
   Rousseau JP, 1942, RADIOLOGY, V38, P281, DOI [10.1148/38.3.281, DOI 10.1148/38.3.281]
   Scott WRJR, 1939, RADIOLOGY, V33, P331, DOI [DOI 10.1148/33.3.331, 10.1148/33.3.331]
   Siewerdsen JH, 2004, MED PHYS, V31, P3057, DOI 10.1118/1.1758350
   Royo LT, 2020, REP PRACT ONCOL RADI, V25, P250, DOI 10.1016/j.rpor.2020.02.004
   Walters B, 2020, PIRS704REVB NRCC
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 26
TC 1
Z9 1
U1 0
U2 0
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD AUG 7
PY 2020
VL 65
IS 15
AR 155019
DI 10.1088/1361-6560/ab9e55
PG 8
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA MX0WO
UT WOS:000557449100001
PM 32554879
DA 2021-01-01
ER

PT J
AU Wang, SM
   Tao, F
   Hou, Y
   Zhang, A
   Xiong, H
   Sun, JJ
   Luo, XP
   Hao, Y
   Li, JX
   Hu, Q
   Liu, AG
AF Wang, Song-mi
   Tao, Fang
   Hou, Yan
   Zhang, Ai
   Xiong, Hao
   Sun, Jun-jie
   Luo, Xiao-ping
   Hao, Yan
   Li, Jian-xin
   Hu, Qun
   Liu, Ai-guo
TI Screening of SARS-CoV-2 in 299 Hospitalized Children with
   Hemato-oncological Diseases: A Multicenter Survey in Hubei, China
SO CURRENT MEDICAL SCIENCE
LA English
DT Article
DE children; COVID-19; hemato-oncological diseases; SARS-CoV-2
AB The SARS-CoV-2 infection status of hospitalized children was surveyed in the department of pediatric hematology and oncology in three different hospitals of epidemic areas in Hubei, China. A cross-sectional study was performed to investigate the clinical characteristics, lung CT scan, SARS-CoV-2 nucleic acid test and serum antibodies of hospitalized children with hemato-oncological diseases from January 23 to April 24, 2020. 299 children were enrolled in this study, including 176 males (58.9%) and 123 females (41.1%), aged from 2 months to 16 years. 255 cases (85.3%) received chemotherapy or other immunosuppressive therapies, and there were 44 cases (14.7%) of other benign diseases. Nucleic acid test was performed on 258 children (86.3%) and one case was positive. 163 cases (54.5%) were tested for serum antibodies, and all of them were negative. Lung CT scan was performed on 247 children (82.6%), and 107 of them showed infectious changes. Only one case (0.33%) of COVID-19 was diagnosed in the group. The prevalence rate of COVID-19 in enrolled children with hemato-oncological diseases in Hubei was 0.33%. Immunosuppressed patients are not prone to produce related antibodies. Comprehensive protective measures and ward management can reduce the risk of SARS-CoV-2 infection in the group patients.
C1 [Wang, Song-mi; Zhang, Ai; Luo, Xiao-ping; Hao, Yan; Hu, Qun; Liu, Ai-guo] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat, Wuhan 430030, Peoples R China.
   [Tao, Fang; Xiong, Hao; Li, Jian-xin] Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Tongji Med Coll, Dept Pediat Hematol & Oncol, Wuhan 430015, Peoples R China.
   [Hou, Yan; Sun, Jun-jie] Hubei Univ Art & Sci, Xiangyang Cent Hosp, Dept Pediat, Affiliated Hosp, Xiangyang 441021, Peoples R China.
RP Hu, Q; Liu, AG (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat, Wuhan 430030, Peoples R China.
EM songmi201275955@126.com; 2453037665@qq.com; julishi@163.com;
   qunhu2013@163.com; drliuaiguo@163.com
FU Huazhong University of Science and Technology Emergency Technology
   Research Project Response to COVID-19 [2020kfyXGYJ020]; Clinical Study
   of the Pediatric Patients with 2019-nCOV [XXGZBDYJ005]
FX This project was supported by Huazhong University of Science and
   Technology Emergency Technology Research Project Response to COVID-19
   (No.2020kfyXGYJ020) and Clinical Study of the Pediatric Patients with
   2019-nCOV (No. XXGZBDYJ005).
CR Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Ogimi C, 2019, J PEDIAT INF DIS SOC, V8, P21, DOI 10.1093/jpids/pix093
   Shen KL, 2020, WORLD J PEDIATR, V16, P219, DOI 10.1007/s12519-020-00344-6
   Sue C, 2000, SEMIN PEDIAT INFECT, V11, P122, DOI 10.1053/pi.2000.4662
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 12
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2096-5230
EI 2523-899X
J9 CURR MED SCI
JI Curr. Med. Sci.
PD AUG
PY 2020
VL 40
IS 4
BP 642
EP 645
DI 10.1007/s11596-020-2228-7
EA AUG 2020
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NF9YT
UT WOS:000557124300004
PM 32767262
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Dersch, R
   Wehrum, T
   Fahndrich, S
   Engelhardt, M
   Rauer, S
   Berger, B
AF Dersch, Rick
   Wehrum, Thomas
   Faehndrich, Sebastian
   Engelhardt, Monika
   Rauer, Sebastian
   Berger, Benjamin
TI COVID-19 pneumonia in a multiple sclerosis patient with severe
   lymphopenia due to recent cladribine treatment
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE Multiple sclerosis; cladribine; COVID-19; prognosis
AB Background: Most cases of COVID-19 are considered mild, but patients with immunosuppressant treatment might be prone to severe courses of disease. Expert panels advise to delay treatment with cell-depleting MS therapies during the COVID-19 pandemic. Methods: We report a case of a patient with relapsing-remitting multiple sclerosis who developed COVID-19 pneumonia 2 weeks after the first week of cladribine therapy. Results: Despite a severe lymphopenia (absolute lymphocyte count 240/mu L), the patient had a moderate course of COVID-19. Conclusion: Apart from maximal supportive treatment, this could be due to cladribine reducing inflammatory response, which probably contributes considerably to severe courses of COVID-19 pneumonia.
C1 [Dersch, Rick; Wehrum, Thomas; Rauer, Sebastian; Berger, Benjamin] Univ Freiburg, Med Ctr, Clin Neurol & Neurophysiol, Fac Med, Breisacher Str 64, D-79106 Freiburg, Germany.
   [Faehndrich, Sebastian] Univ Freiburg, Med Ctr, Med Dept Pneumol, Fac Med, Freiburg, Germany.
   [Engelhardt, Monika] Univ Freiburg, Med Ctr, Hematol Oncol & Stem Cell Transplantat Clin Canc, Med Dept,Fac Med, Freiburg, Germany.
RP Dersch, R (corresponding author), Univ Freiburg, Med Ctr, Clin Neurol & Neurophysiol, Fac Med, Breisacher Str 64, D-79106 Freiburg, Germany.
EM Rick.Dersch@uniklinik-freiburg.de
CR Brownlee W, 2020, NEUROLOGY, V94, P949, DOI 10.1212/WNL.0000000000009507
   Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249
   Laugel B, 2011, J NEUROIMMUNOL, V240, P52, DOI 10.1016/j.jneuroim.2011.09.010
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mian H, 2020, J GERIATR ONCOL, V11, P764, DOI 10.1016/j.jgo.2020.04.008
   Novi G, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.101430
   Prasse A, 2010, AM J RESP CRIT CARE, V182, P540, DOI 10.1164/rccm.200909-1451OC
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
NR 8
TC 4
Z9 4
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD SEP
PY 2020
VL 26
IS 10
BP 1264
EP 1266
AR 1352458520943783
DI 10.1177/1352458520943783
EA AUG 2020
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NP1QZ
UT WOS:000557767000001
PM 32762488
OA Bronze
DA 2021-01-01
ER

PT J
AU Goncalves, A
   Bertrand, J
   Ke, RA
   Comets, E
   de Lamballerie, X
   Malvy, D
   Pizzorno, A
   Terrier, O
   Calatrava, MR
   Mentre, F
   Smith, P
   Perelson, AS
   Guedj, J
AF Goncalves, Antonio
   Bertrand, Julie
   Ke, Ruian
   Comets, Emmanuelle
   de Lamballerie, Xavier
   Malvy, Denis
   Pizzorno, Andres
   Terrier, Olivier
   Calatrava, Manuel Rosa
   Mentre, France
   Smith, Patrick
   Perelson, Alan S.
   Guedj, Jeremie
TI Timing of Antiviral Treatment Initiation is Critical to Reduce
   SARS-CoV-2 Viral Load
SO CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
LA English
DT Article
ID INFECTION; INSIGHTS; KINETICS
AB We modeled the viral dynamics of 13 untreated patients infected with severe acute respiratory syndrome-coronavirus 2 to infer viral growth parameters and predict the effects of antiviral treatments. In order to reduce peak viral load by more than two logs, drug efficacy needs to be > 90% if treatment is administered after symptom onset; an efficacy of 60% could be sufficient if treatment is initiated before symptom onset. Given their pharmacokinetic/pharmacodynamic properties, current investigated drugs may be in a range of 6-87% efficacy. They may help control virus if administered very early, but may not have a major effect in severely ill patients.
C1 [Goncalves, Antonio; Bertrand, Julie; Comets, Emmanuelle; Mentre, France; Guedj, Jeremie] Univ Paris, IAME, INSERM, Paris, France.
   [Ke, Ruian; Perelson, Alan S.] Los Alamos Natl Lab, Theoret Biol & Biophys, Los Alamos, NM USA.
   [de Lamballerie, Xavier] EPV Aix Marseille Univ, UMR Emergence Pathol Virales, Inst Hosp Univ Mediterranee Infect, IRD 190,Inserm 1207,EHESP, Marseille, France.
   [Malvy, Denis] Univ Bordeaux, INSERM, UMR 1219, Bordeaux, France.
   [Malvy, Denis] CHU Bordeaux, Bordeaux, France.
   [Pizzorno, Andres; Terrier, Olivier; Calatrava, Manuel Rosa] Univ Lyon, INSERM, Team VirPath,ENS Lyon, CIRI,U1111,Univ Claude Bernard Lyon 1,CNRS,UMR530, Lyon, France.
   [Smith, Patrick] Certara, Integrated Drug Dev, Princeton, NJ USA.
RP Goncalves, A; Guedj, J (corresponding author), Univ Paris, IAME, INSERM, Paris, France.
EM antonio.goncalves@inserm.fr; jeremie.guedj@inserm.fr
RI Terrier, Olivier/B-6301-2009; Pizzorno, Mario Andres/L-7810-2017
OI Terrier, Olivier/0000-0001-9393-7684; Goncalves,
   Antonio/0000-0002-8759-2429; Smith, Patrick/0000-0002-6003-0805;
   Pizzorno, Mario Andres/0000-0002-0918-6804
FU Roche Pharmaceutical Research and Early Development; national Research
   Agency (ANR) through the ANR-Flash calls for COVID-19French National
   Research Agency (ANR) [TheraCoV ANR-20-COVI-0018]; US Department of
   EnergyUnited States Department of Energy (DOE) [89233218CNA000001]; US
   Department of Energy through the LANL/LDRD ProgramUnited States
   Department of Energy (DOE)
FX Antonio Goncalves is funded by a grant from Roche Pharmaceutical
   Research and Early Development. The study has received financial support
   of the national Research Agency (ANR) through the ANR-Flash calls for
   COVID-19 (TheraCoV ANR-20-COVI-0018). Portions of this work were done
   under the auspices of the US Department of Energy under contract
   89233218CNA000001. We also gratefully acknowledge the support of the US
   Department of Energy through the LANL/LDRD Program for this work (A.S.P.
   and R.K.).
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Baccam P, 2006, J VIROL, V80, P7590, DOI 10.1128/JVI.01623-05
   Banerjee S, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0130
   Best K, 2017, P NATL ACAD SCI USA, V114, P8847, DOI 10.1073/pnas.1704011114
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Czuppon P., PREDICTED SUCCESS PR, DOI [10.1101/2020.05.07.20092965, DOI 10.1101/2020.05.07.20092965, 10.1101/2020.05.07.200929652020.05.07.20092965]
   Denison MR, 2011, RNA BIOL, V8, P270, DOI 10.4161/rna.8.2.15013
   Friberg LE, 2020, CLIN MICROBIOL INFEC, V26, P1133, DOI 10.1016/j.cmi.2019.12.008
   Goncalves A, 2020, AAPS J, V22, DOI 10.1208/s12248-020-0426-7
   Hu X, 2016, BRIT J CLIN PHARMACO, V82, P380, DOI 10.1111/bcp.12968
   Ingraham NE, 2020, LANCET RESP MED, V8, P544, DOI 10.1016/S2213-2600(20)30226-5
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu S, 2019, HEPATOLOGY, V69, P1816, DOI 10.1002/hep.30325
   Maisonnasse P., 2020, HYDROXYCHLOROQUINE T, DOI [10.21203/RS.3.RS-27223/V1, DOI 10.21203/RS.3.RS-27223/V1, 10.21203/rs.3.rs-27223/v1]
   Miao HY, 2011, SIAM REV, V53, P3, DOI 10.1137/090757009
   Morita S, 2016, THER DRUG MONIT, V38, P259, DOI 10.1097/FTD.0000000000000261
   Muus C, 2020, BIORXIV, DOI [10.1101/2020.04.19.049254, DOI 10.1101/2020.04.19.049254]
   Pawelek KA, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002588
   Perelson AS, 2012, J INFECT DIS, V205, P1642, DOI 10.1093/infdis/jis265
   Pizzorno A, 2020, BIORXIV, DOI [10.1101/2020.03.31.017889, DOI 10.1101/2020.03.31.017889]
   Smith AM, 2018, IMMUNOL REV, V285, P97, DOI 10.1111/imr.12692
   Smith PF, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14314
   Stafford MA, 2000, J THEOR BIOL, V203, P285, DOI 10.1006/jtbi.2000.1076
   Wang K, 2014, CLIN PHARMACOKINET, V53, P361, DOI 10.1007/s40262-013-0122-1
   Woelfel R., 2020, CLIN PRESENTATION VI, DOI [DOI 10.1101/2020.03.05.20030502, 10.1101/2020.03.05.20030502]
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 33
TC 6
Z9 6
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2163-8306
J9 CPT-PHARMACOMET SYST
JI CPT-PHARMACOMET. SYST. PHARMACOL.
PD SEP
PY 2020
VL 9
IS 9
BP 509
EP 514
DI 10.1002/psp4.12543
EA AUG 2020
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NP5EN
UT WOS:000556758400001
PM 32558354
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Maiti, S
   Banerjee, A
AF Maiti, Smarajit
   Banerjee, Amrita
TI Epigallocatechin gallate and theaflavin gallate interaction inSARS-CoV-2
   spike-protein central channel with reference to the hydroxychloroquine
   interaction: Bioinformatics and molecular docking study
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article; Early Access
DE ACE2; hydroxychloroquine; pandemic global outbreak; PatchDock;
   SARS-CoV-2 or COVID-19; spike glycoprotein; tea flavonoids
ID TEA CATECHIN; VIRUS; (-)-EPIGALLOCATECHIN-3-GALLATE; PREVENTION; QR-435
AB SARS-CoV-2 or COVID-19 pandemic global outbreak created the most unstable situation of human health-economy. In the past two decades different parts of the word experienced smaller or bigger outbreak related to human coronaviruses. The spike glycoproteins of the COVID-19 (similar to SARS-CoV) attach to the angiotensin-converting enzyme (ACE2) and transit over a stabilized open state for the viral internalization to the host cells and propagate with great efficacy. Higher rate of mutability makes this virus unpredictable/less sensitive to the protein/nucleic acid based drugs. In this emergent situation, drug-induced destabilization of spike binding to RBD could be a good strategy. In the current study we demonstrated by bioinformatics (CASTp: computed atlas of surface topography of protein, PyMol: molecular visualization) and molecular docking (PatchDock and Autodock) experiments that tea flavonoids catechin products mainly epigallocatechin gallate or other like theaflavin gallate demonstrated higher atomic contact energy (ACE) value, binding energy, Ki value, ligand efficiency, surface area and more amino acid interactions than hydroxychloroquine (HCQ) during binding in the central channel of the spike protein. Moreover, out of three distinct binding sites (I, II and III) of spike core when HCQ binds only with site III (farthest from the nCoV-RBD of ACE2 contact), epigallocatechin gallate and theaflavin gallate bind all three sites. As sites I and II are in closer contact with open state location and viral-host contact area, these drugs might have significant effects. Taking into account the toxicity/side effects by chloroquine/HCQ, present drugs may be important. Our laboratory is working on tea flavonoids and other phytochemicals in the protection from toxicity, DNA/mitochondrial damage, inflammation and so on. The present data might be helpful for further analysis of flavonoids in this emergent pandemic situation.
C1 [Maiti, Smarajit; Banerjee, Amrita] Oriental Inst Sci & Technol, Dept Biochem & Biotechnol, Cell & Mol Therapeut Lab, Midnapore, India.
   [Maiti, Smarajit] Agricure Biotech Res Soc, Epidemiol & Human Hlth Div, Midnapore, India.
RP Maiti, S (corresponding author), Oriental Inst Sci & Technol, Dept Biochem & Biotechnol, Cell & Mol Therapeut Lab, Midnapore, India.
EM maitism@rediffmail.com
FU Department of Science and Technology, Government of West Bengal,
   IndiaDepartment of Science & Technology (India)
FX This work was partially funded by Department of Science and Technology,
   Government of West Bengal, India.
CR Acharyya N, 2015, ENVIRON TOXICOL, V30, P1033, DOI 10.1002/tox.21977
   Acharyya N, 2014, J ENVIRON SCI HEAL C, V32, P338, DOI 10.1080/10590501.2014.967061
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Calland N, 2012, HEPATOLOGY, V55, P720, DOI 10.1002/hep.24803
   Ciesek S, 2011, HEPATOLOGY, V54, P1947, DOI 10.1002/hep.24610
   Colpitts CC, 2014, J VIROL, V88, P7806, DOI 10.1128/JVI.00896-14
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Duquerroy S, 2005, VIROLOGY, V335, P276, DOI 10.1016/j.virol.2005.02.022
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Furushima D, 2018, MOLECULES, V23, DOI 10.3390/molecules23071795
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giunta B, 2006, BRAIN RES, V1123, P216, DOI 10.1016/j.brainres.2006.09.057
   Hu B, 2012, CHEM COMMUN, V48, P2421, DOI 10.1039/c2cc17295j
   Huang HC, 2014, ANTIVIR RES, V111, P100, DOI 10.1016/j.antiviral.2014.09.009
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Kaihatsu K, 2018, MOLECULES, V23, DOI 10.3390/molecules23102475
   Li JR, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020176
   Li Shenwei, 2011, Antiviral Chemistry & Chemotherapy, V21, P239, DOI 10.3851/IMP1774
   Maiti Smarajit, 2017, Central Nervous System Agents in Medicinal Chemistry, V17, P187, DOI 10.2174/1871524917666170201145102
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   NAKANE H, 1990, BIOCHEMISTRY-US, V29, P2841, DOI 10.1021/bi00463a029
   Oxford John S, 2007, Am J Ther, V14, P462, DOI 10.1097/MJT.0b013e3180a7206e
   Oxford John S, 2007, Am J Ther, V14, P455, DOI 10.1097/MJT.0b013e3180a6f9c2
   Rismanbaf A, 2020, ARCH ACAD EMERG MED, V8
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weber C, 2015, ANTIVIR RES, V113, P1, DOI 10.1016/j.antiviral.2014.11.001
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yamada H, 2006, J ALTERN COMPLEM MED, V12, P669, DOI 10.1089/acm.2006.12.669
   Yazdany J, 2020, ANN INTERN MED, V172, P754, DOI 10.7326/M20-1334
   You HL, 2018, J CHIN MED ASSOC, V81, P458, DOI 10.1016/j.jcma.2017.11.007
   Zhao CJ, 2014, VIRUSES-BASEL, V6, P938, DOI 10.3390/v6020938
NR 36
TC 3
Z9 3
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
EI 1098-2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
DI 10.1002/ddr.21730
EA AUG 2020
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MV8IB
UT WOS:000556593300001
PM 32770567
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Schlegl, S
   Meule, A
   Favreau, M
   Voderholzer, U
AF Schlegl, Sandra
   Meule, Adrian
   Favreau, Matthias
   Voderholzer, Ulrich
TI Bulimia nervosa in times of theCOVID-19 pandemic-Results from an online
   survey of former inpatients
SO EUROPEAN EATING DISORDERS REVIEW
LA English
DT Article
DE bulimia nervosa; coping strategies; COVID-19 pandemic; health care
   utilisation; relapse; symptom deterioration
ID COGNITIVE-BEHAVIORAL THERAPY; COVID-19; TRIAL
AB Objective The COVID-19 pandemic might pose special challenges to patients with eating disorders (EDs) by interfering with daily routines. The aim of this study was to investigate the impact of the current pandemic on patients with bulimia nervosa (BN). Methods Fifty-five former inpatients with BN completed an online survey on psychological consequences of the COVID-19 pandemic as well as on changes in health care utilisation and on the use and helpfulness of different coping strategies. Results Almost half of patients (49%) reported a deterioration of their ED symptomatology and 62% reported a reduced quality of life. The frequency of binge eating increased in 47% of patients and self-induced vomiting in 36%. Forty-six percent of patients stated a noticeable impairment of psychotherapy. Face-to-face psychotherapy decreased by 56% but videoconferencing therapy was only used by 22% of patients. Enjoyable activities, virtual social contacts with friends and mild physical activities were rated as the most helpful coping strategies among those most used. Discussion Approximately one half to two-thirds of former inpatients with BN experienced a negative impact of the crisis on their ED symptomatology and quality of life. In challenging times when face-to-face therapy options are restricted, e-health treatments such as videoconferencing therapy should be considered to ensure continuity of care.
C1 [Schlegl, Sandra; Meule, Adrian; Voderholzer, Ulrich] Univ Hosp LMU, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany.
   [Meule, Adrian; Favreau, Matthias; Voderholzer, Ulrich] Schoen Clin Roseneck, Prien Am Chiemsee, Germany.
   [Voderholzer, Ulrich] Univ Hosp, Dept Psychiat & Psychotherapy, Freiburg, Germany.
RP Schlegl, S (corresponding author), Univ Hosp LMU, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany.
EM sandra.schlegl@med.uni-muenchen.de
RI Meule, Adrian/W-5150-2017
OI Meule, Adrian/0000-0002-6639-8977; Voderholzer Prof.,
   Ulrich/0000-0003-0261-3145
CR Aldao A, 2010, CLIN PSYCHOL REV, V30, P217, DOI 10.1016/j.cpr.2009.11.004
   Ammar A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061583
   Branley-Bell D., 2020, PSYARXIV, DOI [10.31234/osf.io/bdcwe, DOI 10.31234/OSF.I0/BDCWE]
   Dillman D. A., 2002, SURVEY NONRESPONSE, P3
   Fernandez-Aranda F, 2020, EUR EAT DISORD REV, V28, P239, DOI 10.1002/erv.2738
   Killgore WDS, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113117
   Li JF, 2020, WORLD PSYCHIATRY, V19, P249, DOI 10.1002/wps.20758
   Matheson BE, 2020, INT J EAT DISORDER, V53, P1142, DOI 10.1002/eat.23326
   Mitchell JE, 2008, BEHAV RES THER, V46, P581, DOI 10.1016/j.brat.2008.02.004
   Murphy R, 2020, COGN BEH THER, V13, DOI 10.1017/S1754470X20000161
   Phillipou A, 2020, INT J EAT DISORDER, V53, P1158, DOI 10.1002/eat.23317
   Sanchez-Ortiz VC, 2011, PSYCHOL MED, V41, P407, DOI 10.1017/S0033291710000711
   Schlegl S., EATING DISORDERS TIM
   Termorshuizen JD, 2020, INT J EAT DISORDER, V53, P1780, DOI 10.1002/eat.23353
   Todisco P, 2020, EAT WEIGHT DISORD-ST, DOI 10.1007/s40519-020-00938-z
   Touyz S, 2020, J EAT DISORD, V8, DOI 10.1186/s40337-020-00295-3
   Tregarthen JP, 2015, INT J EAT DISORDER, V48, P972, DOI 10.1002/eat.22386
   Waller G, 2020, INT J EAT DISORDER, V53, P1132, DOI 10.1002/eat.23289
   Weissman RS, 2020, INT J EAT DISORDER, V53, P369, DOI 10.1002/eat.23279
NR 19
TC 0
Z9 0
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1072-4133
EI 1099-0968
J9 EUR EAT DISORD REV
JI Eur. Eat. Disord. Rev.
PD NOV
PY 2020
VL 28
IS 6
BP 847
EP 854
DI 10.1002/erv.2773
EA AUG 2020
PG 8
WC Psychology, Clinical
SC Psychology
GA OI3VE
UT WOS:000556530200001
PM 32767858
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ratnasekera, N
   Perera, I
   Kandapolaarachchige, P
   Surendra, G
   Dantanarayana, A
AF Ratnasekera, Nadisha
   Perera, Irosha
   Kandapolaarachchige, Pushpakumara
   Surendra, Gayan
   Dantanarayana, Ajith
TI Supportive care for oral cancer survivors in COVID-19 lockdown
SO PSYCHO-ONCOLOGY
LA English
DT Article
DE COVID-19 lockdown; mindfulness therapy; nutrition; oral cancer
   survivors; over-the-phone; psycho-oncology; Sri Lanka intervention;
   supportive care
AB Objective Availability and accessibility to routine health care services for cancer patients were a cause of concern during the COVID-19 pandemic, which induced stringent enforcement of lockdown and social distancing in Sri Lanka. Oral cancer patients who have undergone surgery recently encountered problems such as pain, difficulty in swallowing. However, accessing routine treatment and obtaining medication emerged as the most pressing concerns among them. Therefore, we aimed to provide supportive care for affected oral cancer patients. Methods A rapid situational analysis was conducted among 25-randomly selected oral cancer patients of an ongoing interventional study aimed at improving life situation of oral cancer patients. Results Over-the-phone supportive care tailored to the needs of oral cancer patients, provided by a health professional, deemed a simple but helpful intervention. Conclusions Facilitating patients to navigate the health care system to ensure that they can continue in receiving timely treatment was the most critical aspect of the intervention. Interventions tailored to patients' needs could offer better supportive care for cancer patients in COVID-19 pandemic scenario.
C1 [Ratnasekera, Nadisha; Perera, Irosha] Natl Dent Hosp Teaching Sri Lanka, Prevent Oral Hlth Unit, Ward Pl, Colombo 7, Sri Lanka.
   [Kandapolaarachchige, Pushpakumara] Apeksha Hosp, Natl Canc Inst Sri Lanka, Psychiat Unit, Maharagama, Sri Lanka.
   [Surendra, Gayan; Dantanarayana, Ajith] Natl Dent Hosp Teaching Sri Lanka, Off Director, Colombo, Sri Lanka.
RP Perera, I (corresponding author), Natl Dent Hosp Teaching Sri Lanka, Prevent Oral Hlth Unit, Ward Pl, Colombo 7, Sri Lanka.
EM irosha_rukmali@yahoo.com
CR [Anonymous], 2014, CANC INC DAT SRI LAN
   [Anonymous], 2018, CANC INC DAT SRI LAN
   Goswami S, 2019, INDIAN J PALLIAT CAR, V25, P103, DOI 10.4103/IJPC.IJPC_118_18
   Gunasekera S, 2018, J Cancer Policy, V18, P20, DOI 10.1016/j.jcpo.2018.10.001
   Perera IR, 2018, BRIT J ORAL MAX SURG, V56, P901, DOI 10.1016/j.bjoms.2018.09.015
   Schell LK, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011518.pub2
   Semple C, 2011, COCHRANE DB SYST REV, V16
   Semple CJ, 2004, CANCER NURS, V27, P434
   Smith O., 2018, UNIVERSAL HLTH COVER, V38
   Turner J, 2009, EUR J CANCER, V45, P1798, DOI 10.1016/j.ejca.2009.02.023
NR 10
TC 2
Z9 2
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD SEP
PY 2020
VL 29
IS 9
SI SI
BP 1409
EP 1411
DI 10.1002/pon.5463
EA AUG 2020
PG 3
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
   Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA NL5YW
UT WOS:000556732000001
PM 32779826
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tedeschi, D
   Rizzi, A
   Biscaglia, S
   Tumscitz, C
AF Tedeschi, Delio
   Rizzi, Andrea
   Biscaglia, Simone
   Tumscitz, Carlo
TI Acute myocardial infarction and large coronary thrombosis in a patient
   with COVID-19
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Article; Early Access
DE acute myocardial infarction; coronary thrombosis; COVID-19; primary PCI
ID ACUTE INFECTION; RISK
AB This is a case report of a 60-year-old male, without any cardiovascular risk factor and no cardiac history admitted to hospital with a diagnosis of interstitial pneumonia caused by coronavirus disease 2019 (COVID-19). After 7 days, the blood tests showed a significant rise of inflammatory and procoagulant markers, along with a relevant elevation of high-sensitivity Troponin I. Electrocardiogram and transthoracic echocardiogram (TTE) were consistent with a diagnosis of infero-posterolateral acute myocardial infarction and the patient was transferred to the isolated Cath Lab for primary percutaneous coronary intervention (PCI). The angiography showed an acute massive thrombosis of a dominant right coronary artery without clear evidence of atherosclerosis. Despite the optimal pharmacological therapies and different PCI techniques, the final TIMI flow was 0/1 and after 3 hr the clinical condition evolved in cardiac arrest for pulseless electric activity. Acute coronary syndrome-ST-elevation myocardial infarction is a relevant complication of COVID-19. Due to high levels of proinflammatory mediators, diffuse coronary thrombosis could occur even in patients without cardiac history or comorbidities. This clinical case suggests that coronary thrombosis in COVID-19 patients may be unresponsive to optimal pharmacological (GP IIb-IIIa infusion) and mechanical treatment (PCI).
C1 [Tedeschi, Delio; Rizzi, Andrea] Ist Clin S Anna, Intervent Cardiol, Brescia, Italy.
   [Biscaglia, Simone; Tumscitz, Carlo] St Anna Univ Hosp, Cardiol Unit, Ferrara, Italy.
RP Tedeschi, D (corresponding author), Ist Osped Bresciani, Grp San Donato, Ist Clin S Anna Brescia, Intervent Cardiol, Brescia, Italy.
EM deliotds@yahoo.it
RI Tedeschi, Delio/AAX-1380-2020
OI Tedeschi, Delio/0000-0002-1957-7606
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Corrales-Medina VF, 2010, LANCET INFECT DIS, V10, P83, DOI 10.1016/S1473-3099(09)70331-7
   Farooq V, 2016, EUROINTERVENTION, V11, pE1639, DOI 10.4244/EIJV11I14A315
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Warren-Gash C, 2012, J INFECT DIS, V206, P1652, DOI 10.1093/infdis/jis597
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 14
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
EI 1522-726X
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
DI 10.1002/ccd.29179
EA AUG 2020
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MV4UF
UT WOS:000556354400001
PM 32767631
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Qi, XX
   Ke, BX
   Feng, Q
   Yang, DY
   Lian, QH
   Li, ZB
   Lu, LL
   Ke, CW
   Liu, ZQ
   Liao, GC
AF Qi, Xiaoxiao
   Ke, Bixia
   Feng, Qian
   Yang, Deying
   Lian, Qinghai
   Li, Zibo
   Lu, Linlin
   Ke, Changwen
   Liu, Zhongqiu
   Liao, Guochao
TI Construction and immunogenic studies of a mFc fusion receptor binding
   domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2
   infection
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID TUBERCULOSIS VACCINE; SARS-COV; CORONAVIRUS
AB Herein, we report that a recombinant fusion protein, containing a 457 amino acid SARS-CoV-2 receptor binding domain (RBD, residues 319-541) and a mouse IgG1 Fc domain, could induce highly potent neutralizing antibodies and stimulate humoral and cellular immunity in mice. The antibodies also effectively suppressed SARS-CoV-2 RBD binding to soluble ACE2, indicating that RBD-mFc may be further developed as a safe and effective SARS-CoV-2 vaccine.
C1 [Qi, Xiaoxiao; Feng, Qian; Yang, Deying; Lian, Qinghai; Li, Zibo; Lu, Linlin; Liu, Zhongqiu; Liao, Guochao] Guangzhou Univ Chinese Med, Joint Lab Translat Canc Res Chinese Med, Minist Educ Peoples Republ China, Int Inst Translat Chinese Med, Guangzhou 510006, Peoples R China.
   [Ke, Bixia; Ke, Changwen] Guangdong Prov Ctr Dis Control & Prevent, Guangzhou 510006, Peoples R China.
   [Liu, Zhongqiu] Guangzhou Univ Chinese Med, Shunde Hosp, Shunde 510000, Guangdong, Peoples R China.
RP Liu, ZQ; Liao, GC (corresponding author), Guangzhou Univ Chinese Med, Joint Lab Translat Canc Res Chinese Med, Minist Educ Peoples Republ China, Int Inst Translat Chinese Med, Guangzhou 510006, Peoples R China.; Ke, CW (corresponding author), Guangdong Prov Ctr Dis Control & Prevent, Guangzhou 510006, Peoples R China.; Liu, ZQ (corresponding author), Guangzhou Univ Chinese Med, Shunde Hosp, Shunde 510000, Guangdong, Peoples R China.
EM kecw1965@aliyun.com; liuzq@gzucm.edu.cn; liao@gzucm.edu.cn
FU Guangdong Province Universities and Colleges Pearl River Scholar Funded
   Scheme; National Natural Science Foundation of ChinaNational Natural
   Science Foundation of China (NSFC) [81773580]; Department of Science and
   Technology of Guangdong Province, China [2020111107001]; Department of
   Education of Guangdong Province, ChinaNational Natural Science
   Foundation of Guangdong Province [2020KZDZX1057]; Guangdong Key
   Laboratory for Translational Cancer Research of Chinese Medicine
   [2018B030322011]
FX We acknowledge the Guangdong Province Universities and Colleges Pearl
   River Scholar Funded Scheme (Guochao Liao, 2019), the National Natural
   Science Foundation of China (No. 81773580), the Department of Science
   and Technology of Guangdong Province, China (No. 2020111107001), the
   Department of Education of Guangdong Province, China (No.
   2020KZDZX1057), and the Guangdong Key Laboratory for Translational
   Cancer Research of Chinese Medicine (No. 2018B030322011) for offering
   financial support for this work.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Baghani AA, 2017, IRAN J BASIC MED SCI, V20, P122, DOI 10.22038/ijbms.2017.8231
   Bastola R, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-018-1245-3
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Czajkowsky DM, 2012, EMBO MOL MED, V4, P1015, DOI 10.1002/emmm.201201379
   di Mauro G., 2020, INT IMMUNOPHARMACOL, V84, P106519
   Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   He YX, 2006, J IMMUNOL, V176, P6085, DOI 10.4049/jimmunol.176.10.6085
   Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605
   Jamehdar SA, 2019, BIOENGINEERED, V10, P689, DOI 10.1080/21655979.2019.1694388
   Kim E, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102743
   Lan JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112602
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Liao GC, 2015, CHEM COMMUN, V51, P9647, DOI 10.1039/c5cc01794g
   Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Soleimanpour S, 2015, APPL MICROBIOL BIOT, V99, P10467, DOI 10.1007/s00253-015-6952-z
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Ura T, 2014, VACCINES, V2, P624, DOI 10.3390/vaccines2030624
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Zakhartchouk AN, 2007, VACCINE, V25, P136, DOI 10.1016/j.vaccine.2006.06.084
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 26
TC 2
Z9 2
U1 14
U2 14
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PD AUG 7
PY 2020
VL 56
IS 61
BP 8683
EP 8686
DI 10.1039/d0cc03263h
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA MS6MF
UT WOS:000554386800025
PM 32613971
DA 2021-01-01
ER

PT J
AU Liu, AL
   Xu, N
   Li, AJ
AF Liu, Ai-Ling
   Xu, Ning
   Li, Ai-Jun
TI COVID-19 with asthma: A case report
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE COVID-19; Asthma; Glucocorticoids; Respiratory passage mucosa immune
   system; Case report
ID WUHAN; OUTCOMES; CHINA; SARS
AB BACKGROUND Coronavirus disease 2019 (COVID-19) is a public health emergency of international concern. The global population lacks immunity to COVID-19 and is generally susceptible. Underlying conditions, especially chronic respiratory diseases, may affect progression, treatment and prognosis of COVID-19.
   CASE SUMMARY We report a patient with confirmed COVID-19 combined with asthma. It took 41 d from disease onset to discharge to obtain two negative tests for this coronavirus.
   CONCLUSION This case indicates the dynamic clinical characteristics, laboratory and computed tomography findings and adjustment of treatment, and the possible relationship between glucocorticoid therapy and coronavirus clearance.
C1 [Liu, Ai-Ling; Xu, Ning; Li, Ai-Jun] Shandong Univ, Dept Pulm & Crit Care Med, Weihai Municipal Hosp, 70 Heping Rd, Weihai 264200, Shandong, Peoples R China.
RP Liu, AL (corresponding author), Shandong Univ, Dept Pulm & Crit Care Med, Weihai Municipal Hosp, 70 Heping Rd, Weihai 264200, Shandong, Peoples R China.
EM liuailing0730@163.com
OI Liu, Ailing/0000-0002-4848-8426
CR Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Del Donno M, 2000, CHEST, V118, P1142, DOI 10.1378/chest.118.4.1142
   Fukushima C, 2005, J ASTHMA, V42, P601, DOI 10.1080/02770900500216259
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lusuardi M, 2002, EUR RESPIR J, V19, P785, DOI 10.1183/09031936.02.00303902
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Paules C.I., 2020, JAMA
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Prosperini G, 2002, J ALLERGY CLIN IMMUN, V110, P855, DOI 10.1067/mai.2002.130050
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Stellato C, 2007, J ALLERGY CLIN IMMUN, V120, P1247, DOI 10.1016/j.jaci.2007.10.041
   Stern A, 2017, COCHRANE DB SYST REV, V12, pCD007720, DOI DOI 10.1002/14651858.CD007720.PUB3
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, COR DIS COVID 19 OUT
   Wuhan Municipal Health Commission, 2020, REP NOV COR INF PNEU
   Wuhan Municipal Health Commission, 2019, REP CLUST RING PNEUM
NR 25
TC 0
Z9 0
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD AUG 6
PY 2020
VL 8
IS 15
BP 3355
EP U263
DI 10.12998/wjcc.v8.i15.3355
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA NZ4QD
UT WOS:000577079200026
PM 32874993
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ding, L
   She, QR
   Chen, FX
   Chen, ZT
   Jiang, MF
   Huang, HS
   Li, YJ
   Liao, CF
AF Ding, Liang
   She, Qiuru
   Chen, Fengxian
   Chen, Zitong
   Jiang, Meifang
   Huang, Huasi
   Li, Yujin
   Liao, Chaofeng
TI The Internet Hospital Plus Drug Delivery Platform for Health Management
   During the COVID-19 Pandemic: Observational Study
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE internet hospital; drug delivery; internet hospital plus drug delivery;
   IHDD; health management; COVID-19
AB Background: Widespread access to the internet has boosted the emergence of online hospitals. A new outpatient service called "internet hospital plus drug delivery" (IHDD) has been developed in China, but little is known about this platform.
   Objective: The aim of this study is to investigate the characteristics, acceptance, and initial impact of IHDD during the outbreak of COVID-19 in a tertiary hospital in South China
   Methods: The total number of and detailed information on online prescriptions during the first 2 months after work resumption were obtained. Patients' gender, age, residence, associated prescription department, time of prescription, payment, and drug delivery region were included in the analysis.
   Results: A total of 1380 prescriptions were picked up or delivered between March 2 and April 20, 2020. The largest group of patients were 36-59 years old (n=680, 49.3%), followed by the 18-35 years age category (n=573, 41.5%). In total, 39.4% (n=544) of the patients chose to get their medicine by self-pickup, while 60.6% (n=836) preferred to receive their medicine via drug delivery service. The top five online prescription departments were infectious diseases (n=572, 41.4%), nephrology (n=264, 19.1%), endocrinology (n=145, 10.5%), angiocardiopathy (n=107, 7.8%), and neurology (n=42, 3%). Of the 836 delivered prescriptions, 440 (52.6%) were sent to Guangdong Province (including 363 [43.4%] to Shenzhen), and 396 (47.4%) were sent to other provinces in China.
   Conclusions: The IHDD platform is efficient and convenient for various types of patients during the COVID-19 crisis. Although offline visits are essential for patients with severe conditions, IHDD can help to relieve pressure on hospitals by reducing an influx of patients with mild symptoms. Further efforts need to be made to improve the quality and acceptance of IHDD, as well as to regulate and standardize the management of this novel service.
C1 [Ding, Liang] Peoples Hosp Baoan Shenzhen, Clin Trial & Res Ctr, Shenzhen, Peoples R China.
   [She, Qiuru; Chen, Fengxian; Chen, Zitong; Jiang, Meifang; Huang, Huasi; Li, Yujin; Liao, Chaofeng] Peoples Hosp Baoan Shenzhen, Dept Pharm, 118 Longjing 2nd Rd, Shenzhen 518101, Peoples R China.
RP Liao, CF (corresponding author), Peoples Hosp Baoan Shenzhen, Dept Pharm, 118 Longjing 2nd Rd, Shenzhen 518101, Peoples R China.
EM bayylcf@126.com
OI chen, zitong/0000-0003-3467-7311
FU Key Laboratory of Emergency and Trauma (Hainan Medical University);
   Ministry of Education [KLET-201908]; eScience, Technology and Innovation
   Commission of Shenzhen Municipality [731144920168]
FX This research was supported in part by the Key Laboratory of Emergency
   and Trauma (Hainan Medical University), the Ministry of Education
   (KLET-201908), and th eScience, Technology and Innovation Commission of
   Shenzhen Municipality (731144920168). We gratefully acknowledge the help
   of the Information Technology Center, People's Hospital of Baoan
   Shenzhen. We also thank Mr Zhiyong Zhang for assistance with data
   collection.
CR [Anonymous], WORK DYN
   [Anonymous], 2020, NOT ACC ONL CONS SER
   [Anonymous], 2020, SPEC ONL CONS SERV I
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Brooks J, 2020, J MATERN-FETAL NEO M, DOI [10.1080/14767058.2020.1827384, 10.1111/jocn.15274]
   Gong K, 2020, J MED INTERNET RES, V22, DOI 10.2196/18908
   Hong Z, 2020, J MED INTERNET RES, V22, DOI 10.2196/19577
   Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1036
   Public Health, 2020, PUBL HLTH
   Shahid Z, 2020, J AM GERIATR SOC, V68, P926, DOI 10.1111/jgs.16472
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Tang M, 2019, DRUG DISCOV THER, V13, P365, DOI 10.5582/ddt.2019.01093
   Tanne JH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1090
   Tu J, 2015, LANCET GLOB HEALTH, V3, pE445, DOI 10.1016/S2214-109X(15)00042-X
   Whitehead L, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.4883
   Wu D, 2019, B WORLD HEALTH ORGAN, V97, P578, DOI 10.2471/BLT.18.226936
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xie XX, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7854
   Yip WCM, 2010, LANCET, V375, P1120, DOI 10.1016/S0140-6736(10)60063-3
NR 19
TC 0
Z9 0
U1 1
U2 1
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD AUG 6
PY 2020
VL 22
IS 8
AR e19678
DI 10.2196/19678
PG 9
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA NW5MG
UT WOS:000575055400004
PM 32716892
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Funk, CD
   Ardakani, A
AF Funk, Colin D.
   Ardakani, Ali
TI A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19
   by Targeting Leukotrienes
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; leukotrienes; cytokine storm; coronavirus;
   inflammatory response; vascular leak; clinical trial
ID CYSTEINYL-LEUKOTRIENES; VASCULAR-PERMEABILITY; RECEPTOR BLT1;
   5-LIPOXYGENASE; INJURY; BIOSYNTHESIS; MONTELUKAST; IMMUNE; MICE;
   INHIBITION
AB SARS-CoV-2 causing coronavirus disease 2019 (COVID-19) has wreaked havoc during the global pandemic of 2020 infecting millions and leaving over a half million dead. As a new virus, not previously in the human population, but with similarities to other coronaviruses causing severe acute respiratory distress syndrome (SARS/ARDS), and no known treatments, the race to re-purpose existing drugs and to enlist novel therapeutics is underway. In the half-year since the first cases, we have acquired substantial knowledge of this virus and the clinical course of COVID-19 progression. Results from early clinical trials have revealed two treatments (remdesivir, dexamethasone) that mitigate disease progression but clearly, there is much room for improvement. Initial case reports indicated many succumb to COVID-19 of hypoxic respiratory failure due to ARDS. However, ensuing studies revealed an atypical, immune cell-sequestered, vasculature-inflamed state leading to multiorgan thrombotic complications and end organ failure likely due to hyperinflammatory host responses. This Perspective focuses on a potential mechanism for a key COVID-19 disease progression turning point related to vascular and airway inflammation. The leukotriene lipid mediators have been overlooked with discussion centering on cytokine storms unleashing the deadly form of COVID-19. Leukotrienes possess some of the most potent known activities on immune cell trafficking and vascular leakage. We offer a simple treatment paradigm using two generic drugs targeting the hyperinflammatory response that characterizes the turning point from mild to severe/critical COVID-19 by targeting leukotriene biosynthesis with zileuton (Zyflo(R)controlled release formulation) and antagonism of the cysteinyl leukotriene 1 receptor with montelukast (Singulair(R)).
C1 [Funk, Colin D.] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada.
   [Funk, Colin D.; Ardakani, Ali] Novateur Ventures Inc, Sci Res Div, Vancouver, BC, Canada.
RP Funk, CD (corresponding author), Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada.; Funk, CD (corresponding author), Novateur Ventures Inc, Sci Res Div, Vancouver, BC, Canada.
EM funkc@queensu.ca
FU Novateur Ventures, Inc.
FX This research was funded by Novateur Ventures, Inc.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Almerie MQ, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109883
   Alunno A, 2020, RMD OPEN, V6, DOI 10.1136/rmdopen-2020-001295
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Berlin David A, 2020, N Engl J Med, V383, P2451, DOI 10.1056/NEJMcp2009575
   BERNARD GR, 1991, AM REV RESPIR DIS, V144, P263, DOI 10.1164/ajrccm/144.2.263
   BISGAARD H, 1986, ALLERGY, V41, P365, DOI 10.1111/j.1398-9995.1986.tb00314.x
   Bouchette D., 2020, STATPEARLS
   Bozek A, 2020, J ASTHMA, DOI 10.1080/02770903.2020.1786112
   Capra V, 2006, CURR MED CHEM, V13, P3213, DOI 10.2174/092986706778742963
   Capra V, 2007, MED RES REV, V27, P469, DOI 10.1002/med.20071
   Capra V, 2015, PROSTAG OTH LIPID M, V120, P115, DOI 10.1016/j.prostaglandins.2015.03.007
   Casanova JL, 2020, CELL, V181, P1194, DOI 10.1016/j.cell.2020.05.016
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Collin M, 2004, J LEUKOCYTE BIOL, V76, P961, DOI 10.1189/jlb.0604338
   DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887
   DAVIS JM, 1990, SURG GYNECOL OBSTET, V170, P495
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   England James T, 2020, Blood Rev, P100707, DOI 10.1016/j.blre.2020.100707
   Fidan C, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109828
   Flamand N, 2007, CELL MOL LIFE SCI, V64, P2657, DOI 10.1007/s00018-007-7228-2
   FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0
   Funk CD, 2005, NAT REV DRUG DISCOV, V4, P664, DOI 10.1038/nrd1796
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Funk CD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00937
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191, DOI 10.1139/y95-028
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503
   Khodir AE, 2014, CAN J PHYSIOL PHARM, V92, P839, DOI 10.1139/cjpp-2014-0191
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Lee KS, 2004, J ALLERGY CLIN IMMUN, V114, P1093, DOI 10.1016/j.jaci.2004.07.039
   Li SH, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138070
   Liu Y, 2020, NATURE, V582, P557, DOI 10.1038/s41586-020-2271-3
   Maeba S, 2005, ANN ALLERG ASTHMA IM, V94, P670, DOI 10.1016/S1081-1206(10)61326-9
   Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   MAHASE E, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2512
   Mallapaty S, 2020, NATURE, V583, P16, DOI 10.1038/d41586-020-01891-8
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monteiro APT, 2014, AM J RESP CELL MOL, V50, P87, DOI 10.1165/rcmb.2012-0525OC
   Moos MPW, 2008, FASEB J, V22, P4352, DOI 10.1096/fj.08-113274
   Murphy RC, 2005, ANAL BIOCHEM, V346, P1, DOI 10.1016/j.ab.2005.04.042
   Oberfeld B, 2020, CELL, V181, P954, DOI 10.1016/j.cell.2020.04.013
   Pace S, 2017, J CLIN INVEST, V127, P3167, DOI 10.1172/JCI92885
   Panigrahy D, 2020, CANCER METAST REV, V39, P337, DOI 10.1007/s10555-020-09889-4
   Pergola C, 2008, P NATL ACAD SCI USA, V105, P19881, DOI 10.1073/pnas.0809120105
   Peters-Golden M, 2005, J IMMUNOL, V174, P589, DOI 10.4049/jimmunol.174.2.589
   Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   RUBIN P, 1991, AGENT ACTION SUPPL, V35, P103
   Sadik CD, 2012, J LEUKOCYTE BIOL, V91, P207, DOI 10.1189/jlb.0811402
   SALA A, 1991, PROSTAG OTH LIPID M, V42, P1, DOI 10.1016/0090-6980(91)90088-W
   SALA A, 1990, J BIOL CHEM, V265, P21771
   SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055
   Sardu C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051417
   Sasaki F, 2019, INT IMMUNOL, V31, P607, DOI 10.1093/intimm/dxz044
   Secor WE, 1998, PROSTAG OTH LIPID M, V56, P291, DOI 10.1016/S0090-6980(98)00059-8
   SPRAGUE RS, 1989, CRIT CARE CLIN, V5, P315
   Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970
   Tahan F, 2008, CLIN EXP ALLERGY, V38, P805, DOI 10.1111/j.1365-2222.2008.02963.x
   Taube C, 2006, J IMMUNOL, V176, P3157, DOI 10.4049/jimmunol.176.5.3157
   Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vetter P, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1470
   Viner RM, 2020, LANCET, V395, P1741, DOI 10.1016/S0140-6736(20)31129-6
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wermuth H. R., 2020, STATPEARLS
   Werz O, 2006, PHARMACOL THERAPEUT, V112, P701, DOI 10.1016/j.pharmthera.2006.05.009
   WESTCOTT JY, 1991, PROSTAG LEUKOTR ESS, V43, P151, DOI 10.1016/0952-3278(91)90162-X
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yao XL, 1999, J BIOL CHEM, V274, P17202, DOI 10.1074/jbc.274.24.17202
   Zhang XN, 2020, NATURE, V583, P437, DOI 10.1038/s41586-020-2355-0
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 79
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 6
PY 2020
VL 11
AR 1214
DI 10.3389/fphar.2020.01214
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NF7OQ
UT WOS:000563484200001
PM 32848802
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Paolisso, P
   Bergamaschi, L
   D'Angelo, EC
   Donati, F
   Giannella, M
   Tedeschi, S
   Pascale, R
   Bartoletti, M
   Tesini, G
   Biffi, M
   Cosmi, B
   Pizzi, C
   Viale, P
   Galie, N
AF Paolisso, Pasquale
   Bergamaschi, Luca
   D'Angelo, Emanuela Concetta
   Donati, Francesco
   Giannella, Maddalena
   Tedeschi, Sara
   Pascale, Renato
   Bartoletti, Michele
   Tesini, Giulia
   Biffi, Mauro
   Cosmi, Benilde
   Pizzi, Carmine
   Viale, Pierluigi
   Galie, Nazzareno
TI Preliminary Experience With Low Molecular Weight Heparin Strategy in
   COVID-19 Patients
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID; 19; heparin; LMWH (low molecular weight heparin); in-hospital
   mortality; DVT prophylaxis
AB Background Heparin administration in COVID-19 patients is recommended by expert consensus, although evidence about dosage, duration and efficacy are limited. We aim to investigate the association between different dosages of low molecular weight heparin (LMWH) and mortality among COVID-19 hospitalized patients. Methods and Results Retrospective study of 450 laboratory-confirmed COVID-19 patients admitted to Sant'Orsola Bologna Hospital from March 01 to April 10, 2020. Clinical, laboratory and treatment data were collected and analyzed. The in-hospital mortality between COVID-19 patients treated with standard prophylactic LMWH dosage vs. intermediate LMWH dosage was compared. Out of 450 patients, 361 received standard deep vein thrombosis (DVT) prophylaxis enoxaparin treatment (40-60mg daily) and 89 patients received intermediate enoxaparin dosage (40-60 mg twice daily) for 7 days. No significant differences in the main demographic characteristics and laboratory testings at admission were observed in the two heparin regimen subgroups, except for older age and prevalence of hypertension in the group treated with "standard" prophylaxis LMWH dosage. The intermediate LMWH administration was associated with a lower in-hospital all-cause mortality compared to the "standard" prophylactic LMWH dosage (18.8% vs. 5.8%, p = 0.02). This difference remained significant after adjustment with the propensity score for variables that differed significantly between the dosage groups (OR= 0.260, 95% CI 0.089-0.758, p=0.014). Conclusions Intermediate LMWH dosage seems to be associated with lower incidence of mortality compared to standard DVT prophylaxys in hospitalized COVID-19 patients. Our study paves the way to further pathophysiological investigations and controlled studies of anticoagulation therapy in Covid-19 disease.
C1 [Paolisso, Pasquale; Bergamaschi, Luca; D'Angelo, Emanuela Concetta; Donati, Francesco; Biffi, Mauro; Pizzi, Carmine; Galie, Nazzareno] Univ Bologna, Dept Expt Diagnost & Specially Med DIMES, Unit Cardiol, Bologna, Italy.
   [Giannella, Maddalena; Tedeschi, Sara; Pascale, Renato; Bartoletti, Michele; Tesini, Giulia; Viale, Pierluigi] Univ Bologna, S Orsola Hosp, Dept Med & Surg Sci, Unit Infect Dis, Bologna, Italy.
   [Cosmi, Benilde] S Orsola Malpighi Univ Hosp, Unit Angiol & Blood Coagulat, Bologna, Italy.
RP Pizzi, C (corresponding author), Univ Bologna, Dept Expt Diagnost & Specially Med DIMES, Unit Cardiol, Bologna, Italy.
EM carmine.pizzi@unibo.it
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Deshpande C, 2020, ANN INTERN MED, V173, P394, DOI 10.7326/M20-3255
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI13530
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   MCGUIRE WW, 1982, J CLIN INVEST, V69, P543, DOI 10.1172/JCI110480
   D'Atri LP, 2017, FRONT BIOSCI-LANDMRK, V22, P1867, DOI 10.2741/4576
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Spyropoulos AC, 2020, J THROMB HAEMOST, V18, P1859, DOI 10.1111/jth.14929
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 18
TC 1
Z9 1
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 6
PY 2020
VL 11
AR 1124
DI 10.3389/fphar.2020.01124
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NF7PH
UT WOS:000563485900001
PM 32848743
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alghamdi, AN
   Abdel-Moneim, AS
AF Alghamdi, Ahmed N.
   Abdel-Moneim, Ahmed S.
TI Convalescent Plasma: A Potential Life-Saving Therapy for Coronavirus
   Disease 2019 (COVID-19)
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus; plasma therapy; immunetherapy
C1 [Alghamdi, Ahmed N.; Abdel-Moneim, Ahmed S.] Taif Univ, Microbiol Dept, Coll Med, Al Taif, Saudi Arabia.
   [Abdel-Moneim, Ahmed S.] Beni Suef Univ, Fac Vet Med, Virol Dept, Bani Suwayf, Egypt.
RP Abdel-Moneim, AS (corresponding author), Taif Univ, Microbiol Dept, Coll Med, Al Taif, Saudi Arabia.; Abdel-Moneim, AS (corresponding author), Beni Suef Univ, Fac Vet Med, Virol Dept, Bani Suwayf, Egypt.
EM asa@tu.edu.sa
RI Abdel-Moneim, Ahmed S./G-7445-2012
OI Abdel-Moneim, Ahmed S./0000-0002-3148-6782
CR Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Lee JH, 2010, J KOREAN MED SCI, V25, P1398, DOI 10.3346/jkms.2010.25.9.1398
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   Us-Nih. ClinicalTrials.gov, 2020, SARS COV 2 CONV PLAS
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
NR 16
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD AUG 6
PY 2020
VL 8
AR 437
DI 10.3389/fpubh.2020.00437
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NF6XQ
UT WOS:000563439600001
PM 32903641
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Guo, C
   Li, B
   Ma, H
   Wang, XF
   Cai, PF
   Yu, QN
   Zhu, L
   Jin, LY
   Jiang, C
   Fang, JW
   Liu, Q
   Zong, DD
   Zhang, W
   Lu, YC
   Li, K
   Gao, XY
   Fu, BQ
   Liu, LX
   Ma, XL
   Weng, JP
   Wei, HM
   Jin, TC
   Lin, J
   Qu, K
AF Guo, Chuang
   Li, Bin
   Ma, Huan
   Wang, Xiaofang
   Cai, Pengfei
   Yu, Qiaoni
   Zhu, Lin
   Jin, Liying
   Jiang, Chen
   Fang, Jingwen
   Liu, Qian
   Zong, Dandan
   Zhang, Wen
   Lu, Yichen
   Li, Kun
   Gao, Xuyuan
   Fu, Binqing
   Liu, Lianxin
   Ma, Xiaoling
   Weng, Jianping
   Wei, Haiming
   Jin, Tengchuan
   Lin, Jun
   Qu, Kun
TI Single-cell analysis of two severe COVID-19 patients reveals a
   monocyte-associated and tocilizumab-responding cytokine storm
SO NATURE COMMUNICATIONS
LA English
DT Article
AB Several studies show that the immunosuppressive drugs targeting the interleukin-6 (IL-6) receptor, including tocilizumab, ameliorate lethal inflammatory responses in COVID-19 patients infected with SARS-CoV-2. Here, by employing single-cell analysis of the immune cell composition of two severe-stage COVID-19 patients prior to and following tocilizumab-induced remission, we identify a monocyte subpopulation that contributes to the inflammatory cytokine storms. Furthermore, although tocilizumab treatment attenuates the inflammation, immune cells, including plasma B cells and CD8(+) T cells, still exhibit robust humoral and cellular antiviral immune responses. Thus, in addition to providing a high-dimensional dataset on the immune cell distribution at multiple stages of the COVID-19, our work also provides insights into the therapeutic effects of tocilizumab, and identifies potential target cell populations for treating COVID-19-related cytokine storms. Tocilizumab has been used to treat the excessive inflammatory responses in COVID-19 patients. Here, the authors use single-cell RNA sequencing results from two severe COIVD-19 patients to provide high-dimensional immune profiling data, and to implicate potential cellular and molecular insights for the therapeutic effects of tocilizumab.
C1 [Guo, Chuang; Li, Bin; Ma, Huan; Cai, Pengfei; Yu, Qiaoni; Zhu, Lin; Jin, Liying; Jiang, Chen; Liu, Qian; Zong, Dandan; Zhang, Wen; Lu, Yichen; Li, Kun; Gao, Xuyuan; Fu, Binqing; Wei, Haiming; Jin, Tengchuan; Lin, Jun; Qu, Kun] Univ Sci & Technol China, Affiliated Hosp USTC 1, Sch Basic Med Sci,Div Life Sci & Med, Dept Oncol,Div Mol Med,Hefei Natl Lab Phys Sci &, Hefei 230021, Anhui, Peoples R China.
   [Wang, Xiaofang; Liu, Lianxin] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Hepatobiliary Surg, Div Life Sci & Med, Hefei 230021, Anhui, Peoples R China.
   [Fang, Jingwen] Xiaoshan Innovat Polis, HanGene Biotech, Hangzhou 31200, Zhejiang, Peoples R China.
   [Fu, Binqing; Wei, Haiming; Jin, Tengchuan; Lin, Jun; Qu, Kun] Univ Sci & Technol China, CAS Ctr Excellence Mol Cell Sci, CAS Key Lab Innate Immun & Chron Dis, Hefei 230027, Anhui, Peoples R China.
   [Ma, Xiaoling] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Lab Med, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China.
   [Weng, Jianping] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Endocrinol & Metab, Div Life Sci Med, Hefei 230026, Peoples R China.
   [Qu, Kun] Univ Sci & Technol China, Sch Data Sci, Hefei 230026, Peoples R China.
RP Jin, TC; Lin, J; Qu, K (corresponding author), Univ Sci & Technol China, Affiliated Hosp USTC 1, Sch Basic Med Sci,Div Life Sci & Med, Dept Oncol,Div Mol Med,Hefei Natl Lab Phys Sci &, Hefei 230021, Anhui, Peoples R China.; Jin, TC; Lin, J; Qu, K (corresponding author), Univ Sci & Technol China, CAS Ctr Excellence Mol Cell Sci, CAS Key Lab Innate Immun & Chron Dis, Hefei 230027, Anhui, Peoples R China.; Qu, K (corresponding author), Univ Sci & Technol China, Sch Data Sci, Hefei 230026, Peoples R China.
EM jint@ustc.edu.cn; linjun7@ustc.edu.cn; qukun@ustc.edu.cn
OI Guo, Chuang/0000-0002-3912-0793; Lin, Jun/0000-0001-7087-6540
FU National Key R&D Program of China [2017YFA0102900]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [91940306, 81788101, 31970858, 31771428, 91640113, 31700796,
   81871479]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [YD2070002019, WK2070000158]
FX This work was supported by the National Key R&D Program of China
   (2017YFA0102900 to K.Q.), the National Natural Science Foundation of
   China grants (91940306, 81788101, 31970858, 31771428 and 91640113 to
   K.Q., 31700796 to C.G. and 81871479 to J.L.), the Fundamental Research
   Funds for the Central Universities (YD2070002019 and WK2070000158 to
   K.Q.). We thank the USTC supercomputing center and the School of Life
   Science Bioinformatics Center for providing supercomputing resources for
   this project. We thank the CAS interdisciplinary innovation team for
   helpful discussion.
CR Ahn SS, 2018, YONSEI MED J, V59, P452, DOI 10.3349/ymj.2018.59.3.452
   Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]
   Aliee H., 2020, 940655 BIORXIV, DOI [10.1101/2020.02.21.940650, DOI 10.1101/2020.02.21.940650]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Braciale TJ, 2012, NAT REV IMMUNOL, V12, P295, DOI 10.1038/nri3166
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324
   Guan WD, 2018, J INFECT DIS, V218, P1238, DOI 10.1093/infdis/jiy317
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4
   Reyes M, 2020, NAT MED, V26, P333, DOI 10.1038/s41591-020-0752-4
   Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Vento-Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586-018-0698-6
   Wang CF, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102833
   Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833
   Wolock SL, 2019, CELL SYST, V8, P281, DOI 10.1016/j.cels.2018.11.005
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 38
TC 12
Z9 12
U1 8
U2 8
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 6
PY 2020
VL 11
IS 1
AR 3924
DI 10.1038/s41467-020-17834-w
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NC3NO
UT WOS:000561122000001
PM 32764665
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xia, XY
   Li, KN
   Wu, LX
   Wang, ZH
   Zhu, MY
   Huang, B
   Li, J
   Wang, ZY
   Wu, W
   Wu, M
   Li, WL
   Li, L
   Cai, Y
   Bosco, B
   Zhong, AF
   Liu, X
   Lv, TF
   Gan, ZH
   Chen, G
   Pan, YH
   Liu, CD
   Zhang, K
   Xu, XL
   Wang, CJ
   Wang, QH
   Wang, ZH
AF Xia, Xinyi
   Li, Kening
   Wu, Lingxiang
   Wang, Zhihua
   Zhu, Mengyan
   Huang, Bin
   Li, Jie
   Wang, Ziyu
   Wu, Wei
   Wu, Min
   Li, Wanlin
   Li, Lu
   Cai, Yun
   Bosco, Bakwatanisa
   Zhong, Aifang
   Liu, Xiong
   Lv, Tangfeng
   Gan, Zhenhua
   Chen, Guang
   Pan, Yunhu
   Liu, Caidong
   Zhang, Kai
   Xu, Xiaoli
   Wang, Changjun
   Wang, Qianghu
   Wang, Zhihua
TI Improved clinical symptoms and mortality among patients with severe or
   critical COVID-19 after convalescent plasma transfusion
SO BLOOD
LA English
DT Letter
ID THERAPY
C1 [Xia, Xinyi] Nanjing Univ, Sch Med, Jinling Hosp, COVID 19 Res Ctr,Inst Lab Med, Nanjing, Peoples R China.
   [Xia, Xinyi; Wang, Zhihua; Zhong, Aifang] Wuhan Huoshenshan Hosp, Dept Lab Med & Blood Transfus, Wuhan, Peoples R China.
   [Xia, Xinyi; Wang, Zhihua; Liu, Xiong; Lv, Tangfeng; Gan, Zhenhua; Xu, Xiaoli; Wang, Changjun] Wuhan Huoshenshan Hosp, Joint Expert Grp COVID 19, Wuhan, Peoples R China.
   [Li, Kening; Wu, Lingxiang; Zhu, Mengyan; Huang, Bin; Li, Jie; Wang, Ziyu; Wu, Wei; Wu, Min; Li, Wanlin; Li, Lu; Cai, Yun; Bosco, Bakwatanisa; Wang, Qianghu] Nanjing Med Univ, Sch Publ Hlth, Ctr Global Hlth, 818 Tianyuan East Rd, Nanjing 211100, Peoples R China.
   [Li, Kening; Wu, Lingxiang; Zhu, Mengyan; Huang, Bin; Li, Jie; Wang, Ziyu; Wu, Wei; Wu, Min; Li, Wanlin; Li, Lu; Cai, Yun; Bosco, Bakwatanisa; Wang, Qianghu] Nanjing Med Univ, Dept Bioinformat, Nanjing, Peoples R China.
   [Wang, Zhihua] 907th Hosp, Dept Lab Med & Blood Transfus, Nanping, Peoples R China.
   [Zhong, Aifang] 904th Hosp, Med Tech Support Div, Changzhou, Jiangsu, Peoples R China.
   [Liu, Xiong; Wang, Changjun] Ctr Dis Control & Prevent PLA, Beijing, Peoples R China.
   [Lv, Tangfeng; Gan, Zhenhua; Xu, Xiaoli] Nanjing Univ, Sch Med, Jinling Hosp, 305 East Zhongshan Rd, Nanjing 210002, Peoples R China.
   [Lv, Tangfeng; Chen, Guang; Pan, Yunhu; Xu, Xiaoli] Wuhan Huoshenshan Hosp, Dept Infect Dis, Wuhan, Peoples R China.
   [Chen, Guang] 907th Hosp, Dept Resp Med, Nanping, Peoples R China.
   [Pan, Yunhu] 907th Hosp, Intens Care Unit, Nanping, Peoples R China.
   [Liu, Caidong; Zhang, Kai] Nanjing Med Univ, Nanjing Hosp 1, Gen Clin Res Ctr, Nanjing, Peoples R China.
   [Wang, Qianghu] Nanjing Med Univ, Biomed Big Data Ctr, Nanjing, Peoples R China.
RP Wang, QH (corresponding author), Nanjing Med Univ, Sch Publ Hlth, Ctr Global Hlth, 818 Tianyuan East Rd, Nanjing 211100, Peoples R China.; Xu, XL (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, 305 East Zhongshan Rd, Nanjing 210002, Peoples R China.; Wang, CJ (corresponding author), Ctr Dis Control & Prevent PLA, 20 Dongdajie St, Beijing 100071, Peoples R China.
EM xxl2019kt@sina.com; science@hotmail.com; wangqh@njmu.edu.cn
OI Wang, Zhihua/0000-0002-8658-4697
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81572893, 81972358, 81959113]; Key
   Foundation of Wuhan Huoshenshan Hospital [2020[18]]; Key Research &
   Development Program of Jiangsu Province [BE2017733, BE2018713]; Medical
   Innovation Project of Logistics Service [18JS005]; Basic Research
   Program of Jiangsu Province [BK20180036]
FX This study was supported by the National Natural Science Foundation of
   China (grants 81572893, 81972358, and 81959113), the Key Foundation of
   Wuhan Huoshenshan Hospital (grant 2020[18]), the Key Research &
   Development Program of Jiangsu Province (grants BE2017733 and
   BE2018713), the Medical Innovation Project of Logistics Service (grant
   18JS005), and the Basic Research Program of Jiangsu Province (grant
   BK20180036).
CR Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Garraud O, 2016, TRANSFUS CLIN BIOL, V23, P39, DOI 10.1016/j.tracli.2015.12.003
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Joyner Michael, 2020, medRxiv, DOI 10.1101/2020.05.12.20099879
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Liu STH, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.05.20.20102236, DOI 10.1101/2020.05.20.20102236]
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, COR DIS COVID 19 PAN
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zeng FR, 2020, P NATL ACAD SCI USA, V117, P12528, DOI 10.1073/pnas.2006961117
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 18
TC 14
Z9 14
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD AUG 6
PY 2020
VL 136
IS 6
BP 755
EP 759
DI 10.1182/blood.2020007079
PG 5
WC Hematology
SC Hematology
GA MY7DI
UT WOS:000558573400017
PM 32573724
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bouhaddou, M
   Memon, D
   Meyer, B
   White, KM
   Rezelj, VV
   Marrero, MC
   Polacco, BJ
   Melnyk, JE
   Ulferts, S
   Kaake, RM
   Batra, J
   Richards, AL
   Stevenson, E
   Gordon, DE
   Rojc, A
   Obernier, K
   Fabius, JM
   Soucheray, M
   Miorin, L
   Moreno, E
   Koh, C
   Tran, QD
   Hardy, A
   Robinot, R
   Vallet, T
   Nilsson-Payant, BE
   Hernandez-Armenta, C
   Dunham, A
   Weigang, S
   Knerr, J
   Modak, M
   Quintero, D
   Zhou, Y
   Dugourd, A
   Valdeolivas, A
   Patil, T
   Li, QY
   Huttenhain, R
   Cakir, M
   Muralidharan, M
   Kim, M
   Jang, G
   Tutuncuoglu, B
   Hiatt, J
   Guo, JZ
   Xu, JW
   Bouhaddou, S
   Mathy, CJP
   Gaulton, A
   Manners, EJ
   Felix, E
   Shi, Y
   Goff, M
   Lim, JK
   McBride, T
   O'Neal, MC
   Cai, YM
   Chang, JCJ
   Broadhurst, DJ
   Klippsten, S
   De Wit, E
   Leach, AR
   Kortemme, T
   Shoichet, B
   Ott, M
   Saez-Rodriguez, J
   TenOever, BR
   Mullins, RD
   Fischer, ER
   Kochs, G
   Grosse, R
   Garcia-Sastre, A
   Vignuzzi, M
   Johnson, JR
   Shokat, KM
   Swaney, DL
   Beltrao, P
   Krogan, NJ
AF Bouhaddou, Mehdi
   Memon, Danish
   Meyer, Bjoern
   White, Kris M.
   Rezelj, Veronica V.
   Marrero, Miguel Correa
   Polacco, Benjamin J.
   Melnyk, James E.
   Ulferts, Svenja
   Kaake, Robyn M.
   Batra, Jyoti
   Richards, Alicia L.
   Stevenson, Erica
   Gordon, David E.
   Rojc, Ajda
   Obernier, Kirsten
   Fabius, Jacqueline M.
   Soucheray, Margaret
   Miorin, Lisa
   Moreno, Elena
   Koh, Cassandra
   Quang Dinh Tran
   Hardy, Alexandra
   Robinot, Remy
   Vallet, Thomas
   Nilsson-Payant, Benjamin E.
   Hernandez-Armenta, Claudia
   Dunham, Alistair
   Weigang, Sebastian
   Knerr, Julian
   Modak, Maya
   Quintero, Diego
   Zhou, Yuan
   Dugourd, Aurelien
   Valdeolivas, Alberto
   Patil, Trupti
   Li, Qiongyu
   Huttenhain, Ruth
   Cakir, Merve
   Muralidharan, Monita
   Kim, Minkyu
   Jang, Gwendolyn
   Tutuncuoglu, Beril
   Hiatt, Joseph
   Guo, Jeffrey Z.
   Xu, Jiewei
   Bouhaddou, Sophia
   Mathy, Christopher J. P.
   Gaulton, Anna
   Manners, Emma J.
   Felix, Eloy
   Shi, Ying
   Goff, Marisa
   Lim, Jean K.
   McBride, Timothy
   O'Neal, Michael C.
   Cai, Yiming
   Chang, Jason C. J.
   Broadhurst, David J.
   Klippsten, Saker
   De Wit, Emmie
   Leach, Andrew R.
   Kortemme, Tanja
   Shoichet, Brian
   Ott, Melanie
   Saez-Rodriguez, Julio
   TenOever, Benjamin R.
   Mullins, R. Dyche
   Fischer, Elizabeth R.
   Kochs, Georg
   Grosse, Robert
   Garcia-Sastre, Adolfo
   Vignuzzi, Marco
   Johnson, Jeffery R.
   Shokat, Kevan M.
   Swaney, Danielle L.
   Beltrao, Pedro
   Krogan, Nevan J.
TI The Global Phosphorylation Landscape of SARS-CoV-2 Infection
SO CELL
LA English
DT Article
ID NF-KAPPA-B; RESPIRATORY-SYNDROME-CORONAVIRUS; GTPASE-ACTIVATING PROTEIN;
   CELL-CYCLE ARREST; SITE-SPECIFIC PHOSPHORYLATION;
   TISSUE-PLASMINOGEN-ACTIVATOR; ANAPHASE-PROMOTING COMPLEX;
   NECROSIS-FACTOR-ALPHA; P38 MAPK INHIBITOR; HUMAN LA ANTIGEN
AB The causative agent of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected millions and killed hundreds of thousands of people worldwide, highlighting an urgent need to develop antiviral therapies. Here we present a quantitative mass spectrometry-based phosphoproteomics survey of SARS-CoV-2 infection in Vero E6 cells, revealing dramatic rewiring of phosphorylation on host and viral proteins. SARS-CoV-2 infection promoted casein kinase II (CK2) and p38 MAPK activation, production of diverse cytokines, and shutdown of mitotic kinases, resulting in cell cycle arrest. Infection also stimulated a marked induction of CK2-containing filopodial protrusions possessing budding viral particles. Eighty-seven drugs and compounds were identified by mapping global phosphorylation profiles to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.
C1 [Bouhaddou, Mehdi; Polacco, Benjamin J.; Melnyk, James E.; Kaake, Robyn M.; Batra, Jyoti; Richards, Alicia L.; Stevenson, Erica; Gordon, David E.; Rojc, Ajda; Obernier, Kirsten; Fabius, Jacqueline M.; Soucheray, Margaret; Modak, Maya; Quintero, Diego; Zhou, Yuan; Patil, Trupti; Li, Qiongyu; Huttenhain, Ruth; Cakir, Merve; Muralidharan, Monita; Kim, Minkyu; Jang, Gwendolyn; Tutuncuoglu, Beril; Hiatt, Joseph; Guo, Jeffrey Z.; Xu, Jiewei; Bouhaddou, Sophia; Mathy, Christopher J. P.; Shi, Ying; Kortemme, Tanja; Shoichet, Brian; Mullins, R. Dyche; Shokat, Kevan M.; Swaney, Danielle L.; Beltrao, Pedro; Krogan, Nevan J.] QBI COVID 19 Res Grp QCRG, San Francisco, CA 94158 USA.
   [Bouhaddou, Mehdi; Polacco, Benjamin J.; Melnyk, James E.; Kaake, Robyn M.; Batra, Jyoti; Richards, Alicia L.; Stevenson, Erica; Gordon, David E.; Rojc, Ajda; Obernier, Kirsten; Fabius, Jacqueline M.; Soucheray, Margaret; Modak, Maya; Quintero, Diego; Zhou, Yuan; Patil, Trupti; Li, Qiongyu; Huttenhain, Ruth; Cakir, Merve; Muralidharan, Monita; Kim, Minkyu; Jang, Gwendolyn; Tutuncuoglu, Beril; Hiatt, Joseph; Guo, Jeffrey Z.; Xu, Jiewei; Mathy, Christopher J. P.; Shi, Ying; Kortemme, Tanja; Shoichet, Brian; Mullins, R. Dyche; Shokat, Kevan M.; Swaney, Danielle L.; Krogan, Nevan J.] Univ Calif San Francisco, Quantitat Biosci Inst QBI, San Francisco, CA 94158 USA.
   [Bouhaddou, Mehdi; Polacco, Benjamin J.; Kaake, Robyn M.; Batra, Jyoti; Richards, Alicia L.; Stevenson, Erica; Gordon, David E.; Rojc, Ajda; Obernier, Kirsten; Fabius, Jacqueline M.; Soucheray, Margaret; Modak, Maya; Quintero, Diego; Zhou, Yuan; Patil, Trupti; Li, Qiongyu; Huttenhain, Ruth; Cakir, Merve; Muralidharan, Monita; Kim, Minkyu; Jang, Gwendolyn; Tutuncuoglu, Beril; Hiatt, Joseph; Guo, Jeffrey Z.; Xu, Jiewei; Ott, Melanie; Swaney, Danielle L.; Krogan, Nevan J.] J David Gladstone Inst, San Francisco, CA 94158 USA.
   [Bouhaddou, Mehdi; Polacco, Benjamin J.; Melnyk, James E.; Kaake, Robyn M.; Batra, Jyoti; Richards, Alicia L.; Stevenson, Erica; Gordon, David E.; Rojc, Ajda; Obernier, Kirsten; Fabius, Jacqueline M.; Soucheray, Margaret; Modak, Maya; Quintero, Diego; Zhou, Yuan; Patil, Trupti; Li, Qiongyu; Huttenhain, Ruth; Cakir, Merve; Muralidharan, Monita; Kim, Minkyu; Jang, Gwendolyn; Tutuncuoglu, Beril; Hiatt, Joseph; Guo, Jeffrey Z.; Xu, Jiewei; Shi, Ying; Mullins, R. Dyche; Shokat, Kevan M.; Swaney, Danielle L.; Krogan, Nevan J.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA.
   [Memon, Danish; Marrero, Miguel Correa; Hernandez-Armenta, Claudia; Dunham, Alistair; Gaulton, Anna; Manners, Emma J.; Felix, Eloy; Leach, Andrew R.; Beltrao, Pedro] European Mol Biol Lab EMBL, European Bioinformat Inst, Wellcome Genome Campus, Cambridge, England.
   [Meyer, Bjoern; Rezelj, Veronica V.; Koh, Cassandra; Quang Dinh Tran; Hardy, Alexandra; Vallet, Thomas; Vignuzzi, Marco] Inst Pasteur, Viral Populat & Pathogenesis Unit, CNRS, UMR 3569, F-75724 Paris 15, France.
   [White, Kris M.; Miorin, Lisa; Moreno, Elena; Nilsson-Payant, Benjamin E.; Goff, Marisa; Lim, Jean K.; TenOever, Benjamin R.; Garcia-Sastre, Adolfo; Johnson, Jeffery R.; Krogan, Nevan J.] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
   [White, Kris M.; Miorin, Lisa; Moreno, Elena; Mullins, R. Dyche; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.
   [Melnyk, James E.; Shi, Ying; Grosse, Robert; Shokat, Kevan M.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
   [Ulferts, Svenja; Knerr, Julian] Univ Freiburg, Inst Clin & Expt Pharmacol & Toxicol, D-79104 Freiburg, Germany.
   [Robinot, Remy] Inst Pasteur, Dept Virol, Virus & Immun Unit, CNRS,UMR 3569, F-75724 Paris 15, France.
   [Robinot, Remy; Kochs, Georg] Vaccine Res Inst, F-94000 Creteil, France.
   [Weigang, Sebastian; Saez-Rodriguez, Julio] Univ Freiburg, Inst Virol, Med Ctr, D-79104 Freiburg, Germany.
   [Dugourd, Aurelien; Valdeolivas, Alberto] Heidelberg Univ, Bioquant, Fac Med, Inst Computat Biomed, D-69120 Heidelberg, Germany.
   [Dugourd, Aurelien; Valdeolivas, Alberto] Heidelberg Univ Hosp, D-69120 Heidelberg, Germany.
   [McBride, Timothy; O'Neal, Michael C.; Cai, Yiming; Chang, Jason C. J.; Broadhurst, David J.; Klippsten, Saker] Zoic Labs, Culver City, CA 90232 USA.
   [De Wit, Emmie; Fischer, Elizabeth R.] NIAID, NIH, Rocky Mt Labs, Hamilton, MT 59840 USA.
   [Kochs, Georg; Grosse, Robert] Univ Freiburg, Fac Med, D-79008 Freiburg, Germany.
   [Grosse, Robert] Ctr Integrat Biol Signalling Studies CIBSS, D-79104 Freiburg, Germany.
   [Mathy, Christopher J. P.; Kortemme, Tanja] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94158 USA.
   [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
RP Shokat, KM; Swaney, DL; Beltrao, P; Krogan, NJ (corresponding author), QBI COVID 19 Res Grp QCRG, San Francisco, CA 94158 USA.; Shokat, KM; Swaney, DL; Krogan, NJ (corresponding author), Univ Calif San Francisco, Quantitat Biosci Inst QBI, San Francisco, CA 94158 USA.; Swaney, DL; Krogan, NJ (corresponding author), J David Gladstone Inst, San Francisco, CA 94158 USA.; Shokat, KM; Swaney, DL; Krogan, NJ (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA.; Beltrao, P (corresponding author), European Mol Biol Lab EMBL, European Bioinformat Inst, Wellcome Genome Campus, Cambridge, England.; Vignuzzi, M (corresponding author), Inst Pasteur, Viral Populat & Pathogenesis Unit, CNRS, UMR 3569, F-75724 Paris 15, France.; Garcia-Sastre, A; Johnson, JR; Krogan, NJ (corresponding author), Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.; Garcia-Sastre, A (corresponding author), Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.; Grosse, R; Shokat, KM (corresponding author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.; Grosse, R (corresponding author), Univ Freiburg, Fac Med, D-79008 Freiburg, Germany.; Grosse, R (corresponding author), Ctr Integrat Biol Signalling Studies CIBSS, D-79104 Freiburg, Germany.; Garcia-Sastre, A (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
EM robert.grosse@pharmakol.uni-freiburg.de; adolfo.garcia-sastre@mssm.edu;
   marco.vignuzzi@pasteur.fr; jeffrey.johnson@mssm.edu;
   kevan.shokat@ucsf.edu; danielle.swaney@ucsf.edu; pbeltrao@ebi.ac.uk;
   nevan.krogan@ucsf.edu
RI shi, ying/R-4974-2019; Gordon, David/ABF-1817-2020; Saez-Rodriguez,
   Julio/H-7114-2019; Batra, Jyoti/ABI-2086-2020; Nilsson-Payant,
   Benjamin/AAQ-5302-2020
OI Saez-Rodriguez, Julio/0000-0002-8552-8976; Nilsson-Payant,
   Benjamin/0000-0003-2661-7837; Dunham, Alistair/0000-0001-9076-3025;
   Johnson, Jeffrey/0000-0002-4221-298X; Moreno, Elena/0000-0002-2301-4558;
   Ulferts, Svenja/0000-0002-6605-8163; Felix Manzanares,
   Eloy/0000-0002-5512-6810; Cakir, Merve/0000-0003-1803-5693; Correa
   Marrero, Miguel/0000-0002-3840-3273; Meyer, Bjorn/0000-0002-7903-5710;
   Melnyk, James/0000-0003-1915-8089; Hardy, Alexandra/0000-0002-3027-8308;
   Gaulton, Anna/0000-0003-2634-7400; Weigang,
   Sebastian/0000-0002-8415-6920; Memon, Danish/0000-0002-1365-0710;
   Polacco, Benjamin/0000-0003-1570-9234
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P50AI150476,
   U19AI135990, U19AI135972, R01AI143292, R01AI120694, P01A1063302,
   R01AI122747, 1R01CA221969, 1R01CA244550, R01GM133981, 1F32CA236347-01,
   U19AI118610, F32CA239333]; Defense Advance Research Projects Agency
   [HR0011-19-2-0020]; Laboratory for Genomics Research (LGR) Excellence in
   Research Award (ERA) from the Innovative Genomics Institute at UC
   Berkeley [133122P]; CRIP (Center for Research for Influenza
   Pathogenesis), a NIAID [HHSN272201400008C]; NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI135972]; DoDUnited States Department of Defense
   [W81XWH-19-PRMRP-FPA]; JPB Foundation; Open Philanthropy Project
   [2020-215611 [5384]]; Laboratoire d'Excellence ``Integrative Biology of
   Emerging Infectious Diseases'' [ANR-10-LABX-62-IBEID]; DFGGerman
   Research Foundation (DFG) [EXC-2189, 390939984]; European Research
   CouncilEuropean Research Council (ERC) [ERC-2014-STG 638884 PhosFunc];
   Federal Ministry of Education and Research (BMBF)Federal Ministry of
   Education & Research (BMBF) [031L0181B]; Intramural Research Program of
   the NIH, National Institute of Allergy and Infectious DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); F. Hoffmann-La RocheHoffmann-La Roche; Vir
   Biotechnology
FX This research was funded by grants from the National Institutes of
   Health (P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694,
   P01A1063302, and R01AI122747 to N.J.K.; 1R01CA221969 and 1R01CA244550 to
   K.M.S.; R01GM133981 to D.L.S.; 1F32CA236347-01 to J.E.M.; U19AI118610 to
   J.R.J.; and F32CA239333 to M.B.), Defense Advance Research Projects
   Agency HR0011-19-2-0020 (to N.J.K., A.G.S., and K.M.S.); by the
   Laboratory for Genomics Research (LGR) Excellence in Research Award
   (ERA) from the Innovative Genomics Institute at UC Berkeley (grant
   number 133122P); by CRIP (Center for Research for Influenza
   Pathogenesis), a NIAID-supported Center of Excellence for Influenza
   Research and Surveillance (CEIRS; contract HHSN272201400008C) (to
   A.G.S.); by supplements to NIAID grant U19AI135972 and DoD grant
   W81XWH-19-PRMRP-FPA (to A.G.S.); and by the generous support of the JPB
   Foundation, the Open Philanthropy Project (research grant 2020-215611
   [5384]), and other philanthropic donations (to A.G.S.); by the
   Laboratoire d'Excellence ``Integrative Biology of Emerging Infectious
   Diseases'' grant ANR-10-LABX-62-IBEID (to M.V.); by the DFG under
   Germany's Excellence Strategy (EXC-2189, project ID 390939984 to R.G.);
   by a Starting Grant Award from the European Research Council
   (ERC-2014-STG 638884 PhosFunc to P.B.); by the Federal Ministry of
   Education and Research (BMBF, Computational Life Sciences grant
   031L0181B to J.S.R.); by the Intramural Research Program of the NIH,
   National Institute of Allergy and Infectious Diseases (to E.R.F. and
   E.D.W.); and by funding from F. Hoffmann-La Roche and Vir Biotechnology
   and gifts from The Ron Conway Family. K.M.S. is an investigator of the
   Howard Hughes Medical Institute. The views, opinions, and findings
   contained in this study are those of the authors and do not represent
   the official views, policies, or endorsement of the Department of
   Defense or the U.S. Government. We would like to acknowledge Desiree Ho,
   Innovative Genomics Institute, for SARS-CoV-2 virus illustrations. We
   thank Randy Albert for support with the BSL3 facility and procedures at
   the Icahn School of Medicine at Mount Sinai, New York.
CR Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415
   Alfonso R, 2011, CELL MICROBIOL, V13, P1894, DOI 10.1111/j.1462-5822.2011.01679.x
   Ali N, 2000, J BIOL CHEM, V275, P27531
   Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002
   Alvarez DE, 2012, VIROLOGY, V423, P143, DOI 10.1016/j.virol.2011.12.003
   Alvarez MJ, 2016, NAT GENET, V48, P838, DOI 10.1038/ng.3593
   Amin MA, 2014, J CELL SCI, V127, P2818, DOI 10.1242/jcs.150755
   Aoh QL, 2009, MOL BIOL CELL, V20, P1816, DOI 10.1091/mbc.E08-09-0894
   ARAUJO H, 1993, J BIOL CHEM, V268, P5911
   Archambault V, 2012, CELL CYCLE, V11, P1490, DOI 10.4161/cc.19724
   Ariumi Y, 2008, J VIROL, V82, P9639, DOI 10.1128/JVI.00351-08
   Aubrey BJ, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026062
   Auld GC, 2005, BIOCHEM J, V389, P775, DOI 10.1042/BJ20050733
   Bachman J.A., 2019, ASSEMBLING PHOSPHOPR, DOI [10.1101/822668., DOI 10.1101/822668]
   Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bakircioglu M, 2011, AM J HUM GENET, V88, P523, DOI 10.1016/j.ajhg.2011.03.019
   Bandau S, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-36
   Barkley LR, 2012, MOL BIOL CELL, V23, P1943, DOI 10.1091/mbc.E11-10-0829
   Bartrons R, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00331
   Bassermann F, 2005, CELL, V122, P45, DOI 10.1016/j.cell.2005.04.034
   Bayliss R, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120136
   Beeson D., 2013, EMERY RIMOINS PRINCI, P1
   Beli P, 2012, MOL CELL, V46, P212, DOI 10.1016/j.molcel.2012.01.026
   Ben Djoudi Ouadda A., 2018, ONCOTARGET, V9, P11646
   Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016
   Bieling P, 2008, J CELL BIOL, V183, P1223, DOI 10.1083/jcb.200809190
   BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766
   Bitko V, 2008, J VIROL, V82, P7977, DOI 10.1128/JVI.02762-07
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Blethrow JD, 2008, P NATL ACAD SCI USA, V105, P1442, DOI 10.1073/pnas.0708966105
   Bock BC, 2010, J BIOL CHEM, V285, P21644, DOI 10.1074/jbc.M109.096628
   Boeing S, 2016, CELL REP, V15, P1597, DOI 10.1016/j.celrep.2016.04.047
   Bradshaw Nicholas J, 2013, Biomol Concepts, V4, P447, DOI 10.1515/bmc-2013-0023
   BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x
   Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476
   Bruderer R, 2015, MOL CELL PROTEOMICS, V14, P1400, DOI 10.1074/mcp.M114.044305
   Bruinsma W, 2014, J CELL SCI, V127, P801, DOI 10.1242/jcs.137216
   Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841
   Cahill MA, 2016, BBA-REV CANCER, V1866, P339, DOI 10.1016/j.bbcan.2016.07.004
   Cahill MA, 2016, ONCOTARGET, V7, P50822, DOI 10.18632/oncotarget.10691
   Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119
   Cai YY, 2007, J VIROL, V81, P446, DOI 10.1128/JVI.01705-06
   Casado P, 2014, MOL CELL PROTEOMICS, V13, P836, DOI 10.1074/mcp.M113.034751
   Casado P, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003573
   Chang YJ, 2004, J IMMUNOL, V173, P7602, DOI 10.4049/jimmunol.173.12.7602
   Chaurushiya MS, 2009, DNA REPAIR, V8, P1166, DOI 10.1016/j.dnarep.2009.04.016
   Chen CB, 2009, BIOSCIENCE REP, V29, P405, DOI 10.1042/BSR20090096
   Chen HK, 1999, MOL CELL BIOL, V19, P8536
   Chen HY, 2002, J VIROL, V76, P5233, DOI 10.1128/JVI.76.10.5233-5250.2002
   Chen JT, 2013, BMC BIOCHEM, V14, DOI 10.1186/1471-2091-14-18
   Chen JY, 2017, MOL IMMUNOL, V88, P155, DOI 10.1016/j.molimm.2017.06.029
   Chen W, 2004, J BIOL CHEM, V279, P11129, DOI 10.1074/jbc.M313562200
   Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000
   Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849
   Chiu M, 2012, AMINO ACIDS, V43, P2561, DOI 10.1007/s00726-012-1312-0
   Cho H, 2019, NUCLEIC ACIDS RES, V47, P9888, DOI 10.1093/nar/gkz732
   Choi M, 2014, BIOINFORMATICS, V30, P2524, DOI 10.1093/bioinformatics/btu305
   CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Chu J, 2012, MOL BIOL CELL, V23, P59, DOI 10.1091/mbc.E11-06-0487
   Corkery DP, 2015, NUCLEUS-PHILA, V6, P279, DOI 10.1080/19491034.2015.1062194
   Costa-Mattioli M, 2004, MOL CELL BIOL, V24, P6861, DOI 10.1128/mcb.24.15.6861-6870.2004
   Courcelles M, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.25
   Cox DM, 2003, J BIOL CHEM, V278, P15297, DOI 10.1074/jbc.M211312200
   Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323
   D'Amore C, 2019, CURR PROTEIN PEPT SC, V20, P547, DOI 10.2174/1389203720666190119124846
   Das T, 2019, J MOL BIOL, V431, P3900, DOI 10.1016/j.jmb.2019.07.023
   Das T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00104
   Davidson AD, 2020, BIORXIV, DOI [10.1101/2020.03.22.002204, DOI 10.1101/2020.03.22.002204]
   Day TA, 2010, J CELL BIOL, V191, P953, DOI 10.1083/jcb.201006043
   de Haan CAM, 2005, ADV VIRUS RES, V64, P165, DOI 10.1016/S0065-3527(05)64006-7
   Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   DeDiego ML, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002315
   Degryse S, 2018, LEUKEMIA, V32, P788, DOI 10.1038/leu.2017.276
   Deora AB, 2004, J BIOL CHEM, V279, P43411, DOI 10.1074/jbc.M408078200
   Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105
   Diaz-Moreno I, 2009, NAT STRUCT MOL BIOL, V16, P238, DOI 10.1038/nsmb.1558
   Dou XY, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0178-0
   Dove B, 2006, J VIROL, V80, P4147, DOI 10.1128/JVI.80.8.4147-4156.2006
   Eguchi S, 2009, GENES CELLS, V14, P179, DOI 10.1111/j.1365-2443.2008.01260.x
   Elia AEH, 2015, MOL CELL, V59, P867, DOI 10.1016/j.molcel.2015.05.006
   Elias JE, 2007, NAT METHODS, V4, P207, DOI 10.1038/nmeth1019
   Ellis R, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1806-6
   Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906
   Escobar DJ, 2015, J CELL SCI, V128, P1150, DOI 10.1242/jcs.163824
   Eto K, 2012, CELL DEATH DIFFER, V19, P573, DOI 10.1038/cdd.2011.126
   Eulalio A, 2007, NAT REV MOL CELL BIO, V8, P9, DOI 10.1038/nrm2080
   Fallahi E, 2016, GENES-BASEL, V7, DOI 10.3390/genes7060028
   Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3
   Fan Y, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00396
   Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597
   Farquhar MJ, 2008, J VIROL, V82, P8797, DOI 10.1128/JVI.00592-08
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3
   Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145
   Folker ES, 2005, MOL BIOL CELL, V16, P5373, DOI 10.1091/mbc.E04-12-1106
   Foltz DR, 2009, CELL, V137, P472, DOI 10.1016/j.cell.2009.02.039
   Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1
   Franchin C, 2015, BBA-PROTEINS PROTEOM, V1854, P609, DOI 10.1016/j.bbapap.2014.09.017
   Fremin C, 2016, ONCOGENE, V35, P5692, DOI 10.1038/onc.2016.122
   Fu YL, 2014, ANTIVIR RES, V110, P151, DOI 10.1016/j.antiviral.2014.08.004
   Fujimoto M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01807-7
   Gagnon KB, 2010, AM J PHYSIOL-CELL PH, V299, pC614, DOI 10.1152/ajpcell.00074.2010
   Gao G, 2006, CAN J PHYSIOL PHARM, V84, P5, DOI 10.1139/y05-144
   Garcia-Alonso L, 2019, GENOME RES, V29, P1363, DOI 10.1101/gr.240663.118
   Garcia-Moreno M, 2018, WIRES RNA, V9, DOI 10.1002/wrna.1498
   Geuens T, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-016-0407-3
   Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002
   Giurgiu M, 2019, NUCLEIC ACIDS RES, V47, pD559, DOI 10.1093/nar/gky973
   Goel P, 2015, GENE, V557, P1, DOI 10.1016/j.gene.2014.11.051
   Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Growcott EJ, 2018, J MED MICROBIOL, V67, P452, DOI 10.1099/jmm.0.000684
   Grzenda A, 2009, BBA-GENE REGUL MECH, V1789, P443, DOI 10.1016/j.bbagrm.2009.05.007
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo X, 2017, PROTEIN CELL, V8, P255, DOI 10.1007/s13238-017-0382-x
   Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004
   HAJJAR KA, 1991, J BIOL CHEM, V266, P21962
   HAJJAR KA, 1994, J BIOL CHEM, V269, P21191
   Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Handschick K, 2014, MOL CELL, V53, P193, DOI 10.1016/j.molcel.2013.12.002
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Harder LM, 2014, AUTOPHAGY, V10, P339, DOI 10.4161/auto.26863
   He L, 2018, MOL CELL, V70, P949, DOI 10.1016/j.molcel.2018.04.024
   He NH, 2010, MOL CELL, V38, P428, DOI 10.1016/j.molcel.2010.04.013
   HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y
   Heaton NS, 2016, IMMUNITY, V44, P46, DOI 10.1016/j.immuni.2015.12.017
   Hedglin M, 2015, ANNU REV BIOPHYS, V44, P207, DOI 10.1146/annurev-biophys-060414-033841
   Hein JB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10975
   Hensley K, 2016, J ALZHEIMERS DIS, V53, P1, DOI 10.3233/JAD-160076
   Heo Lim, 2020, bioRxiv, DOI 10.1101/2020.03.25.008904
   Hernandez-Armenta C, 2017, BIOINFORMATICS, V33, P1845, DOI 10.1093/bioinformatics/btx082
   Hodel AE, 2002, MOL CELL, V10, P347, DOI 10.1016/S1097-2765(02)00589-0
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024
   Hong S, 2017, ELIFE, V6, DOI 10.7554/eLife.25237
   Horn H, 2014, NAT METHODS, V11, P603, DOI 10.1038/nmeth.2968
   Hou H, 2011, J BIOL CHEM, V286, P9623, DOI 10.1074/jbc.M110.177436
   Hu CW, 2015, MOL CELL PROTEOMICS, V14, P3284, DOI 10.1074/mcp.M115.051383
   Hu F, 2010, ONCOGENE, V29, P5464, DOI 10.1038/onc.2010.275
   Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046
   Huang GY, 2014, STEM CELLS, V32, P1149, DOI 10.1002/stem.1609
   Huang PY, 2001, J VIROL, V75, P5009, DOI 10.1128/JVI.75.11.5009-5017.2001
   Huang YW, 2006, FEBS J, V273, P3248, DOI 10.1111/j.1742-4658.2006.05333.x
   Hwang SK, 2014, CARCINOGENESIS, V35, P1469, DOI 10.1093/carcin/bgu008
   Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200
   Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839
   Inoue Y, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00173
   Intine RV, 2003, MOL CELL, V12, P1301, DOI 10.1016/S1097-2765(03)00429-5
   Ishii T, 2013, FREE RADICAL BIO MED, V65, P102, DOI 10.1016/j.freeradbiomed.2013.06.019
   Ishikawa Y, 2015, FEBS LETT, V589, P1150, DOI 10.1016/j.febslet.2015.03.019
   Izawa I, 2006, CANCER SCI, V97, P167, DOI 10.1111/j.1349-7006.2006.00161.x
   Jacque JM, 2006, NATURE, V441, P641, DOI 10.1038/nature04682
   Jang SH, 2015, PROTEOME SCI, V13, DOI 10.1186/s12953-015-0070-9
   Jassal B, 2020, NUCLEIC ACIDS RES, V48, pD498, DOI 10.1093/nar/gkz1031
   Jiang YH, 2014, MOL CELL, V53, P75, DOI 10.1016/j.molcel.2013.11.001
   Jimenez-Guardeno JM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004320
   Johnson J.R., 2020, GLOBAL POSTTRANSLATI, DOI [10.1101/2020.01.06.896365., DOI 10.1101/2020.01.06.896365]
   Johnson Olubusola Esther, 2011, Journal of Musculoskeletal Research, V14, P1250003, DOI 10.1142/S0218957712500030
   Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Kanzawa N, 2006, FEBS LETT, V580, P6807, DOI 10.1016/j.febslet.2006.11.046
   KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483
   Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028
   Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279
   Kennedy D, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.408
   Khurana N, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00100
   Killoran RC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123934
   Kim YK, 2006, J BIOL CHEM, V281, P36752, DOI 10.1074/jbc.M604785200
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200
   Kjolby M, 2010, CELL METAB, V12, P213, DOI 10.1016/j.cmet.2010.08.006
   KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288
   Kohl B, 2019, NUCLEIC ACIDS RES, V47, P11906, DOI 10.1093/nar/gkz614
   Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955
   Kostenko S, 2009, CELL SIGNAL, V21, P712, DOI 10.1016/j.cellsig.2009.01.009
   Kotula E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080313
   Kovacs KA, 2003, J BIOL CHEM, V278, P36959, DOI 10.1074/jbc.M303147200
   Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627
   Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6
   Kremer BE, 2007, CELL, V130, P837, DOI 10.1016/j.cell.2007.06.053
   Krull S, 2010, EMBO J, V29, P1659, DOI 10.1038/emboj.2010.54
   Kuang XY, 2016, CANCER LETT, V377, P87, DOI 10.1016/j.canlet.2016.04.035
   Kumar R, 2018, VIRUS RES, V253, P48, DOI 10.1016/j.virusres.2018.05.028
   Kumar R, 2014, J VIROL, V88, P6411, DOI 10.1128/JVI.00536-14
   Kunapuli P, 2006, EXP CELL RES, V312, P3739, DOI 10.1016/j.yexcr.2006.06.037
   Kuss SK, 2013, VIRUSES-BASEL, V5, P1824, DOI 10.3390/v5071824
   Labit H, 2012, EMBO J, V31, P3351, DOI 10.1038/emboj.2012.168
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Langfelder P, 2008, BIOINFORMATICS, V24, P719, DOI 10.1093/bioinformatics/btm563
   Larance M, 2010, MOL CELL PROTEOMICS, V9, P682, DOI 10.1074/mcp.M900435-MCP200
   Lau E, 2006, EMBO REP, V7, P425, DOI 10.1038/sj.embor.7400624
   Law AHY, 2007, J VIROL, V81, P416, DOI 10.1128/JVI.02336-05
   Le Sage V, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060152
   Lee J, 2002, BIOCHEM BIOPH RES CO, V298, P765, DOI 10.1016/S0006-291X(02)02562-7
   Lee KY, 2012, J CELL PHYSIOL, V227, P739, DOI 10.1002/jcp.22782
   Lee KY, 2008, MOL CELLS, V26, P5
   Lee S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002297
   Lee WK, 2013, P NATL ACAD SCI USA, V110, P19360, DOI 10.1073/pnas.1304670110
   Leite F, 2015, VIRUS RES, V209, P87, DOI 10.1016/j.virusres.2015.01.024
   Lekmine F, 2004, EXP CELL RES, V295, P173, DOI 10.1016/j.yexcr.2003.12.021
   Lekmine F, 2003, J BIOL CHEM, V278, P27772, DOI 10.1074/jbc.M301364200
   LEUKEL M, 1995, EUR J CELL BIOL, V68, P133
   Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650
   Li FQ, 2008, J CELL BIOL, V181, P1141, DOI 10.1083/jcb.200709091
   Li FQ, 2007, VIROLOGY, V365, P435, DOI 10.1016/j.virol.2007.04.015
   Li G, 2016, BBA-MOL CELL RES, V1863, P572, DOI 10.1016/j.bbamcr.2015.12.021
   Li JBA, 2017, BBA-MOL BASIS DIS, V1863, P2924, DOI 10.1016/j.bbadis.2017.08.012
   Li Q, 2011, RADIAT RES, V176, P17, DOI 10.1667/RR2393.1
   Li Y, 2007, BIOCHEMISTRY-US, V46, P13163, DOI 10.1021/bi700694c
   Li ZH, 2011, RNA BIOL, V8, P305, DOI 10.4161/rna.8.2.15391
   Liang J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12431
   Liao QJ, 2005, ACTA BIOCH BIOPH SIN, V37, P607, DOI 10.1111/j.1745-7270.2005.00082.x
   Lieberman HB, 2017, RADIAT RES, V187, P424, DOI 10.1667/RR003CC.1
   Lilley CE, 2007, TRENDS MICROBIOL, V15, P119, DOI 10.1016/j.tim.2007.01.003
   Lim HC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074334
   Lin JY, 2009, NUCLEIC ACIDS RES, V37, P47, DOI 10.1093/nar/gkn901
   Lin XL, 2013, DNA CELL BIOL, V32, P220, DOI 10.1089/dna.2012.1915
   Lingel H, 2017, CELL DEATH DIFFER, V24, P1739, DOI 10.1038/cdd.2017.102
   Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+
   Lista M.J., 2020, NATURE, V581, P215
   Liu AL, 2015, VIRUS GENES, V50, P189, DOI 10.1007/s11262-014-1151-z
   Liu RY, 2013, CANCER LETT, V335, P351, DOI 10.1016/j.canlet.2013.02.045
   Liu YW, 2013, J PHYSIOL-LONDON, V591, P3605, DOI 10.1113/jphysiol.2013.256263
   Liu Y, 2011, MOL CELL, V44, P502, DOI 10.1016/j.molcel.2011.09.011
   Lobry C, 2007, P NATL ACAD SCI USA, V104, P908, DOI 10.1073/pnas.0606982104
   Lokireddy S, 2015, P NATL ACAD SCI USA, V112, pE7176, DOI 10.1073/pnas.1522332112
   Long L, 2014, J BIOL CHEM, V289, P8916, DOI 10.1074/jbc.M114.551754
   Love M.I., 2014, HEPATOB PANCREAT DIS, V15, P550
   Lu HM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02146-3
   Lu Y, 2014, HEPATOB PANCREAT DIS, V13, P386, DOI 10.1016/S1499-3872(14)60038-2
   Lubas M, 2011, MOL CELL, V43, P624, DOI 10.1016/j.molcel.2011.06.028
   Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830
   Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344
   Luo HB, 2005, FEBS LETT, V579, P2623, DOI 10.1016/j.febslet.2005.03.080
   Ly T, 2017, ELIFE, V6, DOI 10.7554/eLife.27574
   Ly T, 2014, ELIFE, V3, DOI 10.7554/eLife.01630
   Machado-Neto JA, 2014, BMB REP, V47, P660, DOI 10.5483/BMBRep.2014.47.12.020
   Machowska M, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150094
   Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892
   Magron A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140612
   Mahony R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15197-9
   Mancini M, 2017, ONCOTARGET, V8, P88244, DOI 10.18632/oncotarget.21166
   Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005
   Mangin PH, 2009, J THROMB HAEMOST, V7, P900, DOI 10.1111/j.1538-7836.2009.03322.x
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Marcos-Villar L, 2016, J VIROL, V90, P3694, DOI 10.1128/JVI.00053-16
   Fernandez-Golbano IM, 2014, DEV CELL, V30, P746, DOI 10.1016/j.devcel.2014.07.020
   Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x
   MARKLUND U, 1993, J BIOL CHEM, V268, P25671
   Marquette A, 2011, NAT STRUCT MOL BIOL, V18, P584, DOI 10.1038/nsmb.2022
   Mather KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep23675
   Matsuhashi S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092304
   Matsumoto T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126229
   Matsuoka Y, 2003, BRIT J PHARMACOL, V138, P1303, DOI 10.1038/sj.bjp.0705182
   Mbonye UR, 2015, PROTEOMICS, V15, P2078, DOI 10.1002/pmic.201500038
   McCamphill PK, 2015, J NEUROSCI, V35, P4403, DOI 10.1523/JNEUROSCI.2376-14.2015
   McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899
   Mehellou Y, 2018, BIOCHEM BIOPH RES CO, V503, P1868, DOI 10.1016/j.bbrc.2018.07.128
   MEIER UT, 1992, CELL, V70, P127
   MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235
   Mendoza MC, 2011, MOL CELL, V41, P661, DOI 10.1016/j.molcel.2011.02.031
   Menon S, 2014, CELL, V156, P771, DOI 10.1016/j.cell.2013.11.049
   Mizutani T, 2004, BIOCHEM BIOPH RES CO, V319, P1228, DOI 10.1016/j.bbrc.2004.05.107
   Mo M, 2012, TRENDS MICROBIOL, V20, P440, DOI 10.1016/j.tim.2012.05.007
   MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.bi.54.070185.005333
   Morris EJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15289
   Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205
   Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514
   MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86
   Muller S, 2014, CELL REP, V8, P190, DOI 10.1016/j.celrep.2014.06.002
   Na BR, 2015, J CELL BIOL, V209, P143, DOI 10.1083/jcb.201407130
   Nairn AC, 2001, PROG MOLEC, V27, P91
   Nandi AK, 2007, BIOCHEM BIOPH RES CO, V358, P181, DOI 10.1016/j.bbrc.2007.04.125
   Needham EJ, 2019, CELL REP, V29, P1524, DOI 10.1016/j.celrep.2019.10.001
   Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509
   Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180
   Ochoa D, 2020, NAT BIOTECHNOL, V38, P365, DOI 10.1038/s41587-019-0344-3
   Ochoa D, 2016, MOL SYST BIOL, V12, DOI 10.15252/msb.20167295
   Ogiso H, 2004, BIOCHEMISTRY-US, V43, P15510, DOI 10.1021/bi048736m
   OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612
   Old WM, 2009, MOL CELL, V34, P115, DOI 10.1016/j.molcel.2009.03.007
   Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026
   Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475
   Osada N, 2014, DNA RES, V21, P673, DOI 10.1093/dnares/dsu029
   Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469
   Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011
   Paquette M, 2018, CANCERS, V10, DOI 10.3390/cancers10010018
   Park ES, 2000, MOL ENDOCRINOL, V14, P662, DOI 10.1210/mend.14.5.0458
   PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126
   Parplys AC, 2015, NUCLEIC ACIDS RES, V43, P9817, DOI 10.1093/nar/gkv859
   Patel KM, 2015, CIRC RES, V116, P789, DOI 10.1161/CIRCRESAHA.116.305811
   Patnaik A, 2016, CLIN CANCER RES, V22, P1095, DOI 10.1158/1078-0432.CCR-15-1718
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Peng TY, 2008, FEBS J, V275, P4152, DOI 10.1111/j.1742-4658.2008.06564.x
   Penzo C, 2019, CANCERS, V11, DOI 10.3390/cancers11081105
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Pfeiffer JR, 2011, MOL CELL BIOL, V31, P277, DOI 10.1128/MCB.00775-10
   Pires E, 2017, DNA REPAIR, V59, P76, DOI 10.1016/j.dnarep.2017.09.008
   Ponnam S, 2019, P NATL ACAD SCI USA, V116, P15485, DOI 10.1073/pnas.1903033116
   Popov D, 2012, BIOCHEM BIOPH RES CO, V422, P535, DOI 10.1016/j.bbrc.2012.05.048
   Poppe M, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006286
   Porollo A, 2007, PROTEINS, V66, P630, DOI 10.1002/prot.21248
   Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840
   Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367
   Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061
   Proteau A, 2005, J MOL BIOL, V346, P1163, DOI 10.1016/j.jmb.2004.12.034
   Qiao RP, 2016, P NATL ACAD SCI USA, V113, pE2570, DOI 10.1073/pnas.1604929113
   Qiu QH, 2016, INT J ONCOL, V48, P2508, DOI 10.3892/ijo.2016.3481
   Quan BL, 2014, P NATL ACAD SCI USA, V111, P9127, DOI 10.1073/pnas.1409076111
   R Core Team, 2019, R LANG ENV STAT COMP
   Radic V., 2016, NOVEL ROLE SCAMP3 IN
   Radtke K, 2006, CELL MICROBIOL, V8, P387, DOI 10.1111/j.1462-5822.2005.00679.x
   Radulescu AE, 2010, TRENDS CELL BIOL, V20, P214, DOI 10.1016/j.tcb.2010.01.003
   Rahim MN, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120731
   Rai R, 2017, MOL CELL, V65, P801, DOI 10.1016/j.molcel.2017.01.016
   Ramm G, 2006, J BIOL CHEM, V281, P29174, DOI 10.1074/jbc.M603274200
   Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193
   Ravichandran LV, 2001, MOL ENDOCRINOL, V15, P1768, DOI 10.1210/me.15.10.1768
   Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568
   Renganathan H, 2005, BIOCHEM J, V390, P729, DOI 10.1042/BJ20050378
   Revenko AS, 2010, MOL CELL BIOL, V30, P5260, DOI 10.1128/MCB.00484-10
   Riad A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35430-3
   Robinson M, 2018, CELL MOL LIFE SCI, V75, P3693, DOI 10.1007/s00018-018-2882-0
   Robinson-White A, 2002, ANN NY ACAD SCI, V968, P256, DOI 10.1111/j.1749-6632.2002.tb04340.x
   Robitaille AM, 2013, SCIENCE, V339, P1320, DOI 10.1126/science.1228771
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947
   Rogers S, 2015, DATA BRIEF, V5, P45, DOI 10.1016/j.dib.2015.08.010
   Rong BX, 2016, ONCOTARGET, V7, P78980, DOI 10.18632/oncotarget.12982
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Roy R, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1431
   Roy R, 2014, NUCLEIC ACIDS RES, V42, P12483, DOI 10.1093/nar/gku953
   Ryan EL, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010002
   Salvi M, 2009, BIOCHEM BIOPH RES CO, V387, P606, DOI 10.1016/j.bbrc.2009.07.067
   Sanborn KB, 2011, BLOOD, V118, P5862, DOI 10.1182/blood-2011-03-344846
   Sanchez-Martin P, 2018, J CELL SCI, V131, DOI 10.1242/jcs.222836
   Santamaria PG, 2003, J BIOL CHEM, V278, P6687, DOI 10.1074/jbc.M209420200
   Saredi A, 1997, J CELL SCI, V110, P1287
   Schmucker S, 2014, MOL CELL ONCOL, V1, DOI 10.1080/23723548.2014.954507
   Schweppe DK, 2013, J PROTEOMICS, V91, P286, DOI 10.1016/j.jprot.2013.07.023
   Sengupta S, 2013, P NATL ACAD SCI USA, V110, P18826, DOI 10.1073/pnas.1318676110
   Serber Z, 2007, CELL, V128, P441, DOI 10.1016/j.cell.2007.01.018
   Shah PS, 2018, CELL, V175, P1931, DOI 10.1016/j.cell.2018.11.028
   Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166
   Shandilya J, 2014, FEBS LETT, V588, P2198, DOI 10.1016/j.febslet.2014.05.014
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sharma K, 2014, CELL REP, V8, P1583, DOI 10.1016/j.celrep.2014.07.036
   Sharma K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019436
   Shi JH, 2015, MOL IMMUNOL, V68, P546, DOI 10.1016/j.molimm.2015.07.024
   Shi JH, 2008, J BIOL CHEM, V283, P28660, DOI 10.1074/jbc.M802645200
   Shih MC, 2012, ONCOGENE, V31, P2389, DOI 10.1038/onc.2011.419
   Sinclair Alison, 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406010544
   Smith GA, 2002, ANNU REV CELL DEV BI, V18, P135, DOI 10.1146/annurev.cellbio.18.012502.105920
   Smith GL, 2004, VIRUS RES, V106, P189, DOI 10.1016/j.virusres.2004.08.015
   Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200
   Stoilov P, 2004, HUM MOL GENET, V13, P509, DOI 10.1093/hmg/ddh051
   STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9
   Su B, 2001, J BIOL CHEM, V276, P14784, DOI 10.1074/jbc.M010134200
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8
   Tafforeau L, 2011, J VIROL, V85, P13010, DOI 10.1128/JVI.02651-10
   Taggart C, 2000, J BIOL CHEM, V275, P27258
   Tan SX, 2012, MOL CELL BIOL, V32, P4946, DOI 10.1128/MCB.00761-12
   Tan YJ, 2004, J VIROL, V78, P14043, DOI 10.1128/JVI.78.24.14043-14047.2004
   Tanenbaum ME, 2006, EMBO J, V25, P45, DOI 10.1038/sj.emboj.7600916
   Tantos A, 2013, BBA-PROTEINS PROTEOM, V1834, P342, DOI 10.1016/j.bbapap.2012.08.005
   Tarakhovsky A, 2018, J EXP MED, V215, P1777, DOI 10.1084/jem.20180099
   Tavares MR, 2015, LIFE SCI, V131, P1, DOI 10.1016/j.lfs.2015.03.001
   Taylor MP, 2011, NAT REV MICROBIOL, V9, P427, DOI 10.1038/nrmicro2574
   Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899
   Thaker SK, 2019, BMC BIOL, V17, DOI 10.1186/s12915-019-0678-9
   Thejer BM, 2020, BMC MOL CELL BIOL, V21, DOI 10.1186/s12860-020-00256-3
   Tiedje C, 2015, RNA, V21, P262, DOI 10.1261/rna.048090.114
   Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200
   Toughiri R, 2013, J CELL BIOCHEM, V114, P823, DOI 10.1002/jcb.24421
   Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003
   Trigg BJ, 2015, CURR OPIN VIROL, V15, P56, DOI 10.1016/j.coviro.2015.08.001
   TSAI LH, 1993, ONCOGENE, V8, P1593
   Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200
   Tsoi H, 2014, BIOCHEM J, V464, P439, DOI 10.1042/BJ20131461
   Tsvetkov L, 2005, CELL CYCLE, V4, P166, DOI 10.4161/cc.4.1.1348
   Ui A, 2015, MOL CELL, V58, P468, DOI 10.1016/j.molcel.2015.03.023
   Ujike M, 2015, VIRUSES-BASEL, V7, P1700, DOI 10.3390/v7041700
   Valvezan AJ, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00001
   Vind BF, 2011, DIABETOLOGIA, V54, P157, DOI 10.1007/s00125-010-1924-4
   VISHWANATHA JK, 1993, J CELL SCI, V105, P533
   Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200
   Walsh D, 2011, NAT REV MICROBIOL, V9, P860, DOI 10.1038/nrmicro2655
   Walter BL, 2002, J VIROL, V76, P12008, DOI 10.1128/JVI.76.23.12008-12022.2002
   Walter D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10530
   Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000
   Wang L., 2008, COMPLEX HYDROCARBON, V1, P1
   Wang T, 2013, J BIOL CHEM, V288, P20713, DOI 10.1074/jbc.M112.439877
   Wang W, 2007, VIRUS RES, V128, P1, DOI 10.1016/j.virusres.2007.02.007
   WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0
   Wang YC, 1999, VIROLOGY, V265, P96, DOI 10.1006/viro.1999.0025
   Wang ZL, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03033
   Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004
   Wen AY, 2010, J IMMUNOL, V185, P6413, DOI 10.4049/jimmunol.1001829
   WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9
   Wertz IE, 2015, NATURE, V528, P370, DOI 10.1038/nature16165
   Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X
   Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142
   Wohlbold L, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002935
   Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wortzel Inbal, 2011, Genes Cancer, V2, P195, DOI 10.1177/1947601911407328
   Wu CH, 2009, J BIOL CHEM, V284, P5229, DOI 10.1074/jbc.M805747200
   Wu H, 2018, BIOMARK MED, V12, P759, DOI 10.2217/bmm-2017-0443
   Wu XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5961
   Wurm T, 2001, J VIROL, V75, P9345, DOI 10.1128/JVI.75.19.9345-9356.2001
   Xu LH, 2011, J BIOL CHEM, V286, P39546, DOI 10.1074/jbc.M111.242206
   Yang P, 2012, MOL CELL BIOL, V32, P3121, DOI 10.1128/MCB.00204-12
   Yang WW, 2014, CELL, V158, P1210, DOI 10.1016/j.cell.2014.08.003
   Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629
   Yao K, 2017, P NATL ACAD SCI USA, V114, P12791, DOI 10.1073/pnas.1710756114
   Ye ZD, 2008, BBA-GEN SUBJECTS, V1780, P1383, DOI 10.1016/j.bbagen.2008.07.009
   Yee AS, 2004, GENE, V336, P1, DOI 10.1016/j.gene.2004.04.004
   Yim H, 2013, J CELL PHYSIOL, V228, P1221, DOI 10.1002/jcp.24275
   Yoo S.-M., 2019, INT J BIOL CHEM, V283, P15619
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu WB, 2009, MOL CELL BIOCHEM, V325, P61, DOI 10.1007/s11010-008-0020-2
   Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484
   Yui D, 2001, ONCOGENE, V20, P4317, DOI 10.1038/sj.onc.1204576
   Zhang HH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006189
   Zhang HJ, 2019, J CELL MOL MED, V23, P6965, DOI 10.1111/jcmm.14581
   Zhang J, 2020, ELECTRON J DIFFER EQ
   Zhang Q, 2019, VIROL SIN, V34, P175, DOI 10.1007/s12250-019-00122-3
   Zhang S, 2015, INT J GREEN ENERGY, V12, P198, DOI 10.1080/15435075.2014.891522
   Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1
   Zhao JJ, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0259-0
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Q, 2016, NAT GENET, V48, P67, DOI 10.1038/ng.3459
   Zhu GQ, 2017, J IMMUNOL, V198, P1104, DOI 10.4049/jimmunol.1600403
   Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896
   Zou JX, 2007, P NATL ACAD SCI USA, V104, P18067, DOI 10.1073/pnas.0705814104
   ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x
NR 447
TC 29
Z9 29
U1 19
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 6
PY 2020
VL 182
IS 3
BP 685
EP +
DI 10.1016/j.cell.2020.06.034
PG 47
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MY8EK
UT WOS:000558649000014
PM 32645325
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, H
   Zhang, YT
   Huang, BY
   Deng, W
   Quan, YR
   Wang, WL
   Xu, WB
   Zhao, YX
   Li, N
   Zhang, J
   Liang, HY
   Bao, LL
   Xu, YF
   Ding, L
   Zhou, WM
   Gao, H
   Liu, JN
   Niu, PH
   Zhao, L
   Zhen, W
   Fu, H
   Yu, SZ
   Zhang, ZL
   Xu, GX
   Li, CG
   Lou, ZY
   Xu, M
   Qin, C
   Wu, GZ
   Gao, GF
   Tan, WJ
   Yang, XM
AF Wang, Hui
   Zhang, Yuntao
   Huang, Baoying
   Deng, Wei
   Quan, Yaru
   Wang, Wenling
   Xu, Wenbo
   Zhao, Yuxiu
   Li, Na
   Zhang, Jin
   Liang, Hongyang
   Bao, Linlin
   Xu, Yanfeng
   Ding, Ling
   Zhou, Weimin
   Gao, Hong
   Liu, Jiangning
   Niu, Peihua
   Zhao, Li
   Zhen, Wei
   Fu, Hui
   Yu, Shouzhi
   Zhang, Zhengli
   Xu, Guangxue
   Li, Changgui
   Lou, Zhiyong
   Xu, Miao
   Qin, Chuan
   Wu, Guizhen
   Gao, George Fu
   Tan, Wenjie
   Yang, Xiaoming
TI Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent
   Protection against SARS-CoV-2
SO CELL
LA English
DT Article
ID CORONAVIRUS; PNEUMONIA; OUTBREAK
AB The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 mg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibodydependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.
C1 [Wang, Hui; Zhang, Yuntao; Zhao, Yuxiu; Li, Na; Zhang, Jin; Liang, Hongyang; Ding, Ling; Fu, Hui; Yu, Shouzhi; Zhang, Zhengli; Yang, Xiaoming] Beijing Inst Biol Prod Co Ltd, Beijing, Peoples R China.
   [Huang, Baoying; Wang, Wenling; Xu, Wenbo; Zhou, Weimin; Niu, Peihua; Zhao, Li; Zhen, Wei; Wu, Guizhen; Gao, George Fu; Tan, Wenjie] Chinese Ctr Dis Control & Prevent China CDC, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China.
   [Deng, Wei; Bao, Linlin; Xu, Yanfeng; Gao, Hong; Liu, Jiangning; Qin, Chuan] Chinese Acad Med Sci, NHC Key Lab Human Dis Comparat Med, Natl Anim Models Human Dis Resources Ctr, Inst Lab Anim Sci,Beijing Key Lab Anim Models Eme, Beijing, Peoples R China.
   [Deng, Wei; Bao, Linlin; Xu, Yanfeng; Gao, Hong; Liu, Jiangning; Qin, Chuan] Peking Union Med Coll, Comparat Med Ctr, Beijing, Peoples R China.
   [Quan, Yaru; Li, Changgui; Xu, Miao] Natl Inst Food & Drug Control, Beijing, Peoples R China.
   [Xu, Guangxue; Lou, Zhiyong] Tsinghua Univ, MOE Key Lab Prot Sci, Sch Med, Beijing, Peoples R China.
   [Xu, Guangxue; Lou, Zhiyong] Tsinghua Univ, Collaborat Innovat Ctr Biotherapy, Sch Med, Beijing, Peoples R China.
RP Yang, XM (corresponding author), Beijing Inst Biol Prod Co Ltd, Beijing, Peoples R China.; Wu, GZ; Gao, GF; Tan, WJ (corresponding author), Chinese Ctr Dis Control & Prevent China CDC, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China.; Qin, C (corresponding author), Chinese Acad Med Sci, NHC Key Lab Human Dis Comparat Med, Natl Anim Models Human Dis Resources Ctr, Inst Lab Anim Sci,Beijing Key Lab Anim Models Eme, Beijing, Peoples R China.; Qin, C (corresponding author), Peking Union Med Coll, Comparat Med Ctr, Beijing, Peoples R China.; Li, CG; Xu, M (corresponding author), Natl Inst Food & Drug Control, Beijing, Peoples R China.; Lou, ZY (corresponding author), Tsinghua Univ, MOE Key Lab Prot Sci, Sch Med, Beijing, Peoples R China.; Lou, ZY (corresponding author), Tsinghua Univ, Collaborat Innovat Ctr Biotherapy, Sch Med, Beijing, Peoples R China.
EM changguili@aliyun.com; louzy@mail.tsinghua.edu.cn; xumiaobj@126.com;
   qinchuan@pumc.edu.cn; wugz@ivdc.chinacdc.cn; gaofu@chinacdc.cn;
   tanwj@ivdc.chinacdc.cn; yangxiaoming@sinopharm.com
RI qin, chuan/ABG-4508-2020
FU National Program on Key Research Project of China [2020YFA0707500,
   2016YFD0500301, 2017YFC0840300, 2020YFC0842100]; National Natural
   Science Foundation of China (NSFC)National Natural Science Foundation of
   China (NSFC) [31971126]; CAMS Initiative for Innovative Medicine of
   China [2016I2M-2-006]; Beijing Science and Technology Plan
   [Z201100005420014]; National Mega Projects of China for Major Infectious
   Diseases [2017ZX10304402, 2016ZX10004001-003]
FX We thank Dr. Taijiao Jiang for his assistance to prepare the phylogenic
   tree. This work was supported by the National Program on Key Research
   Project of China (2020YFA0707500, 2016YFD0500301, 2017YFC0840300, and
   2020YFC0842100), the National Natural Science Foundation of China (NSFC)
   (31971126), CAMS Initiative for Innovative Medicine of China
   (2016I2M-2-006), National Mega Projects of China for Major Infectious
   Diseases (2017ZX10304402 and 2016ZX10004001-003), and Beijing Science
   and Technology Plan (Z201100005420014).
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chao S., 2020, INFECT NOVEL CORONAV, DOI [10.21203/rs.2.25200/v1, DOI 10.21203/RS.2.25200/V1]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Gary Ebony N, 2020, Curr Opin Immunol, V65, P21, DOI 10.1016/j.coi.2020.01.006
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490
   Ramakrishnan Muthannan Andavar, 2016, World J Virol, V5, P85, DOI 10.5501/wjv.v5.i2.85
   Stern PL, 2020, ANN ALLERG ASTHMA IM, V125, P17, DOI 10.1016/j.anai.2020.01.025
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   van Doremalen N., 2020, CHADOX1 NCOV 19 VACC, DOI [10.1101/2020.05.13, DOI 10.1101/2020.05.13]
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102
   Yu GC, 2017, METHODS ECOL EVOL, V8, P28, DOI 10.1111/2041-210X.12628
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Yu Pin, 2020, Animal Model Exp Med, V3, P93, DOI 10.1002/ame2.12108
   Zhang C, 2016, HUM VACC IMMUNOTHER, V12, P2064, DOI 10.1080/21645515.2016.1165908
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 24
TC 31
Z9 30
U1 15
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 6
PY 2020
VL 182
IS 3
BP 713
EP +
DI 10.1016/j.cell.2020.06.008
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MY8EK
UT WOS:000558649000015
PM 32778225
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Dai, LP
   Zheng, TY
   Xu, K
   Han, YX
   Xu, LL
   Huang, EQ
   An, YL
   Cheng, YJ
   Li, SH
   Liu, M
   Yang, M
   Li, Y
   Cheng, HJ
   Yuan, Y
   Zhang, W
   Ke, CW
   Wong, G
   Qi, JX
   Qin, C
   Yan, JH
   Gao, GF
AF Dai, Lianpan
   Zheng, Tianyi
   Xu, Kun
   Han, Yuxuan
   Xu, Lili
   Huang, Enqi
   An, Yaling
   Cheng, Yingjie
   Li, Shihua
   Liu, Mei
   Yang, Mi
   Li, Yan
   Cheng, Huijun
   Yuan, Yuan
   Zhang, Wei
   Ke, Changwen
   Wong, Gary
   Qi, Jianxun
   Qin, Chuan
   Yan, Jinghua
   Gao, George F.
TI A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS,
   and SARS
SO CELL
LA English
DT Article
ID RECEPTOR-BINDING DOMAIN; ANTIBODY-DEPENDENT ENHANCEMENT; DIPEPTIDYL
   PEPTIDASE 4; HUMAN CORONAVIRUS; SPIKE PROTEIN; NEUTRALIZING ANTIBODIES;
   STRUCTURAL DEFINITION; FUNCTIONAL RECEPTOR; SUBUNIT VACCINE;
   S-GLYCOPROTEIN
AB Vaccines are urgently needed to control the ongoing pandemic COVID-19 and previously emerging MERS/ SARS caused by coronavirus (CoV) infections. The CoV spike receptor-binding domain (RBD) is an attractive vaccine target but is undermined by limited immunogenicity. We describe a dimeric form of MERS-CoV RBD that overcomes this limitation. The RBD-dimer significantly increased neutralizing antibody (NAb) titers compared to conventional monomeric form and protected mice against MERS-CoV infection. Crystal structure showed RBD-dimer fully exposed dual receptor-binding motifs, the major target for NAbs. Structureguided design further yielded a stable version of RBD-dimer as a tandem repeat single-chain (RBD-sc-dimer) which retained the vaccine potency. We generalized this strategy to design vaccines against COVID-19 and SARS, achieving 10- to 100-fold enhancement of NAb titers. RBD-sc-dimers in pilot scale production yielded high yields, supporting their scalability for further clinical development. The framework of immunogen design can be universally applied to other beta-CoV vaccines to counter emerging threats.
C1 [Dai, Lianpan; Zheng, Tianyi; An, Yaling; Cheng, Huijun; Gao, George F.] Chinese Acad Sci, Beijing Inst Life Sci, Res Network Immun & Hlth RNIH, Beijing 100101, Peoples R China.
   [Dai, Lianpan; Zheng, Tianyi; Han, Yuxuan; Qi, Jianxun; Gao, George F.] Univ Chinese Acad Sci, Savaid Med Sch, Beijing 101408, Peoples R China.
   [Dai, Lianpan; Xu, Kun] Hainan Med Univ, Affiliated Hosp 1, Sch Trop Med & Lab Med, Key Lab Trop Translat Med,Minist Educ, Haikou 571199, Hainan, Peoples R China.
   [Xu, Lili; Qin, Chuan] Chinese Acad Med Sci, Inst Lab Anim Sci, Key Lab Anim Models Emerging & Remerging Infect D, Beijing 100032, Peoples R China.
   [Xu, Lili; Qin, Chuan] Peking Union Med Coll, Comparat Med Ctr, Beijing 100032, Peoples R China.
   [Huang, Enqi; Cheng, Yingjie] Anhui Zhifei Longcom Biopharmaceut Co Ltd, Hefei 230088, Anhui, Peoples R China.
   [Li, Shihua; Li, Yan; Yuan, Yuan; Zhang, Wei; Qi, Jianxun; Yan, Jinghua; Gao, George F.] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.
   [Liu, Mei; Yang, Mi; Yan, Jinghua] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Microbial Physiol & Metab Engn, Beijing 100101, Peoples R China.
   [Ke, Changwen] Guangdong Prov Ctr Dis Control & Prevent, Guangzhou 511430, Peoples R China.
   [Wong, Gary] Chinese Acad Sci, Inst Pasteur Shanghai, Shanghai 200031, Peoples R China.
   [Wong, Gary] Laval Univ, Dept Microbiol Infectiol & Immunol, Quebec City, PQ G1V 4G2, Canada.
   [Gao, George F.] Chinese Ctr Dis Control & Prevent China CDC, Beijing 102206, Peoples R China.
RP Dai, LP; Gao, GF (corresponding author), Chinese Acad Sci, Beijing Inst Life Sci, Res Network Immun & Hlth RNIH, Beijing 100101, Peoples R China.; Dai, LP; Gao, GF (corresponding author), Univ Chinese Acad Sci, Savaid Med Sch, Beijing 101408, Peoples R China.; Dai, LP (corresponding author), Hainan Med Univ, Affiliated Hosp 1, Sch Trop Med & Lab Med, Key Lab Trop Translat Med,Minist Educ, Haikou 571199, Hainan, Peoples R China.; Qin, C (corresponding author), Chinese Acad Med Sci, Inst Lab Anim Sci, Key Lab Anim Models Emerging & Remerging Infect D, Beijing 100032, Peoples R China.; Qin, C (corresponding author), Peking Union Med Coll, Comparat Med Ctr, Beijing 100032, Peoples R China.; Yan, JH; Gao, GF (corresponding author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.; Yan, JH (corresponding author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Microbial Physiol & Metab Engn, Beijing 100101, Peoples R China.; Gao, GF (corresponding author), Chinese Ctr Dis Control & Prevent China CDC, Beijing 102206, Peoples R China.
EM dailp@biols.ac.cn; qinchuan@pumc.edu.cn; yanjh@im.ac.cn; gaof@im.ac.cn
RI qin, chuan/ABG-4508-2020
FU National Natural Science Foundation of China, China (NSFC)National
   Natural Science Foundation of China (NSFC) [81991494]; National Science
   and Technology Major Project, China [2016YFE0205800, 2018ZX10101004];
   Strategic Priority Research Program of the CAS, China [XDPB0301]; Youth
   Innovation Promotion Association CAS, China [2018113]
FX We are grateful to Z. Fan (Institute of Microbiology, Chinese Academy of
   Sciences [CAS]) for their technical assistance with SPR experiments. We
   thank Y. Zhang (Institute of Microbiology, CAS) for technical assistance
   with recombinant protein preparation. We thank Q. Wang (Institute of
   Microbiology, CAS) for help with analytical ultracentrifugation
   experiment. We thank W. Tan for (China CDC) for providing us the
   Ad5-hCD26 virus. We thank the staff BL19U beamlines at National Center
   for Protein Sciences Shanghai and Shanghai Synchrotron Radiation
   Facility (Shanghai, China) for assistance during data collection. This
   work is supported by the National Natural Science Foundation of China,
   China (NSFC) (81991494), the National Science and Technology Major
   Project, China (2016YFE0205800 and 2018ZX10101004), and the Strategic
   Priority Research Program of the CAS, China (XDPB0301). L. Dai is
   supported by Youth Innovation Promotion Association CAS, China
   (2018113).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112
   Banerjee A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010041
   Chen YZ, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.18
   Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301
   CORAPI WV, 1992, J VIROL, V66, P6695, DOI 10.1128/JVI.66.11.6695-6705.1992
   Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031
   Du LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081587
   Du LY, 2009, VIROLOGY, V393, P144, DOI 10.1016/j.virol.2009.07.018
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gorse GJ, 2009, J INFECT DIS, V199, P847, DOI 10.1086/597122
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hohdatsu T, 1998, J VET MED SCI, V60, P49, DOI 10.1292/jvms.60.49
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Islam MS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090841
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Jean A, 2013, PEDIATR INFECT DIS J, V32, P325, DOI 10.1097/INF.0b013e3182812787
   Jevsnik M, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-365
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Jiang SB, 2012, EXPERT REV VACCINES, V11, P1405, DOI [10.1586/erv.12.126, 10.1586/ERV.12.126]
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   Kim YS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01093
   Knipe D.M., 2013, FIELDS VIROLOGY
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li ET, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090799
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Li SW, 2020, ECOTOX ENVIRON SAFE, V201, DOI 10.1016/j.ecoenv.2020.110801
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li Y, 2015, CELL RES, V25, P1237, DOI 10.1038/cr.2015.113
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Ma CQ, 2014, VACCINE, V32, P6170, DOI 10.1016/j.vaccine.2014.08.086
   Modjarrad K, 2016, NAT MED, V22, P701, DOI 10.1038/nm.4131
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Nyon MP, 2018, VACCINE, V36, P1853, DOI 10.1016/j.vaccine.2018.02.065
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Syed YY, 2018, DRUG AGING, V35, P1031, DOI 10.1007/s40266-018-0603-x
   Tai WB, 2016, VIROLOGY, V499, P375, DOI 10.1016/j.virol.2016.10.005
   Tang J, 2015, HUM VACC IMMUNOTHER, V11, P1244, DOI 10.1080/21645515.2015.1021527
   VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang C, 2017, ANTIVIR RES, V140, P55, DOI 10.1016/j.antiviral.2016.12.019
   Wang NS, 2019, CELL REP, V28, P3395, DOI 10.1016/j.celrep.2019.08.052
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wei Q., 2020, CHINA CDC WEEKLY, V2, P61
   Wevers BA, 2009, CLIN LAB MED, V29, P715, DOI 10.1016/j.cll.2009.07.007
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Wong ACP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020174
   Woo PCY, 2009, J VIROL, V83, P908, DOI 10.1128/JVI.01977-08
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xiao XD, 2004, BIOCHEM BIOPH RES CO, V322, P93, DOI 10.1016/j.bbrc.2004.07.084
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang NR, 2015, VIRUS RES, V202, P151, DOI 10.1016/j.virusres.2014.11.013
   Zhang SY, 2018, CELL REP, V24, P441, DOI 10.1016/j.celrep.2018.06.041
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zhou HX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10897-4
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 74
TC 17
Z9 16
U1 11
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 6
PY 2020
VL 182
IS 3
BP 722
EP +
DI 10.1016/j.cell.2020.06.035
PG 23
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MY8EK
UT WOS:000558649000016
PM 32645327
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sun, J
   Zhuang, Z
   Zheng, J
   Li, K
   Wong, RLY
   Liu, DL
   Huang, JC
   He, JP
   Zhu, AR
   Zhao, JX
   Li, XB
   Xi, Y
   Chen, RC
   Alshukairi, AN
   Chen, Z
   Zhang, ZY
   Chen, CK
   Huang, XF
   Li, F
   Lai, XM
   Chen, DB
   Wen, LY
   Zhuo, JF
   Zhang, YJ
   Wang, YQ
   Huang, SX
   Dai, J
   Shi, YX
   Zheng, K
   Leidinger, MR
   Chen, JK
   Li, YM
   Zhong, NS
   Meyerholz, DK
   McCray, PB
   Perlman, S
   Zhao, JC
AF Sun, Jing
   Zhuang, Zhen
   Zheng, Jian
   Li, Kun
   Wong, Roy Lok-Yin
   Liu, Donglan
   Huang, Jicheng
   He, Jiangping
   Zhu, Airu
   Zhao, Jingxian
   Li, Xiaobo
   Xi, Yin
   Chen, Rongchang
   Alshukairi, Abeer N.
   Chen, Zhao
   Zhang, Zhaoyong
   Chen, Chunke
   Huang, Xiaofang
   Li, Fang
   Lai, Xiaomin
   Chen, Dingbin
   Wen, Liyan
   Zhuo, Jianfen
   Zhang, Yanjun
   Wang, Yanqun
   Huang, Shuxiang
   Dai, Jun
   Shi, Yongxia
   Zheng, Kui
   Leidinger, Mariah R.
   Chen, Jiekai
   Li, Yimin
   Zhong, Nanshan
   Meyerholz, David K.
   McCray, Paul B., Jr.
   Perlman, Stanley
   Zhao, Jincun
TI Generation of a Broadly Useful Model for COVID-19 Pathogenesis,
   Vaccination, and Treatment
SO CELL
LA English
DT Article
ID SYNDROME CORONAVIRUS INFECTION; MOUSE MODEL; RAPID GENERATION;
   GROWTH-FACTORS; DISEASE; ADENOVIRUS; EFFICACY; DAMAGE
AB COVID-19, caused by SARS-CoV-2, is a virulent pneumonia, with >4,000,000 confirmed cases worldwide and >290,000 deaths as of May 15, 2020. It is critical that vaccines and therapeutics be developed very rapidly. Mice, the ideal animal for assessing such interventions, are resistant to SARS-CoV-2. Here, we overcome this difficulty by exogenous delivery of human ACE2 with a replication-deficient adenovirus (Ad5-hACE2). Ad5-hACE2-sensitized mice developed pneumonia characterized byweight loss, severe pulmonary pathology, and high-titer virus replication in lungs. Type I interferon, T cells, and, most importantly, signal transducer and activator of transcription 1 (STAT1) are critical for virus clearance and disease resolution in these mice. Ad5-hACE2-transduced mice enabled rapid assessments of a vaccine candidate, of human convalescent plasma, and of two antiviral therapies (poly I:C and remdesivir). In summary, we describe a murine model of broad and immediate utility to investigate COVID-19 pathogenesis and to evaluate new therapies and vaccines.
C1 [Sun, Jing; Zhuang, Zhen; Liu, Donglan; Zhu, Airu; Zhao, Jingxian; Xi, Yin; Chen, Zhao; Zhang, Zhaoyong; Chen, Chunke; Huang, Xiaofang; Li, Fang; Lai, Xiaomin; Chen, Dingbin; Wen, Liyan; Zhuo, Jianfen; Zhang, Yanjun; Wang, Yanqun; Li, Yimin; Zhong, Nanshan; Zhao, Jincun] Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Affiliated Hosp 1, Guangzhou 510182, Guangdong, Peoples R China.
   [Zheng, Jian; Li, Kun; Wong, Roy Lok-Yin; McCray, Paul B., Jr.; Perlman, Stanley] Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA 52242 USA.
   [Huang, Jicheng; Li, Xiaobo; Huang, Shuxiang; Dai, Jun; Shi, Yongxia; Zheng, Kui] Guangzhou Customs Dist Technol Ctr, Guangzhou 510700, Peoples R China.
   [He, Jiangping; Chen, Jiekai] Guangzhou Regenerat Med & Hlth Guangdong Lab GRMH, Guangzhou 510530, Guangdong, Peoples R China.
   [Chen, Rongchang] South Univ Sci & Technol China, Shenzhen Inst Resp Dis, Affiliated Hosp 1, Shenzhen Peoples Hosp, Shenzhen, Guangdong, Peoples R China.
   [Alshukairi, Abeer N.] King Faisal Specialist Hosp & Res Ctr, Jeddah, Saudi Arabia.
   [Leidinger, Mariah R.; Meyerholz, David K.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA.
   [Chen, Jiekai] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou 510530, Guangdong, Peoples R China.
   [McCray, Paul B., Jr.; Perlman, Stanley] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
   [Zhao, Jincun] Guangzhou Med Univ, Inst Infect Dis, Guangzhou Peoples Hosp 8, Guangzhou 510060, Guangdong, Peoples R China.
RP Zhao, JC (corresponding author), Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Affiliated Hosp 1, Guangzhou 510182, Guangdong, Peoples R China.; McCray, PB; Perlman, S (corresponding author), Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA 52242 USA.; McCray, PB; Perlman, S (corresponding author), Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.; Zhao, JC (corresponding author), Guangzhou Med Univ, Inst Infect Dis, Guangzhou Peoples Hosp 8, Guangzhou 510060, Guangdong, Peoples R China.
EM paul-mccray@uiowa.edu; stanley-perlman@uiowa.edu; zhaojincun@gird.cn
RI Meyerholz, David/J-8131-2019
OI Meyerholz, David/0000-0003-1552-3253; He, Jiangping/0000-0002-1425-3530;
   Wong, Lok Yin Roy/0000-0002-0727-8289
FU National Key Research and Development Program of China [2018YFC1200100];
   National Science and Technology Major Project [2018ZX10301403];
   Guangdong province [2020B111108001, 2018B020207013]; National Institutes
   of Health USA (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P01 AI060699, RO1
   AI129269]; Center for Gene Therapy for Cystic Fibrosis (NIH) [P30
   DK-54759]; Cystic Fibrosis Foundation; Roy J. Carver Charitable Trust;
   Ministry of Science and Technology [2020YFC0841400]
FX This work is supported by the grants from The National Key Research and
   Development Program of China (2018YFC1200100) (J.Z.), National Science
   and Technology Major Project (2018ZX10301403) (J.Z.), the emergency
   grants for prevention and control of SARS-CoV-2 of Ministry of Science
   and Technology (2020YFC0841400) (J.Z.) and Guangdong province
   (2020B111108001, 2018B020207013) (J.Z.); the National Institutes of
   Health USA (NIH) (P01 AI060699 [S.P., P.B.M.] and RO1 AI129269 [S.P.]);
   and the Pathology Core, which is partially supported by the Center for
   Gene Therapy for Cystic Fibrosis (NIH grant P30 DK-54759), and the
   Cystic Fibrosis Foundation. P.B.M. is supported by the Roy J. Carver
   Charitable Trust. We thank Christine Wohlford-Lenane for technical
   assistance, Dr. Ralph Baric for providing VRP plasmids, and the patients
   who took part in this study.
CR Agrawal AS, 2015, J VIROL, V89, P3659, DOI 10.1128/JVI.03427-14
   Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197
   Bao L., 2020, NATURE, V2020, P7
   BENNETT NT, 1993, AM J SURG, V166, P74, DOI 10.1016/S0002-9610(05)80589-6
   Boudewijns R, 2020, STAT2 SIGNALING DOUB, DOI [DOI 10.1101/2020.04.23.056838, 10.1101/2020.04.23.056838]
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Cockrell AS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.226
   CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   DEUEL T F, 1988, Biofactors, V1, P213
   Frieman MB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000849
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hutchins Andrew Paul, 2014, Cell Regen, V3, P1, DOI 10.1186/2045-9769-3-1
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li K, 2017, P NATL ACAD SCI USA, V114, pE3119, DOI 10.1073/pnas.1619109114
   Li K, 2016, J INFECT DIS, V213, P712, DOI 10.1093/infdis/jiv499
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Meyerholz DK, 2018, LAB INVEST, V98, P844, DOI 10.1038/s41374-018-0057-0
   Nabel GJ, 2004, NAT MED, V10, P135, DOI 10.1038/nm990
   Nagata N, 2008, AM J PATHOL, V172, P1625, DOI 10.2353/ajpath.2008.071060
   Pascal KE, 2015, P NATL ACAD SCI USA, V112, P8738, DOI 10.1073/pnas.1510830112
   Prokunina-Olsson L, 2020, J EXP MED, V217, DOI 10.1084/jem.20200653
   Risso D, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-480
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   WAHL SM, 1989, J CELL BIOCHEM, V40, P193, DOI 10.1002/jcb.240400208
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yoshikawa N, 2009, J VIROL, V83, P5451, DOI 10.1128/JVI.02272-08
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu Pin, 2020, Animal Model Exp Med, V3, P93, DOI 10.1002/ame2.12108
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 44
TC 28
Z9 25
U1 7
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 6
PY 2020
VL 182
IS 3
BP 734
EP +
DI 10.1016/j.cell.2020.06.010
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MY8EK
UT WOS:000558649000017
PM 32643603
OA Green Published
DA 2021-01-01
ER

PT J
AU Hassan, AO
   Case, JB
   Winkler, ES
   Thackray, LB
   Kafai, NM
   Bailey, AL
   McCune, BT
   Fox, JM
   Chen, RTE
   Alsoussi, WB
   Turner, JS
   Schmitz, AJ
   Lei, TT
   Shrihari, S
   Keeler, SP
   Fremont, DH
   Greco, S
   McCray, PB
   Perlman, S
   Holtzman, MJ
   Ellebedy, AH
   Diamond, MS
AF Hassan, Ahmed O.
   Case, James Brett
   Winkler, Emma S.
   Thackray, Larissa B.
   Kafai, Natasha M.
   Bailey, Adam L.
   McCune, Broc T.
   Fox, Julie M.
   Chen, Rita E.
   Alsoussi, Wafaa B.
   Turner, Jackson S.
   Schmitz, Aaron J.
   Lei, Tingting
   Shrihari, Swathi
   Keeler, Shamus P.
   Fremont, Daved H.
   Greco, Suellen
   McCray, Paul B., Jr.
   Perlman, Stanley
   Holtzman, Michael J.
   Ellebedy, Ali H.
   Diamond, Michael S.
TI A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by
   Neutralizing Antibodies
SO CELL
LA English
DT Article
ID MONOCLONAL-ANTIBODIES; RECEPTOR
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic with millions of human infections. One limitation to the evaluation of potential therapies and vaccines to inhibit SARS-CoV-2 infection and ameliorate disease is the lack of susceptible small animals in large numbers. Commercially available laboratory strains of mice are not readily infected by SARS-CoV-2 because of species-specific differences in their angiotensin-converting enzyme 2 (ACE2) receptors. Here, we transduced replication-defective adenoviruses encoding human ACE2 via intranasal administration into BALB/c mice and established receptor expression in lung tissues. hACE2-transduced mice were productively infected with SARS-CoV-2, and this resulted in high viral titers in the lung, lung pathology, and weight loss. Passive transfer of a neutralizing monoclonal antibody reduced viral burden in the lung and mitigated inflammation and weight loss. The development of an accessible mouse model of SARS-CoV-2 infection and pathogenesis will expedite the testing and deployment of therapeutics and vaccines.
C1 [Hassan, Ahmed O.; Case, James Brett; Winkler, Emma S.; Thackray, Larissa B.; Kafai, Natasha M.; McCune, Broc T.; Fox, Julie M.; Chen, Rita E.; Shrihari, Swathi; Keeler, Shamus P.; Holtzman, Michael J.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Winkler, Emma S.; Kafai, Natasha M.; Bailey, Adam L.; Chen, Rita E.; Alsoussi, Wafaa B.; Turner, Jackson S.; Schmitz, Aaron J.; Lei, Tingting; Fremont, Daved H.; Ellebedy, Ali H.; Diamond, Michael S.] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA.
   [Greco, Suellen] Washington Univ, Dept Comparat Med, Sch Med, St Louis, MO 63110 USA.
   [Ellebedy, Ali H.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Fremont, Daved H.] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.
   [Keeler, Shamus P.; Holtzman, Michael J.] Washington Univ, Div Pulm & Crit Care Med, Sch Med, St Louis, MO 63110 USA.
   [Fremont, Daved H.; Ellebedy, Ali H.; Diamond, Michael S.] Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO 63110 USA.
   [McCray, Paul B., Jr.; Perlman, Stanley] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
   [McCray, Paul B., Jr.; Perlman, Stanley] Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA 52242 USA.
RP Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO 63110 USA.
EM diamond@wusm.wustl.edu
RI Keeler, Shamus/ABC-1774-2020
OI Keeler, Shamus/0000-0002-1301-0852; Al Soussi,
   Wafaa/0000-0002-5805-4461; Schmitz, Aaron/0000-0002-8077-6751
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [75N93019C00062, R01 AI127828, P01
   AI60699, R21 AI139813, U01 AI141990, R01 AI130591, R35 HL145242,
   HHSN272201400008C]; Defense Advanced Research Projects AgencyUnited
   States Department of DefenseDefense Advanced Research Projects Agency
   (DARPA) [HR001117S0019]; Helen Hay Whitney Foundation postdoctoral
   fellowship;  [F32 AI138392]
FX This study was supported by NIH contracts and grants (75N93019C00062,
   R01 AI127828, P01 AI60699, R21 AI139813, U01 AI141990, R01 AI130591, R35
   HL145242, and HHSN272201400008C) and the Defense Advanced Research
   Projects Agency (HR001117S0019). B.T.M is supported by F32 AI138392 and
   J.B.C. is supported by a Helen Hay Whitney Foundation postdoctoral
   fellowship. We thank Sean Whelan, Susan Cook, and Jennifer Philips for
   facilitating the high-containment studies with SARS-CoV-2 and Arthur Kim
   for purifying the CR3022 anti-S mAb.
CR Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Boon ACM, 2011, MBIO, V2, DOI 10.1128/mBio.00171-11
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Coleman CM, 2014, J GEN VIROL, V95, P408, DOI 10.1099/vir.0.060640-0
   Cook LE, 2020, J VIROL, V94, DOI 10.1128/JVI.00841-19
   Corti D, 2015, P NATL ACAD SCI USA, V112, P10473, DOI 10.1073/pnas.1510199112
   Davis CW, 2019, CELL, V177, P1566, DOI 10.1016/j.cell.2019.04.036
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1165
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Galani IE, 2017, IMMUNITY, V46, P875, DOI 10.1016/j.immuni.2017.04.025
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hogan RJ, 2004, J VIROL, V78, P11416, DOI 10.1128/JVI.78.20.11416-11421.2004
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Klinkhammer J, 2018, ELIFE, V7, DOI 10.7554/eLife.33354
   Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025
   Ledford Heidi, 2020, Nature, DOI 10.1038/d41586-020-01295-8
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996
   Munster V.J., 2020, BIORXIV, DOI [10.1101/2020.03.21., DOI 10.1101/2020.03.21]
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Ng CT, 2016, CELL, V164, P349, DOI 10.1016/j.cell.2015.12.027
   Noll KE, 2019, CELL HOST MICROBE, V25, P484, DOI 10.1016/j.chom.2019.03.009
   Pinto AK, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004086
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Sheehan KCF, 2006, J INTERF CYTOK RES, V26, P804, DOI 10.1089/jir.2006.26.804
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010
   Sun LL, 2015, CELL HOST MICROBE, V17, P85, DOI 10.1016/j.chom.2014.11.004
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 50
TC 48
Z9 46
U1 9
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 6
PY 2020
VL 182
IS 3
BP 744
EP +
DI 10.1016/j.cell.2020.06.011
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MY8EK
UT WOS:000558649000018
PM 32553273
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Alazmi, M
   Motwalli, O
AF Alazmi, Meshari
   Motwalli, Olaa
TI In silicovirtual screening, characterization, docking and molecular
   dynamics studies of crucial SARS-CoV-2 proteins
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; molecular docking; virtual screening; molecular
   dynamics simulation
ID GROMACS; MODELS
AB The ongoing pandemic COVID-19 (COrona Virus Immuno Deficiency-2019) which is caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome-CoronaVirus-2) has emerged as a pandemic with 400,000 plus deaths till date. We do not have any drug or vaccine available for the inhibition of this deadly virus. The expedition for searching a potential drug or vaccine against COVID-19 will be of massive potential and favor. This study is focused on finding an effective natural origin compound which can put a check on the activity of this virus. We chose important proteins from the SARS-CoV-2 genome such as NSP4, NSP15 and RdRp along-with the human ACE2 receptor which is the first point of contact with the virus. Virtual screening and followed up molecular docking resulted in Baicalin and Limonin as the final lead molecules. 200 ns of MD simulation for each protein-ligand complex provides the insights that Baicalin has a potential to target NSP4, NSP15 and RdRp proteins. Limonin which is largely used in traditional Indian medicine system is found to inhibit the human ACE2 receptor (making it inefficient in binding to the receptor binding domain of SARS-CoV-2). Our studies propose Baicalin and Limonin in combination to be studiedin vitroandin vivoagainst COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Alazmi, Meshari] Univ Hail, Coll Comp Sci & Engn, Dept Comp Sci, POB 2440, Hail 81411, Saudi Arabia.
   [Motwalli, Olaa] Saudi Elect Univ SEU, Coll Comp & Informat, Madinah, Saudi Arabia.
RP Alazmi, M (corresponding author), Univ Hail, Coll Comp Sci & Engn, Dept Comp Sci, POB 2440, Hail 81411, Saudi Arabia.
EM ms.alazmi@uoh.edu.sa
FU Ministry of Health (MOH), Saudi Arabia [928, 928E-20.04.2020]
FX This article has been supported by Ministry of Health (MOH), Saudi
   Arabia under grant No. 928 and ethical approval letter with reference
   number (20-#928E-20.04.2020).
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Alagaili AN, 2014, MBIO, V5, DOI DOI 10.1128/MBIO.00884-14
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Bhakkiyalakshmi E, 2016, EUR J PHARMACOL, V777, P9, DOI 10.1016/j.ejphar.2016.02.054
   Bikadi Z, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-15
   Biovia D., 2017, BIOVIA DISCOVERY STU
   Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93
   Boutet E, 2016, METHODS MOL BIOL, V1374, P23, DOI 10.1007/978-1-4939-3167-5_2
   Carugo O, 2013, ACTA CRYSTALLOGR D, V69, P1333, DOI 10.1107/S090744491301158X
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Danish S., 2013, EXCLI J, V12
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Fahrrolfes R, 2017, NUCLEIC ACIDS RES, V45, pW337, DOI 10.1093/nar/gkx333
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104
   Laskowski R., 1993, J APPL CRYSTALLOGRAP, V24
   Laskowski R., 2006, PROCHECK VALIDATION
   Laskowski R. A., 1994, PROCHECK V 3 0 PROGR
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu XR, 2019, MOL IMMUNOL, V114, P100, DOI 10.1016/j.molimm.2019.07.003
   Nugent T, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-276
   Pal Sourav, 2020, COMPILATION POTENTIA, DOI [10.26434/chemrxiv.12084468.v1, DOI 10.26434/CHEMRXIV.12084468.V1]
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6
   Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822-010-9352-6
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Venkataraman S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020076
   Wang XL, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-020-0424-9
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang J., 2020, MOL DYNAMICS STUDIES
NR 47
TC 2
Z9 2
U1 6
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1803965
EA AUG 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MX2VC
UT WOS:000557584000001
PM 32762537
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Chowdhury, P
AF Chowdhury, Papia
TI In silico investigation of phytoconstituents from Indian medicinal herb
   'Tinospora cordifolia (giloy)' against SARS-CoV-2 (COVID-19) by
   molecular dynamics approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Tinospora cordifolia; berberine; 3CLpro;
   beta-sitosterol
ID FORCE-FIELD; CORONAVIRUS; SARS; OPTIMIZATION; CHLOROQUINE; PROTEINASE;
   INSIGHTS; DOCKING
AB The recent appearance of COVID-19 virus has created a global crisis due to unavailability of any vaccine or drug that can effectively and deterministically work against it. Naturally, different possibilities (including herbal medicines having known therapeutic significance) have been explored by the scientists. The systematic scientific study (beginning with in silico study) of herbal medicines in particular and any drug in general is now possible as the structural components (proteins) of COVID-19 are already characterized. The main protease of COVID-19 virus is M(pro)or 3CL(pro)which is a key CoV enzyme and an attractive drug target as it plays a pivotal role in mediating viral replication and transcription. In the present study, 3CL(pro)is used to study drug:3CL(pro)interactions and thus to investigate whether all or any of the main chemical constituents ofTinospora cordifolia(e.g. berberine (C20H18NO4), beta-sitosterol (C29H50O), coline (C5H14NO), tetrahydropalmatine (C21H25NO4) and octacosanol (C28H58O)) can be used as an anti-viral drug against SARS-CoV-2. The in silico study performed using tools of network pharmacology, molecular docking including molecular dynamics have revealed that among all considered phytochemicals inTinospora cordifolia, berberine can regulate 3CL(pro)protein's function due to its easy inhibition and thus can control viral replication. The selection ofTinospora cordifoliawas motivated by the fact that the main constituents of it are known to be responsible for various antiviral activities and the treatment of jaundice, rheumatism, diabetes, etc. Communicated by Ramaswamy H. Sarma
C1 [Chowdhury, Papia] Jaypee Inst Informat Technol, Dept Phys & Mat Sci & Engn, Noida 201309, Uttar Pradesh, India.
RP Chowdhury, P (corresponding author), Jaypee Inst Informat Technol, Dept Phys & Mat Sci & Engn, Noida 201309, Uttar Pradesh, India.
EM papia.chowdhury@jiit.ac.in
OI Chowdhury, Papia/0000-0001-9702-2553
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Beadling C, 2004, CURR OPIN INFECT DIS, V17, P185, DOI 10.1097/00001432-200406000-00003
   Becke AD, 1997, J CHEM PHYS, V107, P8554, DOI 10.1063/1.475007
   Benson NC, 2012, J PHYS CHEM B, V116, P8722, DOI 10.1021/jp302103t
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Chang CK, 2016, DRUG DISCOV TODAY, V21, P562, DOI 10.1016/j.drudis.2015.11.015
   Cheng FX, 2013, J CHEM INF MODEL, V53, P744, DOI 10.1021/ci4000079
   Corbin KD, 2012, CURR OPIN GASTROEN, V28, P159, DOI 10.1097/MOG.0b013e32834e7b4b
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dassault Systemes BIOVIA, 2017, DISC STUD MOD ENV RE
   Dayer MR, 2017, ARCH CLIN INFECT DIS, V12, DOI 10.5812/archcid.13823
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dewick P. M., 2009, MED NATURAL PRODUCTS
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Frisch M. J., 2004, GAUSSIAN 09 REVISION
   Gajula MNVP, 2016, BIO-PROTOCOL, V6, P1, DOI DOI 10.21769/BIOPROTOC.2051
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   GUAN X, 2020, NEW ENGL J MED, V382, DOI DOI 10.1016/J.CEJ.2019.122935
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772110
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767691
   Jee B, 2018, J BIOMOL STRUCT DYN, V36, P3434, DOI 10.1080/07391102.2017.1389305
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kaisari E., 2020, KEEPING EYE HYDROXYC
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI 10.20944/preprints202003.0226.v1
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kumar A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772112
   Kumar A, 2018, DATA, V3, DOI 10.3390/data3010007
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010
   Michel F. S., 1999, J MOL GRAPHICS MODEL, V17
   Patil R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012029
   Rana M, 2017, J MOL MODEL, V23, DOI 10.1007/s00894-017-3380-2
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Rudkowska I, 2008, J AM COLL NUTR, V27, P588, DOI 10.1080/07315724.2008.10719742
   Salata C, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftaa006
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sharma P, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02437
   Singla N, 2014, CHEM PHYS, V441, P93, DOI 10.1016/j.chemphys.2014.07.009
   Sonkamble V. V., 2015, AM J PHYTOMEDICINE C, V3
   Gutierrez IS, 2016, BIOORGAN MED CHEM, V24, P4812, DOI 10.1016/j.bmc.2016.06.034
   Taylor JC, 2003, NUTRITION, V19, P192, DOI 10.1016/S0899-9007(02)00869-9
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Vanommeslaeghe K, 2012, J CHEM INF MODEL, V52, P3144, DOI 10.1021/ci300363c
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wang B, 2020, NEPHRON, V144, P96, DOI 10.1159/000503882
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang ZF, 2008, J MASS SPECTROM, V43, P327, DOI 10.1002/jms.1320
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yuriev E, 2011, J MOL RECOGNIT, V24, P149, DOI 10.1002/jmr.1077
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 68
TC 2
Z9 2
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1803968
EA AUG 2020
PG 18
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MX8ZK
UT WOS:000558007400001
PM 32762511
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Orsini, A
   Corsi, M
   Santangelo, A
   Riva, A
   Peroni, D
   Foiadelli, T
   Savasta, S
   Striano, P
AF Orsini, Alessandro
   Corsi, Martina
   Santangelo, Andrea
   Riva, Antonella
   Peroni, Diego
   Foiadelli, Thomas
   Savasta, Salvatore
   Striano, Pasquale
TI Challenges and management of neurological and psychiatric manifestations
   in SARS-CoV-2 (COVID-19) patients
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Coronavirus; Brain; CNS; Neurologic; Psychiatric
ID CYTOKINE STORM; CORONAVIRUS; PATHOGENESIS; CHLOROQUINE; INFECTION;
   PNEUMONIA; OUTBREAK; MICE
AB COVID-19 is a pandemic caused by human coronavirus (HCoV) SARS-CoV-2, which originated in Wuhan, China, at the end of 2019 and spread globally during 2020. Due to the difficulty of clinical decision-making during this period, our study group reviewed current literature focusing on the neurological and psychiatric aspects of COVID-19. Despite the knowledge on this newly discovered virus which is constantly evolving, different pieces of evidence reported an association between COVID-19 and neurological symptoms like headache, dizziness, taste and smell disorders and complications involving the nervous system eventually triggered by the pathologic processes elicited by SARS-CoV-2. It seems that younger patients are less prone to develop severe forms of COVID-19. However, neurological signs have been reported in paediatric patients as well, and in some cases, the infection presented neurological sequelae. Furthermore, children with particular neurological diseases or treated with specific drugs (e.g. immune-suppressant therapies) must be carefully monitored during this pandemic. Neurologists should be aware of the main drug-drug interactions and the neurological side effects of COVID-19 treatments. Notably, adverse mental health impact has been reported in patients with SARS-CoV-2, which could be related either to the social strain or to the eventual neurotropic effects of the virus, which in other infections have been proven to promote the onset of psychiatric symptoms. Further, psychiatric population may be more vulnerable to the infection and at higher risk for adverse outcomes.
C1 [Orsini, Alessandro; Santangelo, Andrea; Peroni, Diego] Univ Pisa, Dept Clin & Expt Med, Pediat Clin, Via Roma 67, I-56100 Pisa, Italy.
   [Corsi, Martina] Univ Pisa, Dept Clin & Expt Med, Psychiat Clin, Via Roma 67, I-56100 Pisa, Italy.
   [Riva, Antonella; Striano, Pasquale] IRCCS, Pediat Neurol Unit, Ist Giannina Gaslini, Genoa, Italy.
   [Foiadelli, Thomas; Savasta, Salvatore] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Pediat, Pediat Clin, Pavia, Italy.
   [Striano, Pasquale] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
RP Corsi, M (corresponding author), Univ Pisa, Dept Clin & Expt Med, Psychiat Clin, Via Roma 67, I-56100 Pisa, Italy.
EM aorsini.md@gmail.com; dott.martinacorsi@gmail.com;
   androsantangelo@gmail.com; riva.anto94@gmail.com; perodiego@gmail.com;
   thomas.foiadelli@gmail.com; s.savasta@smatteo.pv.it; strianop@gmail.com
RI Riva, Antonella/ABB-8813-2020
CR AIFA, SPER CLIN COVID 19
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Amor S, 2020, ANN NEUROL
   ANDRIES K, 1980, AM J VET RES, V41, P1372
   Asadi-Pooya AA, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116832
   Assini A, 2020, NEUROL SCI, V41, P1657, DOI 10.1007/s10072-020-04484-5
   Avula A, 2020, BRAIN BEHAV IMMUN, V87, P115, DOI 10.1016/j.bbi.2020.04.077
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Bohmwald K, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00386
   Bove R, 2019, MULT SCLER J, V25, P1526, DOI 10.1177/1352458518793527
   Brooks J, 1997, AIDS Clin Care, V9, P90
   Brownlee W, 2020, NEUROLOGY, V94, P949, DOI 10.1212/WNL.0000000000009507
   Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Camdessanche JP, 2020, REV NEUROL-FRANCE, V176, P516, DOI 10.1016/j.neurol.2020.04.003
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Carlotti APDP, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1894
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Doobay MF, 2007, AM J PHYSIOL-REG I, V292, pR373, DOI 10.1152/ajpregu.00292.2006
   Dube M, 2018, J VIROL, V92, DOI 10.1128/JVI.00404-18
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330
   Guidon AC, 2020, NEUROLOGY, V94, P959, DOI 10.1212/WNL.0000000000009566
   Gummi RR, 2019, MUSCLE NERVE, V60, P693, DOI 10.1002/mus.26689
   Gunnell D, 2020, LANCET PSYCHIAT, V7, P468, DOI 10.1016/S2215-0366(20)30171-1
   Henry BM, 2020, CLIN CHEM LAB MED, V58, P1135, DOI 10.1515/cclm-2020-0272
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Kawohl W, 2020, LANCET PSYCHIAT, V7, P389, DOI 10.1016/S2215-0366(20)30141-3
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Klomek AB, 2020, LANCET PSYCHIAT, V7, P390, DOI 10.1016/S2215-0366(20)30142-5
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Li Jingwen, 2020, Curr Neuropharmacol, DOI 10.2174/1570159X18666200507085335
   Li YC, 2020, J MED VIROL, V92, P707, DOI 10.1002/jmv.25824
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu NQ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112921
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   MAY EF, 1990, ANN NEUROL, V28, P577, DOI 10.1002/ana.410280417
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   MULHAUSER P, 1995, ANN INTERN MED, V123, P76, DOI 10.7326/0003-4819-123-1-199507010-00021
   Muller KI, 2017, NEUROLOGY, V89, P153, DOI 10.1212/WNL.0000000000004085
   Multiple Sclerosis International Federation, GLOB COVID 19 ADV PE
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Oguz-Akarsu E, 2020, MUSCLE NERVE, DOI 10.1002/mus.26992
   Okusaga O, 2011, J AFFECT DISORDERS, V130, P220, DOI 10.1016/j.jad.2010.09.029
   Oxley TJ, N ENGL J MED, pe60
   Panda PK, 2020, INDIAN J PEDIATR, V87, P556, DOI 10.1007/s12098-020-03326-8
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Qubty W, 2018, NEUROLOGY, V90, pE1702, DOI 10.1212/WNL.0000000000005482
   Severance EG, 2011, SCHIZOPHRENIA BULL, V37, P101, DOI 10.1093/schbul/sbp052
   Smith K, 2020, EVID-BASED MENT HEAL, V23, P45, DOI 10.1136/ebmental-2020-300155
   Streng A, 2020, MONATSSCHR KINDERH, V168, P615, DOI 10.1007/s00112-020-00919-7
   Sun D, 2020, WORLD J PEDIATR, V16, P251, DOI 10.1007/s12519-020-00354-4
   Sun JK, 2020, POSTGRAD MED, V132, P604, DOI 10.1080/00325481.2020.1778982
   Szperka CL, 2020, HEADACHE, V60, P833, DOI 10.1111/head.13810
   Tan Xin, 2020, Zhongguo Dang Dai Er Ke Za Zhi, V22, P294
   Tang WJ, 2020, J AFFECT DISORDERS, V274, P1, DOI 10.1016/j.jad.2020.05.009
   To KF, 2004, J PATHOL, V203, P740, DOI 10.1002/path.1597
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Wang HL, 2008, AM J EMERG MED, V26, P711, DOI 10.1016/j.ajem.2007.10.031
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, REP WHO CHI JOINT MI
   WHO, 2005, 2 M INT HLTH REG 200
   Winkelmann A, 2016, NAT REV NEUROL, V12, P217, DOI 10.1038/nrneurol.2016.21
   World Health Organization, 2020, 138 WHO
   Wu XJ, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/792578
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Xiang P, 2020, CHINAXIV20200300015
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Yin R, 2020, J MED VIROL, V92, P1782, DOI 10.1002/jmv.25888
   Zambrelli E, 2020, SLEEP MED, V70, P111, DOI 10.1016/j.sleep.2020.04.006
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 84
TC 4
Z9 4
U1 6
U2 6
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
PD SEP
PY 2020
VL 41
IS 9
BP 2353
EP 2366
DI 10.1007/s10072-020-04544-w
EA AUG 2020
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MY3NO
UT WOS:000556662300002
PM 32767055
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lakshmanan, HHS
   Pore, AA
   Kohs, TCL
   Yazar, F
   Thompson, RM
   Jurney, PL
   Maddala, J
   Olson, SR
   Shatzel, JJ
   Vanapalli, SA
   McCarty, OJT
AF Lakshmanan, Hari Hara Sudhan
   Pore, Adity A.
   Kohs, Tia C. L.
   Yazar, Feyza
   Thompson, Rachel M.
   Jurney, Patrick L.
   Maddala, Jeevan
   Olson, Sven R.
   Shatzel, Joseph J.
   Vanapalli, Siva A.
   McCarty, Owen J. T.
TI Design of a Microfluidic Bleeding Chip to Evaluate Antithrombotic Agents
   for Use in COVID-19 Patients
SO CELLULAR AND MOLECULAR BIOENGINEERING
LA English
DT Article
DE Platelets; Microfluidics; Hemostasis; Thrombosis; Anticoagulant;
   Antithrombotic; COVID-19
ID HIERARCHICAL ORGANIZATION; HEMOSTATIC RESPONSE; THROMBUS FORMATION;
   HEPARIN
AB Introduction Interventions that could prevent thrombosis, clinical decompensation, and respiratory compromise in patients with novel coronavirus disease (COVID-19) are key to decrease mortality rate. Studies show that profound cytokine release and excessive activation of blood coagulation appear to be key drivers of COVID-19 associated mortality. Since limitedin vitromethods exist for assessing the effects of anticoagulants on hemostasis, the development of novel therapies to safely prevent thrombosis in COVID-19 patients relies on preclinical animal models and early phase human trials. Herein we present the design of a microfluidic "bleeding chip" to evaluate the effects of antithrombotic therapies on hemostatic plug formationin vitro. Methods The design of the microfluidic device consists of two orthogonal channels: an inlet that serves as a model blood vessel, and a bleeding channel to model hemostatic plug formation at sites of compromised endothelial barrier function. This is achieved by placing a series of 3 pillars spaced 10 mu m apart at the intersection of the two channels. The pillars and bleeding channel are coated with the extracellular matrix protein collagen. Results Perfusion of human whole blood through the microfluidic bleeding chip led to initial platelet adhesion and aggregation at the pillars followed by hemostatic plug formation and occlusion of the bleeding channel. Conclusions Safe and effective mitigating agents are needed for treatment and prevention of thrombotic complications in COVID-19 patients. This simple microfluidic device holds potential to be developed into a tool for assessing the effects of anticoagulant therapy on hemostasis.
C1 [Lakshmanan, Hari Hara Sudhan; Kohs, Tia C. L.; Thompson, Rachel M.; Maddala, Jeevan; Olson, Sven R.; Shatzel, Joseph J.; McCarty, Owen J. T.] Oregon Hlth & Sci Univ, Dept Biomed Engn, 3303 SW Bond Ave,CH13B, Portland, OR 97239 USA.
   [Pore, Adity A.; Vanapalli, Siva A.] Texas Tech Univ, Dept Chem Engn, Lubbock, TX 79409 USA.
   [Yazar, Feyza; Jurney, Patrick L.] San Jose State Univ, Dept Biomed Engn, San Jose, CA 95192 USA.
   [Olson, Sven R.; Shatzel, Joseph J.; McCarty, Owen J. T.] Oregon Hlth & Sci Univ, Sch Med, Div Hematol & Med Oncol, Portland, OR 97201 USA.
RP Lakshmanan, HHS (corresponding author), Oregon Hlth & Sci Univ, Dept Biomed Engn, 3303 SW Bond Ave,CH13B, Portland, OR 97239 USA.
EM lakshmah@ohsu.edu
OI Jurney, Patrick/0000-0002-4099-2927; Lakshmanan, Hari Hara
   Sudhan/0000-0002-4258-9138
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01HL101972,
   R01HL144113]; American Heart AssociationAmerican Heart Association
   [18UFEL33960363]
FX This work was supported by grants from the National Institutes of Health
   (R01HL101972 and R01HL144113) and the American Heart Association
   (18UFEL33960363). R.M. Thompson is an AHA Undergraduate Research Fellow.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bird R. B., 1960, TRANSPORT PHENOMENA
   Brass LF, 2016, J THROMB HAEMOST, V14, P906, DOI 10.1111/jth.13280
   Cattaneo M, 2020, THROMB HAEMOSTASIS, V120, P1230, DOI 10.1055/s-0040-1712097
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Diamond SL, 2016, CIRC RES, V118, P1348, DOI 10.1161/CIRCRESAHA.115.306824
   Divani AA, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104941
   Fogelson AL, 2015, ANNU REV FLUID MECH, V47, P377, DOI 10.1146/annurev-fluid-010814-014513
   Gavriilaki E, 2020, BRIT J HAEMATOL, V189, pE227, DOI 10.1111/bjh.16783
   Hao C, 2019, PROG MOL BIOL TRANSL, V163, P1, DOI 10.1016/bs.pmbts.2019.02.002
   Herbig BA, 2018, BIOMICROFLUIDICS, V12, DOI 10.1063/1.5021769
   Herbig BA, 2017, CELL MOL BIOENG, V10, P515, DOI 10.1007/s12195-017-0503-x
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lakshmanan HHS, 2020, PLATELETS, DOI 10.1080/09537104.2020.1745170
   Matafonov A, 2014, BLOOD, V123, P1739, DOI 10.1182/blood-2013-04-499111
   McCarty OJT, 2016, J THROMB HAEMOST, V14, P619, DOI 10.1111/jth.13241
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Mitrugno A, 2018, PLATELETS, V29, P383, DOI 10.1080/09537104.2017.1316482
   Nesbitt WS, 2009, NAT MED, V15, P665, DOI 10.1038/nm.1955
   Onishi A, 2016, FRONT BIOSCI-LANDMRK, V21, P1372, DOI 10.2741/4462
   Qin D, 2010, NAT PROTOC, V5, P491, DOI 10.1038/nprot.2009.234
   Rigg RA, 2019, PLATELETS, V30, P126, DOI 10.1080/09537104.2017.1406076
   SAHU A, 1993, MOL IMMUNOL, V30, P679, DOI 10.1016/0161-5890(93)90079-Q
   Sakurai Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02990-x
   Schoeman RM, 2017, CELL MOL BIOENG, V10, P3, DOI 10.1007/s12195-016-0469-0
   Shatzel JJ, 2020, RES PRACT THROMB HAE, V4, P500, DOI 10.1002/rth2.12349
   Stalker TJ, 2013, BLOOD, V121, P1875, DOI 10.1182/blood-2012-09-457739
   Tomaiuolo M, 2019, P NATL ACAD SCI USA, V116, P2243, DOI 10.1073/pnas.1813642116
   van Nieuwkoop C, 2020, THROMB RES, V191, P151, DOI 10.1016/j.thromres.2020.04.042
   Welsh JD, 2017, J THROMB HAEMOST, V15, P526, DOI 10.1111/jth.13600
   Xia YN, 1998, ANNU REV MATER SCI, V28, P153, DOI 10.1146/annurev.matsci.28.1.153
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zilberman-Rudenko J, 2018, CELL MOL BIOENG, V11, P519, DOI 10.1007/s12195-018-0541-z
   Zilberman-Rudenko J, 2017, CELL MOL BIOENG, V10, P16, DOI 10.1007/s12195-016-0470-7
NR 37
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1865-5025
EI 1865-5033
J9 CELL MOL BIOENG
JI Cell. Mol. Bioeng.
PD AUG
PY 2020
VL 13
IS 4
SI SI
BP 331
EP 339
DI 10.1007/s12195-020-00644-x
EA AUG 2020
PG 9
WC Cell & Tissue Engineering; Biophysics; Cell Biology; Engineering,
   Biomedical
SC Cell Biology; Biophysics; Engineering
GA NK8WI
UT WOS:000556638500001
PM 32837586
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Barello, S
   Nania, T
   Dellafiore, F
   Graffigna, G
   Caruso, R
AF Barello, Serena
   Nania, Tiziana
   Dellafiore, Federica
   Graffigna, Guendalina
   Caruso, Rosario
TI 'Vaccine hesitancy' among university students in Italy during the
   COVID-19 pandemic
SO EUROPEAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE COVID-19; Vaccine hesitancy
ID HEALTH-CARE WORKERS; INFLUENZA VACCINATION; MEDICAL-STUDENTS
AB The debate around vaccines has been in the spotlight over the last few years in Europe, both within the scientific community and the general public debate. In this regard, the case of the Italian vaccination debate is particularly worrying given that Italy has been one of the European countries with the highest number of measles cases in the recent past. According to this scenario, we conducted a cross-sectional study on a convenience sample of Italian university students aimed at: (1) exploring their attitudes towards a future vaccine to prevent COVID-19 and; (2) evaluating the impact of the university curricula (healthcare vs. non-healthcare curricula) on the intention to vaccinate. Descriptive analysis on the 735 students that answered to the question on the intention to vaccinate showed that 633 (86.1%) students reported that they would choose to have a vaccination for the COVID-19 coronavirus; on the other side, 102 (13.9%) students reported that they would not or be not sure to vaccine (low intention to vaccinate). This means that in our sample more than one student out of 10 shows low intention to vaccinate (vaccine hesitancy). Furthermore, when running analysis comparing healthcare students versus non-healthcare students we found no significant differences in responses' percentage distribution (p = .097). Understanding the student's perspective about the future COVID-19 vaccine and supporting their health engagement and consciousness may be useful in planning adequate response and multidisciplinary educational strategies-including the psychological perspective on vaccine hesitancy underlying factors - in the post-pandemic period.
C1 [Barello, Serena; Graffigna, Guendalina] Univ Cattolica Sacro Cuore, Food & Hlth Engagement Res Ctr, Dept Psychol, EngageMinds HUB Consumer, Lgo Gemelli 1, I-20143 Milan, Italy.
   [Nania, Tiziana; Dellafiore, Federica; Caruso, Rosario] IRCCS Policlin San Donato, Hlth Profess Res & Dev Unit, Milan, Italy.
RP Barello, S (corresponding author), Univ Cattolica Sacro Cuore, Food & Hlth Engagement Res Ctr, Dept Psychol, EngageMinds HUB Consumer, Lgo Gemelli 1, I-20143 Milan, Italy.
EM serena.barello@unicatt.it
RI Caruso, Rosario/ABH-6445-2020; Barello, Serena/ABD-6168-2020
OI Caruso, Rosario/0000-0002-7736-6209; Barello, Serena/0000-0002-8514-2563
CR Abalkhail MS, 2017, J INFECT PUBLIC HEAL, V10, P644, DOI 10.1016/j.jiph.2017.05.001
   Afonso N, 2014, VACCINE, V32, P502, DOI 10.1016/j.vaccine.2013.11.043
   Allan J, 2004, AM J PREV MED, V27, P471, DOI 10.1016/j.amepre.2004.08.010
   Babcock HM, 2010, CLIN INFECT DIS, V50, P459, DOI 10.1086/650752
   Godlee F, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l4044
   Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3
   La Fauci V, 2019, CLIN TER, V170, pE448, DOI 10.7417/CT.2019.2174
   Larson H, 2013, VACCINES-BASEL, V1, P293, DOI 10.3390/vaccines1030293
   Marotta C, 2017, J Prev Med Hyg, V58, pE93
   Orme J, 2007, PUBLIC HEALTH, V121, P414, DOI 10.1016/j.puhe.2007.02.005
   Pomrehn PR, 2000, ACAD MED S, p[75, 5]
   Rath B, 2015, CURR DRUG SAF, V10, P23, DOI 10.2174/157488631001150407104537
   Ryan KA, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02604
   Seanehia J, 2017, VACCINE, V35, P2676, DOI 10.1016/j.vaccine.2017.03.086
   Signorelli C, 2017, VACCINE, V35, P4057, DOI 10.1016/j.vaccine.2017.06.011
   Suresh PS, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-205
   Talbot TR, 2005, INFECT CONT HOSP EP, V26, P882, DOI 10.1086/502512
   Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z
NR 18
TC 3
Z9 3
U1 9
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0393-2990
EI 1573-7284
J9 EUR J EPIDEMIOL
JI Eur. J. Epidemiol.
PD AUG
PY 2020
VL 35
IS 8
BP 781
EP 783
DI 10.1007/s10654-020-00670-z
EA AUG 2020
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NM3LR
UT WOS:000556656600001
PM 32761440
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tang, LL
   Jiang, YG
   Zhu, MF
   Chen, LJ
   Zhou, XY
   Zhou, CL
   Ye, P
   Chen, XB
   Wang, BH
   Xu, ZY
   Zhang, Q
   Xu, XW
   Gao, H
   Wu, XJ
   Li, D
   Jiang, WL
   Qu, JJ
   Xiang, C
   Li, LJ
AF Tang, Lingling
   Jiang, Yingan
   Zhu, Mengfei
   Chen, Lijun
   Zhou, Xiaoyang
   Zhou, Chenliang
   Ye, Peng
   Chen, Xiaobei
   Wang, Baohong
   Xu, Zhenyu
   Zhang, Qiang
   Xu, Xiaowei
   Gao, Hainv
   Wu, Xiaojun
   Li, Dong
   Jiang, Wanli
   Qu, Jingjing
   Xiang, Charlie
   Li, Lanjuan
TI Clinical study using mesenchymal stem cells for the treatment of
   patients with severe COVID-19
SO FRONTIERS OF MEDICINE
LA English
DT Article
DE Coronavirus disease 2019 (COVID-19); mesenchymal stem cell; acute
   respiratory distress syndrome; stem cell therapeutics
ID CORONAVIRUS; CHINA; DIFFERENTIATION; TRANSPLANTATION; PNEUMONIA;
   OUTBREAK; IMPROVES; PROTEIN; WUHAN
AB The Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was identified in December 2019. The symptoms include fever, cough, dyspnea, early symptom of sputum, and acute respiratory distress syndrome (ARDS). Mesenchymal stem cell (MSC) therapy is the immediate treatment used for patients with severe cases of COVID-19. Herein, we describe two confirmed cases of COVID-19 in Wuhan to explore the role of MSC in the treatment of COVID-19. MSC transplantation increases the immune indicators (including CD4 and lymphocytes) and decreases the inflammation indicators (interleukin-6 and C-reactive protein). High-flow nasal cannula can be used as an initial support strategy for patients with ARDS. With MSC transplantation, the fraction of inspired O-2(FiO(2)) of the two patients gradually decreased while the oxygen saturation (SaO(2)) and partial pressure of oxygen (PO2) improved. Additionally, the patients' chest computed tomography showed that bilateral lung exudate lesions were adsorbed after MSC infusion. Results indicated that MSC transplantation provides clinical data on the treatment of COVID-19 and may serve as an alternative method for treating COVID-19, particularly in patients with ARDS.
C1 [Tang, Lingling; Zhu, Mengfei; Gao, Hainv; Li, Lanjuan] Zhejiang Shuren Univ, Shulan Int Med Coll, Shulan Hangzhou Hosp, Hangzhou 310022, Peoples R China.
   [Jiang, Yingan; Zhou, Xiaoyang; Zhou, Chenliang; Ye, Peng; Chen, Xiaobei; Wu, Xiaojun; Li, Dong; Jiang, Wanli] Wuhan Univ, Dept Infect Dis, Renmin Hosp, Wuhan 430060, Peoples R China.
   [Chen, Lijun; Wang, Baohong; Xu, Xiaowei; Qu, Jingjing; Xiang, Charlie; Li, Lanjuan] Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, Affiliated Hosp 1,Coll Med,Natl Clin Res Ctr Infe, Hangzhou 310003, Peoples R China.
   [Xu, Zhenyu; Zhang, Qiang] Innovat Precis Med IPM Grp, Hangzhou 311215, Peoples R China.
RP Li, LJ (corresponding author), Zhejiang Shuren Univ, Shulan Int Med Coll, Shulan Hangzhou Hosp, Hangzhou 310022, Peoples R China.; Xiang, C; Li, LJ (corresponding author), Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, Affiliated Hosp 1,Coll Med,Natl Clin Res Ctr Infe, Hangzhou 310003, Peoples R China.
EM cxiang@zju.edu.cn; ljli@zju.edu.cn
FU Technological Special Project for Significant New Drugs Development of
   China [2018ZX09201002-005]; National Key R&D Program of China
   [2017YFA0105701]; National Science and Technology Major Project
   [2017ZX10204401]; Emergency Research Fund for COVID-19 of Zhejiang
   Province [2020C03125]; First Affiliated Hospital, College of Medicine,
   Zhejiang University
FX The authors thank Dr. Shusen Zheng and Dr. Tingbo Liang from The First
   Affiliated Hospital, College of Medicine, Zhejiang University for
   support of this work. This work was supported by the Technological
   Special Project for Significant New Drugs Development of China (No.
   2018ZX09201002-005) and National Key R&D Program of China (No.
   2017YFA0105701), the National Science and Technology Major Project (No.
   2017ZX10204401), and the Emergency Research Fund for COVID-19 of
   Zhejiang Province (No. 2020C03125).
CR [Anonymous], 2020, LANCET, V395, P311, DOI 10.1016/S0140-6736(20)30186-0
   Bosch BJ, 2004, P NATL ACAD SCI USA, V101, P8455, DOI 10.1073/pnas.0400576101
   Cahill EF, 2016, STEM CELL TRANSL MED, V5, P1307, DOI 10.5966/sctm.2015-0337
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen Jiajia, 2020, Engineering (Beijing), V6, P1153, DOI 10.1016/j.eng.2020.02.006
   Chen LJ, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-018-1105-9
   Chen LJ, 2017, STEM CELL TRANSL MED, V6, P272, DOI 10.5966/sctm.2015-0265
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen SY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0846-9
   Cohen J, 2020, SCIENCE, V367, P234, DOI 10.1126/science.367.6475.234
   de Castro LL, 2019, J MOL MED, V97, P605, DOI 10.1007/s00109-019-01776-y
   Gao F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.327
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han Y, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080886
   Hashmi S, 2016, LANCET HAEMATOL, V3, pE45, DOI 10.1016/S2352-3026(15)00224-0
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khanmohammadi M, 2014, CELL PROLIFERAT, V47, P615, DOI 10.1111/cpr.12133
   Khoury M, 2020, CYTOTHERAPY, V22, P602, DOI 10.1016/j.jcyt.2020.04.089
   Le Blanc K, 2018, CYTOTHERAPY, V20, P273, DOI 10.1016/j.jcyt.2018.01.009
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li YH, 2019, ENGINEERING, V5, P940, DOI 10.1016/j.eng.2018.11.035
   Liang J, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1053-4
   Liu DM, 2018, INT J RADIAT ONCOL, V101, P945, DOI 10.1016/j.ijrobp.2018.04.007
   Lorusso A, 2020, VET ITAL, V56, P5, DOI 10.12834/VetIt.2173.11599.1
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Marnell L, 2005, CLIN IMMUNOL, V117, P104, DOI 10.1016/j.clim.2005.08.004
   Meng XL, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-57
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Saldana L, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1156-6
   Samsonraj RM, 2017, STEM CELL TRANSL MED, V6, P2173, DOI 10.1002/sctm.17-0129
   Shi M, 2017, STEM CELL TRANSL MED, V6, P2053, DOI 10.1002/sctm.17-0134
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Weiss ARR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01191
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Wu XX, 2014, STEM CELLS DEV, V23, P1245, DOI 10.1089/scd.2013.0390
   Wu YC, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1243-8
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xiang BY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040689
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan ZR, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-018-1101-0
   Zhang Q, 2020, J MED VIROL, V92, P540, DOI [10.1002/jmv.25733, 10.1080/07391102.2020.1771421]
   Zhang Y, 2020, AIDS RES THER, V17, DOI 10.1186/s12981-020-0260-0
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zuo WY, 2018, BIOPRESERV BIOBANK, V16, P158, DOI 10.1089/bio.2017.0057
NR 51
TC 3
Z9 3
U1 6
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2095-0217
EI 2095-0225
J9 FRONT MED-PRC
JI Front. Med.
PD OCT
PY 2020
VL 14
IS 5
BP 664
EP 673
DI 10.1007/s11684-020-0810-9
EA AUG 2020
PG 10
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA OF6TL
UT WOS:000556620600002
PM 32761491
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Dehury, B
   Raina, V
   Misra, N
   Suar, M
AF Dehury, Budheswar
   Raina, Vishakha
   Misra, Namrata
   Suar, Mrutyunjay
TI Effect of mutation on structure, function and dynamics of receptor
   binding domain of human SARS-CoV-2 with host cell receptor ACE2: a
   molecular dynamics simulations study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; receptor binding motif; MD simulation; coronavirus;
   angiotensin-converting enzyme-II
ID RESPIRATORY SYNDROME CORONAVIRUS; PROTEIN-PROTEIN; SARS-COV; SPIKE;
   RECOGNITION; INSIGHTS; AFFINITY
AB Recent studies have pointed the role of angiotensin-converting enzyme-II (ACE2) in mediating the entry of SARS-CoV-2 to the host cell by binding to the receptor-binding domain (RBD) of viral spike protein, and successive priming by cellular proteases initiates the infection. SARS-CoV replication rate and disease severity is controlled by the binding affinity of RBD with ACE2. To understand, how mutations in the conserved residues of RBD affect the molecular interaction with ACE2, we generated five alanine mutants i.e. Y449A, N487A, Y489A, N501A and Y505A in the receptor binding motif (RBM) of the ACE2-RBD SARS-CoV-2 complex (PDB: 6M0J). Computational site directed mutagenesis induced dynamics in wild-type and mutant complexes were extensively studied through all-atoms molecular dynamics (MD) simulations of 150 ns. In silico mutational analysis revealed loss of important intermolecular hydrogen bonds and other non-bonded contacts, critical for molecular recognition of SARS-CoV-2 RBD to ACE2, which is well supported by saturation mutagenesis study of binding interface residues. MD simulations results showed that RBM motif is flexible, where mutant residues are relatively more mobile than corresponding wild-type residues. Global motion analysis through principal component studies revealed that RBD exhibits protuberant in-ward motion towards the human ACE2 binding interface which may be crucial for molecular interaction. Conclusively, the present finding are in congruence with previous experimental reports and provides detailed information on the structural basis of receptor binding by human SARS-CoV-2, which will crucial for the development of novel inhibitors or drugs to combat against SARS-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Dehury, Budheswar; Raina, Vishakha; Misra, Namrata; Suar, Mrutyunjay] Deemed Univ, Kalinga Inst Ind Technol KIIT, Sch Biotechnol, Bhubaneswar 751024, Odisha, India.
   [Misra, Namrata; Suar, Mrutyunjay] Deemed Univ, Kalinga Inst Ind Technol KIIT, KIIT Technol Business Incubator KIIT TBI, Bhubaneswar, India.
RP Dehury, B; Suar, M (corresponding author), Deemed Univ, Kalinga Inst Ind Technol KIIT, Sch Biotechnol, Bhubaneswar 751024, Odisha, India.
EM budheswar.dehury@gmail.com; msuar@kiitbiotech.ac.in
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408
   Chin Alex W H, 2020, Lancet Microbe, V1, pe10, DOI 10.1016/S2666-5247(20)30003-3
   David C. C., 2014, METHODS MOL BIOL, V1084
   Dehury B, 2017, J MOL GRAPH MODEL, V71, P154, DOI 10.1016/j.jmgm.2016.11.012
   Dehury B, 2015, J MOL GRAPH MODEL, V57, P49, DOI 10.1016/j.jmgm.2015.01.005
   Dehury B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097852
   Hekkelman M. L., 2010, NUCL ACIDS RES S2, V38
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hollingsworth SA, 2018, NEURON, V99, P1129, DOI 10.1016/j.neuron.2018.08.011
   Huang J, 2017, NAT METHODS, V14, P71, DOI [10.1038/NMETH.4067, 10.1038/nmeth.4067]
   Huentelman MJ, 2004, HYPERTENSION, V44, P903, DOI 10.1161/01.HYP.0000146120.29648.36
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646
   Kitao A, 1999, CURR OPIN STRUC BIOL, V9, P164, DOI 10.1016/S0959-440X(99)80023-2
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2008, J VIROL, V82, P6984, DOI 10.1128/JVI.00442-08
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2013, ANTIVIR RES, V100, P246, DOI 10.1016/j.antiviral.2013.08.014
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li WH, 2006, J VIROL, V80, P4211, DOI 10.1128/JVI.80.9.4211-4219.2006
   Liu S., 2004, LANCET LONDON ENGLAN, V363, DOI [10.1016/S0140-6736(04)15788-7, DOI 10.1016/S0140-6736(04)15788-7]
   Malik YS, 2020, VET QUART, V40, P68, DOI 10.1080/01652176.2020.1727993
   Maximova T, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004619
   Othman H, 2020, BIOCHEM BIOPH RES CO, V527, P702, DOI 10.1016/j.bbrc.2020.05.028
   Pan AC, 2019, P NATL ACAD SCI USA, V116, P4244, DOI 10.1073/pnas.1815431116
   Qi HC, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138778
   Rodrigues CHM, 2019, NUCLEIC ACIDS RES, V47, pW338, DOI 10.1093/nar/gkz383
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tian X., 2020, ELECTRONICS, V9, P1, DOI DOI 10.1080/22221751.2020.1729069
   Tuffery P, 2012, J R SOC INTERFACE, V9, P20, DOI 10.1098/rsif.2011.0584
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3
   Wu KL, 2012, J BIOL CHEM, V287, P8904, DOI 10.1074/jbc.M111.325803
   Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang Y, 2005, COMPUT BIOL CHEM, V29, P254, DOI 10.1016/j.compbiolchem.2005.04.008
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 42
TC 0
Z9 0
U1 7
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1802348
EA AUG 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MV7FH
UT WOS:000556518400001
PM 32762417
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ghosh, R
   Chakraborty, A
   Biswas, A
   Chowdhuri, S
AF Ghosh, Rajesh
   Chakraborty, Ayon
   Biswas, Ashis
   Chowdhuri, Snehasis
TI Identification of polyphenols fromBroussonetia papyriferaas SARS CoV-2
   main protease inhibitors usingin silicodocking and molecular dynamics
   simulation approaches
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS CoV-2 main protease; docking; molecular dynamics
   simulation; Broussonetia papyriferapolyphenols
ID RESPIRATORY SYNDROME CORONAVIRUS; BROUSSONETIA-PAPYRIFERA; MUTATIONS
   V32I; HIV-1 PROTEASE; PROTEINASE; RESISTANCE; PNEUMONIA; MECHANISM;
   INSIGHT; DESIGN
AB The current COVID-19 pandemic is caused by SARS CoV-2. To date, similar to 463,000 people died worldwide due to this disease. Several attempts have been taken in search of effective drugs to control the spread of SARS CoV-2 infection. The main protease (Mpro) from SARS CoV-2 plays a vital role in viral replication and thus serves as an important drug target. This Mpro shares a high degree of sequence similarity (>96%) with the same protease from SARS CoV-1 and MERS. It was already reported thatBroussonetia papyriferapolyphenols efficiently inhibit the catalytic activity of SARS CoV-1 and MERS Mpro. But whether these polyphenols exhibit any inhibitory effect on SARS CoV-2 Mpro is far from clear. To understand this fact, here we have adopted computational approaches. Polyphenols having proper drug-likeness properties and two repurposed drugs (lopinavir and darunavir; having binding affinity -7.3 to -7.4 kcal/mol) were docked against SARS CoV-2 Mpro to study their binding properties. Only six polyphenols (broussochalcone A, papyriflavonol A, 3'-(3-methylbut-2-enyl)-3',4',7-trihydroxyflavane, broussoflavan A, kazinol F and kazinol J)had interaction with both the catalytic residues (His41 and Cys145) of Mpro and exhibited good binding affinity (-7.6 to -8.2 kcal/mol). Molecular dynamic simulations (100 ns) revealed that all Mpro-polyphenol complexes are more stable, conformationally less fluctuated; slightly less compact and marginally expanded than Mpro-darunavir/lopinavir complex. Even the number of intermolecular H-bond and MM-GBSA analysis suggested that these six polyphenols are more potent Mpro inhibitors than the two repurposed drugs (lopinavir and darunavir) and may serve as promising anti-COVID-19 drugs. Communicated by Ramaswamy H. Sarma
C1 [Ghosh, Rajesh; Chakraborty, Ayon; Biswas, Ashis; Chowdhuri, Snehasis] Indian Inst Technol Bhubaneswar, Sch Basic Sci, Bhubaneswar, India.
RP Biswas, A; Chowdhuri, S (corresponding author), Indian Inst Technol Bhubaneswar, Sch Basic Sci, Argul 752050, Odisha, India.
EM abiswas@iitbbs.ac.in; snehasis@iitbbs.ac.in
OI Chakraborty, Ayon/0000-0002-1155-7862
FU IIT Bhubaneswar
FX RG acknowledges IIT Bhubaneswar for providing fellowship. The authors
   thank IIT Delhi HPC facility for computational resources.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Arun KG, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/10799893.2020.1715432, 10.1080/07391102.2020.1779819]
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bhardwaj VK, 2020, COMPUT METH PROG BIO, V194, DOI 10.1016/j.cmpb.2020.105494
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Bhardwaj VK, 2020, INT J BIOL MACROMOL, V148, P999, DOI 10.1016/j.ijbiomac.2020.01.212
   Biovia D. S., 2017, DISCOVERY STUDIO MOD
   Chakraborty A, 2018, INT J BIOL MACROMOL, V119, P604, DOI 10.1016/j.ijbiomac.2018.07.151
   Chen JZ, 2016, RSC ADV, V6, P58573, DOI 10.1039/c6ra09201b
   Chen JZ, 2015, J CHEM INF MODEL, V55, P1903, DOI 10.1021/acs.jcim.5b00173
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chou KC, 2003, BIOCHEM BIOPH RES CO, V308, P148, DOI 10.1016/S0006-291X(03)01342-1
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dan WJ, 2019, J ENZYM INHIB MED CH, V34, P937, DOI 10.1080/14756366.2019.1604519
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   Ghosh R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779818
   Gyebi GA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764868
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kamaraj B, 2016, J CELL BIOCHEM, V117, P2608, DOI 10.1002/jcb.25555
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mahanta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768902
   Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805
   Morris Garrett M, 2008, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0814s24
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nandi SK, 2016, RSC ADV, V6, P62146, DOI 10.1039/c6ra00167j
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Park JY, 2017, J ENZYM INHIB MED CH, V32, P504, DOI 10.1080/14756366.2016.1265519
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Rajendran V, 2018, J CELL BIOCHEM, V119, P918, DOI 10.1002/jcb.26257
   Rajendran V, 2016, MOL BIOSYST, V12, P2276, DOI 10.1039/c6mb00182c
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ryu HW, 2012, J KOREAN SOC APPL BI, V55, P587, DOI 10.1007/s13765-012-2143-0
   Ryu HW, 2010, J AGR FOOD CHEM, V58, P202, DOI 10.1021/jf903068k
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Venugopal PP, 2020, PROTEINS, V88, P327, DOI 10.1002/prot.25807
   Williams SJ, 2020, BIOCHEM SOC T, V48, P1287, DOI 10.1042/BST20200505
   Yu XX, 2020, INFLUENZA OTHER RESP, V14, P474, DOI 10.1111/irv.12743
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao XS, 2015, ANTIMICROB AGENTS CH, V59, P206, DOI 10.1128/AAC.03999-14
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 65
TC 1
Z9 1
U1 6
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1802347
EA AUG 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MV7CX
UT WOS:000556512200001
PM 32762411
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Colaneri, M
   Valsecchi, P
   Perotti, L
   Ludovisi, S
   Seminari, E
   Pieri, TC
   Sacchi, P
   Bruno, R
AF Colaneri, Marta
   Valsecchi, Pietro
   Perotti, Luciano
   Ludovisi, Serena
   Seminari, Elena
   Pieri, Teresa Chiara
   Sacchi, Paolo
   Bruno, Raffaele
TI Running out of bullets: The challenging management of acute hepatitis
   and SARS-COV-2 from the SMatteo COvid19 Registry (SMACORE)
SO LIVER INTERNATIONAL
LA English
DT Article
DE COVID-19; HBV; hemoperfusion
AB Liver impairment is frequent in patients with novel coronavirus disease (COVID-19) and direct viral tropism for the liver has been proven. Since several of the currently administered drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are possibly hepatotoxic, the management of patients with COVID-19 and liver failure is still an almost unexplored field. Taking this challenging case of acute HBV with persistent hyperbilirubinemia and SARS-COV-2 infection with respiratory distress as a starting point, we here loop through this condition. Where the available therapeutic options are scarce, we here propose hemoperfusion (HP) as an attractive alternative to both delay any late-stage progression of hyper inflammation process in COVID-19 and remove the toxins involved in acute liver failure.
C1 [Colaneri, Marta; Valsecchi, Pietro; Ludovisi, Serena; Seminari, Elena; Pieri, Teresa Chiara; Sacchi, Paolo; Bruno, Raffaele] Fdn IRCCS Policlin San Matteo, Div Infect Dis 1, Pavia, Italy.
   [Perotti, Luciano] Fdn IRCCS Policlin S Matteo, Anesthesia & Intens Care Emergency Dept, Pavia, Italy.
   [Bruno, Raffaele] Univ Pavia, Dept Clin Surg Diagnost & Paediat Sci, Pavia, Italy.
RP Bruno, R (corresponding author), Fdn IRCCS Policlin San Matteo, Div Infect Dis 1, Pavia, Italy.
EM raffaele.bruno@unipv.it
RI Bruno, Raffaele/L-3530-2018
OI Bruno, Raffaele/0000-0002-0235-9207; colaneri, marta/0000-0002-5939-9576
CR Aldhaleei WA, 2020, CUREUS, V12, DOI 10.7759/cureus.8645
   Cai QX, 2020, J HEPATOL, V73, P566, DOI 10.1016/j.jhep.2020.04.006
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen X, 2020, BMJ
   Coutts ER, 2016, EVALUATION ADSORBENT
   European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021
   Guan G W, 2020, Zhonghua Gan Zang Bing Za Zhi, V28, P100, DOI 10.3760/cma.j.issn.1007-3418.2020.02.002
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu C, 2020, Zhonghua Gan Zang Bing Za Zhi, V28, P107, DOI 10.3760/cma.j.issn.1007-3418.2020.02.003
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu J, 2020, CLIN INFECT DIS, V71, P706, DOI 10.1093/cid/ciaa199
   Xie HS, 2020, LIVER INT, V40, P1321, DOI 10.1111/liv.14449
   Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou Xiaojing, 2020, Clin Gastroenterol Hepatol, DOI 10.1016/j.cgh.2020.06.017
NR 17
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1478-3223
EI 1478-3231
J9 LIVER INT
JI Liver Int.
PD NOV
PY 2020
VL 40
IS 11
BP 2655
EP 2659
DI 10.1111/liv.14609
EA AUG 2020
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OK4BD
UT WOS:000555892300001
PM 32679617
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Huang, SS
   Wu, CM
   Jia, YC
   Li, G
   Zhu, Z
   Lu, K
   Yang, YY
   Wang, FR
   Zhu, SQ
AF Huang, Shanshan
   Wu, Chunmei
   Jia, Yuchao
   Li, Guo
   Zhu, Zhou
   Lu, Kai
   Yang, Yuyan
   Wang, Furong
   Zhu, Suiqiang
TI COVID-19 outbreak: The impact of stress on seizures in patients with
   epilepsy
SO EPILEPSIA
LA English
DT Article
DE COVID-19; epilepsy; precipitant; seizure exacerbation; stress
ID LONG-TERM OUTCOMES; FREQUENCY; ANXIETY; DEPRESSION; PREVALENCE; EVENTS;
   CARE; WAR
AB Objective Stress is a known trigger for seizures in patients with epilepsy (PWE). However, the association between stress and seizures has not been thoroughly investigated. In December 2019, an outbreak of coronavirus disease (COVID-19) occurred in Wuhan, Hubei province, China, causing tremendous collateral stress. This study was designed to evaluate the influence of the COVID-19 outbreak on seizures in PWE in the most severely affected area, Wuhan, and its surrounding cities. Methods In this single-center, cross-sectional study, PWE were surveyed via online questionnaires between February 23 and March 5, 2020. Collected data included demographic information, epilepsy-related characteristics (seizure type, frequency, antiepileptic drugs [AEDs], and medication management), direct and perceived threat of COVID-19, and changes in seizures during the outbreak. Psychological comorbidities were evaluated by the Patient Health Questionnaire-9, Generalized Anxiety Disorder-7 items, and Insomnia Severity Index (ISI). Multivariate logistic regression was used to identify precipitants for seizure exacerbation. Results We received 362 completed questionnaires after excluding 12 duplicates (response rate = 63.51%). A total of 31 (8.56%) patients had increased seizures during the outbreak. Exposure history to COVID-19 (P = .001), uncontrolled seizure after AED therapy (P = .020), seizure frequency of two or more times per month before the outbreak (P = .005), change of AED regimen during the outbreak (AED reduction, withdrawal, replacement, skipping altogether;P = .002), and worry about the adverse effect of the outbreak on overall seizure-related issues (severity = moderate to critical;P = .038) were risk factors for increased seizures. Significance A minority of PWE experienced seizure exacerbation during the outbreak of COVID-19. Stress, uncontrolled seizures, and inappropriate change in AED regimen were associated with increased seizures. Based on these findings, stress might be an independent precipitant for triggering seizures in some PWE.
C1 [Huang, Shanshan; Wu, Chunmei; Jia, Yuchao; Li, Guo; Zhu, Zhou; Lu, Kai; Yang, Yuyan; Wang, Furong; Zhu, Suiqiang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
RP Wang, FR; Zhu, SQ (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
EM wangfurong.china@163.com; zhusuiqiang@163.com
FU National Key R&D Program of China [2017YFC1310000]; Fundamental Research
   Funds for the Central UniversitiesFundamental Research Funds for the
   Central Universities [2019kfyXKJC075]
FX The National Key R&D Program of China, Grant/Award Number: NO.
   2017YFC1310000; The Fundamental Research Funds for the Central
   Universities, Grant/Award Number: NO. 2019kfyXKJC075
CR [Anonymous], 2003, Paediatr Child Health, V8, P577
   Becker C, 2015, ANN NEUROL, V78, P128, DOI 10.1002/ana.24414
   Bosnjak J, 2002, EPILEPSY BEHAV, V3, P502, DOI 10.1016/S1525-5050(02)00602-9
   Devinsky O, 2017, NEW ENGL J MED, V376, P2011, DOI 10.1056/NEJMoa1611618
   Frucht MM, 2000, EPILEPSIA, V41, P1534
   Haut SR, 2003, EPILEPSY BEHAV, V4, P511, DOI 10.1016/S1525-5050(03)00182-3
   HAZZARD A, 1990, J PEDIATR PSYCHOL, V15, P543, DOI 10.1093/jpepsy/15.4.543
   Helen Branswell AJ, WHO DECLARES CORONAV
   Jackson MJ, 2005, J NEUROL NEUROSUR PS, V76, pI45, DOI 10.1136/jnnp.2004.060467
   Jernigan DB, 2020, MMWR-MORBID MORTAL W, V69, P216, DOI 10.15585/mmwr.mm6908e1
   Klein P, 2005, NEUROLOGY, V64, P1815, DOI 10.1212/01.WNL.0000162026.52300.3C
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004
   Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006
   Lamberink HJ, 2017, LANCET NEUROL, V16, P523, DOI 10.1016/S1474-4422(17)30114-X
   Malow Beth A, 2004, Epilepsy Curr, V4, P193, DOI 10.1111/j.1535-7597.2004.04509.x
   Mckee HR, 2017, SEIZURE-EUR J EPILEP, V44, P21, DOI 10.1016/j.seizure.2016.12.009
   Mills N, 1997, FAM PRACT, V14, P117, DOI 10.1093/fampra/14.2.117
   Moon HJ, 2016, EPILEPSY BEHAV, V62, P47, DOI 10.1016/j.yebeh.2016.06.038
   Neufeld M Y, 1994, Seizure, V3, P135, DOI 10.1016/S1059-1311(05)80204-3
   Novais A, 2017, NEUROBIOL STRESS, V6, P44, DOI 10.1016/j.ynstr.2016.11.004
   Patel A, 2010, EPILEPSIA, V51, P1277, DOI 10.1111/j.1528-1167.2009.02488.x
   Reuber M, 2011, EPILEPSIA, V52, P2028, DOI 10.1111/j.1528-1167.2011.03162.x
   Salpekar J, 2019, EPILEPSY CURR, V19, P29, DOI 10.1177/1535759718822842
   Sillanp M, 2009, BRAIN, V132, P989, DOI 10.1093/brain/awn357
   Swinkels WAM, 1998, EPILEPSIA, V39, P1203, DOI 10.1111/j.1528-1157.1998.tb01312.x
   TEMKIN NR, 1984, EPILEPSIA, V25, P450, DOI 10.1111/j.1528-1157.1984.tb03442.x
   Pham T, 2017, EPILEPSIA, V58, pE107, DOI 10.1111/epi.13817
   Vacik H W, 2001, J Pediatr Nurs, V16, P429, DOI 10.1053/jpdn.2001.27883
   WEBSTER A, 1989, EPILEPSIA, V30, P162, DOI 10.1111/j.1528-1157.1989.tb05449.x
   Wicker P, 2017, J PUBLIC HEALTH-UK, V39, pE19, DOI 10.1093/pubmed/fdw062
   Wong ML, 2017, SLEEP MED, V33, P76, DOI 10.1016/j.sleep.2016.05.019
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
NR 33
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD SEP
PY 2020
VL 61
IS 9
BP 1884
EP 1893
DI 10.1111/epi.16635
EA AUG 2020
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA OA2ND
UT WOS:000556027200001
PM 32761900
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Montesu, MA
   Biondi, G
   Sotgiu, G
   Sucato, F
   Satta, R
AF Montesu, Maria A.
   Biondi, Gabriele
   Sotgiu, Giovanni
   Sucato, Federica
   Satta, Rosanna
TI Biologic drugs during COVID-19 outbreak
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Letter; Early Access
C1 [Montesu, Maria A.; Biondi, Gabriele; Sucato, Federica; Satta, Rosanna] Univ Sassari, Dept Clin & Expt Med, Sassari, Italy.
   [Sotgiu, Giovanni] Dept Biomed Sci, Clin Epidemiol & Med Stat Unit, Sassari, Italy.
RP Biondi, G (corresponding author), Univ Sassari, Dept Clin & Expt Med, Sassari, Italy.
EM babilon22@hotmail.com
CR Atzori L, 2020, J EUR ACAD DERMATOL, V34, pE247, DOI 10.1111/jdv.16473
   Burlando M, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1770165
   Facheris P, 2020, INT J DERMATOL, V59, pE267, DOI 10.1111/ijd.15008
   Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158
   Gisondi P, 2020, J EUR ACAD DERMATOL, V34, P1196, DOI 10.1111/jdv.16515
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
EI 1365-4632
J9 INT J DERMATOL
JI Int. J. Dermatol.
DI 10.1111/ijd.15088
EA AUG 2020
PG 1
WC Dermatology
SC Dermatology
GA MV2UM
UT WOS:000556218300001
PM 32767379
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ye, QZ
   West, AMV
   Silletti, S
   Corbett, KD
AF Ye, Qiaozhen
   West, Alan M. V.
   Silletti, Steve
   Corbett, Kevin D.
TI Architecture and self-assembly of theSARS-CoV-2 nucleocapsid protein
SO PROTEIN SCIENCE
LA English
DT Article
DE coronavirus; COVID-19; crystal structure; nucleocapsid; SARS-CoV-2
ID C-TERMINAL DOMAINS; SARS CORONAVIRUS; DIMERIZATION DOMAIN;
   CRYSTAL-STRUCTURE; VIRUS; RIBONUCLEOPROTEIN; IDENTIFICATION;
   ASSOCIATION; PNEUMONIA; MECHANISM
AB The COVID-2019 pandemic is the most severe acute public health threat of the twenty-first century. To properly address this crisis with both robust testing and novel treatments, we require a deep understanding of the life cycle of the causative agent, the SARS-CoV-2 coronavirus. Here, we examine the architecture and self-assembly properties of the SARS-CoV-2 nucleocapsid protein, which packages viral RNA into new virions. We determined a 1.4 angstrom resolution crystal structure of this protein's N2b domain, revealing a compact, intertwined dimer similar to that of related coronaviruses including SARS-CoV. While the N2b domain forms a dimer in solution, addition of the C-terminal spacer B/N3 domain mediates formation of a homotetramer. Using hydrogen-deuterium exchange mass spectrometry, we find evidence that at least part of this putatively disordered domain is structured, potentially forming an alpha-helix that self-associates and cooperates with the N2b domain to mediate tetramer formation. Finally, we map the locations of amino acid substitutions in the N protein from over 38,000 SARS-CoV-2 genome sequences. We find that these substitutions are strongly clustered in the protein's N2a linker domain, and that substitutions within the N1b and N2b domains cluster away from their functional RNA binding and dimerization interfaces. Overall, this work reveals the architecture and self-assembly properties of a key protein in the SARS-CoV-2 life cycle, with implications for both drug design and antibody-based testing.
C1 [Ye, Qiaozhen; West, Alan M. V.; Corbett, Kevin D.] Univ Calif San Diego, Dept Cellular & Mol Med, 9500 Gilman Dr,3206, La Jolla, CA 92093 USA.
   [Silletti, Steve; Corbett, Kevin D.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
   [Corbett, Kevin D.] Ludwig Inst Canc Res, La Jolla, CA USA.
RP Corbett, KD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, 9500 Gilman Dr,3206, La Jolla, CA 92093 USA.
EM kcorbett@ucsd.edu
OI Corbett, Kevin/0000-0001-5854-2388
FU Argonne National LaboratoryUnited States Department of Energy
   (DOE)University of Chicago [DE-AC02-06CH11357]; NIH-ORIP HEI
   [S10OD021527]; National Institute of General Medical Sciences; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [P30 GM124165, S10 OD016234]
FX Argonne National Laboratory, Grant/Award Number: DE-AC02-06CH11357;
   NIH-ORIP HEI, Grant/Award Number: S10OD021527; National Institute of
   General Medical Sciences; National Institutes of Health, Grant/Award
   Numbers: P30 GM124165, S10 OD016234
CR Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Barcena M, 2009, P NATL ACAD SCI USA, V106, P582, DOI 10.1073/pnas.0805270106
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI DOI 10.15585/MMWR.MM6912E2
   Buchan DWA, 2013, NUCLEIC ACIDS RES, V41, pW349, DOI 10.1093/nar/gkt381
   Burbelo PD, 2020, J INFECT DIS, V222, P206, DOI 10.1093/infdis/jiaa273
   Chang CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061196
   Chen CY, 2007, J MOL BIOL, V368, P1075, DOI 10.1016/j.jmb.2007.02.069
   Cong YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01691-7
   Cubuk Jasmine, 2020, bioRxiv, DOI 10.1101/2020.06.17.158121
   DAVIES HA, 1981, J GEN VIROL, V53, P67, DOI 10.1099/0022-1317-53-1-67
   de Haan CAM, 2005, ADV VIRUS RES, V64, P165, DOI 10.1016/S0065-3527(05)64006-7
   Dinesh DC, 2020, STRUCTURAL BASIS RNA, DOI [10.1101/2020.04.02.022194, DOI 10.1101/2020.04.02.022194]
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Fan H, 2005, STRUCTURE, V13, P1859, DOI 10.1016/j.str.2005.08.021
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hachim A, 2020, SPIKE IDENTIFICATION, DOI [10.1101/2020.04.30.20085670, DOI 10.1101/2020.04.30.20085670]
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hurst KR, 2010, J VIROL, V84, P10276, DOI 10.1128/JVI.01287-10
   Hurst KR, 2009, J VIROL, V83, P7221, DOI 10.1128/JVI.00440-09
   Jayaram H, 2006, J VIROL, V80, P6612, DOI 10.1128/JVI.00157-06
   Jones DT, 2015, BIOINFORMATICS, V31, P857, DOI 10.1093/bioinformatics/btu744
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Klein S., 2020, SARS COV 2 STRUCTURE, DOI [10.1101/2020.06.23.167064., DOI 10.1101/2020.06.23.167064]
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745
   Lo YS, 2013, FEBS LETT, V587, P120, DOI 10.1016/j.febslet.2012.11.016
   Lumpkin RJ, 2019, MOL CELL PROTEOMICS, V18, P2516, DOI 10.1074/mcp.TIR119.001731
   Luo HB, 2006, BIOCHEMISTRY-US, V45, P11827, DOI 10.1021/bi0609319
   Luo HB, 2004, BIOPHYS CHEM, V112, P15, DOI 10.1016/j.bpc.2004.06.008
   Ma YL, 2010, PROTEIN CELL, V1, P688, DOI 10.1007/s13238-010-0079-x
   MACNAUGHTON MR, 1978, J GEN VIROL, V39, P545, DOI 10.1099/0022-1317-39-3-545
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Surjit M, 2004, BIOCHEM BIOPH RES CO, V317, P1030, DOI 10.1016/j.bbrc.2004.03.154
   Szelazek B, 2017, J VIROL, V91, DOI 10.1128/JVI.02503-16
   Takeda M, 2008, J MOL BIOL, V380, P608, DOI 10.1016/j.jmb.2007.11.093
   Nguyen THV, 2019, ACTA CRYSTALLOGR D, V75, P8, DOI 10.1107/S2059798318014948
   Tropea Joseph E., 2009, V498, P297, DOI 10.1007/978-1-59745-196-3_19
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Williamson BN, 2020, NATURE, DOI 10.1038/s41586-020-2423-5
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yu IM, 2006, J BIOL CHEM, V281, P17134, DOI 10.1074/jbc.M602107200
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 62
TC 8
Z9 7
U1 16
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0961-8368
EI 1469-896X
J9 PROTEIN SCI
JI Protein Sci.
PD SEP
PY 2020
VL 29
IS 9
BP 1890
EP 1901
DI 10.1002/pro.3909
EA AUG 2020
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NF2ZE
UT WOS:000556020700001
PM 32654247
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sahin, D
   Tanacan, A
   Erol, SA
   Anuk, AT
   Eyi, EGY
   Ozgu-Erdinc, AS
   Yucel, A
   Keskin, HL
   Tayman, C
   Unlu, S
   Kirca, F
   Dinc, B
   San, I
   Parpucu, UM
   Surel, AA
   Moraloglu, OT
AF Sahin, Dilek
   Tanacan, Atakan
   Erol, Seyit A.
   Anuk, Ali T.
   Eyi, Elif G. Y.
   Ozgu-Erdinc, A. Seval
   Yucel, Aykan
   Keskin, Huseyin L.
   Tayman, Cuneyt
   Unlu, Serpil
   Kirca, Fisun
   Dinc, Bedia
   San, Ishak
   Parpucu, U. Murat
   Surel, Aziz A.
   Moraloglu, Ozlem T.
TI A pandemic center's experience of managing pregnant women with COVID-19
   infection in Turkey: A prospective cohort study
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE COVID-19; Maternal outcome; Neonatal outcomes; Obstetric outcomes;
   Pregnancy; SARS-CoV-2
AB Objective To evaluate the course and effect of coronavirus disease 2019 (COVID-19) on pregnant women followed up in a Turkish institution. Methods A prospective, single tertiary pandemic center cohort study was conducted on pregnant women with confirmed or suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Positive diagnosis was made on a real-time polymerase chain reaction (RT-PCR) assay of a nasopharyngeal and oropharyngeal specimen. Demographic features, clinical characteristics, and maternal and perinatal outcomes were evaluated. Results SARS-CoV-2 was suspected in 100 pregnant women. Of them, 29 had the diagnosis confirmed by RT-PCR. Eight of the remaining 71 cases had clinical findings highly suspicious for COVID-19. Ten (34.5%) of the confirmed cases had co-morbidities. Cough (58.6%) and myalgia (51.7%) were the leading symptoms. COVID-19 therapy was given to 10 (34.5%) patients. There were no admissions to the intensive care unit. Pregnancy complications were present in 7 (24.1%) patients. Half of the births (5/10) were cesarean deliveries. None of the neonates were positive for SARS-CoV-2. Samples of breastmilk were also negative for the virus. Three neonates were admitted to the neonatal intensive care unit. Conclusion The clinical course of COVID 19 during pregnancy appears to be mild in the present study.
C1 [Sahin, Dilek; Yucel, Aykan; Keskin, Huseyin L.; Tayman, Cuneyt; San, Ishak; Parpucu, U. Murat; Moraloglu, Ozlem T.] Univ Hlth Sci, Ankara City Hosp, Ankara, Turkey.
   [Sahin, Dilek; Tanacan, Atakan; Erol, Seyit A.; Anuk, Ali T.; Eyi, Elif G. Y.; Ozgu-Erdinc, A. Seval; Yucel, Aykan; Keskin, Huseyin L.; Moraloglu, Ozlem T.] Ankara City Hosp, Dept Obstet & Gynecol, Minist Hlth, Ankara, Turkey.
   [Tayman, Cuneyt] Ankara City Hosp, Dept Pediat, Div Neonatol, Minist Hlth, Ankara, Turkey.
   [Unlu, Serpil] Ankara City Hosp, Dept Infect Dis, Minist Hlth, Ankara, Turkey.
   [Kirca, Fisun; Dinc, Bedia] Ankara City Hosp, Dept Med Microbiol, Minist Hlth, Ankara, Turkey.
   [San, Ishak] Minist Hlth, Emergency Hlth Serv, Ankara, Turkey.
   [Parpucu, U. Murat] Gulhane Vocat Sch Hlth Serv, Anaesthesiol & Reanimat Dept, Ankara, Turkey.
   [Surel, Aziz A.] Ankara City Hosp, Gen Hosp, Minist Hlth, Ankara, Turkey.
RP Tanacan, A (corresponding author), 1604th St,9 Cankaya, TR-06800 Ankara, Turkey.
EM atakantanacan@yahoo.com
RI Anuk, Ali Taner/ABD-2966-2020; Anuk, Ali Taner/ABC-1991-2020; Yucel,
   Aykan/B-9247-2013; San, Ishak/AAG-2175-2019; Sahin, Dilek/ABE-3511-2020
OI Anuk, Ali Taner/0000-0001-5437-1008; Yucel, Aykan/0000-0002-5888-692X;
   San, Ishak/0000-0002-9658-9010; Sahin, Dilek/0000-0001-8567-9048;
   Keskin, Huseyin Levent/0000-0002-2268-3821
CR Akalin A, 2020, INT J GYNECOL OBSTET, V150, P354, DOI 10.1002/ijgo.13243
   Akdemir N, 2011, GYNECOL OBSTET REPRO, V17, P4
   Breslin N, COVID 19 INFECT ASYM
   Dai X., 2020, EUR J PREV CARDIOL
   Dashraath P, 2020, AM J OBSTET GYNECOL, V222, P521, DOI 10.1016/j.ajog.2020.03.021
   Dong L, 2020, JAMA
   Ellinghaus D, 2020, N ENGL J MED
   Elshafeey F, 2020, INT J GYNECOL OBSTET, V150, P47, DOI 10.1002/ijgo.13182
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hantoushzadeh S, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.04.030
   Huntley BJF, 2020, OBSTET GYNECOL, V136, P303, DOI 10.1097/AOG.0000000000004010
   Jiang JJ, 2020, INFECT DIS-NOR, V52, P763, DOI 10.1080/23744235.2020.1788222
   Juan J., 2020, ULTRASOUND OBSTET GY
   Knight M., 2020, CHARACTERISTICS OUTC
   Lee TH, 2020, CLIN INFECT DIS
   Luo YW, 2020, LANCET INFECT DIS, V20, P513, DOI 10.1016/S1473-3099(20)30191-2
   McIntosh JJ, 2020, AM J PERINAT, V37, P809, DOI 10.1055/s-0040-1709684
   Mullins E, 2020, ULTRASOUND OBST GYN, V55, P586, DOI 10.1002/uog.22014
   Poon LC, 2020, ULTRASOUND OBST GYN, V55, P700, DOI 10.1002/uog.22013
   Poon LC, 2020, INT J GYNECOL OBSTET, V149, P273, DOI 10.1002/ijgo.13156
   Rasmussen SA, 2020, AM J OBSTET GYNECOL, V222, P415, DOI 10.1016/j.ajog.2020.02.017
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Talbot L, 2016, ANAEST INTENS CARE M, V17, P341, DOI 10.1016/j.mpaic.2016.04.010
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Turkish Ministry of Health General Directorate of Public Health, COVD 19 SARS COV 2 I
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang X, 2020, INT J INFECT DIS, V94, P107, DOI 10.1016/j.ijid.2020.04.023
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI DOI 10.1001/JAMA.2013.281053
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Zaidi FZ, 2020, TRANSFUS APHER SCI
   Zhao J, 2020, RELATIONSHIP ABO BLO
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 34
TC 2
Z9 2
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD OCT
PY 2020
VL 151
IS 1
BP 74
EP 82
DI 10.1002/ijgo.13318
EA AUG 2020
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA NL0MH
UT WOS:000555828500001
PM 32682342
OA Bronze
DA 2021-01-01
ER

PT J
AU Teoh, SL
   Lim, YH
   Lai, NM
   Lee, SWH
AF Teoh, Siew L.
   Lim, Yi H.
   Lai, Nai M.
   Lee, Shaun W. H.
TI Directly Acting Antivirals for COVID-19: Where Do We Stand?
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE rapid review; systematic review; COVID-19; antivirals; pandemic
ID DISEASE 2019
AB The outbreak of a novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 has now become a pandemic with no approved therapeutic agent. At the moment, the genomic structure, characteristics, and pathogenic mechanisms of SARS-CoV-2 have been reported. Based upon this information, several drugs including the directly acting antivirals have been proposed to treat people with coronavirus disease 2019 (COVID-19). This rapid review aims to describe the directly acting antivirals that have been examined for use in the management of COVID-19. Searches were conducted in three electronic databases, supplemented with a search on arXiv, bioRxiv, medRxiv, ChinaXiv,, and Chinese Clinical Trial Registry for studies examining the use of antivirals in COVID-19 to identify for case reports, case series, observational studies, and randomized controlled studies describing the use of antivirals in COVID-19. Data were extracted independently and presented narratively. A total of 98 studies were included, comprising of 38 published studies and 60 registered clinical trials. These drugs include the broad spectrum antivirals such as umifenovir, protease inhibitors such as lopinavir/ritonavir as well as the RNA-dependent RNA polymerase inhibitors, remdesivir, and favipiravir. Other drugs that have been used include the nucleosidase inhibitors and polymerase acidic endonuclease inhibitors which are currently approved for prevention of influenza infections. While some of the drugs appear promising in small case series and reports, more clinical trials currently in progress are required to provide higher quality evidence.
C1 [Teoh, Siew L.; Lai, Nai M.; Lee, Shaun W. H.] Monash Univ Malaysia, Sch Pharm, Subang Jaya, Malaysia.
   [Lim, Yi H.] Taylors Univ, Fac Hlth & Med Sci, Sch Biosci, Subang Jaya, Malaysia.
   [Lai, Nai M.] Taylors Univ, Fac Hlth & Med Sci, Sch Med, Subang Jaya, Malaysia.
   [Lai, Nai M.; Lee, Shaun W. H.] Monash Univ Malaysia, Asian Ctr Evidence Synth Populat, Global Asia 21st Century GA21 Platform, Implementat & Clin Outcomes PICO Hlth & Well Bein, Subang Jaya, Malaysia.
   [Lee, Shaun W. H.] Taylors Univ, Fac Hlth & Med Sci, Sch Pharm, Subang Jaya, Malaysia.
RP Lee, SWH (corresponding author), Monash Univ Malaysia, Sch Pharm, Subang Jaya, Malaysia.; Lee, SWH (corresponding author), Monash Univ Malaysia, Asian Ctr Evidence Synth Populat, Global Asia 21st Century GA21 Platform, Implementat & Clin Outcomes PICO Hlth & Well Bein, Subang Jaya, Malaysia.; Lee, SWH (corresponding author), Taylors Univ, Fac Hlth & Med Sci, Sch Pharm, Subang Jaya, Malaysia.
EM shaun.lee@monash.edu
RI Lai, Nai Ming/H-3163-2019
CR Antinori S, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104899
   Baio G, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0840-9
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432.t, DOI 10.1101/2020.03.17.20037432.T]
   Chen H., 2020, 1 CLIN STUDY USING H, DOI [10.1101/2020.03.22.20034041, DOI 10.1101/2020.03.22.20034041]
   Chen WY, 2020, J MED VIROL, V92, P2702, DOI 10.1002/jmv.26142
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fink SL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27224-4
   Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Giacomelli A., 2020, EARLY ADM LOPINAVIRR, DOI [10.1101/2020.06.05.20123299, DOI 10.1101/2020.06.05.20123299]
   Gillenwater S, 2020, NEW ENGL J MED, V383, P992, DOI 10.1056/NEJMc2022236
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Harter G, 2020, INFECTION, V48, P681, DOI 10.1007/s15010-020-01438-z
   Haviernik J, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040184
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Kim Ji-Won, 2020, Korean J Intern Med, DOI 10.3904/kjim.2020.224
   Koszalka P, 2019, ANTIVIR RES, V164, P91, DOI 10.1016/j.antiviral.2019.02.007
   Lee S. W. H., 2020, PROG DRUG DISCOV BIO, V3, DOI [10.3687/pmmb.a0000090, DOI 10.3687/PMMB.A0000090]
   Lee SWH, 2019, BRIT J CLIN PHARMACO, V85, P2668, DOI 10.1111/bcp.14101
   Li Y, 2020, EXPLORATORY RANDOMIZ, DOI [10.1101/2020.03.19.20038984, DOI 10.1101/2020.03.19.20038984]
   Lian N, 2020, CLIN MICROBIOL INFEC, V26, P917, DOI 10.1016/j.cmi.2020.04.026
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013
   Livingston Edward, 2020, JAMA, V323, P1122, DOI 10.1001/jama.2020.2633
   Locke SC, 2019, DRUG TODAY, V55, P359, DOI 10.1358/dot.2019.55.6.2999889
   Lou Y, 2020, CLIN OUTCOMES PLASMA
   Malosh RE, 2018, CLIN INFECT DIS, V66, P1492, DOI 10.1093/cid/cix1040
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   Panagopoulos P, 2020, J CHEMOTHERAPY, DOI 10.1080/1120009X.2020.1775424
   Rajgor DD, 2020, LANCET INFECT DIS, V20, P776, DOI 10.1016/S1473-3099(20)30244-9
   Shi XD, 2020, J MED VIROL, V92, P1922, DOI 10.1002/jmv.25893
   Stevens MP, 2020, INFECT CONT HOSP EP, V41, P744, DOI 10.1017/ice.2020.69
   Vizcarra P., 2020, LANCET HIV, VS2352, P30164
   Wang RR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105617
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   World Health Organization, 2020, WHO R D BLUEPR NOV C
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xi W.-N., 2020, TREATMENT ARBIDOL MO, DOI [10.1101/2020.05.30.20117598, DOI 10.1101/2020.05.30.20117598]
   Xu P, 2020, MICROBES INFECT, V22, P200, DOI 10.1016/j.micinf.2020.05.012
   Yan D, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00799-2020
   Yang CG, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00249
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang JH, 2020, CRIT REV BIOTECHNOL, V40, P459, DOI [10.1080/07388551.2020.1739618, 10.1159/000511434, 10.1080/15384047.2020.1776075, 10.1159/000506150]
   Zheng CC, 2020, INT J INFECT DIS, V94, P74, DOI 10.1016/j.ijid.2020.03.047
   Zheng F, 2020, MEDRXIV, DOI [10.1101/2020.04.24.20077735, DOI 10.1101/2020.04.24.20077735]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou Y., 2020, PROLONGED SARS COV 2, DOI [10.1101/2020.06.09.20076646, DOI 10.1101/2020.06.09.20076646]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
   Zuo Y, 2020, J MED VIROL, V92, P2666, DOI 10.1002/jmv.26127
NR 61
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD AUG 5
PY 2020
VL 11
AR 1857
DI 10.3389/fmicb.2020.01857
PG 18
WC Microbiology
SC Microbiology
GA NF6MT
UT WOS:000563410300001
PM 32849448
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rodriguez-Rubio, M
   Figueira, JC
   Acuna-Castroviejo, D
   Borobia, AM
   Escames, G
   de la Oliva, P
AF Rodriguez-Rubio, Miguel
   Figueira, Juan Carlos
   Acuna-Castroviejo, Dario
   Borobia, Alberto M.
   Escames, Germaine
   de la Oliva, Pedro
TI A phase II, single-center, double-blind, randomized placebo-controlled
   trial to explore the efficacy and safety of intravenous melatonin in
   patients with COVID-19 admitted to the intensive care unit (MelCOVID
   study): a structured summary of a study protocol for a randomized
   controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomized Controlled Trial; protocol; melatonin; treatment;
   intensive care; ARDS; inflammation
AB Objectives: Primary objective: to evaluate the effect of intravenous melatonin (IVM) on mortality in adult patients admitted to the intensive care unit (ICU) with COVID-19.
   Secondary objectives:
   To evaluate the effect of IVM on ICU length of stay.
   To evaluate the effect of IVM on the length of mechanical ventilation (MV).
   To evaluate if the use of IVM is associated with an increase in the number of ventilator-free days.
   To evaluate if the use of IVM is associated with a reduced number of failing organs as determined by the sequential organ failure assessment (SOFA) scale.
   To evaluate if the use of IVM is associated with a reduction of the frequency and severity of COVID-19-associated thromboembolic phenomena.
   To evaluate if the use of IVM is associated with a decreased systemic inflammatory response assessed by plasma levels of ferritin, D-dimer, C-reactive protein, procalcitonin and interleukin-6.
   To evaluate if the use of IVM is associated with an improvement in hematologic parameters.
   To evaluate if the use of IVM is associated with an improvement in biochemical parameters.
   To evaluate if the use of IVM is associated with an improvement in blood gas analysis parameters.
   To evaluate adverse events during the 28 day study period.
   Trial designPhase II, single center, double-blind, placebo-controlled randomized trial with a two-arm parallel group design and 2:1 allocation ratio.
   ParticipantsOnly critically ill adult patients that fulfill all of the inclusion criteria and none of the exclusion criteria will be included. The study will be conducted in a mixed ICU of a publicly funded tertiary referral center in Madrid, Spain with a 30-bed capacity and 1100 admissions per year.
   Inclusion criteria:
   Patient, family member or legal guardian has provided written Informed Consent.
   Age epsilon 18 years.
   Confirmed SARS-CoV-2 infection with compatible symptoms AND a positive RT-PCR.
   Admission to the ICU with acute hypoxemic respiratory failure attributed to SARS-CoV-2 infection.? ICU length of stay of less than 7 days prior to randomization with or without MV and without signs of improvement in respiratory failure (MURRAY score at randomization greater or equal to the MURRAY score at ICU admission).
   Exclusion criteria:
   Participant in a different COVID-19 study in which the study drug is under clinical development and hasn't been previously authorized for commercialization.
   Liver enzymes > 5 times the upper normal range.
   Chronic kidney disease with GFR < 30 mL/min/1.73 m(2) (stage 4 or greater) or need for hemodialysis.
   Pregnancy. A pregnancy test will be performed on every woman younger than 55 years of age prior to inclusion.
   Terminal surgical or medical illness.
   Autoimmune disease.
   Any patient condition that can prevent the study procedures to be carried out at the treating physician's judgement.Intervention and comparatorAll patients will receive standard-of-care treatment according to the current institutional protocols. In addition, patients will be randomized in a 2:1 ratio to receive:
   Experimental group (12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
   Control group (6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.After 3 days of treatment, 3 intensive care physicians will evaluate the participant and decide whether or not to complete the treatment based on their clinical assessment:
   If objective or subjective signs of improvement or no worsening of the general clinical condition, respiratory failure, inflammatory state or multi-organ failure are observed, the participant will continue the treatment until completion.
   If an adverse effect or clinical impairment is observed that is objectively or subjectively attributable to the study drug the treatment will be stopped.
   Main outcomeMortality in each study group represented in frequency and time-to-event at day 28 after randomization
   Randomization The randomization sequence was created using SAS version 9.4 statistical software (programmed and validated macros) with a 2:1 allocation. No randomization seed was pre-specified. The randomization seed was generated using the time on the computer where the program was executed.
   Blinding (masking)Participants, caregivers and study groups will be blinded to arm allocation.Numbers to be randomized (sample size)A total of 18 patients will be randomized in this trial: 12 to the experimental arm and 6 to the control arm.Trial StatusProtocol version 2.0, June 5(th) 2020.
   Trial status: recruitment not started. The first patient is expected to be recruited in October 2020. The last patient is anticipated to be recruited in August 2021.
   Trial registration EU Clinical Trials Register. Date of trial registration: 10 July 2020. URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001808-42/ES
   Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Rodriguez-Rubio, Miguel; de la Oliva, Pedro] Hosp Univ La Paz, Pediat Intens Care Dept, Madrid, Spain.
   [Rodriguez-Rubio, Miguel; de la Oliva, Pedro] Univ Autonoma Madrid, Sch Med, Dept Pediat, Madrid, Spain.
   [Figueira, Juan Carlos] Hosp Univ La Paz, Intens Care Med Dept, Madrid, Spain.
   [Acuna-Castroviejo, Dario; Escames, Germaine] Univ Granada, Dept Physiol, Fac Med, Biomed Res Ctr, Hlth Sci Technol Pk, Granada, Spain.
   [Acuna-Castroviejo, Dario; Escames, Germaine] Ibs Granada, CIBERfes, Granada, Spain.
   [Acuna-Castroviejo, Dario] San Cecilio Univ Hosp, Clin Labs, Granada, Spain.
   [Borobia, Alberto M.] Hosp Univ La Paz IdiPAZ, Clin Pharmacol Dept, Clin Trial Unit, Madrid, Spain.
   [Borobia, Alberto M.] Univ Autonoma Madrid, Sch Med, Madrid, Spain.
RP de la Oliva, P (corresponding author), Hosp Univ La Paz, Pediat Intens Care Dept, Madrid, Spain.; de la Oliva, P (corresponding author), Univ Autonoma Madrid, Sch Med, Dept Pediat, Madrid, Spain.; Escames, G (corresponding author), Univ Granada, Dept Physiol, Fac Med, Biomed Res Ctr, Hlth Sci Technol Pk, Granada, Spain.
EM gescames@ugr.es; pedro.oliva@salud.madrid.org
RI Rodriguez-Rubio, Miguel/AAQ-6829-2020
OI Rodriguez-Rubio, Miguel/0000-0001-9145-4718; de la Oliva,
   Pedro/0000-0003-2444-0556
FU start-up Pharmamel LTD
FX The start-up Pharmamel LTD financed the trial. The funding body had no
   role on the design of the study or the collection, analysis or
   interpretation of the data nor in the writing of the manuscript.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD AUG 5
PY 2020
VL 21
IS 1
AR 699
DI 10.1186/s13063-020-04632-4
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NC3HE
UT WOS:000561104700003
PM 32758298
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Azoulay, E
   de Waele, J
   Ferrer, R
   Staudinger, T
   Borkowska, M
   Povoa, P
   Iliopoulou, K
   Artigas, A
   Schaller, SJ
   Shankar-Hari, M
   Pellegrini, M
   Darmon, M
   Kesecioglu, J
   Cecconi, M
AF Azoulay, Elie
   de Waele, Jan
   Ferrer, Ricard
   Staudinger, Thomas
   Borkowska, Marta
   Povoa, Pedro
   Iliopoulou, Katerina
   Artigas, Antonio
   Schaller, Stefan J.
   Shankar-Hari, Manu
   Pellegrini, Mariangela
   Darmon, Michael
   Kesecioglu, Jozef
   Cecconi, Maurizio
TI International variation in the management of severe COVID-19 patients
SO CRITICAL CARE
LA English
DT Article
DE Coronavirus; Acute respiratory distress syndrome; Viral infection;
   Remdesivir
AB Background There is little evidence to support the management of severe COVID-19 patients. Methods To document this variation in practices, we performed an online survey (April 30-May 25, 2020) on behalf of the European Society of Intensive Care Medicine (ESICM). A case vignette was sent to ESICM members. Questions investigated practices for a previously healthy 39-year-old patient presenting with severe hypoxemia from COVID-19 infection. Results A total of 1132 ICU specialists (response rate 20%) from 85 countries (12 regions) responded to the survey. The survey provides information on the heterogeneity in patient's management, more particularly regarding the timing of ICU admission, the first line oxygenation strategy, optimization of management, and ventilatory settings in case of refractory hypoxemia. Practices related to antibacterial, antiviral, and anti-inflammatory therapies are also investigated. Conclusions There are important practice variations in the management of severe COVID-19 patients, including differences at regional and individual levels. Large outcome studies based on multinational registries are warranted.
C1 [Azoulay, Elie; Darmon, Michael] Paris Univ, Hop St Louis, St Louis Hosp, AP HP,Med Intens & Reanimat Dept, 1 Ave Claude Vellefaux, F-75010 Paris, France.
   [de Waele, Jan; Borkowska, Marta] Ghent Univ Hosp, Dept Crit Care Med, NL-9000 Ghent, Netherlands.
   [Ferrer, Ricard] Inst Invest Vail dHebron, Shock Organ Dysfunct & Resuscitat Res Grp SODIR, Barcelona, Spain.
   [Ferrer, Ricard] Hosp Univ Vall dHebron, Ctr Invest Biomed Red CIBER Enfermedades Resp, Dept Med Intens, Barcelona, Spain.
   [Staudinger, Thomas] Med Univ Vienna, Vienna Gen Hosp, Dept Med 1, Intens Care Unit, Vienna, Austria.
   [Povoa, Pedro] Univ Nova Lisboa, Hosp Sao Francisco Xavier, NOVA Med Sch, CHRC,Unidade Cuidados Intens Polivalente,CHLO, Estr Forte Alto Do Duque, P-1449005 Lisbon, Portugal.
   [Iliopoulou, Katerina] ICU Nurse Manager Gen Mil Hosp, Hellen Army, Athens, Greece.
   [Artigas, Antonio] Autonomous Univ Barcelona, Sabadell Hosp, Crit Care Ctr, Univ Inst Parc Tauli, Barcelona, Spain.
   [Schaller, Stefan J.] Charite Univ Med Berlin, Berlin, Germany.
   [Schaller, Stefan J.] Free Univ Berlin, Berlin, Germany.
   [Schaller, Stefan J.] Humboldt Univ, Berlin, Germany.
   [Schaller, Stefan J.] Berlin Inst Hlth, Dept Anesthesiol & Surg Intens Care, Berlin, Germany.
   [Shankar-Hari, Manu] Kings Coll London, Guys & St Thomas NHS Fdn Trust, Sch Immunol & Microbial Sci, ICU Support Off,St Thomas Hosp, London, England.
   [Pellegrini, Mariangela] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Surg Sci, Gothenburg, Sweden.
   [Pellegrini, Mariangela] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Cent Intens Care Unit, Gothenburg, Sweden.
   [Pellegrini, Mariangela] Univ Gothenburg, Sahlgrenska Acad, Dept Anesthesia Operat & Intens Care, Gothenburg, Sweden.
   [Pellegrini, Mariangela] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden.
   [Pellegrini, Mariangela] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Anesthesiol & Intens Care Med, Gothenburg, Sweden.
   [Kesecioglu, Jozef] Univ Utrecht, Univ Med Ctr Utrecht, Div Anesthesiol Intens Care & Emergency Med, Dept Intens Care Med, Utrecht, Netherlands.
   [Cecconi, Maurizio] Humanitas Univ, Humanitas Clin & Res Ctr, Milan, Italy.
RP Azoulay, E (corresponding author), Paris Univ, Hop St Louis, St Louis Hosp, AP HP,Med Intens & Reanimat Dept, 1 Ave Claude Vellefaux, F-75010 Paris, France.
EM elie.azoulay@aphp.fr
OI Azoulay, Elie/0000-0002-8162-1508; Schaller, Stefan/0000-0002-6683-9584
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Aziz S, 2020, INTENS CARE MED, V46, P1303, DOI 10.1007/s00134-020-06092-5
   Azoulay E, 2020, INTENS CARE MED, V46, P1651, DOI 10.1007/s00134-020-06120-4
   Bauchner H, 2020, JAMA-J AM MED ASSOC, V323, P2262, DOI 10.1001/jama.2020.8115
   Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478
   Helms J, 2020, INTENS CARE MED, V46, P1502, DOI 10.1007/s00134-020-06082-7
   Sprung CL, 2019, JAMA-J AM MED ASSOC, V322, P1718, DOI 10.1001/jama.2019.14608
NR 7
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD AUG 5
PY 2020
VL 24
IS 1
AR 486
DI 10.1186/s13054-020-03194-w
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA NC2SC
UT WOS:000561065200002
PM 32758266
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Erasmus, JH
   Khandhar, AP
   O'Connor, MA
   Walls, AC
   Hemann, EA
   Murapa, P
   Archer, J
   Leventhal, S
   Fuller, JT
   Lewis, TB
   Draves, KE
   Randall, S
   Guerriero, KA
   Duthie, MS
   Carter, D
   Reed, SG
   Hawman, DW
   Feldmann, H
   Gale, M
   Veesler, D
   Berglund, P
   Fuller, DH
AF Erasmus, Jesse H.
   Khandhar, Amit P.
   O'Connor, Megan A.
   Walls, Alexandra C.
   Hemann, Emily A.
   Murapa, Patience
   Archer, Jacob
   Leventhal, Shanna
   Fuller, James T.
   Lewis, Thomas B.
   Draves, Kevin E.
   Randall, Samantha
   Guerriero, Kathryn A.
   Duthie, Malcolm S.
   Carter, Darrick
   Reed, Steven G.
   Hawman, David W.
   Feldmann, Heinz
   Gale, Michael, Jr.
   Veesler, David
   Berglund, Peter
   Fuller, Deborah Heydenburg
TI An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2
   neutralizing antibody and T cell responses in mice and nonhuman primates
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; IRON-OXIDE NANOPARTICLES; EQUINE
   ENCEPHALITIS-VIRUS; HUMAN MONOCLONAL-ANTIBODY; SARS CORONAVIRUS;
   PRECLINICAL EVALUATION; EXPRESSION VECTORS; IMMUNE-RESPONSE;
   GENE-EXPRESSION; SINDBIS VIRUS
AB The coronavirus disease 2019 (COVID-19) pandemic, caused by infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is having a deleterious impact on health services and the global economy, highlighting the urgent need for an effective vaccine. Such a vaccine would need to rapidly confer protection after one or two doses and would need to be manufactured using components suitable for scale up. Here, we developed an Alphavirus-derived replicon RNA vaccine candidate, repRNA-CoV2S, encoding the SARS-CoV-2 spike (S) protein. The RNA replicons were formulated with lipid inorganic nanoparticles (LIONs) that were designed to enhance vaccine stability, delivery, and immunogenicity. We show that a single intramuscular injection of the LION/repRNA-CoV2S vaccine in mice elicited robust production of anti-SARS-CoV-2 S protein IgG antibody isotypes indicative of a type 1 T helper cell response. A prime/boost regimen induced potent T cell responses in mice including antigen-specific responses in the lung and spleen. Prime-only immunization of aged (17 months old) mice induced smaller immune responses compared to young mice, but this difference was abrogated by booster immunization. In nonhuman primates, prime-only immunization in one intramuscular injection site or prime/boost immunizations in five intramuscular injection sites elicited modest T cell responses and robust antibody responses. The antibody responses persisted for at least 70 days and neutralized SARS-CoV-2 at titers comparable to those in human serum samples collected from individuals convalescing from COVID-19. These data support further development of LION/repRNA-CoV2S as a vaccine candidate for prophylactic protection against SARS-CoV-2 infection.
C1 [Erasmus, Jesse H.; O'Connor, Megan A.; Murapa, Patience; Archer, Jacob; Fuller, James T.; Lewis, Thomas B.; Draves, Kevin E.; Randall, Samantha; Fuller, Deborah Heydenburg] Univ Washington, Dept Microbiol, Seattle, WA 98109 USA.
   [Erasmus, Jesse H.; Khandhar, Amit P.; Duthie, Malcolm S.; Carter, Darrick; Reed, Steven G.; Berglund, Peter] HDT Bio, Seattle, WA 98102 USA.
   [Khandhar, Amit P.; Archer, Jacob; Carter, Darrick] PAI Life Sci, Seattle, WA 98102 USA.
   [O'Connor, Megan A.; Lewis, Thomas B.; Guerriero, Kathryn A.; Gale, Michael, Jr.; Fuller, Deborah Heydenburg] Washington Natl Primate Res Ctr, Seattle, WA 98121 USA.
   [Walls, Alexandra C.; Veesler, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
   [Hemann, Emily A.; Carter, Darrick; Reed, Steven G.; Gale, Michael, Jr.; Fuller, Deborah Heydenburg] Univ Washington, Ctr Innate Immun & Immune Dis, Seattle, WA 98109 USA.
   [Hemann, Emily A.; Gale, Michael, Jr.] Univ Washington, Dept Immunol, Seattle, WA 98109 USA.
   [Leventhal, Shanna; Hawman, David W.; Feldmann, Heinz] NIAID, Lab Virol, Div Intramural Res, NIH, Hamilton, MT 59840 USA.
RP Fuller, DH (corresponding author), Univ Washington, Dept Microbiol, Seattle, WA 98109 USA.; Fuller, DH (corresponding author), Washington Natl Primate Res Ctr, Seattle, WA 98121 USA.; Fuller, DH (corresponding author), Univ Washington, Ctr Innate Immun & Immune Dis, Seattle, WA 98109 USA.
EM fullerdh@uw.edu
OI O'Connor, Megan/0000-0003-2127-5073; Fuller, Deborah/0000-0001-7315-2441
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1F32AI136371, P51OD010425]; NIH/NIAID
   Centers of Excellence for Influenza Research and Surveillance
   [27220140006C]; HDT Bio internal funds; University of Washington Center
   for Innate Immunity and Immune Disease, NIH/NIAID [75N93019C00037];
   NIH/NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [75N93019C00008]; NIGMS/NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [R01GM120553]; NIAID/NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [HHSN272201700059C]; Pew
   Biomedical Scholars Award; Burroughs Wellcome FundBurroughs Wellcome
   Fund; NIAID, NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID)
FX This work was funded by NIH grant no. P51OD010425 (Washington National
   Primate Research Center), NIH/NIAID Centers of Excellence for Influenza
   Research and Surveillance contract 27220140006C (J.H.E.), and HDT Bio
   internal funds. Additional support from the University of Washington
   Center for Innate Immunity and Immune Disease, NIH/NIAID contract
   75N93019C00037 (M.S.D.), NIH/NIAID contract 75N93019C00008 (A.P.K.), the
   NIGMS/NIH R01GM120553 (D.V.), NIAID/NIH HHSN272201700059C (D.V.), a Pew
   Biomedical Scholars Award (D.V.), Fast Grants (D.V.), an Investigators
   in the Pathogenesis of Infectious Disease Award from the Burroughs
   Wellcome Fund (D.V.), and the intramural research program of NIAID, NIH
   (D.W.H., S.L., and H.F.). J.H.E. is a Washington Research Foundation
   postdoctoral fellow and is also supported by NIH grant no. 1F32AI136371.
   The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the funders.
CR Aberle JH, 2005, J VIROL, V79, P15107, DOI 10.1128/JVI.79.24.15107-15113.2005
   Atasheva S., 2016, J VIROL, V87
   Bao L, 2020, REINFECTION COULD NO, DOI [10.1101/2020.03.13.990226, DOI 10.1101/2020.03.13.990226, 10.1101/2020.03.13.990226.]
   Bauer LM, 2016, NANOSCALE, V8, P12162, DOI 10.1039/c6nr01877g
   Berglund P, 1998, NAT BIOTECHNOL, V16, P562, DOI 10.1038/nbt0698-562
   Bernstein DI, 2009, VACCINE, V28, P484, DOI 10.1016/j.vaccine.2009.09.135
   Blade K., 2020, SCIENCE
   BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993
   Calabro S, 2013, VACCINE, V31, P3363, DOI 10.1016/j.vaccine.2013.05.007
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chaplin JW, 2013, J EXP MED, V210, P2135, DOI 10.1084/jem.20130188
   Chen HB, 2005, J IMMUNOL, V175, P591, DOI 10.4049/jimmunol.175.1.591
   Corti D, 2015, P NATL ACAD SCI USA, V112, P10473, DOI 10.1073/pnas.1510199112
   Desbien AL, 2015, EUR J IMMUNOL, V45, P407, DOI 10.1002/eji.201444543
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Duthie MS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02420
   Erasmus, 2020, SCI TRANSL MED, V12
   Erasmus JH, 2018, MOL THER, V26, P2507, DOI 10.1016/j.ymthe.2018.07.010
   Frolov I, 1996, P NATL ACAD SCI USA, V93, P11371, DOI 10.1073/pnas.93.21.11371
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14
   Hubby B, 2007, VACCINE, V25, P8180, DOI 10.1016/j.vaccine.2007.09.038
   Jensen S, 2012, J VIROL, V86, P2900, DOI 10.1128/JVI.05738-11
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Khandhar AP, 2017, NANOSCALE, V9, P1299, DOI 10.1039/c6nr08468k
   Khandhar AP, 2018, J BIOMED MATER RES A, V106, P2440, DOI 10.1002/jbm.a.36438
   KINNEY RM, 1993, J VIROL, V67, P1269, DOI 10.1128/JVI.67.3.1269-1277.1993
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356
   Ljungberg K, 2015, EXPERT REV VACCINES, V14, P177, DOI 10.1586/14760584.2015.965690
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Martin RM, 1998, J IMMUNOL METHODS, V212, P187, DOI 10.1016/S0022-1759(98)00015-5
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Millet J, 2016, BIO-PROTOCOL, V6, pe2035
   Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166
   Morse M, 2015, J IMMUNOTHER CANCER, V3, P444
   Munson P, 2018, HUM VACC IMMUNOTHER, V14, P1820, DOI 10.1080/21645515.2018.1448328
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   O'Connor MA, 2019, AIDS RES HUM RETROV, V35, P295, DOI [10.1089/aid.2018.0184, 10.1089/AID.2018.0184]
   Pinto Dora, 2020, bioRxiv, DOI 10.1101/2020.04.07.023903
   Pushko P, 1997, VIROLOGY, V239, P389, DOI 10.1006/viro.1997.8878
   Reap EA, 2007, VACCINE, V25, P7441, DOI 10.1016/j.vaccine.2007.08.016
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Tseng CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053096
   van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195
   Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607
   Yu EY, 2017, ACS NANO, V11, P12067, DOI 10.1021/acsnano.7b04844
   Yu XW, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay7591
   Zanganeh S, 2016, NAT NANOTECHNOL, V11, P986, DOI [10.1038/NNANO.2016.168, 10.1038/nnano.2016.168]
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhao Y, 2018, MOL PHARMACEUT, V15, P1791, DOI 10.1021/acs.molpharmaceut.7b01103
   ZHOU X, 1994, VACCINE, V12, P1510, DOI 10.1016/0264-410X(94)90074-4
NR 66
TC 3
Z9 3
U1 2
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD AUG 5
PY 2020
VL 12
IS 555
AR eabc9396
DI 10.1126/scitranslmed.abc9396
PG 11
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA MZ0NG
UT WOS:000558819900005
PM 32690628
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tai, WB
   Zhang, XJ
   Drelich, A
   Shi, J
   Hsu, JC
   Luchsinger, L
   Hillyer, CD
   Tseng, CTK
   Jiang, SB
   Du, LY
AF Tai, Wanbo
   Zhang, Xiujuan
   Drelich, Aleksandra
   Shi, Juan
   Hsu, Jason C.
   Luchsinger, Larry
   Hillyer, Christopher D.
   Tseng, Chien-Te K.
   Jiang, Shibo
   Du, Lanying
TI A novel receptor-binding domain (RBD)-based mRNA vaccine against
   SARS-CoV-2
SO CELL RESEARCH
LA English
DT Letter
C1 [Tai, Wanbo; Zhang, Xiujuan; Shi, Juan; Luchsinger, Larry; Hillyer, Christopher D.; Jiang, Shibo; Du, Lanying] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.
   [Drelich, Aleksandra; Hsu, Jason C.; Tseng, Chien-Te K.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
RP Jiang, SB; Du, LY (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.
EM sjiang@nybc.org; ldu@nybc.org
RI Zhang, Xiujuan/AAG-9780-2020; Tai, Wanbo/G-3838-2018
OI Tai, Wanbo/0000-0002-9864-8993
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01AI137472,
   R01AI139092]; New York Blood Center funds [VIM-NYB616, VIM-NYB673]
FX This work was supported by National Institutes of Health (NIH) grants
   (R01AI137472 and R01AI139092) and New York Blood Center funds
   (VIM-NYB616 and VIM-NYB673).
CR Allen CDC, 2007, IMMUNITY, V27, P190, DOI 10.1016/j.immuni.2007.07.009
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 10
TC 2
Z9 2
U1 6
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD OCT
PY 2020
VL 30
IS 10
BP 932
EP 935
DI 10.1038/s41422-020-0387-5
EA AUG 2020
PG 4
WC Cell Biology
SC Cell Biology
GA NV6DH
UT WOS:000556162000003
PM 32759966
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Humeniuk, R
   Mathias, A
   Cao, HY
   Osinusi, A
   Shen, G
   Chng, E
   Ling, J
   Vu, A
   German, P
AF Humeniuk, Rita
   Mathias, Anita
   Cao, Huyen
   Osinusi, Anu
   Shen, Gong
   Chng, Estelle
   Ling, John
   Vu, Amanda
   German, Polina
TI Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral
   for Treatment of COVID-19, in Healthy Subjects
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
ID CORONAVIRUSES; REPLICATION; GS-5734
AB Remdesivir (RDV), a single diastereomeric monophosphoramidate prodrug that inhibits viral RNA polymerases, has potentin vitroantiviral activity against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). RDV received the US Food and Drug Administration (FDA)'s emergency use authorization in the United States and approval in Japan for treatment of patients with severe coronavirus disease 2019 (COVID-19). This report describes two phase I studies that evaluated the safety and pharmacokinetics (PKs) of single escalating and multiple i.v. doses of RDV (solution or lyophilized formulation) in healthy subjects. Lyophilized formulation was evaluated for potential future use in clinical trials due to its storage stability in resource-limited settings. All adverse events were grade 1 or 2 in severity. Overall, RDV exhibited a linear profile following single-dose i.v. administration over 2 hours of RDV solution formulation across the dose range of 3-225 mg. Both lyophilized and solution formulations provided comparable PK parameters. High intracellular concentrations of the active triphosphate (similar to 220-fold to 370-fold higher than thein vitrohalf-maximal effective concentration against SARS-CoV-2 clinical isolate) were achieved following infusion of 75 mg or 150 mg lyophilized formulation over 30 minutes or 2 hours. Following multiple-doses of RDV 150 mg once daily for 7 or 14 days, RDV exhibited a PK profile similar to single-dose administration. Metabolite GS-441524 accumulated similar to 1.9-fold after daily dosing. Overall, RDV exhibited favorable safety and PK profiles that supported once-daily dosing.
C1 [Humeniuk, Rita; Mathias, Anita; Cao, Huyen; Osinusi, Anu; Shen, Gong; Chng, Estelle; Ling, John; Vu, Amanda; German, Polina] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA.
RP Humeniuk, R (corresponding author), Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA.
EM Rita.Humeniuk@gilead.com
FU GileadGilead Sciences
FX This study was supported by Gilead.
CR AminJafari A, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106455
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Cho A, 2012, BIOORG MED CHEM LETT, V22, P2705, DOI 10.1016/j.bmcl.2012.02.105
   Contini C, 2020, J INFECT DEV COUNTR, V14, P254, DOI 10.3855/jidc.12671
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Denison MR, 2011, RNA BIOL, V8, P270, DOI 10.4161/rna.8.2.15013
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Lodise TP, 2020, PHARMACOTHERAPY, V40, P379, DOI 10.1002/phar.2396
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maganti L, 2008, AAPS J, V10, P141, DOI 10.1208/s12248-008-9014-y
   Pruijssers A., REMDESIVIR POTENTLY, DOI 10.1101/2020.04.27.064279v1
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Tang Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep17155
   US Food and Drug Administration, 2020, EM US AUTH
   US Food and Drug Administration. Center for Drug Evaluation and Research, 2005, EST MAX SAF START DO
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94
   World Health Organization, 2020, ROLL UPD COR DIS COV
   Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 28
TC 12
Z9 11
U1 7
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1752-8054
EI 1752-8062
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
PD SEP
PY 2020
VL 13
IS 5
BP 896
EP 906
DI 10.1111/cts.12840
EA AUG 2020
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NM3MV
UT WOS:000555569500001
PM 32589775
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Schulze-Koops, H
   Iking-Konert, C
   Leipe, J
   Hoyer, BF
   Holle, J
   Moosig, F
   Aries, P
   Burmester, G
   Fiehn, C
   Krause, A
   Lorenz, HM
   Schneider, M
   Sewerin, P
   Voormann, A
   Wagner, U
   Kruger, K
   Specker, C
AF Schulze-Koops, Hendrik
   Iking-Konert, Christof
   Leipe, Jan
   Hoyer, Bimba Franziska
   Holle, Julia
   Moosig, Frank
   Aries, Peer
   Burmester, Gerd
   Fiehn, Christoph
   Krause, Andreas
   Lorenz, Hanns-Martin
   Schneider, Matthias
   Sewerin, Philipp
   Voormann, Anna
   Wagner, Ulf
   Krueger, Klaus
   Specker, Christof
CA Kommission Pharmakotherapie
TI Recommendations of the German Society for Rheumatology for management of
   patients with inflammatory rheumatic diseases in the context of the
   SARS-CoV-2/COVID-19 pandemic - Update July 2020
SO ZEITSCHRIFT FUR RHEUMATOLOGIE
LA German
DT Article; Early Access
DE SARS-CoV-2; COVID-19; Treatment management; Recommendations;
   Inflammatory diseases
AB A few days after the SARS-CoV-2 infection was declared a pandemic, the German Society for Rheumatology (DGRh) compiled first recommendations for the care of patients with inflammatory rheumatic diseases (IRD). These first recommendations were based on an expert consensus and were largely non-evidence-based. Now that the first scientific data from registers, cross-sectional studies, case reports and case series are available, the present update is intended to update the previous recommendations and to add new findings. The current recommendations are based on a literature search of publications available up to 15 June 2020 and address preventive measures (such as hygiene measures or vaccinations) and the use of immunomodulatory/immunosuppressive drugs. An important goal of the current recommendations is also to prevent harm to patients with IRD through unjustified restriction of care. The DGRh will continue to update its recommendations in the case of new aspects and will publish them as well as further information on the COVID-19 pandemic on its homepage () in an ongoing process.
C1 [Schulze-Koops, Hendrik; Krause, Andreas; Lorenz, Hanns-Martin; Voormann, Anna; Wagner, Ulf; Specker, Christof] Deutsch Gesell Rheumatol eV, Berlin, Germany.
   [Schulze-Koops, Hendrik] Ludwig Maximilians Univ Munchen, Sekt Rheumatol & Klin Immunol, Med Klin & Poliklin 4, Pettenkoferstr 8a, D-80336 Munich, Germany.
   [Iking-Konert, Christof] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin 3, Sekt Rheumatol, Hamburg, Germany.
   [Leipe, Jan] Univ Krankenhaus Mannheim, Abt Rheumatol, Med Klin 5, Mannheim, Germany.
   [Hoyer, Bimba Franziska] Univ Krankenhaus Schleswig Holstein, Abt Rheumatol, Med Klin 1, Campus Kiel, Kiel, Germany.
   [Holle, Julia; Moosig, Frank] Rheumazentrum Schleswig Holstein Mitte, Neumunster, Germany.
   [Aries, Peer] Rheumatol Struenseehaus, Hamburg, Germany.
   [Burmester, Gerd] Charite Univ Med Berlin, Klin Rheumatol & Klin Immunol, Berlin, Germany.
   [Burmester, Gerd] Freie Univ, Berlin, Germany.
   [Burmester, Gerd] Humboldt Univ, Berlin, Germany.
   [Fiehn, Christoph] Med Ctr Baden Baden, Praxis Rheumatol & Klin Immunol, Baden Baden, Germany.
   [Fiehn, Christoph] ViDia Kliniken Karlsruhe, Baden Baden, Germany.
   [Krause, Andreas] Immanuel Krankenhaus Berlin, Abt Rheumatol Osteol & Klin Immunol, Berlin, Germany.
   [Lorenz, Hanns-Martin] Univ Klinikum Heidelberg, Abt Rheumatol, Med Klin 5, Heidelberg, Germany.
   [Schneider, Matthias; Sewerin, Philipp] Heinrich Heine Univ Dusseldorf, Poliklin Funkt Bereich & Hiller Forschungszentrum, Univ Klinikum Dusseldorf, Dusseldorf, Germany.
   [Wagner, Ulf] Univ Klinikum Leipzig, Abt Rheumatol, Klin & Poliklin Endokrinol Nephrol Rheumatol, Leipzig, Germany.
   [Krueger, Klaus] Rheumatol Praxiszentrum Munchen, St Bonifatius Str 5, D-81541 Munich, Germany.
   [Specker, Christof] Kliniken Essen Mitte, Klin Rheumatol & Klin Immunol, Essen, Germany.
   [Krueger, Klaus] DGRh eV, Kommiss Pharmakotherapie, Berlin, Germany.
RP Schulze-Koops, H (corresponding author), Ludwig Maximilians Univ Munchen, Sekt Rheumatol & Klin Immunol, Med Klin & Poliklin 4, Pettenkoferstr 8a, D-80336 Munich, Germany.; Kruger, K (corresponding author), Rheumatol Praxiszentrum Munchen, St Bonifatius Str 5, D-81541 Munich, Germany.
EM Hendrik.Schulze-Koops@med.uni-muenchen.de;
   Klaus.Krueger@med.uni-muenchen.de
RI Burmester, Gerd R./AAY-7514-2020; Aries, Peer/AAE-6166-2020
CR [Anonymous], 1352020 RKI
   Au K, 2011, ANN RHEUM DIS, V70, P785, DOI 10.1136/ard.2010.128637
   D'Silva KM, 2020, ANN RHEUM DIS, V79, P1156, DOI [10.1136/annrheumdis-2020-217888, 10.1136/annrheumdis-2020-218196, 10.1136/annrheumdis-2020-218179, 10.1136/annrheumdis-2020-218431]
   Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475
   Ferguson LD, 2019, NAT REV RHEUMATOL, V15, P461, DOI 10.1038/s41584-019-0256-0
   Freudenberg S, 2020, Z RHEUMATOL, V79, P584, DOI 10.1007/s00393-020-00833-z
   Furer V, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-001041
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Gonzalez C, 2020, ANN RHEUM DIS, V79, P214
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Hasseli R, 2020, RMD OPEN
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Leipe J, 2020, SEMIN ARTHRITIS RHEU
   Listing J, 2005, ARTHRITIS RHEUM-US, V52, P3403, DOI 10.1002/art.21386
   Mehta B, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-000935
   Michelena X, 2020, SEMIN ARTHRITIS RHEU, V50, P564, DOI 10.1016/j.semarthrit.2020.05.001
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Nurmohamed MT, 2015, NAT REV RHEUMATOL, V11, P693, DOI 10.1038/nrrheum.2015.112
   Schulze-Koops H, 2020, Z RHEUMATOL, V79, P385, DOI 10.1007/s00393-020-00799-y
   Schulze-Koops Hendrik, 2020, Ann Rheum Dis, DOI 10.1136/annrheumdis-2020-218075
   Stone JH, 2017, NEW ENGL J MED, V377, P317, DOI 10.1056/NEJMoa1613849
   Walsh M, 2020, NEW ENGL J MED, V382, P622, DOI 10.1056/NEJMoa1803537
   Ye C, 2020, ANN RHEUM DIS, V79, P1007, DOI 10.1136/annrheumdis-2020-217627
NR 24
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-1855
EI 1435-1250
J9 Z RHEUMATOL
JI Z. Rheumatol.
DI 10.1007/s00393-020-00851-x
EA AUG 2020
PG 6
WC Rheumatology
SC Rheumatology
GA MV2GO
UT WOS:000556181200001
PM 32757030
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Dodds, MG
   Krishna, R
   Goncalves, A
   Rayner, CR
AF Dodds, Michael G.
   Krishna, Rajesh
   Goncalves, Antonio
   Rayner, Craig R.
TI Model-informed drug repurposing: Viral kinetic modelling to prioritize
   rational drug combinations for COVID-19
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article; Early Access
DE combination therapy; COVID-19; modelling; repurposing; viral cell cycle
ID PROTEASE INHIBITORS; POTENT INHIBITOR; VIRUS; REPLICATION; DYNAMICS
AB Aim We hypothesized that viral kinetic modelling could be helpful to prioritize rational drug combinations for COVID-19. The aim of this research was to use a viral cell cycle model of SARS-CoV-2 to explore the potential impact drugs, or combinations of drugs, that act at different stages in the viral life cycle might have on various metrics of infection outcome relevant in the early stages of COVID-19 disease. Methods Using a target-cell limited model structure that has been used to characterize viral load dynamics from COVID-19 patients, we performed simulations to inform on the combinations of therapeutics targeting specific rate constants. The endpoints and metrics included viral load area under the curve (AUC), duration of viral shedding and epithelial cells infected. Based on the known kinetics of the SARS-CoV-2 life cycle, we rank ordered potential targeted approaches involving repurposed, low-potency agents. Results Our simulations suggest that targeting multiple points central to viral replication within infected host cells or release from those cells is a viable strategy for reducing both viral load and host cell infection. In addition, we observed that the time-window opportunity for a therapeutic intervention to effect duration of viral shedding exceeds the effect on sparing epithelial cells from infection or impact on viral load AUC. Furthermore, the impact on reduction on duration of shedding may extend further in patients who exhibit a prolonged shedder phenotype. Conclusions Our work highlights the use of model-informed drug repurposing approaches to better rationalize effective treatments for COVID-19.
C1 [Dodds, Michael G.; Krishna, Rajesh; Rayner, Craig R.] Certara USA Inc, 100 Overlook Ctr,Suite 101, Princeton, NJ 08540 USA.
   [Goncalves, Antonio] Univ Paris, IAME, INSERM, Paris, France.
   [Rayner, Craig R.] Monash Univ, Monash Inst Pharmaceut Sci, Melbourne, Vic, Australia.
RP Rayner, CR (corresponding author), Certara USA Inc, 100 Overlook Ctr,Suite 101, Princeton, NJ 08540 USA.
EM craig.rayner@certara.com
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
FX The authors acknowledge the review of the work by Dr Jeremie Guedj of
   INSERM and Drs Patrick Smith and Kashyap Patel of Certara. The authors
   are grateful to Jim Gallagher of Certara in the generation of the
   graphic. The authors acknowledge review of the work from Drs Dan Hartman
   and Steve Kern from the Bill and Melinda Gates Foundation, and financial
   support from the Bill and Melinda Gates Foundation. This work has been
   supported by the Bill and Melinda Gates Foundation.
CR Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Baccam P, 2006, J VIROL, V80, P7590, DOI 10.1128/JVI.01623-05
   Badley AD, 2005, CELL DEATH DIFFER, V12, P924, DOI 10.1038/sj.cdd.4401580
   Baker EH, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14416
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   BOCHAROV GA, 1994, J THEOR BIOL, V167, P323, DOI 10.1006/jtbi.1994.1074
   Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P6971, DOI 10.1073/pnas.94.13.6971
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cave E, 2020, ASIAN BIOETHICS REV, V12, P235, DOI 10.1007/s41649-020-00118-2
   CDC, 2020, CDC 2019 NOV COR 201
   Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giannella M, 2011, CLIN MICROBIOL INFEC, V17, P1160, DOI 10.1111/j.1469-0691.2010.03399.x
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   Goncalves A, 2020, CPT-PHARMACOMET SYST, V9, P509, DOI 10.1002/psp4.12543
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu YW, 2013, LANCET, V381, P2273, DOI 10.1016/S0140-6736(13)61125-3
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jasenosky LD, 2019, ISCIENCE, V19, P1265, DOI 10.1016/j.isci.2019.07.003
   Kamal MA, 2017, BRIT J CLIN PHARMACO, V83, P1580, DOI 10.1111/bcp.13229
   Li JY, 2020, AM J TROP MED HYG, V102, P1210, DOI 10.4269/ajtmh.20-0275
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lovern M, 2017, CURR PHARM REP, V3, P294
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Nowak MA, 1996, P NATL ACAD SCI USA, V93, P4398, DOI 10.1073/pnas.93.9.4398
   Patick AK, 1998, CLIN MICROBIOL REV, V11, P614, DOI 10.1128/CMR.11.4.614
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Rayner CR, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104805
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Schlosser SF, 2003, ANTIMICROB AGENTS CH, V47, P1912, DOI 10.1128/AAC.47.6.1912-1921.2003
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Nguyen VK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167568
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2019, NOV COR GLOB RES INN
   Wong G, 2015, CELL HOST MICROBE, V18, P398, DOI 10.1016/j.chom.2015.09.013
   World Health Organisation, 2020, 107 WHO
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 49
TC 4
Z9 4
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
DI 10.1111/bcp.14486
EA AUG 2020
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MU5GH
UT WOS:000555701200001
PM 32693436
OA Other Gold
DA 2021-01-01
ER

PT J
AU Capochiani, E
   Frediani, B
   Iervasi, G
   Paolicchi, A
   Sani, S
   Roncucci, P
   Cuccaro, A
   Franchi, F
   Simonetti, F
   Carrara, D
   Bertaggia, I
   Nasso, D
   Riccioni, R
   Scolletta, S
   Valente, S
   Conticini, E
   Gozzetti, A
   Bocchia, M
AF Capochiani, Enrico
   Frediani, Bruno
   Iervasi, Giorgio
   Paolicchi, Aldo
   Sani, Spartaco
   Roncucci, Paolo
   Cuccaro, Annarosa
   Franchi, Federico
   Simonetti, Federico
   Carrara, Davide
   Bertaggia, Ilaria
   Nasso, Daniela
   Riccioni, Rossella
   Scolletta, Sabino
   Valente, Serafina
   Conticini, Edoardo
   Gozzetti, Alessandro
   Bocchia, Monica
TI Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in
   COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; ruxolitinib; respiratory distress syndrome; ICU; treatment
ID CYTOKINE STORM; CORONAVIRUS; PNEUMONIA; OUTBREAK
AB Background: The Coronavirus disease (COVID-19) pandemic is causing millions of infections and hundreds of thousands of deaths worldwide. Cumulative clinical and laboratory evidence suggest that a subset of patients with severe COVID-19 may develop a cytokine storm syndrome during the course of the disease, with severe respiratory impairment requiring ventilatory support. One field of research nowadays is to identify and treat viral-induced hyperinflammation with drugs used in other clinical conditions characterized by an hyperinflammation status. These drugs might help to reduce COVID19 mortality.
   Methods: Ruxolitinib, a JAK1 and JAK2 inhibitor, has been successfully used to treat severe immune-mediated diseases, such as graft vs. host disease and Hemophagocytic lymphohistiocytosis. We used ruxolitinib in 18 patients with clinically progressive COVID-19 related acute respiratory distress syndrome, with a primary endpoint to rapidly reduce the degree of respiratory impairment and as a secondary endpoint to rapidly restore the PaO2/FiO(2)ratio, as an evaluation of clinical status, and monitoring of drug related Adverse Events. Parameters of inflammation responses and organ functions were assessed and monitored. The treatment plan was ruxolitinib 20 mg bid for the first 48 h and subsequent two-step de-escalation at 10 mg bid and 5 mg bid for a maximum of 14 days of treatment.
   Results: Our data collection shows a rapid clinical response with no evolution fromnon-invasive ventilationto mechanical ventilation in 16/18 patients and no response in two patients (overall response rate-ORR 89%). Already after 48 h of ruxolitinib treatment 16/18 patients showed evident clinical improvement, and after 7 days of treatment 11/18 patients showed fully recovered respiratory function (pO(2)> 98% in spontaneous breathing), 4/18 patients had minimal oxygen requirement (2-4 L/m), 1/18 patient showed stable disease, and 2/18 patient showed progressive disease. After 14 days, 16/18 patients showed complete recovery of respiratory function (ORR 89%). Compliance to ruxolitinib planned treatment was 100% and no serious adverse event was recorded. In our case series of 18 critically ill patients with COVID-19 and ARDS, administration of ruxolitinib resulted in a clinical improvement that concurred to modify the standard course of disease. Ruxolitinib can be a therapeutic option for patients with respiratory insufficiency in COVID-19 related ARDS. RESPIRE Study (Ruxolitinib for the treatment of acute rESPIratory distREss syndrome,Identifier: NCT04361903).
C1 [Capochiani, Enrico; Cuccaro, Annarosa; Simonetti, Federico; Bertaggia, Ilaria; Nasso, Daniela; Riccioni, Rossella] Azienda USL Toscana NordOvest, Hematol Unit, Ctr Translat Med, Livorno, Italy.
   [Frediani, Bruno; Conticini, Edoardo] Univ Siena, Azienda Osped Univ Senese, Rheumatol Unit, COVID Unit, Siena, Italy.
   [Iervasi, Giorgio] Italian Natl Res Council CNR, Inst Clin Physiol IFC, Pisa, Italy.
   [Paolicchi, Aldo] Univ Pisa, Azienda Osped Univ Pisana, Clin Pathol Unit, Pisa, Italy.
   [Sani, Spartaco] Azienda USL Toscana NordOvest, Infect Dis Unit, COVID Unit, Livorno, Italy.
   [Roncucci, Paolo] Azienda USL Toscana NordOvest, COVID Unit, Crit Care Unit, Livorno, Italy.
   [Franchi, Federico; Scolletta, Sabino] Univ Siena, Azienda Osped Univ Senese, Anesthesia & Intens Care Unit, COVID Unit, Siena, Italy.
   [Carrara, Davide] Unit Azienda USL Toscana NordOvest, Internal Med Unit, COVID, Viareggio, Italy.
   [Valente, Serafina] Azienda Osped Univ Senese, Cardiol Unit, COVID Unit, Siena, Italy.
   [Gozzetti, Alessandro; Bocchia, Monica] Univ Siena, Azienda Osped Univ Senese, Hematol Unit, Siena, Italy.
RP Bocchia, M (corresponding author), Univ Siena, Azienda Osped Univ Senese, Hematol Unit, Siena, Italy.
EM bocchia@unisi.it
RI Gozzetti, Alessandro/AAN-3112-2020; gozzetti, alessandro/D-9055-2014
OI Gozzetti, Alessandro/0000-0003-0769-6891; gozzetti,
   alessandro/0000-0003-0769-6891
CR Ahmed A, 2019, LANCET HAEMATOL, V6, pE630, DOI 10.1016/S2352-3026(19)30156-5
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   La Rosee F, 2020, LEUKEMIA, V34, P1805, DOI 10.1038/s41375-020-0891-0
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Peng QY, 2020, INTENS CARE MED, V46, P849, DOI 10.1007/s00134-020-05996-6
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Przepiorka D, 2020, ONCOLOGIST, V25, pE328, DOI 10.1634/theoncologist.2019-0627
   Quintas-Cardama A, 2010, BLOOD, V115, P3109, DOI 10.1182/blood-2009-04-214957
   Riviere S, 2014, AM J MED, V127, P1118, DOI 10.1016/j.amjmed.2014.04.034
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Spoerl S, 2014, BLOOD, V123, P3832, DOI 10.1182/blood-2013-12-543736
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 23
TC 1
Z9 1
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD AUG 4
PY 2020
VL 7
AR 466
DI 10.3389/fmed.2020.00466
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA NF6GQ
UT WOS:000563394100001
PM 32850921
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jakhmola, S
   Indari, O
   Baral, B
   Kashyap, D
   Varshney, N
   Das, A
   Chatterjee, S
   Jha, HC
AF Jakhmola, Shweta
   Indari, Omkar
   Baral, Budhadev
   Kashyap, Dharmendra
   Varshney, Nidhi
   Das, Ayan
   Chatterjee, Sayantani
   Jha, Hem Chandra
TI Comorbidity Assessment Is Essential During COVID-19 Treatment
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV2; comorbidities; heart disease; diabetes;
   medications; hypertension; mortality
AB Coronavirus disease 2019 (COVID-19) caused by SARS-CoV2 is associated with various comorbidities; cardiovascular diseases, hypertension, diabetes, liver, lung diseases, and neurological ailments. The majority of the dysfunctions mentioned above are often associated with endothelial deterioration, indicating that endothelium can be the target of SARS-CoV2. Our study is an exclusive observational study that quantitatively analyses COVID-19 related comorbidities. We retrieved the data of % population of COVID-19 hospitalized and deceased patients with associated comorbidities from publicly accessible portals of the five European countries. A two tailedt-test enabled us to determine the significant proportions of deaths compared to hospitalized patients with associated comorbidity. Our study revealed that deaths associated with cardiovascular diseases and diabetes are highly significant (p< 0.0001) compared to hospitalized in countries like Italy, France, and Spain unlike the Netherlands. Deaths from kidney diseases (Italy-p< 0.0001; Sweden-p< 0.0001; Netherlands-p= 0.0001; France-p= 0.0033) and neurological ailments (France-p= 0.0001; Netherlands-p< 0.0001) are significantly higher than the total hospitalized patients affected by the particular comorbidity. We have noted that deaths due to liver diseases are least associated with COVID-19 among all comorbidities. Intriguingly, immunodeficiency shows mixed outcomes in death proportions compared to the hospital admitted individuals. Besides, the treatment regime involves drugs like losartan, ACE inhibitors, angiotensin-receptor blockers, Remdesivir, Chloroquine, Hydroxychloroquine, etc. may modulate the severity of the comorbidities. These comorbidities can create chaos in the existing healthcare system and may worsen the disease outcome.
C1 [Jakhmola, Shweta; Indari, Omkar; Baral, Budhadev; Kashyap, Dharmendra; Varshney, Nidhi; Das, Ayan; Chatterjee, Sayantani; Jha, Hem Chandra] Indian Inst Technol Indore, Discipline Biosci & Biomed Engn, Indore, India.
RP Jha, HC (corresponding author), Indian Inst Technol Indore, Discipline Biosci & Biomed Engn, Indore, India.
EM hemcjha@iiti.ac.in
RI Jha, Hem Chandra/T-2293-2019
OI Indari, Omkar/0000-0002-0196-1036; Jha, Hem Chandra/0000-0002-9698-4547
FU Council of Scientific and Industrial ResearchCouncil of Scientific &
   Industrial Research (CSIR) - India [37(1693)/17/EMR-II]; Department of
   Science and TechnologyDepartment of Science & Technology (India)
   [SB/S2/RJN-132/20/5]; Ministry of Human Resource, Department of
   Biotechnology; CSIRCouncil of Scientific & Industrial Research (CSIR) -
   India; University Grants CommissionUniversity Grants Commission, India;
   DST-inspireDepartment of Science & Technology (India); Indian Institute
   of Technology Indore
FX We thank the Council of Scientific and Industrial Research grant no.
   37(1693)/17/EMR-II, Department of Science and Technology as Ramanujan
   fellowship grant no. SB/S2/RJN-132/20/5, The Ministry of Human Resource,
   Department of Biotechnology, CSIR, University Grants Commission and
   DST-inspire for fellowship to SJ, OI, DK, BB, and NV, respectively, in
   the form of research stipend. The funding organization has not played
   any role in the study design or the preparation of the manuscript. We
   appreciate our lab colleagues for insightful discussions and advice. We
   gratefully acknowledge the Indian Institute of Technology Indore for
   providing facilities and support.
CR Aghagoli G, 2020, J CARDIAC SURG, V35, P1302, DOI 10.1111/jocs.14538
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Epidemiology for Public Health, 2020, CHAR COVID 19 PAT DY
   European Centre for Disease Prevention and Control, 2020, COR DIS 2019 COVID 1
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Harter G, 2020, INFECTION, V48, P681, DOI 10.1007/s15010-020-01438-z
   ISCIII, 2020, 25 ISCIII
   Jewell P, 2016, NEUROL-CLIN PRACT, V6, pE24, DOI 10.1212/CPJ.0000000000000220
   Kerget B, 2017, RESPIR MED CASE REP, V22, P243, DOI 10.1016/j.rmcr.2017.09.003
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Liguori C., 2020, BRAIN BEHAV IMMUN
   Low AT, 2015, HAEMATOLOGICA, V100, pE244, DOI 10.3324/haematol.2014.120816
   Mackenzie JS, 2020, MICROBIOL AUST, V41, P45, DOI 10.1071/MA20013
   Malviya A, 2020, INDIAN HEART J, V72, P131, DOI 10.1016/j.ihj.2020.04.006
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Public Health Agency, 2020, FHM WEEKL REP COV 19
   Public Health France, 2020, COVID 19 EP UPD APR
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   RIVM, 2020, EP SIT COVID 19 NETH
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Sardu C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051417
   Schoonjans F., 2019, MEDCALCS COMP PROPOR
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Teixeira Ricardo Alkmim, 2002, Arq. Bras. Cardiol., V79, P85, DOI 10.1590/S0066-782X2002001000009
   WHO, 2020, COVID 19 DASHB
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yandex.Translate, 2020, DICT ONL TRANSL ENGL
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Ye SH, 2002, HYPERTENSION, V39, P1101, DOI 10.1161/01.HYP.0000018590.26853.C7
   Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 41
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD AUG 4
PY 2020
VL 11
AR 984
DI 10.3389/fphys.2020.00984
PG 7
WC Physiology
SC Physiology
GA NF7SI
UT WOS:000563493900001
PM 32903640
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bosken, YK
   Cholko, T
   Lou, YC
   Wu, KP
   Chang, CEA
AF Bosken, Yuliana K.
   Cholko, Timothy
   Lou, Yuan-Chao
   Wu, Kuen-Phon
   Chang, Chia-en A.
TI Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding
   in SARS-CoV-2 Papain-Like Protease
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE structure-based drug design; computational biology and chemistry;
   non-covalent molecular recognition; conformational change; protein
   entropy; biophysics; protein-protein interaction; protein inhibition
ID MOLECULAR-DYNAMICS; THIOPURINE ANALOGS; SARS; RECOGNITION; AMBER
AB Covid-19 is caused by a novel form of coronavirus for which there are currently no vaccines or anti-viral drugs. This virus, termed SARS-CoV-2 (CoV2), contains Papain-like protease (PLpro) involved in viral replication and immune response evasion. Drugs targeting this protease therefore have great potential for inhibiting the virus, and have proven successful in older coronaviruses. Here, we introduce two effective inhibitors of SARS-CoV-1 (CoV1) and MERS-CoV to assess their potential for inhibiting CoV2 PLpro. We ran 1 mu s molecular dynamics (MD) simulations of CoV2, CoV1, and MERS-CoV ligand-free PLpro to characterize the dynamics of CoV2 PLpro, and made comparisons between the three to elucidate important similarities and differences relevant to drug design and ubiquitin-like protein binding for deubiquitinating and deISGylating activity of CoV2. Next, we simulated the inhibitors bound to CoV1 and CoV2 PLpro in various poses and at different known binding sites to analyze their binding modes. We found that the naphthalene-based ligand shows strong potential as an inhibitor of CoV2 PLpro by binding at the putative naphthalene inhibitor binding site in both computational predictions and experimental assays. Our modeling work suggested strategies to improve naphthalene-based compounds, and our results from molecular docking showed that the newly designed compounds exhibited improved binding affinity. The other ligand, chemotherapy drug 6-mercaptopurine (6MP), showed little to no stable intermolecular interaction with PLpro and quickly dissociated or remained highly mobile. We demonstrate multiple ways to improve the binding affinity of the naphthalene-based inhibitor scaffold by engaging new residues in the unused space of the binding site. Analysis of CoV2 PLpro also brings insights into recognition of ubiquitin-like proteins that may alter innate immune response.
C1 [Bosken, Yuliana K.; Cholko, Timothy; Chang, Chia-en A.] Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA.
   [Lou, Yuan-Chao] Acad Sinica, Biomed Translat Res Ctr, Taipei, Taiwan.
   [Wu, Kuen-Phon] Acad Sinica, Inst Biol Chem, Taipei, Taiwan.
RP Chang, CEA (corresponding author), Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA.
EM chiaenc@ucr.edu
RI Wu, Kuen-Phon/B-7983-2009
OI Wu, Kuen-Phon/0000-0002-1525-6004
FU US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [GM-109045]; US
   National Science FoundationNational Science Foundation (NSF)
   [MCB-1932984]; NSF National Supercomputer Centers COVID-19 HPC
   Consortium [TG-CHE200031]
FX This study was supported by the US National Institutes of Health
   (GM-109045), US National Science Foundation (MCB-1932984), and NSF
   National Supercomputer Centers COVID-19 HPC Consortium (TG-CHE200031).
CR Ai R, 2010, J COMPUT AID MOL DES, V24, P819, DOI 10.1007/s10822-010-9376-y
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Bekes M, 2016, MOL CELL, V62, P572, DOI 10.1016/j.molcel.2016.04.016
   Case D., 2018, AMBER 2018
   Centers for Disease Control and Prevention, 2020, PROV DEATH COUNTS CO
   Chaudhuri R, 2011, J MOL BIOL, V414, P272, DOI 10.1016/j.jmb.2011.09.030
   Chen JH, 2008, CURR OPIN STRUC BIOL, V18, P140, DOI 10.1016/j.sbi.2008.01.003
   Cheng KW, 2015, ANTIVIR RES, V115, P9, DOI 10.1016/j.antiviral.2014.12.011
   Chou CY, 2008, BIOCHEM PHARMACOL, V75, P1601, DOI 10.1016/j.bcp.2008.01.005
   Clasman J. R., 2017, SCI REP, V7, P1
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Gotz AW, 2012, J CHEM THEORY COMPUT, V8, P1542, DOI 10.1021/ct200909j
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Hotelling H, 1933, J EDUC PSYCHOL, V24, P417, DOI 10.1037/h0071325
   Hotelling Harold, 1992, BREAKTHROUGHS STAT, P162, DOI [10.1007/978-1-4612-4380-9_14, DOI 10.1007/978-1-4612-4380-9_14]
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Kemp M, 2016, PROGR MED CHEM, V55, P149, DOI 10.1016/bs.pmch.2015.10.002
   Lee H, 2015, ACS CHEM BIOL, V10, P1456, DOI 10.1021/cb500917m
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Molecular Operating Environment (MOE), 2018, 1010 SHERBR ST W SUI
   Osipiuk J, 2020, CRYSTAL STRUCTURE PA
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Sagui C, 2004, J CHEM PHYS, V120, P73, DOI 10.1063/1.1630791
   Stacklies W, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-101
   Sulea T, 2005, J VIROL, V79, P4550, DOI 10.1128/JVI.79.7.4550-4551.2005
   Tan C, 2007, J PHYS CHEM B, V111, P12263, DOI 10.1021/jp073399n
   Wang CH, 2018, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00087
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wertz Ingrid E, 2019, Drug Discov Today Technol, V31, P109, DOI 10.1016/j.ddtec.2019.02.003
   Ye Y, 2009, MOL BIOSYST, V5, P1797, DOI 10.1039/b907669g
NR 34
TC 0
Z9 0
U1 7
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD AUG 4
PY 2020
VL 7
AR 174
DI 10.3389/fmolb.2020.00174
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA ND9TR
UT WOS:000562243200001
PM 32850963
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Czumbel, LM
   Kiss, S
   Farkas, N
   Mandel, I
   Hegyi, A
   Nagy, A
   Lohinai, Z
   Szakacs, Z
   Hegyi, P
   Steward, MC
   Varga, G
AF Czumbel, Laszlo Mark
   Kiss, Szabolcs
   Farkas, Nelli
   Mandel, Ivan
   Hegyi, Anita
   Nagy, Akos
   Lohinai, Zsolt
   Szakacs, Zsolt
   Hegyi, Peter
   Steward, Martin C.
   Varga, Gabor
TI Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE coronavirus; SARS-CoV-2; COVID-19; diagnostic tests; saliva; systematic
   review; meta-analysis
ID CORONAVIRUS; SPECIMENS
AB Background:COVID-19 is a serious and potentially deadly disease. Early diagnosis of infected individuals will play an important role in stopping its further escalation. The present gold standard for sampling is the nasopharyngeal swab method. However, several recent papers suggested that saliva-based testing is a promising alternative that could simplify and accelerate COVID-19 diagnosis. Objectives:Our aim was to conduct a meta-analysis on the reliability and consistency of SARS-CoV-2 viral RNA detection in saliva specimens. Methods:We have reported our meta-analysis according to the Cochrane Handbook. We searched the Cochrane Library, Embase, Pubmed, Scopus, Web of Science and clinical trial registries for eligible studies published between 1 January and 25 April 2020. The number of positive tests and the total number of tests conducted were collected as raw data. The proportion of positive tests in the pooled data were calculated by score confidence-interval estimation with the Freeman-Tukey transformation. Heterogeneity was assessed using theI(2)measure and the chi(2)-test. Results:The systematic search revealed 96 records after removal of duplicates. Twenty-six records were included for qualitative analysis and 5 records for quantitative synthesis. We found 91% (CI 80-99%) sensitivity for saliva tests and 98% (CI 89-100%) sensitivity for nasopharyngeal swab (NPS) tests in previously confirmed COVID-19 patients, with moderate heterogeneity among the studies. Additionally, we identified 18 registered, ongoing clinical trials of saliva-based tests for detection of the virus. Conclusion:Saliva tests offer a promising alternative to NPS for COVID-19 diagnosis. However, further diagnostic accuracy studies are needed to improve their specificity and sensitivity.
C1 [Czumbel, Laszlo Mark; Steward, Martin C.; Varga, Gabor] Semmelweis Univ, Fac Dent, Dept Oral Biol, Budapest, Hungary.
   [Kiss, Szabolcs; Farkas, Nelli; Szakacs, Zsolt; Hegyi, Peter] Univ Pecs, Med Sch, Inst Translat Med, Pecs, Hungary.
   [Kiss, Szabolcs] Univ Szeged, Doctoral Sch Clin Med, Szeged, Hungary.
   [Mandel, Ivan; Hegyi, Anita; Nagy, Akos] Univ Pecs, Med Sch, Dept Dent Oral & Maxillofacial Surg, Pecs, Hungary.
   [Lohinai, Zsolt] Semmelweis Univ, Fac Dent, Dept Conservat Dent, Budapest, Hungary.
   [Steward, Martin C.] Univ Manchester, Sch Med Sci, Manchester, Lancs, England.
RP Varga, G (corresponding author), Semmelweis Univ, Fac Dent, Dept Oral Biol, Budapest, Hungary.
EM varga.gabor@dent.semmelweis-univ.hu
OI Lohinai, Zsolt/0000-0003-2695-5166
FU Hungarian Human Resources Development Operational Program
   [EFOP-3.6.2-16-2017-00006]; Economic Development and Innovation
   Operative ProgramGrant [GINOP 2.3.2-15-2016-00048]; Institutional
   Developments for Enhancing Intelligent Specialization Grant from the
   National Research, Development and Innovation Office
   [EFOP-3.6.1-16-2016-00022]
FX This study was supported by the Hungarian Human Resources Development
   Operational Program (EFOP-3.6.2-16-2017-00006). Additional support was
   received from an Economic Development and Innovation Operative
   ProgramGrant (GINOP 2.3.2-15-2016-00048) and an Institutional
   Developments for Enhancing Intelligent Specialization Grant
   (EFOP-3.6.1-16-2016-00022) from the National Research, Development and
   Innovation Office.
CR Azzi L, 2020, J INFECTION, V81, pE45, DOI 10.1016/j.jinf.2020.04.005
   Bae S, 2020, ANN INTERN MED, V173, pW22, DOI 10.7326/M20-1342
   Bhattarai KR, 2018, INT J MED SCI, V15, P823, DOI 10.7150/ijms.25146
   Bristol UO, 2020, QUADAS 2 BRIST MED S
   Corstjens PLAM, 2012, J AM DENT ASSOC, V143, P12, DOI DOI 10.14219/JADA.ARCHIVE.2012.0338
   Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142
   Czumbel LM, 2020, SALIVA CANDIDATE COV, DOI [10.1101/2020.05.26.20112565, DOI 10.1101/2020.05.26.20112565]
   Dawes C, 2019, J DENT RES, V98, P133, DOI 10.1177/0022034518816961
   Deng Z, 2020, J MED VIROL, V92, P1728, DOI 10.1002/jmv.25802
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Fang ZX, 2020, J INFECTION, V81, P172, DOI 10.1016/j.jinf.2020.03.013
   FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756
   Ghafouri-Fard S, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110296
   Golatowski C, 2013, CLIN CHIM ACTA, V419, P42, DOI 10.1016/j.cca.2013.01.013
   Gorchakov R, 2019, AM J TROP MED HYG, V100, P427, DOI 10.4269/ajtmh.18-0755
   Han Mi Seon, 2020, Clin Infect Dis, V71, P2236, DOI 10.1093/cid/ciaa447
   Han PP, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050290
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Humphrey SP, 2001, J PROSTHET DENT, V85, P162, DOI 10.1067/mpr.2001.113778
   Kaczor-Urbanowicz KE, 2017, EXP BIOL MED, V242, P459, DOI 10.1177/1535370216681550
   Keremi B, 2017, CURR PHARM DESIGN, V23, P4057, DOI 10.2174/1381612823666170215110648
   Khurshid Z, 2019, J INFECT PUBLIC HEAL, V12, P601, DOI 10.1016/j.jiph.2019.05.004
   Kim YG, 2017, J CLIN MICROBIOL, V55, P226, DOI [10.1128/JCM.01704-16, 10.1128/jcm.01704-16]
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1070, DOI 10.1515/cclm-2020-0285
   Liu L, 2011, J VIROL, V85, P4025, DOI 10.1128/JVI.02292-10
   Lu BJ, 2010, IMMUNOLOGY, V130, P254, DOI 10.1111/j.1365-2567.2010.03231.x
   Miller CS, 2010, BIOMARK MED, V4, P171, DOI 10.2217/BMM.09.68
   Moher D, 2016, REV ESP NUTR HUM DIE, V20, P148, DOI [10.1186/2046-4053-4-1, 10.14306/renhyd.20.2.223]
   Niedrig M, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3611-x
   Silva-Boghossian CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075898
   Sri Santosh Tatikonda, 2020, Cureus, V12, pe7708, DOI 10.7759/cureus.7708
   Sullivan Patrick Sean, 2020, JMIR Public Health Surveill, V6, pe19054, DOI 10.2196/19054
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Varga G., 2015, SURGERYOXFORD INT ED, V33, P581, DOI DOI 10.1016/j.mpsur.2015.09.003
   Wang WK, 2004, EMERG INFECT DIS, V10, P1213, DOI 10.3201/eid1007.031113
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Williams E, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00776-20
   Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774
   World Health Organization, 2020, LAB TEST COR DIS 201
   World Health Organization, 2020, WHO COR DIS COVID 19
   Wylie LA, 2020, SALIVA IS MORE SENSI, DOI [10.1101/2020.04.16.20067835, DOI 10.1101/2020.04.16.20067835]
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 45
TC 6
Z9 6
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD AUG 4
PY 2020
VL 7
AR 465
DI 10.3389/fmed.2020.00465
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA ND8QU
UT WOS:000562168100001
PM 32903849
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Touret, F
   Gilles, M
   Barral, K
   Nougairede, A
   van Helden, J
   Decroly, E
   de Lamballerie, X
   Coutard, B
AF Touret, Franck
   Gilles, Magali
   Barral, Karine
   Nougairede, Antoine
   van Helden, Jacques
   Decroly, Etienne
   de Lamballerie, Xavier
   Coutard, Bruno
TI In vitro screening of a FDA approved chemical library reveals potential
   inhibitors of SARS-CoV-2 replication
SO SCIENTIFIC REPORTS
LA English
DT Article
ID THERAPY
AB A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2<EC50<less than or equal to>20 mu M. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study provides information for the selection of drugs to be further validated in vivo. Disclaimer: This study corresponds to the early stages of antiviral development and the results do not support by themselves the use of the selected drugs to treat SARS-CoV-2 infection.
C1 [Touret, Franck; Gilles, Magali; Nougairede, Antoine; de Lamballerie, Xavier; Coutard, Bruno] Aix Marseille Univ, IRD 190, INSERM 1207, IHU Mediterranee Infect,Unite Virus Emergents UVE, F-13005 Marseille, France.
   [Barral, Karine] Aix Marseille Univ, INSERM U1068, CNRS UMR7258, Inst Paoli Calmettes,CRCM, Marseille, France.
   [van Helden, Jacques] Univ Paris Saclay, CNRS, UMS 3601, Inst Francais Bioinformat IFB, Orsay, France.
   [van Helden, Jacques] Aix Marseille Univ, INSERM, Lab Theory & Approaches Genome Complex TAGC, Marseille, France.
   [Decroly, Etienne] Aix Marseille Univ, CNRS, AFMB UMR 7257, Marseille, France.
RP Touret, F; Coutard, B (corresponding author), Aix Marseille Univ, IRD 190, INSERM 1207, IHU Mediterranee Infect,Unite Virus Emergents UVE, F-13005 Marseille, France.
EM franck.touret@univ-amu.fr; bruno.coutard@univ-amu.fr
RI Touret, Franck/ABD-3236-2020; van Helden, Jacques/D-8590-2013
OI Touret, Franck/0000-0002-4734-2249; van Helden,
   Jacques/0000-0002-8799-8584
FU Inserm through the REACTing (REsearch and ACTion targeting emerging
   infectious diseases) initiative; European Virus Archive Global (EVA
   GLOBAL) - European Union's Horizon 2020 research and innovation
   programme [871029]
FX This work was supported by Inserm through the REACTing (REsearch and
   ACTion targeting emerging infectious diseases) initiative and by the
   European Virus Archive Global (EVA GLOBAL) funded by the European
   Union's Horizon 2020 research and innovation programme under grant
   agreement No 871029. The antiviral screening platform is affiliated to
   the "Tres Grande Infrastructure de Recherche" ChemBioFrance network. We
   thank Dr Marie-Louise Jung from Prestwick-Domain Therapeutics for data
   mining and allowing the disclosure of the information on the PRESTWICK
   CHEMICAL LIBRARY, as well as Pr Drosten and Pr Drexler for providing the
   SARS-CoV-2 through EVA GLOBAL. We would also thank Camille
   Placidi-Italia and Odile Py for excellent technical support.
CR [Anonymous], 2020, HYDR PREV COVID19 PN
   [Anonymous], 2020, EFF SAF DAR COB TREA
   [Anonymous], 2020, TREATM DECR RISK HOS
   [Anonymous], 2020, HYDR VS AZ HOSP PAT
   [Anonymous], 2020, PREPRINT
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Callaway E., 2020, NATURE
   CDCMMWR, 2020, MMWR MORB MORTAL WKL, V69
   Cheng YS, 2019, CURR OPIN PHARMACOL, V48, P92, DOI 10.1016/j.coph.2019.07.006
   Dahlem P, 2004, CRIT CARE MED, V32, P1055, DOI 10.1097/01.CCM.0000120055.52377.BF
   Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Delang L, 2016, SCI REP-UK, V6, DOI 10.1038/srep31819
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Goodwin EC, 2009, J VIROL, V83, P5630, DOI 10.1128/JVI.00203-09
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haviernik J, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040184
   Kuster G. M., 2020, EUR HEART J
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Maisonnasse P., 2020, PREPRINT
   Manganaro R, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104781
   Mercorelli B, 2018, TRENDS MICROBIOL, V26, P865, DOI 10.1016/j.tim.2018.04.004
   Miyara MTF, 2020, QEIOS
   Mumtaz N, 2017, ANTIVIR RES, V146, P161, DOI 10.1016/j.antiviral.2017.09.004
   Oakes JM, 2018, AM J PHYSIOL-REG I, V315, pR895, DOI 10.1152/ajpregu.00099.2018
   Touret F, 2019, ANTIVIR RES, V168, P109, DOI 10.1016/j.antiviral.2019.05.005
   Wang M, 2020, CELL RES, V1, P3, DOI DOI 10.1038/CR.1990.1
   Weston S., 2020, BROAD ANTICORONAVIRA
   Yao X, 2020, CLIN INFECT DIS
NR 33
TC 12
Z9 12
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 4
PY 2020
VL 10
IS 1
AR 13093
DI 10.1038/s41598-020-70143-6
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NC3FS
UT WOS:000561100900024
PM 32753646
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Belhadjer, Z
   Meot, M
   Bajolle, F
   Khraiche, D
   Legendre, A
   Abakka, S
   Auriau, J
   Grimaud, M
   Oualha, M
   Beghetti, M
   Wacker, J
   Ovaert, C
   Hascoet, S
   Selegny, M
   Malekzadeh-Milani, S
   Maltret, A
   Bosser, G
   Giroux, N
   Bonnemains, L
   Bordet, J
   Di Filippo, S
   Mauran, P
   Falcon-Eicher, S
   Thambo, JB
   Lefort, B
   Moceri, P
   Houyel, L
   Renolleau, S
   Bonnet, D
AF Belhadjer, Zahra
   Meot, Mathilde
   Bajolle, Fanny
   Khraiche, Diala
   Legendre, Antoine
   Abakka, Samya
   Auriau, Johanne
   Grimaud, Marion
   Oualha, Mehdi
   Beghetti, Maurice
   Wacker, Julie
   Ovaert, Caroline
   Hascoet, Sebastien
   Selegny, Maelle
   Malekzadeh-Milani, Sophie
   Maltret, Alice
   Bosser, Gilles
   Giroux, Nathan
   Bonnemains, Laurent
   Bordet, Jeanne
   Di Filippo, Sylvie
   Mauran, Pierre
   Falcon-Eicher, Sylvie
   Thambo, Jean-Benoit
   Lefort, Bruno
   Moceri, Pamela
   Houyel, Lucile
   Renolleau, Sylvain
   Bonnet, Damien
TI Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in
   the Context of Global SARS-CoV-2 Pandemic
SO CIRCULATION
LA English
DT Article
DE cardiomyopathies; child; COVID-19; heart failure; mucocutaneous lymph
   node syndrome; myocardial stunning; severe acute respiratory syndrome
   coronavirus 2
ID KAWASAKI-DISEASE; COVID-19; SHOCK
AB Background: Cardiac injury and myocarditis have been described in adults with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children is typically minimally symptomatic. We report a series of febrile pediatric patients with acute heart failure potentially associated with SARS-CoV-2 infection and the multisystem inflammatory syndrome in children as defined by the US Centers for Disease Control and Prevention. Methods: Over a 2-month period, contemporary with the SARS-CoV-2 pandemic in France and Switzerland, we retrospectively collected clinical, biological, therapeutic, and early outcomes data in children who were admitted to pediatric intensive care units in 14 centers for cardiogenic shock, left ventricular dysfunction, and severe inflammatory state. Results: Thirty-five children were identified and included in the study. Median age at admission was 10 years (range, 2-16 years). Comorbidities were present in 28%, including asthma and overweight. Gastrointestinal symptoms were prominent. Left ventricular ejection fraction was <30% in one-third; 80% required inotropic support with 28% treated with extracorporeal membrane oxygenation. Inflammation markers were suggestive of cytokine storm (interleukin-6 median, 135 pg/mL) and macrophage activation (D-dimer median, 5284 ng/mL). Mean BNP (B-type natriuretic peptide) was elevated (5743 pg/mL). Thirty-one of 35 patients (88%) tested positive for SARS-CoV-2 infection by polymerase chain reaction of nasopharyngeal swab or serology. All patients received intravenous immunoglobulin, with adjunctive steroid therapy used in one-third. Left ventricular function was restored in the 25 of 35 of those discharged from the intensive care unit. No patient died, and all patients treated with extracorporeal membrane oxygenation were successfully weaned. Conclusions: Children may experience an acute cardiac decompensation caused by severe inflammatory state after SARS-CoV-2 infection (multisystem inflammatory syndrome in children). Treatment with immunoglobulin appears to be associated with recovery of left ventricular systolic function.
C1 [Belhadjer, Zahra; Meot, Mathilde; Bajolle, Fanny; Khraiche, Diala; Legendre, Antoine; Abakka, Samya; Auriau, Johanne; Grimaud, Marion; Oualha, Mehdi; Malekzadeh-Milani, Sophie; Maltret, Alice; Houyel, Lucile; Renolleau, Sylvain; Bonnet, Damien] M3C Necker Enfants Malades, AP HP, Paris, France.
   [Belhadjer, Zahra; Houyel, Lucile; Renolleau, Sylvain; Bonnet, Damien] Univ Paris, Paris, France.
   [Beghetti, Maurice; Wacker, Julie] Univ Hosp, Pediat Cardiol Unit, Geneva, Switzerland.
   [Ovaert, Caroline] La Timone Univ Hosp, M3C Reg CHD Ctr, Paediat & Congenital Cardiol Dept, Marseille, France.
   [Ovaert, Caroline] Univ Aix Marseille, Marseille Med Genet, INSERM, UMR 1251, Marseille, France.
   [Hascoet, Sebastien] Paris Sud Univ, Grp Hosp St Joseph, M3C Marie Lannelongue Hosp, Paediat & Congenital Cardiac Surg Dept, Le Plessis Robinson, France.
   [Selegny, Maelle] Amiens Picardie Univ Hosp, Pediat Cardiol, Amiens, France.
   [Bosser, Gilles; Giroux, Nathan] CHRU Nancy, Serv Cardiol Congenitale & Pediat, Vandoeuvreles Les Nancy, France.
   [Bonnemains, Laurent; Bordet, Jeanne] Univ Strasbourg, Dept Cardiac Surg, Strasbourg, France.
   [Di Filippo, Sylvie] Hosp Civils Lyon, Cardiovasc Louis Pradel Hosp, Pediat Cardiol & Congenital Heart Dis Dept, Lyon, France.
   [Mauran, Pierre] CHU Reims, Amer Mem Hosp, Ctr Competence M3C, Dept Paediat & Congenital Cardiol, Reims, France.
   [Falcon-Eicher, Sylvie] CHU Dijon Bourgogne, Dijon, France.
   [Thambo, Jean-Benoit] Bordeaux II Univ, Dept Pediat Cardiol, CHU Bordeaux, Bordeaux, France.
   [Lefort, Bruno] Hop Enfants Gatien Clocheville, Unite Cardiol Pediat, INSERM, UMR 1069, Tours, France.
   [Lefort, Bruno] Univ Tours, Tours, France.
   [Moceri, Pamela] CHU Nice, Hop Pasteur, Dept Cardiol, Nice, France.
RP Bonnet, D (corresponding author), Hop Necker Enfants Malad, AP HP, Ctr Reference Malformat Cardiaques Congenitales C, Unite Cardiol Pediat & Chirurg Cardiaque, 149 Rue Sevres, F-75015 Paris, France.
EM damien.bonnet@aphp.fr
OI Fanny, BAJOLLE/0000-0002-1106-0987; HOUYEL, LUCILE/0000-0003-4024-8599;
   Wacker, Julie/0000-0001-5408-1107; BOSSER, Gilles/0000-0002-2790-8604
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Dominguez SR, 2008, PEDIATRICS, V122, pE786, DOI 10.1542/peds.2008-1275
   Harada M, 2012, HISTOPATHOLOGY, V61, P1156, DOI 10.1111/j.1365-2559.2012.04332.x
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Kanegaye JT, 2009, PEDIATRICS, V123, pE783, DOI 10.1542/peds.2008-1871
   KAO CH, 1993, NUCL MED COMMUN, V14, P539, DOI 10.1097/00006231-199307000-00004
   Kone-Paut I, 2018, AUTOIMMUN REV, V17, P768, DOI 10.1016/j.autrev.2018.01.024
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Long B, 2020, AM J EMERG MED, V38, P1504, DOI 10.1016/j.ajem.2020.04.048
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Matsubara T, 2005, CLIN EXP IMMUNOL, V141, P381, DOI 10.1111/j.1365-2249.2005.02821.x
   McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Muniz JCG, 2013, CIRC-CARDIOVASC IMAG, V6, P239, DOI 10.1161/CIRCIMAGING.112.000159
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Rizzo P, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0791-5
   Rowley AH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001582
   Rowley AH, 2011, J INFECT DIS, V203, P1021, DOI 10.1093/infdis/jiq136
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   YUTANI C, 1981, ARCH PATHOL LAB MED, V105, P470
NR 22
TC 118
Z9 118
U1 12
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD AUG 4
PY 2020
VL 142
IS 5
BP 429
EP 436
DI 10.1161/CIRCULATIONAHA.120.048360
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA NA7NF
UT WOS:000560002900006
PM 32418446
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Li, L
   Zhang, W
   Hu, Y
   Tong, XL
   Zheng, SE
   Yang, JT
   Kong, YJ
   Ren, LL
   Wei, Q
   Mei, H
   Hu, CY
   Tao, CH
   Yang, R
   Wang, J
   Yu, YP
   Guo, Y
   Wu, XX
   Xu, ZH
   Zeng, L
   Xiong, N
   Chen, LF
   Wang, J
   Man, N
   Liu, Y
   Xu, HX
   Deng, E
   Zhang, XJ
   Li, CY
   Wang, CH
   Su, SS
   Zhang, LQ
   Wang, JW
   Wu, YY
   Liu, Z
AF Li, Ling
   Zhang, Wei
   Hu, Yu
   Tong, Xunliang
   Zheng, Shangen
   Yang, Juntao
   Kong, Yujie
   Ren, Lili
   Wei, Qing
   Mei, Heng
   Hu, Caiying
   Tao, Cuihua
   Yang, Ru
   Wang, Jue
   Yu, Yongpei
   Guo, Yong
   Wu, Xiaoxiong
   Xu, Zhihua
   Zeng, Li
   Xiong, Nian
   Chen, Lifeng
   Wang, Juan
   Man, Ning
   Liu, Yu
   Xu, Haixia
   Deng, E.
   Zhang, Xuejun
   Li, Chenyue
   Wang, Conghui
   Su, Shisheng
   Zhang, Linqi
   Wang, Jianwei
   Wu, Yanyun
   Liu, Zhong
TI Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in
   Patients With Severe and Life-threatening COVID-19 A Randomized Clinical
   Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
AB Importance Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are needed.
   Objective To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID-19.
   Design, Setting, and Participants Open-label, multicenter, randomized clinical trial performed in 7 medical centers in Wuhan, China, from February 14, 2020, to April 1, 2020, with final follow-up April 28, 2020. The trial included 103 participants with laboratory-confirmed COVID-19 that was severe (respiratory distress and/or hypoxemia) or life-threatening (shock, organ failure, or requiring mechanical ventilation). The trial was terminated early after 103 of a planned 200 patients were enrolled.
   Intervention Convalescent plasma in addition to standard treatment (n = 52) vs standard treatment alone (control) (n = 51), stratified by disease severity.
   Main Outcomes and Measures Primary outcome was time to clinical improvement within 28 days, defined as patient discharged alive or reduction of 2 points on a 6-point disease severity scale (ranging from 1 [discharge] to 6 [death]). Secondary outcomes included 28-day mortality, time to discharge, and the rate of viral polymerase chain reaction (PCR) results turned from positive at baseline to negative at up to 72 hours.
   Results Of 103 patients who were randomized (median age, 70 years; 60 [58.3%] male), 101 (98.1%) completed the trial. Clinical improvement occurred within 28 days in 51.9% (27/52) of the convalescent plasma group vs 43.1% (22/51) in the control group (difference, 8.8% [95% CI, -10.4% to 28.0%]; hazard ratio [HR], 1.40 [95% CI, 0.79-2.49]; P = .26). Among those with severe disease, the primary outcome occurred in 91.3% (21/23) of the convalescent plasma group vs 68.2% (15/22) of the control group (HR, 2.15 [95% CI, 1.07-4.32]; P = .03); among those with life-threatening disease the primary outcome occurred in 20.7% (6/29) of the convalescent plasma group vs 24.1% (7/29) of the control group (HR, 0.88 [95% CI, 0.30-2.63]; P = .83) (P for interaction = .17). There was no significant difference in 28-day mortality (15.7% vs 24.0%; OR, 0.59 [95% CI, 0.22-1.59]; P = .30) or time from randomization to discharge (51.0% vs 36.0% discharged by day 28; HR, 1.61 [95% CI, 0.88-2.95]; P = .12). Convalescent plasma treatment was associated with a negative conversion rate of viral PCR at 72 hours in 87.2% of the convalescent plasma group vs 37.5% of the control group (OR, 11.39 [95% CI, 3.91-33.18]; P < .001). Two patients in the convalescent plasma group experienced adverse events within hours after transfusion that improved with supportive care.
   Conclusion and Relevance Among patients with severe or life-threatening COVID-19, convalescent plasma therapy added to standard treatment, compared with standard treatment alone, did not result in a statistically significant improvement in time to clinical improvement within 28 days. Interpretation is limited by early termination of the trial, which may have been underpowered to detect a clinically important difference.
C1 [Li, Ling; Kong, Yujie; Wang, Jue; Liu, Yu; Xu, Haixia; Deng, E.; Zhang, Xuejun; Li, Chenyue; Liu, Zhong] Chinese Acad Med Sci & Peking Union Med Coll, Inst Blood Transfus, 26 Huacai Rd, Chengdu 610052, Peoples R China.
   [Li, Ling; Kong, Yujie; Wang, Jue; Xu, Haixia; Li, Chenyue; Liu, Zhong] CAMS, Key Lab Transfus Adverse React, Chengdu, Peoples R China.
   [Zhang, Wei; Zeng, Li] Guanggu Dist Maternal & Child Hlth Hosp Hubei Pro, Wuhan, Peoples R China.
   [Zhang, Wei] Second Mil Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Shanghai, Peoples R China.
   [Hu, Yu; Mei, Heng] Huazhong Univ Sci & Technol, Inst Hematol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China.
   [Tong, Xunliang] Beijing Hosp, Dept Pulm & Crit Care Med, Natl Resp Qual Control Ctr, Natl Ctr Gerontol, Beijing, Peoples R China.
   [Zheng, Shangen] Gen Hosp Cent Theater Command PLA, Dept Transfus, Wuhan, Peoples R China.
   [Yang, Juntao] Chinese Acad Med Sci & Peking Union, Inst Basic Med Sci, State Key Lab Med Mol Biol, Beijing, Beijing, Peoples R China.
   [Ren, Lili; Wang, Conghui; Wang, Jianwei] Chinese Acad Med Sci & Peking Union Med Coll, NHC Key Lab Syst Biol Pathogens, Inst Pathogen Biol, Beijing, Peoples R China.
   [Ren, Lili; Wang, Conghui; Wang, Jianwei] Chinese Acad Med Sci & Peking Union Med Coll, Christophe Merieux Lab, Inst Pathogen Biol, Beijing, Peoples R China.
   [Ren, Lili; Wang, Jianwei] Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Resp Dis Pathogen, Beijing, Peoples R China.
   [Wei, Qing; Wang, Juan] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Blood Transfus, Tongji Med Coll, Wuhan, Peoples R China.
   [Hu, Caiying; Xu, Zhihua; Xiong, Nian] Wuhan Red Cross Hosp, Wuhan, Peoples R China.
   [Tao, Cuihua] Wuhan Asia Heart Hosp, Dept Blood Transfus, Wuhan, Peoples R China.
   [Tao, Cuihua] Wuhan Asia Gen Hosp, Dept Blood Transfus, Wuhan, Peoples R China.
   [Yang, Ru] Wuhan Blood Ctr, Wuhan, Peoples R China.
   [Yu, Yongpei] Peking Univ, Clin Res Inst, Hlth Sci Ctr, Beijing, Peoples R China.
   [Guo, Yong; Su, Shisheng] Tsinghua Univ, Sch Med, Dept Biomed Engn, Beijing, Peoples R China.
   [Wu, Xiaoxiong] Huazhong Univ Sci & Technol, Dept Emergency, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China.
   [Xu, Zhihua] Mianyang Cent Hosp, Mianyang, Sichuan, Peoples R China.
   [Zeng, Li] Second Mil Med Univ, Affiliated Hosp 1, Dept Organ Transplantat, Shanghai, Peoples R China.
   [Xiong, Nian] Huazhong Univ Sci & Technol, Dept Neurol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China.
   [Chen, Lifeng] Wuhan Pulm Hosp, Wuhan, Peoples R China.
   [Man, Ning] Wuhan Asia Gen Hosp, Dept Resp Med, Wuhan, Peoples R China.
   [Zhang, Linqi] Tsinghua Univ, Ctr Global Hlth & Infect Dis, Comprehens AIDS Res Ctr, Beijing, Peoples R China.
   [Zhang, Linqi] Tsinghua Univ, Sch Med, Beijing Adv Innovat Ctr Struct Biol, Beijing, Peoples R China.
   [Wu, Yanyun] Univ Miami, Dept Pathol, 1611 NW 12th Ave, Miami, FL 33136 USA.
RP Liu, Z (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Blood Transfus, 26 Huacai Rd, Chengdu 610052, Peoples R China.; Wu, YY (corresponding author), Univ Miami, Dept Pathol, 1611 NW 12th Ave, Miami, FL 33136 USA.
EM yxw1366@med.miami.edu; liuz@ibt.pumc.edu.cn
RI Liu, Zhong/ABH-8584-2020; Wang, Jianwei/AAW-9499-2020; Wang,
   Jianwei/W-5916-2019
OI Wang, Jianwei/0000-0002-1116-4559; Wang, Conghui/0000-0001-7774-097X;
   Zhang, Wei/0000-0001-5292-7308
FU Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
   (CIFMS) [2020-I2M-CoV19-006, 2016-I2M-3-024, 2017-I2M-1-009]; Nonprofit
   Central Research Institute Fund of Chinese Academy of Medical Sciences
   [2018PT32016]
FX This work was supported by the Chinese Academy of Medical Sciences
   Innovation Fund for Medical Sciences (CIFMS) grants 2020-I2M-CoV19-006,
   2016-I2M-3-024 (Dr Z. Liu), and 2017-I2M-1-009 (Dr L. Li) and the
   Nonprofit Central Research Institute Fund of Chinese Academy of Medical
   Sciences grant 2018PT32016 (Dr Z. Liu).
CR [Anonymous], 2020, REC INV COVID 19 CON
   [Anonymous], 2019, ANN SHOT SERIOUS HAZ
   [Anonymous], DAIL UPD COV 19
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Beigel JH, 2019, LANCET RESP MED, V7, P941, DOI 10.1016/S2213-2600(19)30199-7
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Garraud O, 2016, TRANSFUS CLIN BIOL, V23, P39, DOI 10.1016/j.tracli.2015.12.003
   Kleinbaum DG, 1996, SURVIVAL ANAL STAT H, P183
   Kraft CS, 2015, CLIN INFECT DIS, V61, P496, DOI 10.1093/cid/civ334
   National Health Commission of the People's Republic of China, COV 19 TREATM PLAN T
   Network WBR, 2017, POS PAP US CONV PLAS
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
NR 18
TC 120
Z9 118
U1 32
U2 35
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD AUG 4
PY 2020
VL 324
IS 5
BP 460
EP 470
DI 10.1001/jama.2020.10044
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA NC5NN
UT WOS:000561261900017
PM 32492084
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Liu, Z
AF Liu, Zhong
TI Errors in Trial of Effect of Convalescent Plasma Therapy on Time to
   Clinical Improvement in Patients With Severe and Life-threatening
   COVID-19
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Liu, Zhong] Chinese Acad Med Sci & Peking Union Med Coll, Inst Blood Transfus, 26 Huacai Rd, Chengdu 610052, Sichuan, Peoples R China.
RP Liu, Z (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Blood Transfus, 26 Huacai Rd, Chengdu 610052, Sichuan, Peoples R China.
EM liuz@ibt.pumc.edu.cn
RI Liu, Zhong/ABH-8584-2020
CR Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
NR 1
TC 2
Z9 2
U1 2
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD AUG 4
PY 2020
VL 324
IS 5
BP 518
EP 519
DI 10.1001/jama.2020.12607
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA NC5NN
UT WOS:000561261900033
PM 32749486
DA 2021-01-01
ER

PT J
AU Feng, W
   Newbigging, AM
   Le, C
   Pang, B
   Peng, HY
   Cao, YR
   Wu, JJ
   Abbas, G
   Song, J
   Wang, DB
   Cui, MM
   Tao, J
   Tyrrell, DL
   Zhang, XE
   Zhang, HQ
   Le, XC
AF Feng, Wei
   Newbigging, Ashley M.
   Le, Connie
   Pang, Bo
   Peng, Hanyong
   Cao, Yiren
   Wu, Jinjun
   Abbas, Ghulam
   Song, Jin
   Wang, Dian-Bing
   Cui, Mengmeng
   Tao, Jeffrey
   Tyrrell, D. Lorne
   Zhang, Xian-En
   Zhang, Hongquan
   Le, X. Chris
TI Molecular Diagnosis of COVID-19: Challenges and Research Needs
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID MEDIATED ISOTHERMAL AMPLIFICATION; NUCLEOCAPSID PROTEIN; SARS-COV;
   CORONAVIRUS; ASSAY; PNEUMONIA; CHINA; WUHAN
AB Molecular diagnosis of COVID-19 primarily relies on the detection of RNA of the SARS-CoV-2 virus, the causative infectious agent of the pandemic. Reverse transcription polymerase chain reaction (RT-PCR) enables sensitive detection of specific sequences of genes that encode the RNA dependent RNA polymerase (RdRP), nucleocapsid (N), envelope (E), and spike (S) proteins of the virus. Although RT-PCR tests have been widely used and many alternative assays have been developed, the current testing capacity and availability cannot meet the unprecedented global demands for rapid, reliable, and widely accessible molecular diagnosis. Challenges remain throughout the entire analytical process, from the collection and treatment of specimens to the amplification and detection of viral RNA and the validation of clinical sensitivity and specificity. We highlight the main issues surrounding molecular diagnosis of COVID-19, including false negatives from the detection of viral RNA, temporal variations of viral loads, selection and treatment of specimens, and limiting factors in detecting viral proteins. We discuss critical research needs, such as improvements in RT-PCR, development of alternative nucleic acid amplification techniques, incorporating CRISPR technology for point-of-care (POC) applications, validation of POC tests, and sequencing of viral RNA and its mutations. Improved assays are also needed for environmental surveillance or wastewater-based epidemiology, which gauges infection on the community level through analyses of viral components in the community's wastewater. Public health surveillance benefits from large-scale analyses of antibodies in serum, although the current serological tests do not quantify neutralizing antibodies. Further advances in analytical technology and research through multidisciplinary collaboration will contribute to the development of mitigation strategies, therapeutics, and vaccines. Lessons learned from molecular diagnosis of COVID-19 are valuable for better preparedness in response to other infectious diseases.
C1 [Feng, Wei; Newbigging, Ashley M.; Pang, Bo; Peng, Hanyong; Cao, Yiren; Wu, Jinjun; Tao, Jeffrey; Zhang, Hongquan; Le, X. Chris] Univ Alberta, Fac Med & Dent, Dept Lab Med & Pathol, Div Analyt & Environm Toxicol, Edmonton, AB T6G 2G3, Canada.
   [Abbas, Ghulam; Song, Jin; Wang, Dian-Bing; Cui, Mengmeng; Zhang, Xian-En] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.
   [Le, Connie; Tyrrell, D. Lorne] Univ Alberta, Fac Med & Dent, Li Ka Shing Inst Virol, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2E1, Canada.
RP Zhang, HQ; Le, XC (corresponding author), Univ Alberta, Fac Med & Dent, Dept Lab Med & Pathol, Div Analyt & Environm Toxicol, Edmonton, AB T6G 2G3, Canada.; Zhang, XE (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.
EM zhangxe@ibp.ac.cn; hongquan@ualberta.ca; xc.le@ualberta.ca
RI Le, X. Chris/O-4947-2015
OI Le, X. Chris/0000-0002-7690-6701; Wu, Jinjun/0000-0002-2379-1162;
   Newbigging, Ashley/0000-0002-2491-0442; Le, Connie/0000-0003-4864-7420
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR); New Frontiers in Research Fund; Natural Sciences and
   Engineering Research Council of CanadaNatural Sciences and Engineering
   Research Council of CanadaCGIAR; Alberta Innovates; Alberta Health; Li
   Ka Shing Institute of Virology; Vanier Canada Graduate Scholarship;
   M.D.-Ph.D. Studentship from Alberta Innovates; China Scholarship
   Council.China Scholarship Council
FX We thank the Canadian Institutes of Health Research, the New Frontiers
   in Research Fund, the Natural Sciences and Engineering Research Council
   of Canada, Alberta Innovates, Alberta Health, and Li Ka Shing Institute
   of Virology for their support. C.L. acknowledges the support of a Vanier
   Canada Graduate Scholarship and a M.D.-Ph.D. Studentship from Alberta
   Innovates. W.F., B.P., and Y.C. acknowledge scholarships from the China
   Scholarship Council.
CR Abudayyeh OO, 2017, NATURE, V550, P280, DOI 10.1038/nature24049
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ahmed W, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138764
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Azzi L, 2020, J INFECTION, V81, pE45, DOI 10.1016/j.jinf.2020.04.005
   Baek YH, 2020, EMERG MICROBES INFEC, V9, P998, DOI 10.1080/22221751.2020.1756698
   Ben-Assa N., 2020, MEDRXIV, DOI [10.1101/2020.04.22.20072389, DOI 10.1101/2020.04.22.20072389]
   Bessetti J, 2007, PROFILES DNA, V28, P159
   Bivins A, 2020, ENVIRON SCI TECHNOL, V54, P7754, DOI 10.1021/acs.est.0c02388
   Broughton JP, 2020, NAT BIOTECHNOL, V38, P870, DOI 10.1038/s41587-020-0513-4
   Carter LJ, 2020, ACS CENTRAL SCI, V6, P591, DOI 10.1021/acscentsci.0c00501
   CDC, 2020, 2019 NOV COR 2019 NC
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Charlton CL, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00042-18
   Che XY, 2004, J CLIN MICROBIOL, V42, P2629, DOI 10.1128/JCM.42.6.2629-2635.2004
   Chen JS, 2018, SCIENCE, V360, P436, DOI 10.1126/science.aar6245
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen YQ, 2020, ARCH CIV MECH ENG, V20, DOI 10.1007/s43452-019-0002-z
   Chen YF, 2020, J MED VIROL, V92, P833, DOI 10.1002/jmv.25825
   Chen ZQ, 2020, VIROL SIN, V35, P351, DOI 10.1007/s12250-020-00236-z
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Cohen J., 2020, SCIENCE, DOI [10.1126/science.abb5152, DOI 10.1126/SCIENCE.ABB5152]
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cozzuto L, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00211
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Fang Y., 2020, RADIOLOGY, DOI DOI 10.1148/RADI0L.2020200432
   Farnsworth CW, 2020, CLIN CHEM, V66, P875, DOI 10.1093/clinchem/hvaa107
   FDA, 2020, EM US AUTH
   FDA, COR COVID 19 UPD FDA
   FIND, SARS COV 2 DIAGN PIP
   Fomsgaard AS, 2020, EUROSURVEILLANCE, V25, P6, DOI 10.2807/1560-7917.ES.2020.25.14.2000398
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Gootenberg JS, 2017, SCIENCE, V356, P438, DOI 10.1126/science.aam9321
   Graepel KW, 2017, MBIO, V8, DOI 10.1128/mBio.01503-17
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Guo L, 2020, J MOL LIQ, V310, DOI 10.1016/j.molliq.2020.113239
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hurst SJ, 2006, ANAL CHEM, V78, P8313, DOI 10.1021/ac0613582
   Jiang H.-W., 2020, MEDRXIV, DOI [10.1101/ 2020.03.20.20039495, DOI 10.1101/2020.03.20.20039495]
   Kammila S, 2008, J VIROL METHODS, V152, P77, DOI 10.1016/j.jviromet.2008.05.023
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   KUMAR S, 2020, J CLIN MICROBIOL
   La Rosa G, 2020, SCI TOTAL ENVIRON, V736, DOI 10.1016/j.scitotenv.2020.139652
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2015, ANAL CHEM, V87, P274, DOI 10.1021/ac5037236
   Li YH, 2005, J VIROL METHODS, V130, P45, DOI 10.1016/j.jviromet.2005.06.001
   Lin CY, 2020, CLIN CHEM LAB MED, V58, P1089, DOI 10.1515/cclm-2020-0187
   Lin Y, 2003, CELL RES, V13, P141, DOI 10.1038/sj.cr.7290158
   Liu B, 2017, ANAL METHODS-UK, V9, P2633, DOI 10.1039/c7ay00368d
   Liu R, 2020, CLIN CHIM ACTA, V505, P172, DOI 10.1016/j.cca.2020.03.009
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma D, 2018, SYN BIOL, V3, DOI 10.1093/synbio/ysy018
   Mallapaty S, 2020, NATURE, V580, P571, DOI 10.1038/d41586-020-01115-z
   Mao K, 2020, ENVIRON SCI TECHNOL, V54, P3733, DOI 10.1021/acs.est.0c01174
   Medema G., 2020, ENVIRON SCI TECH LET, V7, P511, DOI DOI 10.1021/ACS.ESTLETT.0C00357
   Myhrvold C, 2018, SCIENCE, V360, P444, DOI 10.1126/science.aas8836
   NCBI, COMPL GEN
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Notomi T, 2015, J MICROBIOL, V53, P1, DOI 10.1007/s12275-015-4656-9
   Notomi T, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e63
   Oh MD, 2016, NEW ENGL J MED, V375, P1303, DOI 10.1056/NEJMc1511695
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Opdahl A, 2007, P NATL ACAD SCI USA, V104, P9, DOI 10.1073/pnas.0608568103
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pan Y, 2020, CLIN CHEM, V66, P794, DOI 10.1093/clinchem/hvaa091
   Piepenburg O, 2006, PLOS BIOL, V4, P1115, DOI 10.1371/journal.pbio.0040204
   Quan PL, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18041271
   Randazzo W, 2020, WATER RES, V181, DOI 10.1016/j.watres.2020.115942
   Smithgall MC, 2020, J CLIN VIROL, V128
   Song L., 2020, ANAL CHEM, DOI [10.1021/ acs.analchem.0c01394., DOI 10.1021/ACS.ANALCHEM.0C01394]
   Tilocca B, 2020, MICROBES INFECT, V22, P188, DOI 10.1016/j.micinf.2020.04.002
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   Uhler C, 2020, NAT REV MOL CELL BIO, V21, P247, DOI 10.1038/s41580-020-0242-z
   Vogel G, 2020, SCIENCE, V368, P350, DOI 10.1126/science.368.6489.350
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   WHO, 2020, LAB TEST COR DIS COV
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organisation, MOL ASS DIAGN COVID
   World Health Organization, COR DIS COVID 19 TEC
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiao F, 2020, EMERG INFECT DIS, V26, P1920, DOI 10.3201/eid2608.200681
   Xie CB, 2020, INT J INFECT DIS, V93, P264, DOI 10.1016/j.ijid.2020.02.050
   Xu RS, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0080-z
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Yan C, 2020, CLIN MICROBIOL INFEC, V26, P773, DOI 10.1016/j.cmi.2020.04.001
   Yu FT, 2020, CLIN INFECT DIS, V71, P793, DOI 10.1093/cid/ciaa345
   Yu L, 2020, CLIN CHEM, V66, P975, DOI 10.1093/clinchem/hvaa102
   Zhang B., 2020, MEDRXIV, P1, DOI [10.1101/2020.03.12.20035048, DOI 10.1101/2020.03.12.20035048]
   Zhang G., 2020, BIORXIV, DOI [10.1101/2020.03.19.999318., DOI 10.1101/2020.03.19.999318.]
   Zhang HQ, 2013, CHEM REV, V113, P2812, DOI 10.1021/cr300340p
   Zhao YX, 2015, CHEM REV, V115, P12491, DOI 10.1021/acs.chemrev.5b00428
   Zhen W., 2020, CLIN MICROBIOL
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou RX, 2020, CHEM COMMUN, V56, P3536, DOI 10.1039/d0cc00397b
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 107
TC 3
Z9 3
U1 32
U2 35
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD AUG 4
PY 2020
VL 92
IS 15
BP 10196
EP 10209
DI 10.1021/acs.analchem.0c02060
PG 14
WC Chemistry, Analytical
SC Chemistry
GA MY9SH
UT WOS:000558761500003
PM 32573207
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhang, XJ
   Qin, JJ
   Cheng, X
   Shen, LJ
   Zhao, YC
   Yuan, YF
   Lei, F
   Chen, MM
   Yang, HL
   Bai, LJ
   Song, XH
   Lin, LJ
   Xia, M
   Zhou, F
   Zhou, JH
   She, ZG
   Zhu, LH
   Ma, XL
   Xu, QB
   Ye, P
   Chen, GH
   Liu, LM
   Mao, WM
   Yan, YQ
   Xiao, B
   Lu, ZG
   Peng, G
   Liu, MY
   Yang, J
   Yang, LY
   Zhang, CJ
   Lu, HF
   Xia, XG
   Wang, DH
   Liao, XF
   Wei, X
   Zhang, BH
   Zhang, X
   Yang, J
   Zhao, GN
   Zhang, P
   Liu, PTP
   Loomba, R
   Ji, YX
   Xia, JH
   Wang, YB
   Cai, JJ
   Guo, J
   Li, HL
AF Zhang, Xiao-Jin
   Qin, Juan-Juan
   Cheng, Xu
   Shen, Lijun
   Zhao, Yan-Ci
   Yuan, Yufeng
   Lei, Fang
   Chen, Ming-Ming
   Yang, Huilin
   Bai, Liangjie
   Song, Xiaohui
   Lin, Lijin
   Xia, Meng
   Zhou, Feng
   Zhou, Jianghua
   She, Zhi-Gang
   Zhu, Lihua
   Ma, Xinliang
   Xu, Qingbo
   Ye, Ping
   Chen, Guohua
   Liu, Liming
   Mao, Weiming
   Yan, Youqin
   Xiao, Bing
   Lu, Zhigang
   Peng, Gang
   Liu, Mingyu
   Yang, Jun
   Yang, Luyu
   Zhang, Changjiang
   Lu, Haofeng
   Xia, Xigang
   Wang, Daihong
   Liao, Xiaofeng
   Wei, Xiang
   Zhang, Bing-Hong
   Zhang, Xin
   Yang, Juan
   Zhao, Guang-Nian
   Zhang, Peng
   Liu, Peter P.
   Loomba, Rohit
   Ji, Yan-Xiao
   Xia, Jiahong
   Wang, Yibin
   Cai, Jingjing
   Guo, Jiao
   Li, Hongliang
TI In-Hospital Use of Statins Is Associated with a Reduced Risk of
   Mortality among Individuals with COVID-19
SO CELL METABOLISM
LA English
DT Article
ID NLRP3 INFLAMMASOME ACTIVATION; ATORVASTATIN; THERAPY; ROSUVASTATIN;
   CHOLESTEROL; FLUVASTATIN; SIMVASTATIN; INFECTIONS; MANAGEMENT; FIBROSIS
AB Statins are lipid-lowering therapeutics with favorable anti-inflammatory profiles and have been proposed as an adjunct therapy for COVID-19. However, statins may increase the risk of SARS-CoV-2 viral entry by inducing ACE2 expression. Here, we performed a retrospective study on 13,981 patients with COVID-19 in Hubei Province, China, among which 1,219 received statins. Based on a mixed-effect Cox model after pro-pensity score-matching, we found that the risk for 28-day all-cause mortality was 5.2% and 9.4% in the matched statin and non-statin groups, respectively, with an adjusted hazard ratio of 0.58. The statin use -associated lower risk of mortality was also observed in the Cox time-varying model and marginal structural model analysis. These results give support for the completion of ongoing prospective studies and random-ized controlled trials involving statin treatment for COVID-19, which are needed to further validate the utility of this class of drugs to combat the mortality of this pandemic.
C1 [Zhang, Xiao-Jin; Qin, Juan-Juan; Cheng, Xu; Shen, Lijun; Zhao, Yan-Ci; Chen, Ming-Ming; Yang, Huilin; Lin, Lijin; Zhou, Jianghua; She, Zhi-Gang; Zhu, Lihua; Zhang, Changjiang; Yang, Juan; Li, Hongliang] Wuhan Univ, Sch Basic Med Sci, Renmin Hosp, Dept Cardiol, Wuhan, Peoples R China.
   [Zhang, Xiao-Jin; Qin, Juan-Juan; Cheng, Xu; Shen, Lijun; Zhao, Yan-Ci; Lei, Fang; Chen, Ming-Ming; Yang, Huilin; Bai, Liangjie; Song, Xiaohui; Lin, Lijin; Xia, Meng; Zhou, Feng; Zhou, Jianghua; She, Zhi-Gang; Zhu, Lihua; Zhang, Xin; Yang, Juan; Zhao, Guang-Nian; Zhang, Peng; Ji, Yan-Xiao; Li, Hongliang] Wuhan Univ, Inst Model Anim, Wuhan, Peoples R China.
   [Zhang, Xiao-Jin; Zhou, Feng; Zhao, Guang-Nian; Zhang, Peng; Ji, Yan-Xiao; Li, Hongliang] Wuhan Univ, Zhongnan Hosp, Med Sci Res Ctr, Wuhan, Peoples R China.
   [Yuan, Yufeng; Li, Hongliang] Wuhan Univ, Zhongnan Hosp, Dept Hepatobiliary & Pancreat Surg, Wuhan, Peoples R China.
   [Ma, Xinliang] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19004 USA.
   [Xu, Qingbo] Queen Mary Univ London, William Harvey Res Inst, Ctr Clin Pharmacol, London, England.
   [Ye, Ping] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Cardiol, Wuhan 430072, Peoples R China.
   [Chen, Guohua] Wuhan Hosp Tradit Chinese & Western Med, Wuhan Hosp 1, Dept Neurol, Wuhan 430072, Peoples R China.
   [Liu, Liming] Ezhou Cent Hosp, Dept Gen Surg, Ezhou 436000, Peoples R China.
   [Mao, Weiming] Huanggang Cent Hosp, Dept Gen Surg, Huanggang 438000, Peoples R China.
   [Yan, Youqin] Wuhan Seventh Hosp, Wuhan 430072, Peoples R China.
   [Xiao, Bing] Xiantao First Peoples Hosp, Dept Stomatol, Xiantao 433000, Peoples R China.
   [Lu, Zhigang] Hubei Minzu Univ, Peoples Hosp Jingmen 1, Dept Neurol, Jingmen 448000, Peoples R China.
   [Peng, Gang] Suizhou Cent Hosp, Hubei Med Coll, Dept Hepatobiliary & Pancreat Surg, Suizhou 441300, Peoples R China.
   [Liu, Mingyu] Ninth Hosp Wuhan City, Wuhan 430072, Peoples R China.
   [Yang, Jun] China Three Gorges Univ, Coll Clin Med Sci 1, Dept Cardiol, Yichang 443000, Peoples R China.
   [Yang, Jun] China Three Gorges Univ, Yichang Cent Peoples Hosp, Yichang 443000, Peoples R China.
   [Yang, Jun] China Three Gorges Univ, Inst Cardiovasc Dis, Yichang 443000, Peoples R China.
   [Yang, Luyu] Wuhan Univ, Wuhan Hosp 3, Dept Intens Care Unit, Wuhan, Peoples R China.
   [Yang, Luyu] Wuhan Univ, Tongren Hosp, Wuhan, Peoples R China.
   [Zhang, Changjiang] Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Enshi 445000, Peoples R China.
   [Lu, Haofeng] Changjiang Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Jingzhou, Peoples R China.
   [Xia, Xigang] Jingzhou Cent Hosp, Dept Hepatobiliary Surg, Jingzhou, Peoples R China.
   [Wang, Daihong] Xianning Cent Hosp, Dept Hepatobiliary & Pancreat Surg, Xianning, Hubei, Peoples R China.
   [Liao, Xiaofeng] Hubei Univ Arts & Sci, Affiliated Hosp, Xiangyang Cent Hosp, Xiangyang, Peoples R China.
   [Wei, Xiang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Div Cardiothorac & Vasc Surg, Wuhan, Peoples R China.
   [Zhang, Bing-Hong] Wuhan Univ, Renmin Hosp, Dept Neonatol, Wuhan, Peoples R China.
   [Liu, Peter P.] Univ Ottawa, Inst Heart, Dept Med, Div Cardiol, Ottawa, ON, Canada.
   [Loomba, Rohit] Univ Calif San Diego, Div Gastroenterol & Epidemiol, NAFLD Res Ctr, San Diego, CA 92103 USA.
   [Xia, Jiahong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiovasc Surg, Wuhan, Peoples R China.
   [Wang, Yibin] Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, Dept Anesthesiol, Los Angeles, CA 90095 USA.
   [Wang, Yibin] Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, Dept Physiol, Los Angeles, CA 90095 USA.
   [Wang, Yibin] Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, Dept Med, Los Angeles, CA 90095 USA.
   [Cai, Jingjing] Cent South Univ, Xiangya Hosp 3, Dept Cardiol, Changsha 410000, Peoples R China.
   [Guo, Jiao] Guangdong Pharmaceut Univ, Guangdong TCM Key Lab Metab Dis, Guangdong Metab Dis Res Ctr Integrated Chinese &, Guangzhou 510006, Peoples R China.
   [Guo, Jiao] Guangdong Pharmaceut Univ, Guangdong TCM Key Lab Metab Dis, Key Lab Glucolipid Metab Disorder, Minist Educ China, Guangzhou 510006, Peoples R China.
   [Guo, Jiao] Guangdong Pharmaceut Univ, Guangdong TCM Key Lab Metab Dis, Inst Chinese Med, Guangzhou 510006, Peoples R China.
RP Li, HL (corresponding author), Wuhan Univ, Sch Basic Med Sci, Renmin Hosp, Dept Cardiol, Wuhan, Peoples R China.; Li, HL (corresponding author), Wuhan Univ, Inst Model Anim, Wuhan, Peoples R China.; Li, HL (corresponding author), Wuhan Univ, Zhongnan Hosp, Med Sci Res Ctr, Wuhan, Peoples R China.; Li, HL (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Hepatobiliary & Pancreat Surg, Wuhan, Peoples R China.; Xia, JH (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiovasc Surg, Wuhan, Peoples R China.; Wang, YB (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, Dept Anesthesiol, Los Angeles, CA 90095 USA.; Wang, YB (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, Dept Physiol, Los Angeles, CA 90095 USA.; Wang, YB (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, Dept Med, Los Angeles, CA 90095 USA.; Cai, JJ (corresponding author), Cent South Univ, Xiangya Hosp 3, Dept Cardiol, Changsha 410000, Peoples R China.; Guo, J (corresponding author), Guangdong Pharmaceut Univ, Guangdong TCM Key Lab Metab Dis, Guangdong Metab Dis Res Ctr Integrated Chinese &, Guangzhou 510006, Peoples R China.; Guo, J (corresponding author), Guangdong Pharmaceut Univ, Guangdong TCM Key Lab Metab Dis, Key Lab Glucolipid Metab Disorder, Minist Educ China, Guangzhou 510006, Peoples R China.; Guo, J (corresponding author), Guangdong Pharmaceut Univ, Guangdong TCM Key Lab Metab Dis, Inst Chinese Med, Guangzhou 510006, Peoples R China.
EM jiahong.xia@hust.edu.cn; yibinwang@mednet.ucla.edu;
   caijingjing83@hotmail.com; guoj@gdpu.edu.cn; lihl@whu.edu.cn
OI Cheng, Xu/0000-0002-1577-7627; Lei, Fang/0000-0003-0103-9348
FU National Key R&D Program of China [2016YFF0101504, 2019YFC2004700,
   2020YFC0845500]; Special Fundation for Emergency Research on Prevention
   and Control of COVID-19 of Guangdong Province [2020B1111330003];
   National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81630011, 81970364, 81970070, 81970011, 81870171,
   81700356, 81570412]; Major Research Plan of the National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [91639304]; Hubei Science and Technology Support Project [2019BFC582,
   2018BEC473, 2017BEC001]; Medical Flight Plan of Wuhan University
FX This work was supported by grants from the National Key R&D Program of
   China (2016YFF0101504, 2019YFC2004700, and 2020YFC0845500), the Special
   Fundation for Emergency Research on Prevention and Control of COVID-19
   of Guangdong Province (2020B1111330003), the National Science Foundation
   of China (81630011, 81970364, 81970070, 81970011, 81870171, 81700356,
   and 81570412), the Major Research Plan of the National Natural Science
   Foundation of China (91639304), the Hubei Science and Technology Support
   Project (2019BFC582, 2018BEC473, and 2017BEC001), and the Medical Flight
   Plan of Wuhan University. We thank Dr. Daniel J. Drucker in
   Lunenfeld-Tanenbaum Research Institute, Department of Medicine, Mt.
   Sinai Hospital, University of Toronto for his kind help in raising
   valuable suggestions and editing the paper.
CR Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5
   Bifulco Maurizio, 2020, Eur Heart J Cardiovasc Pharmacother, V6, P410, DOI 10.1093/ehjcvp/pvaa055
   Calfee CS, 2018, LANCET RESP MED, V6, P691, DOI 10.1016/S2213-2600(18)30177-2
   Castiglione V, 2020, EUR HEART J-CARD PHA, V6, P258, DOI 10.1093/ehjcvp/pvaa042
   Craig TR, 2011, AM J RESP CRIT CARE, V183, P620, DOI 10.1164/rccm.201003-0423OC
   Dashti-Khavidaki S, 2020, PHARMACOTHERAPY, V40, P484, DOI 10.1002/phar.2397
   De Spiegeleer A, 2020, J AM MED DIR ASSOC, V21, P909, DOI 10.1016/j.jamda.2020.06.018
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   European Society of Cardiology, 2020, POS STAT ESC COUNC H
   Fan E, 2018, JAMA-J AM MED ASSOC, V319, P698, DOI 10.1001/jama.2017.21907
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20
   Fedson DS, 2015, MBIO, V6, DOI 10.1128/mBio.00716-15
   Fedson DS, 2013, ANTIVIR RES, V99, P417, DOI 10.1016/j.antiviral.2013.06.018
   Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177
   Gallelli L, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-67
   Glesby MJ, 1996, ANN INTERN MED, V124, P999, DOI 10.7326/0003-4819-124-11-199606010-00008
   Haneuse S, 2019, JAMA-J AM MED ASSOC, V321, P602, DOI 10.1001/jama.2018.21554
   Henriksbo BD, 2014, DIABETES, V63, P3742, DOI 10.2337/db13-1398
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu D., 2015, ZHONGHUA NEI KE ZA Z, V54, P467
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   International Society of Hypertension, 2020, STAT INT SOC HYP COV
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Kruger P, 2013, AM J RESP CRIT CARE, V187, P743, DOI 10.1164/rccm.201209-1718OC
   Lei F, 2020, HEPATOLOGY, V72, P389, DOI 10.1002/hep.31301
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mansur A, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0368-6
   Mathur MB, 2018, EPIDEMIOLOGY, V29, pE45, DOI 10.1097/EDE.0000000000000864
   McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   National Health Commission of China, 2020, NEW COR PNEUM PREV C
   Novack V, 2009, INTENS CARE MED, V35, P1255, DOI 10.1007/s00134-009-1429-0
   Papazian L, 2013, JAMA-J AM MED ASSOC, V310, P1692, DOI 10.1001/jama.2013.280031
   Pertzov B, 2019, CLIN MICROBIOL INFEC, V25, P280, DOI 10.1016/j.cmi.2018.11.003
   Ray KK, 2014, EUR HEART J, V35, P960, DOI 10.1093/eurheartj/ehu107
   Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106
   Reiner Z, 2020, ARCH MED SCI, V16, P490, DOI 10.5114/aoms.2020.94655
   Sapey E, 2019, AM J RESP CRIT CARE, V200, P1282, DOI 10.1164/rccm.201812-2328OC
   Sapey E, 2017, AM J RESP CRIT CARE, V196, P1325, DOI 10.1164/rccm.201704-0814OC
   Satoh M, 2014, CLIN SCI, V126, P233, DOI 10.1042/CS20130043
   Sheedy FJ, 2013, NAT IMMUNOL, V14, P812, DOI 10.1038/ni.2639
   Shin YH, 2017, HEART VESSELS, V32, P618, DOI 10.1007/s00380-016-0936-5
   Sinha P, 2018, INTENS CARE MED, V44, P1859, DOI 10.1007/s00134-018-5378-3
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tikoo K, 2015, BIOCHEM PHARMACOL, V93, P343, DOI 10.1016/j.bcp.2014.11.013
   Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
   Vasileva D, 2019, INFLAMM RES, V68, P39, DOI 10.1007/s00011-018-1188-x
   Waljee AK, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002847
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Xu JF, 2012, AM J RESP CRIT CARE, V185, P547, DOI 10.1164/rccm.201108-1574OC
   Yancy CW, 2017, CIRCULATION, V136, pE137, DOI 10.1161/CIR.0000000000000509
   Yuan X, 2014, BIOCHEM BIOPH RES CO, V446, P292, DOI 10.1016/j.bbrc.2014.02.091
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 58
TC 33
Z9 32
U1 8
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD AUG 4
PY 2020
VL 32
IS 2
BP 176
EP +
DI 10.1016/j.cmet.2020.06.015
PG 16
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA MU9FF
UT WOS:000555970500006
PM 32592657
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Monda, VM
   Porcellati, F
   Strollo, F
   Gentile, S
AF Monda, Vincenzo M.
   Porcellati, Francesca
   Strollo, Felice
   Gentile, Sandro
TI ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a
   Role?
SO DIABETES THERAPY
LA English
DT Article
DE ACE2; COVID-19; Diabetes; DPP4; GLP-1; SARS-CoV2
ID INCRETIN-BASED THERAPIES; ANGIOTENSIN
C1 [Monda, Vincenzo M.] Santissima Annunziata Hosp, Diabet Unit, Ferrara, Italy.
   [Porcellati, Francesca] Perugia Univ, Sch Med, Dept Med, Sect Internal Med Endocrinol & Metab, Perugia, Italy.
   [Strollo, Felice] San Raffaele Termini Inst, Endocrinol & Diabet, Rome, Italy.
   [Gentile, Sandro] Campania Univ Luigi Vanvitelli, Dept Internal Med, Naples, Italy.
   [Gentile, Sandro] Nefroctr Res & Nyx Start Up, Naples, Italy.
RP Monda, VM (corresponding author), Santissima Annunziata Hosp, Diabet Unit, Ferrara, Italy.
EM v.monda@ausl.fe.it
RI Strollo, Felice/AAZ-4861-2020
CR Benicky J, 2009, CELL MOL NEUROBIOL, V29, P781, DOI 10.1007/s10571-009-9368-4
   Benigni A, 2010, EMBO MOL MED, V2, P247, DOI 10.1002/emmm.201000080
   Celi A, 2010, EXPERT REV CARDIOVAS, V8, P1723, DOI 10.1586/ERC.10.161
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Fandino J, 2018, INT J ENDOCRINOL, V2018, DOI 10.1155/2018/6920620
   Fang C, 2013, BLOOD, V121, P3023, DOI 10.1182/blood-2012-09-459156
   Gerstein HC, 2019, LANCET, V394, P131, DOI 10.1016/S0140-6736(19)31150-X
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228
   Hedrington MS, 2019, EXPERT OPIN PHARMACO, V20, P133, DOI 10.1080/14656566.2018.1552258
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Iacobellis G, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108125
   Jin TR, 2020, ACTA PHARMACOL SIN B, V10, P1249, DOI 10.1016/j.apsb.2020.05.006
   Kristensen SL, 2019, LANCET DIABETES ENDO, V7, P776, DOI 10.1016/S2213-8587(19)30249-9
   Kuba K, 2006, J MOL MED, V84, P814, DOI 10.1007/s00109-006-0094-9
   Lee YS, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/3094642
   Lovshin JA, 2009, NAT REV ENDOCRINOL, V5, P262, DOI 10.1038/nrendo.2009.48
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Martin JH, 2011, INTERN MED J, V41, P299, DOI 10.1111/j.1445-5994.2011.02439.x
   Mirabelli M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103664
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Romani-Perez M, 2015, ENDOCRINOLOGY, V156, P3559, DOI 10.1210/en.2014-1685
   Santos RAS, 2018, PHYSIOL REV, V98, P505, DOI 10.1152/physrev.00023.2016
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
NR 29
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1869-6953
EI 1869-6961
J9 DIABETES THER
JI Diabetes Ther.
PD SEP
PY 2020
VL 11
IS 9
BP 1909
EP 1914
DI 10.1007/s13300-020-00898-8
EA AUG 2020
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NE8YQ
UT WOS:000555750200001
PM 32749644
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Khan, MT
   Zeb, MT
   Ahsan, H
   Ahmed, A
   Ali, A
   Akhtar, K
   Malik, SI
   Cui, ZL
   Ali, S
   Khan, AS
   Ahmad, M
   Wei, DQ
   Irfan, M
AF Khan, Muhammad Tahir
   Zeb, Muhammad Tariq
   Ahsan, Hina
   Ahmed, Abrar
   Ali, Arif
   Akhtar, Khalid
   Malik, Shaukat Iqbal
   Cui, Zhilei
   Ali, Sajid
   Khan, Anwar Sheed
   Ahmad, Manzoor
   Wei, Dong-Qing
   Irfan, Muhammad
TI SARS-CoV-2 nucleocapsid and Nsp3 binding: an in silico study
SO ARCHIVES OF MICROBIOLOGY
LA English
DT Article; Early Access
DE SARS-CoV-2; N-CTD; Nsp3; interactions
ID PROTEIN-PROTEIN INTERACTIONS; MOLECULAR DOCKING; WEB SERVER;
   ELECTROSTATICS; COMPLEX; HADDOCK
AB Severe acute respiratory syndrome virus 2 (SARS-CoV-2) belongs to the single-stranded positive-sense RNA family. The virus contains a large genome that encodes four structural proteins, small envelope (E), matrix (M), nucleocapsid phosphoprotein (N), spike (S), and 16 nonstructural proteins (nsp1-16) that together, ensure replication of the virus in the host cell. Among these proteins, the interactions of N and Nsp3 are essential that links the viral genome for processing. The N proteins reside at CoV RNA synthesis sites known as the replication-transcription complexes (RTCs). The N-terminal of N has RNA-binding domain (N-NTD), capturing the RNA genome while the C-terminal domain (N-CTD) anchors the viral Nsp3, a component of RTCs. Although the structural information has been recently released, the residues involved in contacts between N-CTD with Nsp3 are still unknown. To find the residues involved in interactions between two proteins, three-dimensional structures of both proteins were retrieved and docked using HADDOCK. Residues at N-CTD were detected in interaction with L499, R500, K501, V502, P503, T504, D505, N506, Y507, I508, T509, K529, K530K532, S533 of Nsp3 and N-NTD to synthesize SARS-CoV-2 RNA. The interaction between Nsp3 and CTD of N protein may be a potential drug target. The current study provides information for better understanding the interaction between N protein and Nsp3 that could be a possible target for future inhibitors.
   [GRAPHICS]
   .
C1 [Khan, Muhammad Tahir; Malik, Shaukat Iqbal] Capital Univ Sci & Technol, Dept Bioinformat & Biosci, Islamabad, Pakistan.
   [Zeb, Muhammad Tariq] Vet Res Inst, In Charge Genom Lab, Peshawar 25000, Pakistan.
   [Ahsan, Hina] Riphah Int Univ, Riphah Inst Pharmaceut Sci, Islamabad, Pakistan.
   [Ahmed, Abrar] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai, Peoples R China.
   [Ali, Arif; Wei, Dong-Qing] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, 1 State Key Lab Microbial Metab, Minist Educ, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
   [Ali, Arif; Wei, Dong-Qing] Shanghai Jiao Tong Univ, Joint Lab Int Cooperat Metab & Dev Sci, Minist Educ, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
   [Ali, Arif; Wei, Dong-Qing] 2 Peng Cheng Lab, Vanke Cloud City Phase 1,Bldg 8,Xili St, Shenzhen 518055, Guangdong, Peoples R China.
   [Akhtar, Khalid] Natl Univ Sci & Technol, Islamabad, Pakistan.
   [Cui, Zhilei] Shanghai Jiao Tong Univ, Dept Resp Med, XinHua Hosp, Sch Med, Shanghai 200025, Peoples R China.
   [Ali, Sajid] Quaid I Azam Univ Islamabad, Islamabad, Pakistan.
   [Khan, Anwar Sheed] Kohat Univ Sci & Technol, Dept Microbiol, Kohat, Pakistan.
   [Ahmad, Manzoor] Sun Yat Sen Univ, Sch Life Sci, Guangzhou, Peoples R China.
   [Irfan, Muhammad] Univ Florida, Coll Dent, Dept Oral Biol, Gainesville, FL 32610 USA.
RP Wei, DQ (corresponding author), Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, 1 State Key Lab Microbial Metab, Minist Educ, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.; Wei, DQ (corresponding author), Shanghai Jiao Tong Univ, Joint Lab Int Cooperat Metab & Dev Sci, Minist Educ, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
EM pi133001@cust.pk; drtariqzeb@gmail.com; hina.ahsan@riphah.edu.pk;
   Abrar22@sjtu.edu.cn; arifali@sjtu.edu.cn; drkhalidakhtar@smme.edu.pk;
   drshaukat@cust.edu.pk; zhileicui@126.com; sajidjan@live.com;
   anwar786kp@hotmail.com; manzoor@mail.sysu.edu.cn; dqwei@sjtu.edu.cn;
   irfanmuhammad@ufl.edu
RI khan, Muhammad Tahir/ABC-6368-2020
OI khan, Muhammad Tahir/0000-0003-1158-2133
FU Natural Science Foundation of Henan Province [162300410060]; Ministry of
   Science and Technology of ChinaMinistry of Science and Technology, China
   [2016YFA0501703]; Science and Technology Commission of Shanghai
   MunicipalityScience & Technology Commission of Shanghai Municipality
   (STCSM) [19430750600]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [61503244,
   61832019]; Joint Research Funds for Medical and Engineering and
   Scientific Research at Shanghai Jiao Tong University [YG2017ZD14]
FX Dong-Qing Wei is supported by the Natural Science Foundation of Henan
   Province (162300410060), the Ministry of Science and Technology of China
   (2016YFA0501703), the Science and Technology Commission of Shanghai
   Municipality (19430750600), the National Natural Science Foundation of
   China (61503244,61832019), and Joint Research Funds for Medical and
   Engineering and Scientific Research at Shanghai Jiao Tong University
   (YG2017ZD14).
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Anand K, 2005, BIRK ADV INFECT DIS, P173
   Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343
   Berman HM, 2008, ACTA CRYSTALLOGR A, V64, P88, DOI 10.1107/S0108767307035623
   Boukharta L, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003585
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Chen S., 2020, BIORXIV, DOI [10.1101/2020.03.06.977876., DOI 10.1101/2020.03.06.977876]
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   De Vries SJ, 2010, NAT PROTOC, V5, P883, DOI 10.1038/nprot.2010.32
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Dinesh DC, 2020, STRUCTURAL BASIS RNA, DOI [10.1101/2020.04.02.022194, DOI 10.1101/2020.04.02.022194]
   Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x
   Hurst KR, 2013, J VIROL, V87, P9159, DOI 10.1128/JVI.01275-13
   Hurst KR, 2010, J VIROL, V84, P10276, DOI 10.1128/JVI.01287-10
   Ibarra AA, 2019, ACS CHEM BIOL, V14, P2252, DOI 10.1021/acschembio.9b00560
   Khan A, 2020, INTERDISCIP SCI, V12, P335, DOI 10.1007/s12539-020-00381-9
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   Koegl Manfred, 2007, Briefings in Functional Genomics & Proteomics, V6, P302, DOI 10.1093/bfgp/elm035
   Lill MA, 2011, J COMPUT AID MOL DES, V25, P13, DOI 10.1007/s10822-010-9395-8
   Liu L, 2008, SCIENCE, V320, P379, DOI 10.1126/science.1155406
   Macindoe G, 2010, NUCLEIC ACIDS RES, V38, pW445, DOI 10.1093/nar/gkq311
   Mandell JG, 2001, PROTEIN ENG, V14, P105, DOI 10.1093/protein/14.2.105
   Massova I, 1999, J AM CHEM SOC, V121, P8133, DOI 10.1021/ja990935j
   Moreira IS, 2007, J COMPUT CHEM, V28, P644, DOI 10.1002/jcc.20566
   Nilofer C, 2017, BIOINFORMATION, V13, P164, DOI 10.6026/97320630013164
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Roth CM, 1996, BIOPHYS J, V70, P977, DOI 10.1016/S0006-3495(96)79641-8
   Sheng J, 2014, J AM CHEM SOC, V136, P13916, DOI 10.1021/ja508015a
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Tang TK, 2005, PROTEOMICS, V5, P925, DOI 10.1002/pmic.200401204
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   Vilar S, 2008, CURR TOP MED CHEM, V8, P1555, DOI 10.2174/156802608786786624
   Wang YB, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020122
   Weiss GA, 2000, P NATL ACAD SCI USA, V97, P8950, DOI 10.1073/pnas.160252097
   Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526
   Zhang Y, 2005, COMPUT BIOL CHEM, V29, P254, DOI 10.1016/j.compbiolchem.2005.04.008
   Zhao L, 2005, CURR OPIN STRUC BIOL, V15, P31, DOI 10.1016/j.sbi.2005.01.005
   Zheng W, 2019, PROTEINS, V87, P1149, DOI 10.1002/prot.25792
NR 38
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0302-8933
EI 1432-072X
J9 ARCH MICROBIOL
JI Arch. Microbiol.
DI 10.1007/s00203-020-01998-6
EA AUG 2020
PG 8
WC Microbiology
SC Microbiology
GA MU5OQ
UT WOS:000555723000002
PM 32749662
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Balmford, B
   Annan, JD
   Hargreaves, JC
   Altoe, M
   Bateman, IJ
AF Balmford, Ben
   Annan, James D.
   Hargreaves, Julia C.
   Altoe, Marina
   Bateman, Ian J.
TI Cross-Country Comparisons of Covid-19: Policy, Politics and the Price of
   Life
SO ENVIRONMENTAL & RESOURCE ECONOMICS
LA English
DT Article
DE Coronavirus; Covid-19; Modeling; Valuation; Price of life
ID SEIR MODEL; STABILITY
AB Coronavirus has claimed the lives of over half a million people world-wide and this death toll continues to rise rapidly each day. In the absence of a vaccine, non-clinical preventative measures have been implemented as the principal means of limiting deaths. However, these measures have caused unprecedented disruption to daily lives and economic activity. Given this developing crisis, the potential for a second wave of infections and the near certainty of future pandemics, lessons need to be rapidly gleaned from the available data. We address the challenges of cross-country comparisons by allowing for differences in reporting and variation in underlying socio-economic conditions between countries. Our analyses show that, to date, differences in policy interventions have out-weighed socio-economic variation in explaining the range of death rates observed in the data. Our epidemiological models show that across 8 countries a further week long delay in imposing lockdown would likely have cost more than half a million lives. Furthermore, those countries which acted more promptly saved substantially more lives than those that delayed. Linking decisions over the timing of lockdown and consequent deaths to economic data, we reveal the costs that national governments were implicitly prepared to pay to protect their citizens as reflected in the economic activity foregone to save lives. These 'price of life' estimates vary enormously between countries, ranging from as low as around $100,000 (e.g. the UK, US and Italy) to in excess of $1million (e.g. Denmark, Germany, New Zealand and Korea). The lowest estimates are further reduced once we correct for under-reporting of Covid-19 deaths.
C1 [Balmford, Ben; Bateman, Ian J.] Univ Exeter, Sch Business, Dept Econ, Land Environm Econ & Policy Inst, Exeter EX4 4PU, Devon, England.
   [Annan, James D.; Hargreaves, Julia C.] Blue Skies Res Ltd, Settle, England.
   [Altoe, Marina] Univ Exeter, Innovat Impact & Business, Exeter, Devon, England.
RP Bateman, IJ (corresponding author), Univ Exeter, Sch Business, Dept Econ, Land Environm Econ & Policy Inst, Exeter EX4 4PU, Devon, England.
EM b.balmford@exeter.ac.uk; jdannan@blueskiesresearch.org.uk;
   jules@blueskiesresearch.org.uk; M.Altoe@exeter.ac.uk;
   i.bateman@exeter.ac.uk
RI Balmford, Ben/U-1032-2019
OI Balmford, Ben/0000-0002-4102-5250
CR Ackerman F, 2002, U PENN LAW REV, V150, P1553, DOI 10.2307/3312947
   Alberini A, 2005, RISK ANAL, V25, P783, DOI 10.1111/j.1539-6924.2005.00646.x
   Ale-Chilet J, 2020, ACTIVITY INCIDENCE E
   Andersen A. L., 2020, ARXIV200504630
   Annan JD, 2020, MODEL CALIBRATION NO, DOI [10.1101/2020.04.14.20065227, DOI 10.1101/2020.04.14.20065227]
   Annan JD, 2020, TWEET POSTED 11 APRI
   [Anonymous], 2020, ECONOMIST
   ANTHONY Laurence, 2019, ANTCONC VERSION 3 5
   Balmford A, 2020, CURR BIOL, V30, pR969, DOI 10.1016/j.cub.2020.06.084
   Barlow A, 2020, GENES-BASEL, V11, DOI 10.3390/genes11010050
   Beltekian D, 2020, CORONAVIRUS PANDEMIC
   Bhala N, 2020, LANCET
   BOLKER B, 1993, IMA J MATH APPL MED, V10, P83
   Branley-Bell D, 2020, EXPLORING IMPACT COV
   Burki TK, 2020, LANCET ONCOL, V21, P628, DOI 10.1016/S1470-2045(20)30201-1
   Burn-Murdoch J, 2020, UK SUFFERS SECOND HI
   Carthy T, 1998, J RISK UNCERTAINTY, V17, P187, DOI 10.1023/A:1007782800868
   Cash R, 2020, LANCET
   Center for Disease Control, 2020, 2019 2020 US FLU SES
   Chaix B, 2020, PSYCHOL DISTRESS COV
   Chini M, 2020, WHY DOES BELGIUM HAV
   Chronopoulos D. K., 2020, CONSUMER SPENDING RE
   Citroner G, 2020, WHAT WE KNOW LONG TE
   DfT, 2016, TRANSP AN GUID DAT B
   Discombe M, 2020, GOVT HAS MISLED PUBL
   Dowd JB, 2020, P NATL ACAD SCI USA, V117, P9696, DOI 10.1073/pnas.2004911117
   Ellis AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114805
   Ferguson N, 2020, REPORT 9 IMPACT NONP
   Fernandes N., 2020, EC EFFECTS CORONAVIR
   Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
   Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101
   Gandjour A, 2020, CLIN EC VALUE SUCCES
   Garg S, 2020, MMWR MORBIDITY MORTA, V69
   Goldsztejn U, 2020, PUBLIC POLICY EC DYN
   Greenstone M, 2020, DOES SOCIAL DISTANCI
   Grey S, 2020, SPECIAL REPORT SHIEL
   Gupta S, 2020, W27027 NAT BUR EC RE
   Hale T, 2020, OXFORD COVID 19 GOV
   Hanspal T, 2020, EXPOSURE COVID 19 ST
   Hensvik L, 2020, WHICH JOBS ARE DONE
   Hevia C., 2020, PERFECT STORM COVID
   Holden ER, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00828
   Hosseini P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012763
   House T, 2020, MODELLING HERD IMMUN
   Hoynes H, 2012, J ECON PERSPECT, V26, P27, DOI 10.1257/jep.26.3.27
   HSE, 2016, APPR VAL UN COSTS
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IMF, 2019, WORLD EC OUTL OCT 20
   International Monetary Fund, 2020, WORLD EC OUTL APR 20
   International Monetary Fund (IMF), 2020, WORLD EC OUTL REP
   JONESLEE M, 1974, J POLIT ECON, V82, P835, DOI 10.1086/260238
   Kavanagh J., 2018, TRUTH DECAY INITIAL
   Khunti K, 2020, BMJ
   Kurmann A, 2020, IMPACT COVID 19 SMAL
   Lekone PE, 2006, BIOMETRICS, V62, P1170, DOI 10.1111/j.1541-0420.2006.00609.x
   LI MY, 1995, MATH BIOSCI, V125, P155, DOI 10.1016/0025-5564(95)92756-5
   Mandel A., 2020, EC COST COVID LOCKDO
   Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)74234-3
   McLay MM, 2020, SHELTER IN PLACE ISN
   Morris C, 2020, CORONAVIRUS WHICH RE
   NICE, 2012, ASS COST EFF
   Nikolopoulos G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019432
   Norgrove D, 2020, D NORGROVE RESPONSE
   Oke J, 2020, COVID 19 COLLATERAL
   ONS, 2020, CLAIM COUNT K0200000
   ONS, 2020, GDP MONTHL EST UK AP
   Pancani L., 2020, FORCED SOCIAL ISOLAT, DOI 10.31234/osf.io/uacfj
   Pei Sen, 2020, medRxiv, DOI 10.1101/2020.05.15.20103655
   Pinto S, 2020, LONG TERM EFFECTS ED
   Public Health England, 2020, COVID 19 REV DISP RI
   Qin A, 2020, CHINA MAY BE BEATING
   Richiardi M, 2020, INPUT OUTPUT ANAL US
   Rocklov J, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa038
   Scally G, 2020, BMJ
   Shaikhet L, 2016, APPL ANAL, V95, P1228, DOI 10.1080/00036811.2015.1058363
   Smith A., 1776, WEALTH NATIONS
   Standard and Poor, 2020, SOV DEBT 2020 GLOB B
   Statista, 2020, NUMB KILL SOLD US WA
   Stern N., 2007, EC CLIMATE CHANGE ST
   Stier A, 2020, COVID 19 ATTACK RATE
   Stojkoski V, 2020, ARXIV200407947
   Sud A, 2020, COLLATERAL DAMAGE IM
   THORNTON J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1401
   Thunstrom L, 2020, J BENEFIT-COST ANAL, V11, P179, DOI 10.1017/bca.2020.12
   Treasury HM, 2018, GREEN BOOK CENTR GOV
   Van Lancker W, 2020, LANCET PUBLIC HEALTH, V5, pE243, DOI 10.1016/S2468-2667(20)30084-0
   Verity Robert, 2020, LANCET INFECT DIS
   Viner RM, 2020, LANCET CHILD ADOLESC
   Walmsley T, 2020, IMPACTS US MACROECON
   World Health Organisation, 2020, COR SYMPT
   World Heath Organization, 2020, COR OV
   Yancy CW, 2020, COVID 19 AFRICAN AM
NR 92
TC 2
Z9 2
U1 12
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0924-6460
EI 1573-1502
J9 ENVIRON RESOUR ECON
JI Environ. Resour. Econ.
PD AUG
PY 2020
VL 76
IS 4
SI SI
BP 525
EP 551
DI 10.1007/s10640-020-00466-5
EA AUG 2020
PG 27
WC Economics; Environmental Studies
SC Business & Economics; Environmental Sciences & Ecology
GA NI2YK
UT WOS:000555732200005
PM 32836862
OA Green Published, Other Gold
DA 2021-01-01
ER

EF